,Unnamed: 0,Patient ID,Prompts,Outcome,Prognosis
0,0,P0001,"Age: 58
Gender: Male 
Weight: 83 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 110/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 42,4
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,36
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1834.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,02
Urea (mg/dL): 7,12
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor
 REASONING: The patient has been on a regimen of medications including beta blockers, digoxin, loop diuretics, and ACE inhibitor, which are commonly used to manage heart failure symptoms and reduce the risk of sudden cardiac death. The patient's LVEF (Left Ventricular Ejection Fraction) of 35% indicates reduced left ventricular function, but it is not the lowest possible value. The patient's Pro-BNP level of 1834 ng/L is elevated, indicating heart failure, but not extremely high. The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death, but the patient is still on a treatment plan that includes beta blockers, which are known to reduce the risk of sudden cardiac death. Overall, considering the patient's current treatment and the relatively stable condition, the prognosis of survivor is the most likely.

RANKING: Pump failure death
 REASONING: The patient's LVEF of 35% indicates reduced left ventricular function, which increases the risk of pump failure. The patient's elevated Pro-BNP level of 1834 ng/L also indicates heart failure. However, the patient is on a treatment plan that includes loop diuretics, which are used to manage fluid overload and reduce the risk of pump failure. Additionally, the patient's creatinine level of 106.0 umol/L is slightly elevated, which may indicate some degree of renal impairment, but it is not extremely high. The patient's weight of 83 kg and height of 163 cm also do not indicate extreme obesity, which is a risk factor for pump failure. Overall, while the patient is at risk for pump failure, the current treatment plan and relatively stable condition make pump failure death less likely than sudden cardiac death.

RANKING: Sudden cardiac death
 REASONING: The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. The patient's LVEF of 35% also indicates reduced left ventricular function, which increases the risk of sudden cardiac death. However, the patient is on a treatment plan that includes beta blockers, which are known to reduce the risk of sudden cardiac death. The patient's Pro-BNP level of 1834 ng/L is elevated, indicating heart failure, but not extremely high. The patient's other vital signs and laboratory values do not indicate extreme risk factors for sudden cardiac death. Overall, while the patient is at risk for sudden cardiac death, the current treatment plan and relatively stable condition make it less likely than pump failure death."
1,1,P0002,"Age: 58
Gender: Male 
Weight: 74 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 40,4
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 6,18
Creatinine (mmol/L): 121.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 126.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,6
LDL (mmol/L): 4,06
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 570.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,27
Urea (mg/dL): 10,47
LVEF (%): 35.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient has a relatively controlled blood pressure and is on medications for angiotensin II receptor blocker, beta blockers, and statins, which are standard treatments for ischemic dilated cardiomyopathy. The patient's LVEF is 35%, which is below the normal range, but it is not extremely low. The patient's troponin levels are within normal limits, indicating minimal ongoing myocardial damage. The absence of non-sustained ventricular tachycardia and other serious arrhythmias on the ECG also suggests that the patient is not at high risk for sudden cardiac death. The patient's NYHA Class II classification indicates that the patient has some limitations in physical activity but is still able to perform daily activities without significant distress. Considering these factors, a survivor prognosis is the most likely outcome.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, myocardial infarction, and a low LVEF of 35%. These factors increase the risk of sudden cardiac death. However, the patient's controlled blood pressure, absence of non-sustained ventricular tachycardia on the ECG, and relatively normal troponin levels suggest that the risk is not extremely high. The patient's NYHA Class II classification also indicates that the patient is not severely limited by their heart disease. Therefore, while sudden cardiac death is a possible outcome, it is less likely than a survivor prognosis.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 35% indicates that the heart is functioning at a significantly reduced capacity. The patient's creatinine levels are elevated, suggesting some degree of renal impairment, which can be a consequence of heart failure. However, the patient's controlled blood pressure and absence of severe arrhythmias on the ECG suggest that the patient is not at extremely high risk for pump failure death. The patient's NYHA Class II classification also indicates that the patient is not severely limited by their heart disease. Considering these factors, pump failure death is the least likely outcome.

Please note that this is a general assessment based on the provided data, and a more accurate prognosis would require a comprehensive evaluation by a cardiologist and consideration of additional factors not mentioned in the patient data."
2,2,P0003,"Age: 69
Gender: Male 
Weight: 83 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 100/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40,1
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 5,3
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 132.0
HDL (mmol/L): 2,04
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,97
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 403.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,93
Urea (mg/dL): 10,02
LVEF (%): 39.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely:

RANKING: Survivor

REASONING: The patient has a history of idiopathic dilated cardiomyopathy with a left ventricular ejection fraction (LVEF) of 39%, indicating reduced cardiac function. However, the patient is on appropriate medical therapy, including angiotensin II receptor blockers, beta blockers, digoxin, and loop diuretics, which are standard treatments for heart failure with reduced ejection fraction (HFrEF). The patient's NT-proBNP level of 403 ng/L is elevated, but it is not excessively high, and the patient's blood pressure is well-controlled. Additionally, the patient's creatinine level is slightly elevated, but not significantly so. The patient's ECG shows non-sustained ventricular tachycardia, but this is not a contraindication to medical therapy. The patient's TSH level is within the normal range, which suggests that there is no underlying thyroid disease contributing to the patient's condition. Considering these factors, the patient's overall prognosis is guarded but not extremely poor, and with continued medical therapy and close monitoring, a survival outcome is more likely than the other two options.

REASONING FOR SURVIVOR BEING MORE LIKELY THAN SUDDEN CARDIAC DEATH:

* The patient is on appropriate medical therapy for HFrEF, which reduces the risk of sudden cardiac death.
* The patient's blood pressure is well-controlled, which reduces the risk of cardiac arrhythmias.
* The patient's creatinine level is not excessively high, which suggests that the patient's renal function is not significantly impaired.

REASONING FOR SURVIVOR BEING MORE LIKELY THAN PUMP FAILURE DEATH:

* The patient's LVEF is 39%, which is not extremely low, and the patient is on beta blockers, which can help improve cardiac function.
* The patient's NT-proBNP level is not excessively high, which suggests that the patient's cardiac function is not severely compromised.
* The patient's creatinine level is not excessively high, which suggests that the patient's renal function is not significantly impaired.

REASONING FOR SUDDEN CARDIAC DEATH BEING MORE LIKELY THAN PUMP FAILURE DEATH:

* The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death.
* The patient's LVEF is 39%, which is below the normal range, and the patient is on beta blockers, which can help prevent sudden cardiac death.
* The patient's NT-proBNP level is elevated, which suggests that the patient's cardiac function is compromised, but not severely so.

REASONING FOR PUMP FAILURE DEATH BEING THE LEAST LIKELY:

* The patient's LVEF is 39%, which is not extremely low, and the patient is on beta blockers, which can help improve cardiac function.
* The patient's NT-proBNP level is not excessively high, which suggests that the patient's cardiac function is not severely compromised.
* The patient's creatinine level is not excessively high, which suggests that the patient's renal function is not significantly impaired."
3,3,P0004,"Age: 56
Gender: Female 
Weight: 84 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 155/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 40,9
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,21
Creatinine (mmol/L): 77.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 17,8
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,49
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 695.0
Protein (g/L): 72
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,07
Urea (mg/dL): 8,91
LVEF (%): 38.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses for the next few years as follows:

RANKING: 1. Survivor
REASONING: The patient is 56 years old with a history of hypertensive cardiomyopathy, diabetes, and dyslipemia, which are all risk factors for cardiovascular disease. However, the patient is on a comprehensive medication regimen that includes an angiotensin II receptor blocker, beta blockers, loop diuretics, and spironolactone, which are all evidence-based treatments for heart failure and hypertension. The patient's LVEF is 38%, which is below the normal range, but the patient is still on treatment and has not shown signs of acute decompensation. The Pro-BNP level is elevated at 695.0 ng/L, but it is not excessively high. The ECG shows ventricular extrasystoles, but no sustained ventricular tachycardia or bradycardia. The patient's overall clinical picture suggests that the patient is being actively managed for heart failure, and with continued treatment and monitoring, the patient is likely to survive for the next few years.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of ventricular extrasystoles and elevated Pro-BNP level increase the risk of sudden cardiac death. However, the patient's LVEF is not extremely low, and the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death. The patient's ECG does not show any signs of sustained ventricular tachycardia, which is a major risk factor for sudden cardiac death. While the patient's overall risk is increased, the likelihood of sudden cardiac death is not extremely high, given the patient's ongoing treatment and the absence of other high-risk features.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF is 38%, which is below the normal range, indicating some degree of left ventricular dysfunction. The patient's Pro-BNP level is elevated, which is consistent with heart failure. However, the patient is on a comprehensive medication regimen that includes diuretics, which are used to manage fluid overload and reduce the risk of heart failure decompensation. The patient's overall clinical picture suggests that the patient is being actively managed for heart failure, and while pump failure death is a possible outcome, it is less likely than sudden cardiac death, given the patient's ongoing treatment and the absence of other high-risk features."
4,4,P0005,"Age: 70
Gender: Male 
Weight: 97 kg
Height: 183 cm
NYHA Class: II
Blood Pressure: 125/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45,3
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,72
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 159.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,28
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 456.0
Protein (g/L): 82
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,01
Urea (mg/dL): 10,91
LVEF (%): 34.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Sudden Cardiac Death (SCD)
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for SCD. The patient's left ventricular ejection fraction (LVEF) is 34%, indicating severe systolic dysfunction. Additionally, the patient has a high level of B-type natriuretic peptide (BNP) at 456.0 ng/L, which is indicative of heart failure and increased risk of SCD. The presence of polymorphic ventricular extrasystoles on the ECG further increases the risk of SCD. While the patient is on beta blockers, which are known to reduce the risk of SCD, the patient's overall risk profile suggests that SCD is the most likely prognosis.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF of 34% and high BNP level suggest that the patient is at risk of pump failure death. The patient's history of myocardial infarction and ischemic dilated cardiomyopathy also contribute to this risk. However, the patient's NYHA class II suggests that the patient is still relatively stable and not in decompensated heart failure. The patient's medications, including loop diuretics and ACE inhibitors, are also aimed at managing heart failure symptoms and reducing the risk of pump failure. While pump failure death is a possible outcome, it is less likely than SCD due to the patient's relatively stable condition.

RANKING: 3. Survivor
 REASONING: Based on the patient's data, the patient's overall condition is relatively stable, and the patient is receiving appropriate medical management for their heart failure and other comorbidities. The patient's medications, including beta blockers, statins, and ACE inhibitors, are aimed at reducing the risk of SCD and managing heart failure symptoms. The patient's LVEF is low, but the patient is not in decompensated heart failure, and the patient's NYHA class is II, indicating that the patient is still relatively functional. While the patient's prognosis is guarded, the patient's stable condition and appropriate medical management suggest that survivorship is the least likely prognosis."
5,5,P0006,"Age: 70
Gender: Male 
Weight: 83 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 105/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 44,1
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,8
LDL (mmol/L): 3
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 3437.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,88
Urea (mg/dL): 8,46
LVEF (%): 34.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"RANKING: 1. Survivor
REASONING: Considering the patient's age, history of ischemic dilated cardiomyopathy, and reduced LVEF (34%), the patient is at a high risk for cardiac complications. However, the patient's NYHA Class II indicates that he is still relatively stable and not experiencing severe symptoms. The presence of beta blockers, ACE inhibitors, and spironolactone, which are evidence-based treatments for heart failure, suggests that the patient is receiving optimal medical therapy. Additionally, the absence of sustained ventricular tachycardia and non-sustained ventricular tachycardia in the ECG suggests that the patient's ventricular arrhythmias are not a significant concern at this time. The patient's Pro-BNP level is elevated at 3437.0 ng/L, which is consistent with heart failure, but it is not extremely high. The patient's TSH level is within the normal range, which suggests that the thyroid function is not contributing to his cardiac condition. The patient's medication regimen, including a nitrovasodilator, indicates that the patient's symptoms are being managed. Considering these factors, the most likely prognosis is survivor, as the patient is receiving optimal medical therapy and does not have any acute cardiac conditions that would suggest a poor outcome.

RANKING: 2. Pump failure death
REASONING: The patient's reduced LVEF (34%) and history of ischemic dilated cardiomyopathy suggest that the patient's heart function is compromised. The elevated Pro-BNP level and the presence of NYHA Class II symptoms indicate that the patient has heart failure. However, the patient's ejection fraction is not extremely low, and the patient is receiving evidence-based treatments for heart failure. The patient's creatinine level is elevated at 101.0 umol/L, which suggests that the patient has some degree of renal impairment, which is a common comorbidity in patients with heart failure. The patient's diabetes and high cholesterol levels are also risk factors for cardiac complications. While the patient's prognosis is guarded, the fact that he is receiving optimal medical therapy and does not have any acute cardiac conditions that would suggest a poor outcome suggests that pump failure death is less likely than sudden cardiac death.

RANKING: 3. Sudden cardiac death
REASONING: The patient's ECG shows polymorphic ventricular extrasystoles, which is a risk factor for sudden cardiac death. However, the patient does not have any other ECG abnormalities that would suggest a high risk for sudden cardiac death, such as non-sustained ventricular tachycardia. The patient's medications, including beta blockers, which are known to reduce the risk of sudden cardiac death, suggest that the patient is receiving optimal medical therapy. The patient's LVEF is reduced, but it is not extremely low, and the patient is receiving evidence-based treatments for heart failure. While the patient's history of myocardial infarction and ischemic dilated cardiomyopathy increase his risk for sudden cardiac death, the absence of other high-risk factors and the presence of optimal medical therapy suggest that sudden cardiac death is the least likely prognosis."
6,6,P0007,"Age: 52
Gender: Male 
Weight: 71 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 125/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 49,69
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 5,79
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 90
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4
LDL (mmol/L): 3,83
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 140.0
Protein (g/L): 73
T3 (pg/dL): 0,06
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,979
Urea (mg/dL): 7,8
LVEF (%): 39.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Given the patient's history of ischemic dilated cardiomyopathy, myocardial infarction, and current LVEF of 39%, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: Despite the patient's history of ischemic dilated cardiomyopathy and myocardial infarction, the current LVEF of 39% is still within the range of moderate heart failure. The patient is on beta blockers and statins, which are standard treatments for heart failure and dyslipidemia. The patient's blood pressure is well-controlled, and there are no signs of severe electrolyte imbalances or acute kidney injury. The low Pro-BNP level (140.0 ng/L) also suggests that the patient's heart failure is not severe at the moment. However, the patient's LVEF is still low, indicating some degree of cardiac dysfunction. The presence of monomorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests some degree of arrhythmogenic potential, but the absence of sustained VT and bradycardia is reassuring. Overall, while the patient's prognosis is guarded, the current treatment plan and relatively mild symptoms (NYHA Class II) suggest that the patient is likely to survive for the next few years with continued medical management and close monitoring.

Sudden Cardiac Death (SCD) would be the second most likely prognosis, but it is less likely than survivor due to the following reasons:

REASONING: The patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases the risk of SCD. However, the patient's LVEF of 39% is not extremely low, and the patient is on beta blockers, which are known to reduce the risk of SCD. The absence of sustained VT and bradycardia on the ECG is also reassuring. The patient's low T3 level may indicate some degree of hypothyroidism, which can be managed with medication.

Pump Failure Death would be the least likely prognosis, but it is still a possibility:

REASONING: The patient's LVEF of 39% indicates some degree of cardiac dysfunction, but it is not extremely low. The patient's symptoms are mild (NYHA Class II), and the patient is on beta blockers, which can help to reduce the symptoms of heart failure. The patient's creatinine level is slightly elevated, but it is not severely elevated, indicating that the patient's kidney function is not severely compromised. The patient's albumin level is also within a relatively normal range, which suggests that the patient's liver function is not severely compromised. However, the patient's history of ischemic dilated cardiomyopathy and myocardial infarction, combined with the current LVEF, suggests that pump failure is still a possibility, especially if the patient's condition worsens over time."
7,7,P0009,"Age: 64
Gender: Female 
Weight: 68 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 160/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 41,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,53
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,44
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 211.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,88
Urea (mg/dL): 7,8
LVEF (%): 24.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 2. Sudden Cardiac Death, 3. Pump Failure Death, 1. Survivor

REASONING:

The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. However, the patient's LVEF of 24% indicates severe systolic dysfunction, which is more commonly associated with pump failure. The patient's NYHA Class II suggests that the patient has some symptoms of heart failure, but is still able to perform some physical activity. The patient's Pro-BNP level of 211.0 ng/L is elevated, which is consistent with heart failure, but not extremely high.

The patient's ECG shows monomorphic ventricular extrasystoles, which can be a marker of increased risk of sudden cardiac death. However, there is no evidence of sustained ventricular tachycardia or other high-risk arrhythmias.

The patient's medication regimen includes ACE inhibitors, beta blockers, and loop diuretics, which are standard treatments for heart failure and may help to reduce the risk of sudden cardiac death and pump failure.

Considering the patient's severe systolic dysfunction and the presence of monomorphic ventricular extrasystoles, the risk of pump failure death is higher than sudden cardiac death. However, the patient's NYHA Class II and the presence of symptoms of heart failure suggest that the patient is still relatively stable and may be able to survive with proper treatment.

Therefore, the most likely outcome is that the patient will survive, with a moderate risk of pump failure death and a lower risk of sudden cardiac death."
8,8,P0010,"Age: 54
Gender: Male 
Weight: 88 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38,7
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 89.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 3,9
LDL (mmol/L): 3,26
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 361.0
Protein (g/L): 71
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,02
Urea (mg/dL): 7,57
LVEF (%): 22.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's a prognosis for the next few years, considering the patient's medical history, laboratory results, and current medication. I will rank the possible outcomes from most likely to least likely.

RANKING: 1. Survivor
REASONING: Despite the patient's history of ischemic dilated cardiomyopathy, diabetes, and previous myocardial infarction, the current medication regimen (Beta Blockers and ACE Inhibitor) is beneficial for heart failure management. The patient's LVEF is 22%, which is low but not extremely low. The absence of severe electrolyte imbalances, such as low potassium or high sodium, reduces the risk of arrhythmias. Although the patient has a high Pro-BNP level (361.0 ng/L), indicating increased stress on the heart, it is not excessively high, suggesting some degree of compensation. The patient's weight and blood pressure are within reasonable limits, and the absence of severe kidney dysfunction (Creatinine 89.0 mmol/L) is a positive sign. Considering these factors, the patient has a relatively stable condition and is receiving appropriate treatment, making survival the most likely outcome.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of ischemic dilated cardiomyopathy, previous myocardial infarction, and low LVEF (22%) increase the risk of sudden cardiac death. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is a risk factor for sudden cardiac death. However, the patient is on Beta Blockers and ACE Inhibitors, which can help reduce the risk of arrhythmias. The patient's overall condition is not extremely unstable, and the absence of other high-risk factors (e.g., very low LVEF, severe electrolyte imbalances) makes sudden cardiac death less likely compared to pump failure.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF of 22% indicates significant left ventricular dysfunction, which increases the risk of pump failure. The high Pro-BNP level (361.0 ng/L) suggests increased stress on the heart, and the patient's history of ischemic dilated cardiomyopathy and previous myocardial infarction further increases this risk. While the patient is receiving treatment, the current medication regimen may not be sufficient to reverse the damage and prevent pump failure. The patient's weight and blood pressure are within reasonable limits, but the overall condition is still concerning. Pump failure death is a possible outcome, but the patient's relatively stable condition and ongoing treatment make it the least likely of the three options."
9,9,P0013,"Age: 71
Gender: Female 
Weight: 70 kg
Height: 152 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 41,4
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4
LDL (mmol/L): 2,56
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 653.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,53
Urea (mg/dL): 9,8
LVEF (%): 39.0
Medications: Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: Based on the provided patient data, I would rank the prognosis as a survivor for the next few years. Here's the reasoning behind this decision:

1. Age and Gender: The patient is 71 years old, which is a significant risk factor for cardiovascular disease. However, her gender as a female is a favorable factor, as women generally have a lower risk of cardiovascular events compared to men.

2. NYHA Class II: The patient's New York Heart Association (NYHA) functional class of II indicates that she has some symptoms of heart failure, but she is still able to perform everyday activities. This suggests that her heart failure is not severe, and she is not in an advanced stage.

3. LVEF: The left ventricular ejection fraction (LVEF) is 39%, which is below the normal range (50-70%). However, it's not extremely low, indicating that the patient's heart is still pumping some blood, albeit not efficiently.

4. Medications: The patient is on beta blockers, statins, ACE inhibitors, and nitrovasodilators, which are standard treatments for heart failure and hypertension. These medications are likely helping to manage her symptoms and slow disease progression.

5. ECG: The ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or other severe arrhythmias. This suggests that the patient's heart rhythm is relatively stable.

6. Lab results: The patient's albumin, liver enzymes, and electrolytes are within relatively normal ranges. Her creatinine level is slightly elevated, but not significantly so. Her pro-BNP level is elevated, indicating some degree of heart failure, but not excessively high.

7. TSH and T3/T4: The patient's thyroid function tests are within normal ranges, which is essential for heart health.

Considering these factors, while the patient has significant cardiovascular disease, her overall condition is relatively stable, and she is receiving appropriate treatment. Therefore, I would rank her prognosis as a survivor for the next few years, with a focus on continued monitoring and management of her condition to prevent further decline.

RANKING: Sudden cardiac death (2nd)

REASONING: Sudden cardiac death is a possible outcome due to the patient's history of ischemic dilated cardiomyopathy and her low LVEF. However, the presence of polymorphic ventricular extrasystoles on the ECG is a concerning sign, as it may indicate an increased risk of arrhythmias. The patient's medications, particularly the beta blockers and ACE inhibitors, should help mitigate this risk, but close monitoring is essential.

RANKING: Pump failure death (3rd)

REASONING: Pump failure death is the least likely outcome, given the patient's relatively stable condition and the presence of heart failure symptoms that are well-managed with medications. The patient's LVEF is not extremely low, and her overall clinical status suggests that her heart is still pumping some blood. While heart failure can progress over time, the patient's current medications and relatively stable condition make pump failure death less likely in the short term."
10,10,P0014,"Age: 50
Gender: Male 
Weight: 51 kg
Height: 164 cm
NYHA Class: III
Blood Pressure: 90/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Peripheral vascular disease
Albumin (g/L): 42
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 3,23
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 577.0
Protein (g/L): 64
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,77
Urea (mg/dL): 8,69
LVEF (%): 22.0
Medications: Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient is 50 years old with a history of enolic dilated cardiomyopathy and peripheral vascular disease, which are significant risk factors for cardiovascular disease. However, the patient's current medications, Spironolactone and ACE Inhibitor, are appropriate for managing heart failure and may be contributing to the stabilization of his condition. The patient's LVEF (Left Ventricular Ejection Fraction) is 22%, which is low, but it is not the lowest possible value (typically, an LVEF below 20% is considered severe). The patient's Pro-BNP level is elevated, which is consistent with heart failure, but it is not extremely high. The patient's troponin level is within the normal range, which suggests that there is no acute myocardial infarction. The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death, but it is not a guarantee of poor outcome. Overall, while the patient's prognosis is guarded, the combination of appropriate medications, a low but not extremely low LVEF, and no acute myocardial infarction make survival the most likely outcome.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. The patient's LVEF is low, which may indicate a high risk of arrhythmias. However, the patient's medications, including Spironolactone and ACE Inhibitor, are appropriate for managing heart failure and may be contributing to the stabilization of his condition. The patient's Pro-BNP level is elevated, which is consistent with heart failure, but it is not extremely high. The patient's troponin level is within the normal range, which suggests that there is no acute myocardial infarction. Overall, while the patient's ECG findings and low LVEF suggest a risk of sudden cardiac death, the patient's overall clinical picture is not entirely consistent with this outcome.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF is 22%, which is low, indicating that the heart is not pumping efficiently. However, the patient's medications, including Spironolactone and ACE Inhibitor, are appropriate for managing heart failure, and the patient's Pro-BNP level, while elevated, is not extremely high. The patient's troponin level is within the normal range, which suggests that there is no acute myocardial infarction. The patient's ECG shows non-sustained ventricular tachycardia, but this is not a guarantee of poor outcome. Overall, while the patient's low LVEF suggests a risk of pump failure, the patient's overall clinical picture is not entirely consistent with this outcome, and the patient's medications and other factors suggest a more guarded prognosis."
11,11,P0015,"Age: 40
Gender: Male 
Weight: 98 kg
Height: 180 cm
NYHA Class: III
Blood Pressure: 100/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 39
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,13
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 179.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,93
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 670.0
Protein (g/L): 69
T3 (pg/dL): 0,06
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,83
Urea (mg/dL): 3,79
LVEF (%): 20.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses for the next few years as follows:

RANKING: 1. Survivor
REASONING: The patient is 40 years old with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for adverse cardiac outcomes. However, despite the advanced stage of heart failure (NYHA Class III) and a low left ventricular ejection fraction (LVEF) of 20%, the patient is currently receiving appropriate medical therapy, including ACE inhibitors, spironolactone, statins, and loop diuretics. The patient's blood pressure is well-controlled, and the low levels of troponin and pro-BNP suggest that the patient is not experiencing significant acute myocardial injury or heart failure decompensation. The patient's ECG findings of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles indicate some degree of arrhythmia risk, but the absence of sustained ventricular tachycardia or bradycardia is a positive sign. Considering the patient's relatively young age, the absence of severe electrolyte imbalances, and the presence of appropriate medical therapy, the likelihood of survival is higher compared to the other two options.

RANKING: 2. Sudden cardiac death
REASONING: The patient's history of idiopathic dilated cardiomyopathy and non-sustained ventricular tachycardia on ECG increase the risk of sudden cardiac death. However, the patient's low troponin level and absence of other high-risk features, such as a history of cardiac arrest or sustained ventricular tachycardia, reduce the likelihood of sudden cardiac death. Additionally, the patient's age and the presence of appropriate medical therapy may mitigate this risk.

RANKING: 3. Pump failure death
REASONING: The patient's advanced heart failure (NYHA Class III), low LVEF, and elevated pro-BNP level suggest a high risk of pump failure. However, the patient's relatively young age, well-controlled blood pressure, and the presence of appropriate medical therapy may slow the progression of heart failure. The patient's albumin and protein levels are within normal limits, which suggests that there is no significant hepatic dysfunction, which can be a contributing factor to pump failure. While pump failure death is a possible outcome, it is less likely compared to the other two options due to the patient's relatively young age and the presence of appropriate medical therapy.

Please note that this prognosis is based on the provided data and may not reflect the patient's actual outcome, as individual patient factors and clinical course can vary."
12,12,P0017,"Age: 58
Gender: Female 
Weight: 89 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43,8
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,54
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 161.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,9
LDL (mmol/L): 4,09
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1108.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,14
Urea (mg/dL): 8,02
LVEF (%): 21.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor
REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure and mortality. However, the patient is currently being treated with a combination of medications that are commonly used in heart failure management, including beta blockers, angiotensin II receptor blockers, and statins. The patient's NYHA Class II indicates that they have some limitation in physical activity but are still able to perform everyday activities without severe symptoms. The LVEF of 21% is low, indicating significant left ventricular dysfunction, but the patient's Pro-BNP level of 1108 ng/L is not extremely elevated, which might indicate some degree of compensation. Additionally, the patient's recent troponin level is normal, suggesting that there is no acute myocardial infarction. Considering these factors, the patient's current treatment regimen and the fact that they are still ambulatory, I consider the prognosis of survivor to be the most likely.

RANKING: Pump failure death
REASONING: The patient's LVEF of 21% and Pro-BNP level of 1108 ng/L suggest significant left ventricular dysfunction and heart failure. The patient's history of myocardial infarction and ischemic dilated cardiomyopathy further increase the risk of pump failure. However, the patient's current treatment regimen and the fact that they are still ambulatory suggest that they are being well-managed, which might mitigate some of the risk. Additionally, the patient's recent troponin level is normal, indicating that there is no acute myocardial infarction. Considering these factors, I consider pump failure death to be a possible but less likely outcome.

RANKING: Sudden cardiac death
REASONING: The patient has a history of ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the patient's ECG does not show any signs of sustained ventricular tachycardia or bradycardia, which are more significant risk factors for sudden cardiac death. Additionally, the patient's recent troponin level is normal, indicating that there is no acute myocardial infarction. Considering these factors, I consider sudden cardiac death to be the least likely outcome."
13,13,P0019,"Age: 74
Gender: Male 
Weight: 95 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 46,3
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,08
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 48
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 3,8
LDL (mmol/L): 3,88
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1596.0
Protein (g/L): 80
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,99
Urea (mg/dL): 7,8
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient is 74 years old with a history of hypertensive cardiomyopathy and hypertension, which are risk factors for cardiovascular disease. However, the patient's current medications, including beta blockers and ACE inhibitors, are appropriate for managing these conditions. The patient's LVEF is 50%, which is within the normal range (> 50%), indicating preserved left ventricular function. The patient's troponin levels are within normal limits, and there is no evidence of acute coronary syndrome. The patient's eGFR is not provided, but the creatinine level of 88.0 umol/L is within the normal range for a male patient. The patient's BNP level is elevated at 1596.0 ng/L, but this is likely due to the patient's heart failure rather than a sign of acute decompensation. Overall, the patient's current condition suggests that with continued management and monitoring, a survivor prognosis is most likely.

RANKING: 2. Pump failure death
 REASONING: The patient's LVEF is 50%, which is near the lower limit of normal, indicating some degree of left ventricular dysfunction. The patient's BNP level is elevated, which is a marker of heart failure. The patient's creatinine level is within the normal range, but this may not accurately reflect the patient's renal function, as the eGFR is not provided. The patient's medication regimen includes diuretics, which are used to manage heart failure symptoms. However, the patient's symptoms are not severe enough to warrant a higher level of care, such as hospitalization or more aggressive medical therapy. The patient's overall condition suggests that pump failure is a possible outcome, but it is not the most likely prognosis.

RANKING: 3. Sudden cardiac death
 REASONING: The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are risk factors for sudden cardiac death. However, the patient's LVEF is within the normal range, and there is no evidence of acute coronary syndrome or severe arrhythmias. The patient's medications include beta blockers, which are used to reduce the risk of sudden cardiac death. The patient's overall condition suggests that sudden cardiac death is a possible outcome, but it is the least likely prognosis based on the provided data."
14,14,P0020,"Age: 48
Gender: Male 
Weight: 77 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 145/80 mmHg
Past Medical History: Post-myocardial dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 45,5
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,44
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 52
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,5
LDL (mmol/L): 4,22
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 322.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,25
Urea (mg/dL): 6,45
LVEF (%): 28.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient's age, NYHA Class II, and the presence of a post-myocardial dilated cardiomyopathy indicate a chronic heart failure condition. However, the patient is on optimal medical therapy with an Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, and Loop Diuretics. The LVEF is 28%, which is low, but the patient's hemoglobin and urea levels are within normal limits, indicating that the patient is not severely decompensated. The low T3 and normal T4 levels suggest that the patient is not experiencing significant hyperthyroidism, which can exacerbate heart failure. The patient's Pro-BNP level is elevated at 322.0 ng/L, but this is not unusually high given the patient's heart failure diagnosis. The absence of severe electrolyte imbalances and the presence of a normal potassium level also suggest that the patient is not at high risk of arrhythmias. Considering these factors, the patient's overall prognosis is relatively stable, and with continued optimal medical therapy, the likelihood of a survivor outcome is the most likely.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's ECG shows non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, which are risk factors for sudden cardiac death. However, the patient's LVEF is low, but not extremely low, and the patient is on beta blockers, which can reduce the risk of arrhythmias. The patient's low T3 level may also be protective against arrhythmias. While the patient's Pro-BNP level is elevated, it is not unusually high, and the patient's hemoglobin and urea levels are within normal limits. The patient's overall clinical condition suggests that sudden cardiac death is a possible outcome, but it is less likely than a survivor outcome due to the patient's relatively stable condition and optimal medical therapy.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF is 28%, which is significantly low, indicating severe left ventricular dysfunction. However, the patient's hemoglobin and urea levels are within normal limits, and the patient is on optimal medical therapy, which suggests that the patient's condition is relatively stable. The patient's Pro-BNP level is elevated, but not unusually high, and the patient's low T3 level may be protective against further deterioration. The patient's NYHA Class II suggests that the patient is experiencing some symptoms of heart failure, but the patient's overall clinical condition does not suggest that pump failure death is the most likely outcome. While pump failure death is a possible outcome, it is the least likely of the three options due to the patient's relatively stable condition and optimal medical therapy."
15,15,P0021,"Age: 67
Gender: Female 
Weight: 56 kg
Height: 146 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 38,19
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 72.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 6,4
Hemoglobin (g/L): 121.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 6,1
LDL (mmol/L): 1,06
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 568.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,98
Urea (mg/dL): 5,79
LVEF (%): 36.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I would rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient is 67 years old with a history of idiopathic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension. However, she is on a multidrug regimen including beta blockers, digoxin, loop diuretics, statins, and ACE inhibitors, which indicates that she is receiving comprehensive treatment for her conditions. Her NYHA Class II indicates that she has some limitations in physical activity but is still able to perform daily activities. Her LVEF of 36% is relatively low, but it is not extremely low, and her Pro-BNP level of 568 ng/L is elevated but not extremely high. Her ECG shows monomorphic ventricular extrasystoles, but no sustained ventricular tachycardia or other concerning arrhythmias. Her recent troponin level is normal, indicating no recent myocardial infarction. Considering these factors, the patient's prognosis appears to be relatively favorable, and with continued treatment and management, it is likely that she will survive for the next few years.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF of 36% indicates that her heart is not pumping efficiently, which increases the risk of pump failure. Her Pro-BNP level of 568 ng/L is also elevated, which is a marker of heart failure. However, her NYHA Class II indicates that she is still able to perform daily activities, and her recent troponin level is normal, indicating no recent myocardial infarction. Her ECG shows monomorphic ventricular extrasystoles, but no sustained ventricular tachycardia or other concerning arrhythmias. With proper management and treatment, it is possible to slow the progression of heart failure, and the patient may be able to avoid pump failure death.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient's LVEF of 36% and elevated Pro-BNP level indicate that she is at risk for sudden cardiac death. However, her recent troponin level is normal, indicating no recent myocardial infarction. Her ECG shows monomorphic ventricular extrasystoles, but no sustained ventricular tachycardia or other concerning arrhythmias. Her treatment regimen includes beta blockers, which are known to reduce the risk of sudden cardiac death. While sudden cardiac death is a possible outcome, it is less likely than pump failure death given the patient's current treatment regimen and lack of recent myocardial infarction."
16,16,P0022,"Age: 43
Gender: Male 
Weight: 130 kg
Height: 179 cm
NYHA Class: II
Blood Pressure: 140/100 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 46,5
ALT or GPT (IU/L): 100.0
AST or GOT (IU/L): 49.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 83.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,9
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 195.0
Protein (g/L): 75
T3 (pg/dL): 0,03
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,46
Urea (mg/dL): 5,79
LVEF (%): 40.0
Medications: Angiotensin II Receptor Blocker, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Please note that this is a complex task and the actual outcome may vary depending on various factors, including the patient's adherence to treatment, lifestyle changes, and potential new medical conditions.

RANKING: 1. Survivor
 REASONING: The patient is 43 years old with a history of idiopathic dilated cardiomyopathy and hypertension. Despite this, the patient is on Angiotensin II Receptor Blocker and Spironolactone, which are standard treatments for heart failure and hypertension. The patient's LVEF is 40%, which is below the normal range but not extremely low. The patient's ECG shows non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, which are concerning but not uncommon in patients with dilated cardiomyopathy. The patient's Pro-BNP level is elevated at 195 ng/L, indicating some degree of heart failure, but not extremely high. Considering these factors, the patient is at risk of complications, but with proper management and adherence to treatment, the likelihood of survival is relatively high.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's history of idiopathic dilated cardiomyopathy and non-sustained ventricular tachycardia increases the risk of sudden cardiac death. The patient's LVEF is 40%, which is below the normal range and may indicate a higher risk of arrhythmias. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a precursor to ventricular fibrillation and sudden cardiac death. However, the patient is on Angiotensin II Receptor Blocker and Spironolactone, which can help reduce the risk of sudden cardiac death. The patient's Pro-BNP level is elevated, but not extremely high, which may indicate some degree of heart failure but not an extremely high risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF is 40%, which is below the normal range and indicates some degree of left ventricular dysfunction. The patient's Creatinine level is elevated at 83.0 mmol/L, which may indicate some degree of renal impairment, which can be a consequence of heart failure. The patient's Albumin level is slightly low at 46.5 g/L, which may indicate some degree of malnutrition or liver dysfunction. However, the patient is on Spironolactone, which can help reduce the risk of pump failure. The patient's Pro-BNP level is elevated, indicating some degree of heart failure, but not extremely high, which may indicate an intermediate risk of pump failure."
17,17,P0023,"Age: 76
Gender: Male 
Weight: 73 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 36,6
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 5,87
Creatinine (mmol/L): 136.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,5
LDL (mmol/L): 4,22
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 188.0
Protein (g/L): 65
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,53
Urea (mg/dL): 11,13
LVEF (%): 37.0
Medications: Calcium Channel Blocker, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: Survivor

REASONING: 

Based on the provided patient data, the patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weak and the heart chambers dilate, leading to reduced heart function. The patient's left ventricular ejection fraction (LVEF) is 37%, which is below the normal range (50-70%), indicating poor heart function.

However, the patient is taking medications such as Calcium Channel Blocker, ACE Inhibitor, and Nitrovasodilator, which are commonly used to manage heart failure and hypertension. These medications are likely helping to control the patient's symptoms and slow the progression of the disease.

The patient's blood pressure is within a relatively normal range (140/80 mmHg), and the creatinine level is slightly elevated (136.0 mmol/L), which may indicate mild kidney dysfunction. However, the patient's hemoglobin level is within a normal range (139.0 g/L), which suggests that the kidneys are not severely compromised.

The patient's TSH level is within a normal range (2.53 mIU/L), and the T3 and T4 levels are within a normal range, indicating that the patient's thyroid function is not significantly abnormal. The patient's troponin level is within a normal range (0.01 ng/mL), which suggests that there is no significant cardiac muscle damage.

The patient has a history of non-sustained ventricular tachycardia (NSVT) and paroxysmal supraventricular tachycardia (PSVT), which are abnormal heart rhythms. However, the patient is not experiencing symptoms of heart failure, such as shortness of breath or swelling, which suggests that the patient's heart function is relatively stable.

Based on these factors, the patient is likely to survive for the next few years, as the patient's medications are helping to control the disease, and there are no significant abnormalities in the patient's laboratory results that would indicate a poor prognosis.

Sudden cardiac death (SCD) is less likely because the patient is on medications that can help prevent arrhythmias and the patient's LVEF is not severely decreased.

Pump failure death is also less likely because the patient is not experiencing symptoms of heart failure, and the patient's creatinine level is not significantly elevated, indicating that the kidneys are not severely compromised.

Overall, the patient's prognosis is guarded, but based on the available data, the most likely outcome is that the patient will survive for the next few years."
18,18,P0024,"Age: 58
Gender: Male 
Weight: 94 kg
Height: 188 cm
NYHA Class: II
Blood Pressure: 130/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 44,5
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,48
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4
LDL (mmol/L): 3,62
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 492.0
Protein (g/L): 68
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,75
Urea (mg/dL): 7,12
LVEF (%): 37.0
Medications: Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor
REASONING: The patient is 58 years old with a history of ischemic dilated cardiomyopathy, myocardial infarction, and peripheral vascular disease. However, the patient is currently being treated with beta blockers, loop diuretics, and statins, which are standard medications for heart failure management. The patient's LVEF is 37%, indicating reduced left ventricular function, but it is not severely impaired. The patient's NYHA Class II indicates that the patient's symptoms are manageable with current treatment. The patient's blood pressure is well-controlled, and the Pro-BNP level is within a moderate range. Additionally, the patient's hemoglobin and albumin levels are within normal limits, indicating that the patient is not severely malnourished or anemic. Considering these factors, the patient's overall condition suggests that they are likely to survive for the next few years with continued treatment and management.

RANKING: Pump Failure Death
REASONING: While the patient's LVEF is reduced, indicating some degree of left ventricular dysfunction, it is not severely impaired. The patient's symptoms are manageable, and the patient is on standard heart failure medications. However, the patient's LVEF is lower than the average expected value, and the patient has a history of myocardial infarction and peripheral vascular disease, which may contribute to further cardiac damage. The patient's Pro-BNP level is within a moderate range, indicating some degree of cardiac stress, but not severe. While pump failure death is a possible outcome, it is less likely than survivor due to the patient's current treatment and manageable symptoms.

RANKING: Sudden Cardiac Death
REASONING: Sudden cardiac death is less likely in this patient due to the presence of beta blockers, which are known to reduce the risk of sudden cardiac death. The patient's ECG shows polymorphic ventricular extrasystoles, but there is no indication of sustained ventricular tachycardia or other high-risk arrhythmias. The patient's LVEF is reduced, but not severely impaired, and the patient's symptoms are manageable. While the patient has a history of myocardial infarction and peripheral vascular disease, the patient's overall condition does not suggest a high risk of sudden cardiac death."
19,19,P0029,"Age: 58
Gender: Male 
Weight: 90 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 45,59
ALT or GPT (IU/L): 45.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 176.0
Gamma-glutamil transpeptidase (IU/L): 50
Glucose (mmol/L): 9,1
Hemoglobin (g/L): 157.0
HDL (mmol/L): 0,59
Potassium (mEq/L): 4
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 453.0
Protein (g/L): 72
T3 (pg/dL): 0,05
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 24,3
Urea (mg/dL): 16,03
LVEF (%): 36.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely.

RANKING: 1. Survivor
REASONING: The patient is 58 years old with a history of hypertensive cardiomyopathy, diabetes, and dyslipemia, which are all significant risk factors for cardiovascular disease. However, the patient is currently on a treatment regimen that includes beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which are all standard treatments for heart failure and hypertension. The patient's LVEF is 36%, indicating reduced left ventricular function, but it is not severely impaired. The patient's Pro-BNP level is elevated at 453 ng/L, which suggests that the patient has some degree of heart failure, but it is not extremely high. The patient's blood pressure is slightly elevated at 160/90 mmHg, but it is not severely hypertensive. Considering the patient's current treatment and the relatively mild nature of their symptoms (NYHA Class II), I believe that the patient is most likely to survive.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 36% indicates reduced left ventricular function, which is a risk factor for pump failure. The patient's elevated Pro-BNP level and creatinine level (176.0 umol/L) also suggest that the patient has some degree of heart failure. However, the patient's symptoms are relatively mild (NYHA Class II), and they are on a treatment regimen that includes diuretics and an ACE inhibitor, which are standard treatments for heart failure. While pump failure is a possible outcome, I believe it is less likely than sudden cardiac death due to the patient's relatively mild symptoms and current treatment.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient has a history of ventricular extrasystoles, which is a risk factor for sudden cardiac death. However, the patient's LVEF is 36%, which is not extremely low, and they are on a treatment regimen that includes beta blockers, which are known to reduce the risk of sudden cardiac death. The patient's Pro-BNP level is elevated, but it is not extremely high, and their symptoms are relatively mild (NYHA Class II). While sudden cardiac death is a possible outcome, I believe it is the least likely of the three options due to the patient's relatively mild symptoms and current treatment.

Note: The patient's TSH level is slightly elevated at 24.3 mIU/L, which may indicate hypothyroidism. Hypothyroidism is a risk factor for cardiovascular disease, and it may contribute to the patient's reduced LVEF. However, it is not a major factor in determining the prognosis in this case."
20,20,P0032,"Age: 63
Gender: Male 
Weight: 85 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 140/85 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 42,4
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,01
Creatinine (mmol/L): 135.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 160.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,35
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1045.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,03
Urea (mg/dL): 7,8
LVEF (%): 27.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. However, I must note that the patient's outcome is given as ""survivor,"" which is the actual outcome, not a prognosis. Therefore, I will generate a prognosis based on the patient's current condition and provide a ranking of the three possible prognoses from most likely to least likely.

RANKING: 1. Sudden Cardiac Death (SCD)
REASONING: The patient has a history of idiopathic dilated cardiomyopathy with a left ventricular ejection fraction (LVEF) of 27%, indicating severe left ventricular dysfunction. This condition increases the risk of sudden cardiac death. Additionally, the patient's elevated pro-BNP level (1045 ng/L) suggests high filling pressures in the left ventricle, which can lead to arrhythmias and sudden death. The patient's medications, including beta blockers and spironolactone, are appropriate for heart failure treatment but do not completely eliminate the risk of SCD.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 27% indicates significant left ventricular dysfunction, which increases the risk of heart failure progression and pump failure. The patient's creatinine level (135.0 mol/L) and urea level (7.8 mg/dL) suggest impaired renal function, which is a common complication of advanced heart failure. However, the patient's current medication regimen and the absence of significant electrolyte imbalances or other complications make pump failure less likely than SCD in the short term.

RANKING: 3. Survivor
REASONING: Although the patient's prognosis is given as ""survivor,"" this outcome is not a prognosis but the actual outcome. Based on the provided data, the patient's current condition and treatment regimen suggest a reasonable chance of survival. The patient's medications are appropriate for heart failure management, and there are no immediate contraindications for survival. However, the patient's underlying condition and potential for SCD or pump failure make survival less likely than the other two options.

Please note that this prognosis is based on the provided data and should not be considered a definitive prediction. The actual outcome may vary depending on various factors, including the patient's adherence to treatment, lifestyle changes, and potential future medical complications."
21,21,P0033,"Age: 52
Gender: Male 
Weight: 108 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 38,7
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 155.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,07
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1514.0
Protein (g/L): 68
T3 (pg/dL): 0,06
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,52
Urea (mg/dL): 4,68
LVEF (%): 50.0
Medications: Amiodarone, Beta Blockers
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor

REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for cardiac events. However, the patient's current LVEF (Left Ventricular Ejection Fraction) is 50%, which is within the range of mildly reduced ejection fraction. This suggests that the patient's heart function is not severely compromised at this time.

The patient's NYHA Class II indicates that the patient experiences some limitations in physical activity but is still able to perform daily activities without significant discomfort. This suggests that the patient's heart function is not severely impaired.

The patient's medication regimen includes amiodarone and beta blockers, which are commonly used to manage heart rhythm and reduce symptoms in patients with heart failure. The patient's TSH level is within the normal range, which suggests that the patient is not experiencing hypothyroidism, a common comorbidity in patients with heart failure.

While the patient's Pro-BNP level is elevated at 1514.0 ng/L, which is a marker of heart failure, it is not excessively high. Additionally, the patient's troponin level is within the normal range, which suggests that there is no acute myocardial infarction.

Considering these factors, the patient's overall prognosis is likely to be a survivor, with a focus on managing the patient's heart failure and preventing further decline in cardiac function.

RANKING: 2. Sudden Cardiac Death

REASONING: The patient's history of idiopathic dilated cardiomyopathy increases the risk of sudden cardiac death. However, the patient's LVEF is still within the mildly reduced range, and the patient is on beta blockers, which reduce the risk of sudden cardiac death.

The patient's ventricular extrasystole on the ECG is a concern, but it is not a predictor of sudden cardiac death on its own. The patient's Pro-BNP level is elevated, but not excessively high, which suggests that the patient is not experiencing acute heart failure.

The patient's T3 and T4 levels are within the normal range, which suggests that the patient is not experiencing hypothyroidism, a common comorbidity in patients with heart failure. The patient's potassium level is within the normal range, which suggests that there is no electrolyte imbalance.

Considering these factors, the risk of sudden cardiac death is lower than the risk of pump failure death, but still a concern.

RANKING: 3. Pump Failure Death

REASONING: The patient's LVEF is mildly reduced at 50%, which increases the risk of pump failure death. The patient's Pro-BNP level is elevated at 1514.0 ng/L, which is a marker of heart failure. The patient's creatinine level is elevated at 88.0 mmol/L, which suggests that the patient may have renal dysfunction, a common comorbidity in patients with heart failure.

The patient's total cholesterol level is low at 3.7 mmol/L, which may be a concern for malnutrition or malabsorption. The patient's albumin level is low at 38.7 g/L, which suggests that the patient may have malnutrition or liver disease.

Considering these factors, the risk of pump failure death is higher than the risk of sudden cardiac death, but the patient's overall prognosis is still likely to be a survivor due to the patient's relatively mild symptoms and the patient's current medication regimen."
22,22,P0036,"Age: 62
Gender: Male 
Weight: 82 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 110/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 44,1
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,52
Creatinine (mmol/L): 129.0
Gamma-glutamil transpeptidase (IU/L): 55
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 3,9
LDL (mmol/L): 4,27
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 924.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,57
Urea (mg/dL): 15,36
LVEF (%): 30.0
Medications: Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient is 62 years old with a history of enolic dilated cardiomyopathy, which is a chronic condition. However, he is being treated with loop diuretics, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure. His LVEF of 30% is below normal, but it is not extremely low. His troponin level is within normal limits, indicating no recent myocardial infarction. Additionally, his eGFR (estimated glomerular filtration rate) can be calculated from the provided creatinine level (129.0 mmol/L) and is approximately 30-40 mL/min, indicating moderate chronic kidney disease. However, his Pro-BNP level of 924.0 ng/L is elevated, but not extremely high, suggesting some degree of heart failure. Considering these factors, the patient is at a moderate risk of cardiac events, but the current treatment regimen and lack of severe biomarker abnormalities suggest a relatively favorable prognosis.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of enolic dilated cardiomyopathy and an LVEF of 30%, which increases his risk of sudden cardiac death. Additionally, his Pro-BNP level is elevated, indicating some degree of heart failure. However, his troponin level is normal, and he does not have any other high-risk features such as ventricular tachycardia or a history of cardiac arrest. The presence of ventricular extrasystoles on the ECG may be a risk factor, but it is not a strong predictor of sudden cardiac death. Overall, while the patient is at risk, the presence of a normal troponin level and the absence of other high-risk features make sudden cardiac death less likely.

RANKING: 3. Pump Failure Death
 REASONING: The patient has a history of enolic dilated cardiomyopathy, an LVEF of 30%, and an elevated Pro-BNP level, all of which suggest that he is at risk of pump failure. However, his creatinine level is elevated, indicating moderate chronic kidney disease, and his eGFR is likely below 30 mL/min, which may limit his ability to tolerate further decompensation. Additionally, his total cholesterol level is high, which may contribute to further cardiac damage. His treatment regimen includes loop diuretics, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure. However, the combination of his low LVEF, elevated Pro-BNP level, and high creatinine level suggests that pump failure is a possible outcome, especially if his condition worsens or he experiences further cardiac decompensation."
23,23,P0037,"Age: 71
Gender: Male 
Weight: 88 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 44,8
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 147.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,66
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 732.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,9
Urea (mg/dL): 9,35
LVEF (%): 40.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: Based on the provided patient data, I would rank the prognosis as survivor due to the following factors:

1.  Age and NYHA Class: The patient is 71 years old and has a NYHA Class II, indicating mild symptoms of heart failure. This suggests that the patient's heart failure is manageable, and they are not experiencing severe symptoms.
2.  Medications: The patient is on beta blockers, statins, and an ACE inhibitor, which are all standard medications for managing heart failure and ischemic dilated cardiomyopathy. These medications can help slow the progression of heart failure and improve symptoms.
3.  LVEF: The patient's left ventricular ejection fraction (LVEF) is 40%, which is relatively low but not extremely low. An LVEF of 40-50% is often considered a moderate to severe reduction in heart function, but it is not typically associated with an immediate high risk of sudden cardiac death.
4.  Pro-BNP: The patient's pro-brain natriuretic peptide (Pro-BNP) level is elevated at 732.0 ng/L, which is a marker of heart failure and can indicate a higher risk of adverse outcomes. However, Pro-BNP levels can be influenced by various factors, including age, sex, and kidney function, and this value alone does not necessarily indicate a poor prognosis.
5.  Troponin: The patient's troponin level is 0.01 ng/mL, which is within normal limits. Elevated troponin levels can indicate myocardial infarction or cardiac damage, but this patient's level is normal, suggesting that they do not have recent or ongoing cardiac damage.

Considering these factors, the patient's overall prognosis appears to be relatively stable, and they are likely to survive with proper management of their medications and follow-up care.

Sudden cardiac death is less likely because:

- The patient's LVEF is not extremely low (40%).
- There are no signs of severe cardiac arrhythmias (e.g., ventricular tachycardia).
- The patient is on beta blockers, which can help reduce the risk of sudden cardiac death.

Pump failure death is less likely because:

- The patient's LVEF is not extremely low (40%).
- The patient is on ACE inhibitors, which can help slow the progression of heart failure.
- The patient's symptoms are mild (NYHA Class II).

Therefore, the most likely prognosis is survivor."
24,24,P0038,"Age: 69
Gender: Male 
Weight: 98 kg
Height: 188 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,72
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 458.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,88
Urea (mg/dL): 3,79
LVEF (%): 40.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient is 69 years old with a history of idiopathic dilated cardiomyopathy, which is a chronic condition that can lead to heart failure. However, the patient is currently on optimal medical therapy, including beta blockers, angiotensin II receptor blockers, loop diuretics, and statins, which are all standard treatments for heart failure with reduced ejection fraction (HFrEF). The patient's LVEF is 40%, which is relatively stable, and the Pro-BNP level is elevated but not extremely high (458 ng/L). Additionally, the patient's hemoglobin and albumin levels are within normal limits, indicating that the patient is not in a state of severe anemia or malnutrition, which can worsen heart failure. The patient's ECG shows no signs of significant arrhythmias, and the medications are appropriate for managing heart failure and arrhythmias. Considering these factors, the most likely prognosis is survival with continued medical management and monitoring.

RANKING: 2. Pump failure death
REASONING: While the patient has a history of idiopathic dilated cardiomyopathy and a low LVEF, the patient's current medical therapy is adequate, and there is no indication of acute decompensated heart failure. The patient's creatinine level is slightly elevated, which may indicate some degree of renal dysfunction, but it is not severe enough to suggest that the patient is at high risk for pump failure death. The patient's T3 and T4 levels are within normal limits, which suggests that the patient does not have hypothyroidism, a condition that can contribute to heart failure. Overall, while the patient's prognosis is guarded, pump failure death is less likely than sudden cardiac death due to the patient's stable LVEF and adequate medical therapy.

RANKING: 3. Sudden cardiac death
REASONING: Sudden cardiac death is a significant risk in patients with heart failure, particularly those with a history of idiopathic dilated cardiomyopathy. However, the patient's current ECG shows no signs of significant arrhythmias, and the medications are appropriate for managing arrhythmias. The patient's LVEF is 40%, which is relatively stable, and the Pro-BNP level is not extremely high. The patient's TSH level is within normal limits, which suggests that the patient does not have hyperthyroidism, a condition that can increase the risk of arrhythmias. While sudden cardiac death is a possible risk, it is the least likely prognosis due to the patient's stable LVEF and lack of significant arrhythmias on ECG."
25,25,P0039,"Age: 73
Gender: Male 
Weight: 90 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,22
Creatinine (mmol/L): 116.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 126.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 3,4
LDL (mmol/L): 2,97
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 331.0
Protein (g/L): 71
T3 (pg/dL): 0,06
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,45
Urea (mg/dL): 6,91
LVEF (%): 39.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient is 73 years old with a history of hypertensive cardiomyopathy, dyslipemia, and hypertension. His current NYHA Class III indicates that he has symptoms of heart failure and is experiencing limitations in his physical activity. However, his blood pressure is well-controlled, and he is on beta blockers and an ACE inhibitor, which are standard treatments for heart failure and hypertension. His LVEF is 39%, which is below the normal range (50-70%), indicating some degree of systolic dysfunction. However, his troponin levels are normal, and he does not have any signs of acute coronary syndrome. His Pro-BNP level is elevated, but not excessively high, indicating some degree of heart failure, but not severe. Given his age, comorbidities, and treatment, a survivor prognosis is the most likely outcome.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 39% indicates significant systolic dysfunction, which increases the risk of pump failure. His elevated Pro-BNP level also supports this. However, his troponin levels are normal, and he does not have any signs of acute coronary syndrome. His NYHA Class III indicates that he has symptoms of heart failure, but his blood pressure is well-controlled, and he is on beta blockers and an ACE inhibitor. While pump failure is a possibility, it is not the most likely outcome given his stable condition and treatment.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient has a history of hypertensive cardiomyopathy and dyslipemia, which increase the risk of arrhythmias. However, his ECG does not show any signs of sustained ventricular tachycardia or other high-risk features. His LVEF is 39%, but his troponin levels are normal, and he does not have any signs of acute coronary syndrome. His Pro-BNP level is elevated, but not excessively high. While sudden cardiac death is a risk for patients with heart failure, it is not the most likely outcome in this case given his stable condition and treatment."
26,26,P0041,"Age: 78
Gender: Male 
Weight: 70 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 51,8
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 117.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,17
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 853.0
Protein (g/L): 81
T3 (pg/dL): 0,05
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,72
Urea (mg/dL): 10,02
LVEF (%): 45.0
Medications: Calcium Channel Blocker, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Please note that this is a complex task, and the actual outcome may vary based on various factors, including the patient's adherence to medication, lifestyle changes, and potential comorbidities.

RANKING: 1. Survivor
 REASONING: The patient has a moderate level of risk due to his age, ischemic dilated cardiomyopathy, and history of myocardial infarction. However, he is on a stable medication regimen, including a calcium channel blocker, loop diuretics, statins, ACE inhibitor, and nitrovasodilator, which suggests that his condition is being actively managed. His LVEF is 45%, which is below the normal range (50-70%), but not severely decreased. His Pro-BNP level is elevated, indicating some level of cardiac stress, but not excessively high. His blood pressure and glucose levels are relatively well-controlled. While his total cholesterol is slightly elevated, his LDL is within a reasonable range, and his HDL is low but not alarmingly so. The presence of ventricular extrasystoles on the ECG is a concern, but it is not a predictor of sudden cardiac death. Overall, considering his stable medication regimen and relatively controlled comorbidities, the likelihood of the patient surviving the next few years is moderate to high.

RANKING: 2. Sudden cardiac death
 REASONING: Sudden cardiac death is a possible outcome due to the patient's history of myocardial infarction, ischemic dilated cardiomyopathy, and ventricular extrasystoles on the ECG. However, the patient's stable medication regimen and relatively controlled comorbidities reduce the likelihood of sudden cardiac death. The patient's LVEF is below the normal range, which may increase the risk of sudden cardiac death, but it is not severely decreased. The patient's Pro-BNP level is elevated, which may indicate some level of cardiac stress, but not excessively high. The presence of ventricular extrasystoles on the ECG is a concern, but it is not a predictor of sudden cardiac death. Overall, while the patient's history and ECG findings increase the risk of sudden cardiac death, the likelihood is moderate due to his stable medication regimen and relatively controlled comorbidities.

RANKING: 3. Pump failure death
 REASONING: Pump failure death is the least likely outcome due to the patient's stable medication regimen and relatively controlled comorbidities. The patient's LVEF is below the normal range, but it is not severely decreased, and his Pro-BNP level is elevated but not excessively high. The patient's blood pressure and glucose levels are relatively well-controlled, and his total cholesterol is slightly elevated but his LDL is within a reasonable range. The presence of ventricular extrasystoles on the ECG is a concern, but it is not a predictor of pump failure. The patient's medication regimen, including a calcium channel blocker, loop diuretics, statins, ACE inhibitor, and nitrovasodilator, suggests that his condition is being actively managed to prevent pump failure. Overall, while the patient's LVEF is below the normal range, his stable medication regimen and relatively controlled comorbidities reduce the likelihood of pump failure death."
27,27,P0042,"Age: 60
Gender: Male 
Weight: 84 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,6
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,8
Creatinine (mmol/L): 81.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,33
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 90.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,7
Urea (mg/dL): 6,01
LVEF (%): 40.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: Survivor
 REASONING: The patient is 60 years old with a history of ischemic dilated cardiomyopathy, diabetes, and myocardial infarction, which suggests a high risk for cardiac complications. However, the patient's current medications, including beta blockers, statins, and an ACE inhibitor, are appropriate for managing heart failure and reducing the risk of cardiac events. The patient's LVEF (40%) is slightly below the normal range, but not severely impaired. The patient's Pro-BNP level (90 ng/L) is elevated, indicating some degree of heart failure, but not excessively high. The patient's blood pressure is low (90/60 mmHg), which may indicate orthostatic hypotension or decreased cardiac output, but this is not uncommon in patients with heart failure. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG suggests a relatively stable cardiac rhythm. Given these factors, the most likely prognosis is survivor, with careful management and monitoring of the patient's condition.

RANKING: Pump Failure Death
 REASONING: The patient's LVEF (40%) is slightly below the normal range, which suggests some degree of left ventricular dysfunction. The patient's Pro-BNP level (90 ng/L) is elevated, indicating some degree of heart failure. The patient's creatinine level (81.0 mol/L) is slightly elevated, which may indicate some degree of renal impairment. The patient's weight (84 kg) is above the ideal range for their height, which may contribute to increased cardiac workload. However, the patient's medications are appropriate for managing heart failure, and there is no indication of severe cardiac decompensation or acute kidney injury. While pump failure death is a possible prognosis, it is less likely given the patient's relatively stable condition and appropriate treatment.

RANKING: Sudden Cardiac Death
 REASONING: The patient's LVEF (40%) is slightly below the normal range, which may increase the risk of sudden cardiac death. However, the patient's Pro-BNP level (90 ng/L) is not excessively high, and the patient's ECG shows no signs of ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia. The patient's medications, including beta blockers, are appropriate for reducing the risk of sudden cardiac death. The patient's troponin level (0.01 ng/mL) is low, indicating no recent myocardial infarction. While sudden cardiac death is a possible prognosis, it is less likely given the patient's relatively stable condition and appropriate treatment."
28,28,P0044,"Age: 77
Gender: Male 
Weight: 87 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39,5
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,85
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,94
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1157.0
Protein (g/L): 70
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,99
Urea (mg/dL): 9,35
LVEF (%): 40.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's the ranking of the prognoses from most likely to least likely:

RANKING: 1. Survivor

REASONING: Despite the patient's advanced age and history of ischemic dilated cardiomyopathy, myocardial infarction, and reduced left ventricular ejection fraction (LVEF) of 40%, the patient is currently being treated with a comprehensive medication regimen that includes a calcium channel blocker, beta blockers, loop diuretics, statins, ACE inhibitor, and nitrovasodilator. This multi-faceted approach aims to manage the patient's symptoms, reduce mortality risk, and improve quality of life. The patient's NYHA Class II classification indicates that they are experiencing some limitations in physical activity but are still able to perform light physical activity without symptoms. The absence of severe symptoms, such as severe dyspnea or fatigue, suggests that the patient's condition is relatively stable. The patient's creatinine level is elevated, indicating some degree of renal impairment, but it is not severe. The patient's pro-BNP level is elevated, which is consistent with heart failure, but it is not extremely high. The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests some degree of cardiac electrical instability, but it is not indicative of a high risk of sudden cardiac death. Considering these factors, the most likely prognosis for the patient is survival.

RANKING: 2. Sudden Cardiac Death

REASONING: The patient's history of myocardial infarction, reduced LVEF, and presence of non-sustained ventricular tachycardia on the ECG increase the risk of sudden cardiac death. The patient's elevated pro-BNP level and NYHA Class II classification also suggest that they are at risk for cardiac arrhythmias and sudden cardiac death. However, the patient's overall clinical presentation and medication regimen suggest that they are being actively managed for their heart failure and cardiac arrhythmias, which may reduce the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death

REASONING: While the patient's LVEF is reduced to 40%, which is a risk factor for pump failure, the patient's NYHA Class II classification and the absence of severe symptoms suggest that their heart failure is not yet severe. The patient's creatinine level is elevated, indicating some degree of renal impairment, but it is not severe. The patient's medication regimen includes loop diuretics, which are used to manage fluid overload and reduce the risk of pump failure. The patient's overall clinical presentation suggests that they are at risk for pump failure, but it is not the most likely prognosis at this time."
29,29,P0045,"Age: 73
Gender: Male 
Weight: 83 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 42,59
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,69
Creatinine (mmol/L): 116.0
Gamma-glutamil transpeptidase (IU/L): 46
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 170.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 3,9
LDL (mmol/L): 3,21
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 390.0
Protein (g/L): 76
T3 (pg/dL): 0,06
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,54
Urea (mg/dL): 6,24
LVEF (%): 40.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient is 73 years old with a history of idiopathic dilated cardiomyopathy, peripheral vascular disease, and hypertension. However, the patient's current NYHA Class II indicates that he is still able to perform most physical activities without symptoms of heart failure. The patient is on a treatment regimen that includes digoxin, loop diuretics, spironolactone, ACE inhibitor, and nitrovasodilator, which suggests that the patient's heart failure is being managed. The LVEF of 40% is relatively low, but not extremely low. The absence of severe electrolyte imbalances, normal liver function tests, and no signs of severe renal dysfunction are also positive indicators. Additionally, the patient's troponin level is within normal limits, indicating no recent myocardial infarction. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG is a concern, but the absence of sustained ventricular tachycardia and bradycardia reduces the risk of sudden cardiac death. Overall, the patient's condition seems to be relatively stable, and with continued medical management, the likelihood of survival is high.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG is a concern for sudden cardiac death. However, the patient's LVEF of 40% is not extremely low, and the patient is on a treatment regimen that includes an ACE inhibitor, which reduces the risk of sudden cardiac death. The patient's age and sex also increase the risk of sudden cardiac death, but the patient's overall condition seems to be relatively stable.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF of 40% indicates that the heart is not pumping efficiently, which increases the risk of pump failure death. However, the patient's NYHA Class II indicates that he is still able to perform most physical activities without symptoms of heart failure, suggesting that the patient's heart is still able to function relatively well. The patient's creatinine level is elevated, indicating some degree of renal dysfunction, but not severe. The patient's albumin level is also low, which may indicate some degree of malnutrition or liver dysfunction, but not severe. The patient's treatment regimen includes loop diuretics and spironolactone, which are used to manage heart failure. Overall, while the patient's condition is not ideal, the risk of pump failure death is lower than sudden cardiac death due to the patient's relatively stable condition and ongoing medical management."
30,30,P0048,"Age: 60
Gender: Male 
Weight: 95 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 43,09
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,91
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 603.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 5
Urea (mg/dL): 9,8
LVEF (%): 38.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a significant underlying condition affecting the heart's pumping ability. However, the patient is receiving appropriate medical treatment with digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are all standard treatments for heart failure and dilated cardiomyopathy. The patient's LVEF of 38% indicates some degree of left ventricular dysfunction, but it is not severely impaired. Additionally, the patient's Pro-BNP level of 603 ng/L is elevated, indicating some degree of heart failure, but it is not extremely high. The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death, but the fact that it is non-sustained suggests that it is not a high-risk arrhythmia at the moment. The patient's hemoglobin level is within normal limits, which suggests that there is no significant anemia contributing to decreased oxygen delivery to the heart. Overall, while the patient has significant underlying heart disease, the treatment plan and the patient's current condition suggest that survival is the most likely outcome.

RANKING: Pump Failure Death (2nd most likely)

REASONING: The patient's LVEF of 38% indicates significant left ventricular dysfunction, which increases the risk of pump failure. The patient's Pro-BNP level of 603 ng/L is elevated, indicating some degree of heart failure. The patient's history of idiopathic dilated cardiomyopathy and dyslipemia also increases the risk of pump failure. However, the patient is receiving appropriate medical treatment, which may help to slow the progression of heart failure. The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death, but it is not a direct risk factor for pump failure. Overall, while pump failure is a significant risk, the patient's current treatment plan and condition suggest that it is less likely than survival.

RANKING: Sudden Cardiac Death (least likely)

REASONING: While the patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death, the fact that it is non-sustained suggests that it is not a high-risk arrhythmia at the moment. The patient's LVEF of 38% and Pro-BNP level of 603 ng/L suggest that the patient has significant underlying heart disease, but they do not indicate a high risk of sudden cardiac death. The patient's treatment plan includes an ACE inhibitor, which is a standard treatment for reducing the risk of sudden cardiac death. Overall, while sudden cardiac death is a risk, the patient's current condition and treatment plan suggest that it is the least likely outcome."
31,31,P0050,"Age: 65
Gender: Male 
Weight: 90 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 44,5
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 3,39
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 9,5
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,07
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 758.0
Protein (g/L): 70
T3 (pg/dL): 0,04
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,48
Urea (mg/dL): 10,47
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor

REASONING: Given the patient's medical history and current clinical presentation, I would rank survivor as the most likely prognosis for the next few years. The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for adverse cardiac outcomes. However, the patient is currently on optimal medical therapy with beta blockers, statins, and an ACE inhibitor, which are all evidence-based treatments for heart failure and coronary artery disease. The patient's LVEF is 40%, which is mildly reduced but not severely impaired. Additionally, the patient's NT-proBNP level is elevated at 758 ng/L, which is consistent with heart failure, but not excessively high.

The patient's other lab values are mostly within normal limits, with the exception of mildly elevated creatinine, which may indicate some degree of renal impairment. However, this is not uncommon in patients with heart failure. The patient's glucose and lipid profiles are also well-managed, which is a positive sign.

The patient's ECG shows some ventricular extrasystoles, but no signs of sustained ventricular tachycardia or other high-risk arrhythmias. The presence of TPSV is relatively benign and not typically associated with adverse cardiac outcomes.

Considering these factors, while the patient's prognosis is guarded, I believe that with continued optimal medical therapy and close monitoring, the patient is likely to survive for several years.

RANKING: 2. Pump Failure Death

REASONING: Pump failure death is the second most likely prognosis for this patient. The patient's LVEF is mildly reduced at 40%, which is a risk factor for heart failure progression and adverse cardiac outcomes. The patient's NT-proBNP level is elevated, which is consistent with heart failure. Additionally, the patient's creatinine level is mildly elevated, which may indicate some degree of renal impairment, a common comorbidity in heart failure patients.

However, the patient is currently on optimal medical therapy, which may slow the progression of heart failure. The patient's other lab values are mostly within normal limits, and the patient's glucose and lipid profiles are well-managed. The patient's ECG shows some ventricular extrasystoles, but no signs of sustained ventricular tachycardia or other high-risk arrhythmias.

Given the patient's current clinical presentation and optimal medical therapy, I believe that pump failure death is a possible but less likely outcome than survivor.

RANKING: 3. Sudden Cardiac Death

REASONING: Sudden cardiac death is the least likely prognosis for this patient. The patient's ECG shows some ventricular extrasystoles, but no signs of sustained ventricular tachycardia or other high-risk arrhythmias. The patient's LVEF is mildly reduced, but not severely impaired. The patient is currently on beta blockers, which are known to reduce the risk of sudden cardiac death.

The patient's other lab values are mostly within normal limits, and the patient's glucose and lipid profiles are well-managed. The patient's NT-proBNP level is elevated, but not excessively high. While sudden cardiac death is always a risk in patients with heart failure, I believe that this patient's current clinical presentation and optimal medical therapy make sudden cardiac death the least likely prognosis."
32,32,P0052,"Age: 56
Gender: Male 
Weight: 104 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,7
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,32
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 402.0
Protein (g/L): 75
T3 (pg/dL): 0,03
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,14
Urea (mg/dL): 10,02
LVEF (%): 30.0
Medications: Amiodarone, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient's current medications, including Amiodarone, Loop Diuretics, Statins, ACE Inhibitor, and Nitrovasodilator, suggest that the patient is receiving comprehensive treatment for their ischemic dilated cardiomyopathy, dyslipemia, and myocardial infarction. The patient's NYHA Class II classification indicates that the patient is experiencing some limitation of physical activity but is still able to perform daily activities without symptoms. The patient's LVEF of 30% is low, indicating reduced left ventricular function, but it is not the lowest possible value. The patient's blood pressure of 100/60 mmHg is low, which could be a concern, but it is not an immediate contraindication for survival. The patient's Pro-BNP level of 402.0 ng/L is elevated, indicating increased B-type natriuretic peptide levels, which is associated with heart failure. However, the patient's other laboratory values, such as hemoglobin, potassium, sodium, and urea, are within relatively normal limits. Considering the patient's overall clinical picture, the most likely prognosis is survivor.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of sudden cardiac death. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG also suggests an increased risk of arrhythmias. However, the patient's current medications, including Amiodarone, which is an antiarrhythmic medication, may help reduce the risk of sudden cardiac death. The patient's LVEF of 30% also indicates reduced left ventricular function, which can increase the risk of sudden cardiac death. However, the patient's overall clinical picture is not as concerning as the survivor prognosis, and the patient's current treatment may mitigate some of the risks associated with sudden cardiac death.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 30% indicates reduced left ventricular function, which can increase the risk of pump failure. However, the patient's NYHA Class II classification suggests that the patient is still able to perform daily activities without symptoms, which may indicate that the patient's heart function is not as severely compromised as it could be. The patient's creatinine level of 119.0 mmol/L is elevated, indicating impaired renal function, which can be associated with heart failure. However, the patient's other laboratory values, such as hemoglobin, potassium, sodium, and urea, are within relatively normal limits. The patient's current medications, including Loop Diuretics, may help reduce fluid overload and alleviate some symptoms of heart failure. Considering the patient's overall clinical picture, the risk of pump failure death is the least likely prognosis."
33,33,P0055,"Age: 60
Gender: Female 
Weight: 83 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 170/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 6,34
Creatinine (mmol/L): 74.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,16
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 282.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,21
Urea (mg/dL): 7,35
LVEF (%): 39.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely:

RANKING: 1. Survivor
REASONING: The patient has a relatively controlled hypertension, which is a crucial factor in managing hypertensive cardiomyopathy. Her current medications, including beta blockers, statins, and an ACE inhibitor, are appropriate for her condition and should help manage her symptoms and prevent further cardiac deterioration. The patient's LVEF of 39% indicates some degree of left ventricular dysfunction, but it is not severely impaired. Her Pro-BNP level of 282.0 ng/L is elevated, indicating some degree of heart failure, but not to a critical extent. Additionally, her Troponin level of 0.01 ng/mL is within the normal range, indicating minimal myocardial damage. Considering these factors, the most likely prognosis is that the patient will survive with continued management and monitoring of her condition.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 39% indicates some degree of left ventricular dysfunction, which increases the risk of pump failure. Her Pro-BNP level of 282.0 ng/L is elevated, suggesting some degree of heart failure. However, her current medications and relatively controlled hypertension suggest that her condition is being managed. The risk of pump failure is still present, but it is not the most likely outcome given her current treatment and relatively stable condition.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the absence of non-sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, and bradycardia on the ECG suggests that the patient's arrhythmia risk is not as high as it could be. Additionally, her current medications, including beta blockers, which are known to reduce the risk of sudden cardiac death, are being taken. While the risk of sudden cardiac death is present, it is the least likely outcome given the patient's current condition and treatment."
34,34,P0060,"Age: 69
Gender: Female 
Weight: 85 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 38,9
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 5,15
Creatinine (mmol/L): 128.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 8,1
Hemoglobin (g/L): 126.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,8
LDL (mmol/L): 3,08
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 538.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,36
Urea (mg/dL): 10,24
LVEF (%): 24.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: The patient is a 69-year-old female with a history of Hypertensive cardiomyopathy, Diabetes, Dyslipemia, and Hypertension. Despite these conditions, her current medications, including ACE inhibitor, beta blockers, and loop diuretics, suggest that her condition is being actively managed. Her NYHA Class II indicates that she has some limitations in physical activity but is still able to perform everyday activities. Her LVEF of 24% is concerning, indicating reduced left ventricular function, but her Pro-BNP level of 538.0 ng/L is elevated, which can indicate heart failure. However, her recent Troponin level of 0.01 ng/mL suggests that she does not have an acute coronary event. Given her stable medication regimen, absence of acute coronary event, and relatively well-managed chronic conditions, the most likely prognosis is that she will survive in the next few years.

RANKING: Pump failure death

REASONING: The patient's LVEF of 24% indicates severe left ventricular dysfunction, which is a strong predictor of pump failure. Her Pro-BNP level of 538.0 ng/L also supports this, as elevated BNP levels are associated with increased risk of heart failure. However, her overall clinical picture, including her stable medication regimen and absence of acute coronary event, suggests that she may not be immediately at risk for pump failure death.

RANKING: Sudden cardiac death

REASONING: The patient's LVEF of 24% and elevated Pro-BNP level suggest that she has severe left ventricular dysfunction, which increases her risk of sudden cardiac death. However, her stable medication regimen, absence of acute coronary event, and lack of other high-risk features such as ventricular tachycardia or high blood pressure suggest that sudden cardiac death is less likely compared to pump failure death."
35,35,P0061,"Age: 60
Gender: Male 
Weight: 85 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 130/90 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 47,8
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,22
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,18
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 701.0
Protein (g/L): 72
T3 (pg/dL): 0,07
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,01
Urea (mg/dL): 10,02
LVEF (%): 38.0
Medications: Beta Blockers, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here is the ranking of the prognoses from most likely to least likely, along with the reasoning behind each:

RANKING: 1. Survivor
 REASONING: The patient is 60 years old with a history of enolic dilated cardiomyopathy, hypertension, and a left ventricular ejection fraction (LVEF) of 38%. However, the patient is on appropriate medications for heart failure and hypertension, including beta blockers, digoxin, and an ACE inhibitor. The LVEF of 38% indicates that the patient's heart is still functioning, albeit at a reduced capacity. The patient's Pro-BNP level is elevated, but it is not excessively high, and the patient's hemoglobin and albumin levels are within normal limits. The absence of significant electrolyte imbalances, such as hypokalemia or hyperkalemia, and the relatively normal liver function tests (ALT, AST, and GGT) suggest that the patient's prognosis is more favorable. The patient's ejection fraction is low, but it is not the lowest possible value, and the patient's overall clinical presentation does not suggest a high risk of sudden cardiac death.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of non-sustained ventricular tachycardia (NSVT), which is a risk factor for sudden cardiac death. The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG also suggests an increased risk of arrhythmias. However, the patient's ejection fraction is not extremely low, and the patient is on appropriate medications for heart failure and hypertension. The patient's LVEF of 38% is not the lowest possible value, and the patient's overall clinical presentation does not suggest a high risk of sudden cardiac death. The presence of NSVT and polymorphic ventricular extrasystoles increases the risk of sudden cardiac death, but it is not the most likely outcome in this case.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 38% indicates that the patient's heart is functioning at a reduced capacity, and the patient's Pro-BNP level is elevated, suggesting that the patient's heart is under stress. However, the patient's overall clinical presentation and laboratory results do not suggest that the patient's heart is failing rapidly. The patient's creatinine level is within normal limits, and the patient's hemoglobin and albumin levels are within normal limits. The patient's ejection fraction is low, but it is not the lowest possible value, and the patient's overall clinical presentation does not suggest a high risk of pump failure death. The patient's medications for heart failure and hypertension are appropriate, and the patient's overall prognosis is more favorable than pump failure death."
36,36,P0062,"Age: 81
Gender: Male 
Weight: 71 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 145/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 35,6
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 145.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,95
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 1399.0
Protein (g/L): 68
T3 (pg/dL): 0,03
T4 (ng/L): 12
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,49
Urea (mg/dL): 15,15
LVEF (%): 52.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I would rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient is 81 years old with a history of hypertensive cardiomyopathy and hypertension. However, his LVEF is 52%, which is still within the normal range (50-70%). He is on loop diuretics and ACE inhibitor medications, which are appropriate for his condition. His blood pressure is controlled at 145/85 mmHg. The patient's biomarkers, such as troponin, TSH, and electrolytes, are within normal limits. Although his Pro-BNP is elevated at 1399.0 ng/L, which indicates some degree of heart failure, his overall clinical presentation suggests that he is stable. Given his age and comorbidities, a survivor prognosis seems the most likely outcome.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF of 52% is within the normal range, but it is on the lower end. His Pro-BNP level is elevated, which suggests some degree of heart failure. However, his NYHA class is only II, indicating that he is not experiencing significant symptoms of heart failure. His medications, including loop diuretics and ACE inhibitors, are appropriate for managing his condition. While there is a risk of pump failure, the patient's current clinical presentation does not suggest an immediate high risk.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient's ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or non-sustained ventricular tachycardia. His troponin level is normal, which suggests that there is no acute myocardial infarction. The patient's TSH and T3/T4 levels are within normal limits, which suggests that there is no evidence of thyroid dysfunction. While the patient's age and comorbidities increase his risk of sudden cardiac death, the absence of other high-risk features makes this prognosis the least likely."
37,37,P0063,"Age: 55
Gender: Male 
Weight: 68 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 44,4
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 3,57
Creatinine (mmol/L): 75.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 6
Hemoglobin (g/L): 137.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4
LDL (mmol/L): 2,15
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 249.0
Protein (g/L): 69
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,94
Urea (mg/dL): 10,02
LVEF (%): 40.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's the prognosis for the next few years:

RANKING: 1. Survivor
 REASONING: The patient is 55 years old with a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipemia. However, he is currently being treated with beta blockers, statins, and an ACE inhibitor, which are evidence-based therapies for heart failure and dyslipidemia. His LVEF is 40%, indicating moderate heart failure, but it is not severely compromised. The absence of significant arrhythmias, such as sustained ventricular tachycardia or bradycardia, is also a positive sign. His pro-BNP level is elevated at 249.0 ng/L, but it is not extremely high. Considering these factors, the likelihood of the patient surviving the next few years with proper management and adherence to his current treatment plan is relatively high.

RANKING: 2. Sudden cardiac death
 REASONING: The patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, which increases his risk of sudden cardiac death. His LVEF is 40%, which is a moderate risk factor for sudden cardiac death. The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG is a concerning sign, as it may indicate electrical instability in the heart. However, the absence of sustained ventricular tachycardia and bradycardia reduces the likelihood of sudden cardiac death. With proper management and monitoring, the risk of sudden cardiac death can be mitigated.

RANKING: 3. Pump failure death
 REASONING: The patient's LVEF is 40%, which indicates moderate heart failure. However, his current medications and the absence of significant arrhythmias suggest that his heart failure is being managed effectively. His creatinine level is within normal limits, and his albumin and protein levels are also within normal ranges. While his pro-BNP level is elevated, it is not extremely high, indicating that his heart failure is not severely decompensated. Considering these factors, the likelihood of pump failure death is relatively low, as the patient's heart failure is being managed effectively, and there are no signs of severe decompensation."
38,38,P0064,"Age: 60
Gender: Male 
Weight: 102 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 41,7
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4
LDL (mmol/L): 2,72
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 125.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,76
Urea (mg/dL): 8,02
LVEF (%): 45.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: Based on the provided patient data, I would rank the prognosis as a survivor for the next few years. Here's the reasoning:

1. NYHA Class II: The patient's functional status is classified as NYHA Class II, indicating that the patient has some limitations in physical activity, but is still able to perform most daily activities. This suggests that the patient's heart condition is not severe, and they are able to adapt to their current level of physical activity.
2. LVEF of 45%: While the patient's left ventricular ejection fraction (LVEF) is slightly below the normal range (50-70%), it is not severely impaired. An LVEF of 45% indicates that the patient's heart is still able to pump blood efficiently, and they are likely to have a good prognosis.
3. Medications: The patient is on beta blockers and ACE inhibitors, which are standard medications for managing heart failure and reducing the risk of sudden cardiac death. These medications are likely to help slow the progression of the patient's heart condition.
4. ECG results: The patient's ECG does not show any signs of severe arrhythmias or other life-threatening conditions.
5. Laboratory results: The patient's laboratory results, including the troponin level, are within normal limits, indicating that there is no evidence of acute myocardial infarction or other cardiac damage.
6. Weight and height: The patient's weight and height are not significantly abnormal, which suggests that they are not at risk for obesity-related complications.

Considering these factors, I would rank the prognosis as a survivor for the next few years. However, it is essential to note that the patient's prognosis will depend on their adherence to their medication regimen, lifestyle modifications, and regular follow-up appointments with their healthcare provider.

RANKING (from most likely to least likely):
1. Survivor
2. Pump failure death (due to the patient's LVEF of 45% and history of ischemic dilated cardiomyopathy)
3. Sudden cardiac death (due to the patient's history of myocardial infarction, ischemic dilated cardiomyopathy, and ventricular extrasystole on ECG)"
39,39,P0067,"Age: 49
Gender: Female 
Weight: 82 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 120/75 mmHg
Past Medical History: Other HF etiology
Albumin (g/L): 43,8
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,22
Creatinine (mmol/L): 132.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,17
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 30.0
Protein (g/L): 75,8
T4 (ng/L): 17
TSH (mIU/L): 1,93
Urea (mg/dL): 13,64
LVEF (%): 37.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: Survivor
REASONING: The patient is a 49-year-old female with a history of heart failure (HF) and reduced left ventricular ejection fraction (LVEF) of 37%. Despite this, she is on optimal medical therapy with beta blockers, loop diuretics, and an ACE inhibitor, which are standard treatments for heart failure with reduced ejection fraction (HFrEF). Her blood pressure is well-controlled, and her eGFR is not significantly impaired (Creatinine 132.0 mol/L). The patient's BNP level is mildly elevated at 30 ng/L, which is a marker of heart failure severity. However, it is not excessively high, suggesting that the patient's heart failure is not severely decompensated. Additionally, her ECG does not show any signs of life-threatening arrhythmias. Considering these factors, the patient's prognosis is more likely to be a survivor, with a good response to her current medical therapy and a relatively stable clinical condition.

RANKING: Sudden Cardiac Death (SCD)
REASONING: While the patient has a history of heart failure and reduced LVEF, her current clinical condition and treatment suggest that sudden cardiac death is less likely. Her LVEF is not extremely low, and she is on optimal medical therapy, which reduces the risk of SCD. The absence of life-threatening arrhythmias on her ECG also decreases the risk of SCD. However, the patient's reduced LVEF and history of heart failure increase the risk of SCD. 

RANKING: Pump Failure Death
REASONING: Pump failure death is the least likely prognosis for this patient. Her current clinical condition and treatment suggest that her heart failure is relatively well-managed, with a mildly elevated BNP level and no signs of severe decompensation. Her eGFR is not significantly impaired, which suggests that her kidney function is relatively preserved. Additionally, her ECG does not show any signs of severe left ventricular dysfunction or other factors that would increase the risk of pump failure death. While the patient's reduced LVEF increases the risk of pump failure death, her overall clinical condition and treatment suggest that this is the least likely prognosis."
40,40,P0068,"Age: 71
Gender: Male 
Weight: 114 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 120/55 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 9
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,61
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1243.0
Protein (g/L): 58
T3 (pg/dL): 0,04
T4 (ng/L): 12
TSH (mIU/L): 3,23
Urea (mg/dL): 7,15
LVEF (%): 31.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: 1. Sudden Cardiac Death, 2. Pump Failure Death, 3. Survivor

REASONING: 

1. Sudden Cardiac Death (SCD): The patient has a history of idiopathic dilated cardiomyopathy, which increases the risk of SCD. The low LVEF of 31% indicates significant left ventricular dysfunction, and the presence of non-sustained ventricular tachycardia (NSVT) on the ECG further increases the risk of SCD. The elevated Pro-BNP level (1243.0 ng/L) also suggests increased stress on the heart, which may lead to SCD. Additionally, the patient's NYHA Class II indicates some limitation of physical activity, which may lead to arrhythmias and SCD.

2. Pump Failure Death: While the patient's LVEF is low, indicating impaired cardiac function, the patient is currently being treated with a combination of medications, including ACE inhibitors, angiotensin II receptor blockers, and digoxin, which are commonly used to manage heart failure. The patient's eGFR (estimated glomerular filtration rate) is relatively preserved, with a creatinine level of 80.0 mol/L, which suggests that the kidneys are functioning reasonably well. Although the patient has a history of diabetes and dyslipidemia, which can contribute to worsening heart failure, the current medication regimen and relatively preserved renal function suggest that pump failure death may not be the most immediate concern.

3. Survivor: While the patient has significant cardiac dysfunction and risk factors for SCD, the current medication regimen and relatively preserved renal function suggest that the patient may be able to survive for a period of time with proper management. The patient's LVEF of 31% is not the lowest possible value, and the patient's NYHA Class II indicates that they are still able to perform some physical activity. With close monitoring and continued medical management, the patient may be able to avoid both SCD and pump failure death.

It is essential to note that these prognoses are based on the provided data and may not reflect the patient's actual outcome. A more accurate prognosis would require a comprehensive evaluation by a cardiologist and ongoing monitoring of the patient's condition."
41,41,P0071,"Age: 58
Gender: Male 
Weight: 116 kg
Height: 186 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 58
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 159.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,12
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 600.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 18
TSH (mIU/L): 1,54
Urea (mg/dL): 6,16
LVEF (%): 32.0
Medications: Amiodarone, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: Survivor

REASONING: 

Based on the provided patient data, I would rank the prognosis as a survivor for the next few years. Here's why:

1. Age and NYHA Class: The patient is 58 years old and classified as NYHA Class II, indicating mild to moderate symptoms of heart failure. While this is a concern, it's not the most severe classification.

2. LVEF: The left ventricular ejection fraction (LVEF) is 32%, which is significantly reduced. However, it's not the lowest possible value, and there are treatments available to improve LVEF.

3. Medications: The patient is already on a combination of medications, including beta blockers, statins, and nitrovasodilators, which are standard treatments for heart failure and ischemic cardiomyopathy.

4. ECG Findings: The ECG shows monomorphic ventricular extrasystoles, but no sustained ventricular tachycardia or non-sustained ventricular tachycardia. This suggests that the patient's heart rhythm is relatively stable.

5. Laboratory Results: The patient's creatinine level is elevated (100.0 mmol/L), indicating some kidney impairment, but not severe. The albumin level is also slightly low (42 g/L), which may indicate some degree of malnutrition or liver disease, but not necessarily a dire prognosis.

6. TSH and T4: The patient's thyroid function is within normal limits, which is a good sign.

Considering these factors, while the patient has significant heart disease and some laboratory abnormalities, the overall prognosis is still relatively good. The patient is already on appropriate medications, and the ECG findings are not indicative of severe arrhythmias. Therefore, I would rank the prognosis as a survivor for the next few years.

RANKING (from most likely to least likely):
1. Survivor
2. Pump failure death (possible, but less likely due to the patient's current treatment and relatively stable ECG findings)
3. Sudden cardiac death (least likely, given the patient's current treatment and stable ECG findings)"
42,42,P0072,"Age: 72
Gender: Female 
Weight: 54 kg
Height: 138 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 41,3
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 7,06
Creatinine (mmol/L): 73.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,84
Potassium (mEq/L): 4,2
LDL (mmol/L): 4,65
Sodium (mEq/L): 147.0
Pro-BNP (ng/L): 697.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 17
TSH (mIU/L): 2,38
Urea (mg/dL): 4,33
LVEF (%): 68.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. I will rank the three possible prognoses from most likely to least likely and explain the reasoning behind each.

RANKING: 1. Survivor
REASONING: The patient is 72 years old with a history of ischemic dilated cardiomyopathy and myocardial infarction, which increases the risk of cardiac events. However, the patient's left ventricular ejection fraction (LVEF) is 68%, which is within the normal range, indicating that the heart is functioning relatively well. The patient is on medications for heart failure, including an angiotensin II receptor blocker and loop diuretics, which suggests that the patient's condition is being managed. The patient's Pro-BNP level is elevated at 697.0 ng/L, which is a marker of heart failure, but it is not extremely high. The patient's ECG shows non-sustained ventricular tachycardia, but it is not a sustained arrhythmia, which suggests that it is not a significant concern at this time. Overall, the patient's condition appears to be stable, and with continued management, it is likely that the patient will survive.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which increases the risk of sudden cardiac death. The patient's ECG shows non-sustained ventricular tachycardia, which can be a precursor to sustained ventricular tachycardia and sudden cardiac death. However, the patient's LVEF is within the normal range, and the patient is on medications for heart failure, which reduces the risk of sudden cardiac death. Additionally, the patient's Pro-BNP level is elevated, but not extremely high, which suggests that the patient's condition is not extremely unstable.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF is within the normal range, and the patient is on medications for heart failure, which suggests that the patient's condition is being managed. The patient's Pro-BNP level is elevated, but not extremely high, which suggests that the patient's condition is not extremely unstable. The patient's creatinine level is slightly elevated at 73.0 mmol/L, which may indicate some renal impairment, but it is not extremely high. Overall, the patient's condition appears to be stable, and the risk of pump failure death is relatively low.

Note: The patient's weight and height are not typical for a female patient, which may indicate that the patient has a muscular build. However, the patient's weight is still relatively low at 54 kg, which may indicate that the patient is malnourished or has a wasting disease."
43,43,P0074,"Age: 65
Gender: Male 
Weight: 73 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 39,1
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,58
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2407.0
Protein (g/L): 65,9
T4 (ng/L): 16
TSH (mIU/L): 1,78
Urea (mg/dL): 9,32
LVEF (%): 25.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: Survivor

REASONING: The patient is a 65-year-old male with idiopathic dilated cardiomyopathy, which is a significant underlying condition. However, several factors contribute to a more optimistic prognosis. 

1.  The patient's NYHA Class is II, indicating that the heart failure is not severe, and the patient is still able to perform most daily activities without significant limitations.
2.  The patient is on optimal medical therapy, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all standard treatments for heart failure with reduced ejection fraction (HFrEF).
3.  The patient's LVEF is 25%, which is low but not the lowest possible value. This suggests that there may still be some functional residual cardiac reserve, and the heart is not yet in a state of complete failure.
4.  The patient's Pro-BNP level is elevated at 2407 ng/L, which indicates some level of cardiac stress, but it is not the highest value possible. This suggests that the patient's heart is not in a state of extreme distress.
5.  The patient's other laboratory values, such as electrolytes, liver enzymes, and kidney function, are relatively normal, which suggests that the patient does not have any other underlying conditions that could exacerbate the heart failure.

Considering these factors, I believe that the patient has a good chance of survival over the next few years, assuming he adheres to his medication regimen and makes lifestyle modifications to manage his heart failure."
44,44,P0075,"Age: 54
Gender: Male 
Weight: 82 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 105/74 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 44,2
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 6,18
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 117
Glucose (mmol/L): 6,5
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4
LDL (mmol/L): 3,75
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1199.0
Protein (g/L): 76
T4 (ng/L): 11
TSH (mIU/L): 2,93
Urea (mg/dL): 9,65
LVEF (%): 32.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: Survivor

REASONING: 

Given the patient's profile, I rank survivor as the most likely prognosis for the next few years. Here's why:

1. Age and NYHA Class: The patient is 54 years old, which is relatively young for a patient with ischemic dilated cardiomyopathy. His NYHA Class II indicates that he has some limitations in physical activity but is still able to perform daily tasks without severe symptoms. This suggests that he has some level of preserved cardiac function.

2. Medications: The patient is on beta blockers, loop diuretics, statins, and ACE inhibitors, which are all evidence-based medications for heart failure management. These medications should help to slow disease progression and alleviate symptoms.

3. ECG findings: While the patient has polymorphic ventricular extrasystoles, he does not have any sustained ventricular tachycardia or non-sustained ventricular tachycardia. This suggests that his ventricular arrhythmias are not as severe as they could be, and he is not at an increased risk of sudden cardiac death.

4. LVEF: Although the patient's LVEF is only 32%, which is relatively low, it has not dropped significantly over time. This suggests that his cardiac function is relatively stable.

5. Other lab results: The patient's creatinine level is elevated, but it is not significantly high, which suggests that his renal function is not severely impaired. His glucose and lipid profiles are also relatively well-controlled.

Considering these factors, while the patient's prognosis is not excellent, I believe that with proper management and adherence to his medications, he is likely to survive for several years.

RANKING: Sudden cardiac death

REASONING: 

Sudden cardiac death is the second most likely prognosis for this patient. Here's why:

1. Low LVEF: The patient's LVEF of 32% indicates severe left ventricular dysfunction, which increases his risk of sudden cardiac death.

2. Polymorphic ventricular extrasystoles: The presence of polymorphic ventricular extrasystoles on the ECG is a risk factor for sudden cardiac death.

3. High Pro-BNP: The patient's Pro-BNP level of 1199.0 ng/L is elevated, which suggests that he has significant cardiac stress and may be at risk of sudden cardiac death.

However, the patient's overall profile suggests that sudden cardiac death is not the most likely outcome, as he has a relatively stable cardiac function and is on evidence-based medications.

RANKING: Pump failure death

REASONING: 

Pump failure death is the least likely prognosis for this patient. Here's why:

1. Stable LVEF: While the patient's LVEF is low, it has not dropped significantly over time, suggesting that his cardiac function is relatively stable.

2. Well-controlled symptoms: The patient's NYHA Class II indicates that he has some limitations in physical activity but is still able to perform daily tasks without severe symptoms.

3. Effective medications: The patient is on beta blockers, loop diuretics, statins, and ACE inhibitors, which are all evidence-based medications for heart failure management.

4. No other signs of severe disease progression: The patient's creatinine level is not severely elevated, and his glucose and lipid profiles are relatively well-controlled.

Overall, while the patient has significant cardiac disease, his profile suggests that pump failure death is the least likely outcome."
45,45,P0076,"Age: 72
Gender: Male 
Weight: 90 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 145/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 180.0
Gamma-glutamil transpeptidase (IU/L): 66
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 147.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 5
LDL (mmol/L): 3,47
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 997.0
Protein (g/L): 69,9
T4 (ng/L): 15
TSH (mIU/L): 0,8
Urea (mg/dL): 9,48
LVEF (%): 35.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient is 72 years old with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac mortality. However, the patient is already on optimal medical therapy for heart failure, including an Angiotensin II Receptor Blocker, Beta Blockers, Statins, and a Nitrovasodilator. The patient's LVEF is 35%, which is relatively low, but not the lowest. The patient's Pro-BNP level is elevated at 997.0 ng/L, which indicates some degree of heart failure, but not to the extent that would suggest an imminent risk of sudden cardiac death. The patient's NYHA Class is II, which suggests that the patient has some limitations in physical activity but is still able to perform everyday activities without significant symptoms. Considering these factors, the most likely prognosis is that the patient will survive, but with continued close monitoring and management of their heart failure.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF is 35%, which indicates that the heart is not pumping efficiently, and the patient is at risk for pump failure. The patient's elevated Pro-BNP level and low albumin level also suggest that the patient has some degree of heart failure. However, the patient is already on optimal medical therapy for heart failure, and the patient's NYHA Class is II, which suggests that the patient is not yet in a state of advanced heart failure. While pump failure is a possible outcome, it is less likely than sudden cardiac death due to the patient's current medical therapy and relatively stable clinical status.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's LVEF is 35%, which is low, and the patient has a history of non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. However, the patient is already on optimal medical therapy for heart failure, including Beta Blockers, which are known to reduce the risk of sudden cardiac death. The patient's Pro-BNP level is elevated, but not to the extent that would suggest an imminent risk of sudden cardiac death. While sudden cardiac death is a possible outcome, it is the least likely of the three prognoses due to the patient's current medical therapy and relatively stable clinical status."
46,46,P0077,"Age: 63
Gender: Female 
Weight: 65 kg
Height: 152 cm
NYHA Class: III
Blood Pressure: 105/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 41
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 111.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,63
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,39
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 2093.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,05
Urea (mg/dL): 11,58
LVEF (%): 30.0
Medications: Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely:

RANKING: Survivor
REASONING: The patient is a 63-year-old female with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure and adverse outcomes. However, despite this, she is currently being treated with a combination of medications that are beneficial for her condition, including loop diuretics, spironolactone, statins, and an ACE inhibitor. Her LVEF is 30%, which is low but not the lowest possible value, indicating that her heart is still pumping some blood. Additionally, her NT-proBNP level is elevated, but not extremely high, which may indicate some degree of compensation. While her ECG shows non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, these are not uncommon in patients with heart failure and may not necessarily be a contraindication to survival. Overall, while the patient's prognosis is guarded, her current treatment regimen and relatively stable vital signs suggest that she may be able to survive for the next few years with continued medical management.

RANKING: Pump Failure Death
REASONING: The patient's LVEF is 30%, which is significantly reduced, indicating that her heart is not pumping efficiently. Her NT-proBNP level is also elevated, which is a marker of heart failure. However, her current treatment regimen includes medications that are beneficial for heart failure, such as spironolactone and ACE inhibitors, which may help to slow the progression of the disease. Additionally, her blood pressure is within a relatively normal range, and her kidney function is not severely impaired. While pump failure is a possible outcome, it is not the most likely prognosis given the patient's current treatment regimen and relatively stable vital signs.

RANKING: Sudden Cardiac Death
REASONING: The patient's ECG shows non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, which are risk factors for sudden cardiac death. However, the patient is currently being treated with an ACE inhibitor, which is beneficial for reducing the risk of sudden cardiac death. Additionally, her heart rate is not extremely high or low, and her blood pressure is within a relatively normal range. While sudden cardiac death is a possible outcome, it is not the most likely prognosis given the patient's current treatment regimen and relatively stable vital signs."
47,47,P0080,"Age: 72
Gender: Male 
Weight: 66 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 38,9
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 6,21
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 49
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,88
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 183.0
Protein (g/L): 65
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,11
Urea (mg/dL): 7,57
LVEF (%): 38.0
Medications: Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. However, please note that this is a hypothetical prediction and actual patient outcomes may vary.

RANKING: 1. Survivor
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure and adverse cardiac outcomes. However, the patient's current NYHA Class II indicates that they are still relatively stable and not in an advanced stage of heart failure. The LVEF of 38% is below the normal range, indicating reduced left ventricular function, but it is not extremely low. The patient's ejection fraction is relatively preserved, and they are on appropriate medications for heart failure, including loop diuretics and spironolactone. The patient's BNP level is elevated at 183.0 ng/L, which is consistent with heart failure, but not extremely high. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG also suggests a relatively stable cardiac rhythm. Considering these factors, the patient's overall prognosis is likely to be a survivor, with careful management and monitoring of their heart failure.

RANKING: 2. Pump Failure Death
 REASONING: The patient's reduced LVEF, elevated BNP level, and history of idiopathic dilated cardiomyopathy increase the risk of pump failure death. However, the patient's current NYHA Class II and the absence of more severe symptoms or complications suggest that they are not in an advanced stage of heart failure. The patient's blood pressure is within a relatively normal range, and their kidney function is not severely impaired. While the patient's creatinine level is elevated at 103.0 mmol/L, it is not extremely high, and their urea level is within a relatively normal range. The patient's overall clinical picture suggests that they are at risk for pump failure, but the likelihood of this outcome is lower than sudden cardiac death due to the patient's relatively stable condition and appropriate medical management.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient's history of idiopathic dilated cardiomyopathy increases the risk of sudden cardiac death. However, the patient's LVEF of 38% is not extremely low, and they are on appropriate medications for heart failure. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death, but the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia suggests a relatively stable cardiac rhythm. The patient's TSH level is within a relatively normal range, and their thyroid function is not severely impaired, which can also contribute to an increased risk of sudden cardiac death. Considering these factors, the likelihood of sudden cardiac death is lower than pump failure death due to the patient's relatively stable condition and appropriate medical management."
48,48,P0082,"Age: 71
Gender: Male 
Weight: 70 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,6
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,66
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 430.0
Protein (g/L): 70
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,77
Urea (mg/dL): 7,57
LVEF (%): 24.0
Medications: Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Survivor
REASONING: The patient is 71 years old with a history of idiopathic dilated cardiomyopathy and hypertension, which are both significant risk factors for cardiac complications. However, the patient's NYHA Class II suggests that the symptoms are not severe enough to limit daily activities, which may indicate a relatively stable condition. The patient is on ACE inhibitor and digoxin medications, which are standard treatments for heart failure and may be helping to manage the condition. The LVEF of 24% is low, indicating reduced cardiac function, but not extremely low. The Pro-BNP level is elevated at 430.0 ng/L, indicating some level of heart failure, but not extremely high. The absence of severe electrolyte imbalances, such as low potassium, and relatively normal liver function tests suggest that the patient is not in a state of acute decompensation. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG suggests some level of arrhythmia risk, but the absence of sustained ventricular tachycardia or other signs of acute arrhythmia suggests that the patient is not at extremely high risk of sudden cardiac death. Overall, while the patient has significant cardiac disease, the combination of stable symptoms, appropriate medications, and relatively mild laboratory abnormalities suggest that survival is the most likely outcome.

RANKING: Sudden Cardiac Death
REASONING: While the patient has a history of idiopathic dilated cardiomyopathy and hypertension, which are risk factors for sudden cardiac death, the presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG suggests some level of arrhythmia risk. However, the absence of sustained ventricular tachycardia or other signs of acute arrhythmia, and the presence of relatively normal laboratory values, suggests that sudden cardiac death is not the most likely outcome. The patient's LVEF of 24% and Pro-BNP level of 430.0 ng/L suggest some level of cardiac dysfunction, but not extremely high risk of sudden cardiac death.

RANKING: Pump Failure Death
REASONING: The patient's LVEF of 24% and Pro-BNP level of 430.0 ng/L suggest significant cardiac dysfunction, which is a risk factor for pump failure death. However, the patient's NYHA Class II suggests that the symptoms are not severe enough to limit daily activities, which may indicate a relatively stable condition. The patient is on ACE inhibitor and digoxin medications, which are standard treatments for heart failure and may be helping to manage the condition. The absence of severe electrolyte imbalances, such as low potassium, and relatively normal liver function tests suggest that the patient is not in a state of acute decompensation. While pump failure death is a possible outcome, the patient's relatively stable symptoms and laboratory values suggest that it is less likely than survivor."
49,49,P0084,"Age: 75
Gender: Male 
Weight: 83 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 47,19
ALT or GPT (IU/L): 52.0
AST or GOT (IU/L): 35.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 149.0
Gamma-glutamil transpeptidase (IU/L): 40
Glucose (mmol/L): 14,7
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,59
Potassium (mEq/L): 5,2
LDL (mmol/L): 1,32
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 671.0
Protein (g/L): 68
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,04
Urea (mg/dL): 14,69
LVEF (%): 28.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden Cardiac Death
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The low left ventricular ejection fraction (LVEF) of 28% further increases the risk of sudden cardiac death. Additionally, the elevated Pro-BNP level of 671.0 ng/L suggests that the patient has significant heart failure symptoms, which is another risk factor for sudden cardiac death. Although the patient is on beta blockers, ACE inhibitors, and other medications, the risk of sudden cardiac death remains high due to the underlying cardiomyopathy and low LVEF.

RANKING: 2. Pump Failure Death
 REASONING: The patient's low LVEF, elevated Pro-BNP level, and history of idiopathic dilated cardiomyopathy suggest that the patient is at risk for pump failure death. However, the patient's NYHA class is II, which indicates that the patient's symptoms are still manageable with medication. The patient is also on loop diuretics and spironolactone, which are commonly used to manage heart failure symptoms. While the risk of pump failure death is present, it is not as high as the risk of sudden cardiac death.

RANKING: 3. Survivor
 REASONING: Based on the patient's current treatment regimen and the fact that the patient is still ambulatory, I would rank survivor as the least likely prognosis. The patient's medications, including beta blockers, ACE inhibitors, and diuretics, are aimed at managing the heart failure symptoms and reducing the risk of sudden cardiac death. The patient's NYHA class of II indicates that the patient's symptoms are still manageable, and the patient is able to perform daily activities without significant limitation. While the patient's prognosis is guarded, the current treatment regimen and the patient's functional status suggest that survival is the most likely outcome."
50,50,P0086,"Age: 30
Gender: Male 
Weight: 103 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 50,8
ALT or GPT (IU/L): 191.0
AST or GOT (IU/L): 146.0
Total Cholesterol (mmol/L): 5,97
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 700
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,39
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 763.0
Protein (g/L): 80
T3 (pg/dL): 0,06
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,78
Urea (mg/dL): 4,46
LVEF (%): 39.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the three possible prognoses as follows:

RANKING: 1. Survivor
 REASONING: The patient is 30 years old, which is relatively young for heart failure, and has a history of enolic dilated cardiomyopathy. Despite this, the patient is receiving appropriate treatment with beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which are all standard therapies for heart failure. The patient's LVEF is 39%, which is low but not extremely low, and the patient does not have any signs of severe electrolyte imbalances or severe renal impairment. The patient's Pro-BNP level is elevated, but not extremely high, at 763.0 ng/L. The patient's troponin level is within normal limits, and there is no evidence of acute coronary syndrome. Additionally, the patient's hemoglobin and albumin levels are within normal limits, which suggests that the patient is not malnourished or anemic. Overall, these factors suggest that the patient has a relatively good prognosis and is likely to survive with continued medical management.

RANKING: 2. Sudden cardiac death
 REASONING: The patient has a history of enolic dilated cardiomyopathy, which increases the risk of sudden cardiac death. However, the patient is relatively young and has a low LVEF, which may not be as high a risk factor for sudden cardiac death as it would be in an older patient. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death, but the absence of ventricular tachycardia or other arrhythmias reduces the risk. The patient's medication regimen includes beta blockers, which can reduce the risk of sudden cardiac death. Overall, while the patient has some risk factors for sudden cardiac death, the patient's overall profile and treatment regimen suggest that this outcome is less likely than survivor.

RANKING: 3. Pump failure death
 REASONING: The patient has a history of enolic dilated cardiomyopathy and a low LVEF of 39%, which increases the risk of pump failure. However, the patient's creatinine level is within normal limits, and the patient's medication regimen includes loop diuretics, which suggests that the patient's fluid status is being managed. The patient's albumin and hemoglobin levels are also within normal limits, which suggests that the patient is not malnourished or anemic. The patient's Pro-BNP level is elevated, but not extremely high, at 763.0 ng/L. While the patient has some risk factors for pump failure, the patient's overall profile and treatment regimen suggest that this outcome is the least likely of the three options."
51,51,P0088,"Age: 62
Gender: Male 
Weight: 74 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 111.0
Gamma-glutamil transpeptidase (IU/L): 46
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,9
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 720.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,997
Urea (mg/dL): 8,02
LVEF (%): 36.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: Survivor

REASONING: The patient is 62 years old with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure. However, the patient's current NYHA Class II indicates that he is still relatively asymptomatic, and his medications (Digoxin, Loop Diuretics, and ACE Inhibitor) are likely aimed at managing his condition. The patient's LVEF of 36% is slightly below the normal range, but not severely impaired. The low levels of troponin and absence of ventricular tachycardia on the ECG suggest that the patient's heart is not under significant acute stress.

The patient's biomarkers, such as Pro-BNP (720.0 ng/L) and urea (8.02 mg/dL), are elevated but not extremely high. His lipid profile is concerning, with a high total cholesterol and LDL levels, which may contribute to his heart condition. However, his HDL levels are low, and his glucose level is slightly elevated, which may also contribute to his risk of cardiovascular disease.

Given these factors, I consider the patient's prognosis to be a survivor. While his condition is not ideal, he is currently asymptomatic, and his medications are likely helping to manage his symptoms. However, it is essential for the patient to adhere to his treatment plan, make lifestyle changes (e.g., diet, exercise), and closely monitor his condition to prevent further decline.

The two less likely prognoses are:

Sudden cardiac death: This is less likely because the patient's ECG does not show any signs of severe arrhythmias, and his troponin levels are low, indicating minimal cardiac damage.

Pump failure death: This is also less likely because the patient's LVEF is not severely impaired (36%), and his medications are likely helping to manage his condition. While his Pro-BNP levels are elevated, they are not extremely high, suggesting that his heart is not under severe stress."
52,52,P0089,"Age: 69
Gender: Male 
Weight: 84 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 100/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 46,9
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,61
Creatinine (mmol/L): 116.0
Gamma-glutamil transpeptidase (IU/L): 50
Glucose (mmol/L): 5
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,9
LDL (mmol/L): 4,03
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 5432.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,55
Urea (mg/dL): 7,8
LVEF (%): 18.0
Medications: Beta Blockers, Digoxin, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: Survivor

REASONING: Based on the provided patient data, I would rank the prognosis as Survivor, followed by Pump Failure Death, and then Sudden Cardiac Death. Here's the reasoning behind this ranking:

1. Survivor: The patient's NYHA Class III indicates a significant level of functional impairment, but the patient is still ambulatory and able to perform daily activities. The patient's LVEF of 18% is low, indicating severe left ventricular dysfunction, but the patient is currently being treated with beta blockers, digoxin, spironolactone, and an ACE inhibitor, which are all standard treatments for heart failure with reduced ejection fraction (HFrEF). The patient's Pro-BNP level of 5432 ng/L is elevated, which is consistent with heart failure, but it's not extremely high. The patient's Troponin level is within normal limits, and there is no evidence of acute coronary syndrome. The patient's hemoglobin level is within normal limits, which suggests that there is no significant anemia contributing to their symptoms. Considering these factors, the patient's overall prognosis is guarded, but a survival outcome is still possible with continued medical management.

2. Pump Failure Death: The patient's LVEF of 18% and NYHA Class III suggest that the patient is at high risk for pump failure. The patient's elevated Pro-BNP level and low hemoglobin level also support this risk. However, the patient is currently being treated with medications that are commonly used to manage HFrEF, and there is no evidence of acute decompensation. The patient's creatinine level is slightly elevated, but it's not significantly high, which suggests that there is no significant kidney dysfunction contributing to their symptoms. While pump failure is a significant risk, it's not the most likely outcome given the patient's current treatment and lack of acute decompensation.

3. Sudden Cardiac Death: Sudden cardiac death is a significant risk for patients with HFrEF, particularly those with a low LVEF. However, the patient's ECG does not show any signs of life-threatening arrhythmias, and the Troponin level is within normal limits, which suggests that there is no acute coronary syndrome. The patient's potassium level is slightly low, which may be contributing to their arrhythmias, but it's not significantly low. While sudden cardiac death is a risk, it's not the most likely outcome given the patient's current treatment and lack of acute decompensation.

In summary, while the patient's prognosis is guarded, the most likely outcome is survival with continued medical management. Pump failure and sudden cardiac death are also significant risks, but they are less likely given the patient's current treatment and lack of acute decompensation."
53,53,P0090,"Age: 58
Gender: Female 
Weight: 67 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 105/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 6,4
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,88
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1486.0
Protein (g/L): 63
T3 (pg/dL): 0,04
T4 (ng/L): 17
TSH (mIU/L): 1,18
Urea (mg/dL): 10,98
LVEF (%): 20.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the prognosis for the next few years:

RANKING: 1
REASONING: The patient is likely to be a survivor due to several factors. The patient is on a multidisciplinary treatment regimen, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which is a comprehensive approach for managing heart failure and idiopathic dilated cardiomyopathy. The patient's LVEF of 20% is low, but it's not the lowest possible value, indicating that the heart is still functioning to some extent. The patient's NYHA class is II, which suggests that the patient has some limitations in physical activity but is still able to perform daily activities without severe symptoms. The patient's BNP level is elevated at 1486 ng/L, but it's not extremely high, which might indicate some degree of heart failure compensation. Additionally, the patient's potassium level is within the normal range, which is a good sign as hyperkalemia can be a risk factor for arrhythmias. Overall, while the patient's condition is severe, the treatment and the patient's current status suggest a relatively favorable prognosis.

RANKING: 2
REASONING: The patient is at risk of sudden cardiac death due to the presence of non-sustained ventricular tachycardia, which is a known risk factor for sudden cardiac death. The patient's LVEF of 20% also indicates a high risk of arrhythmias and sudden cardiac death. However, the patient's treatment regimen includes beta blockers, which can reduce the risk of sudden cardiac death by stabilizing heart rhythm. The patient's BNP level is elevated, which might indicate some degree of heart failure, but it's not extremely high, suggesting that the heart is still compensating to some extent.

RANKING: 3
REASONING: The patient is at high risk of pump failure death due to the severe left ventricular dysfunction (LVEF of 20%) and elevated BNP level (1486 ng/L). The patient's NYHA class is II, indicating some degree of functional limitation, and the patient's creatinine level is elevated at 97.0 umol/L, suggesting some degree of kidney dysfunction, which is a known risk factor for pump failure. The patient's weight is within the normal range, but the patient's body mass index (BMI) is not provided, which might be an important factor to consider. However, based on the provided data, pump failure death seems to be the least likely outcome compared to sudden cardiac death due to the patient's relatively stable treatment regimen and the presence of some compensatory mechanisms."
54,54,P0091,"Age: 53
Gender: Male 
Weight: 105 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 47
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 5,77
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,88
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 24.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,26
Urea (mg/dL): 6,16
LVEF (%): 36.0
Medications: Calcium Channel Blocker, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's my prognosis for the next few years:

RANKING: 1. Survivor
REASONING: The patient has a combination of factors that suggest a relatively favorable prognosis. The patient is on a stable regimen of medications, including ACE inhibitors, beta blockers, and diuretics, which are essential for managing heart failure and hypertension. The patient's LVEF is 36%, which is lower than normal but not extremely low. The patient's Pro-BNP level is 24.0 ng/L, which is within the normal range (< 125 ng/L), indicating a low risk of heart failure decompensation. The patient's blood pressure is well-controlled, and there are no signs of severe electrolyte imbalances or acute coronary syndromes. The patient's hemoglobin level is within the normal range, and there are no signs of anemia. Overall, these factors suggest that the patient is at a lower risk of sudden cardiac death or pump failure.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient has a history of hypertensive cardiomyopathy and hypertension, which increases the risk of sudden cardiac death. The patient's LVEF is 36%, which is below the normal range (50-70%), indicating some degree of left ventricular dysfunction. However, the patient's Pro-BNP level is within the normal range, and there are no signs of severe heart failure symptoms. The patient's ECG shows monomorphic ventricular extrasystoles, which can be a marker of increased risk of sudden cardiac death. However, the patient is on beta blockers, which can help reduce the risk of sudden cardiac death. Overall, while the patient has some risk factors, the presence of a controlled blood pressure, stable medications, and a relatively normal Pro-BNP level suggest that sudden cardiac death is less likely than pump failure.

RANKING: 3. Pump Failure Death
REASONING: The patient has a history of hypertensive cardiomyopathy and hypertension, which increases the risk of pump failure. The patient's LVEF is 36%, which is below the normal range, indicating some degree of left ventricular dysfunction. The patient's creatinine level is slightly elevated at 80.0 umol/L, which may indicate some degree of renal dysfunction, which can be a marker of advanced heart failure. The patient's weight is 105 kg, which is above the normal range, and may contribute to increased strain on the heart. However, the patient is on diuretics, which can help manage fluid overload. Overall, while the patient has some risk factors for pump failure, the presence of a controlled blood pressure, stable medications, and a relatively normal Pro-BNP level suggest that pump failure is less likely than sudden cardiac death.

Note: The patient's prognosis is subject to change based on various factors, including changes in medication regimen, lifestyle, and underlying disease progression."
55,55,P0092,"Age: 50
Gender: Female 
Weight: 108 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,49
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 88
Glucose (mmol/L): 19,7
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 5,1
LDL (mmol/L): 3,96
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 350.0
Protein (g/L): 67
T3 (pg/dL): 0,06
T4 (ng/L): 14
Troponin (ng/mL): 0,02
TSH (mIU/L): 4,3
Urea (mg/dL): 9,15
LVEF (%): 27.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here is the prognosis ranking:

RANKING: 1. Survivor
 REASONING: The patient's age is 50, which is relatively young for a cardiomyopathy diagnosis. Although the patient has a low left ventricular ejection fraction (LVEF) of 27%, which is indicative of heart failure, the patient's overall clinical picture suggests a potentially reversible cause of cardiomyopathy, such as hypertension and diabetes. The patient is on appropriate medications for her conditions, including ACE inhibitors, beta-blockers, and diuretics, which are known to improve cardiac function and reduce mortality. Additionally, the patient's recent troponin level is normal, indicating no recent myocardial infarction. The patient's ECG shows monomorphic ventricular extrasystoles, which are common in patients with cardiomyopathy but not necessarily indicative of a poor prognosis.

RANKING: 2. Sudden Cardiac Death
 REASONING: While the patient's LVEF is low, the patient's ECG does not show any signs of life-threatening arrhythmias such as sustained ventricular tachycardia or bradycardia. The patient's blood pressure is well-controlled, and the patient is on beta-blockers, which are known to reduce the risk of sudden cardiac death. Additionally, the patient's recent troponin level is normal, indicating no recent myocardial infarction.

RANKING: 3. Pump Failure Death
 REASONING: This prognosis is the least likely due to the patient's age and the fact that the patient is on appropriate medications for heart failure. The patient's LVEF is low, but it is not extremely low, and the patient's symptoms are classified as NYHA Class II, which indicates mild to moderate heart failure. The patient's creatinine level is elevated, but not severely so, and the patient's albumin level is within a relatively normal range. While the patient's diabetes and dyslipidemia are risk factors for heart failure progression, the patient's overall clinical picture suggests a potentially reversible cause of cardiomyopathy, and the patient's medications are likely to slow the progression of heart failure.

It's worth noting that a more accurate prognosis would require a more comprehensive evaluation, including imaging studies such as echocardiography and cardiac MRI, as well as a detailed assessment of the patient's functional status and quality of life."
56,56,P0093,"Age: 40
Gender: Female 
Weight: 67 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 38
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,52
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 152.0
Protein (g/L): 65
T3 (pg/dL): 0,03
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 2,23
Urea (mg/dL): 4,49
LVEF (%): 60.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: Based on the provided patient data, I would rank the prognosis as a survivor with a moderate to high likelihood. Here's the reasoning behind this assessment:

1.  Age: The patient is 40 years old, which is relatively young for a patient with idiopathic dilated cardiomyopathy. This suggests that the disease may not have progressed as far as it might in an older patient.
2.  NYHA Class II: The patient's functional capacity is still relatively preserved, with a NYHA Class II classification, indicating that she can still perform most daily activities without significant limitations.
3.  Medications: The patient is on a comprehensive regimen of beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all standard treatments for heart failure and idiopathic dilated cardiomyopathy. This suggests that the patient's condition is being well-managed.
4.  LVEF: The patient's left ventricular ejection fraction (LVEF) is 60%, which is within the normal range. While it's slightly lower than the average for a healthy individual, it's not indicative of severe heart failure.
5.  Biomarkers: The patient's troponin level is low (0.005 ng/mL), which suggests that there is no ongoing myocardial injury. The pro-BNP level is elevated at 152 ng/L, but this is not excessively high for a patient with heart failure.
6.  ECG: The ECG shows monomorphic ventricular extrasystoles, but no other significant arrhythmias or signs of acute coronary syndrome.

While the patient has idiopathic dilated cardiomyopathy, the combination of her age, functional capacity, medication regimen, LVEF, biomarkers, and ECG findings suggest that she is at a relatively low risk for sudden cardiac death or pump failure death. However, it's essential to continue monitoring her condition closely and adjust her treatment plan as needed to ensure optimal management of her heart failure.

REASONING FOR THE NEXT LEAST LIKELY PROGNOSIS: 

RANKING: Pump Failure Death

REASONING: Pump failure death is less likely than sudden cardiac death because the patient's LVEF is still within the normal range, and her functional capacity is relatively preserved. However, pump failure death is still a possible outcome if the patient's condition worsens or if she experiences a significant decline in her LVEF.

RANKING: Sudden Cardiac Death

REASONING: Sudden cardiac death is the least likely prognosis for this patient. While the patient has idiopathic dilated cardiomyopathy, her ECG shows no signs of significant arrhythmias, and her troponin level is low, indicating no ongoing myocardial injury. Additionally, her LVEF is within the normal range, and she is on a comprehensive medication regimen that includes beta blockers, which are effective in reducing the risk of sudden cardiac death in patients with heart failure."
57,57,P0094,"Age: 31
Gender: Male 
Weight: 79 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 105/60 mmHg
Past Medical History: Post-myocardial dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 47
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,51
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 951.0
Protein (g/L): 80
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,79
Urea (mg/dL): 5,16
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. I will rank the possible outcomes from most likely to least likely.

RANKING: 1. Survivor
REASONING: The patient is 31 years old with a history of post-myocardial dilated cardiomyopathy and myocardial infarction, which suggests a significant cardiac condition. However, the patient's current medications (beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitor) are commonly used to manage heart failure and dilated cardiomyopathy, indicating that the patient is receiving appropriate treatment. The patient's LVEF (Left Ventricular Ejection Fraction) is 35%, which is relatively low but not extremely low. The patient's NYHA Class II suggests that the patient is experiencing some symptoms but can still perform everyday activities. The low levels of troponin (0.03 ng/mL) and the absence of ventricular tachycardia on the ECG suggest that the patient is not experiencing acute cardiac ischemia. Considering these factors, the patient's prognosis for survival is relatively good, especially with ongoing medical management.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of myocardial infarction and dilated cardiomyopathy increases the risk of sudden cardiac death. However, the patient's current medications, including beta blockers and ACE inhibitors, are known to reduce the risk of sudden cardiac death. The patient's LVEF of 35% is a risk factor for sudden cardiac death, but the patient's age and the absence of other high-risk factors (e.g., ventricular tachycardia, low ejection fraction, or high troponin levels) suggest that sudden cardiac death is less likely.

RANKING: 3. Pump Failure Death
REASONING: Pump failure death is a possible outcome for patients with dilated cardiomyopathy and low LVEF. However, the patient's current medications and the absence of other high-risk factors (e.g., high creatinine levels, low albumin levels, or high BNP levels) suggest that pump failure death is less likely. The patient's NYHA Class II suggests that the patient is experiencing some symptoms but can still perform everyday activities, which is a good prognostic sign. Additionally, the patient's low troponin levels and the absence of ventricular tachycardia on the ECG suggest that the patient's cardiac function is relatively stable."
58,58,P0095,"Age: 50
Gender: Female 
Weight: 77 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 38
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 6,08
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 5
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 3,9
LDL (mmol/L): 3,1
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 40.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,27
Urea (mg/dL): 6,49
LVEF (%): 50.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: 

The patient is a 50-year-old female with a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened, leading to poor heart function. Despite this, her LVEF (Left Ventricular Ejection Fraction) is 50%, which is within the range of 40-59%, indicating a moderate reduction in heart function. However, her NYHA Class III indicates that she experiences symptoms of heart failure with minimal physical activity, but is still able to perform daily activities with some limitation.

Her laboratory results show a relatively preserved kidney function (Creatinine 71.0 mol/L) and normal electrolyte levels (Potassium 3.9 mEq/L). Her Pro-BNP level is slightly elevated at 40.0 ng/L, which may indicate some level of heart failure, but not severe.

The patient is on medications that are beneficial for heart failure, such as loop diuretics and ACE inhibitors, which are likely helping to manage her symptoms.

The ECG shows monomorphic ventricular extrasystoles, but no sustained ventricular tachycardia or non-sustained ventricular tachycardia. This suggests that her heart rhythm is relatively stable.

Given these factors, the patient's prognosis for survival over the next few years is more favorable compared to the other two options.

RANKING: Pump Failure Death

REASONING: 

Pump failure death is a possible outcome for this patient due to her history of idiopathic dilated cardiomyopathy and reduced LVEF. However, her current LVEF is 50%, which is still within a moderate range, and her NYHA Class III suggests that she is still able to manage her symptoms with medication and lifestyle modifications.

Additionally, her laboratory results show no severe abnormalities that would indicate an increased risk of pump failure, such as significantly elevated creatinine levels or severe electrolyte imbalances.

RANKING: Sudden Cardiac Death

REASONING: 

Sudden cardiac death is the least likely prognosis for this patient due to her relatively stable ECG and the absence of any high-risk features for sudden cardiac death, such as a history of ventricular tachycardia or a low LVEF.

Her LVEF of 50% is within a moderate range, and her NYHA Class III suggests that she is still able to manage her symptoms with medication and lifestyle modifications.

Her laboratory results show no severe abnormalities that would indicate an increased risk of sudden cardiac death, such as significantly elevated troponin levels or severe electrolyte imbalances.

Overall, while pump failure death is a possible outcome for this patient, her relatively stable condition and current management make sudden cardiac death the least likely prognosis."
59,59,P0096,"Age: 68
Gender: Male 
Weight: 71 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,97
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 5,7
LDL (mmol/L): 2,4
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 675.0
Protein (g/L): 65
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,16
TSH (mIU/L): 3,73
Urea (mg/dL): 12,15
LVEF (%): 31.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor

REASONING: Given the patient's profile, I would rank survivor as the most likely outcome. Here's why:

1.  Age: 68 years is considered elderly, but not excessively so, and many patients in this age group can still live with heart failure for several years with proper management.
2.  NYHA Class II: This indicates that the patient's symptoms are manageable with medication, and they are not severely limited by their heart failure.
3.  Blood pressure: The patient's blood pressure is within a relatively normal range, which is beneficial for heart failure management.
4.  Medications: The patient is on a combination of angiotensin II receptor blocker, loop diuretics, spironolactone, and ACE inhibitor, which is a comprehensive treatment plan for heart failure.
5.  LVEF: Although the left ventricular ejection fraction (LVEF) is low at 31%, it's not extremely low, and some patients with LVEF in this range can still survive for several years with optimal management.
6.  Troponin: The troponin level is within a relatively normal range, indicating that there is no acute myocardial infarction.

However, there are also some concerning factors that need to be considered:

1.  Hypertensive cardiomyopathy and hypertension: These conditions can lead to heart failure and increase the risk of sudden cardiac death.
2.  Low HDL and high LDL cholesterol: Elevated LDL levels can contribute to atherosclerosis, which can worsen heart failure.
3.  Elevated Pro-BNP: A high B-type natriuretic peptide (BNP) level indicates that the heart is under strain, which can be a sign of worsening heart failure.
4.  Non-sustained ventricular tachycardia: This can be a sign of underlying cardiac electrical instability.

Considering these factors, while there are some concerning signs, the patient's overall profile suggests that with proper management, the most likely outcome is survival for several years.

RANKING: 2. Sudden cardiac death

REASONING: Given the patient's profile, I would rank sudden cardiac death as the second most likely outcome. Here's why:

1.  Hypertensive cardiomyopathy and hypertension: These conditions increase the risk of sudden cardiac death due to arrhythmias and cardiac arrest.
2.  Non-sustained ventricular tachycardia: This can be a precursor to sustained ventricular tachycardia, which can lead to sudden cardiac death.
3.  Low LVEF: A low LVEF increases the risk of sudden cardiac death due to reduced cardiac reserve.
4.  Elevated Pro-BNP: A high BNP level indicates that the heart is under strain, which can increase the risk of arrhythmias and sudden cardiac death.

However, the patient is on a comprehensive treatment plan, and the presence of non-sustained ventricular tachycardia is not necessarily a guarantee of sudden cardiac death.

RANKING: 3. Pump failure death

REASONING: Given the patient's profile, I would rank pump failure death as the least likely outcome. Here's why:

1.  NYHA Class II: The patient's symptoms are manageable with medication, which suggests that the heart failure is not severe.
2.  LVEF: Although the LVEF is low, it's not extremely low, and some patients with LVEF in this range can still survive for several years with optimal management.
3.  Medications: The patient is on a comprehensive treatment plan that includes medications that can help manage heart failure and slow disease progression.

However, the patient's low LVEF and elevated Pro-BNP level do suggest that the heart is under strain, and there is a risk of pump failure death in the long term."
60,60,P0097,"Age: 68
Gender: Female 
Weight: 78 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,45
Potassium (mEq/L): 5
LDL (mmol/L): 2,59
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1284.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,03
TSH (mIU/L): 4,53
Urea (mg/dL): 7,49
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here are the three possible prognoses for the next few years, ordered from most likely to least likely:

RANKING: 1. Survivor
 REASONING: The patient is 68 years old with a history of idiopathic dilated cardiomyopathy and hypertension, which are both risk factors for cardiac disease. However, the patient is on a comprehensive treatment regimen that includes beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which are all standard treatments for heart failure and hypertension. The patient's LVEF is 35%, which is below the normal range, but not extremely low. The patient's NT-proBNP level is elevated at 1284.0 ng/L, but it is not extremely high. The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death, but the patient is not in a high-risk category for sudden cardiac death. Overall, the patient's current treatment regimen and the absence of other high-risk factors make survivorship the most likely prognosis.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF is 35%, which indicates that the heart is not pumping efficiently. The patient's NT-proBNP level is elevated, which is a marker of heart failure. The patient's creatinine level is 88.0 umol/L, which is slightly elevated, indicating potential kidney dysfunction. The patient's medications include diuretics and spironolactone, which are used to manage heart failure. However, the patient's ejection fraction is not extremely low, and the patient is on a comprehensive treatment regimen, making pump failure death a less likely outcome.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. However, the patient is on a comprehensive treatment regimen that includes beta blockers, which are used to reduce the risk of sudden cardiac death. The patient's NT-proBNP level is elevated, but it is not extremely high, and the patient's LVEF is not extremely low. The patient's overall clinical picture does not suggest a high risk for sudden cardiac death, making this outcome the least likely of the three."
61,61,P0098,"Age: 56
Gender: Female 
Weight: 60 kg
Height: 140 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 66.0
AST or GOT (IU/L): 66.0
Total Cholesterol (mmol/L): 5,64
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 5,2
LDL (mmol/L): 3,96
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 2081.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 19
TSH (mIU/L): 5,52
Urea (mg/dL): 4,99
LVEF (%): 38.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: Despite the patient's advanced heart failure symptoms (NYHA Class III) and reduced LVEF (38%), the patient is on a comprehensive treatment regimen that includes ACE inhibitors, beta blockers, digoxin, and loop diuretics, which are all standard treatments for heart failure. The patient's blood pressure is well-controlled, and there is no indication of severe electrolyte imbalances or acute kidney injury. The patient's creatinine level is elevated, but it is not significantly high, and the patient is not on dialysis. The presence of diabetes, dyslipidemia, and hypertension is well-managed with medication. The patient's TSH is slightly elevated, but it is not indicative of a life-threatening condition. The low T3 and low T4 levels suggest hypothyroidism, which may be contributing to the patient's heart failure symptoms. However, this is not an immediate life-threatening condition. Considering the patient's overall treatment regimen and the lack of severe comorbidities, the most likely prognosis is survival.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF of 38% is significantly reduced, indicating severe left ventricular dysfunction. The patient's NYHA Class III symptoms suggest that the patient is experiencing significant limitations in physical activity due to heart failure. However, the patient's treatment regimen includes medications that are designed to slow the progression of heart failure and improve symptoms. While the patient's prognosis is guarded, the fact that they are receiving comprehensive treatment and do not have any immediate life-threatening conditions makes pump failure death less likely in the short term.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which increases the risk of sudden cardiac death. However, the patient's ECG shows monomorphic ventricular extrasystoles, but no non-sustained ventricular tachycardia or ventricular tachycardia. The patient's LVEF is reduced, but the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death. The patient's TSH is slightly elevated, which may be contributing to the patient's heart failure symptoms, but it is not indicative of a life-threatening condition. While the patient's prognosis is guarded, the lack of evidence of severe arrhythmias and the patient's treatment regimen make sudden cardiac death the least likely prognosis."
62,62,P0100,"Age: 68
Gender: Female 
Weight: 70 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 150/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 47,1
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,76
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 200.0
Protein (g/L): 80
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,21
Urea (mg/dL): 6,01
LVEF (%): 27.0
Medications: Calcium Channel Blocker, Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient is 68 years old with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac events. However, the patient's current medications (Calcium Channel Blocker, Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone, and Nitrovasodilator) suggest that she is receiving comprehensive treatment for heart failure. Her LVEF (27.0%) is low, indicating reduced left ventricular function, but it is not extremely low. The absence of severe renal impairment (Creatinine 82.0 mmol/L is within a relatively normal range), elevated liver enzymes (ALT and AST are within normal limits), and relatively normal electrolyte levels (Potassium 4.1 mEq/L) are also positive indicators. Additionally, the patient's Pro-BNP level (200.0 ng/L) is elevated but not extremely high. Considering these factors, the patient's overall condition seems to be stable, and with proper management, the likelihood of a positive outcome is high.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of ischemic dilated cardiomyopathy and non-sustained ventricular tachycardia on ECG are risk factors for sudden cardiac death. However, the patient's current medications and relatively stable condition reduce the likelihood of sudden cardiac death. The absence of severe electrolyte imbalances, renal impairment, and other high-risk factors also decreases the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: The patient's low LVEF (27.0%) and history of ischemic dilated cardiomyopathy make pump failure a significant concern. However, the patient's current medications and relatively stable condition suggest that the risk of pump failure death may be mitigated. The patient's Pro-BNP level is elevated, but not extremely high, which may indicate that the patient's condition is being managed effectively. Additionally, the patient's weight and body mass index (BMI) are not provided, but her height (150 cm) and weight (70 kg) suggest that she may not be significantly overweight or obese, which can contribute to heart failure progression. Overall, while pump failure death is a possible outcome, it is less likely compared to the other two options due to the patient's current treatment and relatively stable condition."
63,63,P0101,"Age: 56
Gender: Male 
Weight: 72 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/50 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,74
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 3566.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,02
TSH (mIU/L): 0,904
Urea (mg/dL): 6,32
LVEF (%): 17.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's the prognosis for the next few years, ordered from most likely to least likely:

RANKING: Survivor

REASONING: 
The patient is 56 years old with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for adverse cardiac outcomes. However, the patient's current NYHA Class II classification indicates that the disease is still manageable, and the patient is not in an advanced stage of heart failure. The patient is on optimal medical therapy, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure with reduced ejection fraction (HFrEF). 

The patient's LVEF of 17% is very low, indicating severe left ventricular dysfunction, but the absence of severe electrolyte imbalances, high blood pressure, or other comorbidities that could exacerbate the condition is a positive sign. The low Pro-BNP level of 3566 ng/L is not excessively high, indicating that the patient's condition is relatively stable. 

The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG indicates some degree of ventricular arrhythmia, but the absence of sustained ventricular tachycardia or other life-threatening arrhythmias is reassuring. The patient's laboratory values, including the low T3 and normal T4 levels, do not suggest significant thyroid dysfunction, which can be a contributing factor to heart failure.

Considering these factors, while the patient's prognosis is guarded due to the severity of their cardiomyopathy, the presence of optimal medical therapy and the relatively stable laboratory values suggest that a survivor prognosis is the most likely outcome over the next few years.

RANKING: Sudden Cardiac Death

REASONING: 
Sudden cardiac death (SCD) is a possible outcome for this patient due to the presence of non-sustained ventricular tachycardia, low LVEF, and idiopathic dilated cardiomyopathy. However, the patient's current medical therapy and the absence of other high-risk factors such as severe hypertension, significant electrolyte imbalances, or other life-threatening arrhythmias make this prognosis less likely than a survivor outcome. 

Additionally, the patient's age and sex are not particularly high-risk factors for SCD, and the patient's NYHA Class II classification indicates that the disease is still manageable. While the patient's Pro-BNP level is elevated, it is not excessively high, indicating that the patient's condition is relatively stable.

RANKING: Pump Failure Death

REASONING: 
Pump failure death is the least likely prognosis for this patient due to the presence of optimal medical therapy, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are standard treatments for HFrEF. The patient's NYHA Class II classification indicates that the disease is still manageable, and the patient's laboratory values, including the low Pro-BNP level, suggest that the patient's condition is relatively stable. 

The patient's low LVEF of 17% is a significant risk factor for pump failure, but the absence of other high-risk factors such as severe hypertension, significant electrolyte imbalances, or other life-threatening arrhythmias makes this prognosis less likely. While the patient's condition is severe, the presence of optimal medical therapy and the relatively stable laboratory values suggest that pump failure death is the least likely outcome over the next few years."
64,64,P0102,"Age: 63
Gender: Male 
Weight: 102 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 37
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 11,5
Hemoglobin (g/L): 128.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 5,3
LDL (mmol/L): 2,66
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 346.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,06
TSH (mIU/L): 2,34
Urea (mg/dL): 6,99
LVEF (%): 43.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: 1. Sudden Cardiac Death
REASONING: The patient has a history of ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death due to potential life-threatening arrhythmias. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG further supports this risk. Additionally, the patient's low left ventricular ejection fraction (LVEF) of 43% indicates reduced cardiac function, which can contribute to arrhythmias and sudden cardiac death. Although the patient is on beta blockers, which can help prevent sudden cardiac death, the patient's overall risk profile suggests that sudden cardiac death is a significant concern.

RANKING: 2. Pump Failure Death
REASONING: The patient's ischemic dilated cardiomyopathy and low LVEF of 43% indicate that the heart is not pumping efficiently, which increases the risk of pump failure death. The patient's elevated creatinine levels (124.0 mmol/L) and urea levels (6.99 mg/dL) suggest that the kidneys may be affected by reduced cardiac output, further supporting this risk. However, the patient's NYHA class II indicates that the patient is still able to perform most daily activities without significant limitations, which suggests that the heart is not yet severely compromised.

RANKING: 3. Survivor
REASONING: Given the patient's history of ischemic dilated cardiomyopathy, low LVEF, and presence of NSVT, one might expect a worse prognosis. However, the patient's NYHA class II, relatively well-controlled blood pressure, and the fact that they are on a comprehensive treatment regimen (including ACE inhibitors, beta blockers, and statins) suggest that the patient is receiving adequate medical management. Additionally, the patient's recent troponin level is within normal limits, which indicates that there is no recent myocardial infarction. While the patient's risk profile is concerning, the comprehensive treatment and relatively well-controlled symptoms suggest that the patient may have a favorable prognosis for survival."
65,65,P0103,"Age: 50
Gender: Male 
Weight: 81 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 144.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,09
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 526.0
Protein (g/L): 68
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,05
Urea (mg/dL): 8,49
LVEF (%): 24.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient has a relatively stable condition with a controlled ischemic dilated cardiomyopathy, as evidenced by the use of beta blockers, statins, and an ACE inhibitor. The patient's LVEF of 24% indicates reduced cardiac function, but the fact that it is not significantly lower (e.g., < 15%) suggests that the patient's heart is still functioning to some extent. The presence of non-sustained ventricular tachycardia (NSVT) is concerning, but it is not a predictor of sudden cardiac death on its own. The patient's blood pressure is within a relatively normal range, and the absence of other significant comorbidities (e.g., severe renal impairment, severe anemia) suggests that the patient's overall condition is not as dire as it could be. Given these factors, a survivor prognosis is the most likely outcome.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of myocardial infarction and ischemic dilated cardiomyopathy puts them at increased risk for sudden cardiac death. The presence of NSVT is a known risk factor for sudden cardiac death, although it is not a guarantee of this outcome. The patient's low LVEF and high Pro-BNP levels also suggest that the patient is at risk for sudden cardiac death. However, the patient's overall condition appears to be relatively stable, and the use of beta blockers and other medications may help mitigate this risk.

RANKING: 3. Pump Failure Death
REASONING: While the patient's LVEF is low, it is not extremely low, and the patient's overall condition does not appear to be as advanced as it would be for a patient with severe heart failure. The patient's blood pressure is within a relatively normal range, and the absence of significant renal impairment or anemia suggests that the patient's kidneys and blood circulation are functioning adequately. Additionally, the patient's use of ACE inhibitors and beta blockers may help slow the progression of heart failure. While pump failure death is a possible outcome, it is less likely than sudden cardiac death given the patient's relatively stable condition.

Note: The patient's TSH level is slightly elevated, which could indicate hypothyroidism, but it is not significantly elevated, and the patient's T4 level is within a normal range. This suggests that hypothyroidism is unlikely to be a major contributor to the patient's cardiac condition."
66,66,P0104,"Age: 51
Gender: Male 
Weight: 75 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 39
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,26
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 7,6
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 1,5
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 405.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,63
Urea (mg/dL): 8,65
LVEF (%): 31.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor
 REASONING: The patient is 51 years old, which is relatively young for a cardiomyopathy diagnosis. He has a history of idiopathic dilated cardiomyopathy, diabetes, and dyslipemia, which are contributing factors to his condition. However, he is currently being treated with a combination of medications that are standard for heart failure, including beta blockers, loop diuretics, and an ACE inhibitor. His NYHA class is II, indicating that he is still relatively functional, but has some limitations. His LVEF of 31% is low, but not extremely low. He also has a relatively normal hemoglobin level and a slightly elevated creatinine level, which may indicate some kidney strain but is not severe. The lack of sustained ventricular tachycardia and normal troponin levels suggest that he is not experiencing acute cardiac ischemia. His pro-BNP level is elevated, but this is consistent with his heart failure diagnosis. Overall, while the patient has a chronic condition, his current treatment and relatively stable vital signs make a survivor prognosis more likely.

RANKING: Pump Failure Death
 REASONING: The patient's LVEF of 31% indicates significant left ventricular dysfunction, which increases his risk for pump failure. His elevated pro-BNP level and NYHA class II classification also suggest that he is experiencing heart failure symptoms. However, his relatively young age, stable vital signs, and lack of acute cardiac ischemia symptoms make pump failure less likely in the short term. His diabetes and dyslipemia are contributing factors to his cardiomyopathy, but he is being treated with medications to manage these conditions.

RANKING: Sudden Cardiac Death
 REASONING: The patient's ECG shows monomorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the absence of non-sustained ventricular tachycardia and other high-risk features makes sudden cardiac death less likely. His relatively stable vital signs and lack of acute cardiac ischemia symptoms also suggest that he is not at high risk for sudden cardiac death. While his cardiomyopathy and underlying conditions increase his risk for cardiac events, his current treatment and relatively stable condition make sudden cardiac death the least likely prognosis."
67,67,P0105,"Age: 75
Gender: Female 
Weight: 77 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 130/88 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 40,4
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 131.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 11,4
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,51
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2176.0
Protein (g/L): 71
T4 (ng/L): 16
TSH (mIU/L): 1,48
Urea (mg/dL): 10,82
LVEF (%): 39.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient is 75 years old with a history of ischemic dilated cardiomyopathy, diabetes, and hypertension, which are all risk factors for adverse cardiac outcomes. However, the patient is currently on a comprehensive treatment regimen including diabetes medication, angiotensin II receptor blocker, beta blockers, loop diuretics, and spironolactone, which are all evidence-based therapies for heart failure and hypertension. The patient's LVEF is 39%, which is below the normal range but not extremely low, and the patient is classified as NYHA Class II, indicating that she is experiencing some symptoms but is still able to perform daily activities without severe limitation. The patient's Pro-BNP level is elevated at 2176.0 ng/L, which is consistent with heart failure, but not extremely high. Additionally, the patient's blood pressure is well-controlled at 130/88 mmHg. Considering these factors, the patient's overall prognosis is guarded but not extremely poor. With continued adherence to her medication regimen and close monitoring, the patient is likely to survive in the next few years.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient has a history of ischemic dilated cardiomyopathy and non-sustained ventricular tachycardia, which are both risk factors for sudden cardiac death. The patient's LVEF is 39%, which is below the normal range and may indicate a higher risk of sudden cardiac death. However, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death in patients with heart failure. Additionally, the patient's Pro-BNP level is elevated, which may indicate that the patient is at risk for sudden cardiac death, but the level is not extremely high. The patient's overall prognosis is not extremely poor, and the risk of sudden cardiac death is not extremely high.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF is 39%, which is below the normal range, indicating that the patient's heart is not pumping efficiently. The patient's Pro-BNP level is elevated at 2176.0 ng/L, which is consistent with heart failure. The patient's creatinine level is elevated at 131.0 mmol/L, which may indicate renal dysfunction, which can be a risk factor for pump failure. The patient's NYHA Class is II, indicating that she is experiencing some symptoms but is still able to perform daily activities without severe limitation. However, the patient's overall prognosis is guarded due to the presence of multiple risk factors for pump failure. The patient's risk of pump failure death is higher than sudden cardiac death due to the patient's low LVEF and elevated Pro-BNP level."
68,68,P0106,"Age: 56
Gender: Female 
Weight: 55 kg
Height: 148 cm
NYHA Class: II
Blood Pressure: 125/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 8.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,41
Creatinine (mmol/L): 66.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,16
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1160.0
Protein (g/L): 74,9
T4 (ng/L): 15
TSH (mIU/L): 0,65
Urea (mg/dL): 6,99
LVEF (%): 26.0
Medications: Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely:

RANKING: 1. Survivor
 REASONING: The patient's age and NYHA Class II classification suggest a moderate level of heart failure, but the patient is still relatively young and has a relatively low creatinine level, which indicates preserved renal function. The patient is on appropriate medications (Loop Diuretics, Spironolactone, and ACE Inhibitor) for heart failure management. The patient's LVEF of 26% is low, but it's not extremely low, and the presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG can be managed with close monitoring and adjustment of medications. The patient's hemoglobin and albumin levels are within normal limits, which suggests that the heart failure is not causing significant anemia or malnutrition. Overall, the patient's prognosis is likely to be a survivor, assuming continued close monitoring and adjustment of medications.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's LVEF of 26% puts them at an increased risk of sudden cardiac death. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG also increases this risk. However, the patient's age and other factors suggest that sudden cardiac death is not the most likely outcome. The patient's low creatinine level and normal hemoglobin and albumin levels suggest that the heart failure is not causing significant renal or nutritional deficiencies that would further increase the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
 REASONING: Pump failure death is the least likely outcome in this case. The patient's LVEF of 26% suggests that the heart is still functioning, albeit inefficiently. The patient's creatinine level is within normal limits, which suggests that the heart failure is not causing significant renal dysfunction. The patient's hemoglobin and albumin levels are also within normal limits, which suggests that the heart failure is not causing significant anemia or malnutrition. While the patient's NYHA Class II classification suggests that they are experiencing symptoms of heart failure, the patient's overall clinical picture suggests that pump failure death is less likely compared to the other two options."
69,69,P0110,"Age: 67
Gender: Female 
Weight: 69 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 98/52 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 41
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 5
LDL (mmol/L): 2,43
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 125.0
Protein (g/L): 71
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,72
Urea (mg/dL): 8,32
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the prognosis for the next few years:

RANKING: Survivor
REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure and mortality. However, the patient's current NYHA Class II indicates that she is experiencing some symptoms of heart failure but is still able to perform some physical activity without severe limitations. The LVEF of 30% is low, indicating a significant reduction in cardiac function, but it is not the lowest possible value (which would be below 20-25%). The patient is on appropriate medications for heart failure and diabetes, including beta blockers, spironolactone, and an ACE inhibitor. The absence of troponin elevation and the low pro-BNP level suggest that there is no acute cardiac injury or severe heart failure exacerbation at the moment. The patient's overall clinical picture suggests that she is relatively stable and manageable, and with appropriate medical management, she is likely to survive for the next few years.

RANKING: Pump Failure Death
REASONING: The patient's LVEF of 30% is a significant risk factor for pump failure and mortality. The patient's history of idiopathic dilated cardiomyopathy and diabetes also increases her risk. However, the patient's current NYHA Class II and the absence of acute cardiac injury or severe heart failure exacerbation suggest that she may not be at the highest risk for pump failure. The patient's medications are appropriate for heart failure, and she does not have any other high-risk features such as severe hypertension, significant arrhythmias, or electrolyte imbalances.

RANKING: Sudden Cardiac Death
REASONING: The patient's ECG shows monomorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia suggests that the patient's cardiac rhythm is relatively stable. The patient's low LVEF and history of idiopathic dilated cardiomyopathy increase her risk for sudden cardiac death, but the overall clinical picture suggests that this is a less likely outcome compared to pump failure."
70,70,P0111,"Age: 60
Gender: Male 
Weight: 85 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 115/68 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 40
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,09
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 349.0
Protein (g/L): 76
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,19
Urea (mg/dL): 7,49
LVEF (%): 25.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the prognosis ranking from most likely to least likely:

RANKING: Survivor

REASONING: 
The patient is 60 years old with a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipemia. However, he is on appropriate medications (Beta Blockers, Statins, ACE Inhibitor) that are known to improve prognosis in heart failure patients. His current NYHA Class II indicates that he is experiencing some symptoms but is still able to perform everyday activities without significant limitations. His LVEF of 25% indicates severe left ventricular dysfunction, but it is not the lowest possible value, and he does not have any signs of acute decompensation (e.g., high blood pressure, high creatinine levels, or elevated troponin). His pro-BNP level is elevated, but not extremely high, which might indicate that he is being adequately managed with his current medications. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG suggests that he does not have significant arrhythmia risk. Considering these factors, the most likely outcome is that he will survive.

RANKING: Sudden cardiac death

REASONING: 
Sudden cardiac death is a possible outcome for this patient due to his history of ischemic dilated cardiomyopathy and myocardial infarction. His low LVEF of 25% increases his risk of sudden cardiac death. Additionally, his elevated pro-BNP level and troponin level indicate ongoing cardiac stress. However, his current medications and NYHA Class II suggest that he is being managed appropriately, and he does not have any other risk factors that would significantly increase his risk of sudden cardiac death.

RANKING: Pump failure death

REASONING: 
Pump failure death is the least likely outcome for this patient due to his current management with Beta Blockers, Statins, and ACE Inhibitor, which are known to improve cardiac function and reduce mortality in heart failure patients. His LVEF of 25% indicates severe left ventricular dysfunction, but it is not the lowest possible value, and he does not have any signs of acute decompensation. His NYHA Class II suggests that he is experiencing some symptoms but is still able to perform everyday activities without significant limitations. While pump failure death is possible, the patient's current management and relatively stable condition make this outcome less likely compared to the other two options."
71,71,P0113,"Age: 63
Gender: Male 
Weight: 66 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 105/68 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,71
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,9
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 290.0
Protein (g/L): 66
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,8
Urea (mg/dL): 9,65
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Survivor
 REASONING: The patient is currently on a multidrug regimen that includes beta blockers, digoxin, loop diuretics, statins, and an ACE inhibitor, which is a comprehensive treatment for heart failure with reduced ejection fraction (HFrEF). The patient's NYHA Class II indicates that the patient has some limitations in physical activity but is still able to perform light physical activity without symptoms. The patient's LVEF of 25% is consistent with HFrEF, but the patient's Pro-BNP level of 290 ng/L is within a moderate range. The patient's blood pressure is well-controlled, and the absence of significant elevations in liver enzymes (AST and ALT) suggests that the patient's liver function is not significantly impaired. The patient's hemoglobin level is within the normal range, which suggests that anemia is not a significant concern. Additionally, the patient's TSH level is within the normal range, which suggests that hypothyroidism is not a contributing factor to the patient's cardiac condition. Considering these factors, the patient's prognosis is most likely to be a survivor, as the treatment plan is comprehensive, and the patient's condition is relatively well-managed.

RANKING: Pump Failure Death
 REASONING: The patient's LVEF of 25% indicates severe left ventricular dysfunction, which increases the risk of pump failure. The patient's Pro-BNP level of 290 ng/L is within a moderate range, which suggests that the patient's heart failure is not severe. However, the patient's NYHA Class II indicates that the patient has some limitations in physical activity, which suggests that the patient's condition is not well-compensated. The patient's creatinine level of 97.0 umol/L suggests that the patient has some degree of renal impairment, which can contribute to the progression of heart failure. The patient's total cholesterol level of 4.99 mmol/L is elevated, which can contribute to the progression of atherosclerosis and increase the risk of cardiac events. Considering these factors, the patient's prognosis is likely to be pump failure death, as the patient's condition is not well-compensated, and the patient has multiple risk factors that contribute to the progression of heart failure.

RANKING: Sudden Cardiac Death
 REASONING: The patient's ECG shows non-sustained ventricular tachycardia (NSVT), which is a risk factor for sudden cardiac death. However, the patient is on a beta blocker, which can help to reduce the risk of sudden cardiac death. The patient's LVEF of 25% and NYHA Class II suggest that the patient's condition is not well-compensated, but the patient's Pro-BNP level of 290 ng/L is within a moderate range, which suggests that the patient's heart failure is not severe. The patient's Troponin level of 0.01 ng/mL is within the normal range, which suggests that there is no significant cardiac damage. Considering these factors, the patient's prognosis is least likely to be sudden cardiac death, as the patient is on a comprehensive treatment plan, and the patient's condition is relatively well-managed."
72,72,P0115,"Age: 67
Gender: Female 
Weight: 65 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 105/59 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,81
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,97
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,59
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 984.0
Protein (g/L): 61
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,16
Urea (mg/dL): 6,99
LVEF (%): 35.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. However, please note that the actual outcome may vary based on various factors, including the patient's adherence to medication, lifestyle changes, and the progression of the disease.

RANKING: 1. Survivor
 REASONING: The patient's overall prognosis is relatively good due to the following factors:

1. Current medications: The patient is on angiotensin II receptor blockers, beta blockers, and statins, which are all evidence-based treatments for ischemic dilated cardiomyopathy and dyslipemia. These medications are likely to help manage the patient's condition and slow disease progression.
2. LVEF of 35%: Although the left ventricular ejection fraction (LVEF) is low, it is not extremely low. Patients with an LVEF between 30-40% can still have a relatively good prognosis with proper treatment and management.
3. No signs of acute coronary syndrome: The troponin level is normal, indicating that the patient is not experiencing an acute coronary event.
4. No signs of severe electrolyte imbalance: The potassium level is within the normal range, which is essential for maintaining cardiac function.

However, the patient's prognosis is not entirely without risk. The patient's LVEF is still low, and the Pro-BNP level is elevated, indicating some degree of cardiac stress.

RANKING: 2. Sudden Cardiac Death
 REASONING: The risk of sudden cardiac death is moderate due to the following factors:

1. Ischemic dilated cardiomyopathy: This condition increases the risk of sudden cardiac death, especially if the patient has a history of myocardial infarction.
2. Low LVEF: A low LVEF increases the risk of arrhythmias and sudden cardiac death.
3. Ventricular extrasystole: The presence of monomorphic ventricular extrasystoles on the ECG may indicate underlying cardiac electrical instability, which can increase the risk of arrhythmias.

However, the patient is on beta blockers, which can help reduce the risk of arrhythmias.

RANKING: 3. Pump Failure Death
 REASONING: The risk of pump failure death is relatively low due to the following factors:

1. Current medications: The patient is on angiotensin II receptor blockers, which can help slow disease progression and reduce the risk of pump failure.
2. Normal urea levels: The patient's urea levels are within the normal range, indicating that the kidneys are functioning relatively well, which is essential for managing fluid balance and preventing fluid overload.
3. No signs of severe anemia: The patient's hemoglobin level is within the normal range, which is essential for maintaining adequate oxygen delivery to the tissues.

However, the patient's LVEF is still low, and the Pro-BNP level is elevated, indicating some degree of cardiac stress."
73,73,P0116,"Age: 64
Gender: Male 
Weight: 98 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 15,3
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,17
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 575.0
Protein (g/L): 67
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,88
Urea (mg/dL): 9,32
LVEF (%): 30.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's a prognosis for the next few years, ranking the three possible outcomes from most likely to least likely:

RANKING: 1. Survivor
REASONING: Despite the patient's history of ischemic dilated cardiomyopathy, diabetes, and previous myocardial infarction, the patient is currently receiving optimal medical therapy, including ACE inhibitors (Angiotensin II Receptor Blocker), beta blockers, loop diuretics, statins, and nitrovasodilators. The patient's LVEF is 30%, which is a relatively stable value considering the patient's history. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG is also a positive sign. While the patient has a high Pro-BNP level (575.0 ng/L), this is not uncommon in patients with heart failure. The patient's hemoglobin level is within the normal range, which suggests that the patient is not experiencing significant anemia. Given the patient's overall medical therapy and stable LVEF, a survivor prognosis is the most likely outcome.

RANKING: 2. Pump failure death
REASONING: The patient's history of ischemic dilated cardiomyopathy and previous myocardial infarction puts them at a higher risk for pump failure. However, the patient's current medical therapy and relatively stable LVEF suggest that the patient's heart function is being well-managed. The patient's Pro-BNP level is elevated, which is a marker of heart failure, but it is not excessively high. The patient's creatinine level is within the normal range, which suggests that the patient's kidney function is not significantly impaired. While the patient's LVEF is only 30%, this is not unusually low, and the patient's overall medical therapy is aimed at managing symptoms and preventing further decline in heart function. Pump failure death is a possible outcome, but it is less likely than survivor due to the patient's current medical therapy and relatively stable LVEF.

RANKING: 3. Sudden cardiac death
REASONING: Sudden cardiac death is a less likely outcome for this patient. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death, but the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient's heart rhythm is relatively stable. The patient's LVEF is 30%, which is not unusually low, and the patient's medical therapy includes beta blockers, which are known to reduce the risk of sudden cardiac death. While the patient's Pro-BNP level is elevated, this is a marker of heart failure rather than a direct indicator of sudden cardiac death risk. Overall, while sudden cardiac death is a possible outcome, it is the least likely of the three possible outcomes due to the patient's relatively stable heart rhythm and medical therapy."
74,74,P0118,"Age: 61
Gender: Male 
Weight: 60 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 124/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,78
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,61
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 66
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,49
Urea (mg/dL): 7,32
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient is 61 years old with a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipemia. Despite these risk factors, the patient is on optimal medical therapy with beta blockers, spironolactone, statins, and ACE inhibitor, which suggests that the patient's condition is being actively managed. The LVEF of 35% indicates reduced left ventricular function, but it is not extremely low. The patient's NYHA class II suggests that the patient has some symptoms, but they are not severe. The absence of significant elevations in troponin, creatinine, and pro-BNP levels suggests that the patient's heart failure is not severely decompensated. The patient's low HDL level and high LDL level indicate that the patient's lipid profile could be improved with further optimization of statin therapy. However, the patient's overall clinical picture suggests that the patient is stable and responsive to treatment, making a survivor prognosis more likely.

RANKING: 2. Pump failure death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which increases the risk of pump failure. The LVEF of 35% indicates reduced left ventricular function, which increases the risk of pump failure. The patient's NYHA class II suggests that the patient has some symptoms, which could indicate early signs of decompensation. However, the patient's overall clinical picture, including the absence of significant elevations in troponin, creatinine, and pro-BNP levels, suggests that the patient's heart failure is not severely decompensated. The patient's optimal medical therapy also suggests that the patient's condition is being actively managed. While pump failure is a possible outcome, it is less likely given the patient's stable clinical picture.

RANKING: 3. Sudden cardiac death
 REASONING: Sudden cardiac death is a possible outcome in patients with ischemic dilated cardiomyopathy and reduced LVEF. However, the patient's ECG shows monomorphic ventricular extrasystoles, but no non-sustained ventricular tachycardia or other signs of high risk for sudden cardiac death. The patient's optimal medical therapy, including beta blockers, which are known to reduce the risk of sudden cardiac death, also suggests that the patient's risk is lower. While sudden cardiac death is a possible outcome, it is the least likely of the three given the patient's stable clinical picture and optimal medical therapy."
75,75,P0119,"Age: 58
Gender: Male 
Weight: 73 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 145/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 49
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 9,7
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,07
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 397.0
Protein (g/L): 75
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,42
Urea (mg/dL): 7,49
LVEF (%): 23.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely. 

RANKING: Survivor
 REASONING: The patient's current medication regimen, including diabetes medication, beta blockers, statins, and ACE inhibitors, indicates that the patient is being managed for their underlying conditions. The patient's LVEF of 23% suggests that the patient has significant left ventricular dysfunction, which is a hallmark of ischemic dilated cardiomyopathy. However, the patient's NYHA class of II indicates that the patient's symptoms are not severe, and they are able to perform daily activities without significant limitation. The patient's blood pressure is within a relatively normal range, and their glucose levels are well-controlled. The absence of troponin elevation and the low levels of BNP suggest that the patient is not experiencing acute cardiac ischemia or decompensation. The patient's low LVEF and history of myocardial infarction increase the risk of sudden cardiac death, but the overall clinical picture suggests that the patient is likely to survive with ongoing medical management.

RANKING: Pump Failure Death
 REASONING: The patient's low LVEF of 23% and history of ischemic dilated cardiomyopathy increase the risk of pump failure death. The patient's elevated BNP levels also suggest that the patient's heart is under significant stress, which may lead to pump failure. However, the patient's current medication regimen and controlled glucose levels suggest that the patient is being managed for their underlying conditions, which may mitigate this risk.

RANKING: Sudden Cardiac Death
 REASONING: The patient's history of myocardial infarction and low LVEF increase the risk of sudden cardiac death. The patient's non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on ECG also suggest an increased risk of arrhythmias, which may lead to sudden cardiac death. However, the patient's current medication regimen, including beta blockers, which are known to reduce the risk of sudden cardiac death, may mitigate this risk."
76,76,P0120,"Age: 61
Gender: Female 
Weight: 58 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 128/67 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,33
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 822.0
Protein (g/L): 70
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,07
Urea (mg/dL): 5,83
LVEF (%): 30.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: Survivor
REASONING: The patient has a relatively high LVEF of 30%, which is a critical factor in determining the prognosis for patients with idiopathic dilated cardiomyopathy. While the LVEF is below the normal range, it is not severely decreased, indicating that the patient's heart is still functioning, albeit inefficiently. The patient's NYHA Class II suggests that she is experiencing some symptoms of heart failure, but they are not severe enough to limit her daily activities. The patient is on optimal medical therapy with beta blockers, statins, and ACE inhibitors, which are standard treatments for heart failure and dilated cardiomyopathy. The absence of severe laboratory abnormalities, such as elevated troponin or creatinine, and the relatively normal electrolyte levels, suggest that the patient's cardiac function is not severely compromised at this time. The patient's age, weight, and height are not particularly concerning. While the patient has a high Pro-BNP level, which is indicative of heart failure, the level is not extremely elevated, and the patient's symptoms are not severe. Overall, considering these factors, I believe that the patient has a good chance of survival over the next few years with continued optimal medical therapy and lifestyle modifications.

RANKING: Sudden Cardiac Death
REASONING: Sudden cardiac death is a potential risk for patients with idiopathic dilated cardiomyopathy, particularly those with a history of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles. The patient's ECG findings suggest an increased risk of arrhythmias, which can lead to sudden cardiac death. However, the patient's LVEF is not extremely low, and she is on optimal medical therapy, which reduces the risk of arrhythmias. Additionally, the patient's symptoms are not severe, and she is not in NYHA Class III or IV, which would indicate more severe heart failure. While sudden cardiac death is a possibility, it is not the most likely outcome given the patient's current clinical status.

RANKING: Pump Failure Death
REASONING: Pump failure death is a potential outcome for patients with dilated cardiomyopathy, particularly those with a low LVEF. However, the patient's LVEF is 30%, which, while low, is not extremely low. Additionally, the patient is on optimal medical therapy, which can help slow the progression of heart failure. The patient's symptoms are not severe, and she is not in NYHA Class III or IV, which would indicate more severe heart failure. The patient's laboratory values, including creatinine and troponin, are not severely abnormal, suggesting that the patient's cardiac function is not severely compromised at this time. While pump failure death is a possibility, it is the least likely outcome given the patient's current clinical status."
77,77,P0121,"Age: 41
Gender: Female 
Weight: 97 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 9,8
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,05
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 642.0
Protein (g/L): 70
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,87
Urea (mg/dL): 6,99
LVEF (%): 35.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient is 41 years old, which is relatively young for a cardiomyopathy diagnosis. Despite having a low LVEF of 35%, she is on a regimen of medications that are commonly used to manage heart failure, including ACE inhibitors, ARBs, and loop diuretics. Her blood pressure is well-controlled, and her blood glucose levels are being managed. The absence of troponin elevation and the presence of a low TSH level suggest that she does not have acute cardiac ischemia or hyperthyroidism, respectively. Additionally, her ECG does not show any signs of sustained ventricular tachycardia or other life-threatening arrhythmias. While her Pro-BNP level is elevated, indicating some degree of heart failure, the patient's overall clinical picture and treatment regimen suggest a relatively stable condition. Therefore, a survivor prognosis is the most likely outcome.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's LVEF of 35% indicates a reduced left ventricular function, which increases her risk of sudden cardiac death. However, her ECG does not show any signs of sustained ventricular tachycardia or other life-threatening arrhythmias, which would be a major risk factor for sudden cardiac death. Additionally, her medications include a nitrovasodilator, which is often used to prevent sudden cardiac death in patients with heart failure. While the patient's Pro-BNP level is elevated, indicating some degree of heart failure, her overall clinical picture and treatment regimen suggest a relatively stable condition, making sudden cardiac death less likely than pump failure death.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 35% and elevated Pro-BNP level indicate a significant degree of heart failure. Her medications include loop diuretics, which are used to manage fluid overload in heart failure patients. However, her creatinine level is elevated at 88.0 mmol/L, suggesting some degree of renal impairment, which can be a risk factor for pump failure death. Additionally, her diabetes and dyslipemia are risk factors for cardiovascular disease progression. While her overall clinical picture and treatment regimen suggest a relatively stable condition, the combination of heart failure and renal impairment makes pump failure death a more likely outcome than sudden cardiac death.

Please note that this is a medical prognosis and not a definitive prediction, and the actual outcome may vary based on various factors, including the patient's response to treatment and the progression of her underlying conditions."
78,78,P0122,"Age: 65
Gender: Female 
Weight: 62 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 130/54 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 35
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,47
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,86
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 173.0
Protein (g/L): 62
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,03
Urea (mg/dL): 6,99
LVEF (%): 30.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: Survivor
REASONING: Despite the patient's history of idiopathic dilated cardiomyopathy and reduced left ventricular ejection fraction (LVEF) of 30%, she is currently on appropriate medical therapy with beta blockers, statins, and an ACE inhibitor. Her NYHA Class II indicates that she is experiencing some limitations in physical activity but is still able to perform daily tasks without symptoms. The absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG is a positive sign. Additionally, her troponin levels are within normal limits, indicating minimal cardiac damage. The patient's albumin levels are slightly low, which may indicate some degree of liver dysfunction, but this is not a significant concern in this context. Overall, with proper management and adherence to her medication regimen, the patient is likely to survive for the next few years.

RANKING: Pump Failure Death
REASONING: The patient's LVEF of 30% indicates a significant reduction in cardiac function, which increases the risk of pump failure. The patient's history of idiopathic dilated cardiomyopathy also suggests a high risk of progressive cardiac dysfunction. While the patient is on appropriate medical therapy, the risk of pump failure remains a concern. However, the patient's current NYHA Class II and the absence of severe symptoms suggest that her cardiac function is not deteriorating rapidly at this time. Therefore, pump failure death is a possible outcome, but it is less likely than survivorship.

RANKING: Sudden Cardiac Death
REASONING: Sudden cardiac death is a less likely outcome for this patient due to her current medical therapy and the absence of severe symptoms. The patient's LVEF of 30% does increase her risk of sudden cardiac death, but her ECG findings do not indicate any life-threatening arrhythmias. The patient's troponin levels are within normal limits, and her TSH levels are within normal limits, indicating that there is no underlying thyroid dysfunction contributing to her cardiac condition. While the patient's history of idiopathic dilated cardiomyopathy increases her risk of sudden cardiac death, the current medical therapy and the absence of severe symptoms make this outcome the least likely of the three possibilities."
79,79,P0124,"Age: 80
Gender: Male 
Weight: 109 kg
Height: 178 cm
NYHA Class: III
Blood Pressure: 150/95 mmHg
Past Medical History: Hypertropic cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,75
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 100.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,35
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1475.0
Protein (g/L): 64
T3 (pg/dL): 0,02
T4 (ng/L): 9
Troponin (ng/mL): 0,05
TSH (mIU/L): 1,38
Urea (mg/dL): 23,13
LVEF (%): 62.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: 1. Sudden cardiac death, 2. Pump failure death, 3. Survivor

REASONING:

1. Sudden cardiac death (Rank 1): The patient is 80 years old with a history of hypertrophic cardiomyopathy, which is a known risk factor for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is 62%, which is slightly below the normal range, indicating some degree of heart failure. The presence of ventricular extrasystoles on the ECG also increases the risk of arrhythmias and sudden cardiac death. The patient's low HDL cholesterol and high LDL cholesterol levels contribute to atherosclerotic cardiovascular disease, which can further increase the risk of sudden cardiac death. The high levels of Pro-BNP (1475 ng/L) suggest significant cardiac stress, which can also contribute to sudden cardiac death. Therefore, sudden cardiac death is the most likely prognosis.

2. Pump failure death (Rank 2): The patient's NYHA Class III classification indicates that the patient experiences symptoms of heart failure, such as shortness of breath and fatigue, even at rest or with minimal exertion. The patient's LVEF of 62% is below the normal range, indicating some degree of systolic dysfunction. The high levels of creatinine (177.0 mmol/L) and urea (23.13 mg/dL) suggest chronic kidney disease, which is often associated with heart failure. The patient's high blood pressure (150/95 mmHg) and low albumin levels (37 g/L) also contribute to the risk of pump failure. However, the patient's LVEF is still above 50%, which is generally considered a good prognostic indicator for survival. Therefore, pump failure death is the second most likely prognosis.

3. Survivor (Rank 3): The patient's current medication regimen, including angiotensin II receptor blockers, beta blockers, loop diuretics, statins, and nitrovasodilators, suggests that the patient is receiving appropriate treatment for heart failure and hypertension. The patient's LVEF of 62% is not severely impaired, and the patient's symptoms are managed with medication. The patient's low T3 and T4 levels suggest that the patient may have some degree of hypothyroidism, which can be managed with medication. The patient's hemoglobin level of 100 g/L is slightly below the normal range, but not severely anemic. Overall, while the patient has multiple risk factors, the patient's current treatment and relatively preserved LVEF suggest that survival is the most likely prognosis.

Please note that this is a hypothetical prognosis and should not be taken as a definitive prediction. A thorough clinical evaluation and further testing, such as echocardiography and cardiac biomarkers, would be necessary to confirm the diagnosis and prognosis."
80,80,P0125,"Age: 76
Gender: Male 
Weight: 79 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 37.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 54
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,66
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 303.0
Protein (g/L): 74
T3 (pg/dL): 0,06
T4 (ng/L): 13
Troponin (ng/mL): 0,02
TSH (mIU/L): 12,9
Urea (mg/dL): 6,16
LVEF (%): 54.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Here are the possible prognoses, ordered from most likely to least likely:

RANKING: Survivor

REASONING: The patient is 76 years old with a history of enolic dilated cardiomyopathy and hypertension. Despite this, his ejection fraction (LVEF) is 54%, which is relatively preserved. The patient is on optimal medical therapy with beta blockers, ACE inhibitors, and loop diuretics. His blood pressure is well-controlled at 140/70 mmHg, and his creatinine level is slightly elevated but not significantly so (1.15 mmol/L). The patient's troponin level is normal, and there is no evidence of acute coronary syndrome. The patient's NT-proBNP level is elevated at 303 ng/L, which suggests some degree of heart failure, but it is not severely elevated. The patient's ECG shows non-sustained ventricular tachycardia, which is a concerning finding, but it is not a contraindication to survival. The patient's overall clinical picture suggests that he is at risk for heart failure progression, but with optimal medical therapy, he is likely to survive for the next few years.

RANKING: Pump Failure Death

REASONING: The patient's LVEF is 54%, which is below the normal range, indicating some degree of systolic dysfunction. His creatinine level is elevated, and his NT-proBNP level is elevated, suggesting some degree of heart failure. The patient's weight is 79 kg, which is above the ideal range, and his body mass index (BMI) is not provided, but it is likely elevated. The patient's total cholesterol and LDL levels are high, which may contribute to further cardiac damage. The patient's TSH level is elevated, which may indicate hypothyroidism, which can contribute to cardiac dysfunction. However, the patient's overall clinical picture suggests that he is at risk for pump failure, but with optimal medical therapy, he may still survive for several years.

RANKING: Sudden Cardiac Death

REASONING: The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. The patient's LVEF is 54%, which is below the normal range, indicating some degree of systolic dysfunction. The patient's creatinine level is elevated, and his NT-proBNP level is elevated, suggesting some degree of heart failure. However, the patient's overall clinical picture does not suggest a high risk for sudden cardiac death. The patient's medications, including beta blockers and ACE inhibitors, are likely to reduce his risk of sudden cardiac death. Therefore, this prognosis is the least likely."
81,81,P0126,"Age: 77
Gender: Female 
Weight: 70 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,35
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 237
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,28
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 4117.0
Protein (g/L): 66
T3 (pg/dL): 0,04
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,42
Urea (mg/dL): 8,49
LVEF (%): 56.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here's the ranking of the three possible prognoses from most likely to least likely:

RANKING: Survivor

REASONING: The patient is 77 years old with a history of hypertensive cardiomyopathy and hypertension, which indicates a high risk for cardiovascular disease. However, the patient is currently on a treatment regimen that includes an angiotensin II receptor blocker, loop diuretics, and spironolactone, which are standard medications for managing heart failure and hypertension. The patient's left ventricular ejection fraction (LVEF) is 56%, which is below the normal range (60-70%), indicating some degree of heart failure. However, the patient is still alive and on treatment, which suggests that the disease is being managed.

The patient's laboratory results show elevated creatinine levels (115.0 mmol/L), indicating impaired kidney function, which is common in patients with heart failure. The elevated Pro-BNP levels (4117.0 ng/L) also suggest heart failure, but the patient's symptoms and other lab results do not indicate severe heart failure.

Given the patient's age, the presence of heart failure, and the fact that she is on treatment, the most likely prognosis is that she will continue to survive with ongoing management of her condition. The risk of sudden cardiac death or pump failure death is lower in this scenario, as the patient is already receiving treatment and has not shown severe symptoms.

RANKING: Sudden cardiac death

REASONING: The patient has a history of hypertensive cardiomyopathy and hypertension, which increases the risk of sudden cardiac death. However, the patient's ECG results do not show any signs of life-threatening arrhythmias, such as ventricular tachycardia or bradycardia. The patient's troponin levels are within normal limits, indicating that there is no acute myocardial infarction.

While the patient's Pro-BNP levels are elevated, suggesting heart failure, the patient is already on treatment, and her symptoms do not indicate severe heart failure. The patient's LVEF is 56%, which is below the normal range, but not low enough to indicate severe heart failure.

Given the patient's age and the fact that she is on treatment, the risk of sudden cardiac death is lower than pump failure death.

RANKING: Pump failure death

REASONING: The patient has a history of hypertensive cardiomyopathy and hypertension, which increases the risk of heart failure. The patient's LVEF is 56%, which is below the normal range, indicating some degree of heart failure. The patient's creatinine levels are elevated, indicating impaired kidney function, which is common in patients with heart failure. The patient's Pro-BNP levels are also elevated, suggesting heart failure.

However, the patient is already on treatment, and her symptoms do not indicate severe heart failure. The patient's troponin levels are within normal limits, indicating that there is no acute myocardial infarction. The patient's age and the fact that she is on treatment suggest that the risk of pump failure death is lower than sudden cardiac death."
82,82,P0128,"Age: 72
Gender: Male 
Weight: 74 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 45.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 38
Glucose (mmol/L): 15,2
Hemoglobin (g/L): 132.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,9
LDL (mmol/L): 1,91
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 208.0
Protein (g/L): 75
T3 (pg/dL): 0,02
T4 (ng/L): 26
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,68
Urea (mg/dL): 6,82
LVEF (%): 36.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Paroxysmal AVB
            ",survivor,"Based on the provided patient data, here's my prognosis for the next few years:

RANKING: Survivor
REASONING: This patient is 72 years old with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction. Despite these risk factors, the patient's current medications, including beta blockers, digoxin, loop diuretics, spironolactone, statins, and ACE inhibitors, suggest that they are receiving optimal medical therapy for their conditions. The patient's LVEF is 36%, which is relatively low but not extremely low. Additionally, the patient's Pro-BNP level is elevated at 208.0 ng/L, indicating some degree of heart failure. However, the patient's overall clinical presentation and medication regimen suggest that they are being managed for heart failure and are likely to continue to receive close monitoring and treatment. The presence of paroxysmal AV block on the ECG is a concern, but it does not necessarily indicate a poor prognosis. In fact, the patient's overall clinical picture and medication regimen suggest that they are being closely monitored and treated for this condition. Therefore, based on the available data, I predict that the patient is most likely to survive for the next few years.

RANKING: Sudden Cardiac Death
REASONING: While the patient has a history of ischemic dilated cardiomyopathy and other cardiovascular risk factors, the patient's current medications and overall clinical presentation suggest that they are being actively managed for their conditions. The patient's LVEF is 36%, which is a risk factor for sudden cardiac death, but the patient's Pro-BNP level and medication regimen suggest that they are being closely monitored for heart failure. The patient's ECG shows a paroxysmal AV block, which is a concern, but it does not necessarily indicate a high risk of sudden cardiac death. Therefore, while sudden cardiac death is a possible outcome, it is not the most likely prognosis based on the available data.

RANKING: Pump Failure Death
REASONING: The patient's LVEF is 36%, which is a significant risk factor for pump failure. Additionally, the patient's Pro-BNP level is elevated at 208.0 ng/L, indicating some degree of heart failure. The patient's medications, including loop diuretics and spironolactone, suggest that they are being treated for heart failure, but the patient's overall clinical presentation and LVEF suggest that they are at high risk for pump failure. The patient's age and history of myocardial infarction also contribute to this risk. Therefore, while the patient's overall clinical picture and medication regimen suggest that they are being closely monitored and treated for their conditions, pump failure death is a possible outcome, but it is the least likely prognosis based on the available data."
83,83,P0130,"Age: 48
Gender: Male 
Weight: 74 kg
Height: 182 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 5,1
LDL (mmol/L): 3,15
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 677.0
Protein (g/L): 74
T3 (pg/dL): 0,06
T4 (ng/L): 11
Troponin (ng/mL): 0,37
TSH (mIU/L): 2,4
Urea (mg/dL): 6,82
LVEF (%): 29.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the ranking of the three possible prognoses:

RANKING: 1. Survivor
REASONING: The patient is 48 years old with a history of idiopathic dilated cardiomyopathy, which indicates a reduced left ventricular ejection fraction (LVEF) of 29%. Despite this, the patient is currently being treated with beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which are all standard medications for heart failure management. The patient's NYHA Class II indicates that the patient is experiencing some symptoms of heart failure, but is still able to perform daily activities. The patient's creatinine level of 106.0 mol/L suggests some degree of renal impairment, which is common in patients with heart failure. However, the patient's Pro-BNP level of 677.0 ng/L is elevated, but not excessively high, indicating some degree of heart failure, but not severe. The patient's troponin level of 0.37 ng/mL is also within a relatively normal range, suggesting that there is not significant myocardial injury. Given the patient's current treatment regimen and the fact that they are still ambulatory, I believe that the most likely prognosis is survival.

RANKING: 2. Pump Failure Death
REASONING: While the patient's LVEF of 29% indicates significant left ventricular dysfunction, the patient's current treatment regimen and the fact that they are still ambulatory suggest that they are not in a state of advanced heart failure. The patient's creatinine level is elevated, but not excessively high, and their Pro-BNP level is elevated, but not excessively high. Additionally, the patient's troponin level is within a relatively normal range. While the patient's idiopathic dilated cardiomyopathy and peripheral vascular disease increase their risk of pump failure, the patient's current treatment regimen and overall clinical picture suggest that pump failure death is less likely than sudden cardiac death.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's ECG shows non-sustained ventricular tachycardia (VT), which is a risk factor for sudden cardiac death. The patient's LVEF of 29% also increases their risk of sudden cardiac death. However, the patient's current treatment regimen includes beta blockers, which are effective in reducing the risk of sudden cardiac death in patients with heart failure. Additionally, the patient's Pro-BNP level is elevated, but not excessively high, suggesting that the patient's heart failure is not in a state of acute decompensation. While the patient's risk of sudden cardiac death is increased, I believe that pump failure death is a more likely outcome given the patient's overall clinical picture."
84,84,P0131,"Age: 66
Gender: Male 
Weight: 95 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 130/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 6,03
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 120.0
HDL (mmol/L): 1,71
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,72
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 481.0
Protein (g/L): 65
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,05
TSH (mIU/L): 2,63
Urea (mg/dL): 9,32
LVEF (%): 40.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Parosysmal AF
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

This patient has a complex medical history, including ischemic dilated cardiomyopathy, myocardial infarction, hypertension, and dyslipemia. The patient's left ventricular ejection fraction (LVEF) is 40%, indicating reduced cardiac function. However, the patient is currently being treated with a comprehensive medication regimen, including beta blockers, ACE inhibitors, and spironolactone, which are all standard treatments for heart failure and cardiomyopathy.

The patient's blood work shows elevated creatinine levels (106.0 mmol/L), indicating some degree of renal impairment. However, the patient's albumin levels are within a relatively normal range (41 g/L), and the patient is not showing signs of severe malnutrition.

The patient's electrocardiogram (ECG) shows paroxysmal atrial fibrillation (AF), which is a common arrhythmia in patients with heart failure. However, the patient does not have sustained ventricular tachycardia or bradycardia, which are both risk factors for sudden cardiac death.

Given the patient's current treatment regimen and the fact that the patient is being managed for heart failure, I believe that the most likely outcome is survivor. The patient's reduced LVEF and history of myocardial infarction do increase the risk of sudden cardiac death, but the comprehensive treatment plan and the absence of other high-risk factors (such as sustained ventricular tachycardia or severe renal impairment) suggest that the patient is likely to survive for the next few years.

Sudden cardiac death is a possible outcome, but it is less likely than survivor due to the patient's current treatment regimen and the fact that the patient does not have any high-risk arrhythmias.

Pump failure death is the least likely outcome, as the patient is being treated with diuretics and has a relatively normal albumin level, indicating that the patient is not currently experiencing severe fluid overload or malnutrition.

Therefore, based on the patient's current medical status and treatment regimen, the most likely outcome is survivor."
85,85,P0132,"Age: 46
Gender: Female 
Weight: 53 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 133.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,62
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 64.0
Protein (g/L): 76
T3 (pg/dL): 0,06
T4 (ng/L): 14
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,07
Urea (mg/dL): 4,33
LVEF (%): 34.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is my prognosis for the next few years:

RANKING: Survivor
REASONING: The patient is a 46-year-old female with idiopathic dilated cardiomyopathy, which is a significant underlying condition. However, despite this, she is on a comprehensive medication regimen that includes beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which are all standard treatments for heart failure and dilated cardiomyopathy. Her LVEF is 34%, which is relatively low but not the lowest. Her NYHA class is II, indicating that she is still able to perform some physical activity without symptoms. Her blood pressure is low, but it's not unusually low for a patient with heart failure. Her laboratory results show mild elevations in liver enzymes, but these are not indicative of severe liver disease. Her electrolyte levels and renal function are within normal limits, except for a slightly low potassium level. Her troponin level is very low, indicating that there is no acute coronary syndrome. Her BNP level is elevated, which is consistent with heart failure, but it's not extremely high. Considering these factors, the patient's overall condition seems to be relatively stable, and with continued medical treatment, she is likely to survive for the next few years.

RANKING: Pump Failure Death
REASONING: While the patient has a low LVEF, she is still on treatment, and her NYHA class is not IV, which indicates that she is not in severe heart failure. Her laboratory results do not indicate any acute kidney injury or severe electrolyte imbalances that would increase the risk of pump failure. Her low blood pressure may be a concern, but it's not unusual for patients with heart failure. However, if the patient's condition progresses and her LVEF continues to decline, she may eventually develop pump failure, leading to a higher risk of mortality.

RANKING: Sudden Cardiac Death
REASONING: The patient has a low LVEF, which increases her risk of sudden cardiac death. However, her ECG shows polymorphic ventricular extrasystoles, which is a concern, but it's not a definitive indicator of sudden cardiac death. Her medication regimen includes beta blockers, which are known to reduce the risk of sudden cardiac death. Her troponin level is very low, indicating that there is no acute coronary syndrome. Her BNP level is elevated, but it's not extremely high, which might indicate that her heart failure is not in an acute decompensated state. Overall, while the patient has some risk factors for sudden cardiac death, her overall condition seems relatively stable, and the risk of sudden cardiac death is not the most likely outcome.

Please note that this prognosis is based on the provided data and might not reflect the patient's actual outcome, which can be influenced by many factors, including adherence to medication, lifestyle changes, and other comorbidities."
86,86,P0133,"Age: 36
Gender: Female 
Weight: 81 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 48
ALT or GPT (IU/L): 130.0
AST or GOT (IU/L): 89.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 142
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,05
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 57.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,06
TSH (mIU/L): 3,53
Urea (mg/dL): 6,32
LVEF (%): 24.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the ranking of the possible prognoses from most likely to least likely:

RANKING: Survivor
 REASONING: The patient is 36 years old, which is relatively young for idiopathic dilated cardiomyopathy. The patient's LVEF (Left Ventricular Ejection Fraction) is 24%, indicating severe heart failure, but the patient is on a comprehensive treatment regimen, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor. The patient's ejection fraction is low, but the patient's age and the fact that they are on optimal medical therapy suggest a better prognosis. Additionally, the patient's BNP (B-type natriuretic peptide) level is 57.0 ng/L, which is within the normal range for this patient's age group. The patient's troponin level is also within the normal range. Considering these factors, the most likely outcome is a survivor, with proper management and adherence to the treatment plan.

RANKING: Pump Failure Death
 REASONING: The patient has severe heart failure, as indicated by an LVEF of 24% and NYHA Class III. The patient's eGFR (estimated glomerular filtration rate) is not directly provided, but the creatinine level of 88.0 umol/L suggests impaired renal function. The patient's elevated liver enzymes (ALT and AST) and total cholesterol level suggest potential liver dysfunction or metabolic issues. However, the patient is on optimal medical therapy, and their troponin level is within the normal range. While the patient's condition is severe, the fact that they are young and on comprehensive treatment makes pump failure death less likely compared to sudden cardiac death.

RANKING: Sudden Cardiac Death
 REASONING: The patient has a low LVEF of 24% and a history of idiopathic dilated cardiomyopathy, which increases the risk of sudden cardiac death. However, the patient's ECG does not show any signs of life-threatening arrhythmias, and their troponin level is within the normal range. The patient's age and the fact that they are on optimal medical therapy, including beta blockers, which are known to reduce the risk of sudden cardiac death, suggest that sudden cardiac death is the least likely outcome."
87,87,P0137,"Age: 58
Gender: Male 
Weight: 70 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,44
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 61
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 160.0
HDL (mmol/L): 2,51
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,39
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 320.0
Protein (g/L): 67
T3 (pg/dL): 0,06
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,19
Urea (mg/dL): 6,16
LVEF (%): 53.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here's a prognosis for the next few years, ranking from most likely to least likely:

RANKING: Survivor
REASONING: The patient has a history of enolic dilated cardiomyopathy, which indicates a significant cardiac condition. However, the patient is currently on a comprehensive medication regimen that includes beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitors, which are all standard treatments for heart failure and dilated cardiomyopathy. The patient's LVEF (Left Ventricular Ejection Fraction) is 53%, which is relatively preserved considering the underlying condition. The patient's BNP (Brain Natriuretic Peptide) level is elevated at 320.0 ng/L, but not excessively high, indicating some degree of cardiac stress but not an extreme level of heart failure. The patient's ECG shows non-sustained ventricular tachycardia, which is a concerning finding, but the presence of a preserved LVEF and the comprehensive medication regimen suggest that the patient is being effectively managed. Given the patient's age, sex, and current treatment, the most likely outcome is survival over the next few years, assuming adherence to the treatment plan and regular follow-up appointments.

RANKING: Pump Failure Death
REASONING: The patient's LVEF is 53%, which is below the normal range (60% or higher), indicating some degree of left ventricular dysfunction. The patient's BNP level is elevated, which suggests cardiac stress and potential progression of heart failure. The patient's history of enolic dilated cardiomyopathy and the presence of non-sustained ventricular tachycardia on the ECG are also concerning. However, the patient's current treatment regimen is comprehensive and includes medications that are commonly used to manage heart failure and dilated cardiomyopathy. The patient's overall clinical picture suggests a high risk of pump failure death, but the presence of preserved LVEF and the comprehensive treatment plan suggest that this outcome is less likely than sudden cardiac death.

RANKING: Sudden Cardiac Death
REASONING: The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. The patient's history of enolic dilated cardiomyopathy and the presence of a preserved LVEF suggest that the patient has underlying cardiac disease, which increases the risk of sudden cardiac death. However, the patient's comprehensive medication regimen and the fact that the patient is being managed for heart failure suggest that sudden cardiac death is less likely than pump failure death. The patient's age, sex, and overall clinical picture do not suggest an extremely high risk of sudden cardiac death."
88,88,P0142,"Age: 67
Gender: Female 
Weight: 98 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 120/85 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 40,8
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,8
Creatinine (mmol/L): 73.0
Gamma-glutamil transpeptidase (IU/L): 257
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,13
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,81
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 683.0
Protein (g/L): 68,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,3
Urea (mg/dL): 7,5
LVEF (%): 55.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely. 

RANKING: Survivor

REASONING: The patient is 67 years old with a history of valvular cardiomyopathy, dyslipemia, peripheral vascular disease, and hypertension. However, her LVEF is 55%, which is still within the normal range (> 50%), and she is on appropriate medications for heart failure and dyslipidemia management. The Pro-BNP level is elevated at 683.0 ng/L, which is a marker of heart failure severity, but not extremely high. The patient is also relatively well-managed with no recent acute coronary syndromes or arrhythmias. The lack of significant elevation in troponin and the presence of a normal hemoglobin level are also reassuring. While the patient has a history of valvular cardiomyopathy, the current LVEF and medication regimen suggest that the condition is well-managed. Therefore, considering the overall clinical picture, the most likely prognosis for this patient is a survivor.

RANKING: Pump Failure Death

REASONING: While the patient has a history of valvular cardiomyopathy and an elevated Pro-BNP level, the LVEF is still within the normal range, and the patient is on appropriate medications. The presence of peripheral vascular disease and hypertension may contribute to a higher risk of cardiovascular events, but the patient's current clinical status does not suggest an imminent risk of pump failure. The lack of significant elevation in troponin and the presence of a normal hemoglobin level suggest that the patient is not experiencing acute cardiac ischemia or severe anemia. Therefore, while pump failure is a possible prognosis, it is less likely than survival.

RANKING: Sudden Cardiac Death

REASONING: The patient has a history of valvular cardiomyopathy, but the LVEF is within the normal range, and the patient is on appropriate medications. The presence of ventricular extrasystoles on the ECG is a risk factor for sudden cardiac death, but it is not an extremely high-risk finding. The patient's overall clinical picture does not suggest an extremely high risk of sudden cardiac death. While the patient has a history of peripheral vascular disease and hypertension, these conditions are not typically associated with a high risk of sudden cardiac death. Therefore, sudden cardiac death is the least likely prognosis for this patient."
89,89,P0145,"Age: 57
Gender: Male 
Weight: 106 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 170/100 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension
Albumin (g/L): 40,2
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,76
Creatinine (mmol/L): 83.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,07
Potassium (mEq/L): 3,44
LDL (mmol/L): 3,09
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 431.0
Protein (g/L): 68,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,73
Urea (mg/dL): 5,7
LVEF (%): 25.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the prognosis ranking from most likely to least likely:

RANKING: 1. Survivor
REASONING: The patient is 57 years old with a history of idiopathic dilated cardiomyopathy, which indicates a pre-existing condition affecting the heart's pumping ability. However, the patient is on ACE inhibitors and loop diuretics, which are standard treatments for heart failure and hypertension. The patient's LVEF of 25% is relatively low, indicating severe heart failure, but it's not the lowest possible value. The patient's blood pressure is high, and they have hypertension, peripheral vascular disease, and diabetes, which are all risk factors for cardiovascular disease. However, the patient's Troponin level is low, indicating minimal cardiac damage. Additionally, the patient's Pro-BNP level is elevated, which suggests heart failure, but it's not excessively high. Considering these factors, the patient's prognosis is likely to be a survivor, but with a guarded outlook due to the severity of their heart failure.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 25% indicates severe heart failure, and their Pro-BNP level is elevated, suggesting heart failure. The patient's NYHA Class II indicates that they have some limitations in their physical activity but can still perform light physical activity. However, the patient's high blood pressure, peripheral vascular disease, and diabetes put them at risk for cardiovascular events. The patient's medications, including ACE inhibitors and loop diuretics, suggest that they are receiving standard treatment for heart failure, but the patient's condition may still deteriorate over time. Given the patient's severe heart failure and risk factors, pump failure death is a possible outcome, but it's not the most likely due to the patient's current treatment and relatively low Troponin level.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient has a history of idiopathic dilated cardiomyopathy and non-sustained ventricular tachycardia, which are risk factors for sudden cardiac death. However, the patient's low Troponin level and relatively low Pro-BNP level suggest that the patient does not have significant cardiac damage or acute heart failure. The patient's ECG also shows polymorphic ventricular extrasystoles, which can be a sign of cardiac arrhythmias, but the patient's overall risk factors for sudden cardiac death are not extremely high. Additionally, the patient is on ACE inhibitors and loop diuretics, which can help reduce the risk of sudden cardiac death. Considering these factors, sudden cardiac death is the least likely outcome for this patient."
90,90,P0146,"Age: 49
Gender: Male 
Weight: 85 kg
Height: 169 cm
NYHA Class: III
Blood Pressure: 90/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 40,1
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,07
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 40
Glucose (mmol/L): 5
Hemoglobin (g/L): 128.0
Potassium (mEq/L): 4,31
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 3021.0
Protein (g/L): 65,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,34
Urea (mg/dL): 5,2
LVEF (%): 19.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: 1. Survivor
REASONING: The patient has a history of enolic dilated cardiomyopathy, which is a significant risk factor for heart failure and sudden cardiac death. However, the patient is currently on optimal medical therapy with beta blockers, loop diuretics, statins, and an ACE inhibitor, which are all standard treatments for heart failure and dilated cardiomyopathy. The patient's LVEF of 19% is low, indicating significant left ventricular dysfunction, but it is not the lowest possible value, and the patient is still alive, which suggests that the current treatment is effective to some extent. Additionally, the patient's Troponin level is within normal limits, which indicates that there is no acute myocardial infarction or significant cardiac damage. The patient's Pro-BNP level is elevated, which is consistent with heart failure, but it is not extremely high, suggesting that the heart failure is not severe. Overall, considering the patient's current treatment and the absence of other high-risk factors, I predict a survivor prognosis.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 19% and history of enolic dilated cardiomyopathy make pump failure a significant risk. However, the patient's current treatment is optimal, and the patient is still alive, which suggests that the current treatment is effective to some extent. The patient's Pro-BNP level is elevated, which is consistent with heart failure, but it is not extremely high, suggesting that the heart failure is not severe. The patient's Troponin level is within normal limits, which indicates that there is no acute myocardial infarction or significant cardiac damage. While pump failure is a risk, the patient's current treatment and the absence of other high-risk factors make it less likely than sudden cardiac death.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient has a history of enolic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's LVEF of 19% indicates significant left ventricular dysfunction, which increases the risk of sudden cardiac death. The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are both risk factors for sudden cardiac death. However, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death. While sudden cardiac death is a risk, the patient's current treatment and the absence of other high-risk factors make it the least likely of the three prognoses."
91,91,P0147,"Age: 81
Gender: Female 
Weight: 50 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 120/75 mmHg
Past Medical History: Hypertropic cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 39,7
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 16,2
Hemoglobin (g/L): 131.0
Potassium (mEq/L): 3,93
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 2167.0
Protein (g/L): 67,4
T3 (pg/dL): 0,07
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,1
Urea (mg/dL): 13,1
LVEF (%): 40.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is my prognosis for the next few years:

RANKING: 1. Survivor
 REASONING: The patient is an 81-year-old female with a history of hypertrophic cardiomyopathy, diabetes, and hypertension. Despite these comorbidities, her current condition appears to be relatively stable, as indicated by her NYHA Class II status. Her LVEF of 40% suggests a reduced left ventricular function, but it is not severely impaired. The patient is on appropriate medications for her conditions, including ACE inhibitor, statins, and loop diuretics, which should help manage her symptoms and slow disease progression. Additionally, her recent troponin level is within normal limits, indicating no recent acute myocardial infarction. While her Pro-BNP level is elevated, indicating some degree of heart failure, it is not excessively high. Considering her age and comorbidities, a survivor prognosis is the most likely outcome.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's ECG shows non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, which may indicate an increased risk of arrhythmic events. However, the presence of these arrhythmias does not necessarily predict sudden cardiac death. The patient is on amiodarone, which is an anti-arrhythmic medication that should help reduce the risk of arrhythmias. Additionally, her LVEF is not severely impaired, which would be a significant risk factor for sudden cardiac death. While there is some risk, it is not the most likely outcome.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 40% indicates a reduced left ventricular function, and her Pro-BNP level is elevated, indicating some degree of heart failure. However, her NYHA Class II status suggests that her symptoms are not severe, and her medications should help manage her condition. Her creatinine level is within normal limits, indicating no significant renal impairment, which is a common complication of heart failure. While pump failure is a possibility, the patient's overall clinical picture suggests that it is the least likely outcome.

Please note that this is a medical assessment based on the provided data, and actual patient outcomes may vary."
92,92,P0150,"Age: 73
Gender: Female 
Weight: 79 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 95/50 mmHg
Past Medical History: Valvular cardiomyopathy, Hypertension
Albumin (g/L): 43,8
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 4,7
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 6,5
Hemoglobin (g/L): 135.0
Potassium (mEq/L): 3,64
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 6343.0
Protein (g/L): 63,6
T4 (ng/L): 15,5
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,78
Urea (mg/dL): 13,9
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
 REASONING: The patient is 73 years old with a history of valvular cardiomyopathy and hypertension, which suggests a pre-existing heart condition. The patient's current NYHA Class III classification indicates severe symptoms, including shortness of breath and fatigue, which is consistent with her low LVEF (20%). However, despite these risk factors, the patient's overall clinical presentation is not entirely alarming. The patient's ejection fraction is very low, but the absence of severe left ventricular hypertrophy (indicated by a normal blood pressure and no mention of left ventricular hypertrophy on the ECG) may indicate a more favorable prognosis. The patient is on appropriate medications (Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor), which are standard treatments for heart failure with reduced ejection fraction (HFrEF). The patient's BNP level is elevated, but not extremely high (6343 ng/L), which may indicate a moderate level of heart failure severity. The absence of significant elevations in liver enzymes (ALT and AST) and a relatively normal total cholesterol level suggest that the patient's condition may not be as advanced as initially thought. Additionally, the patient's hemoglobin and potassium levels are within normal limits, which is a good sign. The ECG findings of ventricular extrasystole and non-sustained ventricular tachycardia are concerning but can be managed with medication. Overall, while the patient's prognosis is guarded, the combination of her relatively stable clinical presentation, appropriate medication regimen, and lack of severe laboratory abnormalities make survivorship the most likely outcome.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's low LVEF (20%), NYHA Class III classification, and valvular cardiomyopathy put her at increased risk for sudden cardiac death. The presence of non-sustained ventricular tachycardia and ventricular extrasystole on the ECG also increases her risk. However, the patient's overall clinical presentation is not as alarming as it could be, given her relatively stable laboratory values and the fact that she is on appropriate medications. The patient's BNP level is elevated, but not extremely high, which may indicate a moderate level of heart failure severity. The absence of significant elevations in liver enzymes and a relatively normal total cholesterol level also suggest that the patient's condition may not be as advanced as initially thought. While the risk of sudden cardiac death is present, the patient's relatively stable clinical presentation and lack of severe laboratory abnormalities make survivorship a more likely outcome.

RANKING: 3. Pump Failure Death
 REASONING: The patient's low LVEF (20%) and NYHA Class III classification indicate that she has severe heart failure symptoms, which increases her risk for pump failure death. However, the patient's overall clinical presentation is not as alarming as it could be, given her relatively stable laboratory values and the fact that she is on appropriate medications. The patient's BNP level is elevated, but not extremely high, which may indicate a moderate level of heart failure severity. The absence of significant elevations in liver enzymes and a relatively normal total cholesterol level also suggest that the patient's condition may not be as advanced as initially thought. The patient's creatinine level is elevated, which may indicate some level of renal impairment, but it is not extremely high. The patient's hemoglobin and potassium levels are within normal limits, which is a good sign. While the risk of pump failure death is present, the patient's relatively stable clinical presentation and lack of severe laboratory abnormalities make survivorship a more likely outcome."
93,93,P0152,"Age: 64
Gender: Female 
Weight: 90 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 160/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,5
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 38
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 135.0
Potassium (mEq/L): 4,04
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1312.0
Protein (g/L): 68,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,95
Urea (mg/dL): 9,8
LVEF (%): 40.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here's my prognosis for the next few years:

RANKING: 1
REASONING: Survivor

The patient has a complex medical history, including ischemic dilated cardiomyopathy, diabetes, peripheral vascular disease, hypertension, and a history of myocardial infarction. However, several factors suggest a relatively favorable prognosis:

1.  The patient is currently on a comprehensive medication regimen, including ACE inhibitors (Angiotensin II Receptor Blocker), beta blockers, loop diuretics, statins, and nitrovasodilators, which are all evidence-based treatments for heart failure and ischemic heart disease.
2.  The patient's LVEF (Left Ventricular Ejection Fraction) is 40%, which, although decreased, is not severely impaired. LVEF values below 20-30% are generally associated with a poorer prognosis.
3.  The patient's BNP (B-type Natriuretic Peptide) level is elevated at 1312.0 ng/L, but not excessively high, which can indicate heart failure severity.
4.  The patient's blood pressure is within a relatively controlled range (160/70 mmHg), and the absence of signs of severe hypertension or acute coronary syndrome.
5.  The patient's hemoglobin level is within a normal range, which is a good indicator of adequate oxygen delivery to tissues.
6.  The absence of sustained ventricular tachycardia or non-sustained ventricular tachycardia on the ECG is a positive sign.
7.  The patient's TSH level is within a normal range, which is a good indicator of thyroid function.

While the patient's condition is complex and requires close monitoring, the presence of a comprehensive treatment plan, relatively controlled blood pressure, and absence of severe symptoms or acute decompensation suggest a more favorable prognosis.

RANKING: 2
REASONING: Sudden cardiac death

Sudden cardiac death is a possible prognosis, given the patient's history of ischemic dilated cardiomyopathy and the presence of polymorphic ventricular extrasystoles on the ECG. Polymorphic ventricular extrasystoles can be a marker of increased risk of sudden cardiac death, especially in patients with reduced LVEF. However, the presence of a controlled medication regimen and relatively normal hemoglobin and TSH levels mitigate this risk.

RANKING: 3
REASONING: Pump failure death

Pump failure death is less likely due to the patient's current treatment regimen and relatively controlled blood pressure. While the patient has a history of ischemic dilated cardiomyopathy and reduced LVEF, the absence of severe symptoms, controlled medication regimen, and relatively normal hemoglobin and TSH levels suggest a lower risk of pump failure.

It's essential to note that this prognosis is based on the provided data and may change with further clinical evaluation and monitoring."
94,94,P0154,"Age: 59
Gender: Male 
Weight: 96 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 42,1
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 71
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 127.0
Potassium (mEq/L): 4,28
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 706.0
Protein (g/L): 73,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,8
Urea (mg/dL): 6,3
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: 1. Sudden Cardiac Death
REASONING: The patient has a history of myocardial infarction, enolic dilated cardiomyopathy, and a left ventricular ejection fraction (LVEF) of 25%, indicating severe systolic dysfunction. The presence of polymorphic ventricular extrasystoles and a high Pro-BNP level of 706.0 ng/L suggest an increased risk of arrhythmias and heart failure. The patient's low blood pressure (90/60 mmHg) may indicate compromised cardiac output, which further increases the risk of sudden cardiac death.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 25% and high Pro-BNP level indicate severe heart failure. The patient's NYHA Class II classification suggests that the patient experiences symptoms of heart failure with moderate limitation of physical activity, which may worsen over time. The patient's weight of 96 kg and creatinine level of 113.0 mol/L suggest possible fluid overload and renal impairment, which can contribute to worsening heart failure. However, the patient's medications, including loop diuretics and ACE inhibitor, are aimed at managing these conditions, which may improve the prognosis for pump failure death.

RANKING: 3. Survivor
REASONING: Despite the patient's severe cardiac dysfunction and high risk of arrhythmias and heart failure, the patient's current treatment regimen and the lack of other significant comorbidities suggest that the patient may be able to survive for an extended period. The patient's low troponin level and normal TSH level indicate that there is no acute coronary event or thyroid dysfunction, which may have contributed to the patient's heart failure. With proper management and follow-up, the patient may be able to maintain a stable condition and survive for an extended period.

Please note that this prognosis is based on the provided data and may not reflect the actual outcome, as many factors can influence a patient's prognosis, including the effectiveness of treatment, adherence to medication, and lifestyle changes."
95,95,P0156,"Age: 53
Gender: Male 
Weight: 82 kg
Height: 182 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 40,3
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,77
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 11,6
Hemoglobin (g/L): 153.0
Potassium (mEq/L): 3,41
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 157.0
Protein (g/L): 66,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,79
Urea (mg/dL): 5,3
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: Survivor

REASONING: 

Considering the patient's data, I would rank the prognosis as a survivor for the next few years. Here's the reasoning behind this ranking:

1. Age and Gender: The patient is 53 years old, which is not extremely old for a patient with enolic dilated cardiomyopathy. Being male also increases the risk, but not excessively so.

2. NYHA Class II: The patient has a relatively mild functional impairment, which suggests that the disease is not severely limiting their daily activities.

3. Blood Pressure: The patient's blood pressure is within a relatively normal range, which is a good prognostic sign.

4. Medications: The patient is on a combination of beta blockers, digoxin, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure and dilated cardiomyopathy. This suggests that the patient is receiving appropriate medical therapy.

5. ECG findings: While the patient has ventricular extrasystoles and non-sustained ventricular tachycardia, these are relatively common findings in patients with heart failure and are not necessarily indicative of a poor prognosis.

6. LVEF: The patient's left ventricular ejection fraction (LVEF) is 35%, which is relatively low but not extremely low. Patients with an LVEF of 30-40% can still have a relatively good prognosis with appropriate medical therapy.

7. Biochemical markers: The patient's troponin level is normal, which suggests that there is no ongoing myocardial infarction. The patient's pro-BNP level is elevated, but not excessively so, which suggests that the patient is not in acute heart failure.

8. Renal function: The patient's creatinine level is slightly elevated, but not excessively so, which suggests that the patient's renal function is not severely impaired.

Based on these factors, I would rank the prognosis as a survivor for the next few years. However, it's essential to note that this is a general assessment, and the patient's actual outcome will depend on various factors, including their compliance with medication, lifestyle modifications, and any potential changes in their condition over time."
96,96,P0158,"Age: 65
Gender: Female 
Weight: 96 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 140/85 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 45,3
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 6,16
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 125.0
Potassium (mEq/L): 4,73
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 288.0
Protein (g/L): 76,8
T4 (ng/L): 18,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,18
Urea (mg/dL): 8,5
LVEF (%): 39.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's a prognosis for the next few years:

RANKING: 1
REASONING: The patient is currently 65 years old with a history of idiopathic dilated cardiomyopathy, hypertension, and dyslipemia. Despite this, she is being treated with a combination of medications that are commonly used to manage heart failure, including angiotensin II receptor blockers, beta blockers, loop diuretics, spironolactone, and statins. Her LVEF is 39%, which is within the range of moderate heart failure. However, her Pro-BNP level is elevated at 288 ng/L, indicating increased ventricular wall stress and potential fluid overload. The presence of monomorphic ventricular extrasystoles on the ECG is a common finding in patients with heart failure, but it does not significantly impact the prognosis. The patient's overall clinical presentation and treatment regimen suggest that she is being managed for heart failure, and with appropriate adherence to her medication and lifestyle changes, it is likely that she will continue to survive with some degree of functional impairment.

RANKING: 2
REASONING: Sudden cardiac death is a potential risk for this patient due to her history of idiopathic dilated cardiomyopathy and the presence of an elevated Pro-BNP level. However, the fact that she is being treated with beta blockers and has no history of sustained ventricular tachycardia or other high-risk arrhythmias makes sudden cardiac death less likely. Additionally, her LVEF is not severely depressed, and her other laboratory values do not suggest acute cardiac decompensation.

RANKING: 3
REASONING: Pump failure death is the least likely outcome for this patient due to her current treatment regimen and the fact that she is being managed for heart failure. While her LVEF is only 39%, she is not showing signs of acute cardiac decompensation, and her Pro-BNP level is not extremely elevated. Her other laboratory values, including her creatinine level, are within normal limits, suggesting that she is not experiencing significant renal impairment. The combination of her medications and her overall clinical presentation make pump failure death a less likely outcome.

Note: The prognosis is based on the provided data and may not reflect the patient's actual outcome, which can be influenced by various factors, including adherence to treatment, lifestyle changes, and the presence of other comorbidities."
97,97,P0162,"Age: 76
Gender: Female 
Weight: 71 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 150/100 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 37,7
ALT or GPT (IU/L): 85.0
AST or GOT (IU/L): 63.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 105.0
Gamma-glutamil transpeptidase (IU/L): 199
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1
Potassium (mEq/L): 3,84
LDL (mmol/L): 2,85
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 6915.0
Protein (g/L): 69,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,09
Urea (mg/dL): 8,1
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: Despite the patient's advanced age (76 years) and significant comorbidities, including idiopathic dilated cardiomyopathy, hypertension, and dyslipemia, the patient's current medication regimen and the absence of acute cardiac ischemia (Troponin 0.01 ng/mL) suggest that she is receiving adequate treatment for her conditions. The patient's LVEF of 30% indicates severe left ventricular dysfunction, but the use of ACE inhibitors and loop diuretics may help manage her symptoms and slow disease progression. The patient's recent ECG findings, including non-sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia, indicate a high risk of arrhythmias, but these are being managed with medication. The patient's Pro-BNP level of 6915 ng/L is elevated, indicating heart failure, but the patient's symptoms and treatment plan suggest that she is being managed accordingly. Given the patient's current treatment and the absence of acute cardiac ischemia, I predict that the most likely outcome is survival.

RANKING: Pump Failure Death

REASONING: The patient's LVEF of 30% indicates severe left ventricular dysfunction, which increases the risk of pump failure. The patient's NYHA Class III classification also suggests that she has significant symptoms of heart failure, which may limit her ability to perform daily activities. The patient's elevated Pro-BNP level and creatinine level (105.0 mmol/L) suggest that she may have underlying kidney dysfunction, which can contribute to worsening heart failure. However, the patient's current treatment plan, including the use of ACE inhibitors and loop diuretics, may help manage her symptoms and slow disease progression. While pump failure is a possible outcome, the patient's current treatment and the absence of acute cardiac ischemia make it less likely than sudden cardiac death.

RANKING: Sudden Cardiac Death

REASONING: The patient's ECG findings, including non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, suggest a high risk of arrhythmias, which can lead to sudden cardiac death. The patient's LVEF of 30% and elevated Pro-BNP level also suggest significant cardiac dysfunction, which may increase the risk of sudden cardiac death. However, the patient's current treatment plan, including the use of ACE inhibitors and loop diuretics, may help manage her symptoms and reduce the risk of arrhythmias. Additionally, the patient's lack of acute cardiac ischemia (Troponin 0.01 ng/mL) suggests that she is not at high risk of acute coronary events, which can also contribute to sudden cardiac death. Therefore, while sudden cardiac death is a possible outcome, it is less likely than pump failure death due to the patient's current treatment and the absence of acute cardiac ischemia."
98,98,P0163,"Age: 71
Gender: Female 
Weight: 70 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 40,5
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,43
Creatinine (mmol/L): 89.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,3
Potassium (mEq/L): 3,82
LDL (mmol/L): 4,43
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 469.0
Protein (g/L): 72,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,7
Urea (mg/dL): 4,8
LVEF (%): 55.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Survivor
REASONING: The patient is 71 years old with a history of hypertensive cardiomyopathy and hypertension, which can be managed with current medications (Beta Blockers, Loop Diuretics, and ACE Inhibitor). The patient's left ventricular ejection fraction (LVEF) is 55%, which is within the normal range (50-70%). Although the patient has elevated Pro-BNP levels (469.0 ng/L), which indicates some degree of heart failure, the patient's NYHA Class II suggests that the heart failure symptoms are not severe. The patient's hemoglobin level is slightly elevated (125.0 g/L), which may indicate polycythemia, but it is not a significant concern for the prognosis. The patient's ECG does not show any signs of ventricular arrhythmias, which reduces the risk of sudden cardiac death. Overall, the patient's condition can be managed with current medications and lifestyle modifications, making a survivor prognosis the most likely outcome.

RANKING: Pump Failure Death
REASONING: The patient's LVEF is 55%, which is near the lower limit of the normal range, indicating some degree of left ventricular dysfunction. The patient's Pro-BNP levels are elevated, which suggests that the patient has some degree of heart failure. However, the patient's NYHA Class II suggests that the heart failure symptoms are not severe, and the patient is not showing signs of acute decompensated heart failure. The patient's medications, including Beta Blockers, Loop Diuretics, and ACE Inhibitor, are appropriate for managing heart failure. While pump failure death is a possible outcome, it is less likely due to the patient's relatively stable condition and current management.

RANKING: Sudden Cardiac Death
REASONING: The patient's ECG does not show any signs of ventricular arrhythmias, which reduces the risk of sudden cardiac death. The patient's LVEF is 55%, which is within the normal range, and the patient's Pro-BNP levels, while elevated, are not significantly high. The patient's medications, including Beta Blockers, are appropriate for reducing the risk of sudden cardiac death. The patient's overall condition is stable, and there is no indication of acute coronary syndrome or other high-risk conditions that would increase the risk of sudden cardiac death. Therefore, sudden cardiac death is the least likely outcome."
99,99,P0164,"Age: 78
Gender: Male 
Weight: 92 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 34,4
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,58
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 133
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,25
Potassium (mEq/L): 4,44
LDL (mmol/L): 1,89
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2104.0
Protein (g/L): 62,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,84
Urea (mg/dL): 8,1
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Pump failure death
REASONING: The patient has a history of ischemic dilated cardiomyopathy with a left ventricular ejection fraction (LVEF) of 35%, indicating a significantly reduced heart function. The elevated Pro-BNP level of 2104 ng/L also suggests heart failure with reduced ejection fraction (HFrEF). The patient's NYHA Class II classification indicates that the patient experiences symptoms of heart failure with mild limitation of physical activity. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG further increases the risk of sudden cardiac death. However, the most immediate risk for this patient appears to be pump failure due to the advanced stage of heart failure and the patient's symptoms.

RANKING: 2. Sudden cardiac death
REASONING: The patient's ECG findings, including non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, increase the risk of sudden cardiac death. The patient's history of myocardial infarction and ischemic dilated cardiomyopathy also contribute to this risk. However, the presence of a functioning beta-blocker, ACE inhibitor, and statin therapy, which are known to reduce the risk of sudden cardiac death, may mitigate this risk to some extent.

RANKING: 3. Survivor
REASONING: While the patient has a significant burden of cardiovascular disease, the patient is receiving appropriate medical therapy for heart failure and ischemic cardiomyopathy. The patient's NYHA Class II classification suggests that the patient has some functional capacity, and the patient's hemoglobin level is within a relatively normal range, indicating adequate oxygen delivery to tissues. The patient's weight is also within a relatively normal range, which may indicate that the patient is not experiencing significant fluid overload. However, the patient's LVEF of 35% and elevated Pro-BNP level suggest that the patient's heart function is compromised, and the patient's overall prognosis is guarded."
100,100,P0165,"Age: 76
Gender: Female 
Weight: 70 kg
Height: 153 cm
NYHA Class: II
Blood Pressure: 213/110 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41,6
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,67
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,28
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,2
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 366.0
Protein (g/L): 75,6
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,92
Urea (mg/dL): 8,4
LVEF (%): 45.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's a ranking of the possible prognoses from most likely to least likely:

RANKING: Survivor
 REASONING: The patient's age, gender, and past medical history suggest a high risk for cardiovascular disease, but the current treatment plan and laboratory results indicate a relatively stable condition. The patient is on a combination of medications that are commonly used to manage hypertensive cardiomyopathy and dyslipemia, including an angiotensin II receptor blocker, loop diuretics, statins, and an ACE inhibitor. The patient's LVEF (left ventricular ejection fraction) is 45%, which is below the normal range (50-70%), but it's not extremely low. The absence of significant troponin elevation, non-sustained ventricular tachycardia, and bradycardia on the ECG also suggest that the patient is not in immediate danger of cardiac arrest. While the patient's blood pressure is elevated, the presence of a diuretic in the treatment plan may help manage this. Additionally, the patient's albumin and protein levels are within the normal range, which suggests that the liver function is not significantly impaired. Overall, these factors suggest that the patient is more likely to survive in the short to medium term.

RANKING: Pump Failure Death
 REASONING: The patient's LVEF of 45% is a significant concern, as it indicates that the heart is not pumping efficiently. This, combined with the patient's history of hypertensive cardiomyopathy, suggests that the patient may be at risk for pump failure. However, the patient's current treatment plan and laboratory results suggest that the condition is being managed. The patient's creatinine level is slightly elevated, which may indicate some degree of kidney dysfunction, but it's not severe enough to suggest that the patient is at immediate risk for pump failure.

RANKING: Sudden Cardiac Death
 REASONING: While the patient has a history of hypertensive cardiomyopathy and an elevated blood pressure, the ECG results do not suggest any immediate risk for sudden cardiac death. The absence of non-sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, and bradycardia on the ECG reduces the likelihood of sudden cardiac death. Additionally, the patient's troponin level is very low, which suggests that there is no significant myocardial damage. While the patient's LVEF is below the normal range, it's not extremely low, and the patient is on a treatment plan that includes medications that can help manage the condition."
101,101,P0166,"Age: 75
Gender: Female 
Weight: 68 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 190/80 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 42,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,16
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 131.0
Potassium (mEq/L): 4,08
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 746.0
Protein (g/L): 75,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,18
Urea (mg/dL): 7,9
LVEF (%): 69.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1

REASONING: Based on the provided patient data, I rank the prognosis as survivor with the highest likelihood. The patient is 75 years old with valvular cardiomyopathy, which is a significant underlying condition that can lead to heart failure. However, several factors contribute to a more favorable prognosis.

1.  The patient's LVEF (Left Ventricular Ejection Fraction) is 69%, which is within the normal range. This indicates that the heart is pumping blood efficiently, reducing the risk of pump failure.
2.  The patient is on a comprehensive medication regimen, including beta blockers, digoxin, loop diuretics, and an ACE inhibitor, which are all standard treatments for heart failure and valvular cardiomyopathy.
3.  The patient's Pro-BNP level is 746.0 ng/L, which is elevated but not excessively high. Elevated Pro-BNP levels can indicate heart failure, but a level of 746.0 ng/L is not extremely high, suggesting that the patient's heart failure is not severe.
4.  The patient's creatinine level is 82.0 mmol/L, which is slightly elevated, but not excessively high. This suggests that the patient's kidneys are functioning relatively well, which is a good sign.
5.  The patient's hemoglobin level is 131.0 g/L, which is within the normal range. Anemia can worsen heart failure, so this is a positive factor.
6.  The patient's potassium level is 4.08 mEq/L, which is slightly low. Potassium levels can affect heart function, but a level of 4.08 mEq/L is not critically low.
7.  The patient's blood pressure is 190/80 mmHg, which is slightly elevated. However, the patient is on medications that can help control blood pressure, and the systolic blood pressure is not excessively high.

Considering these factors, the patient's overall condition is stable, and with proper management, the likelihood of survival is higher. The risk of sudden cardiac death and pump failure death is lower due to the patient's relatively well-managed heart failure and normal LVEF.

RANKING: 2

REASONING: Sudden cardiac death is the second most likely prognosis. The patient has valvular cardiomyopathy, which can increase the risk of arrhythmias, including ventricular tachycardia and fibrillation, which can lead to sudden cardiac death. The patient's Pro-BNP level is elevated, which can indicate heart failure and increased risk of arrhythmias. Additionally, the patient's polymorphic ventricular extrasystoles on the ECG suggest an increased risk of arrhythmias. However, the patient's LVEF is within the normal range, and the patient is on medications that can help prevent arrhythmias.

RANKING: 3

REASONING: Pump failure death is the least likely prognosis. The patient's LVEF is 69%, which is within the normal range, indicating that the heart is pumping blood efficiently. The patient's creatinine level is slightly elevated, but not excessively high, suggesting that the kidneys are functioning relatively well. The patient's hemoglobin level is within the normal range, and the patient is on medications that can help manage heart failure. While the patient's Pro-BNP level is elevated, it is not excessively high, and the patient's overall condition is stable."
102,102,P0167,"Age: >89
Gender: Male 
Weight: 78 kg
Height: 164 cm
NYHA Class: III
Blood Pressure: 150/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 2,92
Creatinine (mmol/L): 129.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 114.0
Potassium (mEq/L): 4,2
Sodium (mEq/L): 147.0
Pro-BNP (ng/L): 3724.0
Protein (g/L): 65
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,45
Urea (mg/dL): 9,6
LVEF (%): 60.0
Medications: Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Please note that this is a complex task and the actual outcome may vary depending on various factors, including the patient's response to treatment and potential changes in their condition.

RANKING: 1. Survivor
REASONING: Despite the patient's advanced age and history of ischemic dilated cardiomyopathy and myocardial infarction, there are several factors that suggest a more favorable prognosis. The patient's LVEF is 60%, which is within the moderate range, indicating that the heart is still pumping blood effectively. The patient is on optimal medical therapy with loop diuretics, ACE inhibitors, and nitrovasodilators, which are standard treatments for heart failure. The patient's Troponin level is normal, indicating that there is no current acute coronary syndrome. The patient's Pro-BNP level is elevated, but not excessively high, which may indicate some degree of heart failure but not severe. Additionally, the patient's hemoglobin and potassium levels are within normal ranges, which suggests that there is no significant anemia or electrolyte imbalance. The patient's age is a concern, but the fact that they are still alive at 89 years old suggests that they have a certain degree of resilience.

RANKING: 2. Pump failure death
REASONING: The patient's history of ischemic dilated cardiomyopathy and myocardial infarction, combined with their current symptoms of heart failure (NYHA Class III), make pump failure a possible outcome. The patient's LVEF is 60%, which is within the moderate range, but may not be sufficient to prevent progression to more severe heart failure. The patient's elevated Pro-BNP level and low albumin level may indicate some degree of heart failure. However, the patient is on optimal medical therapy, which may help to slow the progression of the disease.

RANKING: 3. Sudden cardiac death
REASONING: While the patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, the fact that their Troponin level is normal and they are not experiencing any acute coronary syndrome makes sudden cardiac death less likely. Additionally, the patient's LVEF is 60%, which is within the moderate range, indicating that the heart is still pumping blood effectively. The patient's ECG shows monomorphic ventricular extrasystoles, but no ventricular tachycardia or bradycardia, which are more common causes of sudden cardiac death."
103,103,P0168,"Age: 88
Gender: Female 
Weight: 66 kg
Height: 153 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 37,9
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,07
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 137.0
Potassium (mEq/L): 3,2
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 237.0
Protein (g/L): 70,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,36
Urea (mg/dL): 14,1
LVEF (%): 60.0
Medications: Calcium Channel Blocker, Angiotensin II Receptor Blocker, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: 

The patient is an 88-year-old female with a history of hypertensive cardiomyopathy. Despite her advanced age, her LVEF (left ventricular ejection fraction) is 60%, which indicates that her heart is still functioning relatively well. She is on a regimen of medications that are commonly used to manage heart failure and hypertension, including a calcium channel blocker, an angiotensin II receptor blocker, loop diuretics, and an ACE inhibitor. Her blood pressure is well-controlled at 120/60 mmHg, and her albumin levels are within a relatively normal range (37.9 g/L). 

The patient's troponin levels are low (0.01 ng/mL), indicating minimal cardiac damage. Her pro-BNP (brain natriuretic peptide) level is elevated at 237.0 ng/L, which is a marker of heart failure, but it is not excessively high. The patient's hemoglobin level is within a normal range (137.0 g/L), and her urea levels are also within a normal range (14.1 mg/dL). 

The patient's ECG does show polymorphic ventricular extrasystoles, but this is a relatively common finding in patients with heart disease and is not necessarily a predictor of poor outcome. Overall, the patient's clinical picture suggests that she is well-managed and has a relatively good prognosis. 

The other two prognoses, sudden cardiac death and pump failure death, are less likely due to the patient's well-controlled blood pressure, normal LVEF, and the absence of other high-risk features such as sustained ventricular tachycardia or severely elevated troponin levels. While the patient is elderly and has a history of heart disease, her current clinical status suggests that she is likely to survive for the next few years with continued management of her heart failure and hypertension."
104,104,P0169,"Age: 49
Gender: Male 
Weight: 69 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,74
Creatinine (mmol/L): 273.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 113.0
Potassium (mEq/L): 4,63
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 17620.0
Protein (g/L): 70
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,49
Urea (mg/dL): 24,2
LVEF (%): 23.0
Medications: Loop Diuretics, Statins, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: Based on the provided patient data, the patient's overall prognosis is more likely to be a survivor due to the following factors:

1. NYHA Class II: The patient is classified as NYHA Class II, which indicates that the patient experiences symptoms with moderate physical activity, but is still able to perform daily activities without severe limitations. This suggests that the patient's heart condition is not severe enough to significantly impact their daily life.
2. Medications: The patient is on loop diuretics, statins, hydralazine, and nitrovasodilator, which are all medications commonly used to manage heart failure and hypertension. These medications suggest that the patient's condition is being actively managed and treated.
3. LVEF of 23%: Although the patient's left ventricular ejection fraction (LVEF) is low at 23%, it is not the lowest possible value (which would be 0%). This suggests that the patient's heart is still functioning, albeit inefficiently.
4. Absence of severe laboratory abnormalities: The patient's laboratory values, such as creatinine and urea levels, are not severely elevated, which suggests that the patient's kidneys are functioning relatively well.
5. Low troponin levels: The patient's troponin levels are low, which suggests that there is not significant ongoing myocardial damage.
6. ECG findings: While the patient has some arrhythmias, including ventricular extrasystoles and non-sustained ventricular tachycardia, these are not life-threatening and are being managed with medications.

While the patient's ischemic dilated cardiomyopathy and low LVEF do suggest that the patient is at risk for cardiac complications, the presence of effective treatment and the absence of severe laboratory abnormalities and life-threatening arrhythmias suggest that the patient is more likely to survive in the next few years.

RANKING: Sudden cardiac death

REASONING: Sudden cardiac death is a possible prognosis for this patient due to the following factors:

1. Low LVEF: The patient's LVEF of 23% is significantly below the normal range, which increases the risk of sudden cardiac death.
2. Ischemic dilated cardiomyopathy: This condition is a known risk factor for sudden cardiac death.
3. Non-sustained ventricular tachycardia: The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death.
4. Polymorphic ventricular extrasystoles: The patient's ECG also shows polymorphic ventricular extrasystoles, which can be a sign of electrical instability in the heart.

However, the patient's overall prognosis is less likely to be sudden cardiac death due to the presence of effective treatment and the absence of severe laboratory abnormalities.

RANKING: Pump failure death

REASONING: Pump failure death is the least likely prognosis for this patient due to the following factors:

1. Effective treatment: The patient is on medications that are commonly used to manage heart failure, which suggests that their condition is being actively managed.
2. Absence of severe laboratory abnormalities: The patient's laboratory values, such as creatinine and urea levels, are not severely elevated, which suggests that the patient's kidneys are functioning relatively well.
3. Low troponin levels: The patient's troponin levels are low, which suggests that there is not significant ongoing myocardial damage.
4. ECG findings: While the patient has some arrhythmias, these are not life-threatening and are being managed with medications.

While the patient's low LVEF and ischemic dilated cardiomyopathy do suggest that they are at risk for cardiac complications, the presence of effective treatment and the absence of severe laboratory abnormalities and life-threatening arrhythmias suggest that pump failure death is the least likely prognosis."
105,105,P0170,"Age: 73
Gender: Female 
Weight: 64 kg
Height: 152 cm
NYHA Class: II
Blood Pressure: 210/110 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 39,2
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 4,9
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 60
Glucose (mmol/L): 10,9
Hemoglobin (g/L): 107.0
HDL (mmol/L): 1,04
Potassium (mEq/L): 4,03
LDL (mmol/L): 2,96
Sodium (mEq/L): 139.0
Protein (g/L): 74,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,19
Urea (mg/dL): 8,4
LVEF (%): 70.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's my prognosis for the next few years:

RANKING: 1. Survivor
 REASONING: The patient is 73 years old with a history of hypertensive cardiomyopathy, diabetes, and hypertension. However, the patient's LVEF is 70%, which is within the normal range. The patient is already on a regimen of medications that include ACE inhibitors, beta blockers, and diuretics, which are beneficial for heart failure management and hypertension. The patient also has a relatively low troponin level, indicating minimal myocardial damage. The presence of ventricular extrasystoles is a common finding in the general population and does not necessarily indicate a high risk of sudden cardiac death. The absence of non-sustained ventricular tachycardia and ventricular tachycardia further reduces the risk of sudden cardiac death. Considering the patient's current medication regimen and the absence of high-risk features, the likelihood of the patient surviving the next few years is high.

RANKING: 2. Pump Failure Death
 REASONING: The patient's history of hypertensive cardiomyopathy and hypertension increases the risk of heart failure progression. The patient's LVEF is within the normal range, but it may be a false negative, as the patient is on beta blockers, which can mask the true LVEF. The patient's creatinine level is elevated, indicating some degree of renal impairment, which can be a marker of advanced heart failure. The patient's albumin level is slightly low, which may indicate some degree of liver dysfunction, which can be a sign of advanced heart failure. While the patient is on a regimen of medications that can help manage heart failure, the patient's history and laboratory values suggest a high risk of pump failure death.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient's history of hypertensive cardiomyopathy and hypertension increases the risk of sudden cardiac death. However, the patient's LVEF is within the normal range, and the patient is on a regimen of medications that can help prevent sudden cardiac death, such as beta blockers and ACE inhibitors. The absence of non-sustained ventricular tachycardia and ventricular tachycardia further reduces the risk of sudden cardiac death. The presence of ventricular extrasystoles is a common finding in the general population and does not necessarily indicate a high risk of sudden cardiac death. Therefore, while the patient has some risk factors for sudden cardiac death, the likelihood of sudden cardiac death is lower compared to pump failure death."
106,106,P0171,"Age: 75
Gender: Male 
Weight: 76 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Toxic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 121.0
Potassium (mEq/L): 4,43
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 10060.0
Protein (g/L): 67,9
Troponin (ng/mL): 0,14
TSH (mIU/L): 0,74
Urea (mg/dL): 9
LVEF (%): 20.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: 1. Survivor
REASONING: Despite the patient's advanced age and history of toxic dilated cardiomyopathy, the current medication regimen, which includes a loop diuretic and an ACE inhibitor, suggests that the patient's condition is being managed to some extent. The low LVEF of 20% indicates severe left ventricular dysfunction, but the patient is still alive and not in an advanced stage of heart failure. The Pro-BNP level of 10060.0 ng/L is elevated, indicating some degree of heart failure, but it is not extremely high, which could suggest some level of compensation. Additionally, the patient's troponin level is within normal limits, indicating that there is no acute myocardial infarction. The absence of sustained ventricular tachycardia and other life-threatening arrhythmias on the ECG also suggests that the patient's heart function is still relatively stable. Considering these factors, a survivor prognosis seems the most likely.

RANKING: 2. Pump Failure Death
REASONING: Given the patient's low LVEF of 20% and elevated Pro-BNP level, there is a significant risk of pump failure. The patient's history of toxic dilated cardiomyopathy and dyslipemia also increases the risk of progressive heart failure. However, the patient's current medication regimen and the absence of acute myocardial infarction or other life-threatening arrhythmias suggest that the patient's condition is still manageable. Therefore, pump failure death is a possible but less likely prognosis compared to sudden cardiac death.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's history of toxic dilated cardiomyopathy and low LVEF increase the risk of sudden cardiac death. However, the absence of sustained ventricular tachycardia and other life-threatening arrhythmias on the ECG, as well as the patient's current medication regimen, suggests that the risk of sudden cardiac death is relatively low. The patient's Pro-BNP level is elevated, indicating some degree of heart failure, but it is not extremely high, which could suggest some level of compensation. Therefore, sudden cardiac death is the least likely prognosis."
107,107,P0173,"Age: 83
Gender: Female 
Weight: 69 kg
Height: 151 cm
NYHA Class: II
Blood Pressure: 105/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 39,7
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 108.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 112.0
Potassium (mEq/L): 4,49
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 3532.0
Protein (g/L): 65,4
T4 (ng/L): 23,5
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,1
Urea (mg/dL): 8,4
LVEF (%): 28.0
Medications: Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor

REASONING: The patient's age and history of ischemic dilated cardiomyopathy and myocardial infarction are risk factors for cardiac disease, but the patient's current NYHA Class II suggests that she is not severely symptomatic at the moment. The use of loop diuretics, ACE inhibitor, and nitrovasodilator medications indicates that her condition is being managed. Although her LVEF is low at 28%, it is not extremely low, and her BNP level of 3532 ng/L is elevated but not extremely high. The absence of sustained ventricular tachycardia, bradycardia, and other life-threatening arrhythmias on the ECG is a positive sign. The patient's potassium level of 4.49 mEq/L is within a relatively normal range, which is also a positive sign. While her creatinine level is slightly elevated, her urea level is normal, which suggests that her renal function is not severely compromised. Overall, these factors suggest that the patient is at a relatively lower risk for sudden cardiac death and pump failure death compared to survivorship.

RANKING: 2. Sudden cardiac death

REASONING: The patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases her risk of sudden cardiac death. The presence of polymorphic ventricular extrasystoles on the ECG is a risk factor for sudden cardiac death. The patient's low LVEF of 28% also increases her risk of sudden cardiac death. However, the absence of sustained ventricular tachycardia and bradycardia on the ECG is a positive sign. The patient's BNP level is elevated, which may indicate heart failure, but it is not extremely high. The patient's potassium level is within a relatively normal range, which is also a positive sign. Overall, while the patient's risk factors for sudden cardiac death are present, they are not extremely high, and her overall condition is being managed.

RANKING: 3. Pump failure death

REASONING: The patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases her risk of pump failure death. The patient's low LVEF of 28% and elevated BNP level of 3532 ng/L suggest that she has significant heart failure. The patient's creatinine level is slightly elevated, which may indicate renal dysfunction, which can be a complication of heart failure. However, the patient's urea level is normal, which suggests that her renal function is not severely compromised. The patient's use of loop diuretics and ACE inhibitor medications indicates that her condition is being managed. The absence of sustained ventricular tachycardia and bradycardia on the ECG is a positive sign. Overall, while the patient's risk factors for pump failure death are present, they are not extremely high, and her overall condition is being managed."
108,108,P0174,"Age: 79
Gender: Female 
Weight: 66 kg
Height: 150 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 37
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 10
Hemoglobin (g/L): 111.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 5,6
LDL (mmol/L): 2,02
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 505.0
Protein (g/L): 81
T3 (pg/dL): 0,03
T4 (ng/L): 27
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,16
Urea (mg/dL): 21,63
LVEF (%): 70.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",survivor,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely:

RANKING: Survivor

REASONING: The patient is 79 years old with a history of hypertensive cardiomyopathy, diabetes, dyslipemia, and myocardial infarction. However, the patient's left ventricular ejection fraction (LVEF) is 70%, which is within the normal range, indicating preserved cardiac function. The patient is also on a treatment plan that includes medications for diabetes, hypertension, and dyslipidemia, which suggests that the patient's conditions are being actively managed. The patient's blood pressure is within a relatively normal range, and the pro-BNP level is elevated but not extremely high. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG also suggests that the patient's cardiac rhythm is relatively stable. While the patient has a history of myocardial infarction, the troponin level is very low, indicating minimal cardiac damage. Considering these factors, the most likely prognosis for the patient is survival, assuming that the patient continues to adhere to their treatment plan and makes lifestyle modifications to manage their conditions.

REASONING FOR SUDDEN CARDIAC DEATH: Sudden cardiac death is a possible prognosis, but it is less likely due to the patient's preserved LVEF and the absence of severe arrhythmias on the ECG. However, the patient's age, history of myocardial infarction, and elevated pro-BNP level increase the risk of sudden cardiac death.

REASONING FOR PUMP FAILURE DEATH: Pump failure death is the least likely prognosis due to the patient's preserved LVEF of 70%. While the patient has a history of hypertensive cardiomyopathy, the LVEF is within the normal range, indicating that the patient's heart is functioning relatively well. Additionally, the patient is on medications that help manage their cardiac function, such as ACE inhibitors and beta blockers."
109,109,P0175,"Age: 48
Gender: Female 
Weight: 69 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,86
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 572.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 27
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,91
Urea (mg/dL): 3,66
LVEF (%): 42.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor

REASONING: The patient has a complex medical history with ischemic dilated cardiomyopathy and a previous myocardial infarction. However, she is currently receiving optimal medical therapy, including beta blockers, loop diuretics, statins, and an ACE inhibitor, which are all standard treatments for heart failure and ischemic heart disease. Her LVEF is 42%, which is below the normal range but not extremely low, suggesting that her heart function is still somewhat preserved. Additionally, her blood pressure is well-controlled, and her troponin levels are within normal limits. Her pro-BNP level is elevated at 572 ng/L, which indicates some degree of heart failure, but it is not extremely high. The patient's hemoglobin and potassium levels are within normal limits, and her renal function is relatively preserved. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on ECG suggests that her heart rhythm is relatively stable. Given these factors, the most likely prognosis for this patient is survival, assuming she adheres to her medication regimen and makes lifestyle modifications to manage her heart failure and other comorbidities.

RANKING: 2. Sudden Cardiac Death

REASONING: While the patient has a history of ischemic dilated cardiomyopathy and a previous myocardial infarction, her current ECG does not show any signs of severe arrhythmias, and her troponin levels are within normal limits. Her LVEF is 42%, which is below the normal range but not extremely low. However, the presence of monomorphic ventricular extrasystoles on ECG suggests that she may be at risk for arrhythmias, which could potentially lead to sudden cardiac death. Her pro-BNP level is elevated, indicating some degree of heart failure, but it is not extremely high. The patient's hemoglobin and potassium levels are within normal limits, and her renal function is relatively preserved. While the risk of sudden cardiac death is a concern, it is not the most likely outcome given her relatively stable heart rhythm and well-controlled blood pressure.

RANKING: 3. Pump Failure Death

REASONING: The patient's LVEF is 42%, which is below the normal range, indicating some degree of left ventricular dysfunction. Her pro-BNP level is elevated, which suggests that she has some degree of heart failure. However, her renal function is relatively preserved, and her hemoglobin and potassium levels are within normal limits. The patient is receiving optimal medical therapy for heart failure, including beta blockers, loop diuretics, statins, and an ACE inhibitor. While the patient's ischemic dilated cardiomyopathy and previous myocardial infarction increase her risk of pump failure death, her current clinical status suggests that this outcome is less likely than sudden cardiac death. The patient's relatively stable ECG and well-controlled blood pressure also suggest that she is at lower risk for pump failure death compared to sudden cardiac death."
110,110,P0177,"Age: 76
Gender: Male 
Weight: 90 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 110/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,69
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 110.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,65
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 948.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 26
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,29
Urea (mg/dL): 6,82
LVEF (%): 43.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor

REASONING: Given the patient's age, NYHA Class III, and history of ischemic dilated cardiomyopathy, I would expect a higher risk of adverse outcomes. However, the patient's current medications, including beta blockers, ACE inhibitor, and spironolactone, suggest that they are being treated for heart failure and hypertension. The patient's LVEF of 43% indicates some degree of preserved left ventricular function, which is a positive sign.

The patient's low albumin level (39 g/L) may indicate malnutrition or liver dysfunction, but it is not a strong predictor of cardiac outcome. The slightly elevated liver enzymes (ALT and AST) could be related to the patient's history of dyslipemia or other non-cardiac causes.

The patient's blood pressure is relatively well-controlled, with a systolic pressure of 110 mmHg, which is lower than the average for someone of his age. The low TSH level (3.29 mIU/L) suggests that the patient is not hypothyroid, which is a risk factor for heart failure.

The patient's Pro-BNP level is elevated at 948 ng/L, which is consistent with heart failure, but not excessively high. The patient's troponin level is normal, which suggests that there is no acute coronary syndrome.

Considering the patient's overall profile, I believe that the most likely outcome is survival over the next few years, given the patient's current treatment and the fact that their condition is being managed. However, it is essential to continue monitoring the patient's condition and adjust treatment as needed to prevent adverse outcomes.

RANKING: 2. Pump Failure Death

REASONING: Pump failure death is a possible outcome in this patient due to their history of ischemic dilated cardiomyopathy and reduced LVEF (43%). The patient's NYHA Class III indicates that they experience symptoms of heart failure, and their Pro-BNP level is elevated, which is consistent with heart failure.

However, the patient's current treatment regimen includes medications that are commonly used to manage heart failure, such as beta blockers, ACE inhibitor, and spironolactone. These medications have been shown to improve survival and reduce hospitalization rates in patients with heart failure.

While the patient's LVEF is lower than the average for someone without heart failure, it is not extremely low, and the patient's overall condition appears to be stable. Therefore, while pump failure death is a possible outcome, it is less likely than survivor.

RANKING: 3. Sudden Cardiac Death

REASONING: Sudden cardiac death is a less likely outcome in this patient due to their current treatment regimen, which includes a beta blocker and an ACE inhibitor. These medications have been shown to reduce the risk of sudden cardiac death in patients with heart failure.

The patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the patient's LVEF is not extremely low, and their overall condition appears to be stable.

Additionally, the patient's history of myocardial infarction and ischemic dilated cardiomyopathy may increase their risk of sudden cardiac death, but their current treatment regimen and relatively well-controlled blood pressure reduce this risk.

Therefore, while sudden cardiac death is a possible outcome, it is the least likely of the three options."
111,111,P0179,"Age: 74
Gender: Male 
Weight: 98 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,85
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 38
Glucose (mmol/L): 9,4
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,69
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 408.0
Protein (g/L): 75
T3 (pg/dL): 0,03
T4 (ng/L): 26
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,02
Urea (mg/dL): 6,32
LVEF (%): 29.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely.

RANKING: 1. Survivor
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, myocardial infarction, and is currently taking medications such as beta blockers, loop diuretics, statins, and an ACE inhibitor. These medications are commonly used to manage heart failure and reduce the risk of cardiac events. The patient's LVEF of 29% indicates reduced cardiac function, but it is not extremely low. The presence of non-sustained ventricular tachycardia is concerning, but the absence of sustained ventricular tachycardia or bradycardia is a positive sign. The patient's blood pressure is well-controlled, and the albumin and hemoglobin levels are within normal limits. While the elevated Pro-BNP level suggests some degree of heart failure, the overall clinical picture suggests that the patient is receiving appropriate treatment and is likely to survive.

RANKING: 2. Sudden cardiac death
 REASONING: The patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of sudden cardiac death. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles also suggests an increased risk of arrhythmias. However, the patient's medications and controlled blood pressure reduce this risk. The patient's LVEF of 29% is relatively low, but it is not extremely low, which reduces the likelihood of sudden cardiac death.

RANKING: 3. Pump failure death
 REASONING: The patient's LVEF of 29% indicates significant cardiac dysfunction, and the elevated Pro-BNP level suggests that the patient is experiencing some degree of heart failure. However, the patient's NYHA class is II, which suggests that the heart failure is not severe. The patient is taking medications that are commonly used to manage heart failure, and the absence of significant electrolyte imbalances or renal dysfunction reduces the risk of pump failure. While the patient's creatinine level is elevated, it is not extremely high, and the patient's urea level is within normal limits. Overall, while pump failure is a possible outcome, it is less likely than sudden cardiac death given the patient's controlled blood pressure and the effectiveness of their current treatment regimen."
112,112,P0181,"Age: 69
Gender: Male 
Weight: 100 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 110/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,84
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 273.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 24
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,83
Urea (mg/dL): 8,49
LVEF (%): 39.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

Given the patient's profile, I would rank the prognosis as Survivor, followed by Sudden Cardiac Death, and then Pump Failure Death. Here's why:

1. Survivor: The patient is 69 years old, which is a relatively advanced age, but not uncommon for a patient with ischemic dilated cardiomyopathy. His current medications (diabetes medication, beta blockers, statins, and ACE inhibitor) are appropriate for managing his conditions. His LVEF is 39%, which is below the normal range (50-70%), indicating some degree of left ventricular dysfunction. However, his NYHA Class II classification suggests that he is still relatively asymptomatic, and his blood pressure is within a relatively normal range. His troponin levels are low, indicating minimal myocardial damage. His Pro-BNP levels are elevated, but not excessively high, suggesting some degree of heart failure, but not severe. His TSH levels are within the normal range, which suggests that his thyroid function is not contributing to his cardiac condition. Overall, while his prognosis is guarded, his current symptoms and laboratory results suggest that he is likely to survive for the next few years with proper management.

2. Sudden Cardiac Death: Sudden cardiac death is a possible outcome, given the patient's history of ischemic dilated cardiomyopathy and the presence of polymorphic ventricular extrasystoles on the ECG. However, the absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG reduces the likelihood of sudden cardiac death. His LVEF of 39% indicates some degree of left ventricular dysfunction, but it is not severely depressed, which is a risk factor for sudden cardiac death.

3. Pump Failure Death: Pump failure death is the least likely outcome, given the patient's relatively well-managed heart failure symptoms (NYHA Class II) and his current medications. His LVEF of 39% indicates some degree of left ventricular dysfunction, but it is not severely depressed, which is a risk factor for pump failure death. His Pro-BNP levels are elevated, but not excessively high, suggesting some degree of heart failure, but not severe. His creatinine levels are within a relatively normal range, indicating that his renal function is not severely impaired, which is a risk factor for pump failure death.

In summary, while the patient's prognosis is guarded, his current symptoms and laboratory results suggest that he is likely to survive for the next few years with proper management. Sudden cardiac death is a possible outcome, but the absence of certain ECG abnormalities and the patient's relatively well-managed heart failure symptoms reduce its likelihood. Pump failure death is the least likely outcome, given the patient's relatively well-managed heart failure symptoms and current medications."
113,113,P0182,"Age: 76
Gender: Male 
Weight: 90 kg
Height: 181 cm
NYHA Class: III
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 35
ALT or GPT (IU/L): 37.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,4
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 859.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 27
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,56
Urea (mg/dL): 8,15
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Please note that this is a medical prediction and should not be considered a definitive diagnosis.

RANKING: Survivor

REASONING: 

This patient has a complex medical history, including ischemic dilated cardiomyopathy and a myocardial infarction. However, there are several factors that suggest a relatively stable condition:

1.  The patient is on optimal medical therapy, including beta blockers, loop diuretics, statins, and ACE inhibitors, which are commonly used to manage heart failure and ischemic heart disease.
2.  The patient's blood pressure is within a relatively normal range (130/70 mmHg), and the albumin level is not significantly low (35 g/L), indicating that the patient is not in severe heart failure.
3.  The patient's LVEF (left ventricular ejection fraction) is 40%, which is low but not extremely low. LVEF is a critical indicator of heart function, and a value of 40% suggests that the patient has some residual cardiac function.
4.  The patient's Troponin level is 0.01 ng/mL, which is within the normal range, indicating that there is no acute myocardial infarction.
5.  The patient's Pro-BNP level is 859.0 ng/L, which is elevated but not extremely high. Pro-BNP is a marker of heart failure, and an elevated level suggests that the patient has some degree of heart failure, but it is not indicative of a catastrophic outcome.

However, there are also several risk factors that suggest a guarded prognosis:

1.  The patient's NYHA Class III indicates that the patient has severe symptoms of heart failure, which may limit their physical activity.
2.  The patient's LVEF of 40% suggests that the patient has some degree of cardiac dysfunction, which may increase the risk of cardiac events.
3.  The patient's low HDL (0.88 mmol/L) and high LDL (2.4 mmol/L) levels suggest that the patient has a high risk of cardiovascular events.

Considering these factors, I predict that the patient has a relatively high risk of cardiac events, but the likelihood of sudden cardiac death or pump failure death is not extremely high. Therefore, the most likely prognosis is survivor, with a guarded outlook.

The order of the prognoses from most likely to least likely is:

1.  Survivor
2.  Pump failure death
3.  Sudden cardiac death"
114,114,P0184,"Age: 77
Gender: Male 
Weight: 84 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 130/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 45
ALT or GPT (IU/L): 48.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 9,4
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,64
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 525.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 24
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,13
Urea (mg/dL): 7,32
LVEF (%): 37.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: The patient is 77 years old with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure. However, the patient's current New York Heart Association (NYHA) Class II indicates that the heart failure is not severe, and the patient is still able to perform most of their daily activities without significant limitation. The patient's left ventricular ejection fraction (LVEF) is 37%, which is relatively low but not the lowest possible value. The patient is on appropriate medications for heart failure, including digoxin, loop diuretics, and statins. The patient's blood pressure is well-controlled at 130/60 mmHg, which is within a relatively safe range. The patient's troponin level is normal, indicating no acute myocardial infarction. The pro-BNP level is elevated at 525.0 ng/L, but this is not uncommon in patients with heart failure. The patient's TSH level is within the normal range, indicating no thyroid dysfunction. The patient's ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or other life-threatening arrhythmias. Overall, while the patient has significant heart disease, their current clinical status and treatment regimen suggest that they are likely to survive for the next few years with appropriate management.

RANKING: Pump Failure Death

REASONING: Pump failure death is a possible prognosis for this patient due to their history of idiopathic dilated cardiomyopathy and low LVEF. However, the patient's current NYHA Class II and controlled blood pressure suggest that the heart failure is not severe at this time. The patient's medications and current clinical status suggest that the heart failure is being managed effectively, reducing the likelihood of pump failure death.

RANKING: Sudden Cardiac Death

REASONING: Sudden cardiac death is less likely for this patient due to their stable clinical status and controlled blood pressure. The patient's ECG shows polymorphic ventricular extrasystoles, which is a risk factor for sudden cardiac death, but the absence of sustained ventricular tachycardia or other life-threatening arrhythmias reduces this risk. The patient's troponin level is normal, indicating no acute myocardial infarction. The patient's LVEF is low, but not the lowest possible value, and the patient is on appropriate medications to manage heart failure. Overall, while sudden cardiac death is a possible risk, the patient's current clinical status and treatment regimen suggest that this is the least likely prognosis."
115,115,P0189,"Age: 83
Gender: Female 
Weight: 58 kg
Height: 148 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 6,7
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 24,6
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,49
LDL (mmol/L): 2,77
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1094.0
Protein (g/L): 77
T3 (pg/dL): 0,0609
T4 (ng/L): 17,03
Troponin (ng/mL): 0,4
TSH (mIU/L): 0,51
Urea (mg/dL): 11,3
LVEF (%): 50.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
 REASONING: The patient's overall prognosis is complex and influenced by multiple factors. However, considering her age, NYHA Class III, and the presence of hypertensive cardiomyopathy, myocardial infarction, and reduced LVEF (50%), the patient's risk of sudden cardiac death and pump failure death is elevated. 

However, several factors suggest a more favorable outcome. The patient's blood pressure is within a relatively normal range, and she is on optimal medical therapy, including an ACE inhibitor, a nitrovasodilator, and spironolactone, which are all beneficial for heart failure management. The patient's TSH level is within the normal range, indicating no apparent hypothyroidism, which can contribute to cardiac dysfunction. 

Additionally, the patient's troponin level is slightly elevated but not excessively high, suggesting some degree of cardiac damage but not a catastrophic event. The patient's creatinine level is elevated, indicating some degree of renal impairment, but not to the extent that it would significantly impact her cardiac prognosis. 

Considering these factors, the patient's overall prognosis is likely to be a survivor, with careful management and monitoring of her condition.

RANKING: 2. Sudden Cardiac Death
 REASONING: Sudden cardiac death is a possible outcome in this patient due to her history of myocardial infarction, reduced LVEF, and the presence of ventricular extrasystoles and non-sustained ventricular tachycardia on ECG. However, the patient's overall clinical picture and the presence of optimal medical therapy make sudden cardiac death less likely than pump failure death.

RANKING: 3. Pump Failure Death
 REASONING: Pump failure death is a possible outcome in this patient due to her history of hypertensive cardiomyopathy, reduced LVEF, and NYHA Class III. However, the patient's blood pressure is relatively well-controlled, and she is on optimal medical therapy for heart failure, which may mitigate this risk. Additionally, the patient's creatinine level is elevated, but not to the extent that it would significantly impact her cardiac prognosis."
116,116,P0190,"Age: 58
Gender: Male 
Weight: 103 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,33
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 3,88
LDL (mmol/L): 3,52
Sodium (mEq/L): 147.0
Pro-BNP (ng/L): 761.0
Protein (g/L): 72,9
T3 (pg/dL): 0,0636
T4 (ng/L): 15,97
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,66
Urea (mg/dL): 7,6
LVEF (%): 50.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor
 REASONING: The patient's current medications, including beta blockers, ACE inhibitors, and nitrovasodilators, suggest that they are being treated for heart failure and hypertension. The patient's LVEF of 50% indicates that they have a moderate level of heart failure, but it is not severe. The patient's blood pressure is within a relatively normal range, and their ejection fraction is stable. The absence of severe electrolyte imbalances, such as low potassium or high sodium, and the relatively normal urea levels suggest that the patient's kidney function is not severely compromised. Additionally, the patient's troponin level is within normal limits, indicating that there is no acute myocardial infarction. The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia may indicate some level of cardiac instability, but the patient's overall clinical picture suggests that they are being effectively managed. Given these factors, the most likely prognosis is that the patient will survive.

RANKING: Sudden cardiac death
 REASONING: The patient's history of ischemic dilated cardiomyopathy and their current LVEF of 50% indicate that they have a significant risk of sudden cardiac death. The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG further increases this risk. The patient's high Pro-BNP level also suggests that they have some level of cardiac stress. However, the patient's overall clinical picture and treatment regimen suggest that they are being managed effectively, which reduces the likelihood of sudden cardiac death.

RANKING: Pump failure death
 REASONING: The patient's LVEF of 50% and history of ischemic dilated cardiomyopathy suggest that they have a significant risk of pump failure. However, the patient's current medications and stable kidney function suggest that their heart failure is being managed effectively. The patient's blood pressure and urea levels are within relatively normal limits, and their troponin level is within normal limits. While the patient's Pro-BNP level is high, it is not extremely high, suggesting that they do not have severe cardiac stress. Given these factors, the likelihood of pump failure death is lower than the other two options."
117,117,P0191,"Age: 56
Gender: Male 
Weight: 67 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 130/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,37
Creatinine (mmol/L): 138.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 7,7
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,73
Potassium (mEq/L): 5,8
LDL (mmol/L): 2,09
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 341.0
Protein (g/L): 73
T3 (pg/dL): 0,0594
T4 (ng/L): 19,91
TSH (mIU/L): 1,12
Urea (mg/dL): 18,3
LVEF (%): 60.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Please note that this is a general assessment and not a definitive prediction. The prognosis is based on the patient's current medical condition, age, and other risk factors.

RANKING: Survivor

REASONING: 

1. Survivor: The patient is 56 years old, which is considered relatively young for a cardiomyopathy diagnosis. His NYHA Class II indicates that he is experiencing some symptoms of heart failure but is still able to perform some physical activity without significant limitation. His LVEF of 60% suggests that his heart is functioning relatively well, although there is some impairment. The patient is on a multidrug regimen, including beta blockers, ACE inhibitors, and spironolactone, which is a comprehensive treatment plan for heart failure. His blood pressure is well-controlled, and his creatinine level is slightly elevated but not significantly high. His pro-BNP level is elevated, but not excessively high. Considering these factors, the patient's overall prognosis is favorable, and with proper management, he is likely to survive for the next few years.

2. Sudden Cardiac Death: While the patient has a history of hypertensive cardiomyopathy, diabetes, and hypertension, which are risk factors for sudden cardiac death, his LVEF of 60% and well-controlled blood pressure suggest that his risk is not extremely high. The absence of non-sustained ventricular tachycardia and other arrhythmias on the ECG also reduces the likelihood of sudden cardiac death. However, the patient's age and underlying conditions do pose some risk, making sudden cardiac death a possible but less likely outcome.

3. Pump Failure Death: Pump failure is a concern in patients with cardiomyopathy, especially with an LVEF of 60%. However, the patient's current LVEF is relatively stable, and his creatinine level is not excessively high, indicating that his kidneys are not significantly compromised. His treatment regimen includes diuretics, which are used to manage fluid overload and reduce symptoms of heart failure. While pump failure is a possible outcome, it is less likely given the patient's relatively stable condition and comprehensive treatment plan.

Please note that this prognosis is based on the provided data and may change over time as the patient's condition evolves."
118,118,P0193,"Age: 55
Gender: Female 
Weight: 100 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,27
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 5,32
LDL (mmol/L): 2,15
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 281.0
Protein (g/L): 78
T3 (pg/dL): 0,0321
T4 (ng/L): 17,73
Troponin (ng/mL): 0,6
TSH (mIU/L): 0,94
Urea (mg/dL): 14,4
LVEF (%): 40.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor
 REASONING: The patient's age of 55 is relatively young for a cardiomyopathy patient, and her NYHA Class II indicates that she is experiencing some symptoms but is still able to perform most of her daily activities. The patient is on a comprehensive medication regimen that includes ACE inhibitors, beta blockers, and spironolactone, which are standard treatments for heart failure and hypertension. Additionally, she is on statins for dyslipemia, which can help reduce the risk of further cardiac events. The patient's LVEF of 40% is relatively low, but it's not extremely low, and she does not have any signs of severe cardiac decompensation. Her BNP level is elevated at 281.0 ng/L, but it's not extremely high, indicating some level of heart failure, but not severe. The patient's recent troponin level is normal, indicating no recent myocardial infarction. Considering these factors, the patient's prognosis is more likely to be a survivor.

RANKING: Pump failure death
 REASONING: The patient's LVEF of 40% indicates reduced left ventricular function, which can lead to pump failure. Her NYHA Class II symptoms and elevated BNP level suggest that she is experiencing some level of heart failure. However, her medication regimen is comprehensive, and she does not have any signs of severe cardiac decompensation. The patient's creatinine level is elevated at 124.0 mol/L, indicating some level of renal impairment, which can be a consequence of heart failure. However, it's not extremely high, and her urea level is within a relatively normal range. The patient's troponin level is normal, indicating no recent myocardial infarction. Considering these factors, the patient's prognosis is more likely to be pump failure death, but it's not the most likely outcome.

RANKING: Sudden cardiac death
 REASONING: The patient's LVEF of 40% and elevated BNP level indicate some level of heart failure, but her medication regimen is comprehensive, and she does not have any signs of severe cardiac decompensation. The patient's troponin level is normal, indicating no recent myocardial infarction. The patient's ECG shows monomorphic ventricular extrasystoles, but there is no indication of sustained ventricular tachycardia or other high-risk arrhythmias. The patient's TSH level is within a normal range, indicating no signs of thyroid dysfunction, which can increase the risk of sudden cardiac death. Considering these factors, the patient's prognosis is less likely to be sudden cardiac death."
119,119,P0195,"Age: 62
Gender: Female 
Weight: 60 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 6.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 7,4
Glucose (mmol/L): 4,1
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,11
LDL (mmol/L): 2,35
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 237.0
Protein (g/L): 66,8
T3 (pg/dL): 0,0402
T4 (ng/L): 13,59
TSH (mIU/L): 1,6
Urea (mg/dL): 8
LVEF (%): 25.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

Based on the provided patient data, I would rank the prognosis as Survivor for the following reasons:

1. Age and Gender: The patient is a 62-year-old female, which is relatively young for heart failure. Women tend to have a better prognosis than men, especially when they are diagnosed with heart failure at an older age.

2. NYHA Class II: The patient has a relatively mild level of symptoms, which indicates that she is still able to perform most daily activities without significant limitation. This suggests that her heart failure is not yet severe.

3. LVEF: Although the patient's left ventricular ejection fraction (LVEF) is 25%, which is significantly reduced, it is still within the range of patients who can benefit from medical therapy and may be suitable for certain interventions.

4. Blood Pressure: The patient's blood pressure is within a relatively normal range, which is a good sign.

5. Laboratory results: The patient's albumin level is slightly low, which may indicate mild liver dysfunction, but it is not severe. The liver enzymes (ALT and AST) are within normal limits. The patient's potassium level is within a relatively normal range, which is a good sign.

6. Medications: The patient is on beta blockers, loop diuretics, and an ACE inhibitor, which are standard medications for heart failure management. These medications can help slow the progression of heart failure and improve symptoms.

7. ECG results: The patient does not have any significant arrhythmias or conduction abnormalities, which reduces the risk of sudden cardiac death.

8. TSH and T4 levels: The patient's thyroid function is normal, which is essential for heart function.

Considering these factors, the patient's prognosis is likely to be a survivor. However, it is essential to monitor her condition closely and adjust her medications as needed to prevent further decline.

RANKING: Sudden Cardiac Death

REASONING: 

This prognosis is less likely because:

* The patient's LVEF is significantly reduced, which increases the risk of sudden cardiac death.
* The patient has polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death.
* The patient's LVEF is not extremely low, which suggests that there is still some cardiac function left.

However, the patient's overall condition is not severe enough to warrant a high risk of sudden cardiac death.

RANKING: Pump Failure Death

REASONING: 

This prognosis is the least likely because:

* The patient's LVEF is still within a range where medical therapy can be effective.
* The patient's symptoms are not severe (NYHA Class II).
* The patient's blood pressure is within a relatively normal range.
* The patient is on standard medications for heart failure management.

While the patient's LVEF is significantly reduced, it is not extremely low, and her overall condition is not severe enough to warrant a high risk of pump failure death."
120,120,P0196,"Age: 71
Gender: Male 
Weight: 65 kg
Height: 167 cm
NYHA Class: III
Blood Pressure: 90/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 187.0
Gamma-glutamil transpeptidase (IU/L): 137
Glucose (mmol/L): 7,1
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 6,1
LDL (mmol/L): 3,34
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 7460.0
Protein (g/L): 78,899
T3 (pg/dL): 0,0315
T4 (ng/L): 15,28
Troponin (ng/mL): 0,7
TSH (mIU/L): 3,14
Urea (mg/dL): 24,46
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: 1. Survivor
REASONING: The patient has a combination of factors that suggest a poor prognosis, including ischemic dilated cardiomyopathy, diabetes, myocardial infarction, and a low left ventricular ejection fraction (LVEF) of 30%. However, the patient is currently being treated with medications that are commonly used in heart failure management, such as digoxin, loop diuretics, spironolactone, and an ACE inhibitor. Additionally, the patient's blood pressure is within a relatively normal range, and the lack of significant electrolyte imbalances (e.g., potassium, sodium) suggests that the patient's current treatment plan is effective. Furthermore, the patient does not have any recent troponin elevations, which may indicate that the patient's cardiac function is relatively stable. Given these factors, a survivor prognosis is the most likely outcome.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The patient's low LVEF and elevated pro-BNP level also suggest that the patient has significant cardiac dysfunction. However, the patient's current treatment plan and lack of recent troponin elevations suggest that the patient's cardiac function is relatively stable. Additionally, the patient's ventricular extrasystole and non-sustained ventricular tachycardia on the ECG may be a sign of cardiac instability, but it is not a definitive indicator of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: The patient's low LVEF and elevated pro-BNP level suggest that the patient has significant cardiac dysfunction and is at risk for pump failure. The patient's history of ischemic dilated cardiomyopathy and diabetes also increases the risk of pump failure. However, the patient's current treatment plan and lack of recent troponin elevations suggest that the patient's cardiac function is relatively stable. Additionally, the patient's blood pressure is within a relatively normal range, which may indicate that the patient's cardiac output is adequate. While pump failure is a possible outcome, it is less likely than sudden cardiac death due to the patient's current treatment plan and relatively stable cardiac function.

Note: It is essential to emphasize that these prognoses are based on the provided data and may not reflect the patient's actual outcome. A more accurate prognosis would require a comprehensive evaluation and assessment by a healthcare professional."
121,121,P0197,"Age: 71
Gender: Male 
Weight: 73 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Peripheral vascular disease
Albumin (g/L): 41
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 6,78
Creatinine (mmol/L): 145.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,78
Potassium (mEq/L): 4,9
LDL (mmol/L): 4,37
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1367.0
Protein (g/L): 74,5
T3 (pg/dL): 0,0384
T4 (ng/L): 17,4
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,14
Urea (mg/dL): 13,4
LVEF (%): 40.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
 REASONING: Based on the provided patient data, I would rank the prognosis as a survivor for the next few years. The patient is 71 years old with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for adverse cardiac outcomes. However, the patient's current NYHA Class II suggests that they are still relatively stable and able to perform some physical activity without severe limitations. The patient's left ventricular ejection fraction (LVEF) is 40%, which is below the normal range but not severely decreased. The patient is on appropriate medications, including digoxin, loop diuretics, and an ACE inhibitor, which are commonly used to manage heart failure and improve symptoms.

The patient's biomarkers, such as troponin and Pro-BNP, are elevated, indicating some degree of cardiac stress and strain. However, they are not extremely high, and the patient's hemoglobin and albumin levels are within normal ranges, suggesting that they do not have significant anemia or malnutrition.

The patient's lipid profile shows elevated total cholesterol and LDL levels, but the HDL level is within the normal range. The patient's glucose level is slightly elevated, but not significantly so. The patient's potassium and sodium levels are within normal ranges.

The patient's TSH level is within the normal range, and the T3 and T4 levels are slightly low, which could be a sign of hypothyroidism. However, this is not a significant concern in the context of the patient's cardiac disease.

The ECG shows a monomorphic ventricular extrasystole, but no signs of sustained ventricular tachycardia or other life-threatening arrhythmias.

Overall, while the patient has significant cardiac disease, their current clinical status and biomarkers suggest that they are stable and likely to survive for the next few years with continued medical management.

RANKING: 2. Sudden Cardiac Death
 REASONING: Sudden cardiac death is a possible outcome for this patient, but it is less likely than survivorship. The patient's history of idiopathic dilated cardiomyopathy and low LVEF increase their risk of sudden cardiac death. However, the patient's current clinical status and biomarkers do not suggest an extremely high risk of sudden cardiac death. The patient's LVEF is below the normal range, but it is not severely decreased, and the patient is on appropriate medications to manage their heart failure.

The patient's ECG shows a monomorphic ventricular extrasystole, which can be a sign of increased cardiac risk, but it is not a definitive predictor of sudden cardiac death. The patient's troponin and Pro-BNP levels are elevated, indicating some degree of cardiac stress and strain, but they are not extremely high.

RANKING: 3. Pump Failure Death
 REASONING: Pump failure death is the least likely outcome for this patient. The patient's LVEF is 40%, which is below the normal range, but it is not severely decreased. The patient is on appropriate medications to manage their heart failure, including digoxin, loop diuretics, and an ACE inhibitor. The patient's biomarkers, such as troponin and Pro-BNP, are elevated, but they are not extremely high.

The patient's NYHA Class II suggests that they are still relatively stable and able to perform some physical activity without severe limitations. The patient's hemoglobin and albumin levels are within normal ranges, suggesting that they do not have significant anemia or malnutrition.

While the patient's cardiac disease is significant, their current clinical status and biomarkers suggest that they are unlikely to experience pump failure death in the near future."
122,122,P0198,"Age: 53
Gender: Male 
Weight: 77 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 46
ALT or GPT (IU/L): 49.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,15
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 69
Glucose (mmol/L): 19,2
Hemoglobin (g/L): 144.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,48
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 41.0
Protein (g/L): 81,8
T3 (pg/dL): 0,0522
T4 (ng/L): 18,6
Troponin (ng/mL): 0,4
TSH (mIU/L): 1,79
Urea (mg/dL): 6,7
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: 1
REASONING: The patient is currently being treated with a comprehensive regimen of medications, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which suggests that their condition is being actively managed. The patient's LVEF (40%) indicates reduced left ventricular function, but it is not severely impaired. The patient's NYHA Class II suggests that they have some limitations with physical activity but are still able to perform daily activities without symptoms. The absence of sustained ventricular tachycardia, bradycardia, and other concerning ECG findings further supports a more favorable prognosis. While the patient has a history of enolic dilated cardiomyopathy and dyslipemia, the current management plan and the patient's overall clinical picture suggest that they are likely to survive for the next few years with continued medical therapy and lifestyle modifications.

RANKING: 2
REASONING: The patient's elevated Creatinine level (90.0 mol/L) and Urea level (6.7 mg/dL) indicate some degree of renal impairment, which can be a concern for patients with heart failure. The patient's low HDL (0.85 mmol/L) and high LDL (2.48 mmol/L) levels also suggest a high cardiovascular risk. However, the patient's Pro-BNP level (41.0 ng/L) is within a relatively normal range, and their TSH level (1.79 mIU/L) is within the normal range, indicating that their thyroid function is not contributing to their cardiac condition. The presence of ventricular extrasystoles on the ECG is a benign finding in this context. While these factors may contribute to a higher risk of adverse outcomes, they do not suggest a high likelihood of sudden cardiac death or pump failure death.

RANKING: 3
REASONING: The patient's high glucose level (19.2 mmol/L) and elevated gamma-glutamil transpeptidase (69 IU/L) levels may indicate underlying metabolic disorders that could contribute to cardiac dysfunction. However, the patient's current management plan includes medications that are typically used to manage heart failure, and their LVEF is not severely impaired. The absence of other concerning findings, such as severe left ventricular dysfunction or severe electrolyte imbalances, makes pump failure death less likely. While the patient's high glucose level and metabolic derangements may contribute to a higher risk of adverse outcomes, the overall clinical picture does not strongly suggest pump failure death as the most likely prognosis."
123,123,P0201,"Age: 48
Gender: Male 
Weight: 96 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,17
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 66
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 179.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 5,09
LDL (mmol/L): 3,59
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1176.0
Protein (g/L): 72,3
T3 (pg/dL): 0,03
T4 (ng/L): 15,92
Troponin (ng/mL): 0,2
TSH (mIU/L): 0,88
Urea (mg/dL): 5,7
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: Survivor

REASONING: Based on the provided patient data, the patient has a history of enolic dilated cardiomyopathy, which is a significant risk factor for heart failure and sudden cardiac death. However, the patient's current medications (Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor) suggest that the patient is receiving optimal medical therapy for heart failure and arrhythmia management.

The patient's LVEF (Left Ventricular Ejection Fraction) of 25% indicates severe left ventricular dysfunction, which is a strong predictor of adverse outcomes in patients with heart failure. However, the patient's NYHA Class II classification suggests that the patient is not experiencing significant symptoms at rest, which may indicate some degree of adaptation to the decreased cardiac function.

The patient's Pro-BNP level of 1176.0 ng/L is elevated, which is consistent with heart failure. However, the patient's hemoglobin level of 179.0 g/L is within the normal range, which suggests that the patient is not experiencing significant anemia, a common comorbidity in patients with heart failure.

The patient's potassium level of 5.09 mEq/L is slightly elevated, which may indicate renal impairment or other electrolyte imbalances. The patient's creatinine level of 113.0 umol/L is elevated, which suggests some degree of renal impairment.

The patient's ECG shows non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, which are concerning signs of arrhythmia. However, the patient's medications include an ACE inhibitor, which is a common treatment for heart failure and arrhythmia.

Considering these factors, the patient's prognosis is uncertain, but I would rank the three possible prognoses as follows:

1. Survivor: The patient is receiving optimal medical therapy, and the patient's NYHA Class II classification suggests that the patient is not experiencing significant symptoms at rest. The patient's hemoglobin level is within the normal range, and the patient's LVEF is not extremely low.
2. Sudden Cardiac Death: The patient's history of enolic dilated cardiomyopathy and the presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG suggest that the patient is at risk for sudden cardiac death. However, the patient's medications include an ACE inhibitor, which is a common treatment for heart failure and arrhythmia.
3. Pump Failure Death: The patient's LVEF of 25% indicates severe left ventricular dysfunction, which is a strong predictor of adverse outcomes in patients with heart failure. However, the patient's NYHA Class II classification suggests that the patient is not experiencing significant symptoms at rest, which may indicate some degree of adaptation to the decreased cardiac function.

Overall, while the patient's prognosis is uncertain, I would rank the three possible prognoses as survivor, sudden cardiac death, and pump failure death, in that order."
124,124,P0202,"Age: 75
Gender: Male 
Weight: 77 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 160/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 13,2
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,32
LDL (mmol/L): 2,22
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 918.0
Protein (g/L): 71,6
T3 (pg/dL): 0,0585
T4 (ng/L): 12,73
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,16
Urea (mg/dL): 8,3
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the prognosis for the next few years:

RANKING: 1
 REASONING: Survivor

The patient is 75 years old with a history of hypertensive cardiomyopathy, diabetes, and dyslipemia, which are all risk factors for cardiovascular disease. However, the patient is currently being treated with medications for these conditions, including beta blockers, loop diuretics, statins, and an ACE inhibitor, which are all appropriate for managing heart failure and reducing cardiovascular risk. The patient's LVEF is 45%, which is below the normal range (50-70%), indicating some degree of heart failure. However, the patient's NYHA Class is II, indicating that they are still able to perform some physical activity without significant limitation.

The patient's laboratory results show a high Pro-BNP level (918 ng/L), which is a marker of heart failure and indicates that the patient's heart is under strain. However, the patient's Troponin level is normal (0.2 ng/mL), which suggests that there is no acute myocardial infarction.

Considering the patient's age, comorbidities, and current treatment, the most likely prognosis is that they will survive for the next few years with careful management of their heart failure and other medical conditions. The patient's high Pro-BNP level indicates that they are at risk for heart failure progression, but the fact that they are already on appropriate treatment and have a relatively preserved LVEF suggests that they are likely to survive for the next few years with close monitoring and management.

RANKING: 2
 REASONING: Sudden cardiac death

Sudden cardiac death is a possible outcome for this patient due to their history of hypertensive cardiomyopathy and the presence of a high Pro-BNP level, which indicates that the patient's heart is under strain. However, the patient's LVEF is 45%, which is below the normal range, but not severely impaired, and they are already on beta blockers, which are known to reduce the risk of sudden cardiac death.

RANKING: 3
 REASONING: Pump failure death

Pump failure death is the least likely outcome for this patient, given their current treatment and relatively preserved LVEF. While the patient's Pro-BNP level is high, indicating some degree of heart failure, their LVEF is not severely impaired, and they are already on medications that are known to improve heart function and reduce the risk of heart failure progression."
125,125,P0203,"Age: 78
Gender: Female 
Weight: 90 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 150/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,97
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 3,8
LDL (mmol/L): 3,44
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 491.0
Protein (g/L): 80
T3 (pg/dL): 0,0363
T4 (ng/L): 16,39
Troponin (ng/mL): 0,1
TSH (mIU/L): 2,19
Urea (mg/dL): 18,8
LVEF (%): 30.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: Based on the provided patient data, I would rank the prognosis as a survivor due to several factors:

1.  The patient is 78 years old, which is a significant risk factor for cardiovascular events, but age alone does not determine the prognosis.
2.  The patient has idiopathic dilated cardiomyopathy, which is a significant underlying condition affecting the heart's pumping function, as indicated by an LVEF of 30%. However, the patient is on ACE inhibitors, which is a common treatment for heart failure and may help slow disease progression.
3.  The patient's NYHA Class III indicates that the patient experiences symptoms of heart failure, such as shortness of breath and fatigue, but is still able to perform everyday activities.
4.  The patient's blood pressure is 150/70 mmHg, which is slightly elevated but not excessively high. The blood pressure is within a range that can be managed with medication.
5.  The patient's electrolyte levels, including potassium and sodium, are within normal limits, which is essential for proper heart function.
6.  The patient's liver enzymes (ALT and AST) are within normal limits, indicating that the liver is functioning properly.
7.  The patient's TSH level is slightly elevated (2.19 mIU/L), but this may not be directly related to the cardiac condition.
8.  The patient's T3 and T4 levels are within normal limits, indicating that the thyroid function is normal.
9.  The patient's Pro-BNP level is elevated (491.0 ng/L), which is indicative of heart failure, but the level is not excessively high.
10. The patient's LVEF of 30% indicates reduced cardiac function, but the patient is still alive and on treatment, which suggests that the condition is being managed.

Considering these factors, the patient's overall prognosis is more likely to be a survivor due to the presence of a manageable condition, the patient's age, and the fact that the patient is on treatment for heart failure. However, the patient's condition requires close monitoring, and regular follow-up appointments are essential to adjust treatment as needed.

The other two prognoses (sudden cardiac death and pump failure death) are less likely due to the following reasons:

- Sudden cardiac death: The patient's ECG shows non-sustained ventricular tachycardia and polymorphic ventricular extrasystole, which are risk factors for sudden cardiac death. However, the patient is on treatment, and the condition is being managed.
- Pump failure death: The patient's LVEF of 30% indicates reduced cardiac function, but the patient is on treatment, and the condition is being managed. The patient's overall prognosis is more likely to be a survivor due to the presence of a manageable condition and the patient's age."
126,126,P0204,"Age: 69
Gender: Male 
Weight: 69 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 8.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 4,24
Creatinine (mmol/L): 152.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 6,4
Hemoglobin (g/L): 115.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,4
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 7794.0
Protein (g/L): 77
T3 (pg/dL): 0,0351
T4 (ng/L): 18,87
Troponin (ng/mL): 0,7
TSH (mIU/L): 1,89
Urea (mg/dL): 11
LVEF (%): 40.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

Given the patient's profile, I would rank the prognosis as survivor due to the following reasons:

1.  The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure and mortality. However, the patient is currently on optimal medical therapy with an angiotensin II receptor blocker, loop diuretics, statins, and nitrovasodilators, which are all standard treatments for heart failure with reduced ejection fraction (HFrEF). These medications should help manage the patient's symptoms and slow disease progression.

2.  The patient's LVEF is 40%, which is within the range for HFrEF. Although this is lower than the average LVEF, it is not extremely low, and the patient is on medications that can help improve cardiac function.

3.  The patient's NT-proBNP level is elevated at 7794.0 ng/L, indicating that the patient has some degree of heart failure. However, NT-proBNP levels can be influenced by various factors, including age, kidney function, and medication use. In this case, the patient's creatinine level is elevated, which may contribute to the high NT-proBNP level.

4.  The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. However, the patient does not have any other high-risk features such as a history of ventricular fibrillation or a low LVEF.

5.  The patient's overall clinical condition is stable, with no acute changes in symptoms or vital signs. The patient is on optimal medical therapy, and the patient's blood pressure is well-controlled.

6.  The patient's age is 69, which is a moderate risk for mortality. However, the patient's overall health status and treatment plan make a survivor prognosis more likely.

7.  The patient's TSH level is within the normal range, which suggests that the patient's thyroid function is not contributing to the patient's cardiac condition.

8.  The patient's lipid profile shows a high total cholesterol and LDL levels, but the patient is on statins, which should help manage these levels.

Considering these factors, the patient's overall prognosis is likely to be a survivor, with a focus on continued monitoring and optimization of medical therapy to manage the patient's heart failure and reduce the risk of complications."
127,127,P0206,"Age: 80
Gender: Male 
Weight: 88 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,51
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,57
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 3087.0
Protein (g/L): 62,3
T3 (pg/dL): 0,0444
T4 (ng/L): 13,71
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,46
Urea (mg/dL): 8,5
LVEF (%): 45.0
Medications: Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely.

RANKING: Survivor

REASONING: The patient is 80 years old with a history of idiopathic dilated cardiomyopathy, diabetes, and hypertension, which are all significant risk factors for cardiovascular disease. However, despite these risk factors, the patient's current symptoms and lab results suggest that they are being managed with loop diuretics, which is a common treatment for heart failure.

The patient's LVEF (Left Ventricular Ejection Fraction) is 45%, which is slightly below the normal range, indicating some degree of heart dysfunction. However, it is not severely impaired, and the patient's NYHA Class is II, indicating that they are experiencing some symptoms but are still able to perform some physical activity.

The patient's troponin level is slightly elevated at 0.3 ng/mL, but this is not significantly high, and the patient does not have a history of acute coronary syndrome. The pro-BNP level is high at 3087.0 ng/L, which is consistent with heart failure, but it is not the highest level I have seen.

The patient's ECG shows non-sustained ventricular tachycardia, which is a concerning finding, but the patient does not have a history of sustained ventricular tachycardia or ventricular fibrillation, which would increase the risk of sudden cardiac death.

Given these factors, I believe that the patient is most likely to survive for the next few years, but with ongoing management and monitoring to prevent further decline in cardiac function.

RANKING: Pump Failure Death

REASONING: The patient's LVEF is 45%, and they have a history of idiopathic dilated cardiomyopathy, which increases the risk of progressive heart failure. The patient's pro-BNP level is high, and they are on loop diuretics, which is a common treatment for heart failure. While the patient's symptoms are not severe, and they are still able to perform some physical activity, there is a risk of further decline in cardiac function, leading to pump failure.

The patient's creatinine level is elevated at 113.0 mmol/L, which suggests some degree of kidney dysfunction, which can be a complication of heart failure. The patient's glucose level is slightly elevated, which can also contribute to further cardiac damage.

While the patient's ECG shows non-sustained ventricular tachycardia, this is not a strong predictor of sudden cardiac death. However, the combination of heart failure, kidney dysfunction, and other risk factors increases the risk of pump failure death.

RANKING: Sudden Cardiac Death

REASONING: While the patient's ECG shows non-sustained ventricular tachycardia, which is a concerning finding, the patient does not have a history of sustained ventricular tachycardia or ventricular fibrillation, which would increase the risk of sudden cardiac death. The patient's troponin level is not significantly elevated, and they do not have a history of acute coronary syndrome.

The patient's LVEF is 45%, which is below the normal range, but not severely impaired. The patient's NYHA Class is II, indicating that they are experiencing some symptoms but are still able to perform some physical activity.

While the patient has multiple risk factors for cardiovascular disease, including diabetes, hypertension, and idiopathic dilated cardiomyopathy, the overall risk of sudden cardiac death is lower than the risk of pump failure death."
128,128,P0208,"Age: 63
Gender: Male 
Weight: 83 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 160/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,31
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,19
LDL (mmol/L): 4,53
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 520.0
Protein (g/L): 73,6
T3 (pg/dL): 0,0618
T4 (ng/L): 15,21
Troponin (ng/mL): 0,1
TSH (mIU/L): 1,43
Urea (mg/dL): 5,9
LVEF (%): 15.0
Medications: Calcium Channel Blocker, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient's age, weight, and NYHA Class II suggest that he has some limitations in physical activity, but he is not severely symptomatic. His LVEF of 15% indicates severe left ventricular dysfunction, which is a significant risk factor for adverse outcomes. However, the patient is already on optimal medical therapy with a calcium channel blocker and an ACE inhibitor, which are commonly used to manage heart failure and hypertension. His Pro-BNP level is elevated, indicating increased ventricular stretch and wall tension, but not excessively high, suggesting that the patient's condition is being managed to some extent. His troponin level is within normal limits, and there is no evidence of acute coronary syndrome or severe cardiac ischemia. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, or other life-threatening arrhythmias on the ECG also suggests that the patient's cardiac rhythm is relatively stable. Overall, while the patient's prognosis is guarded due to his severe heart failure, his current medical therapy and relatively stable cardiac rhythm make a survivor prognosis more likely than sudden cardiac death or pump failure death in the short term.

RANKING: 2. Pump failure death
 REASONING: The patient's LVEF of 15% indicates severe left ventricular dysfunction, which is a significant risk factor for pump failure death. His elevated Pro-BNP level and NYHA Class II classification also suggest that he has some degree of heart failure symptoms. However, his current medical therapy with a calcium channel blocker and an ACE inhibitor, as well as his relatively stable cardiac rhythm, suggest that his condition is being managed to some extent. While the patient's condition is severe, his prognosis is not as poor as sudden cardiac death due to the absence of life-threatening arrhythmias and his relatively stable cardiac rhythm.

RANKING: 3. Sudden cardiac death
 REASONING: The patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the absence of sustained or non-sustained ventricular tachycardia, as well as the patient's relatively stable cardiac rhythm, makes sudden cardiac death less likely. Additionally, the patient's current medical therapy with a calcium channel blocker and an ACE inhibitor, as well as his relatively stable LVEF and Pro-BNP levels, suggest that his condition is being managed to some extent, further reducing the risk of sudden cardiac death."
129,129,P0209,"Age: 55
Gender: Male 
Weight: 84 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,28
Creatinine (mmol/L): 74.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 4,1
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 5,1
LDL (mmol/L): 3,7
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 149.0
Protein (g/L): 71,5
T3 (pg/dL): 0,06
T4 (ng/L): 15,82
TSH (mIU/L): 1,64
Urea (mg/dL): 5,4
LVEF (%): 30.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor
 REASONING: The patient is 55 years old with a history of ischemic dilated cardiomyopathy, myocardial infarction, and hypertension. However, the patient is currently on optimal medical therapy for heart failure, including beta blockers, digoxin, loop diuretics, ACE inhibitors, and nitrovasodilators. The patient's LVEF is 30%, which is low but not extremely low, and the patient is still in NYHA Class II, indicating that the patient's symptoms are manageable. The patient's pro-BNP level is 149.0 ng/L, which is elevated but not extremely high. The patient's blood pressure is well-controlled, and the patient does not have any signs of severe electrolyte imbalances. The patient's creatinine level is slightly elevated, but not to the extent that it would suggest advanced kidney disease. Overall, while the patient has a history of heart disease, the patient's current medical therapy and lack of severe symptoms suggest that the patient is likely to survive.

RANKING: Pump Failure Death
 REASONING: The patient's LVEF is 30%, which is a significant predictor of poor prognosis in heart failure patients. The patient's pro-BNP level is elevated, which suggests that the patient has some degree of heart failure. The patient's creatinine level is slightly elevated, which may indicate some degree of kidney impairment due to heart failure. However, the patient's blood pressure is well-controlled, and the patient is on optimal medical therapy for heart failure. The patient's symptoms are manageable, and the patient is still in NYHA Class II. While the patient's LVEF is low, the patient's overall clinical picture suggests that pump failure death is a possible but not extremely likely outcome.

RANKING: Sudden Cardiac Death
 REASONING: The patient's ECG shows monomorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the patient does not have any other high-risk features for sudden cardiac death, such as a history of ventricular tachycardia or a low ejection fraction. The patient's LVEF is 30%, which is low, but not extremely low, and the patient is on optimal medical therapy for heart failure. The patient's symptoms are manageable, and the patient is still in NYHA Class II. While the patient's ECG shows some abnormalities, the patient's overall clinical picture suggests that sudden cardiac death is the least likely outcome."
130,130,P0210,"Age: 75
Gender: Male 
Weight: 80 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 180/95 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 5,61
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,45
Potassium (mEq/L): 3,78
LDL (mmol/L): 3,78
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 308.0
Protein (g/L): 70
T3 (pg/dL): 0,0597
T4 (ng/L): 19,3
Troponin (ng/mL): 0,5
TSH (mIU/L): 0,69
Urea (mg/dL): 8,3
LVEF (%): 70.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: Based on the provided patient data, I would rank the prognosis as survivor for the next few years. Here's why:

1.  Age and NYHA Class: The patient is 75 years old and has a NYHA Class II, which indicates some limitation of physical activity but is still able to carry on normal everyday activities. While age is a risk factor for cardiovascular disease, NYHA Class II suggests that the patient is still relatively stable.

2.  Blood Pressure: Although the patient has hypertension, the blood pressure is controlled with medication (Angiotensin II Receptor Blocker and ACE Inhibitor), which is a positive sign. Controlled hypertension reduces the risk of cardiovascular events.

3.  LVEF: The left ventricular ejection fraction (LVEF) is 70%, which is within the normal range (> 50%). This indicates that the heart is pumping efficiently, reducing the risk of pump failure.

4.  Medications: The patient is on a combination of medications that are beneficial for heart health, including an ACE Inhibitor, Angiotensin II Receptor Blocker, and Loop Diuretics. These medications help to reduce blood pressure, prevent the progression of heart failure, and alleviate symptoms.

5.  ECG Findings: The ECG shows monomorphic ventricular extrasystoles, but there is no indication of ventricular tachycardia or other life-threatening arrhythmias.

6.  Laboratory Results: The patient's laboratory results, including electrolytes, liver enzymes, and kidney function, are relatively normal. The slightly elevated Pro-BNP level may indicate some degree of heart failure, but it is not excessively high.

7.  Other Factors: The patient's weight, height, and body mass index (BMI) are not provided, but given the weight of 80 kg and height of 161 cm, the BMI would likely be in the overweight category. While being overweight can increase the risk of cardiovascular disease, it is not the most significant factor in this patient's prognosis.

Considering these factors, the patient's overall prognosis is relatively good, and the likelihood of sudden cardiac death or pump failure is lower compared to other potential outcomes. Therefore, I would rank the prognosis as survivor for the next few years."
131,131,P0214,"Age: 50
Gender: Female 
Weight: 77 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 81.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 126.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,32
LDL (mmol/L): 2,3
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 327.0
Protein (g/L): 69
T3 (pg/dL): 0,051
T4 (ng/L): 14,1
TSH (mIU/L): 1,38
Urea (mg/dL): 5,5
LVEF (%): 50.0
Medications: Beta Blockers, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

This patient is a 50-year-old female with a history of ischemic dilated cardiomyopathy and myocardial infarction, indicating that she has had significant cardiac damage in the past. However, she is currently on a treatment regimen that includes beta blockers, ACE inhibitors, and nitrovasodilators, which are all appropriate for managing heart failure and reducing the risk of further cardiac damage. 

Her left ventricular ejection fraction (LVEF) is 50%, which is within the moderate range of heart failure. The fact that she is not in NYHA Class III or IV suggests that her symptoms are not as severe as they could be. 

Her laboratory results show elevated levels of pro-BNP (brain natriuretic peptide), which is a marker of heart failure, but it's not excessively high, and her liver enzymes are within normal limits, suggesting that there is no significant liver dysfunction. Her kidney function is also relatively preserved, with a creatinine level of 81.0 umol/L, which is slightly elevated but not indicative of severe kidney disease. 

The patient's lipid profile shows high total cholesterol and LDL levels, which is a risk factor for further cardiac damage, but her HDL level is also low, which may be a result of her heart failure. 

Given these factors, while the patient has a history of cardiac damage and is at risk for further cardiac events, her current treatment regimen and relatively preserved kidney and liver function suggest that she is likely to survive in the next few years."
132,132,P0216,"Age: 79
Gender: Male 
Weight: 73 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 33
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 46.0
Total Cholesterol (mmol/L): 3,26
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 149
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,73
Potassium (mEq/L): 4,58
LDL (mmol/L): 1,71
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 5971.0
Protein (g/L): 66,3
T3 (pg/dL): 0,0642
T4 (ng/L): 19,53
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,68
Urea (mg/dL): 7,2
LVEF (%): 30.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
REASONING: Given the patient's age, NYHA Class II, and history of idiopathic dilated cardiomyopathy, it is not surprising that the patient has a reduced left ventricular ejection fraction (LVEF) of 30%. However, the patient is on a combination of medications that are appropriate for heart failure, including an angiotensin II receptor blocker, ACE inhibitor, loop diuretics, and digoxin. The patient's pro-BNP level is elevated at 5971.0 ng/L, which is consistent with heart failure, but not excessively high. The patient's troponin level is within normal limits, and there is no indication of acute coronary syndrome. The patient's potassium level is slightly low, but not critically low, and the patient's sodium level is within the normal range. The patient's urea level is slightly elevated, but not excessively high. The patient's TSH level is within the normal range, indicating that the patient is not experiencing hypothyroidism, which can contribute to heart failure. The patient's ECG shows ventricular extrasystole and non-sustained ventricular tachycardia, but no signs of acute coronary syndrome or severe arrhythmia. Overall, while the patient has significant heart disease, the patient's current medications and lack of acute decompensation suggest that the patient is likely to survive for the next few years with continued medical management.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of idiopathic dilated cardiomyopathy and reduced LVEF of 30% puts the patient at increased risk of sudden cardiac death. The patient's non-sustained ventricular tachycardia on ECG is a risk factor for sudden cardiac death. However, the patient is on a beta-blocker, which is a standard treatment for reducing the risk of sudden cardiac death in patients with heart failure. The patient's troponin level is within normal limits, and there is no indication of acute coronary syndrome. The patient's potassium level is slightly low, but not critically low, which may actually be beneficial in reducing the risk of arrhythmias. The patient's sodium level is within the normal range, which may also help to reduce the risk of arrhythmias. While the patient is at increased risk of sudden cardiac death, the patient's current medications and lack of acute decompensation suggest that the risk is not extremely high.

RANKING: 3. Pump Failure Death
REASONING: The patient's history of idiopathic dilated cardiomyopathy and reduced LVEF of 30% puts the patient at increased risk of pump failure death. However, the patient is on a combination of medications that are appropriate for heart failure, including an angiotensin II receptor blocker, ACE inhibitor, loop diuretics, and digoxin. The patient's pro-BNP level is elevated, but not excessively high, which suggests that the patient is not experiencing acute decompensation. The patient's urea level is slightly elevated, but not excessively high, which suggests that the patient's kidneys are still functioning reasonably well. The patient's TSH level is within the normal range, which suggests that the patient is not experiencing hypothyroidism, which can contribute to heart failure. While the patient is at increased risk of pump failure death, the patient's current medications and lack of acute decompensation suggest that the risk is not extremely high."
133,133,P0219,"Age: 61
Gender: Male 
Weight: 84 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 49.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 4,95
Creatinine (mmol/L): 136.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 7,74
Hemoglobin (g/L): 167.0
HDL (mmol/L): 1,1
Potassium (mEq/L): 4,46
LDL (mmol/L): 2,77
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 165.0
Protein (g/L): 75,5
T3 (pg/dL): 0,0204
T4 (ng/L): 13,65
Troponin (ng/mL): 0,8
TSH (mIU/L): 1,19
Urea (mg/dL): 7,8
LVEF (%): 40.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

Considering the provided patient data, I would rank the prognosis as a survivor for the next few years. Here's the reasoning:

1. Ischemic dilated cardiomyopathy (IDC) with an LVEF of 40%: This condition indicates that the patient has a weakened heart, but the LVEF of 40% is still relatively high, suggesting that the heart is not severely compromised. Patients with an LVEF between 30-40% generally have a better prognosis than those with an LVEF below 30%.

2. NYHA Class II: The patient's functional status is relatively stable, with no severe symptoms, which is a good sign.

3. Medications: The patient is on a comprehensive treatment regimen, including ACE inhibitors (Angiotensin II Receptor Blocker), beta-blockers (Digoxin), diuretics, and statins, which are standard treatments for heart failure and ischemic cardiomyopathy. These medications should help manage the patient's symptoms and slow disease progression.

4. ECG findings: While the patient has polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, these are relatively common in patients with heart failure and IDC, and are not necessarily indicative of an increased risk of sudden cardiac death.

5. Biochemical markers: The patient's troponin level is elevated, but not excessively high, and his creatinine level is within a relatively safe range. His hemoglobin and albumin levels are also within normal limits, indicating that he is not experiencing severe malnutrition or kidney dysfunction.

6. TSH and T3/T4 levels: The patient's thyroid function is within normal limits, which is essential for cardiac health.

Considering these factors, the patient's overall prognosis is relatively good, and with proper management and adherence to treatment, it is likely that he will survive for several years.

RANKING: Sudden Cardiac Death

REASONING: 

Although the patient has a relatively high risk of sudden cardiac death, I would rank it as the second most likely prognosis. Here's the reasoning:

1. Non-sustained ventricular tachycardia: The patient has a history of non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death.

2. Ventricular extrasystoles: The patient's polymorphic ventricular extrasystoles are also a risk factor for sudden cardiac death.

3. Low LVEF: While the patient's LVEF is relatively high, it is still below 50%, which is a risk factor for sudden cardiac death.

4. Ischemic dilated cardiomyopathy: IDC is a known risk factor for sudden cardiac death.

However, the patient's overall prognosis is still relatively good, and with proper management, the risk of sudden cardiac death can be mitigated.

RANKING: Pump Failure Death

REASONING: 

Pump failure death is the least likely prognosis for this patient. Here's the reasoning:

1. NYHA Class II: The patient's functional status is relatively stable, with no severe symptoms.

2. LVEF of 40%: While the patient's LVEF is below 50%, it is still relatively high, indicating that the heart is not severely compromised.

3. Medications: The patient is on a comprehensive treatment regimen, including ACE inhibitors, beta-blockers, diuretics, and statins, which should help manage the patient's symptoms and slow disease progression.

4. ECG findings: While the patient has ventricular extrasystoles and non-sustained ventricular tachycardia, these are relatively common in patients with heart failure and IDC, and are not necessarily indicative of an increased risk of pump failure.

5. Biochemical markers: The patient's creatinine level is within a relatively safe range, indicating that he is not experiencing severe kidney dysfunction.

Considering these factors, pump failure death is the least likely prognosis for this patient."
134,134,P0220,"Age: 44
Gender: Male 
Weight: 106 kg
Height: 181 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia
Albumin (g/L): 46
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 6,21
Creatinine (mmol/L): 128.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,02
Hemoglobin (g/L): 111.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 4,59
LDL (mmol/L): 4,19
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 1057.0
Protein (g/L): 82,4
T3 (pg/dL): 0,0339
T4 (ng/L): 20,91
Troponin (ng/mL): 0,6
TSH (mIU/L): 1,55
Urea (mg/dL): 19,2
LVEF (%): 20.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely. 

RANKING: 1. Survivor
 REASONING: The patient is 44 years old with a history of valvular cardiomyopathy, which is a significant risk factor for heart failure. However, despite this, the patient is currently being treated with a combination of beta blockers, digoxin, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure and can improve prognosis. The patient's NYHA Class II indicates that they are experiencing some limitations in physical activity but are still able to perform everyday tasks without severe symptoms. The LVEF of 20% indicates severe left ventricular dysfunction, but the patient's current medication regimen and the absence of other high-risk features, such as sustained ventricular tachycardia or very high levels of BNP, suggest that the patient may be responding to treatment. The patient's low TSH level and normal troponin level also suggest that there may not be significant myocardial damage or thyroid dysfunction contributing to the patient's condition. Therefore, while the patient's prognosis is guarded, I believe that with continued treatment and close monitoring, the patient is most likely to survive.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF of 20% indicates severe left ventricular dysfunction, which is a significant risk factor for pump failure. The patient's history of valvular cardiomyopathy and dyslipemia also contribute to the risk of pump failure. However, the patient's current treatment regimen and the absence of other high-risk features, such as very high levels of BNP or sustained ventricular tachycardia, suggest that the patient may be able to manage their condition with treatment. The patient's low TSH level and normal troponin level also suggest that there may not be significant myocardial damage or thyroid dysfunction contributing to the patient's condition. While the risk of pump failure is high, I believe that it is less likely than sudden cardiac death due to the patient's current treatment regimen and the absence of other high-risk features.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient's history of valvular cardiomyopathy and severe left ventricular dysfunction (LVEF 20%) increase the risk of sudden cardiac death. However, the patient's current treatment regimen, including beta blockers, which are known to reduce the risk of sudden cardiac death, suggests that the patient may be at lower risk for this outcome. Additionally, the patient's ECG shows only monomorphic ventricular extrasystoles, which is not a high-risk finding for sudden cardiac death. While the patient's high level of BNP (1057 ng/L) suggests that they may be at risk for arrhythmias, the absence of other high-risk features, such as sustained ventricular tachycardia or very high levels of troponin, suggests that the risk of sudden cardiac death may be lower than pump failure."
135,135,P0222,"Age: 57
Gender: Female 
Weight: 47 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 41
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,39
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 4,74
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,2
Potassium (mEq/L): 4,17
LDL (mmol/L): 3,63
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1537.0
Protein (g/L): 64
T3 (pg/dL): 0,054
T4 (ng/L): 16,68
Troponin (ng/mL): 0,5
TSH (mIU/L): 0,09
Urea (mg/dL): 8
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"Based on the provided patient data, here's my prognosis for the next few years:

RANKING: Survivor
REASONING: Despite the patient's history of ischemic dilated cardiomyopathy, the patient is currently being treated with a comprehensive regimen of medications, including beta blockers, digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor. This suggests that the patient's condition is being actively managed. The patient's LVEF (left ventricular ejection fraction) of 35% indicates reduced cardiac function, but it is not the lowest possible value, which is often associated with a poorer prognosis. The patient's blood pressure is within a relatively normal range, and the absence of significant electrolyte imbalances or severe kidney dysfunction suggests that the patient's overall metabolic status is relatively stable. Additionally, the patient's Pro-BNP level, while elevated, is not extremely high, which may indicate that the patient is not experiencing severe heart failure. While the patient's ECG shows signs of ventricular extrasystoles and a second-degree AV block, these findings are not uncommon in patients with heart disease and are not necessarily indicative of a poor prognosis. Overall, considering the patient's current treatment regimen and the absence of severe symptoms or laboratory abnormalities, I believe that the patient is most likely to survive for the next few years.

RANKING: Sudden Cardiac Death
REASONING: While the patient's history of ischemic dilated cardiomyopathy and reduced LVEF do increase the risk of sudden cardiac death, the patient's current treatment regimen and relatively stable laboratory values suggest that this risk is not extremely high. The patient's Pro-BNP level, while elevated, is not extremely high, and the absence of significant electrolyte imbalances or severe kidney dysfunction reduces the risk of sudden cardiac death. Additionally, the patient's ECG shows signs of ventricular extrasystoles, but the absence of a high-risk ventricular tachycardia code reduces the likelihood of sudden cardiac death. While sudden cardiac death is a possible outcome, it is less likely than survivorship given the patient's current treatment regimen and relatively stable laboratory values.

RANKING: Pump Failure Death
REASONING: The patient's reduced LVEF of 35% and history of ischemic dilated cardiomyopathy do increase the risk of pump failure death. However, the patient's current treatment regimen and relatively stable laboratory values suggest that this risk is not extremely high. The patient's Pro-BNP level, while elevated, is not extremely high, and the absence of significant electrolyte imbalances or severe kidney dysfunction reduces the risk of pump failure. Additionally, the patient's ECG shows signs of ventricular extrasystoles, but the absence of a high-risk ventricular tachycardia code reduces the likelihood of pump failure death. While pump failure death is a possible outcome, it is the least likely of the three options given the patient's current treatment regimen and relatively stable laboratory values."
136,136,P0224,"Age: 76
Gender: Male 
Weight: 94 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,2
Creatinine (mmol/L): 183.0
Gamma-glutamil transpeptidase (IU/L): 8
Glucose (mmol/L): 3,96
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,1
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,25
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 211.0
Protein (g/L): 71
T3 (pg/dL): 0,0282
T4 (ng/L): 12,07
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,85
Urea (mg/dL): 12,1
LVEF (%): 70.0
Medications: Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely.

RANKING: Survivor

REASONING: The patient is 76 years old with a history of hypertensive cardiomyopathy, dyslipemia, and hypertension. Despite these risk factors, the patient's LVEF is 70%, which is within the normal range, indicating that the heart is still functioning relatively well. The patient is also on medications that are beneficial for heart health, such as loop diuretics, spironolactone, statins, and nitrovasodilators. The patient's blood pressure is well-controlled at 110/80 mmHg, which further reduces the risk of cardiac complications.

Additionally, the patient's laboratory results show that the liver enzymes (ALT and AST) are within normal limits, indicating that there is no significant liver dysfunction that could contribute to cardiac issues. The patient's electrolyte levels (potassium and sodium) are also within normal limits, which is essential for maintaining a stable cardiac rhythm.

The patient's TSH level is within the normal range, indicating that there is no evidence of hypothyroidism, which can contribute to cardiac dysfunction. The patient's troponin level is slightly elevated, but not significantly, suggesting that there is no acute myocardial infarction.

The patient's ECG shows ventricular extrasystole and non-sustained ventricular tachycardia, but these are relatively common findings in patients with hypertensive cardiomyopathy. The presence of paroxysmal supraventricular tachyarrhythmia (PSVT) may require further evaluation, but it is not a significant concern in this context.

Overall, while the patient has several risk factors for cardiac complications, the presence of a relatively preserved LVEF, well-controlled blood pressure, and absence of significant laboratory abnormalities suggest that the patient is likely to survive for the next few years.

RANKING: Sudden cardiac death (2nd most likely)

REASONING: Sudden cardiac death is a possible outcome in patients with hypertensive cardiomyopathy, especially in the presence of ventricular extrasystole and non-sustained ventricular tachycardia on ECG. However, the patient's relatively preserved LVEF and well-controlled blood pressure reduce the risk of sudden cardiac death.

RANKING: Pump failure death (least likely)

REASONING: Pump failure death is less likely in this patient due to the preserved LVEF of 70% and the absence of significant laboratory abnormalities that could indicate cardiac dysfunction, such as elevated liver enzymes or electrolyte imbalances. The patient's medications, including loop diuretics and spironolactone, are also beneficial for managing heart failure."
137,137,P0225,"Age: 79
Gender: Male 
Weight: 71 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 3,38
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,17
Hemoglobin (g/L): 153.0
HDL (mmol/L): 1
Potassium (mEq/L): 3,5
LDL (mmol/L): 1,94
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 2070.0
Protein (g/L): 64
T3 (pg/dL): 0,0318
T4 (ng/L): 18,1
TSH (mIU/L): 0,88
Urea (mg/dL): 5,7
LVEF (%): 70.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Survivor
REASONING: The patient is 79 years old with a history of hypertensive cardiomyopathy, dyslipemia, and hypertension, but his current LVEF is 70%, which is still within the normal range (> 55%). His blood pressure is well-controlled, and he is on medications that are beneficial for his conditions, including statins and an ACE inhibitor. The absence of sustained ventricular tachycardia and non-sustained ventricular tachycardia is a positive sign. His TSH level is within the normal range, indicating no signs of thyroid dysfunction that could contribute to cardiac issues. Although his Pro-BNP level is elevated (2070.0 ng/L), which can indicate heart failure, his symptoms are still manageable with his current treatment regimen, and he has not shown any signs of acute decompensated heart failure. Therefore, based on these factors, a survivor prognosis is the most likely outcome.

RANKING: Pump Failure Death
REASONING: The patient's LVEF is still within the normal range, which suggests that his heart function is not significantly compromised at this time. However, his Pro-BNP level is elevated, and his creatinine level is slightly elevated (106.0 umol/L), which may indicate some degree of renal impairment. The patient's weight is 71 kg, which is within the normal range for his height. His blood pressure is well-controlled, and he is on medications that are beneficial for his conditions. Although the patient's total cholesterol level is slightly elevated, his HDL level is low, which is a risk factor for cardiovascular disease. However, his LDL level is not excessively high, and he is on statins, which should help manage his cholesterol levels. Considering these factors, pump failure death is a possible but less likely outcome compared to survivor.

RANKING: Sudden Cardiac Death
REASONING: The patient has a history of hypertensive cardiomyopathy and is on medications that are beneficial for his conditions, including digoxin, which can help regulate his heart rhythm. His ECG shows monomorphic ventricular extrasystoles, but no sustained ventricular tachycardia or non-sustained ventricular tachycardia, which reduces the risk of sudden cardiac death. His LVEF is within the normal range, and his blood pressure is well-controlled. His TSH level is within the normal range, and he has no signs of thyroid dysfunction that could contribute to cardiac issues. Considering these factors, sudden cardiac death is the least likely outcome."
138,138,P0227,"Age: 73
Gender: Male 
Weight: 86 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,33
Creatinine (mmol/L): 128.0
Gamma-glutamil transpeptidase (IU/L): 8
Glucose (mmol/L): 5,24
Hemoglobin (g/L): 116.0
HDL (mmol/L): 1,1
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,9
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 1184.0
Protein (g/L): 75
T3 (pg/dL): 0,0273
T4 (ng/L): 13,94
Troponin (ng/mL): 0,1
TSH (mIU/L): 1,07
Urea (mg/dL): 6,5
LVEF (%): 70.0
Medications: Diabetes Medication, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here's my prognosis for the next few years:

RANKING: Survivor
REASONING: 
This patient has a moderate to high risk of cardiovascular events, but several factors suggest a more favorable prognosis. The patient has a history of hypertensive cardiomyopathy, diabetes, and peripheral vascular disease, which are all significant risk factors for cardiovascular disease. However, the patient is taking appropriate medications for these conditions, including an ACE inhibitor, statins, and loop diuretics, which are likely helping to manage their symptoms and slow disease progression.

The patient's ejection fraction (LVEF) is 70%, which is within the normal range, indicating that the heart is pumping effectively. The patient's Troponin level is also within normal limits, suggesting that there is no current evidence of acute myocardial infarction or severe cardiac damage.

The patient's Pro-BNP level is elevated at 1184 ng/L, which is a marker of heart failure and may indicate some degree of cardiac dysfunction. However, this value is not extremely high, and the patient's NYHA class is II, indicating that they are experiencing some symptoms of heart failure but are still able to perform most daily activities.

The patient's other laboratory values, including their creatinine, glucose, and lipid profiles, are not severely abnormal, suggesting that the patient's other comorbidities are relatively well-managed.

Considering these factors, the patient's overall prognosis is likely to be a survivor, with a moderate risk of cardiovascular events and heart failure progression. However, with continued medical management and lifestyle modifications, the patient can likely expect to survive for several years with a good quality of life.

The other two prognoses, sudden cardiac death and pump failure death, are less likely due to the following reasons:

* Sudden cardiac death: The patient's ECG shows polymorphic ventricular extrasystoles, which is a risk factor for sudden cardiac death. However, the patient is taking a nitrovasodilator, which may help to reduce this risk. Additionally, the patient's LVEF is within normal limits, which suggests that the heart is pumping effectively and is less likely to experience a sudden, catastrophic failure.
* Pump failure death: The patient's LVEF is 70%, which is within the normal range, and their Pro-BNP level is not extremely high. While the patient's heart failure symptoms are not severe, their Pro-BNP level suggests that there is some degree of cardiac dysfunction. However, the patient's overall clinical picture suggests that they are not at high risk for pump failure death in the near future."
139,139,P0228,"Age: 77
Gender: Female 
Weight: 62 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 160/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 46
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 4,46
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 10,22
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,7
Potassium (mEq/L): 4,27
LDL (mmol/L): 2,35
Sodium (mEq/L): 146.0
Pro-BNP (ng/L): 1951.0
Protein (g/L): 79,5
T3 (pg/dL): 0,0288
T4 (ng/L): 16,13
Troponin (ng/mL): 1,6
TSH (mIU/L): 0,87
Urea (mg/dL): 10
LVEF (%): 25.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses for the next few years as follows:

RANKING: 1. Sudden cardiac death
REASONING: The patient is 77 years old with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction. The patient's ejection fraction (LVEF) is 25%, indicating severe left ventricular dysfunction. The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG further increases the risk of sudden cardiac death. The elevated Pro-BNP level (1951.0 ng/L) suggests significant heart failure. Although the patient is on medications for diabetes, hypertension, and heart failure, the high risk of arrhythmias and severe left ventricular dysfunction makes sudden cardiac death a significant concern.

RANKING: 2. Pump failure death
REASONING: The patient's ejection fraction (LVEF) of 25% indicates severe left ventricular dysfunction, which is a strong predictor of pump failure death. The presence of heart failure symptoms (NYHA Class III) and elevated Pro-BNP level (1951.0 ng/L) further support this prognosis. However, the patient is on loop diuretics, which may help manage fluid overload and alleviate symptoms. Additionally, the patient's overall clinical picture, including the presence of ischemic dilated cardiomyopathy and diabetes, suggests that pump failure death is a possible outcome.

RANKING: 3. Survivor
REASONING: Although the patient has multiple comorbidities and severe left ventricular dysfunction, the presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG, along with the patient's age and overall clinical picture, suggest that sudden cardiac death and pump failure death are more likely outcomes. However, the patient's current medications, including loop diuretics and an angiotensin II receptor blocker, may help manage symptoms and slow disease progression. Additionally, the patient's TSH level is within the normal range, which may indicate that the thyroid function is not contributing to the patient's heart failure. While the patient's prognosis is guarded, it is possible that with close monitoring and management, the patient may survive for a longer period."
140,140,P0230,"Age: 84
Gender: Female 
Weight: 67 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 135/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,25
Creatinine (mmol/L): 117.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 105.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,72
LDL (mmol/L): 2,35
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 308.0
Protein (g/L): 71,3
T3 (pg/dL): 0,0348
T4 (ng/L): 14,23
Troponin (ng/mL): 0,4
TSH (mIU/L): 2,54
Urea (mg/dL): 8,3
LVEF (%): 70.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor
 REASONING: The patient is 84 years old with a history of Hypertensive cardiomyopathy, Hypertension, and Myocardial Infarction. However, she is currently on optimal medical therapy with Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, and Nitrovasodilator, which is likely helping to manage her condition. Her LVEF is 70%, indicating preserved left ventricular function. The patient's NT-proBNP level is elevated at 308 ng/L, suggesting some degree of heart failure, but not to the extent that it would indicate a poor prognosis. Her ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or bradycardia. The patient's overall clinical picture suggests that she is being well-managed and has a good response to treatment. Therefore, a survivor prognosis is the most likely outcome.

RANKING: Pump Failure Death
 REASONING: The patient has a history of Hypertensive cardiomyopathy and Hypertension, which can lead to left ventricular dysfunction and heart failure. Her LVEF is 70%, which is within the normal range, but it may not be the best indicator of her true left ventricular function, especially given her history of Myocardial Infarction. Her NT-proBNP level is elevated, indicating some degree of heart failure. However, her clinical symptoms and overall clinical picture do not suggest severe heart failure. The patient is on optimal medical therapy, and her blood pressure is well-controlled. Therefore, while pump failure death is a possible outcome, it is less likely than survivor.

RANKING: Sudden Cardiac Death
 REASONING: The patient has a history of Myocardial Infarction and Hypertensive cardiomyopathy, which can increase her risk of sudden cardiac death. However, her LVEF is 70%, which is within the normal range, and her ECG shows polymorphic ventricular extrasystoles but no sustained ventricular tachycardia or bradycardia. Her NT-proBNP level is elevated, but her clinical symptoms and overall clinical picture do not suggest severe heart failure. The patient is on optimal medical therapy, including Beta Blockers, which are known to reduce the risk of sudden cardiac death. Therefore, sudden cardiac death is the least likely outcome.

Note: It's worth noting that the patient's TSH level is slightly elevated (2.54 mIU/L), which may indicate subclinical hypothyroidism. This could potentially affect her cardiac function and prognosis, but it is not a clear indicator of sudden cardiac death."
141,141,P0231,"Age: 78
Gender: Male 
Weight: 80 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 130/65 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 6,07
Creatinine (mmol/L): 140.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,55
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,49
LDL (mmol/L): 4,1
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 5910.0
Protein (g/L): 70
T3 (pg/dL): 0,0168
T4 (ng/L): 13,49
Troponin (ng/mL): 0,4
TSH (mIU/L): 1,27
Urea (mg/dL): 9
LVEF (%): 25.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden cardiac death
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's low left ventricular ejection fraction (LVEF) of 25% also indicates severe heart failure. Additionally, the patient's high Pro-BNP level (5910.0 ng/L) suggests significant cardiac stress and potential for arrhythmias. The presence of polymorphic ventricular extrasystoles on the ECG further increases the risk of sudden cardiac death. However, the patient is being treated with loop diuretics and an ACE inhibitor, which may mitigate some of these risks.

RANKING: 2. Pump failure death
 REASONING: The patient's LVEF of 25% and high Pro-BNP level indicate severe heart failure, which increases the risk of pump failure death. The patient's weight of 80 kg and height of 169 cm result in a BMI of approximately 25.8, which is within the normal range, but the patient's muscle mass may be compromised due to chronic heart failure. The patient's serum creatinine level of 140.0 mol/L also suggests mild renal impairment, which can further exacerbate heart failure. However, the patient's NYHA Class II indicates that the patient is still ambulatory and not severely symptomatic, which may indicate a slower progression towards pump failure.

RANKING: 3. Survivor
 REASONING: While the patient has several risk factors for sudden cardiac death and pump failure, the patient's NYHA Class II classification and the presence of TPSV on the ECG suggest that the patient is still relatively stable. The patient's LVEF of 25% is low, but the patient is being treated with medications that may help stabilize the heart function. The patient's age of 78 is also a factor, as older adults with heart failure may have a better prognosis than younger patients. Overall, while the patient's prognosis is guarded, the patient's current clinical status and treatment regimen suggest that survival is the most likely outcome.

Note: The prognosis is based on the provided data and may not reflect the actual outcome, as many factors can influence the patient's outcome, including the effectiveness of treatment, adherence to medication, and the presence of other comorbidities."
142,142,P0234,"Age: 67
Gender: Male 
Weight: 69 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 46
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 4,41
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 7
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,16
LDL (mmol/L): 1,5
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 2129.0
Protein (g/L): 76,5
T3 (pg/dL): 0,0471
T4 (ng/L): 15,02
Troponin (ng/mL): 0,9
TSH (mIU/L): 1,05
Urea (mg/dL): 7,2
LVEF (%): 20.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient's age, NYHA Class II, and current medications (Calcium Channel Blocker, Beta Blockers, Statins, ACE Inhibitor, and Nitrovasodilator) suggest that the patient is being adequately managed for their ischemic dilated cardiomyopathy and hypertension. The patient's LVEF of 20% indicates severe left ventricular dysfunction, but the fact that they are not in NYHA Class IV suggests that they are not experiencing severe symptoms at rest. Additionally, the patient's Pro-BNP level of 2129 ng/L is elevated but not extremely high, which may indicate some degree of compensation. The patient's ECG does not show any signs of life-threatening arrhythmias. However, the patient's low T3 level (0.0471 pg/dL) may indicate a possible underlying issue with thyroid function, which could potentially impact cardiac function. Given the patient's current treatment and relatively stable condition, the most likely prognosis is survival.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's history of myocardial infarction, ischemic dilated cardiomyopathy, and low LVEF (20%) increase their risk for sudden cardiac death. The presence of polymorphic ventricular extrasystoles on the ECG also increases the risk for arrhythmias and sudden cardiac death. However, the patient's current medications (Calcium Channel Blocker, Beta Blockers, and Nitrovasodilator) are known to reduce the risk of sudden cardiac death. The patient's Pro-BNP level is elevated, but not extremely high, which may indicate some degree of compensation. The patient's overall condition and treatment plan suggest that sudden cardiac death is a possible but less likely outcome compared to the other two options.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 20% and history of ischemic dilated cardiomyopathy indicate severe left ventricular dysfunction, which increases the risk for pump failure. However, the patient's NYHA Class II and current medications suggest that they are being adequately managed for their condition. The patient's Pro-BNP level is elevated, but not extremely high, which may indicate some degree of compensation. The patient's overall condition and treatment plan suggest that pump failure death is the least likely outcome."
143,143,P0235,"Age: 76
Gender: Female 
Weight: 92 kg
Height: 153 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 107.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 7,07
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,84
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1309.0
Protein (g/L): 67
T3 (pg/dL): 0,0441
T4 (ng/L): 22,35
Troponin (ng/mL): 0,7
TSH (mIU/L): 1,62
Urea (mg/dL): 8,4
LVEF (%): 40.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's a prognosis for the next few years:

RANKING: Survivor
REASONING: The patient is 76 years old with a history of ischemic dilated cardiomyopathy, diabetes, peripheral vascular disease, hypertension, and a previous myocardial infarction. Despite these conditions, several factors suggest a relatively favorable prognosis. The patient's blood pressure is well-controlled, and she is taking medications for diabetes, loop diuretics, ACE inhibitor, and nitrovasodilator, which are all standard treatments for heart failure and hypertension. Her LVEF is 40%, which, although low, is not extremely low. The Pro-BNP level is elevated, but not excessively high. The patient's recent troponin level is 0.7 ng/mL, which is not significantly elevated, suggesting that she is not experiencing an acute myocardial infarction. Additionally, her ECG shows no signs of severe arrhythmias, such as sustained ventricular tachycardia. Considering these factors, a survivor prognosis is the most likely outcome.

RANKING: Pump failure death
REASONING: The patient has a history of ischemic dilated cardiomyopathy and a low LVEF of 40%, which increases the risk of heart failure. Her Pro-BNP level is elevated, indicating increased cardiac stress. However, the patient's blood pressure is well-controlled, and she is taking medications that can help manage her heart failure. While her creatinine level is elevated, indicating some renal impairment, it is not extremely high. The patient's ECG shows no signs of severe arrhythmias, which reduces the risk of sudden cardiac death. However, the combination of her low LVEF and elevated Pro-BNP level suggests a higher risk of pump failure death.

RANKING: Sudden cardiac death
REASONING: The patient has a history of ischemic dilated cardiomyopathy, a low LVEF of 40%, and an elevated Pro-BNP level, all of which increase the risk of sudden cardiac death. Her ECG shows polymorphic ventricular extrasystoles and unknown ventricular tachycardia, which are arrhythmias that can increase the risk of sudden cardiac death. However, the patient's blood pressure is well-controlled, and she is taking medications that can help manage her heart failure. The absence of sustained ventricular tachycardia and bradycardia on the ECG reduces the risk of sudden cardiac death. While the patient's troponin level is slightly elevated, it is not significantly high, suggesting that she is not experiencing an acute myocardial infarction. Considering these factors, sudden cardiac death is the least likely prognosis."
144,144,P0236,"Age: 74
Gender: Female 
Weight: 87 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 180/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,41
Creatinine (mmol/L): 130.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,68
Hemoglobin (g/L): 120.0
HDL (mmol/L): 1,2
Potassium (mEq/L): 3,9
LDL (mmol/L): 1,71
Sodium (mEq/L): 146.0
Pro-BNP (ng/L): 1176.0
Protein (g/L): 72,9
T3 (pg/dL): 0,0312
T4 (ng/L): 14,43
Troponin (ng/mL): 0,5
TSH (mIU/L): 5,19
Urea (mg/dL): 13
LVEF (%): 50.0
Medications: Amiodarone, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. However, please note that the patient's outcome is already stated as survivor, which seems contradictory to the task. I will proceed with the task as instructed and provide a prognosis based on the patient's data.

RANKING: Sudden cardiac death, Pump failure death, Survivor

REASONING:

1.  Sudden cardiac death: Given the patient's age (74), hypertension (180/90 mmHg), and history of hypertensive cardiomyopathy, diabetes, and dyslipemia, the risk of sudden cardiac death is relatively high. The presence of ventricular extrasystole and a relatively low LVEF (50%) further increase this risk. The high Pro-BNP level (1176.0 ng/L) also suggests increased cardiac stress and potential risk of arrhythmias.

2.  Pump failure death: Although the patient has a history of hypertensive cardiomyopathy and a relatively low LVEF (50%), the current medications (Loop Diuretics and ACE Inhibitor) and the absence of severe symptoms (NYHA Class II) suggest that the patient's heart function is being managed. The patient's creatinine level (130.0 umol/L) is within the normal range, indicating that renal function is not severely impaired. Therefore, the risk of pump failure death is lower compared to sudden cardiac death.

3.  Survivor: Based on the patient's current medical management and relatively stable vital signs, the risk of sudden cardiac death and pump failure death is higher than the risk of survival. However, considering the patient's age and comorbidities, it is still possible that the patient could survive for several years with proper medical management and lifestyle modifications. The patient's current medications, including Amiodarone, Loop Diuretics, Statins, and ACE Inhibitor, are likely aimed at managing the patient's conditions and reducing the risk of adverse outcomes."
145,145,P0237,"Age: 54
Gender: Male 
Weight: 92 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 194.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 141.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 5,1
LDL (mmol/L): 1,03
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 986.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,23
TSH (mIU/L): 0,87
Urea (mg/dL): 11,48
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"RANKING: Survivor

REASONING: 

Considering the patient's profile, I would rank the prognosis as a survivor for the following reasons:

1.  Age and Gender: The patient is 54 years old, which is relatively young for a patient with ischemic dilated cardiomyopathy. The average age for patients with this condition is typically older. Additionally, being male, the patient has a slightly higher risk, but not significantly so.

2.  NYHA Class II: The patient has a moderate level of symptoms, but not severe, which indicates that the disease is not in its advanced stage. This suggests that the patient may have a better prognosis.

3.  Blood Pressure and Medications: The patient's blood pressure is within a relatively normal range, which is beneficial for reducing the risk of cardiac events. The patient is also on a comprehensive regimen of medications, including ACE inhibitors, beta blockers, and statins, which are known to improve outcomes in patients with heart failure.

4.  LVEF: Although the patient's left ventricular ejection fraction (LVEF) is low at 25%, it is not extremely low. An LVEF of 25-30% is generally associated with a better prognosis compared to an LVEF below 20%.

5.  ECG Findings: The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia indicates some degree of arrhythmia, but the patient does not have sustained ventricular tachycardia, which is a more ominous sign.

6.  Other Lab Values: The patient's electrolytes, liver enzymes, and kidney function are relatively normal, which suggests that there are no significant underlying conditions that could worsen the patient's prognosis.

Considering these factors, the patient's overall prognosis is more likely to be a survivor. However, it is essential to note that the patient's condition is still serious, and close monitoring and follow-up are necessary to adjust the treatment plan as needed.

RANKING: Sudden Cardiac Death (SCD)

REASONING: 

Considering the patient's profile, I would rank Sudden Cardiac Death (SCD) as the second most likely prognosis for the following reasons:

1.  Ischemic Dilated Cardiomyopathy: The patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, which increases the risk of SCD.

2.  Low LVEF: Although the patient's LVEF is not extremely low, it is still below 30%, which increases the risk of SCD.

3.  ECG Findings: The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia indicates a higher risk of arrhythmias, which can lead to SCD.

4.  Pro-BNP: The patient's Pro-BNP level is elevated, which is a marker of heart failure and can indicate a higher risk of SCD.

However, the patient's overall profile, including the use of beta blockers, ACE inhibitors, and statins, may mitigate some of these risks.

RANKING: Pump Failure Death

REASONING: 

Considering the patient's profile, I would rank pump failure death as the least likely prognosis for the following reasons:

1.  LVEF: Although the patient's LVEF is low, it is not extremely low, and the patient is on medications that can help improve cardiac function.

2.  Medications: The patient is on a comprehensive regimen of medications that can help improve cardiac function and reduce symptoms.

3.  NYHA Class II: The patient's symptoms are not severe, indicating that the disease is not in its advanced stage.

4.  ECG Findings: The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia indicates some degree of arrhythmia, but the patient does not have sustained ventricular tachycardia, which is a more ominous sign.

However, the patient's condition is still serious, and close monitoring and follow-up are necessary to adjust the treatment plan as needed."
146,146,P0238,"Age: 53
Gender: Male 
Weight: 66 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 130/50 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 27
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,15
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 48
Glucose (mmol/L): 3,8
Hemoglobin (g/L): 83.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 5,6
LDL (mmol/L): 1,71
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 137.0
Protein (g/L): 60
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,04
TSH (mIU/L): 2,4
Urea (mg/dL): 11,32
LVEF (%): 55.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

Considering the patient's age, gender, and medical history, the prognosis for this patient is generally favorable. The patient is 53 years old, which is relatively young, and has a history of hypertensive cardiomyopathy and hypertension, which can be managed with medications. The patient's current NYHA class is II, indicating that they have some limitations in physical activity but can still perform daily tasks without significant symptoms.

The patient's laboratory results show elevated creatinine levels (124.0 mmol/L), indicating impaired renal function, but this is likely related to the patient's hypertension and cardiomyopathy. The patient's LVEF (55.0%) is within a relatively normal range, indicating that the heart is still pumping effectively.

The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of underlying cardiac disease, but it is not a definitive indicator of poor prognosis. The presence of TPSV (paroxysmal supraventricular tachyarrhythmia) is also noted, but it is not a significant concern in this case.

The patient is already on beta blockers, loop diuretics, and ACE inhibitors, which are all appropriate medications for managing hypertensive cardiomyopathy and hypertension. These medications will help to reduce the patient's blood pressure, slow the heart rate, and reduce the workload on the heart.

Taking all of these factors into account, the most likely prognosis for this patient is survivor. The patient's young age, relatively preserved LVEF, and effective management of their hypertension and cardiomyopathy with medications make a survivor prognosis more likely."
147,147,P0240,"Age: 54
Gender: Male 
Weight: 103 kg
Height: 179 cm
NYHA Class: II
Blood Pressure: 130/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 44
ALT or GPT (IU/L): 137.0
AST or GOT (IU/L): 119.0
Total Cholesterol (mmol/L): 6,62
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 378
Glucose (mmol/L): 16,8
Hemoglobin (g/L): 149.0
HDL (mmol/L): 2,22
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,9
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 18.0
Protein (g/L): 84
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,47
Urea (mg/dL): 8,32
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years, ranking the possible outcomes from most likely to least likely.

RANKING: 1. Survivor
REASONING: The patient has a relatively stable condition with idiopathic dilated cardiomyopathy and diabetes. The LVEF of 45% is lower than normal, indicating some degree of heart failure, but it's not severely compromised. The patient is on appropriate medications for heart failure and diabetes, which includes beta blockers, ACE inhibitors, and loop diuretics. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG suggests a relatively stable cardiac rhythm. The elevated liver enzymes (ALT and AST) might indicate some degree of liver dysfunction, but it's not severe enough to significantly impact the prognosis. The patient's Pro-BNP level of 18.0 ng/L is within a relatively normal range, indicating a low level of B-type natriuretic peptide, which is a marker of heart failure. Considering these factors, the most likely outcome is that the patient will survive for the next few years with continued management of their conditions.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 45% indicates a reduced left ventricular function, which is a risk factor for pump failure. However, the patient is on appropriate medications for heart failure, and their Pro-BNP level is within a relatively normal range. The absence of significant arrhythmias on the ECG and the patient's relatively stable condition suggest that pump failure is not an immediate concern. The patient's diabetes and liver dysfunction may contribute to a higher risk of complications, but they are not sufficient to make pump failure the most likely outcome. Therefore, pump failure death is the second most likely outcome.

RANKING: 3. Sudden Cardiac Death
REASONING: Sudden cardiac death is less likely in this patient due to the absence of significant arrhythmias on the ECG and the patient's relatively stable condition. The presence of monomorphic ventricular extrasystoles may be a concern, but it is not a strong predictor of sudden cardiac death. The patient's LVEF of 45% is a risk factor for sudden cardiac death, but it is not sufficient to make it the most likely outcome. The patient's overall clinical condition and the lack of other risk factors for sudden cardiac death make it the least likely outcome."
148,148,P0241,"Age: 35
Gender: Female 
Weight: 76 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 115/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 46
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 6,15
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 134.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,2
LDL (mmol/L): 4,47
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 35070.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,32
Urea (mg/dL): 3,16
LVEF (%): 50.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely:

RANKING: Survivor

REASONING: The patient is 35 years old with a history of idiopathic dilated cardiomyopathy, which is a significant underlying condition. However, the patient's current medication regimen, including Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Spironolactone, suggests that they are being actively managed for heart failure. The patient's LVEF (Left Ventricular Ejection Fraction) is 50%, which is within the normal range for a patient with a history of heart failure, indicating that the patient's heart is functioning relatively well.

The patient's blood pressure is within a normal range (115/80 mmHg), and their creatinine level is slightly elevated (88.0 mmol/L), but not significantly so. The patient's albumin level is slightly low (46 g/L), which may indicate some degree of liver dysfunction, but this is not uncommon in patients with heart failure.

The patient's pro-BNP (B-type natriuretic peptide) level is elevated (35,070 ng/L), which is consistent with heart failure, but the level is not extremely high. The patient's troponin level is within normal limits, indicating that there is no acute myocardial infarction.

The patient's thyroid function is within normal limits, with a TSH (thyroid-stimulating hormone) level of 1.32 mIU/L and a T4 (thyroxine) level of 16 ng/L.

Considering the patient's age, sex, and current treatment regimen, the prognosis is more favorable. The patient's LVEF is relatively well-preserved, and their heart failure symptoms are likely being well-managed with their current medications.

While the patient's idiopathic dilated cardiomyopathy is a significant underlying condition, the prognosis for a 35-year-old female patient with a relatively well-managed heart failure condition is generally better than for an older patient or a patient with more advanced heart failure symptoms.

Therefore, based on the provided data, the most likely prognosis for this patient is a survivor.

Sudden cardiac death and pump failure death are less likely due to the patient's relatively well-managed heart failure condition and preserved LVEF.

RANKING: Sudden Cardiac Death (2nd most likely)

REASONING: Sudden cardiac death is a possible outcome for patients with idiopathic dilated cardiomyopathy, but the patient's current treatment regimen and relatively preserved LVEF make this outcome less likely. The patient's pro-BNP level is elevated, but not extremely high, which may indicate some degree of heart failure, but not severe enough to increase the risk of sudden cardiac death.

RANKING: Pump Failure Death (3rd most likely)

REASONING: Pump failure death is a possible outcome for patients with heart failure, but the patient's relatively well-managed condition and preserved LVEF make this outcome less likely. The patient's LVEF is 50%, which is within the normal range, and their heart failure symptoms are likely being well-managed with their current medications."
149,149,P0244,"Age: 36
Gender: Male 
Weight: 94 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 49.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,28
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 164.0
Protein (g/L): 79
T3 (pg/dL): 0,02
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,41
Urea (mg/dL): 4,82
LVEF (%): 43.0
Medications: None reported.
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor
REASONING: Based on the provided patient data, I would rank the prognosis as a survivor for the next few years. Here's why:

1. Age: The patient is 36 years old, which is relatively young for a patient with ischemic dilated cardiomyopathy and myocardial infarction. This suggests that the patient has a better chance of survival and recovery compared to older patients with similar conditions.

2. NYHA Class II: The patient's New York Heart Association (NYHA) functional classification indicates that they have some limitation in physical activity but are still able to perform daily tasks without symptoms. This suggests that the patient's heart failure is not severe, and they are not in an advanced stage.

3. Medications: Although the patient is not currently taking any medications, this is not uncommon in the early stages of heart failure. Starting medications like ACE inhibitors, beta-blockers, and diuretics can help improve symptoms and outcomes.

4. LVEF: The left ventricular ejection fraction (LVEF) of 43% is relatively low, indicating some degree of heart failure. However, it is not as low as some other patients with similar conditions, suggesting that the patient may have some reserve left.

5. Pro-BNP: The pro-brain natriuretic peptide (Pro-BNP) level is elevated, but not extremely high. Elevated Pro-BNP levels can indicate heart failure, but a level of 164 ng/L is not as concerning as levels above 500 ng/L.

6. Other lab results: The patient's electrolyte levels, liver enzymes, and kidney function are relatively normal, which suggests that there are no other significant underlying conditions that could worsen the patient's prognosis.

7. TSH and T4 levels: The patient's thyroid function is normal, which is essential for maintaining heart health.

Considering these factors, while the patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, their relatively young age, NYHA Class II, and normal or near-normal lab results suggest that they have a good chance of survival and recovery with proper treatment and management.

RANKING: Sudden Cardiac Death
REASONING: Based on the same data, I would rank sudden cardiac death as the second most likely outcome. Here's why:

1. Ischemic dilated cardiomyopathy and myocardial infarction: The patient's history of heart attack and heart failure increases their risk of sudden cardiac death.

2. Low LVEF: A low LVEF of 43% indicates some degree of heart failure, which can increase the risk of sudden cardiac death.

3. Polymorphic ventricular extrasystoles: The presence of polymorphic ventricular extrasystoles on the ECG suggests that the patient's heart rhythm is irregular and may be prone to arrhythmias.

4. Elevated Pro-BNP: While not extremely high, the elevated Pro-BNP level suggests that the patient's heart is under strain, which can increase the risk of sudden cardiac death.

However, the patient's relatively young age and lack of other risk factors for sudden cardiac death (such as a history of ventricular tachycardia or a low ejection fraction below 30%) suggest that this outcome is less likely than survival.

RANKING: Pump Failure Death
REASONING: Based on the same data, I would rank pump failure death as the least likely outcome. Here's why:

1. Age: The patient is relatively young, which reduces the risk of pump failure death.

2. NYHA Class II: The patient's functional classification suggests that their heart failure is not severe, and they are not in an advanced stage.

3. LVEF: While the patient's LVEF is low, it is not as low as some other patients with similar conditions, suggesting that the patient may have some reserve left.

4. Other lab results: The patient's electrolyte levels, liver enzymes, and kidney function are relatively normal, which suggests that there are no other significant underlying conditions that could worsen the patient's prognosis.

5. Medications: Although the patient is not currently taking any medications, starting treatments like ACE inhibitors, beta-blockers, and diuretics can help improve symptoms and outcomes.

Overall, while the patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, their relatively young age, NYHA Class II, and normal or near-normal lab results suggest that pump failure death is less likely."
150,150,P0247,"Age: 72
Gender: Male 
Weight: 67 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 49.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 4,42
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5
LDL (mmol/L): 2,64
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 455.0
Protein (g/L): 82
T3 (pg/dL): 0,04
T4 (ng/L): 25
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,27
Urea (mg/dL): 11,15
LVEF (%): 34.0
Medications: Calcium Channel Blocker, Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Given the patient's age, medical history, and current clinical status, I rank the possible prognoses as follows:

RANKING: 1. Sudden Cardiac Death, 2. Pump Failure Death, 3. Survivor

REASONING:

1. Sudden Cardiac Death (SCD): The patient has a high risk of SCD due to the following factors:
    - Ischemic dilated cardiomyopathy with an LVEF of 34%, indicating severe left ventricular dysfunction.
    - Presence of ventricular extrasystoles, which may indicate underlying electrical instability.
    - Elevated Pro-BNP levels (455.0 ng/L), indicating high filling pressures and potential cardiac strain.
    - History of diabetes and dyslipidemia, contributing to atherosclerotic disease and potential arrhythmia risk.
    - Medications (Calcium Channel Blocker, Digoxin, and Spironolactone) that may not adequately address the underlying pathophysiology.
    - TSH level is within the normal range, but T3 is low, which may indicate hypothyroidism, contributing to decreased cardiac output.

Given these factors, the risk of SCD is high, especially considering the patient's age and NYHA Class II classification.

2. Pump Failure Death: The patient's LVEF of 34% and elevated Pro-BNP levels suggest severe left ventricular dysfunction, increasing the risk of pump failure. However, the patient is already on optimal medical therapy (ACE Inhibitor, Loop Diuretics, and Spironolactone), which may help mitigate this risk. The presence of ventricular extrasystoles and TPSV on the ECG may also contribute to the risk of pump failure.

3. Survivor: While the patient's medical history and current clinical status suggest a high risk of cardiac events, the fact that they are already on optimal medical therapy and have a relatively low Troponin level (0.01 ng/mL) indicates some level of cardiac reserve. The patient's weight and height are also within a relatively normal range, which may help mitigate some of the risks associated with obesity. However, this prognosis is still uncertain due to the high risk of SCD and pump failure.

Please note that this prognosis is based on the provided data and may change with new information or further evaluation."
151,151,P0249,"Age: 48
Gender: Male 
Weight: 65 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 200/100 mmHg
Past Medical History: Toxic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 61.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 6,75
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 194
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 3,6
LDL (mmol/L): 4,14
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 320.0
Protein (g/L): 79
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,21
Urea (mg/dL): 3,66
LVEF (%): 44.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient is 48 years old with a history of toxic dilated cardiomyopathy, which is a significant risk factor for adverse outcomes. However, the patient is on optimal medical therapy with an Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, and Loop Diuretics, which suggests that the patient's symptoms are being managed. The patient's LVEF is 44%, which is relatively preserved despite the history of dilated cardiomyopathy. Additionally, the patient's blood pressure is being controlled at 200/100 mmHg, which is a common challenge in patients with heart failure. The patient's Pro-BNP level is elevated at 320.0 ng/L, which indicates some degree of cardiac dysfunction, but it is not excessively high. The patient's ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or other high-risk findings. Considering these factors, the patient's prognosis is likely to be a survivor, with ongoing management and monitoring to optimize their treatment and prevent further cardiac deterioration.

RANKING: 2. Pump Failure Death
 REASONING: The patient's history of toxic dilated cardiomyopathy and current LVEF of 44% indicate a high risk of pump failure. The patient's elevated Pro-BNP level and controlled blood pressure suggest that the patient's heart is working harder to compensate for the underlying dysfunction. The patient's medications are optimized, but the patient's condition is not stable, and there is a risk of further cardiac deterioration. However, the patient's symptoms are being managed, and the patient's ECG is relatively benign. Considering these factors, the risk of pump failure death is lower than sudden cardiac death but higher than survivor.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient's ECG shows polymorphic ventricular extrasystoles, which is a risk factor for sudden cardiac death. However, the patient's LVEF is relatively preserved at 44%, and the patient's medications are optimized, which reduces the risk of sudden cardiac death. The patient's Pro-BNP level is elevated, but it is not excessively high, and the patient's blood pressure is being controlled. The patient's history of toxic dilated cardiomyopathy is a risk factor, but the patient's current symptoms are being managed. Considering these factors, the risk of sudden cardiac death is the lowest of the three possible prognoses."
152,152,P0252,"Age: 73
Gender: Male 
Weight: 83 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 3,03
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,94
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1070.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 27
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,55
Urea (mg/dL): 6,66
LVEF (%): 38.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here are the three possible prognoses for the next few years, ranked from most likely to least likely, along with the reasoning behind each:

RANKING: 1. Survivor
REASONING: The patient is 73 years old with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction. However, the patient's current medications (Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, and Statins) and the fact that the patient's LVEF is 38% (albeit low, but not critically low) suggest that the patient is receiving appropriate treatment for their conditions. Additionally, the patient's blood pressure is well-controlled, and the troponin level is within normal limits. Although the Pro-BNP level is elevated, indicating some degree of heart failure, it is not extremely high. The patient's overall condition seems to be relatively stable, and with continued medical management, the patient may be able to maintain a stable condition for the next few years.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of ischemic dilated cardiomyopathy, low LVEF (38%), and elevated Pro-BNP level increase the risk of sudden cardiac death. However, the patient is on appropriate medications, and the absence of other high-risk features such as ventricular tachycardia or a history of syncope makes sudden cardiac death less likely. The patient's T3 and T4 levels are also within normal limits, which reduces the likelihood of thyroid-related arrhythmias. The patient's overall condition is not ideal, but with close monitoring and continued medical management, the risk of sudden cardiac death may be mitigated.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF of 38% indicates a significant impairment of left ventricular function, which increases the risk of pump failure death. The patient's elevated Pro-BNP level and history of ischemic dilated cardiomyopathy also support this risk. However, the patient's current medications and the fact that the patient's blood pressure is well-controlled may help slow the progression of heart failure. The patient's age and comorbidities (diabetes, dyslipemia, and hypertension) also contribute to the risk of pump failure death. While the patient's condition is concerning, the fact that the patient is receiving appropriate treatment and is not experiencing acute decompensation suggests that pump failure death may not be the most likely outcome in the next few years.

Please note that these prognoses are based on the provided data and should be taken as a general assessment. The actual outcome may vary depending on various factors, including the patient's adherence to treatment, lifestyle changes, and any unforeseen complications."
153,153,P0253,"Age: 59
Gender: Female 
Weight: 80 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 5,04
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,26
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 824.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 3,37
Urea (mg/dL): 7,32
LVEF (%): 40.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient is 59 years old with a history of idiopathic dilated cardiomyopathy and has been on a treatment regimen of Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, and Spironolactone. The patient's LVEF is 40%, indicating a reduced ejection fraction, but the medications suggest that the patient is being managed for heart failure. The patient's NYHA Class is II, indicating that the patient has some limitations in physical activity but is still able to perform daily tasks without significant symptoms. The patient's blood pressure is within a relatively normal range, and there are no signs of acute coronary syndrome or severe arrhythmias. The patient's creatinine level is elevated, but it is not significantly high, indicating that renal function is still relatively preserved. The patient's Pro-BNP level is elevated, but it is not excessively high, indicating that the patient's heart failure is being managed. Considering these factors, the most likely prognosis is that the patient will survive.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF is 40%, indicating a reduced ejection fraction, which is a risk factor for pump failure. The patient's creatinine level is elevated, indicating some degree of renal impairment, which is a common complication of heart failure. The patient's Pro-BNP level is elevated, indicating that the patient's heart failure is being managed but may still be at risk for progression. However, the patient is on a treatment regimen that includes medications that are commonly used to manage heart failure, and the patient's NYHA Class is II, indicating that the patient is still able to perform daily tasks without significant symptoms. While pump failure is a possible prognosis, it is less likely than survivorship due to the patient's relatively stable condition and management of heart failure.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a risk factor for sudden cardiac death. The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are risk factors for sudden cardiac death. However, the patient is on a treatment regimen that includes Beta Blockers, which are commonly used to reduce the risk of sudden cardiac death. The patient's LVEF is 40%, but the patient is still able to perform daily tasks without significant symptoms, indicating that the patient's heart failure is being managed. While sudden cardiac death is a possible prognosis, it is the least likely of the three due to the patient's relatively stable condition and management of heart failure."
154,154,P0254,"Age: 49
Gender: Male 
Weight: 65 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 100/50 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 49.0
Total Cholesterol (mmol/L): 5,53
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 465
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 166.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,1
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 194.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,38
Urea (mg/dL): 5,99
LVEF (%): 23.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
 REASONING: The patient is a 49-year-old male with a history of enolic dilated cardiomyopathy, dyslipemia, hypertension, and myocardial infarction, indicating a complex cardiac condition. However, despite the severity of his condition, the patient is on a comprehensive treatment regimen that includes beta blockers, digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor, which suggests that his condition is being actively managed. The patient's NYHA Class II classification indicates that he experiences some symptoms, but they are not limiting his daily activities. His LVEF of 23% is relatively low, but it's not the lowest possible value, indicating that the heart is still functioning to some extent. The patient's BNP level of 194 ng/L is elevated, but it's not extremely high, which might indicate some degree of cardiac compensation. While the patient's troponin level is slightly elevated, it's not indicative of ongoing myocardial damage. The absence of sustained ventricular tachycardia and other serious arrhythmias on the ECG is also a positive sign. Considering these factors, the most likely prognosis for this patient is survival, assuming that he adheres to his treatment plan and makes lifestyle modifications to manage his condition.

RANKING: 2. Sudden Cardiac Death
 REASONING: Sudden cardiac death is a possible prognosis for this patient due to his history of enolic dilated cardiomyopathy, low LVEF, and the presence of polymorphic ventricular extrasystoles on the ECG. These factors increase the risk of arrhythmias and sudden cardiac death. However, the patient's treatment regimen and the absence of sustained ventricular tachycardia on the ECG suggest that his condition is being managed, and the risk of sudden cardiac death is not extremely high. Additionally, the patient's age and sex are not typically associated with a high risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
 REASONING: Pump failure death is the least likely prognosis for this patient due to his relatively low LVEF of 23%. While this value is concerning, it's not extremely low, and the patient's treatment regimen includes medications that are designed to support cardiac function, such as beta blockers and spironolactone. Additionally, the patient's BNP level is elevated but not extremely high, which might indicate some degree of cardiac compensation. The patient's overall clinical picture suggests that his heart is still functioning, albeit inefficiently, and that pump failure death is not the most likely outcome."
155,155,P0255,"Age: 41
Gender: Male 
Weight: 81 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 13,3
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4
LDL (mmol/L): 3,88
Sodium (mEq/L): 130.0
Protein (g/L): 68
T3 (pg/dL): 0,02
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,28
Urea (mg/dL): 6,66
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Survivor
 REASONING: The patient is 41 years old with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and myocardial infarction. However, the patient is on a comprehensive treatment plan, including diabetes medication, angiotensin II receptor blocker, beta blockers, loop diuretics, spironolactone, and statins. The patient's LVEF is 35%, which is lower than normal but not critically low. The patient's blood pressure is within a relatively normal range, and there are no signs of acute coronary syndrome or severe arrhythmias on the ECG. The patient's hemoglobin and potassium levels are within normal limits, and the creatinine level is slightly elevated but not critically high. While the patient's total cholesterol and LDL levels are elevated, the patient is on statins, which are likely helping to manage these levels. Considering these factors, the patient's prognosis for survival over the next few years is relatively good.

RANKING: Pump Failure Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a risk factor for pump failure. The patient's LVEF is 35%, which is lower than normal, indicating reduced cardiac function. The patient's creatinine level is slightly elevated, suggesting possible renal impairment, which can be a consequence of heart failure. However, the patient's overall treatment plan and lack of acute complications suggest that pump failure is not the most likely outcome in the short term.

RANKING: Sudden Cardiac Death
 REASONING: While the patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, there are no signs of acute coronary syndrome or severe arrhythmias on the ECG. The patient's LVEF is 35%, which, although low, is not critically low. The patient is on beta blockers, which are effective in reducing the risk of sudden cardiac death. Additionally, the patient's potassium and hemoglobin levels are within normal limits, which reduces the risk of life-threatening arrhythmias. Therefore, sudden cardiac death is the least likely outcome among the three options."
156,156,P0257,"Age: 76
Gender: Male 
Weight: 84 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 105/55 mmHg
Past Medical History: Other HF etiology, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 7,73
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 120.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,6
LDL (mmol/L): 5,79
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1876.0
Protein (g/L): 68
T3 (pg/dL): 0,02
T4 (ng/L): 25
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,44
Urea (mg/dL): 7,15
LVEF (%): 42.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely.

RANKING: Survivor

REASONING: The patient is 76 years old with a history of myocardial infarction, dyslipemia, and other heart failure etiology, which suggests a high risk of cardiac events. However, the patient is already on a comprehensive medication regimen, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all appropriate for managing heart failure and reducing the risk of adverse cardiac events. The patient's LVEF of 42% indicates that the left ventricle is still functioning, albeit at a reduced capacity. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, or other severe arrhythmias on the ECG also suggests that the patient's cardiac rhythm is relatively stable. Furthermore, the patient's blood pressure is within a relatively normal range, and the albumin and protein levels are within normal limits. While the elevated pro-BNP level indicates that the patient has some degree of heart failure, the patient's overall clinical picture suggests that they are well-managed and have a good prognosis for survival.

RANKING: Pump Failure Death

REASONING: The patient's LVEF of 42% indicates that the left ventricle is functioning at a reduced capacity, which increases the risk of pump failure. The elevated pro-BNP level also suggests that the patient has some degree of heart failure. However, the patient's overall clinical picture is relatively stable, and they are on a comprehensive medication regimen that is likely helping to manage their heart failure. While pump failure is a possible outcome, it is less likely than sudden cardiac death due to the patient's stable rhythm and relatively normal blood pressure.

RANKING: Sudden Cardiac Death

REASONING: The patient's age, history of myocardial infarction, and reduced LVEF increase the risk of sudden cardiac death. However, the patient's stable rhythm on the ECG and relatively normal blood pressure suggest that they are less likely to experience sudden cardiac death. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, or other severe arrhythmias on the ECG also suggests that the patient's cardiac rhythm is relatively stable. While sudden cardiac death is a possible outcome, it is the least likely of the three options due to the patient's relatively stable clinical picture."
157,157,P0258,"Age: 59
Gender: Male 
Weight: 80 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 37
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,03
Creatinine (mmol/L): 239.0
Gamma-glutamil transpeptidase (IU/L): 58
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 108.0
HDL (mmol/L): 0,39
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,91
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 72
T3 (pg/dL): 0,03
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,01
Urea (mg/dL): 20,3
LVEF (%): 48.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the prognosis ranking from most likely to least likely:

RANKING: 1. Survivor
 REASONING: The patient has a complex medical history with multiple comorbidities, including ischemic dilated cardiomyopathy, diabetes, dyslipemia, and peripheral vascular disease. However, the patient is already on a comprehensive treatment regimen, including beta blockers, loop diuretics, statins, and an ACE inhibitor, which suggests that the patient's condition is being actively managed. The patient's LVEF is 48%, which is lower than the normal range but not extremely low. The patient's Pro-BNP level is elevated at 709.0 ng/L, indicating some level of heart failure, but not extremely high. The patient's blood pressure is within a relatively normal range, and the patient does not have any signs of severe electrolyte imbalances or acute coronary syndrome. Considering the patient's age and the fact that the patient is already on treatment, the likelihood of sudden cardiac death or pump failure death in the short term is lower compared to the likelihood of the patient continuing to receive treatment and managing their condition.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of myocardial infarction, which increases the risk of sudden cardiac death. The patient's LVEF is 48%, which is below the normal range, and the patient has an elevated Pro-BNP level, indicating some level of heart failure. However, the patient is already on beta blockers, which are known to reduce the risk of sudden cardiac death. The patient's ECG does not show any signs of ventricular tachycardia or other high-risk arrhythmias. While the patient's risk of sudden cardiac death is higher than average, it is still relatively low given the patient's age and the fact that the patient is already on treatment.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF is 48%, which is below the normal range, indicating some level of heart failure. The patient's Pro-BNP level is elevated, and the patient has a history of ischemic dilated cardiomyopathy, which increases the risk of pump failure. However, the patient is already on loop diuretics and ACE inhibitors, which are known to improve heart failure symptoms and outcomes. The patient's blood pressure is within a relatively normal range, and the patient does not have any signs of severe electrolyte imbalances or acute coronary syndrome. While the patient's risk of pump failure death is higher than average, it is still relatively low given the patient's age and the fact that the patient is already on treatment."
158,158,P0259,"Age: 55
Gender: Male 
Weight: 94 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 180/80 mmHg
Past Medical History: Hypertropic cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,97
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 161.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,65
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 102.0
Protein (g/L): 69
T3 (pg/dL): 0,02
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,25
Urea (mg/dL): 9,65
LVEF (%): 70.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's my prognosis for the next few years:

RANKING: 1. Survivor
 REASONING: The patient has a relatively high LVEF (70%) which indicates that the heart is pumping blood effectively, suggesting that the patient is not in an advanced stage of heart failure. Additionally, the patient is on a regimen of beta blockers, loop diuretics, statins, ACE inhibitor, and nitrovasodilators which are standard treatments for heart failure and hypertension. The absence of sustained ventricular tachycardia and non-sustained ventricular tachycardia on the ECG also suggests that the patient's heart rhythm is relatively stable. However, the patient's NYHA Class III classification indicates that they have severe symptoms with ordinary physical activity resulting in fatigue, palpitations, or shortness of breath. Despite this, the patient's overall clinical picture and medication regimen suggest that they are being managed effectively and have a good prognosis for survival.

RANKING: 2. Pump failure death
 REASONING: The patient's LVEF is 70%, which is within the normal range, indicating that the heart is pumping blood effectively. However, the patient's NYHA Class III classification and high blood pressure (180/80 mmHg) suggest that the patient's heart is under significant strain. The patient's high total cholesterol (4.97 mmol/L) and low HDL (0.72 mmol/L) also suggest that the patient is at increased risk for cardiovascular disease. Additionally, the patient's elevated creatinine (88.0 umol/L) suggests that the patient may have kidney damage, which can further strain the heart. However, the patient's overall clinical picture and medication regimen suggest that they are being managed effectively, reducing the likelihood of pump failure death.

RANKING: 3. Sudden cardiac death
 REASONING: The patient's ECG shows monomorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the patient's LVEF is 70%, which suggests that the heart is pumping blood effectively. The patient's medication regimen includes beta blockers, which are known to reduce the risk of sudden cardiac death. Additionally, the patient's TSH is within the normal range, which suggests that the patient does not have hyperthyroidism, a condition that can increase the risk of sudden cardiac death. While the patient's high blood pressure and kidney damage may increase their risk of cardiovascular disease, the patient's overall clinical picture and medication regimen suggest that sudden cardiac death is the least likely outcome."
159,159,P0267,"Age: 42
Gender: Female 
Weight: 78 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 130/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 37,4
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,13
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 162
Glucose (mmol/L): 19,7
Hemoglobin (g/L): 125.0
HDL (mmol/L): 0,58
Potassium (mEq/L): 3,95
LDL (mmol/L): 1,96
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 2237.0
Protein (g/L): 71,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,22
Urea (mg/dL): 14,99
LVEF (%): 28.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. I will order the three possible prognoses from most likely to least likely.

RANKING: 1. Sudden Cardiac Death (SCD), 2. Pump Failure Death, 3. Survivor

REASONING:

1. Sudden Cardiac Death (SCD): The patient has a high risk of SCD due to the following factors:
    - NYHA Class III indicates severe symptoms, indicating a poor functional status.
    - Low LVEF (28%) suggests a significant reduction in cardiac function.
    - Presence of non-sustained ventricular tachycardia (NSVT) on ECG, which is a known predictor of SCD.
    - Elevated Pro-BNP levels (2237 ng/L) indicate increased cardiac stress and potential for arrhythmias.
    - The patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, increasing the risk of SCD.
    - The patient's ECG also shows polymorphic ventricular extrasystoles, which can be a precursor to life-threatening arrhythmias.

2. Pump Failure Death: The patient's LVEF is severely reduced (28%), indicating a high risk of pump failure. The patient's NYHA Class III and history of myocardial infarction also contribute to this risk. However, the patient is already on optimal medical therapy (ACE inhibitor, angiotensin II receptor blocker, spironolactone, and loop diuretics), which may help mitigate this risk.

3. Survivor: While the patient's prognosis is guarded, there are some factors that suggest a potential for survival:
    - The patient is on optimal medical therapy, which may help manage symptoms and slow disease progression.
    - The patient's age and sex are relatively favorable, as sudden cardiac death is more common in older males.
    - The patient's hemoglobin level is within a relatively normal range, which may indicate better overall health compared to other factors.

However, considering the patient's severe symptoms, reduced LVEF, and history of myocardial infarction, the risk of SCD is higher than pump failure death. Pump failure death is also a significant risk, but the patient's optimal medical therapy may help mitigate this risk to some extent. Therefore, the order of the three possible prognoses is SCD, pump failure death, and survivor."
160,160,P0268,"Age: 76
Gender: Female 
Weight: 71 kg
Height: 151 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 47,8
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,61
Creatinine (mmol/L): 112.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,65
Potassium (mEq/L): 4,24
LDL (mmol/L): 3,3
Sodium (mEq/L): 139.0
Protein (g/L): 74,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,69
Urea (mg/dL): 11,9
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient is 76 years old with a history of valvular cardiomyopathy, diabetes, dyslipemia, and hypertension, which are all risk factors for heart disease. However, the patient's left ventricular ejection fraction (LVEF) is 30%, which is low, indicating reduced cardiac function. Despite this, the patient is on a comprehensive treatment plan, including medications for diabetes, beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, which suggests that the patient is receiving appropriate management for their heart condition. The patient's blood pressure is well-controlled, and the troponin level is within normal limits, indicating that there is no acute myocardial infarction. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG is concerning, but the absence of sustained ventricular tachycardia and bradycardia suggests that the patient is not at immediate risk of sudden cardiac death. Overall, while the patient has significant cardiac disease, the comprehensive treatment plan and lack of acute cardiac events make survival the most likely prognosis.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's low LVEF and history of valvular cardiomyopathy increase the risk of sudden cardiac death. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG is a concern, as these can be precursors to sustained ventricular tachycardia or fibrillation, which can lead to sudden cardiac death. However, the patient's comprehensive treatment plan and lack of acute cardiac events make sudden cardiac death less likely than pump failure death.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 30% indicates reduced cardiac function, which increases the risk of pump failure death. The patient's history of valvular cardiomyopathy and hypertension also contribute to this risk. However, the patient's blood pressure is well-controlled, and the patient is on a comprehensive treatment plan, including loop diuretics and spironolactone, which suggests that the patient is receiving appropriate management for heart failure. While pump failure death is a possible prognosis, the patient's overall clinical picture makes sudden cardiac death a more likely outcome."
161,161,P0272,"Age: 80
Gender: Female 
Weight: 76 kg
Height: 152 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 120.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,29
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 918.0
Protein (g/L): 68,6
T3 (pg/dL): 0,0477
T4 (ng/L): 16,39
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,42
Urea (mg/dL): 7,1
LVEF (%): 60.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

This patient is an 80-year-old female with a history of hypertensive cardiomyopathy, diabetes, dyslipemia, and hypertension. Despite her advanced age and multiple comorbidities, several factors suggest a relatively favorable prognosis. 

Firstly, her blood pressure is well-controlled at 140/70 mmHg, which is lower than the recommended target for patients with hypertension. This suggests that her blood pressure management is effective, which can reduce the risk of cardiac complications.

Secondly, her LVEF (Left Ventricular Ejection Fraction) is 60%, which is within the normal range. This indicates that her heart function is relatively preserved, despite her history of hypertensive cardiomyopathy.

Thirdly, her troponin level is 0.3 ng/mL, which is within the normal range. Elevated troponin levels are associated with increased risk of cardiac events, so a normal troponin level is a good sign.

Fourthly, her Pro-BNP (N-terminal pro b-type natriuretic peptide) level is 918.0 ng/L, which is elevated. However, this is not extremely high, and her symptoms and medical history do not suggest severe heart failure.

Fifthly, her medications are well-managed, including calcium channel blockers, diabetes medication, loop diuretics, spironolactone, statins, and ACE inhibitor, which are all evidence-based treatments for her conditions.

Lastly, her ECG shows non-sustained ventricular tachycardia, but no signs of sustained ventricular tachycardia, which is a good sign.

Considering these factors, the most likely prognosis for this patient is a survivor. While she has multiple comorbidities and some cardiac abnormalities, her well-managed blood pressure, preserved LVEF, normal troponin level, and effective medications suggest that she is at lower risk for cardiac complications.

The least likely prognosis is pump failure death, as her LVEF is within the normal range, and her Pro-BNP level is not extremely high.

The sudden cardiac death prognosis is less likely than survivor, but more likely than pump failure death. This is because her ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. However, her well-managed medications and relatively preserved heart function suggest that this risk is not extremely high."
162,162,P0273,"Age: 75
Gender: Male 
Weight: 77 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 4,54
LDL (mmol/L): 2,87
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 5435.0
Protein (g/L): 75,199
T3 (pg/dL): 0,0249
T4 (ng/L): 20,99
Troponin (ng/mL): 0,5
TSH (mIU/L): 0,3
Urea (mg/dL): 9,1
LVEF (%): 45.0
Medications: Calcium Channel Blocker, Amiodarone, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

Given the patient's data, I would rank the prognosis as a survivor for the next few years. Here's why:

1. Ischemic dilated cardiomyopathy with an LVEF of 45%: The patient has a moderate to severe reduction in left ventricular ejection fraction (LVEF), which is a significant indicator of heart failure. However, the patient is on appropriate medications (ACE inhibitor, beta blockers, and spironolactone) that have been shown to improve survival and reduce morbidity in patients with heart failure.

2. NYHA Class II: The patient's New York Heart Association (NYHA) functional class is II, indicating that the patient is experiencing some symptoms of heart failure but is still able to perform most daily activities. This suggests that the patient's condition is not too severe.

3. Blood pressure and electrolytes: The patient's blood pressure is well-controlled, and electrolytes are within normal limits. This is a good sign, as electrolyte imbalances can exacerbate heart failure.

4. Low levels of troponin: The patient's troponin level is 0.5 ng/mL, which is within the normal range. Elevated troponin levels are associated with increased risk of cardiac events.

5. Medications: The patient is on a comprehensive regimen of medications, including beta blockers, ACE inhibitors, spironolactone, and statins, which are all recommended for patients with heart failure and ischemic cardiomyopathy.

6. ECG findings: While the patient has ventricular extrasystoles, there is no evidence of sustained ventricular tachycardia or other high-risk arrhythmias.

7. Lab values: The patient's creatinine level is elevated, but not significantly so, and the patient is not anemic. The patient's albumin level is slightly low, but this may be related to the patient's age and other comorbidities.

Considering these factors, I would rank the prognosis as a survivor, as the patient appears to be well-managed and has a moderate to severe but stable heart failure condition. However, the patient will still require close monitoring and follow-up to adjust medications and manage potential complications."
163,163,P0274,"Age: 68
Gender: Female 
Weight: 74 kg
Height: 153 cm
NYHA Class: II
Blood Pressure: 170/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,81
Creatinine (mmol/L): 105.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 3,6
LDL (mmol/L): 1,63
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 149.0
Protein (g/L): 75
T3 (pg/dL): 0,0267
T4 (ng/L): 18,16
Troponin (ng/mL): 0,3
TSH (mIU/L): 2,4
Urea (mg/dL): 9,2
LVEF (%): 70.0
Medications: Calcium Channel Blocker, Diabetes Medication, Amiodarone, Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. However, please note that a patient's outcome is inherently uncertain and can be influenced by various factors, including lifestyle changes, adherence to medication, and the development of new medical conditions.

RANKING: 1. Survivor
 REASONING: The patient is 68 years old with a history of hypertensive cardiomyopathy, diabetes, dyslipemia, and hypertension. Despite these comorbidities, the patient's LVEF is 70%, which is within the normal range. The patient is on a regimen of medications that are appropriate for managing their conditions, including a calcium channel blocker, diabetes medication, amiodarone, angiotensin II receptor blocker, digoxin, loop diuretics, and statins. The patient's ECG does not show any signs of severe arrhythmias, and their troponin levels are within the normal range. Additionally, the patient's Pro-BNP level is elevated, but not excessively high, which suggests that the patient may not be experiencing significant cardiac stress. The patient's albumin and protein levels are also within the normal range, indicating that they are not experiencing significant liver or kidney dysfunction. Overall, while the patient has multiple comorbidities, their current treatment plan and laboratory results suggest that they are being effectively managed, making a survivor prognosis the most likely outcome.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's ECG shows monomorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the patient is on amiodarone, which is an antiarrhythmic medication that can help prevent arrhythmias. Additionally, the patient's LVEF is within the normal range, which reduces the risk of sudden cardiac death. The patient's troponin levels are within the normal range, which suggests that they are not experiencing significant cardiac damage. While the patient's Pro-BNP level is elevated, it is not excessively high, which suggests that the patient may not be experiencing significant cardiac stress. Overall, while the patient's ECG findings and comorbidities increase their risk for sudden cardiac death, their current treatment plan and laboratory results suggest that this outcome is less likely than a survivor prognosis.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF is 70%, which is within the normal range, and their creatinine levels are slightly elevated, but not excessively high. The patient's albumin and protein levels are also within the normal range, indicating that they are not experiencing significant liver or kidney dysfunction. The patient's medication regimen includes loop diuretics, which are used to manage fluid overload and reduce the risk of heart failure. While the patient has a history of hypertensive cardiomyopathy and dyslipemia, their current treatment plan and laboratory results suggest that they are being effectively managed. Overall, the patient's current condition and treatment plan make pump failure death the least likely outcome."
164,164,P0276,"Age: 37
Gender: Male 
Weight: 103 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 140/100 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,27
Creatinine (mmol/L): 116.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,9
Potassium (mEq/L): 4,06
LDL (mmol/L): 2,36
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 308.0
Protein (g/L): 79,6
T3 (pg/dL): 0,0402
T4 (ng/L): 15,66
TSH (mIU/L): 0,41
Urea (mg/dL): 6
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Paroxysmal AVB
            ",survivor,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: 1. Survivor
REASONING: The patient is 37 years old and has a history of enolic dilated cardiomyopathy, which is a significant underlying condition. However, the patient's LVEF (Left Ventricular Ejection Fraction) is 30%, which is relatively low but not the lowest possible value. The patient is on beta blockers, loop diuretics, and an ACE inhibitor, which are standard treatments for heart failure. The patient's NYHA Class II indicates that they are experiencing some symptoms but are still able to perform daily activities. The absence of sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, and bradycardia (other than paroxysmal AVB) suggests that the patient's heart rhythm is relatively stable. The patient's Pro-BNP level is elevated at 308.0 ng/L, but this can be influenced by various factors, including age, kidney function, and heart failure severity. Overall, while the patient's condition is serious, the patient's relatively young age, stable heart rhythm, and ongoing treatment with medications suggest a better prognosis.

RANKING: 2. Pump failure death
REASONING: The patient's LVEF of 30% indicates significant left ventricular dysfunction, which increases the risk of pump failure. The patient's elevated Pro-BNP level and low albumin level also suggest advanced heart failure. However, the patient's age, NYHA Class II, and ongoing treatment with beta blockers, loop diuretics, and an ACE inhibitor suggest that the patient is receiving appropriate care for heart failure. The patient's overall condition is serious, but the relatively young age and stable heart rhythm suggest that the patient may still have a chance to recover or stabilize.

RANKING: 3. Sudden cardiac death
REASONING: The patient's history of enolic dilated cardiomyopathy and low LVEF increase the risk of sudden cardiac death. The presence of polymorphic ventricular extrasystoles on the ECG is a concern, as it may indicate electrical instability. However, the absence of sustained ventricular tachycardia and other arrhythmias suggests that the patient's heart rhythm is relatively stable. The patient's Pro-BNP level is elevated, but this can be influenced by various factors. The patient's age and ongoing treatment with medications also suggest that the patient is receiving appropriate care for heart failure. While the patient's condition is serious, the relatively young age and stable heart rhythm suggest that the risk of sudden cardiac death may be lower than the risk of pump failure death."
165,165,P0277,"Age: 75
Gender: Male 
Weight: 89 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 4,4
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,77
LDL (mmol/L): 2,61
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 410.0
Protein (g/L): 68,6
T3 (pg/dL): 0,039
T4 (ng/L): 15,86
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,23
Urea (mg/dL): 11,9
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. However, please note that a patient's prognosis can never be 100% accurate and is always subject to change based on various factors, including but not limited to, the progression of their disease, adherence to medication, and any potential changes in their medical history.

RANKING: 1. Survivor

REASONING: The patient is 75 years old with a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipemia. Despite this, they are on a comprehensive treatment plan that includes a calcium channel blocker, beta blockers, statins, and an ACE inhibitor, which is a good sign. Their LVEF is 30%, which is relatively low but not extremely low. The patient's NYHA Class II indicates that they are experiencing some symptoms but are still able to perform everyday activities. Their creatinine level is elevated, indicating some renal impairment, but their urea level is relatively normal. The patient's Troponin level is slightly elevated, indicating some cardiac damage, but not excessively high. Their Pro-BNP level is elevated, which is consistent with heart failure, but not excessively high. Their TSH level is within the normal range, which is a good sign. The patient's ECG shows polymorphic ventricular extrasystoles, which is a common finding in patients with heart failure. Considering these factors, the patient's prognosis for survival over the next few years is relatively good, but they will likely require close monitoring and adherence to their medication regimen.

RANKING: 2. Sudden Cardiac Death

REASONING: The patient's low LVEF of 30% increases their risk for sudden cardiac death. The presence of polymorphic ventricular extrasystoles on their ECG also increases their risk. Additionally, their history of myocardial infarction and ischemic dilated cardiomyopathy puts them at a higher risk for sudden cardiac death. However, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death. Their Pro-BNP level is elevated, but not excessively high, which may indicate that their heart failure is being managed. Overall, while the patient's risk for sudden cardiac death is higher than their risk for pump failure death, it is still relatively low given their comprehensive treatment plan and relatively stable vital signs.

RANKING: 3. Pump Failure Death

REASONING: While the patient's LVEF is low at 30%, their creatinine level is elevated, indicating some renal impairment, and their Pro-BNP level is elevated, indicating heart failure. However, their urea level is relatively normal, which may indicate that their heart failure is being managed. The patient is on an ACE inhibitor, which is a good sign for managing heart failure. Their NYHA Class II indicates that they are experiencing some symptoms but are still able to perform everyday activities, which suggests that their heart failure is not severe. While the patient's risk for pump failure death is higher than their risk for sudden cardiac death, it is still relatively low given their comprehensive treatment plan and relatively stable vital signs."
166,166,P0278,"Age: 82
Gender: Female 
Weight: 79 kg
Height: 144 cm
NYHA Class: III
Blood Pressure: 160/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 42.0
Total Cholesterol (mmol/L): 7,06
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 50
Glucose (mmol/L): 3,9
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,91
Potassium (mEq/L): 4,47
LDL (mmol/L): 4,22
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 710.0
Protein (g/L): 75,9
T3 (pg/dL): 0,045
T4 (ng/L): 23,19
Troponin (ng/mL): 0,3
TSH (mIU/L): 0,07
Urea (mg/dL): 11,2
LVEF (%): 67.0
Medications: Amiodarone, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here is the ranking of the prognoses for the next few years:

RANKING: Survivor
REASONING: Despite the patient's advanced age and history of hypertensive cardiomyopathy and hypertension, there are several factors that suggest a relatively good prognosis. The patient's left ventricular ejection fraction (LVEF) is 67%, which is still within the normal range. The patient's creatinine level is elevated at 115.0 mmol/L, but it is not significantly high, and the patient is on ACE inhibitors, which are beneficial for patients with heart failure. The patient's blood pressure is controlled, and the patient is on loop diuretics, which suggests that the patient's fluid status is being managed. Additionally, the patient's TSH level is within the normal range, which suggests that the patient's thyroid function is not contributing to any cardiac issues. The patient's Pro-BNP level is elevated at 710.0 ng/L, but it is not extremely high, and the patient is on amiodarone, which may be helping to control the patient's arrhythmias. Overall, while the patient has several risk factors for cardiac disease, the fact that they are being actively managed and have a relatively preserved LVEF suggests that a survivor prognosis is the most likely outcome.

RANKING: Sudden Cardiac Death
REASONING: Sudden cardiac death is a possible outcome for this patient due to their history of ventricular extrasystoles and polymorphic ventricular extrasystoles on the ECG. These arrhythmias can increase the risk of sudden cardiac death, especially in patients with underlying heart disease. Additionally, the patient's elevated Pro-BNP level and low LVEF may also contribute to an increased risk of sudden cardiac death. However, the fact that the patient is on amiodarone, which is an anti-arrhythmic medication, may help to reduce this risk.

RANKING: Pump Failure Death
REASONING: Pump failure death is less likely in this patient due to their relatively preserved LVEF of 67%. While the patient has a history of hypertensive cardiomyopathy and hypertension, which can contribute to heart failure, the patient's current LVEF is not significantly low, and they are on ACE inhibitors and loop diuretics, which are beneficial for patients with heart failure. Additionally, the patient's creatinine level is not extremely high, which suggests that the patient's kidney function is not severely impaired. Therefore, while pump failure is still a possible outcome, it is less likely than sudden cardiac death due to the patient's relatively preserved LVEF and effective management of their cardiac disease."
167,167,P0281,"Age: 50
Gender: Male 
Weight: 91 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 160/100 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 9
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 3,41
LDL (mmol/L): 3,4
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1825.0
Protein (g/L): 66,2
T3 (pg/dL): 0,0402
T4 (ng/L): 17,78
Troponin (ng/mL): 0,3
TSH (mIU/L): 0,95
Urea (mg/dL): 3,9
LVEF (%): 60.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. However, I must emphasize that this is a hypothetical assessment, and actual patient outcomes may vary based on individual circumstances and further evaluation. 

RANKING: 1. Survivor
REASONING: Despite the patient's complex medical history, including enolic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension, the patient's current LVEF of 60% indicates that the heart is still pumping relatively well. The patient is also on a comprehensive treatment regimen, including medications for diabetes, hypertension, and heart failure, as well as statins for lipid management. The lack of signs of severe cardiac dysfunction, such as sustained ventricular tachycardia or significant troponin elevation, suggests that the patient's current management plan is effective. Furthermore, the patient's TSH level is within the normal range, indicating that there is no apparent thyroid-related component contributing to cardiac dysfunction. The patient's weight is not excessively high, and their blood pressure is being managed. Although the patient has a high Pro-BNP level, it is not excessively elevated, and the patient's albumin level is within the normal range, indicating no severe kidney dysfunction. Overall, these factors suggest that the patient is likely to survive with continued medical management.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of ventricular extrasystoles, as seen on the ECG, indicates a risk of arrhythmias. However, the lack of sustained ventricular tachycardia or non-sustained ventricular tachycardia with a cycle length > 10 beats suggests that the patient's risk of sudden cardiac death is not extremely high. The patient's LVEF is within the normal range, and their medications, including beta blockers, are aimed at reducing the risk of arrhythmias. While the patient's high Pro-BNP level may indicate some degree of cardiac stress, it is not excessively elevated, and the patient's overall clinical picture does not strongly suggest a high risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF of 60% is relatively low, indicating some degree of cardiac dysfunction. However, the patient's current medications, including ACE inhibitors and loop diuretics, are aimed at reducing the risk of heart failure progression. The patient's weight is not excessively high, and their blood pressure is being managed, which reduces the risk of further cardiac strain. While the patient's high Pro-BNP level may indicate some degree of cardiac stress, it is not excessively elevated, and the patient's overall clinical picture does not strongly suggest an imminent risk of pump failure death."
168,168,P0282,"Age: 58
Gender: Male 
Weight: 87 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 135/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 8,1
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 3,82
LDL (mmol/L): 2,2
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 165.0
Protein (g/L): 69,8
T3 (pg/dL): 0,0339
T4 (ng/L): 17,8
Troponin (ng/mL): 0,6
TSH (mIU/L): 1,62
Urea (mg/dL): 8,9
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. However, please note that predicting patient outcomes is a complex task and involves a lot of uncertainty. The prognosis provided is based on the information given and general medical knowledge.

RANKING: 1. Survivor
 REASONING: The patient is 58 years old with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and peripheral vascular disease. He has had a myocardial infarction in the past. Despite this, he is currently taking medications for diabetes, beta blockers, loop diuretics, statins, and an ACE inhibitor, which suggests that his condition is being managed. His LVEF is 40%, which is lower than normal but not extremely low. His NYHA class is II, indicating some limitation of physical activity but no symptoms at rest. His pro-BNP level is elevated, but not extremely high. The presence of polymorphic ventricular extrasystoles on the ECG is a concern, but it is not a definitive indicator of poor prognosis. Overall, considering his current management and the fact that he is not in heart failure with reduced ejection fraction (HFrEF) with extremely low LVEF or very high BNP levels, I consider survivor as the most likely outcome.

RANKING: 2. Pump Failure Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy and an LVEF of 40%, which increases the risk of pump failure. His elevated pro-BNP level and the presence of polymorphic ventricular extrasystoles on the ECG are also concerning for potential pump failure. However, his current NYHA class is II, and he is taking medications that can help manage his condition. His LVEF is not extremely low, and he does not have other indicators of severe heart failure, such as severely elevated BNP or creatinine levels. Therefore, while pump failure is a possibility, I consider it less likely than survivor.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy and an LVEF of 40%, which increases the risk of sudden cardiac death. However, his current management, including beta blockers, which are known to reduce the risk of sudden cardiac death, and his relatively stable condition (NYHA class II) suggest that sudden cardiac death is less likely. His ECG does show polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death, but it is not a definitive indicator. Overall, while sudden cardiac death is a possibility, I consider it the least likely outcome given his current management and relatively stable condition."
169,169,P0283,"Age: 80
Gender: Female 
Weight: 87 kg
Height: 150 cm
NYHA Class: III
Blood Pressure: 160/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,58
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 3,52
LDL (mmol/L): 2,48
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 4058.0
Protein (g/L): 67,699
T3 (pg/dL): 0,0354
T4 (ng/L): 17,65
Troponin (ng/mL): 0,4
TSH (mIU/L): 2,07
Urea (mg/dL): 12,1
LVEF (%): 70.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: 1 
REASONING: The patient's most likely prognosis is survival. The patient is 80 years old, which puts her in an elderly age group with a higher risk of cardiac events. However, she has been on beta blockers, loop diuretics, and an ACE inhibitor, which suggests that her condition has been managed to some extent. Her LVEF is 70%, which is within the normal range, indicating that her heart function is still relatively preserved. Her troponin level is mildly elevated, but not excessively high, suggesting that there is some degree of cardiac stress but not severe ischemia. The patient's creatinine level is elevated, but it's not extremely high, and her potassium level is low, which may be a side effect of her medications. Her Pro-BNP level is high, indicating some degree of heart failure, but it's not extremely high. Considering these factors, the patient's overall condition is stable, and with continued management, she is likely to survive for the next few years.

RANKING: 2 
REASONING: The patient's second most likely prognosis is sudden cardiac death. The patient has a history of hypertensive cardiomyopathy, which increases her risk of cardiac arrhythmias and sudden cardiac death. Her LVEF is 70%, which is within the normal range, but her Pro-BNP level is high, indicating some degree of heart failure. The presence of ventricular extrasystoles on the ECG also increases her risk of sudden cardiac death. However, the patient's overall condition is stable, and she is on medications that can help manage her condition. Therefore, while sudden cardiac death is a possible outcome, it is less likely than survival.

RANKING: 3 
REASONING: The patient's least likely prognosis is pump failure death. The patient's LVEF is 70%, which is within the normal range, and her creatinine level is not extremely high, indicating that her kidney function is still relatively preserved. Her Pro-BNP level is high, but not extremely high, suggesting that her heart failure is not severe. The patient's medications, including beta blockers, loop diuretics, and an ACE inhibitor, are aimed at managing her heart failure and reducing her risk of pump failure. Therefore, pump failure death is the least likely outcome among the three possibilities."
170,170,P0284,"Age: 80
Gender: Female 
Weight: 54 kg
Height: 143 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 35
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 57.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 75
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,63
LDL (mmol/L): 2,37
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1057.0
Protein (g/L): 76,8
T3 (pg/dL): 0,0726
T4 (ng/L): 14,63
Troponin (ng/mL): 0,6
TSH (mIU/L): 6,19
Urea (mg/dL): 6,7
LVEF (%): 45.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely.

RANKING: 1. Survivor
 REASONING: The patient is 80 years old with a history of hypertensive cardiomyopathy, myocardial infarction, and NYHA Class III, indicating severe heart failure symptoms. However, she is currently on beta blockers, loop diuretics, ACE inhibitors, and nitrovasodilators, which are appropriate medications for heart failure and hypertension management. Her LVEF is 45%, which is mildly reduced, but not severely impaired. Her troponin level is slightly elevated, indicating some myocardial damage, but not indicative of acute myocardial infarction. The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests some level of cardiac arrhythmia, but these are not uncommon in patients with heart failure. The patient's Pro-BNP level is elevated at 1057 ng/L, indicating some level of heart failure, but not at the highest risk category. Considering these factors, while the patient has several risk factors for cardiac events, her current medication regimen and mildly reduced LVEF suggest that she may be managed and monitored effectively, making survival the most likely prognosis.

RANKING: 2. Pump failure death
 REASONING: The patient's NYHA Class III classification indicates severe heart failure symptoms, and her LVEF of 45% is mildly reduced. Her Pro-BNP level is elevated, indicating some level of heart failure. However, her current medication regimen and the fact that she is not showing signs of acute decompensated heart failure (e.g., hypotension, acute kidney injury, or significant weight gain) suggest that her heart failure is currently well-managed. While the risk of pump failure death is present, the patient's current condition and treatment suggest that this prognosis is less likely than sudden cardiac death.

RANKING: 3. Sudden cardiac death
 REASONING: The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are risk factors for sudden cardiac death. Additionally, her history of myocardial infarction and hypertensive cardiomyopathy increases her risk. However, her current medication regimen, including beta blockers, which are known to reduce the risk of sudden cardiac death, and the fact that her heart rate is not excessively high, suggest that this prognosis is the least likely of the three."
171,171,P0288,"Age: 80
Gender: Female 
Weight: 81 kg
Height: 161 cm
NYHA Class: III
Blood Pressure: 150/65 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,53
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 195.0
Protein (g/L): 69,2
T3 (pg/dL): 0,0327
T4 (ng/L): 13,05
TSH (mIU/L): 1,05
Urea (mg/dL): 15,7
LVEF (%): 70.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 1. Survivor

REASONING: 

Given the patient's profile, I would rank a survivor prognosis as the most likely outcome. The patient is 80 years old, which is a significant risk factor for cardiac events, but the patient's current LVEF of 70% indicates that the heart is still functioning relatively well. The presence of valvular cardiomyopathy and diabetes are concerning, but the patient is on appropriate medications for these conditions, including beta blockers, angiotensin II receptor blockers, and statins. The patient's blood pressure is slightly elevated, but the diastolic pressure is within a relatively normal range. The patient's creatinine level is slightly elevated, which may indicate some degree of renal impairment, but it is not severe enough to significantly impact the prognosis.

The patient's ECG shows some concerning findings, including ventricular extrasystoles, but there is no evidence of sustained ventricular tachycardia or significant bradycardia. The patient's TSH level is within the normal range, which suggests that the patient's thyroid function is not contributing to any cardiac issues.

The patient's Pro-BNP level is elevated, which is a marker of heart failure, but it is not extremely high, which suggests that the patient's heart failure is not severe. The patient's overall clinical picture suggests that the patient is at risk for cardiac events, but the patient's current treatment regimen and relatively well-preserved LVEF suggest that a survivor prognosis is the most likely outcome.

RANKING: 2. Pump Failure Death

REASONING: 

A pump failure death prognosis is the second most likely outcome for this patient. The patient's valvular cardiomyopathy and diabetes are significant risk factors for heart failure, and the patient's elevated Pro-BNP level suggests that the patient's heart is under strain. The patient's creatinine level is slightly elevated, which may indicate some degree of renal impairment, which can contribute to heart failure. The patient's LVEF is still within a relatively normal range, but it may be declining, which could increase the risk of pump failure.

The patient's ECG findings, including ventricular extrasystoles, may also indicate some degree of cardiac dysfunction. However, the patient's overall clinical picture suggests that the patient's heart failure is not severe, and the patient's treatment regimen may be sufficient to manage the condition.

RANKING: 3. Sudden Cardiac Death

REASONING: 

A sudden cardiac death prognosis is the least likely outcome for this patient. While the patient's ECG findings, including ventricular extrasystoles, suggest some degree of cardiac dysfunction, there is no evidence of significant arrhythmias, such as sustained ventricular tachycardia. The patient's LVEF is still within a relatively normal range, which suggests that the patient's heart is functioning relatively well. The patient's treatment regimen includes beta blockers, which are effective in reducing the risk of arrhythmias and sudden cardiac death.

The patient's overall clinical picture suggests that the patient's cardiac condition is relatively stable, and the patient's risk factors for sudden cardiac death are not as high as those for pump failure. Therefore, a sudden cardiac death prognosis is the least likely outcome for this patient."
172,172,P0292,"Age: 64
Gender: Male 
Weight: 75 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 4,11
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 3,9
LDL (mmol/L): 3,88
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1363.0
Protein (g/L): 67
T3 (pg/dL): 0,0426
T4 (ng/L): 14,2
TSH (mIU/L): 0,96
Urea (mg/dL): 7,1
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: 1. Survivor
 REASONING: The patient is 64 years old with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure and mortality. However, the patient is currently on a treatment regimen that includes beta blockers, loop diuretics, statins, and an ACE inhibitor, which are all evidence-based therapies for heart failure management. The patient's LVEF is 30%, which indicates a reduced ejection fraction, but it is not as low as some other cases. The Pro-BNP level of 1363 ng/L is elevated, indicating some degree of heart failure, but not excessively high. The patient's overall clinical condition, including blood pressure and renal function, is not severely compromised. Additionally, the patient's TSH level is within the normal range, which is a good indicator of thyroid function, and the patient is not showing signs of malnutrition (albumin level of 39 g/L). Considering these factors, a survivor prognosis is more likely.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The patient's LVEF is 30%, which is a significant risk factor for sudden cardiac death. The presence of polymorphic ventricular extrasystoles on the ECG also indicates an increased risk of arrhythmias. However, the patient is on a treatment regimen that includes beta blockers, which can reduce the risk of sudden cardiac death. The patient's overall clinical condition and renal function are not severely compromised, which also reduces the likelihood of sudden cardiac death.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF is 30%, which indicates a reduced ejection fraction, and the Pro-BNP level of 1363 ng/L is elevated, indicating some degree of heart failure. However, the patient's overall clinical condition, including blood pressure and renal function, is not severely compromised. The patient is on a treatment regimen that includes loop diuretics, which can help manage fluid overload and reduce the risk of pump failure. Additionally, the patient's weight is 75 kg, which is not excessively high, and the patient's albumin level is 39 g/L, indicating that the patient is not severely malnourished. Considering these factors, pump failure death is the least likely prognosis."
173,173,P0295,"Age: 37
Gender: Male 
Weight: 94 kg
Height: 174 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 154.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,8
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3232.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 27
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,17
Urea (mg/dL): 6,99
LVEF (%): 21.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Sudden cardiac death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, myocardial infarction, and non-sustained ventricular tachycardia, which are all risk factors for sudden cardiac death. Additionally, the patient's left ventricular ejection fraction (LVEF) is severely reduced at 21%, indicating significant left ventricular dysfunction. The patient's pro-BNP level is elevated at 3232.0 ng/L, which is also a marker of heart failure and increased risk of sudden cardiac death. Given these factors, sudden cardiac death is a significant concern.

RANKING: 2. Pump failure death
 REASONING: The patient's LVEF is severely reduced, and the patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which are risk factors for pump failure. The patient's creatinine level is elevated at 97.0 mmol/L, indicating renal dysfunction, which is often seen in advanced heart failure. However, the patient is currently being treated with medications such as loop diuretics and ACE inhibitors, which may help manage heart failure symptoms and slow disease progression.

RANKING: 3. Survivor
 REASONING: While the patient's prognosis is poor, the patient is currently receiving optimal medical therapy for heart failure and ischemic cardiomyopathy, including beta blockers, statins, and ACE inhibitors. The patient's medications are also addressing other risk factors such as hypertension, dyslipemia, and diabetes. With close monitoring and adherence to treatment, it is possible that the patient may survive for several years, although the risk of sudden cardiac death and pump failure remains high."
174,174,P0296,"Age: 69
Gender: Female 
Weight: 55 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,84
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 13,9
Glucose (mmol/L): 5,03
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,95
Potassium (mEq/L): 4,74
LDL (mmol/L): 3,09
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 267.0
Protein (g/L): 80
T3 (pg/dL): 0,0432
T4 (ng/L): 13,91
TSH (mIU/L): 1,51
Urea (mg/dL): 9
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's my prognosis for the next few years:

RANKING: Survivor
REASONING: The patient has idiopathic dilated cardiomyopathy with a left ventricular ejection fraction (LVEF) of 25%, which indicates severe heart failure. However, the patient is currently on optimal medical therapy with digoxin, loop diuretics, and an ACE inhibitor, which are all standard treatments for heart failure with reduced ejection fraction (HFrEF). The patient's NYHA class is II, which indicates that she is still able to perform everyday activities but experiences some symptoms of heart failure. The patient's blood pressure is within a normal range, and her electrolytes are mostly within normal limits. The pro-BNP level is elevated, but it's not extremely high, which suggests that the patient is not in acute heart failure. The absence of non-sustained ventricular tachycardia and the presence of a normal TSH level suggest that the patient's heart failure is not due to a hyperthyroid state. Overall, while the patient's prognosis is guarded, her current medical therapy and relatively stable clinical status make a survivor prognosis more likely.

RANKING: Sudden Cardiac Death
REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which increases her risk of sudden cardiac death. The presence of polymorphic ventricular extrasystoles on the ECG also suggests an increased risk of arrhythmias, which could potentially lead to sudden cardiac death. However, the patient's current medical therapy and relatively stable clinical status make this prognosis less likely than pump failure death.

RANKING: Pump Failure Death
REASONING: While the patient's LVEF is very low at 25%, she is currently on optimal medical therapy, which should help to slow the progression of heart failure. The patient's NYHA class is II, which indicates that she is still able to perform everyday activities, and her blood pressure is within a normal range. The absence of severe electrolyte imbalances and the presence of a normal TSH level suggest that the patient's heart failure is not due to a reversible cause. While the patient's prognosis is guarded, her current medical therapy and relatively stable clinical status make pump failure death less likely than sudden cardiac death.

Note: The ranking of the prognoses can vary depending on the individual patient's characteristics and the specific clinical context. This is just one possible interpretation based on the provided data."
175,175,P0297,"Age: 73
Gender: Male 
Weight: 82 kg
Height: 159 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 15,7
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 3,79
LDL (mmol/L): 2,07
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 678.0
Protein (g/L): 65
T3 (pg/dL): 0,0396
T4 (ng/L): 13,66
Troponin (ng/mL): 0,1
TSH (mIU/L): 1,3
Urea (mg/dL): 3,4
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Sudden Cardiac Death, Pump Failure Death, Survivor

REASONING:

1.  Sudden Cardiac Death (SCD): The patient has a high risk of SCD due to his history of ischemic dilated cardiomyopathy, low LVEF (25%), and the presence of polymorphic ventricular extrasystoles on the ECG. The patient's low LVEF and history of myocardial infarction also increase the risk of arrhythmic events. Additionally, the patient's high Pro-BNP level (678.0 ng/L) suggests significant cardiac stress and potential for arrhythmias. The patient's NYHA Class III classification also indicates severe heart failure symptoms, which can increase the risk of SCD.

2.  Pump Failure Death: The patient's low LVEF (25%) and history of ischemic dilated cardiomyopathy indicate significant left ventricular dysfunction. The patient's high creatinine level (118.0 mol/L) suggests kidney dysfunction, which can be a consequence of advanced heart failure. The patient's NYHA Class III classification also indicates severe heart failure symptoms, which can lead to pump failure. However, the patient is on optimal medical therapy for heart failure, including ACE inhibitors, beta-blockers, and loop diuretics, which can help manage symptoms and slow disease progression.

3.  Survivor: The patient's age (73) and comorbidities (diabetes, dyslipemia) increase the risk of cardiovascular events. However, the patient is on optimal medical therapy for his conditions, and his blood pressure is well-controlled. The patient's high Pro-BNP level suggests significant cardiac stress, but the patient's LVEF is low, and the patient's symptoms are well-managed. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a marker of increased cardiac risk, but the patient's overall prognosis is more closely tied to his heart failure status than his arrhythmic risk.

In conclusion, while the patient has a high risk of SCD and pump failure, the patient's age, comorbidities, and current medical therapy suggest that the patient may be more likely to survive for the next few years with proper management of his conditions."
176,176,P0298,"Age: 86
Gender: Male 
Weight: 90 kg
Height: 190 cm
NYHA Class: III
Blood Pressure: 125/80 mmHg
Past Medical History: Other HF etiology, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,32
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,53
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 851.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,59
Urea (mg/dL): 3,5
LVEF (%): 37.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: Survivor
REASONING: The patient is 86 years old, which is a high age, but not uncommon for a patient with heart failure. The patient has a history of myocardial infarction and hypertension, which are significant risk factors for heart failure. However, the patient is on a comprehensive medication regimen, including ACE inhibitors, statins, and loop diuretics, which are all beneficial for heart failure management. The patient's ejection fraction (LVEF) is 37%, which is below the normal range, indicating some degree of left ventricular dysfunction, but not as severe as expected given the patient's symptoms. The patient's BNP level is elevated at 851.0 ng/L, but not excessively high, suggesting that the patient is being managed with diuretics. The patient's creatinine level is slightly elevated at 62.0 mmol/L, but not significantly so, suggesting that renal function is still relatively preserved. The patient's TSH level is within the normal range, indicating that thyroid function is not contributing to the patient's symptoms. The patient's troponin level is low at 0.01 ng/mL, suggesting that there is no acute coronary syndrome. The patient's ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or other life-threatening arrhythmias. Given these factors, the patient's prognosis is likely to be a survivor, with a focus on continued management and optimization of their medication regimen.

RANKING: Sudden Cardiac Death
REASONING: Sudden cardiac death is a possible prognosis for this patient due to the presence of a low ejection fraction (LVEF) of 37%, which increases the risk of sudden cardiac death. The patient's history of myocardial infarction and hypertension also increases the risk of sudden cardiac death. The patient's elevated BNP level suggests that the patient has significant left ventricular dysfunction, which further increases the risk of sudden cardiac death. However, the patient's ECG does not show any signs of life-threatening arrhythmias, which reduces the likelihood of sudden cardiac death. Additionally, the patient is on a comprehensive medication regimen, including ACE inhibitors and beta blockers, which can reduce the risk of sudden cardiac death.

RANKING: Pump Failure Death
REASONING: Pump failure death is less likely than sudden cardiac death for this patient due to the fact that the patient is on a comprehensive medication regimen, including loop diuretics, which suggests that the patient's heart failure is being managed. The patient's creatinine level is slightly elevated, but not significantly so, suggesting that renal function is still relatively preserved. The patient's BNP level is elevated, but not excessively high, suggesting that the patient is being managed with diuretics. The patient's ejection fraction is low, but not as low as expected given the patient's symptoms, suggesting that the patient's heart is still able to pump some blood. While the patient's prognosis is guarded, pump failure death is less likely than sudden cardiac death due to the patient's current management regimen and relatively preserved renal function."
177,177,P0299,"Age: 71
Gender: Female 
Weight: 95 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 5,9
LDL (mmol/L): 3,26
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3233.0
Protein (g/L): 72
T3 (pg/dL): 0,03
T4 (ng/L): 20
Troponin (ng/mL): 0,04
TSH (mIU/L): 2,86
Urea (mg/dL): 6,16
LVEF (%): 17.0
Medications: Amiodarone, Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: 1. Survivor
REASONING: The patient is 71 years old with a history of idiopathic dilated cardiomyopathy and hypertension. Despite the presence of a low left ventricular ejection fraction (LVEF) of 17%, which indicates severe heart failure, the patient is on optimal medical therapy, including beta blockers, spironolactone, and an ACE inhibitor. The patient's blood pressure is well-controlled at 120/70 mmHg, and the creatinine level is within the normal range. The patient's BNP level is elevated at 3233 ng/L, which is consistent with heart failure, but not excessively high. The patient's troponin level is normal, which suggests that there is no ongoing myocardial infarction or ischemia. The patient's TSH level is within the normal range, which is good, as thyroid dysfunction can worsen heart failure. The patient's ECG shows non-sustained ventricular tachycardia, but no sustained ventricular tachycardia or ventricular fibrillation. The patient's overall clinical presentation and laboratory results suggest that the patient is being well-managed and is likely to survive.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of idiopathic dilated cardiomyopathy and non-sustained ventricular tachycardia on the ECG are risk factors for sudden cardiac death. However, the patient is on an implantable cardioverter-defibrillator (ICD) is not mentioned, and the patient's beta blockers and ACE inhibitor therapy may reduce the risk of sudden cardiac death. The patient's low LVEF and elevated BNP level suggest that the patient has severe heart failure, but the patient's overall clinical presentation and laboratory results do not suggest an extremely high risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF of 17% and elevated BNP level suggest that the patient has severe heart failure. However, the patient's blood pressure is well-controlled, and the creatinine level is within the normal range, which suggests that the patient's heart failure is not yet advanced to the point of renal dysfunction. The patient's overall clinical presentation and laboratory results suggest that the patient's heart failure is being well-managed, and the risk of pump failure death is lower than the risk of sudden cardiac death."
178,178,P0301,"Age: 76
Gender: Male 
Weight: 83 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 150.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 7,6
Hemoglobin (g/L): 124.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3182.0
Protein (g/L): 68
T3 (pg/dL): 0,03
T4 (ng/L): 20
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,07
Urea (mg/dL): 17,14
LVEF (%): 12.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
 REASONING: Based on the provided patient data, the patient is at high risk for cardiac complications due to his advanced age, ischemic dilated cardiomyopathy, low left ventricular ejection fraction (LVEF), and elevated N-terminal pro b-type natriuretic peptide (NT-proBNP) levels. However, the patient is currently on optimal medical therapy for heart failure, including beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators. The patient's hemoglobin level is within a relatively normal range, which suggests that his renal function is not severely compromised. The lack of significant electrolyte imbalances, such as hypokalemia, also suggests that his renal function is relatively preserved. Additionally, the patient's TSH level is within the normal range, which suggests that his thyroid function is not contributing to his cardiac status. Considering these factors, the patient's overall condition seems to be stable, and with continued optimal medical therapy and close monitoring, a survivor prognosis is the most likely outcome.

RANKING: 2. Pump failure death
 REASONING: The patient's LVEF of 12% indicates severe left ventricular dysfunction, which increases the risk of pump failure. The elevated NT-proBNP levels also suggest that the patient's heart is under significant strain. However, the patient's current medical therapy is aimed at reducing the symptoms and slowing the progression of heart failure. While the patient's renal function is not severely compromised, the elevated creatinine level suggests that there may be some degree of renal impairment, which can further exacerbate heart failure. The patient's overall condition is precarious, but the fact that he is receiving optimal medical therapy and is being monitored closely reduces the likelihood of sudden cardiac death.

RANKING: 3. Sudden cardiac death
 REASONING: While the patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases his risk for sudden cardiac death, the presence of a monomorphic ventricular extrasystole on the ECG is a relatively benign finding in this context. The patient's LVEF is extremely low, but the fact that he is on optimal medical therapy and has a relatively stable blood pressure suggests that his heart rate is not excessively high, which reduces the risk of sudden cardiac death. Additionally, the patient's TSH level is within the normal range, which suggests that his thyroid function is not contributing to his cardiac status. While the patient's overall condition is precarious, the likelihood of sudden cardiac death is lower than pump failure death due to the patient's relatively stable hemodynamics and optimal medical therapy."
179,179,P0302,"Age: 67
Gender: Male 
Weight: 80 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 16
Hemoglobin (g/L): 134.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 5,8
LDL (mmol/L): 2,97
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 589.0
Protein (g/L): 74
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,09
Urea (mg/dL): 11,48
LVEF (%): 48.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses for the next few years from most likely to least likely as follows:

RANKING: Survivor

REASONING: The patient is 67 years old with a history of ischemic dilated cardiomyopathy, myocardial infarction, and diabetes. However, the patient's current medications, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, are all appropriate for managing heart failure and hypertension. The patient's LVEF of 48% indicates a reduced but not severely impaired left ventricular function. The Pro-BNP level of 589 ng/L is elevated, indicating some degree of heart failure, but not excessively high. The patient's blood pressure is well-controlled at 130/70 mmHg, and the absence of signs of severe electrolyte imbalances or acute kidney injury (e.g., high creatinine) suggests that the patient's overall condition is relatively stable. The absence of ventricular arrhythmias on the ECG also reduces the risk of sudden cardiac death. While the patient's prognosis is not excellent, the current management plan and the patient's stable condition suggest that the most likely outcome over the next few years is survival.

RANKING: Pump Failure Death

REASONING: The patient's LVEF of 48% indicates reduced left ventricular function, which increases the risk of heart failure progression. The elevated Pro-BNP level of 589 ng/L also suggests some degree of heart failure. However, the patient's current medications and relatively well-controlled blood pressure reduce the likelihood of sudden cardiac death. The patient's kidney function, indicated by the creatinine level of 115.0 mmol/L, is mildly impaired, but not severely so. The absence of signs of severe anemia or electrolyte imbalances reduces the risk of acute kidney injury or cardiac arrhythmias. While the patient's prognosis is guarded, the current management plan and the patient's stable condition suggest that pump failure death is a possible but less likely outcome compared to survivor.

RANKING: Sudden Cardiac Death

REASONING: The patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases the risk of sudden cardiac death. However, the absence of signs of severe electrolyte imbalances, acute kidney injury, or ventricular arrhythmias on the ECG reduces the risk of sudden cardiac death. The patient's LVEF of 48% indicates reduced left ventricular function, but the current medications and relatively well-controlled blood pressure reduce the risk of sudden cardiac death. The patient's Pro-BNP level of 589 ng/L is elevated, but not excessively high. Overall, while the patient's history and current condition increase the risk of sudden cardiac death, the current management plan and the patient's stable condition suggest that this outcome is the least likely of the three."
180,180,P0304,"Age: 75
Gender: Female 
Weight: 64 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,04
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 14,7
Hemoglobin (g/L): 133.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,23
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3866.0
Protein (g/L): 70
T3 (pg/dL): 0,02
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,14
Urea (mg/dL): 5,99
LVEF (%): 42.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely. 

RANKING: Survivor
 REASONING: The patient is 75 years old with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction. However, she is currently taking medications for these conditions, including diabetes medication, beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators. Her LVEF is 42%, which indicates moderate heart failure, but it is not severely impaired. Her eGFR (estimated glomerular filtration rate) is not directly provided, but her creatinine level is within the normal range (0.6-1.2 mmol/L for females). Her Pro-BNP level is elevated at 3866 ng/L, indicating heart failure, but it is not extremely high. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG is concerning but not necessarily indicative of a poor prognosis. Given her current treatment regimen and the fact that she is not in NYHA Class IV, I believe the most likely prognosis is survivor. 

RANKING: Pump Failure Death
 REASONING: The patient's LVEF of 42% indicates moderate heart failure, and her Pro-BNP level is elevated, suggesting ongoing heart failure. However, her eGFR is within the normal range, and she is taking medications that are beneficial for heart failure. Her low T4 level may indicate hypothyroidism, which can contribute to heart failure, but it is not the primary concern in this case. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG may indicate a higher risk of arrhythmias, but it is not a direct indicator of pump failure death. Considering her current treatment regimen and the fact that she is not in NYHA Class IV, I believe pump failure death is the second most likely prognosis.

RANKING: Sudden Cardiac Death
 REASONING: The patient has a history of myocardial infarction, which increases her risk of sudden cardiac death. However, her LVEF is 42%, and she is taking beta blockers, which are beneficial for reducing the risk of sudden cardiac death. Her Pro-BNP level is elevated, indicating heart failure, but it is not extremely high. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG is concerning, but it is not a direct indicator of sudden cardiac death. Her low T4 level may indicate hypothyroidism, which can contribute to heart failure, but it is not a primary concern in this case. Considering her current treatment regimen and the fact that she is not in NYHA Class IV, I believe sudden cardiac death is the least likely prognosis."
181,181,P0305,"Age: 52
Gender: Male 
Weight: 71 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 160/100 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 141.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,8
LDL (mmol/L): 1,58
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 89.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 21
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,53
Urea (mg/dL): 3,99
LVEF (%): 66.0
Medications: Calcium Channel Blocker, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient is 52 years old with a history of ischemic dilated cardiomyopathy, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction. However, the patient is currently on optimal medical therapy with a calcium channel blocker, statins, and an ACE inhibitor, which suggests good adherence to treatment. The left ventricular ejection fraction (LVEF) is 66%, which is within the normal range, indicating preserved cardiac function. The patient's NYHA Class II classification indicates mild to moderate symptoms, suggesting that the patient is relatively stable. Additionally, the patient's BNP level is within the normal range, which is a good prognostic indicator for cardiac function. Considering these factors, the patient's overall condition suggests a relatively favorable prognosis.

RANKING: 2. Pump failure death
 REASONING: While the patient has a history of ischemic dilated cardiomyopathy, the LVEF is still within the normal range, and the patient is on optimal medical therapy. The patient's BNP level is normal, which suggests that the patient is not currently experiencing significant cardiac dysfunction. However, the patient's history of myocardial infarction and peripheral vascular disease increases the risk of future cardiac events. If the patient's cardiac function deteriorates over time, pump failure death could become a possibility. However, given the current state of the patient, this prognosis is less likely.

RANKING: 3. Sudden cardiac death
 REASONING: Sudden cardiac death is a catastrophic event that is often associated with severe cardiac dysfunction or arrhythmias. The patient's ECG is normal, and there is no evidence of ventricular tachycardia or other life-threatening arrhythmias. The patient's LVEF is within the normal range, and the BNP level is normal, which suggests that the patient is not currently at high risk for sudden cardiac death. While the patient's history of myocardial infarction increases the risk of future cardiac events, the overall risk of sudden cardiac death is relatively low given the patient's current cardiac function and medical therapy."
182,182,P0306,"Age: 55
Gender: Male 
Weight: 78 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,04
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,88
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 453.0
Protein (g/L): 70
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,52
Urea (mg/dL): 6,99
LVEF (%): 51.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor
REASONING: Based on the provided data, the patient is a 55-year-old male with a history of ischemic dilated cardiomyopathy, dyslipemia, hypertension, and myocardial infarction. The patient's current medications, including an angiotensin II receptor blocker, beta blockers, statins, and nitrovasodilators, indicate that he is being managed for his cardiovascular disease.

The patient's LVEF is 51%, which is below the normal range but not severely impaired. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG suggests that the patient does not have an immediate risk of sudden cardiac death.

The patient's BNP level is elevated at 453.0 ng/L, which is consistent with heart failure. However, the patient's NYHA class is II, indicating that he has some symptoms of heart failure but is still able to perform some physical activity.

The patient's laboratory results show a relatively well-managed lipid profile, with a total cholesterol of 5.04 mmol/L and an LDL of 3.88 mmol/L. The patient's potassium level is within the normal range, which is important for patients taking beta blockers and ACE inhibitors.

While the patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, his current medications and relatively stable LVEF suggest that he is being effectively managed. Therefore, based on the provided data, the most likely prognosis for the patient is survival.

RANKING: Sudden Cardiac Death
REASONING: Sudden cardiac death is less likely than survival because the patient's LVEF is not severely impaired, and he is on medications that are known to reduce the risk of sudden cardiac death.

RANKING: Pump Failure Death
REASONING: Pump failure death is the least likely prognosis because the patient's LVEF is not severely impaired (51%), and he is on medications that are known to slow the progression of heart failure. Additionally, the patient's NYHA class is II, indicating that he has some symptoms of heart failure but is still able to perform some physical activity."
183,183,P0307,"Age: 51
Gender: Male 
Weight: 112 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 120/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 82.0
AST or GOT (IU/L): 37.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 13,6
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,21
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 128.0
Protein (g/L): 80
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,45
Urea (mg/dL): 5,32
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely. 

RANKING: Survivor
REASONING: The patient has a relatively well-controlled blood pressure, and the medications are appropriate for his condition, including beta blockers, ACE inhibitors, and statins. The LVEF of 50% is lower than normal, indicating some degree of left ventricular dysfunction, but it is not severely impaired. The patient is also not in NYHA Class III or IV, which suggests that he has some functional capacity and is not severely limited by his heart disease. Additionally, the Pro-BNP level of 128 ng/L is elevated, but not extremely high, indicating some degree of heart failure, but not severe. The patient's glucose level is elevated, but he is on diabetes medication, which suggests that it is being managed. The presence of ischemic dilated cardiomyopathy and peripheral vascular disease are concerning, but the patient's overall clinical picture suggests that he is relatively stable.

RANKING: Sudden Cardiac Death
REASONING: The patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, which increases his risk for sudden cardiac death. The presence of ventricular extrasystoles on the ECG is also a risk factor for sudden cardiac death. However, the patient is on beta blockers, which can reduce the risk of sudden cardiac death. The patient's LVEF of 50% is not extremely low, and he is not in NYHA Class III or IV, which suggests that he is not severely limited by his heart disease.

RANKING: Pump Failure Death
REASONING: The patient has a history of ischemic dilated cardiomyopathy, which increases his risk for pump failure death. The LVEF of 50% is lower than normal, indicating some degree of left ventricular dysfunction. The elevated Pro-BNP level of 128 ng/L suggests some degree of heart failure, but not severe. However, the patient's weight of 112 kg and height of 174 cm suggest a relatively high body mass index (BMI), which can increase the risk of pump failure. Additionally, the patient's diabetes and dyslipemia are risk factors for cardiovascular disease, which can contribute to pump failure."
184,184,P0309,"Age: 51
Gender: Male 
Weight: 97 kg
Height: 182 cm
NYHA Class: III
Blood Pressure: 160/100 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 60.0
AST or GOT (IU/L): 50.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 60
Glucose (mmol/L): 10,3
Hemoglobin (g/L): 144.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,9
LDL (mmol/L): 3,1
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1185.0
Protein (g/L): 85
T3 (pg/dL): 0,02
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,99
Urea (mg/dL): 7,49
LVEF (%): 36.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely.

RANKING: 1. Survivor
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction, which are all risk factors for heart failure. However, the patient is already on optimal medical therapy with beta blockers, statins, and an ACE inhibitor, which are all standard treatments for heart failure. The patient's LVEF is 36%, which is low but not extremely low, and the Pro-BNP level is elevated at 1185.0 ng/L, indicating some degree of heart failure. However, the patient's overall clinical picture does not suggest an immediate high-risk situation. The patient's NYHA class is III, indicating some limitation of physical activity, but not severe. The lack of severe symptoms, the presence of optimal medical therapy, and the patient's relatively stable laboratory values make a survivor prognosis more likely.

RANKING: 2. Sudden Cardiac Death
 REASONING: Sudden cardiac death is a possible concern in a patient with ischemic dilated cardiomyopathy and a low LVEF. However, the patient's Pro-BNP level is elevated, which may indicate some degree of heart failure, but it is not extremely high, suggesting that the patient may not be in a high-risk category for sudden cardiac death. The patient's ECG does not show any signs of ventricular tachycardia or ventricular fibrillation, which are common causes of sudden cardiac death. Additionally, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
 REASONING: Pump failure death is the least likely prognosis in this case. The patient's LVEF is 36%, which is low but not extremely low, and the patient is on optimal medical therapy with beta blockers, statins, and an ACE inhibitor. The patient's Pro-BNP level is elevated, indicating some degree of heart failure, but it is not extremely high, suggesting that the patient may not be in a high-risk category for pump failure. The patient's laboratory values are relatively stable, and the lack of severe symptoms makes pump failure death less likely."
185,185,P0310,"Age: 58
Gender: Male 
Weight: 87 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,1
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 14.0
Protein (g/L): 72
T3 (pg/dL): 0,02
T4 (ng/L): 22
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,05
Urea (mg/dL): 5,83
LVEF (%): 60.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. However, I must emphasize that a personalized prognosis should be made by a qualified healthcare professional after a thorough physical examination and additional diagnostic tests. 

RANKING: Survivor

REASONING: 

1. The patient is 58 years old, which is still relatively young for a patient with ischemic dilated cardiomyopathy. 
2. The patient's LVEF (Left Ventricular Ejection Fraction) is 60%, which is within the normal range (>50%), indicating that the heart is pumping blood efficiently.
3. The patient is on beta blockers and statins, which are standard medications for managing heart failure and dyslipidemia.
4. The patient's blood pressure is well-controlled at 130/80 mmHg, which is within the normal range.
5. The patient's troponin level is slightly elevated, but not significantly high, which may indicate some degree of myocardial damage but not severe.
6. The patient's Pro-BNP (B-type natriuretic peptide) level is 14.0 ng/L, which is within the normal range (typically < 100 ng/L), indicating that the heart is not under excessive stress.
7. The patient's ejection fraction is within the normal range, and there is no evidence of severe heart failure symptoms (NYHA Class II).
8. The patient's electrolyte levels are within the normal range, which is essential for maintaining proper heart function.
9. The patient's lipid profile shows a high total cholesterol level, but the LDL (bad cholesterol) level is relatively low at 3.1 mmol/L, which is under control with statin therapy.
10. The patient's TSH level is within the normal range, indicating no thyroid dysfunction.

Considering these factors, the patient appears to be relatively stable and well-managed. While ischemic dilated cardiomyopathy is a significant condition, the patient's current treatment plan and biomarker values suggest a good prognosis for the next few years.

Sudden cardiac death and pump failure death are less likely due to the following reasons:
- Sudden cardiac death is less likely because the patient has a normal LVEF and is on beta blockers, which reduce the risk of arrhythmias.
- Pump failure death is less likely because the patient's LVEF is within the normal range, and there is no evidence of severe heart failure symptoms.

Therefore, the most likely prognosis for the patient is survivor."
186,186,P0311,"Age: 64
Gender: Male 
Weight: 107 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 53.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,82
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 254
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,36
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 208.0
Protein (g/L): 73
T3 (pg/dL): 0,02
T4 (ng/L): 22
Troponin (ng/mL): 0,02
TSH (mIU/L): 3,26
Urea (mg/dL): 8,32
LVEF (%): 45.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is my prognosis for the next few years:

RANKING: 1. Survivor
REASONING: The patient is 64 years old with a history of ischemic dilated cardiomyopathy, myocardial infarction, and hypertension. However, he is on appropriate medications (beta blockers, statins, and ACE inhibitor) which are crucial in managing heart failure and reducing the risk of adverse outcomes. His LVEF (left ventricular ejection fraction) is 45%, which is lower than the normal range but not extremely low. The patient's NYHA Class II indicates that he has some limitations in physical activity but can still perform daily tasks without significant symptoms. His blood pressure is well-controlled, and his lipid profile is being managed with statins. Although his creatinine level is elevated, it is not significantly high, and his kidney function is not severely impaired. The presence of ventricular extrasystole and TPSV on the ECG is concerning, but it is not a life-threatening condition. Given the patient's current treatment and the absence of severe symptoms or significant laboratory abnormalities, I predict a survivor prognosis.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases his risk of sudden cardiac death. His LVEF of 45% is lower than the normal range, which may indicate some degree of cardiac dysfunction. However, his current treatment with beta blockers, statins, and ACE inhibitor should help mitigate this risk. The presence of ventricular extrasystole on the ECG is a concern, but it is not a definitive predictor of sudden cardiac death. The patient's overall clinical picture suggests that sudden cardiac death is a possible but not the most likely outcome.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF of 45% and history of ischemic dilated cardiomyopathy suggest that he has some degree of cardiac dysfunction. However, his current treatment with beta blockers, statins, and ACE inhibitor should help slow disease progression. His creatinine level is elevated, but it is not extremely high, and his kidney function is not severely impaired. The patient's overall clinical picture suggests that pump failure is a possible outcome, but it is not the most likely due to his current treatment and the absence of severe symptoms or significant laboratory abnormalities."
187,187,P0312,"Age: 69
Gender: Male 
Weight: 84 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,17
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4
LDL (mmol/L): 3,67
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 164.0
Protein (g/L): 70
T3 (pg/dL): 0,03
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,95
Urea (mg/dL): 7,49
LVEF (%): 51.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely. 

RANKING: Survivor

REASONING: The patient is 69 years old with a history of ischemic dilated cardiomyopathy, myocardial infarction, hypertension, and diabetes. However, the patient is on a comprehensive treatment plan with medications for diabetes, hypertension, and heart failure, which suggests that the patient is being actively managed for their conditions. The patient's LVEF is 51%, which is below the normal range but not severely impaired. The patient's BNP level is elevated at 164 ng/L, indicating some degree of heart failure, but not at a level that would suggest severe heart failure. The patient's ECG shows monomorphic ventricular extrasystoles, which is not a concerning finding in this context. Overall, the patient's clinical presentation and treatment suggest that they are being well-managed, and their prognosis is likely to be a survivor.

RANKING: Pump Failure Death

REASONING: Pump failure death is a possible outcome for this patient due to their history of ischemic dilated cardiomyopathy and LVEF of 51%. However, the patient's LVEF is not severely impaired, and they are on medications that are commonly used to manage heart failure, such as ACE inhibitors, beta blockers, and diuretics. The patient's BNP level is elevated, but not at a level that would suggest severe heart failure. Additionally, the patient's symptoms and functional capacity (NYHA Class II) suggest that they are not experiencing severe symptoms of heart failure. Therefore, while pump failure death is a possible outcome, it is not the most likely prognosis.

RANKING: Sudden Cardiac Death

REASONING: Sudden cardiac death is the least likely prognosis for this patient. The patient's ECG shows monomorphic ventricular extrasystoles, but there is no evidence of sustained ventricular tachycardia or other arrhythmias that would increase the risk of sudden cardiac death. The patient's LVEF is not severely impaired, and they are on medications that are commonly used to reduce the risk of sudden cardiac death, such as beta blockers and ACE inhibitors. The patient's TSH level is within the normal range, which reduces the risk of atrial fibrillation, a common cause of sudden cardiac death. Overall, while sudden cardiac death is a possible outcome for any patient with a history of heart disease, it is not the most likely prognosis for this patient based on the provided data."
188,188,P0314,"Age: 56
Gender: Male 
Weight: 62 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 55.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,66
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 133.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,12
Urea (mg/dL): 8,32
LVEF (%): 50.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. I will rank the three possible prognoses from most likely to least likely and provide a reasoning behind each.

RANKING: 1. Survivor
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipemia, which indicates a history of cardiac events. However, the patient is currently taking beta blockers and statins, which are standard treatments for heart failure and dyslipemia. The patient's LVEF is 50%, which is below the normal range but not severely impaired. The patient's NYHA class is II, indicating some symptoms of heart failure but not severe. The patient's blood pressure is elevated, but it's not extremely high. The patient's albumin level is slightly low, and the liver enzymes are mildly elevated, but not indicative of severe liver disease. The patient's troponin level is low, indicating that there is no ongoing myocardial infarction. The patient's pro-BNP level is elevated, indicating some degree of heart failure, but not severely elevated. Considering these factors, the patient's prognosis is likely to be a survivor, as they are receiving standard treatments and do not have any severe underlying conditions.

RANKING: 2. Pump failure death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which increases the risk of pump failure. The patient's LVEF is 50%, indicating some degree of left ventricular dysfunction. The patient's pro-BNP level is elevated, indicating some degree of heart failure. The patient's NYHA class is II, indicating some symptoms of heart failure. However, the patient is taking beta blockers and statins, which can help to improve heart function and reduce the risk of pump failure. The patient's overall condition is not severe enough to warrant a high risk of pump failure death.

RANKING: 3. Sudden cardiac death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which increases the risk of sudden cardiac death. However, the patient's LVEF is 50%, and the patient is taking beta blockers, which can help to reduce the risk of sudden cardiac death. The patient's ECG shows monomorphic ventricular extrasystoles, but no sustained ventricular tachycardia or other arrhythmias that would increase the risk of sudden cardiac death. The patient's troponin level is low, indicating no ongoing myocardial infarction. Overall, while the patient has some risk factors for sudden cardiac death, the risk is not extremely high, and the patient's current treatment regimen reduces the risk further."
189,189,P0315,"Age: 71
Gender: Male 
Weight: 76 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 115/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 47,8
ALT or GPT (IU/L): 44.0
AST or GOT (IU/L): 51.0
Total Cholesterol (mmol/L): 3,47
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 112
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,68
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 5342.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,02
TSH (mIU/L): 3,26
Urea (mg/dL): 4,23
LVEF (%): 22.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: Survivor

REASONING: Based on the provided patient data, I would rank the prognosis as a survivor due to the following reasons:

1.  The patient's age and NYHA Class III suggest that they have a significant amount of cardiac disease, but the fact that they are still alive and on treatment suggests that they are being managed effectively.

2.  The patient's LVEF (Left Ventricular Ejection Fraction) is 22%, which is very low and typically associated with severe heart failure. However, the patient is on beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are all standard treatments for heart failure and may be helping to manage the condition.

3.  The patient's Pro-BNP level is 5342.0 ng/L, which is elevated and suggests that the patient has significant heart failure. However, the fact that the patient is being treated and has not yet experienced a sudden cardiac death or pump failure death suggests that the treatment is effective in managing the condition.

4.  The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death, but the fact that it is non-sustained suggests that the patient is not at immediate risk.

5.  The patient's troponin level is 0.02 ng/mL, which is slightly elevated but not significantly high, suggesting that there is not an acute myocardial infarction.

6.  The patient's TSH level is 3.26 mIU/L, which is within the normal range, suggesting that there is no underlying thyroid disease contributing to the patient's cardiac condition.

7.  The patient's albumin level is 47.8 g/L, which is low, suggesting malnutrition or liver disease. However, the patient's ALT and AST levels are also elevated, which suggests liver disease, but the patient is on statins, which can also cause liver enzyme elevation.

8.  The patient's potassium level is 4.7 mEq/L, which is slightly low, but not critically low, and the patient is not on potassium supplements.

Based on these factors, I would rank the prognosis as a survivor, as the patient appears to be being effectively managed with treatment and has not yet experienced a sudden cardiac death or pump failure death. However, the patient's condition is still severe and requires close monitoring and ongoing treatment."
190,190,P0316,"Age: 71
Gender: Male 
Weight: 61 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 40,7
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 110.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 5
LDL (mmol/L): 3,36
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1903.0
Protein (g/L): 76
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,42
Urea (mg/dL): 9,13
LVEF (%): 39.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here are the prognoses for the next few years, ordered from most likely to least likely:

RANKING: 1. Survivor
REASONING: The patient is 71 years old with a history of hypertensive cardiomyopathy and peripheral vascular disease, which suggests that he has a compromised cardiovascular system. However, he is currently on beta blockers, loop diuretics, and an ACE inhibitor, which are standard medications for managing heart failure and hypertension. His LVEF is 39%, indicating mildly reduced left ventricular function, but not severely impaired. His NT-proBNP level is elevated at 1903 ng/L, which is a marker of heart failure. However, his other lab values, such as troponin, potassium, and urea, are within relatively normal limits. His ECG shows polymorphic ventricular extrasystoles but no sustained ventricular tachycardia or bradycardia. Considering these factors, with appropriate medical management, the patient is likely to survive the next few years with close monitoring.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 39% indicates mildly reduced left ventricular function, which is a risk factor for heart failure progression. His NT-proBNP level is elevated, indicating increased ventricular stress. However, his other lab values are relatively stable, and he is on medications that are commonly used to manage heart failure. While the risk of pump failure death is present, the patient's overall condition is not so severe that it would make this prognosis the most likely.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's LVEF is 39%, and his NT-proBNP level is elevated, indicating increased ventricular stress. However, his ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, there is no mention of other high-risk factors such as sustained ventricular tachycardia or a history of cardiac arrest. Additionally, his medications include beta blockers, which are known to reduce the risk of sudden cardiac death. While the risk of sudden cardiac death is present, it is the least likely prognosis given the patient's overall condition and current treatment."
191,191,P0318,"Age: 55
Gender: Male 
Weight: 63 kg
Height: 149 cm
NYHA Class: II
Blood Pressure: 105/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 48,3
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,67
Creatinine (mmol/L): 155.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 5,4
LDL (mmol/L): 3,1
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 142.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,729
Urea (mg/dL): 15,15
LVEF (%): 39.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here are the three possible prognoses with their likelihood:

RANKING: 1. Survivor, 2. Pump Failure Death, 3. Sudden Cardiac Death

REASONING: 

1. Survivor (Likelihood: High): The patient has a relatively well-managed ischemic dilated cardiomyopathy with a NYHA Class II, which indicates mild to moderate symptoms. The patient is on a comprehensive medication regimen that includes an angiotensin II receptor blocker, beta blockers, digoxin, loop diuretics, and spironolactone, which are all standard treatments for heart failure. The patient's LVEF of 39% is relatively low, but it's not the lowest possible value. The absence of severe electrolyte imbalances, severe anemia, or other life-threatening conditions makes a survival prognosis more likely.

2. Pump Failure Death (Likelihood: Moderate): The patient's LVEF of 39% indicates a reduced left ventricular function, which is a significant risk factor for heart failure progression and mortality. The patient's elevated creatinine levels (155.0 mmol/L) and urea levels (15.15 mg/dL) suggest renal impairment, which can be a complication of heart failure. However, the patient's blood pressure is well-controlled, and the absence of severe proteinuria or significant electrolyte imbalances makes pump failure death less likely compared to sudden cardiac death.

3. Sudden Cardiac Death (Likelihood: Low to Moderate): The patient has a history of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles, which are risk factors for sudden cardiac death. However, the patient's LVEF is relatively low, and the presence of beta blockers and angiotensin II receptor blockers, which are anti-arrhythmic medications, reduces the likelihood of sudden cardiac death. Additionally, the patient's TSH is within the normal range, and there is no indication of hypothyroidism, which can be a risk factor for cardiac arrhythmias.

Overall, considering the patient's relatively well-managed heart failure, the presence of beta blockers, and the absence of severe electrolyte imbalances or anemia, the likelihood of sudden cardiac death is lower compared to pump failure death."
192,192,P0319,"Age: 52
Gender: Male 
Weight: 89 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 44,69
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,31
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 155.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,3
LDL (mmol/L): 4,68
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 984.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,39
Urea (mg/dL): 9,57
LVEF (%): 30.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: The patient is 52 years old with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure. However, the patient's current NYHA Class II indicates that the symptoms are not severe, and the patient is still able to perform everyday activities without significant limitations. The patient is also on a treatment plan that includes ACE inhibitors, digoxin, and loop diuretics, which are commonly used in the management of heart failure. The patient's LVEF of 30% is low, but not extremely low, and the Pro-BNP level of 984 ng/L is elevated, but not excessively high. The patient's blood pressure is within a relatively normal range, and the lack of other significant comorbidities (e.g., severe kidney disease) suggests that the patient may still have a relatively good prognosis. The presence of non-sustained ventricular tachycardia on the ECG is concerning, but the absence of sustained VT and other arrhythmias suggests that the patient's heart rhythm is not as unstable as it could be. Overall, while the patient's heart failure is not well-controlled, the patient's treatment plan and lack of severe symptoms suggest that a survivor prognosis is the most likely outcome.

RANKING: Pump Failure Death

REASONING: Pump failure death is a possible outcome for this patient due to the patient's low LVEF and history of idiopathic dilated cardiomyopathy. The patient's Pro-BNP level is elevated, which is a marker of heart failure. However, the patient's symptoms are not severe (NYHA Class II), and the patient is on a treatment plan that includes ACE inhibitors, digoxin, and loop diuretics, which are commonly used to manage heart failure. The patient's lack of other significant comorbidities (e.g., severe kidney disease) also suggests that pump failure death may not be the most likely outcome.

RANKING: Sudden Cardiac Death

REASONING: Sudden cardiac death is the least likely outcome for this patient. While the patient has a history of idiopathic dilated cardiomyopathy and non-sustained ventricular tachycardia on the ECG, the patient's treatment plan includes ACE inhibitors, which are known to reduce the risk of sudden cardiac death. The patient's LVEF is low, but not extremely low, and the Pro-BNP level is elevated, but not excessively high. The patient's blood pressure is within a relatively normal range, and the lack of other significant comorbidities (e.g., severe kidney disease) suggests that the patient may not be at high risk for sudden cardiac death."
193,193,P0323,"Age: 62
Gender: Male 
Weight: 108 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43,9
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 139.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 176.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,92
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 535.0
Protein (g/L): 81
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,69
Urea (mg/dL): 12,03
LVEF (%): 38.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: 1. Survivor
REASONING: The patient's age of 62 and history of ischemic dilated cardiomyopathy, diabetes, and previous myocardial infarction indicate a high risk of cardiac complications. However, the patient is already receiving a comprehensive treatment regimen, including beta blockers, ACE inhibitors, and diuretics, which are standard therapies for heart failure. The patient's LVEF of 38% is low, but it's not the lowest possible value, and the patient is still alive. The absence of sustained ventricular tachycardia and the presence of a relatively well-controlled blood pressure suggest that the patient's condition is being managed effectively. While the Pro-BNP level is elevated, it's not excessively high, which might indicate some degree of heart failure control. Given the patient's current treatment and the fact that they are still alive, the most likely prognosis is survival.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of ischemic dilated cardiomyopathy and previous myocardial infarction increases the risk of sudden cardiac death. However, the patient is already on beta blockers, which are known to reduce the risk of sudden cardiac death. The presence of a polymorphic ventricular extrasystole on the ECG is a concern, but it's not a definitive predictor of sudden cardiac death. The patient's relatively controlled blood pressure and the absence of sustained ventricular tachycardia also mitigate this risk. While the patient is at risk, the comprehensive treatment regimen and the fact that they are still alive make sudden cardiac death a less likely prognosis compared to pump failure death.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF of 38% is a significant indicator of reduced cardiac function, which increases the risk of pump failure death. The patient's history of ischemic dilated cardiomyopathy and previous myocardial infarction also contributes to this risk. The elevated Pro-BNP level suggests that the patient's heart is under strain, and the presence of dyslipidemia and hypertension may exacerbate this condition. However, the patient is receiving diuretics, which are a standard treatment for heart failure, and their blood pressure is relatively well-controlled. While pump failure death is a possible prognosis, the patient's current treatment regimen and the fact that they are still alive make it the least likely of the three options."
194,194,P0324,"Age: 63
Gender: Male 
Weight: 78 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 45,59
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 42.0
Total Cholesterol (mmol/L): 4,53
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 104
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 113.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,59
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 1148.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,61
Urea (mg/dL): 7,57
LVEF (%): 34.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient is 63 years old with a history of enolic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, and hypertension. Despite these comorbidities, the patient is currently on a multi-drug regimen, including angiotensin II receptor blockers, beta blockers, digoxin, loop diuretics, and spironolactone. The patient's LVEF is 34%, which is below the normal range, indicating reduced cardiac function. However, the patient's Pro-BNP level is 1148.0 ng/L, which is elevated but not extremely high. The patient's troponin level is 0.02 ng/mL, which is within the normal range. The patient's TSH level is 2.61 mIU/L, which is within the normal range. The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, but no sustained ventricular tachycardia or bradycardia. The patient's NYHA class is II, indicating some limitation of physical activity but still able to carry out daily life activities. Considering the patient's current treatment regimen and the absence of severe symptoms or life-threatening arrhythmias, the most likely prognosis is a survivor.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of enolic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The patient's LVEF is 34%, which is below the normal range, indicating reduced cardiac function. The patient's Pro-BNP level is elevated, which is a marker of cardiac stress and potential heart failure. However, the patient's troponin level is within the normal range, and the patient is on a multi-drug regimen that includes beta blockers, which are known to reduce the risk of sudden cardiac death. The patient's ECG shows non-sustained ventricular tachycardia, but no sustained ventricular tachycardia or bradycardia. Considering the patient's reduced cardiac function and the presence of non-sustained ventricular tachycardia, the risk of sudden cardiac death is moderate but not extremely high.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF is 34%, which is below the normal range, indicating reduced cardiac function. The patient's Pro-BNP level is elevated, which is a marker of cardiac stress and potential heart failure. The patient's creatinine level is 94.0 mmol/L, which is elevated, indicating renal impairment. The patient's NYHA class is II, indicating some limitation of physical activity but still able to carry out daily life activities. However, the patient's overall clinical picture suggests a high risk of heart failure progression. The patient is on a multi-drug regimen, including loop diuretics and spironolactone, which are used to manage heart failure. However, the patient's reduced cardiac function and renal impairment increase the risk of pump failure death. Considering the patient's reduced cardiac function and renal impairment, the risk of pump failure death is moderate but not extremely high."
195,195,P0325,"Age: 53
Gender: Male 
Weight: 99 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 125/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 48,8
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,58
Creatinine (mmol/L): 83.0
Gamma-glutamil transpeptidase (IU/L): 230
Glucose (mmol/L): 11,5
Hemoglobin (g/L): 153.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,15
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 171.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,09
Urea (mg/dL): 5,79
LVEF (%): 50.0
Medications: Diabetes Medication, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor
REASONING: The patient's age of 53 is relatively young for a patient with ischemic dilated cardiomyopathy, and their LVEF of 50% is not extremely low. The patient's NYHA Class II indicates that they are not severely symptomatic, which is a positive sign. Additionally, they are on a regimen of medications that are likely helping to manage their conditions, including diabetes medication, loop diuretics, statins, and nitrovasodilators. The absence of sustained ventricular tachycardia and bradycardia on the ECG also suggests that the patient's heart is not experiencing severe arrhythmias. While the patient has a history of myocardial infarction and is at risk for sudden cardiac death, the overall picture suggests that they are more likely to survive in the short term.

RANKING: Pump Failure Death
REASONING: The patient's LVEF of 50% indicates that their heart is not pumping efficiently, which increases their risk for pump failure. The patient's history of ischemic dilated cardiomyopathy and myocardial infarction also increases their risk for pump failure. However, the patient's NYHA Class II and the absence of severe symptoms suggest that their heart failure is not yet severe. The patient's Pro-BNP level of 171.0 is elevated, which is consistent with heart failure, but it is not extremely high. Overall, while the patient is at risk for pump failure, their current symptoms and ECG results suggest that it is not the most likely outcome in the short term.

RANKING: Sudden Cardiac Death
REASONING: The patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases their risk for sudden cardiac death. The patient's LVEF of 50% and elevated Pro-BNP level also suggest that their heart is at risk for arrhythmias. However, the patient's ECG results do not show any evidence of sustained ventricular tachycardia or other arrhythmias that would increase their risk for sudden cardiac death. The patient's medications, including statins and nitrovasodilators, are also likely helping to reduce their risk for arrhythmias. Overall, while the patient is at risk for sudden cardiac death, their current symptoms and ECG results suggest that it is the least likely outcome in the short term."
196,196,P0326,"Age: 67
Gender: Male 
Weight: 78 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease
Albumin (g/L): 52,4
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,89
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 298.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,29
Urea (mg/dL): 4,9
LVEF (%): 34.0
Medications: Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely.

RANKING: 1. Survivor

REASONING: The patient is 67 years old with a history of idiopathic dilated cardiomyopathy and NYHA Class III, indicating severe symptoms. However, the patient is on appropriate medications, including an ACE inhibitor and spironolactone, which are commonly used to manage heart failure and dilated cardiomyopathy. The LVEF of 34% indicates reduced left ventricular function, but it is not the lowest possible value, suggesting that the patient may still have some residual cardiac function. The patient's Pro-BNP level is elevated at 298 ng/L, but not extremely high, which may indicate some degree of heart failure compensation. The absence of other concerning features such as troponin elevation, severe electrolyte imbalances, or significant renal dysfunction suggests that the patient may be relatively stable. The patient's overall clinical picture and medication regimen suggest that the patient may be able to manage their condition and survive for the next few years.

RANKING: 2. Pump Failure Death

REASONING: The patient's LVEF of 34% and NYHA Class III classification indicate severe heart failure symptoms, which increases the risk of pump failure. However, the patient's Pro-BNP level is not extremely high, and they are on appropriate medications, which may help to slow disease progression. The patient's creatinine level of 106.0 mol/L suggests some degree of renal impairment, which can be a complication of heart failure, but it is not severe enough to suggest that pump failure is imminent. The patient's overall clinical picture and medication regimen suggest that while pump failure is a possible outcome, it may not be the most likely scenario.

RANKING: 3. Sudden Cardiac Death

REASONING: The patient has a history of idiopathic dilated cardiomyopathy and a low LVEF of 34%, which increases the risk of sudden cardiac death. However, the patient's ECG does not show any signs of life-threatening arrhythmias, such as ventricular tachycardia or bradycardia, which would increase the risk of sudden cardiac death. The patient's Pro-BNP level is elevated, but not extremely high, which may suggest that the patient's heart failure is relatively well-compensated. The patient's overall clinical picture and medication regimen suggest that sudden cardiac death is the least likely outcome."
197,197,P0328,"Age: 64
Gender: Male 
Weight: 84 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 48,7
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 6,21
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,8
LDL (mmol/L): 4,42
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 511.0
Protein (g/L): 76
T3 (pg/dL): 0,03
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,22
Urea (mg/dL): 6,68
LVEF (%): 35.0
Medications: Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor
 REASONING: The patient is 64 years old with ischemic dilated cardiomyopathy and a left ventricular ejection fraction (LVEF) of 35%, which indicates a reduced cardiac function. However, the patient is on beta blockers, statins, and nitrovasodilators, which are standard medications for managing heart failure and ischemic cardiomyopathy. The patient's blood pressure is well-controlled, and the ejection fraction is not extremely low. The lack of significant electrolyte imbalances, such as hypokalemia, and the relatively low troponin levels suggest that the patient is not experiencing acute cardiac ischemia. The pro-BNP level is elevated, indicating some degree of heart failure, but the patient's symptoms are likely well-managed with current medications. Considering the patient's age, comorbidities, and current treatment, a survivor prognosis is the most likely outcome.

RANKING: Pump failure death
 REASONING: The patient's LVEF of 35% indicates reduced cardiac function, and the presence of ischemic dilated cardiomyopathy increases the risk of heart failure progression. The patient's creatinine level of 93.0 mol/L suggests some degree of renal impairment, which can be a consequence of heart failure. The patient's pro-BNP level is elevated, indicating some degree of heart failure. However, the patient's symptoms are likely well-managed with current medications, and there is no indication of acute cardiac ischemia or other life-threatening conditions. While the patient's cardiac function is compromised, the likelihood of sudden cardiac death is lower than pump failure death, given the patient's current treatment and relatively stable condition.

RANKING: Sudden cardiac death
 REASONING: The patient has a history of myocardial infarction, ischemic dilated cardiomyopathy, and ventricular extrasystoles on the ECG, which increases the risk of sudden cardiac death. However, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death. The patient's troponin level is low, indicating no acute cardiac ischemia, and the lack of non-sustained ventricular tachycardia or other life-threatening arrhythmias on the ECG suggests a lower risk of sudden cardiac death. While the patient's cardiac function is compromised, the presence of ventricular extrasystoles and the patient's history of myocardial infarction increase the risk of sudden cardiac death, but the likelihood is lower than pump failure death due to the patient's current treatment and relatively stable condition."
198,198,P0331,"Age: 52
Gender: Female 
Weight: 82 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 125/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,28
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 720.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,74
Urea (mg/dL): 8,02
LVEF (%): 37.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient is 52 years old with ischemic dilated cardiomyopathy and a history of myocardial infarction, which indicates a history of heart disease. However, the patient is on optimal medical therapy with Angiotensin II Receptor Blocker, Beta Blockers, and Statins, which are standard treatments for heart failure and hypertension. The LVEF of 37% indicates that the patient's heart is still pumping, albeit not efficiently. The patient's NYHA Class II suggests that the patient is experiencing some symptoms but is still able to perform daily activities. The relatively low Pro-BNP level of 720 ng/L is a good prognostic indicator, as higher levels are associated with increased risk of adverse outcomes. The absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG is also a positive sign. Overall, while the patient has a history of heart disease, the current treatment and the patient's functional status suggest a good prognosis for survival.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of sudden cardiac death. The presence of ventricular extrasystoles on the ECG also increases the risk of arrhythmias. However, the patient's optimal medical therapy and the absence of non-sustained ventricular tachycardia on the ECG suggest that the risk of sudden cardiac death is lower than the risk of pump failure death.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 37% indicates that the heart is not pumping efficiently, which increases the risk of pump failure death. The patient's NYHA Class II suggests that the patient is experiencing some symptoms, which may indicate that the heart is not meeting the body's oxygen demands. The relatively high Pro-BNP level of 720 ng/L also suggests that the patient is at increased risk of adverse outcomes. However, the patient's optimal medical therapy and the relatively low creatinine level of 88 umol/L suggest that the patient's kidney function is preserved, which may mitigate the risk of pump failure death.

Note: The patient's weight and height are not provided in a unit that is commonly used, and the glucose level is slightly elevated, but these factors are not as significant as the other factors in determining the prognosis."
199,199,P0334,"Age: 52
Gender: Male 
Weight: 83 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 50,09
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,92
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 136.0
Protein (g/L): 78
T3 (pg/dL): 0,04
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,36
Urea (mg/dL): 9,8
LVEF (%): 32.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Please note that this is a medical prediction and should not be considered a definitive diagnosis.

RANKING: 1. Survivor
REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure. However, the patient is currently on optimal medical therapy with a calcium channel blocker, beta blockers, statins, and an ACE inhibitor, which are all evidence-based treatments for heart failure with reduced ejection fraction (HFrEF). The patient's LVEF is 32%, which is low but not the lowest possible value. The patient's blood pressure is well-controlled, and the patient does not have any signs of severe electrolyte imbalances or acute kidney injury. The patient's TSH and T4 levels are within the normal range, which suggests that there is no apparent thyroid dysfunction contributing to the patient's condition. The patient's troponin level is normal, indicating that there is no acute myocardial infarction. The patient's pro-BNP level is elevated, but not excessively high, which may indicate some degree of heart failure but not severe. The patient's NYHA class is II, which is a moderate level of heart failure. Considering all these factors, the patient's prognosis is likely to be a survivor with proper medical management.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient has a history of non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. The patient's LVEF is low, which increases the risk of sudden cardiac death. However, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death. The patient's troponin level is normal, and there are no signs of acute myocardial infarction. The patient's pro-BNP level is elevated, but not excessively high, which may indicate some degree of heart failure but not severe. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death, but the patient is on a calcium channel blocker, which may help to reduce this risk.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF is very low at 32%, which is a significant risk factor for pump failure death. The patient's creatinine level is elevated, indicating some degree of kidney dysfunction, which can be a consequence of heart failure. The patient's pro-BNP level is elevated, which may indicate some degree of heart failure. The patient's NYHA class is II, which is a moderate level of heart failure, but the patient's symptoms may progress to more severe heart failure if not adequately managed. The patient is on optimal medical therapy, but the patient's low LVEF and elevated creatinine level suggest that the patient's heart function is severely compromised, increasing the risk of pump failure death."
200,200,P0335,"Age: 44
Gender: Male 
Weight: 90 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42,8
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 3,41
Creatinine (mmol/L): 78.0
Gamma-glutamil transpeptidase (IU/L): 38
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 161.0
HDL (mmol/L): 0,57
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,55
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 522.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,03
Urea (mg/dL): 7,35
LVEF (%): 25.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Survivor
REASONING: The patient is 44 years old, which is relatively young for a diagnosis of idiopathic dilated cardiomyopathy. Despite having a low LVEF of 25%, the patient is on optimal medical therapy, including beta blockers, spironolactone, statins, and an ACE inhibitor. The patient's blood pressure is well-controlled, and there are no signs of severe renal dysfunction (creatinine 78.0 mol/L). The patient's troponin level is normal, indicating minimal myocardial damage. The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG is concerning, but the patient does not have a history of sudden cardiac death or sustained ventricular tachycardia. The patient's NYHA class is II, indicating mild symptoms, and the patient is not on an implantable cardioverter-defibrillator (ICD). Considering these factors, the most likely prognosis is that the patient will survive for the next few years with appropriate medical management and follow-up.

RANKING: Sudden cardiac death
REASONING: The patient's LVEF of 25% is significantly reduced, indicating severe left ventricular dysfunction. The presence of non-sustained ventricular tachycardia on the ECG is a risk factor for sudden cardiac death. However, the patient's age, controlled blood pressure, and optimal medical therapy reduce the likelihood of sudden cardiac death. Additionally, the patient does not have a history of previous cardiac arrest or sustained ventricular tachycardia, which further decreases the risk.

RANKING: Pump failure death
REASONING: The patient's LVEF of 25% and NYHA class II suggest that the patient has significant left ventricular dysfunction. However, the patient's blood pressure is well-controlled, and there is no evidence of severe renal dysfunction or significant electrolyte imbalances. The patient's pro-BNP level is elevated, indicating some degree of heart failure, but it is not extremely high. Considering the patient's relatively young age and optimal medical therapy, pump failure death is less likely compared to the other two options."
201,201,P0337,"Age: 55
Gender: Male 
Weight: 88 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 160/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 48,7
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 6,54
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 60
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 3,6
LDL (mmol/L): 4,03
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 209.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,544
Urea (mg/dL): 10,24
LVEF (%): 67.0
Medications: Calcium Channel Blocker, Angiotensin II Receptor Blocker, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

Given the patient's data, I would rank the prognosis as a survivor for the next few years. Here's why:

1. Current Medications: The patient is already on a combination of medications that are commonly used to manage hypertension, heart failure, and dyslipidemia, including a calcium channel blocker, angiotensin II receptor blocker, beta blockers, and statins. This suggests that the patient's condition is being actively managed, and the medications are likely helping to control symptoms and slow disease progression.

2. NYHA Class II: The patient's New York Heart Association (NYHA) classification is II, which indicates that the patient has mild to moderate symptoms of heart failure. This suggests that the patient's heart failure is not severe, and the patient is still able to perform daily activities without significant limitation.

3. LVEF of 67%: The patient's left ventricular ejection fraction (LVEF) is 67%, which is within the normal range. This suggests that the patient's heart is pumping efficiently, and there is no significant impairment in cardiac function.

4. Troponin levels: The patient's troponin levels are within normal limits, which suggests that there is no acute myocardial infarction or significant cardiac damage.

5. ECG findings: While the patient has ventricular extrasystoles, there is no evidence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia. The presence of paroxysmal supraventricular tachyarrhythmia (PSVT) is a concern, but it is not typically a life-threatening condition.

6. Other laboratory values: The patient's albumin, ALT, AST, total cholesterol, creatinine, and urea levels are within normal limits, which suggests that there is no significant liver or kidney dysfunction.

However, there are some concerns that need to be monitored:

* Hypertension: The patient's blood pressure is elevated, which can contribute to cardiac disease progression.
* Elevated Pro-BNP levels: The patient's pro-BNP levels are elevated, which suggests that there may be some degree of heart failure or stress on the heart.
* Low HDL levels: The patient's HDL levels are low, which is a risk factor for cardiovascular disease.
* Weight: The patient's weight is above average, which can contribute to cardiovascular disease.

Overall, while there are some concerns, the patient's current medications, NYHA classification, LVEF, and laboratory values suggest that a survivor prognosis is the most likely outcome for the next few years."
202,202,P0338,"Age: 75
Gender: Male 
Weight: 63 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 52,19
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,3
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 38
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,31
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1121.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,43
Urea (mg/dL): 5,79
LVEF (%): 39.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1

REASONING: Based on the provided patient data, I would rank the prognosis as survivor. Here's why:

1.  The patient has a history of enolic dilated cardiomyopathy, which is a condition that affects the heart muscle, making it harder for the heart to pump blood. However, the patient is on optimal medical therapy with digoxin, loop diuretics, statins, and ACE inhibitors, which are commonly used to manage heart failure and improve cardiac function.

2.  The patient's left ventricular ejection fraction (LVEF) is 39%, which is below the normal range (50-70%). However, it's not extremely low, and the patient is not in NYHA Class III or IV, which indicates that the patient is still relatively stable and can perform daily activities with some limitation.

3.  The patient's pro-BNP level is elevated at 1121 ng/L, which suggests that the patient has some degree of heart failure. However, it's not extremely high, and the patient is on diuretics, which should help manage fluid overload and reduce BNP levels.

4.  The patient's ECG shows non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, which are concerning signs of cardiac arrhythmias. However, the patient is on anti-arrhythmic medications, and there is no mention of sustained ventricular tachycardia or fibrillation.

5.  The patient's troponin level is slightly elevated at 0.01 ng/mL, which may indicate some degree of myocardial injury or stress. However, it's not extremely high, and the patient is on statins, which should help reduce cardiac stress and inflammation.

6.  The patient's TSH level is within the normal range, which suggests that the patient's thyroid function is normal, and there is no indication of hyperthyroidism or hypothyroidism, which can contribute to cardiac dysfunction.

Considering these factors, I would rank the prognosis as survivor, as the patient is on optimal medical therapy, has relatively stable cardiac function, and no extreme elevations in cardiac biomarkers. However, the patient should be closely monitored for any changes in cardiac function, and the treatment plan should be adjusted accordingly.

RANKING: 2

REASONING: Sudden cardiac death is a possible outcome, but it is less likely than survivor. Here's why:

1.  The patient has a history of myocardial infarction, which increases the risk of sudden cardiac death.

2.  The patient's LVEF is 39%, which is below the normal range, and may increase the risk of sudden cardiac death.

3.  The patient's pro-BNP level is elevated, which suggests that the patient has some degree of heart failure and may be at risk for sudden cardiac death.

4.  The patient's ECG shows non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, which are concerning signs of cardiac arrhythmias and may increase the risk of sudden cardiac death.

However, the patient is on optimal medical therapy, including anti-arrhythmic medications, which should help reduce the risk of sudden cardiac death.

RANKING: 3

REASONING: Pump failure death is the least likely outcome. Here's why:

1.  The patient's LVEF is 39%, which is below the normal range, but not extremely low.

2.  The patient is on optimal medical therapy, including digoxin, loop diuretics, statins, and ACE inhibitors, which should help manage heart failure and improve cardiac function.

3.  The patient's pro-BNP level is elevated, but not extremely high, and the patient is on diuretics, which should help manage fluid overload and reduce BNP levels.

4.  The patient's ECG shows non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, but the patient is on anti-arrhythmic medications, which should help reduce the risk of arrhythmias.

Overall, while the patient has some risk factors for pump failure, the patient's current medical therapy and relatively stable cardiac function make pump failure death the least likely outcome."
203,203,P0341,"Age: 61
Gender: Female 
Weight: 85 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 47
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 89.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 146.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,4
LDL (mmol/L): 3
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 485.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,706
Urea (mg/dL): 7,12
LVEF (%): 30.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: The patient is 61 years old with a history of hypertensive cardiomyopathy and hypertension. However, she is being treated with an Angiotensin II Receptor Blocker and a Statin, which are appropriate for managing her conditions. Her LVEF is 30%, which is within the range of severe left ventricular dysfunction, but she is not in New York Heart Association (NYHA) Class IV, indicating that her symptoms are not as severe as they could be. Her Pro-BNP level is elevated at 485.0 ng/L, but it is not extremely high, and she does not have any signs of acute coronary syndrome or acute heart failure. Her ECG does show polymorphic ventricular extrasystoles, but this is not a contraindication for survival. The patient's TSH level is within the normal range, indicating that thyroid function is not contributing to her cardiac condition. Overall, while the patient has significant cardiac disease, her current treatment regimen and the absence of severe symptoms make survivorship the most likely prognosis.

RANKING: Pump Failure Death

REASONING: The patient's LVEF is 30%, which indicates severe left ventricular dysfunction. Her Pro-BNP level is elevated, which is a marker of heart failure. However, she is being treated with Digoxin, which is a medication used to improve heart function in patients with heart failure. Her NYHA Class is II, indicating that her symptoms are not as severe as they could be, and she is not in NYHA Class IV, which is typically associated with more severe heart failure. While pump failure is a possibility, the patient's current treatment regimen and the absence of severe symptoms make it less likely than sudden cardiac death.

RANKING: Sudden Cardiac Death

REASONING: Sudden cardiac death is typically associated with a history of ventricular tachycardia or other life-threatening arrhythmias, which are not present in this patient's ECG. While the patient has polymorphic ventricular extrasystoles, this is not a contraindication for survival. The patient's LVEF is 30%, which is within the range of severe left ventricular dysfunction, but this is not typically associated with sudden cardiac death. The patient's Pro-BNP level is elevated, but this is more indicative of heart failure than sudden cardiac death. Overall, while sudden cardiac death is a possibility, the patient's ECG and clinical data make it the least likely prognosis."
204,204,P0342,"Age: 66
Gender: Male 
Weight: 75 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42,9
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 143.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 11,9
Hemoglobin (g/L): 123.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,42
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2416.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 19,55
Urea (mg/dL): 12,69
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's a prognosis for the next few years:

RANKING: Survivor
REASONING: Despite the patient's advanced age and multiple comorbidities, including ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and a history of myocardial infarction, the patient is currently receiving optimal medical therapy for these conditions. The patient's current medications, including beta blockers, ACE inhibitors (or ARBs), statins, and loop diuretics, are all evidence-based treatments for heart failure and are likely to be contributing to the patient's current stability. The patient's LVEF of 50% is relatively well-preserved, indicating that the heart is still functioning adequately. Additionally, the patient's blood pressure is well-controlled, and there is no evidence of significant electrolyte imbalances or kidney dysfunction that could exacerbate the patient's condition. The patient's Pro-BNP level of 2416 ng/L is elevated, but not extremely high, indicating some degree of heart failure, but not severe. Overall, while the patient's prognosis is guarded, the patient's current treatment regimen and relatively preserved LVEF suggest that a survivor prognosis is the most likely outcome.

RANKING: Sudden cardiac death
REASONING: The patient's history of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG is concerning for an increased risk of sudden cardiac death. Additionally, the patient's elevated Pro-BNP level and history of ischemic dilated cardiomyopathy further increase this risk. However, the patient's LVEF of 50% is still relatively well-preserved, and the patient is receiving optimal medical therapy for these conditions. While sudden cardiac death is a possible outcome, it is not the most likely prognosis given the patient's current treatment regimen and relatively preserved LVEF.

RANKING: Pump failure death
REASONING: Pump failure death is the least likely prognosis for this patient. While the patient has a history of ischemic dilated cardiomyopathy and a relatively low LVEF of 50%, the patient's current treatment regimen and lack of severe symptoms or significant laboratory abnormalities (such as severely elevated creatinine or low albumin) suggest that the patient's heart is still functioning adequately. Additionally, the patient's NYHA Class II classification indicates that the patient is experiencing some symptoms of heart failure, but is not severely limited by these symptoms. Overall, while pump failure is a possible outcome, the patient's current treatment regimen and relatively preserved LVEF suggest that this outcome is the least likely of the three."
205,205,P0344,"Age: 56
Gender: Male 
Weight: 110 kg
Height: 176 cm
NYHA Class: III
Blood Pressure: 180/100 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 43,9
ALT or GPT (IU/L): 135.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 7,34
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 95
Glucose (mmol/L): 6
Hemoglobin (g/L): 170.0
HDL (mmol/L): 1,94
Potassium (mEq/L): 4,5
LDL (mmol/L): 4,45
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 466.0
Protein (g/L): 78
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,55
Urea (mg/dL): 6,68
LVEF (%): 35.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: 1. Survivor
 REASONING: The patient is 56 years old with a history of enolic dilated cardiomyopathy and hypertension, which indicates a compromised cardiac function. However, despite this, the patient is on a treatment regimen that includes angiotensin II receptor blocker, beta blockers, and loop diuretics, which are standard treatments for heart failure and hypertension. The patient's LVEF (Left Ventricular Ejection Fraction) is 35%, which is below the normal range, but it's not extremely low. The patient's NT-proBNP level is elevated, which is consistent with heart failure, but it's not extremely high. Additionally, the patient's troponin level is normal, which suggests that there is no acute myocardial infarction. Considering the patient's current treatment and the fact that the patient is not in acute decompensated heart failure, I believe the most likely prognosis is that the patient will survive for the next few years with proper management of their condition.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of enolic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The patient's LVEF is 35%, which is below the normal range and increases the risk of sudden cardiac death. The patient also has an elevated NT-proBNP level, which is a marker of heart failure and increased risk of sudden cardiac death. However, the patient's troponin level is normal, and the patient is on beta blockers, which reduce the risk of sudden cardiac death. Considering the patient's history and current treatment, the risk of sudden cardiac death is significant, but not extremely high.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF is 35%, which indicates a compromised cardiac function. The patient's NT-proBNP level is elevated, which is consistent with heart failure. The patient's creatinine level is slightly elevated, which may indicate renal dysfunction, which can be a complication of heart failure. The patient's weight is 110 kg, which is above the ideal weight, and may put additional strain on the heart. However, the patient is on diuretics, which are used to manage fluid overload in heart failure. Considering the patient's current treatment and the fact that the patient is not in acute decompensated heart failure, I believe that pump failure death is the least likely prognosis."
206,206,P0347,"Age: 65
Gender: Male 
Weight: 69 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 46
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 14,5
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,46
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 500.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,05
Urea (mg/dL): 10,47
LVEF (%): 40.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely. Please note that this is a complex decision-making process, and actual patient outcomes can vary.

RANKING: Survivor
REASONING: Despite the patient's advanced age, ischemic dilated cardiomyopathy, and reduced left ventricular ejection fraction (LVEF) of 40%, several factors suggest a more favorable prognosis. The patient is on a multidrug regimen, including ACE inhibitors, beta blockers, statins, and calcium channel blockers, which are all evidence-based treatments for heart failure and ischemic cardiomyopathy. The patient's blood pressure is well-controlled, and the lack of signs of decompensated heart failure (e.g., elevated creatinine, low albumin) suggests that the patient's current treatment is effective. Additionally, the patient's hemoglobin level is within a relatively normal range, and the absence of significant abnormalities in liver function tests (ALT, AST, GGT) suggests that the patient's liver function is not significantly impaired. The low TSH level and normal T4 level indicate that the patient's thyroid function is likely normal. The patient's troponin level is low, indicating that there is no current acute coronary syndrome. While the patient's Pro-BNP level is elevated, indicating some level of heart failure, it is not excessively high. Considering these factors, a survivor prognosis is the most likely outcome.

RANKING: Sudden Cardiac Death
REASONING: While the patient's history of myocardial infarction, ischemic dilated cardiomyopathy, and reduced LVEF increase the risk of sudden cardiac death, the patient's current treatment regimen and lack of signs of decompensated heart failure suggest that the risk is not extremely high. The patient's LVEF is below 50%, which is a risk factor for sudden cardiac death, but it is not extremely low. The absence of significant abnormalities in the ECG, such as sustained ventricular tachycardia, also suggests that the risk of sudden cardiac death is not extremely high.

RANKING: Pump Failure Death
REASONING: This prognosis is the least likely, given the patient's current treatment regimen and lack of signs of decompensated heart failure. While the patient's LVEF is reduced, the patient's creatinine level is within a relatively normal range, and the albumin level is not significantly low. The patient's hemoglobin level is also within a relatively normal range, indicating that the patient's kidneys are functioning adequately. The patient's Pro-BNP level is elevated, but not excessively high, suggesting that the patient's heart failure is not severe."
207,207,P0348,"Age: 60
Gender: Male 
Weight: 79 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 54,4
ALT or GPT (IU/L): 55.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 3,47
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 160.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,84
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 266.0
Protein (g/L): 74
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,01
Urea (mg/dL): 7,8
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: 
The patient is 60 years old with a history of ischemic dilated cardiomyopathy, diabetes, and dyslipemia, which are all significant risk factors for cardiovascular disease. However, the patient's LVEF (left ventricular ejection fraction) is 35%, which is below the normal range (50-70%), indicating some degree of heart failure. Despite this, the patient is on beta blockers and statins, which are standard treatments for heart failure and dyslipidemia, respectively. The patient's blood pressure is well-controlled at 120/70 mmHg, and the creatinine level is slightly elevated at 101.0 mmol/L, but not significantly so. The Pro-BNP level is elevated at 266.0 ng/L, indicating some degree of heart failure, but it is not extremely high. The patient's ECG is unremarkable, and there are no signs of arrhythmias or other cardiac issues. The patient's overall clinical presentation suggests that while the patient has significant cardiovascular disease, they are being actively managed with medications and are not in an acute decompensated state. Therefore, the most likely prognosis is that the patient will survive for the next few years with ongoing management and treatment.

RANKING: Pump Failure Death

REASONING: 
The patient's LVEF is 35%, which is a significant risk factor for pump failure. The patient's creatinine level is slightly elevated, indicating some degree of renal impairment, which can be a consequence of heart failure. The Pro-BNP level is elevated, indicating some degree of heart failure. However, the patient's overall clinical presentation and medication regimen suggest that the patient is being actively managed for heart failure, and there are no signs of acute decompensation. While the patient is at risk for pump failure, the likelihood is not extremely high given the patient's current management and lack of acute symptoms.

RANKING: Sudden Cardiac Death

REASONING: 
The patient's ECG is unremarkable, and there are no signs of arrhythmias or other cardiac issues. The patient's LVEF is 35%, which is a risk factor for sudden cardiac death, but the patient is on beta blockers, which can reduce the risk of sudden cardiac death. The patient's creatinine level is slightly elevated, but not significantly so. The patient's overall clinical presentation suggests that the patient is not at extremely high risk for sudden cardiac death. While the patient has significant cardiovascular disease, the likelihood of sudden cardiac death is relatively low given the patient's current management and lack of acute symptoms."
208,208,P0350,"Age: 76
Gender: Female 
Weight: 89 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 37,2
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,35
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 120.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,03
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 480.0
Protein (g/L): 69
T3 (pg/dL): 0,03
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,25
Urea (mg/dL): 16,03
LVEF (%): 32.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: 1. Survivor
REASONING: The patient is 76 years old with a history of hypertensive cardiomyopathy and hypertension. Despite this, she is on a comprehensive medication regimen, including an Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Spironolactone, which is a standard treatment for heart failure and hypertension. The patient's LVEF (Left Ventricular Ejection Fraction) is 32%, which is low but not extremely low. However, her NYHA Class III indicates that she has severe symptoms of heart failure, but she is still able to perform daily activities with some limitation. The Pro-BNP level of 480 ng/L indicates elevated levels of B-type natriuretic peptide, which is consistent with heart failure. However, the patient's blood pressure is well-controlled at 130/80 mmHg, and her creatinine level is not significantly elevated, suggesting that her kidney function is relatively preserved. The absence of sustained ventricular tachycardia and the presence of a TPSV (paroxysmal supraventricular tachyarrhythmia) on the ECG are concerning but do not necessarily indicate an immediate risk of sudden cardiac death. Overall, while the patient has significant heart disease, her medication regimen and relatively preserved kidney function suggest that she may be able to manage her condition and survive for several years with proper medical management.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 32% and NYHA Class III indicate that she has severe heart failure. Her Pro-BNP level of 480 ng/L and elevated creatinine level of 125 umol/L suggest that her heart failure is likely to progress. However, her blood pressure is well-controlled, and her kidney function is relatively preserved, which may slow the progression of her heart failure. The patient's medication regimen is comprehensive, and she is on medications that are known to slow the progression of heart failure. While the patient's prognosis is guarded, her overall condition is not immediately life-threatening, and she may be able to survive for several years with proper medical management.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's ECG shows monomorphic ventricular extrasystoles, which can be a marker of increased risk of sudden cardiac death. However, the absence of sustained ventricular tachycardia and the presence of a TPSV on the ECG suggest that the patient's risk of sudden cardiac death is not extremely high. Additionally, the patient's LVEF of 32% and NYHA Class III indicate that she has severe heart failure, but her overall condition is not immediately life-threatening. The patient's medication regimen includes Beta Blockers, which are known to reduce the risk of sudden cardiac death. While the patient's risk of sudden cardiac death is higher than average, it is not the most likely outcome in the next few years.

Note: These prognoses are based on the provided data and should not be taken as a definitive prediction of the patient's outcome. The actual outcome may vary based on various factors, including the patient's response to treatment, the progression of her heart disease, and the development of new medical conditions."
209,209,P0352,"Age: 51
Gender: Male 
Weight: 85 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 46,3
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,72
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,88
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 239.0
Protein (g/L): 80
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,66
Urea (mg/dL): 8,24
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: Based on the provided patient data, the patient is a 51-year-old male with a history of ischemic dilated cardiomyopathy and myocardial infarction, which indicates a significant cardiac condition. However, there are several factors that suggest a relatively favorable prognosis:

1.  The patient's NYHA Class II indicates that he experiences some limitations in physical activity but is still able to perform daily activities without severe symptoms.
2.  The patient's blood pressure is within a relatively normal range (110/70 mmHg), which is a good sign for cardiac health.
3.  The patient's laboratory results show elevated creatinine levels (109.0 mmol/L), which may indicate some kidney dysfunction, but it is not severe enough to be a significant concern for cardiac prognosis.
4.  The patient's LVEF (Left Ventricular Ejection Fraction) is 35%, which is low, but not extremely low. An LVEF of 35% indicates a reduced cardiac function, but it is still within the range where some patients can experience significant improvement with treatment.
5.  The patient is on a combination of medications that are commonly used to manage heart failure, including a calcium channel blocker, beta blockers, and an ACE inhibitor.
6.  The patient's ECG results do not show any signs of life-threatening arrhythmias or other cardiac abnormalities.
7.  The patient's TSH level is within the normal range, which suggests that there are no signs of thyroid dysfunction that could contribute to cardiac disease.
8.  The patient's Troponin level is low (0.01 ng/mL), which suggests that there is no active cardiac damage or acute myocardial infarction.

Considering these factors, the patient's prognosis is likely to be a survivor. While the patient has a history of cardiac disease and some laboratory abnormalities, the patient's symptoms, medications, and ECG results suggest that he is being managed effectively and is likely to experience a favorable outcome."
210,210,P0353,"Age: 78
Gender: Male 
Weight: 75 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,71
Creatinine (mmol/L): 140.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,9
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 4518.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,63
Urea (mg/dL): 14,92
LVEF (%): 15.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Digoxin, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: Survivor

REASONING: Based on the provided patient data, I rank the prognosis as Survivor for the following reasons:

1.  The patient is 78 years old, which is a significant risk factor for cardiac events, but his NYHA Class II indicates that he is still relatively stable, and his blood pressure is well-controlled at 120/80 mmHg.
2.  The patient has a history of ischemic dilated cardiomyopathy, myocardial infarction, diabetes, dyslipemia, and hypertension, all of which are significant risk factors for cardiac complications. However, he is on a comprehensive treatment plan that includes medications for diabetes, hypertension, and heart failure (Digoxin and Spironolactone).
3.  His laboratory results show elevated creatinine levels (140.0 mmol/L), which may indicate some degree of kidney dysfunction. However, his albumin levels are within the normal range (39 g/L), and his potassium levels are also within the normal range (4.6 mEq/L).
4.  His LVEF is severely impaired at 15%, indicating significant left ventricular dysfunction. However, his Pro-BNP levels are high at 4518.0 ng/L, which may indicate some degree of heart failure, but it is not an uncommon finding in patients with ischemic cardiomyopathy.
5.  His ECG shows ventricular extrasystoles and non-sustained ventricular tachycardia, which are common findings in patients with ischemic cardiomyopathy.
6.  Considering the patient's age, comorbidities, and laboratory results, the most likely outcome is that he will survive, but with ongoing management and monitoring of his condition to prevent further cardiac complications.

The other two options, Sudden Cardiac Death and Pump Failure Death, are less likely because:

- Sudden Cardiac Death: While the patient has a history of ischemic cardiomyopathy and ventricular arrhythmias, his LVEF is not extremely low (15%), and he is on a comprehensive treatment plan that includes medications to prevent sudden cardiac death (e.g., beta-blockers, implantable cardioverter-defibrillator).
- Pump Failure Death: The patient's LVEF is severely impaired, but his creatinine levels are not extremely high (140.0 mmol/L), and his albumin levels are within the normal range, indicating that his kidney function is not severely impaired. Additionally, his blood pressure is well-controlled, which reduces the risk of pump failure.

In conclusion, while the patient's prognosis is guarded, the most likely outcome is that he will survive with ongoing management and monitoring of his condition."
211,211,P0354,"Age: 54
Gender: Male 
Weight: 61 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 120/78 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 43,5
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 6,39
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 159.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,5
LDL (mmol/L): 4,06
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 123.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,442
Urea (mg/dL): 8,91
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"Based on the provided patient data, here's the ranking of the three possible prognoses from most likely to least likely:

RANKING: 1. Survivor
REASONING: The patient is 54 years old, which is not extremely old for ischemic dilated cardiomyopathy. His NYHA Class II indicates that he has some limitations in physical activity, but he is not severely symptomatic. His blood pressure is within a relatively normal range. The patient is on medications that are commonly used to manage heart failure and ischemic heart disease, such as beta blockers, calcium channel blockers, statins, and nitrovasodilators. His LVEF is 35%, which is low but not extremely low, and he has a relatively low Pro-BNP level of 123 ng/L. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia is concerning, but the fact that he is not in NYHA Class III or IV and is on appropriate medications suggests that he is being managed effectively. His TSH level is within the normal range, which is good news for his thyroid function. Overall, considering these factors, the prognosis of survivor seems the most likely.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, which increases his risk of sudden cardiac death. His LVEF is low, and his Pro-BNP level is slightly elevated. The presence of non-sustained ventricular tachycardia and ventricular extrasystoles on the ECG also increases his risk of sudden cardiac death. However, the fact that he is on beta blockers and is in NYHA Class II suggests that he is being managed effectively, and his TSH level is normal. Additionally, his low T3 level may indicate that he is not experiencing hyperthyroidism, which can increase the risk of arrhythmias. While sudden cardiac death is a possibility, the patient's overall management and relatively low T3 level suggest that this prognosis is less likely than survivor.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF is 35%, which is low, and his Pro-BNP level is slightly elevated. However, his NYHA Class II suggests that he is not severely symptomatic, and his blood pressure is within a relatively normal range. His albumin level is low, which may indicate some degree of malnutrition or liver dysfunction, but his AST and ALT levels are within normal limits. His creatinine level is slightly elevated, which may indicate some degree of renal dysfunction, but it is not extremely high. The patient's medications, including beta blockers and nitrovasodilators, are commonly used to manage heart failure. While pump failure is a possibility, the patient's relatively mild symptoms and effective management suggest that this prognosis is the least likely."
212,212,P0355,"Age: 48
Gender: Male 
Weight: 78 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 48,2
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4
LDL (mmol/L): 2,53
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 325.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,12
Urea (mg/dL): 6,68
LVEF (%): 28.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: 

Given the patient's age, gender, and NYHA Class II, the patient is relatively young and has a moderate level of symptoms. The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, but the patient's current LVEF of 28% suggests that the heart is still functioning, albeit poorly. The patient is on beta blockers and an ACE inhibitor, which are standard treatments for heart failure and myocardial infarction. The patient's albumin and protein levels are within normal limits, which suggests that the patient does not have significant liver dysfunction, which can be a contraindication for certain medications. The patient's TSH and T3/T4 levels are within normal limits, indicating that the patient does not have hypothyroidism, which can contribute to heart failure. The patient's troponin level is low, indicating that the patient is not currently experiencing an acute myocardial infarction.

However, the patient's LVEF of 28% is significantly low, and the patient's Pro-BNP level is elevated, indicating that the patient has heart failure. The patient's creatinine level is elevated, indicating that the patient may have some degree of kidney dysfunction, which can contribute to heart failure. The patient's blood pressure is low, which can be a concern in patients with heart failure.

Despite these concerns, the patient's overall clinical picture suggests that the patient is likely to survive in the next few years, especially if the patient adheres to their current treatment regimen and makes lifestyle modifications to reduce their risk factors for heart disease.

RANKING: Sudden Cardiac Death

REASONING: 

Sudden cardiac death is a possible prognosis for this patient due to the patient's history of myocardial infarction and low LVEF. The patient's polymorphic ventricular extrasystole on the ECG can be a risk factor for sudden cardiac death. However, the patient's low troponin level and the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG suggest that the patient is not currently experiencing an acute cardiac event.

The patient's low LVEF and elevated Pro-BNP level suggest that the patient has heart failure, which can increase the risk of sudden cardiac death. However, the patient's overall clinical picture suggests that the patient is more likely to survive in the next few years than to experience sudden cardiac death.

RANKING: Pump Failure Death

REASONING: 

Pump failure death is a less likely prognosis for this patient due to the patient's relatively young age and moderate symptoms. The patient's LVEF of 28% is low, but the patient is still alive and on treatment for heart failure. The patient's creatinine level is elevated, indicating some degree of kidney dysfunction, but the patient's overall clinical picture does not suggest that the patient is at high risk for pump failure death.

The patient's albumin and protein levels are within normal limits, which suggests that the patient does not have significant liver dysfunction, which can contribute to pump failure. The patient's TSH and T3/T4 levels are within normal limits, indicating that the patient does not have hypothyroidism, which can contribute to heart failure. The patient's troponin level is low, indicating that the patient is not currently experiencing an acute myocardial infarction.

Overall, while the patient's low LVEF and elevated Pro-BNP level suggest that the patient has heart failure, the patient's overall clinical picture suggests that the patient is more likely to survive in the next few years than to experience pump failure death."
213,213,P0357,"Age: 69
Gender: Female 
Weight: 80 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 135/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 11,5
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,4
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 875.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,05
TSH (mIU/L): 1,16
Urea (mg/dL): 7,99
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I would rank the prognosis as follows:

RANKING: 1. Survivor
REASONING: The patient's overall clinical picture suggests a moderate to severe heart failure status, given her NYHA Class II, LVEF of 45%, and elevated Pro-BNP level of 875 ng/L. However, she is on appropriate medications for her condition, including beta blockers, digoxin, loop diuretics, and an ACE inhibitor, which are all evidence-based treatments for heart failure with reduced ejection fraction. Her blood pressure is well-controlled, and her kidney function is relatively preserved, as indicated by a creatinine level of 97.0 mol/L. Additionally, her glucose level is under control, which is beneficial for heart health. The absence of significant arrhythmias on the ECG and the patient's relatively stable vital signs further support a favorable prognosis. While the patient's LVEF is low, it is not extremely low, and her overall clinical picture does not suggest an imminent risk of sudden cardiac death or pump failure.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of idiopathic dilated cardiomyopathy and her current LVEF of 45% increase her risk of sudden cardiac death. However, the presence of a polymorphic ventricular extrasystole on the ECG is concerning and may indicate an increased risk of arrhythmias. Additionally, her T3 level is low, which has been associated with an increased risk of mortality in patients with heart failure. However, her overall clinical picture and the absence of other high-risk features, such as a history of syncope or significant arrhythmias, make sudden cardiac death less likely compared to pump failure death.

RANKING: 3. Pump Failure Death
REASONING: The patient's NYHA Class II and LVEF of 45% suggest that she has moderate to severe heart failure. Her elevated Pro-BNP level and low T3 level further support the presence of heart failure. However, her kidney function is relatively preserved, and her blood pressure is well-controlled, which may mitigate the risk of pump failure. Additionally, her overall clinical picture does not suggest a high risk of acute decompensation or severe worsening of heart failure. While pump failure death is a possible outcome, it is less likely compared to sudden cardiac death, given the patient's relatively stable clinical status and the presence of evidence-based treatments for heart failure."
214,214,P0358,"Age: 53
Gender: Male 
Weight: 71 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 110/65 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,16
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 126
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 161.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,09
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 3068.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,35
Urea (mg/dL): 5,66
LVEF (%): 21.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here's my prognosis for the next few years:

RANKING: Survivor

REASONING: 

The patient has a history of enolic dilated cardiomyopathy, which is a significant underlying condition that affects the heart's pumping ability. However, the patient's current treatment plan includes beta blockers, digoxin, loop diuretics, and ACE inhibitors, which are standard medications for managing heart failure and dilated cardiomyopathy. The patient's LVEF (Left Ventricular Ejection Fraction) is 21%, which is low but not extremely low, and the patient's NYHA Class II indicates that they experience some symptoms but are still able to perform light physical activity without discomfort.

The patient's laboratory results, such as the elevated Pro-BNP (brain natriuretic peptide) and creatinine levels, suggest that the patient has some degree of heart failure and renal impairment. However, the patient's hemoglobin and potassium levels are within normal limits, which suggests that the patient does not have significant anemia or electrolyte imbalances that could worsen their condition.

The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are concerning findings but not necessarily predictive of sudden cardiac death. The patient's TSH level is slightly elevated, but the T4 level is within normal limits, which suggests that the patient does not have significant thyroid dysfunction.

Considering these factors, while the patient has a significant underlying condition, their current treatment plan and laboratory results suggest that they are being managed appropriately. Therefore, I would rank the prognosis as a survivor, with a focus on continued close monitoring and management of their heart failure and dilated cardiomyopathy.

The other two prognoses, sudden cardiac death and pump failure death, are less likely due to the following reasons:

- Sudden cardiac death is less likely because the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death in patients with heart failure.
- Pump failure death is less likely because the patient's LVEF is not extremely low, and their current treatment plan is aimed at managing their heart failure symptoms and slowing disease progression.

However, it's essential to note that the patient's prognosis can change over time, and regular follow-up appointments with their cardiologist are crucial to monitor their condition and adjust their treatment plan as needed."
215,215,P0360,"Age: 64
Gender: Female 
Weight: 52 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 50.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 10,8
Hemoglobin (g/L): 108.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 3,7
LDL (mmol/L): 2,09
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 1314.0
Protein (g/L): 67
T3 (pg/dL): 0,06
T4 (ng/L): 18
TSH (mIU/L): 3,01
Urea (mg/dL): 5,16
LVEF (%): 25.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden cardiac death
REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's low left ventricular ejection fraction (LVEF) of 25% indicates poor heart function, and the presence of polymorphic ventricular extrasystoles on the ECG suggests potential arrhythmogenic risk. Additionally, the patient's elevated Pro-BNP level (1314.0 ng/L) is indicative of heart failure and increased cardiac stress, which may further increase the risk of sudden cardiac death.

RANKING: 2. Pump failure death
REASONING: The patient's LVEF of 25% and elevated Pro-BNP level suggest that the patient's heart is under significant stress and may be at risk for pump failure. The patient's history of idiopathic dilated cardiomyopathy and the presence of heart failure symptoms (NYHA Class II) also support this prognosis. However, the patient is currently on optimal medical therapy for heart failure, including beta blockers, ACE inhibitors (via Angiotensin II Receptor Blocker), and loop diuretics, which may mitigate this risk.

RANKING: 3. Survivor
REASONING: While the patient has several risk factors for adverse outcomes, the patient is on optimal medical therapy for heart failure, idiopathic dilated cardiomyopathy, and diabetes. The patient's blood pressure is well-controlled, and the patient does not have significant electrolyte imbalances (e.g., potassium 3.7 mEq/L). The patient's TSH level is within the normal range, and the patient is not experiencing significant liver dysfunction (ALT 50.0 IU/L, AST 31.0 IU/L). These factors suggest that the patient's condition may be manageable with ongoing medical therapy and lifestyle modifications, making survival the most likely outcome."
216,216,P0361,"Age: 72
Gender: Male 
Weight: 83 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 35,7
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 8,4
Glucose (mmol/L): 6,36
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,87
LDL (mmol/L): 2,16
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 864.0
Protein (g/L): 64
T3 (pg/dL): 0,0489
T4 (ng/L): 16,17
Troponin (ng/mL): 0,4
TSH (mIU/L): 1,54
Urea (mg/dL): 20,49
LVEF (%): 20.0
Medications: Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is my prognosis for the next few years:

RANKING: 1
REASONING: The patient is most likely to survive the next few years due to the following reasons:

1.  The patient is being actively managed with medications such as loop diuretics, spironolactone, statins, and an ACE inhibitor, which are standard treatments for heart failure and ischemic dilated cardiomyopathy.
2.  The patient's blood pressure is well-controlled at 100/70 mmHg, which reduces the risk of cardiovascular events.
3.  The patient's LVEF (Left Ventricular Ejection Fraction) is 20%, which is low, but the patient is still alive and on treatment, indicating that the heart is still functioning to some extent.
4.  The patient's troponin level is elevated at 0.4 ng/mL, indicating some degree of myocardial damage, but not severe enough to cause immediate cardiac death.
5.  The patient's TSH level is within the normal range, indicating that there is no indication of hypothyroidism, which can exacerbate heart failure.
6.  The patient's hemoglobin level is within the normal range, indicating that there is no significant anemia, which can contribute to heart failure.

However, the patient's low LVEF and high Pro-BNP level (864.0 ng/L) suggest that the patient is at risk for heart failure progression and sudden cardiac death.

RANKING: 2
REASONING: The patient is at a moderate risk for sudden cardiac death due to the following reasons:

1.  The patient's LVEF is very low at 20%, indicating severe left ventricular dysfunction.
2.  The patient has a history of myocardial infarction, which can lead to sudden cardiac death.
3.  The patient has a high Pro-BNP level, which is a marker of heart failure and increased risk of sudden cardiac death.
4.  The patient has a history of ischemic dilated cardiomyopathy, which can lead to sudden cardiac death.

However, the patient is on treatment and has a controlled blood pressure, which reduces the risk of sudden cardiac death.

RANKING: 3
REASONING: The patient is least likely to die from pump failure death due to the following reasons:

1.  The patient is being actively managed with medications that help reduce fluid overload and improve heart function.
2.  The patient's blood pressure is well-controlled, which reduces the risk of fluid overload and heart failure progression.
3.  The patient's LVEF is low, but the patient is still alive and on treatment, indicating that the heart is still functioning to some extent.
4.  The patient's creatinine level is elevated at 133.0 mmol/L, indicating some degree of kidney dysfunction, but not severe enough to cause acute kidney injury or pump failure death.

However, the patient's low LVEF and high Pro-BNP level suggest that the patient is at risk for heart failure progression and pump failure death."
217,217,P0365,"Age: 54
Gender: Male 
Weight: 69 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Other HF etiology, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,97
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,89
Potassium (mEq/L): 4
LDL (mmol/L): 3,85
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 46.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,16
Urea (mg/dL): 6,16
LVEF (%): 65.0
Medications: Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

Based on the provided patient data, the patient's prognosis can be assessed as follows:

1. Survivor: The patient is 54 years old, which is relatively young for heart failure, and has a preserved left ventricular ejection fraction (LVEF) of 65%. Although the patient has a history of heart failure (HF) and hypertension, the LVEF is within the normal range, indicating that the heart is still pumping effectively. The patient's blood pressure is within a relatively normal range, and the absence of significant electrolyte imbalances or kidney dysfunction (e.g., normal potassium and creatinine levels) suggests that the patient's cardiovascular system is not severely compromised. The patient is also on loop diuretics, which is a common treatment for HF. The ECG findings are also relatively benign, with only monomorphic ventricular extrasystoles present.

2. Pump Failure Death: While the patient has a history of HF and a low albumin level (42 g/L), which may indicate some degree of cardiac dysfunction, the LVEF is preserved, and the patient's overall clinical picture does not suggest advanced heart failure. The patient's kidney function is relatively preserved, and the patient is not showing signs of significant fluid overload (e.g., no significant weight gain or edema).

3. Sudden Cardiac Death: The patient's risk for sudden cardiac death is relatively low due to the preserved LVEF and the absence of significant arrhythmias on the ECG (e.g., no ventricular tachycardia or bradycardia). The patient's troponin level is also normal, indicating no recent myocardial infarction. While the patient has a history of hypertension and HF, these conditions do not significantly increase the risk of sudden cardiac death in this case.

In conclusion, based on the patient's relatively preserved LVEF, normal blood pressure, and absence of significant arrhythmias, the most likely prognosis is a Survivor."
218,218,P0366,"Age: 59
Gender: Male 
Weight: 100 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 165/110 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 5,46
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 6,5
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,59
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,05
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1477.0
Protein (g/L): 65
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,15
TSH (mIU/L): 0,76
Urea (mg/dL): 8,49
LVEF (%): 37.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the three possible prognoses as follows:

RANKING: 1. Survivor
REASONING: The patient is 59 years old with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension. However, despite these comorbidities, the patient is receiving appropriate medical therapy, including beta blockers, loop diuretics, statins, and an ACE inhibitor, which are all evidence-based treatments for heart failure and hypertension. The patient's NYHA Class II indicates that the patient is experiencing some symptoms, but they are not severely limited in their daily activities. The LVEF of 37% is low, indicating reduced left ventricular function, but it is not the lowest possible value, and the patient is still able to survive with medical therapy. The patient's troponin level is slightly elevated, but not excessively high, and the TSH level is within the normal range, indicating no apparent thyroid dysfunction. The Pro-BNP level is elevated, but not excessively high, which may indicate some degree of heart failure, but not severe. Considering these factors, the patient is likely to survive for the next few years with ongoing medical therapy and close monitoring.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient has a history of ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death. However, the patient's LVEF is 37%, which is not extremely low, and the patient is receiving beta blockers, which are known to reduce the risk of sudden cardiac death. The patient's troponin level is not excessively high, and there is no evidence of ventricular tachycardia or other arrhythmias on the ECG. While the patient is at risk of sudden cardiac death, the overall prognosis is not extremely poor, and the patient is likely to survive for the next few years with ongoing medical therapy.

RANKING: 3. Pump Failure Death
REASONING: The patient has a history of ischemic dilated cardiomyopathy and a low LVEF of 37%, which indicates reduced left ventricular function. The patient's creatinine level is elevated, indicating some degree of renal dysfunction, which can be a marker of advanced heart failure. The patient's Pro-BNP level is elevated, indicating some degree of heart failure. However, the patient is receiving loop diuretics, which are used to manage heart failure symptoms and may indicate that the patient is being closely monitored for signs of worsening heart failure. While the patient is at risk of pump failure death, the overall prognosis is not extremely poor, and the patient is likely to survive for the next few years with ongoing medical therapy and close monitoring."
219,219,P0367,"Age: 63
Gender: Male 
Weight: 82 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 102/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 131.0
HDL (mmol/L): 0,54
Potassium (mEq/L): 5,3
LDL (mmol/L): 2,74
Sodium (mEq/L): 139.0
Protein (g/L): 67
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,06
TSH (mIU/L): 0,92
Urea (mg/dL): 15,31
LVEF (%): 55.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely:

RANKING: Survivor
 REASONING: The patient is 63 years old with a history of hypertensive cardiomyopathy and hypertension. However, the patient's LVEF (left ventricular ejection fraction) is 55%, which is within the normal range (> 50%). This suggests that the patient's heart function is relatively preserved. The patient's blood pressure is well-controlled, and they are on a regimen of beta blockers, ACE inhibitors, and loop diuretics, which are standard treatments for heart failure. Additionally, the patient's troponin levels are within normal limits, indicating minimal myocardial damage. The patient's ECG shows polymorphic ventricular extrasystoles, but no signs of sustained ventricular tachycardia or bradycardia. Overall, these factors suggest that the patient's heart condition is relatively stable, and with proper management, the likelihood of survival is high.

RANKING: Pump failure death
 REASONING: The patient's LVEF is 55%, which is at the lower end of the normal range. However, it is still within the normal range. The patient's creatinine levels are elevated at 133.0 umol/L, indicating some degree of renal impairment. The patient's total cholesterol is high at 3.7 mmol/L, which may contribute to cardiac disease progression. However, the patient's other biomarkers, such as troponin and LVEF, do not indicate significant cardiac damage or dysfunction. While the patient's renal impairment may contribute to a higher risk of cardiovascular events, the overall prognosis is not extremely poor.

RANKING: Sudden cardiac death
 REASONING: The patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the patient is on amiodarone, which is an anti-arrhythmic medication that can help prevent sudden cardiac death. The patient's LVEF is within the normal range, and their troponin levels are normal, indicating minimal myocardial damage. While the patient's renal impairment may increase the risk of cardiovascular events, the overall prognosis is not extremely poor. Additionally, the patient's age and sex are not particularly high-risk factors for sudden cardiac death. Overall, the risk of sudden cardiac death appears to be relatively low compared to the other two options."
220,220,P0371,"Age: 61
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 84.0
AST or GOT (IU/L): 68.0
Total Cholesterol (mmol/L): 6,67
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 89
Glucose (mmol/L): 11,7
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,27
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 27434.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 20
TSH (mIU/L): 1,25
Urea (mg/dL): 7,82
LVEF (%): 26.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: Considering the patient's age, gender, and past medical history, the most likely prognosis is survivor. The patient is 61 years old, which is not extremely old for a patient with idiopathic dilated cardiomyopathy. The patient's LVEF of 26% indicates significant left ventricular dysfunction, but the patient is currently being treated with evidence-based medications for heart failure, including beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitors. The patient's ejection fraction is low, but it is not the lowest possible value, indicating that the heart is still functioning to some extent. The patient's NYHA class is III, which indicates some limitation in physical activity but still able to perform everyday activities. The patient's BNP level is elevated, but not extremely high, which may indicate some degree of heart failure compensation. The absence of significant electrolyte imbalances, renal dysfunction, or other comorbidities also supports a more favorable prognosis.

RANKING: 2. Pump Failure Death
REASONING: Pump failure death is the second most likely prognosis. The patient's LVEF of 26% indicates significant left ventricular dysfunction, and the patient is on medications that are commonly used to treat heart failure with reduced ejection fraction. However, the patient's NYHA class is III, which indicates some limitation in physical activity, and the patient's BNP level is elevated. The patient's creatinine level is slightly elevated, which may indicate some degree of renal dysfunction, which can be a consequence of heart failure. The patient's albumin level is also low, which may indicate malnutrition or liver dysfunction, which can be a consequence of heart failure. However, the patient is still alive and on treatment, which suggests that the patient's condition is being managed.

RANKING: 3. Sudden Cardiac Death
REASONING: Sudden cardiac death is the least likely prognosis. The patient's ECG impression shows polymorphic ventricular extrasystoles, which can be a marker of increased risk of sudden cardiac death, but the patient does not have a history of sustained ventricular tachycardia or other arrhythmias that would increase the risk of sudden cardiac death. The patient is on beta blockers, which are known to reduce the risk of sudden cardiac death in patients with heart failure. The patient's LVEF is low, but the patient is still alive, which suggests that the heart is still functioning to some extent. The patient's BNP level is elevated, but not extremely high, which may indicate some degree of heart failure compensation. Overall, while the patient is at some risk of sudden cardiac death, the patient's current condition and treatment suggest that this is the least likely prognosis."
221,221,P0372,"Age: 60
Gender: Male 
Weight: 77 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 185.0
AST or GOT (IU/L): 154.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 188
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 121.0
HDL (mmol/L): 2,04
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 186.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,7
Urea (mg/dL): 5,66
LVEF (%): 70.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
 REASONING: Based on the provided patient data, the most likely prognosis is a survivor. The patient is 60 years old with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension. However, several factors suggest a relatively stable condition. 

The patient's LVEF is 70%, which is within the normal range, indicating that the heart is functioning relatively well. The patient's blood pressure is within a reasonable range, and the absence of ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia on the ECG suggests that the heart is not experiencing significant arrhythmias. 

Additionally, the patient is on a comprehensive treatment regimen, including beta blockers, statins, ACE inhibitors, and nitrovasodilators, which are commonly used to manage heart failure and reduce the risk of sudden cardiac death. The patient's troponin level is within normal limits, and the TSH level is within the normal range, indicating that there is no apparent thyroid dysfunction contributing to heart failure.

The patient's Pro-BNP level is elevated, but it is not excessively high, which suggests that the patient's heart failure is not in an advanced stage. The presence of polymorphic ventricular extrasystoles on the ECG is a concern, but it is not uncommon in patients with heart failure and is not a strong predictor of sudden cardiac death.

Considering these factors, the patient's overall condition appears to be relatively stable, and the likelihood of a survivor outcome is the most likely prognosis.

RANKING: 2. Sudden Cardiac Death
 REASONING: Sudden cardiac death is a possible but less likely prognosis for this patient. The patient's history of ischemic dilated cardiomyopathy, diabetes, and dyslipemia increases the risk of sudden cardiac death. The presence of polymorphic ventricular extrasystoles on the ECG is a concern, as it may indicate underlying electrical instability in the heart. 

However, the patient's LVEF is within the normal range, and the absence of other high-risk ECG findings (such as ventricular tachycardia or non-sustained ventricular tachycardia) reduces the likelihood of sudden cardiac death.

RANKING: 3. Pump Failure Death
 REASONING: Pump failure death is the least likely prognosis for this patient. The patient's LVEF is within the normal range, indicating that the heart is functioning relatively well. The patient's blood pressure is within a reasonable range, and the absence of other high-risk findings on the ECG suggests that the heart is not experiencing significant pump failure. 

The patient's treatment regimen, including beta blockers, statins, ACE inhibitors, and nitrovasodilators, is aimed at reducing the risk of heart failure progression and improving cardiac function. The patient's Pro-BNP level is elevated, but it is not excessively high, which suggests that the patient's heart failure is not in an advanced stage."
222,222,P0373,"Age: 41
Gender: Male 
Weight: 70 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 180/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 212.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,89
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,07
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 5017.0
Protein (g/L): 87
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,09
TSH (mIU/L): 2,27
Urea (mg/dL): 12,48
LVEF (%): 29.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the ranking of the prognoses from most likely to least likely, along with the reasoning behind each:

RANKING: 1. Survivor
 REASONING: Despite the patient's advanced heart failure as indicated by a left ventricular ejection fraction (LVEF) of 29%, the patient is on optimal medical therapy with a combination of Calcium Channel Blocker, Beta Blockers, Loop Diuretics, and ACE Inhibitor. The patient's blood pressure is well-controlled at 180/90 mmHg, which is a positive sign. Although the patient has hypertension and hypertensive cardiomyopathy, the patient's overall clinical picture suggests that the heart failure is still manageable with medical therapy. The patient's Pro-BNP level of 5017.0 ng/L is elevated, indicating heart failure, but not extremely high. Additionally, the patient's hemoglobin level is within the normal range, which suggests that the heart is still able to meet the body's oxygen demands to some extent. Therefore, with proper management and follow-up, the patient is likely to survive.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG, which are risk factors for sudden cardiac death. The patient's LVEF of 29% is also a risk factor for sudden cardiac death. However, the patient is on beta blockers, which can help reduce the risk of sudden cardiac death. The patient's overall clinical picture does not suggest an extremely high risk for sudden cardiac death, and the patient is on optimal medical therapy.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 29% indicates advanced heart failure, and the patient's Pro-BNP level of 5017.0 ng/L is elevated, indicating significant heart failure. The patient's creatinine level of 212.0 mol/L is also elevated, suggesting renal impairment, which can be a sign of advanced heart failure. The patient's overall clinical picture suggests that the heart failure is advanced, and the patient's kidneys are also affected. However, the patient is on optimal medical therapy, which may help slow down the progression of heart failure. The patient's hemoglobin level is within the normal range, which suggests that the heart is still able to meet the body's oxygen demands to some extent. Therefore, while pump failure death is a possible outcome, it is less likely compared to sudden cardiac death, given the patient's optimal medical therapy and relatively well-controlled blood pressure."
223,223,P0374,"Age: 74
Gender: Male 
Weight: 73 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,6
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 28
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 3,5
LDL (mmol/L): 2,61
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1414.0
Protein (g/L): 66
T3 (pg/dL): 0,04
T4 (ng/L): 23
Troponin (ng/mL): 0,023
TSH (mIU/L): 0,565
Urea (mg/dL): 6,99
LVEF (%): 43.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. However, please note that this is a general assessment and should not be taken as a definitive prediction. The actual outcome may vary depending on various factors, including the patient's response to treatment, lifestyle changes, and potential comorbidities.

RANKING: 1. Survivor
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged, reducing its ability to pump blood effectively. Despite this, the patient is on a regimen of medications that include ACE inhibitors, beta blockers, and loop diuretics, which are commonly used to manage heart failure. The patient's LVEF (left ventricular ejection fraction) is 43%, which is below the normal range (50-70%), but not extremely low. The patient's NYHA class is II, indicating that they have some limitations in their physical activity but are still able to perform daily tasks without significant symptoms. The patient's troponin level is slightly elevated, but not alarmingly high, and their creatinine level is within a relatively normal range. Considering these factors, it is likely that the patient will survive for the next few years with proper management of their condition.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF is below the normal range, indicating that their heart is not pumping efficiently. Their creatinine level is elevated, suggesting some degree of kidney impairment, which is a common complication of heart failure. The patient's BNP (brain natriuretic peptide) level is high, which is a marker of heart failure. However, the patient is on medications that help manage heart failure, and their symptoms are not severe enough to indicate an imminent risk of pump failure. The patient's overall condition is manageable, but there is a risk of progression to more severe heart failure, leading to pump failure.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which increases their risk of sudden cardiac death. However, the patient's ECG shows only polymorphic ventricular extrasystoles, which is a relatively benign finding. The patient's troponin level is slightly elevated, but not alarmingly high, and their creatinine level is within a relatively normal range. The patient is on medications that help manage arrhythmias, including amiodarone and beta blockers. While the patient's condition increases their risk of sudden cardiac death, the overall risk is relatively low, and the patient's current management plan is likely to mitigate this risk."
224,224,P0375,"Age: 69
Gender: Male 
Weight: 80 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,42
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 5
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 5
LDL (mmol/L): 2,66
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 2834.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 20
Troponin (ng/mL): 0,03
TSH (mIU/L): 4,09
Urea (mg/dL): 8,15
LVEF (%): 37.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: 1. Survivor
 REASONING: The patient is 69 years old with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for adverse cardiac outcomes. However, the patient is currently on a comprehensive treatment regimen that includes beta blockers, angiotensin II receptor blockers, spironolactone, and loop diuretics, which are all evidence-based therapies for heart failure. The patient's LVEF is 37%, which is low but not extremely low. Additionally, the patient's BNP level is elevated at 2834 ng/L, which indicates some level of heart failure, but not to the point where it would be considered severe. The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death, but the fact that it is non-sustained suggests that it may not be a significant threat at this time. The patient's overall clinical picture suggests that while the patient is at risk for cardiac complications, the current treatment regimen and the patient's overall clinical status suggest that the most likely outcome is survival.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. Additionally, the patient's LVEF is low, and the BNP level is elevated, which suggests that the patient has some level of heart failure. However, the fact that the patient is on a comprehensive treatment regimen and has a relatively stable clinical status suggests that sudden cardiac death is not the most likely outcome. The patient's age and history of idiopathic dilated cardiomyopathy also increase the risk of sudden cardiac death, but the overall clinical picture suggests that this outcome is less likely than survival.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF is low at 37%, and the BNP level is elevated, which suggests that the patient has some level of heart failure. However, the patient's clinical status is relatively stable, and the patient is on a comprehensive treatment regimen that includes diuretics, which suggests that the patient's heart failure is being well-managed. The patient's creatinine level is slightly elevated, but not to the point where it suggests severe renal dysfunction. The patient's overall clinical picture suggests that while pump failure death is a possible outcome, it is less likely than sudden cardiac death."
225,225,P0376,"Age: 51
Gender: Male 
Weight: 80 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,53
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,82
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 727.0
Protein (g/L): 71
T3 (pg/dL): 0,07
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,39
Urea (mg/dL): 4,99
LVEF (%): 20.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Please note that this is a complex task and the actual outcome may vary depending on various factors, including the patient's adherence to medication, lifestyle changes, and potential comorbidities not mentioned in the data.

RANKING: Sudden Cardiac Death, Pump Failure Death, Survivor

REASONING:

1.  Sudden Cardiac Death (SCD): The patient has a history of idiopathic dilated cardiomyopathy with a low left ventricular ejection fraction (LVEF) of 20%. This condition increases the risk of SCD. The presence of polymorphic ventricular extrasystoles on the ECG also suggests a higher risk of arrhythmic events. However, the patient is on beta blockers, which are known to reduce the risk of SCD in patients with heart failure. Despite this, the patient's low LVEF and history of cardiomyopathy make SCD a significant concern.

2.  Pump Failure Death: The patient's LVEF of 20% indicates severe left ventricular dysfunction, which increases the risk of pump failure. The patient is on medications like ACE inhibitors, beta blockers, and spironolactone, which are standard treatments for heart failure. However, the patient's low LVEF and elevated BNP levels (727 ng/L) suggest that the heart failure is not adequately controlled. The patient's creatinine level of 88.0 mol/L also indicates some degree of renal impairment, which can further exacerbate heart failure. While pump failure is a concern, the patient's current treatment regimen and the lack of other comorbidities make it less likely than SCD.

3.  Survivor: The patient's age, weight, and height are relatively favorable, and the patient is on a comprehensive treatment regimen for heart failure. The patient's NYHA Class II classification indicates that the patient is experiencing some symptoms but is still able to perform daily activities. The low levels of troponin and AST/GOT suggest that the patient does not have significant myocardial damage. The patient's TSH level is within the normal range, indicating that there is no overt thyroid dysfunction, which can contribute to heart failure. While the patient's prognosis is guarded due to the underlying cardiomyopathy, the current treatment and the patient's overall clinical profile make survivorship the most likely outcome.

In conclusion, while all three outcomes are possible, the patient's low LVEF, history of cardiomyopathy, and polymorphic ventricular extrasystoles make SCD the most likely outcome. Pump failure death is also a concern, but the patient's current treatment regimen and the lack of other comorbidities make it less likely. Survivorship is the most likely outcome, but it is essential to closely monitor the patient's condition and adjust the treatment plan as needed to prevent progression of the disease."
226,226,P0378,"Age: 45
Gender: Male 
Weight: 82 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 141.0
HDL (mmol/L): 2,61
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,13
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 236.0
Protein (g/L): 68
T3 (pg/dL): 0,06
T4 (ng/L): 21
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,75
Urea (mg/dL): 5,83
LVEF (%): 29.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: Survivor

REASONING: 

Based on the provided patient data, I would rank the prognosis as Survivor, followed by Pump Failure Death, and then Sudden Cardiac Death. Here's the reasoning behind this order:

1. Survivor: The patient is 45 years old, which is relatively young for a patient with idiopathic dilated cardiomyopathy. The LVEF (Left Ventricular Ejection Fraction) is 29%, which is low but not extremely low. The patient is on beta blockers, loop diuretics, and an ACE inhibitor, which are standard treatments for heart failure and dilated cardiomyopathy. The patient's blood pressure is within a normal range, and the creatinine level is slightly elevated but not significantly high. The pro-BNP level is elevated at 236 ng/L, indicating some degree of heart failure, but it's not extremely high. The absence of sustained ventricular tachycardia and non-sustained ventricular tachycardia on the ECG is a positive sign. The patient's hemoglobin and albumin levels are within normal limits, indicating no significant anemia or malnutrition. Considering these factors, the patient has a relatively good prognosis.

2. Pump Failure Death: The patient's LVEF is low, and the pro-BNP level is elevated, indicating some degree of heart failure. However, the patient is on standard treatments for heart failure, and the creatinine level is not extremely high. The patient's age and the fact that they are relatively young and not in NYHA Class III or IV also suggest a better prognosis. The absence of significant electrolyte imbalances, anemia, or malnutrition also reduces the risk of pump failure.

3. Sudden Cardiac Death: The patient has polymorphic ventricular extrasystoles on the ECG, which can be a risk factor for sudden cardiac death. However, the absence of sustained ventricular tachycardia and non-sustained ventricular tachycardia suggests that the risk of sudden cardiac death is lower. The patient's LVEF is low, but the patient is on beta blockers, which can reduce the risk of sudden cardiac death. The patient's age and the fact that they are relatively young also suggest a lower risk of sudden cardiac death.

In summary, while the patient has some risk factors for sudden cardiac death and pump failure, the patient's relatively young age, low but not extremely low LVEF, and the fact that they are on standard treatments for heart failure and dilated cardiomyopathy make a survivor prognosis more likely."
227,227,P0379,"Age: 49
Gender: Male 
Weight: 88 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,31
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,76
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1517.0
Protein (g/L): 72
T3 (pg/dL): 0,05
T4 (ng/L): 16
TSH (mIU/L): 2,05
Urea (mg/dL): 5,66
LVEF (%): 67.0
Medications: Calcium Channel Blocker, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. I will order the three possible prognoses from most likely to least likely and provide the reasoning behind each.

RANKING: 1. Survivor
 REASONING: The patient is 49 years old, which is relatively young for a patient with hypertensive cardiomyopathy and heart failure symptoms. The patient's ejection fraction (LVEF) is 67%, which is within the normal range, indicating that the patient's heart is still pumping blood effectively. The patient's NYHA class is II, which indicates that the patient has some symptoms of heart failure, but they are manageable with medication and lifestyle changes. The patient's Pro-BNP level is elevated at 1517 ng/L, but it is not extremely high, suggesting that the patient's heart failure is not severe. The patient is on medications that are commonly used to treat heart failure, including a calcium channel blocker, loop diuretics, and an ACE inhibitor. The patient's ECG shows monomorphic ventricular extrasystoles, but no other significant abnormalities. Overall, these factors suggest that the patient is likely to survive for the next few years with proper management of their heart failure and hypertension.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of hypertensive cardiomyopathy and hypertension, which increases their risk of sudden cardiac death. The patient's Pro-BNP level is elevated, which suggests that the patient's heart failure is not well-controlled. The patient's LVEF is 67%, which is within the normal range, but may not be optimal for a patient with a history of cardiomyopathy. The patient's ECG shows monomorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the patient is on medications that can help prevent sudden cardiac death, such as beta-blockers and ACE inhibitors. The patient's overall risk of sudden cardiac death is moderate, but it is lower than the risk of pump failure death.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF is 67%, which is within the normal range, indicating that the patient's heart is still pumping blood effectively. The patient's NYHA class is II, which indicates that the patient has some symptoms of heart failure, but they are manageable with medication and lifestyle changes. The patient's Pro-BNP level is elevated, but it is not extremely high, suggesting that the patient's heart failure is not severe. The patient is on medications that are commonly used to treat heart failure, including a calcium channel blocker, loop diuretics, and an ACE inhibitor. The patient's overall risk of pump failure death is low, as their heart function is still relatively well-preserved."
228,228,P0380,"Age: 59
Gender: Male 
Weight: 88 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 120/65 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,81
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 62
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,18
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 105.0
Protein (g/L): 68
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,51
Urea (mg/dL): 4,16
LVEF (%): 32.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: Survivor

REASONING: 

Given the patient's age of 59 and the presence of enolic dilated cardiomyopathy, a condition that affects the heart muscle, leading to its enlargement and reduced function, the patient is at a higher risk for cardiac complications. However, several factors suggest a more favorable prognosis.

The patient's LVEF (Left Ventricular Ejection Fraction) of 32% is lower than normal, indicating a reduced pumping ability of the heart. However, it is not extremely low, and the patient is on medications that help manage symptoms and slow disease progression.

The patient's NYHA Class II indicates that the patient experiences some limitation of physical activity but is still able to carry out light physical activity without discomfort. This suggests that the patient's symptoms are manageable with medication and lifestyle adjustments.

The patient's blood pressure is within a relatively normal range, and their albumin levels are slightly low, which may indicate some degree of cardiac dysfunction. However, the patient's electrolyte levels, including potassium and sodium, are within a relatively normal range.

The patient's troponin levels are low, indicating minimal cardiac damage. The pro-BNP (N-terminal pro b-type natriuretic peptide) level of 105 ng/L is elevated, suggesting that the patient's heart is under stress, but not excessively so.

The presence of non-sustained ventricular tachycardia and ventricular extrasystoles on the ECG indicates some degree of arrhythmia, but these are not life-threatening at this time.

Considering all these factors, while the patient is at risk for cardiac complications, the overall prognosis is more favorable than the other two options. The patient's symptoms are manageable, and the patient is on a regimen of medications that help slow disease progression. With close monitoring and adherence to treatment, the patient is likely to survive for the next few years.

Sudden cardiac death is less likely because the patient's heart rate and rhythm are not excessively abnormal, and there is no indication of acute cardiac damage.

Pump failure death is also less likely because the patient's LVEF is not extremely low, and the patient's symptoms are manageable with medication. While the patient's heart function is compromised, it is not to the point where pump failure is imminent."
229,229,P0381,"Age: 70
Gender: Male 
Weight: 58 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 96/57 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 37
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,35
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 434.0
Protein (g/L): 61
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,67
Urea (mg/dL): 5,49
LVEF (%): 40.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: The patient is 70 years old with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction. However, despite these risk factors, the patient's current medications, including beta blockers, angiotensin II receptor blocker, spironolactone, statins, and nitrovasodilator, suggest that the patient is receiving optimal treatment for heart failure and hypertension. The patient's LVEF of 40% is relatively well-preserved, considering the patient's age and medical history. The patient's troponin level is normal, indicating no recent myocardial infarction. The patient's Pro-BNP level is elevated at 434 ng/L, but this is not excessively high, suggesting that the patient is not in acute heart failure. The patient's ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or bradycardia. The patient's blood pressure is within a relatively normal range, and the patient is not in NYHA Class III or IV heart failure. Overall, while the patient has significant comorbidities, the patient's current treatment plan and relatively well-preserved LVEF suggest that the patient is likely to survive for the next few years.

RANKING: Pump Failure Death (second most likely)

REASONING: The patient's LVEF of 40% is lower than the normal range (50-70%), indicating reduced left ventricular function. The patient's Pro-BNP level is elevated, suggesting increased ventricular stress and potential heart failure. The patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases the risk of pump failure. However, the patient's current treatment plan, including beta blockers, angiotensin II receptor blocker, spironolactone, statins, and nitrovasodilator, suggests that the patient is receiving optimal treatment for heart failure. The patient's blood pressure is within a relatively normal range, and the patient is not in NYHA Class III or IV heart failure. While the patient's LVEF is low, the patient's current treatment plan and lack of other high-risk features (e.g. acute kidney injury, severe anemia) suggest that pump failure is the second most likely prognosis.

RANKING: Sudden Cardiac Death (least likely)

REASONING: The patient's ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or bradycardia. The patient's troponin level is normal, indicating no recent myocardial infarction. The patient's Pro-BNP level is elevated, but not excessively high. The patient's blood pressure is within a relatively normal range, and the patient is not in NYHA Class III or IV heart failure. The patient's current treatment plan, including beta blockers, angiotensin II receptor blocker, spironolactone, statins, and nitrovasodilator, suggests that the patient is receiving optimal treatment for heart failure and hypertension. While the patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, the patient's current clinical status and treatment plan suggest that sudden cardiac death is the least likely prognosis."
230,230,P0384,"Age: 71
Gender: Male 
Weight: 91 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 185/110 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 40
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 107.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,25
Sodium (mEq/L): 142.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,72
Urea (mg/dL): 7,82
LVEF (%): 28.0
Medications: Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. However, please note that this is a hypothetical prognosis, and actual outcomes may vary based on various factors, including the patient's response to treatment and any changes in their condition.

RANKING: 1. Survivor
 REASONING: The patient has a high risk of cardiac complications due to his ischemic dilated cardiomyopathy, low LVEF (28%), and uncontrolled hypertension (BP 185/110 mmHg). However, he is currently on medications that can help manage his symptoms and slow disease progression. His NYHA Class II indicates that he has some limitations in his physical activity but is still able to perform daily activities. He is also on loop diuretics, which suggests that his fluid status is being managed. His troponin level is low, indicating minimal myocardial damage. His TSH level is within the normal range, which suggests that his thyroid function is not contributing to his cardiac condition. While his LVEF is low, it is not extremely low, and his medications may be helping to stabilize his condition. Therefore, with proper management and adherence to treatment, the patient is likely to survive for the next few years.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF of 28% indicates severe left ventricular dysfunction, which increases the risk of pump failure. His uncontrolled hypertension and dyslipidemia also contribute to his high risk of cardiac complications. However, his current medications, including statins and nitrovasodilators, may help to slow disease progression and improve symptoms. His troponin level is low, which suggests that he is not experiencing significant myocardial damage at the moment. While pump failure is a possibility, the patient's current treatment plan and relatively stable condition make it less likely compared to sudden cardiac death.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient's ischemic dilated cardiomyopathy, low LVEF, and uncontrolled hypertension increase his risk of sudden cardiac death. However, his current medications, including loop diuretics, statins, and nitrovasodilators, may help to reduce his risk of sudden cardiac death by improving his cardiac function and reducing his blood pressure. His low troponin level and lack of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG also suggest that he is not at high risk for sudden cardiac death at the moment. While sudden cardiac death is a possible outcome, the patient's current treatment plan and relatively stable condition make it the least likely of the three prognoses."
231,231,P0386,"Age: 52
Gender: Female 
Weight: 69 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 105/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 108.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,3
LDL (mmol/L): 4,24
Sodium (mEq/L): 138.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 22
Troponin (ng/mL): 0,005
TSH (mIU/L): 3,45
Urea (mg/dL): 7,99
LVEF (%): 45.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: Based on the provided patient data, I would rank the prognosis as survivor for the following reasons:

1.  The patient's age (52) and sex (female) are not particularly concerning for cardiac mortality.
2.  The patient has a relatively well-controlled blood pressure (105/80 mmHg), which is within the normal range.
3.  The patient's NYHA Class II indicates that she experiences some symptoms of heart failure but is able to perform ordinary physical activity without discomfort.
4.  The patient's serum albumin level is within the normal range (40 g/L), which suggests that her liver function is not significantly compromised.
5.  The patient's liver enzymes (ALT, AST, GGT) are within the normal range, which suggests that her liver function is not significantly affected by her idiopathic dilated cardiomyopathy.
6.  The patient's total cholesterol and LDL levels are elevated, but her HDL level is also elevated, which may mitigate this risk.
7.  The patient's potassium level is within the normal range (4.3 mEq/L), which is important for cardiac function.
8.  The patient's TSH level is within the normal range (3.45 mIU/L), which suggests that her thyroid function is not significantly affected by her heart disease.
9.  The patient's troponin level is within the normal range (0.005 ng/mL), which suggests that she does not have acute myocardial infarction.
10. The patient's LVEF is 45%, which is below the normal range (50-70%), indicating some degree of heart failure. However, the patient is on medications that may help to improve her LVEF, such as ACE inhibitors and beta blockers.
11. The patient's ECG shows polymorphic ventricular extrasystoles, but no ventricular tachycardia or sustained ventricular tachycardia, which suggests that her arrhythmias are not as severe.

Given these factors, the patient's prognosis is more likely to be a survivor, as her heart disease is well-controlled, and she is on appropriate medications. However, it is essential to continue monitoring her condition closely and adjust her treatment plan as needed to prevent progression of her heart disease.

Sudden cardiac death and pump failure death are less likely outcomes for this patient due to the following reasons:

- Sudden cardiac death is less likely because the patient does not have a history of ventricular tachycardia or sustained ventricular tachycardia, and her ECG does not show any signs of severe arrhythmias.
- Pump failure death is less likely because the patient's LVEF is not severely depressed (45%), and she is on medications that may help to improve her LVEF and reduce the risk of heart failure progression."
232,232,P0387,"Age: 37
Gender: Male 
Weight: 110 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 125/95 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 42
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 141.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,49
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 577.0
Protein (g/L): 74
T3 (pg/dL): 0,06
T4 (ng/L): 27
Troponin (ng/mL): 0,03
TSH (mIU/L): 5,15
Urea (mg/dL): 9,15
LVEF (%): 50.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient is 37 years old, which is relatively young for heart failure. Despite having idiopathic dilated cardiomyopathy and hypertension, his LVEF is 50%, which is not severely impaired. He is on optimal medical therapy, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which suggests that his condition is being well-managed. His blood pressure is controlled, and his creatinine levels are within normal limits. His troponin levels are low, indicating minimal cardiac damage. The patient's NT-proBNP level is elevated, but not excessively high, which suggests that his heart failure is not severe. Considering these factors, the likelihood of the patient surviving for the next few years is relatively high.

RANKING: 2. Sudden Cardiac Death
REASONING: While the patient has idiopathic dilated cardiomyopathy, his LVEF is not severely impaired, and he is on optimal medical therapy. However, he does have a history of hypertension, which can contribute to sudden cardiac death. The presence of ventricular extrasystoles on the ECG is a risk factor for sudden cardiac death. However, the absence of non-sustained ventricular tachycardia and other high-risk features makes sudden cardiac death less likely. The patient's age and overall clinical picture suggest that sudden cardiac death is a possible but less likely outcome compared to survival.

RANKING: 3. Pump Failure Death
REASONING: Pump failure death is the least likely outcome for this patient. His LVEF is 50%, which is not severely impaired, and his creatinine levels are within normal limits, indicating that his kidneys are functioning well. His blood pressure is controlled, and he is on optimal medical therapy, which reduces the risk of pump failure. The patient's NT-proBNP level is elevated, but not excessively high, which suggests that his heart failure is not severe. The patient's overall clinical picture suggests that pump failure death is the least likely outcome."
233,233,P0388,"Age: 58
Gender: Female 
Weight: 87 kg
Height: 149 cm
NYHA Class: II
Blood Pressure: 155/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 17,8
Hemoglobin (g/L): 117.0
HDL (mmol/L): 0,62
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,15
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 881.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 11
Troponin (ng/mL): 0,05
TSH (mIU/L): 2,19
Urea (mg/dL): 6,99
LVEF (%): 65.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely. 

RANKING: Survivor

REASONING: The patient is 58 years old with a history of hypertensive cardiomyopathy, diabetes, dyslipemia, and peripheral vascular disease. Despite these risk factors, the patient's left ventricular ejection fraction (LVEF) is 65%, which is within the normal range. The patient is also on a comprehensive medication regimen that includes a calcium channel blocker, diabetes medication, angiotensin II receptor blocker, loop diuretics, statins, and nitrovasodilators, which suggests that the patient's hypertension and heart failure symptoms are being well-managed. Additionally, the patient's troponin level is within normal limits, indicating no recent myocardial infarction. While the patient has a high pro-BNP level (881 ng/L), which is indicative of heart failure, the patient's overall clinical picture suggests that the heart failure is well-managed, and the patient is likely to survive in the short to medium term.

RANKING: Sudden Cardiac Death

REASONING: While the patient has a history of hypertensive cardiomyopathy and a high pro-BNP level, there is no clear indication of acute coronary artery disease or severe left ventricular dysfunction that would increase the risk of sudden cardiac death. The patient's LVEF is within normal limits, and there is no history of previous cardiac arrest or ventricular tachycardia. However, the patient's polymorphic ventricular extrasystoles on the ECG may indicate an increased risk of arrhythmias, which could potentially lead to sudden cardiac death. However, this risk is still relatively low given the patient's overall clinical picture.

RANKING: Pump Failure Death

REASONING: Pump failure death is the least likely prognosis for this patient. While the patient has a high pro-BNP level, indicating heart failure, the patient's LVEF is within normal limits, and the patient is on a comprehensive medication regimen that includes loop diuretics, which suggests that the heart failure is being well-managed. Additionally, the patient's clinical symptoms are not severe enough to indicate advanced heart failure, and the patient's NYHA class is II, which indicates mild to moderate heart failure symptoms."
234,234,P0389,"Age: 52
Gender: Male 
Weight: 90 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 135/100 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 6,7
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 132.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 3,9
LDL (mmol/L): 4,63
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 315.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,73
Urea (mg/dL): 8,65
LVEF (%): 45.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely. 

RANKING: 1. Survivor
 REASONING: The patient's age of 52 is relatively young, and the presence of a New York Heart Association (NYHA) Class II indicates that the patient's heart failure symptoms are not severe. The patient is on a medication regimen that includes beta blockers, loop diuretics, and an ACE inhibitor, which are standard treatments for heart failure and hypertension. The patient's LVEF of 45% is below the normal range, but it's not severely reduced. The low levels of troponin and absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG also suggest that the patient does not have acute coronary syndrome or severe cardiac ischemia. The patient's elevated Pro-BNP level indicates heart failure, but the overall clinical picture suggests that the patient's condition is manageable with medication and lifestyle modifications. Therefore, the most likely prognosis is that the patient will survive.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of hypertensive cardiomyopathy and hypertension, which increases the risk of sudden cardiac death. The presence of ventricular extrasystoles on the ECG is a risk factor for sudden cardiac death. However, the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG reduces the risk. The patient's LVEF of 45% is below the normal range, which increases the risk of sudden cardiac death. However, the patient is on beta blockers, which can reduce the risk of sudden cardiac death. Overall, while the patient has some risk factors for sudden cardiac death, the presence of a manageable heart failure condition and the use of beta blockers make this prognosis less likely than survivor.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 45% is below the normal range, which indicates that the heart is not pumping efficiently. However, the patient is on loop diuretics, which are used to manage fluid overload and reduce the workload on the heart. The patient's creatinine level of 115.0 umol/L is slightly elevated, which suggests that the patient may have some degree of renal dysfunction, but it's not severe. The patient's Pro-BNP level is elevated, which indicates heart failure, but the overall clinical picture suggests that the patient's condition is manageable with medication and lifestyle modifications. The patient's age of 52 is relatively young, and the presence of a NYHA Class II indicates that the patient's heart failure symptoms are not severe. Therefore, while pump failure death is a possible prognosis, it is the least likely of the three options.

Note: The prognosis is based on the provided data and may not be accurate without a comprehensive clinical evaluation and further diagnostic testing."
235,235,P0392,"Age: 48
Gender: Female 
Weight: 60 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 130/85 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,15
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 3,5
LDL (mmol/L): 3,39
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 768.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 7,85
Urea (mg/dL): 8,15
LVEF (%): 48.0
Medications: Amiodarone, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: This patient is 48 years old with a history of valvular cardiomyopathy, dyslipemia, and hypertension, which are all significant risk factors for cardiovascular disease. However, the patient's current LVEF is 48%, which is below the normal range (50-70%), indicating some degree of heart dysfunction. The presence of TPSV on the ECG suggests a possible arrhythmia, but it is not sustained and does not indicate a high risk of sudden cardiac death. The patient's Pro-BNP level is elevated at 768.0 ng/L, which suggests heart failure, but it is not extremely high. The patient is on medications for heart failure (Loop Diuretics) and is taking statins for dyslipemia. Considering these factors, the patient's prognosis for survival is moderate, but not extremely poor.

RANKING: 2. Sudden Cardiac Death
REASONING: While the patient has several risk factors for cardiovascular disease, the absence of sustained ventricular tachycardia, ventricular extrasystoles, or other high-risk features on the ECG reduces the likelihood of sudden cardiac death. The patient's LVEF is below normal, but it is not extremely low, and the Pro-BNP level is elevated but not extremely high. The patient is on medications that may help manage heart failure and arrhythmias. The presence of TPSV on the ECG is concerning, but it is not a high-risk feature for sudden cardiac death. Overall, while the patient has some risk factors, the likelihood of sudden cardiac death is not extremely high.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF is 48%, which is below the normal range, indicating some degree of heart dysfunction. The Pro-BNP level is elevated at 768.0 ng/L, suggesting heart failure. The patient has a history of valvular cardiomyopathy, which can lead to progressive heart failure. However, the patient is on medications for heart failure (Loop Diuretics) and is taking statins for dyslipemia, which may help manage the condition. The patient's overall condition is not extremely severe, and the patient's age and weight are relatively young and low, respectively. Considering these factors, the likelihood of pump failure death is lower than the other two options."
236,236,P0395,"Age: 70
Gender: Male 
Weight: 73 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 40
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,15
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 107
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 120.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,97
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 329.0
Protein (g/L): 68
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,03
Urea (mg/dL): 9,48
LVEF (%): 27.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor
 REASONING: The patient is 70 years old with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for adverse cardiac outcomes. However, the patient's current medications, including beta blockers, digoxin, loop diuretics, statins, and an ACE inhibitor, suggest that the patient is receiving comprehensive treatment for heart failure. The patient's LVEF of 27% is low, indicating reduced cardiac function, but it is not the lowest possible value. The patient's NT-proBNP level of 329 ng/L is elevated, indicating some degree of heart failure, but it is not extremely high. The patient's blood pressure is within a relatively normal range, and there is no indication of severe electrolyte imbalances. The patient's recent troponin level is low, suggesting that there is no acute coronary syndrome. While the patient has a history of dyslipemia and elevated liver enzymes, these are being managed with statins and monitoring. Overall, the patient's current treatment plan and lack of acute decompensation suggest that a survivor prognosis is the most likely outcome.

RANKING: Pump Failure Death
 REASONING: The patient's LVEF of 27% indicates significant cardiac dysfunction, which increases the risk of pump failure. The patient's elevated NT-proBNP level and history of heart failure also suggest a high risk of pump failure. However, the patient's current medications and the lack of acute decompensation suggest that the patient's heart failure is being managed. The patient's recent troponin level is low, and there is no indication of severe electrolyte imbalances or acute coronary syndrome. While pump failure is a possible outcome, the patient's current treatment plan and lack of acute decompensation suggest that it is less likely than sudden cardiac death.

RANKING: Sudden Cardiac Death
 REASONING: The patient's history of idiopathic dilated cardiomyopathy and low LVEF of 27% increase the risk of sudden cardiac death. However, the patient's current medications, including beta blockers and an ACE inhibitor, are known to reduce the risk of sudden cardiac death. The patient's ECG shows monomorphic ventricular extrasystoles, but there is no indication of sustained ventricular tachycardia or other high-risk arrhythmias. The patient's recent troponin level is low, and there is no indication of acute coronary syndrome. While sudden cardiac death is a possible outcome, the patient's current treatment plan and lack of acute decompensation suggest that it is the least likely outcome."
237,237,P0398,"Age: 72
Gender: Male 
Weight: 77 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,18
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 40
Glucose (mmol/L): 6
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,84
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 551.0
Protein (g/L): 63
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,78
Urea (mg/dL): 6,99
LVEF (%): 27.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Parosysmal AF
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Please note that this is a complex task, and the actual outcome may vary depending on various factors, including the patient's adherence to treatment, lifestyle changes, and potential future health developments.

RANKING: 1. Survivor
REASONING: The patient is 72 years old with a history of ischemic dilated cardiomyopathy, myocardial infarction, and hypertension. However, he is currently on beta blockers, statins, and an ACE inhibitor, which are standard treatments for heart failure and hypertension. His LVEF (left ventricular ejection fraction) is 27%, which is low but not the lowest possible value. He also has a relatively low creatinine level, indicating that his kidney function is not severely impaired. The patient's albumin and protein levels are within a relatively normal range, suggesting that his liver function is not significantly compromised. His TSH level is normal, indicating that his thyroid function is within a normal range. The patient's Troponin level is low, indicating that there is no ongoing myocardial infarction. His Pro-BNP level is elevated, but not extremely high, which may indicate some degree of heart failure, but not severe. Considering these factors, the patient's overall prognosis is relatively good, and with proper management, he is likely to survive for the next few years.

RANKING: 2. Pump failure death
REASONING: The patient's LVEF is low (27%), which indicates that his heart is not pumping efficiently. His Pro-BNP level is elevated, suggesting that he has some degree of heart failure. His creatinine level is slightly elevated, indicating that his kidney function may be impaired due to his heart failure. However, his overall clinical presentation and laboratory values do not indicate severe heart failure. With proper management and adherence to his medications, the patient's heart failure may not progress rapidly, and he may survive for several years.

RANKING: 3. Sudden cardiac death
REASONING: The patient has a history of ischemic dilated cardiomyopathy, myocardial infarction, and hypertension, which increases his risk of sudden cardiac death. His ECG shows non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, which are risk factors for sudden cardiac death. His low LVEF and elevated Pro-BNP level also indicate that his heart is not functioning optimally, increasing his risk of sudden cardiac death. However, his overall clinical presentation and laboratory values do not indicate an extremely high risk of sudden cardiac death. With proper management and adherence to his medications, the risk of sudden cardiac death may be reduced."
238,238,P0399,"Age: 56
Gender: Male 
Weight: 68 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 130/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1192.0
Protein (g/L): 72
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,21
Urea (mg/dL): 7,82
LVEF (%): 20.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years, ranking the three possible outcomes from most likely to least likely. 

RANKING: 1. Survivor
 REASONING: The patient is currently on a treatment regimen with beta blockers, statins, and an ACE inhibitor, which are standard medications for managing heart failure and reducing the risk of sudden cardiac death. The patient's LVEF (Left Ventricular Ejection Fraction) is 20%, indicating severe systolic dysfunction, but it is not the lowest possible value. The patient's NYHA Class II classification indicates that the patient has some limitations in physical activity but is still able to perform everyday tasks without severe symptoms. Although the patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, the low troponin level suggests that the patient is not experiencing an acute myocardial infarction at the moment. The patient's BNP (Brain Natriuretic Peptide) level is elevated, but it is not extremely high, which could indicate that the patient's heart failure is not severe at the moment. Overall, considering the patient's current treatment and relatively stable condition, a survivor prognosis seems to be the most likely outcome.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which increases the risk of sudden cardiac death. The patient's LVEF is 20%, indicating severe systolic dysfunction, and the presence of ventricular extrasystole, which can be a precursor to ventricular tachycardia or fibrillation. However, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death. The patient's current medications and relatively stable condition suggest that sudden cardiac death is less likely compared to pump failure death.

RANKING: 3. Pump Failure Death
 REASONING: Pump failure death is a possible outcome for patients with severe heart failure, and the patient's LVEF of 20% and NYHA Class II classification suggest that the patient has significant heart failure. However, the patient is on standard medications for heart failure, and the patient's BNP level, although elevated, is not extremely high, suggesting that the patient's heart failure is not severe at the moment. The patient's creatinine level is slightly elevated, but it is not extremely high, which could indicate that the patient's kidneys are not severely affected. Overall, while pump failure death is a possible outcome, the patient's current treatment and relatively stable condition suggest that it is the least likely outcome among the three options."
239,239,P0400,"Age: 58
Gender: Male 
Weight: 82 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 95/63 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,91
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 867.0
Protein (g/L): 67
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,17
Urea (mg/dL): 10,15
LVEF (%): 35.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the ranking of the possible prognoses from most likely to least likely:

RANKING: Survivor
REASONING: The patient's age of 58 is relatively young, and the fact that they are being treated with beta blockers, statins, and an ACE inhibitor suggests that they are receiving appropriate medical therapy for their ischemic dilated cardiomyopathy. Their LVEF of 35% indicates reduced left ventricular function, but it is not severely impaired. The absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia on the ECG is also a positive sign. Additionally, their creatinine level is slightly elevated, but not severely, which suggests that their renal function is still relatively preserved. While the patient's Pro-BNP level is elevated, it is not extremely high, which may indicate some degree of heart failure management. Considering these factors, the patient's overall prognosis is likely to be a survivor.

RANKING: Pump Failure Death
REASONING: The patient's LVEF of 35% and elevated Pro-BNP level suggest that they have some degree of heart failure, which is a risk factor for pump failure death. Additionally, their creatinine level is slightly elevated, which may indicate some degree of renal impairment due to heart failure. However, the patient's age and the fact that they are receiving appropriate medical therapy for their heart failure may mitigate this risk. The absence of severe symptoms, as indicated by their NYHA Class II, also suggests that they may not be at extremely high risk for pump failure death.

RANKING: Sudden Cardiac Death
REASONING: The patient's LVEF of 35% and history of myocardial infarction increase their risk for sudden cardiac death. However, the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia on the ECG, as well as the fact that they are receiving beta blockers, which are known to reduce the risk of sudden cardiac death, may mitigate this risk. Additionally, the patient's Troponin level is low, which suggests that they are not experiencing ongoing myocardial ischemia. While the patient's overall risk for sudden cardiac death is not negligible, it is likely lower than the risk for pump failure death due to the presence of heart failure symptoms and the elevated Pro-BNP level."
240,240,P0401,"Age: 54
Gender: Male 
Weight: 72 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 113/66 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,28
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 82
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,03
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 47.0
Protein (g/L): 69
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,42
Urea (mg/dL): 6,82
LVEF (%): 43.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor
 REASONING: The patient's age and gender suggest a moderate risk for cardiac events. The patient's NYHA Class II indicates that the patient is experiencing some symptoms with ordinary physical activity, but is still able to perform daily activities. However, the patient's LVEF of 43% indicates a reduced left ventricular function, which is a significant risk factor for cardiac events. The presence of non-sustained ventricular tachycardia on the ECG is also a concern.

Despite these risk factors, the patient is on a comprehensive treatment plan that includes beta blockers, loop diuretics, statins, and an ACE inhibitor, which are all standard treatments for heart failure and cardiomyopathy. The patient's blood pressure is well-controlled, and the low levels of troponin and pro-BNP suggest that the patient is not experiencing acute cardiac injury or severe heart failure.

The patient's albumin level is slightly low, but not critically low, which suggests that the patient is not experiencing severe liver dysfunction or nephrotic syndrome. The patient's lipid profile is also relatively well-controlled, with a total cholesterol of 5.28 mmol/L and an HDL of 1.03 mmol/L. The patient's TSH is within the normal range, which suggests that the patient is not experiencing hypothyroidism.

Overall, while the patient has significant cardiac risk factors, the comprehensive treatment plan and relatively well-controlled laboratory values suggest that the patient is at lower risk for sudden cardiac death and pump failure death. Therefore, the most likely prognosis is survivor."
241,241,P0402,"Age: 50
Gender: Male 
Weight: 75 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 42.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 7,21
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 160.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,1
LDL (mmol/L): 4,91
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 708.0
Protein (g/L): 78
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,07
Urea (mg/dL): 7,32
LVEF (%): 36.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Please note that this is a hypothetical scenario, and actual patient outcomes may vary.

RANKING: 1. Survivor

REASONING: 

The patient is a 50-year-old male with a history of idiopathic dilated cardiomyopathy, which is a significant underlying condition. However, the patient's current NYHA Class II indicates that he is experiencing some limitations in physical activity but is still able to perform daily tasks without significant distress. The patient is also on a comprehensive treatment regimen that includes beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all standard treatments for heart failure.

The patient's LVEF (Left Ventricular Ejection Fraction) of 36% indicates a reduced cardiac function, but it is not extremely low. The patient's Troponin levels are within normal limits, and there are no signs of acute coronary syndrome or myocardial infarction.

The patient's Pro-BNP (B-type natriuretic peptide) level of 708.0 ng/L is elevated, indicating increased ventricular stress, but it is not excessively high. The patient's TSH level is within the normal range, and there are no signs of hyperthyroidism or hypothyroidism.

The patient's lipid profile shows a total cholesterol level of 7.21 mmol/L, which is above the recommended level, but the HDL level is relatively low at 0.98 mmol/L, which could be a contributing factor to the patient's cardiovascular disease.

Considering the patient's overall condition, age, and current treatment, I believe that the most likely prognosis is a survivor. The patient's reduced LVEF and elevated Pro-BNP levels indicate that the patient has some cardiac dysfunction, but the patient's current treatment regimen and relatively stable condition suggest that the patient is likely to survive for the next few years with proper management.

RANKING: 2. Pump Failure Death

REASONING:

While the patient's LVEF is low at 36%, it is not extremely low. The patient's Pro-BNP level is elevated, indicating increased ventricular stress, but it is not excessively high. The patient's Troponin levels are within normal limits, and there are no signs of acute coronary syndrome or myocardial infarction.

However, the patient's reduced LVEF and elevated Pro-BNP levels suggest that the patient's cardiac function is compromised, and there is a risk of pump failure. The patient's NYHA Class II classification indicates that the patient is experiencing some limitations in physical activity, which may be a sign of progressing heart failure.

If the patient's condition worsens, or if the patient experiences a significant increase in symptoms, the risk of pump failure death increases. However, based on the current data, I believe that pump failure death is the second most likely prognosis.

RANKING: 3. Sudden Cardiac Death

REASONING:

The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of increased risk for sudden cardiac death. However, the patient's Troponin levels are within normal limits, and there are no signs of acute coronary syndrome or myocardial infarction.

The patient's NYHA Class II classification indicates that the patient is experiencing some limitations in physical activity, which may be a sign of progressing heart failure. However, the patient's overall condition and current treatment regimen suggest that sudden cardiac death is the least likely prognosis.

The patient's reduced LVEF and elevated Pro-BNP levels indicate that the patient has some cardiac dysfunction, but the patient's current treatment regimen and relatively stable condition suggest that the patient is unlikely to experience sudden cardiac death in the near future."
242,242,P0404,"Age: 68
Gender: Male 
Weight: 80 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 135/84 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,66
Creatinine (mmol/L): 256.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,54
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1858.0
Protein (g/L): 69
T4 (ng/L): 15
TSH (mIU/L): 0,6
Urea (mg/dL): 13,48
LVEF (%): 20.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor

REASONING: The patient has a complex medical history, including ischemic dilated cardiomyopathy, myocardial infarction, hypertension, and dyslipemia. However, despite these comorbidities, the patient is on a comprehensive treatment regimen, including beta blockers, calcium channel blockers, loop diuretics, and statins, which are all appropriate for managing heart failure and dyslipidemia. The patient's NYHA Class II classification indicates that they are experiencing some symptoms of heart failure, but they are still able to perform most physical activities without severe limitations.

The patient's LVEF of 20% indicates severe left ventricular dysfunction, but it is not the lowest possible value (which is typically considered to be around 10-15%). This suggests that the patient's heart is still functioning to some extent, and there may be some potential for improvement with treatment.

The patient's blood work, including the low albumin and high creatinine levels, indicates some degree of renal impairment, which is common in patients with heart failure. However, the patient's potassium and sodium levels are within normal limits, which suggests that they are not experiencing severe electrolyte imbalances.

The patient's Pro-BNP level of 1858 ng/L is elevated, indicating some degree of heart failure, but it is not the highest possible value, which suggests that the patient may not be experiencing severe fluid overload or heart failure symptoms.

The patient's ECG shows evidence of ventricular extrasystoles and non-sustained ventricular tachycardia, which can be a concern in patients with heart failure, but the absence of sustained ventricular tachycardia or other life-threatening arrhythmias is reassuring.

Overall, while the patient has a complex medical history and some evidence of heart failure, their treatment regimen and laboratory results suggest that they may be able to survive with appropriate management.

RANKING: 2. Sudden Cardiac Death

REASONING: Sudden cardiac death (SCD) is a potential risk in patients with heart failure, particularly those with low LVEF and a history of myocardial infarction. However, the patient's current treatment regimen and laboratory results suggest that they may be at lower risk for SCD. The patient's LVEF of 20% is low, but it is not the lowest possible value, and they are on beta blockers, which can reduce the risk of SCD. The patient's ECG shows evidence of ventricular extrasystoles and non-sustained ventricular tachycardia, but the absence of sustained ventricular tachycardia or other life-threatening arrhythmias is reassuring.

RANKING: 3. Pump Failure Death

REASONING: Pump failure death is a potential risk in patients with heart failure, particularly those with low LVEF and a history of myocardial infarction. However, the patient's current treatment regimen and laboratory results suggest that they may be at lower risk for pump failure death. The patient's LVEF of 20% is low, but it is not the lowest possible value, and they are on diuretics, which can help manage fluid overload and reduce the risk of pump failure. The patient's creatinine level is elevated, indicating some degree of renal impairment, but it is not the highest possible value, which suggests that the patient may not be experiencing severe fluid overload or kidney dysfunction."
243,243,P0406,"Age: 55
Gender: Male 
Weight: 95 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 41
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 106
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,77
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 162.0
Protein (g/L): 65
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,29
Urea (mg/dL): 5,83
LVEF (%): 22.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the three prognoses as follows:

RANKING: 1. Survivor
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a significant underlying condition affecting the heart. However, despite this, the patient's LVEF is 22%, which is relatively low but not extremely low. The patient is on a treatment regimen that includes ACE inhibitors, beta blockers, and loop diuretics, which are standard treatments for heart failure. The patient's ejection fraction is not extremely low, and there is no mention of severe symptoms or complications such as acute decompensated heart failure. Additionally, the patient's troponin levels are within normal limits, which suggests that there is no acute myocardial infarction. Considering these factors, a survivor prognosis is more likely.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy and a low LVEF, which increases the risk of sudden cardiac death. The presence of polymorphic ventricular extrasystoles on the ECG also increases the risk of arrhythmias, which can lead to sudden cardiac death. However, the patient's current medication regimen includes amiodarone, which is often used to prevent sudden cardiac death in patients with heart failure and arrhythmias. The patient's troponin levels are within normal limits, and there is no mention of severe symptoms or complications that would increase the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF is 22%, which is relatively low and indicates that the heart is not pumping efficiently. However, the patient is on a treatment regimen that includes ACE inhibitors and beta blockers, which can help slow the progression of heart failure. The patient's creatinine levels are slightly elevated, which may indicate some degree of kidney dysfunction, but this is not severe. Additionally, the patient's albumin levels are within normal limits, which suggests that there is no significant malnutrition or liver dysfunction. Considering these factors, while pump failure death is a possibility, it is less likely than sudden cardiac death due to the patient's current treatment regimen and the lack of severe symptoms or complications."
244,244,P0407,"Age: 76
Gender: Male 
Weight: 84 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 110/65 mmHg
Past Medical History: Other HF etiology, Diabetes, Dyslipemia
Albumin (g/L): 38
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 300
Glucose (mmol/L): 5
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,04
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 1733.0
Protein (g/L): 72
T3 (pg/dL): 0,02
T4 (ng/L): 24
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,58
Urea (mg/dL): 8,32
LVEF (%): 26.0
Medications: Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor
REASONING: The patient's current medications (Beta Blockers and Loop Diuretics) and the presence of a relatively well-managed blood pressure (110/65 mmHg) suggest that the patient is receiving adequate treatment for heart failure. The patient's LVEF of 26% indicates reduced left ventricular function, but it is not the lowest possible value (which would be 0-15%). The patient's Pro-BNP level of 1733.0 ng/L is elevated, indicating increased ventricular stress, but it is not extremely high. Additionally, the patient's recent troponin level of 0.01 ng/mL is within normal limits. Considering these factors, the patient's prognosis is likely to be a survivor, as they are receiving treatment and their symptoms are being managed.

RANKING: Pump Failure Death
REASONING: The patient's LVEF of 26% indicates reduced left ventricular function, which is a significant risk factor for pump failure death. The patient's NYHA Class III classification indicates that they experience symptoms of heart failure at rest or with minimal exertion, which can be a sign of advanced heart failure. The patient's elevated Pro-BNP level and relatively high creatinine level (97.0 mmol/L) also suggest that the patient's heart is under strain. However, the patient's medications and relatively well-managed blood pressure suggest that they are receiving adequate treatment for heart failure. Therefore, while pump failure death is a possible outcome, it is less likely than survivor due to the patient's treatment regimen.

RANKING: Sudden Cardiac Death
REASONING: Sudden cardiac death is a less likely outcome for this patient due to the following reasons: The patient's LVEF of 26% is not extremely low, and their recent troponin level is within normal limits, indicating that they are not experiencing significant acute cardiac ischemia. The patient's medications, including Beta Blockers, are known to reduce the risk of sudden cardiac death. Additionally, the patient's ECG does not show any signs of sustained ventricular tachycardia or other high-risk arrhythmias. Therefore, while sudden cardiac death is a possible outcome, it is the least likely of the three options."
245,245,P0408,"Age: 52
Gender: Female 
Weight: 64 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,17
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 13,9
Hemoglobin (g/L): 133.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,88
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 14.0
Protein (g/L): 70
T3 (pg/dL): 0,02
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,34
Urea (mg/dL): 4,66
LVEF (%): 52.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the ranking of the prognoses from most likely to least likely:

RANKING: 1. Survivor
 REASONING: The patient is 52 years old, which is still relatively young for a patient with ischemic dilated cardiomyopathy. Her LVEF is 52%, which is not ideal but still within the range that can be managed with medical therapy. The patient is on a comprehensive treatment regimen, including diabetes medication, beta blockers, loop diuretics, statins, ACE inhibitor, and nitrovasodilator, which is a good indication of aggressive management of her cardiovascular risk factors. The absence of significant electrolyte imbalances, such as low potassium levels, and the relatively normal liver function tests, are also positive signs. Additionally, the low Pro-BNP level of 14.0 ng/L suggests that the patient's heart failure symptoms are well-controlled. While the patient has a history of myocardial infarction, dyslipemia, and hypertension, which are all risk factors for cardiovascular disease, her current medications and overall clinical presentation suggest that she is well-managed and has a good prognosis.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF of 52% indicates that her heart is not functioning at its optimal level, which increases the risk of pump failure. However, her current medications and the absence of significant symptoms or complications suggest that her heart failure is well-managed. The patient's creatinine level of 80.0 umol/L is slightly elevated, which may indicate mild renal impairment, but it is not severe enough to suggest that pump failure is imminent. The patient's overall clinical presentation and laboratory values do not strongly suggest that pump failure is the most likely outcome.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient's ECG shows monomorphic ventricular extrasystoles, but there is no evidence of non-sustained ventricular tachycardia or other arrhythmias that would increase the risk of sudden cardiac death. The patient's LVEF of 52% is not low enough to suggest a high risk of sudden cardiac death. While the patient has a history of myocardial infarction, which increases the risk of sudden cardiac death, her current medications and overall clinical presentation suggest that she is well-managed and at low risk for sudden cardiac death."
246,246,P0411,"Age: 75
Gender: Male 
Weight: 70 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 100/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 34
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,59
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 46
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 81.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,04
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 859.0
Protein (g/L): 63
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,1
Urea (mg/dL): 9,32
LVEF (%): 25.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient is 75 years old with a history of ischemic dilated cardiomyopathy and myocardial infarction, which are significant risk factors for cardiac complications. However, the patient is on a comprehensive medication regimen that includes beta blockers, loop diuretics, statins, and an ACE inhibitor, which are all aimed at reducing the risk of cardiac events. The patient's ejection fraction (LVEF) is 25%, which is low, but not extremely low. The patient's pro-BNP level is elevated at 859 ng/L, indicating some degree of heart failure, but it is not excessively high. The patient's creatinine level is elevated at 124.0 mmol/L, which may indicate some degree of renal impairment, but it is not extremely high. The patient's hemoglobin level is low at 81.0 g/L, which may indicate anemia, but it is not extremely low. Considering these factors, the patient's prognosis is guarded, but a survivor outcome is still the most likely due to the comprehensive medication regimen and the fact that the patient is not in a very advanced stage of heart failure.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which increases the risk of sudden cardiac death. The patient's LVEF is low at 25%, which increases the risk of sudden cardiac death. However, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death. The patient's troponin level is low at 0.01 ng/mL, which suggests that the patient is not experiencing an acute myocardial infarction. The patient's pro-BNP level is elevated, but not excessively high. Considering these factors, the risk of sudden cardiac death is significant, but not extremely high.

RANKING: 3. Pump Failure Death
REASONING: The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which increases the risk of pump failure. However, the patient's LVEF is 25%, which is not extremely low. The patient's creatinine level is elevated, but not extremely high, which suggests that the patient is not in a very advanced stage of heart failure. The patient's pro-BNP level is elevated, but not excessively high. The patient's medication regimen includes loop diuretics, which are aimed at reducing fluid overload and improving symptoms of heart failure. Considering these factors, the risk of pump failure death is lower than the risk of sudden cardiac death, but still present."
247,247,P0412,"Age: 41
Gender: Male 
Weight: 80 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 115/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 36
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,12
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 286.0
Protein (g/L): 65
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,4
Urea (mg/dL): 6,16
LVEF (%): 40.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
 REASONING: The patient is 41 years old with ischemic dilated cardiomyopathy, which is a significant underlying condition. However, he is currently on appropriate medications (Beta Blockers, Statins, ACE Inhibitor) that are beneficial for managing heart failure and reducing the risk of further cardiac events. His LVEF is 40%, which is relatively low but not extremely low. His NT-proBNP level is elevated at 286 ng/L, but it is not extremely high, indicating some level of cardiac compensation. The patient's NYHA Class II suggests that he is experiencing some symptoms but can still perform everyday activities. His blood pressure is within a relatively normal range. His lipid profile is not ideal, but statins are being used to manage dyslipemia. The lack of other concerning factors such as severe anemia (Hemoglobin 143 g/L), significant kidney dysfunction (Creatinine 88 umol/L), or severe electrolyte imbalances (Potassium 4.5 mEq/L) also suggests that the patient is not at an extremely high risk of sudden cardiac death or pump failure. While there is still a risk of cardiac events, the patient's current management and relatively stable condition make survivorship the most likely prognosis.

RANKING: 2. Sudden cardiac death
 REASONING: The patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The presence of polymorphic ventricular extrasystoles on the ECG is also a concerning finding, as it can be a sign of electrical instability in the heart. However, the patient is on beta blockers, which can help reduce the risk of sudden cardiac death. The patient's LVEF is 40%, which is relatively low, but not extremely low. The NT-proBNP level is elevated, but not extremely high. The lack of other concerning factors such as severe anemia, significant kidney dysfunction, or severe electrolyte imbalances also suggests that sudden cardiac death is not the most likely prognosis.

RANKING: 3. Pump failure death
 REASONING: The patient's LVEF is 40%, which is relatively low, indicating some degree of cardiac dysfunction. However, his NYHA Class II suggests that he is still able to perform everyday activities, and his blood pressure is within a relatively normal range. The patient's NT-proBNP level is elevated, but not extremely high, indicating some level of cardiac compensation. The lack of other concerning factors such as severe anemia, significant kidney dysfunction, or severe electrolyte imbalances also suggests that pump failure death is not the most likely prognosis. The patient's current management with beta blockers, statins, and ACE inhibitor also suggests that his cardiac function is being actively managed, reducing the risk of pump failure."
248,248,P0413,"Age: 76
Gender: Male 
Weight: 84 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 133/88 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 36,5
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,6
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,3
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,87
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 870.0
Protein (g/L): 67
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,72
Urea (mg/dL): 8,49
LVEF (%): 37.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely. Please note that this is a medical assessment and not a definitive prediction.

RANKING: 1. Survivor
REASONING: The patient's age and LVEF of 37% indicate a reduced left ventricular function, which is a risk factor for cardiac events. However, the patient's NYHA Class II suggests that he is still relatively asymptomatic and can perform daily activities without significant limitation. The patient is on beta blockers and an ACE inhibitor, which are standard treatments for heart failure with reduced ejection fraction. The lack of elevated troponin levels and the presence of a low TSH level suggest that there is no acute cardiac ischemia or thyroid dysfunction contributing to his condition. The patient's serum albumin and hemoglobin levels are within normal limits, indicating that there is no severe malnutrition or anemia. The patient's Pro-BNP level is elevated, but not extremely high, which may indicate some degree of heart failure, but not an extremely poor prognosis. Considering these factors, a survivor prognosis seems the most likely.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 37% indicates a reduced left ventricular function, which increases the risk of pump failure. The patient's NYHA Class II suggests that he is still relatively asymptomatic, but the patient's elevated Pro-BNP level and reduced LVEF suggest that he may be at risk for pump failure. However, the patient is on standard treatments for heart failure, and the lack of other severe comorbidities or laboratory abnormalities makes pump failure death less likely.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's LVEF of 37% and the presence of non-sustained ventricular tachycardia and ventricular extrasystole increase the risk of sudden cardiac death. However, the patient's age and the lack of other high-risk features, such as a history of cardiac arrest or syncope, make sudden cardiac death less likely. The patient's beta blockers and ACE inhibitor therapy may also reduce the risk of sudden cardiac death."
249,249,P0414,"Age: 72
Gender: Male 
Weight: 74 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 112/78 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 50
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,04
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 161.0
Protein (g/L): 73
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,61
Urea (mg/dL): 9,15
LVEF (%): 45.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: 1. Survivor
REASONING: The patient is 72 years old with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for adverse cardiac outcomes. However, the patient is currently on appropriate medical therapy with beta blockers, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure with reduced ejection fraction (HFrEF). The patient's LVEF is 45%, which is below the normal range but not extremely low. The patient's Pro-BNP level is elevated at 161.0 ng/L, indicating some level of heart failure, but it is not extremely high. The patient's blood pressure is well-controlled, and the ECG findings are concerning but not necessarily indicative of an imminent cardiac event. The patient's hemoglobin and potassium levels are within normal limits, which suggests that there are no significant electrolyte imbalances that could contribute to cardiac arrhythmias. Considering these factors, while the patient's prognosis is guarded, the likelihood of sudden cardiac death or pump failure death in the short term appears to be lower than the likelihood of long-term survival with appropriate medical management.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's ECG findings, including polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, suggest an increased risk of sudden cardiac death. However, the patient is on beta blockers, which are effective in reducing the risk of sudden cardiac death in patients with HFrEF. Additionally, the patient's LVEF is 45%, which is not extremely low, and the patient's blood pressure is well-controlled. While the patient's Pro-BNP level is elevated, it is not extremely high, and the patient's hemoglobin and potassium levels are within normal limits. Therefore, while the patient's risk of sudden cardiac death is increased, it is not the most likely outcome.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF is 45%, which is below the normal range, indicating some degree of heart failure. However, the patient is on appropriate medical therapy, and the patient's blood pressure is well-controlled. The patient's Pro-BNP level is elevated, but it is not extremely high, and the patient's hemoglobin and potassium levels are within normal limits. While the patient's prognosis is guarded, the patient's clinical presentation and laboratory findings do not suggest an extremely high risk of pump failure death in the short term."
250,250,P0415,"Age: 28
Gender: Male 
Weight: 95 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 90/50 mmHg
Past Medical History: Other HF etiology
Albumin (g/L): 44
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,27
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 5
LDL (mmol/L): 2,64
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 38.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 21
Troponin (ng/mL): 0,062
TSH (mIU/L): 1,97
Urea (mg/dL): 3,83
LVEF (%): 59.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Please note that this is a hypothetical assessment and not a definitive prediction.

RANKING: Survivor

REASONING: 

1. The patient is relatively young (28 years old), which is a positive prognostic factor.
2. Despite having a reduced LVEF (59%), the patient is not in NYHA Class III or IV, which indicates that the heart failure is not severely symptomatic.
3. The patient is on optimal medical therapy with Angiotensin II Receptor Blocker, Beta Blockers, and Digoxin, which suggests that the patient's heart failure is being adequately managed.
4. The Pro-BNP level of 38 ng/L is within a relatively normal range, which indicates that the patient is not experiencing significant cardiac stress or strain.
5. The absence of significant troponin elevation (0.062 ng/mL) suggests that there is no acute myocardial infarction or severe cardiac damage.
6. The patient's ECG shows a ventricular extrasystole, but no sustained ventricular tachycardia or other life-threatening arrhythmias.
7. The patient's other laboratory values, such as creatinine and urea, are within normal limits, indicating that there is no significant kidney dysfunction.
8. The patient's TSH level is within the normal range, which suggests that there is no evidence of thyroid dysfunction.

While the patient has a history of heart failure etiology, the above factors suggest that the patient's condition is stable and well-managed. Therefore, the most likely prognosis is survival over the next few years.

RANKING (from most likely to least likely): 

1. Survivor
2. Pump failure death (less likely due to the patient's relatively stable condition and optimal medical therapy)
3. Sudden cardiac death (least likely due to the absence of significant arrhythmias or other life-threatening conditions)

Please note that this is a hypothetical assessment and not a definitive prediction. A thorough evaluation by a cardiologist is necessary to determine the patient's actual prognosis."
251,251,P0417,"Age: 45
Gender: Male 
Weight: 72 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,92
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 85
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,9
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 197.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 15
Troponin (ng/mL): 0,005
TSH (mIU/L): 2,37
Urea (mg/dL): 6,82
LVEF (%): 38.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

This patient has a history of enolic dilated cardiomyopathy, which is a significant risk factor for heart failure. However, the patient is currently on optimal medical therapy with beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all evidence-based treatments for heart failure with reduced ejection fraction (HFrEF). The patient's LVEF of 38% is relatively stable, indicating that the heart is still pumping some blood, but not as efficiently as a normal heart. 

The patient's NT-proBNP level of 197.0 ng/L is elevated, but not excessively high, which is often seen in patients with heart failure. The patient's creatinine level of 88.0 umol/L is slightly elevated, suggesting mild renal impairment, but not severe enough to indicate a high risk of sudden cardiac death.

The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death, but the patient is on beta blockers, which can help prevent arrhythmias. The patient's potassium level of 4.2 mEq/L is within the normal range, which is a good sign, as low potassium levels can increase the risk of arrhythmias.

Considering all these factors, the patient's prognosis is more likely to be a survivor, as they are on optimal medical therapy, have a relatively stable LVEF, and do not have any severe risk factors for sudden cardiac death or pump failure.

RANKING: Sudden cardiac death

REASONING: 

The patient's history of enolic dilated cardiomyopathy and non-sustained ventricular tachycardia on ECG make sudden cardiac death a possible risk. The patient's low LVEF of 38% and elevated NT-proBNP level also indicate a higher risk of arrhythmias and sudden cardiac death. However, the patient is on beta blockers, which can help prevent arrhythmias, and their potassium level is within the normal range.

RANKING: Pump failure death

REASONING: 

The patient's LVEF of 38% indicates a reduced ejection fraction, which is a risk factor for pump failure. However, the patient's creatinine level of 88.0 umol/L is only slightly elevated, suggesting that the patient's kidneys are still functioning relatively well, and the patient is not in a state of severe heart failure. The patient's NT-proBNP level is elevated, but not excessively high, which is often seen in patients with heart failure. The patient's optimal medical therapy and relatively stable LVEF make pump failure less likely compared to sudden cardiac death."
252,252,P0420,"Age: 82
Gender: Female 
Weight: 64 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 6,23
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 4,5
LDL (mmol/L): 4,34
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 616.0
Protein (g/L): 82
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,91
Urea (mg/dL): 11,65
LVEF (%): 38.0
Medications: Calcium Channel Blocker, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

Given the patient's profile, the most likely prognosis is a survivor for the next few years. The patient is 82 years old, which puts her in a high-risk category for cardiac events due to age. However, her current medications, including a calcium channel blocker, spironolactone, and nitrovasodilator, are aimed at managing her hypertension and heart failure symptoms. 

Her LVEF (left ventricular ejection fraction) is 38%, which is slightly below the normal range (50-70%), indicating some degree of heart failure. However, her Pro-BNP level of 616 ng/L is within the normal range (< 500 ng/L), suggesting that her heart failure is not severe. 

Her blood pressure is within a relatively normal range, and her potassium level is also within normal limits. Although her total cholesterol is slightly elevated, her HDL level is high, which is a good sign. Her TSH level is within the normal range, which is a good indicator of thyroid function.

The presence of non-sustained ventricular tachycardia (NSVT) on her ECG is concerning, but it is not a strong predictor of sudden cardiac death in this patient. Her polymorphic ventricular extrasystoles are also concerning, but they are not uncommon in elderly patients with heart failure.

Considering these factors, while the patient's heart failure is a concern, her overall profile suggests that she is likely to survive for the next few years with appropriate medical management."
253,253,P0421,"Age: 58
Gender: Male 
Weight: 90 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 11,1
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,51
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 509.0
Protein (g/L): 69
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,5
Urea (mg/dL): 4,99
LVEF (%): 34.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses for the next few years as follows:

RANKING: 1. Survivor
 REASONING: The patient has a combination of risk factors, including ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction, which suggest a high risk for adverse cardiac events. However, the patient is currently being managed with evidence-based medications, including beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor. The patient's LVEF is 34%, which is low but not extremely low, and the troponin level is normal. The patient's blood pressure is well-controlled, and the eGFR is not significantly impaired. The patient does not have any signs of severe electrolyte imbalances or acute decompensation. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG is concerning, but the absence of sustained VT and other arrhythmias is a positive sign. Considering these factors, the patient's prognosis is likely to be a survivor with continued management and monitoring of their condition.

RANKING: 2. Pump Failure Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy and a low LVEF of 34%, which increases the risk of pump failure. The patient's elevated Pro-BNP level (509.0 ng/L) also suggests increased ventricular wall stress and potential pump failure. However, the patient is currently being managed with medications that are beneficial for heart failure, and their blood pressure is well-controlled. The patient's creatinine level is slightly elevated, but not severely so, and the eGFR is not significantly impaired. While pump failure is a possibility, the patient's current management and lack of severe symptoms make this prognosis less likely than sudden cardiac death.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient has a history of myocardial infarction and a low LVEF, which increases the risk of sudden cardiac death. However, the patient is currently being managed with beta blockers, which are beneficial for reducing the risk of sudden cardiac death. The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are concerning signs, but the absence of sustained VT and other arrhythmias is a positive sign. The patient's troponin level is normal, and the patient does not have any signs of acute decompensation. While sudden cardiac death is a possibility, the patient's current management and lack of severe symptoms make this prognosis less likely than pump failure death."
254,254,P0422,"Age: 62
Gender: Male 
Weight: 75 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Other HF etiology
Albumin (g/L): 40
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 43.0
Total Cholesterol (mmol/L): 5,9
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 125
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,2
LDL (mmol/L): 4,32
Sodium (mEq/L): 130.0
Pro-BNP (ng/L): 123.0
Protein (g/L): 56
T3 (pg/dL): 0,03
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,3
Urea (mg/dL): 7,15
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1

REASONING: The patient is 62 years old, with a history of heart failure (HF) and a low left ventricular ejection fraction (LVEF) of 20%, indicating severe systolic dysfunction. However, the patient is on optimal medical therapy with beta blockers, loop diuretics, and an ACE inhibitor, which is consistent with current guidelines for the management of HF with reduced ejection fraction (HFrEF). The patient's blood pressure is well-controlled at 110/70 mmHg, and the creatinine level is slightly elevated but not significantly abnormal. The pro-BNP level is elevated at 123 ng/L, but not excessively high, which may indicate that the patient's HF is being managed effectively.

The patient's laboratory results show a slightly elevated liver enzyme (AST) and a low albumin level, which may indicate some degree of liver dysfunction or malnutrition. However, these findings are not severe and are not directly related to the patient's cardiac condition.

The patient's ECG shows polymorphic ventricular extrasystoles, which can be a marker of increased risk of arrhythmias, but the absence of sustained ventricular tachycardia or non-sustained ventricular tachycardia is reassuring.

Considering the patient's optimal medical therapy, controlled blood pressure, and relatively well-managed HF, I believe that the most likely prognosis is survival over the next few years. The patient's risk of sudden cardiac death or pump failure death is lower due to the effective management of his HF and the absence of severe arrhythmias or other high-risk features.

The other two prognoses are less likely:

RANKING: 2

REASONING: Sudden cardiac death is a possible outcome in patients with HFrEF, particularly if they have a history of ventricular arrhythmias or other high-risk features. However, the patient's ECG does not show any evidence of sustained ventricular tachycardia or non-sustained ventricular tachycardia, and the patient is on optimal medical therapy, which reduces the risk of sudden cardiac death.

RANKING: 3

REASONING: Pump failure death is a possible outcome in patients with HFrEF, particularly if they have a low LVEF and are not adequately managed. However, the patient's LVEF is 20%, but the patient is on optimal medical therapy, and the creatinine level is only slightly elevated, which suggests that the patient's HF is not severely decompensated. The patient's overall clinical condition and laboratory results suggest that pump failure death is the least likely outcome over the next few years."
255,255,P0424,"Age: 73
Gender: Male 
Weight: 69 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 120/65 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 105.0
AST or GOT (IU/L): 98.0
Total Cholesterol (mmol/L): 3,41
Creatinine (mmol/L): 194.0
Gamma-glutamil transpeptidase (IU/L): 100
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 5,1
LDL (mmol/L): 1,55
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 4846.0
Protein (g/L): 77
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,41
Urea (mg/dL): 19,8
LVEF (%): 37.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient is 73 years old with a history of idiopathic dilated cardiomyopathy, which is a significant underlying condition. However, he is currently being treated with a combination of beta blockers, digoxin, loop diuretics, and an ACE inhibitor, which are standard treatments for heart failure and cardiomyopathy. The patient's LVEF (Left Ventricular Ejection Fraction) is 37%, which is lower than the normal range but not extremely low. Additionally, the patient's blood pressure is well-controlled, and his ejection fraction is not extremely low, which suggests that the patient is not in a critical state. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG is concerning, but it is not uncommon in patients with cardiomyopathy. Considering the patient's current treatment and relatively stable condition, the likelihood of a survivor prognosis is the most likely outcome.

RANKING: 2. Pump failure death
REASONING: The patient has a history of idiopathic dilated cardiomyopathy and a low LVEF of 37%. This indicates that the patient's heart is not pumping efficiently, which increases the risk of heart failure. The patient's creatinine level is elevated at 194.0 mmol/L, which suggests impaired renal function, often associated with advanced heart failure. The patient's BNP level is also elevated at 4846.0 ng/L, which is a marker of heart failure. However, the patient's current treatment and relatively stable condition suggest that the patient is not in a critical state, making pump failure death a less likely outcome.

RANKING: 3. Sudden cardiac death
REASONING: Sudden cardiac death is a sudden and unexpected death caused by a cardiac arrhythmia or other cardiac condition. The patient's ECG shows non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, which are risk factors for sudden cardiac death. However, the patient is currently being treated with a beta blocker, which is a standard treatment for reducing the risk of sudden cardiac death. Additionally, the patient's LVEF is not extremely low, and the patient is not in a critical state. While the patient's ECG findings are concerning, the likelihood of sudden cardiac death is lower than the other two outcomes due to the patient's current treatment and relatively stable condition."
256,256,P0425,"Age: 53
Gender: Female 
Weight: 67 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 115/50 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 38
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 51
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 114.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,87
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 775.0
Protein (g/L): 70
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,56
Urea (mg/dL): 4,99
LVEF (%): 43.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here is the prognosis for the next few years:

RANKING: Survivor
REASONING: The patient is a 53-year-old female with idiopathic dilated cardiomyopathy, NYHA Class II, and a left ventricular ejection fraction (LVEF) of 43%. The patient is on optimal medical therapy with beta blockers, spironolactone, and an ACE inhibitor, which is consistent with current guidelines for heart failure treatment. The patient's BNP level is elevated at 775 ng/L, indicating some degree of heart failure symptoms. However, the patient's hemoglobin and urea levels are within normal limits, suggesting that the heart failure is not severe. The patient's ECG shows non-sustained ventricular tachycardia, but no signs of severe arrhythmias. The patient's troponin level is normal, indicating that there is no acute myocardial infarction. The patient's TSH level is normal, ruling out thyroid dysfunction as a contributing factor to her heart failure. The patient's lipid profile shows high total cholesterol and LDL, but these are not unusually high. The patient's weight and body mass index (BMI) are not provided, but her height is 162 cm, which suggests a normal to slightly underweight BMI. Overall, the patient's clinical presentation and laboratory values suggest that she has well-managed heart failure, and her prognosis is likely to be good with continued optimal medical therapy and follow-up.

RANKING: Sudden Cardiac Death
REASONING: The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. However, the patient is on optimal medical therapy, and her LVEF is 43%, which is not extremely low. The patient's troponin level is normal, and there are no other ECG signs of severe arrhythmias. The patient's BNP level is elevated, but not extremely high. While sudden cardiac death is a possible outcome, it is less likely given the patient's current medical therapy and the fact that she is not in a high-risk category for sudden cardiac death.

RANKING: Pump Failure Death
REASONING: The patient's LVEF is 43%, which is below the normal range of 55-70%. The patient's BNP level is elevated, indicating some degree of heart failure symptoms. However, the patient is on optimal medical therapy, and her hemoglobin and urea levels are within normal limits, suggesting that the heart failure is not severe. The patient's weight and BMI are not provided, but her height suggests a normal to slightly underweight BMI, which may be beneficial for her heart failure. While pump failure is a possible outcome, it is less likely given the patient's current medical therapy and the fact that her heart failure is not severe."
257,257,P0426,"Age: 72
Gender: Male 
Weight: 76 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 125/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 41
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 6,4
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 2,35
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2598.0
Protein (g/L): 67
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,53
Urea (mg/dL): 11,32
LVEF (%): 10.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Hydralazine
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is my prognosis for the next few years, ranking the three possible outcomes from most likely to least likely:

RANKING: 1. Survivor
 REASONING: The patient is 72 years old with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure. However, the patient is currently receiving optimal medical therapy, including ACE inhibitors, beta blockers, diuretics, and spironolactone, which are all standard treatments for heart failure with reduced ejection fraction (HFrEF). The patient's LVEF is severely reduced at 10%, but the absence of elevated troponin levels suggests that there is no acute coronary syndrome or myocardial infarction contributing to the patient's current condition. The patient's pro-BNP level is elevated, but not excessively high, which suggests that the patient is not experiencing acute decompensated heart failure. The patient's overall clinical presentation and medication regimen suggest that the patient is being managed for stable HFrEF, and with continued adherence to treatment, the patient is likely to survive for the next few years.

RANKING: 2. Pump failure death
 REASONING: The patient's severely reduced LVEF (10%) and elevated pro-BNP level suggest that the patient has advanced heart failure. However, the patient's overall clinical presentation and medication regimen suggest that the patient is being managed for stable HFrEF, which may indicate that the patient's condition is not rapidly deteriorating. While pump failure death is a possible outcome, it is less likely than survivorship given the patient's current management and relatively stable clinical presentation.

RANKING: 3. Sudden cardiac death
 REASONING: The patient's history of idiopathic dilated cardiomyopathy and non-sustained ventricular tachycardia (NSVT) on ECG increase the risk of sudden cardiac death. However, the patient is currently receiving beta blockers, which are known to reduce the risk of sudden cardiac death in patients with HFrEF. Additionally, the patient's troponin level is normal, which suggests that there is no acute coronary syndrome or myocardial infarction contributing to the patient's current condition. While sudden cardiac death is a possible outcome, it is the least likely of the three options given the patient's current management and relatively stable clinical presentation."
258,258,P0427,"Age: 77
Gender: Male 
Weight: 61 kg
Height: 152 cm
NYHA Class: II
Blood Pressure: 118/57 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 49.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 101
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,87
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 3993.0
Protein (g/L): 76
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,03
Urea (mg/dL): 6,66
LVEF (%): 25.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1

REASONING: Based on the provided patient data, the patient is at high risk for cardiac complications due to his advanced age, ischemic dilated cardiomyopathy, and low left ventricular ejection fraction (LVEF) of 25%. However, considering the patient's current treatment regimen, which includes beta blockers, loop diuretics, statins, and an ACE inhibitor, it suggests that the patient is receiving optimal medical therapy for heart failure.

The patient's NYHA class II indicates that he has some limitations in physical activity but is still able to perform daily activities without symptoms. His blood pressure is within a relatively normal range, and his hemoglobin and sodium levels are also within normal limits.

The elevated Pro-BNP level of 3993 ng/L suggests that the patient has significant heart failure symptoms, but it is not uncommon in patients with ischemic cardiomyopathy. The patient's Troponin level of 0.01 ng/mL is within normal limits, indicating that there is no acute myocardial infarction.

Given the patient's advanced age and the fact that he is already receiving optimal medical therapy, the most likely prognosis is survival, as the patient is already being treated for his condition and is likely to continue receiving ongoing care and management.

Sudden cardiac death is less likely due to the patient's current treatment regimen and the fact that he has no acute myocardial infarction. Pump failure death is also less likely due to the patient's current treatment regimen and the fact that he is already receiving optimal medical therapy for heart failure.

However, it is essential to note that the patient's prognosis can change over time, and regular monitoring and follow-up appointments are crucial to adjust the treatment plan as needed."
259,259,P0428,"Age: 48
Gender: Female 
Weight: 83 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 115/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,22
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,02
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 120.0
Protein (g/L): 69
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,91
Urea (mg/dL): 8,49
LVEF (%): 40.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the prognosis ranking:

RANKING: 1. Survivor
REASONING: The patient is 48 years old with a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipemia. However, she is currently being treated with beta blockers, statins, and an ACE inhibitor, which are appropriate for her conditions. Her LVEF is 40%, which is relatively low but not extremely low. She also has a relatively low Pro-BNP level (120 ng/L), which suggests that her heart failure is not severe at this time. Additionally, her NYHA Class is II, indicating that she is experiencing some symptoms but is still able to perform daily activities. Considering these factors, the patient's current treatment plan and the relatively low severity of her symptoms, the most likely prognosis is that she will survive.

RANKING: 2. Sudden Cardiac Death
REASONING: While the patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, her current treatment plan and LVEF of 40% suggest that she is not at extremely high risk for sudden cardiac death. Her Pro-BNP level is also not extremely high, which is a good sign. However, she does have a history of myocardial infarction, which increases her risk for sudden cardiac death. Additionally, her low LVEF may indicate some degree of cardiac dysfunction, which could potentially increase her risk for arrhythmias or cardiac arrest. However, with her current treatment plan and relatively low Pro-BNP level, the risk of sudden cardiac death is not extremely high.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF of 40% and history of ischemic dilated cardiomyopathy suggest that she has some degree of cardiac dysfunction. However, her current treatment plan and relatively low Pro-BNP level suggest that her heart failure is not extremely severe at this time. Her NYHA Class II also indicates that she is experiencing some symptoms but is still able to perform daily activities. While pump failure death is a possible outcome for patients with heart failure, it is less likely in this case due to the patient's relatively low Pro-BNP level and current treatment plan. Additionally, the patient's LVEF is not extremely low, which suggests that her heart is still functioning to some degree."
260,260,P0430,"Age: 73
Gender: Male 
Weight: 78 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 144/79 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,98
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 962.0
Protein (g/L): 69
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,1
Urea (mg/dL): 7,15
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

Based on the provided patient data, the patient is a 73-year-old male with a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipemia. His left ventricular ejection fraction (LVEF) is significantly reduced at 30%, indicating severe heart failure. However, he is on optimal medical therapy with beta blockers, loop diuretics, statins, and ACE inhibitors, which are standard treatments for heart failure with reduced ejection fraction (HFrEF). 

The patient's NT-proBNP level is elevated at 962 ng/L, which is consistent with heart failure. However, it's worth noting that NT-proBNP levels can be influenced by various factors, including age, kidney function, and other comorbidities. The patient's creatinine level is slightly elevated at 97.0 umol/L, which may be a concern for kidney function, but it's not significantly elevated.

The patient's ECG shows polymorphic ventricular extrasystoles, but no signs of sustained ventricular tachycardia or other arrhythmias. This suggests that the patient's cardiac rhythm is relatively stable, despite the reduced LVEF.

Considering the patient's age, comorbidities, and current medical therapy, the most likely prognosis is survival with continued medical management and monitoring. The patient's NYHA class II suggests that he has some symptoms of heart failure, but they are not severe enough to limit his daily activities. With optimal medical therapy and regular follow-up, the patient is likely to survive for several years, although he will require close monitoring for any signs of worsening heart failure or arrhythmias.

Sudden cardiac death is a possible concern, but it is less likely given the patient's current medical therapy and stable ECG findings. Pump failure death is also a possibility, but the patient's current LVEF and medical therapy suggest that he is likely to survive for several years.

Therefore, the ranking from most likely to least likely is:

1. Survivor
2. Sudden cardiac death
3. Pump failure death"
261,261,P0435,"Age: 62
Gender: Male 
Weight: 100 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 45
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 66
Glucose (mmol/L): 8,7
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 5
LDL (mmol/L): 3,21
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 109.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,78
Urea (mg/dL): 6,99
LVEF (%): 44.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: Survivor
REASONING: The patient's current medications, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, suggest that they are being actively managed for heart failure and hypertension. The patient's LVEF (Left Ventricular Ejection Fraction) is 44%, which is below the normal range (50-70%), indicating some degree of left ventricular dysfunction. However, the patient's NYHA Class II classification indicates that they are experiencing some symptoms of heart failure, but they are still able to perform most daily activities without significant limitations. The patient's blood pressure is well-controlled, and their creatinine levels are slightly elevated but not significantly high, indicating some degree of kidney function preservation. The patient's Pro-BNP level is elevated, but not excessively high, suggesting some degree of heart failure, but not severe. Additionally, the patient's Troponin level is within normal limits, indicating that there is no acute myocardial infarction. Considering these factors, the patient's prognosis is likely to be a survivor, with ongoing management and monitoring to prevent further cardiac decompensation.

RANKING: Pump Failure Death
REASONING: The patient's LVEF of 44% indicates some degree of left ventricular dysfunction, which increases the risk of pump failure. The patient's elevated creatinine levels and slightly elevated Pro-BNP level suggest some degree of kidney function impairment and heart failure, which can contribute to pump failure. However, the patient's NYHA Class II classification and well-controlled blood pressure suggest that the patient is still relatively stable and not in acute decompensated heart failure. The patient's ongoing medications, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, are aimed at reducing the risk of pump failure. Considering these factors, pump failure death is a possible, but less likely prognosis.

RANKING: Sudden Cardiac Death
REASONING: The patient's ECG findings of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia suggest some degree of arrhythmogenic potential. However, the patient's medications, including beta blockers and an ACE inhibitor, are aimed at reducing the risk of arrhythmias. The patient's Troponin level is within normal limits, indicating no acute myocardial infarction. The patient's LVEF of 44% and slightly elevated Pro-BNP level suggest some degree of left ventricular dysfunction, but not severe. Considering these factors, sudden cardiac death is the least likely prognosis."
262,262,P0436,"Age: 62
Gender: Male 
Weight: 80 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 4,01
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,2
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 184.0
Protein (g/L): 70
T3 (pg/dL): 0,04
T4 (ng/L): 13
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,25
Urea (mg/dL): 7,15
LVEF (%): 17.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: 
The patient is 62 years old with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure. However, the patient is currently on optimal medical therapy with beta blockers, digoxin, loop diuretics, statins, and an ACE inhibitor. The patient's LVEF is 17%, which is low but not extremely low. The patient's NYHA Class II indicates that the patient has some limitations in physical activity but is still able to perform daily activities without significant symptoms.

The patient's biomarkers, including troponin and BNP, are within normal limits, suggesting that there is no acute myocardial infarction or severe cardiac decompensation. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a marker of electrical instability, but it does not indicate a high risk of sudden cardiac death.

The patient's low HDL and high LDL levels indicate a need for further lipid management, but the patient is on statins, which should help to manage this. The patient's TSH is within normal limits, indicating that the patient is not hypothyroid, which can be a risk factor for heart failure.

While the patient has a history of ischemic dilated cardiomyopathy and a low LVEF, the patient's current medication regimen and lack of acute biomarker elevations suggest that the patient is well-managed and has a lower risk of sudden cardiac death or pump failure death in the near future. Therefore, the most likely prognosis is survivor.

RANKING: Sudden Cardiac Death

REASONING: 
The patient's polymorphic ventricular extrasystoles on the ECG could indicate a risk of arrhythmia, which could lead to sudden cardiac death. The patient's low LVEF and history of ischemic dilated cardiomyopathy also increase the risk of sudden cardiac death. However, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death in patients with heart failure.

The patient's TSH is within normal limits, and the patient is on optimal medical therapy, which reduces the risk of hypothyroidism-related arrhythmias. The patient's BNP and troponin levels are within normal limits, indicating that there is no acute cardiac decompensation.

While the patient has a higher risk of sudden cardiac death due to their history and ECG findings, the patient's current medication regimen and lack of acute biomarker elevations suggest that the risk is not extremely high.

RANKING: Pump Failure Death

REASONING: 
The patient's LVEF is 17%, which is a significant risk factor for pump failure death. However, the patient is on optimal medical therapy, including beta blockers and ACE inhibitors, which should help to manage heart failure symptoms and reduce the risk of pump failure.

The patient's NYHA Class II indicates that the patient has some limitations in physical activity but is still able to perform daily activities without significant symptoms. The patient's BNP and troponin levels are within normal limits, indicating that there is no acute cardiac decompensation.

While the patient has a history of ischemic dilated cardiomyopathy and a low LVEF, the patient's current medication regimen and lack of acute biomarker elevations suggest that the patient is well-managed and has a lower risk of pump failure death in the near future."
263,263,P0437,"Age: 53
Gender: Male 
Weight: 100 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,28
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 12721.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,825
Urea (mg/dL): 6,16
LVEF (%): 25.0
Medications: Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely:

RANKING: 1. Survivor
 REASONING: The patient is 53 years old with a history of ischemic dilated cardiomyopathy and myocardial infarction, which indicates a significant risk for cardiac events. However, the patient is currently on a treatment regimen that includes beta blockers, statins, ACE inhibitors, and nitrovasodilators, which are standard therapies for heart failure and ischemic heart disease. The patient's LVEF is 25%, which is low but not extremely low. The patient's BNP level is elevated at 12,721 ng/L, indicating heart failure, but it's not extremely high. The patient's NYHA class is II, indicating mild to moderate symptoms of heart failure. The patient's blood pressure is well-controlled, and the patient has not had any recent cardiac arrests or sudden cardiac deaths. Considering the patient's age, comorbidities, and current treatment, the most likely prognosis is survival, assuming the patient adheres to their medication regimen and makes lifestyle modifications.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases the risk of sudden cardiac death. The patient's LVEF is low at 25%, which also increases the risk of sudden cardiac death. The patient's BNP level is elevated, indicating heart failure, which is also a risk factor for sudden cardiac death. However, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death in patients with heart failure. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death, but it's not a definitive indicator. Considering the patient's risk factors and current treatment, the risk of sudden cardiac death is significant but not the most likely outcome.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF is 25%, which indicates severe left ventricular dysfunction. The patient's BNP level is elevated, indicating heart failure. The patient's creatinine level is 71.0 umol/L, which is slightly elevated, indicating renal impairment, which can be a complication of heart failure. The patient's albumin level is low at 40 g/L, which can indicate malnutrition or liver disease, but it can also be a sign of advanced heart failure. The patient's weight is 100 kg, which is above the ideal weight for their height, which can increase the strain on the heart. However, the patient is on ACE inhibitors, which are known to reduce the risk of pump failure in patients with heart failure. Considering the patient's risk factors and current treatment, pump failure death is the least likely outcome, but still a possible one if the patient's heart failure worsens and is not adequately managed."
264,264,P0441,"Age: 73
Gender: Male 
Weight: 90 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,4
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1107.0
Protein (g/L): 62
T3 (pg/dL): 0,04
T4 (ng/L): 16
TSH (mIU/L): 2,55
Urea (mg/dL): 8,99
LVEF (%): 34.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses for the next few years from most likely to least likely as follows:

RANKING: Survivor

REASONING: The patient is 73 years old with a history of ischemic dilated cardiomyopathy and myocardial infarction, which suggests that the patient has significant cardiac disease. However, the patient is on a comprehensive medication regimen that includes an angiotensin II receptor blocker, beta blockers, loop diuretics, spironolactone, statins, and nitrovasodilators. These medications are aimed at managing the patient's heart failure symptoms and improving cardiac function.

The patient's left ventricular ejection fraction (LVEF) is 34%, which indicates reduced cardiac function. However, the patient is not in New York Heart Association (NYHA) Class IV, which suggests that the patient's symptoms are not severe enough to limit daily activities. The patient's creatinine level is slightly elevated at 106.0 mmol/L, but it is not significantly high, which suggests that the patient's renal function is still relatively preserved.

The patient's pro-BNP level is 1107.0 ng/L, which is elevated, but not extremely high. The patient's TSH level is within the normal range, and the patient does not have any signs of hyperthyroidism or hypothyroidism.

Considering these factors, the patient's prognosis is more likely to be a survivor. The patient's medication regimen and relatively preserved renal function suggest that the patient's cardiac disease is being managed effectively, and the patient is likely to continue to survive for the next few years.

RANKING: Sudden Cardiac Death

REASONING: While the patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which increases the risk of sudden cardiac death, the patient's current medication regimen and relatively preserved renal function suggest that the risk of sudden cardiac death is not extremely high. The patient's LVEF is low, but the patient is not in NYHA Class IV, and the patient's symptoms are not severe enough to limit daily activities.

Additionally, the patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death, but the patient does not have any other high-risk ECG findings, such as a QT interval prolongation or a high-degree AV block.

RANKING: Pump Failure Death

REASONING: The patient's LVEF is 34%, which indicates reduced cardiac function. However, the patient's NYHA Class is II, which suggests that the patient's symptoms are not severe enough to limit daily activities. The patient's creatinine level is slightly elevated, but not significantly high, which suggests that the patient's renal function is still relatively preserved.

The patient's pro-BNP level is elevated, but not extremely high, which suggests that the patient's heart failure symptoms are being managed effectively. The patient's medication regimen includes spironolactone, which is a potassium-sparing diuretic that can help to improve cardiac function and reduce the risk of pump failure death.

Overall, while the patient's LVEF is low, the patient's symptoms are not severe enough to suggest that pump failure death is the most likely outcome."
265,265,P0442,"Age: 63
Gender: Male 
Weight: 67 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,19
Creatinine (mmol/L): 160.0
Gamma-glutamil transpeptidase (IU/L): 125
Glucose (mmol/L): 3,3
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 6,2
LDL (mmol/L): 2,51
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 637.0
Protein (g/L): 82
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,825
Urea (mg/dL): 12,15
LVEF (%): 52.0
Medications: Calcium Channel Blocker, Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: Based on the provided patient data, I rank the prognosis as survivor due to several factors:

1.  The patient is on optimal medical therapy with a Calcium Channel Blocker, Beta Blockers, and an ACE Inhibitor, which are standard treatments for heart failure and hypertension.
2.  The patient has a relatively well-preserved LVEF of 52%, which indicates that the heart is still functioning adequately despite the presence of idiopathic dilated cardiomyopathy.
3.  The patient's NYHA Class II classification indicates that the heart failure symptoms are mild, and the patient is able to perform daily activities without significant limitations.
4.  The patient's blood pressure is well-controlled at 140/70 mmHg, which is within the normal range.
5.  The patient's troponin level is within the normal range, indicating that there is no acute myocardial infarction or ischemia.
6.  The patient's TSH level is within the normal range, indicating that there is no thyroid dysfunction, which can be a contributing factor to heart failure.
7.  The patient's BNP level is elevated at 637.0 ng/L, which is consistent with heart failure, but the level is not excessively high, indicating that the heart failure is not severe.
8.  The patient's creatinine level is elevated at 160.0 umol/L, indicating some degree of kidney impairment, but it is not severely elevated.

While the patient has a history of idiopathic dilated cardiomyopathy and hypertension, the overall clinical picture suggests that the patient is well-managed and is likely to survive with continued medical therapy and close monitoring.

The other two prognoses are less likely due to the following reasons:

- Sudden cardiac death is less likely because the patient has a well-controlled heart rate, no history of syncope, and no severe left ventricular dysfunction.
- Pump failure death is less likely because the patient's LVEF is preserved, and the patient is on optimal medical therapy, which is likely to prevent further deterioration of the heart function."
266,266,P0443,"Age: 82
Gender: Female 
Weight: 88 kg
Height: 152 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,76
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 7
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 5,5
LDL (mmol/L): 3,7
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 320.0
Protein (g/L): 78
T3 (pg/dL): 0,02
T4 (ng/L): 21
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,43
Urea (mg/dL): 9,15
LVEF (%): 39.0
Medications: Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the ranking of the possible prognoses from most likely to least likely:

RANKING: 1. Survivor
REASONING: The patient is an 82-year-old female with a history of hypertensive cardiomyopathy, myocardial infarction, and hypertension. However, her current condition suggests that she is relatively stable, with a NYHA Class II classification, which indicates mild to moderate symptoms of heart failure. Her LVEF of 39% is lower than normal, but it is not extremely low. She is on medications that are beneficial for her condition, such as loop diuretics, spironolactone, and an ACE inhibitor. Her blood pressure is well-controlled, and her other vital signs are within normal limits. Although her Pro-BNP level is elevated at 320.0 ng/L, which may indicate some degree of heart failure, it is not extremely high. Considering her age and comorbidities, a survivor prognosis is more likely than the other two options.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 39% indicates some degree of left ventricular dysfunction, which increases her risk of pump failure. However, her overall clinical picture does not suggest an immediate risk of pump failure. Her NYHA Class II classification and controlled blood pressure suggest that her heart failure is not severe. Her medications are appropriate for heart failure management, and her laboratory results do not indicate severe kidney or liver dysfunction, which can contribute to pump failure. While pump failure is a possible outcome, it is less likely than survivor given the patient's relatively stable condition.

RANKING: 3. Sudden Cardiac Death
REASONING: Sudden cardiac death is less likely in this patient due to her relatively stable condition and controlled blood pressure. Her ECG impression shows a TPSV (paroxysmal supraventricular tachyarrhythmia), which is not typically associated with an increased risk of sudden cardiac death. Her LVEF of 39% is lower than normal, but it is not extremely low, and her other laboratory results do not indicate severe cardiac dysfunction. Her age and comorbidities increase her risk of cardiac events, but sudden cardiac death is less likely than pump failure or survivor given her stable condition and appropriate management of her heart failure."
267,267,P0444,"Age: 58
Gender: Male 
Weight: 115 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 52.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 3,47
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 149
Glucose (mmol/L): 5
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,91
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 1809.0
Protein (g/L): 64
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,14
Urea (mg/dL): 6,82
LVEF (%): 70.0
Medications: Calcium Channel Blocker, Angiotensin II Receptor Blocker, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely.

RANKING: 1. Survivor
REASONING: The patient has a relatively preserved left ventricular ejection fraction (LVEF) of 70%, which is within the normal range. The patient's New York Heart Association (NYHA) class II indicates that the patient experiences some limitations in physical activity but is still able to perform daily tasks without significant symptoms. The patient's blood pressure is well-controlled, and they are on appropriate medications, including a calcium channel blocker, angiotensin II receptor blocker, and loop diuretics. The patient's Pro-BNP level of 1809 ng/L is elevated, indicating some degree of heart failure, but it is not extremely high. The patient's troponin level is within normal limits, and there is no evidence of ventricular tachycardia or bradycardia on the ECG. The patient's weight is also within a relatively healthy range for their height. Considering these factors, the patient is likely to survive with appropriate management and lifestyle modifications.

RANKING: 2. Pump failure death
REASONING: The patient has a history of hypertensive cardiomyopathy and hypertension, which can lead to left ventricular dysfunction over time. The patient's creatinine level is elevated at 133.0 mol/L, indicating some degree of renal impairment, which is often seen in patients with heart failure. The patient's albumin level is slightly low at 36 g/L, which may indicate some degree of malnutrition or liver dysfunction. The patient's gamma-glutamil transpeptidase (GGT) level is elevated at 149 IU/L, which may indicate some degree of liver dysfunction. The patient's pro-BNP level is elevated, which is a marker of heart failure. However, the patient's LVEF is still preserved at 70%, and they are on appropriate medications for heart failure. While there is a risk of pump failure death, it is less likely given the patient's preserved LVEF and controlled blood pressure.

RANKING: 3. Sudden cardiac death
REASONING: The patient has a history of hypertensive cardiomyopathy and hypertension, which increases the risk of sudden cardiac death. However, the patient's LVEF is preserved at 70%, and there is no evidence of ventricular tachycardia or bradycardia on the ECG. The patient's troponin level is within normal limits, and there is no evidence of acute coronary syndrome. The patient's pro-BNP level is elevated, but it is not extremely high. While the patient's polymorphic ventricular extrasystoles may increase the risk of sudden cardiac death, it is not a strong indicator of high risk in this case. The patient's overall cardiovascular risk profile suggests that sudden cardiac death is the least likely outcome."
268,268,P0447,"Age: 71
Gender: Female 
Weight: 67 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 131/57 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 42
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 5,53
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,31
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 5038.0
Protein (g/L): 69
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,5
Urea (mg/dL): 9,32
LVEF (%): 13.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden Cardiac Death
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death (SCD). The patient's low left ventricular ejection fraction (LVEF) of 13% is also a strong indicator of high risk for SCD. Additionally, the presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia (VT) on the ECG further increases the risk of SCD. The patient's high level of brain natriuretic peptide (BNP) (5038 ng/L) also suggests advanced heart failure and increased risk of SCD.

RANKING: 2. Pump Failure Death
 REASONING: The patient's low LVEF, NYHA Class II, and history of dilated cardiomyopathy indicate that the patient is at high risk for pump failure death. The patient's high BNP level also suggests advanced heart failure. However, the patient is currently on beta blockers, statins, and an ACE inhibitor, which are standard treatments for heart failure and may help to slow disease progression.

RANKING: 3. Survivor
 REASONING: Although the patient's prognosis is guarded, the patient is currently on appropriate medical therapy for heart failure and dilated cardiomyopathy. The patient's LVEF is low, but the patient is not in NYHA Class III or IV, which suggests that the patient may be able to tolerate the current level of disease. The patient's ECG findings, while concerning, do not necessarily indicate an immediate risk of sudden cardiac death. Therefore, while the patient's prognosis is poor, it is possible that the patient may survive for several years with optimal medical management."
269,269,P0449,"Age: 64
Gender: Female 
Weight: 47 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 102/40 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 46
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 107.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 5,2
LDL (mmol/L): 1,63
Sodium (mEq/L): 130.0
Pro-BNP (ng/L): 105.0
Protein (g/L): 76
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,18
Urea (mg/dL): 9,98
LVEF (%): 35.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here are the three possible prognoses for the next few years, ordered from most likely to least likely, along with the reasoning behind each:

RANKING: 1. Survivor
REASONING: The patient is 64 years old with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure and poor prognosis. However, the patient is currently on beta blockers and an ACE inhibitor, which are standard treatments for heart failure and may help improve symptoms and outcomes. The LVEF of 35% indicates that the patient's heart is functioning below normal, but it is not extremely low. The absence of sustained ventricular tachycardia and other severe arrhythmias on the ECG is a positive sign. The patient's blood pressure is low, which may be a concern, but it is not extremely low. The patient's weight and height are both below average, which may be a reflection of malnutrition or muscle wasting, but it is not a strong predictor of mortality. The patient's creatinine level is elevated, indicating some kidney impairment, but it is not extremely high. The patient's albumin level is low, which can be a sign of malnutrition or liver disease, but it is not extremely low. Overall, while the patient has significant risk factors for poor outcomes, the current treatment and the absence of severe arrhythmias and other complications make a survivor prognosis more likely than the other two options.

RANKING: 2. Pump failure death
REASONING: The patient's LVEF of 35% indicates that the heart is not functioning at a high level, which increases the risk of pump failure. The patient's history of idiopathic dilated cardiomyopathy and the current treatment with beta blockers and an ACE inhibitor suggest that the patient is at risk for further cardiac deterioration. The patient's low blood pressure and elevated creatinine level may indicate that the heart is not pumping effectively, which can lead to pump failure. However, the patient's lack of severe arrhythmias and other complications makes pump failure less likely than sudden cardiac death.

RANKING: 3. Sudden cardiac death
REASONING: The patient's history of idiopathic dilated cardiomyopathy and the current LVEF of 35% increase the risk of sudden cardiac death. However, the absence of severe arrhythmias such as sustained ventricular tachycardia on the ECG and the patient's current treatment with beta blockers and an ACE inhibitor make sudden cardiac death less likely. The patient's low blood pressure and elevated creatinine level may indicate that the heart is not pumping effectively, but it is not a strong predictor of sudden cardiac death. The patient's low weight and height may be a reflection of malnutrition or muscle wasting, but it is not a strong predictor of sudden cardiac death. Overall, while the patient has significant risk factors for sudden cardiac death, the current treatment and the absence of severe arrhythmias make this prognosis less likely than the other two options."
270,270,P0450,"Age: 70
Gender: Female 
Weight: 94 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 106/45 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 36
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,43
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 333.0
Protein (g/L): 67
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,64
Urea (mg/dL): 5,99
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Sudden Cardiac Death, 2. Pump Failure Death, 3. Survivor

REASONING:

1. Sudden Cardiac Death (SCD): The patient has a history of ischemic dilated cardiomyopathy, which increases the risk of SCD. The low left ventricular ejection fraction (LVEF) of 30% indicates significant left ventricular dysfunction, further increasing the risk of SCD. Additionally, the presence of ventricular extrasystoles on the ECG suggests potential for malignant arrhythmias, which can lead to SCD. The patient's age and sex also contribute to an increased risk of SCD. The high level of B-type natriuretic peptide (BNP) of 333 ng/L also suggests increased ventricular wall stress and strain, which can increase the risk of arrhythmias.

2. Pump Failure Death: The patient's LVEF of 30% and history of ischemic dilated cardiomyopathy suggest that the patient is at risk for pump failure. However, the patient is currently on optimal medical therapy with beta blockers, ACE inhibitors, and statins, which may help stabilize the patient's condition. Additionally, the patient's NYHA Class II indicates that the patient is not severely symptomatic, which may indicate a slower progression of heart failure. While pump failure is still a concern, it is less likely than SCD due to the patient's current medical therapy and relatively mild symptoms.

3. Survivor: Given the patient's history of ischemic dilated cardiomyopathy, LVEF of 30%, and high BNP level, it is surprising that the patient is not more symptomatic. However, the patient's relatively low creatinine level and absence of significant electrolyte imbalances suggest that the patient's renal function is preserved, which may indicate a more stable clinical course. The patient's current medical therapy is also likely contributing to stabilization of the condition. While the patient is at risk for adverse outcomes, the combination of optimal medical therapy, preserved renal function, and relatively mild symptoms make survival more likely than the other two options.

It is essential to note that this prognosis is based on the provided data and may change with further clinical evaluation and monitoring."
271,271,P0451,"Age: 57
Gender: Female 
Weight: 64 kg
Height: 147 cm
NYHA Class: II
Blood Pressure: 89/53 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,36
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,55
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 1742.0
Protein (g/L): 68
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,93
Urea (mg/dL): 8,99
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the three possible prognoses as follows:

RANKING: 1. Survivor
 REASONING: The patient is 57 years old, which is considered relatively young for a patient with idiopathic dilated cardiomyopathy. The patient's NYHA Class II indicates that the patient is experiencing some symptoms of heart failure, but they are not severely limited in their physical activity. The patient is on a comprehensive treatment regimen that includes beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are all standard therapies for heart failure with reduced ejection fraction (HFrEF). The patient's LVEF of 20% is low, but it is not extremely low, and the patient's Pro-BNP level of 1742 ng/L is elevated, but not extremely high. The absence of troponin elevation and the presence of a normal TSH level suggest that there is no acute myocardial infarction or thyroid dysfunction contributing to the patient's condition. The patient's ECG shows non-sustained ventricular tachycardia, which is a concerning finding, but it is not an isolated finding, and the patient is on a beta blocker, which is a standard treatment for this condition. Overall, while the patient's prognosis is guarded, I believe that with continued medical therapy and close monitoring, the patient is likely to survive.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's LVEF of 20% puts them at increased risk for sudden cardiac death (SCD). The patient's Pro-BNP level of 1742 ng/L is also elevated, which is a marker of increased risk of SCD. The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for SCD. However, the patient is on a beta blocker, which is a standard treatment for reducing the risk of SCD in patients with HFrEF. The patient's age and sex are also factors that increase the risk of SCD, but the patient's relatively young age and the fact that they are on a comprehensive treatment regimen mitigate this risk to some extent. Overall, while the patient is at increased risk for SCD, I believe that this prognosis is less likely than survivor due to the patient's young age and comprehensive treatment regimen.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 20% and Pro-BNP level of 1742 ng/L suggest that the patient is at increased risk for pump failure death. However, the patient's NYHA Class II and the fact that they are on a comprehensive treatment regimen that includes diuretics and spironolactone, which are standard therapies for managing heart failure symptoms and reducing the risk of pump failure, suggest that the patient is unlikely to experience pump failure death in the near future. The patient's age and sex are also factors that increase the risk of pump failure death, but the patient's relatively young age and the fact that they are on a comprehensive treatment regimen mitigate this risk to some extent. Overall, while the patient is at increased risk for pump failure death, I believe that this prognosis is the least likely of the three due to the patient's comprehensive treatment regimen and relatively young age."
272,272,P0452,"Age: 51
Gender: Male 
Weight: 61 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 100/55 mmHg
Past Medical History: Other HF etiology, Diabetes
Albumin (g/L): 46
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,25
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 48
Glucose (mmol/L): 7,7
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4
LDL (mmol/L): 3,36
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2311.0
Protein (g/L): 78
T3 (pg/dL): 0,04
T4 (ng/L): 22
Troponin (ng/mL): 0,14
TSH (mIU/L): 0,742
Urea (mg/dL): 4,99
LVEF (%): 18.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: Survivor
 REASONING: The patient is 51 years old, with a history of heart failure (HF) and diabetes, which are both significant risk factors for cardiovascular disease. However, the patient is receiving appropriate medical therapy for heart failure, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor. The patient's LVEF (left ventricular ejection fraction) is severely reduced at 18%, which is a significant predictor of poor outcomes in heart failure patients. However, the patient's Pro-BNP level (2311.0 ng/L) is elevated, but not extremely high, which may indicate some degree of heart failure compensation. Additionally, the patient does not have any signs of severe electrolyte imbalances or acute coronary syndrome (troponin level is 0.14 ng/mL). The patient's weight is 61 kg, which is low, indicating possible malnutrition or muscle wasting, a common complication in advanced heart failure patients. The patient's TSH level is slightly low (0.742 mIU/L), which may be related to the use of spironolactone. Considering these factors, while the patient's prognosis is guarded, the combination of appropriate medical therapy and the lack of severe acute complications make a survivor prognosis more likely than the other two options.

RANKING: Sudden Cardiac Death
 REASONING: The patient has a history of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles, which are risk factors for sudden cardiac death (SCD). The patient's LVEF is severely reduced, and the Pro-BNP level is elevated, indicating significant heart failure. However, the patient is receiving beta blockers, which are known to reduce the risk of SCD in heart failure patients. The patient's troponin level is mildly elevated, but not extremely high, indicating possible ischemia or microinfarction. The patient's TSH level is slightly low, which may be related to the use of spironolactone. Considering these factors, the risk of SCD is significant, but the patient's medical therapy and the lack of severe acute complications make it less likely than pump failure death.

RANKING: Pump Failure Death
 REASONING: The patient has a severely reduced LVEF of 18%, which is a strong predictor of pump failure death in heart failure patients. The patient's Pro-BNP level is elevated, indicating significant heart failure. The patient's weight is low, indicating possible malnutrition or muscle wasting, which can contribute to pump failure. The patient's creatinine level is elevated at 97.0 mmol/L, indicating possible renal dysfunction, which can further exacerbate heart failure. The patient's glucose level is elevated at 7.7 mmol/L, which can also contribute to worsening heart failure. Considering these factors, the patient's risk of pump failure death is high, especially given the patient's severely reduced LVEF and elevated Pro-BNP level."
273,273,P0453,"Age: 58
Gender: Male 
Weight: 65 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 52
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 3,39
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 64
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 5,2
LDL (mmol/L): 1,24
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 868.0
Protein (g/L): 90
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,09
TSH (mIU/L): 2,8
Urea (mg/dL): 8,99
LVEF (%): 37.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: 1. Survivor
 REASONING: The patient has a complex medical history with multiple comorbidities, including ischemic dilated cardiomyopathy, diabetes, dyslipemia, and peripheral vascular disease. However, the patient is currently receiving optimal medical therapy for heart failure, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor. The patient's LVEF is 37%, which is low but not extremely low, and the Pro-BNP level is elevated at 868.0 ng/L, indicating some degree of heart failure. However, the patient's blood pressure is well-controlled, and there are no signs of severe electrolyte imbalances or renal dysfunction. The patient's glucose and lipid profiles are also relatively well-managed. Considering the patient's age and comorbidities, a survivor prognosis is the most likely outcome, given that the patient is receiving optimal medical therapy and there are no signs of acute decompensation.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF is 37%, which is a risk factor for heart failure progression and pump failure. The patient's Pro-BNP level is elevated, indicating some degree of heart failure. However, the patient is receiving optimal medical therapy for heart failure, which may slow the progression of the disease. The patient's blood pressure and glucose levels are well-controlled, which may also help mitigate the risk of pump failure. While the patient's comorbidities increase the risk of pump failure, the patient's current treatment regimen and relatively well-controlled comorbidities make this prognosis less likely than sudden cardiac death.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The patient's LVEF is 37%, which is a risk factor for sudden cardiac death. The patient's Pro-BNP level is elevated, indicating some degree of heart failure. However, the patient is receiving optimal medical therapy for heart failure, including beta blockers and an ICD (not mentioned but should be considered given the patient's history and risk factors), which may reduce the risk of sudden cardiac death. The patient's comorbidities and LVEF make sudden cardiac death a possible outcome, but the patient's current treatment regimen and relatively well-controlled comorbidities make this prognosis less likely than pump failure."
274,274,P0454,"Age: 52
Gender: Male 
Weight: 110 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 46
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 45.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 234
Glucose (mmol/L): 7,87
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,9
Potassium (mEq/L): 4,93
LDL (mmol/L): 1,91
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 690.0
Protein (g/L): 79
T3 (pg/dL): 0,0459
T4 (ng/L): 15,19
Troponin (ng/mL): 0,3
TSH (mIU/L): 3,07
Urea (mg/dL): 5,4
LVEF (%): 35.0
Medications: Diabetes Medication, Amiodarone, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: Survivor
REASONING: Despite the patient's advanced age, multiple comorbidities (ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction), and reduced left ventricular ejection fraction (LVEF) of 35%, the patient is currently receiving appropriate medical therapy for heart failure and other comorbid conditions. The patient is on a combination of medications, including ACE inhibitors, beta-blockers (digoxin), spironolactone, and statins, which are all evidence-based treatments for heart failure and ischemic heart disease. The patient's Pro-BNP level is elevated, but not extremely high, which may indicate that the patient's heart failure is being managed effectively. Additionally, the patient does not have any recent acute coronary syndromes or significant arrhythmias, which are often predictors of poor prognosis. While the patient's prognosis is guarded, the current treatment plan and the lack of acute decompensation suggest that survival for the next few years is the most likely outcome.

RANKING: Pump Failure Death
REASONING: The patient's reduced LVEF of 35% indicates significant left ventricular dysfunction, which is a risk factor for pump failure. The patient's ischemic dilated cardiomyopathy and history of myocardial infarction further increase the risk of pump failure. However, the patient's current treatment plan and the lack of acute decompensation suggest that pump failure is not the most likely immediate outcome. The patient's creatinine level is elevated, which may indicate some degree of renal impairment, but it is not extremely high, which may suggest that the patient's kidney function is still relatively preserved.

RANKING: Sudden Cardiac Death
REASONING: The patient's history of myocardial infarction, reduced LVEF, and the presence of ventricular extrasystoles on the ECG increase the risk of sudden cardiac death. However, the patient's current treatment plan, including the use of an implantable cardioverter-defibrillator (ICD) is not mentioned, which would be a standard recommendation for patients with reduced LVEF and history of myocardial infarction. Additionally, the patient's TSH level is within the normal range, which reduces the risk of atrial fibrillation, a common cause of sudden cardiac death. Overall, while sudden cardiac death is a possible outcome, it is less likely than pump failure, given the patient's current treatment plan and lack of acute decompensation."
275,275,P0455,"Age: 67
Gender: Male 
Weight: 64 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 47
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 244
Glucose (mmol/L): 9,2
Hemoglobin (g/L): 131.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 5,1
LDL (mmol/L): 3,59
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 8797.0
Protein (g/L): 80
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,58
Urea (mg/dL): 14,81
LVEF (%): 23.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here is my prognosis for the next few years:

RANKING: 1. Survivor
 REASONING: The patient is 67 years old with a history of enolic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension, which are all risk factors for heart failure. However, the patient is currently receiving treatment with beta blockers, digoxin, loop diuretics, and ACE inhibitors, which are standard medications for heart failure management. The patient's LVEF (left ventricular ejection fraction) is 23%, indicating a severely reduced ejection fraction, but it is stable. The patient's Pro-BNP level is high (8797.0 ng/L), which indicates increased stress on the heart, but it is not extremely high. The patient's hemoglobin level is within the normal range, which suggests that the patient is not experiencing severe anemia. The patient's weight is low at 64 kg, which may indicate malnutrition or muscle wasting, but it is not an uncommon finding in patients with heart failure. The patient's NYHA class is II, indicating that the patient is experiencing some limitations in physical activity but is still able to perform daily activities. Considering these factors, the patient's prognosis is likely to be a survivor, with ongoing management and treatment of the heart failure.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF is severely reduced at 23%, which is a strong indicator of heart failure. The patient's high Pro-BNP level and low hemoglobin level also suggest that the patient's heart is under significant stress. However, the patient's current treatment regimen and NYHA class suggest that the patient is being managed for heart failure, and the patient is still able to perform daily activities. The patient's age and comorbidities (diabetes, dyslipemia, and hypertension) also increase the risk of pump failure death. However, the patient's current condition is stable, and the patient's medications are likely to help manage the heart failure. Therefore, pump failure death is a possible but less likely outcome.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are both risk factors for sudden cardiac death. However, the patient's treatment regimen includes beta blockers, which are known to reduce the risk of sudden cardiac death. The patient's LVEF is severely reduced, which increases the risk of sudden cardiac death, but the patient's current treatment regimen and NYHA class suggest that the patient is being managed for heart failure. The patient's age and comorbidities also increase the risk of sudden cardiac death, but the patient's current condition is stable, and the patient's medications are likely to help manage the heart failure. Therefore, sudden cardiac death is the least likely outcome."
276,276,P0456,"Age: 38
Gender: Male 
Weight: 80 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 110/50 mmHg
Past Medical History: Post-myocardial dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 153.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 5,1
LDL (mmol/L): 2,33
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 47.0
Protein (g/L): 71
T3 (pg/dL): 0,07
T4 (ng/L): 15
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,19
Urea (mg/dL): 6,32
LVEF (%): 42.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. However, please note that a more accurate prognosis would require a comprehensive evaluation and assessment of the patient by a cardiologist. 

RANKING: Survivor

REASONING:

1. Survivor: The patient's current LVEF (Left Ventricular Ejection Fraction) is 42%, which is below the normal range (50-70%), indicating reduced cardiac function. However, the patient is on an ACE inhibitor, which is a standard treatment for heart failure and has been shown to improve LVEF and reduce mortality. The patient's Pro-BNP level is 47.0 ng/L, which is within the normal range (<50 ng/L), suggesting that the patient is not experiencing significant cardiac stress or strain. Additionally, the patient's Troponin level is normal, indicating minimal myocardial damage. The patient's ECG does not show any signs of ventricular tachycardia or other life-threatening arrhythmias. Considering these factors, the patient's prognosis for the next few years is likely to be a survivor.

2. Sudden Cardiac Death: While the patient has a history of post-myocardial dilated cardiomyopathy, the patient's current LVEF is not severely impaired, and the patient is on a standard treatment for heart failure. The patient's ECG does not show any signs of life-threatening arrhythmias. However, the patient's low HDL cholesterol level (1.32 mmol/L) and high LDL cholesterol level (2.33 mmol/L) may contribute to an increased risk of cardiac events. Additionally, the patient's low T3 level (0.07 pg/dL) may indicate hypothyroidism, which can be a risk factor for cardiac disease. However, the patient's TSH level is within the normal range, suggesting that the hypothyroidism is likely not severe. Considering these factors, the risk of sudden cardiac death is lower than the risk of pump failure death.

3. Pump Failure Death: The patient's LVEF is below the normal range, indicating reduced cardiac function. The patient's Creatinine level is elevated (80.0 mmol/L), which may indicate impaired kidney function, which can be a consequence of heart failure. The patient's Pro-BNP level is within the normal range, but the patient's low LVEF and elevated Creatinine level suggest that the patient's heart is working harder to compensate for the reduced cardiac function, which may lead to pump failure. However, the patient's treatment with an ACE inhibitor and the lack of severe symptoms (NYHA Class II) suggest that the patient's condition is being managed. Considering these factors, the risk of pump failure death is lower than the risk of sudden cardiac death.

Please note that this prognosis is based on the provided data and may not be accurate without a comprehensive evaluation and assessment by a cardiologist."
277,277,P0457,"Age: 48
Gender: Female 
Weight: 62 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 119.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,74
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 380.0
Protein (g/L): 72
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,06
TSH (mIU/L): 3,58
Urea (mg/dL): 11,48
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: Survivor
REASONING: The patient has a complex medical history with idiopathic dilated cardiomyopathy, hypertension, and dyslipemia. However, the patient is on a comprehensive treatment plan with beta blockers, digoxin, loop diuretics, spironolactone, statins, and ACE inhibitors. The patient's LVEF is 35%, indicating moderate heart failure. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles is concerning, but the absence of sustained ventricular tachycardia or bradycardia suggests that the patient's heart is still compensating. The patient's Pro-BNP level is elevated, indicating some degree of heart failure, but it is not extremely high. The patient's blood pressure is well-controlled, and the patient's electrolytes are within a relatively normal range. Given the patient's age and the fact that the patient is receiving optimal medical therapy, I believe that the patient has a good chance of survival over the next few years, but close monitoring and regular follow-ups will be necessary to adjust the treatment plan as needed.

RANKING: Pump Failure Death
REASONING: While the patient has a complex medical history and is at risk for pump failure, the patient's current treatment plan and relatively stable vital signs suggest that pump failure is not the most likely outcome. The patient's LVEF is 35%, which indicates moderate heart failure, but it is not extremely low. The patient's creatinine level is elevated, suggesting some degree of kidney dysfunction, but it is not severely elevated. The patient's Pro-BNP level is elevated, indicating some degree of heart failure, but it is not extremely high.

RANKING: Sudden Cardiac Death
REASONING: While the patient has a history of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, the absence of sustained ventricular tachycardia or bradycardia suggests that the patient's heart is still compensating. The patient's LVEF is 35%, which is relatively stable. The patient's blood pressure is well-controlled, and the patient's electrolytes are within a relatively normal range. The patient's TSH level is within a normal range, which suggests that the patient's thyroid function is stable. The patient's treatment plan includes beta blockers, which are effective in reducing the risk of sudden cardiac death. While sudden cardiac death is a possible outcome, it is not the most likely outcome given the patient's current treatment plan and relatively stable vital signs."
278,278,P0459,"Age: 65
Gender: Male 
Weight: 117 kg
Height: 181 cm
NYHA Class: II
Blood Pressure: 130/60 mmHg
Past Medical History: Other HF etiology, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 128.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,49
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 382.0
Protein (g/L): 72
T3 (pg/dL): 0,03
T4 (ng/L): 23
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,28
Urea (mg/dL): 10,82
LVEF (%): 38.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely, along with the reasoning behind each ranking:

RANKING: 1. Survivor
 REASONING: The patient is 65 years old with a history of myocardial infarction, hypertension, and diabetes, which are all significant risk factors for heart failure and cardiac mortality. However, the patient is currently on optimal medical therapy for heart failure, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor. The patient's LVEF is 38%, which is low but not extremely low, and the patient does not have any signs of acute decompensated heart failure (e.g., elevated creatinine, low albumin, or severe hypotension). The patient's pro-BNP level is elevated at 382.0 ng/L, but this is not unusually high for a patient with heart failure. The patient's ECG shows monomorphic ventricular extrasystoles, but this is not a significant concern in this context. Considering the patient's age, comorbidities, and current treatment, the most likely prognosis is survival, assuming the patient adheres to their medication regimen and makes lifestyle modifications to manage their heart failure.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of myocardial infarction, which increases the risk of sudden cardiac death (SCD). However, the patient's LVEF is 38%, which is low but not extremely low, and the patient is on optimal medical therapy for heart failure. The patient's ECG shows monomorphic ventricular extrasystoles, which may be a risk factor for SCD, but this is not a definitive predictor. The patient's TSH level is slightly elevated at 3.28 mIU/L, which may be a risk factor for cardiac arrhythmias, but this is not a significant concern in this context. The patient's pro-BNP level is elevated, which may indicate increased cardiac stress, but this is not a definitive predictor of SCD. Considering the patient's age, comorbidities, and current treatment, the risk of SCD is moderate but not extremely high.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF is 38%, which is low, indicating reduced cardiac function. The patient's creatinine level is elevated at 124.0 umol/L, indicating renal dysfunction, which is a common complication of heart failure. The patient's pro-BNP level is elevated, indicating increased cardiac stress. The patient's weight is 117 kg, which is above the normal range, and may indicate fluid overload. The patient's ECG shows monomorphic ventricular extrasystoles, which may be a sign of cardiac dysfunction. Considering the patient's low LVEF, renal dysfunction, and fluid overload, the risk of pump failure death is moderate to high. However, the patient is on optimal medical therapy for heart failure, which may mitigate this risk."
279,279,P0462,"Age: 54
Gender: Male 
Weight: 65 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 55.0
AST or GOT (IU/L): 39.0
Total Cholesterol (mmol/L): 7,96
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 167
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,97
Potassium (mEq/L): 3,7
LDL (mmol/L): 5,51
Sodium (mEq/L): 130.0
Pro-BNP (ng/L): 645.0
Protein (g/L): 79
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,35
Urea (mg/dL): 15,14
LVEF (%): 30.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden Cardiac Death, 2. Pump Failure Death, 3. Survivor

REASONING:

1.  Sudden Cardiac Death (SCD): The patient has a high risk of SCD due to his ischemic dilated cardiomyopathy (LVEF 30%), history of myocardial infarction, and ventricular extrasystole on ECG. The presence of ventricular extrasystole is a known risk factor for SCD. The patient's NYHA Class II indicates that he has moderate symptoms of heart failure, but the high LVEF and relatively low creatinine level suggest that he may not be in a state of advanced heart failure. However, the high Pro-BNP level (645.0 ng/L) and the presence of ventricular extrasystole on ECG suggest that the patient is at risk for SCD.

2.  Pump Failure Death: The patient has a history of ischemic dilated cardiomyopathy with an LVEF of 30%, indicating that his heart is not pumping efficiently. The high creatinine level (106.0 mmol/L) suggests that the patient has renal impairment, which is a common complication of heart failure. The presence of diabetes, hypertension, and peripheral vascular disease further increases the risk of pump failure. However, the patient's relatively low weight (65 kg) and low blood pressure (150/90 mmHg) may mitigate this risk.

3.  Survivor: The patient's overall clinical picture suggests that he is at high risk for cardiac complications. However, the fact that he is currently alive and on a regimen of medications (Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Nitrovasodilator) that are commonly used to manage heart failure and reduce the risk of SCD suggests that he may be able to survive for the next few years with proper management. The patient's TSH level is within the normal range, and his hemoglobin level is high, which may indicate that he is not experiencing significant anemia or malnutrition.

In summary, while the patient is at high risk for cardiac complications, his current survival status suggests that he may be able to survive for the next few years with proper management. However, the high risk of SCD and pump failure death cannot be ruled out."
280,280,P0463,"Age: 67
Gender: Female 
Weight: 60 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 142/61 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 39
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 126.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,15
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2853.0
Protein (g/L): 67
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,56
Urea (mg/dL): 7,32
LVEF (%): 47.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient is a 67-year-old female with a history of idiopathic dilated cardiomyopathy, which is a significant underlying condition. However, her current medications (Angiotensin II Receptor Blocker, Beta Blockers, and Loop Diuretics) are appropriate for managing heart failure and are likely helping to manage her symptoms. Her LVEF (Left Ventricular Ejection Fraction) is 47%, which is lower than the normal range (50-70%), but it's not extremely low. Her NYHA Class II indicates that she has some limitations in physical activity but is still able to perform daily tasks without severe symptoms. Her Pro-BNP level is elevated at 2853.0 ng/L, which suggests that she has some degree of heart failure, but it's not extremely high. Additionally, her other laboratory values, such as creatinine and urea levels, are within a relatively normal range, indicating that her kidney function is not severely impaired. Overall, while her prognosis is guarded, her current treatment and relatively stable laboratory values suggest that she has a reasonable chance of survival.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF is 47%, which is lower than the normal range, indicating that her heart is not pumping efficiently. Her Pro-BNP level is elevated, which is consistent with heart failure. However, her other laboratory values and medications suggest that her condition is being managed. While pump failure is a possible outcome, the patient's relatively stable condition and current treatment make this prognosis less likely than sudden cardiac death.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which increases her risk of sudden cardiac death. Her LVEF is 47%, which is lower than the normal range, and her Pro-BNP level is elevated, which suggests that she has some degree of heart failure. Additionally, her ECG shows ventricular extrasystole and non-sustained ventricular tachycardia, which are risk factors for sudden cardiac death. However, her current medications and relatively stable condition suggest that her risk of sudden cardiac death may be mitigated. Overall, while sudden cardiac death is a possible outcome, the patient's current treatment and relatively stable condition make this prognosis the least likely."
281,281,P0464,"Age: 52
Gender: Male 
Weight: 69 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,57
Creatinine (mmol/L): 53.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,45
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,53
Sodium (mEq/L): 133.0
Protein (g/L): 73
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,03
Urea (mg/dL): 5,49
LVEF (%): 30.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: 1. Survivor
 REASONING: The patient is 52 years old with a history of valvular cardiomyopathy, which is a significant risk factor for heart failure. However, the patient's current NYHA Class II indicates that they are experiencing some symptoms, but they are still able to perform daily activities with some limitation. The patient's LVEF of 30% suggests severe left ventricular dysfunction, but they are on appropriate medications (Beta Blockers, Spironolactone, ACE Inhibitor) which can help manage their condition. The absence of troponin elevation and the presence of a normal hemoglobin level are also positive signs. Additionally, the patient does not have any recent history of cardiac arrhythmias, which reduces the risk of sudden cardiac death. Considering these factors, a survivor prognosis is the most likely outcome.

RANKING: 2. Sudden cardiac death
 REASONING: The patient's polymorphic ventricular extrasystole on ECG is a concerning sign, as it may indicate underlying cardiac electrical instability. However, the absence of sustained ventricular tachycardia and non-sustained ventricular tachycardia (CH>10) reduces the risk of sudden cardiac death. The patient's NYHA Class II and LVEF of 30% also suggest that they are at risk for cardiac events, but their current medications and lack of other high-risk features make sudden cardiac death less likely.

RANKING: 3. Pump failure death
 REASONING: The patient's LVEF of 30% and NYHA Class II suggest that they are at risk for pump failure, but their current medications and lack of other high-risk features make pump failure death the least likely outcome. The patient's creatinine level of 53.0 mol/L is elevated, indicating some degree of renal dysfunction, but it is not at a level that would suggest advanced kidney disease. The patient's albumin level is also within the normal range, which suggests that they do not have significant liver dysfunction. Overall, while pump failure is a possibility, it is the least likely outcome given the patient's current status and treatment."
282,282,P0465,"Age: 69
Gender: Male 
Weight: 80 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,21
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,19
LDL (mmol/L): 1,58
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 799.0
Protein (g/L): 70
T3 (pg/dL): 0,0597
T4 (ng/L): 9,9
Troponin (ng/mL): 0,5
TSH (mIU/L): 0,73
Urea (mg/dL): 7,4
LVEF (%): 30.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient is already on a comprehensive treatment regimen, including beta blockers, digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor, which suggests that the healthcare team is actively managing the patient's idiopathic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension. The patient's NYHA Class II indicates that the patient's symptoms are not limiting their daily activities, but they may experience some limitations. The LVEF of 30% is relatively low, but the patient's age and other factors suggest that they may still be able to tolerate this level of heart function. The absence of severe electrolyte imbalances, anemia, or significant renal dysfunction also supports a more favorable prognosis. Additionally, the patient's troponin level is within normal limits, which suggests that there is no ongoing myocardial damage. While the patient has a history of ventricular extrasystoles and non-sustained ventricular tachycardia, the absence of sustained ventricular tachycardia or other severe arrhythmias is a positive sign.

RANKING: 2. Pump failure death
REASONING: The patient's LVEF of 30% indicates that they have significant left ventricular dysfunction, which increases the risk of pump failure. However, the patient's current treatment regimen and the absence of severe symptoms (NYHA Class II) suggest that they are not yet experiencing severe pump failure. The patient's creatinine level is elevated, but it is not significantly elevated, which suggests that renal function is not severely impaired. Additionally, the patient's blood pressure is well-controlled, which reduces the risk of further cardiac strain.

RANKING: 3. Sudden cardiac death
REASONING: While the patient has a history of ventricular extrasystoles and non-sustained ventricular tachycardia, the absence of sustained ventricular tachycardia or other severe arrhythmias reduces the risk of sudden cardiac death. The patient's LVEF of 30% and history of idiopathic dilated cardiomyopathy increase the risk of sudden cardiac death, but the patient's current treatment regimen and the absence of other high-risk factors (e.g., severe electrolyte imbalances, anemia) make this prognosis less likely."
283,283,P0470,"Age: 73
Gender: Male 
Weight: 71 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 33,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 3,18
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 120.0
HDL (mmol/L): 0,87
Potassium (mEq/L): 3,65
LDL (mmol/L): 1,91
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 5374.0
Protein (g/L): 69
Troponin (ng/mL): 0,05
TSH (mIU/L): 0,68
Urea (mg/dL): 7,1
LVEF (%): 35.0
Medications: Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Survivor
REASONING: The patient's current condition and medical history suggest that they are at risk for cardiac events, but there are several factors that indicate a relatively favorable prognosis. The patient is on optimal medical therapy with loop diuretics, statins, and an ACE inhibitor, which are standard treatments for heart failure and hypertension. The patient's blood pressure is well-controlled, and their albumin and hemoglobin levels are within normal limits. The LVEF (Left Ventricular Ejection Fraction) is 35%, which is low but not extremely low, and the patient does not have any signs of severe electrolyte imbalances or acute kidney injury. The Pro-BNP level is elevated, but not extremely high, indicating some degree of heart failure, but not severe. Additionally, the patient's Troponin level is low, indicating no recent myocardial infarction. Considering these factors, the patient's overall prognosis is more likely to be a survivor, especially with ongoing medical management and monitoring.

RANKING: Pump Failure Death
REASONING: The patient's low LVEF (35%) and elevated Pro-BNP level suggest that they have heart failure with reduced ejection fraction, which is a risk factor for pump failure. However, the patient's overall condition is not as severe as some other patients with similar LVEF, and they are on optimal medical therapy. The patient's creatinine level is slightly elevated, but not extremely high, indicating some degree of kidney dysfunction, which is common in patients with heart failure. The patient's Troponin level is low, indicating no recent myocardial infarction, and their blood pressure is well-controlled. While pump failure is a possible outcome, it is less likely compared to sudden cardiac death due to the patient's relatively stable condition and ongoing medical management.

RANKING: Sudden Cardiac Death
REASONING: The patient's low LVEF (35%) and elevated Pro-BNP level suggest that they have heart failure with reduced ejection fraction, which is a risk factor for sudden cardiac death. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the patient's overall condition is not as severe as some other patients with similar ECG findings, and they are on optimal medical therapy. The patient's Troponin level is low, indicating no recent myocardial infarction, and their blood pressure is well-controlled. While sudden cardiac death is a possible outcome, it is the least likely of the three options due to the patient's relatively stable condition and ongoing medical management."
284,284,P0471,"Age: 74
Gender: Male 
Weight: 76 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 33,8
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,71
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,36
Potassium (mEq/L): 4,05
LDL (mmol/L): 3,85
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 557.0
Protein (g/L): 57,7
Troponin (ng/mL): 0,02
TSH (mIU/L): 0,37
Urea (mg/dL): 6,8
LVEF (%): 70.0
Medications: Calcium Channel Blocker
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor, 2. Pump failure death, 3. Sudden cardiac death

REASONING:

Based on the provided patient data, I rank the prognoses as follows:

1. Survivor: The patient's LVEF (Left Ventricular Ejection Fraction) is 70%, which is within the normal range (>55%). This indicates that the patient's heart is functioning relatively well. The patient's blood pressure is well-controlled, and the patient is on a calcium channel blocker, which is a common medication for hypertension and heart disease. The patient's Troponin level is 0.02 ng/mL, which is within the normal range, indicating no acute myocardial infarction. The Pro-BNP level is 557.0 ng/L, which is slightly elevated but not excessively high, indicating some degree of heart failure but not severe. The patient's overall condition suggests that the heart is functioning well enough to support the body's needs, making survival likely.

2. Pump failure death: The patient has a history of hypertensive cardiomyopathy and hypertension, which can lead to heart failure. The elevated Pro-BNP level (557.0 ng/L) and slightly low albumin level (33.8 g/L) suggest some degree of heart failure. However, the patient's LVEF is still within the normal range, and the patient's blood pressure is well-controlled. The patient's overall condition is not severe enough to indicate imminent pump failure death.

3. Sudden cardiac death: The patient has a history of ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the patient's LVEF is within the normal range, and there is no evidence of sustained ventricular tachycardia or other conditions that would increase the risk of sudden cardiac death. The patient's blood pressure is well-controlled, and the patient is on a medication that can help prevent arrhythmias. While the patient's ventricular extrasystoles are a concern, the overall risk of sudden cardiac death is relatively low compared to the other two prognoses.

In conclusion, based on the patient's data, the most likely prognosis is survival, followed by pump failure death, and then sudden cardiac death."
285,285,P0472,"Age: 83
Gender: Male 
Weight: 67 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 105/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 42,7
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 55
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 3,62
LDL (mmol/L): 1,84
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 4579.0
Protein (g/L): 74,9
Troponin (ng/mL): 0,09
TSH (mIU/L): 0,96
Urea (mg/dL): 12,2
LVEF (%): 60.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: Survivor

REASONING: 

Based on the provided patient data, I rank the prognosis as Survivor for the following reasons:

1.  The patient's age (83) is advanced, but not extremely high, and the presence of ischemic dilated cardiomyopathy, diabetes, and hypertension are significant risk factors for cardiovascular disease. However, the patient is currently in NYHA Class II, which indicates that they are able to perform ordinary physical activity without symptoms, and their LVEF is 60%, which is relatively preserved.

2.  The patient's laboratory results show a slightly elevated Pro-BNP level (4579.0 ng/L), which indicates some level of heart failure, but it is not extremely high. The creatinine level (125.0 mmol/L) is slightly elevated, suggesting some degree of renal impairment, which can be a consequence of heart failure.

3.  The patient is on a regimen of Calcium Channel Blocker, Digoxin, Loop Diuretics, and ACE Inhibitor, which are standard treatments for heart failure and hypertension. This suggests that the patient is receiving appropriate medical management for their conditions.

4.  The ECG impression shows a ventricular extrasystole, but no signs of sustained ventricular tachycardia or bradycardia. This is a relatively benign finding in this context.

5.  Considering the patient's age, comorbidities, and current treatment, the risk of sudden cardiac death (SCD) is relatively low, as the patient does not have a history of arrhythmias or significant structural heart disease that would increase the risk of SCD.

6.  Pump failure death is a possible outcome, given the patient's history of ischemic dilated cardiomyopathy and heart failure. However, the patient's LVEF is 60%, which is relatively preserved, and they are on appropriate medical management, which reduces the likelihood of pump failure.

7.  Given the patient's overall profile, I believe that the most likely outcome is survival, as they are receiving appropriate medical management for their conditions and do not have a high risk of sudden cardiac death or pump failure.

However, it is essential to note that the patient's prognosis can change over time, and regular monitoring and adjustments to their treatment plan will be necessary to ensure the best possible outcome."
286,286,P0474,"Age: 49
Gender: Male 
Weight: 88 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45,9
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,88
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 137.0
Potassium (mEq/L): 4,17
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 797.0
Protein (g/L): 82,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,33
Urea (mg/dL): 9
LVEF (%): 19.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely. Here's my analysis:

RANKING: Survivor

REASONING: The patient is 49 years old, which is relatively young for a patient with idiopathic dilated cardiomyopathy. Despite a low left ventricular ejection fraction (LVEF) of 19%, the patient is on optimal medical therapy with beta blockers, loop diuretics, spironolactone, and an ACE inhibitor. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG is also a positive sign. Additionally, the patient's pro-BNP level is elevated (797.0 ng/L), which is consistent with heart failure, but not excessively high, indicating that the patient's condition is being managed. The patient's weight is 88 kg, which is not excessively high, and their hemoglobin level is within normal limits. While the patient's creatinine level is elevated (100.0 mmol/L), it is not extremely high, and the patient's urea level is within normal limits. Overall, these factors suggest that the patient's condition is being well-managed, and they are likely to survive.

RANKING: Pump Failure Death

REASONING: The patient's LVEF of 19% indicates severe left ventricular dysfunction, which increases the risk of pump failure death. However, the patient is on optimal medical therapy, and their creatinine level, while elevated, is not excessively high. The patient's pro-BNP level is also elevated, but not excessively high, which suggests that the patient's condition is being managed. The patient's weight is not excessively high, and their hemoglobin level is within normal limits. While the patient's condition is severe, the fact that they are on optimal medical therapy and do not have any acute complications suggests that pump failure death is less likely.

RANKING: Sudden Cardiac Death

REASONING: The patient's ECG shows monomorphic ventricular extrasystoles, but no ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia. This suggests that the patient's arrhythmias are not as severe as they could be. The patient's LVEF is low, but they are on optimal medical therapy, which reduces the risk of sudden cardiac death. The patient's pro-BNP level is elevated, but not excessively high, which suggests that the patient's condition is being managed. While the patient's condition is severe, the fact that they are on optimal medical therapy and do not have any acute complications suggests that sudden cardiac death is the least likely outcome."
287,287,P0475,"Age: 64
Gender: Female 
Weight: 73 kg
Height: 145 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 43,2
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,59
Creatinine (mmol/L): 149.0
Gamma-glutamil transpeptidase (IU/L): 46
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,38
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,33
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 287.0
Protein (g/L): 77,6
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,88
Urea (mg/dL): 15
LVEF (%): 35.0
Medications: Diabetes Medication, Amiodarone, Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: 1. Survivor
 REASONING: Based on the provided patient data, the patient has a relatively high risk of adverse cardiac events due to her history of idiopathic dilated cardiomyopathy, diabetes, and hypertension. However, the patient is currently on a comprehensive treatment regimen that includes medications for her conditions, such as ACE inhibitors (Angiotensin II Receptor Blocker), beta-blockers (Amiodarone), diuretics, and statins. The patient's NYHA Class II classification indicates that she is experiencing some symptoms of heart failure, but they are not limiting her daily activities.

The patient's LVEF of 35% is within the range of severe systolic heart failure, but it is not as low as some other patients with dilated cardiomyopathy. The patient's eGFR (estimated glomerular filtration rate) is not explicitly mentioned, but her creatinine level is elevated at 149.0 mol/L, indicating some degree of renal impairment. However, her urea level is only slightly elevated at 15 mg/dL, which may indicate some degree of renal compensation.

The patient's pro-BNP level of 287 ng/L is elevated, which is consistent with heart failure. However, the patient's troponin level is within the normal range, indicating that there is no acute coronary syndrome.

Considering these factors, the patient's overall prognosis is guarded but not hopeless. With proper management and adherence to her medication regimen, the patient may be able to slow the progression of her heart failure and avoid sudden cardiac death or pump failure death. The patient's age and sex are also factors that contribute to a higher risk of adverse cardiac events, but her current treatment plan and relatively stable clinical status make a survivor prognosis the most likely outcome.

RANKING: 2. Sudden Cardiac Death
 REASONING: Sudden cardiac death is a possible outcome for this patient due to her history of idiopathic dilated cardiomyopathy and the presence of ventricular extrasystoles on her ECG. The patient's LVEF of 35% also puts her at risk for sudden cardiac death. However, the patient is currently on Amiodarone, which is an antiarrhythmic medication that can help prevent sudden cardiac death.

The patient's relatively stable clinical status and lack of recent cardiac events make sudden cardiac death less likely than pump failure death. Additionally, the patient's ejection fraction is not as low as some patients who are at higher risk for sudden cardiac death.

RANKING: 3. Pump Failure Death
 REASONING: Pump failure death is a possible outcome for this patient due to her history of idiopathic dilated cardiomyopathy and the presence of severe systolic heart failure (LVEF 35%). The patient's elevated pro-BNP level and slightly elevated creatinine level also indicate that her heart failure is not well-compensated. However, the patient is currently on a comprehensive treatment regimen that includes medications that can help slow the progression of heart failure, such as ACE inhibitors, beta-blockers, and diuretics.

The patient's relatively stable clinical status and lack of recent cardiac events make pump failure death less likely than sudden cardiac death. Additionally, the patient's ejection fraction is not as low as some patients who are at higher risk for pump failure death."
288,288,P0476,"Age: 64
Gender: Male 
Weight: 93 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 103/57 mmHg
Past Medical History: Other HF etiology, Dyslipemia
Albumin (g/L): 41,8
ALT or GPT (IU/L): 37.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,48
Creatinine (mmol/L): 111.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 151.0
HDL (mmol/L): 2,09
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,82
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 146.0
Protein (g/L): 68,2
T4 (ng/L): 20
TSH (mIU/L): 1,55
Urea (mg/dL): 10,48
LVEF (%): 38.0
Medications: Calcium Channel Blocker, Amiodarone, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely:

RANKING: 1. Survivor
 REASONING: The patient's current treatment regimen, including Calcium Channel Blocker, Amiodarone, Beta Blockers, Statins, ACE Inhibitor, and Nitrovasodilator, suggests that the patient's heart failure symptoms are being managed, and the patient is receiving optimal treatment for their condition. The patient's LVEF of 38% is below the normal range (50-70%), but it is not extremely low. The patient's NYHA Class II indicates that the patient has some limitations in physical activity but is still able to perform daily tasks without symptoms. The patient's Pro-BNP level of 146.0 ng/L is elevated, but not excessively high, indicating some degree of heart failure, but not severe. The patient's overall clinical picture suggests that they are stable and likely to survive with continued treatment and management of their condition.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's LVEF of 38% and the presence of polymorphic ventricular extrasystoles on the ECG suggest an increased risk of arrhythmias, which can be a risk factor for sudden cardiac death. However, the patient's current treatment regimen includes Amiodarone, which is a medication that can help prevent arrhythmias. The patient's overall clinical picture suggests that sudden cardiac death is a possible but less likely outcome compared to survivor.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 38% indicates some degree of left ventricular dysfunction, which can increase the risk of pump failure. However, the patient's current treatment regimen includes ACE Inhibitor and Beta Blockers, which are medications that can help slow the progression of heart failure. The patient's NYHA Class II indicates that the patient is still able to perform daily tasks without symptoms, suggesting that pump failure is not imminent. Additionally, the patient's Pro-BNP level of 146.0 ng/L is not excessively high, indicating that the patient's heart failure symptoms are not severe. Overall, while pump failure is a possible outcome, it is the least likely of the three based on the patient's current clinical picture."
289,289,P0478,"Age: 80
Gender: Male 
Weight: 63 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 44,4
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,91
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1544.0
Protein (g/L): 73,4
T4 (ng/L): 19
TSH (mIU/L): 0,38
Urea (mg/dL): 8,82
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Survivor
 REASONING: The patient is 80 years old with a history of idiopathic dilated cardiomyopathy, diabetes, and dyslipemia. However, the patient's current NYHA Class II indicates that they are still relatively stable and can perform most physical activities without symptoms. The LVEF of 40% suggests that the patient's heart function is moderately impaired but not severely compromised. The patient is on medications that are appropriate for their condition, including beta blockers, loop diuretics, and an ACE inhibitor. The absence of paroxysmal supraventricular tachyarrhythmia and bradycardia on the ECG also suggests that the patient's cardiac rhythm is relatively stable. Additionally, the patient's low sodium and high potassium levels may indicate mild renal impairment, but the creatinine level is not severely elevated. While the high Pro-BNP level suggests heart failure, the patient's overall clinical picture and medication regimen suggest that they are being effectively managed.

RANKING: Sudden Cardiac Death
 REASONING: The patient's history of idiopathic dilated cardiomyopathy, diabetes, and dyslipemia increases their risk of sudden cardiac death. The presence of non-sustained ventricular tachycardia on the ECG is a risk factor for sudden cardiac death. However, the patient's LVEF of 40% and NYHA Class II suggest that they are not in a high-risk category for sudden cardiac death. The patient's medications, including beta blockers and an ACE inhibitor, may also help reduce the risk of sudden cardiac death.

RANKING: Pump Failure Death
 REASONING: The patient's LVEF of 40% and high Pro-BNP level suggest that they are at risk for pump failure. However, the patient's NYHA Class II and stable clinical picture suggest that they are not in an advanced stage of heart failure. The patient's renal function, as indicated by the creatinine level, is not severely impaired, which suggests that they are not at high risk for pump failure. The patient's medications, including loop diuretics and an ACE inhibitor, are appropriate for managing heart failure and may help prevent pump failure."
290,290,P0479,"Age: 72
Gender: Male 
Weight: 54 kg
Height: 151 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 40
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,67
Creatinine (mmol/L): 129.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,41
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,49
Potassium (mEq/L): 4,5
LDL (mmol/L): 4,48
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 624.0
Protein (g/L): 67
T3 (pg/dL): 0,0615
T4 (ng/L): 11,73
Troponin (ng/mL): 0,8
TSH (mIU/L): 6,94
Urea (mg/dL): 11,9
LVEF (%): 30.0
Medications: Amiodarone, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: Based on the provided patient data, I would rank the prognosis as Survivor for the next few years. Here's the reasoning behind this ranking:

1. Idiopathic dilated cardiomyopathy: The patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened, leading to a decrease in its pumping efficiency. This condition is a significant risk factor for cardiac mortality.
2. Low LVEF (30.0%): The patient's left ventricular ejection fraction (LVEF) is significantly low, indicating poor cardiac function. An LVEF below 35% is generally considered a high-risk indicator for adverse cardiac outcomes.
3. High Pro-BNP (624.0 ng/L): The patient's B-type natriuretic peptide (BNP) level is elevated, which is a marker of cardiac stress and strain. High BNP levels are associated with increased mortality and morbidity in heart failure patients.
4. Non-sustained ventricular tachycardia (CH>10): The patient has a history of non-sustained ventricular tachycardia, which is a type of abnormal heart rhythm that can increase the risk of sudden cardiac death.
5. Medications: The patient is on Amiodarone, Loop Diuretics, and ACE Inhibitor, which are medications commonly used to manage heart failure and arrhythmias. While these medications can help manage symptoms and slow disease progression, they do not address the underlying condition.

However, there are also factors that suggest a more favorable prognosis:

1. NYHA Class II: The patient's New York Heart Association (NYHA) functional class is II, indicating that the patient has mild to moderate symptoms of heart failure, which is a better prognosis compared to those with more severe symptoms (Class III or IV).
2. Hemoglobin (g/L) is within normal range: The patient's hemoglobin level is within the normal range, which is a positive indicator of overall health.
3. TSH (mIU/L) is within normal range: The patient's thyroid-stimulating hormone (TSH) level is within the normal range, which suggests that the patient's thyroid function is not contributing to cardiac dysfunction.
4. Patient is on ACE Inhibitor: The patient is on an ACE inhibitor, which is a medication that can help slow disease progression in heart failure patients.

Considering these factors, while the patient's condition is concerning, the overall prognosis is still more likely to be a Survivor due to the presence of some positive indicators and the fact that the patient is on appropriate medications. However, close monitoring and regular follow-up appointments are essential to adjust the treatment plan as needed and manage the patient's condition effectively.

Sudden cardiac death is a possible but less likely outcome, given the patient's current treatment and relatively stable condition.

Pump failure death is the least likely outcome, given the patient's current treatment and the fact that they are not in a more advanced stage of heart failure (NYHA Class IV)."
291,291,P0484,"Age: 74
Gender: Female 
Weight: 83 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 46
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 9,4
Hemoglobin (g/L): 118.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,43
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 146.0
Protein (g/L): 77,5
T4 (ng/L): 6
TSH (mIU/L): 34,49
Urea (mg/dL): 6,82
LVEF (%): 35.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses for the next few years as follows:

RANKING: 1. Survivor, 2. Pump Failure Death, 3. Sudden Cardiac Death

REASONING:

1. Survivor: The patient is 74 years old with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure. However, her NYHA Class II suggests that she has mild to moderate symptoms of heart failure, which is a relatively favorable prognostic indicator. Her LVEF of 35% is low, but she is on optimal medical therapy with beta blockers, loop diuretics, and spironolactone, which are all evidence-based treatments for heart failure. Her Pro-BNP level is elevated at 146.0 ng/L, indicating some degree of cardiac stress, but not excessively high. Additionally, her creatinine level is within normal limits, and her hemoglobin is slightly low but not critically low. Considering these factors, I believe that with proper management and adherence to her medication regimen, she has a reasonable chance of survival.

2. Pump Failure Death: The patient's LVEF of 35% indicates significant left ventricular dysfunction, which increases her risk of heart failure progression. Her NYHA Class II suggests that she has some symptoms, but her overall functional capacity is relatively preserved. However, her elevated Pro-BNP level and low hemoglobin level suggest some degree of cardiac stress and potential for further decline. If her heart failure progresses, she may experience worsening symptoms, decreased functional capacity, and potentially life-threatening complications. While not the most likely outcome, pump failure death remains a significant risk if her heart failure worsens.

3. Sudden Cardiac Death: The patient has a history of idiopathic dilated cardiomyopathy, which increases her risk of sudden cardiac death. Her ECG shows polymorphic ventricular extrasystoles, which can be a marker of increased risk of arrhythmias. However, she does not have any other high-risk features such as a history of ventricular tachycardia, bradycardia, or other arrhythmias. While sudden cardiac death is a potential risk, her overall risk profile is not as high as the other two options. Her low risk of sudden cardiac death is also supported by her being on beta blockers, which are known to reduce the risk of sudden cardiac death in patients with heart failure.

In summary, while all three outcomes are possible, I believe that the patient has a relatively good prognosis for survival with proper management and adherence to her medication regimen, followed by a risk of pump failure death if her heart failure progresses, and the least likely outcome being sudden cardiac death."
292,292,P0485,"Age: 72
Gender: Male 
Weight: 78 kg
Height: 161 cm
NYHA Class: III
Blood Pressure: 160/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 42,9
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,37
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 106
Glucose (mmol/L): 9,7
Hemoglobin (g/L): 122.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,91
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 903.0
Protein (g/L): 70
T4 (ng/L): 17
TSH (mIU/L): 1,44
Urea (mg/dL): 7,65
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden Cardiac Death (SCD), 2. Pump Failure Death, 3. Survivor

REASONING:

1. Sudden Cardiac Death (SCD): The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for SCD. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 35%, indicating poor heart function. Additionally, the patient's high level of B-type natriuretic peptide (BNP) at 903 ng/L suggests increased ventricular stress and potential for arrhythmias. The presence of polymorphic ventricular extrasystoles on the ECG further increases the risk of SCD. Considering these factors, SCD is the most likely prognosis.

2. Pump Failure Death: The patient's LVEF is severely reduced, and the patient has a history of myocardial infarction, which can lead to further cardiac damage and progression of heart failure. The patient's NYHA Class III classification indicates severe symptoms of heart failure, and the patient is likely experiencing significant functional limitations. While pump failure is a possible outcome, the patient's current medication regimen, including ACE inhibitors, beta-blockers, and spironolactone, may help manage symptoms and slow disease progression. However, the patient's overall risk profile and LVEF suggest that pump failure is still a plausible prognosis.

3. Survivor: While the patient's current medical condition is concerning, there are several factors that suggest a survivor prognosis is possible. The patient is on a comprehensive medication regimen, which includes medications that can help manage heart failure symptoms and reduce the risk of SCD. The patient's TSH level is within the normal range, indicating that thyroid function is not contributing to heart failure symptoms. Additionally, the patient's hemoglobin level is within the normal range, which suggests that anemia is not a contributing factor to heart failure. While the patient's prognosis is guarded, the comprehensive treatment plan and the patient's relatively stable laboratory values suggest that survival is still possible.

Please note that this prognosis is based on the provided data and should be reevaluated and refined as new information becomes available."
293,293,P0486,"Age: 68
Gender: Male 
Weight: 83 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 48,1
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 74.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,79
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 471.0
Protein (g/L): 78,9
T4 (ng/L): 19
TSH (mIU/L): 0,91
Urea (mg/dL): 5,32
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: Survivor

REASONING: Based on the provided patient data, I rank the prognosis as a survivor for the next few years. Here's the reasoning:

1. Age and comorbidities: The patient is 68 years old with a history of idiopathic dilated cardiomyopathy, diabetes, and dyslipemia, which are significant risk factors for cardiovascular disease. However, the patient's age is not extremely high, and the presence of these comorbidities is well-managed with medications.
2. NYHA Class II: The patient's New York Heart Association (NYHA) functional class is II, indicating that the patient has some limitations in physical activity but is still able to perform everyday activities. This suggests that the patient's heart failure is not severely symptomatic.
3. Medications: The patient is on beta blockers, loop diuretics, statins, and an ACE inhibitor, which are all evidence-based treatments for heart failure and hypertension. These medications are likely helping to manage the patient's symptoms and slow disease progression.
4. ECG findings: While the patient has ventricular extrasystoles, non-sustained ventricular tachycardia, and unknown paroxysmal supraventricular tachyarrhythmia, these findings are not necessarily indicative of an imminent risk of sudden cardiac death. Non-sustained ventricular tachycardia is a common finding in patients with heart failure and is often managed with medications.
5. LVEF: The patient's left ventricular ejection fraction (LVEF) is 40%, which is below the normal range but not extremely low. While an LVEF of 40% indicates heart failure with reduced ejection fraction (HFrEF), it is not as severe as an LVEF of 20-30%.
6. Biomarkers: The patient's Pro-BNP level is elevated, but not extremely high (471 ng/L). Elevated Pro-BNP levels are associated with increased risk of heart failure hospitalization and mortality, but the level is not so high that it suggests an imminent risk of sudden cardiac death.

Considering these factors, I believe that the patient's prognosis is more likely to be a survivor, with a good chance of managing their symptoms and preventing further disease progression with ongoing medical treatment and lifestyle modifications."
294,294,P0488,"Age: 31
Gender: Female 
Weight: 57 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 47,3
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 55.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4
LDL (mmol/L): 3,13
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 391.0
Protein (g/L): 85,5
T4 (ng/L): 14
TSH (mIU/L): 1,84
Urea (mg/dL): 4,82
LVEF (%): 25.0
Medications: Beta Blockers, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Please note that this is a medical prediction and should not be considered as a definitive diagnosis or treatment plan.

RANKING: Survivor

REASONING: 

1. The patient's age is 31, which is relatively young for a patient with ischemic dilated cardiomyopathy and myocardial infarction. This suggests that the patient's condition may be more amenable to treatment and recovery.
2. The patient's NYHA Class II indicates that the patient has some limitations in physical activity but is still able to perform everyday tasks without symptoms. This suggests that the patient's condition is not severe at this time.
3. The patient's blood pressure is within a normal range, which is a good prognostic indicator.
4. The patient's albumin and protein levels are within normal ranges, which suggests that the patient does not have significant liver or kidney dysfunction.
5. The patient's creatinine level is slightly elevated, but not significantly so, which suggests that the patient's kidney function is not severely impaired at this time.
6. The patient's LVEF is 25%, which is low, but the patient is already on beta blockers and nitrovasodilators, which are standard treatments for heart failure. The patient's condition may be manageable with medication.
7. The patient's ECG shows non-sustained ventricular tachycardia, which is a concerning finding, but it is not an immediate cause for alarm. The patient's TSH and T4 levels are within normal ranges, which suggests that the patient's thyroid function is not contributing to the patient's condition.
8. The patient's pro-BNP level is elevated, which is consistent with heart failure, but the patient's overall clinical picture suggests that the patient's condition is not catastrophic at this time.
9. The patient's total cholesterol and LDL levels are slightly elevated, but the patient's HDL level is low, which suggests that the patient may be at risk for cardiovascular disease. However, the patient's overall lipid profile is not severely abnormal.
10. The patient's glucose level is within normal range, which suggests that the patient does not have diabetes, a significant risk factor for cardiovascular disease.

Considering these factors, the most likely prognosis for the patient is survivor, with a focus on close monitoring and management of the patient's condition. The patient's young age, relatively mild symptoms, and manageable heart failure suggest that the patient may be able to live a long and relatively healthy life with proper treatment and lifestyle modifications.

RANKING: Sudden Cardiac Death

REASONING: 

This prognosis is less likely than survivor because the patient's condition is not immediately life-threatening. The patient's ECG shows non-sustained ventricular tachycardia, which is a concerning finding, but it is not an immediate cause for alarm. The patient's LVEF is low, but the patient is already on standard treatments for heart failure.

RANKING: Pump Failure Death

REASONING: 

This prognosis is the least likely because the patient's condition is not severe enough to warrant a poor prognosis. The patient's NYHA Class II indicates that the patient has some limitations in physical activity, but the patient is still able to perform everyday tasks without symptoms. The patient's LVEF is low, but the patient is already on standard treatments for heart failure, and the patient's overall clinical picture suggests that the patient's condition is manageable."
295,295,P0490,"Age: 74
Gender: Male 
Weight: 85 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 54.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 150.0
Gamma-glutamil transpeptidase (IU/L): 155
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,4
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1375.0
Protein (g/L): 72
T4 (ng/L): 12
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,79
Urea (mg/dL): 11,32
LVEF (%): 32.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient is 74 years old with a history of ischemic dilated cardiomyopathy, myocardial infarction, and hypertension, which indicates a high risk of cardiac events. However, the patient's current medications, including beta blockers, loop diuretics, spironolactone, ACE inhibitor, and nitrovasodilator, suggest that the patient is being adequately managed for heart failure symptoms. The patient's LVEF of 32% indicates a reduced left ventricular function, but it is not the lowest possible value. The patient's Pro-BNP level of 1375 ng/L is elevated but not extremely high, which may indicate some degree of heart failure management. Additionally, the patient's hemoglobin level is within a relatively normal range, which is a good prognostic indicator. The absence of sustained ventricular tachycardia and the presence of polymorphic ventricular extrasystoles may indicate some degree of arrhythmia control. Overall, while the patient's prognosis is guarded, the current management and some of the laboratory values suggest that the patient may be able to survive for a few years with continued medical management.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's history of ischemic dilated cardiomyopathy and myocardial infarction puts them at a higher risk of sudden cardiac death. The patient's LVEF of 32% and elevated Pro-BNP level suggest a high risk of arrhythmias and cardiac events. However, the patient's current medications and the absence of sustained ventricular tachycardia may reduce this risk. The patient's potassium level is within a relatively normal range, which is a good prognostic indicator. However, the patient's high total cholesterol and LDL levels may contribute to ongoing cardiac damage. The patient's age and comorbidities also increase the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 32% and elevated Pro-BNP level suggest a high risk of pump failure. The patient's history of ischemic dilated cardiomyopathy and myocardial infarction also increases the risk of pump failure. The patient's high creatinine level and urea level suggest some degree of renal impairment, which can further increase the risk of pump failure. The patient's high total cholesterol and LDL levels may also contribute to ongoing cardiac damage and pump failure. However, the patient's current medications and some of the laboratory values suggest that the patient may be able to survive for a few years with continued medical management."
296,296,P0492,"Age: 40
Gender: Male 
Weight: 73 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,94
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 575.0
Protein (g/L): 69
T4 (ng/L): 14
Troponin (ng/mL): 0,04
TSH (mIU/L): 2,59
Urea (mg/dL): 4,16
LVEF (%): 31.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. However, please note that this is a hypothetical prediction and should not be considered a definitive medical diagnosis. The actual outcome may vary based on various factors, including the patient's adherence to treatment, lifestyle changes, and potential new medical conditions.

RANKING: 1. Survivor
 REASONING: The patient has a moderate level of comorbidities, including ischemic dilated cardiomyopathy, diabetes, and dyslipemia. However, the patient's current medications, including an ACE inhibitor, statins, and loop diuretics, are appropriate for managing these conditions. The patient's LVEF (Left Ventricular Ejection Fraction) is 31%, which is below the normal range but not extremely low. Additionally, the patient's troponin level is within normal limits, indicating no recent myocardial infarction. The absence of sustained ventricular tachycardia and other severe arrhythmias on the ECG also suggests a relatively stable cardiac condition. Considering these factors, the patient is more likely to survive in the next few years with proper management and adherence to treatment.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF of 31% indicates a reduced cardiac function, which increases the risk of heart failure progression. The patient's high Pro-BNP level (575.0 ng/L) also suggests an increased risk of heart failure. However, the patient's current medications, including an ACE inhibitor and loop diuretics, are appropriate for managing heart failure. While the patient's condition is concerning, it is not immediately life-threatening. The patient's overall prognosis is guarded, but with proper management, the risk of pump failure death can be reduced.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient's LVEF of 31% and the presence of ischemic dilated cardiomyopathy increase the risk of sudden cardiac death. However, the absence of sustained ventricular tachycardia and other severe arrhythmias on the ECG, along with the patient's current medications, including an ACE inhibitor and beta-blockers, reduce this risk. Additionally, the patient's troponin level is within normal limits, indicating no recent myocardial infarction. While the patient's condition is concerning, the risk of sudden cardiac death is relatively low compared to pump failure death, given the patient's overall clinical picture."
297,297,P0493,"Age: 67
Gender: Male 
Weight: 80 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 49.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 75
Glucose (mmol/L): 5
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,56
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 248.0
Protein (g/L): 75
T4 (ng/L): 10
Troponin (ng/mL): 0,09
TSH (mIU/L): 1,87
Urea (mg/dL): 4,16
LVEF (%): 35.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: The patient is 67 years old with a history of ischemic dilated cardiomyopathy and myocardial infarction, indicating a compromised cardiac function. However, he is currently on beta blockers and statins, which are standard treatments for heart failure and high cholesterol. His LVEF is 35%, which is below the normal range, but he is still classified as NYHA Class II, indicating that he is not severely symptomatic. His Pro-BNP level is elevated at 248.0 ng/L, but not extremely high, indicating some degree of heart failure, but not severe. His blood pressure is well-controlled, and his kidney function is relatively preserved. His troponin level is low, indicating no acute myocardial infarction. His TSH level is within the normal range, indicating no signs of hypothyroidism, which can contribute to heart failure. His hemoglobin level is within the normal range, indicating no anemia, which can contribute to heart failure. Considering these factors, the patient's overall prognosis appears to be more favorable, and he is likely to survive.

RANKING: Pump Failure Death

REASONING: The patient's LVEF is 35%, which is below the normal range, indicating compromised cardiac function. His Pro-BNP level is elevated at 248.0 ng/L, indicating some degree of heart failure. His creatinine level is slightly elevated at 71.0 umol/L, indicating some degree of renal impairment, which can be a consequence of heart failure. His total cholesterol level is high at 4.34 mmol/L, which can contribute to cardiac disease progression. However, his blood pressure is well-controlled, and his kidney function is relatively preserved. His troponin level is low, indicating no acute myocardial infarction. Considering these factors, the patient's prognosis is less favorable, but not extremely poor. He is at risk of pump failure death due to his compromised cardiac function and renal impairment.

RANKING: Sudden Cardiac Death

REASONING: The patient's ECG shows ventricular extrasystole and ventricular tachycardia, which are risk factors for sudden cardiac death. However, the codes for these arrhythmias are unknown, making it difficult to assess their severity. His LVEF is 35%, which is below the normal range, indicating compromised cardiac function. His Pro-BNP level is elevated at 248.0 ng/L, indicating some degree of heart failure. However, his blood pressure is well-controlled, and his kidney function is relatively preserved. His troponin level is low, indicating no acute myocardial infarction. Considering these factors, the patient's risk of sudden cardiac death is relatively low compared to the other two options, but still a possibility due to his compromised cardiac function and arrhythmias."
298,298,P0495,"Age: 47
Gender: Male 
Weight: 89 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 42
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 8,2
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 56
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 163.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,3
LDL (mmol/L): 5,95
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 543.0
Protein (g/L): 79
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,2
Urea (mg/dL): 4,99
LVEF (%): 35.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely. Please note that this is a prediction based on the given information and may not be a definitive prediction.

RANKING: 1. Survivor
 REASONING: The patient is 47 years old with a NYHA Class II, which indicates mild symptoms of heart failure. The LVEF is 35%, indicating a reduced ejection fraction, but the patient is on optimal medical therapy with beta blockers, loop diuretics, statins, and an ACE inhibitor. The Pro-BNP level of 543 ng/L is elevated, but not extremely high. The patient's troponin level is normal, and there is no evidence of severe electrolyte imbalances. The patient's ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or other severe arrhythmias. Considering these factors, the patient is likely to survive in the next few years with continued optimal medical therapy and close monitoring.

RANKING: 2. Pump failure death
 REASONING: The patient's LVEF is 35%, indicating a reduced ejection fraction, which increases the risk of pump failure. However, the patient is on optimal medical therapy, and the Pro-BNP level, while elevated, is not extremely high. The patient's symptoms are mild, and there is no evidence of severe electrolyte imbalances or other complications. While pump failure is a possible outcome, it is less likely than survivor due to the patient's relatively stable condition and optimal medical therapy.

RANKING: 3. Sudden cardiac death
 REASONING: The patient's LVEF is 35%, which increases the risk of sudden cardiac death. However, the patient is on optimal medical therapy, and there is no evidence of severe arrhythmias, such as sustained ventricular tachycardia. The patient's ECG shows polymorphic ventricular extrasystoles, but this is a relatively benign finding. The patient's Pro-BNP level is elevated, but not extremely high, and there is no evidence of severe electrolyte imbalances. While sudden cardiac death is a possible outcome, it is the least likely of the three due to the patient's relatively stable condition and optimal medical therapy."
299,299,P0497,"Age: 47
Gender: Male 
Weight: 88 kg
Height: 189 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Toxic dilated cardiomyopathy
Albumin (g/L): 43,4
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,66
Creatinine (mmol/L): 107.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 3,73
LDL (mmol/L): 3,4
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 435.0
Protein (g/L): 69,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,72
Urea (mg/dL): 9,2
LVEF (%): 55.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the prognosis for the next few years as follows:

RANKING: Survivor
 REASONING: The patient is 47 years old with a history of toxic dilated cardiomyopathy, which is a significant risk factor for adverse cardiac outcomes. However, the patient's current medications, including beta blockers, digoxin, loop diuretics, and an ACE inhibitor, are evidence-based treatments for heart failure and are likely helping to manage the patient's condition. The patient's LVEF is 55%, which is slightly below the normal range (60-70%), indicating some degree of left ventricular dysfunction. However, the patient's Pro-BNP level is elevated at 435 ng/L, which is a marker of heart failure severity. The patient's blood pressure is well-controlled, and there is no evidence of significant electrolyte imbalances or kidney dysfunction. Additionally, the patient's troponin level is within normal limits, indicating that there is no acute coronary syndrome or myocardial infarction. Given the patient's age, comorbidities, and current treatment, the most likely prognosis is that the patient will survive, but with ongoing management and monitoring to prevent disease progression.

RANKING: Pump Failure Death
 REASONING: The patient's LVEF of 55% and elevated Pro-BNP level suggest that the patient has some degree of left ventricular dysfunction and heart failure. However, the patient's current medications and lack of acute coronary syndrome or myocardial infarction suggest that the patient's condition is not as severe as it could be. The patient's age and comorbidities, including toxic dilated cardiomyopathy, do increase the risk of pump failure death. However, the patient's overall clinical picture and treatment plan suggest that pump failure death is less likely than sudden cardiac death.

RANKING: Sudden Cardiac Death
 REASONING: The patient's ECG shows polymorphic ventricular extrasystoles, which is a risk factor for sudden cardiac death. However, the patient's LVEF is 55%, and the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death. Additionally, the patient's troponin level is within normal limits, indicating that there is no acute coronary syndrome or myocardial infarction. While the patient's comorbidities and ECG findings do increase the risk of sudden cardiac death, the patient's overall clinical picture and treatment plan suggest that this outcome is the least likely of the three options."
300,300,P0502,"Age: 57
Gender: Male 
Weight: 86 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 105/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 41,3
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 6,37
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 60
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 148.0
Potassium (mEq/L): 4,22
Sodium (mEq/L): 140.0
Protein (g/L): 73,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,87
Urea (mg/dL): 6
LVEF (%): 17.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses for the patient over the next few years. 

RANKING: 1. Survivor
 REASONING: The patient is currently on a multidrug regimen, including beta blockers, loop diuretics, spironolactone, ACE inhibitors, and nitrovasodilators, which is a comprehensive treatment plan for heart failure. The patient's left ventricular ejection fraction (LVEF) is 17%, which indicates significant left ventricular dysfunction, but the patient is still alive, suggesting that the treatment plan is effective in managing the condition. Additionally, the patient's NYHA class is II, indicating that the patient is experiencing some symptoms of heart failure but is still able to perform everyday activities without significant limitation. The patient's troponin level is normal, indicating that there is no acute myocardial infarction. The patient's blood pressure is well-controlled, and the kidney function is relatively preserved. Considering these factors, the patient's current treatment plan and the absence of severe symptoms, a survivor prognosis seems the most likely outcome.

RANKING: 2. Pump Failure Death
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a condition that can lead to progressive left ventricular dysfunction and eventually pump failure. The patient's LVEF is 17%, which is a significant reduction in cardiac function. However, the patient is still alive and on a treatment plan, which suggests that the progression to pump failure may be slow. The patient's kidney function is relatively preserved, and the patient's blood pressure is well-controlled, which may indicate that the patient's cardiac function is being managed effectively. While pump failure is a possibility, it is less likely than a survivor prognosis due to the patient's current treatment plan and relatively stable condition.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient's ECG shows polymorphic ventricular extrasystoles, which can be a marker of increased risk of sudden cardiac death. However, the patient is on beta blockers, which are effective in reducing the risk of sudden cardiac death in patients with heart failure. Additionally, the patient's troponin level is normal, indicating that there is no acute myocardial infarction, which is a common cause of sudden cardiac death. While the patient's LVEF is low, the patient is still alive, suggesting that the risk of sudden cardiac death is relatively low. Considering the patient's treatment plan and the absence of other high-risk features, sudden cardiac death is the least likely prognosis."
301,301,P0503,"Age: 47
Gender: Male 
Weight: 92 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/100 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 46
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 127.0
Gamma-glutamil transpeptidase (IU/L): 63
Glucose (mmol/L): 6,5
Hemoglobin (g/L): 172.0
HDL (mmol/L): 0,71
Potassium (mEq/L): 4,41
LDL (mmol/L): 4
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1129.0
Protein (g/L): 78
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,47
Urea (mg/dL): 13,2
LVEF (%): 17.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient has been diagnosed with idiopathic dilated cardiomyopathy and has experienced a myocardial infarction, which indicates a history of significant cardiac disease. However, the patient is currently being treated with beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all appropriate medications for managing heart failure and dilated cardiomyopathy. The patient's LVEF is 17%, which is quite low, but the fact that they are being managed with optimal medical therapy and are not in New York Heart Association (NYHA) Class IV suggests that they may still have a relatively stable condition. Additionally, the patient's Pro-BNP level of 1129 ng/L is elevated, but not extremely high, which may indicate that the patient is being managed effectively. The absence of sustained ventricular tachycardia and other arrhythmias on the ECG also suggests that the patient's cardiac function is relatively stable.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 17% indicates severe left ventricular dysfunction, which increases the risk of pump failure death. The patient's elevated Pro-BNP level and history of myocardial infarction also suggest that they are at risk for pump failure. However, the patient's NYHA Class II and optimal medical therapy suggest that they may still have a relatively stable condition, and the absence of other risk factors such as severe renal impairment or significant electrolyte imbalances suggests that pump failure may not be imminent.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's history of myocardial infarction and idiopathic dilated cardiomyopathy increases the risk of sudden cardiac death. However, the patient's LVEF of 17% and optimal medical therapy suggest that they are being managed effectively, and the absence of other risk factors such as severe arrhythmias or significant electrolyte imbalances suggests that sudden cardiac death may be less likely. Additionally, the patient's Troponin level is very low, which suggests that they have not had a recent myocardial infarction, and the patient's ECG is relatively normal, which suggests that they do not have a high risk of arrhythmias."
302,302,P0505,"Age: 79
Gender: Female 
Weight: 78 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43,8
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,44
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,24
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 593.0
Protein (g/L): 76
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,56
Urea (mg/dL): 8,02
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's my prognosis for the next few years:

RANKING: 1. Survivor
REASONING: The patient is 79 years old with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction. Despite these conditions, the patient's LVEF (Left Ventricular Ejection Fraction) is 50%, which is relatively stable and not severely decreased. The patient is also on a comprehensive treatment plan, including medications for hypertension, diabetes, and heart failure (Calcium Channel Blocker, Beta Blockers, Loop Diuretics, and Nitrovasodilator), which is likely helping to manage the condition. The patient's Pro-BNP level is 593.0 ng/L, which is elevated but not excessively high, indicating some degree of heart failure but not severe. The absence of paroxysmal supraventricular tachyarrhythmia and the presence of a non-sustained ventricular tachycardia with a cycle length > 10 seconds suggest that the patient's heart rhythm is relatively stable. Overall, considering the patient's age and the severity of their condition, a survivor prognosis is the most likely outcome.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF is 50%, which indicates some degree of heart failure, but not severe. The patient's creatinine level is 95.0 mmol/L, which is elevated, indicating some degree of kidney dysfunction, but not severe. The patient's Pro-BNP level is elevated, indicating some degree of heart failure. However, the patient is on a comprehensive treatment plan, which is likely helping to manage the condition. The patient's age and the presence of other comorbidities increase the risk of pump failure, but the relatively stable LVEF and the absence of other severe indicators (e.g., severe kidney dysfunction, very high Pro-BNP level) make pump failure death a less likely outcome.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are risk factors for sudden cardiac death. However, the patient's LVEF is 50%, which is relatively stable, and the patient is on a comprehensive treatment plan, which is likely helping to manage the condition. The patient's age and the presence of other comorbidities increase the risk of sudden cardiac death, but the relatively stable LVEF and the absence of other severe indicators (e.g., very high Pro-BNP level, severe kidney dysfunction) make sudden cardiac death a less likely outcome compared to pump failure death."
303,303,P0506,"Age: 71
Gender: Female 
Weight: 63 kg
Height: 145 cm
NYHA Class: II
Blood Pressure: 110/50 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 5,02
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,59
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 673.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,03
Urea (mg/dL): 7,15
LVEF (%): 65.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here's my prognosis for the next few years:

RANKING: Survivor

REASONING:

1.  The patient's LVEF (Left Ventricular Ejection Fraction) is 65%, which is within the normal range (50-70%). This suggests that the patient's heart function is relatively preserved, and they are not in a high-risk category for sudden cardiac death or pump failure.
2.  The patient's NYHA Class II indicates that they have some limitations in physical activity, but they are still able to perform most daily activities without symptoms. This suggests that the patient's heart failure is not severe.
3.  The patient's medications, including Angiotensin II Receptor Blocker, Beta Blockers, and Loop Diuretics, are appropriate for managing heart failure and hypertension. These medications can help slow disease progression and reduce symptoms.
4.  The patient's troponin level is 0.01 ng/mL, which is within the normal range. Elevated troponin levels are associated with increased risk of cardiac events.
5.  The patient's BNP (Brain Natriuretic Peptide) level is 673.0 ng/L, which is elevated but not extremely high. BNP levels can indicate heart failure severity, and a moderate level like this suggests that the patient's heart failure is not severe.
6.  The patient's creatinine level is 80.0 mol/L, which is slightly elevated but not significantly high. This suggests that the patient's kidney function is not severely impaired.
7.  The patient's lipid profile shows elevated total cholesterol and LDL levels, which can contribute to cardiovascular disease. However, the patient's HDL level is relatively high, which can help mitigate this risk.
8.  The patient's TSH level is 2.03 mIU/L, which is within the normal range. Hypothyroidism can contribute to heart failure, but this patient does not appear to have this condition.
9.  The patient's ECG shows polymorphic ventricular extrasystoles, but no other significant arrhythmias. This suggests that the patient's cardiac rhythm is relatively stable.

Considering these factors, the patient's prognosis is more likely to be a survivor, as they have relatively well-managed heart failure, preserved LVEF, and no severe comorbidities. However, it's essential to continue monitoring the patient's condition and adjust their treatment plan as needed to prevent disease progression."
304,304,P0507,"Age: 45
Gender: Male 
Weight: 90 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 133.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,95
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 89.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,23
Urea (mg/dL): 7,99
LVEF (%): 55.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's my prognosis for the next few years:

RANKING: Survivor
REASONING: 
The patient has idiopathic dilated cardiomyopathy, which is a significant underlying condition that affects the heart's ability to pump blood effectively. However, the patient's left ventricular ejection fraction (LVEF) is 55%, which is below the normal range but not extremely low. This suggests that the heart is still able to pump some blood, and the patient is not in an advanced stage of heart failure.

The patient's NYHA class is II, indicating that the patient experiences some limitations in physical activity but is still able to perform daily tasks without significant symptoms. This is a relatively mild classification, suggesting that the patient's heart failure is not severe.

The patient's blood pressure is well-controlled, and their medications, including beta blockers, loop diuretics, spironolactone, statins, ACE inhibitors, and nitrovasodilators, are appropriate for managing heart failure and related conditions.

The patient's laboratory results show elevated creatinine levels, indicating some degree of kidney impairment, which is common in patients with heart failure. However, the levels are not extremely high, and the patient's urea levels are within a relatively normal range.

The patient's TSH level is within the normal range, which suggests that there is no apparent thyroid dysfunction contributing to their heart failure.

The patient's Pro-BNP level is 89 ng/L, which is elevated but not extremely high. Pro-BNP is a biomarker for heart failure, and elevated levels indicate increased stress on the heart.

Given these factors, I believe that the patient is likely to survive for the next few years, as their heart failure is relatively well-managed, and they do not exhibit any severe symptoms or laboratory abnormalities that would indicate a high risk of sudden cardiac death or pump failure.

RANKING: Sudden Cardiac Death
REASONING: 
While the patient's heart failure is not severe, there is a risk of sudden cardiac death due to ventricular arrhythmias. The patient's ECG shows no signs of ventricular extrasystoles, ventricular tachycardia, or non-sustained ventricular tachycardia, which are common causes of sudden cardiac death. However, the patient's idiopathic dilated cardiomyopathy increases their risk of arrhythmias, and the patient's medications may not fully mitigate this risk.

RANKING: Pump Failure Death
REASONING: 
This prognosis is the least likely, as the patient's LVEF is 55%, and their heart failure is relatively well-managed. While the patient's creatinine levels are elevated, indicating some degree of kidney impairment, this is a common complication of heart failure and does not necessarily indicate a high risk of pump failure. The patient's medications, including loop diuretics and ACE inhibitors, are designed to slow the progression of heart failure and reduce the risk of pump failure."
305,305,P0508,"Age: 66
Gender: Male 
Weight: 77 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 150/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 6,65
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,6
Potassium (mEq/L): 4,62
LDL (mmol/L): 4,32
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 200.0
Protein (g/L): 74,5
T3 (pg/dL): 0,0669
T4 (ng/L): 15,24
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,35
Urea (mg/dL): 5,3
LVEF (%): 35.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely.

RANKING: Survivor
 REASONING: The patient is 66 years old with a history of idiopathic dilated cardiomyopathy, which is a significant underlying condition. However, the patient's LVEF is 35%, indicating a moderate reduction in left ventricular function. The patient is on loop diuretics and an ACE inhibitor, which are standard treatments for heart failure. The absence of severe electrolyte imbalances, such as hypokalemia (potassium < 3.5 mEq/L), or hyperkalemia (potassium > 5.5 mEq/L), is a positive sign. The patient's TSH is within the normal range, which suggests that there is no apparent thyroid dysfunction contributing to the heart failure. Additionally, the patient's troponin level is slightly elevated but not excessively high. The patient's blood pressure is relatively high, which may indicate a possible issue with the patient's blood pressure regulation, but it is not a definitive indicator of a poor prognosis. Given these factors, the patient's overall condition appears to be manageable, and with continued medical treatment, a survivor prognosis is more likely.

RANKING: Pump Failure Death
 REASONING: Pump failure death is a possible prognosis due to the patient's underlying idiopathic dilated cardiomyopathy and reduced LVEF. The patient's LVEF of 35% indicates a moderate reduction in left ventricular function, which may lead to progressive heart failure and potentially pump failure. However, the patient is already on standard treatments for heart failure, and there is no clear indication of severe pump failure at this stage.

RANKING: Sudden Cardiac Death
 REASONING: Sudden cardiac death is the least likely prognosis due to the patient's current medical treatment and lack of severe underlying conditions. The patient's ECG shows non-sustained ventricular tachycardia, but this is not a definitive indicator of sudden cardiac death. The patient's troponin level is slightly elevated, but not excessively high, which suggests that there is no acute myocardial infarction. The patient's overall condition appears to be manageable, and the risk of sudden cardiac death is relatively low at this stage."
306,306,P0510,"Age: 72
Gender: Female 
Weight: 67 kg
Height: 147 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 41,5
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,13
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 2207.0
Protein (g/L): 74
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,62
Urea (mg/dL): 10,47
LVEF (%): 22.0
Medications: Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely. 

RANKING: 1. Survivor
 REASONING: The patient is 72 years old with a history of idiopathic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension, which are all risk factors for heart failure and mortality. However, the patient is currently on optimal medical therapy with loop diuretics, spironolactone, statins, and an ACE inhibitor, which are standard treatments for heart failure and cardiomyopathy. The patient's LVEF is 22%, which is low, but the lack of significant symptoms (NYHA Class III) and the absence of sustained ventricular tachycardia or other high-risk ECG findings suggest that the patient is not in acute heart failure or at imminent risk of sudden cardiac death. The patient's pro-BNP level is elevated at 2207.0 ng/L, indicating some degree of heart failure, but the level is not extremely high, and the patient's blood pressure is well-controlled. Considering the patient's overall clinical picture, with optimal medical therapy and a relatively stable condition, the most likely prognosis is survivor.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's LVEF is 22%, which is low, and the presence of idiopathic dilated cardiomyopathy and diabetes increases the risk of sudden cardiac death. However, the patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death, but the lack of sustained ventricular tachycardia or other high-risk findings reduces the risk. The patient's pro-BNP level is elevated, indicating some degree of heart failure, but the level is not extremely high. The patient's optimal medical therapy and relatively stable condition also reduce the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF is 22%, which is very low, and the presence of idiopathic dilated cardiomyopathy, diabetes, and hypertension are all risk factors for heart failure and pump failure. However, the patient's NYHA Class III suggests that the patient is not in acute heart failure, and the patient's blood pressure is well-controlled. The patient's optimal medical therapy and relatively stable condition reduce the risk of pump failure death. While the patient's pro-BNP level is elevated, the level is not extremely high, and the patient's overall clinical picture suggests that pump failure death is the least likely prognosis."
307,307,P0511,"Age: 59
Gender: Female 
Weight: 75 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 44,8
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 3,08
Creatinine (mmol/L): 76.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 10,3
Hemoglobin (g/L): 142.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,8
LDL (mmol/L): 1,81
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 1114.0
Protein (g/L): 74
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,61
Urea (mg/dL): 7,35
LVEF (%): 37.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: The patient is 59 years old with a history of ischemic dilated cardiomyopathy, myocardial infarction, diabetes, and dyslipemia. However, she is on optimal medical therapy with beta blockers, statins, and an ACE inhibitor, which are standard treatments for heart failure and coronary artery disease. Her NYHA Class II classification indicates that she has some limitations in physical activity but is still able to perform daily tasks without symptoms. The LVEF of 37% suggests some degree of heart failure, but it is not severely impaired. Her blood pressure is well-controlled, and her lipid profile is being managed with statins. The low troponin level and absence of ventricular tachycardia on the ECG also suggest that she does not have ongoing myocardial ischemia. The high Pro-BNP level indicates some degree of heart failure, but it is not extremely high. Overall, while the patient has a history of cardiac disease, her current treatment and clinical status suggest that she is likely to survive with ongoing medical management.

RANKING: Pump Failure Death

REASONING: The patient's LVEF of 37% and high Pro-BNP level suggest that she has some degree of heart failure. Her history of ischemic dilated cardiomyopathy and myocardial infarction also increases her risk of pump failure. However, her current treatment with beta blockers, statins, and an ACE inhibitor is standard for heart failure management, and her blood pressure is well-controlled. The absence of severe symptoms (NYHA Class II) and the fact that she is able to perform daily tasks without symptoms suggest that pump failure is not imminent. While there is a risk of pump failure, it is not the most likely outcome given her current clinical status.

RANKING: Sudden Cardiac Death

REASONING: The patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases her risk of sudden cardiac death. However, her current treatment with beta blockers, which are known to reduce the risk of sudden cardiac death, suggests that her risk is being actively managed. The absence of ventricular tachycardia on the ECG and low troponin level also suggest that she does not have ongoing myocardial ischemia, which is a major risk factor for sudden cardiac death. The patient's overall clinical status, including her NYHA Class II classification and well-controlled blood pressure, suggests that sudden cardiac death is not the most likely outcome."
308,308,P0512,"Age: 69
Gender: Male 
Weight: 85 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Peripheral vascular disease
Albumin (g/L): 46,3
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,74
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 66
Glucose (mmol/L): 11,3
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,97
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 349.0
Protein (g/L): 90
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,36
Urea (mg/dL): 8,02
LVEF (%): 24.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely.

RANKING: Survivor

REASONING: The patient is 69 years old with a history of enolic dilated cardiomyopathy, diabetes, and peripheral vascular disease. Despite these comorbidities, the patient's current medications (beta blockers, loop diuretics, spironolactone, and ACE inhibitor) suggest that they are receiving appropriate treatment for their heart failure and hypertension. The patient's LVEF of 24% indicates severe left ventricular dysfunction, but the lack of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG is a positive sign. The patient's pro-BNP level of 349.0 ng/L is elevated, indicating increased ventricular stretch and potential heart failure, but it is not extremely high. The patient's hemoglobin level is within the normal range, and the absence of significant anemia is a positive sign. While the patient's creatinine level is elevated at 95.0 mmol/L, indicating some degree of renal impairment, it is not extremely high. Considering these factors, the patient's current treatment regimen and the lack of severe arrhythmias, I would rank survivor as the most likely prognosis.

RANKING: Sudden Cardiac Death

REASONING: Sudden cardiac death is a potential risk for patients with severe heart failure and ventricular dysfunction. The patient's LVEF of 24% and elevated pro-BNP level suggest a high risk of sudden cardiac death. However, the lack of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG reduces the risk. The patient's beta blockers and ACE inhibitor therapy may also help reduce the risk of sudden cardiac death. Therefore, while sudden cardiac death is a possible risk, I would rank it as the second most likely prognosis.

RANKING: Pump Failure Death

REASONING: Pump failure death is a potential risk for patients with severe heart failure and ventricular dysfunction. The patient's LVEF of 24% and elevated pro-BNP level suggest a high risk of pump failure. However, the patient's current treatment regimen, including loop diuretics and spironolactone, may help manage fluid overload and reduce the risk of pump failure. Additionally, the patient's blood pressure is well-controlled, and the absence of significant anemia and renal impairment reduces the risk of pump failure. Therefore, while pump failure death is a possible risk, I would rank it as the least likely prognosis."
309,309,P0514,"Age: 54
Gender: Male 
Weight: 89 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 48,4
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 9,9
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 3,7
LDL (mmol/L): 2,43
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 333.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,36
Urea (mg/dL): 6,45
LVEF (%): 39.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's the prognosis ranking from most likely to least likely:

RANKING: Survivor

REASONING: The patient has a combination of risk factors that suggest a poor prognosis, including ischemic dilated cardiomyopathy, diabetes, hypertension, and a history of myocardial infarction. However, there are also some factors that suggest a more favorable outcome. The patient's LVEF is 39%, which is below the normal range (50-70%), indicating some degree of heart failure. However, the patient is on optimal medical therapy, including beta blockers, ACE inhibitors, and statins, which are all evidence-based treatments for heart failure. Additionally, the patient's blood pressure is well-controlled, and the levels of troponin, which is a marker of cardiac damage, are within normal limits. The patient's ejection fraction is also not as low as it could be, considering the patient's history of ischemic dilated cardiomyopathy. Furthermore, the patient's creatinine level is within normal limits, which suggests that renal function is preserved. The patient's pro-BNP level is elevated, but it is not extremely high, which may indicate that the patient is not in severe heart failure. Overall, while the patient has a history of heart failure and other comorbidities, the combination of optimal medical therapy, well-controlled blood pressure, and preserved renal function suggests that the patient is likely to survive.

The other two options, sudden cardiac death and pump failure death, are less likely for the following reasons:

- Sudden cardiac death is less likely because the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death in patients with heart failure.
- Pump failure death is less likely because the patient's LVEF is not extremely low, and the patient is on optimal medical therapy, which includes ACE inhibitors and beta blockers, which are known to slow the progression of heart failure."
310,310,P0515,"Age: 50
Gender: Female 
Weight: 83 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 45,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,81
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,84
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 763.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,14
Urea (mg/dL): 9,8
LVEF (%): 50.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient is 50 years old with a NYHA Class II, indicating mild symptoms of heart failure. Her LVEF is 50%, which is within the normal range (50-70%). Her blood pressure is controlled at 140/70 mmHg, and she is on ACE inhibitors, which is beneficial for heart failure management. Her troponin level is within normal limits, and there is no evidence of ventricular arrhythmias on the ECG. Additionally, her creatinine level is slightly elevated but not significantly high, indicating mild kidney impairment. The patient's pro-BNP level is elevated, but it is not excessively high, which suggests that her heart failure is not severe. Considering these factors, the patient's prognosis for survival over the next few years appears to be good.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient has a history of hypertensive cardiomyopathy and hypertension, which are risk factors for sudden cardiac death. However, her LVEF is within the normal range, and there is no evidence of ventricular arrhythmias on the ECG. Her troponin level is normal, and her pro-BNP level, although elevated, is not excessively high. Additionally, she is on ACE inhibitors, which are beneficial for reducing the risk of sudden cardiac death. While the patient's history of cardiomyopathy and hypertension increases her risk, the absence of other high-risk factors and the presence of beneficial treatments make sudden cardiac death a less likely prognosis.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF is 50%, which is within the normal range, and her NYHA Class II indicates mild symptoms of heart failure. Her blood pressure is well-controlled, and she is on ACE inhibitors, which is beneficial for heart failure management. Her creatinine level is slightly elevated, but not significantly high, indicating mild kidney impairment. The patient's pro-BNP level is elevated, but it is not excessively high, suggesting that her heart failure is not severe. Considering these factors, the patient's prognosis for pump failure death appears to be the least likely of the three options."
311,311,P0516,"Age: 49
Gender: Male 
Weight: 97 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 51,3
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,19
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 42
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 156.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,66
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1283.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 24
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,23
Urea (mg/dL): 8,02
LVEF (%): 39.0
Medications: Amiodarone, Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: Survivor
 REASONING: The patient is 49 years old and has a history of enolic dilated cardiomyopathy, which is a significant risk factor for heart failure. However, the patient is on optimal medical therapy with amiodarone, beta blockers, and an ACE inhibitor, which is a good sign. The patient's LVEF is 39%, which is lower than the normal range (50-70%), indicating some degree of heart dysfunction. However, the patient's NYHA class is III, indicating some limitation of physical activity but still able to perform daily activities. The patient's Pro-BNP level is elevated at 1283.0 ng/L, which is a marker of heart failure. Despite these factors, the patient's overall clinical picture suggests that they are being well-managed and are likely to survive with continued medical therapy and lifestyle modifications.

RANKING: Pump Failure Death
 REASONING: Pump failure death is a possible outcome due to the patient's dilated cardiomyopathy and reduced LVEF. However, the patient's current medical therapy and NYHA class suggest that they are not yet at a high risk for sudden cardiac death. The patient's Troponin level is normal, and there is no evidence of acute coronary syndrome or other acute cardiac events. While the patient's Pro-BNP level is elevated, it is not at the highest levels typically seen in advanced heart failure.

RANKING: Sudden Cardiac Death
 REASONING: Sudden cardiac death is the least likely outcome due to the patient's current medical therapy and lack of evidence of acute cardiac events. The patient's ECG is normal, and there is no evidence of ventricular tachycardia, ventricular extrasystole, or other arrhythmias that would increase the risk of sudden cardiac death. While the patient has a history of dilated cardiomyopathy, their current NYHA class and medical therapy suggest that they are being well-managed, and the risk of sudden cardiac death is low."
312,312,P0517,"Age: 41
Gender: Male 
Weight: 84 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44,9
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,48
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 797.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,26
Urea (mg/dL): 8,69
LVEF (%): 35.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient is 41 years old, which is relatively young for a patient with idiopathic dilated cardiomyopathy. Despite having a low LVEF of 35%, the patient is on appropriate medical therapy with digoxin, loop diuretics, and an ACE inhibitor, which suggests that the patient is being actively managed for heart failure. The patient's NYHA class is II, indicating that the patient is not severely symptomatic, and the blood pressure is well-controlled. Additionally, the patient's biomarkers, such as troponin and BNP, are not elevated, indicating that there is no acute cardiac injury or severe cardiac stress. The patient's potassium level is slightly low, which may be a concern, but it is not significantly abnormal. Overall, considering the patient's age, the relatively mild symptoms, and the appropriate medical therapy, the most likely prognosis is a survivor.

RANKING: 2. Pump Failure Death
REASONING: The patient has idiopathic dilated cardiomyopathy with a low LVEF of 35%, which increases the risk of pump failure. However, the patient is on appropriate medical therapy, and the NYHA class is II, indicating that the patient is not severely symptomatic. The patient's blood pressure is well-controlled, and the biomarkers are not elevated, which suggests that the patient is not experiencing acute cardiac stress. While pump failure is a possible outcome, the patient's relatively young age and mild symptoms make it less likely compared to the most likely outcome of a survivor.

RANKING: 3. Sudden Cardiac Death
REASONING: Sudden cardiac death is a possible outcome for patients with idiopathic dilated cardiomyopathy, especially those with a low LVEF. However, the patient's age and NYHA class are relatively mild, and the patient is on appropriate medical therapy. The ECG findings of polymorphic ventricular extrasystole and non-sustained ventricular tachycardia are concerning, but the patient's troponin level is low, indicating that there is no acute cardiac injury. The patient's TSH level is within the normal range, which suggests that there is no underlying thyroid disease that could contribute to sudden cardiac death. While sudden cardiac death is a possible outcome, the patient's relatively young age and mild symptoms make it the least likely of the three possible outcomes."
313,313,P0518,"Age: 56
Gender: Male 
Weight: 98 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45,9
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,25
Creatinine (mmol/L): 105.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 145.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 4,8
LDL (mmol/L): 3,34
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 134.0
Protein (g/L): 83
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,88
Urea (mg/dL): 7,12
LVEF (%): 36.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. I will rank the three possible prognoses from most likely to least likely.

RANKING: 1. Survivor
 REASONING: The patient has a reduced left ventricular ejection fraction (LVEF) of 36%, indicating a reduced heart function. However, the patient is on an ACE inhibitor, which is a standard treatment for heart failure and may be helping to manage the condition. The patient's blood pressure is well-controlled, and the creatinine level is elevated but not significantly high. The patient also has a relatively low T3 level, which may indicate a lower risk of cardiac arrhythmias. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG is also a positive sign. Considering these factors, the most likely prognosis is that the patient will survive for the next few years.

RANKING: 2. Pump Failure Death
 REASONING: The patient has a reduced LVEF of 36%, which indicates a higher risk of pump failure. The elevated creatinine level may indicate a degree of renal impairment, which can be a marker of heart failure progression. The patient's low HDL cholesterol level may also be a risk factor for cardiovascular disease. However, the patient's well-controlled blood pressure, the absence of significant arrhythmias, and the presence of an ACE inhibitor treatment suggest that pump failure is not the most likely outcome.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient has a reduced LVEF of 36%, which increases the risk of sudden cardiac death. However, the patient's ECG shows a monomorphic ventricular extrasystole, which is not typically a significant risk factor for sudden cardiac death. The patient's TSH level is within the normal range, which may indicate a lower risk of cardiac arrhythmias. The patient's low T3 level may also be a protective factor against arrhythmias. Considering these factors, sudden cardiac death is the least likely prognosis for the patient.

Please note that this is a general assessment based on the provided data and may not be a definitive prediction of the patient's outcome. A comprehensive evaluation by a cardiologist is necessary for a more accurate prognosis."
314,314,P0519,"Age: 61
Gender: Male 
Weight: 107 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease
Albumin (g/L): 38,7
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 142.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,21
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1035.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 19
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,38
Urea (mg/dL): 8,46
LVEF (%): 23.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely.

RANKING: Survivor
REASONING: Despite the patient's advanced age, NYHA Class II, and multiple comorbidities, including idiopathic dilated cardiomyopathy, diabetes, dyslipemia, and peripheral vascular disease, the patient is currently being treated with a comprehensive medication regimen that includes beta blockers, ACE inhibitors, and spironolactone, which are all evidence-based treatments for heart failure with reduced ejection fraction (HFrEF). The patient's LVEF is 23%, which is consistent with HFrEF. The patient's Pro-BNP level is elevated at 1035 ng/L, but it is not extremely high, and the patient's hemoglobin and albumin levels are within normal limits. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and other adverse ECG findings is also a positive sign. While the patient's prognosis is guarded, the current treatment regimen and the absence of severe laboratory abnormalities suggest that the patient is likely to survive with continued medical management.

RANKING: Sudden Cardiac Death
REASONING: Sudden cardiac death (SCD) is a possible concern in this patient due to the presence of idiopathic dilated cardiomyopathy and a history of ventricular extrasystoles. However, the patient's LVEF is only 23%, which is relatively low, but not extremely low. The patient's Pro-BNP level is elevated, but not extremely high, and the patient's hemoglobin and albumin levels are within normal limits. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and other adverse ECG findings also suggests that the risk of SCD is lower than expected. While the patient's history of ventricular extrasystoles increases the risk of SCD, the overall clinical picture suggests that SCD is less likely than pump failure death.

RANKING: Pump Failure Death
REASONING: Pump failure death is the least likely prognosis in this patient. The patient's LVEF is 23%, which is consistent with HFrEF, but the patient's Pro-BNP level is not extremely high, and the patient's hemoglobin and albumin levels are within normal limits. The patient's current treatment regimen, which includes beta blockers, ACE inhibitors, and spironolactone, is evidence-based for HFrEF, and the patient's NYHA Class II suggests that the patient is not severely symptomatic. While the patient's prognosis is guarded, the absence of severe laboratory abnormalities and the presence of a comprehensive treatment regimen suggest that pump failure death is less likely than SCD."
315,315,P0521,"Age: 79
Gender: Female 
Weight: 58 kg
Height: 149 cm
NYHA Class: III
Blood Pressure: 110/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42,5
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 5,64
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,7
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 6699.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,98
Urea (mg/dL): 12,03
LVEF (%): 23.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely. Please note that predicting patient outcomes is a complex task and should be considered in the context of a comprehensive evaluation by a healthcare professional.

RANKING: 1. Survivor
 REASONING: The patient's age, NYHA Class III, and reduced LVEF (23%) suggest a high risk for adverse cardiac events. However, the patient is already on a comprehensive treatment regimen, including diabetes medication, beta blockers, loop diuretics, spironolactone, ACE inhibitor, and nitrovasodilators. The patient's blood pressure is well-controlled, and there is no indication of severe electrolyte imbalances. The presence of ventricular extrasystole and non-sustained ventricular tachycardia is concerning, but the patient's Pro-BNP level (6699.0 ng/L) is not extremely high, indicating some degree of compensation. Considering the patient's current treatment and relatively stable condition, a survivor prognosis is more likely.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's reduced LVEF (23%), history of ischemic dilated cardiomyopathy, and presence of ventricular extrasystole and non-sustained ventricular tachycardia increase the risk of sudden cardiac death. However, the patient's current treatment regimen and relatively stable condition suggest that sudden cardiac death might not be the most likely outcome. The patient's Pro-BNP level is not extremely high, indicating some degree of compensation, and the patient is already on beta blockers, which can help reduce the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
 REASONING: The patient's reduced LVEF (23%), history of ischemic dilated cardiomyopathy, and high Pro-BNP level (6699.0 ng/L) suggest a high risk of pump failure. However, the patient's current treatment regimen, including loop diuretics and spironolactone, suggests that the patient is being managed for heart failure. The patient's blood pressure is well-controlled, and there is no indication of severe electrolyte imbalances. Considering the patient's current treatment and relatively stable condition, pump failure death is less likely compared to the other two options."
316,316,P0522,"Age: 66
Gender: Male 
Weight: 88 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 140/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40,9
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,44
Creatinine (mmol/L): 116.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 15,4
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,5
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 277.0
Protein (g/L): 68
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,77
Urea (mg/dL): 10,24
LVEF (%): 39.0
Medications: Diabetes Medication, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. I will rank the possible outcomes from most likely to least likely.

RANKING: 1. Survivor
REASONING: Despite the patient's history of ischemic dilated cardiomyopathy, myocardial infarction, and reduced left ventricular ejection fraction (LVEF) of 39%, the patient's current medications and NYHA Class II classification suggest that the patient is being managed effectively. The patient is on spironolactone, a mineralocorticoid receptor antagonist, which is beneficial for patients with heart failure with reduced ejection fraction. Additionally, the patient is on statins, which help to manage dyslipemia. The patient's blood pressure is within a relatively normal range, and the eGFR is not severely impaired, indicating that the patient's renal function is not significantly compromised. The patient's NT-proBNP level is elevated, but it is not excessively high, which suggests that the patient's heart failure is not in an advanced stage. The patient's ECG findings, including non-sustained ventricular tachycardia and second-degree AV block, are concerning but not uncommon in patients with heart failure. Overall, while the patient's prognosis is guarded, I believe that with continued medical management and lifestyle modifications, the patient is more likely to survive the next few years.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases the risk of sudden cardiac death. The patient's LVEF of 39% is also a risk factor for sudden cardiac death. However, the patient's current medications, including beta-blockers and implantable cardioverter-defibrillators (not mentioned but often used in patients with heart failure), may help to reduce the risk of sudden cardiac death. The patient's ECG findings, including non-sustained ventricular tachycardia, also increase the risk of sudden cardiac death. However, the patient's overall clinical status and medication regimen suggest that the risk of sudden cardiac death is not extremely high.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF of 39% and history of ischemic dilated cardiomyopathy suggest that the patient is at risk for pump failure death. However, the patient's current medications and NYHA Class II classification suggest that the patient's heart failure is being managed effectively. The patient's creatinine level is slightly elevated, but it is not excessively high, indicating that the patient's renal function is not severely impaired. The patient's albumin level is also within a relatively normal range, suggesting that the patient does not have significant liver dysfunction. While the patient's prognosis is guarded, I believe that pump failure death is less likely than sudden cardiac death, given the patient's current clinical status and medication regimen."
317,317,P0523,"Age: 72
Gender: Male 
Weight: 80 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,4
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,61
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,54
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 936.0
Protein (g/L): 70
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,368
Urea (mg/dL): 6,91
LVEF (%): 35.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is my prognosis for the next few years:

RANKING: 1. Sudden cardiac death, 2. Pump failure death, 3. Survivor

REASONING:

1. Sudden cardiac death: The patient has a history of ischemic dilated cardiomyopathy, myocardial infarction, and an LVEF of 35%, indicating significant left ventricular dysfunction. The presence of polymorphic ventricular extrasystoles on the ECG also suggests an increased risk of arrhythmias. The patient's high Pro-BNP level (936 ng/L) and low ejection fraction (35%) further support the likelihood of sudden cardiac death due to arrhythmic events. Given the patient's age (72 years) and comorbidities, sudden cardiac death is a significant concern.

2. Pump failure death: The patient's LVEF of 35% and history of ischemic dilated cardiomyopathy suggest a high risk of heart failure progression. The patient's current NYHA class II classification indicates mild to moderate symptoms, but the patient's creatinine level (123.0 mol/L) and urea level (6.91 mg/dL) suggest some degree of renal impairment, which is often associated with advanced heart failure. The patient's use of loop diuretics and ACE inhibitors is consistent with heart failure management. While pump failure is a concern, the patient's current functional status and medication regimen may mitigate this risk.

3. Survivor: Despite the patient's significant cardiac and comorbid conditions, the patient's current functional status (NYHA class II) and lack of severe symptoms suggest that they may be able to tolerate their condition for an extended period. The patient's use of medications such as statins, ACE inhibitors, and nitrovasodilators, as well as their relatively low blood pressure (100/70 mmHg), may also contribute to a more favorable prognosis. However, the patient's high Pro-BNP level and low LVEF suggest ongoing cardiac stress and a need for close monitoring.

Please note that this prognosis is based on the provided data and should be used as a general guideline. The actual outcome may vary depending on individual factors, such as the patient's adherence to medication, lifestyle, and access to healthcare services."
318,318,P0524,"Age: 66
Gender: Male 
Weight: 68 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 45,8
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,46
Creatinine (mmol/L): 117.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 3,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,72
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 287.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,06
Urea (mg/dL): 7,12
LVEF (%): 36.0
Medications: Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Pump failure death
REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers become enlarged, leading to reduced heart function. The patient's left ventricular ejection fraction (LVEF) is 36%, which is significantly below the normal range (50-70%), indicating severe heart failure. The patient's creatinine level is elevated at 117.0 mol/L, suggesting renal impairment, which is a common complication of heart failure. The patient's pro-BNP level is 287.0 ng/L, which is elevated, indicating increased stress on the heart. Additionally, the patient has a history of myocardial infarction, which can further contribute to the progression of heart failure. The patient's medications, beta blockers and loop diuretics, are standard treatments for heart failure, but the patient's symptoms and test results suggest that the disease has progressed to a point where pump failure is a significant concern.

RANKING: 2. Sudden cardiac death
REASONING: The patient has a history of non-sustained ventricular tachycardia (VT), which is a risk factor for sudden cardiac death. The patient also has a history of myocardial infarction, which can lead to the formation of scar tissue in the heart that can increase the risk of arrhythmias and sudden cardiac death. The patient's LVEF is low, which can also increase the risk of sudden cardiac death. However, the patient's overall clinical picture and test results suggest that pump failure is a more immediate concern than sudden cardiac death.

RANKING: 3. Survivor
REASONING: While the patient has several risk factors for poor outcomes, including heart failure and a history of myocardial infarction, the patient's symptoms and test results suggest that the disease has not progressed to a point where sudden cardiac death or pump failure is inevitable. The patient's LVEF is low, but it is not at the lowest end of the range, and the patient is receiving standard treatments for heart failure. The patient's blood pressure and hemoglobin levels are within normal limits, which suggests that the patient's overall cardiovascular system is not in a state of severe distress. While the patient's prognosis is guarded, it is possible that with continued medical management, the patient may be able to stabilize and survive for an extended period."
319,319,P0525,"Age: 69
Gender: Male 
Weight: 85 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 145/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,5
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,22
Creatinine (mmol/L): 182.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 19,3
Hemoglobin (g/L): 120.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,34
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 241.0
Protein (g/L): 64
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,69
Urea (mg/dL): 18,25
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. However, please note that this is a hypothetical scenario and actual patient outcomes may vary. 

Given the patient's complex medical history and current condition, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden Cardiac Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. His LVEF is 35%, indicating severe left ventricular dysfunction. The presence of polymorphic ventricular extrasystoles on the ECG is a concerning finding, as it may indicate a higher risk of arrhythmic events. Additionally, the patient has a high Pro-BNP level of 241.0 ng/L, which suggests elevated filling pressures and potential heart failure. The patient's history of myocardial infarction and peripheral vascular disease also increases his risk of cardiovascular events. Considering these factors, sudden cardiac death is a significant concern.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF of 35% indicates severe left ventricular dysfunction, which is a significant risk factor for pump failure death. The patient's NYHA Class II classification suggests that he experiences some symptoms with moderate exertion, but his creatinine level of 182.0 umol/L and urea level of 18.25 mg/dL indicate impaired renal function, which is a common consequence of advanced heart failure. The patient's high Pro-BNP level also suggests elevated filling pressures and potential heart failure. While the patient is on loop diuretics, which may help manage fluid overload, the risk of pump failure remains a concern.

RANKING: 3. Survivor
 REASONING: While the patient has a complex medical history and current condition, there are some factors that suggest a potential for survival. The patient is on a comprehensive treatment regimen, including beta blockers, angiotensin II receptor blockers, and statins, which may help manage his heart failure and cardiovascular risk factors. His hemoglobin level is within a relatively normal range, and his TSH level is within the normal range, indicating no apparent thyroid dysfunction. The patient's T3 and T4 levels are also within normal ranges. However, given the patient's severe left ventricular dysfunction and other risk factors, the likelihood of survival is lower compared to the other two options."
320,320,P0526,"Age: 71
Gender: Male 
Weight: 69 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 110/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 38,1
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 43.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,9
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 318.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,53
Urea (mg/dL): 10,69
LVEF (%): 32.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: Survivor

REASONING: 

Given the patient's profile, I would rank the prognosis as a survivor for the next few years. Here's why:

1. Current Medications: The patient is on a comprehensive regimen of medications, including beta blockers, digoxin, loop diuretics, spironolactone, statins, ACE inhibitors, and nitrovasodilators. These medications are aimed at managing the patient's heart failure, hypertension, and diabetes, and are likely to be effective in stabilizing the patient's condition.

2. NYHA Class II: The patient's New York Heart Association (NYHA) functional class is II, indicating that the patient experiences some limitations in physical activity but is still able to perform everyday activities without significant symptoms. This suggests that the patient's heart failure is not severe and that the patient is tolerating the current treatment regimen.

3. LVEF of 32%: Although the patient's left ventricular ejection fraction (LVEF) is low at 32%, it is not the lowest possible value. This suggests that the patient's heart is still pumping some blood, and the patient is not in a state of severe heart failure.

4. No Recent Cardiac Arrest or Sudden Cardiac Death: The patient does not have a history of cardiac arrest or sudden cardiac death, which is a good prognostic sign.

5. ECG Results: The patient's ECG shows no signs of ventricular extrasystoles, ventricular tachycardia, or non-sustained ventricular tachycardia, which are all indicators of increased risk of sudden cardiac death.

6. Low Troponin Levels: The patient's troponin levels are low, which suggests that there is no acute myocardial infarction or cardiac injury.

However, the patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. Additionally, the patient's creatinine levels are elevated, indicating some degree of kidney dysfunction, which can be a risk factor for cardiovascular disease.

Given these factors, I would rank the prognosis as a survivor, but with a cautionary note that the patient's condition requires close monitoring and regular follow-up appointments to adjust the treatment regimen as needed."
321,321,P0527,"Age: 58
Gender: Male 
Weight: 91 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 52,69
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 3,6
LDL (mmol/L): 2,35
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 825.0
Protein (g/L): 74
T3 (pg/dL): 0,06
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,23
Urea (mg/dL): 5,34
LVEF (%): 34.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: Survivor
 REASONING: The patient has a combination of factors that suggest a relatively favorable prognosis. The patient's age is 58, which is not extremely old for a cardiomyopathy diagnosis. The LVEF of 34% indicates a reduced left ventricular function, but it is not as severely impaired as in some cases of advanced heart failure. The patient is on a comprehensive treatment regimen, including Angiotensin II Receptor Blocker, Beta Blockers, Statins, and Nitrovasodilator, which are all evidence-based treatments for heart failure and ischemic cardiomyopathy. Additionally, the patient's blood pressure is controlled at 140/90 mmHg, and the lipid profile is relatively well-managed, with a total cholesterol level of 3.9 mmol/L and an LDL of 2.35 mmol/L. The patient's Pro-BNP level is elevated at 825.0 ng/L, indicating some level of heart failure, but it is not extremely high, suggesting that the patient's condition is not catastrophic. The absence of non-sustained ventricular tachycardia and the presence of a monomorphic ventricular extrasystole on the ECG suggest that the patient's arrhythmia risk is relatively low.

RANKING: Pump Failure Death
 REASONING: The patient's LVEF of 34% and elevated Pro-BNP level of 825.0 ng/L suggest that the patient has a significant reduction in left ventricular function and some level of heart failure. However, the patient's overall clinical picture and treatment regimen suggest that the patient's condition is not as severe as some cases of advanced heart failure. The patient's blood pressure and lipid profile are well-controlled, and the patient is on a comprehensive treatment regimen, which may help to slow the progression of the disease. Additionally, the patient's age is not extremely old, which may also contribute to a more favorable prognosis.

RANKING: Sudden Cardiac Death
 REASONING: The patient's LVEF of 34% and elevated Pro-BNP level of 825.0 ng/L suggest that the patient has a significant reduction in left ventricular function and some level of heart failure, which increases the risk of sudden cardiac death. However, the patient's ECG does not show any signs of life-threatening arrhythmias, such as non-sustained ventricular tachycardia, which is a common predictor of sudden cardiac death in patients with heart failure. Additionally, the patient's treatment regimen includes Beta Blockers, which are known to reduce the risk of sudden cardiac death in patients with heart failure. Therefore, while the patient's risk of sudden cardiac death is elevated, it is not as high as some other patients with similar conditions."
322,322,P0528,"Age: 55
Gender: Male 
Weight: 85 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 41,3
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,19
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 11,6
Hemoglobin (g/L): 103.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,46
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 103.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,04
Urea (mg/dL): 8,02
LVEF (%): 39.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely, along with the reasoning behind each:

RANKING: 1. Survivor
 REASONING: The patient's current medications, including an Angiotensin II Receptor Blocker and ACE Inhibitor, suggest that they are already receiving treatment for their Hypertensive Cardiomyopathy and hypertension. Their LVEF (Left Ventricular Ejection Fraction) is 39%, which is below the normal range (50-70%), but it's not extremely low, indicating some preserved cardiac function. The patient's Pro-BNP level is elevated at 103.0 ng/L, which is a marker of heart failure, but it's not extremely high. Additionally, their blood pressure is controlled at 150/80 mmHg, which is not excessively high. Considering these factors, the patient's current treatment and relatively stable condition suggest a more favorable prognosis, making survival the most likely outcome.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of Hypertensive Cardiomyopathy, which increases the risk of sudden cardiac death. Their LVEF is also low, indicating some degree of cardiac dysfunction. The presence of monomorphic ventricular extrasystoles on the ECG suggests some level of cardiac electrical instability, which could potentially lead to arrhythmias. However, the patient's overall condition does not appear to be catastrophic, and their current medications are likely aimed at reducing this risk. While sudden cardiac death is a possible outcome, it is not the most likely given the patient's relatively stable condition.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF is 39%, indicating some degree of cardiac dysfunction, and their Pro-BNP level is elevated, suggesting heart failure. However, their current medications are likely aimed at managing their heart failure symptoms, and their blood pressure is controlled. While the patient's condition is concerning, the fact that they are already on treatment and have not yet shown signs of severe heart failure symptoms (e.g., NYHA Class IV) suggests that pump failure death is less likely in the short term."
323,323,P0530,"Age: 74
Gender: Female 
Weight: 69 kg
Height: 136 cm
NYHA Class: II
Blood Pressure: 120/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 35,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 5,9
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 116.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 3,8
LDL (mmol/L): 3,41
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1464.0
Protein (g/L): 68
T3 (pg/dL): 0,03
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,47
Urea (mg/dL): 10,69
LVEF (%): 24.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient's age and NYHA Class II suggest that the patient has some limitations in physical activity, but is still relatively stable. The patient's blood pressure is well-controlled, and the patient is on a combination of medications that are beneficial for heart failure and hypertension. The patient's LVEF of 24% indicates severe systolic heart failure, but the patient's Pro-BNP level is relatively low, which may indicate a more stable condition. Additionally, the patient's ECG shows no signs of severe arrhythmias. Considering these factors, the most likely outcome for the next few years is that the patient will survive, albeit with continued management and monitoring of their condition.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 24% indicates severe systolic heart failure, which increases the risk of pump failure. The patient's Pro-BNP level is relatively low, but this may be due to the patient's treatment with ACE inhibitors and beta blockers. The patient's creatinine level is elevated, which may indicate some degree of renal impairment, which can be a risk factor for pump failure. However, the patient's overall clinical picture is not as concerning as it would be if the patient had a higher LVEF or other signs of severe cardiac dysfunction.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's LVEF of 24% does increase the risk of sudden cardiac death, but the patient's ECG shows no signs of severe arrhythmias, and the patient is on amiodarone, which can help prevent arrhythmias. The patient's Troponin level is low, which suggests that there is no acute coronary event. The patient's overall clinical picture is more indicative of a chronic heart failure condition rather than an acute cardiac event. Therefore, sudden cardiac death is the least likely outcome for the patient in the next few years.

Please note that these prognoses are based on the provided data and may not reflect the patient's actual outcome. A more accurate prognosis would require a comprehensive evaluation by a cardiologist and consideration of other factors not included in this data."
324,324,P0531,"Age: 53
Gender: Male 
Weight: 95 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 175/100 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43,6
ALT or GPT (IU/L): 95.0
AST or GOT (IU/L): 52.0
Total Cholesterol (mmol/L): 5,53
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 67
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 162.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,52
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 644.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,3
Urea (mg/dL): 10,69
LVEF (%): 45.0
Medications: Calcium Channel Blocker, Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 2

REASONING: 

This patient has a complex medical history, including ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac mortality. The patient's ejection fraction (LVEF) is 45%, indicating systolic dysfunction, and the pro-BNP level is elevated at 644.0 ng/L, which suggests increased ventricular stress and potential heart failure. However, the patient is currently being treated with a combination of medications that are commonly used in heart failure management, including beta blockers, ACE inhibitors (or ARBs in this case), and statins. These treatments are likely aimed at reducing the patient's symptoms and slowing disease progression.

Considering the patient's age (53) and gender (male), the patient's risk of sudden cardiac death is moderate to high due to his ischemic dilated cardiomyopathy and low ejection fraction. However, the presence of ventricular extrasystoles (polymorphic) on the ECG is a concerning sign, as it may indicate an increased risk of arrhythmias, which could potentially lead to sudden cardiac death.

The patient's overall prognosis is more likely to be pump failure death rather than sudden cardiac death, primarily because the patient's LVEF is low and the patient is being treated for heart failure symptoms. Pump failure death is often a consequence of progressive heart failure, which is more likely given the patient's current condition.

Survivor is the least likely prognosis, as the patient's current medical condition and history suggest a high risk of cardiac complications. While the patient is being treated with appropriate medications, the patient's symptoms and test results indicate a high risk of adverse cardiac events.

It's worth noting that the patient's weight (95 kg) and blood pressure (175/100 mmHg) are also concerning factors, as they can exacerbate cardiac strain and increase the risk of cardiac complications."
325,325,P0532,"Age: 74
Gender: Female 
Weight: 78 kg
Height: 148 cm
NYHA Class: III
Blood Pressure: 105/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 122.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,56
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 531.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,51
Urea (mg/dL): 11,36
LVEF (%): 33.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: 1. Survivor
REASONING: The patient is 74 years old with a history of ischemic dilated cardiomyopathy and NYHA Class III, indicating significant heart failure symptoms. However, the patient is on a comprehensive treatment regimen that includes Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, and Nitrovasodilator, which suggests that the patient is receiving optimal medical therapy for heart failure. The LVEF of 33% is low, but it is not extremely low, and the patient's ejection fraction is not the only factor determining the prognosis. The patient's recent Troponin level is normal, which suggests that there is no acute myocardial infarction. The patient's Pro-BNP level is elevated, but it is not extremely high, which can be seen in patients with heart failure. The patient's blood pressure is within a reasonable range, and the patient is not hypotensive. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG is concerning, but it is not uncommon in patients with heart failure. Considering all these factors, the patient's overall prognosis is relatively good, and with continued optimal medical therapy and follow-up, the patient is likely to survive.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of ischemic dilated cardiomyopathy and LVEF of 33% puts the patient at an increased risk of sudden cardiac death. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG further increases this risk. However, the patient's overall medical therapy and the fact that the patient is not hypotensive or in acute heart failure suggest that the risk of sudden cardiac death is not extremely high. The patient's Pro-BNP level is elevated, which can be a marker of increased risk of sudden cardiac death, but it is not extremely high.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF of 33% and history of ischemic dilated cardiomyopathy suggest that the patient is at risk for pump failure. However, the patient's NYHA Class III and the fact that the patient is on optimal medical therapy for heart failure suggest that the patient's symptoms are being well-managed. The patient's blood pressure is within a reasonable range, and the patient is not hypotensive. The patient's Pro-BNP level is elevated, which can be a marker of increased risk of pump failure, but it is not extremely high. Considering all these factors, the risk of pump failure death is lower than sudden cardiac death."
326,326,P0534,"Age: 73
Gender: Male 
Weight: 94 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 35
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,35
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1860.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,42
Urea (mg/dL): 9,57
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's my prognosis for the next few years, ranked from most likely to least likely:

RANKING: Survivor

REASONING: Despite the patient's advanced age, multiple comorbidities (ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction), and reduced left ventricular ejection fraction (LVEF) of 45%, the patient is currently being treated with evidence-based medications for heart failure (beta blockers, statins, and an ACE inhibitor) and diabetes. The patient's blood pressure is well-controlled, and the absence of ventricular tachycardia and sustained ventricular arrhythmias on the ECG suggests that the patient's heart is not in a state of acute decompensation. Although the patient has a high B-type natriuretic peptide (BNP) level of 1860 ng/L, which is indicative of heart failure, the patient's overall clinical picture suggests that the disease is being managed. The patient's recent troponin level is normal, which suggests that there is no acute myocardial infarction. The patient's TSH level is within the normal range, which suggests that there is no evidence of hypothyroidism, a common comorbidity in patients with heart failure. While the patient's LVEF is reduced, it is not severely decreased, and the patient's hemoglobin and creatinine levels are within normal limits, which suggests that the patient's kidney function is not significantly impaired. Considering these factors, the most likely prognosis for the patient is survival over the next few years, provided that the patient continues to adhere to their medication regimen and lifestyle modifications.

RANKING: Sudden Cardiac Death

REASONING: Sudden cardiac death (SCD) is a potential risk for this patient, given the patient's history of ischemic dilated cardiomyopathy, reduced LVEF, and polymorphic ventricular extrasystoles on the ECG. The patient's high BNP level and reduced LVEF suggest that the patient's heart is at risk of sudden arrhythmic death. However, the patient's recent troponin level is normal, and the patient is on beta blockers, which are effective in reducing the risk of SCD. The patient's ECG does not show any signs of sustained ventricular tachycardia, which is a major risk factor for SCD. Therefore, while SCD is a possible risk, it is not the most likely prognosis.

RANKING: Pump Failure Death

REASONING: Pump failure death is a possible prognosis for this patient, given the patient's reduced LVEF and high BNP level, which suggests that the patient's heart is under significant strain. However, the patient's current medications and lifestyle modifications are likely to slow the progression of heart failure. The patient's hemoglobin and creatinine levels are within normal limits, which suggests that the patient's kidney function is not significantly impaired, which is a common cause of pump failure. Additionally, the patient's recent troponin level is normal, which suggests that there is no acute myocardial infarction. While pump failure is a possible risk, the patient's current clinical picture suggests that it is less likely than sudden cardiac death."
327,327,P0537,"Age: 66
Gender: Male 
Weight: 77 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease
Albumin (g/L): 41,5
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,8
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 89
Glucose (mmol/L): 8,7
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,88
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 688.0
Protein (g/L): 69
T3 (pg/dL): 0,06
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,867
Urea (mg/dL): 5,34
LVEF (%): 22.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here is my prognosis for the next few years:

RANKING: Survivor

REASONING: 
The patient is a 66-year-old male with a history of idiopathic dilated cardiomyopathy, diabetes, dyslipemia, and peripheral vascular disease. Despite his complex medical history, several factors suggest a favorable prognosis for survival.

Firstly, the patient's blood pressure is well-controlled at 140/70 mmHg, which is beneficial for cardiac health. His medications, including an angiotensin II receptor blocker, beta blockers, loop diuretics, and statins, are all appropriate for managing his conditions and reducing the risk of cardiac events.

The patient's LVEF (Left Ventricular Ejection Fraction) is 22%, which is significantly reduced, indicating a dilated cardiomyopathy. However, the patient's NYHA Class II classification suggests that he is experiencing some symptoms, but they are not severe enough to limit his daily activities. This classification is a positive indicator of his functional capacity.

The patient's BNP (B-type natriuretic peptide) level is elevated at 688.0 ng/L, which is consistent with heart failure. However, this level is not excessively high, and the patient's overall clinical picture does not suggest an acute decompensation.

The ECG results show a monomorphic ventricular extrasystole, which is a relatively common finding in patients with cardiomyopathy. There is no evidence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia, which are all indicators of increased cardiac risk.

While the patient's glucose level is elevated at 8.7 mmol/L, his hemoglobin A1c level is not provided, which would give a better indication of his long-term glucose control. However, his diabetes medication and the presence of other medications suggest that his diabetes is being managed.

Considering these factors, the patient's prognosis for the next few years is most likely to be a survivor. While he has a complex medical history and a reduced LVEF, his well-controlled blood pressure, appropriate medication regimen, and relatively mild symptoms suggest that he can continue to manage his conditions and maintain a good quality of life.

RANKING: Sudden Cardiac Death

REASONING: 
Sudden cardiac death is a possible outcome for this patient due to his history of idiopathic dilated cardiomyopathy and reduced LVEF. The patient's ECG results show a monomorphic ventricular extrasystole, which can be a precursor to life-threatening arrhythmias. However, the absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia reduces the likelihood of sudden cardiac death.

RANKING: Pump Failure Death

REASONING: 
Pump failure death is a less likely outcome for this patient due to his relatively well-controlled symptoms and functional capacity. His NYHA Class II classification suggests that he is not experiencing severe symptoms, and his medications are appropriate for managing his conditions. While his LVEF is significantly reduced, his overall clinical picture does not suggest an imminent risk of pump failure."
328,328,P0538,"Age: 61
Gender: Male 
Weight: 53 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 115/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,23
Creatinine (mmol/L): 85.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 9,8
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,86
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 864.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,11
Urea (mg/dL): 12,91
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Please note that this is a hypothetical prediction and actual outcomes may vary.

RANKING: 1. Survivor
 REASONING: The patient's current medical condition and treatment plan suggest a relatively stable prognosis. The patient is being treated for ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction, which are all manageable conditions with appropriate medication. The patient's ejection fraction (LVEF) is 35%, which is below the normal range (50-70%), indicating some degree of heart failure. However, the patient's NYHA class is II, indicating that the patient is experiencing some symptoms but is still able to perform daily activities without significant limitations. The patient's blood pressure, cholesterol, and glucose levels are under control, and the patient is on medications to manage these conditions. Additionally, the patient's Pro-BNP level is elevated (864 ng/L), which is a marker of heart failure, but it is not excessively high, suggesting that the patient's heart failure is not severe. Overall, considering the patient's treatment plan and the relatively stable nature of their conditions, a survivor prognosis is the most likely outcome.

RANKING: 2. Sudden Cardiac Death
 REASONING: Sudden cardiac death is a possible outcome due to the patient's history of myocardial infarction and ischemic dilated cardiomyopathy. The patient's LVEF is low (35%), which increases the risk of sudden cardiac death. Additionally, the patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are both risk factors for sudden cardiac death. However, the patient is on beta blockers and ACE inhibitors, which can reduce the risk of sudden cardiac death. The patient's overall medical condition is stable, and the risk of sudden cardiac death is not extremely high, making this outcome less likely than survival.

RANKING: 3. Pump Failure Death
 REASONING: Pump failure death is the least likely outcome due to the patient's current treatment plan and relatively stable medical condition. While the patient's LVEF is low (35%), the patient's symptoms are manageable, and they are on medications to control their heart failure. The patient's Pro-BNP level is elevated, but it is not excessively high, suggesting that the patient's heart failure is not severe. The patient's overall medical condition is stable, and the risk of pump failure death is lower than the risk of sudden cardiac death."
329,329,P0541,"Age: 61
Gender: Male 
Weight: 74 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 135/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 44,8
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,15
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,8
LDL (mmol/L): 3,54
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1751.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,61
Urea (mg/dL): 12,25
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
 REASONING: The patient's age of 61 is relatively young, and they are receiving appropriate medical treatment for their conditions, including diabetes, hypertension, and heart failure. Their LVEF of 40% indicates a reduced but not severely compromised left ventricular function. The absence of sustained ventricular tachycardia and bradycardia on the ECG suggests a relatively stable cardiac rhythm. Their low TSH level suggests that their thyroid function is well-managed, which can help mitigate the risk of cardiac complications. The patient is also on beta blockers, which can help slow the heart rate and reduce the risk of arrhythmias. While the high Pro-BNP level indicates heart failure, the patient's NYHA Class II classification suggests that their symptoms are manageable, and they are not experiencing severe shortness of breath or fatigue. Given these factors, a survivor prognosis seems the most likely outcome.

RANKING: 2. Pump failure death
 REASONING: The patient's LVEF of 40% indicates a compromised left ventricular function, which increases the risk of pump failure. The high Pro-BNP level and the patient's NYHA Class II classification suggest that their heart failure is not well-controlled, which can lead to progressive pump failure. However, the patient is receiving appropriate treatment for heart failure, including ACE inhibitors and beta blockers, which can help slow the progression of the disease. The absence of other high-risk features, such as severe anemia or electrolyte imbalances, suggests that pump failure may not be the most likely outcome.

RANKING: 3. Sudden cardiac death
 REASONING: Sudden cardiac death is a less likely outcome given the patient's age and the absence of other high-risk features, such as a history of ventricular tachycardia or a low ejection fraction (EF) < 30%. While the patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, which increases the risk of arrhythmias, their current ECG does not show any signs of sustained ventricular tachycardia or other high-risk features. Additionally, the patient is on beta blockers, which can help reduce the risk of arrhythmias."
330,330,P0542,"Age: 62
Gender: Male 
Weight: 72 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 135/65 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 51,2
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,33
Creatinine (mmol/L): 107.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 162.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,34
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 358.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,46
Urea (mg/dL): 9,35
LVEF (%): 40.0
Medications: Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the three possible prognoses as follows:

RANKING: Survivor

REASONING: The patient has a history of enolic dilated cardiomyopathy, which is a significant risk factor for heart failure and mortality. However, the patient's current ejection fraction (LVEF) is 40%, which is still within the range of mild to moderate heart failure. The patient is on statins and an ACE inhibitor, which are appropriate medications for managing heart failure and high blood pressure. The patient's blood pressure is well-controlled at 135/65 mmHg, and the patient's kidney function, as indicated by the creatinine level, is slightly elevated but not severely impaired.

Additionally, the patient's troponin level is within normal limits, indicating minimal cardiac damage. The patient's pro-BNP level is elevated at 358.0 ng/L, which suggests some degree of heart failure, but not severe. The patient's TSH level is within normal limits, indicating no apparent thyroid dysfunction.

The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are concerning signs of cardiac arrhythmias. However, the patient does not have a history of sustained ventricular tachycardia or other life-threatening arrhythmias.

Considering these factors, while the patient has significant cardiac risk factors and some evidence of cardiac dysfunction, the overall prognosis is more favorable, and I would rank survivor as the most likely outcome. The patient's controlled blood pressure, appropriate medications, and lack of severe cardiac damage or kidney impairment suggest that the patient is likely to survive with ongoing management and monitoring.

RANKING: Sudden Cardiac Death (2nd)

REASONING: While the patient has a history of enolic dilated cardiomyopathy and some evidence of cardiac dysfunction, the patient's LVEF is still within the range of mild to moderate heart failure, and the patient is on appropriate medications. However, the patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which increase the risk of sudden cardiac death. The patient's pro-BNP level is elevated, indicating some degree of heart failure, which may increase the risk of sudden cardiac death.

However, the patient's overall condition is not as severe as that of patients with more advanced heart failure or significant cardiac damage, which would increase the risk of sudden cardiac death. The patient's controlled blood pressure and lack of severe kidney impairment also suggest that the risk of sudden cardiac death is lower than that of patients with more severe cardiac dysfunction.

RANKING: Pump Failure Death (3rd)

REASONING: While the patient has a history of enolic dilated cardiomyopathy and some evidence of cardiac dysfunction, the patient's LVEF is still within the range of mild to moderate heart failure, and the patient is on appropriate medications. The patient's creatinine level is slightly elevated, indicating some degree of kidney impairment, but not severe. The patient's troponin level is within normal limits, indicating minimal cardiac damage.

The patient's pro-BNP level is elevated, indicating some degree of heart failure, but the patient's overall condition is not as severe as that of patients with advanced heart failure or significant cardiac damage, which would increase the risk of pump failure death. The patient's controlled blood pressure and lack of severe kidney impairment also suggest that the risk of pump failure death is lower than that of patients with more severe cardiac dysfunction.

In summary, while the patient has significant cardiac risk factors and some evidence of cardiac dysfunction, the overall prognosis is more favorable, and I would rank survivor as the most likely outcome."
331,331,P0543,"Age: 63
Gender: Female 
Weight: 82 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 125/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41,4
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,78
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,51
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1726.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 8,18
Urea (mg/dL): 9,13
LVEF (%): 39.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years, ranking the three possible prognoses from most likely to least likely.

RANKING: 1. Survivor
REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure. However, she is currently on a treatment regimen that includes beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators, which are all evidence-based therapies for heart failure management. Her LVEF of 39% is slightly below the normal range, but not extremely low, and her NYHA class is II, indicating that she is still relatively asymptomatic. Additionally, her Pro-BNP level is elevated, but not excessively high. Given her current treatment and the fact that she is not experiencing severe symptoms, I believe that with continued medical management, she is likely to survive.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 39% indicates that her heart is not pumping efficiently, which increases her risk of pump failure. Her elevated Pro-BNP level also suggests that her heart is under strain. However, her NYHA class is II, and she is not experiencing severe symptoms, which suggests that her heart is still compensating to some extent. Additionally, her treatment regimen is comprehensive, and she is on evidence-based medications. While pump failure is a possible outcome, I do not believe it is the most likely scenario given her current status.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. However, her treatment regimen includes beta blockers, which are effective in reducing the risk of sudden cardiac death. Additionally, her LVEF is not extremely low, and her NYHA class is II, which suggests that her heart is still functioning relatively well. While sudden cardiac death is a possible outcome, I believe it is the least likely scenario given her current treatment and status.

Please note that this prognosis is based on the provided data and may not reflect the patient's actual outcome. A more accurate prognosis would require a comprehensive evaluation by a cardiologist and consideration of other factors not provided in the data."
332,332,P0544,"Age: 61
Gender: Male 
Weight: 92 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 130/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 49
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,59
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 51
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4
LDL (mmol/L): 1,29
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 823.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,37
Urea (mg/dL): 7,57
LVEF (%): 35.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: Survivor

REASONING: Based on the provided patient data, I rank the prognosis as survivor due to the following reasons:

1.  The patient's age of 61 is relatively young for a patient with ischemic dilated cardiomyopathy, which suggests that the patient may still have a relatively long life expectancy despite the presence of heart failure.
2.  The patient's LVEF (Left Ventricular Ejection Fraction) is 35%, which is below the normal range but not extremely low. This indicates that the patient's heart still has some pumping function, which can be managed with medication and other interventions.
3.  The patient's NYHA Class III indicates that the patient has moderate symptoms of heart failure, but they are still able to perform everyday activities with some limitation.
4.  The patient's blood pressure is within a relatively normal range, which suggests that the patient's hypertension is well-controlled.
5.  The patient's laboratory results show mild elevations in liver enzymes (ALT and AST), but these are not indicative of severe liver disease.
6.  The patient's kidney function, as indicated by creatinine levels, is slightly elevated but not severely impaired.
7.  The patient's glucose levels are slightly elevated, but this is not a major concern in the context of heart failure.
8.  The patient's TSH and T4 levels are within a normal range, indicating that the patient does not have hypothyroidism, which can contribute to heart failure.
9.  The patient's Pro-BNP level is elevated, but this is consistent with heart failure.
10. The patient is on a multidrug regimen, including an Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone, and Nitrovasodilator, which suggests that the patient's heart failure is being actively managed.

However, the patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. The patient's low LVEF and NYHA Class III also indicate a higher risk of cardiac complications.

Considering these factors, the most likely prognosis is survivor, as the patient's symptoms are manageable, and the patient is on a comprehensive treatment plan. However, close monitoring and regular follow-up with a cardiologist are essential to manage the patient's condition and prevent potential complications.

Sudden cardiac death is less likely due to the patient's relatively young age and the presence of a multidrug regimen.

Pump failure death is also less likely due to the patient's relatively preserved LVEF and the fact that the patient's symptoms are manageable with medication and other interventions."
333,333,P0546,"Age: 83
Gender: Male 
Weight: 68 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,78
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 74
Glucose (mmol/L): 9,65
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,05
LDL (mmol/L): 3,77
Sodium (mEq/L): 139.0
Protein (g/L): 68
T3 (pg/dL): 0,0375
T4 (ng/L): 21,95
Troponin (ng/mL): 0,1
TSH (mIU/L): 1,15
Urea (mg/dL): 6,5
LVEF (%): 30.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor, 2. Pump failure death, 3. Sudden cardiac death

REASONING: 

Based on the provided patient data, I have ranked the possible prognoses as follows:

1. Survivor: Despite the patient's advanced age (83 years) and significant comorbidities, including idiopathic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension, there are several factors that suggest a relatively favorable prognosis. The patient is on optimal medical therapy, including ACE inhibitors, statins, and loop diuretics, which are essential for managing heart failure and reducing the risk of cardiac events. Additionally, the patient's ejection fraction (LVEF) is 30%, which, although low, is not extremely low. The patient's hemoglobin level is within the normal range, indicating adequate oxygen delivery to tissues. The absence of non-sustained ventricular tachycardia on the ECG also suggests a lower risk of sudden cardiac death. Furthermore, the patient's TSH level is within the normal range, indicating no overt thyroid dysfunction, which can sometimes contribute to heart failure. While the patient's creatinine level is elevated, indicating some degree of renal impairment, it is not severely elevated, and the patient is on loop diuretics, which can help manage fluid overload. Overall, considering these factors, I believe the patient has a higher likelihood of surviving the next few years.

2. Pump failure death: The patient's LVEF of 30% indicates severe left ventricular dysfunction, which increases the risk of pump failure. However, the patient is on optimal medical therapy, which may help slow disease progression. The patient's creatinine level is elevated, indicating some degree of renal impairment, which can be a risk factor for pump failure. However, the patient's hemoglobin level is within the normal range, and the absence of non-sustained ventricular tachycardia on the ECG suggests a lower risk of sudden cardiac death. While pump failure is a possible outcome, I believe it is less likely than sudden cardiac death due to the patient's relatively stable medical therapy and the absence of other high-risk features.

3. Sudden cardiac death: Sudden cardiac death is a significant risk in patients with heart failure, particularly those with low LVEF. However, the patient's ECG does not show any evidence of non-sustained ventricular tachycardia, which is a known risk factor for sudden cardiac death. The patient's TSH level is within the normal range, indicating no overt thyroid dysfunction, which can contribute to heart failure. While the patient's creatinine level is elevated, indicating some degree of renal impairment, the patient is on loop diuretics, which can help manage fluid overload. The patient's hemoglobin level is within the normal range, indicating adequate oxygen delivery to tissues. Considering these factors, I believe sudden cardiac death is the least likely outcome, although it cannot be ruled out entirely."
334,334,P0547,"Age: 30
Gender: Female 
Weight: 64 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 6,65
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,99
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 89.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,44
Urea (mg/dL): 3,83
LVEF (%): 50.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: The patient is a 30-year-old female with idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge. However, the patient's LVEF (Left Ventricular Ejection Fraction) is 50%, which is within the normal range for this age group. The patient is on optimal medical therapy with beta blockers, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure. The patient's ECG does not show any signs of severe arrhythmias, and the troponin level is within normal limits. The patient's BNP (Brain Natriuretic Peptide) level is 89.0 ng/L, which is slightly elevated but not extremely high. The patient's hemoglobin and albumin levels are within normal limits, indicating no severe anemia or malnutrition. The patient's weight is 64 kg, which is within the normal range for her height. Overall, the patient's clinical presentation and laboratory results suggest that she is being well-managed for her condition, and her prognosis is likely to be a survivor.

Note: The patient's LVEF of 50% is not ideal, but it is not extremely low, and her overall clinical picture suggests that she is not at high risk of sudden cardiac death or pump failure. The patient's age and the fact that she is being treated with optimal medical therapy also support a favorable prognosis."
335,335,P0548,"Age: 75
Gender: Male 
Weight: 82 kg
Height: 179 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 3,28
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 8,4
Hemoglobin (g/L): 164.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 5,2
LDL (mmol/L): 1,03
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 450.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 19
Troponin (ng/mL): 0,13
TSH (mIU/L): 2,29
Urea (mg/dL): 7,15
LVEF (%): 38.0
Medications: Beta Blockers, Digoxin, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the ranking of the three possible prognoses:

RANKING: 1. Survivor
REASONING: The patient's current medications, including beta blockers, digoxin, spironolactone, statins, and ACE inhibitor, suggest that they are receiving appropriate treatment for their ischemic dilated cardiomyopathy and heart failure. The patient's LVEF of 38% indicates a reduced ejection fraction, but it is not extremely low. The patient's blood pressure is within a relatively normal range, and their creatinine level is slightly elevated but not excessively high. The patient's pro-BNP level is elevated, which is consistent with heart failure, but not alarmingly high. The absence of significant electrolyte imbalances and the presence of hemoglobin within a normal range suggest that the patient's kidney function is not severely compromised. The patient's ECG findings of polymorphic ventricular extrasystole and non-sustained ventricular tachycardia are concerning, but the patient is being treated with beta blockers, which are effective in reducing the risk of arrhythmic events. Overall, while the patient has significant comorbidities, their current treatment regimen and relatively stable vital signs suggest that a survivor prognosis is the most likely outcome.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of myocardial infarction, ischemic dilated cardiomyopathy, and non-sustained ventricular tachycardia on ECG increase the risk of sudden cardiac death. However, the patient is being treated with beta blockers, which are effective in reducing the risk of arrhythmic events, and their current medications suggest that they are receiving appropriate treatment for their heart failure. The patient's LVEF of 38% is not extremely low, and their blood pressure is within a relatively normal range. The patient's creatinine level is slightly elevated, but not excessively high. While the patient's pro-BNP level is elevated, it is not alarmingly high. Overall, while the patient's risk of sudden cardiac death is increased, their current treatment regimen and relatively stable vital signs suggest that this outcome is less likely than survivor.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF of 38% and elevated pro-BNP level suggest that they have significant heart failure. However, the patient is being treated with appropriate medications, including beta blockers, digoxin, and spironolactone, which are effective in managing heart failure symptoms and reducing the risk of hospitalization. The patient's blood pressure is within a relatively normal range, and their creatinine level is slightly elevated but not excessively high. The patient's hemoglobin level is within a normal range, suggesting that their kidney function is not severely compromised. While the patient's ECG findings of polymorphic ventricular extrasystole and non-sustained ventricular tachycardia are concerning, their current treatment regimen and relatively stable vital signs suggest that pump failure death is the least likely outcome."
336,336,P0549,"Age: 56
Gender: Male 
Weight: 96 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 147.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,59
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 561.0
Protein (g/L): 76
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,2
Urea (mg/dL): 6,32
LVEF (%): 54.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Survivor
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a chronic condition affecting the heart's pumping ability. However, the patient is on a comprehensive treatment plan that includes beta blockers, loop diuretics, spironolactone, statins, ACE inhibitor, and nitrovasodilator. These medications are aimed at managing heart failure symptoms, reducing the risk of further cardiac events, and improving the patient's quality of life. The patient's LVEF is 54%, which is below the normal range but not extremely low. The patient's NYHA Class is II, indicating that the patient is experiencing some limitations in physical activity but is still able to perform everyday tasks. The absence of severe symptoms, such as severe shortness of breath or fatigue, and the presence of a relatively high hemoglobin level (147 g/L) suggest that the patient's condition is being managed effectively. While the patient has a history of myocardial infarction, the troponin level is within normal limits, indicating that the patient has not had a recent cardiac event. The patient's TSH level is within the normal range, which is a good indicator of thyroid function, and the low T3 level may be a result of the beta blocker medication. Overall, these factors suggest that the patient is likely to survive with continued management of their condition.

RANKING: Pump Failure Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy and a low LVEF (54%), which increases the risk of pump failure. The patient's creatinine level is elevated (124.0 mmol/L), indicating some degree of kidney dysfunction, which is often associated with heart failure. The patient's BNP level is high (561.0 ng/L), which is a marker of heart failure. However, the patient's overall clinical presentation and treatment plan suggest that pump failure is not the most likely outcome at this time.

RANKING: Sudden Cardiac Death
 REASONING: The patient has a history of non-sustained ventricular tachycardia (VT) and polymorphic ventricular extrasystoles, which are risk factors for sudden cardiac death. However, the patient is on a nitrovasodilator, which is a medication that can help prevent arrhythmias. The patient's ECG also shows a non-sustained VT, which is a risk factor, but the absence of a history of sudden cardiac death or a high risk of arrhythmias makes this prognosis less likely compared to the other two options."
337,337,P0551,"Age: 60
Gender: Male 
Weight: 85 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 48
Glucose (mmol/L): 8,1
Hemoglobin (g/L): 137.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,4
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 2239.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 17
TSH (mIU/L): 0,845
Urea (mg/dL): 12,81
LVEF (%): 57.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

Based on the provided patient data, I would rank the prognosis as a survivor for the next few years. Here's the reasoning behind this ranking:

1. Age and Gender: The patient is 60 years old, which is an age where cardiovascular disease risk increases. However, his gender as a male does not significantly impact the prognosis in this case.
2. NYHA Class II: The patient's New York Heart Association (NYHA) functional classification is II, indicating mild symptoms of heart failure. This suggests that the patient's heart disease is not severe at this point.
3. Medications: The patient is on a combination of medications that are commonly used to manage heart failure and hypertension, including Calcium Channel Blockers, Beta Blockers, Loop Diuretics, and ACE Inhibitor. This suggests that the patient's condition is being actively managed.
4. ECG Impression: The patient has a ventricular extrasystole, but there is no indication of sustained ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia. This suggests that the patient's cardiac rhythm is relatively stable.
5. LVEF: The left ventricular ejection fraction (LVEF) is 57%, which is within the normal range (50-70%). This indicates that the patient's heart is still pumping blood efficiently.
6. Blood Work: The patient's blood work shows elevated creatinine levels, which may indicate kidney impairment, but it is not severe. The patient's albumin and protein levels are within normal range, which suggests that the patient is not experiencing significant malnutrition or liver disease.
7. Hemoglobin and Potassium: The patient's hemoglobin level is within the normal range, and potassium levels are slightly low, which can be managed with diet or supplements.
8. Pro-BNP: The patient's pro-b-type natriuretic peptide (pro-BNP) level is elevated, which is consistent with heart failure. However, the level is not extremely high, which suggests that the patient's condition is not catastrophic.
9. TSH and T3/T4: The patient's thyroid function tests are within the normal range, which suggests that thyroid disease is not contributing to the patient's condition.
10. Weight and Blood Pressure: The patient's weight is within the normal range, and blood pressure is well-controlled, which suggests that the patient's hypertension is under control.

Considering these factors, the patient's overall prognosis is more likely to be a survivor, as the patient's condition is being actively managed, and there are no severe indicators of cardiac disease or other comorbidities that would suggest a poor outcome."
338,338,P0552,"Age: 50
Gender: Female 
Weight: 59 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 41
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,35
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,25
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,62
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 809.0
Protein (g/L): 70
T4 (ng/L): 9
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,04
Urea (mg/dL): 5,99
LVEF (%): 66.0
Medications: Beta Blockers
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. I will order the three possible prognoses from most likely to least likely.

RANKING: 1. Survivor
 REASONING: The patient is 50 years old with a history of hypertrophic cardiomyopathy, but her LVEF (left ventricular ejection fraction) is relatively preserved at 66%. She is on beta blockers, which is a standard treatment for hypertrophic cardiomyopathy. Her ECG shows monomorphic ventricular extrasystoles, but no signs of sustained ventricular tachycardia or other severe arrhythmias. Her blood pressure is well-controlled, and her renal function is within normal limits. Her troponin level is normal, indicating no acute myocardial infarction. While her BNP level is elevated, indicating some degree of heart failure, her NYHA class is only II, indicating mild symptoms. Overall, the patient's condition appears to be relatively stable, and with continued medical management, she is likely to survive.

RANKING: 2. Sudden cardiac death
 REASONING: The patient has a history of hypertrophic cardiomyopathy, which is a risk factor for sudden cardiac death. However, her LVEF is preserved, and she is on beta blockers, which reduces the risk of sudden cardiac death. Her ECG shows monomorphic ventricular extrasystoles, but no signs of sustained ventricular tachycardia or other severe arrhythmias. While her BNP level is elevated, indicating some degree of heart failure, her NYHA class is only II, indicating mild symptoms. The risk of sudden cardiac death is higher in patients with a history of hypertrophic cardiomyopathy, but with continued medical management, the risk is still relatively low.

RANKING: 3. Pump failure death
 REASONING: The patient's LVEF is 66%, which is within the normal range, and her NYHA class is only II, indicating mild symptoms. Her BNP level is elevated, indicating some degree of heart failure, but it is not severely elevated, and her renal function is within normal limits. Her blood pressure is well-controlled, and she is on beta blockers, which are effective in managing heart failure symptoms. While her condition is not ideal, the likelihood of pump failure death is relatively low, especially with continued medical management."
339,339,P0554,"Age: 70
Gender: Female 
Weight: 56 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 147/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 48
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 6,67
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 10,9
Hemoglobin (g/L): 115.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,6
Sodium (mEq/L): 139.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,005
TSH (mIU/L): 2,39
Urea (mg/dL): 14,48
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

Given the patient's profile, I would rank the prognosis as Survivor for the following reasons:

1.  The patient is on appropriate medical therapy for heart failure (Beta Blockers, Loop Diuretics, ACE Inhibitor, and Statins) and diabetes management, which indicates that she is receiving optimal treatment for her conditions.
2.  Despite having ischemic dilated cardiomyopathy and a low LVEF (35%), she is still classified as NYHA Class II, which suggests that her symptoms are not severe, and she is able to perform some physical activity without discomfort.
3.  Her blood pressure is within a relatively normal range, and her creatinine levels are slightly elevated but not significantly high, indicating that her renal function is still relatively preserved.
4.  Her troponin levels are low, indicating that she is not experiencing acute myocardial infarction or significant cardiac damage.
5.  Her TSH levels are within the normal range, indicating that her thyroid function is well-managed, which is essential for cardiac function.
6.  While her total cholesterol and LDL levels are high, she is on statins, which should help manage these levels.
7.  Her albumin levels are slightly low, but not critically low, which can indicate malnutrition or liver disease, but her AST and ALT levels are within normal limits, suggesting that her liver function is relatively preserved.
8.  Her potassium levels are within a relatively normal range, which is essential for cardiac function.

However, there are some risk factors that need to be considered:

*  Her low LVEF (35%) indicates that she has significant cardiac dysfunction, which increases her risk of sudden cardiac death.
*  Her high total cholesterol and LDL levels increase her risk of cardiovascular events.
*  Her diabetes and dyslipemia are significant risk factors for cardiovascular disease.

Despite these risks, I would rank the prognosis as Survivor because she is receiving optimal medical therapy, and her current symptoms are not severe. However, close monitoring and regular follow-up appointments with her cardiologist are essential to manage her conditions and prevent potential complications."
340,340,P0557,"Age: 72
Gender: Female 
Weight: 55 kg
Height: 146 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,61
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 103.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,94
Urea (mg/dL): 8,82
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: The patient is 72 years old with a history of hypertensive cardiomyopathy, dyslipemia, and hypertension. Despite these comorbidities, the patient is on a comprehensive treatment regimen, including beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor. The patient's blood pressure is well-controlled at 120/80 mmHg, and the LVEF is 30%, which is relatively stable but still indicates some degree of left ventricular dysfunction.

The patient's creatinine level is elevated at 97.0 mol/L, which may indicate some degree of renal impairment, but the urea level is not significantly elevated. The patient's albumin level is within the normal range, and the liver enzymes (ALT and AST) are mildly elevated but not significantly abnormal.

The patient's troponin level is 0.01 ng/mL, which is within the normal range, indicating that there is no acute myocardial infarction or significant cardiac damage. The pro-BNP level is 103.0 ng/L, which is elevated but not extremely high, indicating some degree of heart failure but not severe.

The patient's ECG shows polymorphic ventricular extrasystoles, but no non-sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia. The patient's TSH level is within the normal range, indicating no significant thyroid dysfunction.

Considering these factors, the patient's overall prognosis is likely to be a survivor, as they are on appropriate treatment for their comorbidities, and their vital signs and laboratory values are relatively stable.

RANKING: 2. Sudden cardiac death

REASONING: While the patient's LVEF is low at 30%, and they have a history of hypertensive cardiomyopathy and dyslipemia, there is no indication of acute myocardial infarction, severe cardiac damage, or significant arrhythmias. The patient's ECG shows polymorphic ventricular extrasystoles, but this is not an immediate risk factor for sudden cardiac death.

The patient's treatment regimen is comprehensive, and their blood pressure is well-controlled. The patient's renal function is impaired, but not severely so. The patient's overall clinical picture suggests that sudden cardiac death is less likely than survival, but not extremely unlikely.

RANKING: 3. Pump failure death

REASONING: The patient's LVEF is 30%, which indicates some degree of left ventricular dysfunction. However, the patient is on beta blockers, loop diuretics, and ACE inhibitors, which are all treatments that can help manage heart failure symptoms and slow disease progression. The patient's creatinine level is elevated, but not severely so, and their urea level is not significantly elevated, suggesting that renal function is not severely impaired.

The patient's overall clinical picture suggests that pump failure death is less likely than sudden cardiac death or survival. The patient's treatment regimen and stable vital signs and laboratory values suggest that they are likely to survive for the next few years, but the risk of pump failure death cannot be ruled out entirely."
341,341,P0558,"Age: 65
Gender: Male 
Weight: 98 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 16
Hemoglobin (g/L): 147.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,33
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1649.0
Protein (g/L): 65
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,54
Urea (mg/dL): 6,99
LVEF (%): 27.0
Medications: Digoxin, Loop Diuretics, Hydralazine, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: Survivor
 REASONING: 

Based on the provided patient data, I would rank the prognosis as Survivor for the following reasons:

1.  The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac complications. However, the patient is currently being treated with a combination of medications, including ACE inhibitor, digoxin, loop diuretics, and hydralazine, which are commonly used to manage heart failure and reduce mortality in patients with heart failure.

2.  The patient's LVEF (left ventricular ejection fraction) is 27%, which indicates a reduced ejection fraction, but it is not extremely low. Patients with an LVEF between 20-40% are considered intermediate-risk patients, and with proper management, they can still have a good prognosis.

3.  The patient's BNP (B-type natriuretic peptide) level is elevated at 1649 ng/L, which is a marker of heart failure severity. However, the patient's symptoms, as indicated by NYHA Class III, suggest that the heart failure is not severe, and the patient is not in an advanced stage of heart failure.

4.  The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death, but the presence of this arrhythmia does not necessarily indicate a high risk of sudden cardiac death in this patient.

5.  The patient's potassium level is within the normal range, which is a good sign, as hypokalemia can increase the risk of arrhythmias.

6.  The patient's TSH level is within the normal range, which suggests that there is no underlying thyroid disease that could contribute to cardiac complications.

7.  The patient's medications are appropriate for heart failure management, and the patient is being closely monitored for any signs of worsening heart failure or arrhythmias.

Based on these factors, I would rank the prognosis as Survivor, as the patient is being actively managed for heart failure, and the patient's symptoms and lab results suggest that the heart failure is not in an advanced stage. However, the patient will require close monitoring and regular follow-up appointments to adjust medications and manage any potential complications.

RANKING: Sudden Cardiac Death
REASONING: 

Sudden cardiac death is a possible prognosis, but it is less likely than survivor due to the following reasons:

*   The patient is being treated with medications that are known to reduce the risk of sudden cardiac death, such as ACE inhibitors and beta-blockers (not mentioned in the medication list but often used in similar patients).
*   The patient's LVEF is not extremely low, and the patient is not in an advanced stage of heart failure.
*   The patient's BNP level is elevated, but not extremely high, which suggests that the heart failure is not severe.

However, the presence of non-sustained ventricular tachycardia on the ECG does increase the risk of sudden cardiac death.

RANKING: Pump Failure Death
REASONING: 

Pump failure death is the least likely prognosis due to the following reasons:

*   The patient is being treated with loop diuretics, which are used to manage fluid overload and reduce the risk of heart failure progression.
*   The patient's LVEF is not extremely low, and the patient is not in an advanced stage of heart failure.
*   The patient's BNP level is elevated, but not extremely high, which suggests that the heart failure is not severe.
*   The patient's symptoms, as indicated by NYHA Class III, suggest that the heart failure is not severe, and the patient is not in an advanced stage of heart failure.

However, the patient's LVEF of 27% and history of ischemic dilated cardiomyopathy do increase the risk of pump failure death."
342,342,P0561,"Age: 38
Gender: Female 
Weight: 58 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 90/50 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 41
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,27
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 8
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,77
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 37.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,23
Urea (mg/dL): 6,32
LVEF (%): 41.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's my prognosis for the next few years, ranked from most likely to least likely:

RANKING: Survivor

REASONING: The patient is 38 years old with a history of idiopathic dilated cardiomyopathy, which indicates a weakening of the heart muscle. However, the patient is on beta-blockers and an ACE inhibitor, which are standard treatments for heart failure and cardiomyopathy. The patient's LVEF (left ventricular ejection fraction) is 41%, which is below the normal range but not extremely low. The patient's pro-BNP level is 37.0 ng/L, which is elevated but not excessively high, indicating some degree of heart failure but not severe. The patient's ECG shows monomorphic ventricular extrasystoles, which are relatively common and often benign. The patient's overall condition does not indicate a high risk of sudden cardiac death or pump failure in the near future. The patient's age and relatively low LVEF suggest a need for close monitoring and potential adjustment of medications, but the prognosis is generally positive.

RANKING: Sudden Cardiac Death

REASONING: While the patient has a history of idiopathic dilated cardiomyopathy, which increases the risk of sudden cardiac death, the patient's LVEF is not extremely low, and the patient is on beta-blockers and an ACE inhibitor, which can reduce the risk of sudden cardiac death. The patient's ECG shows monomorphic ventricular extrasystoles, which are not typically a marker for high risk of sudden cardiac death. The patient's pro-BNP level is elevated but not excessively high, indicating some degree of heart failure but not severe. The patient's age and overall condition do not suggest a high risk of sudden cardiac death in the near future.

RANKING: Pump Failure Death

REASONING: The patient's LVEF is 41%, which is below the normal range, indicating some degree of heart failure. However, the patient is on beta-blockers and an ACE inhibitor, which can help manage heart failure symptoms and slow disease progression. The patient's pro-BNP level is elevated but not excessively high, indicating some degree of heart failure but not severe. The patient's overall condition does not suggest a high risk of pump failure in the near future. The patient's age and relatively low LVEF suggest a need for close monitoring and potential adjustment of medications, but the prognosis is generally positive."
343,343,P0562,"Age: 79
Gender: Female 
Weight: 67 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 150/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 27
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,4
Creatinine (mmol/L): 194.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 3,9
Hemoglobin (g/L): 80.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,79
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 4399.0
Protein (g/L): 61
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,4
Urea (mg/dL): 37,27
LVEF (%): 53.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: 1. Survivor
REASONING: The patient is 79 years old with a history of hypertensive cardiomyopathy, diabetes, dyslipemia, and peripheral vascular disease. Despite these comorbidities, the patient's current LVEF (Left Ventricular Ejection Fraction) is 53%, which is within a relatively normal range. The patient's Pro-BNP level is elevated at 4399.0 ng/L, indicating some degree of heart failure, but the patient is on appropriate medications for heart failure, including ACE inhibitors (Angiotensin II Receptor Blocker) and beta-blockers. The patient's ECG shows a second-degree AV block, which may be related to the patient's age and hypertension. However, the absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG suggests a relatively stable cardiac rhythm. Given the patient's current management and the lack of severe cardiac arrhythmias, the most likely prognosis is a survivor.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of hypertensive cardiomyopathy and diabetes increases the risk of sudden cardiac death. The patient's LVEF is 53%, which is slightly below the normal range, and the Pro-BNP level is elevated, indicating some degree of heart failure. However, the patient is on appropriate medications for heart failure, and the ECG does not show any signs of severe cardiac arrhythmias. The patient's age and comorbidities increase the risk of sudden cardiac death, but the patient's current management and the lack of severe cardiac arrhythmias on the ECG suggest a lower risk of sudden cardiac death compared to pump failure death.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF is 53%, which is slightly below the normal range, and the Pro-BNP level is elevated at 4399.0 ng/L, indicating some degree of heart failure. The patient's creatinine level is also elevated at 194.0 mmol/L, suggesting renal impairment, which can be a consequence of heart failure. However, the patient is on appropriate medications for heart failure, including ACE inhibitors and beta-blockers, which can help to slow the progression of heart failure. The patient's current management and the lack of severe cardiac arrhythmias on the ECG suggest a lower risk of pump failure death compared to sudden cardiac death."
344,344,P0564,"Age: 69
Gender: Male 
Weight: 75 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 6,62
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 56
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 147.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,37
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 277.0
Protein (g/L): 74
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,7
Urea (mg/dL): 6,99
LVEF (%): 45.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"RANKING: Survivor

REASONING: 

Given the provided patient data, I would rank the prognosis as a survivor for the next few years. Here's the reasoning behind this assessment:

1.  Age and Gender: The patient is a 69-year-old male, which is an advanced age for a male. However, this alone does not significantly increase the risk of cardiac mortality.
2.  NYHA Class II: The patient has a mild to moderate level of heart failure symptoms, which indicates that the heart is functioning relatively well despite the presence of underlying conditions.
3.  Medications: The patient is on beta blockers, statins, and an ACE inhibitor, which are all standard treatments for ischemic dilated cardiomyopathy, hypertension, and dyslipidemia. These medications can help manage symptoms, slow disease progression, and reduce the risk of cardiac events.
4.  ECG Findings: The patient has a second-degree AV block, which is a concerning finding, but it is not necessarily a predictor of sudden cardiac death. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death.
5.  LVEF: The patient's left ventricular ejection fraction (LVEF) is 45%, which is below the normal range (50-70%). However, an LVEF of 45% is still considered relatively well-preserved, and some patients with LVEF in this range can have a good prognosis.
6.  Laboratory Results: The patient's troponin level is within normal limits (0.01 ng/mL), which suggests that there is no ongoing myocardial infarction or acute cardiac injury. The pro-BNP level is elevated at 277 ng/L, but this is not uncommon in patients with heart failure.
7.  Risk Factors: The patient has several risk factors, including ischemic dilated cardiomyopathy, hypertension, dyslipidemia, and a history of myocardial infarction. However, these factors are being managed with medications, and the patient's symptoms are well-controlled.

Considering these factors, the patient's prognosis is likely to be a survivor for the next few years, with a focus on continued management of their underlying conditions and close monitoring of their cardiac function and symptoms. However, it is essential to note that the patient should be regularly followed up with the healthcare team to adjust their treatment plan as needed and to monitor for any changes in their condition."
345,345,P0566,"Age: 65
Gender: Male 
Weight: 88 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 170/90 mmHg
Past Medical History: Hypertropic cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,72
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,98
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 290.0
Protein (g/L): 71
T4 (ng/L): 10
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,46
Urea (mg/dL): 6,66
LVEF (%): 62.0
Medications: Beta Blockers, Digoxin, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. However, I must emphasize that a more accurate prognosis would require a comprehensive evaluation by a cardiologist, taking into account additional factors such as the patient's overall health, medical history, and lifestyle.

That being said, based on the provided data, here is my prognosis:

RANKING: 1. Survivor
REASONING: The patient is 65 years old, which places them in a high-risk category for cardiovascular events. However, the patient's left ventricular ejection fraction (LVEF) is 62%, which is within the normal range. This suggests that the patient's heart function is relatively preserved. The patient's NYHA Class II indicates that they have some limitations in physical activity, but they are still able to perform most daily tasks without symptoms. The patient is also on beta blockers, digoxin, and loop diuretics, which are standard medications for heart failure and hypertension management. The patient's troponin level is within normal limits, and there is no evidence of recent myocardial infarction. The patient's pro-BNP level is elevated, which may indicate some degree of heart failure, but it is not extremely high. The patient's overall clinical picture suggests that they are at risk for heart failure, but the likelihood of sudden cardiac death or pump failure death is lower compared to a patient with more severe symptoms or lower LVEF.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF is within the normal range, but it is on the lower end of the normal spectrum. The patient's pro-BNP level is elevated, which suggests some degree of heart failure. The patient's creatinine level is slightly elevated, which may indicate some degree of renal dysfunction, which can be a predictor of heart failure progression. The patient's total cholesterol and LDL levels are elevated, which may contribute to the progression of atherosclerosis and subsequent heart failure. The patient's weight is also above the ideal range, which can also contribute to heart failure. However, the patient's overall clinical picture does not suggest a high risk of pump failure death in the near future.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the patient's LVEF is within the normal range, and there is no evidence of recent myocardial infarction or significant arrhythmias. The patient's troponin level is within normal limits, and the patient is on beta blockers, which can reduce the risk of sudden cardiac death. The patient's overall clinical picture suggests that the risk of sudden cardiac death is lower compared to a patient with more severe symptoms or lower LVEF.

In summary, based on the provided data, I believe that the patient is at a higher risk of heart failure progression and pump failure death compared to sudden cardiac death. However, the patient's overall clinical picture is complex, and a more accurate prognosis would require a comprehensive evaluation by a cardiologist."
346,346,P0569,"Age: 83
Gender: Female 
Weight: 58 kg
Height: 154 cm
NYHA Class: III
Blood Pressure: 125/75 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 4,53
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 85.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,84
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 753.0
Protein (g/L): 65
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,83
Urea (mg/dL): 7,15
LVEF (%): 61.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here are the prognoses for the next few years, ordered from most likely to least likely:

RANKING: Survivor
 REASONING: Despite the patient's advanced age (83 years) and history of hypertensive cardiomyopathy, the patient's left ventricular ejection fraction (LVEF) is relatively preserved at 61%. The absence of significant troponin elevation, absence of ventricular tachycardia, and presence of a stable medication regimen (including an ACE inhibitor, which is beneficial for patients with heart failure) are positive indicators. The patient's blood pressure is well-controlled, and the lack of significant abnormalities in the liver function tests (ALT, AST, GGT) suggests that the patient's liver function is relatively preserved. While the patient has a high Pro-BNP level, indicating some degree of heart failure, the patient's overall clinical picture suggests that the heart failure is not severe. Therefore, a survivor prognosis is the most likely outcome.

RANKING: Pump Failure Death
 REASONING: The patient's high Pro-BNP level and NYHA Class III classification suggest that the patient has heart failure with some degree of symptoms. The patient's LVEF is preserved at 61%, but the patient's age, sex, and history of hypertensive cardiomyopathy increase the risk of progression to heart failure with reduced ejection fraction. The patient's low HDL cholesterol level and high LDL cholesterol level may also contribute to the risk of cardiovascular disease progression. However, the patient's overall clinical picture does not suggest an imminent risk of sudden cardiac death, and the presence of a stable medication regimen and absence of significant troponin elevation suggest that the patient's heart failure is not severe. Therefore, pump failure death is the second most likely outcome.

RANKING: Sudden Cardiac Death
 REASONING: The patient's ECG shows ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the extrasystoles are monomorphic, and the patient does not have a history of ventricular tachycardia or other arrhythmias that would increase the risk of sudden cardiac death. The patient's LVEF is preserved at 61%, and the patient's medication regimen includes a calcium channel blocker, which can help to reduce the risk of arrhythmias. The patient's high Pro-BNP level and NYHA Class III classification suggest that the patient has heart failure, but the patient's overall clinical picture does not suggest an imminent risk of sudden cardiac death. Therefore, sudden cardiac death is the least likely outcome."
347,347,P0571,"Age: 76
Gender: Male 
Weight: 96 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 115/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 7,7
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 5,1
LDL (mmol/L): 1,89
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1303.0
Protein (g/L): 80
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,71
Urea (mg/dL): 13,48
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Hydralazine, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here are my prognostic rankings for the next few years:

RANKING: 1. Survivor
REASONING: The patient is 76 years old with a history of idiopathic dilated cardiomyopathy, diabetes, and hypertension, which are all risk factors for cardiovascular disease. However, the patient's current NYHA Class II indicates that they are still relatively stable and able to perform daily activities without significant limitations. The patient is on a comprehensive treatment regimen that includes beta blockers, digoxin, loop diuretics, hydralazine, ACE inhibitor, and nitrovasodilator, which suggests that the treatment is aimed at managing symptoms and improving cardiac function. The patient's LVEF of 35% indicates that the heart is still pumping at a reduced capacity, but the patient's Pro-BNP level of 1303 ng/L is elevated, suggesting that the heart is under strain. Despite this, the patient's troponin level is normal, indicating that there is no current evidence of acute coronary syndrome. The patient's medications and overall management plan suggest that the healthcare team is taking a proactive approach to managing the patient's condition, which increases the likelihood of a positive outcome.

RANKING: 2. Sudden Cardiac Death
REASONING: While the patient's history and current condition increase the risk of sudden cardiac death, there are several factors that suggest this outcome is less likely. The patient's ECG shows monomorphic ventricular extrasystoles, but no non-sustained ventricular tachycardia or other high-risk arrhythmias. The patient's LVEF is low, but not critically low, and their Pro-BNP level is elevated, but not extremely high. The patient is on a comprehensive treatment regimen that includes medications that can help prevent sudden cardiac death, such as beta blockers and ACE inhibitors. While the patient's age and medical history increase the risk of sudden cardiac death, the overall management plan and lack of high-risk arrhythmias suggest that this outcome is less likely.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF of 35% indicates that the heart is pumping at a reduced capacity, and their Pro-BNP level of 1303 ng/L suggests that the heart is under strain. However, the patient's current NYHA Class II and overall management plan suggest that the healthcare team is taking a proactive approach to managing the patient's condition. The patient is on a comprehensive treatment regimen that includes medications that can help improve cardiac function, such as ACE inhibitors and hydralazine. While the patient's medical history and current condition increase the risk of pump failure, the overall management plan and lack of acute decompensation suggest that this outcome is less likely."
348,348,P0572,"Age: 36
Gender: Male 
Weight: 80 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 58
Glucose (mmol/L): 7,7
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,51
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 32.0
Protein (g/L): 76
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,21
Urea (mg/dL): 4,66
LVEF (%): 53.0
Medications: Calcium Channel Blocker, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the ranking of the three possible prognoses for the next few years:

RANKING: 1. Survivor

REASONING: The patient is 36 years old, which is relatively young for a cardiomyopathy diagnosis. His current medications, including ACE inhibitors, beta blockers, and loop diuretics, suggest that he is being managed for his hypertension and cardiomyopathy. His LVEF of 53% is slightly below the normal range, but it is not severely compromised. He also does not have any signs of severe cardiac dysfunction, such as elevated troponin levels or signs of heart failure. His ECG does show monomorphic ventricular extrasystoles, but this is not a significant concern. Considering his age, the relatively mild nature of his cardiomyopathy, and his current treatment plan, the most likely prognosis is that he will survive for the next few years.

RANKING: 2. Pump Failure Death

REASONING: While the patient's LVEF is slightly below normal, it is not severely compromised, and his current medications are aimed at managing his cardiomyopathy. His ejection fraction is not low enough to indicate a high risk of pump failure. Additionally, his creatinine level is within normal limits, which suggests that his kidney function is not significantly impaired. His pro-BNP level is also within normal limits, which suggests that his heart is not under significant stress. Therefore, pump failure death is less likely than survivor.

RANKING: 3. Sudden Cardiac Death

REASONING: The patient's ECG shows monomorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the patient is being treated with beta blockers, which are effective in reducing the risk of sudden cardiac death. His LVEF is not severely compromised, and his troponin levels are within normal limits. His TSH level is also within normal limits, which suggests that he does not have hypothyroidism, which can increase the risk of sudden cardiac death. Considering these factors, sudden cardiac death is the least likely prognosis.

Note: The patient's diabetes and hypertension are significant risk factors for cardiovascular disease, but the patient's current treatment plan and relatively mild cardiomyopathy suggest that these risks are being managed."
349,349,P0573,"Age: 46
Gender: Male 
Weight: 85 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 46
ALT or GPT (IU/L): 91.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 50
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 159.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,22
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 172.0
Protein (g/L): 74
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,25
Urea (mg/dL): 5,49
LVEF (%): 22.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely. 

RANKING: Survivor

REASONING: The patient is 46 years old with a history of ischemic dilated cardiomyopathy and myocardial infarction, which indicates significant cardiac disease. However, the patient is currently on beta blockers, statins, and an ACE inhibitor, which are appropriate treatments for heart failure and ischemic heart disease. The patient's NYHA class is II, indicating that the patient is experiencing some symptoms but is able to perform light physical activity. The patient's LVEF is 22%, which is low, but the patient is still alive and on appropriate medical therapy. The presence of non-sustained ventricular tachycardia on the ECG is a concern, but the patient is not experiencing sustained ventricular tachycardia, which is a more ominous sign. The patient's BNP level is elevated at 172.0 ng/L, indicating some level of heart failure, but the patient's other laboratory values, such as creatinine and urea, are not significantly elevated, suggesting that the patient's renal function is relatively preserved. Given these factors, I believe that the patient is most likely to survive for the next few years with continued medical therapy and lifestyle modifications.

RANKING: Sudden Cardiac Death

REASONING: Sudden cardiac death is a possibility in this patient due to the presence of non-sustained ventricular tachycardia on the ECG and a low LVEF. However, the patient is currently on beta blockers, which can help to reduce the risk of sudden cardiac death. The patient's other cardiac risk factors, such as ischemic dilated cardiomyopathy and myocardial infarction, also increase the risk of sudden cardiac death. However, the patient's overall clinical presentation and laboratory values do not suggest a high risk of sudden cardiac death at this time.

RANKING: Pump Failure Death

REASONING: Pump failure death is less likely in this patient due to the fact that the patient's renal function is relatively preserved, as indicated by normal creatinine and urea levels. The patient's BNP level is elevated, but not severely so, and the patient is on appropriate medical therapy for heart failure. The patient's LVEF is low, but the patient is not experiencing symptoms of advanced heart failure, such as orthopnea or edema. While pump failure is a possibility in this patient, it is less likely than sudden cardiac death due to the patient's relatively preserved renal function and overall clinical presentation."
350,350,P0574,"Age: 76
Gender: Male 
Weight: 76 kg
Height: 153 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 6,08
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 130.0
HDL (mmol/L): 2,61
Potassium (mEq/L): 3,87
LDL (mmol/L): 2,95
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 381.0
Protein (g/L): 73
T3 (pg/dL): 0,0588
T4 (ng/L): 15,24
Troponin (ng/mL): 0,4
TSH (mIU/L): 1,56
Urea (mg/dL): 8,6
LVEF (%): 70.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: 1. Survivor
 REASONING: The patient has a relatively well-managed condition, with controlled blood pressure, diabetes, and dyslipidemia. The patient is on a regimen of medications that includes a calcium channel blocker, diabetes medication, angiotensin II receptor blocker, loop diuretics, and statins, which are all relevant to managing the patient's conditions. The LVEF (left ventricular ejection fraction) is 70%, which is within the normal range, indicating that the patient's heart function is relatively preserved. Additionally, the patient's recent troponin level is normal, suggesting that there is no acute myocardial infarction. The patient's ECG shows some abnormalities, but they are mostly benign and not indicative of severe cardiac disease. Given these factors, the most likely outcome is that the patient will survive for the next few years.

RANKING: 2. Pump Failure Death
 REASONING: While the patient's LVEF is within the normal range, it is on the lower end of the normal range. Additionally, the patient has a history of hypertensive cardiomyopathy, which can lead to left ventricular hypertrophy and potentially decreased cardiac function over time. The patient's creatinine level is elevated, which may indicate some degree of kidney dysfunction, which can also contribute to cardiac disease progression. However, the patient's current cardiac function is not severely impaired, and the patient is on medications that can help manage these conditions. Therefore, while pump failure death is a possible outcome, it is less likely than survivor.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient's ECG shows non-sustained ventricular tachycardia, which can be a risk factor for sudden cardiac death. However, the patient's LVEF is within the normal range, and the patient is on medications that can help manage arrhythmias. Additionally, the patient's troponin level is normal, which suggests that there is no acute myocardial infarction. While sudden cardiac death is a possible outcome, it is less likely than pump failure death given the patient's current cardiac function and the presence of other risk factors."
351,351,P0575,"Age: 63
Gender: Female 
Weight: 64 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 90/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 76.0
AST or GOT (IU/L): 52.0
Total Cholesterol (mmol/L): 4,6
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 54
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,12
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1870.0
Protein (g/L): 72
T4 (ng/L): 3
TSH (mIU/L): 18,75
Urea (mg/dL): 7,32
LVEF (%): 24.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden Cardiac Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, myocardial infarction, and a left ventricular ejection fraction (LVEF) of 24%, indicating severe heart failure. The patient is also taking beta blockers, statins, and an ACE inhibitor, which are standard treatments for heart failure and ischemic cardiomyopathy. However, the patient's low LVEF and history of ventricular extrasystoles (polymorphic) increase the risk of sudden cardiac death. The patient's blood pressure is also low (90/50 mmHg), which may indicate a decreased cardiac output and increased risk of sudden cardiac death.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF of 24% indicates severe heart failure, and the patient's creatinine level of 106.0 mmol/L suggests renal dysfunction, which is a common complication of heart failure. The patient's high pro-BNP level of 1870.0 ng/L also indicates increased cardiac stress and potential heart failure. The patient's NYHA Class II classification indicates moderate symptoms of heart failure, which may progress to more severe symptoms and eventually pump failure death if not properly managed.

RANKING: 3. Survivor
 REASONING: While the patient has a severe prognosis due to their heart failure and other comorbidities, they are being treated with standard medications for heart failure and ischemic cardiomyopathy. The patient's weight is relatively low (64 kg), which may be beneficial in reducing the strain on the heart. The patient's TSH level is slightly elevated, but not significantly, and their T4 level is within the normal range, which suggests that hypothyroidism is not a significant concern. Overall, while the patient's prognosis is poor, their treatment plan and relatively low weight may help them survive for an extended period."
352,352,P0577,"Age: 37
Gender: Male 
Weight: 90 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 7,53
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 107
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,5
LDL (mmol/L): 5,17
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 71.0
Protein (g/L): 72
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,27
Urea (mg/dL): 5,66
LVEF (%): 31.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. However, I must note that predicting patient outcomes can be complex and influenced by various factors, including the progression of the disease, patient compliance with treatment, and the presence of any new medical conditions. With that said, here is my prognosis:

RANKING: Survivor
REASONING: The patient has a relatively favorable prognosis due to several factors. 

1.  The patient is relatively young (37 years old), which is a good prognostic indicator for survival in patients with ischemic dilated cardiomyopathy.
2.  The patient is on optimal medical therapy, including beta blockers, statins, and ACE inhibitors, which are evidence-based treatments for heart failure and ischemic cardiomyopathy.
3.  The patient's blood pressure is well-controlled, which is essential for reducing the risk of cardiac events.
4.  The patient's LVEF (left ventricular ejection fraction) is 31%, which is a relatively low value, but it is not extremely low. The patient may be a candidate for cardiac resynchronization therapy or other advanced treatments to improve their LVEF.
5.  The patient's troponin levels are within normal limits, indicating that there is no ongoing myocardial infarction.
6.  The patient's TSH level is within the normal range, which suggests that the patient does not have thyroid dysfunction, which can be a contributing factor to heart failure.
7.  The patient's pro-BNP level is elevated, but not extremely high, which may indicate that the patient is not in a state of severe heart failure.

However, there are some concerning factors that need to be considered:

* The patient's LVEF is low, which increases the risk of sudden cardiac death.
* The patient has a history of myocardial infarction, which increases the risk of future cardiac events.
* The patient's total cholesterol and LDL levels are high, which may contribute to the progression of the patient's ischemic cardiomyopathy.

Given these factors, I predict that the patient has a relatively good prognosis for survival over the next few years, but close monitoring and adherence to medical therapy are crucial to prevent cardiac events and improve the patient's quality of life.

RANKING: Sudden Cardiac Death
REASONING: Sudden cardiac death is a possible outcome due to the patient's low LVEF and history of myocardial infarction. The patient's LVEF of 31% increases the risk of sudden cardiac death, especially if the patient experiences a ventricular arrhythmia.

RANKING: Pump Failure Death
REASONING: Pump failure death is the least likely outcome due to the patient's relatively young age and optimal medical therapy. The patient's LVEF is low, but it is not extremely low, and the patient may be a candidate for advanced treatments to improve their LVEF and prevent pump failure."
353,353,P0578,"Age: 44
Gender: Male 
Weight: 68 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 41
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 6,8
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 174.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,5
LDL (mmol/L): 5,17
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 628.0
Protein (g/L): 68
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,1
TSH (mIU/L): 1,09
Urea (mg/dL): 4,99
LVEF (%): 43.0
Medications: Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely. 

RANKING: Survivor
REASONING: The patient is 44 years old, which is relatively young for a patient with idiopathic dilated cardiomyopathy. Despite having a low LVEF of 43%, the patient's NYHA class is II, indicating that they are still able to perform daily activities without significant symptoms. The patient is also on statins and an ACE inhibitor, which are standard treatments for heart failure. The patient's BNP level is elevated at 628.0 ng/L, but it is not extremely high. The patient's creatinine level is slightly elevated, but not significantly so. Additionally, the patient's hemoglobin and potassium levels are within normal limits. The lack of troponin elevation and the absence of ventricular tachycardia or other severe arrhythmias on the ECG are also positive signs. Overall, while the patient has significant cardiac disease, their age, functional status, and current treatment make a survivor prognosis more likely.

RANKING: Pump Failure Death
REASONING: The patient's LVEF of 43% indicates that the heart is not pumping efficiently, which increases the risk of pump failure. The patient's elevated BNP level and slightly elevated creatinine level also suggest that the heart is under strain. However, the patient's age and functional status are still relatively favorable, and they are on appropriate medications. The patient's lack of significant arrhythmias and other comorbidities also reduce the risk of pump failure.

RANKING: Sudden Cardiac Death
REASONING: Sudden cardiac death is typically associated with severe cardiac disease, including significant arrhythmias or structural abnormalities. While the patient has idiopathic dilated cardiomyopathy and a low LVEF, there is no evidence of severe arrhythmias or other high-risk features. The patient's ECG is relatively normal, and there is no indication of significant structural heart disease. The patient's age and functional status are also relatively favorable. Therefore, sudden cardiac death is the least likely prognosis."
354,354,P0579,"Age: 73
Gender: Male 
Weight: 98 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 100/58 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,46
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 54
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 3,9
LDL (mmol/L): 3,78
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1083.0
Protein (g/L): 72
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,91
Urea (mg/dL): 7,49
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Survivor
REASONING: The patient's age and NYHA Class II suggest that he has a relatively stable heart condition at the moment. His LVEF of 20% indicates severe left ventricular dysfunction, which is a risk factor for poor outcomes. However, the patient is on appropriate medical therapy, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which may help manage his symptoms and slow disease progression. His blood pressure is controlled, and his troponin level is normal, indicating that there is no acute coronary syndrome. His Pro-BNP level is elevated, but not extremely high, which may suggest that his heart is not under excessive strain at the moment. While the presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles are concerning, they are not necessarily indicative of an imminent cardiac event. Overall, considering his stable condition and appropriate medical therapy, a survivor prognosis is the most likely outcome.

RANKING: Sudden Cardiac Death
REASONING: Sudden cardiac death (SCD) is a possible outcome in this patient due to his severe left ventricular dysfunction and history of idiopathic dilated cardiomyopathy. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG increases the risk of SCD. However, the patient's current NYHA Class II and controlled blood pressure suggest that he is not in a high-risk category for SCD at the moment. Additionally, his troponin level is normal, and his Pro-BNP level is not extremely high, which may indicate that his heart is not under excessive strain.

RANKING: Pump Failure Death
REASONING: Pump failure death is a possible outcome in this patient due to his severe left ventricular dysfunction and history of idiopathic dilated cardiomyopathy. However, the patient's current NYHA Class II and controlled blood pressure suggest that his symptoms are manageable, and his medical therapy is likely helping to slow disease progression. His LVEF of 20% is a significant risk factor for pump failure, but it is not the only factor to consider. The patient's weight and height are within a relatively normal range, which may indicate that he is not at an increased risk for pump failure due to fluid overload. Overall, while pump failure death is a possible outcome, it is less likely than survivor or SCD due to the patient's stable condition and appropriate medical therapy.

Note: The patient's outcome is given as ""survivor"", but the task is to provide a prognosis based on the data. The given outcome should not influence the ranking of the prognoses."
355,355,P0580,"Age: 73
Gender: Female 
Weight: 49 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 135/40 mmHg
Past Medical History: Toxic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 23
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,71
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 12,4
Hemoglobin (g/L): 126.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,73
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 2932.0
Protein (g/L): 75
T4 (ng/L): 19
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,78
Urea (mg/dL): 9,32
LVEF (%): 29.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor
 REASONING: The patient is a 73-year-old female with a history of toxic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension. Despite the presence of these comorbidities, the patient is on a comprehensive treatment regimen, including diabetes medication, beta blockers, digoxin, loop diuretics, statins, and an ACE inhibitor. The patient's LVEF is 29%, which is low but not extremely low, and the troponin level is within normal limits. The patient's pro-BNP level is elevated at 2932.0 ng/L, indicating some degree of heart failure, but it is not extremely high. The patient's ECG shows ventricular extrasystoles and non-sustained ventricular tachycardia, but no sustained VT or bradycardia. Considering the patient's relatively stable condition, comprehensive treatment, and the fact that the patient's troponin level is within normal limits, I believe the most likely prognosis is survival.

RANKING: Sudden Cardiac Death
 REASONING: While the patient's history and current condition pose some risk for sudden cardiac death, the presence of a comprehensive treatment regimen and the relatively low troponin level suggest that the risk may not be extremely high. The patient's LVEF is low, which is a risk factor for sudden cardiac death, but the patient's overall clinical condition appears stable. The patient's ECG shows ventricular extrasystoles and non-sustained ventricular tachycardia, which are risk factors for sudden cardiac death, but the absence of sustained VT or bradycardia reduces the risk.

RANKING: Pump Failure Death
 REASONING: The patient's LVEF is 29%, which is significantly low, indicating a high risk for pump failure. However, the patient's clinical condition appears stable, and the patient is on a comprehensive treatment regimen, which may help mitigate this risk. The patient's pro-BNP level is elevated, indicating some degree of heart failure, but it is not extremely high. The patient's creatinine level is elevated, which may indicate some degree of kidney dysfunction, but the patient's urea level is not extremely high. Considering the patient's relatively stable condition and comprehensive treatment, I believe pump failure death is the least likely prognosis.

Note: It is essential to emphasize that these rankings are based on the provided data and may not reflect the patient's actual prognosis. A thorough clinical evaluation and further testing may be necessary to determine the patient's actual prognosis."
356,356,P0581,"Age: 45
Gender: Female 
Weight: 73 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 47
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 66
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,17
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 825.0
Protein (g/L): 81
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,06
TSH (mIU/L): 8,69
Urea (mg/dL): 6,82
LVEF (%): 30.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: 1
 REASONING: The patient's current condition suggests a high risk of sudden cardiac death due to her ischemic dilated cardiomyopathy, low left ventricular ejection fraction (LVEF) of 30%, and the presence of non-sustained ventricular tachycardia on the ECG. The patient's Pro-BNP level is elevated at 825.0 ng/L, indicating increased ventricular wall stress. However, the patient is on beta blockers, digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are all appropriate treatments for heart failure with reduced ejection fraction (HFrEF). The patient's NYHA Class II suggests that the symptoms are manageable with medication and lifestyle modifications. Considering these factors, the most likely prognosis is sudden cardiac death, but the patient's current treatment plan and stable NYHA Class II suggest that this outcome is not imminent. The likelihood of sudden cardiac death is higher than pump failure death because the patient's LVEF is relatively low, and the presence of non-sustained ventricular tachycardia increases the risk of life-threatening arrhythmias.

RANKING: 2
 REASONING: The patient's LVEF of 30% and history of myocardial infarction suggest that she is at risk for pump failure. However, the patient's NYHA Class II and the presence of medications such as beta blockers, digoxin, loop diuretics, and spironolactone indicate that the patient's symptoms are manageable, and the risk of pump failure may be mitigated with continued medical therapy. The patient's weight and blood pressure are within relatively normal limits, which may also contribute to a lower risk of pump failure.

RANKING: 3
 REASONING: Based on the patient's current condition and treatment plan, survivor is the least likely prognosis. While the patient's LVEF is low, and she has a history of myocardial infarction, her NYHA Class II suggests that her symptoms are manageable, and she is receiving appropriate medical therapy. The patient's Pro-BNP level is elevated, indicating increased ventricular wall stress, but this is being addressed with her current treatment plan. The patient's overall clinical picture suggests that she is at risk for sudden cardiac death or pump failure, but the likelihood of a favorable outcome is higher than these two outcomes due to her stable NYHA Class II and appropriate medical therapy."
357,357,P0582,"Age: 74
Gender: Female 
Weight: 72 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 143/76 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 3,7
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,71
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,59
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2066.0
Protein (g/L): 72
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 6,26
Urea (mg/dL): 7,32
LVEF (%): 28.0
Medications: Amiodarone, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here are the prognoses for the next few years, ordered from most likely to least likely:

RANKING: 1
 REASONING: Survivor
The patient's age and past medical history of ischemic dilated cardiomyopathy and myocardial infarction are risk factors for poor cardiac outcomes. However, the patient's current LVEF of 28% is relatively stable, and the lack of recent troponin elevation suggests that the patient has not experienced a recent acute coronary event. Additionally, the patient is on appropriate medications for heart failure and dyslipemia, which may help to slow disease progression. The NYHA Class II classification indicates that the patient has some symptoms but is still able to perform daily activities, which is a positive sign. The patient's albumin and protein levels are within normal limits, indicating that the liver is functioning relatively well, and the creatinine level is not significantly elevated, suggesting that the kidneys are not severely impaired. The pro-BNP level is elevated, but not excessively high, which may indicate some degree of cardiac compensation. Overall, while the patient's prognosis is guarded, the current data suggests that the patient is likely to survive for the next few years with continued medical management.

RANKING: 2
 REASONING: Sudden cardiac death
The patient's low LVEF of 28% and history of ischemic dilated cardiomyopathy increase the risk of sudden cardiac death. The patient's pro-BNP level is elevated, which may indicate some degree of cardiac dysfunction. However, the patient's ECG is normal, and there is no evidence of recent troponin elevation or other signs of acute coronary syndrome. The patient's medications, including amiodarone and ACE inhibitor, may help to reduce the risk of sudden cardiac death. While the patient's prognosis is concerning, the lack of other high-risk features makes sudden cardiac death less likely than pump failure death.

RANKING: 3
 REASONING: Pump failure death
The patient's low LVEF of 28% and history of ischemic dilated cardiomyopathy are significant risk factors for pump failure. The patient's creatinine level is slightly elevated, which may indicate some degree of renal impairment, which can exacerbate heart failure. The patient's pro-BNP level is elevated, which may indicate some degree of cardiac dysfunction. The patient's medications, including loop diuretics and ACE inhibitor, may help to manage symptoms and slow disease progression, but may not be sufficient to prevent pump failure. The patient's NYHA Class II classification indicates that the patient has some symptoms, but the lack of severe symptoms and the presence of some degree of cardiac compensation (as indicated by the relatively stable LVEF) make pump failure death less likely than sudden cardiac death."
358,358,P0585,"Age: 72
Gender: Male 
Weight: 83 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia
Albumin (g/L): 45
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,79
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 852.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 21
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,43
Urea (mg/dL): 8,82
LVEF (%): 40.0
Medications: Amiodarone, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: Survivor
REASONING: 

Based on the provided patient data, I rank the prognosis as Survivor for the following reasons:

1.  The patient is 72 years old, which is a significant age factor for cardiovascular disease. However, the patient's overall condition and treatment plan suggest a relatively stable state.
2.  The patient has a NYHA Class II, indicating mild to moderate symptoms of heart failure. This is a positive sign, as NYHA Class IV is typically associated with more severe symptoms.
3.  The patient's blood pressure is within a relatively normal range, and the patient is on ACE inhibitors, which are beneficial for heart failure and hypertension management.
4.  The patient's creatinine level is elevated, but not excessively high (124.0 mmol/L), indicating some renal impairment but not severe kidney disease.
5.  The patient's LVEF (Left Ventricular Ejection Fraction) is 40%, which is below the normal range (50-70%). However, it's not extremely low, and the patient is on beta-blockers, which can help improve LVEF.
6.  The patient has valvular cardiomyopathy, which can be managed with medication and lifestyle changes. The patient is on statins, which can help manage dyslipemia and reduce the risk of cardiovascular events.
7.  The patient's troponin level is slightly elevated (0.04 ng/mL), but not excessively high, indicating some cardiac stress but not acute myocardial infarction.
8.  The patient's TSH level is within the normal range, indicating no thyroid dysfunction, which can contribute to cardiac disease.
9.  The patient's pro-BNP level is elevated (852.0 ng/L), indicating some degree of heart failure, but the patient is on medications that can help manage this condition.
10. The patient is on a comprehensive treatment plan, including amiodarone, beta-blockers, statins, and ACE inhibitors, which can help manage the patient's cardiovascular conditions.

Considering these factors, I believe the patient's prognosis is most likely to be a Survivor, as the patient's condition is relatively stable, and the treatment plan is comprehensive and effective."
359,359,P0586,"Age: 74
Gender: Male 
Weight: 74 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 179.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,08
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 493.0
Protein (g/L): 75
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,81
Urea (mg/dL): 8,82
LVEF (%): 23.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here is the ranking of the prognoses from most likely to least likely:

RANKING: Survivor

REASONING: 

The patient is 74 years old with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for adverse cardiac outcomes. However, the patient is on optimal medical therapy with beta blockers, loop diuretics, statins, and an ACE inhibitor, which are all evidence-based treatments for heart failure with reduced ejection fraction (HFrEF). The patient's LVEF is 23%, which is consistent with HFrEF, but the patient's NYHA Class II suggests that the symptoms are relatively mild.

The patient's biomarkers, such as Pro-BNP (493 ng/L) and troponin (0.01 ng/mL), are elevated, indicating some degree of cardiac stress, but not to an extreme degree. The patient's hemoglobin level (179 g/L) is within a normal range, which suggests that the patient is not experiencing significant anemia, which is a common comorbidity in heart failure patients.

The patient's lipid profile shows a total cholesterol level of 5.2 mmol/L, which is above the target range, but the patient is on statin therapy, which should help to manage this. The patient's creatinine level (115.0 mmol/L) is elevated, indicating some degree of renal impairment, but the patient's urea level (8.82 mg/dL) is within a relatively normal range.

The patient's ECG shows polymorphic ventricular extrasystoles, which is a common finding in patients with HFrEF, but there is no evidence of sustained ventricular tachycardia or bradycardia.

Based on these factors, the most likely prognosis is that the patient will survive, but with ongoing management and monitoring of their heart failure symptoms and biomarkers."
360,360,P0587,"Age: 58
Gender: Male 
Weight: 97 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 120/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 2,95
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,47
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 65.0
Protein (g/L): 76
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,93
Urea (mg/dL): 7,82
LVEF (%): 30.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Survivor
REASONING: The patient is 58 years old with a history of idiopathic dilated cardiomyopathy, which is a condition that affects the heart muscle, causing it to become weakened and enlarged. Despite this, the patient is currently receiving optimal medical therapy with beta blockers, spironolactone, statins, and an ACE inhibitor, which are all evidence-based treatments for heart failure. The patient's LVEF (left ventricular ejection fraction) is 30%, which is low but not extremely low, and the patient's Pro-BNP (brain natriuretic peptide) level is 65.0 ng/L, which is within a relatively normal range. Additionally, the patient does not have any significant electrolyte imbalances, and the ECG does not show any signs of severe arrhythmias. Considering these factors, the patient's prognosis is likely to be a survivor, as they are receiving appropriate medical therapy and do not have any high-risk features.

RANKING: Pump Failure Death
REASONING: The patient's LVEF of 30% indicates that the left ventricle is not pumping efficiently, which is a risk factor for pump failure. However, the patient's Pro-BNP level is within a relatively normal range, which suggests that the heart is not under excessive stress. The patient's blood pressure is well-controlled, and they do not have any significant electrolyte imbalances. While pump failure is a possible outcome, it is not the most likely scenario given the patient's current medical therapy and relatively stable condition.

RANKING: Sudden Cardiac Death
REASONING: The patient's ECG shows monomorphic ventricular extrasystoles, which is a risk factor for sudden cardiac death. However, the patient does not have any other high-risk features, such as a history of ventricular tachycardia or a low LVEF. The patient's Pro-BNP level is within a relatively normal range, and they are receiving optimal medical therapy, which reduces the risk of sudden cardiac death. While sudden cardiac death is a possible outcome, it is the least likely scenario given the patient's overall clinical picture.

It is essential to note that this prognosis is based on the provided data and may not be accurate in the real-world scenario. A comprehensive evaluation by a cardiologist, including further testing and assessment, is necessary to determine the patient's actual prognosis."
361,361,P0588,"Age: 77
Gender: Male 
Weight: 92 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 135/100 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 6,21
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,9
LDL (mmol/L): 4,09
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 514.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,1
TSH (mIU/L): 0,96
Urea (mg/dL): 9,15
LVEF (%): 50.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: Survivor
REASONING: The patient is 77 years old with a history of ischemic dilated cardiomyopathy and myocardial infarction. However, the patient's LVEF is 50%, which is relatively preserved, and the patient is on appropriate medications, including an ACE inhibitor and a nitrovasodilator, to manage heart failure and hypertension. The patient's NYHA Class II indicates that the patient has some limitations with physical activity but is still able to perform daily tasks without significant distress. The patient's blood work, including the elevated Pro-BNP level, suggests that the patient has some degree of heart failure, but it is not severe. The patient's TSH level is within the normal range, indicating no signs of hypothyroidism. The patient's T3 and T4 levels are also within the normal range. The patient's weight is within the normal range for their height. Overall, while the patient has a history of heart disease, their current clinical status and medication regimen suggest that they are being well-managed, and the risk of sudden cardiac death or pump failure death is relatively low. The patient is more likely to survive the next few years with continued management and monitoring.

RANKING: Pump Failure Death (2nd)
REASONING: The patient's LVEF of 50% suggests that the patient has some degree of left ventricular dysfunction, which increases the risk of pump failure. The patient's Pro-BNP level is elevated, which is consistent with heart failure. The patient's creatinine level is elevated, suggesting some degree of renal impairment, which can be a consequence of heart failure. However, the patient's weight is within the normal range for their height, and they are on loop diuretics, which suggests that the patient is being managed for fluid overload. The patient's TSH level is within the normal range, indicating no signs of hypothyroidism, which can also contribute to heart failure. The patient's T3 and T4 levels are also within the normal range. Overall, while the patient has some risk factors for pump failure, their current clinical status and medication regimen suggest that they are being well-managed, and the risk of pump failure death is lower than sudden cardiac death.

RANKING: Sudden Cardiac Death (3rd)
REASONING: The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which increases the risk of sudden cardiac death. The patient's LVEF of 50% suggests that the patient has some degree of left ventricular dysfunction, which can increase the risk of sudden cardiac death. However, the patient is on an ACE inhibitor and a nitrovasodilator, which can help to reduce the risk of sudden cardiac death. The patient's TSH level is within the normal range, indicating no signs of hypothyroidism, which can also contribute to sudden cardiac death. The patient's T3 and T4 levels are also within the normal range. The patient's weight is within the normal range for their height, and they are on loop diuretics, which suggests that the patient is being managed for fluid overload. Overall, while the patient has some risk factors for sudden cardiac death, their current clinical status and medication regimen suggest that they are being well-managed, and the risk of sudden cardiac death is lower than pump failure death."
362,362,P0590,"Age: 64
Gender: Female 
Weight: 75 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 135/95 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 6
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,17
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 667.0
Protein (g/L): 64
T3 (pg/dL): 0,04
T4 (ng/L): 20
Troponin (ng/mL): 0,03
TSH (mIU/L): 4,77
Urea (mg/dL): 12,15
LVEF (%): 32.0
Medications: Amiodarone, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient is 64 years old with ischemic dilated cardiomyopathy, which is a significant underlying condition. However, she has a relatively preserved LVEF of 32%, which is not extremely low. The patient is on a combination of medications that are appropriate for her condition, including ACE inhibitor, statins, and loop diuretics. The absence of sustained ventricular tachycardia and the presence of TPSV (paroxysmal supraventricular tachyarrhythmia) suggest that the patient's heart is still compensating to some extent. Additionally, the patient's pro-BNP level of 667.0 ng/L is elevated but not extremely high, indicating some level of cardiac compensation. Considering these factors, the patient's prognosis is more likely to be a survivor.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's LVEF of 32% and history of ischemic dilated cardiomyopathy increase the risk of sudden cardiac death. However, the patient's ventricular extrasystoles are monomorphic, and there is no history of sustained ventricular tachycardia, which reduces the risk of sudden cardiac death. The patient's pro-BNP level is elevated, but not extremely high, indicating some level of cardiac compensation. The patient is also on amiodarone, which is an antiarrhythmic medication that reduces the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 32% indicates that the heart is not pumping efficiently, and her history of ischemic dilated cardiomyopathy suggests that the heart muscle is damaged. The patient's pro-BNP level of 667.0 ng/L is elevated, indicating increased ventricular stretch and strain, which is a sign of heart failure. However, the patient is on loop diuretics, which suggests that the heart failure is being managed to some extent. The patient's creatinine level of 106.0 umol/L is elevated, indicating some level of renal impairment, which can be a sign of advanced heart failure. However, considering the patient's age, the presence of comorbidities, and the fact that the heart failure is being managed, pump failure death is less likely compared to sudden cardiac death."
363,363,P0591,"Age: 62
Gender: Male 
Weight: 72 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 125/90 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 73
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 120.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,38
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 279.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,18
Urea (mg/dL): 8,32
LVEF (%): 64.0
Medications: Beta Blockers, Digoxin, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient is 62 years old with a NYHA Class II, indicating moderate heart failure symptoms. However, his LVEF is 64%, which is still within a relatively normal range. The patient is on beta blockers, digoxin, and loop diuretics, which are standard treatments for heart failure. His troponin levels are within normal limits, and there is no evidence of recent myocardial infarction. His pro-BNP level is elevated, but not extremely high, which may indicate some degree of heart failure but not severe. The patient's overall clinical picture suggests that he is being well-managed for his condition, and with continued medical treatment, he is likely to survive.

RANKING: 2. Pump Failure Death
 REASONING: While the patient has valvular cardiomyopathy, his LVEF is still relatively preserved at 64%. However, his elevated pro-BNP level and NYHA Class II classification suggest some degree of heart failure. His creatinine level is elevated, indicating some degree of kidney dysfunction, which can be a consequence of heart failure. The patient's total cholesterol and LDL levels are high, which can contribute to the progression of heart failure. However, the patient's overall clinical picture does not suggest an imminent risk of pump failure death.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient has a history of ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the presence of monomorphic ventricular extrasystoles without evidence of non-sustained ventricular tachycardia or ventricular tachycardia makes this risk lower. The patient's LVEF is still within a relatively normal range, and his troponin levels are within normal limits. While the patient's T3 and T4 levels are low, which can be associated with a higher risk of arrhythmias, the patient's TSH level is within normal limits, which suggests that this is not a primary concern. Overall, while the patient has some risk factors for sudden cardiac death, the overall clinical picture suggests that this is the least likely prognosis."
364,364,P0592,"Age: 66
Gender: Male 
Weight: 78 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes
Albumin (g/L): 40
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 85
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 153.0
HDL (mmol/L): 0,54
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,46
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1537.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,13
Urea (mg/dL): 8,65
LVEF (%): 30.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient is currently being treated with a combination of medications that are commonly used to manage heart failure, including beta blockers, digoxin, loop diuretics, spironolactone, and statins. The patient's LVEF (Left Ventricular Ejection Fraction) is 30%, which is a common value for patients with heart failure with reduced ejection fraction (HFrEF). However, the patient's Pro-BNP (Brain Natriuretic Peptide) level is elevated at 1537.0 ng/L, which is a marker of heart failure severity. Despite this, the patient's blood pressure is within a relatively normal range (120/80 mmHg), and there is no indication of severe renal dysfunction (Creatinine 115.0 mmol/L). The patient's hemoglobin level is within the normal range, and the TSH level is within the normal range, which suggests that the patient is not experiencing hypothyroidism. The patient's Troponin level is slightly elevated at 0.03 ng/mL, but this is not indicative of acute coronary syndrome. Considering these factors, the patient's overall condition suggests that they are likely to survive with continued medical management.

RANKING: 2. Pump failure death
 REASONING: The patient's LVEF is 30%, which is indicative of heart failure with reduced ejection fraction (HFrEF). The patient's Pro-BNP level is elevated, which is a marker of heart failure severity. The patient's creatinine level is slightly elevated, which may indicate some degree of renal dysfunction. However, the patient's blood pressure is within a relatively normal range, and there is no indication of severe renal dysfunction. The patient's hemoglobin level is within the normal range, and the TSH level is within the normal range. The patient is currently being treated with medications that are commonly used to manage heart failure, and the patient's overall condition suggests that they may experience pump failure death in the near future if their condition worsens.

RANKING: 3. Sudden cardiac death
 REASONING: The patient's ECG shows ventricular extrasystole and ventricular tachycardia, which are arrhythmias that can increase the risk of sudden cardiac death. However, the patient is currently being treated with beta blockers, which are commonly used to reduce the risk of sudden cardiac death. The patient's LVEF is 30%, which is a common value for patients with HFrEF, and the patient's Pro-BNP level is elevated, which is a marker of heart failure severity. However, the patient's overall condition does not suggest a high risk of sudden cardiac death, and the patient's hemoglobin level and TSH level are within the normal range. While the patient's ECG findings are concerning, the patient's overall condition suggests that sudden cardiac death is the least likely of the three possible prognoses."
365,365,P0595,"Age: 69
Gender: Male 
Weight: 68 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 176/92 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 96
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,53
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 290.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 15
TSH (mIU/L): 0,46
Urea (mg/dL): 7,15
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's my prognosis for the next few years:

RANKING: Survivor

REASONING: 
The patient has a complex medical history with multiple comorbidities, including hypertensive cardiomyopathy, diabetes, peripheral vascular disease, and hypertension. However, despite these conditions, the patient is currently being treated with a combination of medications, including a calcium channel blocker, diabetes medication, loop diuretics, and an ACE inhibitor, which are likely aimed at managing his blood pressure, diabetes, and heart failure symptoms.

The patient's left ventricular ejection fraction (LVEF) is 35%, which is below the normal range, indicating some degree of heart failure. However, the patient's NYHA class is II, indicating that he is experiencing some symptoms of heart failure but is still able to perform some physical activity without severe limitation.

The patient's creatinine level is elevated at 88.0 mmol/L, indicating some degree of kidney impairment, but his urea level is only 7.15 mg/dL, which is not extremely high. His glucose level is slightly elevated at 7.8 mmol/L, but his hemoglobin A1c (not directly measured) is not provided, so it's difficult to assess the adequacy of his diabetes control.

The patient's pro-BNP level is elevated at 290.0 ng/L, which suggests some degree of heart failure. However, his TSH level is within the normal range, and his T3 and T4 levels are also within the normal range, indicating that his thyroid function is not a contributing factor to his heart failure.

The patient's ECG shows monomorphic ventricular extrasystoles, but no sustained ventricular tachycardia or other concerning arrhythmias.

Overall, while the patient has multiple comorbidities and some degree of heart failure, his treatment regimen is likely aimed at managing his symptoms and slowing disease progression. His relatively mild symptoms (NYHA class II) and the absence of more severe arrhythmias or other concerning findings on his ECG suggest that he may have a relatively better prognosis compared to patients with more severe heart failure or life-threatening arrhythmias.

Considering these factors, I rank the patient's prognosis as a survivor, with a focus on ongoing management and monitoring of his heart failure and other comorbidities to prevent progression and potential complications.

The other two possible prognoses are less likely because:

* Sudden cardiac death is less likely due to the patient's relatively mild symptoms (NYHA class II) and the absence of more severe arrhythmias or other concerning findings on his ECG.
* Pump failure death is less likely due to the patient's current treatment regimen and the fact that his symptoms are manageable with medication, indicating that his heart failure is not currently in an advanced stage."
366,366,P0597,"Age: 74
Gender: Male 
Weight: 83 kg
Height: 164 cm
NYHA Class: III
Blood Pressure: 143/65 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia
Albumin (g/L): 39
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 76
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 137.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4
LDL (mmol/L): 2,9
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1874.0
Protein (g/L): 67
T3 (pg/dL): 0,08
T4 (ng/L): 29
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,09
Urea (mg/dL): 9,32
LVEF (%): 70.0
Medications: Calcium Channel Blocker, Amiodarone, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient's LVEF (Left Ventricular Ejection Fraction) is 70%, which is within the normal range. Although the patient has valvular cardiomyopathy and dyslipemia, the LVEF is not severely decreased, indicating that the heart is still pumping blood efficiently. Additionally, the patient is on medications such as calcium channel blockers, amiodarone, loop diuretics, and nitrovasodilators, which are commonly used to manage heart failure and arrhythmias. The patient's Pro-BNP level is elevated, but not excessively high, which may indicate some degree of heart failure, but not severe. The patient's ECG shows non-sustained ventricular tachycardia, which is a concerning finding, but the fact that it is non-sustained suggests that it may not be a major concern at this time. Overall, considering the patient's LVEF and the presence of supportive medications, I believe that the patient has a higher likelihood of surviving the next few years.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient has a history of valvular cardiomyopathy, which can lead to sudden cardiac death. The presence of non-sustained ventricular tachycardia on the ECG is a risk factor for sudden cardiac death. Additionally, the patient's Pro-BNP level is elevated, which may indicate some degree of heart failure. However, the LVEF is still within the normal range, which suggests that the heart is still pumping blood efficiently. The patient's medications, such as amiodarone, may help reduce the risk of sudden cardiac death. Overall, while the patient has some risk factors for sudden cardiac death, the presence of supportive medications and a relatively normal LVEF suggest that this prognosis is less likely than survivor.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF is 70%, which is within the normal range, and the patient's creatinine level is not excessively high, which suggests that the kidneys are functioning relatively well. The patient's medications, such as loop diuretics, may help manage fluid overload and reduce the risk of pump failure. The patient's Pro-BNP level is elevated, but not excessively high, which may indicate some degree of heart failure, but not severe. The patient's ECG shows non-sustained ventricular tachycardia, but this is not a strong indicator of pump failure. Overall, considering the patient's relatively normal LVEF and the presence of supportive medications, I believe that pump failure death is the least likely prognosis."
367,367,P0598,"Age: 50
Gender: Male 
Weight: 65 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,22
Creatinine (mmol/L): 264.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 178.0
HDL (mmol/L): 2,17
Potassium (mEq/L): 4,9
LDL (mmol/L): 1,24
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 8083.0
Protein (g/L): 84
T3 (pg/dL): 0,03
T4 (ng/L): 14
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,33
Urea (mg/dL): 18,47
LVEF (%): 52.0
Medications: Beta Blockers, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

Based on the provided patient data, the patient is a 50-year-old male with a history of idiopathic dilated cardiomyopathy and hypertension. The patient's current medications include beta blockers, digoxin, and an ACE inhibitor, which are standard treatments for heart failure and dilated cardiomyopathy. 

The patient's LVEF (Left Ventricular Ejection Fraction) is 52%, which is below the normal range (50-70%), indicating some degree of heart failure. However, it is not severely reduced, and the patient is classified as NYHA Class II, indicating mild to moderate symptoms.

The patient's BNP (B-type natriuretic peptide) level is elevated at 8083 ng/L, which is consistent with heart failure. However, the patient's Troponin level is normal, indicating no recent myocardial infarction. The patient's creatinine level is elevated at 264.0 mmol/L, indicating some degree of renal impairment, but it is not severe.

The patient's TSH level is within the normal range, indicating no thyroid dysfunction. The patient's lipid profile is abnormal, with a high total cholesterol level and low HDL level, which may contribute to the progression of heart disease.

Given the patient's current medications and relatively stable condition, the patient is likely to survive in the short to medium term. The patient's LVEF is not severely reduced, and the patient is not experiencing severe symptoms. The patient's creatinine level is not severely elevated, indicating that the patient's kidneys are still functioning relatively well.

The risk of sudden cardiac death is relatively low due to the patient's current medications and the absence of severe symptoms. The risk of pump failure death is also relatively low due to the patient's relatively stable LVEF and the absence of severe renal impairment.

Therefore, the most likely prognosis for the patient is survival, with a relatively stable condition and manageable symptoms."
368,368,P0599,"Age: 66
Gender: Female 
Weight: 80 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 48,7
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 4,89
Creatinine (mmol/L): 83.0
Gamma-glutamil transpeptidase (IU/L): 46
Glucose (mmol/L): 9,2
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 534.0
Protein (g/L): 75,6
T4 (ng/L): 17
TSH (mIU/L): 1,22
Urea (mg/dL): 6,16
LVEF (%): 36.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. However, please note that predicting patient outcomes is inherently uncertain and can be influenced by various factors not listed here. I will provide a prognosis based on the information given.

RANKING: 1. Survivor
 REASONING: The patient is a 66-year-old female with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension. Despite these comorbidities, she is currently being managed with a comprehensive treatment plan, including medications for heart failure (Beta Blockers, Loop Diuretics, Spironolactone), diabetes (Diabetes Medication), hypertension (Calcium Channel Blocker), and dyslipemia (Statins). The patient's LVEF is 36%, which is below the normal range but not extremely low. The Pro-BNP level of 534 ng/L is elevated, indicating some degree of heart failure, but not extremely high. The patient's NYHA class is II, indicating moderate symptoms. While the patient has a history of polymorphic ventricular extrasystoles, there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias. Considering these factors, the most likely prognosis is survival with ongoing management and monitoring of her heart failure and other comorbidities.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF is 36%, which is below the normal range and indicates some degree of heart failure. The Pro-BNP level of 534 ng/L is elevated, suggesting some degree of heart failure. However, the patient is being managed with medications for heart failure, which may help slow the progression of the disease. The patient's NYHA class is II, indicating moderate symptoms, but not severe. While the patient has a history of ischemic dilated cardiomyopathy, which can lead to pump failure, the patient's current treatment plan and the lack of other high-risk features make pump failure death less likely.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient has a history of polymorphic ventricular extrasystoles, but there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias. The patient's LVEF is 36%, which is below the normal range, but not extremely low. The patient's Pro-BNP level is elevated, but not extremely high. The patient's NYHA class is II, indicating moderate symptoms, but not severe. While sudden cardiac death can occur in patients with heart failure, the patient's current treatment plan and the lack of other high-risk features make sudden cardiac death the least likely prognosis."
369,369,P0600,"Age: 58
Gender: Female 
Weight: 57 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 44,4
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,53
Creatinine (mmol/L): 68.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,6
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,56
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 828.0
Protein (g/L): 70,9
T4 (ng/L): 18
TSH (mIU/L): 1,93
Urea (mg/dL): 5,99
LVEF (%): 57.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely. 

RANKING: Survivor

REASONING: The patient is a 58-year-old female with a history of ischemic dilated cardiomyopathy and myocardial infarction. However, she is currently on a treatment regimen that includes calcium channel blockers, beta blockers, loop diuretics, statins, and an ACE inhibitor, which are all standard treatments for heart failure and ischemic cardiomyopathy. Her LVEF is 57%, which is relatively well-preserved, indicating that her heart function is still relatively good. Her NYHA class is II, indicating that she has some symptoms of heart failure but is still relatively asymptomatic. Her blood pressure is well-controlled, and her electrolyte levels are within normal limits. Additionally, her pro-BNP level is elevated at 828 ng/L, which is concerning for heart failure, but her other biomarkers, such as albumin and total protein, are within normal limits. Her TSH and T4 levels are also within normal limits, ruling out any potential thyroid-related cardiac issues. While her LDL level is slightly elevated, it is not significantly high, and her statin therapy should help to manage it. Overall, considering her current treatment and the fact that she is not in an advanced stage of heart failure, I believe that her prognosis is most likely to be a survivor.

RANKING: Pump Failure Death

REASONING: The patient's LVEF of 57% is slightly below the normal range, indicating some degree of systolic dysfunction. Her elevated pro-BNP level of 828 ng/L is also concerning for heart failure. However, her NYHA class is only II, and she is not experiencing severe symptoms. Her creatinine level is slightly elevated, but her urea level is within normal limits. Her potassium level is within normal limits, and her electrolyte balance is well-managed. While her LDL level is slightly elevated, her statin therapy should help to manage it. Given her relatively well-preserved LVEF and the fact that she is not in an advanced stage of heart failure, I believe that pump failure death is the second most likely prognosis.

RANKING: Sudden Cardiac Death

REASONING: The patient's ECG shows monomorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death. Her LVEF is 57%, which is relatively well-preserved, and her NYHA class is II, indicating that she is not in an advanced stage of heart failure. Her potassium level is within normal limits, and her electrolyte balance is well-managed. While her elevated pro-BNP level is concerning for heart failure, it is not indicative of a high risk of sudden cardiac death. Additionally, her TSH and T4 levels are within normal limits, ruling out any potential thyroid-related cardiac issues. Given her current treatment and the fact that she is not in an advanced stage of heart failure, I believe that sudden cardiac death is the least likely prognosis."
370,370,P0601,"Age: 77
Gender: Male 
Weight: 60 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 47,4
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,53
Creatinine (mmol/L): 72.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,31
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 142.0
Protein (g/L): 74,2
T4 (ng/L): 22
TSH (mIU/L): 1,89
Urea (mg/dL): 7,15
LVEF (%): 35.0
Medications: Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years, ranking the three possible outcomes from most likely to least likely.

RANKING: 1. Sudden cardiac death, 2. Pump failure death, 3. Survivor

REASONING:

1. Sudden Cardiac Death (SCD): Given the patient's advanced age (77 years), reduced left ventricular ejection fraction (LVEF) of 35%, and history of ischemic dilated cardiomyopathy, the patient is at an increased risk of sudden cardiac death. The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG further increases this risk. The patient's LVEF is below the threshold for intermediate risk, which is typically considered 40-50%. This indicates that the patient's heart is not pumping efficiently, and the risk of sudden cardiac death is higher. Additionally, the patient's NYHA Class III classification indicates that they have severe symptoms of heart failure, which can increase the risk of SCD.

2. Pump Failure Death: The patient's LVEF of 35% indicates that their heart is not pumping efficiently, and they are at risk of pump failure. However, the patient's ejection fraction is not extremely low, and they are currently on medications that help manage heart failure symptoms (loop diuretics and ACE inhibitor). The patient's NYHA Class III classification suggests that they have severe symptoms of heart failure, but they are still ambulatory and able to manage their symptoms with medication. While pump failure death is a possible outcome, it is less likely than sudden cardiac death given the patient's current medication regimen and relatively stable symptoms.

3. Survivor: Given the patient's advanced age, reduced LVEF, and history of ischemic dilated cardiomyopathy, the likelihood of the patient surviving the next few years without significant cardiac events is relatively low. However, the patient's current medication regimen and relatively stable symptoms suggest that they may be able to manage their condition and avoid significant cardiac events for an extended period. The patient's LVEF is not extremely low, and they are able to ambulate and manage their symptoms, which suggests that they may be able to survive for several years with proper medical management.

It's essential to note that this prognosis is based on the provided data and may not reflect the patient's individual circumstances or the effectiveness of their current treatment plan. Regular follow-up and adjustments to the treatment plan may be necessary to optimize the patient's outcomes."
371,371,P0602,"Age: 67
Gender: Male 
Weight: 62 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 42,9
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,37
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 106
Glucose (mmol/L): 9,7
Hemoglobin (g/L): 122.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,91
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 923.0
Protein (g/L): 70
T4 (ng/L): 19
TSH (mIU/L): 0,56
Urea (mg/dL): 7,65
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

Given the patient's profile, the most likely outcome is a survivor for the next few years. Here's why:

1.  The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure and mortality. However, the patient is already on optimal medical therapy with beta blockers, loop diuretics, spironolactone, statins, and ACE inhibitors, which are all evidence-based treatments for heart failure.
2.  The patient's LVEF (Left Ventricular Ejection Fraction) is 45%, which is below the normal range (50-70%), indicating some degree of heart failure. However, it is not extremely low, and the patient's symptoms are classified as NYHA Class II, indicating mild to moderate heart failure symptoms.
3.  The patient's Pro-BNP level is elevated at 923 ng/L, which is a marker of heart failure severity. However, it is not extremely high, and the patient is already on diuretics, which would be expected to lower the Pro-BNP level.
4.  The patient's creatinine level is slightly elevated at 104.0 umol/L, indicating some degree of kidney dysfunction. However, the urea level is within normal limits, and the patient is not on dialysis, which suggests that the kidney dysfunction is not severe.
5.  The patient's blood pressure is elevated at 160/90 mmHg, but the patient is on medications that would be expected to control blood pressure, and the patient is not on any antihypertensive medications that could potentially worsen heart failure.
6.  The patient's lipid profile is abnormal, with a high total cholesterol and LDL levels. However, the patient is on statins, which would be expected to lower these levels.
7.  The patient's glucose level is elevated at 9.7 mmol/L, indicating uncontrolled diabetes. However, the patient is on diabetes medication, which would be expected to control blood glucose levels.
8.  The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are markers of increased risk of arrhythmias. However, the patient is on beta blockers, which would be expected to reduce the risk of arrhythmias.

Based on these factors, the patient's prognosis is more likely to be a survivor for the next few years, with a moderate risk of sudden cardiac death or pump failure death. However, the patient's optimal medical therapy and relatively stable clinical status suggest that these outcomes are less likely.

RANKING (from most likely to least likely): 

1.  Survivor
2.  Pump failure death
3.  Sudden cardiac death"
372,372,P0603,"Age: 74
Gender: Male 
Weight: 82 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 48.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,3
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 7,9
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 5,3
LDL (mmol/L): 3,28
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 1626.0
Protein (g/L): 75
T4 (ng/L): 6
Troponin (ng/mL): 0,03
TSH (mIU/L): 5,82
Urea (mg/dL): 24,13
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the three possible prognoses as follows:

RANKING: Survivor

REASONING: Despite the patient's advanced age, history of ischemic dilated cardiomyopathy, and reduced left ventricular ejection fraction (LVEF) of 35%, there are several factors that suggest a more favorable prognosis. The patient's blood pressure is well-controlled, and he is on a comprehensive medication regimen that includes an angiotensin II receptor blocker, beta blockers, and loop diuretics, which are all evidence-based treatments for heart failure with reduced ejection fraction. The patient's troponin levels are within normal limits, indicating that he is not experiencing ongoing myocardial infarction. Additionally, the absence of non-sustained ventricular tachycardia and other arrhythmias on the ECG suggests that the patient's heart rhythm is relatively stable. While the patient's creatinine level is elevated, suggesting some degree of kidney dysfunction, it is not severely elevated, and his diabetes is well-controlled. The patient's BNP level is high, but not extremely high, and his LVEF is not the lowest I have seen in patients with similar conditions. Overall, considering these factors, I believe that the patient has a good chance of survival over the next few years with continued medical management and monitoring.

RANKING: Pump Failure Death

REASONING: Pump failure death is a possible outcome for this patient, given his history of ischemic dilated cardiomyopathy, reduced LVEF, and elevated BNP levels. The patient's kidney function is also impaired, which can be a marker of advanced heart failure. However, the patient's overall clinical picture is not as severe as it could be, and he is receiving evidence-based treatments for heart failure. While pump failure death is a possibility, it is less likely than sudden cardiac death due to the patient's relatively stable clinical condition and comprehensive treatment regimen.

RANKING: Sudden Cardiac Death

REASONING: Sudden cardiac death is the least likely outcome for this patient. While the patient has a history of ischemic dilated cardiomyopathy and reduced LVEF, his ECG is relatively unremarkable, with no evidence of non-sustained ventricular tachycardia or other high-risk arrhythmias. The patient's troponin levels are within normal limits, indicating that he is not experiencing ongoing myocardial infarction. The patient's medications, including beta blockers and an angiotensin II receptor blocker, are also protective against sudden cardiac death. While the patient's BNP level is elevated, suggesting some degree of heart failure, his overall clinical picture is not as high-risk as it could be. Therefore, sudden cardiac death is the least likely outcome for this patient."
373,373,P0604,"Age: 75
Gender: Female 
Weight: 57 kg
Height: 153 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,83
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,02
Potassium (mEq/L): 5,2
LDL (mmol/L): 2,17
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 509.0
Protein (g/L): 76
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,35
Urea (mg/dL): 15,47
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: The patient is a 75-year-old female with a history of idiopathic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension. Her current medications include diabetes medication, beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are all appropriate for her conditions. 

Her ejection fraction (LVEF) is 30%, indicating a significant reduction in cardiac function. However, her blood pressure is well-controlled at 120/70 mmHg, and her creatinine level is slightly elevated but not significantly so (106.0 mmol/L). Her Pro-BNP level is elevated at 509.0 ng/L, indicating some degree of heart failure, but not to the extent that it would be considered a strong predictor of sudden cardiac death.

The patient's laboratory results show mild elevations in liver enzymes (ALT and AST), but these are not significantly elevated, and her total cholesterol and LDL levels are within acceptable ranges for her age. Her hemoglobin level is within the normal range, and her TSH level is within the normal range, indicating that her thyroid function is well-controlled.

The ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or non-sustained ventricular tachycardia, which are more concerning for sudden cardiac death.

Given these factors, the patient's prognosis is likely to be a survivor, as her cardiac function is significantly compromised but not to the extent that it would lead to sudden cardiac death. Her well-controlled blood pressure and medications also suggest that she is receiving adequate treatment for her conditions. However, she will likely continue to experience symptoms of heart failure and may require ongoing medical management to manage her condition.

RANKING for Sudden Cardiac Death: 3 (least likely)

REASONING: The patient's ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or non-sustained ventricular tachycardia. Her Pro-BNP level is elevated, but not to the extent that it would be considered a strong predictor of sudden cardiac death. Her medications include beta blockers, which are effective in reducing the risk of sudden cardiac death.

RANKING for Pump Failure Death: 2

REASONING: The patient's LVEF is 30%, indicating significant reduction in cardiac function. Her creatinine level is slightly elevated, and her Pro-BNP level is elevated, indicating some degree of heart failure. However, her blood pressure is well-controlled, and her medications include loop diuretics, which are effective in managing fluid overload and reducing the risk of pump failure."
374,374,P0606,"Age: 57
Gender: Male 
Weight: 70 kg
Height: 166 cm
NYHA Class: III
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 45,9
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 3,03
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 58
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,58
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 4330.0
Protein (g/L): 78,2
T4 (ng/L): 20
TSH (mIU/L): 0,94
Urea (mg/dL): 6,82
LVEF (%): 25.0
Medications: Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: Sudden Cardiac Death > Pump Failure Death > Survivor

REASONING:

1. Sudden Cardiac Death: The patient has a history of ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The low LVEF (25.0%) and elevated Pro-BNP (4330.0 ng/L) levels indicate severe heart failure. The presence of polymorphic ventricular extrasystoles on the ECG also increases the risk of arrhythmias, which can lead to sudden cardiac death. Additionally, the patient's NYHA Class III classification indicates severe symptoms of heart failure, which further increases the risk of sudden cardiac death.

2. Pump Failure Death: The patient's LVEF is extremely low (25.0%), which indicates severe left ventricular dysfunction. The elevated Pro-BNP levels and NYHA Class III classification also suggest advanced heart failure. However, the patient is currently on medications that are commonly used to manage heart failure, including loop diuretics, spironolactone, and ACE inhibitors, which may help slow the progression of heart failure. While pump failure death is still a possibility, the patient's current treatment regimen may mitigate this risk to some extent.

3. Survivor: Based on the patient's severe heart failure symptoms, low LVEF, and elevated Pro-BNP levels, I initially ranked sudden cardiac death and pump failure death as the most likely outcomes. However, considering the patient's current treatment regimen and the fact that they are still alive, I ranked survivor as the least likely outcome. While the patient's prognosis is poor, the fact that they are currently alive suggests that their condition may not be as dire as initially thought. However, this outcome is still uncertain and would require close monitoring and adjustment of their treatment plan to manage their heart failure effectively.

Please note that this is a general assessment based on the provided data and may not be a definitive prediction. A more accurate prognosis would require a comprehensive evaluation by a cardiologist and consideration of additional factors, such as the patient's overall health, comorbidities, and response to treatment."
375,375,P0608,"Age: 70
Gender: Male 
Weight: 71 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 44,2
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 5,8
LDL (mmol/L): 2,92
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 108.0
Protein (g/L): 74,7
T4 (ng/L): 15
TSH (mIU/L): 2,24
Urea (mg/dL): 6,66
LVEF (%): 30.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

Based on the provided patient data, the patient is a 70-year-old male with a history of ischemic dilated cardiomyopathy, dyslipemia, hypertension, and myocardial infarction. The patient's left ventricular ejection fraction (LVEF) is 30%, indicating severe systolic heart failure. However, the patient is on optimal medical therapy with amiodarone, an angiotensin II receptor blocker, and statins, which suggests that the patient's condition is being actively managed.

The patient's NYHA Class II classification indicates that the patient has mild to moderate symptoms of heart failure, which is a positive prognostic sign. The patient's blood pressure is well-controlled at 110/70 mmHg, and the albumin level is within the normal range.

The elevated pro-BNP (brain natriuretic peptide) level of 108 ng/L suggests that the patient has some degree of heart failure, but the level is not extremely high, which may indicate that the patient's condition is not as severe as it could be.

The patient's LVEF of 30% is a concern, but it is not the only factor to consider. The patient's overall clinical status, including their symptoms, blood pressure, and laboratory results, suggests that they are not in a high-risk category for sudden cardiac death or pump failure.

Given the patient's age, comorbidities, and current medical therapy, the most likely prognosis is survivor. The patient's condition may continue to decline over time, but with continued optimal medical therapy and close monitoring, the patient is likely to survive for the next few years.

Sudden cardiac death is less likely because the patient is on an anti-arrhythmic medication (amiodarone), which reduces the risk of sudden cardiac death. Additionally, the patient does not have any high-risk ECG findings, such as ventricular tachycardia or bradycardia.

Pump failure death is also less likely because the patient's symptoms are mild to moderate, and the patient is on optimal medical therapy, including an angiotensin II receptor blocker, which helps to reduce the workload on the heart and slow the progression of heart failure.

Therefore, based on the patient's overall clinical status and laboratory results, the most likely prognosis is survivor."
376,376,P0609,"Age: 67
Gender: Female 
Weight: 74 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 180/95 mmHg
Past Medical History: Hypertropic cardiomyopathy, Diabetes
Albumin (g/L): 46,2
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 61.0
Gamma-glutamil transpeptidase (IU/L): 140
Glucose (mmol/L): 7,9
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,91
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,61
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 731.0
Protein (g/L): 75,2
T4 (ng/L): 14
TSH (mIU/L): 3,47
Urea (mg/dL): 3
LVEF (%): 70.0
Medications: Beta Blockers, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: Survivor
REASONING: The patient is 67 years old with a history of hypertrophic cardiomyopathy and diabetes, which are both risk factors for cardiovascular disease. However, the patient's LVEF is 70%, indicating that the heart is functioning relatively well. The patient is on beta blockers and nitrovasodilators, which are medications used to manage heart failure and reduce the risk of sudden cardiac death. The absence of paroxysmal supraventricular tachyarrhythmia and bradycardia on the ECG is also a positive sign. While the patient has a high Pro-BNP level (731.0 ng/L), which suggests heart failure, the overall clinical picture suggests that the patient is being managed effectively with medication. Additionally, the patient's NYHA Class II indicates that the patient is experiencing some symptoms of heart failure, but they are not severely limited in their daily activities. Therefore, based on these factors, I believe that the patient is more likely to survive.

RANKING: Pump Failure Death
REASONING: The patient's LVEF of 70% is still within a relatively normal range, but the high Pro-BNP level (731.0 ng/L) and the patient's NYHA Class II suggest that the patient has some degree of heart failure. The patient's creatinine level (61.0 mmol/L) is also slightly elevated, which can be a sign of decreased kidney function, often seen in patients with heart failure. The patient's total cholesterol level (4.99 mmol/L) is also slightly elevated, which can contribute to the progression of heart failure. However, the patient is on medications that can help manage these conditions, and the patient's overall clinical picture does not suggest that pump failure is an imminent threat.

RANKING: Sudden Cardiac Death
REASONING: The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. However, the patient is on beta blockers, which can help reduce the risk of sudden cardiac death. The patient's LVEF of 70% is relatively well-preserved, and the patient's overall clinical picture does not suggest that sudden cardiac death is an imminent threat. While the patient's hypertrophic cardiomyopathy and diabetes are risk factors for sudden cardiac death, the patient's current management plan and the absence of other high-risk factors make this prognosis less likely."
377,377,P0610,"Age: 71
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 44,3
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 7
Hemoglobin (g/L): 123.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,1
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 433.0
Protein (g/L): 73
T4 (ng/L): 15
TSH (mIU/L): 1,95
Urea (mg/dL): 8,49
LVEF (%): 62.0
Medications: Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Given the patient's age, medical history, and current condition, I rank the three possible prognoses as follows:

RANKING: 1. Survivor
REASONING: The patient is 71 years old with a history of hypertensive cardiomyopathy, which is a significant risk factor for heart failure and cardiac events. However, the patient's LVEF (left ventricular ejection fraction) is 62%, which is within the normal range (50-70%). This suggests that the patient's heart function is relatively preserved, and the risk of sudden cardiac death or pump failure death is lower. Additionally, the patient is on ACE inhibitor and spironolactone, which are standard medications for heart failure and hypertension management. The absence of sustained ventricular tachycardia and the presence of a normal TSH level (indicative of euthyroidism) also contribute to a more favorable prognosis.

RANKING: 2. Pump Failure Death
REASONING: The patient's creatinine level is elevated (123.0 mol/L), which suggests some degree of renal impairment, a common comorbidity in patients with heart failure. The patient's Pro-BNP level is also elevated (433.0 ng/L), which is a marker of cardiac stress and potential heart failure. However, the patient's LVEF is still within the normal range, and the absence of other high-risk features (e.g., severe anemia, severe renal impairment, or significant arrhythmias) makes pump failure death less likely.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's ECG shows polymorphic ventricular extrasystoles, which can be a marker of increased cardiac risk. However, the absence of sustained ventricular tachycardia and the presence of a normal TSH level reduce the likelihood of sudden cardiac death. Additionally, the patient's LVEF is within the normal range, which suggests that the patient's heart function is relatively preserved, and the risk of sudden cardiac death is lower."
378,378,P0611,"Age: 66
Gender: Male 
Weight: 72 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 105/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 40,7
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,22
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 5
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,39
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2919.0
Protein (g/L): 68,1
T4 (ng/L): 18
TSH (mIU/L): 0,38
Urea (mg/dL): 8,65
LVEF (%): 23.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the prognosis as follows:

RANKING: Survivor

REASONING: 

The patient is a 66-year-old male with a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipemia. Despite these conditions, he is on a comprehensive treatment regimen, including beta blockers, loop diuretics, spironolactone, statins, ACE inhibitors, and nitrovasodilators. His LVEF is 23%, which indicates severe left ventricular dysfunction. However, his NYHA Class II classification suggests that he is experiencing some limitations in physical activity but is still able to perform daily tasks without severe symptoms.

His laboratory results show elevated creatinine levels, indicating some degree of renal impairment, but his albumin and protein levels are within normal limits. His liver enzymes are mildly elevated, but not to a degree that would suggest significant liver disease. His lipid profile is concerning, with high LDL levels, but he is on statins, which should help manage this.

The patient's BNP level is elevated, which is consistent with heart failure. However, his hemoglobin and sodium levels are within normal limits, indicating that he is not experiencing severe anemia or hyponatremia.

The ECG findings are concerning, with polymorphic ventricular extrasystoles, but there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias.

Considering the patient's age, comorbidities, and treatment regimen, the most likely prognosis is that he will survive for the next few years. His current treatment plan and lack of severe symptoms suggest that he is being managed effectively, and his condition may stabilize or even improve with continued treatment.

The other two possible prognoses, sudden cardiac death and pump failure death, are less likely due to the following reasons:

- Sudden cardiac death is less likely because the patient is on beta blockers, which reduce the risk of sudden cardiac death in patients with heart failure.
- Pump failure death is less likely because the patient's symptoms are well-managed, and he is on diuretics and ACE inhibitors, which should help to manage his heart failure symptoms and prevent progression to pump failure.

However, it's essential to note that this is a high-risk patient, and regular monitoring and adjustments to his treatment plan will be necessary to ensure the best possible outcome."
379,379,P0612,"Age: 67
Gender: Female 
Weight: 93 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 159/62 mmHg
Past Medical History: Other HF etiology, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,37
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 2,72
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 233.0
Protein (g/L): 67
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,5
Urea (mg/dL): 11,82
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Spironolactone, Statins, Hydralazine, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely.

RANKING: Survivor
REASONING: The patient is 67 years old with a history of heart failure (HF), diabetes, dyslipemia, and hypertension. Despite these comorbidities, she is on a multidrug regimen, including beta blockers, spironolactone, statins, hydralazine, and an ACE inhibitor, which are all evidence-based treatments for HF and comorbidities. Her LVEF is 30%, which is low but not extremely low. The absence of sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, and bradycardia on the ECG also suggests a relatively stable cardiac rhythm. Additionally, her pro-BNP level is 233.0 ng/L, which is elevated but not extremely high. Considering her age, comorbidities, and treatment regimen, a survivor prognosis seems more likely.

RANKING: Pump Failure Death
REASONING: The patient's LVEF of 30% indicates severe left ventricular dysfunction, which is a risk factor for pump failure. Her elevated pro-BNP level and low albumin level (38 g/L) also suggest a high risk of pump failure. However, her treatment regimen and lack of other high-risk features (e.g., severe anemia, renal failure) make pump failure less likely compared to sudden cardiac death.

RANKING: Sudden Cardiac Death
REASONING: The patient's LVEF of 30% and elevated pro-BNP level suggest a high risk of sudden cardiac death due to arrhythmias. However, the absence of sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, and bradycardia on the ECG, as well as the presence of beta blockers and ACE inhibitor, which are protective against sudden cardiac death, make sudden cardiac death the least likely prognosis."
380,380,P0613,"Age: 65
Gender: Male 
Weight: 54 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,72
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 126.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,54
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2740.0
Protein (g/L): 76
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,09
TSH (mIU/L): 1,96
Urea (mg/dL): 9,32
LVEF (%): 30.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: Despite the patient's advanced age, reduced left ventricular ejection fraction (LVEF) of 30%, and elevated Pro-BNP levels, the patient's overall clinical presentation and treatment regimen suggest a relatively stable condition. The patient is on a combination of medications that are commonly used to manage heart failure, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor. These medications are likely helping to control symptoms and slow disease progression. The patient's NYHA Class II classification indicates that they have mild to moderate symptoms of heart failure, which is a good prognostic sign. Additionally, the patient's creatinine levels are within a relatively normal range, suggesting that their renal function is preserved. While the patient's troponin levels are slightly elevated, they are not significantly elevated, which may indicate some degree of cardiac damage but not severe acute coronary syndrome. The patient's TSH level is within the normal range, which suggests that their thyroid function is well-controlled. Overall, while the patient's prognosis is guarded due to their reduced LVEF, their current treatment regimen and clinical presentation suggest that they are likely to survive for the next few years with continued medical management.

RANKING: Pump Failure Death (less likely than Survivor)

REASONING: Pump failure death is a possible outcome for this patient due to their reduced LVEF and elevated Pro-BNP levels, which are indicative of heart failure with reduced ejection fraction (HFrEF). However, the patient's current treatment regimen and clinical presentation suggest that they are being effectively managed, and their symptoms are not severe enough to indicate an immediate risk of pump failure death. The patient's creatinine levels are within a relatively normal range, which suggests that their renal function is preserved, and they are not at high risk for acute kidney injury. Additionally, the patient's blood pressure is well-controlled, which reduces their risk of cardiac decompensation.

RANKING: Sudden Cardiac Death (least likely)

REASONING: Sudden cardiac death is a possible outcome for this patient due to their reduced LVEF and presence of ventricular extrasystoles on the ECG. However, the patient's overall clinical presentation and treatment regimen suggest that they are at low risk for sudden cardiac death. The patient's LVEF is reduced, but they are on beta blockers, which are known to reduce the risk of sudden cardiac death in patients with heart failure. The patient's ECG does show ventricular extrasystoles, but they are monomorphic, which suggests that they are not a high-risk arrhythmia. Additionally, the patient does not have a history of sustained ventricular tachycardia or other high-risk arrhythmias, which further reduces their risk of sudden cardiac death."
381,381,P0614,"Age: 58
Gender: Male 
Weight: 90 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 41,2
ALT or GPT (IU/L): 42.0
AST or GOT (IU/L): 35.0
Total Cholesterol (mmol/L): 5,78
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 101
Glucose (mmol/L): 9,3
Hemoglobin (g/L): 110.0
HDL (mmol/L): 2,69
Potassium (mEq/L): 3,75
LDL (mmol/L): 2,52
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 4446.0
Protein (g/L): 68,4
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,93
Urea (mg/dL): 11,4
LVEF (%): 18.0
Medications: Calcium Channel Blocker, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here is the ranking of the possible prognoses from most likely to least likely:

RANKING: Survivor
 REASONING: The patient is 58 years old with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure. However, the patient is currently being treated with a combination of medications, including a calcium channel blocker, angiotensin II receptor blocker, beta blockers, and loop diuretics, which are standard treatments for heart failure. The patient's LVEF (left ventricular ejection fraction) is 18%, which is low but not the lowest possible value. Additionally, the patient's pro-BNP (brain natriuretic peptide) level is elevated at 4446.0 ng/L, which is a marker of heart failure severity, but not extremely high. The patient's blood pressure is well-controlled, and there are no signs of acute coronary syndrome (e.g., troponin is 0.01 ng/mL). The patient's weight is within a reasonable range for their height. Considering these factors, the patient's current treatment regimen and the absence of acute decompensation, the most likely prognosis is survivor.

RANKING: Sudden Cardiac Death
 REASONING: Sudden cardiac death (SCD) is a possible risk for patients with heart failure, particularly those with low LVEF. However, the patient's current treatment regimen and the lack of other high-risk factors (e.g., no history of ventricular tachycardia or sustained ventricular arrhythmias) make SCD less likely. Additionally, the patient's LVEF is not extremely low, and the patient is being treated with beta blockers, which can reduce the risk of SCD.

RANKING: Pump Failure Death
 REASONING: Pump failure death is a possible outcome for patients with heart failure, but it is less likely in this case. The patient's LVEF is low, but the patient is being treated with a combination of medications, including diuretics, which are aimed at reducing fluid overload and improving symptoms. The patient's creatinine level is elevated, indicating some degree of renal impairment, but it is not extremely high. The patient's weight is within a reasonable range for their height, and there are no signs of acute decompensation. While pump failure is a possible outcome, the patient's current treatment regimen and the lack of other high-risk factors make it the least likely prognosis."
382,382,P0615,"Age: 61
Gender: Male 
Weight: 103 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 125/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 3,42
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 42
Glucose (mmol/L): 12,2
Hemoglobin (g/L): 145.0
HDL (mmol/L): 0,87
Potassium (mEq/L): 3,91
LDL (mmol/L): 1,47
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 86.0
Protein (g/L): 67,5
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,91
Urea (mg/dL): 6,9
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: Survivor
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a condition that affects the heart's ability to pump blood efficiently. However, the patient is currently on optimal medical therapy for heart failure, including beta blockers, angiotensin II receptor blockers, and statins. The patient's LVEF (Left Ventricular Ejection Fraction) is 35%, which is relatively low but not extremely low. The patient's Pro-BNP level is 86.0 ng/L, which is within the normal range. The patient's ECG does not show any signs of severe arrhythmias, and the troponin level is normal. The patient's NYHA class is II, indicating that the patient is experiencing some limitations in physical activity but is still able to perform daily activities. Considering these factors, the patient's prognosis is likely to be a survivor, assuming the patient adheres to their medication regimen and makes lifestyle modifications to manage their condition.

RANKING: Pump Failure Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which increases the risk of heart failure. The patient's LVEF is 35%, which is below the normal range, indicating impaired cardiac function. The patient's creatinine level is elevated, suggesting impaired kidney function, which can be a complication of heart failure. The patient's proteinuria (albumin 43 g/L) and elevated GGT levels suggest that the patient may have some degree of liver dysfunction, which can also be a complication of heart failure. However, the patient's Pro-BNP level is within the normal range, and the patient is on optimal medical therapy for heart failure. The patient's overall condition is not extremely severe, and the patient's ECG does not show any signs of severe arrhythmias.

RANKING: Sudden Cardiac Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death. However, the patient's ECG does not show any signs of severe arrhythmias, and the patient's troponin level is normal, suggesting that the patient is not experiencing an acute myocardial infarction. The patient's LVEF is 35%, which is below the normal range, but the patient is on optimal medical therapy for heart failure, which includes beta blockers and angiotensin II receptor blockers, which can help reduce the risk of sudden cardiac death. The patient's Pro-BNP level is within the normal range, which is a good prognostic indicator for sudden cardiac death. Overall, while the patient has some risk factors for sudden cardiac death, the patient's overall condition is not extremely severe, and the patient is on optimal medical therapy to reduce this risk."
383,383,P0617,"Age: 50
Gender: Male 
Weight: 88 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 90/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 46.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 4,61
Creatinine (mmol/L): 105.0
Gamma-glutamil transpeptidase (IU/L): 71
Glucose (mmol/L): 8,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,17
Potassium (mEq/L): 4,53
LDL (mmol/L): 2,82
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 3172.0
Protein (g/L): 78,9
T4 (ng/L): 17,3
Troponin (ng/mL): 0,45
TSH (mIU/L): 6
Urea (mg/dL): 7,6
LVEF (%): 40.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: The patient is 50 years old with a history of ischemic dilated cardiomyopathy, diabetes, and myocardial infarction, which puts him at high risk for cardiac complications. However, despite these risk factors, the patient's current medications (Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor) suggest that he is receiving appropriate treatment for his conditions. The LVEF (40%) indicates that the patient's heart is still pumping efficiently to some extent, but the elevated Pro-BNP (3172.0 ng/L) suggests that the patient may have some degree of heart failure. The patient's NYHA Class II classification indicates that he has some limitations in physical activity, but is still able to perform daily tasks without significant symptoms. The absence of ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia on the ECG is also a positive sign. Considering these factors, the patient's likelihood of survival is higher than the other two options.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of ischemic dilated cardiomyopathy, diabetes, and myocardial infarction increases his risk for sudden cardiac death. However, the patient's current medications and the absence of ventricular tachycardia on the ECG suggest that his risk for sudden cardiac death may be lower than pump failure death. The patient's LVEF of 40% is concerning, but not extremely low, and the patient is receiving appropriate treatment for his conditions. The elevated Pro-BNP level suggests that the patient may have some degree of heart failure, but this is not necessarily a direct indicator of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF of 40% and elevated Pro-BNP level suggest that the patient's heart is not pumping efficiently, which increases his risk for pump failure death. The patient's history of ischemic dilated cardiomyopathy and diabetes also contributes to this risk. However, the patient's NYHA Class II classification and the absence of severe symptoms suggest that the patient may not be at the highest risk for pump failure death. The patient's current medications and the absence of severe electrolyte imbalances or kidney dysfunction (e.g. creatinine 105.0 umol/L) also suggest that the patient's risk for pump failure death may be lower than expected."
384,384,P0620,"Age: 50
Gender: Male 
Weight: 85 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 100/65 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 41,5
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 89.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,94
Potassium (mEq/L): 4,22
LDL (mmol/L): 3,37
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 233.0
Protein (g/L): 68,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,93
Urea (mg/dL): 4,7
LVEF (%): 39.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the prognosis ranking from most likely to least likely:

RANKING: 1. Survivor
REASONING: The patient has idiopathic dilated cardiomyopathy, which is a chronic condition. Despite the reduced left ventricular ejection fraction (LVEF) of 39%, the patient is on optimal medical therapy, including beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor. This treatment regimen is aimed at managing symptoms, slowing disease progression, and reducing the risk of adverse outcomes. The patient's blood pressure is within a relatively normal range, and there is no evidence of acute cardiac injury (elevated troponin). The patient's pro-BNP level is elevated, indicating some degree of heart failure, but not excessively high. The patient's hemoglobin level is within a normal range, and there is no evidence of anemia. Considering these factors, the most likely outcome is that the patient will survive, albeit with ongoing management of their heart failure.

RANKING: 2. Pump Failure Death
REASONING: While the patient has a reduced LVEF, indicating some degree of systolic dysfunction, there is no evidence of severe hemodynamic compromise or acute cardiac injury. The patient is on optimal medical therapy, and their blood pressure is well-controlled. The patient's creatinine level is mildly elevated, but not excessively high, indicating some degree of renal impairment, which may be related to their heart failure. However, the patient's urea level is within a relatively normal range, and there is no evidence of acute kidney injury. Given the patient's current treatment regimen and the absence of severe symptoms or complications, pump failure death is a less likely outcome.

RANKING: 3. Sudden Cardiac Death
REASONING: Sudden cardiac death is a sudden, unexpected death due to cardiac causes, often related to ventricular arrhythmias. While the patient has a history of idiopathic dilated cardiomyopathy, there is no evidence of significant arrhythmias (e.g., ventricular tachycardia, non-sustained ventricular tachycardia) on the ECG. The patient's LVEF is reduced, but not severely so, and their pro-BNP level is elevated, indicating some degree of heart failure. However, the patient's overall clinical presentation and treatment regimen do not suggest a high risk of sudden cardiac death. The patient's potassium level is within a normal range, and there is no evidence of electrolyte imbalances that could contribute to arrhythmias. Therefore, sudden cardiac death is the least likely outcome."
385,385,P0621,"Age: 56
Gender: Male 
Weight: 78 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 120/85 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 33,7
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 3,46
Creatinine (mmol/L): 148.0
Gamma-glutamil transpeptidase (IU/L): 103
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 156.0
HDL (mmol/L): 0,73
Potassium (mEq/L): 2,94
LDL (mmol/L): 2,23
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 16094.0
Protein (g/L): 60,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,55
Urea (mg/dL): 11,8
LVEF (%): 16.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient has a low LVEF of 16%, indicating severe systolic heart failure. However, the patient is on optimal medical therapy with beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all evidence-based treatments for heart failure with reduced ejection fraction (HFrEF). The patient's NT-proBNP level is elevated at 16094.0 ng/L, which is consistent with severe heart failure. Despite the presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG, the patient does not have any other high-risk features such as a history of sudden cardiac death, syncope, or significant electrolyte imbalances. The patient's hemoglobin level is within normal limits, which suggests that the patient is not experiencing significant anemia. The patient's albumin level is also within normal limits, which suggests that the patient does not have significant liver dysfunction. Overall, while the patient's prognosis is guarded, the patient's current medical therapy and the absence of high-risk features make survivorship the most likely outcome.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 16% indicates severe systolic heart failure, and the patient's NT-proBNP level is elevated, which suggests that the patient is experiencing significant cardiac stress. The patient's creatinine level is elevated at 148.0 mmol/L, which suggests that the patient may be experiencing renal dysfunction due to heart failure. However, the patient's urine output is not specified, and the patient's urea level is only slightly elevated at 11.8 mg/dL, which suggests that the patient may not be experiencing significant acute kidney injury. The patient's glucose level is within normal limits, which suggests that the patient is not experiencing significant hyperglycemia. The patient's potassium level is slightly low at 2.94 mEq/L, which may be due to the patient's diuretic therapy. Overall, while the patient's prognosis is poor, the patient's renal function and glucose levels do not suggest that pump failure death is imminent.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's LVEF of 16% and elevated NT-proBNP level suggest that the patient is experiencing significant cardiac stress. However, the patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. However, the patient's troponin level is normal at 0.01 ng/mL, which suggests that the patient is not experiencing acute coronary syndrome. The patient's potassium level is slightly low, which may be due to the patient's diuretic therapy. The patient's TSH level is within normal limits, which suggests that the patient is not experiencing hyperthyroidism, which is a risk factor for sudden cardiac death. Overall, while the patient's ECG findings suggest a risk of sudden cardiac death, the patient's other clinical and laboratory findings do not suggest that sudden cardiac death is the most likely outcome."
386,386,P0623,"Age: 52
Gender: Female 
Weight: 73 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 105/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 45,9
ALT or GPT (IU/L): 104.0
AST or GOT (IU/L): 49.0
Total Cholesterol (mmol/L): 5,81
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 79
Glucose (mmol/L): 5
Hemoglobin (g/L): 144.0
Potassium (mEq/L): 4,4
Sodium (mEq/L): 145.0
Protein (g/L): 75,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,17
Urea (mg/dL): 7,6
LVEF (%): 28.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: 1. Survivor

REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and enlarged due to a heart attack. However, the patient is currently being treated with Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Statins, which are all evidence-based treatments for heart failure and ischemic cardiomyopathy. The patient's LVEF (Left Ventricular Ejection Fraction) is 28%, which is low but not extremely low. Additionally, the patient's troponin levels are normal, indicating that there is no ongoing myocardial infarction. The patient's blood pressure and potassium levels are within normal limits, and the patient does not have any signs of severe liver or kidney dysfunction. The patient's NYHA Class II indicates that the patient has some symptoms of heart failure, but they are not severe. Considering these factors, the most likely prognosis is that the patient will survive for the next few years with proper medical management.

RANKING: 2. Pump Failure Death

REASONING: The patient's LVEF is 28%, which is a significant decrease in cardiac function. The patient's history of ischemic dilated cardiomyopathy and myocardial infarction also increases the risk of pump failure. However, the patient is being treated with evidence-based medications, and the patient's troponin levels are normal, indicating that there is no ongoing myocardial infarction. The patient's blood pressure and potassium levels are within normal limits, which reduces the risk of arrhythmias. While the patient's liver enzymes are slightly elevated, they are not severely elevated, and the patient's kidney function is relatively preserved. Considering these factors, the second most likely prognosis is pump failure death, but this risk is mitigated by the patient's current medical management.

RANKING: 3. Sudden Cardiac Death

REASONING: The patient's ECG shows monomorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the patient does not have any signs of severe arrhythmias or cardiac dysfunction, such as non-sustained ventricular tachycardia or bradycardia. The patient's LVEF is low, but the patient is being treated with beta blockers, which can help reduce the risk of arrhythmias. The patient's troponin levels are normal, and the patient's blood pressure and potassium levels are within normal limits. While the patient's liver enzymes are slightly elevated, they are not severely elevated, and the patient's kidney function is relatively preserved. Considering these factors, the risk of sudden cardiac death is lower than pump failure death, making it the least likely prognosis."
387,387,P0625,"Age: 57
Gender: Female 
Weight: 70 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 37,6
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,71
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 54
Glucose (mmol/L): 19,7
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,39
Potassium (mEq/L): 4,35
LDL (mmol/L): 3,73
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1935.0
Protein (g/L): 70,2
T4 (ng/L): 9,4
Troponin (ng/mL): 0,01
TSH (mIU/L): 7,15
Urea (mg/dL): 8,6
LVEF (%): 48.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient is 57 years old with a history of Hypertensive cardiomyopathy, Diabetes, Dyslipemia, and Myocardial Infarction, which are all significant risk factors for cardiovascular disease. However, the patient is currently on a comprehensive treatment regimen that includes medications for diabetes, hypertension, and hyperlipidemia, which may help mitigate these risks. The patient's LVEF is 48%, which is below the normal range (50-70%), indicating some degree of left ventricular dysfunction, but it is not severely impaired. The patient's Pro-BNP level is elevated at 1935.0 ng/L, which suggests some degree of heart failure, but the patient's symptoms and overall clinical picture are not severe enough to indicate an extremely poor prognosis. The presence of TPSV on the ECG is a concern, but it is not a contraindication for survival. Overall, while the patient's prognosis is guarded, the presence of a comprehensive treatment plan and the absence of severe symptoms or complications suggest that survival is the most likely outcome.

RANKING: 2. Pump failure death
REASONING: The patient's LVEF of 48% indicates some degree of left ventricular dysfunction, which increases the risk of pump failure. The elevated Pro-BNP level of 1935.0 ng/L also suggests that the patient's heart is under stress and may be at risk for further decline. However, the patient's symptoms and overall clinical picture are not severe enough to indicate an extremely high risk of pump failure. The patient's ejection fraction is not severely impaired, and the patient is on medications that may help mitigate the risk of heart failure progression.

RANKING: 3. Sudden cardiac death
REASONING: While the patient has a history of Myocardial Infarction and is at risk for sudden cardiac death, the patient's current clinical picture does not suggest an extremely high risk. The patient's LVEF is not severely impaired, and the patient is on medications that may help mitigate the risk of arrhythmias and sudden cardiac death. The presence of polymorphic ventricular extrasystoles on the ECG is a concern, but it is not a contraindication for survival. The patient's overall clinical picture and treatment plan suggest that sudden cardiac death is the least likely outcome."
388,388,P0627,"Age: 74
Gender: Male 
Weight: 67 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 47
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,67
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,4
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 1312.0
Protein (g/L): 64
T3 (pg/dL): 0,04
T4 (ng/L): 13
TSH (mIU/L): 2,56
Urea (mg/dL): 5,49
LVEF (%): 37.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely:

RANKING: 1. Survivor
REASONING: The patient is 74 years old with a history of idiopathic dilated cardiomyopathy and hypertension, which are significant risk factors for heart failure. However, the patient is on optimal medical therapy with beta blockers, digoxin, loop diuretics, and ACE inhibitors, which suggests that the patient's heart failure is being well-managed. The LVEF of 37% is relatively low, but it is not the lowest possible value, indicating that the patient's heart is still pumping some blood. The patient's albumin level is slightly low, which may indicate some degree of malnutrition or liver dysfunction, but it is not severely low. The patient's Pro-BNP level is elevated at 1312.0 ng/L, which is consistent with heart failure, but it is not extremely high. The patient's TSH level is slightly elevated, which may indicate hypothyroidism, but it is not severely elevated. The ECG findings of ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia are concerning, but they are not extremely severe. Overall, while the patient has significant risk factors for heart failure, the patient's current medical therapy and the lack of severe abnormalities in the laboratory values suggest that the patient is likely to survive.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of idiopathic dilated cardiomyopathy and hypertension puts them at risk for sudden cardiac death. The patient's LVEF of 37% is low, which increases the risk of sudden cardiac death. The patient's Pro-BNP level is elevated, which is consistent with heart failure and may indicate a higher risk of sudden cardiac death. However, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death. The patient's ECG findings of ventricular extrasystoles and non-sustained ventricular tachycardia are concerning, but they are not extremely severe. Overall, while the patient is at risk for sudden cardiac death, the patient's current medical therapy and the lack of severe abnormalities in the laboratory values suggest that sudden cardiac death is less likely than survivor.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF of 37% is relatively low, which indicates that the patient's heart is not pumping efficiently. The patient's Pro-BNP level is elevated, which is consistent with heart failure. However, the patient is on optimal medical therapy with beta blockers, digoxin, loop diuretics, and ACE inhibitors, which suggests that the patient's heart failure is being well-managed. The patient's albumin level is slightly low, which may indicate some degree of malnutrition or liver dysfunction, but it is not severely low. The patient's TSH level is slightly elevated, which may indicate hypothyroidism, but it is not severely elevated. Overall, while the patient's heart failure is significant, the patient's current medical therapy and the lack of severe abnormalities in the laboratory values suggest that pump failure death is the least likely prognosis."
389,389,P0628,"Age: 68
Gender: Female 
Weight: 94 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 34
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,85
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 9
Hemoglobin (g/L): 133.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,25
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 1747.0
Protein (g/L): 75
T4 (ng/L): 8
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,7
Urea (mg/dL): 5,66
LVEF (%): 50.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: Survivor

REASONING: 

Given the provided patient data, I would rank the prognosis as Survivor for the following reasons:

1. Age and Gender: The patient is a 68-year-old female, which is a common demographic for heart failure and cardiovascular disease. However, her age and gender alone do not determine her prognosis.

2. NYHA Class II: The patient's New York Heart Association (NYHA) classification indicates that she experiences some limitations in physical activity but is still able to perform daily activities without discomfort. This classification suggests that her heart failure is not severe, which is a positive prognostic indicator.

3. Current Medications: The patient is on a regimen of beta blockers, digoxin, loop diuretics, statins, and ACE inhibitors, which are standard treatments for heart failure and hypertension. These medications are aimed at reducing symptoms, improving heart function, and preventing further cardiac damage.

4. ECG Findings: The ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or non-sustained ventricular tachycardia. This suggests that the patient's heart rhythm is relatively stable.

5. Blood Work: The patient's blood work shows elevated Pro-BNP levels (1747 ng/L), which is consistent with heart failure. However, her other blood work values, such as hemoglobin, albumin, and potassium, are within normal ranges.

6. LVEF: The patient's left ventricular ejection fraction (LVEF) is 50%, which is slightly below the normal range (55-70%). However, it is not severely impaired, indicating that her heart is still pumping effectively.

Considering these factors, I believe that the patient is likely to survive for the next few years. However, regular follow-up and monitoring are essential to adjust her treatment plan and address any potential complications.

RANKING: Sudden Cardiac Death

REASONING: 

Sudden cardiac death (SCD) is a possible prognosis for this patient, but it is less likely than survivor. The reasons for this ranking are:

1. Hypertensive Cardiomyopathy and Myocardial Infarction: The patient has a history of hypertensive cardiomyopathy and myocardial infarction, which increases her risk of sudden cardiac death.

2. Elevated Pro-BNP Levels: The patient's Pro-BNP levels are elevated, indicating increased stress on the heart, which may increase the risk of sudden cardiac death.

3. Polymorphic Ventricular Extrasystoles: The patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death.

However, these factors do not outweigh the patient's relatively stable heart function, her current medication regimen, and her NYHA classification.

RANKING: Pump Failure Death

REASONING: 

Pump failure death is the least likely prognosis for this patient. The reasons for this ranking are:

1. LVEF of 50%: While the patient's LVEF is slightly below the normal range, it is not severely impaired, indicating that her heart is still pumping effectively.

2. Stable Medications: The patient is on a regimen of medications that are aimed at improving heart function and preventing further cardiac damage.

3. NYHA Class II: The patient's NYHA classification indicates that she is still able to perform daily activities without discomfort, suggesting that her heart failure is not severe.

4. Blood Work: The patient's blood work values, such as hemoglobin, albumin, and potassium, are within normal ranges, indicating that her overall health is relatively stable.

While pump failure death is possible, the patient's current condition and treatment plan suggest that it is the least likely prognosis."
390,390,P0630,"Age: 61
Gender: Male 
Weight: 90 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 110/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes
Albumin (g/L): 44
ALT or GPT (IU/L): 45.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 126.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 5,2
LDL (mmol/L): 1,66
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 848.0
Protein (g/L): 71
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,98
Urea (mg/dL): 6,99
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. I will rank the three possible prognoses from most likely to least likely.

RANKING: 1. Survivor
REASONING: The patient is 61 years old with ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure. However, the patient is on optimal medical therapy, including beta blockers, statins, and ACE inhibitors, which are known to improve outcomes in patients with heart failure. The patient's LVEF is 35%, which is relatively low, but not extremely low. The patient's NT-proBNP level is elevated at 848 ng/L, indicating some degree of heart failure. However, the patient's hemoglobin and albumin levels are within normal limits, suggesting that the patient is not in severe heart failure. The patient's diabetes is well-controlled, and the absence of ventricular tachycardia on the ECG is a good sign. Considering these factors, the patient's prognosis is likely to be a survivor, with a good chance of long-term survival with continued optimal medical therapy.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient has a history of ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The patient's LVEF is low at 35%, which also increases the risk of sudden cardiac death. The patient's NT-proBNP level is elevated, indicating some degree of heart failure, which may also contribute to the risk of sudden cardiac death. However, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death. The absence of ventricular tachycardia on the ECG is a good sign, but the presence of polymorphic ventricular extrasystoles is a risk factor for sudden cardiac death. Overall, while the risk of sudden cardiac death is present, it is not the most likely outcome due to the patient's optimal medical therapy and relatively stable cardiac function.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF is 35%, which is relatively low, indicating some degree of heart failure. However, the patient's hemoglobin and albumin levels are within normal limits, suggesting that the patient is not in severe heart failure. The patient's NT-proBNP level is elevated, indicating some degree of heart failure, but it is not extremely high. The patient is on optimal medical therapy, including beta blockers, statins, and ACE inhibitors, which are known to improve outcomes in patients with heart failure. The patient's diabetes is well-controlled, and the absence of ventricular tachycardia on the ECG is a good sign. Considering these factors, the risk of pump failure death is relatively low, making it the least likely outcome.

Overall, the patient's prognosis is likely to be a survivor, with a good chance of long-term survival with continued optimal medical therapy."
391,391,P0631,"Age: 39
Gender: Male 
Weight: 123 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 51
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,86
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 37.0
Protein (g/L): 76
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,81
Urea (mg/dL): 5,49
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's the prognosis for the next few years, ordered from most likely to least likely:

RANKING: 1
REASONING: Survivor

The patient is 39 years old with a history of idiopathic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension. Despite these risk factors, the patient's current treatment regimen includes a combination of medications that aim to manage these conditions, such as calcium channel blockers, beta blockers, loop diuretics, statins, and an ACE inhibitor. The patient's LVEF is 25%, which indicates a significant reduction in left ventricular function, but it is not the lowest possible value. The patient's Pro-BNP level is 37.0 ng/L, which is within a relatively normal range, indicating that the patient's cardiac function is not severely compromised at the moment.

The patient's ECG does not show any signs of severe arrhythmias, such as ventricular tachycardia or bradycardia. While the presence of monomorphic ventricular extrasystoles is concerning, it is not uncommon in patients with cardiomyopathy and is not typically a strong predictor of sudden cardiac death.

Given the patient's age, the fact that they are receiving appropriate treatment for their conditions, and the relatively normal Pro-BNP level, I believe that the most likely outcome for this patient is survival over the next few years.

RANKING: 2
REASONING: Sudden Cardiac Death

While sudden cardiac death is a possible outcome for this patient, it is less likely than survival. The patient's LVEF is low, and they have a history of idiopathic dilated cardiomyopathy, which increases their risk of sudden cardiac death. However, the patient's ECG does not show any signs of severe arrhythmias, and their Pro-BNP level is within a relatively normal range. The patient is also receiving treatment with beta blockers, which are known to reduce the risk of sudden cardiac death in patients with cardiomyopathy.

RANKING: 3
REASONING: Pump Failure Death

Pump failure death is the least likely outcome for this patient. While the patient's LVEF is low, they are receiving treatment with loop diuretics, which help to manage fluid overload and reduce the workload on the heart. The patient's creatinine level is within a relatively normal range, indicating that their kidney function is not severely compromised, which is a good prognostic sign. Additionally, the patient's albumin and protein levels are within normal ranges, indicating that they do not have significant liver dysfunction or malnutrition, which can contribute to pump failure."
392,392,P0632,"Age: 73
Gender: Male 
Weight: 81 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 125/75 mmHg
Past Medical History: Other HF etiology, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 162.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,92
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 1395.0
Protein (g/L): 70
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,28
Urea (mg/dL): 7,99
LVEF (%): 35.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: Survivor
REASONING: The patient is 73 years old with a history of heart failure (HF) and hypertension, which increases the risk of adverse cardiac outcomes. However, several factors in the provided data suggest a relatively favorable prognosis for this patient.

1.  The patient is on optimal medical therapy with beta blockers and an ACE inhibitor, which are standard treatments for heart failure and hypertension.
2.  The patient's LVEF is 35%, which is low but not extremely low. An LVEF of 35% is often associated with a relatively good prognosis in patients with heart failure.
3.  The patient's NT-proBNP level is 1395.0 ng/L, which is elevated but not extremely high. Elevated NT-proBNP levels are associated with a worse prognosis in heart failure patients, but levels above 2000 ng/L are generally considered high-risk.
4.  The patient has a relatively normal hemoglobin level (162 g/L), which is a good sign as anemia is a common comorbidity in heart failure patients and can worsen outcomes.
5.  The patient's ECG shows non-sustained ventricular tachycardia, which is a concerning finding but not an immediate cause for alarm. The presence of ventricular extrasystoles is also common in the general population and may not be a significant concern in this context.
6.  The patient's creatinine level is 88.0 umol/L, which is elevated but not extremely high. Elevated creatinine levels can indicate renal impairment, which is common in heart failure patients. However, the patient is not on dialysis, and the creatinine level is not extremely high, suggesting that the patient's renal function is not severely impaired.

Considering these factors, the patient's overall prognosis is relatively good, and I would rank the prognosis as survivor. While the patient has several risk factors for adverse cardiac outcomes, the presence of optimal medical therapy, relatively good LVEF, and normal hemoglobin level suggest that the patient may be able to manage their condition and survive for several years.

RANKING: Sudden Cardiac Death
REASONING: Sudden cardiac death is a possible outcome for this patient due to the presence of non-sustained ventricular tachycardia on the ECG. Non-sustained ventricular tachycardia is a risk factor for sudden cardiac death, especially in patients with heart failure. However, the patient is on optimal medical therapy, and the presence of ventricular extrasystoles is not an immediate cause for alarm.

RANKING: Pump Failure Death
REASONING: Pump failure death is the least likely outcome for this patient due to the patient's relatively good LVEF (35%) and the presence of optimal medical therapy. While the patient has a history of heart failure, the LVEF is not extremely low, and the patient is on standard treatments for heart failure. The patient's creatinine level is also not extremely high, suggesting that the patient's renal function is not severely impaired."
393,393,P0633,"Age: 51
Gender: Male 
Weight: 97 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 58.0
AST or GOT (IU/L): 35.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 70
Glucose (mmol/L): 7,9
Hemoglobin (g/L): 168.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4
LDL (mmol/L): 2,2
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 193.0
Protein (g/L): 74
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2
Urea (mg/dL): 5,66
LVEF (%): 20.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor
 REASONING: The patient is 51 years old with ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac complications. However, the patient is on beta blockers, statins, and an ACE inhibitor, which are all standard medications for managing heart failure and reducing the risk of sudden cardiac death. The patient's LVEF is 20%, which indicates severe left ventricular dysfunction, but the lack of sustained ventricular tachycardia and the patient's relatively low troponin level (0.01 ng/mL) suggest that the patient's heart is not experiencing acute ischemia. The patient's BNP level is elevated at 193.0 ng/L, indicating some level of heart failure, but the patient's NYHA class is II, which suggests that the patient is still relatively stable and not experiencing severe symptoms. Considering these factors, the most likely prognosis is survivor, as the patient is being treated with appropriate medications and does not have acute cardiac ischemia or severe symptoms.

RANKING: Sudden Cardiac Death
 REASONING: The patient has a history of myocardial infarction, which increases the risk of sudden cardiac death. The presence of non-sustained ventricular tachycardia on the ECG is a risk factor for sudden cardiac death. However, the patient's LVEF is 20%, which is relatively low, but not extremely low. The patient's troponin level is low, which suggests that the patient is not experiencing acute ischemia. The patient is on beta blockers, which can reduce the risk of sudden cardiac death. While the patient's risk factors for sudden cardiac death are present, the patient's relatively stable NYHA class and the lack of acute ischemia make sudden cardiac death less likely than pump failure death.

RANKING: Pump Failure Death
 REASONING: The patient's LVEF is 20%, which is extremely low and indicates severe left ventricular dysfunction. The patient's creatinine level is elevated at 97.0 mmol/L, which suggests that the patient may have renal dysfunction, which can be a complication of heart failure. The patient's BNP level is elevated at 193.0 ng/L, which indicates that the patient has some level of heart failure. The patient's NYHA class is II, which suggests that the patient is still relatively stable, but the patient's low LVEF and elevated BNP level suggest that the patient's heart function is compromised. While the patient is on beta blockers, statins, and an ACE inhibitor, which can help manage heart failure, the patient's severe left ventricular dysfunction makes pump failure death a possible outcome. However, the patient's relatively stable NYHA class and the lack of acute ischemia make pump failure death less likely than sudden cardiac death."
394,394,P0634,"Age: 76
Gender: Male 
Weight: 72 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 114/77 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 3,67
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 141.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 5,1
LDL (mmol/L): 1,66
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 716.0
Protein (g/L): 76
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,67
Urea (mg/dL): 10,48
LVEF (%): 38.0
Medications: Diabetes Medication, Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient is 76 years old with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension. Despite these comorbidities, the patient is on optimal medical therapy with beta blockers, spironolactone, statins, and an ACE inhibitor, which suggests that the patient is being managed appropriately for heart failure. The patient's NYHA Class II classification indicates that the patient has some symptoms of heart failure, but they are manageable with medication and lifestyle modifications. The patient's LVEF of 38% is relatively preserved, and the troponin level is within normal limits, indicating that there is no acute coronary syndrome. The patient's Pro-BNP level is elevated, but it is not excessively high, which might indicate some degree of heart failure but not severe decompensation. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG is also reassuring. Overall, while the patient has significant comorbidities, the current management and lack of acute complications make a survivor prognosis more likely.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient has a history of ischemic dilated cardiomyopathy and a low LVEF of 38%, which increases the risk of sudden cardiac death. The presence of ventricular extrasystoles on the ECG may also indicate an increased risk of arrhythmias. However, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death. Additionally, the absence of other high-risk features such as ventricular tachycardia or non-sustained ventricular tachycardia on the ECG makes sudden cardiac death less likely.

RANKING: 3. Pump Failure Death
REASONING: While the patient has heart failure with a low LVEF, the patient's current management with spironolactone, beta blockers, and ACE inhibitors suggests that the patient's heart failure is being managed. The patient's NYHA Class II classification indicates that the patient has some symptoms of heart failure, but they are manageable with medication and lifestyle modifications. The patient's creatinine level is elevated, but it is not excessively high, which might indicate some degree of renal impairment but not severe kidney dysfunction. The patient's albumin level is low, which might indicate malnutrition or liver dysfunction, but it is not a clear indicator of pump failure. Overall, while the patient has significant comorbidities, the current management and lack of acute complications make pump failure death less likely."
395,395,P0636,"Age: 39
Gender: Male 
Weight: 79 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 115/85 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 47
ALT or GPT (IU/L): 52.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 7,01
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 162
Glucose (mmol/L): 5
Hemoglobin (g/L): 167.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 5,1
LDL (mmol/L): 4,5
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 114.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,701
Urea (mg/dL): 6,82
LVEF (%): 29.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient is 39 years old, which is relatively young for a patient with idiopathic dilated cardiomyopathy. The LVEF of 29% indicates a significant reduction in cardiac function, but it is not the lowest possible value. The patient is on a combination of medications, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure with reduced ejection fraction. The absence of significant electrolyte imbalances, anemia, or severe kidney dysfunction (creatinine 102 umol/L) suggests that the patient's kidney function is relatively preserved. Additionally, the low TSH level (0.701 mIU/L) and normal T3 and T4 levels suggest that thyroid function is within a normal range, which can be a contributing factor to heart failure. The patient's blood pressure is well-controlled, and the lack of signs of severe cardiac arrhythmias on the ECG is a positive sign. Considering these factors, the most likely prognosis is that the patient will survive.

RANKING: 2. Pump failure death
REASONING: The patient's LVEF of 29% indicates a significant reduction in cardiac function, which is a risk factor for pump failure. The elevated pro-BNP level (114 ng/L) suggests that the patient's heart is under strain, and the patient's symptoms and physical examination findings are consistent with heart failure. However, the patient's age, the fact that they are on appropriate medications, and the absence of severe kidney dysfunction or electrolyte imbalances suggest that pump failure is not the most likely immediate outcome.

RANKING: 3. Sudden cardiac death
REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The presence of polymorphic ventricular extrasystoles on the ECG is a risk factor for sudden cardiac death. However, the patient's LVEF of 29% is not the lowest possible value, and the patient is on beta blockers, which can reduce the risk of sudden cardiac death. Additionally, the patient's age and the fact that they are on other medications for heart failure suggest that sudden cardiac death is less likely than pump failure."
396,396,P0637,"Age: 58
Gender: Male 
Weight: 75 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 6,85
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 163.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 4,8
LDL (mmol/L): 4,84
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 269.0
Protein (g/L): 73
T3 (pg/dL): 0,06
T4 (ng/L): 14
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,83
Urea (mg/dL): 6,16
LVEF (%): 25.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient is 58 years old with a history of enolic dilated cardiomyopathy, which is a significant risk factor for heart failure and poor prognosis. However, the patient's NYHA Class II indicates that he is still relatively stable and able to perform some physical activity without symptoms. His LVEF of 25% is low, but not extremely low, and he is on an ACE inhibitor, which is a standard treatment for heart failure. His creatinine level is slightly elevated, but not severely so, and his blood pressure is well-controlled. His Troponin level is low, indicating minimal myocardial damage. The absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG is also a positive sign. Considering these factors, the most likely outcome is that the patient will survive, but with continued monitoring and management of his heart failure.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 25% indicates that his heart is significantly impaired, which increases the risk of pump failure. His elevated creatinine level and low albumin level suggest that he may have some degree of renal impairment, which can further exacerbate heart failure. His high total cholesterol and LDL levels may also contribute to the progression of his heart disease. However, the patient's age and NYHA Class II suggest that he may still have some reserve capacity and may be able to manage his symptoms with medication and lifestyle changes. Therefore, while pump failure is a possible outcome, it is not the most likely one.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's polymorphic ventricular extrasystoles on the ECG are a risk factor for sudden cardiac death, but the absence of ventricular tachycardia and non-sustained ventricular tachycardia suggests that the risk is not extremely high. The patient's low TSH level and high T3 level may indicate some degree of thyroid dysfunction, which can increase the risk of arrhythmias, but the T4 level is within the normal range. The patient's Troponin level is low, indicating minimal myocardial damage, and his blood pressure is well-controlled. While sudden cardiac death is a possible outcome, it is the least likely of the three options due to the absence of more severe ECG abnormalities and the patient's relatively stable clinical status."
397,397,P0638,"Age: 55
Gender: Male 
Weight: 82 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 48
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 12,5
Hemoglobin (g/L): 147.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,71
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 775.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,18
Urea (mg/dL): 8,15
LVEF (%): 31.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: Survivor

REASONING: Based on the provided patient data, I would rank the prognosis as Survivor due to the following reasons:

1.  The patient is on optimal medical therapy with Beta Blockers, Spironolactone, Statins, and an ACE Inhibitor, which are all standard treatments for heart failure and ischemic dilated cardiomyopathy.
2.  The patient's LVEF is 31%, which is low but not extremely low. While it indicates some degree of heart failure, it is not at the most severe end of the spectrum.
3.  The patient's blood pressure is well-controlled at 130/70 mmHg, which reduces the risk of further cardiac damage.
4.  The patient's Troponin level is low at 0.005 ng/mL, indicating minimal ongoing cardiac damage.
5.  The patient's Pro-BNP level is elevated at 775.0 ng/L, but this is not extremely high, and the patient's ejection fraction is relatively stable.
6.  The patient's creatinine level is elevated at 99.0 umol/L, indicating some degree of renal impairment, but it is not extremely high.
7.  The patient's hemoglobin level is within the normal range, and there is no indication of anemia.
8.  The patient's lipid profile is not ideal, but the patient is on statins, which should help to improve it.

While the patient has a history of ischemic dilated cardiomyopathy, myocardial infarction, and other comorbidities, the fact that they are on optimal medical therapy and have a relatively stable LVEF and Troponin level suggests that they are likely to survive for the next few years.

The other two options, Sudden Cardiac Death and Pump Failure Death, are less likely due to the following reasons:

*   Sudden Cardiac Death is less likely because the patient is on beta blockers, which reduce the risk of sudden cardiac death.
*   Pump Failure Death is less likely because the patient's LVEF is not extremely low, and they are on optimal medical therapy to manage their heart failure.

Overall, while the patient has a history of significant cardiac disease, their current medical therapy and stable LVEF and Troponin levels suggest that they are likely to survive for the next few years."
398,398,P0639,"Age: 49
Gender: Male 
Weight: 90 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,97
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,63
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,53
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 59.0
Protein (g/L): 76
T3 (pg/dL): 0,06
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,742
Urea (mg/dL): 6,49
LVEF (%): 50.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's the prognosis ranking from most likely to least likely:

RANKING: 1. Survivor
REASONING: The patient is 49 years old with a history of idiopathic dilated cardiomyopathy, which is a chronic condition. Despite this, the patient is on beta blockers and an ACE inhibitor, which are standard treatments for heart failure and cardiomyopathy. The patient's LVEF is 50%, which is relatively well-preserved considering the underlying condition. The lack of significant elevations in troponin, BNP, and creatinine suggests that the patient's heart function is stable. The absence of sustained ventricular tachycardia and other concerning ECG findings also suggests a lower risk of sudden cardiac death. The patient's overall clinical presentation and laboratory values suggest that the patient is being well-managed and is likely to survive in the next few years.

RANKING: 2. Sudden Cardiac Death
REASONING: While the patient has a history of idiopathic dilated cardiomyopathy, which increases the risk of sudden cardiac death, the patient's current management with beta blockers and an ACE inhibitor reduces this risk. The patient's LVEF of 50% is not severely impaired, and the lack of significant troponin elevation and BNP suggests that the patient's heart function is stable. However, the presence of polymorphic ventricular extrasystoles on the ECG increases the risk of arrhythmias and sudden cardiac death. The patient's age and underlying condition also increase this risk. However, given the patient's current management and stable clinical presentation, sudden cardiac death is less likely than pump failure death.

RANKING: 3. Pump Failure Death
REASONING: Pump failure death is the least likely prognosis for this patient. The patient's LVEF of 50% is relatively well-preserved, and the lack of significant elevations in BNP and creatinine suggests that the patient's heart function is stable. The patient's weight is within a relatively normal range for their height, and their blood pressure is well-controlled. The patient's current management with beta blockers and an ACE inhibitor is aimed at reducing the risk of heart failure progression, and the patient's overall clinical presentation suggests that the patient is being well-managed. While the patient has a history of idiopathic dilated cardiomyopathy, which increases the risk of heart failure progression, the patient's current clinical status and management suggest that pump failure death is the least likely outcome."
399,399,P0640,"Age: 69
Gender: Male 
Weight: 85 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 41,2
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,82
Creatinine (mmol/L): 166.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 162.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,33
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 1660.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,97
Urea (mg/dL): 10,91
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is my prognosis for the next few years, ranked from most likely to least likely:

RANKING: 1. Survivor
REASONING: The patient is 69 years old with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure. However, the patient is currently on optimal medical therapy with digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which suggests that the patient is receiving adequate treatment for heart failure. The LVEF of 30% is low, but the patient is not in NYHA Class IV, which indicates that the patient is not severely symptomatic. The lack of elevated troponin levels and the absence of other high-risk features such as severe renal impairment (creatinine 166.0 mmol/L is within a relatively normal range for a 69-year-old male) or severe anemia (Hemoglobin 162.0 g/L) also suggest a better prognosis. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG is concerning, but the absence of sustained ventricular tachycardia or other high-risk arrhythmias suggests that the patient is at relatively low risk for sudden cardiac death.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's LVEF of 30% and the presence of non-sustained ventricular tachycardia on the ECG are risk factors for sudden cardiac death. However, the patient's low heart rate (110/60 mmHg) and the absence of other high-risk features such as severe hypertension, severe anemia, or severe renal impairment suggest that sudden cardiac death is less likely than pump failure death. The patient's ejection fraction is low, but the patient is not in NYHA Class IV, which suggests that the patient is not severely symptomatic and may be able to tolerate a moderate level of physical activity.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF of 30% and NYHA Class II classification suggest that the patient has a moderate level of heart failure symptoms. However, the patient is on optimal medical therapy and has a relatively low creatinine level, which suggests that the patient's renal function is not severely impaired. The patient's hemoglobin level is also within a relatively normal range, which suggests that the patient is not severely anemic. While the patient's low ejection fraction and NYHA Class II classification suggest that pump failure is a possibility, the patient's overall clinical picture suggests that sudden cardiac death is a more likely outcome than pump failure death."
400,400,P0641,"Age: 68
Gender: Male 
Weight: 98 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 155/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 35,8
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,02
Creatinine (mmol/L): 131.0
Gamma-glutamil transpeptidase (IU/L): 55
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,08
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 718.0
Protein (g/L): 71
T3 (pg/dL): 0,02
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,71
Urea (mg/dL): 9,35
LVEF (%): 64.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Please note that this is a hypothetical assessment and not a definitive prediction. 

RANKING: 1. Survivor
 REASONING: The patient is 68 years old with a history of hypertensive cardiomyopathy, peripheral vascular disease, and hypertension. However, he is currently on a treatment regimen that includes a calcium channel blocker, digoxin, loop diuretics, and an ACE inhibitor, which suggests that his heart condition is being managed. His LVEF is 64%, which is within the normal range (> 55%). His troponin levels are normal, indicating that there is no acute coronary syndrome. The patient's BNP levels are elevated at 718.0 ng/L, which may indicate heart failure, but it is not excessively high. His NYHA class is II, which suggests that he is not severely symptomatic. Considering these factors, the patient's overall prognosis is likely to be a survivor, with a focus on continued management of his heart condition and monitoring for any signs of worsening symptoms.

RANKING: 2. Pump failure death
 REASONING: The patient's LVEF is 64%, which is within the normal range, but it is on the lower end. His BNP levels are elevated, which may indicate heart failure. His creatinine levels are also elevated at 131.0 mmol/L, which may indicate kidney dysfunction, possibly due to his heart failure. However, his NT-proBNP levels are not excessively high, and he is on a treatment regimen that includes diuretics, which may help manage his fluid status. While there is a risk of pump failure, it is not the most likely outcome given his current treatment and relatively normal LVEF.

RANKING: 3. Sudden cardiac death
 REASONING: The patient has a history of hypertensive cardiomyopathy, peripheral vascular disease, and hypertension, which increases his risk of sudden cardiac death. However, his LVEF is within the normal range, and his troponin levels are normal, indicating that there is no acute coronary syndrome. His ECG shows polymorphic ventricular extrasystoles, but there is no evidence of sustained ventricular tachycardia or bradycardia. While his TSH is slightly elevated, it is not excessively high, and his T4 levels are normal. His overall risk factors for sudden cardiac death are present, but they are not as high as in patients with more severe heart disease or those with a history of ventricular arrhythmias."
401,401,P0642,"Age: 72
Gender: Male 
Weight: 76 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 37,3
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 7
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,51
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 413.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,44
Urea (mg/dL): 5,13
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the prognoses from most likely to least likely as follows:

RANKING: Survivor
REASONING: The patient is 72 years old with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac complications. However, the patient's current medications, including beta blockers and ACE inhibitors (implied by the use of loop diuretics and calcium channel blockers), are likely aimed at managing the heart failure symptoms and reducing the risk of sudden cardiac death. The patient's LVEF is 30%, which is a moderate reduction, but not extremely low. The patient's BNP level is elevated at 413 ng/L, indicating some degree of heart failure, but not to the extent that would suggest an extremely poor prognosis. The patient's hemoglobin is within a relatively normal range, which suggests that the heart is not significantly compromising renal function. The patient's TSH is within a normal range, which suggests that the thyroid function is not contributing to the patient's cardiac condition. The absence of sustained ventricular tachycardia and the presence of polymorphic ventricular extrasystoles suggest that the patient's heart rhythm is relatively stable. Overall, while the patient has significant cardiac risk factors, the current treatment regimen and the absence of severe cardiac dysfunction suggest a relatively stable condition, making survival the most likely prognosis.

RANKING: Pump Failure Death
REASONING: The patient's LVEF is 30%, indicating moderate heart failure. The patient's BNP level is elevated, which suggests some degree of heart failure. The patient's creatinine level is slightly elevated, indicating some degree of renal impairment, which is a common complication of heart failure. The patient's hemoglobin is within a relatively normal range, but the patient's weight is 76 kg, which is above the ideal weight for their height, suggesting that the patient may be experiencing fluid overload, a common complication of heart failure. The patient's medications, including loop diuretics, are aimed at managing fluid overload and reducing the risk of heart failure progression. However, the patient's condition is not so severe that it would suggest an immediate risk of pump failure death.

RANKING: Sudden Cardiac Death
REASONING: The patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the patient's LVEF is 30%, which is a moderate reduction, and the patient's BNP level is elevated, suggesting that the patient's heart failure is not so severe that it would suggest an immediate risk of sudden cardiac death. The patient's medications, including beta blockers, are aimed at reducing the risk of sudden cardiac death. The patient's hemoglobin is within a relatively normal range, which suggests that the heart is not significantly compromising renal function, which is a common cause of sudden cardiac death. Overall, while the patient's ECG shows some risk factors for sudden cardiac death, the patient's overall condition and current treatment regimen suggest that sudden cardiac death is the least likely prognosis."
402,402,P0644,"Age: 72
Gender: Male 
Weight: 85 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 120/75 mmHg
Past Medical History: Hypertropic cardiomyopathy, Dyslipemia
Albumin (g/L): 43,7
ALT or GPT (IU/L): 94.0
AST or GOT (IU/L): 95.0
Total Cholesterol (mmol/L): 6,1
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 3,9
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 823.0
Protein (g/L): 85
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,18
TSH (mIU/L): 2,38
Urea (mg/dL): 6,91
LVEF (%): 60.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely:

RANKING: 1. Survivor
REASONING: The patient is 72 years old with a history of hypertrophic cardiomyopathy and dyslipemia, but is currently being treated with calcium channel blockers, beta blockers, and statins, which are appropriate medications for his conditions. His LVEF is 60%, indicating mild to moderate left ventricular dysfunction. His blood pressure is well-controlled at 120/75 mmHg. Although his troponin level is slightly elevated at 0.18 ng/mL, it is not significantly high. His pro-BNP level is 823.0 ng/L, which is elevated but not extremely high. The patient's NYHA Class II indicates that he is experiencing some symptoms of heart failure but is still able to perform some physical activity. Considering these factors, the patient's current treatment regimen and the absence of severe symptoms or laboratory abnormalities, a survivor prognosis is the most likely outcome.

RANKING: 2. Pump failure death
REASONING: The patient has a history of hypertrophic cardiomyopathy, which can lead to heart failure. His LVEF of 60% indicates mild to moderate left ventricular dysfunction, which can progress to more severe heart failure. His elevated pro-BNP level and slightly elevated troponin level suggest some degree of cardiac stress. However, the patient is being treated with medications that can help manage his conditions, and his blood pressure is well-controlled. While the patient is at risk for pump failure, the fact that he is currently asymptomatic (NYHA Class II) and has a relatively well-controlled condition suggests that pump failure death is less likely in the short term.

RANKING: 3. Sudden cardiac death
REASONING: The patient has a history of hypertrophic cardiomyopathy, which is a risk factor for sudden cardiac death. However, his LVEF is 60%, which is not extremely low, and his ECG does not show any signs of ventricular tachycardia or other life-threatening arrhythmias. His troponin level is slightly elevated, but not extremely high. While the patient's pro-BNP level is elevated, it is not extremely high. The patient's treatment regimen includes beta blockers, which can help reduce the risk of sudden cardiac death. Considering these factors, sudden cardiac death is the least likely outcome among the three possibilities."
403,403,P0645,"Age: 59
Gender: Male 
Weight: 85 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 44,3
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 5,25
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,84
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 395.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,7
Urea (mg/dL): 4,68
LVEF (%): 39.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient has a history of ischemic dilated cardiomyopathy with a left ventricular ejection fraction (LVEF) of 39%, indicating reduced cardiac function. However, the patient is on optimal medical therapy with beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators. The patient's blood pressure is well-controlled, and the Pro-BNP level is elevated but not extremely high. The patient's glucose and lipid profiles are also relatively well-managed. The absence of sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, and bradycardia on the ECG is a positive sign. The patient's overall clinical profile suggests that the patient is receiving adequate treatment and has a reasonable prognosis.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF of 39% indicates reduced cardiac function, which increases the risk of pump failure. However, the patient's symptoms are classified as NYHA Class II, indicating mild to moderate symptoms. The patient's Pro-BNP level is elevated, which is consistent with heart failure. The patient's creatinine level is mildly elevated, suggesting some degree of renal impairment, but it is not severe. The patient's overall clinical profile suggests that the patient is at risk for pump failure, but the risk is not extremely high.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy and a reduced LVEF, which increases the risk of sudden cardiac death. However, the patient is on optimal medical therapy, and the ECG does not show any signs of sustained ventricular tachycardia or other high-risk features for sudden cardiac death. The patient's Pro-BNP level is elevated, but it is not extremely high, and the patient's overall clinical profile suggests that the risk of sudden cardiac death is lower than the risk of pump failure."
404,404,P0646,"Age: 61
Gender: Male 
Weight: 74 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 47,59
ALT or GPT (IU/L): 53.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,66
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 174.0
Protein (g/L): 78
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,12
Urea (mg/dL): 10,24
LVEF (%): 35.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: The patient has a history of ischemic dilated cardiomyopathy, which indicates that the heart muscle has been damaged due to a heart attack. However, the patient is currently taking medications that are beneficial for heart failure, including an Angiotensin II Receptor Blocker, Loop Diuretics, Statins, ACE Inhibitor, and Nitrovasodilator. The patient's LVEF (Left Ventricular Ejection Fraction) is 35%, which is low but not extremely low. The patient's NYHA Class II indicates that the patient experiences some limitation in physical activity but is still able to perform light physical activity. The patient's Pro-BNP (B-type natriuretic peptide) level is elevated at 174.0 ng/L, which is a marker of heart failure, but it is not extremely high. The patient's TSH (Thyroid-stimulating hormone) level is within the normal range, and the T3 and T4 levels are low, which is consistent with primary hypothyroidism. The patient's Troponin level is normal, indicating that there is no current myocardial infarction. The patient's potassium level is slightly low, but this is likely due to the use of diuretics. Overall, while the patient has a history of heart disease and is currently experiencing heart failure, the patient's current medications and relatively stable condition suggest that a survivor prognosis is the most likely outcome.

RANKING: Pump Failure Death

REASONING: Pump failure death is a possible outcome due to the patient's history of ischemic dilated cardiomyopathy and low LVEF. The patient's Pro-BNP level is elevated, which is a marker of heart failure. However, the patient's current medications and relatively stable condition suggest that the patient is being effectively managed. The patient's NYHA Class II indicates that the patient is still able to perform light physical activity, which is a good prognostic sign.

RANKING: Sudden Cardiac Death

REASONING: Sudden cardiac death is the least likely outcome for this patient. The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are abnormal heart rhythms, but they are not life-threatening in this case. The patient's Troponin level is normal, indicating that there is no current myocardial infarction. The patient's medications are likely helping to manage the patient's heart condition, and the patient's NYHA Class II indicates that the patient is still able to perform light physical activity. While the patient's LVEF is low, it is not extremely low, and the patient's Pro-BNP level is not extremely high. Overall, while the patient has some risk factors for sudden cardiac death, the patient's current condition and medications suggest that this outcome is the least likely."
405,405,P0648,"Age: 72
Gender: Female 
Weight: 78 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 130/90 mmHg
Past Medical History: Hypertropic cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39,9
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,15
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 7,1
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 3,6
LDL (mmol/L): 2,97
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 126.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2
Urea (mg/dL): 8,46
LVEF (%): 60.0
Medications: Beta Blockers
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: Survivor
 REASONING: The patient is 72 years old with a history of hypertrophic cardiomyopathy, diabetes, dyslipemia, and hypertension. However, despite these comorbidities, the patient is on beta-blocker therapy, which is a standard treatment for hypertrophic cardiomyopathy. The left ventricular ejection fraction (LVEF) is 60%, which is within the normal range, indicating that the heart is pumping efficiently. The patient's troponin level is normal, suggesting that there is no acute coronary syndrome. The pro-BNP level is elevated at 126 ng/L, but it is not extremely high, which might indicate some degree of heart failure but not severe. The patient's ECG shows monomorphic ventricular extrasystoles, which can be a benign finding in some cases. Overall, considering the patient's age, comorbidities, and treatment, a survivor prognosis seems most likely.

RANKING: Pump failure death
 REASONING: The patient has a history of hypertrophic cardiomyopathy, which can lead to heart failure over time. The LVEF is 60%, which is within the normal range, but it may not be a reliable indicator of the patient's long-term prognosis. The patient's pro-BNP level is elevated, which suggests some degree of heart failure. However, the patient's overall clinical status does not suggest severe heart failure. The patient's creatinine level is elevated at 90.0 mmol/L, which may indicate some degree of renal impairment, but it is not extremely high. Considering the patient's age and comorbidities, pump failure death is a possible prognosis, but it seems less likely than a survivor prognosis.

RANKING: Sudden cardiac death
 REASONING: The patient has a history of hypertrophic cardiomyopathy, which can increase the risk of sudden cardiac death. However, the patient's ECG does not show any signs of ventricular tachycardia or other arrhythmias that would increase the risk of sudden cardiac death. The patient's troponin level is normal, and the patient is on beta-blocker therapy, which can reduce the risk of sudden cardiac death. While the patient's pro-BNP level is elevated, it does not suggest a high risk of sudden cardiac death. Overall, considering the patient's age, comorbidities, and clinical status, sudden cardiac death seems the least likely prognosis."
406,406,P0652,"Age: 68
Gender: Female 
Weight: 62 kg
Height: 144 cm
NYHA Class: II
Blood Pressure: 200/110 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45,1
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,39
Creatinine (mmol/L): 78.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,8
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 170.0
Protein (g/L): 71,7
T4 (ng/L): 15
TSH (mIU/L): 5,21
Urea (mg/dL): 5,49
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. I will rank the three possible prognoses from most likely to least likely and explain the reasoning behind the order.

RANKING: 1. Survivor
REASONING: Despite the patient's advanced age, NYHA Class II, and history of idiopathic dilated cardiomyopathy, several factors suggest a relatively favorable prognosis. The patient's LVEF of 35% indicates moderate heart failure, but it is not severely impaired. The patient is on optimal medical therapy with a calcium channel blocker, loop diuretics, and an ACE inhibitor, which is appropriate for managing hypertension and heart failure. The patient's blood pressure is well-controlled, and there is no evidence of significant renal impairment (creatinine 78.0 mol/L). The patient's albumin level is within the normal range, and liver enzymes are mildly elevated but not significantly abnormal. The patient's Pro-BNP level is elevated, indicating heart failure, but not excessively high, suggesting some degree of compensation. The absence of significant arrhythmias, such as sustained ventricular tachycardia or atrial fibrillation, is also a positive sign. Overall, these factors suggest that the patient has a relatively stable and manageable condition, making a survivor prognosis the most likely.

RANKING: 2. Pump Failure Death
REASONING: While the patient's LVEF of 35% indicates a significant impairment of left ventricular function, the patient's current symptoms and clinical status suggest that the heart failure is not yet in an advanced stage. The patient's NYHA Class II classification indicates that the patient experiences some limitation of physical activity but is still able to perform daily activities without significant symptoms. The patient's blood pressure is well-controlled, and the absence of significant arrhythmias and renal impairment suggests that the patient's heart failure is not yet in a critical state. However, the patient's LVEF is low, and the patient has a history of idiopathic dilated cardiomyopathy, which may progress over time. Therefore, pump failure death is a possible but less likely prognosis compared to survivor.

RANKING: 3. Sudden Cardiac Death
REASONING: Sudden cardiac death is a less likely prognosis for this patient due to the following reasons: the patient's ECG shows non-sustained ventricular tachycardia, but no sustained ventricular tachycardia or other high-risk arrhythmias are present. The patient is on optimal medical therapy, and the blood pressure is well-controlled, which reduces the risk of sudden cardiac death. The patient's LVEF is low, but it is not severely impaired, and the patient is not in a high-risk category for sudden cardiac death. The patient's age and sex also do not significantly increase the risk of sudden cardiac death. While sudden cardiac death is always a possibility in patients with heart failure, the patient's current clinical status and ECG findings make it the least likely prognosis."
407,407,P0653,"Age: 73
Gender: Male 
Weight: 88 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 45,3
ALT or GPT (IU/L): 6.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,15
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 3,9
LDL (mmol/L): 4,37
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 655.0
Protein (g/L): 80
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,87
Urea (mg/dL): 10,69
LVEF (%): 39.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient is 73 years old with a history of enolic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension. Despite these comorbidities, the patient is on optimal medical therapy with beta blockers, loop diuretics, and an ACE inhibitor, which suggests that the patient's condition is being actively managed. The patient's LVEF is 39%, which is relatively low but not the lowest possible value. The patient's Pro-BNP level is elevated at 655 ng/L, but it is not extremely high, which might indicate that the patient's heart failure is not in an advanced stage. Additionally, the patient's blood pressure is well-controlled at 120/80 mmHg, which is a positive sign. Considering these factors, the patient's prognosis is more likely to be a survivor.

RANKING: 2. Pump failure death
 REASONING: The patient's LVEF is 39%, which is below the normal range, indicating some degree of left ventricular dysfunction. The patient's Pro-BNP level is elevated, which suggests that the patient has some degree of heart failure. However, the patient's condition is being actively managed with optimal medical therapy, and the patient's blood pressure is well-controlled. The patient's creatinine level is slightly elevated at 124.0 mmol/L, which may indicate some degree of renal dysfunction, but it is not extremely high. Considering these factors, the patient's prognosis is more likely to be pump failure death than sudden cardiac death.

RANKING: 3. Sudden cardiac death
 REASONING: The patient's LVEF is 39%, which is below the normal range, indicating some degree of left ventricular dysfunction. However, the patient's condition is being actively managed with optimal medical therapy, and the patient's blood pressure is well-controlled. The patient's Pro-BNP level is elevated, but it is not extremely high. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death, but it is not a definitive predictor. Considering these factors, the patient's prognosis is less likely to be sudden cardiac death compared to pump failure death."
408,408,P0654,"Age: 70
Gender: Female 
Weight: 75 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 45,9
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,73
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1789.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,09
Urea (mg/dL): 8,46
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: Sudden Cardiac Death, Pump Failure Death, Survivor

REASONING:

1.  Sudden Cardiac Death: Given the patient's history of ischemic dilated cardiomyopathy, previous myocardial infarction, and non-sustained ventricular tachycardia, the risk of sudden cardiac death is high. The patient's low LVEF (25%) and elevated Pro-BNP levels (1789 ng/L) also indicate severe heart failure. Although the patient is on beta blockers, statins, and ACE inhibitors, the presence of ventricular extrasystoles and non-sustained ventricular tachycardia increases the risk of life-threatening arrhythmias. Therefore, sudden cardiac death is the most likely prognosis.

2.  Pump Failure Death: The patient's low LVEF (25%), elevated Pro-BNP levels (1789 ng/L), and history of ischemic dilated cardiomyopathy and previous myocardial infarction suggest a high risk of pump failure. The patient's NYHA Class II classification also indicates moderate heart failure symptoms. However, the patient's relatively well-managed diabetes and controlled blood pressure, along with the presence of medications, may slow the progression of heart failure. Therefore, pump failure death is the second most likely prognosis.

3.  Survivor: Given the patient's advanced age (70 years), low LVEF (25%), and history of ischemic dilated cardiomyopathy, the likelihood of survival is lower compared to younger patients. However, the patient's relatively well-managed diabetes, controlled blood pressure, and the presence of medications may contribute to a slightly better prognosis. Additionally, the patient's recent non-sustained ventricular tachycardia may be a manageable condition with medical therapy. Therefore, while the risk of sudden cardiac death and pump failure is higher, the patient's overall clinical picture suggests a slightly better chance of survival compared to the other two options."
409,409,P0655,"Age: 55
Gender: Male 
Weight: 107 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 46,1
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 108.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 159.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,08
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 408.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,96
Urea (mg/dL): 6,91
LVEF (%): 24.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses for the next few years from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient has a relatively high left ventricular ejection fraction (LVEF) of 24% despite having ischemic dilated cardiomyopathy, which indicates some degree of preserved cardiac function. The patient is on optimal medical therapy with beta blockers, loop diuretics, statins, and ACE inhibitors, which are all evidence-based treatments for heart failure with reduced ejection fraction. The patient's blood pressure is well-controlled, and there is no significant electrolyte imbalance. The patient's creatinine level is mildly elevated, but it is not significantly high. The patient's troponin level is low, indicating no recent myocardial infarction. The patient's TSH level is within the normal range, and the T3 and T4 levels are low, which may indicate hypothyroidism, but this is not directly related to the cardiac prognosis. The patient's LVEF is relatively stable, and the patient is not showing any signs of rapid clinical deterioration. Therefore, the most likely prognosis for this patient is survival.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of myocardial infarction, ischemic dilated cardiomyopathy, and non-sustained ventricular tachycardia, which are all risk factors for sudden cardiac death. However, the patient is on optimal medical therapy, and the LVEF is relatively high, which may mitigate this risk. The patient's TSH level is within the normal range, which may indicate that the patient's hypothyroidism is not contributing to an increased risk of sudden cardiac death. The patient's LVEF is relatively stable, and the patient is not showing any signs of rapid clinical deterioration. Therefore, while sudden cardiac death is a possible risk, it is not the most likely prognosis.

RANKING: 3. Pump Failure Death
 REASONING: The patient has a relatively low LVEF of 24%, which indicates significant left ventricular dysfunction. The patient's creatinine level is mildly elevated, indicating some degree of renal impairment, which may be related to the patient's heart failure. The patient's pro-BNP level is high, indicating elevated filling pressures and possible volume overload. However, the patient is on optimal medical therapy, and the LVEF is relatively stable, which may mitigate this risk. The patient's blood pressure is well-controlled, and there is no significant electrolyte imbalance. The patient's troponin level is low, indicating no recent myocardial infarction. Therefore, while pump failure death is a possible risk, it is not the most likely prognosis due to the patient's relatively stable LVEF and optimal medical therapy."
410,410,P0658,"Age: 59
Gender: Male 
Weight: 69 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 130/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42,9
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 81.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,82
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 469.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,53
Urea (mg/dL): 12,47
LVEF (%): 39.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

Based on the provided patient data, I would rank the prognosis as Survivor due to the following reasons:

1.  The patient is on a comprehensive treatment plan that includes medications for diabetes, beta blockers, statins, ACE inhibitors, and nitrovasodilators, which suggests that the patient is being actively managed for their conditions.
2.  The patient's LVEF (Left Ventricular Ejection Fraction) is 39%, which indicates that the patient's heart is still pumping effectively, albeit at a reduced capacity. This suggests that the patient's heart is not yet in a state of severe failure.
3.  The patient's Pro-BNP (brain natriuretic peptide) level is 469.0 ng/L, which is elevated, but not excessively high. Elevated Pro-BNP levels can indicate heart failure, but the level is not high enough to suggest imminent heart failure.
4.  The patient's Troponin level is 0.01 ng/mL, which is within the normal range, indicating that there is no acute myocardial infarction.
5.  The patient's TSH (thyroid-stimulating hormone) level is 1.53 mIU/L, which is within the normal range, indicating that the patient's thyroid function is normal.
6.  The patient's HDL (high-density lipoprotein) cholesterol level is 1.11 mmol/L, which is low, but not excessively low. This may be a concern, but it's not a major red flag.
7.  The patient's albumin level is 42.9 g/L, which is slightly low, but not critically low.

Considering these factors, the patient's prognosis is likely to be a survivor, as they are on a comprehensive treatment plan, and their LVEF is still within a relatively acceptable range. However, close monitoring and continued management of their conditions are still necessary to prevent further decline.

RANKING: Sudden Cardiac Death

REASONING: 

Based on the provided patient data, I would rank Sudden Cardiac Death as the second most likely prognosis due to the following reasons:

1.  The patient has a history of ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death.
2.  The patient's LVEF is 39%, which is relatively low, indicating that the patient's heart is not pumping effectively.
3.  The patient has a history of myocardial infarction, which increases the risk of sudden cardiac death.
4.  The patient's Pro-BNP level is elevated, which can indicate heart failure and increase the risk of sudden cardiac death.

However, the patient is on a comprehensive treatment plan, and their LVEF is not extremely low, which reduces the likelihood of sudden cardiac death.

RANKING: Pump Failure Death

REASONING: 

Based on the provided patient data, I would rank Pump Failure Death as the least likely prognosis due to the following reasons:

1.  The patient's LVEF is 39%, which is relatively high compared to patients who are at risk of pump failure.
2.  The patient is on a comprehensive treatment plan, which suggests that their heart failure is being actively managed.
3.  The patient's Pro-BNP level is elevated, but not excessively high, which suggests that the patient's heart failure is not severe.
4.  The patient's creatinine level is 81.0 umol/L, which is slightly elevated, but not critically high, indicating that the patient's kidney function is not severely impaired.

While the patient has a history of ischemic dilated cardiomyopathy and other comorbidities, their current treatment plan and relatively high LVEF make pump failure death less likely."
411,411,P0659,"Age: 77
Gender: Male 
Weight: 68 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 140/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 48,3
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 138.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,72
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 1071.0
Protein (g/L): 74
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,04
TSH (mIU/L): 6,33
Urea (mg/dL): 13,36
LVEF (%): 50.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely:

RANKING: Survivor

REASONING: The patient is 77 years old with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac events. However, the patient is on a treatment regimen that includes beta blockers, loop diuretics, statins, and an ACE inhibitor, which are all standard treatments for heart failure and ischemic heart disease. The patient's LVEF is 50%, which is below the normal range but not severely impaired, indicating that the patient still has some preserved cardiac function.

The patient's NYHA Class II classification indicates that the patient has some limitations in physical activity but is still able to perform daily activities without symptoms. The patient's blood pressure is well-controlled, and the creatinine level is slightly elevated but not significantly high.

The patient's Pro-BNP level is elevated at 1071.0 ng/L, which indicates some degree of cardiac stress, but the level is not extremely high. The patient's troponin level is normal, which suggests that there is no acute myocardial infarction.

The patient's lipid profile shows high total cholesterol and LDL levels, but the patient is on statins, which should help to manage these levels.

Overall, while the patient has several risk factors for cardiac events, the patient's treatment regimen and the lack of severe symptoms or acute cardiac events suggest that the most likely prognosis is survival.

The two less likely prognoses are:

RANKING: Sudden Cardiac Death

REASONING: While the patient has a history of ischemic dilated cardiomyopathy and a low LVEF, the patient is on a treatment regimen that includes beta blockers, which can help to reduce the risk of sudden cardiac death. The patient's ECG is normal, with no signs of ventricular tachycardia or bradycardia, which further reduces the risk of sudden cardiac death.

RANKING: Pump Failure Death

REASONING: While the patient has a history of ischemic dilated cardiomyopathy and a low LVEF, the patient's symptoms are not severe (NYHA Class II), and the patient is on a treatment regimen that includes loop diuretics, which should help to manage fluid overload and reduce the risk of pump failure. The patient's creatinine level is slightly elevated, but not severely high, which suggests that the patient's kidneys are still functioning relatively well."
412,412,P0660,"Age: 49
Gender: Male 
Weight: 81 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 155/80 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 50,59
ALT or GPT (IU/L): 56.0
AST or GOT (IU/L): 53.0
Total Cholesterol (mmol/L): 7,89
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 821
Glucose (mmol/L): 11
Hemoglobin (g/L): 166.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,1
LDL (mmol/L): 5,02
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 114.0
Protein (g/L): 86
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 11,8
Urea (mg/dL): 6,91
LVEF (%): 50.0
Medications: Diabetes Medication, Amiodarone, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses for the next few years as follows:

RANKING: 1. Survivor
REASONING: The patient has a complex medical history, including valvular cardiomyopathy, diabetes, and hypertension. However, several factors suggest a relatively favorable prognosis. The patient's left ventricular ejection fraction (LVEF) is 50%, which is slightly below the normal range (50-70%), but still within the mildly reduced range. The patient is on medications that are commonly used to manage heart failure and arrhythmias, including ACE inhibitors, loop diuretics, and amiodarone. The patient's blood pressure is well-controlled, and there is no evidence of significant kidney dysfunction (creatinine level is slightly elevated, but not severely so). The patient's hemoglobin and albumin levels are within normal ranges, suggesting that the patient is not experiencing significant anemia or malnutrition. While the patient's TSH level is slightly elevated, this is likely related to the amiodarone therapy rather than a sign of thyroid dysfunction. Overall, the patient's clinical presentation and laboratory results suggest that they are at risk for complications, but the prognosis is not immediately dire.

RANKING: 2. Pump failure death
REASONING: The patient's LVEF is 50%, which suggests that the patient's heart is functioning at a reduced capacity. The patient's creatinine level is slightly elevated, which may indicate some degree of kidney dysfunction, potentially related to the patient's heart failure. The patient's pro-BNP level is elevated, which is a marker of heart failure. However, the patient's symptoms are mild (NYHA Class II), and the patient is on medications that are commonly used to manage heart failure. While the patient's risk of pump failure death is higher than average, the patient's overall clinical presentation and laboratory results suggest that this outcome is not the most likely.

RANKING: 3. Sudden cardiac death
REASONING: The patient has a history of ventricular extrasystoles, which is a risk factor for sudden cardiac death. However, the patient's ECG does not show any evidence of sustained ventricular tachycardia or other high-risk arrhythmias. The patient is on amiodarone, which is a medication that is commonly used to prevent sudden cardiac death in patients with arrhythmias. While the patient's TSH level is slightly elevated, this is likely related to the amiodarone therapy rather than a sign of thyroid dysfunction. The patient's overall clinical presentation and laboratory results suggest that the risk of sudden cardiac death is relatively low."
413,413,P0662,"Age: 61
Gender: Female 
Weight: 64 kg
Height: 142 cm
NYHA Class: II
Blood Pressure: 135/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43,9
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,61
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 191.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,95
Urea (mg/dL): 11,36
LVEF (%): 60.0
Medications: Diabetes Medication, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. I will consider the patient's age, gender, medical history, laboratory results, and current medication regimen.

RANKING: Survivor

REASONING: 

This patient is a 61-year-old female with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction. Her current NYHA class is II, indicating moderate symptoms, but she is still able to perform most daily activities. 

Her laboratory results show elevated Pro-BNP levels (191.0 ng/L), which is a marker of heart failure, but her LVEF is 60%, indicating that her heart function is relatively preserved. She is on a regimen of beta blockers, statins, and diabetes medication, which are all appropriate for her conditions.

However, her low HDL (1.11 mmol/L) and high LDL (2.61 mmol/L) levels suggest that she may not be adequately controlled on her current lipid-lowering therapy. Her TSH level is within the normal range, but her T3 and T4 levels are slightly low, which may indicate hypothyroidism.

Considering these factors, the most likely prognosis for this patient is a survivor. She has a history of heart failure, but her current LVEF is preserved, and she is on appropriate medications. With proper management of her lipid levels, blood sugar control, and monitoring of her thyroid function, it is likely that she will continue to survive with her current conditions.

Sudden cardiac death is less likely because her LVEF is still within a relatively normal range, and she does not have any other high-risk features such as a history of ventricular tachycardia or a low ejection fraction.

Pump failure death is also less likely because her LVEF is preserved, and she does not have any signs of severe heart failure such as elevated creatinine levels or severe shortness of breath. However, her Pro-BNP levels are elevated, indicating that she may be at risk for heart failure progression.

Therefore, the order of the prognoses from most likely to least likely is: Survivor, Pump failure death, Sudden cardiac death."
414,414,P0663,"Age: 66
Gender: Male 
Weight: 117 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 160/105 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45,59
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 55
Glucose (mmol/L): 10,3
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,79
Sodium (mEq/L): 146.0
Pro-BNP (ng/L): 419.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,79
Urea (mg/dL): 8,02
LVEF (%): 50.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor, 2. Pump failure death, 3. Sudden cardiac death

REASONING: 

1. Survivor: Given the patient's age, history of ischemic dilated cardiomyopathy, and reduced left ventricular ejection fraction (LVEF) of 50%, the patient is at an increased risk for heart failure. However, the patient's NYHA Class II indicates that they are not severely symptomatic, which suggests that they may be relatively stable at this point. The patient's blood pressure is elevated, but it's not extremely high, and they are on an ACE inhibitor, which is a standard treatment for heart failure and hypertension. The patient's troponin level is low, indicating that they are not experiencing an acute myocardial infarction. The patient's TSH level is within the normal range, indicating that there is no apparent thyroid dysfunction contributing to their cardiac condition. Considering these factors, the patient's prognosis is likely to be a survivor, at least in the short to medium term, with proper management of their condition.

2. Pump failure death: The patient's LVEF of 50% indicates that their heart is not pumping efficiently, which increases the risk of heart failure. The patient's creatinine level of 99.0 mmol/L suggests that they may have some degree of renal impairment, which can be a consequence of heart failure. The patient's albumin level is low, which can indicate malnutrition or liver disease, but it may also be a sign of heart failure. The patient's total cholesterol level is high, which can contribute to atherosclerosis and worsen cardiac function. Considering these factors, the patient is at risk for pump failure, which can lead to death if left untreated or if the condition worsens.

3. Sudden cardiac death: The patient's ECG shows monomorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the patient does not have a history of sustained ventricular tachycardia or other arrhythmias that would increase the risk of sudden cardiac death. The patient's troponin level is low, indicating that they are not experiencing an acute myocardial infarction, which can be a cause of sudden cardiac death. While the patient's LVEF is reduced, it is not severely impaired, and they are on an ACE inhibitor, which can help to reduce the risk of arrhythmias. Therefore, while sudden cardiac death is a possible outcome, it is less likely than pump failure death, given the patient's overall condition and management.

It's essential to note that this prognosis is based on the provided information and may not be comprehensive. A more accurate assessment would require a thorough physical examination, additional diagnostic tests, and a more detailed medical history."
415,415,P0664,"Age: 59
Gender: Male 
Weight: 105 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38,1
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,46
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 11,2
Hemoglobin (g/L): 152.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,64
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 135.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,56
Urea (mg/dL): 12,03
LVEF (%): 22.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor
REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for adverse outcomes. However, the patient is already on optimal medical therapy for heart failure, including beta blockers, loop diuretics, spironolactone, and ACE inhibitors. The patient's LVEF is 22%, which is relatively low, but the lack of sustained ventricular tachycardia and ventricular extrasystoles on the ECG suggests that the patient is not at immediate risk of sudden cardiac death. The patient's Pro-BNP level is elevated at 135 ng/L, but this is not extremely high, and the patient's blood pressure is well-controlled. The patient's kidney function, as indicated by the creatinine level, is also relatively preserved. Considering these factors, the most likely outcome is that the patient will survive, albeit with ongoing heart failure management.

RANKING: Pump Failure Death
REASONING: The patient has a history of ischemic dilated cardiomyopathy and a low LVEF of 22%, which increases the risk of pump failure. The patient's creatinine level is elevated at 102.0 mmol/L, indicating impaired kidney function, which can be a marker of advanced heart failure. The patient's total cholesterol level is high at 5.46 mmol/L, which may contribute to further cardiac damage. However, the patient is already on optimal medical therapy for heart failure, which may mitigate some of these risks.

RANKING: Sudden Cardiac Death
REASONING: The patient has a history of ischemic dilated cardiomyopathy and a low LVEF of 22%, which increases the risk of sudden cardiac death. However, the patient's ECG does not show any signs of sustained ventricular tachycardia or ventricular fibrillation, which are common causes of sudden cardiac death. The patient's Pro-BNP level is elevated, but not extremely high, and the patient's blood pressure is well-controlled. The patient's kidney function is also relatively preserved. Additionally, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death. Therefore, while the patient is at risk for sudden cardiac death, it is not the most likely outcome based on the provided data."
416,416,P0666,"Age: 71
Gender: Female 
Weight: 86 kg
Height: 147 cm
NYHA Class: III
Blood Pressure: 150/85 mmHg
Past Medical History: Hypertropic cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43,2
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,85
Creatinine (mmol/L): 272.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,73
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,32
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2627.0
Protein (g/L): 74
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,06
TSH (mIU/L): 2,06
Urea (mg/dL): 31,4
LVEF (%): 65.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely.

RANKING: Survivor

REASONING: The patient is 71 years old, which is an advanced age for a cardiac condition. However, her left ventricular ejection fraction (LVEF) is 65%, which is still within the normal range (50-70%). The presence of hypertrophic cardiomyopathy and previous myocardial infarction are concerning factors, but the patient is currently on a treatment regimen that includes beta blockers, which are known to help manage symptoms and reduce the risk of further cardiac events. The patient's ejection fraction is still within the normal range, and her creatinine levels are elevated, but not severely. Her Pro-BNP levels are high, but not excessively high, which could indicate heart failure with preserved ejection fraction. The presence of polymorphic ventricular extrasystoles on the ECG is concerning, but not necessarily indicative of a poor prognosis. Considering these factors, the most likely prognosis is survival, assuming the patient adheres to her medication regimen and lifestyle modifications.

RANKING: Pump Failure Death

REASONING: The patient's LVEF is still within the normal range, which reduces the likelihood of pump failure death. However, her creatinine levels are elevated, which could indicate underlying kidney disease or reduced cardiac output. Her Pro-BNP levels are high, which could also indicate heart failure with preserved ejection fraction. While these factors are concerning, they do not necessarily point to pump failure death as the most likely outcome.

RANKING: Sudden Cardiac Death

REASONING: Sudden cardiac death is a less likely prognosis for this patient. The patient has a history of myocardial infarction and hypertrophic cardiomyopathy, which could increase the risk of sudden cardiac death. However, the presence of beta blockers and calcium channel blockers in her medication regimen reduces this risk. The patient's LVEF is within the normal range, which also reduces the likelihood of sudden cardiac death. The polymorphic ventricular extrasystoles on the ECG are concerning, but not necessarily indicative of a high risk of sudden cardiac death. Overall, while sudden cardiac death is a possible outcome, it is less likely than survivor or pump failure death."
417,417,P0668,"Age: 67
Gender: Female 
Weight: 70 kg
Height: 146 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 45,7
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,87
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 7
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,77
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 1356.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,39
Urea (mg/dL): 14,92
LVEF (%): 68.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely.

RANKING: 1. Survivor
REASONING: The patient is 67 years old with a history of hypertensive cardiomyopathy, diabetes, dyslipemia, and peripheral vascular disease. Despite these comorbidities, the patient's left ventricular ejection fraction (LVEF) is 68%, which is within the normal range (> 55%). The patient is also on a combination of medications that are typical for heart failure management, including ACE inhibitors, beta blockers, and loop diuretics. Additionally, the patient does not have any significant electrolyte imbalances or acute coronary syndrome indicators, such as elevated troponin levels. The presence of ventricular extrasystoles on the ECG is a common finding in the general population and is not typically associated with a poor prognosis. Therefore, considering these factors, the most likely prognosis for this patient is a survivor.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF is within the normal range, which suggests that the patient's heart function is not severely impaired at this point. However, the patient's Pro-BNP level is elevated at 1356.0 ng/L, which is a marker of heart failure. The patient's creatinine level is also slightly elevated, which may indicate some degree of renal impairment, but it is not significantly high. The patient's blood pressure is also well-controlled, and they are on medications that are typically used to manage heart failure. While the patient's comorbidities and elevated Pro-BNP level suggest that they may be at risk for heart failure progression, the patient's current LVEF and medication regimen suggest that pump failure death is less likely than sudden cardiac death.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's LVEF is within the normal range, which reduces the likelihood of sudden cardiac death due to ventricular arrhythmias. The patient's ECG does show ventricular extrasystoles, but this is a common finding and not typically associated with a high risk of sudden cardiac death. The patient's medication regimen, which includes beta blockers and ACE inhibitors, also reduces the risk of arrhythmias. While the patient's comorbidities and elevated Pro-BNP level suggest that they may be at risk for cardiovascular events, the patient's overall cardiac function and medication regimen make sudden cardiac death the least likely prognosis."
418,418,P0669,"Age: 80
Gender: Male 
Weight: 74 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 43,1
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,4
Creatinine (mmol/L): 138.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,77
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 901.0
Protein (g/L): 78,3
T4 (ng/L): 16
TSH (mIU/L): 7,12
Urea (mg/dL): 15,64
LVEF (%): 40.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: Despite the patient's advanced age and multiple comorbidities, including ischemic dilated cardiomyopathy, diabetes, and peripheral vascular disease, the patient is currently receiving optimal medical therapy for heart failure, including ACE inhibitors (spironolactone and loop diuretics), beta-blockers (amiodarone), and statins. The patient's LVEF of 40% is relatively well-preserved, and the lack of evidence of severe renal dysfunction (creatinine 138.0 umol/L) and electrolyte imbalances (potassium 5.4 mEq/L) suggests that the patient's kidneys are functioning relatively well. Additionally, the patient's NT-proBNP level of 901.0 pg/mL is elevated but not excessively high, which may indicate that the patient's heart failure is being managed effectively. The patient's overall clinical status, as reflected by the NYHA Class II, suggests that the patient is experiencing some symptoms of heart failure but is still able to perform daily activities without significant limitation. Therefore, based on these factors, the most likely prognosis is that the patient will survive.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of sudden cardiac death. However, the patient's current medical therapy, including amiodarone, which is an anti-arrhythmic medication, suggests that the patient's risk of sudden cardiac death may be mitigated. Additionally, the lack of evidence of severe ventricular arrhythmias on the ECG (no ventricular tachycardia or non-sustained ventricular tachycardia) suggests that the patient's risk of sudden cardiac death may be relatively low. However, the patient's advanced age and multiple comorbidities still increase the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF of 40% and NT-proBNP level of 901.0 pg/mL suggest that the patient's heart failure is likely to progress over time, leading to worsening symptoms and potentially pump failure. The patient's age and multiple comorbidities also increase the risk of pump failure. However, the patient's current medical therapy and relatively well-preserved kidney function suggest that the patient's risk of pump failure may be manageable with continued medical therapy. The patient's overall clinical status, as reflected by the NYHA Class II, also suggests that the patient's symptoms are currently well-managed. Therefore, while pump failure is a possible outcome, it is the least likely of the three prognoses."
419,419,P0670,"Age: 75
Gender: Female 
Weight: 73 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Hypertropic cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 44,8
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 77.0
Gamma-glutamil transpeptidase (IU/L): 67
Glucose (mmol/L): 9,7
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,79
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 359.0
Protein (g/L): 69,7
T4 (ng/L): 17
TSH (mIU/L): 1,28
Urea (mg/dL): 6,99
LVEF (%): 40.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses for the next few years as follows:

RANKING: 1. Survivor
REASONING: The patient is 75 years old with a history of hypertrophic cardiomyopathy, diabetes, dyslipemia, and hypertension. However, the patient is being treated with medications for these conditions, including an ACE inhibitor, angiotensin II receptor blocker, loop diuretics, and statins, which are all appropriate for managing heart failure and hypertension. The patient's LVEF is 40%, which is below the normal range (50-70%), indicating some degree of left ventricular dysfunction. However, the patient's NYHA class is II, indicating that the patient has some limitations in physical activity but is still able to perform daily activities without significant symptoms. The patient's Pro-BNP level is elevated at 359 ng/L, which is indicative of heart failure, but it is not extremely high. The patient's ECG shows monomorphic ventricular extrasystoles, which can be a benign finding in some cases. Overall, the patient's treatment plan and current symptoms suggest that they are being managed appropriately, and the patient's age and comorbidities are not unusually severe. Therefore, I believe that a survivor prognosis is the most likely outcome.

RANKING: 2. Pump failure death
REASONING: The patient's LVEF is 40%, indicating some degree of left ventricular dysfunction, and their Pro-BNP level is elevated, which is indicative of heart failure. However, the patient's NYHA class is II, and they are being treated with medications that are appropriate for managing heart failure. The patient's age and comorbidities are significant risk factors for cardiovascular disease, but they are not unusually severe. The patient's ECG shows monomorphic ventricular extrasystoles, which can be a benign finding in some cases. While the patient's heart failure is not being well-controlled, the patient's overall condition does not appear to be catastrophic, and the patient is receiving treatment. Therefore, I believe that pump failure death is the second most likely outcome.

RANKING: 3. Sudden cardiac death
REASONING: The patient's ECG shows monomorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the patient's LVEF is 40%, and their Pro-BNP level is elevated, which suggests that the patient's heart failure is not being well-controlled. The patient's NYHA class is II, and they are being treated with medications that are appropriate for managing heart failure. While the patient's ECG findings suggest some risk of arrhythmias, the patient's overall condition does not appear to be catastrophic, and the patient is receiving treatment. The patient's age and comorbidities are significant risk factors for cardiovascular disease, but they are not unusually severe. Therefore, I believe that sudden cardiac death is the least likely outcome.

Note: It's worth noting that the patient's TSH level is slightly elevated at 1.28 mIU/L, which may indicate hypothyroidism. This could potentially contribute to the patient's heart failure and worsen their prognosis. However, without further information, it's difficult to determine the significance of this finding."
420,420,P0672,"Age: 70
Gender: Female 
Weight: 66 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 42,5
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 72.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,87
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 824.0
Protein (g/L): 69,7
T4 (ng/L): 16
TSH (mIU/L): 3,09
Urea (mg/dL): 5,99
LVEF (%): 35.0
Medications: Diabetes Medication, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. However, please note that this is a hypothetical analysis and actual patient outcomes can vary based on numerous factors.

RANKING: Survivor

REASONING: The patient is a 70-year-old female with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for adverse cardiac outcomes. However, there are several factors that suggest a more favorable prognosis.

1.  The patient's NYHA Class II indicates that she is experiencing some symptoms of heart failure, but they are not severe, and she is still able to perform daily activities without significant limitation.
2.  Her blood pressure is within a relatively normal range, which is beneficial for cardiac health.
3.  She is on optimal medical therapy with diabetes medication, statins, and an ACE inhibitor, which are all evidence-based treatments for heart failure and ischemic cardiomyopathy.
4.  Her LVEF of 35% is low, but it is not extremely low, and she does not have any signs of severe heart failure symptoms.
5.  Her BNP level is elevated, but it is not extremely high, which may indicate that she is not in acute heart failure.
6.  Her ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or other significant arrhythmias.
7.  Her laboratory values are relatively normal, with the exception of mildly elevated liver enzymes, which could be related to her statin therapy.

Considering these factors, I believe that the patient has a relatively good prognosis for survival over the next few years. While she does have significant underlying cardiac disease, her symptoms are well-managed, and she is on optimal medical therapy.

RANKING: Sudden Cardiac Death

REASONING: Sudden cardiac death is a possible outcome for this patient, but it is less likely than survivorship. The factors that increase the risk of sudden cardiac death include:

1.  Her history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death.
2.  Her low LVEF of 35%, which indicates that her heart is not pumping efficiently.
3.  Her elevated BNP level, which may indicate that she is at risk for acute heart failure or arrhythmias.
4.  Her polymorphic ventricular extrasystoles on ECG, which can be a precursor to more serious arrhythmias.

However, these risks are somewhat mitigated by her relatively normal blood pressure, optimal medical therapy, and lack of severe symptoms.

RANKING: Pump Failure Death

REASONING: Pump failure death is the least likely outcome for this patient, as she does not have any signs of severe heart failure symptoms, and her LVEF is not extremely low. Additionally, her blood pressure is relatively normal, and she is on optimal medical therapy. While her ischemic dilated cardiomyopathy is a significant risk factor for heart failure, her current symptoms and laboratory values do not suggest that she is at high risk for pump failure."
421,421,P0673,"Age: 79
Gender: Female 
Weight: 70 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 150/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 45,2
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,97
Creatinine (mmol/L): 60.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,99
Potassium (mEq/L): 3,6
LDL (mmol/L): 2,56
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 58.0
Protein (g/L): 68,9
T4 (ng/L): 15
TSH (mIU/L): 1,63
Urea (mg/dL): 4,99
LVEF (%): 67.0
Medications: Calcium Channel Blocker, Beta Blockers, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here are the prognoses for the next few years, ordered from most likely to least likely:

RANKING: Survivor
REASONING: The patient is 79 years old with a history of hypertensive cardiomyopathy, dyslipemia, and hypertension. However, her LVEF is 67%, which is within the normal range (> 50%), indicating that her heart function is relatively preserved. She is on medications that are commonly used to manage heart failure, such as calcium channel blockers, beta blockers, and nitrovasodilators. Her ECG shows no signs of sustained ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia, which are all indicators of potential cardiac instability. Her Pro-BNP level is 58.0 ng/L, which is within the normal range (< 125 ng/L), suggesting that her heart is not under excessive stress. Additionally, her creatinine level is within the normal range, indicating that her kidney function is preserved. Considering these factors, the patient's overall prognosis appears to be relatively favorable, and the most likely outcome is that she will survive.

RANKING: Pump Failure Death
REASONING: The patient's LVEF is 67%, which is within the normal range, but it is on the lower end of the normal range. Her creatinine level is slightly elevated at 60.0 mmol/L, indicating that her kidney function is mildly impaired. Her Pro-BNP level is within the normal range, but it is on the higher end of the normal range, suggesting that her heart may be under some stress. Additionally, her blood pressure is slightly elevated at 150/85 mmHg, which may indicate underlying hypertension. While these factors are not immediately concerning, they do suggest that the patient's heart function may be compromised to some extent. If these factors continue to progress, it is possible that the patient may experience pump failure, leading to death.

RANKING: Sudden Cardiac Death
REASONING: The patient's ECG shows polymorphic ventricular extrasystoles, which can be a marker of increased risk of sudden cardiac death. However, there is no evidence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia, which are more significant indicators of sudden cardiac death risk. The patient's LVEF is within the normal range, and her Pro-BNP level is within the normal range, suggesting that her heart function is relatively preserved. While the polymorphic ventricular extrasystoles are concerning, they are not a definitive indicator of sudden cardiac death risk. Therefore, sudden cardiac death is the least likely outcome of the three."
422,422,P0674,"Age: 66
Gender: Male 
Weight: 71 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 44,5
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 6,52
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 168.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,03
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 209.0
Protein (g/L): 71,3
T4 (ng/L): 12
TSH (mIU/L): 1,1
Urea (mg/dL): 5,99
LVEF (%): 35.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here are the three possible prognoses for the next few years, ordered from most likely to least likely:

RANKING: 1. Survivor
REASONING: The patient is 66 years old with a history of ischemic dilated cardiomyopathy, myocardial infarction, and hypertension. However, the patient's LVEF is 35%, which indicates moderate heart failure. Despite this, the patient is on medications such as loop diuretics and ACE inhibitors, which are standard treatments for heart failure. The patient's blood pressure is controlled at 160/90 mmHg, and the electrolyte levels are within the normal range. The patient's albumin and protein levels are slightly low, but not critically so. The patient's creatinine level is elevated at 95.0 mmol/L, indicating some renal impairment, but it is not severe. The Pro-BNP level is elevated at 209.0 ng/L, which is consistent with heart failure. Considering these factors, the patient's overall condition is manageable with medication, and with proper management, the patient is likely to survive for the next few years.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF is 35%, indicating moderate heart failure. The patient's creatinine level is elevated, suggesting some degree of renal impairment, which can be a sign of advanced heart failure. The patient's Pro-BNP level is elevated, indicating increased ventricular stress. However, the patient is on standard treatments for heart failure, and the blood pressure is controlled. The patient's age and history of myocardial infarction also contribute to the risk of pump failure. However, the patient's overall condition is not severe enough to warrant a high likelihood of pump failure death.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The patient's LVEF is 35%, indicating moderate heart failure, and the Pro-BNP level is elevated, indicating increased ventricular stress. However, the patient's blood pressure is controlled, and the patient is on standard treatments for heart failure. The patient's ECG shows polymorphic ventricular extrasystole, which can be a risk factor for sudden cardiac death. However, the absence of non-sustained ventricular tachycardia and other risk factors for sudden cardiac death makes this prognosis less likely."
423,423,P0675,"Age: 55
Gender: Male 
Weight: 74 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 140/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,34
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,39
Hemoglobin (g/L): 121.0
HDL (mmol/L): 2,4
Potassium (mEq/L): 4,96
LDL (mmol/L): 2,75
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 447.0
Protein (g/L): 69
T3 (pg/dL): 0,03
T4 (ng/L): 12,72
Troponin (ng/mL): 0,3
TSH (mIU/L): 0,38
Urea (mg/dL): 4,2
LVEF (%): 50.0
Medications: Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: The patient's age, gender, and NYHA Class II indicate a moderate level of heart failure symptoms. However, the patient's LVEF of 50% is relatively preserved, which is a good prognostic indicator. The patient is on appropriate medications for heart failure, including beta blockers, statins, ACE inhibitors, and nitrovasodilators, which are all evidence-based treatments for ischemic dilated cardiomyopathy. The patient's blood pressure is well-controlled, and the troponin level is low, indicating minimal ongoing myocardial damage. Additionally, the patient's pro-BNP level is elevated, but not extremely high, suggesting that the patient's heart failure is being managed effectively. While the patient has a history of myocardial infarction and dyslipemia, these factors are being addressed through medication. The patient's ECG shows no signs of severe arrhythmias, which is a good prognostic sign. Overall, the patient's condition appears to be well-managed, and the prognosis for survival is relatively good.

RANKING: Sudden Cardiac Death

REASONING: While the patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death, the patient's LVEF is 50%, and the patient is on appropriate medications to reduce the risk of sudden cardiac death. The patient's ECG shows no signs of severe arrhythmias, and the troponin level is low, indicating minimal ongoing myocardial damage. However, the patient's pro-BNP level is elevated, suggesting that the patient may be at risk for sudden cardiac death due to underlying heart failure. However, the patient's overall condition appears to be well-managed, and the risk of sudden cardiac death is not extremely high.

RANKING: Pump Failure Death

REASONING: The patient's LVEF of 50% indicates that the patient's heart is functioning relatively well, and the patient is on appropriate medications to manage heart failure. While the patient's pro-BNP level is elevated, indicating underlying heart failure, the patient's condition appears to be well-managed, and the risk of pump failure death is relatively low. The patient's NYHA Class II indicates that the patient's heart failure symptoms are not severe, and the patient is able to perform daily activities without significant limitation. Overall, the patient's prognosis for pump failure death is the least likely of the three options."
424,424,P0676,"Age: 67
Gender: Male 
Weight: 79 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 165/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,9
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,35
Creatinine (mmol/L): 158.0
Gamma-glutamil transpeptidase (IU/L): 50
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,95
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2034.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,62
Urea (mg/dL): 8,02
LVEF (%): 39.0
Medications: Calcium Channel Blocker, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 2
REASONING: 

Based on the provided patient data, I would rank the prognosis as follows: 

1. Sudden cardiac death (least likely)
2. Pump failure death
3. Survivor (most likely)

Here's the reasoning behind this ranking:

The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. However, the patient is already on an ACE inhibitor, which is a medication that reduces the risk of sudden cardiac death. Additionally, the patient's LVEF (Left Ventricular Ejection Fraction) is 39%, which is relatively low but not extremely low. 

The patient's Pro-BNP level is elevated at 2034.0 ng/L, which is indicative of heart failure. However, the patient is on loop diuretics, which is a common treatment for heart failure. The patient's weight is also relatively high at 79 kg, which may contribute to the heart failure symptoms.

The patient's Troponin level is low at 0.02 ng/mL, which suggests that the patient is not experiencing an acute myocardial infarction. The patient's TSH level is also within the normal range, which suggests that the patient's thyroid function is not contributing to the heart failure symptoms.

The patient's ECG shows polymorphic ventricular extrasystoles, which is a risk factor for sudden cardiac death. However, the patient does not have any other ECG abnormalities that would suggest a high risk of sudden cardiac death.

Considering all these factors, I would rank the prognosis as follows: 

Pump failure death is the most likely outcome because the patient has a history of ischemic dilated cardiomyopathy and an elevated Pro-BNP level, which are both risk factors for heart failure. However, the patient is already on treatment for heart failure, which may help to mitigate this risk.

Sudden cardiac death is the least likely outcome because the patient is on an ACE inhibitor, which reduces the risk of sudden cardiac death, and the patient's Troponin level is low, which suggests that the patient is not experiencing an acute myocardial infarction.

Survivor is the most likely outcome because the patient is already on treatment for heart failure and ischemic dilated cardiomyopathy, and the patient's ECG does not show any other abnormalities that would suggest a high risk of sudden cardiac death."
425,425,P0677,"Age: 60
Gender: Male 
Weight: 78 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,09
LDL (mmol/L): 2,92
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 67.0
Protein (g/L): 68,5
T3 (pg/dL): 0,063
T4 (ng/L): 16,14
Troponin (ng/mL): 0,1
TSH (mIU/L): 1
Urea (mg/dL): 5,2
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor
 REASONING: The patient's current condition suggests a relatively stable cardiovascular status despite having a history of ischemic dilated cardiomyopathy and myocardial infarction. The patient's left ventricular ejection fraction (LVEF) is 40%, which is below the normal range (50-70%), indicating some degree of heart failure. However, the patient is on optimal medical therapy, including beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators, which are all evidence-based treatments for heart failure and ischemic cardiomyopathy. The patient's Pro-BNP level is within a relatively normal range, which is a good prognostic indicator for patients with heart failure. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG also suggests a lower risk of sudden cardiac death. Considering the patient's stable condition and optimal medical therapy, a survivor prognosis is the most likely outcome.

RANKING: Sudden Cardiac Death
 REASONING: While the patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, the absence of certain high-risk features, such as low LVEF (<30%), high Pro-BNP levels, or certain arrhythmias on the ECG, makes sudden cardiac death less likely. However, the presence of polymorphic ventricular extrasystoles on the ECG is a concern, as it may indicate underlying electrical instability. Additionally, the patient's low HDL cholesterol and high LDL cholesterol levels may contribute to ongoing atherosclerotic disease, which could potentially increase the risk of sudden cardiac death.

RANKING: Pump Failure Death
 REASONING: Pump failure death is the least likely outcome for this patient, given the patient's relatively stable condition and optimal medical therapy. The patient's LVEF is 40%, which is below the normal range, but the patient is on evidence-based treatments for heart failure, and the Pro-BNP level is within a relatively normal range. The patient's creatinine level is also within a relatively normal range, suggesting that the patient does not have significant kidney dysfunction, which can be a predictor of pump failure."
426,426,P0678,"Age: 55
Gender: Male 
Weight: 97 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 127.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 134.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5,09
LDL (mmol/L): 2,25
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 416.0
Protein (g/L): 69,6
T3 (pg/dL): 0,0435
T4 (ng/L): 13,4
Troponin (ng/mL): 0,1
TSH (mIU/L): 0,63
Urea (mg/dL): 8,2
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here is the ranking of the prognoses from most likely to least likely:

RANKING: 1. Survivor

REASONING: The patient is 55 years old with a history of ischemic dilated cardiomyopathy, which indicates that his heart muscle is weakened due to a heart attack. However, he is on optimal medical therapy with beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators, which are commonly used to manage heart failure and reduce the risk of cardiac events. His LVEF (Left Ventricular Ejection Fraction) is 40%, which is below the normal range but not extremely low, suggesting that his heart is still functioning to some extent. The patient's Pro-BNP (Brain Natriuretic Peptide) level is elevated at 416.0 ng/L, which is a marker of heart failure severity, but it is not extremely high. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG indicates some degree of cardiac electrical instability, but the patient is not experiencing sustained arrhythmias or other life-threatening conditions at the moment. Given the patient's age, comorbidities, and current medical therapy, the most likely prognosis is survival with continued medical management and monitoring.

RANKING: 2. Sudden Cardiac Death

REASONING: While the patient has a history of ischemic dilated cardiomyopathy and is at risk for sudden cardiac death, his current medical therapy and the absence of more severe cardiac dysfunction (e.g., extremely low LVEF, high Pro-BNP levels) suggest that sudden cardiac death is less likely. The patient's LVEF is 40%, which is below normal but not extremely low, and his Pro-BNP level is elevated but not extremely high. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG indicates some degree of cardiac electrical instability, but it is not a strong predictor of sudden cardiac death. The patient's age and comorbidities increase his risk, but the likelihood of sudden cardiac death is lower than pump failure death.

RANKING: 3. Pump Failure Death

REASONING: Pump failure death is a possible outcome for a patient with ischemic dilated cardiomyopathy and a low LVEF (40%). However, the patient's current medical therapy and the absence of more severe cardiac dysfunction (e.g., extremely low LVEF, high Pro-BNP levels, severe renal dysfunction) suggest that pump failure death is less likely. The patient's LVEF is below normal, but it is not extremely low, and his Pro-BNP level is elevated but not extremely high. The patient's creatinine level is slightly elevated (127.0 umol/L), but it is not severely elevated, which suggests that his renal function is not severely impaired. The patient's age and comorbidities increase his risk of pump failure death, but the likelihood is lower than sudden cardiac death due to his current medical therapy and the absence of more severe cardiac dysfunction."
427,427,P0681,"Age: 79
Gender: Female 
Weight: 55 kg
Height: 142 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 7,21
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 13,4
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,14
LDL (mmol/L): 5,22
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3501.0
Protein (g/L): 66,8
T3 (pg/dL): 0,0522
T4 (ng/L): 14,85
TSH (mIU/L): 2,37
Urea (mg/dL): 7,8
LVEF (%): 25.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient is 79 years old with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure. However, the patient is on beta blockers, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure. The patient's LVEF is 25%, which is low but not extremely low, and the patient's NYHA Class is II, indicating mild to moderate symptoms. The patient's creatinine level is elevated, but it is not extremely high, and the patient's BNP level is high, but not extremely high. The patient also has a history of hypertension, which can contribute to heart failure. Considering these factors, the patient's prognosis is guarded, but with appropriate medical management and monitoring, the patient may be able to survive for several years.

RANKING: 2. Pump Failure Death
 REASONING: The patient's low LVEF (25%) and high BNP level (3501.0 ng/L) suggest that the patient has significant heart failure. The patient's creatinine level is elevated, indicating possible kidney dysfunction, which can be a consequence of heart failure. However, the patient is on medications that are known to improve heart failure outcomes, and the patient's NYHA Class is II, indicating that the patient is not in severe heart failure. The patient's overall condition is critical, but it is not immediately life-threatening.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient's ECG shows ventricular extrasystole and non-sustained ventricular tachycardia, which can be risk factors for sudden cardiac death. However, the patient's LVEF is low, but not extremely low, and the patient is on medications that can reduce the risk of sudden cardiac death. The patient's overall condition is critical, but the risk of sudden cardiac death is lower than the risk of pump failure death, given the patient's relatively stable clinical condition and the presence of heart failure symptoms."
428,428,P0682,"Age: 59
Gender: Male 
Weight: 83 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 145/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 44,4
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,43
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 176.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 3,9
LDL (mmol/L): 3,7
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1780.0
Protein (g/L): 70
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,08
Urea (mg/dL): 9,13
LVEF (%): 62.0
Medications: Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's the ranking of the possible prognoses from most likely to least likely:

RANKING: Survivor

REASONING: The patient is 59 years old with a history of ischemic dilated cardiomyopathy, which suggests that they have had a previous heart attack or heart muscle damage. However, they are on beta blockers, statins, and nitrovasodilators, which are common treatments for heart failure and ischemic heart disease. The left ventricular ejection fraction (LVEF) is 62%, which is within the normal range (50-70%), indicating that the heart is still pumping efficiently. The patient's NYHA Class II suggests that they have some symptoms of heart failure, but they are still able to perform everyday activities without significant limitation.

The patient's blood work shows elevated creatinine levels (95.0 mmol/L), which may indicate some kidney impairment, but it is not severe. The pro-BNP level is elevated at 1780.0 ng/L, which is consistent with heart failure, but the patient's LVEF is within normal limits, which may suggest that the heart is still compensating for the elevated pro-BNP levels.

The patient's lipid profile shows high total cholesterol and LDL levels, which are a concern for further cardiovascular events. However, they are on statins, which should help manage these levels. The patient's glucose level is slightly elevated, but not severely so.

The ECG shows monomorphic ventricular extrasystoles, which are common in patients with heart disease, but not indicative of a poor prognosis.

Overall, while the patient has some risk factors for cardiovascular disease, their current treatment and LVEF suggest that they are at lower risk for sudden cardiac death or pump failure death in the next few years. Therefore, the most likely prognosis is survivor.

RANKING: Sudden cardiac death (less likely)

REASONING: Sudden cardiac death is a risk in patients with ischemic dilated cardiomyopathy, especially if they have a history of ventricular arrhythmias or low LVEF. However, the patient's LVEF is within normal limits, and they do not have a history of ventricular tachycardia or other arrhythmias that would increase their risk for sudden cardiac death.

RANKING: Pump failure death (least likely)

REASONING: Pump failure death is a risk in patients with heart failure, especially if they have a low LVEF or severe symptoms. However, the patient's LVEF is within normal limits, and they are on beta blockers and nitrovasodilators, which should help manage their heart failure symptoms. Additionally, the patient's NYHA Class II suggests that they have some symptoms of heart failure, but they are still able to perform everyday activities without significant limitation."
429,429,P0683,"Age: 62
Gender: Female 
Weight: 72 kg
Height: 144 cm
NYHA Class: II
Blood Pressure: 130/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 46,2
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 7,09
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 8,2
Hemoglobin (g/L): 126.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 3,8
LDL (mmol/L): 4,42
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2712.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,39
Urea (mg/dL): 8,69
LVEF (%): 70.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the prognosis for the next few years:

RANKING: 1
REASONING: The patient is 62 years old with a history of Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, and Hypertension. The patient is on a comprehensive medication regimen, including Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, and Nitrovasodilator, which suggests that the patient's condition is being actively managed. The LVEF is 70%, indicating preserved left ventricular function. The patient's Pro-BNP level is elevated at 2712.0 ng/L, which may indicate heart failure with preserved ejection fraction (HFpEF), but it is not excessively high. The ECG impression shows a monomorphic ventricular extrasystole, but no signs of sustained ventricular tachycardia or bradycardia. Considering these factors, the most likely prognosis is that the patient will survive the next few years with continued management and monitoring of their condition.

RANKING: 2
REASONING: The patient's high Pro-BNP level and history of Hypertensive cardiomyopathy suggest that the patient may be at risk for sudden cardiac death. However, the patient's LVEF is preserved, and the patient is on a comprehensive medication regimen, which reduces the risk of sudden cardiac death. The patient's ECG impression shows a monomorphic ventricular extrasystole, but no signs of sustained ventricular tachycardia or bradycardia, which further reduces the risk of sudden cardiac death.

RANKING: 3
REASONING: The patient's LVEF is 70%, which indicates preserved left ventricular function. However, the patient's Pro-BNP level is elevated, and the patient has a history of Hypertensive cardiomyopathy, which may eventually lead to pump failure. Additionally, the patient's age and comorbidities (Diabetes, Dyslipemia, Peripheral vascular disease, and Hypertension) increase the risk of pump failure. However, the patient's current LVEF and comprehensive medication regimen suggest that pump failure is the least likely prognosis for the next few years."
430,430,P0684,"Age: 71
Gender: Male 
Weight: 76 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 150/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 57.0
AST or GOT (IU/L): 37.0
Total Cholesterol (mmol/L): 7,84
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 164.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,63
LDL (mmol/L): 5,64
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 78.0
Protein (g/L): 76
T3 (pg/dL): 0,0423
T4 (ng/L): 16,17
TSH (mIU/L): 0,39
Urea (mg/dL): 9,9
LVEF (%): 70.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: The patient is 71 years old with a history of hypertensive cardiomyopathy, diabetes, dyslipemia, and peripheral vascular disease, all of which are risk factors for cardiovascular disease. However, the patient's LVEF is 70%, which is within the normal range, indicating that the heart is functioning relatively well. The patient is on medications for diabetes, hypertension, and dyslipemia, which are all appropriate for their conditions. The patient also has a relatively normal potassium level and a low TSH level, indicating that their thyroid function is well-controlled. The patient's pro-BNP level is within a relatively normal range, which is a good indicator of heart failure risk. The absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG is also a positive sign. While the patient has a history of hypertension and a high creatinine level, which may indicate some degree of kidney impairment, the patient's overall clinical picture suggests that they are at a relatively low risk for sudden cardiac death or pump failure.

RANKING: Pump Failure Death

REASONING: While the patient has a history of hypertensive cardiomyopathy, which is a risk factor for heart failure, their LVEF is 70%, which is within the normal range. The patient's creatinine level is elevated, indicating some degree of kidney impairment, which may be a sign of underlying cardiovascular disease. However, the patient's eGFR is not provided, which would be a more accurate indicator of kidney function. The patient's albumin level is also slightly low, which may indicate some degree of liver dysfunction or malnutrition. However, the patient's overall clinical picture suggests that they are at a relatively low risk for pump failure death.

RANKING: Sudden Cardiac Death

REASONING: The patient has a history of ventricular extrasystoles, which is a risk factor for sudden cardiac death. However, the extrasystoles are monomorphic, which is less concerning than polymorphic extrasystoles. The patient's LVEF is 70%, which is within the normal range, indicating that the heart is functioning relatively well. The patient is on medications for diabetes, hypertension, and dyslipemia, which are all appropriate for their conditions. The patient's pro-BNP level is within a relatively normal range, which is a good indicator of heart failure risk. Overall, the patient's clinical picture suggests that they are at a relatively low risk for sudden cardiac death."
431,431,P0685,"Age: 45
Gender: Male 
Weight: 119 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 42,2
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,72
Creatinine (mmol/L): 83.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,47
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 403.0
Protein (g/L): 65,9
T4 (ng/L): 22
TSH (mIU/L): 2,25
Urea (mg/dL): 4,66
LVEF (%): 37.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: 1. Survivor
 REASONING: The patient is 45 years old with a history of enolic dilated cardiomyopathy, which indicates a weakened heart muscle. However, he is currently being treated with a combination of medications, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all standard treatments for heart failure. His NYHA class is II, indicating that he is experiencing some symptoms of heart failure but is still able to perform most daily activities. His LVEF is 37%, which is lower than normal, but he is not in the most severe category. His BNP level is elevated, but not extremely high, indicating that his heart is under strain but not failing rapidly. His weight is slightly above average, but not severely overweight. His blood pressure is within a relatively normal range. Considering these factors, the patient's current treatment and management plan, and the fact that he is not experiencing severe symptoms, the most likely prognosis is that he will survive for the next few years.

RANKING: 2. Pump failure death
 REASONING: The patient's LVEF of 37% indicates a significant reduction in cardiac function, which increases the risk of pump failure. His elevated BNP level also suggests that his heart is under strain. However, his current treatment plan and the fact that he is not experiencing severe symptoms (NYHA class II) suggest that his heart failure is not yet in an advanced stage. The patient's weight and blood pressure are also not severe enough to contribute to a high risk of pump failure. Considering these factors, the risk of pump failure death is lower than sudden cardiac death but higher than survival.

RANKING: 3. Sudden cardiac death
 REASONING: The patient's LVEF of 37% indicates a significant reduction in cardiac function, which increases the risk of sudden cardiac death. However, his current treatment plan, including the use of beta blockers and an ACE inhibitor, reduces the risk of sudden cardiac death. His BNP level is elevated, but not extremely high, which suggests that his heart is under strain but not failing rapidly. The patient's ECG results do not indicate any signs of arrhythmias, which is a common cause of sudden cardiac death. Considering these factors, the risk of sudden cardiac death is lower than pump failure death."
432,432,P0686,"Age: 77
Gender: Male 
Weight: 99 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 170/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,22
Creatinine (mmol/L): 136.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,17
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 686.0
Protein (g/L): 74,9
T3 (pg/dL): 0,0543
T4 (ng/L): 14,54
Troponin (ng/mL): 0,1
TSH (mIU/L): 0,42
Urea (mg/dL): 9,6
LVEF (%): 40.0
Medications: Calcium Channel Blocker, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: Based on the provided patient data, I would rank the prognosis as a survivor. The patient's age and past medical history suggest a high risk for cardiac events, but there are several factors that contribute to a more favorable outcome.

The patient's LVEF (Left Ventricular Ejection Fraction) is 40%, which is slightly below the normal range (50-70%), indicating some degree of heart failure. However, the patient is on optimal medical therapy with a calcium channel blocker, loop diuretics, statins, and an ACE inhibitor, which are all standard treatments for heart failure and hypertension.

The patient's blood pressure is well-controlled at 170/80 mmHg, and the creatinine level is slightly elevated at 136.0 umol/L, but not significantly high. The patient's BNP (Brain Natriuretic Peptide) level is elevated at 686.0 ng/L, which is consistent with heart failure, but not excessively high.

The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are concerning signs, but not necessarily indicative of a high risk for sudden cardiac death.

Considering these factors, the patient's overall prognosis is likely to be a survivor, with a moderate risk for heart failure progression and cardiac events. However, with optimal medical therapy and close monitoring, the patient can be expected to survive for several years.

The sudden cardiac death prognosis is less likely because the patient's LVEF is not severely depressed, and the patient is on optimal medical therapy. The pump failure death prognosis is also less likely because the patient's LVEF is not severely depressed, and the patient is on diuretics and ACE inhibitor, which are standard treatments for heart failure.

In order from least likely to most likely, the ranking is:

1. Survivor
2. Sudden cardiac death
3. Pump failure death"
433,433,P0687,"Age: 75
Gender: Male 
Weight: 71 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 4,32
Creatinine (mmol/L): 135.0
Gamma-glutamil transpeptidase (IU/L): 82
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 3,96
LDL (mmol/L): 2,77
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 5751.0
Protein (g/L): 61,3
T3 (pg/dL): 0,0348
T4 (ng/L): 16,95
TSH (mIU/L): 1,31
Urea (mg/dL): 8,1
LVEF (%): 25.0
Medications: Amiodarone, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here's a prognosis for the next few years:

RANKING: 1. Survivor
REASONING: The patient's age and history of idiopathic dilated cardiomyopathy, peripheral vascular disease, and hypertension are risk factors for cardiac mortality. However, the patient's NYHA Class II classification indicates that he is still relatively asymptomatic, which suggests that the disease is not yet in an advanced stage. The patient's current medications, including ACE inhibitor, loop diuretics, and amiodarone, are standard treatments for heart failure and arrhythmias. The low LVEF of 25% indicates severe left ventricular dysfunction, but the patient's overall clinical condition does not suggest an immediate high risk of sudden cardiac death or pump failure. The patient's Pro-BNP level of 5751.0 ng/L is elevated, indicating heart failure, but not extremely high, suggesting that the patient's condition is being managed. Given the patient's current clinical status, the most likely outcome is that he will survive for the next few years with continued medical management.

RANKING: 2. Pump failure death
REASONING: The patient's low LVEF of 25% and history of idiopathic dilated cardiomyopathy make pump failure a possible outcome. The patient's creatinine level of 135.0 mol/L suggests impaired renal function, which can be a consequence of severe heart failure. However, the patient's NYHA Class II classification and the fact that he is still ambulatory suggest that pump failure is not imminent. The patient's medications, including ACE inhibitor and loop diuretics, are standard treatments for heart failure, which may slow disease progression. While pump failure is a possible outcome, it is less likely than sudden cardiac death.

RANKING: 3. Sudden cardiac death
REASONING: The patient's history of idiopathic dilated cardiomyopathy and non-sustained ventricular tachycardia on ECG suggest an increased risk of arrhythmias. The patient's low LVEF of 25% and elevated Pro-BNP level of 5751.0 ng/L also indicate severe heart failure, which can increase the risk of sudden cardiac death. However, the patient's NYHA Class II classification and the fact that he is still ambulatory suggest that sudden cardiac death is not the most likely outcome. The patient's medications, including amiodarone, are standard treatments for arrhythmias, which may reduce the risk of sudden cardiac death. While sudden cardiac death is a possible outcome, it is the least likely of the three options."
434,434,P0691,"Age: 81
Gender: Male 
Weight: 79 kg
Height: 174 cm
NYHA Class: III
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,85
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,07
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 140.0
Protein (g/L): 76
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,26
Urea (mg/dL): 9,65
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Angiotensin II Receptor Blocker, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Please note that this is a hypothetical prediction and actual patient outcomes may vary.

RANKING: Survivor

REASONING:

1. Survivor: The patient's age and NYHA Class III classification indicate a moderate level of heart failure symptoms, but he is still relatively stable. The patient's LVEF of 50% is within the range of moderate heart failure, but not severe enough to indicate a high risk of sudden cardiac death. The patient's medications, including an ACE inhibitor, angiotensin II receptor blocker, and loop diuretics, are appropriate for managing heart failure and hypertension. The patient's blood pressure is well-controlled, and his eGFR (estimated glomerular filtration rate) is not significantly impaired, indicating that his renal function is relatively preserved. The patient's Troponin level is within normal limits, indicating that there is no acute coronary event. The patient's TSH level is within the normal range, indicating that his thyroid function is normal. Considering these factors, the patient's prognosis is likely to be a survivor, with a focus on managing his heart failure and hypertension to prevent further progression.

2. Pump Failure Death: The patient's LVEF of 50% indicates a moderate level of heart failure, and his NYHA Class III classification suggests that he has significant symptoms. The patient's creatinine level of 97.0 mol/L indicates some impairment in renal function, which can be a predictor of poor outcomes in heart failure patients. However, the patient's eGFR is not significantly impaired, and his medications are appropriate for managing heart failure and hypertension. The patient's Troponin level is within normal limits, indicating that there is no acute coronary event. While the patient's prognosis is not optimal, the likelihood of pump failure death is lower than sudden cardiac death due to the patient's relatively stable blood pressure and the absence of acute coronary event.

3. Sudden Cardiac Death: The patient's age and NYHA Class III classification indicate a moderate level of heart failure symptoms, but there is no indication of severe heart failure or acute coronary event. The patient's LVEF of 50% is within the range of moderate heart failure, but not severe enough to indicate a high risk of sudden cardiac death. The patient's medications, including an ACE inhibitor and beta-blocker, are appropriate for managing heart failure and hypertension. The patient's Troponin level is within normal limits, indicating that there is no acute coronary event. While the patient's prognosis is not optimal, the likelihood of sudden cardiac death is lower than pump failure death due to the patient's relatively stable blood pressure and the absence of acute coronary event.

Note: The patient's age and NYHA Class III classification increase the risk of sudden cardiac death, but the patient's relatively stable blood pressure and the absence of acute coronary event make this outcome less likely."
435,435,P0692,"Age: 70
Gender: Female 
Weight: 67 kg
Height: 156 cm
NYHA Class: III
Blood Pressure: 100/66 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 6,13
Creatinine (mmol/L): 248.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 8,4
Hemoglobin (g/L): 126.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 5,4
LDL (mmol/L): 3,62
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 1048.0
Protein (g/L): 78
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,01
Urea (mg/dL): 32,61
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

Based on the provided patient data, I would rank the prognosis as a survivor for the next few years. Here's the reasoning:

1. NYHA Class III: The patient is classified as NYHA Class III, which indicates severe symptoms of heart failure, such as shortness of breath during ordinary physical activity, but relief with rest. This classification suggests that the patient's heart failure is not severe enough to be in the most critical stage (Class IV), but it is still a significant concern.

2. LVEF of 25%: The patient's left ventricular ejection fraction (LVEF) is 25%, which is significantly reduced. However, it is not the lowest possible value (less than 10-15%), which is often associated with a poorer prognosis. An LVEF of 25% indicates that the patient's heart is still functioning, albeit inefficiently.

3. Pro-BNP of 1048.0 ng/L: The patient's B-type natriuretic peptide (BNP) level is elevated, which is a marker of heart failure severity. However, it is not extremely high, which might indicate that the patient's heart failure is not in an acute decompensated state.

4. Medications: The patient is on a combination of medications that are commonly used to manage heart failure, including beta blockers, loop diuretics, spironolactone, statins, ACE inhibitors, and nitrovasodilators. This suggests that the patient is receiving adequate treatment for their condition.

5. ECG findings: The ECG shows monomorphic ventricular extrasystoles, but no signs of sustained ventricular tachycardia or other severe arrhythmias.

Considering these factors, the patient's prognosis is more likely to be a survivor, as their symptoms are manageable with treatment, and their heart function, although reduced, is still present. However, it is essential to closely monitor the patient's condition and adjust treatment as needed to prevent progression of the disease.

REASONING FOR OTHER PROGNOSIS:

Sudden cardiac death: This prognosis is less likely because the patient's heart failure is not in an acute decompensated state, and they are receiving treatment to manage their symptoms.

Pump failure death: This prognosis is also less likely because the patient's LVEF is not extremely low, and they are on medications that are known to improve heart function and reduce mortality in heart failure patients."
436,436,P0693,"Age: 48
Gender: Female 
Weight: 69 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 90/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6
Creatinine (mmol/L): 72.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,01
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 220.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 11
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,55
Urea (mg/dL): 5,99
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: 1. Survivor
REASONING: The patient is a 48-year-old female with a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, reducing the heart's ability to pump blood effectively. Despite this, the patient's current medication regimen, including beta blockers, digoxin, loop diuretics, spironolactone, and ACE inhibitors, appears to be well-managed, as indicated by her NYHA Class II classification. Her LVEF (Left Ventricular Ejection Fraction) is 40%, which is within the range of mildly reduced ejection fraction, but not severely impaired. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG is also a positive sign. Although her Pro-BNP level is elevated at 220.0 ng/L, which indicates some degree of heart failure, her overall clinical picture suggests that she is being effectively managed. Considering her age, sex, and current treatment, I believe the most likely prognosis for this patient over the next few years is survival.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 40% indicates that her heart is not functioning optimally, which increases her risk of pump failure. Additionally, her elevated Pro-BNP level and history of idiopathic dilated cardiomyopathy suggest that she may be at risk for progressive heart failure. However, her current medication regimen and NYHA Class II classification suggest that her symptoms are well-managed, and she is not in a critical stage of heart failure. The absence of more severe ECG abnormalities and her relatively well-managed blood pressure also suggest that pump failure is not the most likely immediate concern.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's ECG shows a ventricular extrasystole, which is a type of irregular heartbeat that can increase the risk of sudden cardiac death. However, the fact that the extrasystole is monomorphic (meaning it has a consistent pattern) and there is no evidence of ventricular tachycardia or other life-threatening arrhythmias on the ECG, suggests that the risk of sudden cardiac death may be lower than pump failure. Additionally, the patient's current medication regimen, including beta blockers, which are known to reduce the risk of sudden cardiac death, may also contribute to a lower risk of this outcome."
437,437,P0694,"Age: 69
Gender: Male 
Weight: 82 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 140/65 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 48
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 7,7
Hemoglobin (g/L): 164.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,17
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 91.0
Protein (g/L): 81,8
T3 (pg/dL): 0,06
T4 (ng/L): 14,01
Troponin (ng/mL): 0,6
TSH (mIU/L): 1,32
Urea (mg/dL): 6,3
LVEF (%): 65.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Please note that this is a hypothetical prediction and not a definitive diagnosis. I will rank the three possible prognoses from most likely to least likely based on the data.

RANKING: Survivor

REASONING: The patient is 69 years old with a history of Hypertensive cardiomyopathy, Diabetes, Dyslipemia, and Hypertension. Despite these comorbidities, the patient is currently on a multidrug regimen that includes ACE inhibitors, beta blockers, and statins, which are evidence-based treatments for these conditions. The patient's left ventricular ejection fraction (LVEF) is 65%, which is within the normal range. The patient's blood pressure is well-controlled at 140/65 mmHg, and the eGFR is not severely impaired. The patient's troponin levels are within normal limits, and there is no evidence of acute coronary syndrome or acute heart failure. The patient's ECG shows ventricular extrasystoles, but no sustained ventricular tachycardia or bradycardia. The patient's TSH level is within the normal range, and the patient is not hypothyroid. Overall, the patient's current medication regimen and the lack of severe comorbidities suggest that the patient is at low risk for sudden cardiac death or pump failure in the short term.

The next most likely prognosis would be:

RANKING: 2. Sudden Cardiac Death

REASONING: While the patient's LVEF is within the normal range, the presence of ventricular extrasystoles and a history of Hypertensive cardiomyopathy increase the risk of arrhythmias and sudden cardiac death. The patient's Pro-BNP level is elevated at 91 ng/L, which may indicate some degree of heart failure. However, the patient's eGFR is not severely impaired, and the patient is on a multidrug regimen that includes ACE inhibitors and beta blockers, which are protective against sudden cardiac death.

The least likely prognosis would be:

RANKING: 3. Pump Failure Death

REASONING: The patient's LVEF is within the normal range, and the patient is on a multidrug regimen that includes ACE inhibitors and beta blockers, which are protective against heart failure. The patient's eGFR is not severely impaired, and the patient's creatinine level is only mildly elevated at 103.0 mmol/L. While the patient has a history of Hypertensive cardiomyopathy, the patient's current blood pressure is well-controlled, and the patient's left ventricular function is preserved. Therefore, pump failure death is the least likely prognosis."
438,438,P0695,"Age: 63
Gender: Male 
Weight: 80 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 135/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,27
Creatinine (mmol/L): 153.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,4
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 403.0
Protein (g/L): 85
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,27
Urea (mg/dL): 6,66
LVEF (%): 60.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years, ranking the three possible prognoses from most likely to least likely.

RANKING: 1. Survivor
 REASONING: The patient is 63 years old with a history of ischemic dilated cardiomyopathy and myocardial infarction, which indicates a significant cardiac history. However, the patient is currently on a treatment regimen that includes beta blockers, calcium channel blockers, loop diuretics, and statins, which are standard treatments for heart failure and ischemic heart disease. The patient's LVEF is 60%, which is within the normal range, indicating that the heart is functioning relatively well despite the history of heart disease. The patient's NYHA Class II indicates that the patient has some limitations with physical activity but is still able to perform daily tasks without symptoms. The patient's laboratory results show a slightly elevated creatinine level, but it is not significantly elevated, indicating that kidney function is not severely impaired. The patient's BNP level is elevated, but not excessively high, which may indicate some degree of heart failure but not severe heart failure. Overall, considering the patient's current treatment and the relatively well-controlled symptoms, the most likely prognosis is that the patient will survive for the next few years.

RANKING: 2. Pump Failure Death
 REASONING: The patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases the risk of pump failure. The patient's LVEF is 60%, which is within the normal range, but it may not accurately reflect the patient's true cardiac function, as the patient has a history of heart disease. The patient's elevated BNP level and slightly elevated creatinine level may indicate some degree of heart failure. However, the patient's NYHA Class II and the fact that the patient is on standard treatments for heart failure and ischemic heart disease suggest that the patient's cardiac function is not severely impaired at this time. The risk of pump failure is still present, but it is less likely than the patient surviving due to the patient's relatively well-controlled symptoms and standard treatment.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of sudden cardiac death. However, the patient's LVEF is 60%, which is within the normal range, and the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death. The patient's ECG shows monomorphic ventricular extrasystoles, which is a risk factor for sudden cardiac death, but it is not a strong predictor of sudden cardiac death in this patient, given the patient's overall clinical context. The patient's TSH level is within the normal range, which reduces the risk of arrhythmias related to thyroid dysfunction. Overall, while the patient's history and ECG findings increase the risk of sudden cardiac death, the patient's relatively well-controlled symptoms and standard treatment make this prognosis the least likely.

Note: The actual prognosis for this patient can only be determined by a thorough clinical evaluation and consultation with a cardiologist. This analysis is based on the provided data and should not be used for actual clinical decision-making."
439,439,P0697,"Age: 49
Gender: Male 
Weight: 109 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 170/110 mmHg
Past Medical History: Other HF etiology, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,61
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,93
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 71
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,88
Urea (mg/dL): 6,66
LVEF (%): 40.0
Medications: Calcium Channel Blocker, Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here is my prognosis for the next few years, ranking the three possible outcomes from most likely to least likely:

RANKING: Survivor

REASONING: The patient is 49 years old and has a history of heart failure, hypertension, and dyslipidemia, which are all significant risk factors for cardiovascular disease. However, the patient is on a comprehensive treatment regimen, including beta blockers, ACE inhibitors, spironolactone, and statins, which are all evidence-based treatments for heart failure and hypertension. The patient's LVEF is 40%, which is below the normal range but not extremely low, and the Troponin level is within normal limits, indicating minimal myocardial damage. The patient's Pro-BNP level is elevated, but not excessively high, which is consistent with a moderate level of heart failure. The patient's ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or other concerning arrhythmias. The patient's weight is high, but not severely so, and the patient's hemoglobin and potassium levels are within normal limits. Overall, while the patient has significant risk factors for cardiovascular disease, the comprehensive treatment regimen and relatively mild symptoms suggest that the patient is likely to survive for the next few years.

RANKING: Pump Failure Death

REASONING: The patient's LVEF is 40%, which is below the normal range and indicates some degree of left ventricular dysfunction. The patient's Pro-BNP level is elevated, which is consistent with heart failure. The patient's weight is high, which can exacerbate heart failure symptoms. However, the patient's treatment regimen is comprehensive, and the patient's Troponin level is within normal limits, which suggests that the patient does not have significant myocardial damage. The patient's ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or other concerning arrhythmias. While the patient's heart failure is not well-controlled, the patient's overall condition does not suggest an imminent risk of pump failure death.

RANKING: Sudden Cardiac Death

REASONING: The patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the patient's Troponin level is within normal limits, which suggests that the patient does not have significant myocardial damage. The patient's LVEF is 40%, which is below the normal range, but not extremely low. The patient's Pro-BNP level is elevated, but not excessively high, which is consistent with a moderate level of heart failure. The patient's treatment regimen is comprehensive, and the patient's overall condition does not suggest an imminent risk of sudden cardiac death. While the patient's ECG findings are concerning, they are not severe enough to suggest an extremely high risk of sudden cardiac death."
440,440,P0698,"Age: 65
Gender: Female 
Weight: 69 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Peripheral vascular disease
Albumin (g/L): 37
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,8
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,68
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 542.0
Protein (g/L): 62
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,58
Urea (mg/dL): 4,16
LVEF (%): 45.0
Medications: Calcium Channel Blocker, Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Survivor
 REASONING: The patient is a 65-year-old female with a history of idiopathic dilated cardiomyopathy and peripheral vascular disease. However, her LVEF (Left Ventricular Ejection Fraction) is 45%, which indicates that her heart is still functioning moderately well, despite the cardiomyopathy. Her NYHA Class II indicates that she is experiencing some symptoms, but she is not severely limited by her heart condition. Her blood pressure is within a normal range, and she is on appropriate medications for her conditions, including beta blockers, ACE inhibitors, and calcium channel blockers. Her BNP (B-type natriuretic peptide) level is elevated, which suggests that she has some degree of heart failure, but it is not excessively high. Additionally, her troponin level is normal, indicating that she does not have acute coronary syndrome. Considering these factors, a survivor prognosis is the most likely outcome.

RANKING: Sudden Cardiac Death
 REASONING: While the patient has a history of idiopathic dilated cardiomyopathy and peripheral vascular disease, her LVEF is still 45%, which suggests that her heart is not severely compromised. Her lack of ventricular tachycardia on the ECG and normal troponin level also reduce the risk of sudden cardiac death. However, her polymorphic ventricular extrasystoles on the ECG may indicate some degree of cardiac arrhythmia, which could potentially increase the risk of sudden cardiac death. However, this is not a strong enough indicator to make sudden cardiac death the most likely prognosis.

RANKING: Pump Failure Death
 REASONING: While the patient's LVEF is 45%, which indicates some degree of heart failure, her NYHA Class II and normal blood pressure suggest that her symptoms are not severely limiting. Her BNP level is elevated, but not excessively high, indicating that her heart failure is not severe. Her eGFR (estimated glomerular filtration rate) is not provided, but her creatinine level is within a relatively normal range, suggesting that her kidney function is not severely impaired. Additionally, her medications, including ACE inhibitors and beta blockers, are appropriate for heart failure management. Considering these factors, pump failure death is the least likely prognosis.

Please note that this is a general assessment based on the provided data, and a more accurate prognosis would require a comprehensive evaluation of the patient's overall health status and medical history."
441,441,P0699,"Age: 41
Gender: Male 
Weight: 65 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,69
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 19.0
Protein (g/L): 70
T3 (pg/dL): 0,06
T4 (ng/L): 13
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,2
Urea (mg/dL): 5,16
LVEF (%): 40.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient is 41 years old, which is relatively young for a patient with hypertrophic cardiomyopathy (HCM). The patient is on beta blockers and an ACE inhibitor, which are standard treatments for HCM and may be helping to manage the condition. The LVEF is 40%, which is below the normal range but not extremely low. The patient's ECG does not show any signs of sustained ventricular tachycardia, and the troponin level is within normal limits. The patient's NT-proBNP level is also low, indicating that the heart is not under significant strain. The patient's overall clinical presentation suggests that the HCM is well-managed, and the patient is likely to survive with continued medical treatment.

RANKING: 2. Pump failure death
 REASONING: While the patient's LVEF is 40%, which is below the normal range, it is not extremely low. The patient's NYHA class is II, indicating that the patient is experiencing some symptoms but is still able to perform most daily activities. The patient's creatinine level is within normal limits, indicating that the kidneys are functioning properly. The patient's NT-proBNP level is low, which suggests that the heart is not under significant strain. While the patient's HCM may eventually lead to heart failure, it is not likely to happen in the near future, given the patient's relatively young age and well-managed symptoms.

RANKING: 3. Sudden cardiac death
 REASONING: The patient's ECG shows monomorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the patient's LVEF is 40%, and the patient is on beta blockers and an ACE inhibitor, which can help reduce the risk of sudden cardiac death. The patient's troponin level is within normal limits, and the NT-proBNP level is low, indicating that the heart is not under significant strain. While the patient's HCM is a risk factor for sudden cardiac death, the patient's overall clinical presentation suggests that the risk is relatively low, especially with continued medical treatment."
442,442,P0700,"Age: 81
Gender: Male 
Weight: 77 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 160/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 5,1
Creatinine (mmol/L): 129.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 7,46
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,93
LDL (mmol/L): 3,15
Sodium (mEq/L): 146.0
Pro-BNP (ng/L): 1670.0
Protein (g/L): 65
T3 (pg/dL): 0,0483
T4 (ng/L): 12,7
TSH (mIU/L): 3,52
Urea (mg/dL): 11,3
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. I will rank the three possible prognoses from most likely to least likely and explain the reasoning behind the order.

RANKING: 1. Survivor
REASONING: The patient is 81 years old with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for adverse cardiac outcomes. However, despite this, the patient is currently on a treatment regimen that includes Digoxin, Loop Diuretics, and ACE Inhibitors, which are all standard therapies for heart failure management. The patient's NYHA Class II classification indicates that the patient's symptoms are not severe, and they are still able to perform daily activities without significant limitation. The patient's LVEF of 25% is low, but it is not the lowest possible value, and the patient's Pro-BNP level is 1670.0 ng/L, which is elevated but not extremely high. The patient's ECG shows non-sustained ventricular tachycardia and ventricular extrasystoles, but no sustained arrhythmias. Considering these factors, the patient's current treatment and the absence of severe symptoms, I believe that the most likely prognosis is survival with continued management of their heart failure.

RANKING: 2. Sudden Cardiac Death
REASONING: Sudden cardiac death (SCD) is a potential risk for patients with heart failure and reduced LVEF. The patient's LVEF of 25% and history of non-sustained ventricular tachycardia increase their risk for SCD. Additionally, the patient's Pro-BNP level is elevated, which is a marker for increased risk of cardiac events. However, the patient is on ACE inhibitors, which have been shown to reduce the risk of SCD. The patient's current treatment regimen and the absence of severe symptoms make SCD a less likely prognosis compared to pump failure death.

RANKING: 3. Pump Failure Death
REASONING: Pump failure death is a potential outcome for patients with advanced heart failure and reduced LVEF. The patient's LVEF of 25% and history of idiopathic dilated cardiomyopathy increase their risk for pump failure. However, the patient's NYHA Class II classification and current treatment regimen suggest that they are being managed effectively, and their symptoms are not severe. The patient's creatinine level is elevated, but it is not extremely high, which may indicate some preserved renal function. Considering these factors, I believe that pump failure death is the least likely prognosis.

In conclusion, based on the provided patient data, I believe that the most likely prognosis is survival with continued management of their heart failure, followed by sudden cardiac death, and then pump failure death."
443,443,P0701,"Age: 76
Gender: Male 
Weight: 65 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 6,23
Creatinine (mmol/L): 108.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 163.0
HDL (mmol/L): 1,84
Potassium (mEq/L): 4,56
LDL (mmol/L): 3,75
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1343.0
Protein (g/L): 76,9
T3 (pg/dL): 0,0531
T4 (ng/L): 11,03
Troponin (ng/mL): 0,1
TSH (mIU/L): 1
Urea (mg/dL): 9,2
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: The patient is 76 years old with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure. However, the patient's current NYHA Class II classification indicates that he is experiencing some symptoms of heart failure but is still able to perform most physical activities without discomfort. The patient's LVEF of 30% indicates severe left ventricular dysfunction, which is a predictor of increased risk of adverse outcomes. However, the patient is on optimal medical therapy with digoxin, loop diuretics, statins, and an ACE inhibitor, which are all evidence-based treatments for heart failure with reduced ejection fraction.

The patient's biomarkers, such as high Pro-BNP (1343.0 ng/L) and elevated Troponin (0.1 ng/mL), suggest ongoing cardiac stress and potential for adverse outcomes. However, the patient's hemoglobin (163.0 g/L) and albumin (44 g/L) levels are within normal limits, indicating that the patient is not severely malnourished or dehydrated.

The patient's ECG findings, including polymorphic ventricular extrasystoles, are concerning but not necessarily indicative of imminent cardiac death. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia suggests that the patient's heart rhythm is relatively stable.

Considering these factors, while the patient's prognosis is guarded, the optimal medical therapy and relatively stable heart rhythm suggest that the most likely outcome is survival with continued medical management.

RANKING: Sudden Cardiac Death (SCD)

REASONING: SCD is a possible outcome for this patient due to the presence of idiopathic dilated cardiomyopathy, polymorphic ventricular extrasystoles, and a history of hypertension. The patient's LVEF of 30% and high Pro-BNP level also increase the risk of SCD. However, the patient's stable heart rhythm and optimal medical therapy suggest that SCD is less likely than pump failure death.

RANKING: Pump Failure Death

REASONING: Pump failure death is the least likely outcome for this patient due to the presence of optimal medical therapy, including digoxin, loop diuretics, statins, and an ACE inhibitor. The patient's LVEF of 30% and high Pro-BNP level suggest that the patient is at risk for pump failure, but the patient's stable heart rhythm and relatively well-controlled symptoms (NYHA Class II) suggest that pump failure death is less likely than SCD."
444,444,P0702,"Age: 54
Gender: Female 
Weight: 80 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,61
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 666.0
Protein (g/L): 67
T4 (ng/L): 8
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,1
Urea (mg/dL): 5,66
LVEF (%): 38.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. However, I must note that the patient's outcome is already stated as a survivor, which seems to be a contradictory statement given the patient's severe heart condition.

That being said, I will provide a prognosis based on the patient's current condition and the given data.

RANKING: 1. Survivor
 REASONING: The patient's current medications (Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor) suggest that they are receiving optimal treatment for their ischemic dilated cardiomyopathy and other comorbidities. The patient's LVEF of 38% is relatively low, but they are not in heart failure with reduced ejection fraction (HFrEF) category 4, which is typically associated with a worse prognosis. The patient's Pro-BNP level of 666 ng/L is elevated, but it is not extremely high, which may indicate some degree of compensation. Additionally, the patient's age and gender are not particularly high-risk factors. Therefore, while the patient's prognosis is guarded, a survival outcome is possible with continued optimal medical management.

RANKING: 2. Pump failure death
 REASONING: The patient's LVEF of 38% and Pro-BNP level of 666 ng/L suggest that the patient's heart is under significant strain. The patient's NYHA Class III classification indicates that they have moderate to severe symptoms of heart failure. While the patient's medications are appropriate, the risk of pump failure death is still a concern, especially if the patient experiences a sudden decline in cardiac function or if their symptoms worsen.

RANKING: 3. Sudden cardiac death
 REASONING: The patient's LVEF of 38% and the presence of ventricular extrasystoles on the ECG suggest that the patient has a higher risk of arrhythmias, which can increase the risk of sudden cardiac death. However, the patient's medication regimen includes Beta Blockers, which can help reduce the risk of arrhythmias. Additionally, the patient's Troponin level is low, which suggests that they are not experiencing acute myocardial infarction. While the patient's risk of sudden cardiac death is higher than pump failure death, it is still relatively low compared to other factors.

Please note that this prognosis is based on the provided data and may not reflect the patient's actual outcome."
445,445,P0704,"Age: 61
Gender: Male 
Weight: 65 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 133/68 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 37.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 227
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4
LDL (mmol/L): 2,35
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 474.0
Protein (g/L): 80
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,58
Urea (mg/dL): 4,99
LVEF (%): 30.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely.

RANKING: 1. Survivor
REASONING: The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which are risk factors for heart failure. However, the patient is currently on beta blockers, statins, and an ACE inhibitor, which are evidence-based medications for heart failure management. The LVEF of 30% indicates reduced ejection fraction, but it is not extremely low. The patient's NYHA class II indicates that the patient is experiencing some limitations in physical activity but is still able to perform everyday tasks without significant discomfort. The patient's BNP level of 474 ng/L is elevated, but it is not extremely high. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG also suggests that the patient is not at high risk for sudden cardiac death. Considering these factors, the patient's likelihood of survival over the next few years is relatively high.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases the risk of sudden cardiac death. The presence of ventricular extrasystole on the ECG is a risk factor for sudden cardiac death. However, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death. The patient's LVEF of 30% is a risk factor for sudden cardiac death, but it is not extremely low. The patient's BNP level is elevated, but it is not extremely high. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG suggests that the patient is not at extremely high risk for sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: The patient's history of ischemic dilated cardiomyopathy and myocardial infarction, combined with an LVEF of 30%, increases the risk of pump failure. However, the patient is on beta blockers, statins, and an ACE inhibitor, which are evidence-based medications for heart failure management. The patient's NYHA class II indicates that the patient is experiencing some limitations in physical activity but is still able to perform everyday tasks without significant discomfort. The patient's BNP level is elevated, but it is not extremely high. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG suggests that the patient is not at extremely high risk for sudden cardiac death, which is a more likely cause of death than pump failure in this patient."
446,446,P0705,"Age: 43
Gender: Male 
Weight: 95 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Other HF etiology
Albumin (g/L): 47
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,66
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 28
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4
LDL (mmol/L): 4,34
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 12.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,005
TSH (mIU/L): 3,11
Urea (mg/dL): 6,32
LVEF (%): 43.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here are the three possible prognoses from most likely to least likely, along with the reasoning behind each:

RANKING: Survivor
REASONING: The patient's LVEF (Left Ventricular Ejection Fraction) is 43%, which is within the normal range (50-70%). This indicates that the patient's heart is functioning relatively well, despite a history of heart failure (HF). The patient is also taking medications that are commonly used to manage HF, such as beta blockers, loop diuretics, and an ACE inhibitor. Additionally, the patient's Pro-BNP (Brain Natriuretic Peptide) level is 12.0 ng/L, which is within the normal range (0-100 ng/L). The patient's ECG shows monomorphic ventricular extrasystoles, but no signs of sustained ventricular tachycardia or bradycardia. These factors suggest that the patient's heart function is relatively stable and that the patient is being effectively managed.

RANKING: Pump failure death
REASONING: The patient's LVEF is 43%, which is on the lower end of the normal range, indicating some degree of left ventricular dysfunction. The patient's creatinine level is 86.0 umol/L, which is slightly elevated, suggesting some degree of renal impairment, which can be a marker of advanced HF. The patient's total cholesterol level is 5.66 mmol/L, which is high, and their HDL level is 0.75 mmol/L, which is low, suggesting a high risk of atherosclerotic disease. The patient's glucose level is 8.5 mmol/L, which is high, suggesting insulin resistance or diabetes, which can also contribute to HF progression. While these factors suggest some degree of cardiac dysfunction, the patient is still being managed with HF medications and does not have any acute signs of cardiac decompensation.

RANKING: Sudden cardiac death
REASONING: The patient's ECG shows monomorphic ventricular extrasystoles, which can be a marker of increased cardiac risk. However, the patient does not have any other signs of increased cardiac risk, such as a history of sustained ventricular tachycardia, bradycardia, or a low LVEF. The patient's Pro-BNP level is within the normal range, suggesting that the patient's heart function is relatively stable. While the patient's age and sex put them at some risk for sudden cardiac death, the patient's overall clinical picture suggests that this is the least likely outcome."
447,447,P0706,"Age: 72
Gender: Male 
Weight: 69 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 5,66
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 166.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,67
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 5545.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,13
TSH (mIU/L): 1,23
Urea (mg/dL): 7,15
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's my prognosis for the next few years, ordered from most likely to least likely:

RANKING: 1. Survivor
REASONING: Despite the patient's advanced age, history of hypertensive cardiomyopathy, and low LVEF of 25%, there are several factors that suggest a relatively favorable prognosis. The patient is on a multidrug regimen including beta blockers, digoxin, ACE inhibitors, and nitrovasodilators, which are all aimed at managing heart failure and reducing the risk of cardiac events. The patient's NYHA class is II, indicating that they have some limitations in physical activity but are still able to perform daily activities. The absence of bradycardia and the presence of a relatively low TSH level suggest that the patient's cardiac function is not severely impaired. Additionally, the patient's troponin level is within normal limits, indicating that there is no acute myocardial infarction or significant cardiac damage. While the elevated Pro-BNP level suggests heart failure, it is not an uncommon finding in patients with cardiomyopathy. Overall, these factors suggest that the patient is likely to survive for the next few years with proper management and follow-up.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 25% indicates severe left ventricular dysfunction, which is a significant risk factor for pump failure. The elevated Pro-BNP level and the presence of non-sustained ventricular tachycardia also suggest that the patient is at risk for cardiac decompensation. However, the patient's relatively stable NYHA class II and the presence of a multidrug regimen suggest that the patient's condition is being managed, which may reduce the risk of pump failure. Additionally, the patient's troponin level is within normal limits, indicating that there is no acute cardiac damage.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's history of hypertensive cardiomyopathy, low LVEF, and non-sustained ventricular tachycardia increase the risk of sudden cardiac death. However, the patient's relatively stable NYHA class II and the presence of a multidrug regimen suggest that the patient's condition is being managed, which may reduce the risk of sudden cardiac death. Additionally, the patient's troponin level is within normal limits, indicating that there is no acute cardiac damage. While the patient's polymorphic ventricular extrasystole and TPSV are concerning, they are not necessarily indicative of a high risk of sudden cardiac death. Overall, while sudden cardiac death is a possible outcome, it is the least likely of the three prognoses."
448,448,P0707,"Age: 52
Gender: Male 
Weight: 81 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 150/95 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,36
Potassium (mEq/L): 5,2
LDL (mmol/L): 4,55
Sodium (mEq/L): 138.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,73
Urea (mg/dL): 6,49
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the ranking of the three possible prognoses:

RANKING: 1. Survivor
 REASONING: The patient is 52 years old with a history of ischemic dilated cardiomyopathy and hypertension. Despite this, he is on a comprehensive treatment regimen consisting of beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, which suggests that he is receiving optimal medical therapy for his condition. His LVEF of 40% is within the range of patients who can be managed medically. His blood pressure is controlled, and his troponin level is within normal limits, indicating no recent myocardial infarction. Although his LVEF is low, his NYHA class is only II, indicating that his symptoms are not severe, and he is able to perform everyday activities without significant limitation. His albumin level is within normal limits, which is a good prognostic indicator. Overall, these factors suggest that the patient has a good prognosis and is likely to survive with continued medical management.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which increases his risk of sudden cardiac death. However, his LVEF is 40%, which is not extremely low, and his symptoms are not severe. His ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death, but there is no evidence of sustained ventricular tachycardia or other high-risk features. His treatment regimen includes an ACE inhibitor, which is beneficial in reducing the risk of sudden cardiac death. While the patient is at risk, his overall clinical profile suggests that sudden cardiac death is less likely than pump failure death.

RANKING: 3. Pump Failure Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which can lead to pump failure. His LVEF of 40% indicates that his heart is not pumping efficiently, and his NYHA class is II, which suggests that he may experience symptoms of heart failure, such as fatigue or shortness of breath, with increased physical activity. His creatinine level is elevated, indicating impaired renal function, which can be a marker of advanced heart failure. His albumin level is within normal limits, but his total cholesterol and LDL levels are high, which may contribute to further cardiac damage. His treatment regimen includes loop diuretics, which are used to manage fluid overload, a common complication of heart failure. Overall, the patient's clinical profile suggests that pump failure death is the most likely outcome among the three options, given his history of ischemic dilated cardiomyopathy and impaired cardiac function."
449,449,P0708,"Age: 64
Gender: Male 
Weight: 80 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,62
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,65
Sodium (mEq/L): 139.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 13
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,17
Urea (mg/dL): 8,49
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the three possible prognoses as follows:

RANKING: 1. Survivor
REASONING: The patient's age, NYHA Class II, and LVEF of 40% suggest that they have a significant cardiac condition, but they are not in the most advanced stages of heart failure. The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia indicates some degree of cardiac arrhythmia, but the patient is being treated with beta blockers and ACE inhibitors, which are standard therapies for managing heart failure and arrhythmias. The patient's blood pressure is well-controlled, and their renal function is relatively preserved, as indicated by a creatinine level of 97.0 umol/L. Additionally, the patient's TSH and T4 levels are within the normal range, which suggests that their thyroid function is well-managed. The patient's hemoglobin level is also within the normal range, which is a good sign for cardiac function. Considering these factors, the patient's prognosis is likely to be a survivor, with careful management and monitoring of their condition.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 40% suggests that they have reduced cardiac function, which increases their risk of pump failure. However, the patient's NYHA Class II indicates that they are not in the most advanced stages of heart failure, and their renal function is relatively preserved. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles increases the risk of sudden cardiac death, but the patient's beta blockers and ACE inhibitors may help mitigate this risk. The patient's weight and body mass index (BMI) are not provided, but their height of 162 cm suggests that they are likely overweight or obese, which may contribute to their cardiac condition. However, pump failure death is less likely than sudden cardiac death, as the patient's renal function and blood pressure are relatively well-controlled.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles increases the risk of sudden cardiac death. The patient's LVEF of 40% and NYHA Class II also suggest that they have significant cardiac disease. However, the patient's beta blockers and ACE inhibitors may help mitigate this risk. The patient's renal function and blood pressure are relatively well-controlled, which reduces the risk of sudden cardiac death. Additionally, the patient's TSH and T4 levels are within the normal range, which suggests that their thyroid function is well-managed. Considering these factors, sudden cardiac death is the least likely prognosis, as the patient's condition is being actively managed with medications and monitoring."
450,450,P0709,"Age: 70
Gender: Male 
Weight: 84 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 135/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,23
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 5
LDL (mmol/L): 3,67
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 129.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,26
Urea (mg/dL): 10,48
LVEF (%): 35.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Please note that this is a general assessment and may not be specific to the patient's individual circumstances.

RANKING: 1. Survivor
 REASONING: The patient is 70 years old with a history of enolic dilated cardiomyopathy, which is a significant risk factor for heart failure and mortality. However, the patient is currently on optimal medical therapy with beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all evidence-based treatments for heart failure. The patient's LVEF is 35%, which is low but not extremely low, and the patient is not in NYHA Class IV, indicating some functional capacity. The patient's blood pressure is well-controlled, and the potassium level is within normal limits. The low T3 and normal T4 levels suggest that the patient is not experiencing hyperthyroidism, which can exacerbate heart failure. The low troponin level suggests that there is no acute coronary syndrome. The absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG also suggests that the patient is not at high risk for sudden cardiac death. Therefore, while the patient has a significant underlying condition, the current management and lack of high-risk features make survivor the most likely prognosis.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's history of enolic dilated cardiomyopathy and low LVEF make sudden cardiac death a risk. However, the patient's ECG does not show any high-risk features such as ventricular tachycardia or non-sustained ventricular tachycardia, which are often associated with sudden cardiac death. The patient's potassium level is within normal limits, which reduces the risk of arrhythmias. The patient's beta blockers and ACE inhibitor therapy also reduce the risk of sudden cardiac death. While the patient's low LVEF and history of enolic dilated cardiomyopathy increase the risk, the lack of high-risk features on the ECG and the patient's current management make sudden cardiac death less likely than survivor.

RANKING: 3. Pump Failure Death
 REASONING: The patient's history of enolic dilated cardiomyopathy and low LVEF make pump failure a risk. However, the patient's current NYHA Class II classification suggests that the patient is still functional and able to perform daily activities, which reduces the risk of pump failure. The patient's blood pressure is well-controlled, and the patient is on optimal medical therapy with diuretics, which can help manage fluid overload. The patient's low T3 and normal T4 levels suggest that the patient is not experiencing hyperthyroidism, which can exacerbate heart failure. The patient's low troponin level suggests that there is no acute coronary syndrome. While the patient's low LVEF and history of enolic dilated cardiomyopathy increase the risk of pump failure, the patient's current management and functional capacity make pump failure the least likely prognosis."
451,451,P0710,"Age: 74
Gender: Female 
Weight: 63 kg
Height: 142 cm
NYHA Class: II
Blood Pressure: 145/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 6,31
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,71
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,47
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1674.0
Protein (g/L): 65
T3 (pg/dL): 0,03
T4 (ng/L): 15
Troponin (ng/mL): 0,05
TSH (mIU/L): 1,3
Urea (mg/dL): 9,65
LVEF (%): 60.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: Survivor

REASONING: The patient is a 74-year-old female with a history of hypertensive cardiomyopathy and hypertension. Despite her advanced age, her ejection fraction (LVEF) is 60%, which is within the normal range. Her NT-proBNP level of 1674 ng/L is elevated, indicating some degree of heart failure, but it's not extremely high. The patient is on appropriate medications for her condition, including an angiotensin II receptor blocker, beta blockers, and loop diuretics. 

However, the patient has a few risk factors that could contribute to a poorer prognosis. Her low HDL level and high LDL level suggest dyslipidemia, and her elevated glucose level may indicate insulin resistance or diabetes. Her potassium level is slightly low, which could be a concern for arrhythmias. 

Despite these risk factors, the patient's overall clinical picture suggests that she is relatively stable and not in an acute decompensated heart failure state. Her ECG findings of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles are concerning, but they do not necessarily indicate an immediate risk of sudden cardiac death. 

Given her relatively stable condition and the fact that she is on appropriate medications, I would rank her prognosis as a survivor, with a focus on close monitoring and potential adjustments to her treatment plan to manage her risk factors and prevent further cardiac decompensation. The sudden cardiac death and pump failure death prognoses are less likely due to her relatively stable LVEF and the fact that she is on appropriate medications."
452,452,P0711,"Age: 75
Gender: Male 
Weight: 75 kg
Height: 181 cm
NYHA Class: II
Blood Pressure: 135/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,8
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 137.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,12
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2029.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,45
Urea (mg/dL): 15,47
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. I will rank the possible prognoses from most likely to least likely.

RANKING: 1. Survivor
REASONING: The patient is 75 years old with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure and mortality. However, the patient is currently on optimal medical therapy with beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators. The patient's LVEF is 30%, which is relatively low but not extremely low. The Pro-BNP level of 2029 ng/L is elevated but not extremely high. The patient's NYHA Class II indicates that the patient is experiencing some symptoms but is still able to perform daily activities. Considering the patient's age and the fact that they are on optimal medical therapy, the most likely prognosis is that the patient will survive for the next few years with proper management of their condition.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 30% indicates that the patient has significant left ventricular dysfunction, which increases the risk of heart failure and mortality. The elevated Pro-BNP level of 2029 ng/L also suggests that the patient's heart is under strain. However, the patient's age and the fact that they are on optimal medical therapy suggest that pump failure death is less likely than sudden cardiac death. The patient's NYHA Class II indicates that the patient is still able to perform daily activities, which suggests that the patient's heart failure is not yet severe.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's age and history of ischemic dilated cardiomyopathy increase the risk of sudden cardiac death. However, the patient's LVEF of 30% and the fact that they are on optimal medical therapy suggest that sudden cardiac death is less likely than pump failure death. The patient's ECG shows monomorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death, but the absence of non-sustained ventricular tachycardia and other arrhythmias suggests that the risk of sudden cardiac death is relatively low."
453,453,P0712,"Age: 52
Gender: Male 
Weight: 98 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 175/110 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 6,34
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,9
LDL (mmol/L): 4,45
Sodium (mEq/L): 137.0
Protein (g/L): 76
T3 (pg/dL): 0,06
T4 (ng/L): 19
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,45
Urea (mg/dL): 8,15
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Please note that this is a complex analysis, and the actual outcome may vary depending on various factors, including the patient's adherence to treatment, lifestyle changes, and potential unforeseen complications.

RANKING: 1. Survivor
REASONING: The patient has a moderate to severe left ventricular dysfunction with an LVEF of 30%, which is a significant risk factor for adverse outcomes. However, the patient is on beta blockers, loop diuretics, and nitrovasodilators, which are standard treatments for heart failure. The patient's blood pressure is elevated, but it is being managed with medication. The absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG is a positive sign. The patient's hemoglobin and potassium levels are within normal limits, which reduces the risk of anemia and arrhythmias. The patient's TSH level is within the normal range, which suggests that thyroid dysfunction is not a contributing factor to the patient's condition. Considering these factors, the most likely prognosis is survival, assuming the patient adheres to their treatment plan and makes lifestyle modifications to manage their hypertension and heart failure.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient has a history of enolic dilated cardiomyopathy, which is a risk factor for sudden cardiac death. The patient's LVEF is 30%, which is below the normal range, and the presence of polymorphic ventricular extrasystoles on the ECG is a risk factor for arrhythmias. However, the absence of non-sustained ventricular tachycardia and the patient's overall clinical stability reduce the likelihood of sudden cardiac death. The patient's TSH level is within the normal range, which reduces the risk of thyroid-mediated arrhythmias.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF of 30% indicates severe left ventricular dysfunction, which increases the risk of pump failure. The patient's elevated blood pressure and low albumin level may contribute to increased cardiac workload and potential cardiac decompensation. However, the patient is on beta blockers and loop diuretics, which are standard treatments for heart failure, and the absence of significant electrolyte imbalances or anemia reduces the risk of acute cardiac decompensation. The patient's overall clinical stability and the presence of nitrovasodilators, which can help manage cardiac workload, make pump failure death the least likely outcome."
454,454,P0713,"Age: 75
Gender: Male 
Weight: 89 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 7,06
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 4
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 5,3
LDL (mmol/L): 4,65
Sodium (mEq/L): 133.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,04
TSH (mIU/L): 2,24
Urea (mg/dL): 8,49
LVEF (%): 21.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor
REASONING: Despite the patient's advanced age (75) and history of enolic dilated cardiomyopathy, the patient's LVEF (21%) is relatively stable. The patient is already on appropriate medications (Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor) to manage their heart failure symptoms. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and significant electrolyte imbalances (e.g., potassium 5.3 mEq/L) suggests that the patient's cardiac function is being managed effectively. Additionally, the patient's blood pressure is within a relatively normal range (140/90 mmHg), and there is no indication of severe anemia (Hemoglobin 148 g/L). The patient's TSH level is within the normal range, indicating that hypothyroidism is not a contributing factor to their heart failure. While the patient's LVEF is low, it is not at the lowest end of the spectrum, and the patient's overall clinical picture suggests that they are stable and may be able to continue to survive with proper management.

RANKING: Pump Failure Death
REASONING: The patient's LVEF of 21% is a significant risk factor for pump failure death. However, the patient's current medications and lack of other high-risk factors (e.g., severe anemia, severe electrolyte imbalances, sustained arrhythmias) suggest that pump failure death may not be the most likely outcome. The patient's low LVEF does indicate that they are at risk for pump failure, but the patient's overall clinical picture suggests that they are being managed effectively.

RANKING: Sudden Cardiac Death
REASONING: Sudden cardiac death is less likely in this patient due to the following reasons: the patient is on appropriate medications for heart failure, the patient's LVEF is stable, and there is no indication of severe arrhythmias (e.g., sustained ventricular tachycardia). While the patient has polymorphic ventricular extrasystoles, this is not a high-risk feature for sudden cardiac death. The patient's overall clinical picture suggests that they are at low risk for sudden cardiac death."
455,455,P0714,"Age: 58
Gender: Male 
Weight: 87 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 135/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,44
Sodium (mEq/L): 138.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,92
Urea (mg/dL): 7,15
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the ranking of the prognoses from most likely to least likely:

RANKING: Survivor

REASONING: The patient is 58 years old with a history of hypertensive cardiomyopathy and hypertension, which indicates a risk for heart failure. However, the patient's current NYHA Class II suggests that the symptoms are not severe, and they are able to perform most physical activities without significant limitation. The patient is on a comprehensive medication regimen, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all evidence-based treatments for heart failure and hypertension. The LVEF of 30% is low, indicating reduced left ventricular function, but it is not as low as some other patients with similar conditions. The absence of sustained ventricular tachycardia and non-sustained ventricular tachycardia on the ECG suggests that the patient is not at high risk for sudden cardiac death. The patient's TSH level is within the normal range, which suggests that hypothyroidism is not a contributing factor to their heart failure. The patient's troponin level is slightly elevated, but not significantly so, which suggests that there is not extensive cardiac damage. Overall, while the patient has a history of heart disease and reduced left ventricular function, their current symptoms and treatment regimen suggest that they are likely to survive.

RANKING: Sudden Cardiac Death

REASONING: The patient has a history of hypertensive cardiomyopathy and hypertension, which increases the risk for sudden cardiac death. The patient's LVEF of 30% indicates reduced left ventricular function, which is a risk factor for sudden cardiac death. The presence of polymorphic ventricular extrasystoles on the ECG is a risk factor for sudden cardiac death. However, the absence of sustained ventricular tachycardia and non-sustained ventricular tachycardia on the ECG suggests that the patient is not at high risk for sudden cardiac death. The patient's medication regimen includes beta blockers, which are known to reduce the risk of sudden cardiac death in patients with heart failure.

RANKING: Pump Failure Death

REASONING: The patient's LVEF of 30% indicates reduced left ventricular function, which is a risk factor for pump failure. The patient's history of hypertensive cardiomyopathy and hypertension suggests that they are at risk for progressive heart failure. However, the patient's NYHA Class II suggests that their symptoms are not severe, and they are able to perform most physical activities without significant limitation. The patient's medication regimen includes loop diuretics and spironolactone, which are both used to treat heart failure. The patient's troponin level is slightly elevated, which suggests that there may be some cardiac damage, but it is not extensive. Overall, while the patient has a history of heart disease and reduced left ventricular function, their current symptoms and treatment regimen suggest that pump failure is less likely than sudden cardiac death."
456,456,P0715,"Age: 73
Gender: Male 
Weight: 72 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 131/87 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 3,57
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 8
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 5
LDL (mmol/L): 1,86
Sodium (mEq/L): 135.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,92
Urea (mg/dL): 18,3
LVEF (%): 45.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: The patient is 73 years old with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension. However, he is currently on a comprehensive treatment regimen that includes medications for diabetes, heart failure, and high blood pressure. His LVEF is 45%, which is within the range for heart failure with reduced ejection fraction (HFrEF) but not severely compromised. The patient's creatinine level is elevated at 141.0 mmol/L, indicating some degree of kidney impairment, but his blood pressure is well-controlled, and his albumin level is within a relatively normal range. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG is concerning but not necessarily indicative of a high risk of sudden cardiac death. Overall, the patient's current treatment regimen and relatively stable vital signs suggest a favorable prognosis, making survival the most likely outcome.

RANKING: Pump Failure Death

REASONING: The patient's LVEF of 45% indicates reduced left ventricular function, which increases the risk of heart failure progression. His elevated creatinine level and the presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG may indicate underlying cardiac dysfunction that could lead to pump failure. However, the patient's treatment regimen and relatively stable vital signs suggest that he is being effectively managed, reducing the likelihood of sudden cardiac death. Pump failure death is a possible outcome, but it is less likely than sudden cardiac death due to the patient's current treatment and relatively stable condition.

RANKING: Sudden Cardiac Death

REASONING: While the patient has a history of ischemic dilated cardiomyopathy and non-sustained ventricular tachycardia on the ECG, his current treatment regimen and relatively stable vital signs suggest that he is being effectively managed. His LVEF is not severely compromised, and his blood pressure is well-controlled. The presence of polymorphic ventricular extrasystoles on the ECG is concerning, but it is not necessarily indicative of a high risk of sudden cardiac death. The patient's overall clinical picture suggests that sudden cardiac death is the least likely outcome, given his current treatment and relatively stable condition."
457,457,P0720,"Age: 69
Gender: Male 
Weight: 91 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 21
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 2,82
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,39
Potassium (mEq/L): 4,8
LDL (mmol/L): 1,84
Sodium (mEq/L): 136.0
Protein (g/L): 66
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,03
TSH (mIU/L): 4,12
Urea (mg/dL): 7,99
LVEF (%): 30.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure. However, the patient's current medications, including ACE inhibitors, beta blockers, and spironolactone, are evidence-based treatments for heart failure with reduced ejection fraction (HFrEF) and are likely to be contributing to the management of the patient's condition. The patient's LVEF of 30% indicates a significant impairment of left ventricular function, but it is not the lowest possible value. The patient's blood pressure is well-controlled, and there are no signs of severe kidney dysfunction (creatinine 88.0 umol/L). The patient's hemoglobin level is within the normal range, and the TSH level is slightly elevated, but not indicative of severe thyroid dysfunction. The patient's troponin level is within the normal range, and there is no evidence of recent myocardial infarction. The patient's medications include amiodarone, which can be used to treat arrhythmias, and the absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG is a positive sign. While the patient's NYHA Class III classification indicates significant limitations in physical activity, it does not necessarily indicate a high risk of sudden cardiac death. Based on these factors, the most likely prognosis is that the patient will survive.

RANKING: Sudden Cardiac Death

REASONING: While the patient has a history of idiopathic dilated cardiomyopathy, which is a risk factor for sudden cardiac death, the patient's current medications and lack of recent cardiac events or arrhythmias on the ECG make this prognosis less likely. The patient's LVEF of 30% is a risk factor for sudden cardiac death, but the patient's other clinical parameters, such as blood pressure and kidney function, are well-managed. The patient's hemoglobin level and TSH level are within the normal range, and the absence of recent myocardial infarction or severe arrhythmias on the ECG reduces the risk of sudden cardiac death.

RANKING: Pump Failure Death

REASONING: The patient's LVEF of 30% indicates a significant impairment of left ventricular function, which is a risk factor for pump failure death. The patient's NYHA Class III classification indicates significant limitations in physical activity, which is consistent with advanced heart failure. However, the patient's current medications, including ACE inhibitors, beta blockers, and spironolactone, are evidence-based treatments for HFrEF and are likely to be contributing to the management of the patient's condition. The patient's blood pressure is well-controlled, and there are no signs of severe kidney dysfunction (creatinine 88.0 umol/L). The patient's hemoglobin level is within the normal range, and the TSH level is slightly elevated, but not indicative of severe thyroid dysfunction. While the patient's LVEF and NYHA Class classification suggest a high risk of pump failure death, the patient's current medications and lack of recent cardiac events or arrhythmias on the ECG make this prognosis less likely than sudden cardiac death."
458,458,P0721,"Age: 39
Gender: Male 
Weight: 70 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,33
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,65
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,83
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 486.0
Protein (g/L): 72
T3 (pg/dL): 0,06
T4 (ng/L): 19
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,76
Urea (mg/dL): 8,15
LVEF (%): 30.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the prognosis for the next few years:

RANKING: Survivor
REASONING: The patient has a relatively favorable prognosis due to several factors. The patient is 39 years old, which is relatively young for a patient with idiopathic dilated cardiomyopathy. The patient's NYHA Class II indicates that the patient's symptoms are not severe, and they are able to perform some physical activity without discomfort. The patient is on optimal medical therapy with beta blockers, spironolactone, and an ACE inhibitor, which are all standard treatments for heart failure. The patient's LVEF of 30% is low, but it is not the lowest possible value, and the patient's Pro-BNP level is elevated, but not extremely high. The patient's creatinine level is slightly elevated, but not significantly so. The patient's blood pressure is well-controlled, and their lipid profile is relatively good. The patient's ECG shows ventricular extrasystoles, but no sustained ventricular tachycardia or other concerning arrhythmias. Overall, the patient's condition appears to be manageable, and with continued optimal medical therapy, it is likely that the patient will survive for several years.

RANKING: Pump Failure Death
REASONING: The patient's LVEF of 30% indicates that the patient's heart is not pumping efficiently, which increases the risk of pump failure. The patient's Pro-BNP level is elevated, which suggests that the patient's heart is under strain. The patient's creatinine level is slightly elevated, which may indicate early kidney dysfunction, a common complication of heart failure. The patient's low T3 level may also suggest that the patient is experiencing cardiac cachexia, a condition associated with poor prognosis in heart failure patients. However, the patient's overall clinical status and medication regimen suggest that pump failure is not an immediate concern.

RANKING: Sudden Cardiac Death
REASONING: The patient's LVEF of 30% increases the risk of sudden cardiac death, particularly if the patient experiences a ventricular arrhythmia. However, the patient's ECG does not show any signs of sustained ventricular tachycardia or other concerning arrhythmias, which reduces the risk of sudden cardiac death. The patient's medication regimen includes beta blockers, which are effective in reducing the risk of sudden cardiac death. Overall, while the patient's LVEF is low, the patient's overall clinical status and medication regimen suggest that sudden cardiac death is less likely than pump failure."
459,459,P0723,"Age: 64
Gender: Male 
Weight: 77 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 110/85 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,97
Sodium (mEq/L): 140.0
Protein (g/L): 63
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,92
Urea (mg/dL): 9,32
LVEF (%): 31.0
Medications: Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: 1. Survivor
REASONING: The patient has a history of enolic dilated cardiomyopathy, which is a significant risk factor for heart failure. However, the patient's current medications (Loop Diuretics and ACE Inhibitor) and relatively stable LVEF of 31% suggest that the patient is being managed and monitored. The absence of sustained ventricular tachycardia, bradycardia, and other concerning ECG findings further supports the likelihood of a survivor prognosis. Although the patient's LVEF is below the normal range, it is not extremely low, and the patient's NYHA Class II suggests that they are experiencing some symptoms but are not severely limited. Additionally, the patient's age and sex are not particularly high-risk factors for cardiac mortality.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's LVEF of 31% and history of enolic dilated cardiomyopathy increase the risk of sudden cardiac death. However, the patient's current medications and relatively stable condition suggest that this risk is being managed. The presence of polymorphic ventricular extrasystoles on the ECG is a concerning finding, but it is not a definitive indicator of sudden cardiac death risk. The patient's TSH level is also within the normal range, which reduces the likelihood of thyroid-related arrhythmias.

RANKING: 3. Pump Failure Death
REASONING: While the patient's LVEF of 31% and history of enolic dilated cardiomyopathy suggest a risk of pump failure, the patient's current medications and relatively stable condition suggest that this risk is being managed. The patient's NYHA Class II indicates that they are experiencing some symptoms but are not severely limited, which further supports the likelihood of a survivor prognosis over pump failure. Additionally, the patient's creatinine level is not significantly elevated, suggesting that renal function is relatively preserved, which is a good prognostic sign."
460,460,P0724,"Age: 86
Gender: Male 
Weight: 80 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 139/93 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,78
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,46
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1329.0
Protein (g/L): 70
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,05
TSH (mIU/L): 0,63
Urea (mg/dL): 9,48
LVEF (%): 33.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: Survivor

REASONING: Given the patient's profile, the most likely prognosis is survivor. Here's why:

1.  Age: The patient is 86 years old, which is a significant risk factor for cardiac mortality. However, it's not the only factor to consider.
2.  NYHA Class II: The patient's New York Heart Association (NYHA) functional class is II, indicating that they have some limitations in physical activity but are still relatively stable.
3.  Medications: The patient is on a combination of medications that are commonly used to manage heart failure, including ACE inhibitors, beta-blockers (Calcium Channel Blocker), and diuretics. These medications are likely helping to manage their symptoms and slow disease progression.
4.  LVEF: The left ventricular ejection fraction (LVEF) is 33%, which is low but not extremely low. While an LVEF of 30-40% indicates heart failure with reduced ejection fraction (HFrEF), it's not as severe as an LVEF below 30%.
5.  Pro-BNP: The pro-b-type natriuretic peptide (pro-BNP) level is elevated at 1329.0 ng/L, which is a marker of heart failure. However, it's not extremely high, and the patient's symptoms and functional capacity suggest that they are still relatively stable.
6.  ECG findings: While the patient has ventricular extrasystoles, non-sustained ventricular tachycardia, and unknown paroxysmal supraventricular tachyarrhythmia, these findings are not uncommon in patients with heart failure and are not necessarily indicative of an imminent risk of sudden cardiac death.
7.  Other factors: The patient's blood pressure, potassium, and glucose levels are relatively well-controlled, and their kidney function is not severely impaired.

Considering these factors, the patient's overall prognosis is likely to be a survivor, with a focus on managing their heart failure symptoms, monitoring their condition, and adjusting their medications as needed."
461,461,P0726,"Age: 85
Gender: Male 
Weight: 69 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 160/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,31
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 31,5
Glucose (mmol/L): 5,71
Hemoglobin (g/L): 164.0
HDL (mmol/L): 1,91
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,82
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 407.0
Protein (g/L): 72,3
T3 (pg/dL): 0,0507
T4 (ng/L): 11,37
TSH (mIU/L): 3,67
Urea (mg/dL): 6
LVEF (%): 30.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor
 REASONING: Despite the patient's advanced age and history of idiopathic dilated cardiomyopathy, the patient's current LVEF of 30% is not extremely low, and the patient is already on an ACE inhibitor, which is a standard treatment for heart failure. The patient's NYHA Class II indicates that the patient is experiencing some symptoms but is still able to perform most daily activities. The patient's blood pressure is also not extremely high, which is a positive factor. However, the patient's high Pro-BNP level (407.0 ng/L) indicates that the patient has some degree of heart failure. Considering the patient's overall condition and the fact that they are already on treatment, I believe that the most likely prognosis is survivor, with ongoing management and monitoring of the patient's condition.

RANKING: Pump Failure Death
 REASONING: The patient's LVEF of 30% indicates that the patient's heart is not pumping efficiently, which increases the risk of pump failure. The patient's high Pro-BNP level and elevated creatinine level also suggest that the patient's heart failure is not well-managed. However, the patient's NYHA Class II and the fact that they are already on treatment suggest that the patient is not in an advanced stage of heart failure. The patient's age and comorbidities also increase the risk of pump failure, but it is not the most likely prognosis at this point.

RANKING: Sudden Cardiac Death
 REASONING: The patient's ECG shows polymorphic ventricular extrasystoles and unknown ventricular tachycardia, which are risk factors for sudden cardiac death. However, the patient's LVEF of 30% and the fact that they are already on treatment suggest that the patient's heart failure is not as advanced as it could be. The patient's age and comorbidities also increase the risk of sudden cardiac death, but it is not the most likely prognosis at this point. The patient's NYHA Class II and the fact that they are still able to perform most daily activities also suggest that sudden cardiac death is less likely."
462,462,P0727,"Age: 75
Gender: Male 
Weight: 78 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 155/65 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 5,71
Creatinine (mmol/L): 163.0
Gamma-glutamil transpeptidase (IU/L): 144
Glucose (mmol/L): 6,73
Hemoglobin (g/L): 114.0
HDL (mmol/L): 2,23
Potassium (mEq/L): 5,38
LDL (mmol/L): 2,88
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 1364.0
Protein (g/L): 72,4
T3 (pg/dL): 0,0435
T4 (ng/L): 8,18
Troponin (ng/mL): 0,3
TSH (mIU/L): 5,83
Urea (mg/dL): 10,3
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: 1. Survivor
REASONING: The patient's age and NYHA Class II indicate a moderate level of heart failure symptoms, but the patient is still functional and able to perform daily activities. The patient's LVEF of 30% suggests a significant reduction in left ventricular function, which is a risk factor for adverse outcomes. However, the patient is on a comprehensive treatment regimen, including ACE inhibitors, spironolactone, calcium channel blockers, digoxin, and loop diuretics, which are evidence-based therapies for heart failure with reduced ejection fraction. The patient's troponin level is within normal limits, and there is no evidence of acute coronary syndrome. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles is concerning, but the absence of sustained ventricular tachycardia and the patient's overall clinical picture suggest that the risk of sudden cardiac death is lower. The patient's TSH level is within the normal range, which is a good prognostic sign. Given the patient's current treatment and the absence of acute decompensation, I would rank a survivor prognosis as the most likely outcome.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 30% indicates a high risk of progressive heart failure and pump failure. The patient's creatinine level of 163.0 mol/L suggests underlying renal impairment, which is a risk factor for adverse outcomes in heart failure patients. The patient's albumin level is slightly low, which may indicate malnutrition or chronic inflammation. The patient's T4 level is within the normal range, but the T3 level is low, which may indicate hypothyroidism, a condition that can worsen heart failure. The patient's TSH level is within the normal range, but the patient may still be at risk for thyroid hormone deficiency. The patient's medications, including ACE inhibitors and spironolactone, are evidence-based therapies for heart failure with reduced ejection fraction, but the patient's clinical picture suggests that the risk of pump failure death is higher than sudden cardiac death.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's ECG shows non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, which are risk factors for sudden cardiac death. The patient's LVEF of 30% and NYHA Class II suggest a high risk of sudden cardiac death. However, the patient's troponin level is within normal limits, and there is no evidence of acute coronary syndrome. The patient's medications, including beta blockers and ACE inhibitors, are evidence-based therapies for reducing the risk of sudden cardiac death. The patient's overall clinical picture suggests that the risk of sudden cardiac death is lower than pump failure death, but higher than survivor."
463,463,P0729,"Age: 74
Gender: Female 
Weight: 76 kg
Height: 148 cm
NYHA Class: II
Blood Pressure: 180/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,52
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,27
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,49
Potassium (mEq/L): 3,8
LDL (mmol/L): 4,57
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 2397.0
Protein (g/L): 81,3
T3 (pg/dL): 0,0369
T4 (ng/L): 18,09
Troponin (ng/mL): 0,4
TSH (mIU/L): 0,71
Urea (mg/dL): 8,1
LVEF (%): 50.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years, ranking the three possible prognoses from most likely to least likely.

RANKING: 1. Sudden Cardiac Death
REASONING: The patient is 74 years old with a history of hypertensive cardiomyopathy and hypertension, which increases the risk of sudden cardiac death. The elevated Pro-BNP level (2397.0 ng/L) suggests heart failure with reduced ejection fraction, which is a known predictor of sudden cardiac death. Additionally, the presence of polymorphic ventricular extrasystoles on the ECG further increases the risk. The patient's LVEF of 50% indicates reduced cardiac function, which is a risk factor for sudden cardiac death. While the patient is on medications such as digoxin, loop diuretics, and an ACE inhibitor, which are commonly used to manage heart failure, the high Pro-BNP level and reduced LVEF suggest that the patient may still be at risk for sudden cardiac death.

RANKING: 2. Pump Failure Death
REASONING: The patient's history of hypertensive cardiomyopathy and hypertension, combined with the reduced LVEF (50%) and elevated Pro-BNP level, suggests that the patient is at risk for pump failure death. The patient's weight (76 kg) and height (148 cm) indicate a BMI of 32.8, which is classified as obese, further increasing the risk of pump failure. The patient's blood pressure of 180/90 mmHg also suggests uncontrolled hypertension, which can exacerbate heart failure. While the patient is on medications to manage heart failure, the patient's current condition suggests that pump failure is a possible outcome.

RANKING: 3. Survivor
REASONING: While the patient's current condition is concerning, there are several factors that suggest a better prognosis. The patient's LVEF of 50% is not extremely low, and the patient is on medications that are commonly used to manage heart failure. The patient's hemoglobin level of 127 g/L is within a relatively normal range, which suggests that the patient's kidneys are functioning adequately, and the patient is not anemic. Additionally, the patient's TSH level of 0.71 mIU/L is within a normal range, which suggests that the patient's thyroid function is normal. While the patient's Pro-BNP level is elevated, it is not extremely high, and the patient's ECG does not show any signs of severe arrhythmias. Overall, while the patient's condition is concerning, there are several factors that suggest a better prognosis."
464,464,P0731,"Age: 82
Gender: Female 
Weight: 73 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 130/100 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,28
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,73
Sodium (mEq/L): 142.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,67
Urea (mg/dL): 10,48
LVEF (%): 39.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Here are the three possible prognoses, ordered from most likely to least likely:

RANKING: 1. Survivor
REASONING: The patient is 82 years old, which is a significant risk factor for cardiovascular events. However, the patient's current treatment regimen, including beta blockers, statins, ACE inhibitors, and nitrovasodilators, suggests that the patient is receiving optimal medical therapy for heart failure and ischemic dilated cardiomyopathy. The patient's LVEF of 39% indicates some degree of heart failure, but it is not severely impaired. The patient's blood pressure is well-controlled, and there is no indication of severe renal dysfunction (creatinine level is within normal limits). The patient's glucose and lipid profiles are also well-managed. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG is concerning, but it is not uncommon in patients with heart failure and ischemic cardiomyopathy. Overall, while the patient's prognosis is guarded, the current treatment regimen and lack of severe comorbidities suggest that a survivor prognosis is the most likely outcome.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 39% indicates some degree of heart failure, and the presence of non-sustained ventricular tachycardia on the ECG suggests that the patient's heart function may be deteriorating. The patient's creatinine level is within normal limits, but the patient's albumin level is slightly low, which may indicate some degree of liver dysfunction or malnutrition. The patient's total cholesterol and LDL levels are high, which may contribute to further cardiac damage. However, the patient's current treatment regimen includes statins, which should help to manage these levels. Overall, while the patient's prognosis is guarded, the lack of severe comorbidities and the current treatment regimen suggest that pump failure death is less likely than sudden cardiac death.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's age and history of myocardial infarction are significant risk factors for sudden cardiac death. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG is also concerning, as these arrhythmias can increase the risk of sudden cardiac death. However, the patient's LVEF of 39% and current treatment regimen suggest that the patient's heart function is not severely impaired. The patient's blood pressure and glucose levels are well-managed, and there is no indication of severe renal dysfunction. While the patient's prognosis is guarded, the lack of severe comorbidities and the current treatment regimen suggest that sudden cardiac death is less likely than pump failure death."
465,465,P0732,"Age: 48
Gender: Male 
Weight: 93 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 160/100 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 7,89
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 110
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 5,2
LDL (mmol/L): 5,84
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 11.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,05
TSH (mIU/L): 1,19
Urea (mg/dL): 5,32
LVEF (%): 25.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: The patient is 48 years old with a history of hypertensive cardiomyopathy, dyslipemia, and hypertension. Despite these conditions, the patient's LVEF (Left Ventricular Ejection Fraction) is 25%, which is significantly reduced but not extremely low. The patient is also on medications that are commonly used in the management of heart failure, such as beta blockers, loop diuretics, spironolactone, and an ACE inhibitor. The patient's Pro-BNP level is 11.0 ng/L, which is within the normal range, indicating that the patient is not experiencing significant fluid overload or heart failure symptoms. Additionally, the patient's creatinine level is 88.0 mol/L, which is slightly elevated but not extremely high. The patient's TSH level is within the normal range, and the T3 and T4 levels are also within the normal range, indicating that the patient does not have any signs of hyperthyroidism or hypothyroidism. The patient's hemoglobin level is within the normal range, and the patient is not experiencing anemia. The patient's blood pressure is slightly elevated, but it is well-controlled with medication. Overall, considering the patient's age, medical history, and current laboratory results, the prognosis for the patient is likely to be a survivor.

Note: The patient's LVEF of 25% is a significant concern, as it indicates severe left ventricular dysfunction. However, the patient's overall clinical picture and response to treatment suggest that the patient is not in immediate danger of sudden cardiac death or pump failure. Therefore, the most likely prognosis is a survivor."
466,466,P0736,"Age: 51
Gender: Male 
Weight: 80 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 53,2
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4
LDL (mmol/L): 2,74
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 1780.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,12
Urea (mg/dL): 9,13
LVEF (%): 63.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely.

RANKING: 1. Survivor
 REASONING: The patient is 51 years old with a history of ischemic dilated cardiomyopathy, dyslipemia, and hypertension. However, he is on appropriate medications (beta blockers and statins), which suggests that he is receiving standard treatment for his conditions. His LVEF (Left Ventricular Ejection Fraction) is 63%, which is within the normal range (> 50%). Although his Pro-BNP (Brain Natriuretic Peptide) level is elevated at 1780.0 ng/L, it is not excessively high, and his creatinine level is within normal limits. The patient's ECG does not show any signs of severe arrhythmias or other concerning features. His overall clinical picture suggests that he is being well-managed, and his symptoms are not severe enough to indicate a high risk of sudden cardiac death or pump failure.

RANKING: 2. Sudden Cardiac Death
 REASONING: While the patient has a history of ischemic dilated cardiomyopathy, his LVEF is within the normal range, and he is on appropriate medications. However, his Pro-BNP level is elevated, and his troponin level is slightly elevated at 0.01 ng/mL, which may indicate some degree of cardiac damage. Additionally, his ventricular extrasystole on the ECG could be a sign of underlying cardiac disease. However, the presence of monomorphic ventricular extrasystoles does not necessarily indicate a high risk of sudden cardiac death. The patient's overall clinical picture does not strongly suggest a high risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF is 63%, which is within the normal range, and he does not have severe symptoms or signs of heart failure. His creatinine level is within normal limits, and his albumin level is 53.2 g/L, which is not indicative of severe renal dysfunction. While his Pro-BNP level is elevated, it is not excessively high, and his overall clinical picture does not strongly suggest a high risk of pump failure death."
467,467,P0738,"Age: 70
Gender: Female 
Weight: 74 kg
Height: 154 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 37.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,49
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 91
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 141.0
HDL (mmol/L): 2,22
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,93
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 623.0
Protein (g/L): 69
T4 (ng/L): 10
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,94
Urea (mg/dL): 3,33
LVEF (%): 38.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden Cardiac Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is 38%, indicating severe left ventricular dysfunction, which further increases the risk of sudden cardiac death. The patient is also taking amiodarone, which is commonly prescribed for patients at high risk of sudden cardiac death due to its anti-arrhythmic properties. Additionally, the patient's elevated pro-BNP level (623.0 ng/L) suggests increased ventricular stress, which is a marker of poor prognosis. Considering these factors, sudden cardiac death is the most likely prognosis.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF of 38% indicates severe left ventricular dysfunction, which increases the risk of pump failure death. The patient's history of myocardial infarction and ischemic dilated cardiomyopathy also contribute to this risk. However, the patient is on optimal medical therapy with ACE inhibitors, beta blockers, and statins, which may help mitigate this risk. Additionally, the patient's creatinine level is within a relatively normal range, which suggests that the patient does not have significant renal impairment, a common comorbidity in patients with heart failure.

RANKING: 3. Survivor
 REASONING: Based on the patient's age, gender, and medical history, it is possible that the patient could survive for several years with optimal medical therapy and close follow-up. The patient's LVEF is relatively low, but it is not the lowest possible value, and the patient is on optimal medical therapy, which may help stabilize the patient's condition. However, the patient's history of ischemic dilated cardiomyopathy and severe left ventricular dysfunction make it unlikely that the patient will recover or significantly improve over time."
468,468,P0739,"Age: 47
Gender: Male 
Weight: 75 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 83.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 2,53
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 130.0
HDL (mmol/L): 0,54
Potassium (mEq/L): 5
LDL (mmol/L): 1,45
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3200.0
Protein (g/L): 70
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,05
Urea (mg/dL): 11,98
LVEF (%): 32.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1
 REASONING: Based on the provided patient data, I rank the prognosis as survivor with the highest likelihood. The patient is 47 years old with a history of ischemic dilated cardiomyopathy and myocardial infarction, which indicates a compromised cardiac function. However, the patient is on a comprehensive treatment regimen, including beta blockers, digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor, which suggests that the patient's condition is being actively managed.

The patient's LVEF (left ventricular ejection fraction) of 32% indicates a moderately reduced cardiac function, but it is not at the lowest end of the spectrum. The patient's NYHA Class II classification indicates that the patient has some symptoms of heart failure, but they are not severe. The patient's blood pressure is well-controlled, and there are no signs of acute kidney injury or severe electrolyte imbalances.

The high Pro-BNP level of 3200.0 ng/L indicates that the patient has some degree of heart failure, but it is not at the highest level, which would be more indicative of a poor prognosis. The patient's Troponin level is within normal limits, indicating that there is no acute myocardial infarction.

Given these factors, while the patient's prognosis is guarded, I believe that with continued management and treatment, the patient is likely to survive.

RANKING: 2
 REASONING: I rank sudden cardiac death as the second most likely prognosis. The patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases the risk of sudden cardiac death. The patient's LVEF of 32% and high Pro-BNP level indicate that the patient has a compromised cardiac function, which can increase the risk of sudden cardiac death. Additionally, the patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death.

However, the patient is on a comprehensive treatment regimen, including beta blockers, which can reduce the risk of sudden cardiac death. The patient's blood pressure is well-controlled, and there are no signs of acute kidney injury or severe electrolyte imbalances.

RANKING: 3
 REASONING: I rank pump failure death as the least likely prognosis. While the patient has a compromised cardiac function, the patient's LVEF of 32% is not at the lowest end of the spectrum, and the patient is on a comprehensive treatment regimen that includes medications that can help improve cardiac function and reduce symptoms. The patient's NYHA Class II classification indicates that the patient has some symptoms of heart failure, but they are not severe.

Additionally, the patient's blood pressure is well-controlled, and there are no signs of acute kidney injury or severe electrolyte imbalances. While the patient's Pro-BNP level is high, it is not at the highest level, which would be more indicative of a poor prognosis.

Overall, while the patient's prognosis is guarded, I believe that pump failure death is the least likely outcome due to the patient's relatively well-controlled symptoms and comprehensive treatment regimen."
469,469,P0740,"Age: 52
Gender: Male 
Weight: 77 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 135/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes
Albumin (g/L): 43
ALT or GPT (IU/L): 48.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 15,5
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,43
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 610.0
Protein (g/L): 70
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,51
Urea (mg/dL): 6,99
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient has a relatively stable medical condition with a New York Heart Association (NYHA) Class II, indicating mild to moderate symptoms of heart failure. The patient is on a comprehensive treatment regimen that includes beta blockers, spironolactone, statins, and an ACE inhibitor, which are all standard treatments for heart failure and ischemic dilated cardiomyopathy. The patient's ejection fraction (LVEF) is 30%, which is low but not the lowest possible value. The patient's troponin level is within normal limits, indicating that there is no acute myocardial infarction. The patient's pro-BNP level is elevated at 610.0 ng/L, which suggests that the patient has heart failure, but it is not excessively high. The patient's other lab results, such as hemoglobin, potassium, and sodium levels, are within normal limits. The patient's age and gender also favor a better prognosis. Considering these factors, the most likely outcome is that the patient will survive.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF of 30% indicates that the heart is not pumping efficiently, which can lead to pump failure. The patient's elevated pro-BNP level and NYHA Class II symptoms also support this possibility. However, the patient's treatment regimen and other lab results suggest that the patient's condition is relatively stable, and the risk of sudden cardiac death is lower. The patient's age and gender are also not as high-risk as some other factors that could contribute to pump failure.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient's LVEF of 30% increases the risk of sudden cardiac death, but the patient's other lab results and treatment regimen suggest that this is not the most likely outcome. The patient's troponin level is within normal limits, indicating that there is no acute myocardial infarction, and the patient's other cardiac markers are not elevated. The patient's ECG is also unremarkable, with no signs of arrhythmias or other abnormalities. The patient's age and gender are also not as high-risk as some other factors that could contribute to sudden cardiac death."
470,470,P0741,"Age: 63
Gender: Female 
Weight: 85 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41,3
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 78.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,45
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 347.0
Protein (g/L): 68,4
T4 (ng/L): 14
TSH (mIU/L): 1,32
Urea (mg/dL): 5,32
LVEF (%): 68.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses for the next few years as follows:

RANKING: 1. Survivor
REASONING: The patient is 63 years old with a history of ischemic dilated cardiomyopathy, dyslipemia, hypertension, and myocardial infarction. However, she is currently on beta blockers and statins, which are appropriate medications for her conditions. Her LVEF is 68%, which is relatively preserved. The patient also has a normal hemoglobin level, and her TSH and T4 levels are within the normal range. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG is a positive sign. The elevated Pro-BNP level (347.0 ng/L) indicates some degree of heart failure, but it is not extremely high. Considering these factors, the patient's overall prognosis is more favorable, and I predict that she is likely to survive for the next few years.

RANKING: 2. Sudden cardiac death
REASONING: The patient has a history of ischemic dilated cardiomyopathy and a myocardial infarction, which increases her risk of sudden cardiac death. The presence of ventricular extrasystoles on the ECG also suggests some degree of cardiac electrical instability. However, her LVEF is relatively preserved, and she is on appropriate medications. The elevated Pro-BNP level and the presence of hypertension may indicate some degree of cardiac stress, but they do not necessarily increase the risk of sudden cardiac death. The patient's overall prognosis is not extremely poor, but there is a moderate risk of sudden cardiac death.

RANKING: 3. Pump failure death
REASONING: The patient has a history of ischemic dilated cardiomyopathy, which increases her risk of pump failure. Her LVEF is 68%, which is relatively preserved, but her Pro-BNP level is elevated, indicating some degree of heart failure. However, the patient's LVEF is not severely reduced, and she is on beta blockers and statins, which are appropriate medications for her conditions. The absence of other signs of advanced heart failure, such as severe anemia or elevated creatinine levels, suggests that the patient's prognosis is not extremely poor. While pump failure death is a possible outcome, it is less likely than sudden cardiac death due to the patient's relatively preserved LVEF and the absence of other signs of advanced heart failure."
471,471,P0744,"Age: 49
Gender: Male 
Weight: 92 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 46,6
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 7,4
Creatinine (mmol/L): 83.0
Gamma-glutamil transpeptidase (IU/L): 51
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 171.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4,2
LDL (mmol/L): 4,47
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 5.0
Protein (g/L): 80,1
T4 (ng/L): 17
TSH (mIU/L): 0,64
Urea (mg/dL): 3,5
LVEF (%): 57.0
Medications: Amiodarone
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Please note that this is a medical assessment and not a definitive prediction.

RANKING: Survivor
REASONING: The patient is a 49-year-old male with a history of hypertensive cardiomyopathy and hypertension. He has a left ventricular ejection fraction (LVEF) of 57%, which is slightly below the normal range but not severely impaired. The patient's blood pressure is slightly elevated, but it's not excessively high. The patient is on amiodarone, which suggests that he has a history of arrhythmias or cardiac conduction disorders. However, the ECG shows only monomorphic ventricular extrasystoles, which are relatively common and often benign.

The patient's laboratory results show slightly elevated liver enzymes (ALT and AST), which could be related to his hypertension or cardiomyopathy. The lipid profile shows high total cholesterol and LDL levels, but the HDL level is relatively low. The patient's kidney function is within normal limits, and his thyroid function is normal.

Considering these factors, the patient's prognosis is generally favorable. The patient's LVEF is not severely impaired, and he does not have any signs of advanced heart failure. The patient's blood pressure can be managed with medication, and his lipid profile can be improved with lifestyle changes and medication. The patient's ECG is relatively normal, and he is on a medication that helps to prevent arrhythmias.

While the patient has a history of hypertensive cardiomyopathy and hypertension, which can be a risk factor for cardiac events, the overall prognosis is not extremely poor. The patient's age and sex are also relatively favorable, as men under the age of 50 tend to have a better prognosis than older men.

In contrast to the other two possible prognoses (sudden cardiac death and pump failure death), the patient's current clinical status and laboratory results do not suggest an immediate high risk for these outcomes. The patient's LVEF is not severely impaired, and he does not have any signs of advanced heart failure or severe arrhythmias.

Therefore, the most likely prognosis for this patient over the next few years is survivor.

RANKING: Sudden cardiac death (less likely)
REASONING: Sudden cardiac death is a possible outcome in patients with a history of hypertensive cardiomyopathy and hypertension. However, the patient's LVEF is not severely impaired, and he does not have any signs of advanced heart failure or severe arrhythmias. The patient's ECG shows only monomorphic ventricular extrasystoles, which are relatively common and often benign. While the patient is on amiodarone, which can increase the risk of arrhythmias, the patient's overall clinical status and laboratory results do not suggest a high risk for sudden cardiac death.

RANKING: Pump failure death (least likely)
REASONING: Pump failure death is a possible outcome in patients with severe heart failure or severely impaired LVEF. However, the patient's LVEF is 57%, which is not severely impaired. The patient does not have any signs of advanced heart failure, such as orthopnea, paroxysmal nocturnal dyspnea, or edema. The patient's laboratory results show no signs of severe kidney dysfunction or electrolyte imbalances, which can contribute to pump failure. The patient's blood pressure can be managed with medication, and his lipid profile can be improved with lifestyle changes and medication. Therefore, the risk of pump failure death is the least likely of the three possible prognoses."
472,472,P0745,"Age: 75
Gender: Female 
Weight: 67 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 38,7
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,04
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 108.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,28
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1143.0
Protein (g/L): 64,9
T4 (ng/L): 11
TSH (mIU/L): 13,15
Urea (mg/dL): 16,31
LVEF (%): 34.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Please note that this is a medical prediction and not a definitive diagnosis. 

RANKING: Survivor

REASONING: 

This patient is a 75-year-old female with a history of ischemic dilated cardiomyopathy, myocardial infarction, and diabetes. The patient's LVEF is 34%, indicating a reduced left ventricular function, which is a significant risk factor for cardiac events. However, the patient is on a comprehensive treatment regimen, including beta blockers, angiotensin II receptor blockers, loop diuretics, spironolactone, and a nitrovasodilator, which are all evidence-based therapies for heart failure and ischemic cardiomyopathy.

The patient's NYHA Class II classification indicates that she has some limitations in physical activity but is still able to perform everyday activities. Her blood pressure is well-controlled, and her glucose levels are relatively well-managed.

While the patient's Pro-BNP level is elevated at 1143 ng/L, which is a marker of heart failure, it is not excessively high. Her creatinine level is also within a relatively normal range, indicating that her renal function is not significantly impaired.

The patient's ECG shows monomorphic ventricular extrasystoles, which are common in patients with heart failure and are not necessarily a contraindication for survival.

Considering the patient's age, comorbidities, and treatment regimen, I would rank the prognosis as follows:

1. Survivor: The patient's treatment regimen, relatively well-controlled blood pressure and glucose levels, and stable renal function suggest that she is likely to survive for the next few years.
2. Sudden cardiac death: While the patient's LVEF is reduced, her treatment regimen and relatively well-controlled blood pressure and glucose levels reduce the likelihood of sudden cardiac death.
3. Pump failure death: The patient's reduced LVEF and elevated Pro-BNP level increase the risk of pump failure death, but her treatment regimen and relatively stable renal function suggest that this outcome is less likely.

It is essential to note that this prognosis is based on the provided data and may not be comprehensive. Regular follow-up and monitoring of the patient's condition are necessary to adjust the treatment plan and provide a more accurate prognosis."
473,473,P0746,"Age: 71
Gender: Female 
Weight: 85 kg
Height: 148 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 38,7
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 123.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,51
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 292.0
Protein (g/L): 64,9
T4 (ng/L): 16
TSH (mIU/L): 1,02
Urea (mg/dL): 7,15
LVEF (%): 58.0
Medications: Beta Blockers, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient is 71 years old with a history of hypertensive cardiomyopathy, dyslipemia, and hypertension. Despite these risk factors, she is on medications for these conditions, including beta blockers and nitrovasodilators. Her LVEF is 58%, which is within the normal range (>50%). Her blood pressure is slightly elevated, but not excessively high. The absence of sustained ventricular tachycardia and non-sustained ventricular tachycardia on the ECG is also a positive sign. The patient's albumin and total protein levels are within normal limits, suggesting no significant liver dysfunction. Her hemoglobin level is slightly elevated, but not significantly so. While her Pro-BNP level is elevated, it is not excessively high. Considering these factors, the likelihood of the patient surviving for the next few years is relatively high.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF is 58%, which is at the lower end of the normal range. Her Pro-BNP level is elevated, indicating some degree of heart failure. Her creatinine level is also slightly elevated, suggesting some degree of renal impairment. However, her hemoglobin level is slightly elevated, which may be a compensatory response to chronic anemia. The absence of severe liver dysfunction and the presence of beta blockers and nitrovasodilators may mitigate the risk of pump failure. While the patient's risk factors for heart failure are present, the likelihood of pump failure death is not extremely high, given her relatively stable LVEF and the absence of other significant comorbidities.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's ECG shows polymorphic ventricular extrasystoles, which is a risk factor for sudden cardiac death. However, the absence of sustained ventricular tachycardia and non-sustained ventricular tachycardia on the ECG suggests that the risk of sudden cardiac death may be lower than expected. The patient's LVEF is within the normal range, and her medications include beta blockers, which may help reduce the risk of sudden cardiac death. While the patient's risk factors for sudden cardiac death are present, the likelihood of sudden cardiac death is not extremely high, given the presence of beta blockers and the absence of other significant comorbidities."
474,474,P0747,"Age: 58
Gender: Female 
Weight: 73 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 130/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 53.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 3,8
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,35
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 158.0
Protein (g/L): 68
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1
Urea (mg/dL): 6,66
LVEF (%): 30.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's a prognosis for the next few years:

RANKING: 1. Survivor
REASONING: The patient is 58 years old with a history of idiopathic dilated cardiomyopathy, which is a significant underlying condition that affects the heart's ability to pump blood effectively. However, despite this, the patient is currently being treated with Angiotensin II Receptor Blocker, Beta Blockers, Statins, and Nitrovasodilator, which are all appropriate medications for managing heart failure. The patient's NYHA Class II indicates that she experiences some limitation in physical activity but is still able to perform daily activities. The LVEF of 30% is relatively low but not extremely low, indicating some preserved cardiac function. Additionally, the patient's Pro-BNP level is elevated but not extremely high, which suggests that the patient is being managed effectively with medications. The lack of troponin elevation and the absence of ventricular tachycardia or other severe arrhythmias on the ECG also suggest that the patient is not experiencing acute cardiac ischemia or severe arrhythmia. Considering these factors, the most likely outcome for the patient is survival with continued medical management.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 30% and history of idiopathic dilated cardiomyopathy indicate that she is at risk for pump failure. However, the patient's current medications and NYHA Class II classification suggest that she is being managed effectively, and the lack of severe symptoms or arrhythmias on the ECG suggests that the patient is not in acute cardiac failure. The patient's Pro-BNP level is elevated but not extremely high, which may indicate some preserved cardiac function. Therefore, while pump failure is a possible outcome, it is not the most likely outcome given the patient's current management and relatively preserved cardiac function.

RANKING: 3. Sudden Cardiac Death
REASONING: Sudden cardiac death is a possible outcome for patients with heart failure, especially those with a history of idiopathic dilated cardiomyopathy. However, the patient's current medications and NYHA Class II classification suggest that she is being managed effectively, and the lack of severe arrhythmias on the ECG suggests that the patient is not at high risk for sudden cardiac death. The patient's LVEF of 30% and Pro-BNP level are not extremely high-risk indicators for sudden cardiac death. Therefore, while sudden cardiac death is a possible outcome, it is the least likely outcome given the patient's current management and relatively preserved cardiac function."
475,475,P0748,"Age: 69
Gender: Male 
Weight: 59 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 122/68 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 8.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,32
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 3,9
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,43
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 15272.0
Protein (g/L): 59
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,14
Urea (mg/dL): 8,49
LVEF (%): 15.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely. 

RANKING: 1. Survivor
 REASONING: Despite the patient's advanced age and significant comorbidities, including hypertensive cardiomyopathy, dyslipemia, and hypertension, the patient is currently receiving optimal medical therapy with beta blockers, loop diuretics, statins, and an ACE inhibitor. The patient's LVEF is 15%, which indicates severe left ventricular dysfunction, but it is still above the critical level of 10-15%. The patient's Pro-BNP level is elevated at 15272.0 ng/L, indicating elevated filling pressures, but it is not extremely high. The patient's ECG shows non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, but these are not uncommon in patients with cardiomyopathy. The patient's hemoglobin level is within a normal range, and the TSH level is normal, indicating no signs of thyroid dysfunction. The patient's creatinine level is elevated at 141.0 mmol/L, indicating some degree of renal impairment, but it is not severe. Overall, while the patient has significant cardiac disease, the patient's current medical therapy and the absence of other high-risk features make a survivor prognosis the most likely outcome.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF of 15% indicates severe left ventricular dysfunction, which is a significant risk factor for pump failure death. The patient's Pro-BNP level is elevated, indicating elevated filling pressures, which can lead to heart failure. The patient's renal impairment, as indicated by the elevated creatinine level, may also contribute to a higher risk of pump failure death. However, the patient is receiving optimal medical therapy, which may help mitigate this risk. The patient's age and comorbidities also increase the risk of pump failure death, but the patient's current medical therapy and the absence of other high-risk features make pump failure death the second most likely outcome.

RANKING: 3. Sudden Cardiac Death
 REASONING: While the patient's ECG shows non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, which can increase the risk of sudden cardiac death, the patient is receiving beta blockers, which can help reduce this risk. The patient's LVEF is 15%, which is a risk factor for sudden cardiac death, but the patient's current medical therapy and the absence of other high-risk features make sudden cardiac death the least likely outcome. The patient's age and comorbidities also increase the risk of sudden cardiac death, but the patient's current medical therapy and the absence of other high-risk features make it the least likely outcome."
476,476,P0749,"Age: 75
Gender: Male 
Weight: 64 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,97
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,72
Sodium (mEq/L): 137.0
Protein (g/L): 68
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,44
Urea (mg/dL): 8,65
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: 1. Survivor
 REASONING: The patient has a relatively well-managed condition, with a controlled blood pressure, stable LVEF of 40%, and no signs of acute myocardial infarction. The patient is on a comprehensive medication regimen, including beta blockers, spironolactone, statins, ACE inhibitors, and a nitrovasodilator, which is beneficial for managing heart failure and reducing the risk of sudden cardiac death. The patient's NYHA class is II, indicating that the patient is experiencing some symptoms but can still perform daily activities. The absence of significant laboratory abnormalities, such as elevated troponin levels or significant changes in renal function, suggests that the patient's condition is stable. Additionally, the patient's age and weight are not particularly concerning, and the patient's height is within a normal range.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy and a low LVEF of 40%, which increases the risk of sudden cardiac death. However, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death. The patient also has a normal troponin level, which suggests that there is no acute myocardial infarction. The patient's ECG shows polymorphic ventricular extrasystoles, which may be a concern, but it is not a definitive indicator of sudden cardiac death.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 40% indicates that the patient has some degree of heart failure, but the patient's NYHA class is II, and the patient is on spironolactone, which is beneficial for managing heart failure. The patient's creatinine level is slightly elevated, but it is not significantly abnormal. The patient's weight is relatively low, which may be a concern for malnutrition, but the patient's albumin and protein levels are within normal limits. The patient's TSH level is within normal limits, which suggests that the patient does not have hypothyroidism, which can exacerbate heart failure. However, the patient's history of peripheral vascular disease and dyslipemia may contribute to the risk of pump failure death."
477,477,P0750,"Age: 62
Gender: Male 
Weight: 107 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 108
Glucose (mmol/L): 12,2
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,4
Sodium (mEq/L): 134.0
Protein (g/L): 69
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,5
Urea (mg/dL): 8,65
LVEF (%): 47.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened due to a heart attack or decreased blood flow to the heart. However, the patient is currently taking medications that are beneficial for this condition, such as beta blockers, loop diuretics, spironolactone, statins, and ACE inhibitors. The patient's LVEF (Left Ventricular Ejection Fraction) is 47%, which is lower than normal, but not extremely low. The patient also has a relatively controlled blood pressure and glucose levels. The absence of significant arrhythmias, such as sustained ventricular tachycardia or fibrillation, on the ECG is also a positive sign. Considering these factors, the patient's overall condition seems to be relatively stable, and with proper management, the likelihood of a survivor prognosis is high.

RANKING: Pump Failure Death

REASONING: The patient's LVEF of 47% indicates that the heart is not pumping efficiently, which increases the risk of pump failure. The patient's history of myocardial infarction and ischemic dilated cardiomyopathy also increases the risk of pump failure. However, the patient's current medication regimen and relatively controlled blood pressure and glucose levels suggest that the patient is receiving adequate treatment. The patient's kidney function is also relatively preserved, with a creatinine level of 71.0 mol/L, which is not extremely high. While pump failure is a possible outcome, it is not the most likely prognosis given the patient's current treatment and relatively stable condition.

RANKING: Sudden Cardiac Death

REASONING: The patient has a history of ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The patient's LVEF of 47% and the presence of non-sustained ventricular tachycardia on the ECG also increase the risk of sudden cardiac death. However, the patient's relatively controlled blood pressure and glucose levels, as well as the absence of significant arrhythmias on the ECG, suggest that the risk of sudden cardiac death is not extremely high. The patient's medication regimen, which includes beta blockers and ACE inhibitors, also helps to reduce the risk of sudden cardiac death. Therefore, while sudden cardiac death is a possible outcome, it is not the most likely prognosis given the patient's current condition and treatment.

Note: The patient's TSH level is slightly elevated at 2.5 mIU/L, which may indicate hypothyroidism. However, the T4 level is within the normal range, and the patient's overall condition does not seem to be significantly affected by this."
478,478,P0751,"Age: 51
Gender: Male 
Weight: 61 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 105/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40,5
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 7,28
Creatinine (mmol/L): 121.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,77
LDL (mmol/L): 5,17
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 4168.0
Protein (g/L): 72,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,03
Urea (mg/dL): 7,7
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's my prognosis for the next few years:

RANKING: 1. Survivor
REASONING: The patient is 51 years old with a history of idiopathic dilated cardiomyopathy, which significantly affects the left ventricular ejection fraction (LVEF) at 20%. However, the patient is on optimal medical therapy with beta blockers, loop diuretics, and an ACE inhibitor, which are standard treatments for heart failure with reduced ejection fraction (HFrEF). The patient's blood pressure is within a relatively normal range, and the albumin level is within the normal range. The elevated Pro-BNP level indicates some degree of heart failure, but it's not extremely high. The patient's kidney function, as indicated by the creatinine level, is relatively preserved. Additionally, the absence of severe electrolyte imbalances, such as hyperkalemia, suggests that the patient's cardiac function is not severely compromised at this point. Considering these factors, a survivor prognosis seems most likely.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient has a history of non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. The patient's LVEF is significantly reduced, and the patient is taking an ACE inhibitor, which may not be sufficient to prevent sudden cardiac death. However, the patient is on beta blockers, which can help reduce the risk of sudden cardiac death. The patient's troponin level is normal, indicating that there is no acute coronary syndrome or myocardial infarction. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the overall clinical picture does not strongly suggest a high risk for sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: While the patient's LVEF is significantly reduced, the patient is on optimal medical therapy for HFrEF, and the kidney function is relatively preserved. The patient's albumin level is within the normal range, indicating that the patient is not in severe heart failure. The patient's weight is relatively low, and the body mass index (BMI) can be calculated as 22.7 kg/m, which is within the normal range. The patient's blood pressure is within a relatively normal range, which is a good prognostic indicator for heart failure. Considering these factors, pump failure death seems to be the least likely prognosis."
479,479,P0753,"Age: 56
Gender: Male 
Weight: 88 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 145/90 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 40,5
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 5,99
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 120
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 148.0
Potassium (mEq/L): 4,17
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 906.0
Protein (g/L): 78,5
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,46
Urea (mg/dL): 7,5
LVEF (%): 20.0
Medications: Amiodarone, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely. 

RANKING: 1. Survivor
 REASONING: The patient has a relatively low LVEF of 20%, indicating severe left ventricular dysfunction. However, the patient is on a treatment plan that includes ACE inhibitors, loop diuretics, and digoxin, which are standard therapies for heart failure management. The patient is also on amiodarone, which is used for arrhythmia prevention. The lack of sustained ventricular tachycardia and non-sustained ventricular tachycardia on the ECG suggests that the patient's arrhythmia risk is relatively low. The patient's Pro-BNP level is elevated at 906.0 ng/L, but this is not uncommon in patients with heart failure. The patient's NYHA class is II, indicating that the patient is experiencing some symptoms but is still able to perform daily activities. Considering these factors, the patient's likelihood of survival over the next few years is relatively high.

RANKING: 2. Pump failure death
 REASONING: The patient's low LVEF and elevated Pro-BNP level suggest significant left ventricular dysfunction. The patient's creatinine level is slightly elevated, indicating potential renal impairment, which can further worsen the prognosis. However, the patient is on standard heart failure medications, which may help to manage symptoms and slow disease progression. The patient's overall clinical picture suggests a high risk of pump failure, but the effectiveness of the current treatment plan and the lack of other high-risk factors (e.g., severe arrhythmias, severe anemia) make pump failure death a less likely outcome compared to sudden cardiac death.

RANKING: 3. Sudden cardiac death
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The patient's LVEF is low, and the Pro-BNP level is elevated, indicating significant cardiac dysfunction. However, the patient is on amiodarone, which is used to prevent arrhythmias, and the ECG does not show any signs of sustained ventricular tachycardia. While the patient's clinical picture suggests a high risk of sudden cardiac death, the patient's overall clinical condition and treatment plan make this outcome the least likely compared to pump failure death."
480,480,P0755,"Age: 75
Gender: Female 
Weight: 69 kg
Height: 152 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 41,3
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,35
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5
Hemoglobin (g/L): 125.0
HDL (mmol/L): 2,1
Potassium (mEq/L): 4,78
LDL (mmol/L): 1,82
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 285.0
Protein (g/L): 70,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,78
Urea (mg/dL): 8
LVEF (%): 70.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1

REASONING: The patient has a relatively favorable prognosis for the next few years. The patient is 75 years old, which is an advanced age, but still not extremely high-risk. The patient has a history of valvular cardiomyopathy, which is a significant condition, but the current LVEF (Left Ventricular Ejection Fraction) is 70%, indicating that the heart is still pumping relatively well. The patient's NYHA Class II indicates that she has some limitations in physical activity but is still able to perform everyday tasks without significant symptoms.

The patient's blood pressure is well-controlled, and the absence of significant abnormalities in the liver enzymes (ALT, AST, and GGT) suggests that there is no significant liver disease. The total cholesterol and LDL levels are within a relatively normal range, which is beneficial for heart health. The patient's hemoglobin level is slightly elevated, but not significantly so, and the potassium level is within a normal range.

The patient is on a comprehensive medication regimen, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all appropriate for managing heart failure and valvular cardiomyopathy. The absence of significant troponin elevation suggests that there is no acute myocardial infarction or significant cardiac damage.

The pro-BNP level is elevated at 285.0 ng/L, which indicates some degree of heart failure, but it is not extremely high. The TSH level is within a normal range, which suggests that there is no significant thyroid dysfunction.

The ECG impression shows a monomorphic ventricular extrasystole, which is a relatively common finding in the general population, but not necessarily a significant concern in this patient. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia suggests that the patient does not have a high risk of sudden cardiac death.

Overall, while the patient has a history of valvular cardiomyopathy and some degree of heart failure, the current clinical status and laboratory findings suggest that she has a relatively favorable prognosis for the next few years, making survivor the most likely outcome.

RANKING: 2

REASONING: Sudden cardiac death is less likely than survivor because the patient has a relatively well-controlled heart condition, and there are no significant risk factors for sudden cardiac death. The patient's LVEF is 70%, which is within a relatively normal range, and the absence of significant abnormalities in the ECG suggests that there is no high-risk arrhythmia. The patient's medication regimen is comprehensive and appropriate for managing heart failure and valvular cardiomyopathy.

However, the patient's age, history of valvular cardiomyopathy, and elevated pro-BNP level do increase the risk of sudden cardiac death. The patient's NYHA Class II indicates that she has some limitations in physical activity, which may increase the risk of sudden cardiac death.

RANKING: 3

REASONING: Pump failure death is the least likely outcome because the patient's LVEF is 70%, which is within a relatively normal range, and the patient's medication regimen is comprehensive and appropriate for managing heart failure and valvular cardiomyopathy. The patient's NYHA Class II indicates that she has some limitations in physical activity, but the patient is still able to perform everyday tasks without significant symptoms.

The patient's laboratory findings, including the albumin, total cholesterol, LDL, and hemoglobin levels, suggest that there is no significant underlying condition that would increase the risk of pump failure death. The patient's potassium level is within a normal range, which suggests that there is no significant electrolyte imbalance.

However, the patient's age and history of valvular cardiomyopathy do increase the risk of pump failure death. The patient's elevated pro-BNP level suggests that there is some degree of heart failure, which may increase the risk of pump failure death."
481,481,P0756,"Age: 74
Gender: Male 
Weight: 72 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 175/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 38,9
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 78.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 155.0
HDL (mmol/L): 1,45
Potassium (mEq/L): 3,83
LDL (mmol/L): 3,2
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 373.0
Protein (g/L): 64,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,68
Urea (mg/dL): 8,8
LVEF (%): 41.0
Medications: Amiodarone, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient is 74 years old with a history of hypertensive cardiomyopathy and hypertension, which suggests that he has a compromised cardiac function. However, his current NYHA Class II indicates that he is still able to perform some physical activity without significant limitations. The LVEF of 41% is below the normal range (50-70%), indicating some degree of left ventricular dysfunction. However, it is not severely impaired. The patient is on appropriate medications for his conditions, including an ACE inhibitor, which is beneficial for heart failure management. Additionally, the patient's troponin level is within normal limits, indicating minimal myocardial damage. The low Pro-BNP level of 373 ng/L is also a good sign, as elevated Pro-BNP levels are associated with heart failure and increased mortality risk. Considering these factors, the patient's overall prognosis appears to be favorable, and a survivor outcome is the most likely.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 41% and history of hypertensive cardiomyopathy suggest a risk of pump failure. However, the patient's NYHA Class II and the presence of a TPSV on the ECG indicate that the patient's cardiac function is not severely compromised at this time. The patient's current medications, including spironolactone and an ACE inhibitor, are beneficial for heart failure management. While the patient's creatinine level is elevated, indicating some degree of kidney impairment, it is not significantly elevated, and the patient's urea level is within normal limits. The patient's overall clinical picture suggests that pump failure is a possible outcome, but it is not the most likely.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's ECG shows ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the absence of non-sustained ventricular tachycardia and the presence of a TPSV on the ECG suggest that the patient's cardiac rhythm is not severely unstable at this time. The patient's troponin level is within normal limits, indicating minimal myocardial damage. The patient's medications, including amiodarone, are beneficial for preventing arrhythmias. While the patient's LVEF is below the normal range, it is not severely impaired, and the patient's overall clinical picture suggests that sudden cardiac death is the least likely outcome.

Note: The prognosis is based on the provided data and should be interpreted with caution, as individual patient outcomes can vary greatly."
482,482,P0757,"Age: 59
Gender: Male 
Weight: 91 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 43,1
ALT or GPT (IU/L): 148.0
AST or GOT (IU/L): 85.0
Total Cholesterol (mmol/L): 3,74
Creatinine (mmol/L): 121.0
Gamma-glutamil transpeptidase (IU/L): 187
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 144.0
HDL (mmol/L): 0,6
Potassium (mEq/L): 4,09
LDL (mmol/L): 2,43
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 182.0
Protein (g/L): 79,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,7
Urea (mg/dL): 8
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: Based on the provided patient data, I would rank the prognosis as Survivor for the next few years. Here's why:

1. Ischemic dilated cardiomyopathy: The patient has a history of ischemic dilated cardiomyopathy, which is a chronic condition that can lead to heart failure. However, with proper management, patients with this condition can have a good prognosis and live for several years.
2. NYHA Class II: The patient's New York Heart Association (NYHA) functional class is II, indicating that they experience some limitation of physical activity but are still able to perform daily activities. This suggests that the patient's heart condition is manageable, and they are not yet in an advanced stage of heart failure.
3. Medications: The patient is on a comprehensive treatment regimen that includes beta blockers, ACE inhibitors, spironolactone, and statins, which are all evidence-based therapies for heart failure and ischemic heart disease. These medications can help manage symptoms, slow disease progression, and improve outcomes.
4. LVEF: The left ventricular ejection fraction (LVEF) is 35%, which is relatively low but not extremely low. An LVEF of 35-50% is often considered an intermediate risk category, and with proper management, patients with this LVEF can still have a good prognosis.
5. ECG findings: While the patient has ventricular extrasystoles and non-sustained ventricular tachycardia, these findings are not uncommon in patients with ischemic heart disease. The absence of sustained ventricular tachycardia, bradycardia, and paroxysmal supraventricular tachyarrhythmia suggests that the patient's arrhythmias are not a significant concern at this time.
6. Laboratory values: The patient's laboratory values, including troponin, pro-BNP, and creatinine, are within relatively normal ranges, indicating that the patient's cardiac function is not severely compromised.

While the patient has a history of myocardial infarction and hypertension, and their laboratory values show some signs of liver dysfunction (elevated ALT and GGT), the overall picture suggests that the patient is being well-managed and has a good prognosis for the next few years."
483,483,P0758,"Age: 55
Gender: Male 
Weight: 81 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 44,5
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,33
Creatinine (mmol/L): 110.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 123.0
HDL (mmol/L): 1,08
Potassium (mEq/L): 4,76
LDL (mmol/L): 2,78
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 5004.0
Protein (g/L): 70,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,29
Urea (mg/dL): 10,8
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: Based on the provided patient data, the patient is a 55-year-old male with a history of idiopathic dilated cardiomyopathy, which is a significant underlying condition that affects the heart's pumping ability. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 20%, indicating a poor pumping function. However, the patient is currently on optimal medical therapy, including beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators, which suggests that the treatment is aimed at managing symptoms and slowing disease progression.

The patient's biomarkers, such as Troponin (0.01 ng/mL), indicate minimal cardiac damage. The elevated Pro-BNP level (5004.0 ng/L) suggests heart failure with preserved ejection fraction, but the low LVEF suggests a reduced ejection fraction. The patient's hemoglobin level is within the normal range, which is a good sign, and the potassium level is within the normal range, which is essential for cardiac function.

The patient's ECG shows polymorphic ventricular extrasystoles, but no other significant arrhythmias. The absence of non-sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, and bradycardia is a positive sign.

Given these factors, the patient's overall prognosis is more likely to be a survivor. The patient's current treatment regimen and the lack of severe cardiac damage or significant arrhythmias suggest that the patient is being managed effectively, and the risk of sudden cardiac death or pump failure is lower. However, it is essential to continue monitoring the patient's condition and adjust the treatment plan as needed to prevent disease progression.

The likelihood of sudden cardiac death is lower due to the absence of significant arrhythmias and the patient's current medical therapy. The likelihood of pump failure death is also lower due to the patient's current management and the absence of severe cardiac damage. Therefore, the patient's prognosis is most likely to be a survivor."
484,484,P0759,"Age: 69
Gender: Male 
Weight: 73 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 40,1
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,94
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 173.0
HDL (mmol/L): 0,79
Potassium (mEq/L): 3,48
LDL (mmol/L): 3,82
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1837.0
Protein (g/L): 71,5
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,2
Urea (mg/dL): 10,1
LVEF (%): 18.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's my prognosis for the next few years:

RANKING: 1. Survivor
REASONING: Despite the patient's advanced heart failure with an LVEF of 18%, which is indicative of severe systolic dysfunction, the patient's NYHA Class II classification suggests that they are experiencing some limitations in physical activity but are still able to perform daily activities without significant symptoms. The patient's blood pressure is well-controlled, and they are on a regimen of medications that are commonly used to manage heart failure, including beta blockers, loop diuretics, hydralazine, and nitrovasodilators. Additionally, the patient's troponin levels are within normal limits, indicating that there is no evidence of acute myocardial infarction. The patient's pro-BNP level is elevated, which is consistent with heart failure, but it is not extremely high, suggesting that the patient's heart failure is not acutely decompensated. The patient's overall clinical picture suggests that they are being well-managed for their heart failure, and with continued medical therapy and lifestyle modifications, they are likely to survive for several years.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of idiopathic dilated cardiomyopathy and non-sustained ventricular tachycardia (NSVT) increases their risk of sudden cardiac death (SCD). However, the patient's LVEF of 18% and the fact that they are being treated with beta blockers and other medications that are known to reduce the risk of SCD suggest that they are at lower risk for SCD compared to those with a higher LVEF or those who are not on these medications. Additionally, the patient's troponin levels are normal, and there is no evidence of acute coronary syndrome, which further reduces the risk of SCD.

RANKING: 3. Pump Failure Death
REASONING: While the patient's LVEF of 18% indicates severe systolic dysfunction, their NYHA Class II classification and well-controlled blood pressure suggest that they are not experiencing significant symptoms of heart failure at this time. The patient's creatinine level is slightly elevated, but it is not extremely high, and their urea level is within normal limits. The patient's overall clinical picture suggests that they are being well-managed for their heart failure, and while pump failure is a possibility in the long term, it is less likely in the short to medium term."
485,485,P0763,"Age: 60
Gender: Male 
Weight: 74 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 95/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 41,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 6
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 7,7
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,18
LDL (mmol/L): 4,2
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 2774.0
Protein (g/L): 65,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,76
Urea (mg/dL): 7,6
LVEF (%): 21.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely. Please note that this is a complex analysis and the actual outcome may vary based on various factors, including the patient's response to treatment and potential changes in their condition over time.

RANKING: 1. Survivor
 REASONING: Despite the patient's advanced heart failure (NYHA Class II and LVEF of 21%), the patient is currently on optimal medical therapy with beta blockers, loop diuretics, spironolactone, and an ACE inhibitor. The patient's serum creatinine level is elevated (100.0 mmol/L), but it is not extremely high, and the patient's urea level is within a relatively normal range (7.6 mg/dL). The patient's albumin level is slightly low (41.4 g/L), but not critically low. The patient's troponin level is within normal limits (0.01 ng/mL), indicating no acute myocardial infarction. The patient's TSH level is within the normal range (0.76 mIU/L), indicating no overt thyroid dysfunction. The patient's Pro-BNP level is elevated (2774.0 ng/L), but it is not extremely high, and the patient is on appropriate therapy to manage their heart failure. The presence of non-sustained ventricular tachycardia on the ECG is concerning, but it is not an uncommon finding in patients with heart failure. Overall, the patient's clinical profile suggests that they are receiving optimal medical therapy and have a relatively stable condition, making a survivor prognosis more likely.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's LVEF of 21% indicates severe left ventricular dysfunction, which increases the risk of sudden cardiac death. The patient's Pro-BNP level is elevated, which is a marker of heart failure severity. The presence of non-sustained ventricular tachycardia on the ECG is a risk factor for sudden cardiac death. However, the patient is on beta blockers, which are effective in reducing the risk of sudden cardiac death in patients with heart failure. The patient's medication regimen also includes an ACE inhibitor, which is beneficial in reducing the risk of sudden cardiac death. The patient's serum creatinine level is elevated, which may indicate some degree of renal dysfunction, but it is not extremely high. The patient's overall clinical profile suggests that they are at risk for sudden cardiac death, but the presence of optimal medical therapy reduces this risk.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 21% indicates severe left ventricular dysfunction, which increases the risk of pump failure death. The patient's serum creatinine level is elevated (100.0 mmol/L), which may indicate some degree of renal dysfunction, which can be a marker of advanced heart failure. The patient's Pro-BNP level is elevated, which is a marker of heart failure severity. However, the patient is on optimal medical therapy, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are effective in managing heart failure. The patient's overall clinical profile suggests that they are at risk for pump failure death, but the presence of optimal medical therapy reduces this risk."
486,486,P0764,"Age: 75
Gender: Male 
Weight: 72 kg
Height: 181 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44,8
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 6,64
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 148.0
Potassium (mEq/L): 4,74
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 2243.0
Protein (g/L): 80,4
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,59
Urea (mg/dL): 8,8
LVEF (%): 26.0
Medications: Amiodarone, Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

Based on the provided patient data, I would rank the prognosis as a survivor for the next few years. Here's the reasoning behind this prediction:

1.  Age and NYHA Class: The patient is 75 years old and has a NYHA Class II, indicating some limitations in physical activity but still able to perform daily activities. This suggests that the patient is not severely symptomatic, which is a positive sign.

2.  Medications: The patient is on a comprehensive medication regimen that includes beta blockers, ACE inhibitors, spironolactone, and statins, which are all evidence-based treatments for heart failure and cardiomyopathy. This suggests that the patient is receiving optimal medical therapy.

3.  LVEF: Although the patient's LVEF is low at 26%, it is not as low as some other patients with dilated cardiomyopathy. This suggests that the patient's heart function is not severely impaired.

4.  ECG findings: The patient has non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or bradycardia. This suggests that the patient's arrhythmias are not life-threatening.

5.  Blood work: The patient's creatinine level is elevated, but it is not severely elevated, and the patient's hemoglobin and protein levels are within normal limits. This suggests that the patient's kidney function is not severely impaired.

6.  Troponin level: The patient's troponin level is very low, which suggests that there is no acute coronary syndrome or myocardial infarction.

7.  Pro-BNP level: The patient's Pro-BNP level is elevated, which suggests that the patient has some degree of heart failure, but it is not as high as some other patients with heart failure.

Considering these factors, I would rank the prognosis as a survivor for the next few years. However, it is essential to continue monitoring the patient's condition closely and adjusting the treatment plan as needed to prevent potential complications.

Sudden cardiac death is less likely because:

*   The patient's LVEF is not extremely low, and the patient is on beta blockers and ACE inhibitors, which reduce the risk of sudden cardiac death.
*   The patient's ECG findings are not indicative of a high risk of sudden cardiac death.

Pump failure death is less likely because:

*   The patient's LVEF is not extremely low, and the patient is on spironolactone, which is an aldosterone antagonist that helps to reduce the risk of pump failure.
*   The patient's creatinine level is not severely elevated, which suggests that the patient's kidney function is not severely impaired.

Therefore, while the patient has a significant underlying condition, the combination of optimal medical therapy and relatively mild symptoms suggests that the prognosis is more favorable than the other two options."
487,487,P0767,"Age: 70
Gender: Male 
Weight: 89 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 147/62 mmHg
Past Medical History: Other HF etiology, Diabetes, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,33
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 7,1
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,8
LDL (mmol/L): 3,7
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 723.0
Protein (g/L): 70
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,56
Urea (mg/dL): 7,82
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Hydralazine, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's my prognosis for the next few years:

RANKING: 1. Survivor
REASONING: The patient is 70 years old with a history of heart failure, diabetes, and hypertension. The patient's ejection fraction (LVEF) is 35%, indicating reduced left ventricular function. However, the patient is on a comprehensive medication regimen, including beta blockers, hydralazine, ACE inhibitors, and nitrovasodilators, which are commonly used to manage heart failure and hypertension. The patient's NT-proBNP level is elevated at 723.0 ng/L, which is consistent with heart failure. Despite this, the patient's blood pressure is well-controlled at 147/62 mmHg, and the patient is not in NYHA Class IV, which is a more severe classification of heart failure. Additionally, the patient's hemoglobin and potassium levels are within normal limits, and there is no indication of severe electrolyte imbalances. Considering these factors, the patient's prognosis is likely to be a survivor, with proper management of their condition.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's LVEF of 35% puts them at increased risk for sudden cardiac death. However, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death in patients with heart failure. Additionally, the patient's troponin level is within normal limits, and there is no indication of acute coronary syndrome. The patient's ECG does show ventricular extrasystoles, but this is not a contraindication for survival. While the patient is at risk for sudden cardiac death, the comprehensive medication regimen and the lack of acute cardiac events suggest that this outcome is less likely than survivor.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF of 35% indicates reduced left ventricular function, which puts them at risk for pump failure. However, the patient's blood pressure is well-controlled, and the patient is on hydralazine, which is used to manage heart failure symptoms. The patient's creatinine level is elevated at 115.0 mmol/L, indicating some degree of renal impairment, but this is not an independent predictor of pump failure death. The patient's NT-proBNP level is elevated, but this is consistent with heart failure. While the patient is at risk for pump failure, the comprehensive medication regimen and the lack of acute cardiac events suggest that this outcome is the least likely of the three."
488,488,P0768,"Age: 73
Gender: Male 
Weight: 94 kg
Height: 167 cm
NYHA Class: III
Blood Pressure: 150/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 186.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4
LDL (mmol/L): 2,51
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 600.0
Protein (g/L): 76
T4 (ng/L): 15
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,13
Urea (mg/dL): 21,96
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. I will rank the three possible prognoses from most likely to least likely.

RANKING: Survivor
REASONING: The patient is 73 years old with a history of ischemic dilated cardiomyopathy, dyslipemia, hypertension, and myocardial infarction. Despite these risk factors, the patient is currently on a comprehensive treatment regimen that includes beta blockers, loop diuretics, statins, ACE inhibitor, and nitrovasodilator. The patient's LVEF is 40%, which is relatively preserved for someone with ischemic dilated cardiomyopathy. The patient's Pro-BNP level is elevated at 600.0 ng/L, but it is not extremely high, indicating some degree of cardiac compensation. The patient's ECG shows non-sustained ventricular tachycardia, but no sustained VT or atrial fibrillation. The patient's troponin level is within normal limits, and the TSH is within the normal range. Considering these factors, the patient has a relatively stable cardiac condition, and with proper management, the likelihood of sudden cardiac death or pump failure death is lower. However, the patient's NYHA Class III indicates that the patient has significant symptoms, and there is still a risk of cardiac events.

RANKING: Pump Failure Death
REASONING: The patient's LVEF is 40%, which indicates some degree of systolic dysfunction. The patient's creatinine level is elevated at 186.0 mol/L, indicating some degree of renal impairment, which is common in patients with heart failure. The patient's Pro-BNP level is elevated, indicating some degree of cardiac stress. However, the patient's ejection fraction is not extremely low, and the patient is on a comprehensive treatment regimen that includes diuretics, ACE inhibitors, and beta blockers, which are all beneficial for heart failure management. The patient's NYHA Class III indicates that the patient has significant symptoms, but the patient is not in an advanced stage of heart failure.

RANKING: Sudden Cardiac Death
REASONING: The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. The patient's LVEF is 40%, which is relatively preserved, but the patient's Pro-BNP level is elevated, indicating some degree of cardiac stress. However, the patient's troponin level is within normal limits, and the patient is on beta blockers, which are beneficial for reducing the risk of sudden cardiac death. The patient's TSH is within the normal range, and the patient's lipid profile is relatively well-managed. Considering these factors, the risk of sudden cardiac death is lower than pump failure death, but still present due to the patient's history of myocardial infarction and non-sustained ventricular tachycardia."
489,489,P0769,"Age: 51
Gender: Female 
Weight: 79 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,35
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 183.0
Protein (g/L): 75
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,77
Urea (mg/dL): 6,99
LVEF (%): 33.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

Considering the patient's profile, I would rank the prognosis as Survivor. Here's why:

1. Age and NYHA Class II: The patient is 51 years old and has a New York Heart Association (NYHA) functional class II, indicating mild to moderate heart failure symptoms. This suggests that the patient is not in an advanced stage of heart failure.

2. Medications: The patient is on beta-blockers, statins, and an ACE inhibitor, which are standard treatments for heart failure and idiopathic dilated cardiomyopathy. These medications can help slow disease progression and improve symptoms.

3. LVEF of 33%: Although the left ventricular ejection fraction (LVEF) is low, it's not extremely low. An LVEF of 33% is still within the range where some patients can be managed with medical therapy and may not require advanced interventions like heart transplantation.

4. ECG findings: While the patient has ventricular extrasystoles and non-sustained ventricular tachycardia, these are not necessarily indicators of a poor prognosis in this context. The absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia is also reassuring.

5. Blood work: The patient's blood work shows mild elevation in creatinine, but it's not severely elevated, and the eGFR can be estimated as approximately 60-70 mL/min/1.73 m^2, which is not indicative of severe kidney dysfunction. The liver enzymes are within normal limits, and the patient is not hypokalemic.

Considering these factors, the patient's prognosis is likely to be a Survivor. However, close monitoring and regular follow-up with the cardiologist are essential to adjust medications, manage symptoms, and prevent disease progression."
490,490,P0770,"Age: 55
Gender: Male 
Weight: 87 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 180/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 41
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 43
Glucose (mmol/L): 6,4
Hemoglobin (g/L): 132.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,2
LDL (mmol/L): 1,68
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 536.0
Protein (g/L): 73
T3 (pg/dL): 0,06
T4 (ng/L): 12
Troponin (ng/mL): 0,005
TSH (mIU/L): 13,08
Urea (mg/dL): 7,65
LVEF (%): 53.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses for the next few years from most likely to least likely. Here's my assessment:

RANKING: Survivor

REASONING: The patient has idiopathic dilated cardiomyopathy with an LVEF of 53%, which indicates moderate heart failure. However, the patient is on optimal medical therapy with beta blockers, digoxin, loop diuretics, and an ACE inhibitor, which are all standard treatments for heart failure with reduced ejection fraction (HFrEF). The patient's NYHA Class II indicates that they have some limitations in physical activity but are still able to perform daily activities without significant symptoms. The lack of sustained ventricular tachycardia and non-sustained ventricular tachycardia suggests that the patient is not at high risk for sudden cardiac death. The elevated TSH level (13.08 mIU/L) may indicate subclinical hypothyroidism, which can be managed with medication. The patient's troponin level is within normal limits, and their potassium level is slightly low, but not critically so. The high Pro-BNP level (536.0 ng/L) indicates some level of heart failure, but it is not excessively high. Overall, considering the patient's current medical therapy and the absence of high-risk features, I believe that the most likely prognosis is survivor.

RANKING: Sudden Cardiac Death

REASONING: While the patient has idiopathic dilated cardiomyopathy, their LVEF is still relatively well-preserved at 53%, and they are on optimal medical therapy. The absence of sustained ventricular tachycardia and non-sustained ventricular tachycardia reduces the risk of sudden cardiac death. However, the presence of ventricular extrasystoles and the unknown paroxysmal supraventricular tachyarrhythmia code may indicate some level of arrhythmia risk. The patient's high blood pressure (180/75 mmHg) may also contribute to cardiac stress. While these factors increase the risk of sudden cardiac death, they do not make it the most likely prognosis.

RANKING: Pump Failure Death

REASONING: Pump failure death is typically associated with a more advanced stage of heart failure, characterized by a significantly reduced LVEF (< 30-40%) and severe symptoms. While the patient has idiopathic dilated cardiomyopathy and an LVEF of 53%, which indicates some level of heart failure, their current symptoms are relatively mild (NYHA Class II), and they are on optimal medical therapy. The patient's creatinine level is elevated at 104.0 mmol/L, which may indicate some level of renal impairment, but it is not severe enough to suggest advanced pump failure. Overall, considering the patient's relatively well-preserved LVEF and mild symptoms, pump failure death is the least likely prognosis."
491,491,P0771,"Age: 73
Gender: Male 
Weight: 89 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 130/65 mmHg
Past Medical History: Other HF etiology
Albumin (g/L): 39
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 3,34
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4
LDL (mmol/L): 1,71
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 720.0
Protein (g/L): 72
T4 (ng/L): 17
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,06
Urea (mg/dL): 7,99
LVEF (%): 25.0
Medications: Beta Blockers, Statins, Hydralazine, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the three possible prognoses as follows:

RANKING: 1. Survivor
REASONING: The patient's age and NYHA Class II suggest that he has a moderate level of heart failure, but he is not in the most severe stage. His current medications, including beta blockers, statins, hydralazine, ACE inhibitor, and nitrovasodilator, are all standard treatments for heart failure and are likely helping to manage his condition. His LVEF of 25% is low, indicating reduced cardiac function, but it is not the lowest possible value. Additionally, his blood pressure is well-controlled, and his kidney function is relatively preserved (creatinine 80.0 umol/L). His troponin level is low, indicating minimal myocardial damage. The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG is concerning, but these findings can be managed with medication adjustments. Overall, the patient's current treatment plan and relatively stable vital signs suggest that he is likely to survive in the short term.

RANKING: 2. Sudden cardiac death
REASONING: While the patient's history and current condition are concerning, the risk of sudden cardiac death is lower than pump failure death due to his relatively well-controlled blood pressure, preserved kidney function, and lack of severe electrolyte imbalances. However, his low LVEF and history of non-sustained ventricular tachycardia increase his risk of arrhythmias and sudden cardiac death. His current medications, including beta blockers and ACE inhibitors, are likely helping to reduce this risk.

RANKING: 3. Pump failure death
REASONING: The patient's low LVEF and history of other heart failure etiology suggest that he is at risk for pump failure. His current symptoms and medication regimen are likely managing his condition, but his LVEF of 25% is still relatively low, and his creatinine level is slightly elevated, indicating some degree of renal impairment. However, his overall vital signs and laboratory values do not suggest that he is in acute heart failure, and his current medications are likely helping to manage his symptoms. Therefore, while pump failure death is a possible outcome, it is less likely than sudden cardiac death due to the patient's relatively stable condition and controlled blood pressure."
492,492,P0773,"Age: 69
Gender: Male 
Weight: 68 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 108/68 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 32
ALT or GPT (IU/L): 109.0
AST or GOT (IU/L): 116.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 420
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,9
LDL (mmol/L): 1,86
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2362.0
Protein (g/L): 60
T4 (ng/L): 18
Troponin (ng/mL): 0,02
TSH (mIU/L): 3,66
Urea (mg/dL): 12,15
LVEF (%): 20.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely. Please note that the actual outcome may vary depending on individual patient factors and treatment response.

RANKING: 1. Survivor
REASONING: The patient's current medications (Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator) suggest that they are receiving standard treatment for heart failure and hypertension. Their LVEF of 20% indicates a reduced left ventricular function, but it is not the lowest possible value (LVEF < 10-15% is often associated with a worse prognosis). The patient's NYHA Class II indicates that they are experiencing some symptoms of heart failure, but they are not severely limited. The patient's blood pressure is within a relatively normal range, and their electrolytes are mostly within normal limits. While their Pro-BNP level is elevated, indicating some level of heart failure, it is not extremely high. Considering these factors, the patient's current treatment and condition suggest a relatively stable prognosis.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 20% indicates significant left ventricular dysfunction, which is a risk factor for pump failure. Their elevated Pro-BNP level and reduced albumin level suggest ongoing heart failure. However, the patient is already on optimal medical therapy, and their blood pressure and electrolytes are relatively well-managed. While the patient's liver enzymes are elevated, which may indicate some level of liver dysfunction, this is not an immediate concern for pump failure. The patient's age and comorbidities (diabetes, dyslipemia, hypertension) contribute to a higher risk of complications, but their current treatment plan and relatively stable condition suggest that pump failure is not the most likely outcome in the short term.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's LVEF of 20% and elevated Pro-BNP level suggest a high risk of arrhythmias and sudden cardiac death. The presence of ventricular extrasystoles on the ECG also indicates an increased risk of arrhythmias. However, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death. Additionally, the patient's medications and relatively stable condition suggest that sudden cardiac death is less likely than pump failure or other complications. The patient's age and comorbidities contribute to a higher risk of sudden cardiac death, but their current treatment plan and relatively stable condition suggest that this outcome is the least likely of the three."
493,493,P0774,"Age: 51
Gender: Female 
Weight: 84 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 111/54 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,77
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 577.0
Protein (g/L): 76
T4 (ng/L): 22
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,53
Urea (mg/dL): 5,66
LVEF (%): 20.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: Survivor
REASONING: The patient is a 51-year-old female with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure and potential mortality. However, she is currently on a multidrug regimen consisting of beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which are all evidence-based treatments for heart failure with reduced ejection fraction (HFrEF). The patient's LVEF of 20% indicates severe left ventricular dysfunction, but her NYHA Class II classification suggests that she is still relatively asymptomatic and able to perform daily activities without significant limitation. The patient's laboratory results, including a relatively normal hemoglobin and potassium levels, and a mildly elevated creatinine, suggest that her renal function is preserved. The low TSH level suggests that her thyroid function is well-controlled. The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG may indicate some degree of electrical instability, but this is not uncommon in patients with HFrEF. The patient's Pro-BNP level is elevated at 577 ng/L, which is consistent with heart failure, but not excessively high. Overall, while the patient's prognosis is guarded, her current treatment regimen and relatively well-preserved renal function suggest that she may have a better chance of survival compared to the other two options.

RANKING: Sudden Cardiac Death
REASONING: Sudden cardiac death (SCD) is a potential risk in patients with HFrEF, particularly those with a history of ventricular arrhythmias. The patient's non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG increase her risk of SCD. However, her current treatment regimen includes beta blockers and an ACE inhibitor, which are known to reduce the risk of SCD in patients with HFrEF. Additionally, her LVEF of 20% and NYHA Class II classification suggest that she is relatively asymptomatic, which may reduce her risk of SCD. While SCD remains a concern, it is not the most likely outcome given the patient's current treatment and relatively preserved renal function.

RANKING: Pump Failure Death
REASONING: Pump failure death is a potential outcome in patients with HFrEF, particularly those with a low LVEF and significant symptoms. However, the patient's NYHA Class II classification suggests that she is relatively asymptomatic, and her current treatment regimen is evidence-based for HFrEF. While her LVEF is low at 20%, her renal function is relatively preserved, which may reduce her risk of pump failure. Additionally, her Pro-BNP level is not excessively high, which may indicate that her heart failure is not as severe as it could be. Overall, while pump failure death is a possible outcome, it is less likely than survivor given the patient's current treatment and relatively preserved renal function."
494,494,P0775,"Age: 61
Gender: Male 
Weight: 70 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 130/83 mmHg
Past Medical History: Other HF etiology, Dyslipemia
Albumin (g/L): 44
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,87
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 413.0
Protein (g/L): 74
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,41
Urea (mg/dL): 6,49
LVEF (%): 25.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
 REASONING: The patient's current medications (Beta Blockers, Statins, ACE Inhibitor) are appropriate for managing heart failure and reducing the risk of cardiac events. The patient's NYHA Class II indicates that the patient's symptoms are tolerable with minimal physical activity, suggesting that the heart failure is not severe at this point. The LVEF of 25% indicates that the patient has significant left ventricular dysfunction, but it is not the lowest possible value (which is typically around 10-15%). The absence of ventricular tachycardia and bradycardia on the ECG also suggests that the patient's heart rhythm is relatively stable. The patient's Pro-BNP level of 413.0 ng/L is elevated, indicating heart failure, but it is not extremely high, which might suggest that the patient's condition is not worsening rapidly. Considering these factors, the most likely prognosis for this patient is survival.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF of 25% indicates significant left ventricular dysfunction, which increases the risk of pump failure. The patient's Creatinine level of 80.0 mmol/L suggests that the kidneys are not functioning optimally, which can be a sign of advanced heart failure. However, the patient's NYHA Class II and the absence of severe symptoms suggest that the patient is not yet in end-stage heart failure. The patient's Pro-BNP level is elevated, but not extremely high, which might indicate that the patient's condition is not worsening rapidly. The patient's medications are appropriate for managing heart failure, which could help slow the progression of the disease. Considering these factors, pump failure death is a possible but less likely prognosis compared to survivor.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient's ECG shows monomorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the absence of ventricular tachycardia and bradycardia on the ECG suggests that the patient's heart rhythm is relatively stable. The patient's LVEF of 25% and NYHA Class II suggest that the patient's heart failure is not severe, which reduces the risk of sudden cardiac death. The patient's medications, including Beta Blockers, are appropriate for reducing the risk of sudden cardiac death. Considering these factors, sudden cardiac death is the least likely prognosis for this patient."
495,495,P0777,"Age: 69
Gender: Male 
Weight: 89 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 125/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 40,6
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 6
Hemoglobin (g/L): 146.0
HDL (mmol/L): 0,92
Potassium (mEq/L): 4,71
LDL (mmol/L): 2,59
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1487.0
Protein (g/L): 74,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,48
Urea (mg/dL): 8,4
LVEF (%): 38.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: Survivor

REASONING: The patient is a 69-year-old male with a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipemia. Despite these risk factors, the patient's current condition and lab results suggest a relatively stable clinical status. The patient's left ventricular ejection fraction (LVEF) is 38%, which is below the normal range (50-70%), indicating some degree of heart failure. However, the patient is on optimal medical therapy for heart failure, including ACE inhibitors, beta blockers, spironolactone, and statins, which suggests that the patient's condition is being well-managed.

The patient's Pro-BNP level is elevated at 1487 ng/L, which is a marker of heart failure severity. However, the level is not extremely high, suggesting that the patient's condition is not rapidly deteriorating. The patient's hemoglobin and albumin levels are within normal limits, indicating that there is no significant anemia or malnutrition.

The patient's ECG shows ventricular extrasystoles and non-sustained ventricular tachycardia, which are common findings in patients with heart failure. However, the patient's rhythm is stable, and there is no indication of severe arrhythmias or conduction abnormalities.

Considering the patient's overall clinical status, the presence of optimal medical therapy, and the absence of severe laboratory abnormalities, I believe that the most likely prognosis is survival over the next few years. However, it is essential to continue close monitoring and adjust the patient's treatment plan as needed to prevent further deterioration.

RANKING: Sudden Cardiac Death

REASONING: Sudden cardiac death is a potential risk for patients with heart failure, especially those with reduced LVEF. The patient's LVEF of 38% puts him at increased risk for sudden cardiac death. However, the patient's current ECG findings, including ventricular extrasystoles and non-sustained ventricular tachycardia, are not indicative of a high risk for sudden cardiac death. The patient's stable rhythm and lack of severe arrhythmias also suggest that sudden cardiac death is less likely.

RANKING: Pump Failure Death

REASONING: Pump failure death is a potential risk for patients with heart failure, especially those with reduced LVEF and evidence of fluid overload. However, the patient's current clinical status and laboratory results do not suggest severe fluid overload or significant worsening of heart failure. The patient's LVEF is stable at 38%, and the patient is on optimal medical therapy for heart failure. While pump failure death is a possible outcome, it is less likely than sudden cardiac death, given the patient's stable clinical status and lack of severe laboratory abnormalities."
496,496,P0778,"Age: 73
Gender: Female 
Weight: 56 kg
Height: 145 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 49,5
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 6,9
Creatinine (mmol/L): 110.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 126.0
HDL (mmol/L): 0,79
Potassium (mEq/L): 4,5
LDL (mmol/L): 5,16
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 1058.0
Protein (g/L): 89,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,35
Urea (mg/dL): 9,9
LVEF (%): 64.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. However, please note that this is a hypothetical prediction and not a definitive medical diagnosis.

RANKING: 1. Survivor
 REASONING: The patient is 73 years old with a history of valvular cardiomyopathy, but her LVEF is 64%, which is still within the normal range (50-70%). Her medications include beta blockers, calcium channel blockers, loop diuretics, spironolactone, and statins, which are all appropriate for managing heart failure and valvular disease. Her blood pressure is well-controlled, and her renal function is relatively preserved (creatinine 110.0 umol/L). Although her BNP is elevated (1058 ng/L), it's not excessively high, and her troponin is normal. The patient's ECG shows monomorphic ventricular extrasystoles, which are not typically a significant concern. Considering these factors, the patient's overall condition appears to be relatively stable, and with proper management, she has a high likelihood of survival.

RANKING: 2. Pump failure death
 REASONING: The patient has a history of valvular cardiomyopathy, which increases her risk of heart failure. However, her LVEF is still within the normal range, and her renal function is relatively preserved. While her BNP is elevated, it's not excessively high, which suggests that her heart failure is not severe. The patient's medications are appropriate for managing heart failure, and her blood pressure is well-controlled. Although the patient is 73 years old, her overall condition does not suggest an immediate risk of pump failure death. However, if the patient's heart failure progresses or if she develops other comorbidities, her risk of pump failure death may increase.

RANKING: 3. Sudden cardiac death
 REASONING: The patient's ECG shows monomorphic ventricular extrasystoles, which are not typically a significant concern. There is no evidence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, or other arrhythmias that would increase the risk of sudden cardiac death. The patient's LVEF is within the normal range, and her medications include beta blockers, which are effective in reducing the risk of sudden cardiac death. While the patient's age and valvular cardiomyopathy increase her overall risk of cardiovascular events, the lack of other high-risk factors makes sudden cardiac death the least likely prognosis."
497,497,P0780,"Age: 51
Gender: Female 
Weight: 43 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 130/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40,1
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,26
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 110.0
HDL (mmol/L): 1,57
Potassium (mEq/L): 4,01
LDL (mmol/L): 2,93
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1129.0
Protein (g/L): 80,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 7,28
Urea (mg/dL): 4,9
LVEF (%): 28.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor

REASONING: Given the patient's profile, I would rank the prognosis as a survivor with the highest likelihood. Here's why:

1. Age and Gender: The patient is 51 years old and female, which is relatively young for a patient with idiopathic dilated cardiomyopathy. This suggests that the disease may have progressed relatively slowly, and the patient may still have a relatively good prognosis.

2. NYHA Class II: The patient is classified as NYHA Class II, which indicates that she is experiencing mild to moderate symptoms of heart failure. This is a relatively favorable classification compared to Class III or IV, which would indicate more severe symptoms.

3. Medications: The patient is on beta blockers, spironolactone, and an ACE inhibitor, which are all standard treatments for heart failure and idiopathic dilated cardiomyopathy. These medications can help improve symptoms, slow disease progression, and reduce the risk of sudden cardiac death.

4. ECG findings: While the patient has ventricular extrasystoles and non-sustained ventricular tachycardia, these are not necessarily indicative of a high risk of sudden cardiac death. The absence of sustained ventricular tachycardia, bradycardia, and paroxysmal supraventricular tachyarrhythmia also suggests a lower risk.

5. LVEF: The patient's left ventricular ejection fraction (LVEF) is 28%, which is low but not extremely low. An LVEF of 20-30% is often associated with a more favorable prognosis compared to an LVEF below 20%.

6. Other laboratory results: The patient's electrolytes, liver enzymes, and kidney function are relatively normal, which suggests that there are no other underlying conditions that may worsen the prognosis.

Considering these factors, I believe that the patient's prognosis is more likely to be a survivor, with a good chance of maintaining her current level of function and quality of life for the next few years.

RANKING: 2. Sudden Cardiac Death

REASONING: While sudden cardiac death is always a risk for patients with heart failure and arrhythmias, I would rank this prognosis as less likely than a survivor. The patient's relatively young age, mild symptoms, and standard medications reduce the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death

REASONING: Pump failure death is a possible outcome for patients with heart failure and low LVEF. However, I would rank this prognosis as the least likely due to the patient's relatively young age, mild symptoms, and standard medications, which can help slow disease progression and improve symptoms. Additionally, the patient's LVEF of 28% is not extremely low, which may indicate a more favorable prognosis."
498,498,P0782,"Age: 77
Gender: Female 
Weight: 43 kg
Height: 146 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 43,6
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 11,5
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,12
Potassium (mEq/L): 4,09
LDL (mmol/L): 1,89
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 481.0
Protein (g/L): 80,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,44
Urea (mg/dL): 6,9
LVEF (%): 25.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely. 

RANKING: 1. Survivor
REASONING: The patient is 77 years old with a history of ischemic dilated cardiomyopathy, diabetes, and myocardial infarction. However, despite these risk factors, the patient is currently being managed with a comprehensive medication regimen, including beta blockers, ACE inhibitors, statins, and loop diuretics. The patient's blood pressure is well-controlled, and the ejection fraction (LVEF) is 25%, which, although low, is not the lowest possible value. The absence of severe electrolyte imbalances (e.g., low potassium) and a relatively normal creatinine level also suggest that the patient's renal function is not severely compromised. Furthermore, the patient's recent troponin level is within normal limits, indicating that there is no recent myocardial infarction. The patient's pro-BNP level is elevated, which is consistent with heart failure, but the patient's symptoms and physical examination (NYHA Class II) suggest that the heart failure is not severe. Considering these factors, the patient's overall prognosis is more favorable, making survivorship the most likely outcome.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 25% indicates severe left ventricular dysfunction, which is a significant risk factor for pump failure death. The patient's history of ischemic dilated cardiomyopathy and myocardial infarction also increases the risk of pump failure. However, the patient's current medication regimen and controlled blood pressure suggest that the patient is being managed effectively for heart failure. The patient's renal function is relatively preserved, which reduces the risk of uremic cardiomyopathy. The patient's recent troponin level is normal, indicating that there is no recent myocardial infarction. While pump failure is a significant risk, the patient's current management and relatively preserved renal function make it the second most likely outcome.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases the risk of sudden cardiac death. The patient's LVEF of 25% also increases the risk of arrhythmias, including ventricular tachycardia, which can lead to sudden cardiac death. However, the patient is being managed with amiodarone, which is a class III anti-arrhythmic medication that is effective in preventing sudden cardiac death in patients with ventricular arrhythmias. The patient's recent troponin level is normal, indicating that there is no recent myocardial infarction. While the patient's history and LVEF increase the risk of sudden cardiac death, the patient's current management with amiodarone and controlled blood pressure make it the least likely outcome."
499,499,P0783,"Age: 76
Gender: Female 
Weight: 84 kg
Height: 145 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 39,8
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,26
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 8,7
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 3,59
LDL (mmol/L): 3,15
Sodium (mEq/L): 140.0
Protein (g/L): 75,4
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,88
Urea (mg/dL): 10
LVEF (%): 59.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here is the ranking of the prognoses from most likely to least likely:

RANKING: Survivor

REASONING: The patient is a 76-year-old female with a history of hypertensive cardiomyopathy and hypertension. Her current NYHA Class II indicates that she has some limitations in her physical activity but is still able to perform everyday activities. Her blood pressure is well-controlled, and her current medications, including a calcium channel blocker, digoxin, loop diuretics, and an ACE inhibitor, suggest that her heart failure is being managed.

Her LVEF of 59% indicates that her heart is functioning at a moderate level, which is a relatively good indicator of cardiac function. The absence of significant troponin elevation and the normal ECG results further support the notion that her cardiac function is stable.

While her creatinine level is elevated, her urea level is within the normal range, which suggests that her renal function is not severely impaired. Her hemoglobin and potassium levels are also within normal limits, which reduces the risk of anemia and arrhythmias.

Considering these factors, the most likely prognosis for this patient is that she will survive for the next few years, with ongoing management of her hypertension and heart failure.

RANKING: Sudden Cardiac Death

REASONING: While the patient's LVEF of 59% is a concern, it is not low enough to indicate a high risk of sudden cardiac death. Her ECG results do not show any signs of ventricular tachycardia, ventricular extrasystoles, or other arrhythmias that could indicate a high risk of sudden cardiac death. Additionally, her medications, including digoxin and a calcium channel blocker, are not typically associated with an increased risk of sudden cardiac death.

RANKING: Pump Failure Death

REASONING: While the patient's LVEF of 59% indicates some impairment of cardiac function, it is not low enough to indicate a high risk of pump failure death. Her creatinine level is elevated, but her urea level is within the normal range, which suggests that her renal function is not severely impaired. Her hemoglobin and potassium levels are also within normal limits, which reduces the risk of anemia and arrhythmias. Additionally, her NYHA Class II indicates that she is still able to perform everyday activities, which suggests that her cardiac function is not severely impaired."
500,500,P0785,"Age: 72
Gender: Male 
Weight: 81 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 42,6
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,54
Creatinine (mmol/L): 130.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,84
Potassium (mEq/L): 3,29
LDL (mmol/L): 3,3
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 4250.0
Protein (g/L): 71,8
Troponin (ng/mL): 0,15
TSH (mIU/L): 2,92
Urea (mg/dL): 13,5
LVEF (%): 30.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor
 REASONING: The patient's current medical condition and treatment plan suggest a relatively stable and controlled state. The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, but the current ejection fraction (LVEF) is 30%, which is lower than normal but not extremely low. The patient is on a comprehensive medication regimen, including an angiotensin II receptor blocker, beta blockers, loop diuretics, spironolactone, and statins, which are standard treatments for heart failure and ischemic cardiomyopathy. The patient's blood pressure is well-controlled, and the lack of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG is a positive sign. The patient's Pro-BNP level is elevated, but not extremely high, which may indicate some degree of heart failure but not necessarily an extremely poor prognosis. Considering these factors, the patient's overall condition suggests a relatively stable and manageable disease state, making a survivor prognosis more likely.

RANKING: Sudden Cardiac Death
 REASONING: Sudden cardiac death is a possible but less likely outcome for this patient. The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which increases the risk of sudden cardiac death. However, the patient is on a comprehensive medication regimen, including beta blockers, which are known to reduce the risk of sudden cardiac death in patients with heart failure. The patient's LVEF is 30%, which is relatively low, but not extremely low, and the lack of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG suggests a lower risk of sudden cardiac death. The patient's Pro-BNP level is elevated, but not extremely high, which may indicate some degree of heart failure but not necessarily an extremely high risk of sudden cardiac death.

RANKING: Pump Failure Death
 REASONING: Pump failure death is the least likely outcome for this patient. The patient's LVEF is 30%, which is relatively low, but the patient is on a comprehensive medication regimen, including loop diuretics and spironolactone, which are standard treatments for heart failure. The patient's blood pressure is well-controlled, and the lack of signs of severe heart failure, such as severe anemia (Hemoglobin 133.0 g/L), severe renal impairment (Creatinine 130.0 mmol/L), or severe electrolyte imbalance (Potassium 3.29 mEq/L), suggests that the patient's heart failure is not in an advanced stage. The patient's Pro-BNP level is elevated, but not extremely high, which may indicate some degree of heart failure but not necessarily an extremely high risk of pump failure death."
501,501,P0786,"Age: 64
Gender: Female 
Weight: 71 kg
Height: 153 cm
NYHA Class: II
Blood Pressure: 150/70 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 43,1
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,67
Creatinine (mmol/L): 131.0
Gamma-glutamil transpeptidase (IU/L): 149
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,57
Potassium (mEq/L): 4,26
LDL (mmol/L): 3,66
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 614.0
Protein (g/L): 81,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,53
Urea (mg/dL): 9,9
LVEF (%): 45.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

Based on the provided patient data, I would rank the prognosis as a survivor for the next few years. Here's the reasoning behind this ranking:

1. Valvular cardiomyopathy: The patient has a history of valvular cardiomyopathy, which is a significant cardiac condition. However, the left ventricular ejection fraction (LVEF) is 45%, which is below the normal range but not extremely low. This suggests that the patient's heart is still functioning, albeit with some impairment.

2. NYHA Class II: The patient's New York Heart Association (NYHA) class is II, indicating that the patient experiences some limitation of physical activity but is still able to perform everyday activities. This suggests that the patient's cardiac condition is not severe enough to significantly impact daily life.

3. Medications: The patient is on a comprehensive medication regimen, including diabetes medication, an angiotensin II receptor blocker, loop diuretics, spironolactone, and statins. This suggests that the patient is receiving appropriate treatment for their cardiac and metabolic conditions.

4. ECG findings: The ECG shows ventricular extrasystole and paroxysmal supraventricular tachycardia (PSVT), but no ventricular tachycardia or bradycardia. This suggests that the patient's cardiac rhythm is relatively stable.

5. Blood work: The patient's blood work shows elevated creatinine and urea levels, indicating some renal impairment. However, the albumin and protein levels are within normal limits, suggesting that the patient's kidneys are not severely compromised.

6. Pro-BNP: The pro-B-type natriuretic peptide (pro-BNP) level is elevated at 614.0 ng/L, which suggests that the patient's heart is under strain. However, this is not extremely high, and the patient is receiving appropriate treatment.

Considering these factors, I believe that the patient's prognosis is most likely to be a survivor for the next few years. While the patient has significant cardiac and metabolic conditions, the patient's LVEF is not extremely low, and the patient is receiving comprehensive treatment. The patient's NYHA class is II, indicating that the patient is still able to perform everyday activities, and the ECG findings are relatively stable. Therefore, I rank the prognosis as a survivor.

RANKING: Sudden Cardiac Death (2nd)

REASONING: 

While the patient's cardiac condition is significant, the risk of sudden cardiac death is lower than the risk of pump failure death. The patient's LVEF is 45%, which is below the normal range, but not extremely low. The patient is receiving appropriate treatment, and the ECG findings are relatively stable. However, the patient's history of myocardial infarction and valvular cardiomyopathy increases the risk of sudden cardiac death.

RANKING: Pump Failure Death (3rd)

REASONING: 

While the patient's LVEF is 45%, which is below the normal range, the patient's NYHA class is II, indicating that the patient is still able to perform everyday activities. The patient's blood work shows elevated creatinine and urea levels, indicating some renal impairment, but the albumin and protein levels are within normal limits. The patient is receiving comprehensive treatment, including diuretics and spironolactone, which suggests that the patient's heart failure is being managed. Therefore, while the patient's risk of pump failure death is higher than the risk of sudden cardiac death, it is still less likely than the risk of pump failure death."
502,502,P0787,"Age: 74
Gender: Female 
Weight: 60 kg
Height: 142 cm
NYHA Class: II
Blood Pressure: 105/60 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 41,7
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,56
Potassium (mEq/L): 3,59
LDL (mmol/L): 3,34
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1069.0
Protein (g/L): 68,6
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,86
Urea (mg/dL): 8,3
LVEF (%): 55.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: Survivor

REASONING: 

This patient's prognosis can be evaluated based on her clinical presentation, laboratory findings, and echocardiographic data. The patient is 74 years old with a history of valvular cardiomyopathy and is classified as NYHA Class II, indicating some limitation of physical activity but no symptoms at rest. The patient's ejection fraction (LVEF) is 55%, which is within the normal range, but considering her age and valvular cardiomyopathy, it may indicate some degree of left ventricular dysfunction.

The patient's laboratory findings show elevated Pro-BNP (1069 ng/L), which is indicative of heart failure, but the levels are not extremely high. The liver enzymes (ALT, AST, GGT) are mildly elevated, which may suggest some degree of liver dysfunction, possibly related to her medications (e.g., amiodarone). The lipid profile shows high total cholesterol and LDL levels, which are a risk factor for cardiovascular disease. The patient's kidney function is relatively preserved, with a creatinine level of 79.0 mol/L.

The patient's ECG shows non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, which are concerning for arrhythmogenic potential. However, the patient is on amiodarone, which is an anti-arrhythmic medication, and digoxin, which may help control heart rate and rhythm.

Considering these factors, the patient's prognosis is likely to be a survivor. The patient's LVEF is relatively preserved, and her kidney function is well-preserved. The patient is on appropriate medications for her condition, and the ECG findings, although concerning, are not necessarily indicative of a high risk of sudden cardiac death.

The least likely prognosis is pump failure death because the patient's LVEF is within the normal range, and there is no evidence of severe left ventricular dysfunction.

The second least likely prognosis is sudden cardiac death. While the patient has arrhythmogenic ECG findings, the patient is on amiodarone, which is an anti-arrhythmic medication, and digoxin, which may help control heart rate and rhythm. The patient's overall clinical presentation does not suggest a high risk of sudden cardiac death.

Therefore, the order of likelihood is: Survivor (most likely), Pump failure death (second least likely), and Sudden cardiac death (least likely)."
503,503,P0789,"Age: 45
Gender: Male 
Weight: 88 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Hypertropic cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 6,47
Creatinine (mmol/L): 111.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,6
LDL (mmol/L): 4,24
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 35.0
Protein (g/L): 76
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,45
Urea (mg/dL): 8,32
LVEF (%): 58.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses for the next few years from most likely to least likely.

RANKING: 1. Survivor
 REASONING: The patient is 45 years old with a history of hypertrophic cardiomyopathy and hypertension, which are both significant risk factors for cardiovascular disease. However, the patient's left ventricular ejection fraction (LVEF) is 58%, which is within the normal range. This suggests that the patient's heart function is relatively preserved. The patient is also on beta blockers and an ACE inhibitor, which are standard treatments for heart failure and hypertension. Additionally, the patient's BNP level is 35 ng/L, which is within the normal range. While the patient has a history of ventricular extrasystole, there is no indication of sustained ventricular tachycardia or other high-risk arrhythmias. The patient's overall clinical presentation suggests that they are at moderate risk for cardiac events, but the presence of preserved LVEF and normal BNP levels make survival more likely.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of hypertrophic cardiomyopathy, which is a known risk factor for sudden cardiac death. However, the patient's LVEF is 58%, which is not extremely low, and the BNP level is normal. Additionally, there is no indication of sustained ventricular tachycardia or other high-risk arrhythmias on the ECG. While the patient's history of hypertrophic cardiomyopathy increases their risk for sudden cardiac death, the presence of preserved LVEF and normal BNP levels make this prognosis less likely than survivor.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF is 58%, which is within the normal range, and the BNP level is normal. This suggests that the patient's heart function is relatively preserved, and there is no indication of heart failure. The patient's NYHA class is III, which indicates some limitation of physical activity, but this is not necessarily indicative of pump failure. The patient's creatinine level is elevated, but this could be due to a variety of factors, including hypertension or other kidney disease. Overall, the patient's clinical presentation suggests that pump failure is the least likely prognosis."
504,504,P0791,"Age: 75
Gender: Male 
Weight: 85 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 125/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 45.0
AST or GOT (IU/L): 35.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 162.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4
LDL (mmol/L): 1,81
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2542.0
Protein (g/L): 70
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,2
Urea (mg/dL): 11,65
LVEF (%): 40.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

Given the patient's age and medical history, the prognosis is challenging to determine. However, considering the patient's current clinical status and laboratory results, I would rank the prognosis as follows:

1. Survivor: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure and mortality. However, the patient is currently on optimal medical therapy, including ACE inhibitors, beta-blockers (Digoxin), and statins, which have been shown to improve survival and reduce morbidity in patients with heart failure. The patient's LVEF is 40%, which is relatively low but not extremely low. The patient's NYHA class is II, indicating that the patient is experiencing some symptoms of heart failure but is still able to perform most daily activities. The patient's Pro-BNP level is elevated, but not extremely high, which may indicate some degree of heart failure but not severe. The patient's blood pressure is well-controlled, and the patient's kidney function is relatively preserved. The patient's glucose level is well-controlled, which is important for reducing the risk of cardiovascular events. The patient's medications, including spironolactone, are also beneficial for heart failure patients. Considering these factors, the patient has a relatively good prognosis and is likely to survive.

2. Pump failure death: The patient's LVEF is 40%, which is a significant risk factor for heart failure and mortality. The patient's Pro-BNP level is elevated, indicating some degree of heart failure. The patient's kidney function is relatively preserved, but the patient's creatinine level is slightly elevated, which may indicate some degree of kidney impairment. The patient's medications, including ACE inhibitors and beta-blockers, are beneficial for heart failure patients, but the patient's symptoms and laboratory results suggest that the patient is at risk for pump failure.

3. Sudden cardiac death: The patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of sudden cardiac death. The patient's LVEF is 40%, which is a significant risk factor for sudden cardiac death. The patient's Pro-BNP level is elevated, indicating some degree of heart failure, which may increase the risk of sudden cardiac death. The patient's medications, including beta-blockers and ACE inhibitors, are beneficial for reducing the risk of sudden cardiac death, but the patient's symptoms and laboratory results suggest that the patient is at risk. However, the patient's overall clinical status and laboratory results do not strongly suggest that sudden cardiac death is the most likely outcome.

In conclusion, considering the patient's current clinical status and laboratory results, I believe that the most likely outcome is survivor, followed by pump failure death, and then sudden cardiac death."
505,505,P0795,"Age: 73
Gender: Male 
Weight: 76 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 87/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 3,8
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 97
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,07
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1961.0
Protein (g/L): 74
T4 (ng/L): 17
TSH (mIU/L): 4,3
Urea (mg/dL): 6,32
LVEF (%): 25.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. However, please note that I will not predict the patient outcome as'survivor' as per the task. Instead, I will rank the three possible prognoses from most likely to least likely.

RANKING: 2
 REASONING: The patient is 73 years old with ischemic dilated cardiomyopathy and a low left ventricular ejection fraction (LVEF) of 25%. This indicates that the patient has significant cardiac dysfunction. The patient's blood pressure is low, which may be related to his cardiac condition or medication. His creatinine level is elevated, indicating some degree of renal impairment. The elevated Pro-BNP level further supports the presence of heart failure.

However, the patient is on optimal medical therapy with beta blockers, statins, and an ACE inhibitor, which are all evidence-based treatments for heart failure with reduced ejection fraction. The patient's NYHA class is II, which indicates that he is experiencing some symptoms of heart failure but is still able to perform most daily activities.

Considering these factors, the most likely prognosis is pump failure death, as the patient's cardiac function is severely impaired, and he has multiple risk factors for cardiac decompensation. However, the patient's current treatment regimen and relatively mild symptoms suggest that this outcome is not imminent.

RANKING: 3
 REASONING: The patient's low blood pressure, renal impairment, and elevated Pro-BNP level increase his risk for sudden cardiac death. However, the presence of a polymorphic ventricular extrasystole on the ECG is not a strong predictor of sudden cardiac death in this context. The patient's LVEF is low, but he is on optimal medical therapy, which reduces his risk for sudden cardiac death.

RANKING: 1
 REASONING: The patient's age, ischemic dilated cardiomyopathy, and low LVEF make him a high-risk candidate for sudden cardiac death. However, his current treatment regimen and relatively mild symptoms suggest that this outcome is less likely in the near future. The patient's overall clinical presentation and risk factors suggest that pump failure death is a more likely outcome in the next few years."
506,506,P0796,"Age: 61
Gender: Female 
Weight: 69 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 108/70 mmHg
Past Medical History: Other HF etiology, Dyslipemia, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,42
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,48
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 1614.0
Protein (g/L): 78
T4 (ng/L): 15
TSH (mIU/L): 3,01
Urea (mg/dL): 9,48
LVEF (%): 20.0
Medications: Beta Blockers, Digoxin, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely:

RANKING: 1. Survivor

REASONING: The patient is 61 years old, which is considered elderly, but not extremely old. Her NYHA Class II indicates that she has some limitations in physical activity but is still able to perform daily activities. Her blood pressure is within a relatively normal range, and she is on medications that are beneficial for her condition (beta blockers, digoxin, statins, and ACE inhibitor). Her LVEF is low at 20%, but she has been on medications that can help improve heart function. Her eGFR (estimated glomerular filtration rate) can be estimated from the creatinine level, which is 80.0 mmol/L. Assuming a female sex, age of 61, and weight of 69 kg, her eGFR is approximately 53 mL/min/1.73 m^2, which is close to the lower limit of normal. This suggests that her kidney function is not severely impaired. Her Pro-BNP level is elevated at 1614.0 ng/L, but this is not uncommon in patients with heart failure. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG is concerning, but the patient is on medications that can help manage these arrhythmias.

RANKING: 2. Pump failure death

REASONING: The patient's LVEF of 20% is significantly low, indicating severe left ventricular dysfunction. Her NYHA Class II classification suggests that she has some limitations in physical activity, which is consistent with heart failure symptoms. Her elevated Pro-BNP level and low albumin level suggest that she has some degree of fluid overload and possibly malnutrition. However, her kidney function is relatively preserved, and she is on medications that can help manage heart failure. While pump failure death is a possibility, the patient's relatively preserved kidney function and the fact that she is on medications that can help manage her condition make this prognosis less likely than sudden cardiac death.

RANKING: 3. Sudden cardiac death

REASONING: The patient's LVEF of 20% and the presence of non-sustained ventricular tachycardia on the ECG increase the risk of sudden cardiac death. However, the fact that she is on beta blockers, which can help prevent sudden cardiac death, and has a relatively preserved kidney function, makes this prognosis less likely. Additionally, the patient's age and sex are not particularly high-risk factors for sudden cardiac death. While sudden cardiac death is a possible outcome, it is the least likely of the three prognoses given the patient's relatively preserved kidney function and the fact that she is on medications that can help manage her condition."
507,507,P0797,"Age: 81
Gender: Male 
Weight: 77 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 6
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,85
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 1511.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 21
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,54
Urea (mg/dL): 8,9
LVEF (%): 20.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Please note that this is a medical prediction and not a definitive diagnosis.

RANKING: 1. Survivor
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure and mortality. However, the patient is currently on optimal medical therapy with an Angiotensin II Receptor Blocker, Loop Diuretics, Statins, and a Nitrovasodilator. The patient's NYHA Class II suggests that the patient's symptoms are manageable with medical therapy, and the patient is not in an advanced stage of heart failure. The LVEF of 20% is very low, indicating severe systolic dysfunction, but the patient's Pro-BNP level of 1511 ng/L is not extremely elevated, which might indicate some degree of compensation. The patient's creatinine level is elevated, but not excessively high, suggesting that renal function is not severely impaired. The patient's TSH level is within the normal range, which suggests that there is no indication of hypothyroidism, which can contribute to heart failure. The patient's Troponin level is slightly elevated, but not excessively high, which might indicate some degree of cardiac ischemia, but not acute myocardial infarction. Considering these factors, the patient's prognosis is more likely to be a survivor, as the patient is on optimal medical therapy and does not have any acute indicators of high risk.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The patient's LVEF of 20% is very low, indicating severe systolic dysfunction, which increases the risk of sudden cardiac death. The patient's Pro-BNP level of 1511 ng/L is not extremely elevated, but the presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG suggests that the patient may be at risk for arrhythmic events. However, the patient's NYHA Class II and the fact that the patient is on optimal medical therapy suggest that the patient's symptoms are manageable, and the risk of sudden cardiac death is not extremely high.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 20% is very low, indicating severe systolic dysfunction, which increases the risk of pump failure death. The patient's creatinine level of 79.0 mmol/L is elevated, suggesting that renal function is impaired, which can contribute to the progression of heart failure. The patient's albumin level of 38 g/L is low, indicating some degree of malnutrition, which can also contribute to the progression of heart failure. However, the patient's NYHA Class II and the fact that the patient is on optimal medical therapy suggest that the patient's symptoms are manageable, and the risk of pump failure death is not extremely high. The patient's overall clinical picture suggests that the patient is more likely to experience sudden cardiac death or remain a survivor rather than die from pump failure."
508,508,P0800,"Age: 72
Gender: Male 
Weight: 64 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 5,5
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 162.0
HDL (mmol/L): 1,13
Potassium (mEq/L): 4,38
LDL (mmol/L): 3,88
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 6088.0
Protein (g/L): 72,5
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,81
Urea (mg/dL): 6,8
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient is 72 years old with a history of valvular cardiomyopathy, which is a significant risk factor for heart failure. However, the patient is currently on optimal medical therapy with digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which suggests that the patient's symptoms are being well-managed. The patient's LVEF is 30%, which is below the normal range, but it's not extremely low. Additionally, the patient's BNP level is elevated at 6088.0 ng/L, which indicates heart failure with reduced ejection fraction (HFrEF), but the patient is being treated with evidence-based therapies. The patient's ECG shows non-sustained ventricular tachycardia, but this is not uncommon in patients with cardiomyopathy. Considering the patient's age and the fact that they are on optimal medical therapy, I believe the most likely outcome is survival.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's LVEF is 30%, which increases the risk of sudden cardiac death. Additionally, the patient's BNP level is elevated, and they have a history of valvular cardiomyopathy, which are both risk factors for sudden cardiac death. However, the patient is on optimal medical therapy, which reduces the risk of sudden cardiac death. The presence of non-sustained ventricular tachycardia on the ECG is a concern, but it's not a guarantee of sudden cardiac death. Given the patient's age and the fact that they are on optimal medical therapy, I believe sudden cardiac death is the second most likely outcome.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF is 30%, which indicates reduced cardiac function, but it's not extremely low. The patient is on optimal medical therapy, which should help to slow the progression of heart failure. While the patient's BNP level is elevated, indicating HFrEF, it's not extremely high, and the patient's symptoms are being well-managed with diuretics and ACE inhibitors. The patient's ECG shows non-sustained ventricular tachycardia, but this is not a direct indicator of pump failure. Considering the patient's age and the fact that they are on optimal medical therapy, I believe pump failure death is the least likely outcome.

Note: The patient's troponin level is 0.01 ng/mL, which is slightly elevated, but not significantly so. This could indicate some degree of cardiac stress or injury, but it's not a strong indicator of acute coronary syndrome or pump failure."
509,509,P0801,"Age: 72
Gender: Female 
Weight: 60 kg
Height: 154 cm
NYHA Class: III
Blood Pressure: 95/60 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 33,4
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,64
Creatinine (mmol/L): 137.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 10,9
Hemoglobin (g/L): 123.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 3,36
LDL (mmol/L): 2,14
Sodium (mEq/L): 129.0
Pro-BNP (ng/L): 2233.0
Protein (g/L): 71,3
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,81
Urea (mg/dL): 13,2
LVEF (%): 70.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: Based on the provided patient data, I would rank the prognosis as survivor for the following reasons:

1.  The patient is 72 years old, which is a high-risk age group for cardiovascular events, but her LVEF is 70%, indicating preserved left ventricular function, which is a positive prognostic sign.
2.  The patient has a history of valvular cardiomyopathy, diabetes, and hypertension, which are all risk factors for cardiovascular disease, but her current LVEF and lack of elevated troponin levels suggest that the disease may be well-managed.
3.  The patient's albumin level is slightly low (33.4 g/L), which may indicate malnutrition or liver disease, but it is not significantly low enough to suggest liver failure or severe malnutrition.
4.  The patient's creatinine level is elevated (137.0 mmol/L), which may indicate kidney disease, but it is not severely elevated, and the patient is on ACE inhibitors, which are beneficial for patients with kidney disease.
5.  The patient's Pro-BNP level is elevated (2233.0 ng/L), which suggests heart failure, but the level is not extremely high, and the patient is on medications that are commonly used to treat heart failure.
6.  The patient's ECG shows monomorphic ventricular extrasystoles, but no sustained ventricular tachycardia or other signs of severe cardiac arrhythmias.
7.  The patient's medications, including amiodarone, digoxin, loop diuretics, spironolactone, and ACE inhibitors, are commonly used to treat heart failure and arrhythmias, and are likely helping to manage the patient's condition.

While the patient's prognosis is not excellent, her overall condition is relatively stable, and her medications and LVEF suggest that she is being well-managed. Therefore, I would rank the prognosis as survivor.

Sudden cardiac death is less likely because the patient's LVEF is preserved, and she is on medications that are commonly used to prevent sudden cardiac death. Pump failure death is also less likely because the patient's LVEF is 70%, and she is on medications that are commonly used to treat heart failure."
510,510,P0802,"Age: 52
Gender: Male 
Weight: 61 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 105/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 37,9
ALT or GPT (IU/L): 49.0
AST or GOT (IU/L): 46.0
Total Cholesterol (mmol/L): 5,29
Creatinine (mmol/L): 126.0
Gamma-glutamil transpeptidase (IU/L): 75
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 120.0
HDL (mmol/L): 0,99
Potassium (mEq/L): 5,43
LDL (mmol/L): 3,78
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 11001.0
Protein (g/L): 68,4
Troponin (ng/mL): 0,09
TSH (mIU/L): 3,64
Urea (mg/dL): 13,5
LVEF (%): 21.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: Despite the patient's advanced heart failure (NYHA Class III), ischemic dilated cardiomyopathy, and previous myocardial infarction, there are several factors that suggest a favorable prognosis. The patient is on optimal medical therapy for heart failure, including beta blockers, loop diuretics, spironolactone, statins, ACE inhibitor, and nitrovasodilator. The patient's blood pressure is well-controlled, and there is no indication of significant electrolyte imbalances. The low troponin level (0.09 ng/mL) suggests that there is no acute myocardial infarction, and the LVEF of 21% is consistent with the patient's NYHA Class III classification.

However, the patient's elevated pro-BNP level (11001.0 ng/L) and non-sustained ventricular tachycardia on the ECG suggest that the patient is at risk for sudden cardiac death. Despite this, the patient's overall clinical picture and response to medical therapy suggest that the risk of sudden cardiac death is not the most likely outcome.

RANKING: Sudden Cardiac Death

REASONING: The patient's non-sustained ventricular tachycardia and elevated pro-BNP level suggest that the patient is at risk for sudden cardiac death. The patient's low LVEF and history of myocardial infarction also increase this risk. However, the patient's response to medical therapy and the absence of other high-risk features, such as a history of syncope or near-syncope, make sudden cardiac death less likely than pump failure death.

RANKING: Pump Failure Death

REASONING: Pump failure death is the least likely outcome in this patient. The patient's LVEF of 21% and NYHA Class III classification suggest that the patient has significant heart failure, but the patient's response to medical therapy and the absence of other high-risk features, such as renal failure or severe anemia, suggest that pump failure death is less likely than sudden cardiac death."
511,511,P0803,"Age: 48
Gender: Male 
Weight: 70 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 105/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45,7
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 6,69
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 194
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,08
Potassium (mEq/L): 4
LDL (mmol/L): 5,11
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 2954.0
Protein (g/L): 77,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,45
Urea (mg/dL): 5,2
LVEF (%): 17.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: Based on the provided patient data, I would rank the prognosis as Survivor. Here's the reasoning behind this decision:

1.  The patient's age (48) and gender (male) are relatively young for a patient with ischemic dilated cardiomyopathy, which suggests that the disease progression might be slower.
2.  The patient's LVEF (Left Ventricular Ejection Fraction) of 17% is very low, indicating significant heart failure, but it's not the lowest value I've seen. Patients with LVEF > 10-15% can still have a good prognosis with optimal medical therapy.
3.  The patient is on a comprehensive treatment regimen, including beta blockers, loop diuretics, spironolactone, statins, ACE inhibitors, and nitrovasodilators, which is essential for managing heart failure and preventing further cardiac damage.
4.  The patient's blood pressure (105/70 mmHg) is well-controlled, which is beneficial for reducing cardiac workload and minimizing further cardiac damage.
5.  The patient's serum creatinine (94.0 mol/L) is within the normal range, indicating that renal function is preserved, which is a good prognostic sign.
6.  The patient's troponin level (0.01 ng/mL) is low, suggesting that there is no ongoing myocardial infarction or acute cardiac damage.
7.  The patient's BNP (Brain Natriuretic Peptide) level (2954.0 ng/L) is elevated, which is consistent with heart failure, but it's not the highest value I've seen, and it's not increasing rapidly.
8.  The patient's ECG shows non-sustained ventricular tachycardia (VT), which is concerning, but it's not a life-threatening arrhythmia at this point.

Considering these factors, I would rank the prognosis as Survivor, with a good chance of improved or stable cardiac function with continued optimal medical therapy and lifestyle modifications. However, the patient should be closely monitored for any signs of disease progression or complications.

Sudden Cardiac Death (SCD) and Pump Failure Death are less likely, but still possible, given the patient's history of ischemic dilated cardiomyopathy and low LVEF. However, the patient's current treatment regimen and relatively preserved renal function make these outcomes less likely in the short term.

RANKING: Sudden Cardiac Death (SCD)

REASONING: This prognosis is less likely due to the patient's age, relatively well-controlled blood pressure, and comprehensive treatment regimen. However, the patient's low LVEF and history of ischemic dilated cardiomyopathy increase the risk of SCD.

RANKING: Pump Failure Death

REASONING: This prognosis is the least likely, given the patient's preserved renal function, relatively low BNP level, and comprehensive treatment regimen. While the patient's LVEF is very low, it's not the lowest value I've seen, and the patient is on optimal medical therapy to manage heart failure."
512,512,P0805,"Age: 60
Gender: Female 
Weight: 77 kg
Height: 148 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,83
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,35
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,3
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 227.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 15
Troponin (ng/mL): 3,4
TSH (mIU/L): 1,63
Urea (mg/dL): 25,1
LVEF (%): 40.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: Survivor
 REASONING: 

This patient has a complex medical history with multiple comorbidities, including ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction. However, despite these risk factors, several factors suggest a more favorable prognosis. 

1.  The patient is on a comprehensive treatment regimen, including medications that target her heart failure, hypertension, and diabetes. This suggests that her condition is being actively managed.
2.  The patient's blood pressure is well-controlled at 110/70 mmHg, which is within a normal range, reducing the risk of further cardiac damage.
3.  The patient's hemoglobin level is within a normal range, indicating that her kidneys are functioning relatively well, which is crucial for patients with heart failure.
4.  Her LVEF is 40%, which is below the normal range but not extremely low. While it indicates some degree of heart dysfunction, it is not severe enough to suggest imminent pump failure.
5.  The patient's troponin level is elevated at 3.4 ng/mL, indicating some degree of cardiac damage, but not to the extent that would suggest a high risk of sudden cardiac death.
6.  The patient's BNP level is elevated at 227 ng/L, but this is not unusually high for someone with heart failure, and it may be related to her underlying condition rather than a sign of impending doom.
7.  The patient's TSH level is within a normal range, which suggests that her thyroid function is not contributing to her cardiac condition.
8.  The patient's ECG shows some abnormalities, including ventricular extrasystoles, but no signs of sustained ventricular tachycardia or bradycardia.

Considering these factors, the patient's overall prognosis is more likely to be a survivor, as her condition is being actively managed, and she does not exhibit any extreme risk factors for sudden cardiac death or pump failure. However, close monitoring and follow-up will be necessary to adjust her treatment plan as needed and prevent further cardiac deterioration."
513,513,P0808,"Age: 44
Gender: Male 
Weight: 86 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 49.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,67
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,47
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 497.0
Protein (g/L): 74
T3 (pg/dL): 0,06
T4 (ng/L): 15
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,24
Urea (mg/dL): 5,83
LVEF (%): 19.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor

REASONING: Given the patient's data, I would rank survivor as the most likely prognosis for the next few years. The patient is 44 years old, which is relatively young for a patient with idiopathic dilated cardiomyopathy. The patient is on a comprehensive treatment regimen, including beta blockers, digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are all standard treatments for heart failure with reduced ejection fraction (HFrEF). The patient's NYHA Class II indicates that the patient is experiencing some symptoms of heart failure, but is still able to perform most daily activities without significant limitation. The patient's LVEF of 19% is low, but it is not the lowest possible value, and the patient is not in cardiac arrest or cardiogenic shock.

Additionally, the patient's laboratory results show that the liver enzymes (AST and ALT) are within normal limits, which suggests that the patient does not have significant liver dysfunction, which can be a contraindication for certain treatments. The patient's potassium level is within the normal range, which is important for patients on digoxin therapy. The patient's troponin level is low, indicating that there is no acute myocardial infarction. The patient's TSH level is within the normal range, which suggests that the patient does not have hypothyroidism, which can exacerbate heart failure.

The patient's Pro-BNP level is elevated, which is consistent with heart failure, but it is not the highest possible value, and the patient is on beta blockers and ACE inhibitors, which can help reduce BNP levels. The patient's creatinine level is elevated, indicating some degree of renal dysfunction, but it is not the highest possible value, and the patient is on a diuretic, which can help manage fluid overload.

Given these factors, I would rank survivor as the most likely prognosis for the patient. However, it is essential to continue monitoring the patient's condition closely and adjust the treatment plan as needed to optimize the patient's outcomes.

RANKING: 2. Sudden cardiac death

REASONING: Sudden cardiac death is the second most likely prognosis for the patient. The patient has a history of idiopathic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The patient's LVEF of 19% is low, which increases the risk of sudden cardiac death. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a marker of increased risk of sudden cardiac death.

However, the patient is on beta blockers and an ACE inhibitor, which can help reduce the risk of sudden cardiac death by reducing the risk of arrhythmias. The patient's troponin level is low, indicating that there is no acute myocardial infarction, which can also contribute to sudden cardiac death.

RANKING: 3. Pump failure death

REASONING: Pump failure death is the least likely prognosis for the patient. The patient is on a comprehensive treatment regimen, including beta blockers, digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor, which can help manage heart failure symptoms and slow disease progression. The patient's LVEF of 19% is low, but it is not the lowest possible value, and the patient is not in cardiac arrest or cardiogenic shock. The patient's creatinine level is elevated, indicating some degree of renal dysfunction, but it is not the highest possible value, and the patient is on a diuretic, which can help manage fluid overload.

Additionally, the patient's NYHA Class II indicates that the patient is experiencing some symptoms of heart failure, but is still able to perform most daily activities without significant limitation. The patient's laboratory results show that the liver enzymes (AST and ALT) are within normal limits, which suggests that the patient does not have significant liver dysfunction, which can be a contraindication for certain treatments.

Overall, while the patient has a history of idiopathic dilated cardiomyopathy and a low LVEF, the comprehensive treatment regimen and the patient's relatively young age make pump failure death the least likely prognosis."
514,514,P0810,"Age: 62
Gender: Female 
Weight: 78 kg
Height: 161 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4
LDL (mmol/L): 2,51
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 335.0
Protein (g/L): 68
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,47
Urea (mg/dL): 6,49
LVEF (%): 30.0
Medications: Beta Blockers, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. I will rank the possible prognoses from most likely to least likely.

RANKING: Survivor

REASONING: Despite the patient's advanced heart failure symptoms (NYHA Class III) and reduced left ventricular ejection fraction (LVEF 30%), several factors suggest a relatively favorable prognosis. 

1.  The patient is on optimal medical therapy, including beta blockers and an ACE inhibitor, which are cornerstone treatments for heart failure.
2.  The absence of sustained ventricular tachycardia or other high-risk ECG findings reduces the likelihood of sudden cardiac death.
3.  The patient's Troponin level is low (0.01 ng/mL), indicating minimal cardiac damage.
4.  The Pro-BNP level is elevated (335.0 ng/L), but within a range that is often seen in patients with heart failure.
5.  The patient's albumin level is within the normal range (40 g/L), which may indicate preserved renal function.
6.  The patient's hemoglobin level is within the normal range (128.0 g/L), which may suggest adequate oxygen delivery to tissues.
7.  The patient's TSH level is within the normal range (1.47 mIU/L), which may indicate preserved thyroid function, as thyroid dysfunction can exacerbate heart failure.

While the patient has a reduced LVEF and is experiencing symptoms of heart failure, the combination of optimal medical therapy, absence of high-risk ECG findings, and preserved laboratory values suggests a relatively favorable prognosis. However, close monitoring and regular follow-up appointments are essential to adjust the treatment plan as needed and prevent potential complications.

RANKING: Sudden cardiac death

REASONING: This prognosis is less likely due to the patient's relatively stable ECG findings, absence of high-risk features such as sustained ventricular tachycardia, and the presence of optimal medical therapy.

RANKING: Pump failure death

REASONING: This prognosis is the least likely due to the patient's relatively preserved renal function (albumin level and urea level), adequate oxygen delivery (hemoglobin level), and the presence of optimal medical therapy, which may slow disease progression."
515,515,P0811,"Age: 65
Gender: Male 
Weight: 57 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,8
LDL (mmol/L): 3,47
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 264.0
Protein (g/L): 78
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,62
Urea (mg/dL): 9,65
LVEF (%): 25.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

Based on the provided patient data, I would rank the prognosis as a survivor for the next few years. Here's the reasoning behind this ranking:

1. Age and NYHA Class: The patient is 65 years old and has a NYHA Class II, indicating that he has some limitations in his physical activity but is still able to perform daily activities. This suggests that the patient is not in the most severe stage of heart failure.

2. Medications: The patient is on beta blockers, spironolactone, statins, and an ACE inhibitor, which are all evidence-based treatments for heart failure with reduced ejection fraction (HFrEF) and ischemic dilated cardiomyopathy. These medications are likely to help manage the patient's symptoms and slow disease progression.

3. LVEF: Although the patient's LVEF is only 25%, it's not the lowest value I've seen. Some patients with LVEF as low as 20-30% can still have a relatively stable clinical course.

4. ECG findings: The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG suggests that the patient is not at an increased risk of sudden cardiac death.

5. Other lab values: The patient's creatinine level is slightly elevated, but it's not severely abnormal. His potassium level is also within a relatively normal range. The patient's glucose level is slightly elevated, but it's not a major concern.

6. Pro-BNP: The patient's Pro-BNP level is elevated at 264.0 ng/L, but it's not the highest value I've seen. Elevated Pro-BNP levels are associated with increased risk of heart failure hospitalization and mortality, but the patient's overall clinical picture suggests that he is still relatively stable.

Considering these factors, I would rank the prognosis as a survivor for the next few years. However, it's essential to continue monitoring the patient's condition closely and adjust his treatment plan as needed to prevent disease progression and minimize the risk of complications."
516,516,P0812,"Age: 77
Gender: Female 
Weight: 100 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 35
ALT or GPT (IU/L): 47.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 116.0
HDL (mmol/L): 1,91
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,1
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1659.0
Protein (g/L): 60
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 6,83
Urea (mg/dL): 4,16
LVEF (%): 52.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: Survivor

REASONING: 

Based on the provided patient data, I would rank the prognosis as survivor for the following reasons:

1. Hypertensive cardiomyopathy and NYHA Class III: The patient has a history of hypertensive cardiomyopathy and is classified as NYHA Class III, indicating moderate to severe symptoms of heart failure. However, with appropriate treatment and management, patients with hypertensive cardiomyopathy can have a relatively good prognosis.
2. Medications: The patient is on a combination of Angiotensin II Receptor Blocker, Beta Blockers, and Loop Diuretics, which are standard treatments for heart failure and hypertension. These medications can help manage symptoms, slow disease progression, and improve survival.
3. LVEF 52%: Although the left ventricular ejection fraction (LVEF) is slightly below the normal range (50-70%), it is not severely impaired, indicating that the heart is still functioning relatively well.
4. Low Troponin levels: The patient's troponin levels are within the normal range, suggesting that there is no acute myocardial infarction or significant cardiac damage.
5. Pro-BNP levels: The patient's Pro-BNP levels are elevated (1659.0 ng/L), indicating heart failure, but not excessively high, suggesting that the patient's heart failure is being managed.

Considering these factors, the patient's prognosis is likely to be a survivor, with a good chance of managing their heart failure and hypertension with ongoing treatment and lifestyle modifications.

RANKING: Sudden Cardiac Death

REASONING: 

This prognosis is less likely due to the following reasons:

1. No acute myocardial infarction: The patient's troponin levels are normal, indicating no recent myocardial infarction, which is a common cause of sudden cardiac death.
2. No ventricular tachycardia or sustained ventricular arrhythmias: The patient's ECG does not show any signs of ventricular tachycardia or sustained ventricular arrhythmias, which are risk factors for sudden cardiac death.
3. Pro-BNP levels are not extremely high: While the Pro-BNP levels are elevated, they are not excessively high, suggesting that the patient's heart failure is not severe.

However, this prognosis is still possible due to the patient's age, NYHA Class III, and hypertensive cardiomyopathy.

RANKING: Pump Failure Death

REASONING: 

This prognosis is the least likely due to the following reasons:

1. LVEF 52%: Although the LVEF is slightly below the normal range, it is not severely impaired, indicating that the heart is still functioning relatively well.
2. No signs of severe heart failure: The patient's Pro-BNP levels, although elevated, are not excessively high, suggesting that the patient's heart failure is not severe.
3. Medications are in place: The patient is on standard treatments for heart failure and hypertension, which can help manage symptoms and slow disease progression.

While pump failure death is a possibility in patients with heart failure, the patient's current LVEF and Pro-BNP levels suggest that this prognosis is less likely."
517,517,P0813,"Age: 67
Gender: Male 
Weight: 65 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 150/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 100
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4
LDL (mmol/L): 2,12
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1270.0
Protein (g/L): 74
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,14
Urea (mg/dL): 8,32
LVEF (%): 38.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here are the prognoses for the next few years, ordered from most likely to least likely:

RANKING: Survivor
REASONING: The patient has a moderate to severe left ventricular dysfunction (LVEF 38%), which is a significant risk factor for adverse cardiac outcomes. However, the patient is already on optimal medical therapy, including beta blockers, ACE inhibitors, statins, and a nitrovasodilator, which are all evidence-based treatments for heart failure and ischemic cardiomyopathy. The patient's Pro-BNP level is elevated at 1270 ng/L, which indicates a high risk of heart failure hospitalization, but the patient's current medication regimen and the absence of other high-risk features (e.g., low ejection fraction <20-25%, severe symptoms, or recent hospitalization for heart failure) suggest that the patient is likely to survive with continued medical therapy and close monitoring.

RANKING: Pump Failure Death
REASONING: The patient's LVEF of 38% and elevated Pro-BNP level suggest a high risk of pump failure. However, the patient's current medication regimen and the absence of other high-risk features (e.g., severe symptoms, recent hospitalization for heart failure, or low ejection fraction <20-25%) make pump failure death less likely than sudden cardiac death. The patient's NYHA Class II classification indicates that the patient has mild to moderate symptoms, which is a positive prognostic sign.

RANKING: Sudden Cardiac Death
REASONING: Sudden cardiac death is a major concern in patients with ischemic cardiomyopathy and a low ejection fraction. The patient's LVEF of 38% and the presence of polymorphic ventricular extrasystoles on the ECG increase the risk of sudden cardiac death. However, the patient's current medication regimen, including beta blockers and an ACE inhibitor, is likely to reduce the risk of sudden cardiac death. Additionally, the patient's low Troponin level (0.01 ng/mL) suggests that the patient is not experiencing acute coronary syndrome, which further reduces the risk of sudden cardiac death. Overall, while sudden cardiac death is a possible outcome, it is less likely than pump failure death or survivor due to the patient's current medical therapy and the absence of other high-risk features."
518,518,P0814,"Age: 72
Gender: Female 
Weight: 90 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 54.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,13
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,76
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 453.0
Protein (g/L): 75
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,919
Urea (mg/dL): 5,16
LVEF (%): 28.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses for the next few years as follows:

RANKING: 1. Survivor
REASONING: The patient is 72 years old with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension. Despite these comorbidities, she is on a comprehensive treatment regimen that includes medications for diabetes, heart failure, and high blood pressure. Her current medications, such as beta blockers, loop diuretics, and spironolactone, are commonly used to manage heart failure symptoms and improve prognosis. Her LVEF of 28% indicates reduced left ventricular function, but it is not the lowest value, and she does not have any signs of severe hemodynamic instability. Her BNP level of 453 ng/L is elevated, indicating some level of heart failure, but it is not extremely high. The absence of ventricular tachycardia and the presence of only polymorphic ventricular extrasystoles on the ECG suggest that the patient does not have severe arrhythmogenic potential. Overall, considering the patient's age, comorbidities, and current treatment, a survivor prognosis seems most likely.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 28% indicates reduced left ventricular function, which is a risk factor for heart failure progression and pump failure. Her elevated BNP level and the presence of dyspnea (implied by NYHA Class II) suggest ongoing heart failure symptoms. However, her current treatment regimen is comprehensive, and she does not have any signs of severe hemodynamic instability or acute decompensation. The risk of pump failure death is present, but it is not the most likely outcome given her current treatment and the absence of severe symptoms.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's LVEF of 28% and elevated BNP level suggest some level of heart failure, but her ECG does not show any signs of severe arrhythmogenic potential (e.g., ventricular tachycardia). Her medications, including beta blockers, are known to reduce the risk of sudden cardiac death. While the patient has a history of ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death, the absence of other high-risk factors (e.g., non-sustained ventricular tachycardia, low LVEF, or severe electrolyte imbalances) makes this outcome less likely."
519,519,P0815,"Age: 38
Gender: Female 
Weight: 103 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,34
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 59
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 121.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,01
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 96.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,59
Urea (mg/dL): 6,32
LVEF (%): 56.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient is 38 years old and has a relatively young age, which is in favor of a better prognosis. The patient has a history of hypertensive cardiomyopathy and hypertension, but is being managed with beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which suggests that the condition is being well-controlled. The LVEF is 56%, which is below the normal range but not severely impaired. The patient also has a relatively normal creatinine level and a low pro-BNP level, indicating that the heart is functioning relatively well despite the cardiomyopathy. The absence of significant electrolyte imbalances, such as low potassium, and a normal TSH level suggest that the patient's thyroid function is not contributing to the cardiomyopathy. The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, but these findings are not necessarily indicative of a poor prognosis in this patient, especially given the well-controlled blood pressure and the absence of other risk factors. Overall, the patient's current treatment regimen and relatively stable cardiac function suggest a favorable prognosis.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF is 56%, which is below the normal range, indicating some degree of left ventricular dysfunction. However, the patient is being managed with medications that are known to improve cardiac function and reduce morbidity and mortality in patients with heart failure. The patient's creatinine level is within normal limits, suggesting that the kidneys are functioning well, and the low pro-BNP level suggests that the heart is functioning relatively well despite the cardiomyopathy. While the patient has a history of hypertensive cardiomyopathy, which can lead to pump failure, the patient's current treatment regimen and relatively stable cardiac function suggest that the risk of pump failure death is lower than the risk of sudden cardiac death.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are risk factors for sudden cardiac death. However, the patient's LVEF is 56%, which is not severely impaired, and the patient is being managed with medications that are known to reduce the risk of sudden cardiac death. The patient's creatinine level is within normal limits, suggesting that the kidneys are functioning well, and the low pro-BNP level suggests that the heart is functioning relatively well despite the cardiomyopathy. While the patient's history of hypertensive cardiomyopathy and the ECG findings suggest a risk of sudden cardiac death, the patient's current treatment regimen and relatively stable cardiac function suggest that this risk is lower than the risk of pump failure death."
520,520,P0816,"Age: 76
Gender: Male 
Weight: 60 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 37
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,3
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 6,5
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,65
Sodium (mEq/L): 143.0
Protein (g/L): 68
T4 (ng/L): 19
Troponin (ng/mL): 0,5
TSH (mIU/L): 0,46
Urea (mg/dL): 6,1
LVEF (%): 15.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely. Please note that this is a prediction based on the information given and should not be taken as a definitive medical diagnosis or treatment plan.

RANKING: 1. Survivor
REASONING: The patient's current medication regimen, including Digoxin, Loop Diuretics, ACE Inhibitor, and Nitrovasodilator, suggests that the patient is being managed for heart failure and may be experiencing some level of control over their condition. The patient's LVEF of 15% is very low, indicating severe left ventricular dysfunction, but they are still alive, which indicates that they are currently tolerating their condition. Additionally, the patient's recent troponin level is within normal limits, suggesting that they are not experiencing acute myocardial infarction. While the patient's NYHA Class II classification indicates some level of limitation in physical activity, it is not as severe as Class III or IV, which would suggest a higher risk of mortality. Therefore, based on these factors, a survivor prognosis is the most likely outcome.

RANKING: 2. Pump failure death
REASONING: The patient's LVEF of 15% and history of ischemic dilated cardiomyopathy indicate that they are at high risk for heart failure progression and potential pump failure. However, the patient's current medication regimen and the absence of acute myocardial infarction suggest that they may be experiencing some level of control over their condition. Additionally, the patient's recent troponin level is within normal limits, which reduces the likelihood of acute cardiac decompensation. Therefore, while pump failure is a possible outcome, it is less likely than a survivor prognosis.

RANKING: 3. Sudden cardiac death
REASONING: The patient's history of myocardial infarction, ischemic dilated cardiomyopathy, and non-sustained ventricular tachycardia on ECG suggest that they are at risk for sudden cardiac death. However, the patient's current medication regimen, including an ACE inhibitor, which is known to reduce the risk of sudden cardiac death, and the absence of acute myocardial infarction suggest that the risk may be mitigated. Additionally, the patient's recent troponin level is within normal limits, which reduces the likelihood of acute cardiac decompensation. Therefore, while sudden cardiac death is a possible outcome, it is the least likely of the three options."
521,521,P0817,"Age: 66
Gender: Male 
Weight: 66 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Other HF etiology, Peripheral vascular disease
Albumin (g/L): 46
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 5,53
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 75
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 163.0
HDL (mmol/L): 1,71
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,26
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 4111.0
Protein (g/L): 78
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,02
TSH (mIU/L): 8,58
Urea (mg/dL): 10,65
LVEF (%): 25.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",survivor,"RANKING: 1

REASONING: 

Based on the provided patient data, I would rank the prognosis as survivor. Here's the reasoning behind this choice:

1.  Age and NYHA Class II: The patient is 66 years old and has a New York Heart Association (NYHA) Class II, indicating that the patient has mild to moderate symptoms of heart failure. This suggests that the patient's heart condition is manageable with current treatment, and the patient is not at an advanced stage of heart failure.

2.  Medications: The patient is on a combination of medications, including ACE Inhibitor, Digoxin, Loop Diuretics, and Spironolactone, which are commonly used to manage heart failure and hypertension. This indicates that the patient is receiving appropriate treatment for their condition.

3.  ECG Impression: The ECG shows a first-degree atrioventricular block (AVB), which is a relatively benign condition. The absence of ventricular tachycardia and non-sustained ventricular tachycardia suggests that the patient is not at high risk for sudden cardiac death.

4.  LVEF: The left ventricular ejection fraction (LVEF) is 25%, which is low but not extremely low. While a low LVEF is a risk factor for heart failure, an LVEF of 25% is still within the range that can be managed with medical therapy.

5.  Pro-BNP: The Pro-BNP level is elevated at 4111.0 ng/L, which suggests that the patient has some degree of heart failure. However, this level is not extremely high, and the patient is already on medications that help reduce BNP levels.

6.  Other factors: The patient's weight and height are within a relatively normal range, and the blood pressure is well-controlled. The patient's lipid profile shows a high total cholesterol and LDL, but the HDL is within a relatively normal range.

Considering these factors, the patient's prognosis is likely to be a survivor, with a focus on continued management and monitoring of their heart condition to prevent progression of heart failure.

RANKING: 2

REASONING: 

Sudden cardiac death is less likely than survivor due to the following reasons:

*   The patient's ECG shows a first-degree AVB, which is a relatively benign condition.
*   The patient is on medications that help manage heart failure and reduce the risk of sudden cardiac death.
*   The patient's LVEF is low but not extremely low, and the patient is receiving treatment to manage heart failure.

However, the patient's low LVEF and elevated Pro-BNP level do suggest that the patient is at some risk for sudden cardiac death.

RANKING: 3

REASONING: 

Pump failure death is the least likely prognosis due to the following reasons:

*   The patient's NYHA Class II indicates that the patient has mild to moderate symptoms of heart failure, which suggests that the patient's heart condition is manageable with current treatment.
*   The patient is on medications that help manage heart failure and reduce the risk of pump failure.
*   The patient's LVEF is low but not extremely low, and the patient is receiving treatment to manage heart failure.

However, the patient's elevated Pro-BNP level and low LVEF do suggest that the patient is at some risk for pump failure."
522,522,P0818,"Age: 50
Gender: Male 
Weight: 60 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 49
ALT or GPT (IU/L): 44.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 138.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 179.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,28
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 42.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,46
Urea (mg/dL): 9,48
LVEF (%): 35.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. However, please note that this is a hypothetical prediction and should not be used for actual clinical decision-making without a thorough evaluation and discussion with a healthcare professional.

RANKING: 1. Survivor
 REASONING: The patient has a history of enolic dilated cardiomyopathy, which indicates a significant reduction in left ventricular ejection fraction (LVEF) to 35%. However, the patient is currently receiving optimal medical therapy, including beta blockers, digoxin, loop diuretics, statins, and an ACE inhibitor, which are all evidence-based treatments for heart failure with reduced ejection fraction (HFrEF). The patient's blood pressure is well-controlled, and there are no signs of severe electrolyte imbalances or acute kidney injury. The pro-BNP level is mildly elevated, which may indicate some degree of heart failure, but it is not excessively high. The patient's TSH level is within the normal range, which reduces the likelihood of thyroid-related cardiomyopathy. The patient's LVEF is relatively stable at 35%, and the absence of paroxysmal supraventricular tachyarrhythmias and bradycardia suggests that the patient's heart rate and rhythm are relatively stable. While the patient has non-sustained ventricular tachycardia, this is a common finding in patients with HFrEF and does not necessarily indicate a poor prognosis. Overall, the patient's current medical therapy and the absence of severe symptoms or complications make a survivor prognosis the most likely outcome.

RANKING: 2. Sudden Cardiac Death
 REASONING: Sudden cardiac death (SCD) is a potential risk in patients with HFrEF, particularly those with a history of non-sustained ventricular tachycardia. However, the patient's current medical therapy, including beta blockers, which are known to reduce the risk of SCD, suggests that the risk of SCD may be mitigated. The patient's LVEF is relatively stable, and there are no signs of severe electrolyte imbalances or acute kidney injury, which can increase the risk of SCD. While the patient's TSH level is within the normal range, thyroid-related cardiomyopathy is still a potential risk, and the patient's T3 level is slightly low, which may indicate some degree of thyroid dysfunction. However, the patient's T4 level is within the normal range, and the TSH level is not excessively high, which reduces the likelihood of thyroid-related cardiomyopathy. Overall, while the patient is at risk for SCD, the current medical therapy and the absence of severe symptoms or complications make it a less likely outcome compared to survivor.

RANKING: 3. Pump Failure Death
 REASONING: Pump failure death is a potential outcome in patients with HFrEF, particularly those with a history of enolic dilated cardiomyopathy. However, the patient's current medical therapy, including loop diuretics and ACE inhibitors, suggests that the patient's heart failure is being well-managed. The patient's LVEF is relatively stable at 35%, and there are no signs of severe symptoms or complications, such as acute kidney injury or severe electrolyte imbalances. The patient's pro-BNP level is mildly elevated, but not excessively high, which may indicate some degree of heart failure, but not necessarily pump failure. The patient's TSH level is within the normal range, which reduces the likelihood of thyroid-related cardiomyopathy. Overall, while pump failure death is a potential risk in patients with HFrEF, the current medical therapy and the absence of severe symptoms or complications make it the least likely outcome."
523,523,P0819,"Age: 65
Gender: Male 
Weight: 76 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 105/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 68.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,13
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 6
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,84
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 199.0
Protein (g/L): 64
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,69
Urea (mg/dL): 5,49
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's my prognosis for the next few years, ranking the possible outcomes from most likely to least likely:

RANKING: Survivor

REASONING: The patient is 65 years old with a history of hypertensive cardiomyopathy and hypertension, which is a significant risk factor for heart failure. However, the patient is currently on optimal medical therapy with beta blockers, spironolactone, and an ACE inhibitor, which is beneficial for managing heart failure symptoms and slowing disease progression. The patient's LVEF (Left Ventricular Ejection Fraction) is 35%, which is low but not extremely low. The presence of monomorphic ventricular extrasystoles on the ECG is a common finding in patients with heart failure, but it does not necessarily indicate a high risk of sudden cardiac death. The patient's Pro-BNP level is elevated at 199 ng/L, but it is not extremely high, which suggests that the patient is not in acute heart failure. The patient's hemoglobin and sodium levels are within normal limits, which is a good sign. The patient's TSH level is also within normal limits, indicating that there is no apparent thyroid dysfunction contributing to the patient's heart condition. Overall, while the patient has a history of heart disease and is at risk for further cardiac events, the patient's current medical therapy and relatively stable laboratory values suggest that the most likely outcome is that the patient will survive for the next few years.

RANKING: Pump Failure Death

REASONING: The patient's LVEF is 35%, which is below the normal range (50-70%). This indicates that the patient has some degree of systolic dysfunction, which increases the risk of pump failure. The patient's elevated Pro-BNP level and history of heart failure also increase the risk of pump failure. However, the patient's current medical therapy and relatively stable laboratory values suggest that the risk of pump failure is not extremely high.

RANKING: Sudden Cardiac Death

REASONING: The patient's ECG shows monomorphic ventricular extrasystoles, which can be a marker of increased risk of sudden cardiac death. However, the patient does not have any other high-risk features for sudden cardiac death, such as a history of ventricular tachycardia or a very low LVEF. The patient's Pro-BNP level is elevated, but not extremely high, which suggests that the patient is not in acute heart failure. The patient's hemoglobin and sodium levels are within normal limits, which is a good sign. Overall, while the patient has some risk factors for sudden cardiac death, the patient's current medical therapy and relatively stable laboratory values suggest that this outcome is less likely than the other two options."
524,524,P0820,"Age: 70
Gender: Male 
Weight: 75 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 134/61 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,35
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1017.0
Protein (g/L): 73
T4 (ng/L): 18
Troponin (ng/mL): 0,04
TSH (mIU/L): 4,22
Urea (mg/dL): 11,82
LVEF (%): 15.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Loop Diuretics, Statins, Hydralazine, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. I will order the three possible prognoses from most likely to least likely.

RANKING: 1. Sudden Cardiac Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which significantly increases the risk of sudden cardiac death. The patient's LVEF of 15% is extremely low, indicating severe left ventricular dysfunction. The presence of polymorphic ventricular extrasystoles on the ECG further increases the risk of arrhythmias and sudden cardiac death. The patient's NYHA Class III indicates severe symptoms of heart failure, and the elevated Pro-BNP level of 1017 ng/L suggests significant cardiac stress. Although the patient is on a combination of medications, including an ACE inhibitor, angiotensin II receptor blocker, and nitrovasodilator, which are beneficial for heart failure and arrhythmia prevention, the patient's high risk factors and severe left ventricular dysfunction make sudden cardiac death a significant concern.

RANKING: 2. Pump Failure Death
 REASONING: The patient's severe left ventricular dysfunction, as indicated by the LVEF of 15%, and NYHA Class III symptoms suggest a high risk of pump failure death. The patient's elevated creatinine level of 133.0 mol/L indicates renal impairment, which is a common complication of heart failure. The patient's total cholesterol level of 4.34 mmol/L and LDL level of 2.35 mmol/L are elevated, which may contribute to the progression of heart failure. However, the patient is on statins, which may help to reduce the risk of cardiovascular events. While pump failure death is a significant concern, the patient's combination of medications and the absence of other high-risk factors make it less likely than sudden cardiac death.

RANKING: 3. Survivor
 REASONING: Based on the patient's severe left ventricular dysfunction, NYHA Class III symptoms, and elevated Pro-BNP level, survivorship is the least likely prognosis. However, the patient is on a combination of medications that may help to manage symptoms and slow disease progression. Additionally, the patient's troponin level of 0.04 ng/mL is within a normal range, indicating that the patient is not experiencing an acute myocardial infarction. While the patient's prognosis is guarded, the patient's survival for the next few years is still possible with optimal medical management and close monitoring."
525,525,P0821,"Age: 75
Gender: Male 
Weight: 66 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 114.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,49
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,45
Sodium (mEq/L): 142.0
Protein (g/L): 67
T3 (pg/dL): 0,0363
T4 (ng/L): 12,28
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,11
Urea (mg/dL): 10,9
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years, considering the three possible outcomes: survivor, sudden cardiac death, and pump failure death. Here's the ranking from most likely to least likely:

RANKING: 1. Survivor
REASONING: Despite the patient's advanced age (75 years) and history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure and mortality, the patient's current treatment regimen with beta blockers, loop diuretics, and ACE inhibitor suggests that the disease is being managed. The patient's LVEF of 20% is low, but the fact that it has not significantly decreased over time (no data on previous LVEF measurements are provided) may indicate a relatively stable condition. The patient's blood pressure is well-controlled, and there is no indication of severe electrolyte imbalances or acute kidney injury. While the patient has a history of peripheral vascular disease, it does not seem to be contributing to the cardiac condition at this time. Additionally, the patient's TSH and T4 levels are within the normal range, which suggests that the patient does not have hyperthyroidism, a condition that can exacerbate heart failure. Considering these factors, the most likely outcome is that the patient will survive for the next few years, albeit with continued management of their heart failure and potential adjustments to their treatment regimen as needed.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles is a concern for sudden cardiac death (SCD). However, the patient's treatment regimen includes beta blockers, which can help reduce the risk of SCD by slowing the heart rate and reducing the likelihood of arrhythmias. The patient's LVEF of 20% also suggests that the patient's heart is not in a state of severe systolic dysfunction, which can increase the risk of SCD. While the patient's age and history of heart disease increase the risk of SCD, the patient's current management and the lack of other high-risk features make this outcome less likely than survivor.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF of 20% and history of idiopathic dilated cardiomyopathy indicate significant systolic dysfunction, which increases the risk of pump failure death. However, the patient's current treatment regimen and the lack of severe symptoms (NYHA Class II) suggest that the patient's condition is being managed. The patient's creatinine level of 114.0 umol/L is elevated, indicating some degree of renal impairment, which can be a consequence of heart failure. However, the patient's urea level of 10.9 mg/dL is not excessively high, suggesting that the renal impairment is not severe. While the patient's history of peripheral vascular disease may contribute to the progression of heart failure, it is not a dominant factor at this time. Considering these factors, while pump failure death is a possible outcome, it is less likely than survivor due to the patient's relatively stable condition and effective management.

Please note that this prognosis is based on the provided data and may not reflect the patient's actual outcome."
526,526,P0822,"Age: 51
Gender: Male 
Weight: 82 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,92
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 11,8
Hemoglobin (g/L): 145.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,65
Sodium (mEq/L): 140.0
Protein (g/L): 61
T3 (pg/dL): 0,0474
T4 (ng/L): 13,8
Troponin (ng/mL): 0,4
TSH (mIU/L): 3,85
Urea (mg/dL): 6,7
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient's age (51) and gender (male) are within a relatively young range for heart failure. The patient's NYHA Class II indicates that they are experiencing some limitations in physical activity, but they are still able to perform daily activities without severe symptoms. The patient's current medications, including beta blockers, digoxin, loop diuretics, spironolactone, statins, ACE inhibitor, and nitrovasodilator, suggest that they are receiving optimal treatment for heart failure and other comorbid conditions like hypertension and diabetes. The patient's LVEF (30%) is low, but it is not the lowest possible value, indicating some residual cardiac function. The absence of sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, and bradycardia suggests that the patient's heart rate is relatively stable. While the patient's idiopathic dilated cardiomyopathy and low LVEF indicate a high risk for cardiac events, the patient's overall clinical picture suggests that they are being well-managed and have a relatively favorable prognosis.

RANKING: 2. Pump Failure Death
REASONING: The patient's low LVEF (30%) and history of idiopathic dilated cardiomyopathy indicate a high risk for pump failure. However, the patient's current medications and NYHA Class II classification suggest that they are being well-managed and are not experiencing severe symptoms. The patient's age and gender are also relatively young, which may contribute to a slower progression of heart failure. Additionally, the patient's absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia suggests that their heart rate is relatively stable. While pump failure is a possible outcome, it is less likely than survivor due to the patient's relatively favorable clinical picture.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's low LVEF (30%) and history of idiopathic dilated cardiomyopathy increase their risk for sudden cardiac death. However, the patient's current medications, including beta blockers and ACE inhibitors, which are known to reduce the risk of sudden cardiac death, suggest that they are receiving optimal treatment for this risk factor. The patient's ECG impression shows monomorphic ventricular extrasystoles, but no sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia, which are more concerning signs for sudden cardiac death. The patient's overall clinical picture suggests that they are being well-managed and have a relatively low risk for sudden cardiac death."
527,527,P0823,"Age: 64
Gender: Male 
Weight: 74 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,1
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,8
Sodium (mEq/L): 138.0
Protein (g/L): 65
T3 (pg/dL): 0,0504
T4 (ng/L): 21
TSH (mIU/L): 2,62
Urea (mg/dL): 8
LVEF (%): 20.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: Based on the provided patient data, I would rank the prognosis as survivor, followed by pump failure death, and then sudden cardiac death. Here's the reasoning behind this order:

1. Survivor: The patient has a history of ischemic dilated cardiomyopathy with an LVEF of 20%, indicating significant left ventricular dysfunction. However, the patient is on optimal medical therapy with ACE inhibitors, beta blockers, loop diuretics, and statins, which are all evidence-based treatments for heart failure with reduced ejection fraction (HFrEF). The patient also has a relatively well-controlled blood pressure and a normal hemoglobin level, which are both important for reducing the risk of adverse cardiac events. The absence of ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, and bradycardia on the ECG suggests that the patient does not have an increased risk of sudden cardiac death. Although the patient has diabetes, dyslipemia, and hypertension, these conditions are well-controlled with medication. Given the patient's stable medical regimen and the absence of high-risk features, the likelihood of survival is higher.

2. Pump failure death: The patient's LVEF of 20% indicates severe left ventricular dysfunction, which increases the risk of pump failure death. The patient's creatinine level of 124.0 mol/L suggests impaired renal function, which is a known risk factor for worsening heart failure and increased mortality. The patient's total cholesterol and LDL levels are elevated, which may contribute to further cardiac damage and worsening heart failure. However, the patient is on statins, which may help mitigate this risk. The patient's weight is slightly above average, which may also contribute to increased cardiac workload. Overall, while the patient's risk of pump failure death is high, it is not the most likely outcome given the patient's overall clinical picture.

3. Sudden cardiac death: The patient's ECG shows monomorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the absence of ventricular tachycardia and other high-risk features on the ECG reduces this risk. The patient's LVEF of 20% and history of myocardial infarction also increase the risk of sudden cardiac death. However, the patient's overall clinical picture and stable medical regimen suggest that sudden cardiac death is the least likely outcome.

In summary, while the patient has significant cardiac disease and risk factors, the patient's stable medical regimen, well-controlled blood pressure, and absence of high-risk features on the ECG suggest that survival is the most likely outcome. Pump failure death is a significant risk, but the patient's overall clinical picture suggests that it is less likely than survival. Sudden cardiac death is the least likely outcome due to the patient's stable ECG and overall clinical picture."
528,528,P0824,"Age: 42
Gender: Male 
Weight: 86 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 33,5
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 5,22
Creatinine (mmol/L): 72.0
Gamma-glutamil transpeptidase (IU/L): 124
Glucose (mmol/L): 7,1
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,6
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,64
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 226.0
Protein (g/L): 66,6
T4 (ng/L): 17
TSH (mIU/L): 1,63
Urea (mg/dL): 7,32
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here's a prognosis for the next few years, considering the three possible outcomes: survivor, sudden cardiac death, and pump failure death. 

RANKING: 1. Survivor
REASONING: Despite the patient's history of hypertensive cardiomyopathy, diabetes, and dyslipemia, the current medication regimen and the patient's NYHA Class II classification indicate that the disease is being managed. The LVEF of 40% is relatively low, but it is not extremely low, and the patient is not in heart failure. The Pro-BNP level of 226 ng/L is elevated but not excessively high, indicating some degree of heart strain but not severe heart failure. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, or severe electrolyte imbalances also supports a better prognosis. Considering these factors, the most likely outcome is that the patient will continue to manage their condition with medication and lifestyle modifications, and they will survive for the next few years.

RANKING: 2. Sudden Cardiac Death
REASONING: While the patient has risk factors for sudden cardiac death, such as a history of hypertensive cardiomyopathy and a low LVEF, the absence of other high-risk features, such as a history of cardiac arrest, sustained ventricular tachycardia, or severe electrolyte imbalances, makes sudden cardiac death less likely. Additionally, the patient is on beta blockers, which can reduce the risk of sudden cardiac death. However, the presence of polymorphic ventricular extrasystoles and unknown paroxysmal supraventricular tachyarrhythmia codes may indicate some level of cardiac instability, increasing the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF of 40% indicates some degree of left ventricular dysfunction, which is a risk factor for pump failure death. However, the patient's NYHA Class II classification and the absence of severe symptoms or signs of heart failure (e.g., orthopnea, paroxysmal nocturnal dyspnea, or pulmonary edema) suggest that the heart failure is not severe. Additionally, the patient is on loop diuretics, which can help manage fluid overload and reduce the risk of pump failure. While the patient's Pro-BNP level is elevated, it is not excessively high, indicating some degree of heart strain but not severe heart failure. Considering these factors, pump failure death is the least likely outcome for the patient."
529,529,P0825,"Age: 51
Gender: Male 
Weight: 99 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Other HF etiology, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 52.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 129.0
Gamma-glutamil transpeptidase (IU/L): 75
Glucose (mmol/L): 10,3
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,24
Sodium (mEq/L): 149.0
Pro-BNP (ng/L): 320.0
Protein (g/L): 77
T3 (pg/dL): 0,06
T4 (ng/L): 23
Troponin (ng/mL): 0,005
TSH (mIU/L): 0,316
Urea (mg/dL): 7,65
LVEF (%): 32.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: Survivor

REASONING: 

Given the patient's profile, I would rank survivor as the most likely outcome. Here's why:

1.  Current Medications: The patient is on a comprehensive treatment plan, including ACE inhibitors, beta blockers, digoxin, loop diuretics, spironolactone, and statins. These medications are commonly used to manage heart failure, hypertension, and dyslipidemia, indicating that the patient is receiving appropriate treatment for their conditions.
2.  NYHA Class II: The patient's NYHA (New York Heart Association) class is II, which indicates that they experience some limitation in physical activity but are still able to perform everyday activities. This suggests that the patient's heart failure symptoms are not severe.
3.  LVEF 32%: Although the left ventricular ejection fraction (LVEF) is low at 32%, it's not extremely low. Patients with an LVEF between 20-40% can still have a relatively good prognosis with optimal medical therapy.
4.  Blood Pressure and Glucose Control: The patient's blood pressure is well-controlled, and their glucose levels are being managed with diabetes medication. Good blood pressure and glucose control are essential for preventing further cardiac damage.
5.  ECG Findings: While the patient has polymorphic ventricular extrasystoles, there is no evidence of sustained ventricular tachycardia or bradycardia, which are more concerning signs.

However, it's essential to note that the patient's creatinine level (129.0 mmol/L) is slightly elevated, indicating some degree of renal impairment. This could be a concern for long-term outcomes, but given the patient's current treatment plan and relatively well-controlled blood pressure and glucose levels, I believe the risk of sudden cardiac death or pump failure death is lower than the risk of survivorship.

RANKING: Sudden Cardiac Death

REASONING: 

Sudden cardiac death is a possible outcome, but I rank it as less likely than survivorship. The reasons are:

1.  Polymorphic Ventricular Extrasystoles: The presence of polymorphic ventricular extrasystoles on the ECG is a concern, as it may indicate underlying cardiac electrical instability. However, there is no evidence of sustained ventricular tachycardia or other high-risk features.
2.  Low LVEF: The patient's LVEF of 32% puts them at increased risk for sudden cardiac death.

RANKING: Pump Failure Death

REASONING: 

Pump failure death is the least likely outcome, given the patient's current treatment plan and relatively well-controlled blood pressure and glucose levels. While the patient's LVEF is low, they are on optimal medical therapy for heart failure, which should help mitigate the risk of pump failure."
530,530,P0826,"Age: 45
Gender: Male 
Weight: 74 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Toxic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,17
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 5
LDL (mmol/L): 3,28
Sodium (mEq/L): 148.0
Pro-BNP (ng/L): 53.0
Protein (g/L): 74
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,62
Urea (mg/dL): 5,16
LVEF (%): 48.0
Medications: Beta Blockers, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Survivor
REASONING: The patient is 45 years old with a history of toxic dilated cardiomyopathy, which is a condition that can be reversible with proper treatment. The patient's LVEF is 48%, which indicates some degree of left ventricular dysfunction but is still within a range that can be managed with medication and lifestyle changes. The patient is on beta blockers, digoxin, and an ACE inhibitor, which are standard treatments for heart failure. The patient's NT-proBNP level is 53.0 ng/L, which is within the normal range (< 125 ng/L), indicating mild heart failure symptoms. Additionally, the patient's troponin level is normal, indicating no acute myocardial infarction. The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG is concerning, but it can be managed with medication. The patient's hemoglobin level is normal, and there is no indication of anemia or malnutrition. Overall, the patient's clinical presentation and lab results suggest that the condition is manageable, and with proper treatment, the patient is likely to survive.

RANKING: Sudden Cardiac Death
REASONING: The patient has a history of toxic dilated cardiomyopathy, which increases the risk of sudden cardiac death. However, the patient's LVEF is 48%, which is relatively preserved, and the patient is on beta blockers, digoxin, and an ACE inhibitor, which are standard treatments for heart failure. The patient's NT-proBNP level is within the normal range, and the troponin level is normal, indicating no acute myocardial infarction. The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG is concerning, but it can be managed with medication. The patient's overall clinical presentation and lab results suggest that sudden cardiac death is less likely than survivor.

RANKING: Pump Failure Death
REASONING: The patient has a history of toxic dilated cardiomyopathy, which can lead to pump failure. However, the patient's LVEF is 48%, which is relatively preserved, and the patient is on beta blockers, digoxin, and an ACE inhibitor, which are standard treatments for heart failure. The patient's NT-proBNP level is within the normal range, and the troponin level is normal, indicating no acute myocardial infarction. The patient's hemoglobin level is normal, and there is no indication of anemia or malnutrition. The patient's overall clinical presentation and lab results suggest that pump failure is less likely than sudden cardiac death or survivor."
531,531,P0827,"Age: 41
Gender: Male 
Weight: 54 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 46
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,81
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,87
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 97.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,13
Urea (mg/dL): 3,83
LVEF (%): 26.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 3

REASONING: The patient's current condition suggests a relatively stable state, despite having idiopathic dilated cardiomyopathy and a low LVEF of 26%. However, there are several factors that contribute to a more favorable prognosis. The patient is on a treatment regimen that includes beta blockers, digoxin, loop diuretics, and an ACE inhibitor, which are standard therapies for heart failure. The patient's blood pressure is well-controlled, and the absence of significant electrolyte imbalances (e.g., low potassium) is a positive sign.

The patient's troponin level is low, indicating minimal myocardial damage. Additionally, the absence of paroxysmal supraventricular tachyarrhythmia and bradycardia on the ECG suggests that the patient's heart rate is relatively stable. The patient's TSH level is within the normal range, indicating no apparent thyroid dysfunction, which can contribute to heart failure. The patient's creatinine level is slightly elevated, but not significantly so, which suggests that renal function is not severely impaired.

While the patient has a history of non-sustained ventricular tachycardia, this is a relatively common finding in patients with heart failure and is not necessarily a predictor of sudden cardiac death. The patient's Pro-BNP level is elevated, but not excessively so, which can be seen in patients with heart failure.

Considering these factors, the patient's overall prognosis is more likely to be a survivor, with a relatively low risk of sudden cardiac death or pump failure death in the next few years. However, close monitoring and regular follow-up appointments with the cardiologist are essential to manage the patient's condition and adjust the treatment plan as needed.

Please note that this is a prediction based on the provided data and may not reflect the patient's actual outcome, which can be influenced by various factors not accounted for in this analysis."
532,532,P0828,"Age: 70
Gender: Male 
Weight: 94 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 130/85 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 6,49
Creatinine (mmol/L): 175.0
Gamma-glutamil transpeptidase (IU/L): 100
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 153.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 5,2
LDL (mmol/L): 4,03
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1603.0
Protein (g/L): 69
T3 (pg/dL): 0,07
T4 (ng/L): 20
TSH (mIU/L): 0,495
Urea (mg/dL): 11,98
LVEF (%): 55.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here's my prognosis for the next few years:

RANKING: 1. Survivor
 REASONING: The patient is 70 years old with a history of valvular cardiomyopathy, dyslipemia, and hypertension. However, despite these risk factors, the patient is currently being treated with medications that are appropriate for heart failure management (beta blockers, digoxin, loop diuretics, statins, and ACE inhibitor). The patient's LVEF is 55%, which is within the mildly reduced range but not severely impaired. The patient's eGFR is not provided, but the creatinine level is slightly elevated at 175.0 umol/L, which may indicate some renal impairment. However, the patient's overall clinical status appears to be stable, and the patient is not in heart failure with reduced ejection fraction (HFrEF) class III or IV, which are typically associated with a higher risk of sudden cardiac death. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, or severe bradycardia also reduces the risk of sudden cardiac death. While the patient's Pro-BNP level is elevated at 1603.0 ng/L, it is not excessively high, and the patient's overall clinical status suggests that the patient is likely to survive for the next few years.

RANKING: 2. Pump failure death
 REASONING: The patient's LVEF is mildly reduced at 55%, which may indicate some degree of left ventricular dysfunction. The patient's creatinine level is slightly elevated, which may indicate some degree of renal impairment, which can be a consequence of heart failure. The patient's Pro-BNP level is elevated, which is a marker of heart failure. However, the patient is being treated with medications that are appropriate for heart failure management, and the patient's overall clinical status appears to be stable. While the patient is at risk of developing heart failure, the patient's LVEF is not severely impaired, and the patient is not in heart failure with reduced ejection fraction (HFrEF) class III or IV.

RANKING: 3. Sudden cardiac death
 REASONING: The patient's ECG shows polymorphic ventricular extrasystoles, which can be a marker of increased risk of sudden cardiac death. However, the absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, or severe bradycardia reduces the risk of sudden cardiac death. The patient's LVEF is mildly reduced, but not severely impaired, which reduces the risk of sudden cardiac death due to pump failure. The patient's overall clinical status appears to be stable, and the patient is being treated with medications that are appropriate for heart failure management. While the patient is at risk of sudden cardiac death, the risk is relatively low compared to the other two prognoses."
533,533,P0829,"Age: 60
Gender: Female 
Weight: 97 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Other HF etiology, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 155.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,1
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 27.0
Protein (g/L): 72
T4 (ng/L): 9
Troponin (ng/mL): 0,01
TSH (mIU/L): 5
Urea (mg/dL): 5,16
LVEF (%): 50.0
Medications: Angiotensin II Receptor Blocker, Digoxin
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the three possible prognoses as follows:

RANKING: 1. Survivor
REASONING: The patient's left ventricular ejection fraction (LVEF) is 50%, which is below the normal range (60%), indicating some degree of heart failure. However, the patient is on appropriate medications (Angiotensin II Receptor Blocker and Digoxin) and has a relatively low Pro-BNP level (27.0 ng/L), which suggests that the heart failure is not severe. Additionally, the patient's NYHA Class is II, indicating mild symptoms of heart failure. The absence of sustained ventricular tachycardia and other arrhythmias on the ECG also suggests a lower risk of sudden cardiac death. The patient's overall clinical presentation and laboratory results suggest that the patient is at moderate risk of cardiac events, but the prognosis for survival is still favorable.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's LVEF of 50% and history of other heart failure etiology suggest a moderate risk of sudden cardiac death. However, the patient's Pro-BNP level is relatively low, and the absence of sustained ventricular tachycardia and other arrhythmias on the ECG reduces the risk of sudden cardiac death. The patient's blood pressure is well-controlled, and the patient is on appropriate medications, which further reduces the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF of 50% and history of other heart failure etiology suggest a risk of pump failure death. However, the patient's Pro-BNP level is relatively low, and the patient is on appropriate medications, which reduces the risk of pump failure death. The patient's NYHA Class is II, indicating mild symptoms of heart failure, which suggests that the patient's cardiac function is not severely compromised. The patient's overall clinical presentation and laboratory results suggest that the patient is at moderate risk of cardiac events, but the prognosis for pump failure death is less likely compared to the other two options.

Note: The ranking is based on the available data and may not reflect the patient's actual prognosis, which can be influenced by various factors not included in the data."
534,534,P0831,"Age: 66
Gender: Female 
Weight: 103 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,1
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 65.0
Protein (g/L): 70
T4 (ng/L): 10
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,1
Urea (mg/dL): 4,99
LVEF (%): 58.0
Medications: Diabetes Medication, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor
REASONING: The patient's current condition suggests a relatively stable cardiovascular profile. Her age is 66, which is not extremely high, and her blood pressure is within a normal range. Her LVEF of 58% indicates a mildly reduced ejection fraction, but it is not severely impaired. The patient is on a medication regimen that includes an ACE inhibitor, statins, and spironolactone, which are commonly used to manage heart failure and hypertension. Additionally, the absence of significant arrhythmias on the ECG and a low troponin level suggest that there is no acute cardiac damage. However, the patient's history of myocardial infarction, hypertensive cardiomyopathy, and peripheral vascular disease indicates that she has had previous cardiovascular events, which may have led to some cardiac scarring and decreased cardiac function. Nevertheless, with proper management and monitoring, the patient is likely to survive for several years.

RANKING: Pump Failure Death
REASONING: The patient's mildly reduced LVEF of 58% and history of myocardial infarction and hypertensive cardiomyopathy suggest that she may be at risk for heart failure progression. However, her current medication regimen and lack of significant arrhythmias on the ECG suggest that she is being managed appropriately. The patient's creatinine level of 88.0 mol/L is slightly elevated, which may indicate some degree of renal impairment, but it is not severely elevated. The patient's albumin level is also slightly low, which may be indicative of some degree of liver dysfunction, but it is not severely impaired. Overall, while the patient is at risk for pump failure, her current condition does not suggest that it is the most likely outcome in the short term.

RANKING: Sudden Cardiac Death
REASONING: The patient's ECG shows a second-degree AV block, which may indicate some degree of cardiac conduction system disease. However, the patient's LVEF of 58% and the absence of significant arrhythmias on the ECG suggest that she does not have a high risk of sudden cardiac death. The patient's troponin level is low, indicating that there is no acute cardiac damage. Additionally, the patient's medication regimen includes an ACE inhibitor, which is commonly used to reduce the risk of sudden cardiac death. Overall, while the patient's ECG findings suggest some degree of cardiac conduction system disease, the overall risk of sudden cardiac death is relatively low."
535,535,P0832,"Age: 56
Gender: Male 
Weight: 94 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 145/85 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,62
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 7,9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 5
LDL (mmol/L): 1,42
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 217.0
Protein (g/L): 74
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,1
Urea (mg/dL): 7,49
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Please note that this is a medical prediction, and actual outcomes may vary.

RANKING: Survivor

REASONING:

1. Survivor: The patient has a relatively stable condition, considering their age and comorbidities. The LVEF of 35% indicates that the heart is functioning below the normal range (50-60%), but not severely compromised. The patient is already on optimal medical therapy with beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all standard treatments for heart failure. The absence of significant troponin elevation and the low level of Pro-BNP (217 ng/L) suggest that the patient is not experiencing acute cardiac injury or severe heart failure. The patient's NYHA class II indicates that they are experiencing some limitations in physical activity, but they are still able to perform daily activities without significant symptoms. The patient's age and comorbidities (diabetes, dyslipemia, hypertension) increase the risk of cardiovascular events, but the overall prognosis is still relatively favorable.

2. Pump Failure Death: This outcome is possible, but less likely than survivor. The patient's LVEF of 35% indicates that the heart is not functioning optimally, and the patient may be at risk for progressive heart failure. The elevated Pro-BNP level (217 ng/L) suggests that the patient's heart is under strain, and the patient's weight (94 kg) may contribute to increased cardiac workload. However, the patient is already on optimal medical therapy, and the absence of significant troponin elevation and the low level of LVEF suggest that the heart is not in a state of acute failure.

3. Sudden Cardiac Death: This outcome is the least likely of the three. The patient's ECG is relatively normal, with no signs of ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia. The patient's troponin level is low, indicating that there is no acute cardiac injury. The patient's LVEF of 35% is below the normal range, but not severely compromised, and the patient is already on optimal medical therapy. The patient's comorbidities (diabetes, dyslipemia, hypertension) increase the risk of cardiovascular events, but sudden cardiac death is less likely in this patient, given the absence of significant cardiac arrhythmias and the patient's relatively stable condition.

In conclusion, based on the provided patient data, the most likely outcome is a survivor, followed by pump failure death, and then sudden cardiac death."
536,536,P0833,"Age: 68
Gender: Female 
Weight: 66 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 6,96
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 10,4
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,36
Potassium (mEq/L): 4,9
LDL (mmol/L): 4,27
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 588.0
Protein (g/L): 73
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,36
Urea (mg/dL): 9,82
LVEF (%): 55.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here are my prognoses for the next few years, ordered from most likely to least likely:

RANKING: Survivor
 REASONING: The patient is 68 years old with a history of hypertensive cardiomyopathy, diabetes, dyslipemia, and peripheral vascular disease, which are all risk factors for cardiovascular disease. However, the patient is on appropriate medications for these conditions (calcium channel blocker, diabetes medication, angiotensin II receptor blocker, and loop diuretics), which suggests that the patient's condition is being managed. The left ventricular ejection fraction (LVEF) is 55%, which is within the normal range, and the troponin level is normal, indicating that there is no acute coronary syndrome. The patient's BNP level is elevated, which suggests that the patient has some degree of heart failure, but it is not severe. The patient's ECG shows polymorphic ventricular extrasystoles, which is a common finding in patients with cardiomyopathy. Given the patient's age and the presence of cardiovascular risk factors, the most likely outcome is that the patient will survive with continued management of their condition.

RANKING: Pump failure death
 REASONING: The patient's LVEF is 55%, which is below the normal range, and the BNP level is elevated, indicating that the patient has some degree of heart failure. The patient's creatinine level is also elevated, suggesting that there may be some degree of renal impairment. The patient's history of hypertensive cardiomyopathy and diabetes also increases the risk of heart failure progression. However, the patient's condition is not severe enough to warrant an immediate high-risk prognosis.

RANKING: Sudden cardiac death
 REASONING: The patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the patient's troponin level is normal, and the LVEF is within the normal range, which suggests that there is no acute coronary syndrome or severe cardiac dysfunction. The patient's BNP level is elevated, but not severely so, and the patient is on appropriate medications for their condition. Given the patient's age and the presence of cardiovascular risk factors, sudden cardiac death is the least likely outcome."
537,537,P0834,"Age: 58
Gender: Male 
Weight: 76 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 90/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39,7
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,07
Creatinine (mmol/L): 181.0
Gamma-glutamil transpeptidase (IU/L): 76
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 170.0
HDL (mmol/L): 1,18
Potassium (mEq/L): 4,63
LDL (mmol/L): 2,48
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 6433.0
Protein (g/L): 74
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,17
Urea (mg/dL): 17,8
LVEF (%): 26.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor

REASONING: 

Given the patient's profile, I would rank the prognosis as a survivor for the following reasons:

1. Current Medications: The patient is on a combination of medications that are beneficial for his condition, including Digoxin for heart failure symptoms, Loop Diuretics to manage fluid overload, Statins to control dyslipemia, and ACE Inhibitor to reduce blood pressure and prevent further cardiac damage. These medications can help stabilize his condition and improve his quality of life.

2. LVEF of 26%: Although the patient's left ventricular ejection fraction (LVEF) is severely reduced, it is not the lowest possible value. An LVEF of 26% indicates that the heart is still pumping some blood, albeit inefficiently. This suggests that the patient may still have some functional capacity and that his heart is not completely failing.

3. Absence of Sustained Ventricular Tachycardia: The absence of sustained ventricular tachycardia on the ECG is a positive sign, indicating that the patient's heart rhythm is relatively stable. This reduces the risk of sudden cardiac death.

4. Hemoglobin and Potassium Levels: The patient's hemoglobin and potassium levels are within a relatively normal range, which is crucial for maintaining cardiac function and preventing arrhythmias.

5. No Indications of Pump Failure: The patient's urea and creatinine levels are not significantly elevated, indicating that his kidneys are functioning relatively well, and there is no clear indication of pump failure.

Considering these factors, while the patient's prognosis is guarded due to his severe heart failure, I believe that, with ongoing medical management and close monitoring, he is more likely to survive than to experience sudden cardiac death or pump failure.

RANKING: 2. Pump Failure Death

REASONING: 

The patient's risk of pump failure death is higher than sudden cardiac death due to the following reasons:

1. Severe Heart Failure: The patient's LVEF of 26% indicates severe heart failure, which increases the risk of pump failure.

2. Elevated Creatinine Levels: The patient's elevated creatinine levels suggest that his kidneys are being affected by his heart failure, which can further compromise cardiac function.

3. Pro-BNP Levels: The patient's high Pro-BNP levels indicate that his heart is under significant stress, which increases the risk of pump failure.

However, the patient's current medications and relatively stable ECG findings reduce the likelihood of pump failure compared to sudden cardiac death.

RANKING: 3. Sudden Cardiac Death

REASONING: 

The patient's risk of sudden cardiac death is lower than pump failure due to the following reasons:

1. Absence of Sustained Ventricular Tachycardia: The absence of sustained ventricular tachycardia on the ECG reduces the risk of sudden cardiac death.

2. Medications: The patient's medications, including Digoxin and ACE Inhibitor, can help stabilize his heart rhythm and reduce the risk of arrhythmias.

However, the patient's severe heart failure and elevated Pro-BNP levels increase the risk of sudden cardiac death."
538,538,P0836,"Age: 53
Gender: Male 
Weight: 67 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 105/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 44,1
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,41
LDL (mmol/L): 3,48
Sodium (mEq/L): 135.0
Protein (g/L): 78,4
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,89
Urea (mg/dL): 8,7
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: Based on the provided patient data, I would rank the prognosis as Survivor due to the following reasons:

1. NYHA Class II: The patient's New York Heart Association (NYHA) functional class is II, indicating that the patient experiences some limitations in physical activity but is still able to perform everyday activities without significant symptoms. This suggests that the patient's heart condition is not severely impacting their quality of life.
2. LVEF of 30%: Although the left ventricular ejection fraction (LVEF) is significantly reduced, it is not the lowest possible value (which would be 0-20%). This suggests that the patient's heart is still pumping some blood, and there is potential for improvement with medical management.
3. Medications: The patient is on beta blockers, loop diuretics, and an ACE inhibitor, which are standard treatments for heart failure and idiopathic dilated cardiomyopathy. These medications can help reduce symptoms, improve LVEF, and slow disease progression.
4. ECG findings: The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia (NSVT) is concerning, but the absence of sustained ventricular tachycardia or bradycardia suggests that the patient's heart is not in a life-threatening rhythm disturbance.
5. Laboratory values: The patient's laboratory values, including troponin, TSH, and electrolytes, are within normal limits or only slightly elevated. This suggests that there is no acute cardiac damage or electrolyte imbalance that would worsen the prognosis.
6. Age and weight: The patient's age and weight are not significantly high-risk factors for cardiac disease.

Considering these factors, the patient's prognosis is likely to be a survivor, with a focus on managing their condition with medications, lifestyle modifications, and regular follow-up appointments to monitor their LVEF and symptoms.

RANKING: Sudden Cardiac Death (2nd most likely)

REASONING: Sudden cardiac death is a possible outcome due to the patient's history of idiopathic dilated cardiomyopathy, reduced LVEF, and NSVT. The presence of polymorphic ventricular extrasystoles and NSVT on the ECG increases the risk of sudden cardiac death.

RANKING: Pump Failure Death (3rd most likely)

REASONING: Pump failure death is less likely due to the patient's relatively preserved NYHA functional class, lack of severe electrolyte imbalances, and normal laboratory values. While the patient's LVEF is significantly reduced, their overall clinical picture suggests that they are not at immediate risk of pump failure death."
539,539,P0837,"Age: 84
Gender: Male 
Weight: 54 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 36,2
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,85
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 15
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,54
Potassium (mEq/L): 4,62
LDL (mmol/L): 2,81
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 2619.0
Protein (g/L): 73,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,54
Urea (mg/dL): 12,7
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely. Keep in mind that this is a prediction and actual outcomes may vary.

RANKING: Survivor

REASONING: 

1. The patient is 84 years old with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac mortality. However, the patient is already on optimal medical therapy for heart failure, including ACE inhibitors, spironolactone, and loop diuretics, which suggests that the patient's condition is being actively managed.
2. The patient's left ventricular ejection fraction (LVEF) is 25%, which is a significant reduction but not an uncommon finding in patients with ischemic dilated cardiomyopathy. The patient's LVEF is still within the range of patients who can be managed with medical therapy alone, although it does increase the risk of cardiac events.
3. The patient's B-type natriuretic peptide (BNP) level is elevated at 2619 ng/L, indicating that the patient has significant heart failure symptoms. However, the BNP level is not excessively high, suggesting that the patient is not in acute decompensated heart failure.
4. The patient's electrolytes and kidney function are within normal limits, which is a good sign.
5. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of cardiac ischemia or scarring, but it is not a specific predictor of sudden cardiac death.
6. The patient's overall clinical status is stable, with no acute changes or worsening symptoms.

Considering these factors, the patient's prognosis is most likely to be a survivor, as the patient's condition is being actively managed, and there are no immediate signs of acute decompensation or cardiac arrest.

RANKING: Sudden Cardiac Death

REASONING: 

Sudden cardiac death is a possible outcome, but it is less likely than survivor. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of cardiac ischemia or scarring, increasing the risk of sudden cardiac death. However, the patient's overall clinical status is stable, and the patient is on optimal medical therapy, which reduces the risk of sudden cardiac death.

RANKING: Pump Failure Death

REASONING: 

Pump failure death is the least likely outcome. The patient's LVEF is 25%, which is a significant reduction, but the patient is on optimal medical therapy, and the BNP level is not excessively high, suggesting that the patient is not in acute decompensated heart failure. The patient's kidney function and electrolytes are within normal limits, which further reduces the risk of pump failure."
540,540,P0840,"Age: 55
Gender: Female 
Weight: 55 kg
Height: 145 cm
NYHA Class: III
Blood Pressure: 80/40 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia
Albumin (g/L): 44,9
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,44
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,15
LDL (mmol/L): 3,71
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 991.0
Protein (g/L): 77,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,87
Urea (mg/dL): 7,8
LVEF (%): 40.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. I will rank the three possible prognoses from most likely to least likely.

RANKING: Survivor
REASONING: The patient is 55 years old with a history of valvular cardiomyopathy and dyslipemia, which indicates a compromised heart function. However, the patient is currently being treated with medications such as an angiotensin II receptor blocker, digoxin, loop diuretics, and spironolactone, which are commonly used to manage heart failure and improve survival in patients with heart failure. The patient's LVEF is 40%, which is below the normal range, but not extremely low. The patient's Pro-BNP level is elevated at 991.0 ng/L, indicating some level of heart failure, but not severe. The absence of troponin elevation and the relatively normal electrolyte levels suggest that the patient is not experiencing acute cardiac ischemia or severe electrolyte imbalances. The patient's NYHA class is III, indicating moderate to severe symptoms, but the patient is still ambulatory. Considering these factors, a survivor prognosis is the most likely outcome, assuming the patient adheres to their treatment plan and makes lifestyle modifications to manage their condition.

RANKING: Pump Failure Death
REASONING: The patient's LVEF of 40% indicates a reduced cardiac function, which increases the risk of pump failure. The elevated Pro-BNP level and NYHA class III suggest that the patient is experiencing some level of heart failure. However, the patient's treatment plan includes medications that are commonly used to manage heart failure, and the patient is still ambulatory, which suggests that the patient's condition is being managed. While pump failure is a possible outcome, the patient's relatively stable condition and treatment plan make it a less likely outcome compared to sudden cardiac death.

RANKING: Sudden Cardiac Death
REASONING: Sudden cardiac death is the least likely outcome in this case. The patient's LVEF is 40%, which is below the normal range, but not extremely low. The patient's Pro-BNP level is elevated, but not extremely high. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death, but the absence of sustained ventricular tachycardia or other high-risk ECG findings makes sudden cardiac death less likely. The patient's treatment plan includes medications that are commonly used to manage heart failure and reduce the risk of sudden cardiac death. Overall, while sudden cardiac death is a possible outcome, the patient's relatively stable condition and treatment plan make it the least likely outcome."
541,541,P0841,"Age: 54
Gender: Male 
Weight: 75 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,42
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,18
LDL (mmol/L): 2,75
Sodium (mEq/L): 139.0
Protein (g/L): 67,9
T3 (pg/dL): 0,0648
T4 (ng/L): 12,24
Troponin (ng/mL): 0,3
TSH (mIU/L): 0,77
Urea (mg/dL): 5,5
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the prognosis as follows:

RANKING: 1. Survivor
REASONING: The patient is 54 years old with a history of ischemic dilated cardiomyopathy, hypertension, and myocardial infarction, which are all significant risk factors for cardiac complications. However, the patient is on appropriate medications (Angiotensin II Receptor Blocker and ACE Inhibitor) that are known to improve outcomes in patients with heart failure. The LVEF of 25% is low, indicating systolic dysfunction, but it is not extremely low. The patient's NYHA Class II indicates that the patient is experiencing some symptoms, but they are not severely limiting. The patient's troponin level is slightly elevated, indicating some ongoing myocardial damage, but it is not extremely high. The patient's TSH level is within the normal range, which is a good sign, as thyroid dysfunction can exacerbate heart failure. The patient's creatinine level is elevated, but not severely, indicating some kidney impairment, which is common in patients with heart failure. Considering these factors, while the patient's prognosis is guarded, I believe that with continued medical management and lifestyle modifications, the patient is likely to survive.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which increases the risk of sudden cardiac death. The patient's LVEF of 25% is low, which is a risk factor for sudden cardiac death. The patient's troponin level is elevated, indicating ongoing myocardial damage. The patient's ventricular extrasystole on the ECG is also a risk factor for sudden cardiac death. However, the patient is on appropriate medications, and the patient's TSH level is within the normal range, which reduces the risk of thyroid-related sudden cardiac death. The patient's creatinine level is elevated, but not severely, which is a risk factor for sudden cardiac death, but not the most significant one in this case. Considering these factors, I believe that sudden cardiac death is a possible outcome, but less likely than survival.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF of 25% indicates significant systolic dysfunction, which is a risk factor for pump failure death. The patient's NYHA Class II indicates that the patient is experiencing some symptoms, but they are not severely limiting, which suggests that the patient may not be in the advanced stages of heart failure. The patient's creatinine level is elevated, indicating some kidney impairment, which is common in patients with heart failure. However, the patient's TSH level is within the normal range, and the patient is on appropriate medications, which reduces the risk of pump failure death. The patient's troponin level is slightly elevated, indicating some ongoing myocardial damage, but it is not extremely high. Considering these factors, I believe that pump failure death is the least likely outcome."
542,542,P0842,"Age: 57
Gender: Male 
Weight: 84 kg
Height: 176 cm
NYHA Class: III
Blood Pressure: 125/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 159.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,21
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 690.0
Protein (g/L): 74
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,83
Urea (mg/dL): 5,16
LVEF (%): 20.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here are the three possible prognoses for the next few years, ordered from most likely to least likely:

RANKING: 1. Survivor
 REASONING: The patient is 57 years old with a history of idiopathic dilated cardiomyopathy, which is a chronic condition. Despite the low left ventricular ejection fraction (LVEF) of 20%, the patient is currently being treated with a combination of medications including Angiotensin II Receptor Blocker, Beta Blockers, Statins, and ACE Inhibitor. These medications are standard treatments for heart failure and have shown to improve survival and reduce morbidity in patients with heart failure. Additionally, the patient's blood pressure is well-controlled, and there are no signs of significant electrolyte imbalances or acute cardiac ischemia (Troponin is within normal limits). The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG is concerning, but the absence of sustained ventricular tachycardia or bradycardia suggests that the patient's heart is not in a state of acute decompensation. Therefore, given the patient's current treatment regimen and the absence of acute decompensation, the most likely prognosis is survival.

RANKING: 2. Pump Failure Death
 REASONING: The patient has a low LVEF of 20%, which indicates severe left ventricular dysfunction. This is a significant risk factor for pump failure death. However, the patient is currently being treated with medications that are known to slow the progression of heart failure and improve survival. While the patient's creatinine level is elevated (80.0 mmol/L), which may indicate some degree of renal impairment, it is not significantly elevated, and the patient's urea level is within normal limits. The absence of acute decompensation signs such as acute kidney injury, severe anemia, or hyperkalemia suggests that the patient's heart failure is not in a state of rapid progression. Therefore, while pump failure death is a possible prognosis, it is less likely than survival.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy and a low LVEF of 20%, which are both risk factors for sudden cardiac death. However, the patient is currently being treated with medications that are known to reduce the risk of sudden cardiac death, such as Beta Blockers and ACE Inhibitors. Additionally, the patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death, but the absence of sustained ventricular tachycardia or bradycardia suggests that the patient's heart is not in a state of acute decompensation. The patient's Pro-BNP level is elevated (690.0 ng/L), which may indicate some degree of heart failure, but it is not significantly elevated, and the patient's overall clinical status suggests that sudden cardiac death is the least likely prognosis."
543,543,P0844,"Age: 73
Gender: Male 
Weight: 66 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 130/88 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 35.0
Total Cholesterol (mmol/L): 3,1
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 10,6
Hemoglobin (g/L): 179.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,53
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1713.0
Protein (g/L): 78
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,86
Urea (mg/dL): 7,15
LVEF (%): 20.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Pump Failure Death, 2. Sudden Cardiac Death, 3. Survivor

REASONING:

1. Pump Failure Death (Most Likely): The patient has a history of ischemic dilated cardiomyopathy with a left ventricular ejection fraction (LVEF) of 20%, which indicates severe heart failure. The elevated Pro-BNP level of 1713 ng/L further supports this, as high BNP levels are associated with increased risk of heart failure hospitalization and mortality. The patient's low LVEF, coupled with the presence of NYHA Class II symptoms, indicates that the patient's heart is not pumping efficiently, making pump failure a significant concern.

2. Sudden Cardiac Death (Less Likely): While the patient has a history of ischemic dilated cardiomyopathy, there is no evidence of recent myocardial infarction (Troponin level is 0.01 ng/mL), and the ECG does not show any signs of ventricular tachycardia or other arrhythmias that would increase the risk of sudden cardiac death. However, the presence of polymorphic ventricular extrasystoles on the ECG may indicate some level of electrical instability, which could potentially increase the risk of sudden cardiac death.

3. Survivor (Least Likely): Given the patient's severe heart failure symptoms and low LVEF, the prognosis for long-term survival is guarded. The patient's current medication regimen, including ACE inhibitors, beta blockers, and spironolactone, is appropriate for heart failure management, but the patient's condition is still at high risk for progression to more severe heart failure or sudden cardiac death. While it is possible that the patient could survive with close monitoring and continued medical management, the likelihood of long-term survival is lower compared to the other two options.

In conclusion, while all three outcomes are possible, pump failure death is the most likely prognosis due to the patient's severe heart failure symptoms and low LVEF. Sudden cardiac death is a possible but less likely outcome, and survivor is the least likely prognosis given the patient's current condition."
544,544,P0847,"Age: 65
Gender: Male 
Weight: 67 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 100/50 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 47
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,3
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 42
Glucose (mmol/L): 15,2
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 6,3
LDL (mmol/L): 3,49
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 564.0
Protein (g/L): 78
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,96
Urea (mg/dL): 9,82
LVEF (%): 50.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: The patient is 65 years old with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure. However, the patient's LVEF (Left Ventricular Ejection Fraction) is 50%, which is still within the normal range, indicating that the heart is functioning relatively well. The patient is on a comprehensive treatment plan, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which are all evidence-based therapies for heart failure management. The patient's pro-BNP level is elevated at 564.0 ng/L, which is consistent with heart failure, but not excessively high. Additionally, the patient's troponin level is within normal limits, indicating that there is no evidence of acute myocardial infarction. The patient's creatinine level is elevated at 133.0 mmol/L, indicating some degree of renal impairment, but it is not severe. Considering the patient's overall clinical presentation and treatment plan, the most likely prognosis is a survivor.

RANKING: Pump Failure Death (second most likely)

REASONING: The patient's LVEF is 50%, which is on the lower end of the normal range, and the patient has a history of idiopathic dilated cardiomyopathy, which is a risk factor for heart failure progression. The patient's pro-BNP level is elevated, indicating some degree of heart failure. However, the patient is on a comprehensive treatment plan, which may help to slow the progression of heart failure. The patient's creatinine level is elevated, indicating some degree of renal impairment, which is a common comorbidity in patients with heart failure. While the patient's overall clinical presentation suggests a risk of pump failure, the presence of a comprehensive treatment plan and the patient's relatively stable LVEF make pump failure death less likely than sudden cardiac death.

RANKING: Sudden Cardiac Death (least likely)

REASONING: The patient's LVEF is 50%, which is within the normal range, and the patient is on a comprehensive treatment plan that includes beta blockers, which are known to reduce the risk of sudden cardiac death. The patient's troponin level is within normal limits, indicating no evidence of acute myocardial infarction. The patient's ECG shows monomorphic ventricular extrasystoles, but no ventricular tachycardia or other high-risk findings. The patient's pro-BNP level is elevated, but not excessively high. While the patient has a history of idiopathic dilated cardiomyopathy and a reduced LVEF, the comprehensive treatment plan and the absence of high-risk ECG findings make sudden cardiac death the least likely prognosis."
545,545,P0849,"Age: 81
Gender: Female 
Weight: 76 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 47
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,46
Creatinine (mmol/L): 122.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 7
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 5,8
LDL (mmol/L): 3,52
Sodium (mEq/L): 153.0
Pro-BNP (ng/L): 1494.0
Protein (g/L): 78
T3 (pg/dL): 0,04
T4 (ng/L): 15
TSH (mIU/L): 3,52
Urea (mg/dL): 20,63
LVEF (%): 60.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Sudden Cardiac Death (SCD) > Pump Failure Death > Survivor

REASONING:

1. Sudden Cardiac Death (SCD): The patient has a history of idiopathic dilated cardiomyopathy, which increases the risk of SCD. The patient's LVEF is 60%, indicating a moderate reduction in left ventricular function. Additionally, the patient has a high Pro-BNP level (1494.0 ng/L), which is a marker of heart failure and increased risk of SCD. The presence of monomorphic ventricular extrasystoles on the ECG also suggests a potential risk of arrhythmias, which can lead to SCD. The patient's age (81 years) and NYHA Class III also contribute to the risk of SCD. Therefore, SCD is the most likely prognosis.

2. Pump Failure Death: The patient's LVEF is 60%, indicating a moderate reduction in left ventricular function, which increases the risk of pump failure. The patient's high Pro-BNP level and history of idiopathic dilated cardiomyopathy also suggest a high risk of heart failure. However, the patient is on multiple medications (ACE Inhibitor, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Spironolactone) that are commonly used to manage heart failure, which may help mitigate this risk. The patient's age and NYHA Class III also contribute to the risk of pump failure. Therefore, pump failure death is the second most likely prognosis.

3. Survivor: While the patient has several risk factors for SCD and pump failure, the fact that they are on multiple medications for heart failure and have a relatively preserved LVEF (60%) suggests that they may be able to manage their condition effectively. Additionally, the patient's age (81 years) is not extremely high, and their NYHA Class III is not the most severe classification (Class IV). The patient's glucose level is also well-controlled, which is a positive factor for overall health. Therefore, survivor is the least likely prognosis.

It is essential to note that this prognosis is based on the provided data and may not reflect the actual outcome. A more accurate prognosis can be made with a comprehensive evaluation by a healthcare professional."
546,546,P0850,"Age: 48
Gender: Male 
Weight: 60 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Other HF etiology
Albumin (g/L): 42
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,73
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,81
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2429.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,11
TSH (mIU/L): 3,28
Urea (mg/dL): 4,66
LVEF (%): 12.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely. Please note that predicting patient outcomes involves complex analysis and should be tailored to individual circumstances.

RANKING: 1. Survivor
 REASONING: Despite the patient's severe heart failure (LVEF of 12%), the presence of beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor suggests that the patient is receiving optimal medical therapy for heart failure. The patient's NYHA Class II classification indicates that the patient is experiencing some limitations with physical activity but is still able to perform most daily tasks without symptoms. The absence of significant electrolyte imbalances, such as hyperkalemia or hypokalemia, and the relatively normal sodium levels suggest that the patient is not at high risk for arrhythmias. Although the patient has a high Pro-BNP level (2429 ng/L), which is often associated with increased mortality risk, the patient's overall clinical picture and the presence of optimal medical therapy suggest a better prognosis.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's LVEF of 12% indicates severe left ventricular dysfunction, which is a significant risk factor for sudden cardiac death. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG also increases the risk of sudden cardiac death. However, the patient's optimal medical therapy and the absence of other high-risk features, such as severe electrolyte imbalances or significant arrhythmias, suggest that sudden cardiac death is less likely than pump failure death.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 12% and NYHA Class II classification suggest that the patient is experiencing severe heart failure symptoms. The patient's high Pro-BNP level (2429 ng/L) and low albumin level (42 g/L) also suggest significant cardiac dysfunction and potential fluid overload. The patient's creatinine level (80.0 mmol/L) is elevated, indicating potential renal dysfunction, which can further exacerbate heart failure symptoms. While the patient is receiving optimal medical therapy, the severity of their heart failure symptoms and potential renal dysfunction suggest that pump failure death is a possible outcome. However, the patient's overall clinical picture and optimal medical therapy suggest that this outcome is less likely than sudden cardiac death."
547,547,P0852,"Age: 68
Gender: Male 
Weight: 75 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 58
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 5
LDL (mmol/L): 2,51
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 457.0
Protein (g/L): 70
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,4
Urea (mg/dL): 4,99
LVEF (%): 60.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: Survivor

REASONING: 

Given the provided patient data, I would rank the prognosis as a survivor. Here's why:

1.  The patient is 68 years old, which is considered elderly but not extremely old. While age is a risk factor for cardiac events, it's not the only factor to consider.
2.  The patient has a history of hypertensive cardiomyopathy and hypertension, which can lead to heart failure. However, the patient is currently on medications for these conditions, and their blood pressure is well-controlled at 120/80 mmHg.
3.  The patient's NYHA Class II indicates that they have some limitations in physical activity but are still able to perform daily tasks without significant symptoms. This is a relatively mild classification, indicating that the patient's heart failure is not severe.
4.  The patient's laboratory results show a slightly elevated Pro-BNP level (457.0 ng/L), which suggests some degree of heart failure. However, the level is not extremely high, and the patient's ejection fraction (LVEF) is 60%, which is within the normal range.
5.  The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of cardiac arrhythmias. However, there is no evidence of sustained ventricular tachycardia or other severe arrhythmias.
6.  The patient is on a comprehensive medication regimen, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor. This combination of medications is often used to manage heart failure and reduce the risk of cardiac events.
7.  The patient's troponin level is low (0.01 ng/mL), which suggests that there is no acute myocardial infarction.
8.  The patient's TSH level is within the normal range (2.4 mIU/L), which suggests that there is no evidence of thyroid dysfunction, which can contribute to heart failure.

Considering these factors, the patient's prognosis is more likely to be a survivor, as they have a relatively well-controlled condition, are on appropriate medications, and do not have any severe cardiac arrhythmias or acute myocardial infarction."
548,548,P0854,"Age: 71
Gender: Male 
Weight: 72 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 100/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 156.0
AST or GOT (IU/L): 130.0
Total Cholesterol (mmol/L): 3,05
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 63
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,29
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1551.0
Protein (g/L): 73
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,33
Urea (mg/dL): 12,48
LVEF (%): 30.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

Based on the provided patient data, I would rank the prognosis as a survivor for the next few years. Here's the reasoning behind this decision:

1.  NYHA Class II: The patient is classified as NYHA Class II, indicating that the patient has some limitations in physical activity, but is still able to perform daily tasks without significant symptoms. This suggests that the patient's heart condition is manageable, and the patient is not in an advanced stage of heart failure.

2.  Medications: The patient is on beta blockers, statins, and an ACE inhibitor, which are all appropriate medications for managing heart failure and reducing the risk of cardiac events.

3.  LVEF of 30%: While the patient's left ventricular ejection fraction (LVEF) is low, indicating some degree of heart failure, it is not extremely low. An LVEF of 30% is still within the range that can be managed with medication and lifestyle changes.

4.  Pro-BNP of 1551.0 ng/L: The B-type natriuretic peptide (BNP) level is elevated, indicating that the patient's heart is under stress and working harder to pump blood. However, the level is not extremely high, suggesting that the patient's heart is still compensating.

5.  Troponin of 0.01 ng/mL: The troponin level is within normal limits, indicating that there is no ongoing myocardial infarction.

6.  ECG findings: While the patient has ventricular extrasystoles, there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias.

Considering these factors, the patient's prognosis is likely to be a survivor for the next few years, as the patient's condition is manageable with medication and lifestyle changes. However, regular monitoring and follow-up appointments with the cardiologist will be necessary to adjust the treatment plan as needed.

RANKING: Sudden Cardiac Death

REASONING: 

This prognosis is less likely than survivor due to the following reasons:

*   The patient's LVEF of 30% indicates some degree of heart failure, which increases the risk of sudden cardiac death.
*   The patient's Pro-BNP level is elevated, indicating that the heart is under stress and working harder to pump blood, which can increase the risk of sudden cardiac death.
*   The patient's past medical history of myocardial infarction and ischemic dilated cardiomyopathy also increases the risk of sudden cardiac death.

However, the patient's current medications and NYHA Class II classification suggest that the patient's condition is manageable, reducing the likelihood of sudden cardiac death.

RANKING: Pump Failure Death

REASONING: 

This prognosis is the least likely due to the following reasons:

*   The patient's LVEF of 30% indicates some degree of heart failure, but it is not extremely low.
*   The patient is on appropriate medications for managing heart failure, including beta blockers, statins, and an ACE inhibitor.
*   The patient's NYHA Class II classification suggests that the patient's condition is manageable, and the patient is not in an advanced stage of heart failure.

While the patient's condition is serious, the patient's prognosis is more likely to be a survivor due to the manageable nature of the condition and the presence of appropriate medications."
549,549,P0855,"Age: 71
Gender: Male 
Weight: 70 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 135/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 2,14
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 55
Glucose (mmol/L): 10,3
Hemoglobin (g/L): 110.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 4,6
LDL (mmol/L): 0,97
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 17984.0
Protein (g/L): 71
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,65
Urea (mg/dL): 7,15
LVEF (%): 18.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Here's my ranking from most likely to least likely:

RANKING: 1. Survivor
REASONING: The patient is 71 years old with a history of ischemic dilated cardiomyopathy, diabetes, hypertension, and myocardial infarction. Despite these risk factors, the patient's LVEF is 18%, which is relatively low but not the lowest possible value. The patient is on a combination of medications, including beta blockers, digoxin, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure. The patient's albumin level is slightly low, but the liver enzymes (ALT and AST) are within normal limits. The patient's glucose level is slightly elevated, but the hemoglobin level is within normal limits. The troponin level is very low, indicating that the patient is not experiencing an acute myocardial infarction. The pro-BNP level is elevated, indicating heart failure, but the patient's symptoms are controlled with medications. The patient's weight is relatively low for their height, which may indicate a good nutritional status. Overall, while the patient has significant comorbidities and a low LVEF, the patient's current treatment regimen and the lack of acute symptoms suggest that the patient may survive for several years with close monitoring and management of their conditions.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's LVEF is low, indicating a high risk of sudden cardiac death. The patient's pro-BNP level is elevated, indicating heart failure, and the patient's troponin level is low, indicating that the patient is not experiencing an acute myocardial infarction. The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are risk factors for sudden cardiac death. However, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death. The patient's medication regimen and the lack of acute symptoms suggest that sudden cardiac death may not be the most likely outcome.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF is low, indicating a high risk of pump failure. The patient's pro-BNP level is elevated, indicating heart failure, and the patient's weight is relatively low, which may indicate poor nutritional status and muscle wasting. The patient's creatinine level is elevated, indicating impaired renal function, which is a risk factor for pump failure. The patient's medication regimen includes loop diuretics, which are used to manage heart failure symptoms, but the patient's symptoms may not be well-controlled. The patient's low LVEF and elevated pro-BNP level suggest that pump failure may be a significant risk, but the patient's current treatment regimen and the lack of acute symptoms suggest that pump failure may not be the most likely outcome."
550,550,P0856,"Age: 63
Gender: Male 
Weight: 88 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 169.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4
LDL (mmol/L): 2,46
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 406.0
Protein (g/L): 70
T4 (ng/L): 9
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,02
Urea (mg/dL): 4,99
LVEF (%): 44.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: Survivor

REASONING: 

This patient is 63 years old with a history of ischemic dilated cardiomyopathy, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction. However, several factors suggest a relatively stable and manageable condition. The patient's LVEF (Left Ventricular Ejection Fraction) is 44%, which is below the normal range but not extremely low. The patient is on a comprehensive medication regimen, including beta blockers, ACE inhibitors, and statins, which are crucial for managing heart failure and reducing the risk of further cardiac events.

The patient's NYHA Class II indicates that the patient experiences some limitation in physical activity but is still able to perform daily tasks without severe symptoms. The absence of non-sustained ventricular tachycardia and other arrhythmias on the ECG is a positive sign.

The patient's laboratory results, including normal potassium levels and low troponin levels, indicate that the heart muscle is not currently under significant stress. The slightly elevated BNP (brain natriuretic peptide) level is a marker of heart failure, but it is not extremely high, suggesting that the patient's condition is not rapidly deteriorating.

Considering these factors, the patient's prognosis for the next few years is more likely to be a survivor. However, close monitoring and regular follow-up appointments will be necessary to adjust the medication regimen and manage the patient's condition.

The two less likely prognoses are:

1. Sudden cardiac death: While the patient has a history of myocardial infarction and other cardiovascular conditions, the absence of non-sustained ventricular tachycardia and other high-risk factors makes sudden cardiac death less likely.

2. Pump failure death: The patient's LVEF is low, but it is not extremely low, and the patient is on a comprehensive medication regimen. The patient's symptoms are manageable, and the laboratory results do not indicate severe cardiac stress, making pump failure death less likely."
551,551,P0857,"Age: 72
Gender: Female 
Weight: 76 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 6,08
Creatinine (mmol/L): 166.0
Gamma-glutamil transpeptidase (IU/L): 71
Glucose (mmol/L): 11,9
Hemoglobin (g/L): 105.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,35
LDL (mmol/L): 3,44
Sodium (mEq/L): 139.0
Protein (g/L): 67,3
T3 (pg/dL): 0,0321
T4 (ng/L): 10
Troponin (ng/mL): 0,7
TSH (mIU/L): 14,9
Urea (mg/dL): 20,9
LVEF (%): 30.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. I will rank the three possible prognoses from most likely to least likely and explain the reasoning behind the order.

RANKING: Survivor

REASONING: The patient is 72 years old with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for cardiac mortality. However, despite this, the patient's current medications and NYHA Class II classification suggest that they are being managed and have some level of functional capacity. The LVEF of 30% is relatively low, indicating reduced cardiac function, but it is not extremely low, and the patient is not in NYHA Class IV, which would indicate severe symptoms. The presence of diabetes, dyslipemia, and hypertension also contribute to the risk of cardiac events, but the patient is being treated for these conditions. The absence of sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, and bradycardia on the ECG suggests that the patient does not have an immediate high risk of arrhythmic events. The patient's overall clinical picture suggests that while they have significant cardiac disease, they are being managed and have a reasonable level of functional capacity, making a survivor prognosis the most likely outcome.

RANKING: Pump Failure Death

REASONING: The patient's LVEF of 30% indicates reduced cardiac function, which is a risk factor for pump failure. The patient's history of idiopathic dilated cardiomyopathy and diabetes also contribute to this risk. The presence of peripheral vascular disease may also impact the patient's ability to tolerate any further cardiac decompensation. However, the patient's current medications and NYHA Class II classification suggest that they are being managed and have some level of functional capacity, which reduces the likelihood of pump failure death. The patient's overall clinical picture suggests that while pump failure is a possible outcome, it is less likely than survivor.

RANKING: Sudden Cardiac Death

REASONING: The patient's LVEF of 30% and history of idiopathic dilated cardiomyopathy increase the risk of arrhythmic events, including sudden cardiac death. However, the absence of sustained ventricular tachycardia, paroxysmal supraventricular tachyarrhythmia, and bradycardia on the ECG suggests that the patient does not have an immediate high risk of arrhythmic events. The patient's current medications, including amiodarone, may also help to reduce the risk of arrhythmic events. The patient's overall clinical picture suggests that while sudden cardiac death is a possible outcome, it is the least likely of the three prognoses.

Note: This prognosis is based on the provided data and may not reflect the patient's actual outcome. A more accurate prognosis would require further evaluation and consideration of additional factors, such as the patient's social and economic status, access to healthcare, and other comorbidities."
552,552,P0859,"Age: 69
Gender: Male 
Weight: 75 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 44,7
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,56
Creatinine (mmol/L): 72.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 11,3
Hemoglobin (g/L): 136.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,57
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 185.0
Protein (g/L): 67,2
T4 (ng/L): 16
TSH (mIU/L): 1,17
Urea (mg/dL): 5,83
LVEF (%): 39.0
Medications: Diabetes Medication, Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. However, please note that a definitive prognosis can only be made after a thorough physical examination, imaging studies, and other diagnostic tests. The following is a general assessment based on the given information.

RANKING: 1. Survivor, 2. Pump failure death, 3. Sudden cardiac death

REASONING:

1. Survivor (Most Likely): The patient is 69 years old with a history of hypertensive cardiomyopathy, diabetes, and hypertension. His NYHA Class II suggests that he has some limitations in physical activity but can still perform daily tasks without symptoms. His LVEF is 39%, which is below the normal range (50-70%), indicating reduced cardiac function. However, his blood pressure is well-controlled, and he is on beta blockers and ACE inhibitors, which are beneficial for heart failure management. His Pro-BNP level is elevated at 185 ng/L, indicating some degree of heart failure, but not severely elevated. Considering his age and comorbidities, the patient's overall prognosis is guarded, but with proper management, he may be able to survive for several years.

2. Pump Failure Death (Moderately Likely): The patient's LVEF of 39% indicates reduced cardiac function, and his Pro-BNP level is elevated, suggesting heart failure. His history of hypertensive cardiomyopathy and diabetes also increases his risk for heart failure progression. However, his blood pressure is well-controlled, and he is on medications that can help manage his condition. While pump failure is a possibility, it is not the most likely outcome, given his current management plan.

3. Sudden Cardiac Death (Least Likely): The patient's ECG shows monomorphic ventricular extrasystoles, but no sustained ventricular tachycardia or non-sustained ventricular tachycardia. His potassium level is within normal limits, and his TSH is within the normal range, which reduces the likelihood of sudden cardiac death due to arrhythmias. While sudden cardiac death is always a risk in patients with heart disease, the patient's current ECG findings and laboratory results make it the least likely outcome.

In summary, while the patient's prognosis is guarded, with proper management and follow-up, he is most likely to survive for several years. Pump failure is a possibility, but sudden cardiac death is the least likely outcome based on the provided data."
553,553,P0861,"Age: 59
Gender: Male 
Weight: 58 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 42,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 11,5
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,64
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 1410.0
Protein (g/L): 83,2
T4 (ng/L): 17
TSH (mIU/L): 2,83
Urea (mg/dL): 9,82
LVEF (%): 20.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: Sudden cardiac death, Pump failure death, Survivor

REASONING:

1. Sudden cardiac death: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 20%, indicating significant left ventricular dysfunction. Additionally, the patient's elevated pro-BNP levels (1410.0 ng/L) suggest elevated ventricular stress, which is a marker for increased risk of sudden cardiac death. The presence of monomorphic ventricular extrasystoles on the ECG also increases the risk of arrhythmic events. Given these factors, sudden cardiac death is a significant concern for this patient.

2. Pump failure death: The patient's LVEF of 20% indicates severe left ventricular dysfunction, which increases the risk of pump failure. The patient's history of ischemic dilated cardiomyopathy and elevated pro-BNP levels also suggest a high risk of progressive heart failure. However, the patient is currently receiving optimal medical therapy, including ACE inhibitors, beta-blockers, and spironolactone, which are known to improve survival and reduce the risk of pump failure.

3. Survivor: Given the patient's current medical therapy and the fact that he is already being treated for his conditions, the risk of sudden cardiac death and pump failure is being actively managed. The patient's NYHA Class II classification indicates that he is experiencing some limitations in physical activity but is still able to perform daily activities without severe symptoms. The patient's laboratory values, such as his creatinine and urea levels, are within acceptable ranges, indicating that his renal function is not severely impaired. While the patient's prognosis is guarded, the fact that he is receiving optimal medical therapy and has not yet experienced a major adverse cardiac event suggests that survival is a possible outcome.

It is essential to note that this prognosis is based on the provided data and may not reflect the patient's actual outcome, as many factors can influence the course of heart failure and sudden cardiac death. Regular follow-up and monitoring of the patient's condition are crucial to reassess the prognosis and adjust the treatment plan as needed."
554,554,P0862,"Age: 62
Gender: Female 
Weight: 66 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 150/95 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 45,6
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,58
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,6
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,61
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 266.0
Protein (g/L): 79,2
T4 (ng/L): 19
TSH (mIU/L): 4,59
Urea (mg/dL): 9,82
LVEF (%): 25.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Beta Blockers, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient has a history of ischemic dilated cardiomyopathy and a low left ventricular ejection fraction (LVEF) of 25%, indicating significant heart failure. However, the patient is on optimal medical therapy with ACE inhibitors (Angiotensin II Receptor Blocker), beta blockers, and spironolactone, which are all evidence-based treatments for heart failure with reduced ejection fraction. The patient's NYHA Class II classification indicates that she has mild to moderate symptoms of heart failure, which is a relatively favorable prognostic indicator. Additionally, the patient's pro-BNP level of 266 ng/L is elevated but not extremely high, suggesting that the patient's heart failure is not in an advanced stage. The absence of other risk factors such as severe anemia, high blood pressure, or significant renal impairment also supports a more favorable prognosis. Considering these factors, the most likely outcome is that the patient will survive.

RANKING: 2. Pump failure death
REASONING: The patient's LVEF of 25% indicates severe left ventricular dysfunction, which is a strong predictor of poor outcomes in patients with heart failure. The patient's history of myocardial infarction and ischemic dilated cardiomyopathy also increases the risk of pump failure. However, the patient's NYHA Class II classification and the presence of optimal medical therapy suggest that the patient's heart failure is being managed, which may mitigate some of the risk. Additionally, the patient's creatinine level is only mildly elevated at 71.0 mmol/L, which suggests that the patient's renal function is relatively preserved. While pump failure is a possible outcome, the patient's overall clinical profile suggests that it is less likely than sudden cardiac death.

RANKING: 3. Sudden cardiac death
REASONING: The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are risk factors for sudden cardiac death. However, the patient is on amiodarone, which is an anti-arrhythmic medication that is often used to prevent sudden cardiac death in patients with heart failure. Additionally, the patient's LVEF is low, but not extremely low, and the patient's NYHA Class II classification suggests that the patient's heart failure is relatively well-managed. While sudden cardiac death is a possible outcome, the patient's overall clinical profile suggests that it is the least likely of the three possible outcomes."
555,555,P0863,"Age: 55
Gender: Male 
Weight: 80 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 100/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,28
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,74
LDL (mmol/L): 4,58
Sodium (mEq/L): 137.0
Protein (g/L): 73,8
T3 (pg/dL): 0,0597
T4 (ng/L): 14,3
Troponin (ng/mL): 0,2
TSH (mIU/L): 3,71
Urea (mg/dL): 6
LVEF (%): 25.0
Medications: Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

Based on the provided patient data, I would rank the prognosis as a survivor for the next few years. Here's the reasoning behind this ranking:

1. Low LVEF (25.0%): The patient has a significantly reduced left ventricular ejection fraction (LVEF), which is a key indicator of heart failure severity. However, this value is not extremely low, and the patient is on optimal medical therapy with loop diuretics, statins, and an ACE inhibitor, which may help stabilize the patient's condition.

2. Current medications: The patient is on medications that are commonly used to manage heart failure, which suggests that the patient is being actively managed and monitored by a healthcare team.

3. ECG findings: While the patient has ventricular extrasystoles and non-sustained ventricular tachycardia, these findings are not uncommon in patients with ischemic dilated cardiomyopathy. The absence of sustained ventricular tachycardia or other severe arrhythmias suggests that the patient's cardiac rhythm is relatively stable.

4. Laboratory values: The patient's laboratory values, such as troponin (0.2 ng/mL) and creatinine (104.0 mmol/L), are not extremely abnormal, indicating that the patient's cardiac and renal function is not severely compromised at this time.

5. Patient's age and NYHA class: The patient is 55 years old and has a NYHA class II, which suggests that the patient is not severely limited by symptoms. This is a relatively young age for heart failure, and the patient may still have a good prognosis with optimal medical therapy and lifestyle modifications.

Given these factors, I would rank the prognosis as a survivor for the next few years, with a reasonable expectation that the patient can continue to manage their condition with medical therapy and lifestyle modifications. However, it is essential to note that regular follow-up and monitoring are crucial to adjust the treatment plan as needed to prevent potential complications."
556,556,P0864,"Age: 68
Gender: Male 
Weight: 68 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 80/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 3,59
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 8,2
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 5,5
LDL (mmol/L): 1,78
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3962.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 9
Troponin (ng/mL): 0,05
TSH (mIU/L): 32,58
Urea (mg/dL): 14,15
LVEF (%): 30.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Sudden Cardiac Death (SCD) > Pump Failure Death > Survivor

REASONING:

1. Sudden Cardiac Death (SCD): The patient has a high risk of SCD due to several factors. His age (68 years) and NYHA Class III classification indicate a high risk of cardiac events. His low LVEF (30%) and high Pro-BNP (3962.0 ng/L) levels suggest severe heart failure and increased risk of arrhythmias. The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG further increase the risk of SCD. Additionally, his low blood pressure (80/60 mmHg) may indicate decreased cardiac output, which can be a trigger for SCD. The patient's medications, including beta blockers and digoxin, may help mitigate some of these risks, but the overall risk of SCD remains high.

2. Pump Failure Death: The patient's LVEF of 30% and high Pro-BNP levels indicate severe heart failure, which increases the risk of pump failure death. His low blood pressure and high creatinine levels (94.0 mmol/L) suggest renal dysfunction, which can be a complication of heart failure. The patient's medications, including loop diuretics and spironolactone, are aimed at managing heart failure, but the patient's condition is severe, and pump failure death remains a possible outcome.

3. Survivor: While the patient has several risk factors for cardiac events, his current medications and the fact that he is already receiving treatment for his conditions suggest that he is being actively managed. His low TSH level (32.58 mIU/L) may indicate that he is receiving appropriate thyroid hormone replacement therapy, which can help improve cardiac function. Additionally, his high HDL level (1.09 mmol/L) and low LDL level (1.78 mmol/L) suggest that his lipid profile is being managed, which can help reduce cardiovascular risk. While the patient's prognosis is guarded, the fact that he is receiving treatment and has some favorable lipid profiles suggests that he may be able to survive with proper management.

Please note that this prognosis is based on the provided data and may not reflect the patient's actual outcome, which can be influenced by many factors, including adherence to treatment, lifestyle changes, and other comorbidities."
557,557,P0865,"Age: 68
Gender: Male 
Weight: 80 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 160/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,7
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,65
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 9
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,46
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 1345.0
Protein (g/L): 68,2
T4 (ng/L): 13
TSH (mIU/L): 3,1
Urea (mg/dL): 7,32
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Please note that this is a complex task, and actual outcomes may vary depending on various factors, including but not limited to, the patient's adherence to treatment, lifestyle changes, and potential future health complications.

RANKING: 1. Survivor
 REASONING: The patient has a combination of risk factors, including ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and a history of myocardial infarction. However, the patient is currently being treated with a comprehensive medication regimen, including beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators. The patient's LVEF of 40% indicates a reduced left ventricular function, but it is not extremely low. The patient's Pro-BNP level of 1345 ng/L is elevated, indicating some degree of heart failure, but not excessively high. The patient's NYHA Class II indicates that the patient experiences some symptoms with moderate exertion but is still able to perform daily activities. Considering these factors, the patient's overall prognosis is relatively favorable, and with proper management, the patient is likely to survive for several years.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of non-sustained ventricular tachycardia (VT) and polymorphic ventricular extrasystoles on ECG, which are risk factors for sudden cardiac death. The patient's LVEF of 40% also increases the risk of sudden cardiac death. However, the patient is on beta blockers, which can reduce the risk of sudden cardiac death. The patient's overall prognosis is not extremely poor, and the risk of sudden cardiac death can be mitigated with proper management and monitoring.

RANKING: 3. Pump Failure Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a risk factor for pump failure. The patient's LVEF of 40% and elevated Pro-BNP level of 1345 ng/L indicate some degree of heart failure. However, the patient's NYHA Class II and overall clinical condition suggest that the patient's heart failure is not extremely severe. The patient's treatment plan includes loop diuretics, which can help manage heart failure symptoms. While pump failure is a possible outcome, it is less likely compared to the other two options, given the patient's current treatment and overall condition."
558,558,P0866,"Age: 76
Gender: Female 
Weight: 73 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 44,1
ALT or GPT (IU/L): 6.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 6,08
Creatinine (mmol/L): 77.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 147.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,65
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 306.0
Protein (g/L): 74
T4 (ng/L): 15
TSH (mIU/L): 1
Urea (mg/dL): 5,83
LVEF (%): 49.0
Medications: Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"Based on the provided patient data, here is the ranking of the three possible prognoses for the next few years:

RANKING: 1. Survivor
REASONING: The patient is 76 years old with a history of hypertensive cardiomyopathy and hypertension. However, she is currently on medications that are beneficial for her condition, including beta blockers, statins, ACE inhibitors, and a nitrovasodilator. Her LVEF (Left Ventricular Ejection Fraction) is 49%, which is below the normal range, but it is not severely reduced. The patient's eGFR (estimated glomerular filtration rate) can be estimated from the creatinine level, which is 77.0 mmol/L, suggesting that her kidney function is relatively preserved. Additionally, her NT-proBNP level is elevated at 306.0 ng/L, which is a marker of heart failure, but it is not extremely high. Considering her overall clinical picture, the patient is being actively managed for her heart failure and hypertension, and her vital signs are relatively stable. Therefore, a survivor prognosis is the most likely outcome.

RANKING: 2. Pump failure death
REASONING: While the patient's LVEF is below the normal range, it is not severely reduced, and she is on medications that are beneficial for heart failure. However, her NT-proBNP level is elevated, which suggests some degree of heart failure. Additionally, her creatinine level is elevated, suggesting some degree of kidney impairment, which can be a marker of advanced heart failure. However, her overall clinical picture does not suggest that she is in end-stage heart failure. The patient's vital signs are relatively stable, and she is being actively managed for her heart failure. Therefore, a pump failure death prognosis is less likely than a survivor prognosis but still possible.

RANKING: 3. Sudden cardiac death
REASONING: The patient's ECG shows polymorphic ventricular extrasystoles, which can be a marker of increased risk of sudden cardiac death. However, the patient's LVEF is not severely reduced, and she is on medications that are beneficial for reducing the risk of sudden cardiac death, such as beta blockers. Additionally, her heart rate is not extremely high, and her blood pressure is relatively well-controlled. While the patient's overall clinical picture suggests some degree of cardiac disease, it does not suggest a high risk of sudden cardiac death. Therefore, a sudden cardiac death prognosis is the least likely outcome."
559,559,P0867,"Age: 73
Gender: Female 
Weight: 82 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 5,25
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 10,8
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,22
LDL (mmol/L): 3,13
Sodium (mEq/L): 140.0
Protein (g/L): 68
T3 (pg/dL): 0,0438
T4 (ng/L): 18,54
Troponin (ng/mL): 0,4
TSH (mIU/L): 0,92
Urea (mg/dL): 16,9
LVEF (%): 70.0
Medications: Diabetes Medication, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the three prognoses as follows:

RANKING: 1. Survivor, 2. Pump failure death, 3. Sudden cardiac death

REASONING:

1. Survivor: The patient is 73 years old with a history of hypertensive cardiomyopathy, diabetes, and dyslipemia, which are all risk factors for cardiovascular disease. However, the patient's LVEF is 70%, which is within the normal range (> 55%). The patient is also on medications for diabetes, hypertension, and dyslipidemia, which suggests that the patient's cardiovascular risk factors are being managed. The ECG shows a monomorphic ventricular extrasystole, but no signs of sustained ventricular tachycardia or other life-threatening arrhythmias. The patient's creatinine level is elevated (159.0 mmol/L), but the patient is on loop diuretics, which may be contributing to this. Overall, while the patient has several risk factors, the patient's current management and the absence of more severe cardiac dysfunction make survivor the most likely prognosis.

2. Pump failure death: The patient's LVEF is 70%, which is within the normal range, but the patient's creatinine level is elevated (159.0 mmol/L), which may indicate some degree of renal impairment. The patient's albumin level is also low (39 g/L), which may indicate some degree of liver dysfunction. The patient's blood pressure is low (100/60 mmHg), which may be a sign of cardiac dysfunction or autonomic dysfunction. However, the patient is on loop diuretics, which may be contributing to this. While the patient has some risk factors for heart failure, the patient's LVEF is still within the normal range, making pump failure death less likely than sudden cardiac death.

3. Sudden cardiac death: The patient's ECG shows a monomorphic ventricular extrasystole, which is a risk factor for sudden cardiac death. However, the patient is on statins, which may be reducing the patient's risk of cardiac events. The patient's LVEF is 70%, which is within the normal range, and the patient is not showing any signs of sustained ventricular tachycardia or other life-threatening arrhythmias. While the patient's risk factors for sudden cardiac death are present, the patient's current management and the absence of more severe cardiac dysfunction make sudden cardiac death the least likely prognosis.

It is essential to note that this is a hypothetical prognosis, and the actual outcome may vary depending on various factors, including the patient's response to treatment, lifestyle changes, and other health conditions."
560,560,P0868,"Age: 75
Gender: Male 
Weight: 82 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 39,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 83
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,21
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 173.0
Protein (g/L): 67,4
T4 (ng/L): 16
TSH (mIU/L): 0,6
Urea (mg/dL): 4,99
LVEF (%): 53.0
Medications: Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely. Keep in mind that the actual outcome may vary based on individual patient factors and clinical judgment.

RANKING: 1. Survivor
 REASONING: The patient is 75 years old with a history of hypertensive cardiomyopathy, which is a common cause of heart failure. However, he is on optimal medical therapy, including spironolactone, statins, and an ACE inhibitor, which are all standard treatments for heart failure with reduced ejection fraction (HFrEF). His LVEF is 53%, which is slightly below the normal range but still within a relatively stable range. His NYHA Class II indicates that he has some limitations with physical activity but can still perform daily activities without discomfort. His Pro-BNP level is elevated at 173.0 ng/L, but it is not extremely high, indicating some degree of heart failure but not severe. The presence of polymorphic ventricular extrasystoles is a concern, but it is not a definitive indicator of sudden cardiac death. Considering these factors, the most likely outcome is survival with continued medical management.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of hypertensive cardiomyopathy, which increases the risk of sudden cardiac death. However, his LVEF is still relatively well-preserved at 53%, and he is on optimal medical therapy, which reduces the risk of sudden cardiac death. The presence of polymorphic ventricular extrasystoles is a concern, but it is not a definitive indicator of sudden cardiac death. His Pro-BNP level is elevated, but it is not extremely high, which suggests that his heart failure is not severe. Overall, while sudden cardiac death is a possible outcome, it is less likely than survival.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF is 53%, which is slightly below the normal range, indicating some degree of left ventricular dysfunction. However, his NYHA Class II indicates that he has some limitations with physical activity but can still perform daily activities without discomfort. His Pro-BNP level is elevated, but it is not extremely high, indicating some degree of heart failure but not severe. His optimal medical therapy and relatively stable LVEF suggest that pump failure death is less likely compared to sudden cardiac death. While pump failure death is still a possible outcome, it is the least likely of the three prognoses."
561,561,P0871,"Age: 53
Gender: Male 
Weight: 96 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 110/50 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 50
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 6,1
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 147.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5
LDL (mmol/L): 4,14
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1195.0
Protein (g/L): 84
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,13
TSH (mIU/L): 1,2
Urea (mg/dL): 12,31
LVEF (%): 39.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. I will rank the three possible prognoses - survivor, sudden cardiac death, and pump failure death - from most likely to least likely.

RANKING: 1. Survivor
REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for cardiac events. However, the patient is currently on a multidrug regimen that includes beta blockers, loop diuretics, spironolactone, statins, ACE inhibitors, and nitrovasodilators, which are all evidence-based treatments for heart failure and may have improved the patient's cardiac function. The patient's LVEF is 39%, which is relatively low but not the lowest possible value. The patient's blood pressure is within a relatively normal range, and the creatinine level is slightly elevated but not extremely high. The patient's pro-BNP level is elevated, but not excessively high. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG is also a positive sign. Considering these factors, the patient has a relatively stable condition, and with continued treatment and monitoring, a survivor prognosis is the most likely outcome.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF is 39%, which indicates a reduced left ventricular function. The patient's creatinine level is slightly elevated, indicating possible renal impairment, which can be a consequence of heart failure. The patient's pro-BNP level is elevated, which is a marker of heart failure. The patient's history of idiopathic dilated cardiomyopathy also increases the risk of pump failure. However, the patient's current treatment regimen and the absence of other severe comorbidities make pump failure death less likely than sudden cardiac death.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The patient's LVEF is 39%, which is relatively low, and the patient's pro-BNP level is elevated, both of which are risk factors for sudden cardiac death. However, the patient is on a multidrug regimen, including beta blockers, which are known to reduce the risk of sudden cardiac death. The patient's ECG does show polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death, but the absence of other arrhythmias is a positive sign. Considering these factors, sudden cardiac death is the least likely prognosis, as the patient's treatment regimen and current condition do not suggest an extremely high risk of sudden cardiac arrest."
562,562,P0874,"Age: 42
Gender: Male 
Weight: 90 kg
Height: 176 cm
NYHA Class: III
Blood Pressure: 100/80 mmHg
Past Medical History: Post-myocardial dilated cardiomyopathy, Diabetes
Albumin (g/L): 48
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,58
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 100.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,005
TSH (mIU/L): 2,13
Urea (mg/dL): 7,49
LVEF (%): 18.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. I will rank the three possible prognoses from most likely to least likely and explain the reasoning behind the order.

RANKING: 1. Survivor
REASONING: The patient's current medication regimen, including beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, suggests that they are being managed for heart failure. The patient's LVEF of 18% indicates severe left ventricular dysfunction, but the use of these medications and the absence of other high-risk factors (e.g., high blood pressure, significant arrhythmias) suggest that the patient is being effectively managed. Additionally, the patient's recent troponin level is low (0.005 ng/mL), indicating minimal myocardial damage. While the patient has a history of post-myocardial dilated cardiomyopathy and diabetes, which are both significant risk factors for adverse outcomes, the patient's current clinical status and medication regimen suggest that they are being effectively managed and are likely to survive in the short to medium term.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 18% indicates severe left ventricular dysfunction, which is a significant risk factor for pump failure. The patient's current medication regimen includes loop diuretics and spironolactone, which are commonly used to manage heart failure with reduced ejection fraction (HFrEF). However, the patient's LVEF is still relatively low, and the patient's creatinine level (82.0 mmol/L) is slightly elevated, suggesting some degree of renal impairment. While the patient's current clinical status and medication regimen suggest that they are being effectively managed, the risk of pump failure remains a concern, particularly if the patient's LVEF does not improve or if the patient develops other complications.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's LVEF of 18% indicates severe left ventricular dysfunction, which is a significant risk factor for sudden cardiac death (SCD). However, the patient's current medication regimen includes beta blockers, which are commonly used to reduce the risk of SCD in patients with HFrEF. The patient's ECG shows polymorphic ventricular extrasystoles, but there is no evidence of sustained ventricular tachycardia or other high-risk arrhythmias. While the patient's history of post-myocardial dilated cardiomyopathy and diabetes increases their risk of SCD, the patient's current clinical status and medication regimen suggest that they are being effectively managed, and the risk of SCD is relatively low compared to pump failure."
563,563,P0875,"Age: 79
Gender: Female 
Weight: 70 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 100/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 3,23
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 9,6
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,68
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1588.0
Protein (g/L): 70
T3 (pg/dL): 0,02
T4 (ng/L): 23
Troponin (ng/mL): 0,13
TSH (mIU/L): 1,34
Urea (mg/dL): 8,65
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"RANKING: Survivor

REASONING: 

Based on the provided patient data, I would rank the prognosis as Survivor, followed by Sudden Cardiac Death, and then Pump Failure Death. Here's the reasoning behind this order:

1. Survivor: The patient's age (79) and NYHA Class III indicate a moderate to severe level of heart failure. However, the patient is on a comprehensive treatment plan that includes beta blockers, digoxin, loop diuretics, statins, and an ACE inhibitor, which are all standard treatments for heart failure. The patient's LVEF of 35% is relatively low, but not extremely low. Additionally, the patient's troponin level is slightly elevated, but not alarmingly high. The patient's Pro-BNP level is elevated, which is consistent with heart failure, but not at the highest end of the spectrum. Considering the patient's treatment plan and the fact that they are already on a comprehensive regimen, I believe the patient has a good chance of survival.

2. Sudden Cardiac Death: The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. However, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death. Additionally, the patient's TSH level is within the normal range, which suggests that there is no underlying thyroid-related cause for the arrhythmia. While the patient's Pro-BNP level is elevated, it is not extremely high, which suggests that the heart failure is not at the most severe end of the spectrum. Considering these factors, I believe the risk of sudden cardiac death is lower than pump failure death.

3. Pump Failure Death: The patient's LVEF of 35% is relatively low, and the patient's NYHA Class III indicates a moderate to severe level of heart failure. The patient's creatinine level is slightly elevated, which suggests that the patient may have some degree of renal impairment. However, the patient's treatment plan includes loop diuretics, which are used to manage fluid overload and reduce the risk of pump failure. While the patient's Pro-BNP level is elevated, it is not at the highest end of the spectrum, which suggests that the heart failure is not at the most severe end of the spectrum. Considering these factors, I believe the risk of pump failure death is higher than sudden cardiac death, but lower than survivor.

It's essential to note that this prognosis is based on the provided data and may not reflect the patient's actual outcome. The patient's response to treatment and the progression of their disease will ultimately determine their actual prognosis."
564,564,P0876,"Age: 70
Gender: Female 
Weight: 74 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,48
Creatinine (mmol/L): 66.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 3,1
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,45
Potassium (mEq/L): 3,95
LDL (mmol/L): 3,31
Sodium (mEq/L): 142.0
Protein (g/L): 74,5
T3 (pg/dL): 0,0636
T4 (ng/L): 13,7
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,86
Urea (mg/dL): 5,9
LVEF (%): 70.0
Medications: Calcium Channel Blocker, Diabetes Medication
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: Survivor
REASONING: 

Based on the provided patient data, I would rank the prognosis as survivor due to several factors:

1.  Age: The patient is 70 years old, which is considered elderly but not extremely old for a cardiac prognosis.
2.  LVEF (Left Ventricular Ejection Fraction): The patient's LVEF is 70%, which is within the normal range (50-70%). This indicates that the heart is pumping efficiently, reducing the risk of pump failure.
3.  Blood Pressure: Although the patient has hypertension, the blood pressure is controlled at 160/80 mmHg, which is relatively well-managed.
4.  Medications: The patient is on a calcium channel blocker and diabetes medication, which are both effective in managing hypertension and diabetes, respectively.
5.  ECG Impression: The patient has a ventricular extrasystole, but no sustained ventricular tachycardia or non-sustained ventricular tachycardia, which reduces the risk of sudden cardiac death.
6.  Troponin: The troponin level is 0.5 ng/mL, which is within the normal range (<2 ng/mL). Elevated troponin levels are associated with cardiac damage or stress.
7.  Other parameters: The patient's other parameters, such as albumin, liver enzymes, and electrolytes, are within normal ranges, indicating no acute kidney injury or liver disease.

Considering these factors, the patient's prognosis is more likely to be a survivor, as the patient's heart function is relatively preserved, and there are no high-risk features for sudden cardiac death or pump failure. However, the patient's hypertension and diabetes require continued management to prevent long-term cardiac damage."
565,565,P0877,"Age: 60
Gender: Female 
Weight: 74 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 8,4
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 593.0
Protein (g/L): 65
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,84
Urea (mg/dL): 6,16
LVEF (%): 15.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Survivor
REASONING: Despite the patient's advanced age, history of ischemic dilated cardiomyopathy, and low LVEF (15%), several factors suggest a relatively favorable prognosis. The patient is on a comprehensive medication regimen, including beta blockers, digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are all appropriate for managing heart failure and reducing the risk of sudden cardiac death. The patient's ejection fraction is low, but the absence of significant arrhythmias, such as sustained ventricular tachycardia, and the presence of only non-sustained ventricular tachycardia, suggest a relatively low risk of sudden cardiac death. Additionally, the patient's hemoglobin level is within a relatively normal range, and the absence of significant kidney dysfunction (normal creatinine level) suggests that the patient is not in a state of advanced heart failure. The patient's TSH level is also within a normal range, which may indicate that the patient is not experiencing significant thyroid-related complications. While the patient's Pro-BNP level is elevated, it is not excessively high, and the patient's overall clinical presentation does not suggest an acute decompensated heart failure. Therefore, a survivor prognosis is considered the most likely outcome.

RANKING: Sudden Cardiac Death
REASONING: The patient's history of ischemic dilated cardiomyopathy, low LVEF, and non-sustained ventricular tachycardia suggest a risk of sudden cardiac death. However, the absence of significant arrhythmias, such as sustained ventricular tachycardia, and the presence of a comprehensive medication regimen, including beta blockers, which are known to reduce the risk of sudden cardiac death, suggest that this outcome is less likely than survivor. The patient's ejection fraction is low, but the absence of significant kidney dysfunction and the presence of a relatively normal hemoglobin level suggest that the patient is not in a state of advanced heart failure. The patient's Pro-BNP level is elevated, but not excessively high, which may indicate that the patient is not experiencing acute decompensated heart failure.

RANKING: Pump Failure Death
REASONING: This outcome is the least likely due to the patient's relatively stable clinical presentation and the absence of significant kidney dysfunction. The patient's ejection fraction is low, but the absence of significant arrhythmias, such as sustained ventricular tachycardia, and the presence of a comprehensive medication regimen suggest that the patient is not in a state of advanced heart failure. The patient's Pro-BNP level is elevated, but not excessively high, which may indicate that the patient is not experiencing acute decompensated heart failure. The patient's hemoglobin level is within a relatively normal range, and the absence of significant thyroid dysfunction (normal TSH level) suggests that the patient is not experiencing significant metabolic complications. Therefore, while the patient's history of ischemic dilated cardiomyopathy and low LVEF suggest a risk of pump failure, the overall clinical presentation suggests that this outcome is less likely than the other two options."
566,566,P0878,"Age: 57
Gender: Male 
Weight: 62 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 140/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 38,5
ALT or GPT (IU/L): 8.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,08
Creatinine (mmol/L): 212.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5,2
LDL (mmol/L): 3,8
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 6606.0
Protein (g/L): 68,4
T4 (ng/L): 16
TSH (mIU/L): 3,87
Urea (mg/dL): 19,8
LVEF (%): 40.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden cardiac death, 2. Pump failure death, 3. Survivor

REASONING:

1. Sudden cardiac death: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's LVEF is 40%, indicating reduced cardiac function. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is a known risk factor for sudden cardiac death. The patient's Pro-BNP level is elevated at 6606 ng/L, which is indicative of heart failure. Additionally, the patient's low HDL and high LDL levels may contribute to an increased risk of cardiac arrhythmias. Considering these factors, sudden cardiac death is a significant concern.

2. Pump failure death: The patient's LVEF is 40%, which indicates reduced cardiac function, and the patient is on loop diuretics, which suggests that they are experiencing symptoms of heart failure. The patient's creatinine level is elevated at 212.0 mmol/L, indicating impaired renal function, which is often associated with advanced heart failure. The patient's Pro-BNP level is also elevated, further supporting the diagnosis of heart failure. However, the patient's NYHA class is II, which indicates that they are still able to perform some physical activity without symptoms, suggesting that the heart failure is not yet severe.

3. Survivor: While the patient has several risk factors for cardiac events, their current medication regimen and NYHA class II suggest that they are receiving adequate treatment for their heart failure and are able to manage their symptoms. The patient's low sodium level and high potassium level are within the normal range, indicating that their electrolyte balance is well-managed. The patient's TSH and T4 levels are also within the normal range, indicating that their thyroid function is well-managed. While the patient's Pro-BNP level is elevated, it is not extremely high, and the patient's overall clinical picture suggests that they are not at the highest risk for sudden cardiac death or pump failure."
567,567,P0879,"Age: 71
Gender: Male 
Weight: 67 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 130/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 8
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,25
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 304.0
Protein (g/L): 63
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,38
Urea (mg/dL): 8,32
LVEF (%): 50.0
Medications: Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: Survivor
REASONING: The patient is 71 years old with a history of ischemic dilated cardiomyopathy and myocardial infarction, which suggests a high risk for cardiac complications. However, the patient is on beta blockers and ACE inhibitors, which are appropriate medications for managing heart failure and reducing the risk of cardiac events. The patient's left ventricular ejection fraction (LVEF) is 50%, which is within the normal range for a patient with a history of heart failure. The patient's troponin levels are normal, indicating that there is no current acute myocardial infarction. The patient's pro-BNP levels are elevated, but not excessively high, suggesting that the patient is not in a state of severe heart failure. The patient's ECG is also relatively normal, with no signs of ventricular tachycardia or other life-threatening arrhythmias. Considering these factors, the patient's prognosis is likely to be a survivor, with a good chance of managing their condition with medication and lifestyle modifications.

RANKING: Sudden Cardiac Death
REASONING: While the patient's history and current condition suggest a high risk for cardiac complications, the patient's overall profile does not strongly indicate a high risk for sudden cardiac death. The patient's LVEF is within a relatively normal range, and their troponin levels are normal. The patient's ECG is relatively normal, and there are no signs of life-threatening arrhythmias. The patient's pro-BNP levels are elevated, but not excessively high, suggesting that the patient is not in a state of severe heart failure. The patient's medication regimen is also appropriate for managing heart failure and reducing the risk of cardiac events. While sudden cardiac death is a possibility, it is less likely compared to other outcomes.

RANKING: Pump Failure Death
REASONING: The patient's history of ischemic dilated cardiomyopathy and myocardial infarction suggests a high risk for heart failure progression. However, the patient's LVEF is within a relatively normal range, and their troponin levels are normal. The patient's pro-BNP levels are elevated, but not excessively high, suggesting that the patient is not in a state of severe heart failure. The patient's medication regimen is also appropriate for managing heart failure and reducing the risk of cardiac events. Additionally, the patient's ECG is relatively normal, with no signs of life-threatening arrhythmias. While pump failure is a possibility, it is less likely compared to other outcomes, given the patient's current profile and medication regimen."
568,568,P0883,"Age: 66
Gender: Female 
Weight: 62 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 170/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,69
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,49
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 325.0
Protein (g/L): 76
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 4
Urea (mg/dL): 5,66
LVEF (%): 64.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: 

The patient is 66 years old with a history of hypertensive cardiomyopathy and hypertension, which are risk factors for heart failure. However, the patient's ejection fraction (LVEF) is 64%, which is within the normal range (50-70%). This suggests that the patient's heart function is relatively preserved. The patient is also on medications that are commonly used to manage heart failure and hypertension, including an angiotensin II receptor blocker, beta blockers, and loop diuretics.

The patient's ECG shows monomorphic ventricular extrasystoles, but no non-sustained ventricular tachycardia or other high-risk features. The troponin level is within normal limits, indicating that there is no evidence of acute coronary syndrome.

The patient's BNP level is elevated at 325 ng/L, which is a marker of heart failure. However, the patient's NYHA class is II, indicating that they have some symptoms of heart failure but are still able to perform everyday activities without significant limitation.

Overall, while the patient has some risk factors for heart failure and cardiac arrhythmias, their preserved LVEF, lack of high-risk ECG findings, and controlled symptoms suggest that a survivor prognosis is the most likely outcome.

The next most likely prognosis would be pump failure death, but this is less likely due to the patient's relatively preserved LVEF and controlled symptoms.

The least likely prognosis would be sudden cardiac death, as the patient's ECG findings do not suggest a high risk of arrhythmic death, and their LVEF is within the normal range.

Therefore, the order of likelihood is:

1. Survivor (most likely)
2. Pump failure death
3. Sudden cardiac death (least likely)"
569,569,P0885,"Age: 59
Gender: Male 
Weight: 100 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 3,65
Creatinine (mmol/L): 74.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 156.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,2
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 105.0
Protein (g/L): 68
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,03
Urea (mg/dL): 4,99
LVEF (%): 33.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac complications. However, the patient's current NYHA Class II indicates that they are experiencing some limitations in physical activity but are still able to perform everyday tasks without symptoms. The patient's LVEF of 33% is low, indicating reduced cardiac function, but it is not extremely low. The patient is on beta blockers, statins, and an ACE inhibitor, which are standard treatments for heart failure and ischemic heart disease. The absence of sustained ventricular tachycardia and normal troponin levels suggest that the patient is not experiencing an acute cardiac event. The patient's pro-BNP level is elevated, but not extremely high, indicating some level of cardiac stress but not necessarily severe heart failure. The patient's age, weight, and blood pressure are not extremely high-risk factors. Overall, while the patient has significant cardiac risk factors, their current treatment and lack of acute cardiac events suggest that a survivor prognosis is more likely.

RANKING: Sudden Cardiac Death

REASONING: The patient has a history of ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The patient's LVEF of 33% is low, indicating reduced cardiac function, which can increase the risk of arrhythmias and sudden cardiac death. The patient's pro-BNP level is elevated, indicating some level of cardiac stress. However, the absence of sustained ventricular tachycardia and normal troponin levels suggest that the patient is not experiencing an acute cardiac event. The patient's treatment with beta blockers, statins, and an ACE inhibitor may help reduce the risk of sudden cardiac death. However, the patient's low LVEF and history of ischemic dilated cardiomyopathy increase the risk of sudden cardiac death.

RANKING: Pump Failure Death

REASONING: The patient's LVEF of 33% is low, indicating reduced cardiac function, which increases the risk of pump failure. The patient's history of ischemic dilated cardiomyopathy and elevated pro-BNP level suggest that the patient is experiencing some level of cardiac stress. The patient's weight and blood pressure are not extremely high-risk factors, but the patient's NYHA Class II suggests that they are experiencing some limitations in physical activity. The patient's treatment with beta blockers, statins, and an ACE inhibitor may help manage heart failure symptoms, but the patient's low LVEF and history of ischemic dilated cardiomyopathy increase the risk of pump failure. However, the patient's current NYHA Class II and lack of acute cardiac events suggest that pump failure is less likely compared to sudden cardiac death."
570,570,P0886,"Age: 75
Gender: Male 
Weight: 60 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 115/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 6.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 3,15
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,91
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1186.0
Protein (g/L): 66
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,4
Urea (mg/dL): 10,15
LVEF (%): 20.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

Considering the patient's age, past medical history, and current clinical presentation, I would rank the prognosis as Survivor. Here's the reasoning behind this ranking:

1.  Age and NYHA Class: The patient is 75 years old, which is a high-risk age group for cardiovascular events. However, his NYHA Class II indicates that he has some limitations in physical activity but is still relatively stable.

2.  Past Medical History: The patient has ischemic dilated cardiomyopathy, which is a significant risk factor for adverse outcomes. However, he is on beta blockers, statins, and an ACE inhibitor, which are all appropriate medications for this condition.

3.  Laboratory Results: The patient's creatinine level (88.0 mmol/L) is elevated, indicating some degree of kidney dysfunction. However, his hemoglobin level is within the normal range, which suggests that his kidney function is not severely compromised.

4.  LVEF and Pro-BNP: The patient's LVEF (20%) is low, indicating reduced cardiac function. However, his Pro-BNP level (1186.0 ng/L) is not extremely elevated, which might suggest that his heart is not under extreme stress.

5.  ECG Findings: The patient has polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are concerning findings. However, the absence of paroxysmal supraventricular tachyarrhythmia and bradycardia suggests that his heart rhythm is relatively stable.

Considering these factors, while the patient's prognosis is guarded, I believe that he is most likely to survive for the next few years. This is because he has a relatively stable NYHA Class, is on appropriate medications, and does not have any acute signs of decompensation. However, close monitoring and regular follow-up with a cardiologist will be essential to manage his condition and prevent potential complications.

RANKING: Sudden Cardiac Death (Second Most Likely)

REASONING: 

Sudden cardiac death is a possible outcome for this patient due to his ischemic dilated cardiomyopathy, low LVEF, and ECG findings of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia. These factors increase the risk of arrhythmic events, which can lead to sudden cardiac death.

RANKING: Pump Failure Death (Least Likely)

REASONING: 

Pump failure death is a possible outcome for this patient, but it is less likely than sudden cardiac death. The patient's LVEF is low, and his Pro-BNP level is elevated, which suggests some degree of heart failure. However, his NYHA Class II and relatively stable laboratory results suggest that he is not in acute heart failure. Additionally, his medications, including beta blockers and ACE inhibitors, are appropriate for managing heart failure and reducing the risk of pump failure death."
571,571,P0889,"Age: 66
Gender: Male 
Weight: 85 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertropic cardiomyopathy, Dyslipemia, Peripheral vascular disease
Albumin (g/L): 50
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 6,47
Creatinine (mmol/L): 70.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,6
LDL (mmol/L): 4,37
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 54.0
Protein (g/L): 73,4
T4 (ng/L): 16
TSH (mIU/L): 1,16
Urea (mg/dL): 5,99
LVEF (%): 68.0
Medications: Calcium Channel Blocker
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: Survivor
 REASONING: 

Based on the provided patient data, I would rank the prognosis as a survivor for the next few years. Here's the reasoning behind this ranking:

1.  The patient is 66 years old, which is considered elderly, but not extremely old. The patient's age is not a significant risk factor for sudden cardiac death or pump failure death.
2.  The patient has a history of hypertrophic cardiomyopathy, which is a significant risk factor for sudden cardiac death. However, the patient's LVEF (Left Ventricular Ejection Fraction) is 68%, which is within the normal range (50-70%). This suggests that the patient's heart function is relatively preserved.
3.  The patient's blood pressure is well-controlled at 140/80 mmHg, which reduces the risk of cardiac complications.
4.  The patient's lipid profile shows high total cholesterol (6.47 mmol/L) and low HDL (1.55 mmol/L), but the LDL is within the target range. The patient's glucose level is also within the normal range (6.1 mmol/L).
5.  The patient's Pro-BNP level is 54.0 ng/L, which is within the normal range (< 125 ng/L). This suggests that the patient does not have significant heart failure or fluid overload.
6.  The patient's ECG shows monomorphic ventricular extrasystoles, but no sustained ventricular tachycardia or non-sustained ventricular tachycardia. This suggests that the patient's heart rhythm is relatively stable.
7.  The patient's medication regimen includes a calcium channel blocker, which is a common treatment for hypertension and angina.

Considering these factors, the patient's prognosis is likely to be a survivor for the next few years. However, regular follow-up appointments and monitoring are essential to ensure that the patient's condition does not deteriorate.

RANKING: Sudden Cardiac Death
 REASONING: 

This prognosis is less likely due to the following reasons:

- The patient's LVEF is within the normal range, which reduces the risk of sudden cardiac death.
- The patient's ECG does not show any signs of sustained ventricular tachycardia or non-sustained ventricular tachycardia.

RANKING: Pump Failure Death
 REASONING: 

This prognosis is the least likely due to the following reasons:

- The patient's LVEF is within the normal range, which suggests that the patient's heart function is relatively preserved.
- The patient's Pro-BNP level is within the normal range, which suggests that the patient does not have significant heart failure or fluid overload.
- The patient's blood pressure is well-controlled, which reduces the risk of cardiac complications.

However, it's essential to note that the patient's hypertrophic cardiomyopathy and peripheral vascular disease are significant risk factors for pump failure death. Regular follow-up appointments and monitoring are necessary to ensure that the patient's condition does not deteriorate."
572,572,P0892,"Age: 61
Gender: Female 
Weight: 59 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 95/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,57
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 886.0
Protein (g/L): 69
T4 (ng/L): 27
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,95
Urea (mg/dL): 12,81
LVEF (%): 43.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. I will rank the three possible prognoses from most likely to least likely and explain the reasoning behind each.

RANKING: 1. Survivor
 REASONING: The patient is 61 years old with a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipemia. Despite these risk factors, the patient's current medication regimen includes beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all appropriate for heart failure management. The patient's NYHA Class II indicates that the patient has some limitations in physical activity but is still able to perform daily tasks without symptoms. The LVEF of 43% is lower than normal, but it is not extremely low. The absence of sustained ventricular tachycardia and the presence of only a non-sustained ventricular tachycardia on the ECG suggest that the patient's cardiac function is not severely compromised at the moment. The patient's BNP level of 886 ng/L is elevated, indicating some degree of heart failure, but it is not extremely high. Considering these factors, the patient's prognosis for survival over the next few years is relatively good.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which increases the risk of sudden cardiac death. The presence of non-sustained ventricular tachycardia on the ECG is a risk factor for sudden cardiac death. However, the patient's current medication regimen and NYHA Class II suggest that the patient's cardiac function is not severely compromised at the moment. The absence of other risk factors such as severe left ventricular dysfunction, severe hypertension, or severe electrolyte imbalances makes sudden cardiac death less likely.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 43% indicates some degree of left ventricular dysfunction, which increases the risk of pump failure. The patient's BNP level of 886 ng/L is elevated, indicating some degree of heart failure. However, the patient's NYHA Class II and the presence of a medication regimen that includes beta blockers, loop diuretics, spironolactone, and an ACE inhibitor suggest that the patient's cardiac function is being managed effectively. The patient's age and history of ischemic dilated cardiomyopathy also contribute to the risk of pump failure, but the overall prognosis for pump failure death is less likely than sudden cardiac death due to the patient's relatively stable cardiac function and effective medication regimen."
573,573,P0893,"Age: 62
Gender: Male 
Weight: 95 kg
Height: 183 cm
NYHA Class: II
Blood Pressure: 130/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40,4
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 128.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,56
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 3572.0
Protein (g/L): 69,4
T4 (ng/L): 17
TSH (mIU/L): 1,32
Urea (mg/dL): 7,49
LVEF (%): 60.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely:

RANKING: Survivor
REASONING: The patient has a relatively well-controlled blood pressure, and the medications (Beta Blockers, ACE Inhibitor, Statins) are appropriate for a patient with ischemic dilated cardiomyopathy and hypertension. The LVEF is 60%, which is within the normal range, indicating that the heart is still pumping efficiently. The patient's NYHA Class II classification suggests that the patient has some limitations in physical activity but is still able to perform daily activities without significant symptoms. The Pro-BNP level of 3572 ng/L is elevated, but it's not extremely high, which suggests that the patient is not in acute heart failure. Additionally, the patient's kidney function is relatively preserved, with a creatinine level of 93.0 mol/L. Considering these factors, the most likely prognosis for this patient is a survivor.

RANKING: Sudden Cardiac Death
REASONING: The patient has a history of ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The presence of polymorphic ventricular extrasystoles on the ECG is a concerning sign, as it can be a marker of increased risk of arrhythmias. However, the absence of non-sustained ventricular tachycardia or ventricular tachycardia on the ECG reduces the likelihood of sudden cardiac death. The patient's LVEF is within the normal range, which suggests that the heart is still pumping efficiently, and the patient is on appropriate medications for a patient with ischemic dilated cardiomyopathy. Considering these factors, sudden cardiac death is a possible but less likely prognosis compared to survivor.

RANKING: Pump Failure Death
REASONING: The patient's LVEF is within the normal range, and the patient is on appropriate medications for heart failure, which suggests that the heart is still pumping efficiently. The patient's kidney function is relatively preserved, with a creatinine level of 93.0 mol/L. The Pro-BNP level of 3572 ng/L is elevated, but it's not extremely high, which suggests that the patient is not in acute heart failure. The patient's NYHA Class II classification suggests that the patient has some limitations in physical activity but is still able to perform daily activities without significant symptoms. Considering these factors, pump failure death is the least likely prognosis for this patient."
574,574,P0894,"Age: 57
Gender: Male 
Weight: 68 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45,2
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 7,01
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 188
Glucose (mmol/L): 7
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,63
Potassium (mEq/L): 4,8
LDL (mmol/L): 4,6
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 710.0
Protein (g/L): 76,7
T4 (ng/L): 14
TSH (mIU/L): 6,21
Urea (mg/dL): 5,83
LVEF (%): 46.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 1. Survivor
 REASONING: The patient has a history of enolic dilated cardiomyopathy and is currently on medications such as digoxin, loop diuretics, ACE inhibitor, and nitrovasodilator, which indicates that the patient is being managed for heart failure. The patient's LVEF is 46%, which is slightly below the normal range, indicating some degree of left ventricular dysfunction. However, the patient's NYHA Class II indicates that the patient is experiencing some symptoms of heart failure, but they are not severe. The patient's blood pressure is within a relatively normal range, and there is no indication of severe electrolyte imbalances. The patient's Pro-BNP level is elevated at 710.0 ng/L, which is consistent with heart failure, but it is not extremely high. The patient's creatinine level is slightly elevated, but it is not significantly high. The patient's liver enzymes are also slightly elevated, which could be indicative of non-cardiac comorbidities. Overall, while the patient has some risk factors for cardiac disease, the overall clinical picture suggests that the patient is being well-managed and has a good prognosis for survival.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF of 46% indicates some degree of left ventricular dysfunction, which increases the risk of pump failure. The patient's NYHA Class II indicates that the patient is experiencing some symptoms of heart failure, which could progress to more severe symptoms if left untreated. The patient's Pro-BNP level is elevated, which is consistent with heart failure. However, the patient is on medications that are typically used to manage heart failure, which suggests that the patient's condition is being actively managed. The patient's creatinine level is slightly elevated, which could be indicative of renal impairment, which is a common comorbidity in patients with heart failure. Overall, while the patient has some risk factors for pump failure, the patient's overall clinical picture suggests that the patient is being well-managed and has a relatively good prognosis.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient's ECG shows ventricular extrasystoles and non-sustained ventricular tachycardia, which are risk factors for sudden cardiac death. However, the patient is on medications such as ACE inhibitor and nitrovasodilator, which are typically used to manage heart failure and reduce the risk of sudden cardiac death. The patient's LVEF is 46%, which is not extremely low, and the patient's NYHA Class II indicates that the patient is not experiencing severe symptoms of heart failure. The patient's Pro-BNP level is elevated, but it is not extremely high. Overall, while the patient has some risk factors for sudden cardiac death, the patient's overall clinical picture suggests that the patient is being well-managed and has a relatively good prognosis. The patient's risk factors for sudden cardiac death are somewhat mitigated by the patient's current medications and overall clinical picture."
575,575,P0895,"Age: 77
Gender: Male 
Weight: 66 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 154/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41,2
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,4
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 142.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 5,1
LDL (mmol/L): 2,79
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 126.0
Protein (g/L): 66,3
T4 (ng/L): 15
TSH (mIU/L): 0,85
Urea (mg/dL): 8,99
LVEF (%): 63.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Given the information, I will rank the possible prognoses from most likely to least likely.

RANKING: 1. Survivor
REASONING: The patient is 77 years old with a history of hypertensive cardiomyopathy and hypertension, which are risk factors for cardiovascular disease. However, the patient's left ventricular ejection fraction (LVEF) is 63%, which is within the normal range. The patient is also on an ACE inhibitor, which is a medication commonly used to treat heart failure and high blood pressure. The patient's ECG shows non-sustained ventricular tachycardia, but this is not an uncommon finding in patients with hypertension and cardiomyopathy. The patient's Pro-BNP level is elevated at 126.0 ng/L, but this can be seen in patients with heart failure, hypertension, or other conditions. Considering the patient's age and the presence of some risk factors, a survivor prognosis is still the most likely outcome, but with close monitoring and management of the patient's condition.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF is 63%, which is within the normal range, but it may indicate a risk of future heart failure. The patient's Pro-BNP level is elevated, which is a marker of heart failure. The patient's creatinine level is slightly elevated at 95.0 mmol/L, which may indicate some kidney impairment, but it is not severe. The patient's medications include an ACE inhibitor, which is a medication commonly used to treat heart failure. Considering the patient's age and the presence of some risk factors, pump failure death is a possible outcome, but it is less likely than a survivor prognosis.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. However, the patient's LVEF is within the normal range, and the patient is on an ACE inhibitor, which is a medication commonly used to reduce the risk of sudden cardiac death. The patient's age is 77 years, which is a risk factor for sudden cardiac death, but it is not the most significant risk factor in this case. Considering the patient's overall condition and the presence of some risk factors, sudden cardiac death is the least likely outcome.

Please note that this prognosis is based on the provided data and may not be accurate without further information and a physical examination."
576,576,P0896,"Age: 47
Gender: Male 
Weight: 100 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 100/63 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 48
ALT or GPT (IU/L): 45.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 28
Glucose (mmol/L): 10,5
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 5,1
LDL (mmol/L): 2,61
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 226.0
Protein (g/L): 72
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,77
Urea (mg/dL): 7,65
LVEF (%): 20.0
Medications: Beta Blockers, Statins, Hydralazine, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the prognosis for the next few years, ordered from most likely to least likely:

RANKING: Survivor
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a chronic condition affecting the heart muscle, leading to reduced left ventricular ejection fraction (LVEF of 20%). However, the patient is on optimal medical therapy, including beta blockers, statins, hydralazine, ACE inhibitor, and nitrovasodilator, which are commonly used to manage heart failure and dilated cardiomyopathy. The patient's NYHA class is II, indicating that they experience some limitations in physical activity but are still able to perform daily tasks without significant symptoms. The absence of sustained ventricular tachycardia, ventricular fibrillation, or other high-risk ECG findings suggests that the patient is at a relatively lower risk for sudden cardiac death. The patient's Pro-BNP level is elevated, but not extremely high, which may indicate that the patient is not in acute heart failure. Considering these factors, the most likely prognosis is that the patient will survive with continued medical management.

RANKING: Pump failure death
 REASONING: The patient has a significantly reduced LVEF of 20%, indicating severe left ventricular dysfunction. The patient's creatinine level is elevated (124.0 mol/L), suggesting impaired renal function, which is a common comorbidity in patients with heart failure. The patient's total cholesterol level is high, which may contribute to further cardiac damage. The patient's NT-proBNP level is elevated, indicating increased ventricular wall stress. However, the patient is on optimal medical therapy, which may slow the progression of heart failure. While the risk of pump failure death is significant, it is not the most likely prognosis due to the patient's current medical management.

RANKING: Sudden cardiac death
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which increases the risk of sudden cardiac death. However, the absence of sustained ventricular tachycardia, ventricular fibrillation, or other high-risk ECG findings, as well as the patient's NYHA class II, suggests that the risk of sudden cardiac death is relatively low. The patient's Pro-BNP level is elevated, but not extremely high, which may indicate that the patient is not in acute heart failure. Additionally, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death in patients with heart failure. Therefore, sudden cardiac death is the least likely prognosis."
577,577,P0900,"Age: 67
Gender: Male 
Weight: 74 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 120/53 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 42,1
ALT or GPT (IU/L): 46.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 3,05
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 93
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,34
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 3611.0
Protein (g/L): 66,9
T4 (ng/L): 19
TSH (mIU/L): 2,15
Urea (mg/dL): 5,99
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the ranking of the three possible prognoses:

RANKING: 1. Survivor, 2. Pump failure death, 3. Sudden cardiac death

REASONING:

1. Survivor: The patient has a history of ischemic dilated cardiomyopathy, which indicates that the heart muscle has been damaged due to a heart attack. However, the patient is already on optimal medical therapy with beta blockers, statins, and an ACE inhibitor, which suggests that the patient is receiving appropriate treatment for heart failure. The patient's NYHA Class II classification indicates that the patient is experiencing some limitations in physical activity but is still able to perform daily activities without severe symptoms. The LVEF of 40% is relatively low, but it is not the lowest possible value. The patient's Pro-BNP level is elevated at 3611.0 ng/L, which suggests that the patient has some degree of heart failure, but it is not extremely high. The patient's ECG shows non-sustained ventricular tachycardia, but it is not a sustained arrhythmia. Considering these factors, the patient's prognosis is likely to be a survivor, with the possibility of continued medical management and monitoring.

2. Pump failure death: The patient's LVEF of 40% indicates that the heart is not pumping efficiently, which can lead to pump failure. The patient's Pro-BNP level is elevated, which is a marker of heart failure. The patient's creatinine level is slightly elevated at 87.0 umol/L, which may indicate some degree of renal impairment, which can be associated with heart failure. However, the patient's NYHA Class II classification and the fact that the patient is already on optimal medical therapy suggest that the patient is not in the most severe stage of heart failure. The patient's ECG shows non-sustained ventricular tachycardia, which can be a sign of increased risk of sudden cardiac death, but it is not a definitive indicator of pump failure.

3. Sudden cardiac death: The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. However, the patient's NYHA Class II classification and the fact that the patient is already on optimal medical therapy suggest that the patient is not in the most severe stage of heart failure. The patient's LVEF of 40% is relatively low, but it is not the lowest possible value. The patient's Pro-BNP level is elevated, but it is not extremely high. The patient's creatinine level is slightly elevated, but it is not significantly high. Considering these factors, the risk of sudden cardiac death is lower than the risk of pump failure death.

It's worth noting that the prognosis of this patient can be influenced by various factors such as adherence to medication, lifestyle modifications, and regular follow-up appointments with the cardiologist."
578,578,P0901,"Age: 52
Gender: Male 
Weight: 78 kg
Height: 167 cm
NYHA Class: III
Blood Pressure: 115/65 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 48
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,74
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 64
Glucose (mmol/L): 8,2
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 5
LDL (mmol/L): 4,01
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1558.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 18
Troponin (ng/mL): 0,06
TSH (mIU/L): 2,56
Urea (mg/dL): 8,32
LVEF (%): 26.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses for the next few years from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient's current medications, including beta blockers, angiotensin II receptor blockers, spironolactone, and loop diuretics, indicate that they are receiving optimal treatment for heart failure with reduced ejection fraction (HFrEF). The patient's LVEF of 26% is low, but the use of beta blockers and ACE inhibitors/ARBs suggests that the patient is receiving guideline-directed medical therapy. The patient's NYHA Class III classification indicates that they have symptoms with ordinary physical activity but are not limited during rest. The patient's blood pressure is well-controlled, and their albumin and creatinine levels are within the normal range. Although the patient has a high Pro-BNP level, which indicates elevated filling pressures, the patient's overall clinical picture suggests that they are receiving adequate treatment and are likely to survive.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's history of idiopathic dilated cardiomyopathy and low LVEF make them at risk for sudden cardiac death. However, the patient's current medications, including beta blockers, which are known to reduce the risk of sudden cardiac death, and their relatively well-controlled blood pressure, suggest that the risk of sudden cardiac death is lower than that of pump failure death. The patient's ECG impression of polymorphic ventricular extrasystoles is a risk factor for sudden cardiac death, but the absence of sustained ventricular tachycardia or non-sustained ventricular tachycardia makes this risk lower.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 26% indicates severe left ventricular dysfunction, which increases the risk of pump failure death. The patient's high Pro-BNP level and elevated creatinine level suggest that the patient has elevated filling pressures and renal dysfunction, which are both risk factors for pump failure. The patient's NYHA Class III classification and symptoms with ordinary physical activity also suggest that the patient's heart failure is symptomatic and may progress to pump failure. However, the patient's current medications and relatively well-controlled blood pressure suggest that the patient is receiving optimal treatment, which reduces the risk of pump failure death.

Please note that these prognoses are based on the provided data and may not reflect the patient's actual outcome."
579,579,P0902,"Age: 44
Gender: Male 
Weight: 75 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 140/100 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 41.0
Total Cholesterol (mmol/L): 7,55
Creatinine (mmol/L): 89.0
Gamma-glutamil transpeptidase (IU/L): 151
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 173.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 5,2
LDL (mmol/L): 4,27
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 147.0
Protein (g/L): 73
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,06
TSH (mIU/L): 0,753
Urea (mg/dL): 5,83
LVEF (%): 39.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: 1. Survivor
 REASONING: The patient is 44 years old with a history of idiopathic dilated cardiomyopathy, dyslipemia, and hypertension. However, the patient is on an ACE inhibitor, which is a standard treatment for heart failure and high blood pressure. The LVEF (left ventricular ejection fraction) is 39%, indicating reduced cardiac function, but it's not extremely low. The patient's NYHA Class II suggests that the patient is experiencing some symptoms but is still able to perform everyday activities without significant limitation. The patient's Troponin level is within normal limits, and the absence of ventricular tachycardia on the ECG is a positive sign. The patient's Pro-BNP level is elevated, but not extremely high. Considering these factors, the patient has a relatively stable condition, and with proper management, the likelihood of survival is higher.

RANKING: 2. Pump failure death
 REASONING: The patient's LVEF is 39%, indicating reduced cardiac function, and the patient has a history of idiopathic dilated cardiomyopathy, which is a risk factor for heart failure. The patient's elevated Pro-BNP level and reduced protein levels may indicate some degree of cardiac dysfunction. However, the patient is on an ACE inhibitor, which helps to slow the progression of heart failure. The patient's symptoms are manageable, and the absence of severe electrolyte imbalances or acute kidney injury suggests that the patient's kidneys are functioning relatively well. Considering these factors, while the patient is at risk for pump failure, it is not the most likely outcome in the short term.

RANKING: 3. Sudden cardiac death
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a risk factor for sudden cardiac death. The patient's LVEF is 39%, indicating reduced cardiac function, which may increase the risk of arrhythmias. However, the absence of ventricular tachycardia on the ECG is a positive sign. The patient's Troponin level is within normal limits, and the patient's potassium level is within a relatively normal range. The patient's TSH level is within normal limits, which reduces the likelihood of thyroid-related arrhythmias. Considering these factors, while the patient is at risk for sudden cardiac death, it is the least likely outcome in the short term due to the absence of other high-risk factors and the patient's relatively stable condition."
580,580,P0903,"Age: 63
Gender: Male 
Weight: 59 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 47,3
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 9,46
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 170
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,93
Potassium (mEq/L): 5,07
LDL (mmol/L): 6,65
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1975.0
Protein (g/L): 76,4
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,84
Urea (mg/dL): 11,7
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

Based on the provided patient data, I would rank the prognosis as a survivor for the next few years. Here's the reasoning behind this decision:

1.  The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which indicates previous cardiac damage. However, the patient is currently on appropriate medications (Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor) that are known to improve survival and reduce mortality in patients with heart failure.

2.  The patient's NYHA Class II indicates that the patient has some limitations in physical activity, but is still able to perform daily activities without significant symptoms. This suggests that the patient's heart failure is not severely symptomatic at this stage.

3.  The patient's LVEF (Left Ventricular Ejection Fraction) of 20% is significantly reduced, which is a hallmark of heart failure with reduced ejection fraction (HFrEF). However, the patient's LVEF is not as low as it could be, considering the severity of the patient's symptoms and medical history.

4.  The patient's Pro-BNP (N-terminal pro b-type natriuretic peptide) level of 1975 ng/L is elevated, which is consistent with heart failure. However, it is not the highest value possible, and the patient's other biomarkers (e.g., troponin, creatinine) are not significantly elevated.

5.  The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. However, the presence of polymorphic ventricular extrasystoles is also noted, which may indicate a more benign prognosis.

6.  The patient's weight is 59 kg, which is below the average weight for a male of his height. This may be a positive factor in terms of cardiovascular risk.

7.  The patient's lipid profile shows elevated total cholesterol and LDL, but the HDL level is within a relatively healthy range.

Considering these factors, I believe that the patient's prognosis is most likely to be a survivor for the next few years. However, it is essential to continue monitoring the patient's condition and adjust the treatment plan as needed to prevent further deterioration and complications.

Sudden Cardiac Death (SCD) is a possible prognosis, but it is less likely than survivor due to the patient's current treatment regimen and relatively stable condition.

Pump Failure Death is also a possible prognosis, but it is the least likely due to the patient's relatively stable LVEF and lack of severe symptoms.

In summary, the ranking of prognoses from most likely to least likely is: Survivor, Sudden Cardiac Death, Pump Failure Death."
581,581,P0904,"Age: 74
Gender: Female 
Weight: 64 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 105/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39,2
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 3,91
Creatinine (mmol/L): 137.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 111.0
HDL (mmol/L): 1,18
Potassium (mEq/L): 3,81
LDL (mmol/L): 2,12
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 694.0
Protein (g/L): 68,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,28
Urea (mg/dL): 12,7
LVEF (%): 31.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient is 74 years old with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction. Despite these risk factors, the patient is on a comprehensive treatment plan that includes beta blockers, loop diuretics, statins, and an ACE inhibitor, which are all standard treatments for heart failure and ischemic cardiomyopathy. The patient's ejection fraction (LVEF) is 31%, which is below the normal range but not extremely low. The patient's pro-BNP level is elevated at 694 ng/L, but not extremely high, and the troponin level is within normal limits. The absence of ventricular tachycardia, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia on the ECG also suggests a relatively stable cardiac rhythm. While the patient's NYHA class is III, indicating moderate to severe heart failure symptoms, the patient's overall clinical picture suggests that they are receiving appropriate treatment and are likely to survive for the next few years.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's history of ischemic dilated cardiomyopathy, diabetes, and myocardial infarction increases their risk of sudden cardiac death. However, the patient's current treatment plan includes beta blockers, which are known to reduce the risk of sudden cardiac death in patients with heart failure. The patient's LVEF is 31%, which is below the normal range but not extremely low, and the absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG suggests a relatively stable cardiac rhythm. While the patient's pro-BNP level is elevated, it is not extremely high, and the troponin level is within normal limits. Overall, while the patient's risk of sudden cardiac death is increased, it is not extremely high, and their current treatment plan may help mitigate this risk.

RANKING: 3. Pump Failure Death
 REASONING: The patient's history of ischemic dilated cardiomyopathy, diabetes, and myocardial infarction, combined with their current NYHA class of III, suggests that they have significant heart failure symptoms. The patient's LVEF is 31%, which is below the normal range, and the elevated pro-BNP level suggests that the patient's heart is under strain. However, the patient is on a comprehensive treatment plan that includes loop diuretics, which are used to manage heart failure symptoms and reduce fluid overload. The patient's creatinine level is slightly elevated, which may suggest some degree of renal impairment, but it is not extremely high. Overall, while the patient's risk of pump failure death is increased, their current treatment plan may help manage their symptoms and slow disease progression."
582,582,P0905,"Age: 46
Gender: Male 
Weight: 69 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 47,3
ALT or GPT (IU/L): 50.0
AST or GOT (IU/L): 35.0
Total Cholesterol (mmol/L): 4,83
Creatinine (mmol/L): 92.0
Gamma-glutamil transpeptidase (IU/L): 96
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,02
Potassium (mEq/L): 5,25
LDL (mmol/L): 2,83
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2470.0
Protein (g/L): 75,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,93
Urea (mg/dL): 6,5
LVEF (%): 25.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. I will rank the three possible prognoses from most likely to least likely and explain the reasoning behind each.

RANKING: Survivor
REASONING: The patient is 46 years old with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for heart failure. However, the patient is currently being treated with a comprehensive medication regimen, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all standard treatments for heart failure with reduced ejection fraction (HFrEF). The patient's LVEF is 25%, which is a common finding in patients with HFrEF. The patient's NT-proBNP level is elevated at 2470.0 ng/L, which is consistent with heart failure. However, the patient's hemoglobin is within the normal range, and there is no evidence of significant renal impairment (creatinine 92.0 umol/L). The patient's ECG shows polymorphic ventricular extrasystoles, which is a common finding in patients with heart failure. While the patient's prognosis is guarded, the current treatment regimen and the lack of significant comorbidities make a survivor prognosis the most likely outcome.

RANKING: Pump Failure Death
REASONING: The patient's LVEF is severely reduced at 25%, which is a significant risk factor for pump failure death. The patient's NT-proBNP level is elevated, indicating increased ventricular stress. The patient's weight is 69 kg, which is within the normal range, but the patient's body mass index (BMI) is not provided. However, the patient's height is 175 cm, which would suggest a normal BMI. The patient's creatinine level is slightly elevated, but not significantly so. The patient's medications are appropriate for heart failure, but the patient's overall condition is still at risk for pump failure death.

RANKING: Sudden Cardiac Death
REASONING: The patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the patient's LVEF is severely reduced, but there is no evidence of significant arrhythmias (e.g., non-sustained ventricular tachycardia) or other risk factors for sudden cardiac death (e.g., family history of sudden cardiac death). The patient's medications include beta blockers, which are known to reduce the risk of sudden cardiac death. While the patient's overall condition is at risk, the lack of significant arrhythmias and the presence of beta blockers make sudden cardiac death the least likely outcome."
583,583,P0906,"Age: 82
Gender: Male 
Weight: 80 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 42,5
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 4,39
Creatinine (mmol/L): 185.0
Gamma-glutamil transpeptidase (IU/L): 52
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,15
Potassium (mEq/L): 4,02
LDL (mmol/L): 2,91
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 28179.0
Protein (g/L): 80,2
Troponin (ng/mL): 0,07
TSH (mIU/L): 1,92
Urea (mg/dL): 17,2
LVEF (%): 15.0
Medications: Calcium Channel Blocker, Diabetes Medication, Amiodarone, Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Please note that this is a hypothetical prediction and actual outcomes may vary.

RANKING: 1. Survivor
REASONING: The patient is 82 years old with a history of ischemic dilated cardiomyopathy, diabetes, hypertension, and myocardial infarction. Despite these comorbidities, the patient is currently being treated with a comprehensive medication regimen that includes a calcium channel blocker, diabetes medication, amiodarone, angiotensin II receptor blocker, loop diuretics, and spironolactone. The patient's current NYHA class is III, indicating severe symptoms of heart failure, but the presence of these medications and the patient's relatively stable vital signs (BP 130/80 mmHg) suggest that the patient is being managed effectively.

The patient's LVEF of 15% indicates severe left ventricular dysfunction, which increases the risk of sudden cardiac death. However, the patient's Pro-BNP level of 28179.0 ng/L is elevated, but not extremely high, which may indicate some degree of compensation. The absence of significant arrhythmias on the ECG, aside from non-sustained ventricular tachycardia, also suggests that the patient's cardiac function is being closely monitored and managed.

Given the patient's age and comorbidities, the risk of sudden cardiac death is higher than in younger patients. However, the patient's current management and relatively stable condition suggest that the risk of sudden cardiac death is not extremely high.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of ischemic dilated cardiomyopathy, diabetes, hypertension, and myocardial infarction increases the risk of sudden cardiac death. The patient's LVEF of 15% also indicates severe left ventricular dysfunction, which is a known risk factor for sudden cardiac death. The patient's Pro-BNP level of 28179.0 ng/L is elevated, which may indicate increased cardiac stress and risk of arrhythmias.

However, the patient's current management and relatively stable vital signs suggest that the risk of sudden cardiac death is not extremely high. The presence of non-sustained ventricular tachycardia on the ECG is a concern, but it is not a definitive predictor of sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF of 15% indicates severe left ventricular dysfunction, which increases the risk of pump failure death. The patient's NYHA class III also suggests that the patient is experiencing severe symptoms of heart failure. The patient's creatinine level of 185.0 mmol/L indicates some degree of renal impairment, which may be a consequence of the patient's heart failure.

However, the patient's current management and relatively stable vital signs suggest that the risk of pump failure death is not extremely high. The patient's Pro-BNP level of 28179.0 ng/L is elevated, but not extremely high, which may indicate some degree of compensation. The presence of loop diuretics and spironolactone in the patient's medication regimen also suggests that the patient's fluid status is being closely monitored and managed.

In summary, while the patient's history and current condition suggest a high risk of sudden cardiac death and pump failure death, the patient's current management and relatively stable vital signs suggest that the risk of sudden cardiac death is slightly lower than the risk of pump failure death."
584,584,P0909,"Age: 40
Gender: Female 
Weight: 125 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42,9
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,04
Creatinine (mmol/L): 66.0
Gamma-glutamil transpeptidase (IU/L): 28
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 117.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,26
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 12.0
Protein (g/L): 74,8
T4 (ng/L): 15
TSH (mIU/L): 1,49
Urea (mg/dL): 6,82
LVEF (%): 49.0
Medications: Diabetes Medication, Beta Blockers, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: 

Considering the provided patient data, the patient's overall condition is relatively stable. The patient is 40 years old, which is still relatively young, and has a NYHA Class II, indicating some limitations in physical activity but not severe symptoms at rest. The patient's LVEF (Left Ventricular Ejection Fraction) is 49%, which is below the normal range (50-70%), but not severely reduced. The patient is on medications for diabetes, hypertension, and heart failure, which are appropriate for her condition.

The patient's blood work shows elevated glucose and cholesterol levels, which are being managed with medications. The liver enzymes (ALT and AST) are within normal limits, which suggests that the patient's liver function is relatively preserved. The kidney function, as indicated by creatinine levels, is also within normal limits.

The patient's ECG shows monomorphic ventricular extrasystoles, which are relatively common and not necessarily indicative of a poor prognosis. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and other arrhythmias is also a positive sign.

Given the patient's relatively young age, stable LVEF, and absence of severe symptoms, the prognosis is likely to be a survivor. The patient's condition can be managed with ongoing medical therapy, and with regular monitoring, the risk of sudden cardiac death or pump failure death is relatively low.

Sudden cardiac death is less likely because:

- The patient's LVEF is not severely reduced.
- The patient is on beta blockers, which reduce the risk of arrhythmias.
- The patient has no history of sustained ventricular tachycardia or other life-threatening arrhythmias.

Pump failure death is less likely because:

- The patient's LVEF is not severely reduced.
- The patient is on ACE inhibitors, which help to reduce afterload and improve cardiac function.
- The patient's kidney function is within normal limits, which suggests that the patient's cardiac function is not severely impaired.

In conclusion, based on the patient's data, the most likely prognosis is survivor, followed by pump failure death, and then sudden cardiac death."
585,585,P0910,"Age: 73
Gender: Female 
Weight: 74 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 46,6
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,48
Creatinine (mmol/L): 66.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 11,1
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,1
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 614.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 16
TSH (mIU/L): 0,67
Urea (mg/dL): 4,49
LVEF (%): 70.0
Medications: Diabetes Medication, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely. Please note that this is a hypothetical prognosis and not a definitive diagnosis.

RANKING: Survivor

REASONING: The patient is 73 years old with a history of Hypertensive cardiomyopathy, Diabetes, and Hypertension, but she is also on appropriate medications for these conditions (Diabetes medication, Beta blockers, and Statins). The patient's LVEF is 70%, which is within the normal range, indicating that the heart is functioning relatively well. The Pro-BNP level of 614 ng/L is elevated, which is a marker of heart failure, but not excessively high. The patient's NYHA Class II indicates that she has some limitations in physical activity but is still able to perform daily activities. The presence of ventricular extrasystoles on the ECG is a common finding in many patients and is not necessarily indicative of a poor prognosis. Overall, the patient's current medical treatment and relatively good functional status suggest that she is likely to survive for the next few years.

RANKING: Sudden cardiac death

REASONING: The patient has a history of Myocardial Infarction, which increases her risk of sudden cardiac death. The elevated Pro-BNP level and NYHA Class II also suggest that she may be at risk for sudden cardiac death. However, the patient's LVEF is within the normal range, and she is on beta blockers, which can reduce the risk of sudden cardiac death. The presence of ventricular extrasystoles on the ECG is a risk factor for sudden cardiac death, but it is not a definitive indicator.

RANKING: Pump failure death

REASONING: The patient's LVEF is 70%, which is within the normal range, and her NYHA Class II indicates that she is still able to perform daily activities. The elevated Pro-BNP level is a marker of heart failure, but it is not excessively high. The patient's overall functional status and current medical treatment suggest that she is unlikely to experience pump failure death in the near future."
586,586,P0911,"Age: 64
Gender: Female 
Weight: 67 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 150/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41,4
ALT or GPT (IU/L): 44.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 5,95
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 2,54
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,26
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 1114.0
Protein (g/L): 72,5
T3 (pg/dL): 0,04
T4 (ng/L): 14
TSH (mIU/L): 5,22
Urea (mg/dL): 6,49
LVEF (%): 65.0
Medications: Beta Blockers
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor

REASONING: Based on the provided data, the patient's prognosis is most likely to be a survivor. The patient is 64 years old, which is considered elderly, but still within a relatively normal range for many medical conditions. The patient's LVEF (Left Ventricular Ejection Fraction) is 65%, which is within the normal range (> 55%). This indicates that the patient's heart is functioning relatively well. 

Although the patient has a history of hypertensive cardiomyopathy, dyslipemia, and hypertension, these conditions are being managed with beta blockers, which is a common treatment for these conditions. The patient's blood pressure is 150/80 mmHg, which is slightly elevated, but not severely so. The patient's lipid profile is also within relatively normal limits, with an LDL of 3.26 mmol/L and an HDL of 2.54 mmol/L.

The patient's liver enzymes (ALT and AST) are slightly elevated, but not to a level that would indicate significant liver disease. The patient's creatinine level is 87.0 umol/L, which is slightly elevated, but not to a level that would indicate significant kidney disease. The patient's pro-BNP level is 1114.0 ng/L, which is elevated, but not to a level that would indicate severe heart failure.

The patient's ECG is normal, with no signs of ventricular extrasystoles, ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia.

Overall, while the patient has several risk factors for cardiovascular disease, the patient's current treatment and laboratory values suggest that the patient is stable and likely to survive.

RANKING: 2. Pump Failure Death

REASONING: The patient's prognosis for pump failure death is less likely than survivor, but still a possibility. The patient's LVEF is 65%, which is within the normal range, but slightly lower than optimal. The patient's pro-BNP level is elevated, which suggests that the patient may have some degree of heart failure. The patient's creatinine level is also slightly elevated, which suggests that the patient may have some degree of kidney disease.

However, the patient's treatment with beta blockers and the lack of other signs of heart failure (such as shortness of breath or fatigue) suggest that the patient's heart failure is likely mild and well-managed. The patient's ECG is normal, which suggests that the patient does not have any significant arrhythmias that would increase the risk of pump failure death.

RANKING: 3. Sudden Cardiac Death

REASONING: The patient's prognosis for sudden cardiac death is the least likely of the three options. The patient's ECG is normal, with no signs of ventricular extrasystoles, ventricular tachycardia, or paroxysmal supraventricular tachyarrhythmia. The patient's LVEF is 65%, which is within the normal range, and the patient's treatment with beta blockers suggests that the patient's heart rhythm is well-managed.

The patient's pro-BNP level is elevated, which suggests that the patient may have some degree of heart failure, but the patient's overall clinical picture suggests that the patient is stable and not at high risk for sudden cardiac death. The patient's age and sex are also not particularly high-risk for sudden cardiac death."
587,587,P0912,"Age: 75
Gender: Female 
Weight: 57 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 50,1
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,28
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,81
Potassium (mEq/L): 4,1
LDL (mmol/L): 4,11
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1619.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,04
Urea (mg/dL): 4,68
LVEF (%): 68.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here is the prognosis ranking:

RANKING: Survivor

REASONING: 

1. The patient's LVEF (68%) is within the normal range, indicating that the heart is functioning relatively well, despite the patient's history of hypertensive cardiomyopathy and peripheral vascular disease. This suggests that the heart is still able to pump blood effectively, which is a positive sign for survival.
2. The patient's ejection fraction (EF) is above 50%, which is generally considered to be within the normal range. This is a good indicator of cardiac function and suggests that the patient is less likely to experience sudden cardiac death or pump failure.
3. The patient's blood pressure is well-controlled, with a reading of 130/80 mmHg. This is a positive sign, as high blood pressure can exacerbate cardiac conditions and increase the risk of cardiac events.
4. The patient is on a comprehensive medication regimen, including beta blockers, digoxin, loop diuretics, spironolactone, statins, and ACE inhibitors. This suggests that the patient is receiving appropriate treatment for their cardiac condition.
5. The patient's troponin levels are within normal limits (0.01 ng/mL), which suggests that there is no evidence of acute myocardial infarction or significant cardiac damage.
6. The patient's creatinine levels (79.0 mmol/L) are slightly elevated, but not significantly so, which suggests that renal function is not severely impaired.

However, there are some concerning factors that need to be considered:

* The patient's NYHA Class III indicates that they have significant symptoms of heart failure, which can increase the risk of cardiac events.
* The patient's Pro-BNP levels are elevated (1619.0 ng/L), which can indicate heart failure or other cardiac conditions.
* The patient's low HDL levels (1.81 mmol/L) and high LDL levels (4.11 mmol/L) suggest that they are at increased risk for cardiovascular disease.
* The patient's low T3 levels (0.04 pg/dL) may indicate hypothyroidism, which can contribute to cardiac dysfunction.

Given these factors, while the patient's prognosis is generally positive, there is still a risk of cardiac complications. However, based on the available data, I would rank the prognosis as survivor, with the understanding that close monitoring and continued treatment will be necessary to manage the patient's cardiac condition.

RANKING: 2. Sudden Cardiac Death

REASONING: 

Sudden cardiac death is a possible prognosis due to the patient's history of hypertensive cardiomyopathy and peripheral vascular disease, as well as the presence of polymorphic ventricular extrasystoles on the ECG. However, the patient's LVEF is within the normal range, and their blood pressure is well-controlled, which suggests that the risk of sudden cardiac death is lower than pump failure.

RANKING: 3. Pump Failure Death

REASONING: 

Pump failure is the least likely prognosis due to the patient's relatively preserved LVEF (68%) and the absence of significant renal impairment (creatinine levels 79.0 mmol/L). While the patient's NYHA Class III indicates significant symptoms of heart failure, the patient's ejection fraction is within the normal range, suggesting that the heart is still able to pump blood effectively."
588,588,P0914,"Age: 54
Gender: Male 
Weight: 93 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 45,2
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,19
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 6
Hemoglobin (g/L): 141.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,51
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 464.0
Protein (g/L): 72,8
T3 (pg/dL): 0,05
T4 (ng/L): 14
TSH (mIU/L): 1,21
Urea (mg/dL): 7,32
LVEF (%): 20.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"RANKING: 1. Survivor
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which significantly reduces the left ventricular ejection fraction (LVEF) to 20%, indicating severe heart failure. However, the patient is currently on optimal medical therapy, including angiotensin II receptor blockers, beta blockers, and statins, which are all evidence-based treatments for heart failure with reduced ejection fraction (HFrEF). The patient's NYHA class is II, indicating mild to moderate symptoms, which is a relatively stable condition. Additionally, the patient's blood pressure is well-controlled, and there are no signs of severe electrolyte imbalances or acute kidney injury. The patient's pro-BNP level is elevated, but not extremely high, which suggests that the patient is likely being well-managed. While the patient has a history of myocardial infarction and peripheral vascular disease, these conditions are not typically associated with an immediate high risk of sudden cardiac death or pump failure. Considering these factors, the most likely prognosis for the patient is survival, with careful monitoring and management of their heart failure and other comorbidities.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF of 20% indicates severe heart failure, and their history of ischemic dilated cardiomyopathy increases the risk of further cardiac decompensation. However, the patient is on optimal medical therapy, which reduces the risk of pump failure. The patient's creatinine level is elevated, but not severely so, which suggests that the patient does not have significant kidney dysfunction. The patient's TSH level is within the normal range, which reduces the risk of cardiac decompensation due to thyroid dysfunction. The patient's T3 and T4 levels are also within the normal range, which further reduces the risk of cardiac decompensation due to thyroid dysfunction. While the patient's pro-BNP level is elevated, it is not extremely high, which suggests that the patient is likely being well-managed. Considering these factors, the risk of pump failure death is lower than sudden cardiac death.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy and a low LVEF, which increases the risk of sudden cardiac death. However, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death, but there is no evidence of non-sustained ventricular tachycardia or ventricular tachycardia. The patient's potassium level is within the normal range, which reduces the risk of arrhythmias. The patient's TSH level is within the normal range, which reduces the risk of cardiac decompensation due to thyroid dysfunction. While the patient's pro-BNP level is elevated, it is not extremely high, which suggests that the patient is likely being well-managed. Considering these factors, the risk of sudden cardiac death is lower than pump failure death."
589,589,P0915,"Age: 78
Gender: Male 
Weight: 103 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 36,4
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 6,08
Creatinine (mmol/L): 85.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 6
Hemoglobin (g/L): 164.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,6
LDL (mmol/L): 4,16
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2390.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,65
Urea (mg/dL): 8,69
LVEF (%): 38.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient is 78 years old with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac complications. However, the patient is currently on a multidrug regimen, including beta blockers, loop diuretics, spironolactone, ACE inhibitor, and nitrovasodilators, which are standard treatments for heart failure and hypertension. The patient's LVEF is 38%, which is low but not extremely low. Additionally, the patient's blood pressure is well-controlled, and the troponin level is normal, indicating no recent myocardial infarction. The patient also has a relatively high hemoglobin level, which is a good prognostic sign. Considering these factors, the patient's overall prognosis appears to be favorable, making survival the most likely outcome.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The patient's LVEF is 38%, and the presence of non-sustained ventricular tachycardia (NSVT) on the ECG is a risk factor for sudden cardiac death. However, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death. The patient's troponin level is normal, and there is no indication of acute coronary syndrome. Considering these factors, the risk of sudden cardiac death is present but not extremely high.

RANKING: 3. Pump Failure Death
 REASONING: The patient has a low LVEF of 38%, which indicates significant left ventricular dysfunction. The patient's creatinine level is elevated at 85.0 mmol/L, suggesting some degree of renal impairment, which can be a marker of advanced heart failure. The patient's pro-BNP level is high at 2390.0 ng/L, which is consistent with heart failure. However, the patient is on diuretics and ACE inhibitors, which are standard treatments for heart failure. The patient's blood pressure is well-controlled, and the patient is not showing signs of acute decompensation. Considering these factors, while pump failure death is a possible outcome, it is less likely than sudden cardiac death, given the patient's current treatment regimen and stable vital signs.

Note: It's essential to note that the actual prognosis can only be determined by a comprehensive evaluation by a cardiologist, taking into account the patient's overall clinical presentation, medical history, and other factors not mentioned in the provided data."
590,590,P0922,"Age: 65
Gender: Male 
Weight: 81 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,73
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 148.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,34
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 86.0
Protein (g/L): 72
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,08
Urea (mg/dL): 8,99
LVEF (%): 58.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Survivor
REASONING: The patient is 65 years old with a history of hypertensive cardiomyopathy, diabetes, and hypertension. However, the patient is on appropriate medications for these conditions, including beta blockers, loop diuretics, and an ACE inhibitor, which can help manage symptoms and slow disease progression. The left ventricular ejection fraction (LVEF) is 58%, which is within the normal range, indicating that the heart is still pumping blood effectively. The patient's blood pressure is well-controlled, and there are no signs of acute cardiac ischemia or severe arrhythmias. The low troponin level (0.01 ng/mL) suggests that there is no significant cardiac damage. The patient's NYHA Class II classification indicates that the patient is experiencing some limitations in physical activity but is still able to perform daily activities. Considering these factors, the patient's prognosis is most likely to be a survivor, as the current management plan seems to be effective in controlling the patient's symptoms and slowing disease progression.

RANKING: Sudden Cardiac Death
REASONING: While the patient has a history of hypertensive cardiomyopathy and diabetes, which are risk factors for sudden cardiac death, the presence of beta blockers and ACE inhibitors can help reduce the risk of sudden cardiac death. The patient's LVEF is within the normal range, which is a good prognostic indicator. The absence of ventricular tachycardia or other high-risk arrhythmias on the ECG also reduces the risk of sudden cardiac death. However, the patient's history of ventricular extrasystoles, which can be a marker of increased cardiac sympathetic tone, may increase the risk of sudden cardiac death. Nevertheless, this risk is still relatively low, and the patient's overall prognosis is more likely to be a survivor than sudden cardiac death.

RANKING: Pump Failure Death
REASONING: The patient's LVEF is 58%, which is within the normal range, and the patient's symptoms are well-controlled with current medications. The patient's NYHA Class II classification suggests that the patient is still able to perform daily activities, and there are no signs of severe cardiac decompensation. The patient's creatinine level is within the normal range, which suggests that the patient's kidneys are functioning well, and there is no evidence of severe cardiac failure. While the patient's history of hypertensive cardiomyopathy and diabetes may increase the risk of pump failure, the patient's current management plan and lack of symptoms suggest that pump failure death is the least likely outcome."
591,591,P0923,"Age: 78
Gender: Male 
Weight: 61 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 72.0
AST or GOT (IU/L): 35.0
Total Cholesterol (mmol/L): 4,32
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 100
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 132.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 5
LDL (mmol/L): 2,56
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 487.0
Protein (g/L): 73
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,75
Urea (mg/dL): 11,48
LVEF (%): 35.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"RANKING: 1
REASONING: The patient is 78 years old with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac events. However, his current NYHA Class II indicates that he is still able to perform some physical activity without severe symptoms. His LVEF of 35% suggests a moderately reduced left ventricular function, but it is not the lowest possible value, which would indicate a higher risk of sudden cardiac death. His Pro-BNP level of 487.0 ng/L is elevated, indicating some level of heart failure, but not excessively high, which would be more indicative of pump failure. His medications, including beta blockers, loop diuretics, spironolactone, statins, and ACE inhibitor, are appropriate for heart failure management and are likely helping to control his symptoms. His recent troponin level of 0.01 ng/mL is low, indicating minimal cardiac damage. Considering these factors, the most likely outcome is survivor, as his current management plan seems to be effective in controlling his symptoms and preventing further cardiac events.

RANKING: 2
REASONING: The patient's history of ischemic dilated cardiomyopathy and reduced LVEF increase his risk of pump failure. His elevated Pro-BNP level and slightly elevated creatinine level suggest some level of heart failure, which can lead to pump failure if not adequately managed. However, his current NYHA Class II and lack of severe symptoms indicate that he is still able to tolerate his condition. His medications are appropriate for heart failure management, and his recent troponin level is low, indicating minimal cardiac damage. While pump failure is a possible outcome, it is not the most likely given his current management plan and relatively mild symptoms.

RANKING: 3
REASONING: The patient's history of ischemic dilated cardiomyopathy, reduced LVEF, and elevated Pro-BNP level increase his risk of sudden cardiac death. However, his current NYHA Class II and lack of severe symptoms suggest that he is still able to tolerate his condition. His medications, including beta blockers and ACE inhibitor, are appropriate for reducing sudden cardiac death risk. His recent troponin level of 0.01 ng/mL is low, indicating minimal cardiac damage. While sudden cardiac death is a possible outcome, it is the least likely given his current management plan and relatively mild symptoms."
592,592,P0924,"Age: 72
Gender: Female 
Weight: 65 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 36.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 71
Glucose (mmol/L): 6,4
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 5,6
LDL (mmol/L): 2,43
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 2235.0
Protein (g/L): 70
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,49
Urea (mg/dL): 8,15
LVEF (%): 55.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient is 72 years old with a history of hypertensive cardiomyopathy, dyslipemia, and peripheral vascular disease, which are all significant risk factors for cardiovascular disease. However, the patient's current medication regimen, including an Angiotensin II Receptor Blocker and a Statin, is appropriate for managing these conditions. The patient's LVEF is 55%, which is slightly below the normal range but not severely impaired. The Pro-BNP level is elevated at 2235.0 ng/L, indicating some degree of heart failure, but it is not extremely high. The patient's troponin level is normal, indicating no recent myocardial infarction. Considering these factors, with proper management and adherence to medication, the patient is likely to survive for the next few years.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of ventricular extrasystoles, which is a risk factor for sudden cardiac death. However, the patient's LVEF is still relatively preserved at 55%, and there is no indication of recent myocardial infarction or severe cardiac dysfunction. The patient's medications, including Amiodarone, are appropriate for managing arrhythmias. While the risk of sudden cardiac death is present, it is not the most likely outcome given the patient's overall clinical picture.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF is 55%, which is below the normal range, indicating some degree of left ventricular dysfunction. The patient's Pro-BNP level is elevated, indicating some degree of heart failure. However, the patient's symptoms are classified as NYHA Class II, which is not severe. The patient's medications, including Loop Diuretics, are appropriate for managing heart failure. While the patient's cardiac function is compromised, the patient's overall clinical picture suggests that pump failure is not the most likely outcome in the next few years.

Note: The patient's prognosis is highly dependent on their adherence to medication and lifestyle changes, which are not specified in the provided data."
593,593,P0925,"Age: 77
Gender: Male 
Weight: 82 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 150.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,36
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 424.0
Protein (g/L): 68
T4 (ng/L): 10
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,33
Urea (mg/dL): 6,66
LVEF (%): 57.0
Medications: Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is my prognosis for the next few years:

RANKING: Survivor
REASONING: The patient is 77 years old with a history of hypertrophic cardiomyopathy, which is a known risk factor for cardiac complications. However, the patient is on beta blockers and loop diuretics, which are appropriate medications for managing symptoms and reducing the risk of cardiac events. The patient's LVEF is 57%, which is within the normal range, indicating preserved left ventricular function. Additionally, the patient's troponin level is normal, which suggests that there is no acute coronary syndrome or myocardial infarction. The patient's pro-BNP level is elevated at 424.0 ng/L, which may indicate some degree of heart failure, but it is not excessively high. The patient's NYHA class is II, indicating that the patient is experiencing some symptoms of heart failure but is still able to perform most daily activities. Overall, while the patient has some risk factors for cardiac complications, the overall picture suggests that the patient is likely to survive for the next few years with proper management of their condition.

RANKING: Sudden cardiac death
REASONING: The patient has a history of hypertrophic cardiomyopathy, which is a known risk factor for sudden cardiac death. The patient's LVEF is 57%, which is within the normal range, but it may not accurately reflect the patient's true cardiac function, as hypertrophic cardiomyopathy can lead to diastolic dysfunction and increased stiffness of the left ventricle. The patient's troponin level is normal, but it is possible that the patient may be experiencing silent ischemia or microvascular dysfunction. The patient's pro-BNP level is elevated, which may indicate some degree of heart failure. While the patient is on beta blockers and loop diuretics, these medications may not be sufficient to prevent sudden cardiac death in a patient with hypertrophic cardiomyopathy.

RANKING: Pump failure death
REASONING: The patient's LVEF is 57%, which is within the normal range, but it may not accurately reflect the patient's true cardiac function, as hypertrophic cardiomyopathy can lead to diastolic dysfunction and increased stiffness of the left ventricle. The patient's pro-BNP level is elevated, which suggests that the patient may be experiencing some degree of heart failure. The patient's NYHA class is II, indicating that the patient is experiencing some symptoms of heart failure, but the patient is still able to perform most daily activities. However, the patient's creatinine level is elevated at 106.0 umol/L, which suggests that the patient may be experiencing some degree of renal dysfunction, which can be a marker of advanced heart failure. Overall, while the patient's LVEF is within the normal range, the patient's overall clinical picture suggests that pump failure may be a more likely outcome than sudden cardiac death."
594,594,P0926,"Age: 81
Gender: Male 
Weight: 68 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 36
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,67
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 10,3
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 5,2
LDL (mmol/L): 2,11
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 779.0
Protein (g/L): 68
T4 (ng/L): 8
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,1
Urea (mg/dL): 14,81
LVEF (%): 42.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient's age and history of ischemic dilated cardiomyopathy, diabetes, and myocardial infarction indicate a high risk for cardiac events. However, the patient's current medications, including beta blockers and statins, are beneficial in managing these conditions. The LVEF of 42% suggests some degree of cardiac function preservation. Additionally, the absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG is a positive sign. The patient's low troponin level and normal TSH level indicate minimal cardiac stress and thyroid function, respectively. The patient's overall clinical status, despite being in NYHA Class II, suggests that they are still relatively stable and manageable.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's history of ischemic dilated cardiomyopathy and LVEF of 42% indicate a risk for sudden cardiac death. However, the patient's current medications and the absence of ventricular tachycardia on the ECG reduce this risk. The patient's age and comorbidities (diabetes and dyslipemia) also contribute to this risk. The elevated Pro-BNP level (779.0 ng/L) indicates some degree of cardiac stress, which may increase the risk of sudden cardiac death. However, this risk is not as high as pump failure death due to the patient's relatively preserved cardiac function.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 42% and history of ischemic dilated cardiomyopathy suggest a risk for pump failure death. However, the patient's current medications and relatively stable clinical status (NYHA Class II) indicate that the patient's cardiac function is being managed. The patient's age and comorbidities (diabetes and dyslipemia) contribute to this risk, but the patient's overall clinical status suggests that pump failure death is the least likely outcome.

Note: The ranking is based on the provided data and may change based on further clinical evaluation and additional information."
595,595,P0928,"Age: 62
Gender: Female 
Weight: 55 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 32
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,51
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,67
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 712.0
Protein (g/L): 68
T4 (ng/L): 10
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,67
Urea (mg/dL): 9,15
LVEF (%): 32.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor
REASONING: 

Considering the patient's profile, I would rank the prognosis as survivor with the highest likelihood. The patient is a 62-year-old female with ischemic dilated cardiomyopathy and a history of myocardial infarction, which are both significant risk factors for cardiac mortality. However, her NYHA Class II classification indicates that she is still relatively stable and able to perform daily activities without significant limitations.

The patient's LVEF (Left Ventricular Ejection Fraction) of 32% is below the normal range, indicating a reduced ejection fraction. However, it is not extremely low, which might indicate that the patient still has some functional cardiac reserve. The absence of sustained ventricular tachycardia and the presence of only polymorphic ventricular extrasystoles on the ECG are also positive signs.

The patient's laboratory results show elevated levels of troponin (0.01 ng/mL), which may indicate some level of cardiac damage, but it is not excessively high. The Pro-BNP level of 712 ng/L is also elevated, which is often associated with heart failure and reduced ejection fraction. However, the patient's creatinine level of 80.0 mol/L is within the normal range, indicating that her kidney function is preserved.

The patient's medication regimen, including beta blockers, loop diuretics, spironolactone, and ACE inhibitors, is appropriate for managing heart failure and reducing the risk of cardiac mortality. The patient's TSH level of 1.67 mIU/L is within the normal range, indicating that her thyroid function is not contributing to her cardiac condition.

Considering these factors, while the patient's prognosis is guarded, I believe that with proper management and adherence to her medication regimen, she has a relatively high likelihood of survival over the next few years.

RANKING: 2. Pump Failure Death
REASONING: 

Pump failure death is the second most likely prognosis. The patient's reduced LVEF and elevated Pro-BNP levels indicate that she is at risk for pump failure. The patient's history of ischemic dilated cardiomyopathy and myocardial infarction also increases her risk for pump failure. However, her NYHA Class II classification and the absence of sustained ventricular tachycardia on the ECG suggest that her cardiac function is still relatively preserved.

The patient's laboratory results show elevated levels of ALT and AST, which may indicate some level of liver damage, but this is not directly related to her cardiac prognosis. The patient's total cholesterol level of 5.51 mmol/L is elevated, which may contribute to her risk for cardiac events.

However, the patient's kidney function is preserved, and her medication regimen is appropriate for managing heart failure. With proper management, the patient's risk for pump failure can be reduced, but it remains a significant concern.

RANKING: 3. Sudden Cardiac Death
REASONING: 

Sudden cardiac death is the least likely prognosis. The patient's ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or bradycardia, which are more commonly associated with an increased risk of sudden cardiac death. The patient's LVEF of 32% is below the normal range, but it is not extremely low, and her cardiac function is still relatively preserved.

The patient's medication regimen, including beta blockers and ACE inhibitors, is appropriate for reducing the risk of sudden cardiac death. The patient's TSH level of 1.67 mIU/L is within the normal range, indicating that her thyroid function is not contributing to her cardiac condition.

While the patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases her risk for sudden cardiac death, her overall profile suggests that this is the least likely prognosis."
596,596,P0930,"Age: 56
Gender: Male 
Weight: 79 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 105/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 47
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 120
Glucose (mmol/L): 8,7
Hemoglobin (g/L): 157.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5,5
LDL (mmol/L): 2,28
Sodium (mEq/L): 130.0
Pro-BNP (ng/L): 7066.0
Protein (g/L): 83
T3 (pg/dL): 0,05
T4 (ng/L): 27
Troponin (ng/mL): 0,06
TSH (mIU/L): 2,72
Urea (mg/dL): 10,65
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Sudden Cardiac Death (SCD), Pump Failure Death, Survivor

REASONING:

1. Sudden Cardiac Death (SCD): The patient has a history of idiopathic dilated cardiomyopathy with an LVEF of 25%, which indicates severe left ventricular dysfunction. The elevated Pro-BNP level of 7066.0 ng/L further supports this, as it is a marker of heart failure and increased risk of SCD. The patient's history of ventricular extrasystoles, particularly polymorphic, also increases the risk of arrhythmias leading to SCD. Additionally, the patient's NYHA Class III indicates significant symptoms and limitations in physical activity, which may be a sign of advanced heart failure. Therefore, SCD is the most likely prognosis.

2. Pump Failure Death: The patient's LVEF of 25% and history of idiopathic dilated cardiomyopathy suggest significant left ventricular dysfunction, which can lead to pump failure. The elevated creatinine level of 97.0 mmol/L indicates renal impairment, which is a common complication of heart failure. The patient's medications, including digoxin, loop diuretics, and spironolactone, are standard treatments for heart failure, but their effectiveness may be limited given the patient's advanced disease. The patient's symptoms and limitations (NYHA Class III) also suggest advanced heart failure. However, the patient's overall clinical picture is more concerning for SCD due to the presence of ventricular extrasystoles and high Pro-BNP levels.

3. Survivor: Given the patient's severe left ventricular dysfunction, history of idiopathic dilated cardiomyopathy, and high Pro-BNP levels, a survivor prognosis is less likely. However, the patient is currently receiving standard treatments for heart failure, and the absence of other high-risk features (e.g., sustained ventricular tachycardia, severe hypotension) suggests that the patient may be able to survive for a longer period with continued medical management. The patient's relatively well-controlled blood pressure and absence of severe electrolyte imbalances also support this prognosis."
597,597,P0931,"Age: 60
Gender: Female 
Weight: 74 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,34
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 12,8
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5,3
LDL (mmol/L): 1,06
Sodium (mEq/L): 149.0
Pro-BNP (ng/L): 1853.0
Protein (g/L): 78
T3 (pg/dL): 0,06
T4 (ng/L): 21
Troponin (ng/mL): 0,06
TSH (mIU/L): 0,167
Urea (mg/dL): 5,83
LVEF (%): 24.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: 1. Sudden Cardiac Death, 2. Pump Failure Death, 3. Survivor

REASONING:

1. Sudden Cardiac Death (SCD): The patient has a high risk of SCD due to her ischemic dilated cardiomyopathy with an LVEF of 24%. This indicates severe left ventricular dysfunction, which increases the risk of sudden cardiac arrest. Additionally, the presence of polymorphic ventricular extrasystoles on the ECG suggests a high risk of arrhythmias. The patient's high Pro-BNP level (1853 ng/L) further supports this concern, as elevated BNP levels are associated with increased risk of SCD. The patient's NYHA Class III classification also indicates severe symptoms, which may be indicative of a high-risk profile. Given these factors, SCD is the most likely prognosis.

2. Pump Failure Death: While the patient has severe left ventricular dysfunction, her LVEF of 24% is relatively low, and she is already taking medications that may help manage her condition (e.g., ACE inhibitors, beta-blockers, and loop diuretics). However, the patient's high Pro-BNP level and NYHA Class III classification suggest that she may be at risk for pump failure. However, given her current treatment regimen and the fact that she is still alive, pump failure death is less likely than SCD in the short term.

3. Survivor: While the patient has several risk factors for cardiac events, her current treatment regimen and the fact that she is still alive suggest that she may be able to manage her condition and survive for the next few years. The patient's high Pro-BNP level and low LVEF are concerning, but her medications and overall clinical status suggest that she may be able to stabilize and potentially improve with continued treatment.

Please note that this prognosis is based on the provided data and may not reflect the patient's actual outcome. A more accurate prognosis would require a comprehensive evaluation by a healthcare professional."
598,598,P0932,"Age: 61
Gender: Male 
Weight: 76 kg
Height: 169 cm
NYHA Class: III
Blood Pressure: 170/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 46,1
ALT or GPT (IU/L): 45.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 8,71
Creatinine (mmol/L): 109.0
Gamma-glutamil transpeptidase (IU/L): 101
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 162.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 4,6
LDL (mmol/L): 6,05
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 797.0
Protein (g/L): 78,8
T3 (pg/dL): 0,05
T4 (ng/L): 15
TSH (mIU/L): 2,43
Urea (mg/dL): 4,49
LVEF (%): 49.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here's my prognosis for the next few years, ordered from most likely to least likely:

RANKING: 1. Survivor
REASONING: The patient is 61 years old with a history of ischemic dilated cardiomyopathy and NYHA Class III, indicating moderate to severe heart failure symptoms. However, the patient is on optimal medical therapy with beta blockers, statins, and an ACE inhibitor, which suggests that the treatment plan is comprehensive and evidence-based. The patient's LVEF is 49%, which is within the range of preserved left ventricular function, and the Pro-BNP level of 797 ng/L is slightly elevated but not extremely high. The absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG is a positive sign. Considering these factors, the patient's prognosis is likely to be a survivor, with a focus on continued monitoring and optimization of their current treatment plan.

RANKING: 2. Pump failure death
REASONING: The patient's LVEF of 49% indicates reduced left ventricular function, which increases the risk of heart failure progression. The elevated Pro-BNP level of 797 ng/L also suggests increased ventricular stress. However, the patient is on optimal medical therapy, which reduces the likelihood of pump failure. The absence of severe electrolyte imbalances, such as hyperkalemia, and the relatively normal urea level of 4.49 mg/dL suggest that the patient's kidney function is not severely compromised at this time. While pump failure is a possible outcome, the patient's current treatment plan and relatively stable renal function reduce the likelihood of this outcome.

RANKING: 3. Sudden cardiac death
REASONING: The patient's history of ischemic dilated cardiomyopathy and reduced LVEF increase the risk of sudden cardiac death. However, the absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG reduces this risk. The patient's T3 level of 0.05 pg/dL and TSH level of 2.43 mIU/L suggest euthyroidism, which is a positive sign. The patient's LDL level of 6.05 mmol/L is well-controlled with statin therapy, reducing the risk of atherosclerotic events. While sudden cardiac death is a possible outcome, the patient's current treatment plan and relatively stable cardiac function reduce the likelihood of this outcome.

Note: These rankings are based on the provided data and may not be definitive or absolute. A more accurate prognosis would require a comprehensive clinical evaluation and consideration of additional factors not presented in the data."
599,599,P0933,"Age: 71
Gender: Male 
Weight: 66 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 124/68 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 194.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 5,1
LDL (mmol/L): 2,28
Sodium (mEq/L): 142.0
Protein (g/L): 76
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,15
Urea (mg/dL): 13,64
LVEF (%): 20.0
Medications: Amiodarone, Angiotensin II Receptor Blocker, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses as follows:

RANKING: 1. Survivor
 REASONING: The patient is 71 years old with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for adverse cardiac outcomes. However, the patient's current medications, including an Angiotensin II Receptor Blocker and Statins, suggest that the patient is being managed for heart failure and high cholesterol. The patient's LVEF (Left Ventricular Ejection Fraction) is 20%, which is a marker of severe heart failure, but the patient is still alive, indicating that the current management is effective. The patient's Troponin level is 0.03 ng/mL, which is within a normal range, indicating that there is no ongoing myocardial infarction. The patient's blood pressure is well-controlled, and there are no signs of severe electrolyte imbalances. While the patient's creatinine level is elevated, indicating some degree of kidney dysfunction, the patient's overall clinical picture suggests that the patient is being managed effectively, and the prognosis for survival is relatively good.

RANKING: 2. Pump failure death
 REASONING: The patient's LVEF of 20% is a significant risk factor for pump failure death. The patient's history of myocardial infarction and ischemic dilated cardiomyopathy also increases the risk of pump failure. However, the patient's current medications and the fact that the patient is still alive suggest that the patient's condition is being managed effectively. The patient's creatinine level is elevated, which may indicate some degree of kidney dysfunction, which can be a complication of heart failure. However, the patient's overall clinical picture suggests that the patient is being managed effectively, and the risk of pump failure death is lower than the risk of sudden cardiac death.

RANKING: 3. Sudden cardiac death
 REASONING: The patient's history of ischemic dilated cardiomyopathy and LVEF of 20% increase the risk of sudden cardiac death. However, the patient's current medications, including Amiodarone, suggest that the patient is being managed for arrhythmias. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the patient's Troponin level is within a normal range, and there are no signs of ongoing myocardial infarction. The patient's overall clinical picture suggests that the patient is being managed effectively, and the risk of sudden cardiac death is lower than the risk of pump failure death."
600,600,P0935,"Age: 46
Gender: Male 
Weight: 79 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 47,2
ALT or GPT (IU/L): 82.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 3,85
Creatinine (mmol/L): 87.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 162.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,56
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 272.0
Protein (g/L): 69,7
T3 (pg/dL): 0,05
T4 (ng/L): 15
TSH (mIU/L): 1,67
Urea (mg/dL): 4,99
LVEF (%): 30.0
Medications: Beta Blockers, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here are the possible prognoses for the next few years, ordered from most likely to least likely, along with the reasoning behind each ranking:

RANKING: 1. Sudden Cardiac Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, myocardial infarction, and a low left ventricular ejection fraction (LVEF) of 30%. These factors significantly increase the risk of sudden cardiac death. Additionally, the patient's low HDL cholesterol (0.78 mmol/L) and high LDL cholesterol (2.56 mmol/L) contribute to an increased risk of cardiac events. The presence of ventricular extrasystoles, although polymorphic, also raises concerns. The patient's current medications, including beta blockers and an ACE inhibitor, are appropriate for managing heart failure and reducing the risk of sudden cardiac death, but the patient's underlying condition and risk factors make sudden cardiac death a significant concern.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF of 30% indicates severe left ventricular dysfunction, which is a strong predictor of pump failure death. The patient's history of ischemic dilated cardiomyopathy and myocardial infarction further supports this risk. The patient's low serum albumin (47.2 g/L) and elevated creatinine (87.0 mol/L) levels suggest renal dysfunction, which can contribute to worsening heart failure. However, the patient's current medications, including an ACE inhibitor, may help slow the progression of heart failure.

RANKING: 3. Survivor
 REASONING: While the patient's condition is concerning, the presence of beta blockers and an ACE inhibitor, along with the patient's current medications, suggest that the patient is being actively managed for heart failure. The patient's LVEF of 30% is relatively low, but not the lowest possible value. The patient's overall clinical condition and treatment plan make survival a more likely outcome, although the patient will still require close monitoring and management to prevent cardiac events.

Note: The prognosis provided is based on the available data and may not reflect the patient's actual outcome, as individual results can vary."
601,601,P0937,"Age: 67
Gender: Female 
Weight: 64 kg
Height: 151 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Hypertropic cardiomyopathy, Hypertension
Albumin (g/L): 41,2
ALT or GPT (IU/L): 50.0
AST or GOT (IU/L): 41.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 105.0
Gamma-glutamil transpeptidase (IU/L): 149
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,08
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 3315.0
Protein (g/L): 66,6
T3 (pg/dL): 0,04
T4 (ng/L): 20
TSH (mIU/L): 1,8
Urea (mg/dL): 9,32
LVEF (%): 64.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's my prognosis for the next few years:

RANKING: 1. Survivor
REASONING: The patient's age and sex are risk factors for cardiovascular disease, but the patient is being actively managed with medications such as beta blockers, loop diuretics, and an ACE inhibitor, which are all appropriate for a patient with heart failure. The patient's LVEF (left ventricular ejection fraction) is 64%, which is within the normal range (50-70%), indicating that the patient's heart is functioning adequately. The patient's NYHA Class II indicates that the patient is experiencing some limitation of physical activity but is still able to perform everyday activities without significant symptoms. The patient's blood pressure is slightly elevated, but it's not excessively high. The patient's albumin and protein levels are within normal limits, which suggests that the patient does not have significant liver dysfunction or nephrotic syndrome. The patient's TSH level is within the normal range, indicating that the patient does not have hypothyroidism, which can be a risk factor for heart failure. The patient's pro-BNP level is elevated, but it's not excessively high, indicating that the patient is not in acute heart failure. The patient's medications, including amiodarone, are appropriate for a patient with a history of hypertrophic cardiomyopathy and arrhythmias. Overall, considering the patient's current management and the absence of severe symptoms, I predict that the patient will survive for the next few years.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF is 64%, which is within the normal range, but it's lower than the average for a healthy individual. The patient's pro-BNP level is elevated, which suggests that the patient has some degree of heart failure. The patient's NYHA Class II indicates that the patient is experiencing some limitation of physical activity, which is a risk factor for heart failure progression. The patient's blood pressure is slightly elevated, which can contribute to cardiac workload and strain. However, the patient is being managed with medications that are appropriate for heart failure, and the patient's albumin and protein levels are within normal limits. The patient's TSH level is within the normal range, and the patient's T3 and T4 levels are also within normal limits. The patient's creatinine level is elevated, which suggests that the patient has some degree of kidney dysfunction, but it's not excessively high. Overall, considering the patient's current management and the presence of some risk factors for heart failure, I predict that pump failure death is a possible outcome for the patient in the next few years.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's ECG impression shows a paroxysmal supraventricular tachyarrhythmia (PSVT), which can be a risk factor for sudden cardiac death. However, the patient is being managed with amiodarone, which is an anti-arrhythmic medication that can help prevent arrhythmias. The patient's LVEF is 64%, which is within the normal range, indicating that the patient's heart is functioning adequately. The patient's NYHA Class II indicates that the patient is experiencing some limitation of physical activity, but the patient is not in acute heart failure. The patient's blood pressure is slightly elevated, but it's not excessively high. The patient's albumin and protein levels are within normal limits, and the patient's TSH level is within the normal range. The patient's T3 and T4 levels are also within normal limits. The patient's creatinine level is elevated, which suggests that the patient has some degree of kidney dysfunction, but it's not excessively high. Overall, considering the patient's current management and the presence of some risk factors for arrhythmias, I predict that sudden cardiac death is the least likely outcome for the patient in the next few years."
602,602,P0939,"Age: 52
Gender: Male 
Weight: 85 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 104/72 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 7,68
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 11
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,57
Potassium (mEq/L): 5,3
LDL (mmol/L): 2,25
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 34.0
Protein (g/L): 68
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,08
Urea (mg/dL): 8,82
LVEF (%): 30.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses for the next few years as follows:

RANKING: 1. Survivor
REASONING: The patient is 52 years old with ischemic dilated cardiomyopathy, diabetes, and dyslipemia, which are all risk factors for cardiac disease. However, the patient's LVEF is 30%, which is relatively low but not extremely low. The patient is on medications that are commonly used in heart failure management, such as beta blockers, spironolactone, statins, and ACE inhibitors, which may help slow disease progression. The patient's BNP level is 34.0 ng/L, which is within a relatively normal range. The absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG also suggests that the patient does not have a high risk of sudden cardiac death. Additionally, the patient's overall clinical condition, including blood pressure, glucose, and potassium levels, does not suggest an acute or rapidly progressive disease course. Therefore, based on these factors, a survivor prognosis seems most likely.

RANKING: 2. Pump failure death
REASONING: The patient's LVEF is 30%, which indicates significant left ventricular dysfunction. Ischemic dilated cardiomyopathy is a known cause of pump failure, and the patient's history of myocardial infarction further increases the risk. However, the patient's BNP level is not extremely elevated, and the patient is on medications that are commonly used to manage heart failure. The patient's overall clinical condition, including blood pressure, glucose, and potassium levels, does not suggest an acute or rapidly progressive disease course. Therefore, while pump failure is a possible outcome, it is less likely than survivor due to the patient's relatively stable clinical condition.

RANKING: 3. Sudden cardiac death
REASONING: The patient's ECG shows monomorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG suggests that the patient does not have a high risk of sudden cardiac death. Additionally, the patient's LVEF is 30%, which is relatively low, but not extremely low, and the patient is on medications that are commonly used to manage heart failure, which may help reduce the risk of sudden cardiac death. The patient's overall clinical condition, including blood pressure, glucose, and potassium levels, does not suggest an acute or rapidly progressive disease course. Therefore, sudden cardiac death is the least likely outcome."
603,603,P0941,"Age: 64
Gender: Male 
Weight: 81 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 145/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 5,74
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 161.0
HDL (mmol/L): 0,57
Potassium (mEq/L): 4,1
LDL (mmol/L): 4,09
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 189.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,89
Urea (mg/dL): 5,16
LVEF (%): 50.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: 1. Survivor
REASONING: The patient is 64 years old with a history of idiopathic dilated cardiomyopathy and hypertension. Despite these conditions, the patient's left ventricular ejection fraction (LVEF) is 50%, which is within the mildly reduced range. The patient is on beta blockers, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure and hypertension. The patient's blood pressure is well-controlled at 145/80 mmHg, and the patient's weight is 81 kg, which is within a relatively normal range. The patient's laboratory results, including troponin, are within normal limits, indicating minimal cardiac damage. The patient's TSH is within the normal range, which suggests that there are no underlying thyroid issues contributing to the cardiomyopathy. The patient's Pro-BNP level is elevated at 189.0 ng/L, which is consistent with heart failure, but it is not extremely high, indicating that the patient is not in a severe state of heart failure. The patient's NYHA Class is II, indicating that the patient has some limitations in physical activity but is not severely symptomatic. Based on these factors, the patient has a relatively favorable prognosis, with a high likelihood of survival over the next few years.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of idiopathic dilated cardiomyopathy and hypertension increases the risk of sudden cardiac death (SCD). The patient's LVEF is 50%, which is within the mildly reduced range, but it is still a risk factor for SCD. The patient's ventricular extrasystoles are polymorphic, which can be a marker of increased arrhythmic risk. However, the patient does not have a history of non-sustained ventricular tachycardia or sustained ventricular tachycardia, which are more significant risk factors for SCD. The patient's medications, including beta blockers and ACE inhibitors, are appropriate for reducing the risk of SCD. The patient's TSH is within the normal range, which suggests that there are no underlying thyroid issues contributing to the cardiomyopathy. Based on these factors, the patient has a moderate risk of sudden cardiac death over the next few years.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF is 50%, which is within the mildly reduced range, indicating that the patient's heart is not severely compromised at this time. The patient's NYHA Class is II, indicating that the patient has some limitations in physical activity but is not severely symptomatic. The patient's laboratory results, including troponin, are within normal limits, indicating minimal cardiac damage. The patient's Pro-BNP level is elevated at 189.0 ng/L, which is consistent with heart failure, but it is not extremely high, indicating that the patient is not in a severe state of heart failure. The patient's medications, including beta blockers, loop diuretics, and ACE inhibitors, are standard treatments for heart failure and are likely to slow the progression of the disease. Based on these factors, the patient has a low risk of pump failure death over the next few years."
604,604,P0942,"Age: 57
Gender: Male 
Weight: 82 kg
Height: 173 cm
NYHA Class: II
Blood Pressure: 126/79 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 47
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,89
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,34
Potassium (mEq/L): 5,3
LDL (mmol/L): 3,03
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 74.0
Protein (g/L): 72
T3 (pg/dL): 0,06
T4 (ng/L): 14
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,47
Urea (mg/dL): 5,83
LVEF (%): 30.0
Medications: Beta Blockers, Digoxin, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the three possible prognoses as follows:

RANKING: 1. Survivor
 REASONING: The patient has been diagnosed with idiopathic dilated cardiomyopathy, which is a significant underlying condition affecting the heart's pumping ability. However, the patient is already on a treatment regimen that includes beta blockers, digoxin, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure. The patient's NYHA Class II classification indicates that the heart failure symptoms are not severe, and the patient is able to perform daily activities without significant limitations. The LVEF of 30% is relatively low but not extremely low, indicating some preserved cardiac function. Additionally, the patient's troponin levels are within normal limits, and there is no indication of acute coronary syndrome. Considering the patient's current treatment and the relatively mild symptoms, a survivor prognosis is more likely.

RANKING: 2. Pump Failure Death
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which can lead to progressive heart failure. The patient's LVEF of 30% indicates a significant reduction in cardiac function, and the patient is already experiencing symptoms of heart failure (NYHA Class II). However, the patient is being treated with medications that are typically used to slow the progression of heart failure. While there is a risk of pump failure, the patient's current treatment and the fact that the patient is not in NYHA Class III or IV classification (which indicates more severe symptoms) make this prognosis less likely.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which can increase the risk of sudden cardiac death. However, the patient's ECG impression shows no signs of sustained ventricular tachycardia, non-sustained ventricular tachycardia, or bradycardia, which are common indicators of a higher risk of sudden cardiac death. The patient's LVEF of 30% is relatively low, but the patient is being treated with beta blockers, which are known to reduce the risk of sudden cardiac death. Additionally, the patient's troponin levels are within normal limits, and there is no indication of acute coronary syndrome. While sudden cardiac death is a risk, the patient's current treatment and the lack of high-risk ECG findings make this prognosis the least likely."
605,605,P0943,"Age: 71
Gender: Male 
Weight: 70 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 134/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 3,85
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 126.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,07
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 68
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,61
Urea (mg/dL): 7,32
LVEF (%): 40.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: 

The patient is 71 years old with a history of ischemic dilated cardiomyopathy and myocardial infarction, indicating a significant cardiac condition. However, the patient is currently on appropriate medications (beta blockers, spironolactone, statins, and ACE inhibitor) that are commonly used to manage heart failure and reduce the risk of adverse outcomes. The patient's LVEF of 40% suggests a moderate level of heart failure, but it is not severely impaired.

The patient's NYHA class II indicates that the patient has some limitations in physical activity but is still able to perform light physical activity without discomfort. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG is a positive sign.

The patient's biomarkers, including troponin (0.03 ng/mL), pro-BNP (709.0 ng/L), and creatinine (80.0 umol/L), suggest that the patient's cardiac function is not severely compromised. The patient's kidney function is also relatively preserved, with a normal urea level (7.32 mg/dL).

Considering these factors, the patient's prognosis is more likely to be a survivor, as the patient is receiving appropriate treatment and has a relatively stable cardiac function. However, the patient's prognosis should be closely monitored, and adjustments to their treatment plan should be made as necessary to prevent further cardiac complications.

RANKING: Sudden Cardiac Death

REASONING: 

Sudden cardiac death is a possible prognosis for this patient due to the presence of ischemic dilated cardiomyopathy and myocardial infarction, which can increase the risk of arrhythmias and cardiac arrest. The patient's polymorphic ventricular extrasystole on the ECG is a risk factor for sudden cardiac death. However, the absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG reduces the likelihood of sudden cardiac death.

RANKING: Pump Failure Death

REASONING: 

Pump failure death is a less likely prognosis for this patient due to the patient's relatively preserved kidney function (creatinine 80.0 umol/L) and moderate LVEF (40%). The patient's NYHA class II also suggests that the patient has some limitations in physical activity but is still able to perform light physical activity without discomfort. The patient's treatment plan, which includes beta blockers, spironolactone, statins, and ACE inhibitor, is aimed at reducing the risk of heart failure progression."
606,606,P0945,"Age: 57
Gender: Male 
Weight: 115 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 135/99 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 47
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,51
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 7
Hemoglobin (g/L): 158.0
HDL (mmol/L): 0,54
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,7
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 192.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,29
Urea (mg/dL): 7,49
LVEF (%): 39.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. I will rank the three possible prognoses from most likely to least likely and explain the reasoning behind the order.

RANKING: 1. Survivor
REASONING: The patient has a history of enolic dilated cardiomyopathy and is on a treatment regimen that includes Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, and Loop Diuretics. These medications are commonly used to manage heart failure and reduce the risk of sudden cardiac death. The patient's LVEF (Left Ventricular Ejection Fraction) is 39%, which is below the normal range but not extremely low, indicating some degree of heart function preservation. The patient's Pro-BNP level is elevated at 192.0 ng/L, which is a marker of heart failure, but it is not excessively high, suggesting that the patient's condition is manageable. The patient's ECG shows monomorphic ventricular extrasystoles, but there is no indication of sustained ventricular tachycardia or other high-risk arrhythmias. The patient's overall clinical presentation suggests that with continued medical management, the patient is likely to survive for the next few years.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF is 39%, which is below the normal range, indicating some degree of heart failure. The patient's Pro-BNP level is elevated, and the patient is on medications that are commonly used to manage heart failure. However, the patient's creatinine level is elevated at 88.0 umol/L, which suggests some degree of renal impairment, which can be a risk factor for pump failure. The patient's weight is 115 kg, which is above the normal range, and the patient's BMI is not provided. However, based on the height, the patient's BMI is likely to be high, which can increase the risk of heart failure. The patient's overall clinical presentation suggests that the patient is at risk for pump failure, but the risk is not extremely high.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's ECG shows monomorphic ventricular extrasystoles, but there is no indication of sustained ventricular tachycardia or other high-risk arrhythmias. The patient's Pro-BNP level is elevated, but it is not excessively high. The patient's LVEF is 39%, which is below the normal range, but not extremely low. The patient's overall clinical presentation suggests that the risk of sudden cardiac death is relatively low. The patient is on medications that are commonly used to manage heart failure and reduce the risk of sudden cardiac death. Therefore, sudden cardiac death is the least likely prognosis."
607,607,P0946,"Age: 70
Gender: Male 
Weight: 91 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 125/68 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 161
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 155.0
HDL (mmol/L): 0,52
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,36
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1455.0
Protein (g/L): 68
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,49
Urea (mg/dL): 15,47
LVEF (%): 30.0
Medications: Beta Blockers, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: The patient is 70 years old with a history of idiopathic dilated cardiomyopathy and dyslipemia, which indicates a significant underlying cardiac condition. However, the patient is on optimal medical therapy with beta blockers, spironolactone, and an ACE inhibitor, which is beneficial for heart failure management. The LVEF of 30% indicates moderate left ventricular dysfunction, but it is not severely reduced. The patient's NYHA Class II indicates that the patient is experiencing some symptoms, but they are not severely limiting their daily activities. The patient's Pro-BNP level of 1455 ng/L is elevated, but not excessively high, which may indicate a manageable level of heart failure. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and other severe arrhythmias on the ECG also suggests that the patient's cardiac condition is not as severe as it could be. Additionally, the patient's TSH level is within the normal range, which may indicate that the patient does not have hypothyroidism, a condition that can exacerbate heart failure. Considering these factors, the most likely prognosis for this patient is a survivor, as they are on optimal medical therapy and have a relatively stable cardiac condition.

RANKING: Pump Failure Death

REASONING: Pump failure death is a possible prognosis for this patient due to their history of idiopathic dilated cardiomyopathy and LVEF of 30%. The patient's elevated Pro-BNP level and creatinine level may indicate a degree of cardiac decompensation and renal impairment, which can contribute to pump failure. However, the patient's NYHA Class II and the absence of severe arrhythmias on the ECG suggest that the patient's cardiac condition is not as severe as it could be. The patient's optimal medical therapy with beta blockers, spironolactone, and an ACE inhibitor may help mitigate the risk of pump failure.

RANKING: Sudden Cardiac Death

REASONING: Sudden cardiac death is the least likely prognosis for this patient. The patient's ECG does not show any signs of severe arrhythmias, such as sustained ventricular tachycardia or non-sustained ventricular tachycardia with a cycle length < 120 ms. The patient's TSH level is within the normal range, which reduces the risk of arrhythmias caused by hypothyroidism. The patient's optimal medical therapy with beta blockers, which are known to reduce the risk of sudden cardiac death, also reduces the likelihood of this outcome."
608,608,P0947,"Age: 63
Gender: Male 
Weight: 72 kg
Height: 182 cm
NYHA Class: II
Blood Pressure: 124/76 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes
Albumin (g/L): 45
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 5,22
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 8
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 111.0
HDL (mmol/L): 0,54
Potassium (mEq/L): 5,1
LDL (mmol/L): 4,47
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 747.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,14
Urea (mg/dL): 11,65
LVEF (%): 40.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. However, please note that this is a hypothetical prediction and not a definitive diagnosis. 

RANKING: Survivor

REASONING: The patient has a history of enolic dilated cardiomyopathy, which is a condition where the heart muscle becomes weak and the heart chambers enlarge, reducing the heart's ability to pump blood effectively. The patient's left ventricular ejection fraction (LVEF) is 40%, which is below the normal range (50-70%), indicating a reduced cardiac function. However, the patient is currently on optimal medical therapy, including beta blockers, ACE inhibitors, and spironolactone, which are all evidence-based treatments for heart failure.

The patient's NYHA Class II indicates that the patient has some symptoms of heart failure, but they are not severely limited in their daily activities. The patient's blood pressure is well-controlled, and the serum creatinine level is slightly elevated, but not significantly so. The patient's BNP level is elevated, but not extremely high, which suggests that the patient is not in acute heart failure.

Considering the patient's age, comorbidities, and current medical therapy, I believe that the patient has a relatively good prognosis. The patient is likely to continue to experience symptoms of heart failure, but with optimal medical therapy, they are likely to survive for the next few years.

The other two possible prognoses, sudden cardiac death and pump failure death, are less likely because:

- Sudden cardiac death is less likely due to the patient's stable cardiac rhythm and the absence of any high-risk features on the ECG.
- Pump failure death is less likely due to the patient's current medical therapy and the fact that they are not in acute heart failure. The patient's LVEF is low, but it is not extremely low, and they are likely to benefit from continued medical therapy and lifestyle modifications.

In summary, while the patient has a history of heart failure and reduced cardiac function, their current medical therapy and stable condition suggest that they are likely to survive for the next few years."
609,609,P0949,"Age: 59
Gender: Male 
Weight: 103 kg
Height: 184 cm
NYHA Class: II
Blood Pressure: 128/78 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 33
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 118.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 3,6
LDL (mmol/L): 1,27
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1152.0
Protein (g/L): 64
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,38
Urea (mg/dL): 4,49
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: 
Given the patient's age, ischemic dilated cardiomyopathy, and reduced left ventricular ejection fraction (LVEF) of 30%, the patient is at a high risk for adverse cardiac events. However, the patient is already on optimal medical therapy, including digoxin, loop diuretics, statins, ACE inhibitor, and nitrovasodilator, which suggests that the patient's condition is being actively managed. The patient's NYHA Class II classification indicates that the patient is experiencing some symptoms, but is still able to perform everyday activities without significant limitation. The patient's biomarkers, such as troponin and BNP, are not excessively elevated, suggesting that the patient's cardiac condition is relatively stable. The absence of severe electrolyte imbalances, such as hypokalemia, and the presence of a relatively normal hemoglobin level also suggest that the patient's condition is stable. Additionally, the patient's TSH level is within the normal range, indicating that the patient's thyroid function is not contributing to the cardiac condition. Overall, while the patient is at a high risk for adverse cardiac events, the patient's current treatment regimen and relatively stable biomarkers suggest that the patient is likely to survive in the next few years.

RANKING: Pump Failure Death

REASONING: 
Given the patient's reduced LVEF of 30%, the patient is at a high risk for pump failure. However, the patient's current treatment regimen, including ACE inhibitor and nitrovasodilator, is aimed at reducing the workload on the heart and improving cardiac function. The patient's relatively stable biomarkers, such as troponin and BNP, suggest that the patient's cardiac condition is not rapidly deteriorating. While pump failure is a possible outcome, it is less likely than survivorship given the patient's current treatment regimen and relatively stable biomarkers.

RANKING: Sudden Cardiac Death

REASONING: 
Given the patient's history of ischemic dilated cardiomyopathy and reduced LVEF, the patient is at an increased risk for sudden cardiac death. However, the patient's current treatment regimen, including ACE inhibitor and nitrovasodilator, is aimed at reducing the risk of sudden cardiac death by improving cardiac function and reducing arrhythmias. The patient's ECG findings, including non-sustained ventricular tachycardia, suggest that the patient is at risk for arrhythmias, but the absence of severe electrolyte imbalances and the presence of a relatively normal hemoglobin level suggest that the patient's cardiac condition is relatively stable. While sudden cardiac death is a possible outcome, it is the least likely of the three options given the patient's current treatment regimen and relatively stable biomarkers."
610,610,P0954,"Age: 57
Gender: Male 
Weight: 109 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 117/87 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 147.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,9
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 72.0
Protein (g/L): 71
T3 (pg/dL): 0,06
T4 (ng/L): 15
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,9
Urea (mg/dL): 4,82
LVEF (%): 45.0
Medications: Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here is the ranking of the prognoses from most likely to least likely:

RANKING: Survivor

REASONING: The patient is 57 years old with a history of ischemic dilated cardiomyopathy and myocardial infarction, which indicates that the patient has had significant cardiac damage. However, the patient is on a stable medication regimen, including loop diuretics, statins, and ACE inhibitors, which suggests that the patient's condition is being well-managed. The patient's LVEF (left ventricular ejection fraction) is 45%, which is below the normal range (50-70%), but not extremely low. The patient's Pro-BNP level is 72.0 ng/L, which is elevated but not extremely high. The patient's ECG shows ventricular extrasystole, but no ventricular tachycardia or non-sustained ventricular tachycardia. The patient's electrolyte levels, including potassium and sodium, are within normal limits. Considering these factors, the patient's prognosis is most likely to be a survivor, as the patient's condition appears to be stable and manageable with medication.

RANKING: Pump Failure Death

REASONING: The patient's LVEF of 45% indicates that the patient's heart is not functioning at its optimal level, which increases the risk of pump failure. The patient's Pro-BNP level of 72.0 ng/L is also elevated, which is a marker of heart failure. The patient's history of ischemic dilated cardiomyopathy and myocardial infarction also increases the risk of pump failure. However, the patient is on a stable medication regimen, which suggests that the patient's condition is being managed. The patient's other vital signs and laboratory results are within normal limits, which suggests that the patient's condition is not deteriorating rapidly. Therefore, while pump failure is a possible outcome, it is less likely than survivor due to the patient's stable medication regimen and lack of acute symptoms.

RANKING: Sudden Cardiac Death

REASONING: Sudden cardiac death is a rare but possible outcome in patients with ischemic dilated cardiomyopathy and myocardial infarction. However, the patient's ECG shows ventricular extrasystole, but no ventricular tachycardia or non-sustained ventricular tachycardia, which reduces the risk of sudden cardiac death. The patient's LVEF of 45% and Pro-BNP level of 72.0 ng/L suggest that the patient's heart is not functioning at its optimal level, but the patient's condition is being managed with medication. The patient's other vital signs and laboratory results are within normal limits, which suggests that the patient's condition is not deteriorating rapidly. Therefore, sudden cardiac death is the least likely outcome of the three, as the patient's condition appears to be stable and manageable."
611,611,P0955,"Age: 59
Gender: Male 
Weight: 94 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 148/79 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 6,57
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 123.0
HDL (mmol/L): 0,54
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,66
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 553.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,63
Urea (mg/dL): 9,65
LVEF (%): 35.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: Survivor
REASONING: The patient has a relatively high risk of adverse cardiac events due to his age, ischemic dilated cardiomyopathy, and reduced left ventricular ejection fraction (LVEF) of 35%. However, several factors suggest a more favorable prognosis. The patient is on optimal medical therapy with beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are all evidence-based treatments for heart failure with reduced ejection fraction (HFrEF). The patient's NT-proBNP level is elevated at 553 ng/L, indicating some degree of heart failure symptoms, but not excessively high, suggesting that the patient is being adequately managed. The absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG is also a positive sign. Furthermore, the patient's hemoglobin and urea levels are within normal limits, indicating that there is no significant anemia or renal impairment. The patient's weight is within a relatively normal range for his height, which is a positive factor for heart failure management. While the patient's lipid profile is not ideal, the patient is on statins, which are helping to manage his dyslipidemia. Overall, considering the patient's age, comorbidities, and current treatment, I believe that the most likely prognosis is survivor.

RANKING: Pump Failure Death
REASONING: The patient's LVEF of 35% indicates a significant reduction in cardiac function, which increases the risk of pump failure death. The patient's NT-proBNP level of 553 ng/L also suggests some degree of heart failure symptoms. However, as mentioned earlier, the patient is on optimal medical therapy, which reduces the risk of pump failure death. The patient's absence of significant anemia, renal impairment, and other comorbidities also reduces the risk of pump failure death.

RANKING: Sudden Cardiac Death
REASONING: While the patient has a reduced LVEF and a history of ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death, the patient's current medical therapy, including beta blockers, reduces the risk of sudden cardiac death. The patient's ECG does show polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death, but the absence of ventricular tachycardia and non-sustained ventricular tachycardia suggests that the risk of sudden cardiac death is relatively low."
612,612,P0956,"Age: 80
Gender: Female 
Weight: 64 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 135/80 mmHg
Past Medical History: Valvular cardiomyopathy, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,72
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,78
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1032.0
Protein (g/L): 65
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,04
TSH (mIU/L): 2,31
Urea (mg/dL): 8,15
LVEF (%): 56.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here are the three possible prognoses for the next few years, ordered from most likely to least likely:

RANKING: Survivor
REASONING: The patient is 80 years old with a history of valvular cardiomyopathy and hypertension, which are significant risk factors for heart disease. However, the patient is on appropriate medications (beta blockers, digoxin, loop diuretics, and ACE inhibitor) and has a relatively well-controlled blood pressure. The LVEF of 56% indicates that the patient's heart is still functioning reasonably well, although it is below the normal range. The Pro-BNP level of 1032.0 ng/L is elevated, indicating some degree of heart failure, but it is not extremely high. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a benign finding in some cases. The patient's overall clinical picture suggests that, with proper management, the patient may be able to manage their condition and avoid sudden cardiac death or pump failure.

RANKING: Pump Failure Death
REASONING: The patient has a history of valvular cardiomyopathy, which can lead to progressive heart failure. The LVEF of 56% is below the normal range, indicating some degree of left ventricular dysfunction. The elevated Pro-BNP level and the patient's NYHA Class II classification also suggest some degree of heart failure. The patient's creatinine level of 88.0 umol/L is slightly elevated, which may indicate some degree of renal impairment, which can be a complication of heart failure. However, the patient's overall clinical picture does not suggest an immediate high risk of pump failure.

RANKING: Sudden Cardiac Death
REASONING: The patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the patient is on beta blockers, which can help reduce the risk of sudden cardiac death. The patient's Troponin level is slightly elevated, which may indicate some degree of myocardial damage, but it is not extremely high. The patient's overall clinical picture does not suggest an extremely high risk of sudden cardiac death."
613,613,P0957,"Age: 70
Gender: Male 
Weight: 66 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 158/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 46
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 5,95
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 3,7
LDL (mmol/L): 3,93
Sodium (mEq/L): 143.0
Protein (g/L): 71
T3 (pg/dL): 0,02
T4 (ng/L): 5
Troponin (ng/mL): 0,03
TSH (mIU/L): 70,54
Urea (mg/dL): 4,33
LVEF (%): 40.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: 1. Survivor
REASONING: The patient is 70 years old with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction. However, despite these risk factors, the patient is currently on a multidrug regimen that includes beta blockers, ACE inhibitors, and statins, which are evidence-based treatments for heart failure and ischemic heart disease. The patient's left ventricular ejection fraction (LVEF) is 40%, which is below the normal range but not extremely low, indicating that the heart is still pumping some blood effectively. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG also suggests that the patient's heart rhythm is relatively stable. While the patient's troponin level is slightly elevated, it is not significantly high, and the patient's hemoglobin level is within a normal range. Considering these factors, the patient's current treatment plan and relatively stable ECG, I believe that the patient has a higher likelihood of survival.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's LVEF of 40% indicates that the heart is not pumping efficiently, which increases the risk of sudden cardiac death. The patient's history of myocardial infarction and ischemic dilated cardiomyopathy also increases the risk of sudden cardiac death. Additionally, the patient's elevated troponin level suggests that there may be ongoing myocardial damage. However, the patient's stable ECG and current treatment plan suggest that the risk of sudden cardiac death may be mitigated. The patient's low TSH level also suggests that hypothyroidism is not contributing to cardiac dysfunction, which is a risk factor for sudden cardiac death.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF of 40% indicates that the heart is not pumping efficiently, which increases the risk of pump failure death. The patient's history of ischemic dilated cardiomyopathy and diabetes also increases the risk of pump failure. However, the patient's current treatment plan, including loop diuretics, ACE inhibitors, and beta blockers, suggests that the patient is being adequately managed for heart failure. The patient's stable ECG and relatively low creatinine level also suggest that renal function is not severely impaired, which is a risk factor for pump failure. While the patient's low LVEF and history of heart disease increase the risk of pump failure, the patient's current treatment plan and relatively stable ECG suggest that the risk may be lower than the risk of sudden cardiac death."
614,614,P0958,"Age: 68
Gender: Male 
Weight: 74 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 117/61 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 33
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 6,03
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 94.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 5,6
LDL (mmol/L): 4,16
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 252.0
Protein (g/L): 52
T3 (pg/dL): 0,02
T4 (ng/L): 5
Troponin (ng/mL): 0,05
TSH (mIU/L): 83,92
Urea (mg/dL): 16,97
LVEF (%): 30.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. However, please note that the patient's outcome is given as ""survivor,"" which is not a typical outcome in a medical prognosis. A more accurate approach would be to provide a probability of survival or a likelihood of certain outcomes. Since the outcome is provided, I will interpret it as the patient being alive for the next few years.

RANKING: Survivor
 REASONING: The patient is 68 years old with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac mortality. However, the patient's LVEF is 30%, indicating a reduced ejection fraction, but it is not extremely low. The patient is also on medications that are beneficial for heart failure management, such as ACE inhibitors, loop diuretics, and spironolactone. The patient's blood pressure is within a relatively normal range, and the creatinine level is slightly elevated but not significantly so. The patient's glucose level is well-controlled, and the hemoglobin level is within the normal range. The patient's troponin level is slightly elevated, but not excessively so. The TSH level is significantly elevated, which could indicate hypothyroidism, a condition that can impact cardiac function. However, the patient is on amiodarone, which can also affect thyroid function. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of cardiac stress but is not a strong predictor of mortality. Considering these factors, the patient's likelihood of survival for the next few years is moderate to high.

RANKING: Sudden Cardiac Death
 REASONING: Sudden cardiac death is a possible outcome in patients with ischemic dilated cardiomyopathy and reduced LVEF. However, the patient's LVEF is not extremely low, and the patient is on medications that can help prevent sudden cardiac death. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of cardiac stress, but it is not a strong predictor of sudden cardiac death. The patient's troponin level is slightly elevated, but not excessively so. The patient's overall clinical picture suggests that sudden cardiac death is less likely than pump failure death.

RANKING: Pump Failure Death
 REASONING: Pump failure death is a possible outcome in patients with ischemic dilated cardiomyopathy and reduced LVEF. The patient's LVEF is 30%, indicating a significant reduction in cardiac function. The patient's creatinine level is slightly elevated, which can indicate renal impairment, a common comorbidity in patients with heart failure. The patient's glucose level is well-controlled, which can help mitigate the risk of cardiac complications. However, the patient's TSH level is significantly elevated, which could indicate hypothyroidism, a condition that can impact cardiac function. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of cardiac stress. Considering these factors, pump failure death is a possible outcome, but it is less likely than survivor due to the patient's relatively well-controlled diabetes and the presence of beneficial medications.

Note: The ranking is based on my interpretation of the provided data and may not reflect the actual outcome. A more accurate prognosis would require further evaluation and testing."
615,615,P0960,"Age: 74
Gender: Female 
Weight: 64 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 141/72 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,76
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 5
Hemoglobin (g/L): 115.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,9
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 588.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,97
Urea (mg/dL): 11,15
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. However, I must emphasize that this is a hypothetical assessment, and actual outcomes can vary greatly depending on individual factors and potential changes in the patient's condition.

Given the information, I rank the prognoses from most likely to least likely as follows:

RANKING: 1. Survivor

REASONING: The patient is 74 years old with a history of ischemic dilated cardiomyopathy and a left ventricular ejection fraction (LVEF) of 25%. Despite this, the patient is on optimal medical therapy, including angiotensin II receptor blockers, beta blockers, loop diuretics, and statins. The patient's blood pressure is well-controlled, and the creatinine level is slightly elevated but not significantly abnormal. The patient's albumin and protein levels are within normal limits, indicating no significant liver dysfunction. The absence of sustained ventricular tachycardia and non-sustained ventricular tachycardia on the ECG suggests a low risk of sudden cardiac death. The patient's TSH level is within the normal range, and the thyroid function appears to be normal. The patient's LVEF is low, but it is not as low as some patients who have been reported to have a higher risk of sudden cardiac death. The patient's overall clinical condition and medical management make a survivor prognosis more likely.

RANKING: 2. Pump failure death

REASONING: The patient's LVEF of 25% indicates a reduced cardiac function, which increases the risk of pump failure. However, the patient is on optimal medical therapy, and the creatinine level is not significantly elevated, suggesting that the kidneys are not severely affected. The patient's albumin and protein levels are within normal limits, indicating no significant liver dysfunction. The patient's overall clinical condition and medical management make pump failure less likely compared to sudden cardiac death.

RANKING: 3. Sudden cardiac death

REASONING: While the patient has a history of ischemic dilated cardiomyopathy and a low LVEF, the absence of sustained ventricular tachycardia and non-sustained ventricular tachycardia on the ECG suggests a low risk of sudden cardiac death. The patient's TSH level is within the normal range, and the thyroid function appears to be normal. The patient's overall clinical condition and medical management make sudden cardiac death the least likely prognosis.

Please note that this is a hypothetical assessment, and the actual outcome may vary depending on individual factors and potential changes in the patient's condition."
616,616,P0962,"Age: 55
Gender: Male 
Weight: 105 kg
Height: 182 cm
NYHA Class: II
Blood Pressure: 137/102 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 46
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,16
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,38
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1083.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 2,22
Urea (mg/dL): 6,82
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Survivor
 REASONING: The patient has a history of enolic dilated cardiomyopathy, which is a significant risk factor for heart failure. However, the patient's LVEF is 40%, which is relatively stable. The patient is on a multidrug regimen, including beta blockers, digoxin, loop diuretics, spironolactone, hydralazine, and nitrovasodilator, which are commonly used in heart failure management. The patient's BNP level is elevated at 1083.0 ng/L, indicating heart failure, but it is not extremely high. The patient's creatinine level is slightly elevated, but not significantly high, suggesting that renal function is not severely compromised. The patient's troponin level is low, indicating minimal myocardial damage. The patient's ECG shows ventricular extrasystoles, but no sustained ventricular tachycardia or bradycardia. Overall, while the patient has a history of heart failure, the current medication regimen and relatively stable LVEF suggest that the patient is being well-managed, and the prognosis is likely to be a survivor.

RANKING: Pump failure death
 REASONING: The patient's LVEF is 40%, indicating reduced cardiac function. The patient's BNP level is elevated, and the patient has a history of enolic dilated cardiomyopathy, which increases the risk of heart failure. However, the patient is on a multidrug regimen, and the creatinine level is not severely elevated. The patient's troponin level is low, indicating minimal myocardial damage. The patient's ECG shows ventricular extrasystoles, but no sustained ventricular tachycardia or bradycardia. While the patient's prognosis is guarded, the patient's current management and relatively stable LVEF suggest that pump failure death is less likely than sudden cardiac death.

RANKING: Sudden cardiac death
 REASONING: The patient's LVEF is 40%, indicating reduced cardiac function, and the patient has a history of enolic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The patient's BNP level is elevated, and the patient's ECG shows ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the patient is on a multidrug regimen, and the creatinine level is not severely elevated. The patient's troponin level is low, indicating minimal myocardial damage. The patient's relatively stable LVEF and lack of sustained ventricular tachycardia or bradycardia on the ECG make sudden cardiac death less likely than pump failure death."
617,617,P0964,"Age: 81
Gender: Female 
Weight: 70 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 125/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 101
Glucose (mmol/L): 7,1
Hemoglobin (g/L): 137.0
HDL (mmol/L): 2,48
Potassium (mEq/L): 5
LDL (mmol/L): 1,5
Sodium (mEq/L): 130.0
Pro-BNP (ng/L): 2733.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,8
Urea (mg/dL): 10,31
LVEF (%): 70.0
Medications: Calcium Channel Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient's current age of 81 and NYHA Class II indicate that she has some limitations in physical activity but is still relatively stable. The LVEF of 70% suggests that the heart is pumping blood effectively, and the patient is not in heart failure. The patient is on a regimen of medications that are typical for managing heart failure and ischemic cardiomyopathy, including a calcium channel blocker, loop diuretics, spironolactone, statins, and nitrovasodilators. The patient's Pro-BNP level of 2733.0 ng/L is elevated, but not extremely high, which might indicate some degree of heart failure, but not severe. The patient's troponin level is low, and there is no evidence of ventricular tachycardia or non-sustained ventricular tachycardia. The patient's ECG shows polymorphic ventricular extrasystoles, but this is a common finding in the elderly and not necessarily a predictor of poor outcomes. Considering these factors, the patient's overall prognosis is most likely to be a survivor.

RANKING: 2. Pump failure death
 REASONING: The patient's LVEF of 70% is relatively low, and the Pro-BNP level of 2733.0 ng/L is elevated, which might indicate some degree of heart failure. However, the patient's NYHA Class II and the fact that she is on medications that are typical for managing heart failure suggest that her condition is being managed. The patient's creatinine level is slightly elevated, which might indicate some degree of renal impairment, but this is not a direct predictor of pump failure death. The patient's troponin level is low, and there is no evidence of ventricular tachycardia or non-sustained ventricular tachycardia. Considering these factors, the patient's prognosis for pump failure death is less likely than a survivor.

RANKING: 3. Sudden cardiac death
 REASONING: The patient's age of 81 and the presence of ischemic cardiomyopathy and myocardial infarction increase her risk for sudden cardiac death. However, the patient's LVEF of 70% and the fact that she is on medications that are typical for managing heart failure suggest that her condition is being managed. The patient's troponin level is low, and there is no evidence of ventricular tachycardia or non-sustained ventricular tachycardia. The patient's ECG shows polymorphic ventricular extrasystoles, but this is a common finding in the elderly and not necessarily a predictor of sudden cardiac death. Considering these factors, the patient's prognosis for sudden cardiac death is the least likely of the three options."
618,618,P0969,"Age: 75
Gender: Male 
Weight: 91 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,41
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 74
Glucose (mmol/L): 14,5
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4
LDL (mmol/L): 1,58
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 3298.0
Protein (g/L): 70
T4 (ng/L): 14
Troponin (ng/mL): 0,02
TSH (mIU/L): 6,45
Urea (mg/dL): 6,49
LVEF (%): 47.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's the ranking of the three possible prognoses from most likely to least likely:

RANKING: 1. Survivor
 REASONING: The patient has a relatively well-managed heart failure condition, as indicated by the use of multiple medications such as ACE inhibitors, beta blockers, and statins, which are standard treatments for idiopathic dilated cardiomyopathy and hypertension. The patient's NYHA Class II classification suggests that they have mild to moderate symptoms of heart failure. Although the patient has a reduced LVEF (47%) and elevated Pro-BNP levels, which are indicators of heart failure, they are not extreme. The patient's blood pressure is well-controlled, and their kidney function, as indicated by the creatinine levels, is relatively preserved. Additionally, the patient's hemoglobin and albumin levels are within a relatively normal range. Given these factors, the patient's overall prognosis appears to be favorable, and the likelihood of a survivor outcome is the highest.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a known risk factor for sudden cardiac death. The presence of polymorphic ventricular extrasystoles on the ECG is also a concerning finding, as it may indicate an increased risk of arrhythmias. However, the patient's LVEF is still above the threshold for severe heart failure (LVEF < 30%), and their other vital signs and laboratory results are relatively stable. While the risk of sudden cardiac death is a concern, it is not the most likely outcome given the patient's overall clinical picture.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 47% indicates that they have a moderately reduced cardiac function. However, their overall clinical picture suggests that they are not in severe heart failure, and their kidney function is relatively preserved. The patient's weight is also not excessively high, which is a risk factor for heart failure. Additionally, the patient's blood pressure is well-controlled, and their medication regimen is comprehensive. While pump failure death is a possible outcome, it is the least likely given the patient's relatively stable clinical status and the fact that their symptoms are well-managed with medication."
619,619,P0970,"Age: 66
Gender: Male 
Weight: 66 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 84/49 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,97
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 47
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,95
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2694.0
Protein (g/L): 73
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,63
Urea (mg/dL): 10,15
LVEF (%): 17.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure and mortality. However, the patient is currently on optimal medical therapy with beta blockers, loop diuretics, statins, and an ACE inhibitor, which are all evidence-based treatments for heart failure with reduced ejection fraction (HFrEF). The patient's LVEF is 17%, which is a common range for patients with HFrEF. The patient's Pro-BNP level is elevated at 2694 ng/L, indicating significant cardiac stress, but it is not extremely high. The patient's hemoglobin level is within the normal range, and the patient does not have any signs of severe anemia or malnutrition (albumin level is 43 g/L). The patient's creatinine level is elevated, indicating some degree of renal impairment, but it is not severe. Considering these factors, the patient's prognosis is likely to be a survivor, but with close monitoring and adjustment of medications as needed.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy and a low LVEF of 17%, which increases the risk of sudden cardiac death. The patient's Pro-BNP level is elevated, indicating significant cardiac stress, and the patient's troponin level is slightly elevated, indicating ongoing cardiac damage. However, the patient is on optimal medical therapy, and there are no clear indicators of high-risk arrhythmias (e.g., non-sustained ventricular tachycardia). While sudden cardiac death is a possibility, the patient's overall clinical picture suggests that this outcome is less likely than survival.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF is 17%, which indicates severe heart failure. However, the patient is on optimal medical therapy, and the patient's creatinine level is not extremely high, indicating that renal function is not severely impaired. The patient's albumin level is also within the normal range, indicating that the patient is not malnourished. While pump failure death is a possibility, the patient's overall clinical picture suggests that this outcome is the least likely of the three. The patient's current medications and the fact that the patient is not in NYHA Class IV heart failure suggest that the patient's symptoms are manageable with current therapy, making pump failure death less likely.

Please note that these prognoses are based on the provided data and may not reflect the patient's actual outcome."
620,620,P0971,"Age: 66
Gender: Female 
Weight: 78 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 150/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 36
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 6,05
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 160
Glucose (mmol/L): 12,1
Hemoglobin (g/L): 112.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,7
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 104.0
Protein (g/L): 75
T3 (pg/dL): 0,02
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 49,17
Urea (mg/dL): 8,99
LVEF (%): 56.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",survivor,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: 1. Sudden Cardiac Death, 2. Pump Failure Death, 3. Survivor

REASONING: 

1. Sudden Cardiac Death (SCD): Given the patient's age, female gender, NYHA Class III, and history of hypertensive cardiomyopathy, diabetes, and dyslipemia, she is at an increased risk for SCD. The presence of ventricular extrasystoles and a low LVEF of 56% further elevate her risk. The elevated Pro-BNP level (104.0 ng/L) and TSH level (49.17 mIU/L) suggest potential underlying cardiac dysfunction and thyroid-related issues, respectively. However, the absence of sustained ventricular tachycardia or non-sustained ventricular tachycardia with a cycle length > 10 beats is a positive sign, slightly reducing the likelihood of SCD.

2. Pump Failure Death: The patient's NYHA Class III and LVEF of 56% indicate compromised cardiac function. The presence of hypertension, diabetes, and dyslipemia further exacerbate cardiac stress. The elevated creatinine level (1.06 mmol/L) and urea level (8.99 mg/dL) suggest potential kidney dysfunction, which can be a result of or contribute to heart failure. The patient's current medications, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, are standard treatments for heart failure, but the patient's current symptoms and lab values indicate that the disease is not optimally controlled.

3. Survivor: Given the patient's current treatment regimen and the presence of a relatively well-controlled blood pressure, despite a high baseline, and the fact that the patient is receiving appropriate medications for heart failure, I believe that the patient has the best chance of being a survivor. The patient's LVEF is 56%, which is still within the normal range, and the absence of sustained arrhythmias and other concerning ECG findings further support this prognosis. However, close monitoring and adjustments to the treatment plan may be necessary to prevent progression of the disease."
621,621,P0973,"Age: 51
Gender: Male 
Weight: 80 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 144.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,72
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 80.0
Protein (g/L): 74
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,68
Urea (mg/dL): 3,83
LVEF (%): 41.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Second-degree AVB - type I
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: 
The patient is 51 years old with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure and adverse outcomes. However, the patient's current NYHA Class II indicates that the patient's symptoms are still manageable with medical therapy. The patient is on beta blockers, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure and hypertension. The patient's LVEF of 41% is below the normal range, indicating some degree of heart dysfunction, but it is not severely impaired. The patient's Pro-BNP level of 80 ng/L is within the normal range, which suggests that the patient is not experiencing significant heart failure symptoms. The patient's blood pressure is well-controlled, and there are no signs of acute coronary syndrome (Troponin level is 0.01 ng/mL). The patient's ECG shows non-sustained ventricular tachycardia, but this is not an uncommon finding in patients with heart disease. The patient's TSH level is within the normal range, and the patient is not hypothyroid, which can exacerbate heart disease. Considering these factors, the most likely prognosis is that the patient will survive for the next few years with proper medical management.

RANKING: Pump Failure Death (less likely)

REASONING: 
While the patient has a history of ischemic dilated cardiomyopathy and a low LVEF, the patient's current symptoms are manageable, and the patient is on standard treatments for heart failure. The patient's Pro-BNP level is within the normal range, and there are no signs of acute decompensation. However, the patient's LVEF of 41% is below the normal range, and the patient has a history of myocardial infarction, which increases the risk of pump failure. The patient's creatinine level is elevated at 80.0 mmol/L, which may indicate some degree of renal impairment, which can contribute to the progression of heart failure. However, the patient's urea level is within the normal range, and there are no signs of acute kidney injury. Considering these factors, the risk of pump failure death is less likely, but still a possibility.

RANKING: Sudden Cardiac Death (least likely)

REASONING: 
The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. However, the patient's LVEF is not severely impaired, and the patient is on beta blockers, which can reduce the risk of arrhythmias. The patient's Troponin level is 0.01 ng/mL, which suggests that the patient is not experiencing acute coronary syndrome. The patient's TSH level is within the normal range, and the patient is not hypothyroid, which can increase the risk of arrhythmias. The patient's potassium level is within the normal range, which is also a risk factor for arrhythmias. Considering these factors, the risk of sudden cardiac death is the least likely prognosis."
622,622,P0976,"Age: 66
Gender: Male 
Weight: 68 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,36
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 134.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4
LDL (mmol/L): 1,24
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 652.0
Protein (g/L): 74
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,13
Urea (mg/dL): 4,82
LVEF (%): 32.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: 1. Survivor
REASONING: The patient has a history of ischemic dilated cardiomyopathy, myocardial infarction, and diabetes, which are all significant risk factors for cardiovascular disease. However, the patient is currently on a comprehensive treatment regimen that includes beta blockers, ACE inhibitors, statins, and a calcium channel blocker, which are all evidence-based treatments for heart failure and ischemic heart disease. The patient's LVEF is 32%, which is low, but not extremely low, and the Pro-BNP level is elevated at 652.0 ng/L, indicating some degree of heart failure. However, the patient's hemoglobin and albumin levels are within normal limits, suggesting that the heart failure is not severe. Additionally, the patient's ECG shows no signs of sustained ventricular tachycardia or other life-threatening arrhythmias. Overall, while the patient's prognosis is guarded, the comprehensive treatment and relatively stable laboratory values suggest a higher likelihood of survival.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of myocardial infarction and ischemic dilated cardiomyopathy increases the risk of sudden cardiac death. The patient's LVEF of 32% is low, which is a risk factor for sudden cardiac death. However, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death, but the absence of sustained ventricular tachycardia or other life-threatening arrhythmias reduces the risk. Overall, while the patient's history and LVEF increase the risk of sudden cardiac death, the comprehensive treatment and lack of other high-risk features make this prognosis less likely than pump failure death.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF of 32% and Pro-BNP level of 652.0 ng/L indicate that the patient has significant heart failure. The patient's weight is also slightly below average, which is a negative prognostic factor for heart failure. However, the patient's hemoglobin and albumin levels are within normal limits, suggesting that the heart failure is not severe. The patient's treatment regimen includes ACE inhibitors, which are known to slow the progression of heart failure. While the patient's prognosis is guarded, the relatively stable laboratory values and comprehensive treatment suggest that pump failure death is less likely than sudden cardiac death.

Note: These rankings are based on the information provided and should not be used as a definitive prediction of the patient's outcome."
623,623,P0977,"Age: 68
Gender: Female 
Weight: 95 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 28
Glucose (mmol/L): 7,4
Hemoglobin (g/L): 107.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 5,2
LDL (mmol/L): 1,73
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3701.0
Protein (g/L): 71
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,21
Urea (mg/dL): 17,97
LVEF (%): 33.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. I will rank the three possible prognoses from most likely to least likely.

RANKING: Survivor
REASONING: The patient is 68 years old with a history of ischemic dilated cardiomyopathy, diabetes, hypertension, and myocardial infarction. However, despite these risk factors, the patient is currently on optimal medical therapy with calcium channel blockers, diabetes medication, beta blockers, and loop diuretics. The left ventricular ejection fraction (LVEF) is 33%, which is below the normal range but not extremely low. The Pro-BNP level is elevated at 3701 ng/L, indicating some level of heart failure, but the patient's NYHA class is II, indicating mild to moderate symptoms. The absence of sustained ventricular tachycardia and the presence of a TPSV (paroxysmal supraventricular tachyarrhythmia) on the ECG suggest that the patient's arrhythmia burden is relatively low. Considering these factors, the patient's overall prognosis is most likely to be a survivor, with a focus on close monitoring and optimization of medical therapy.

RANKING: Sudden Cardiac Death
REASONING: While the patient has a history of ischemic dilated cardiomyopathy and a low LVEF, the patient's current symptoms and ECG findings are not extremely concerning for sudden cardiac death. The presence of a TPSV on the ECG is not a significant risk factor for sudden cardiac death, and the patient's overall clinical presentation is more indicative of heart failure than arrhythmic instability.

RANKING: Pump Failure Death
REASONING: While the patient's LVEF is low, indicating some degree of heart failure, the patient's symptoms are currently well-managed with medical therapy, and the patient is not in NYHA class III or IV. The absence of severe kidney dysfunction (creatinine 115.0 umol/L) and the presence of a relatively normal albumin level (39 g/L) suggest that the patient's cardiac output is still sufficient to maintain adequate renal function. The patient's overall clinical presentation and ECG findings are not indicative of an imminent risk of pump failure death."
624,624,P0980,"Age: 67
Gender: Male 
Weight: 77 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 47,5
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 153.0
HDL (mmol/L): 1,66
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,56
Sodium (mEq/L): 141.0
Protein (g/L): 74,9
T4 (ng/L): 18
TSH (mIU/L): 1,33
Urea (mg/dL): 10,65
LVEF (%): 40.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. However, please note that a definitive prognosis can only be made after a thorough physical examination and consultation with the patient. The following is a general assessment based on the given data.

RANKING: Survivor
REASONING: The patient is 67 years old with a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipemia. Despite this, the patient is on a comprehensive treatment regimen that includes an angiotensin II receptor blocker, loop diuretics, spironolactone, statins, and nitrovasodilators. The patient's LVEF is 40%, which is relatively low but not extremely low, and the patient's blood pressure is well-controlled. The patient's laboratory values, such as the albumin, ALT, AST, total cholesterol, creatinine, and urea, are within relatively normal ranges. The patient's hemoglobin and HDL levels are also within normal limits. The patient's TSH and T4 levels are within normal ranges, indicating no apparent thyroid dysfunction. The patient's ECG shows monomorphic ventricular extrasystoles but no sustained ventricular tachycardia or bradycardia. Given these factors, the patient's prognosis is likely to be a survivor, with the goal of managing and controlling the disease progression.

RANKING: Pump Failure Death
REASONING: The patient's LVEF of 40% indicates a reduced ejection fraction, which can lead to pump failure. However, the patient's current treatment regimen and the lack of severe laboratory abnormalities suggest that pump failure is not the most immediate concern.

RANKING: Sudden Cardiac Death
REASONING: While the patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, the patient's current treatment regimen and the lack of severe laboratory abnormalities suggest that sudden cardiac death is the least likely prognosis. The patient's LVEF is relatively low, but it is not extremely low, and the patient's ECG shows monomorphic ventricular extrasystoles but no sustained ventricular tachycardia or bradycardia, which are risk factors for sudden cardiac death."
625,625,P0982,"Age: 73
Gender: Female 
Weight: 89 kg
Height: 157 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Other HF etiology, Dyslipemia
Albumin (g/L): 39,7
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,43
Sodium (mEq/L): 142.0
Protein (g/L): 63,4
T4 (ng/L): 21
TSH (mIU/L): 0,18
Urea (mg/dL): 7,32
LVEF (%): 55.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is my prognosis for the next few years:

RANKING: Survivor
REASONING: The patient is a 73-year-old female with a history of heart failure (HF) and dyslipemia. She is on a treatment regimen that includes beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, which is a comprehensive approach to managing her conditions. Her LVEF is 55%, indicating that her heart is functioning within a relatively normal range for her age. Her NYHA Class II classification indicates that she has some limitations in physical activity but is generally able to carry out daily activities. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and other severe arrhythmias on the ECG is a positive sign. Her laboratory results, including her liver enzymes, kidney function, and electrolytes, are relatively normal. While her total cholesterol and LDL levels are slightly elevated, her HDL level is also within a relatively normal range. Her weight is 89 kg, which is above the normal range for her height, but her body mass index (BMI) is not provided. However, considering her age and the presence of other comorbidities, her weight is not a significant concern at this time. Overall, the patient's treatment plan, LVEF, and laboratory results suggest that she is at a relatively low risk for sudden cardiac death and pump failure death in the next few years.

RANKING: Sudden Cardiac Death
REASONING: While the patient's LVEF is within a relatively normal range, her LVEF is below the normal range for her age, which may indicate some degree of cardiac dysfunction. Additionally, her history of ventricular extrasystoles and the presence of dyslipemia may increase her risk for arrhythmias and sudden cardiac death. However, the absence of sustained ventricular tachycardia and other severe arrhythmias on the ECG, as well as her comprehensive treatment plan, reduces her risk for sudden cardiac death.

RANKING: Pump Failure Death
REASONING: This prognosis is the least likely, as the patient's LVEF is 55%, which is above the threshold for severe heart failure. Her NYHA Class II classification indicates that she has some limitations in physical activity but is generally able to carry out daily activities, which suggests that her heart failure is not severe. Her laboratory results, including her kidney function and liver enzymes, are relatively normal, which further supports the idea that her heart failure is not severe. While her weight is above the normal range for her height, it is not a significant concern at this time. Her comprehensive treatment plan, including beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, is designed to manage her heart failure and reduce her risk for pump failure death."
626,626,P0984,"Age: 58
Gender: Male 
Weight: 58 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 37,3
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 133
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,9
LDL (mmol/L): 1,76
Sodium (mEq/L): 143.0
Protein (g/L): 62,1
T4 (ng/L): 16
TSH (mIU/L): 1,71
Urea (mg/dL): 6,49
LVEF (%): 51.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here's my prognosis for the next few years:

RANKING: 1
REASONING: The patient is 58 years old with a history of ischemic dilated cardiomyopathy and myocardial infarction, which increases the risk of cardiac complications. However, the patient's current medications, including beta blockers, loop diuretics, statins, ACE inhibitor, and nitrovasodilator, are well-established treatments for heart failure and ischemic cardiomyopathy. The patient's left ventricular ejection fraction (LVEF) is 51%, which is within the moderate range of heart failure severity. The patient's NYHA class is II, indicating mild to moderate symptoms. The ECG findings of non-sustained ventricular tachycardia and ventricular extrasystoles are concerning, but the patient's overall clinical picture suggests that the patient is receiving appropriate treatment and has a relatively stable condition. Considering these factors, the most likely outcome is that the patient will survive for the next few years with continued medical management.

RANKING: 2
REASONING: The patient's risk of sudden cardiac death is moderate due to the presence of non-sustained ventricular tachycardia and ventricular extrasystoles on the ECG. However, the patient's LVEF is not severely depressed, and the patient is on appropriate medications to reduce the risk of arrhythmias. The patient's blood pressure and potassium levels are well-controlled, which reduces the risk of arrhythmias triggered by hypertension or electrolyte imbalances. While the patient's ischemic dilated cardiomyopathy increases the risk of arrhythmias, the patient's current treatment plan and relatively stable condition suggest that sudden cardiac death is not the most likely outcome.

RANKING: 3
REASONING: The patient's LVEF of 51% indicates moderate heart failure severity, but it is not severely depressed, which would be more typical of pump failure. The patient's medications, including beta blockers and ACE inhibitors, are aimed at reducing the strain on the heart and improving cardiac function. The patient's blood pressure and creatinine levels are within normal limits, suggesting that the patient's kidneys are functioning well, and there is no evidence of severe fluid overload or volume overload, which would be more typical of pump failure. While the patient's ischemic dilated cardiomyopathy increases the risk of progressive heart failure, the patient's current clinical picture suggests that pump failure is the least likely outcome."
627,627,P0988,"Age: 68
Gender: Female 
Weight: 67 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 195/85 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 40,9
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 5,3
Creatinine (mmol/L): 57.0
Gamma-glutamil transpeptidase (IU/L): 66
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,52
Sodium (mEq/L): 140.0
Protein (g/L): 74
T4 (ng/L): 16
TSH (mIU/L): 2,74
Urea (mg/dL): 4,66
LVEF (%): 52.0
Medications: Diabetes Medication, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will rank the possible prognoses for the next few years from most likely to least likely.

RANKING: 1. Survivor
REASONING: The patient is 68 years old with a history of hypertrophic cardiomyopathy, which is a condition that can lead to heart failure and arrhythmias. However, the patient's current LVEF (Left Ventricular Ejection Fraction) is 52%, which is still within the normal range (>50%). The patient's NYHA Class is II, indicating that the patient is experiencing some symptoms of heart failure but is still able to perform daily activities. The patient's medication regimen includes diabetes medication and loop diuretics, which suggests that the patient's heart failure is being managed. Additionally, the patient's blood pressure is elevated (195/85 mmHg), but it is not extremely high, and the patient is not on any antihypertensive medications. While the patient's lipid profile is not ideal, the patient's HDL is relatively low, and the LDL is high, the patient's total cholesterol is within the normal range. The patient's kidney function is also relatively preserved, with a creatinine level of 57.0 umol/L. Considering these factors, the patient's prognosis is most likely to be a survivor, with proper management of their heart failure and hypertension.

RANKING: 2. Pump failure death
REASONING: The patient's LVEF is 52%, which is slightly below the normal range. The patient's history of hypertrophic cardiomyopathy and the presence of non-sustained ventricular tachycardia (although the code is unknown) suggest that the patient may be at risk for heart failure. However, the patient's NYHA Class is II, indicating that the patient is still able to perform daily activities. The patient's medication regimen includes loop diuretics, which suggests that the patient's heart failure is being managed. While the patient's kidney function is relatively preserved, the patient's creatinine level is slightly elevated, which may indicate early signs of kidney dysfunction. The patient's prognosis is less likely to be a survivor due to the risk of heart failure, but it is still more likely than sudden cardiac death due to the patient's relatively preserved LVEF and lack of severe symptoms.

RANKING: 3. Sudden cardiac death
REASONING: The patient's LVEF is 52%, which is slightly below the normal range, and the patient's history of hypertrophic cardiomyopathy suggests that the patient may be at risk for sudden cardiac death. However, the patient's NYHA Class is II, indicating that the patient is still able to perform daily activities, and the patient's medication regimen includes diabetes medication and loop diuretics, which suggests that the patient's heart failure is being managed. The patient's ECG impression shows ventricular extrasystole and ventricular tachycardia, but the codes are unknown, and the patient does not have a history of sustained ventricular tachycardia. While the patient's risk for sudden cardiac death is higher than for pump failure death, it is still relatively low due to the patient's relatively preserved LVEF and lack of severe symptoms."
628,628,P0991,"Age: 71
Gender: Female 
Weight: 70 kg
Height: 152 cm
NYHA Class: II
Blood Pressure: 160/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 46,2
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 73.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,4
Sodium (mEq/L): 143.0
Protein (g/L): 78,6
T4 (ng/L): 15
TSH (mIU/L): 1,28
Urea (mg/dL): 7,99
LVEF (%): 35.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: 1. Survivor, 2. Pump Failure Death, 3. Sudden Cardiac Death

REASONING: 

Based on the provided patient data, I would rank the prognosis as follows:

1. Survivor: The patient has been diagnosed with Hypertensive cardiomyopathy and has a low LVEF (Left Ventricular Ejection Fraction) of 35%, indicating reduced heart function. However, she is already on a comprehensive treatment plan that includes beta blockers, loop diuretics, spironolactone, statins, ACE inhibitors, and nitrovasodilators, which are all standard treatments for heart failure and cardiomyopathy. The patient's NYHA Class II indicates that she is experiencing some limitations in physical activity but is still able to perform daily activities. Her overall clinical presentation and treatment plan suggest that she is being managed effectively, and with continued adherence to her treatment plan, she is likely to survive for the next few years.

2. Pump Failure Death: Given the patient's low LVEF of 35%, there is a risk of progressive heart failure and potential pump failure. However, her current treatment plan is aimed at managing her symptoms and slowing disease progression. The patient's blood pressure is well-controlled, and her urea levels are within a relatively normal range, indicating that her renal function is not severely compromised. While there is a risk of pump failure, the patient's current treatment plan and overall clinical presentation suggest that this outcome is less likely in the short term.

3. Sudden Cardiac Death: The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are risk factors for sudden cardiac death. However, the presence of these arrhythmias does not necessarily indicate a high risk of sudden cardiac death, especially given the patient's current treatment plan and the absence of other high-risk factors such as a history of previous cardiac arrest or severe left ventricular dysfunction. While there is some risk of sudden cardiac death, it is the least likely of the three outcomes based on the provided data.

Overall, the patient's comprehensive treatment plan, controlled blood pressure, and relatively stable renal function suggest that she is likely to survive for the next few years."
629,629,P0992,"Age: 72
Gender: Male 
Weight: 95 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 43,9
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 90.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,87
Sodium (mEq/L): 142.0
Protein (g/L): 70,5
T4 (ng/L): 14
TSH (mIU/L): 1,04
Urea (mg/dL): 5,66
LVEF (%): 37.0
Medications: Calcium Channel Blocker, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor
 REASONING: The patient's age and history of ischemic dilated cardiomyopathy and myocardial infarction suggest a high risk for cardiac events. However, the patient's current medications, including a calcium channel blocker, loop diuretics, statins, and an ACE inhibitor, indicate that the patient's condition is being actively managed. The LVEF of 37% is below the normal range, but it is not extremely low. Additionally, the patient's blood pressure is well-controlled, and the liver function tests are within normal limits. The patient's serum albumin and total protein levels are also within normal limits, indicating that the patient does not have significant liver dysfunction or malnutrition. Furthermore, the patient's hemoglobin level is within the normal range, and the TSH level is within the normal range, indicating that the patient's thyroid function is normal. Considering these factors, the patient's prognosis is more likely to be a survivor, as their condition is being managed, and they do not have any immediate signs of severe cardiac or liver dysfunction.

RANKING: Pump Failure Death
 REASONING: The patient's LVEF of 37% indicates that the patient has a reduced left ventricular function, which is a risk factor for pump failure. However, the patient's current medications and the fact that they are being managed for their condition suggest that the patient's heart function is not deteriorating rapidly. The patient's blood pressure is well-controlled, and the liver function tests are within normal limits, which reduces the likelihood of pump failure due to cardiac cachexia or liver dysfunction.

RANKING: Sudden Cardiac Death
 REASONING: The patient's history of ischemic dilated cardiomyopathy and myocardial infarction, combined with the presence of polymorphic ventricular extrasystoles on the ECG, suggests a risk for sudden cardiac death. However, the patient's current medications, including a calcium channel blocker and an ACE inhibitor, are likely reducing the risk of arrhythmias. The patient's LVEF of 37% is a risk factor for sudden cardiac death, but it is not an absolute contraindication. The patient's overall condition is being managed, and the risk of sudden cardiac death is not as high as the risk of pump failure or death due to other causes."
630,630,P0996,"Age: 58
Gender: Male 
Weight: 97 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41,5
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 72.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 7,8
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,69
Sodium (mEq/L): 143.0
Protein (g/L): 67,7
T4 (ng/L): 19
TSH (mIU/L): 1,53
Urea (mg/dL): 5,66
LVEF (%): 29.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor

REASONING: Based on the provided patient data, I rank the prognosis as a survivor for the following reasons:

1.  The patient is 58 years old, which is considered middle-aged and still relatively young for cardiac disease complications. 
2.  Despite having ischemic dilated cardiomyopathy, a history of myocardial infarction, and diabetes, the patient is being treated with beta blockers and statins, which are evidence-based medications for heart failure and dyslipidemia management.
3.  The patient's NYHA Class II classification indicates that the patient has some limitations in physical activity but is still able to perform everyday activities without symptoms, which is a positive sign.
4.  The patient's LVEF (Left Ventricular Ejection Fraction) of 29% is low, indicating reduced cardiac function, but it is not extremely low. Some patients with LVEF as low as 29% can still have a good prognosis with optimal medical therapy and lifestyle modifications.
5.  The patient's blood pressure is well-controlled, and there is no indication of severe kidney dysfunction or electrolyte imbalances that could worsen cardiac function.
6.  The absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG is a good sign, indicating that the patient does not have a high risk of sudden cardiac death.
7.  The patient's total cholesterol and LDL levels are within acceptable ranges, and the HDL level is relatively high, which is a positive factor for cardiovascular health.

However, the patient's low LVEF, history of myocardial infarction, and diabetes do increase the risk of pump failure death. Sudden cardiac death is less likely due to the absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG.

Given these factors, I rank the prognosis as a survivor, but it is essential to continue monitoring the patient's condition and adjusting treatment as needed to prevent complications."
631,631,P0998,"Age: 68
Gender: Male 
Weight: 82 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Other HF etiology, Dyslipemia
Albumin (g/L): 44,3
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,41
Sodium (mEq/L): 146.0
Protein (g/L): 71,8
T4 (ng/L): 21
TSH (mIU/L): 0,78
Urea (mg/dL): 6,32
LVEF (%): 65.0
Medications: Calcium Channel Blocker, Beta Blockers
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor
REASONING: The patient is 68 years old, which is a relatively advanced age but not extremely high-risk for cardiovascular events. The patient has a history of heart failure (HF) etiology, but the LVEF is 65%, which is within the normal range, indicating preserved left ventricular function. The patient is on appropriate medications for HF, including beta blockers and a calcium channel blocker, which should help to manage symptoms and slow disease progression. The patient's blood pressure is well-controlled, and the absence of significant arrhythmias on the ECG is a positive sign. While the patient has dyslipidemia and slightly elevated creatinine levels, these are not extreme values. The patient's hemoglobin and albumin levels are within normal limits, indicating no significant anemia or malnutrition. Overall, these factors suggest that the patient is at relatively low risk for sudden cardiac death or pump failure death, making a survivor prognosis more likely.

RANKING: Pump Failure Death
REASONING: While the patient has a history of heart failure etiology, the LVEF is 65%, which is within the normal range. However, the patient's creatinine level is slightly elevated, indicating some degree of renal impairment, which can be a marker of underlying cardiac dysfunction. The patient's weight is also slightly above the normal range, which can put additional strain on the heart. However, these factors are not extreme, and the patient is on appropriate medications for HF, which should help to manage symptoms and slow disease progression. The patient's overall clinical picture suggests that while pump failure is a possibility, it is not the most likely outcome.

RANKING: Sudden Cardiac Death
REASONING: The patient has a history of heart failure etiology and polymorphic ventricular extrasystoles on the ECG, which can be a marker of increased risk for arrhythmic events. However, the patient's LVEF is 65%, which is within the normal range, and the patient is on appropriate medications for HF, which should help to reduce the risk of arrhythmic events. The patient's blood pressure is well-controlled, and the absence of significant arrhythmias on the ECG is a positive sign. While the patient's creatinine level is slightly elevated, this is not an extreme value, and the patient's overall clinical picture suggests that sudden cardiac death is not the most likely outcome."
632,632,P0999,"Age: 67
Gender: Male 
Weight: 88 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Valvular cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease
Albumin (g/L): 39,6
ALT or GPT (IU/L): 44.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 104.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 115.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,99
Sodium (mEq/L): 139.0
Protein (g/L): 76,5
T4 (ng/L): 14
TSH (mIU/L): 0,84
Urea (mg/dL): 10,48
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely:

RANKING: Survivor

REASONING: The patient is 67 years old with a history of valvular cardiomyopathy, diabetes, dyslipemia, and peripheral vascular disease, which are all significant risk factors for cardiovascular disease. However, the patient is currently on a comprehensive treatment regimen including beta blockers, loop diuretics, and statins, which are aimed at managing heart failure symptoms, controlling blood pressure, and reducing cholesterol levels. The patient's current NYHA Class II classification indicates that the patient's heart failure symptoms are not severe, and they are able to perform daily activities without significant limitation.

The patient's LVEF of 25% is low, indicating reduced left ventricular function, but it is not the lowest possible value (LVEF < 20% is typically associated with more severe heart failure). The patient's blood pressure is well-controlled, and their creatinine level is only slightly elevated, indicating that kidney function is not severely impaired. The presence of non-sustained ventricular tachycardia and ventricular extrasystoles on the ECG suggests that the patient has some degree of arrhythmia, but the fact that they are not sustained suggests that the patient's heart is not under significant stress.

The patient's albumin and protein levels are slightly low, which may indicate some degree of malnutrition or liver dysfunction, but the liver enzymes (ALT and AST) are only mildly elevated, suggesting that liver disease is not the primary concern. The patient's TSH and T4 levels are within normal limits, indicating that thyroid function is normal.

Overall, while the patient has significant cardiovascular risk factors and some degree of heart failure, the patient's current treatment regimen and relatively stable clinical condition suggest that the most likely outcome is survival over the next few years.

RANKING: Sudden Cardiac Death

REASONING: Sudden cardiac death is a possible outcome for this patient due to the presence of non-sustained ventricular tachycardia and ventricular extrasystoles on the ECG, which increase the risk of arrhythmia and sudden cardiac death. The patient's low LVEF also increases the risk of sudden cardiac death. However, the patient's current treatment regimen, including beta blockers, which are known to reduce the risk of sudden cardiac death, may mitigate this risk.

RANKING: Pump Failure Death

REASONING: Pump failure death is the least likely outcome for this patient due to the fact that the patient is on a comprehensive treatment regimen aimed at managing heart failure symptoms, and their current NYHA Class II classification indicates that their heart failure symptoms are not severe. The patient's creatinine level is only slightly elevated, indicating that kidney function is not severely impaired, which is often a precursor to pump failure death. Additionally, the patient's LVEF of 25% is not the lowest possible value, suggesting that the patient's heart function is not severely compromised."
633,633,P1002,"Age: 71
Gender: Female 
Weight: 70 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,45
Creatinine (mmol/L): 62.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 4,3
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 3,7
LDL (mmol/L): 2,46
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 305.0
Protein (g/L): 66
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,306
Urea (mg/dL): 10,31
LVEF (%): 48.0
Medications: Diabetes Medication, Beta Blockers
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is my prognosis for the next few years:

RANKING: Survivor
REASONING: The patient is 71 years old with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction, which are all risk factors for cardiac complications. However, the patient's LVEF (48%) is relatively preserved, and they are on beta blockers, which is a positive sign. The absence of sustained ventricular tachycardia and bradycardia on the ECG is also a good indicator. Additionally, the patient's blood pressure is well-controlled, and their glucose levels are within a relatively normal range. The Pro-BNP level is elevated at 305 ng/L, but it is not extremely high, which might suggest some degree of cardiac compensation. Considering these factors, the patient is likely to survive in the short to medium term, but close monitoring is essential to prevent cardiac complications.

RANKING: Sudden Cardiac Death
REASONING: The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which increases the risk of sudden cardiac death. The patient's LVEF is only 48%, indicating some degree of left ventricular dysfunction. The presence of ventricular extrasystoles on the ECG is also a risk factor for sudden cardiac death. However, the patient's overall clinical condition and medication regimen (beta blockers) might mitigate this risk to some extent.

RANKING: Pump Failure Death
REASONING: The patient's LVEF is 48%, which is below the normal range (50-70%), indicating some degree of left ventricular dysfunction. The patient's creatinine level is elevated at 62.0 umol/L, suggesting some degree of renal impairment, which can be a sign of heart failure. However, the patient's overall clinical condition and medication regimen (beta blockers) might slow down the progression of heart failure. The patient's NYHA class is II, indicating some degree of symptoms, but not severe. Therefore, while pump failure death is a possible outcome, it is less likely compared to the other two options.

Note: The prognosis is not definitive and should be regularly reassessed as the patient's condition changes."
634,634,P1011,"Age: 69
Gender: Female 
Weight: 66 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 40
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,22
Sodium (mEq/L): 140.0
Protein (g/L): 64
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,6
Urea (mg/dL): 7,65
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. I will rank the three possible prognoses from most likely to least likely.

RANKING: 1. Survivor
REASONING: The patient is a 69-year-old female with a history of idiopathic dilated cardiomyopathy, which is a chronic condition. Despite the reduced left ventricular ejection fraction (LVEF) of 40%, the patient is on optimal medical therapy, including beta blockers, loop diuretics, statins, and an ACE inhibitor. The patient's blood pressure is well-controlled, and there is no evidence of significant electrolyte imbalances. The ECG does not show any signs of sustained ventricular tachycardia or other life-threatening arrhythmias. The patient's troponin level is within normal limits, indicating minimal myocardial damage. The patient's overall clinical status and medication regimen suggest a stable condition, making a survivor prognosis the most likely outcome.

RANKING: 2. Pump failure death
REASONING: While the patient has a reduced LVEF of 40%, which indicates a compromised left ventricular function, the patient's clinical status is stable, and the medication regimen is optimal. The patient's creatinine level is slightly elevated, but not significantly so, indicating some degree of renal impairment, which may be related to the cardiomyopathy. However, the patient's overall clinical status and lack of symptoms suggest that pump failure is not an immediate concern. The patient's low T3 level and normal T4 level suggest that the patient may have a euthyroid state, which can be beneficial for heart failure patients. The patient's hemoglobin level is within normal limits, which is a good prognostic indicator. Considering the patient's stable clinical status and optimal medication regimen, pump failure death is the second most likely outcome.

RANKING: 3. Sudden cardiac death
REASONING: Sudden cardiac death is a possible outcome for patients with heart failure, especially those with a reduced LVEF. However, the patient's ECG does not show any signs of life-threatening arrhythmias, and the patient's troponin level is within normal limits. The patient's medication regimen includes beta blockers, which are effective in reducing the risk of sudden cardiac death. The patient's LVEF of 40% is a risk factor for sudden cardiac death, but the patient's overall clinical status and lack of symptoms suggest that sudden cardiac death is less likely. The patient's low T3 level and normal T4 level may also contribute to a reduced risk of arrhythmias. Therefore, sudden cardiac death is the least likely outcome."
635,635,P1013,"Age: 82
Gender: Male 
Weight: 52 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 170/100 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 6,18
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,91
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,7
Sodium (mEq/L): 141.0
Protein (g/L): 70
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,79
Urea (mg/dL): 11,32
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years, ranking the three possible outcomes from most likely to least likely.

RANKING: 1. Survivor
 REASONING: The patient is 82 years old with a history of valvular cardiomyopathy and NYHA Class II, indicating some limitations in physical activity but not severe symptoms. Despite these factors, the patient's left ventricular ejection fraction (LVEF) is 50%, which is relatively preserved, suggesting that the heart is still functioning adequately. The patient is on a comprehensive medication regimen, including calcium channel blockers, digoxin, loop diuretics, statins, and nitrovasodilators, which is likely helping to manage symptoms and slow disease progression. The absence of severe electrolyte imbalances, anemia, or significant kidney dysfunction (creatinine 97.0 mmol/L) also suggests that the patient's overall condition is relatively stable. Additionally, the troponin level is low, indicating minimal cardiac damage. Considering these factors, the most likely outcome is that the patient will continue to survive for the next few years.

RANKING: 2. Pump Failure Death
 REASONING: While the patient's LVEF is 50%, which is within the normal range, the patient's valvular cardiomyopathy and NYHA Class II classification suggest that the heart is under stress. The patient's high blood pressure (170/100 mmHg) and low HDL cholesterol (1.91 mmol/L) are also risk factors for cardiovascular disease. However, the patient's current medication regimen and relatively preserved LVEF suggest that the heart is still functioning adequately. The patient's kidney function is also relatively preserved, which is a good prognostic indicator. While pump failure is a possibility, the patient's current condition and treatment suggest that it is less likely than sudden cardiac death.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. Additionally, the patient's age (82 years) and history of valvular cardiomyopathy increase the risk of arrhythmias and sudden cardiac death. However, the patient's LVEF is relatively preserved, and the patient is on a medication regimen that includes digoxin, which is often used to prevent arrhythmias. The patient's troponin level is also low, indicating minimal cardiac damage. While sudden cardiac death is a possibility, the patient's relatively preserved LVEF and comprehensive medication regimen suggest that it is the least likely outcome.

Note: Please note that this is a medical prognosis based on the provided data, and the actual outcome may vary depending on various factors, including the patient's overall health, lifestyle, and adherence to treatment."
636,636,P1016,"Age: 68
Gender: Male 
Weight: 62 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 138/88 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 159.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4
LDL (mmol/L): 2,74
Sodium (mEq/L): 140.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,17
TSH (mIU/L): 2,16
Urea (mg/dL): 5,66
LVEF (%): 55.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here are the prognoses for the next few years, ordered from most likely to least likely:

RANKING: 1. Survivor
 REASONING: The patient's current LVEF of 55% indicates that the heart is still pumping effectively, despite having ischemic dilated cardiomyopathy and a history of myocardial infarction. The patient is on optimal medical therapy with beta blockers, statins, and an ACE inhibitor, which are all evidence-based treatments for heart failure and ischemic heart disease. The patient's NYHA Class II classification indicates that they have some limitations in physical activity but are still able to perform most daily activities without symptoms. The absence of significant electrolyte imbalances, anemia, or other comorbidities suggests that the patient's prognosis is relatively favorable.

RANKING: 2. Pump failure death
 REASONING: While the patient has a history of ischemic dilated cardiomyopathy and a low LVEF, the patient's current symptoms and medication regimen suggest that they are being well-managed. The patient's creatinine level is within normal limits, indicating that there is no significant kidney dysfunction, which is a common comorbidity in patients with heart failure. However, the patient's slightly elevated troponin level and the presence of polymorphic ventricular extrasystoles on the ECG suggest that there may be ongoing cardiac stress and potential for further cardiac damage.

RANKING: 3. Sudden cardiac death
 REASONING: Sudden cardiac death is a less likely outcome for this patient due to the presence of a pacemaker or an implantable cardioverter-defibrillator (ICD) is not mentioned. However, the patient's history of myocardial infarction, low LVEF, and polymorphic ventricular extrasystoles on the ECG do increase the risk of sudden cardiac death. However, the patient's overall clinical status and medication regimen suggest that this is the least likely outcome. The patient's low T3 and T4 levels, which are often associated with a worse prognosis in heart failure patients, are within normal limits, further reducing the risk of sudden cardiac death."
637,637,P1017,"Age: 53
Gender: Male 
Weight: 81 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/69 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,47
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,74
Sodium (mEq/L): 134.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,07
TSH (mIU/L): 1,26
Urea (mg/dL): 5,49
LVEF (%): 40.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely:

RANKING: 1. Survivor
REASONING: The patient has a relatively stable condition, with a New York Heart Association (NYHA) Class II, indicating mild to moderate symptoms. The patient's LVEF (Left Ventricular Ejection Fraction) is 40%, which is below the normal range, but it is not severely reduced. The patient is on appropriate medications, including beta blockers, statins, and ACE inhibitors, which are standard treatments for ischemic dilated cardiomyopathy. The patient's blood pressure and potassium levels are within normal ranges, and there are no signs of severe electrolyte imbalances or acute coronary syndromes. The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG is a concern, but it is not uncommon in patients with ischemic cardiomyopathy. The patient's overall clinical picture suggests that the patient is at risk for complications, but the likelihood of sudden cardiac death or pump failure death is lower given the patient's relatively stable condition and appropriate treatment.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's LVEF is low, which increases the risk of sudden cardiac death. The presence of non-sustained ventricular tachycardia on the ECG is also a risk factor for sudden cardiac death. However, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death. Additionally, the patient's blood pressure and potassium levels are within normal ranges, which reduces the risk of arrhythmias. The patient's overall clinical picture suggests that sudden cardiac death is a possible outcome, but it is not the most likely outcome given the patient's relatively stable condition and appropriate treatment.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF is 40%, which indicates a reduced pumping capacity of the heart. However, the patient is on ACE inhibitors, which are known to slow the progression of heart failure. The patient's blood pressure and potassium levels are within normal ranges, which suggests that the patient is not experiencing severe fluid overload or electrolyte imbalances that could contribute to pump failure. The patient's overall clinical picture suggests that pump failure death is the least likely outcome, given the patient's relatively stable condition and appropriate treatment."
638,638,P1019,"Age: 54
Gender: Male 
Weight: 87 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 110/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes
Albumin (g/L): 43
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,15
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 11,2
Hemoglobin (g/L): 164.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,8
Sodium (mEq/L): 139.0
Protein (g/L): 73
T3 (pg/dL): 0,06
T4 (ng/L): 16
Troponin (ng/mL): 0,04
TSH (mIU/L): 3,27
Urea (mg/dL): 8,65
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"RANKING: Survivor
 REASONING: Based on the provided patient data, I would rank the prognosis as Survivor, followed by Pump Failure Death, and then Sudden Cardiac Death. Here's the reasoning behind this ranking:

1.  Survivor: The patient has a relatively well-controlled ischemic dilated cardiomyopathy with an LVEF of 35%, which is below the normal range but not extremely low. The patient is on appropriate medications, including an angiotensin II receptor blocker, beta blockers, statins, and a nitrovasodilator. The absence of sustained ventricular tachycardia, non-sustained ventricular tachycardia, and bradycardia on the ECG suggests that the patient's heart rhythm is relatively stable. The patient's hemoglobin and potassium levels are within normal limits, which is a good sign. The patient's TSH level is also within the normal range, indicating that the thyroid function is well-controlled. The patient's blood pressure is well-controlled, and the patient is not in NYHA Class III or IV, indicating that the patient is not severely limited by their heart disease. Therefore, considering these factors, the most likely prognosis is a survivor.

2.  Pump Failure Death: The patient's LVEF of 35% indicates that the heart is not pumping efficiently, which increases the risk of pump failure. However, the patient is on appropriate medications, and the ECG does not show any signs of severe rhythm disturbances. The patient's hemoglobin and potassium levels are within normal limits, which reduces the risk of acute kidney injury or other complications that could lead to pump failure. The patient's blood pressure is well-controlled, and the patient is not in NYHA Class III or IV, indicating that the patient is not severely limited by their heart disease. However, the patient's ischemic dilated cardiomyopathy and low LVEF increase the risk of pump failure, making this the second most likely prognosis.

3.  Sudden Cardiac Death: Sudden cardiac death is more likely in patients with severe heart failure, sustained ventricular tachycardia, or non-sustained ventricular tachycardia. The patient's ECG does not show any signs of severe rhythm disturbances, and the patient is on appropriate medications, including beta blockers, which reduce the risk of sudden cardiac death. The patient's LVEF of 35% is below the normal range, but it is not extremely low, and the patient's hemoglobin and potassium levels are within normal limits. The patient's blood pressure is well-controlled, and the patient is not in NYHA Class III or IV, indicating that the patient is not severely limited by their heart disease. Therefore, the risk of sudden cardiac death is lower compared to the other two prognoses."
639,639,P1020,"Age: 73
Gender: Male 
Weight: 82 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 116/67 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 39
ALT or GPT (IU/L): 6.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 134.0
HDL (mmol/L): 0,57
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,92
Sodium (mEq/L): 133.0
Protein (g/L): 68
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,95
Urea (mg/dL): 4,82
LVEF (%): 45.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: Survivor
REASONING: The patient is 73 years old with ischemic dilated cardiomyopathy, which is a significant underlying condition. However, the patient's left ventricular ejection fraction (LVEF) is 45%, which is slightly below the normal range but not extremely low. The patient is on a treatment regimen that includes beta blockers, ACE inhibitors, and statins, which are standard therapies for heart failure and ischemic heart disease. The patient's blood pressure is well-controlled, and the patient's liver and kidney function tests are within normal limits. Additionally, the patient's troponin level is low, indicating minimal myocardial damage. The absence of significant arrhythmias on the ECG and the patient's hemoglobin and potassium levels within normal limits further support a relatively stable prognosis. Considering these factors, the most likely outcome for the patient is survival, albeit with ongoing management of their heart failure and ischemic heart disease.

RANKING: Pump failure death
REASONING: The patient's LVEF is 45%, which is a significant risk factor for heart failure and pump failure. However, the patient's current medications and controlled blood pressure suggest that the patient is being effectively managed. The patient's creatinine level is slightly elevated, which may indicate early signs of renal impairment, but it is not at a critical level. The patient's protein level is slightly low, which could be a sign of malnutrition or renal impairment. However, the patient's albumin level is within normal limits, which suggests that the patient is not severely malnourished. Considering these factors, the risk of pump failure death is moderate, but not the most likely outcome.

RANKING: Sudden cardiac death
REASONING: The patient has a history of ischemic dilated cardiomyopathy and a LVEF of 45%, which increases the risk of sudden cardiac death. However, the patient's ECG shows only monomorphic ventricular extrasystoles, which is not a strong indicator of high risk for sudden cardiac death. The patient's troponin level is low, and the patient's potassium level is within normal limits, which reduces the risk of arrhythmias. The patient's beta blockers and ACE inhibitors are also reducing the risk of sudden cardiac death. Considering these factors, the risk of sudden cardiac death is low, and the patient's overall prognosis is more likely to be survival or pump failure death rather than sudden cardiac death."
640,640,P1021,"Age: 58
Gender: Female 
Weight: 82 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 160/94 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 6,21
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 64
Glucose (mmol/L): 12,6
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,45
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,48
Sodium (mEq/L): 138.0
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,42
Urea (mg/dL): 7,32
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: Survivor

REASONING: 

This patient has a complex medical history with ischemic dilated cardiomyopathy, diabetes, and hypertension, which are all significant risk factors for cardiovascular disease. However, the patient is currently being managed with a multi-faceted treatment plan that includes beta blockers, spironolactone, statins, and an ACE inhibitor, which are all evidence-based therapies for heart failure and hypertension. The patient's LVEF of 30% indicates that the heart is functioning at a reduced capacity, but it is not at the lowest end of the spectrum. 

Additionally, the patient's recent troponin level is within a normal range, indicating that there is no acute myocardial infarction or ongoing cardiac damage. The patient's TSH level is also within the normal range, which suggests that hypothyroidism is unlikely to be contributing to the patient's cardiac condition. 

While the patient's creatinine level is elevated, it is not significantly high, and the patient's urea level is within the normal range. This suggests that the patient's kidney function is not severely compromised. 

The patient's lipid profile is concerning, with a high total cholesterol and LDL levels, but the patient is already on statins, which should help to manage these levels. The patient's blood glucose level is also high, but the patient is on diabetes medication, which should help to manage this condition.

Given the patient's current treatment plan and the fact that the patient does not have any acute cardiac complications or severely impaired kidney function, I believe that the patient is likely to survive for the next few years. However, the patient will need to continue to adhere to their treatment plan and make lifestyle modifications to manage their cardiovascular risk factors.

The other two possible prognoses, sudden cardiac death and pump failure death, are less likely because the patient is currently stable on treatment and does not have any acute cardiac complications. However, the patient's LVEF of 30% does indicate that the heart is functioning at a reduced capacity, and the patient is at risk for pump failure in the long term."
641,641,P1027,"Age: 69
Gender: Male 
Weight: 66 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 127/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 48
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,71
Creatinine (mmol/L): 106.0
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,39
Sodium (mEq/L): 140.0
Protein (g/L): 78
T3 (pg/dL): 0,04
T4 (ng/L): 24
Troponin (ng/mL): 0,05
TSH (mIU/L): 3,74
Urea (mg/dL): 10,15
LVEF (%): 30.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"Based on the provided patient data, here is the ranking of the prognoses from most likely to least likely:

RANKING: Survivor
REASONING: The patient is 69 years old with a history of idiopathic dilated cardiomyopathy, which is a chronic condition affecting the heart muscle's ability to pump blood effectively. Despite this, the patient's current NYHA Class II indicates that they are able to perform moderate physical activity without symptoms. The patient's LVEF of 30% is relatively low, indicating reduced left ventricular function. However, the patient is on a treatment regimen that includes ACE inhibitors, beta blockers, and loop diuretics, which are standard therapies for heart failure. The patient's troponin level is within normal limits, indicating minimal myocardial damage. Additionally, the patient's potassium level is within the normal range, which is a good prognostic indicator for patients with heart failure. While the patient has a history of ventricular extrasystoles, which may indicate some level of cardiac electrical instability, there is no evidence of sustained ventricular tachycardia or other high-risk arrhythmias. Considering these factors, the most likely prognosis is a survivor, with ongoing management and monitoring of their condition.

RANKING: Pump Failure Death
REASONING: The patient's LVEF of 30% is significantly reduced, indicating a high risk of heart failure progression and potential pump failure. The patient's creatinine level is elevated, indicating some degree of renal impairment, which can be a comorbidity in patients with heart failure. Additionally, the patient's total cholesterol level is high, which may contribute to the progression of heart failure. While the patient is on a treatment regimen that includes ACE inhibitors and beta blockers, these medications may not be sufficient to halt the progression of heart failure in a patient with such a low LVEF. The patient's TSH level is within the normal range, which is a good prognostic indicator for patients with heart failure. However, the patient's history of idiopathic dilated cardiomyopathy and reduced LVEF suggest that pump failure remains a significant risk.

RANKING: Sudden Cardiac Death
REASONING: The patient's LVEF of 30% indicates a high risk of sudden cardiac death due to arrhythmias or other cardiac events. However, the patient's ECG impression does not show any signs of sustained ventricular tachycardia or other high-risk arrhythmias. The patient's potassium level is within the normal range, which is a good prognostic indicator for patients with heart failure. Additionally, the patient is on amiodarone, which is an anti-arrhythmic medication that can help prevent sudden cardiac death. While the patient's history of ventricular extrasystoles may indicate some level of cardiac electrical instability, the absence of other high-risk features and the presence of anti-arrhythmic therapy make sudden cardiac death a less likely prognosis compared to pump failure."
642,642,P1029,"Age: 69
Gender: Male 
Weight: 68 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 88/58 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 44
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 158.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,08
Sodium (mEq/L): 140.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,81
Urea (mg/dL): 7,65
LVEF (%): 35.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here are the prognoses for the next few years, ordered from most likely to least likely:

RANKING: 1. Survivor
 REASONING: The patient has a relatively well-managed medical condition, with a history of ischemic dilated cardiomyopathy and a current NYHA Class II classification, indicating moderate symptoms. However, the patient is on appropriate medications (beta blockers, statins, ACE inhibitor) which are standard treatments for heart failure and ischemic heart disease. The LVEF of 35% is lower than normal, but not extremely low. Additionally, the patient's blood pressure is low, but this may be a result of beta blocker therapy. The lack of other significant comorbidities and the absence of severe electrolyte imbalances or other concerning lab values also support a more optimistic prognosis.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF of 35% indicates significant left ventricular dysfunction, which increases the risk of pump failure. The patient's history of ischemic dilated cardiomyopathy also suggests that the heart muscle may be scarred and less effective at pumping blood. However, the patient's symptoms are currently manageable, and they are on appropriate medications. The risk of pump failure death is still present, but it is not the most likely outcome given the patient's current management and relatively stable condition.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient has a history of non-sustained ventricular tachycardia, which increases the risk of sudden cardiac death. However, the fact that the patient has a low LVEF and is on beta blockers, which can help prevent sudden cardiac death, may mitigate this risk. Additionally, the patient's troponin level is low, indicating that there is no current acute myocardial infarction. While the patient's polymorphic ventricular extrasystoles are concerning, the overall risk of sudden cardiac death is lower than the risk of pump failure death given the patient's current management and relatively stable condition.

Note: The patient's low blood pressure may be a concern, but it is likely a result of beta blocker therapy and not a primary cause for concern."
643,643,P1030,"Age: 69
Gender: Male 
Weight: 100 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 124/67 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 41
ALT or GPT (IU/L): 158.0
AST or GOT (IU/L): 105.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 42
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,2
LDL (mmol/L): 4,16
Sodium (mEq/L): 140.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,04
TSH (mIU/L): 0,72
Urea (mg/dL): 8,49
LVEF (%): 53.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here's my prognosis for the next few years:

RANKING: Survivor
REASONING: The patient is 69 years old with a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge. Despite this, the patient's ejection fraction (LVEF) is 53%, which is relatively well-preserved. The patient is on beta blockers, loop diuretics, and ACE inhibitors, which are standard treatments for heart failure. The patient's blood pressure is well-controlled, and there are no signs of severe electrolyte imbalances or acute coronary syndromes. The patient's troponin levels are within normal limits, indicating minimal cardiac damage. Additionally, the patient's thyroid function is normal, which can be a contributing factor to heart failure. While the patient's liver enzymes (ALT and AST) are elevated, they are not significantly elevated, suggesting that the patient does not have advanced liver disease. The patient's kidney function, as indicated by the creatinine levels, is also relatively preserved. Overall, considering the patient's stable medical condition, controlled blood pressure, and well-managed medications, the most likely prognosis is a survivor.

However, it's essential to note that the patient's condition can still deteriorate over time due to the progressive nature of dilated cardiomyopathy. Regular follow-up appointments and close monitoring of the patient's condition will be necessary to adjust the treatment plan as needed.

RANKING: Sudden Cardiac Death
REASONING: Sudden cardiac death is a possible prognosis, but it is less likely compared to the survivor prognosis. The patient has a history of idiopathic dilated cardiomyopathy, which increases the risk of sudden cardiac death. However, the patient's LVEF is 53%, which is relatively well-preserved, and the patient is on beta blockers, which can reduce the risk of sudden cardiac death. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death, but there is no evidence of non-sustained ventricular tachycardia or other arrhythmias that would significantly increase the risk.

RANKING: Pump Failure Death
REASONING: Pump failure death is the least likely prognosis. The patient's LVEF is 53%, which is relatively well-preserved, and the patient is on ACE inhibitors, which can help slow the progression of heart failure. The patient's blood pressure is well-controlled, and there are no signs of severe electrolyte imbalances or acute coronary syndromes. While the patient's liver enzymes are elevated, they are not significantly elevated, suggesting that the patient does not have advanced liver disease. The patient's kidney function is also relatively preserved, which is essential for the heart to function properly. Overall, considering the patient's stable medical condition, controlled blood pressure, and well-managed medications, pump failure death is the least likely prognosis."
644,644,P1031,"Age: 78
Gender: Male 
Weight: 65 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 114/68 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 41
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 56
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,97
Sodium (mEq/L): 135.0
Protein (g/L): 68
T3 (pg/dL): 0,05
T4 (ng/L): 22
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,86
Urea (mg/dL): 10,15
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",survivor,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: Despite the patient's advanced age and history of ischemic dilated cardiomyopathy, several factors suggest a more favorable prognosis. The patient's LVEF (left ventricular ejection fraction) is 25%, which is relatively low, but still within the range of possible survival with appropriate management. The patient is on a combination of medications that are standard for heart failure, including beta blockers, ACE inhibitors, and spironolactone, which are all beneficial for improving survival and reducing hospitalization rates in heart failure patients. The patient's blood pressure is well-controlled, and the lack of significant elevation in troponin levels suggests that the patient is not experiencing ongoing ischemic damage.

Additionally, the patient's TSH level is within the normal range, which is a good sign as hyperthyroidism can worsen heart failure symptoms. The absence of significant abnormalities in liver function tests (ALT, AST, and GGT) suggests that the patient's liver function is preserved, which is important for metabolizing medications.

The patient's weight is relatively low, which may be a sign of malnutrition or muscle wasting, but it is not uncommon in patients with heart failure. The patient's hemoglobin level is within the normal range, which is a good sign as anemia can worsen heart failure symptoms.

While the patient's creatinine level is elevated, indicating some degree of kidney dysfunction, the patient is not on dialysis, and the level is not extremely high. The patient's sodium level is within the normal range, which is a good sign as hyponatremia can worsen heart failure symptoms.

The patient's ECG shows a first-degree AV block, which is a relatively benign finding, and the absence of sustained ventricular tachycardia or non-sustained ventricular tachycardia suggests that the patient is not at high risk for sudden cardiac death.

Overall, while the patient's prognosis is guarded, the combination of appropriate medical therapy, well-controlled blood pressure, and lack of significant abnormalities in liver and kidney function suggest that the patient is likely to survive with continued medical management.

RANKING: Sudden cardiac death (less likely)

REASONING: Sudden cardiac death is a possible outcome in patients with ischemic dilated cardiomyopathy, especially those with a low LVEF. However, the patient's ECG shows a first-degree AV block, which is not a typical precursor to sudden cardiac death. The patient's LVEF is low, but the patient is on beta blockers, which are beneficial for reducing the risk of sudden cardiac death.

Additionally, the patient's troponin level is within the normal range, which suggests that the patient is not experiencing ongoing ischemic damage. The patient's potassium level is within the normal range, which is a good sign as hypokalemia can increase the risk of arrhythmias.

RANKING: Pump failure death (least likely)

REASONING: Pump failure death is a possible outcome in patients with advanced heart failure, but the patient's LVEF is 25%, which is relatively low, but still within the range of possible survival with appropriate management. The patient is on a combination of medications that are beneficial for improving survival and reducing hospitalization rates in heart failure patients.

The patient's blood pressure is well-controlled, and the lack of significant elevation in troponin levels suggests that the patient is not experiencing ongoing ischemic damage. The patient's creatinine level is elevated, but the patient is not on dialysis, and the level is not extremely high. The patient's sodium level is within the normal range, which is a good sign as hyponatremia can worsen heart failure symptoms.

Overall, while the patient's prognosis is guarded, the combination of appropriate medical therapy, well-controlled blood pressure, and lack of significant abnormalities in liver and kidney function suggest that the patient is less likely to die from pump failure."
645,645,P1054,"Age: 58
Gender: Male 
Weight: 91 kg
Height: 176 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41,7
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 145.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,08
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 4492.0
Protein (g/L): 78
T3 (pg/dL): 0,05
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,45
Urea (mg/dL): 12,03
LVEF (%): 20.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely:

RANKING: 1. Survivor
REASONING: The patient is already on a comprehensive treatment plan that includes medications such as beta blockers, loop diuretics, spironolactone, statins, ACE inhibitors, and nitrovasodilators. This suggests that the patient's heart failure and other comorbidities are being actively managed. The patient's low LVEF of 20% indicates severe heart failure, but the fact that they are still alive and on treatment suggests that the current management plan is effective. Additionally, the patient's recent troponin level is low (0.01 ng/mL), indicating that there is no recent myocardial infarction. The patient's TSH level is within the normal range, and the T3 and T4 levels are also within the normal range, which suggests that there is no thyroid dysfunction contributing to heart failure. The patient's potassium level is slightly low (4.4 mEq/L), but this is not significantly low enough to be a major concern. The patient's weight is 91 kg, which is above the ideal weight for their height, but it is not significantly high. Overall, while the patient has a severe heart condition, their current management plan and lab results suggest that they are likely to survive.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 20% indicates severe heart failure, which is a significant risk factor for pump failure death. The patient's creatinine level is elevated (95.0 umol/L), which suggests that there may be some renal impairment, which can be a contributing factor to pump failure. However, the patient's urea level is within the normal range (12.03 mg/dL), which suggests that the renal impairment is not severe. The patient's BNP level is elevated (4492.0 ng/L), which suggests that the patient's heart is under significant strain. However, the patient is on a comprehensive treatment plan that includes medications that can help manage heart failure, such as ACE inhibitors, beta blockers, and spironolactone. Overall, while the patient's LVEF is very low, their current management plan and lab results suggest that pump failure death is a possible but not the most likely outcome.

RANKING: 3. Sudden Cardiac Death
REASONING: The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are risk factors for sudden cardiac death. However, the patient is on amiodarone, which is an anti-arrhythmic medication that can help manage arrhythmias. The patient's troponin level is low (0.01 ng/mL), which suggests that there is no recent myocardial infarction. The patient's TSH level is within the normal range, and the T3 and T4 levels are also within the normal range, which suggests that there is no thyroid dysfunction contributing to arrhythmias. The patient's potassium level is slightly low (4.4 mEq/L), but this is not significantly low enough to be a major concern. Overall, while the patient's ECG shows some concerning features, their current management plan and lab results suggest that sudden cardiac death is the least likely outcome."
646,646,P1056,"Age: 79
Gender: Male 
Weight: 78 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 111/76 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 147.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,65
Sodium (mEq/L): 137.0
Protein (g/L): 76
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,005
TSH (mIU/L): 1,62
Urea (mg/dL): 9,82
LVEF (%): 39.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Sinus Node Dysfunction
            ",survivor,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: The patient is 79 years old with a history of hypertensive cardiomyopathy and hypertension. However, his current blood pressure is well-controlled, and he is on medications such as ACE inhibitor, loop diuretics, and nitrovasodilators, which are commonly used to manage heart failure and hypertension. His LVEF (left ventricular ejection fraction) is 39%, which is slightly below the normal range (50-70%), indicating some degree of left ventricular dysfunction. However, it is not severely impaired, and he is not in NYHA Class IV, which is typically associated with more severe symptoms.

The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. However, the presence of sinus node dysfunction and the absence of other high-risk features, such as a history of cardiac arrest or severe left ventricular dysfunction, make sudden cardiac death less likely.

The patient's creatinine level is elevated (106.0 mol/L), which may indicate some degree of renal impairment. However, his urea level is within a relatively normal range (9.82 mg/dL), and his albumin level is also within a normal range (43 g/L). This suggests that the renal impairment is not severe.

The patient's total cholesterol level is high (4.86 mmol/L), but his HDL level is relatively low (0.83 mmol/L), which may be a concern for cardiovascular disease. However, his LDL level is also within a relatively normal range (3.65 mmol/L).

Considering all these factors, the most likely prognosis for this patient is survivor, as he is on appropriate medications, has well-controlled blood pressure, and does not have any high-risk features that would suggest sudden cardiac death or pump failure."
647,647,P1057,"Age: 72
Gender: Female 
Weight: 72 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 104/62 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 44
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 5,3
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 10,7
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,59
Sodium (mEq/L): 139.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,33
TSH (mIU/L): 0,76
Urea (mg/dL): 12,31
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",survivor,"Based on the provided patient data, I would rank the prognosis as follows:

RANKING: Survivor

REASONING: The patient is 72 years old with a history of idiopathic dilated cardiomyopathy, diabetes, and dyslipemia. Her LVEF is 35%, indicating a reduced left ventricular function. However, she is on optimal medical therapy for heart failure, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor. Her blood pressure is well-controlled, and her kidney function is relatively preserved, with a creatinine level of 88.0 umol/L. The patient's eGFR can be estimated to be around 60-70 mL/min/1.73m^2, indicating mild kidney impairment. 

While the presence of non-sustained ventricular tachycardia (NSVT) is a concerning finding, it is often seen in patients with cardiomyopathy and is not necessarily an indicator of poor prognosis. The absence of paroxysmal supraventricular tachyarrhythmia, bradycardia, and significant electrolyte imbalances are also favorable signs.

Considering her overall clinical picture, the patient's likelihood of survival is higher compared to the other two options. However, it is essential to note that her LVEF is still quite low, and she has a history of diabetes and dyslipemia, which can contribute to cardiac remodeling and further decline in cardiac function. Regular follow-up and close monitoring of her condition will be crucial to prevent further deterioration.

The least likely prognosis is pump failure death, as the patient's current treatment regimen and relatively preserved kidney function suggest that her heart failure is being well-managed. The sudden cardiac death prognosis is also less likely due to the absence of significant electrolyte imbalances, bradycardia, and other high-risk factors.

Sudden cardiac death prognosis is more likely than pump failure death but less likely than survival, as the patient's NSVT and low LVEF increase her risk of arrhythmic events. However, the presence of beta blockers and ACE inhibitors, which are known to reduce the risk of sudden cardiac death, may mitigate this risk to some extent."
648,648,P1058,"Age: 77
Gender: Male 
Weight: 63 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 131/60 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia
Albumin (g/L): 40
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,28
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 136.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,9
Sodium (mEq/L): 140.0
Protein (g/L): 72
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,58
Urea (mg/dL): 9,98
LVEF (%): 19.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years, ranking the possible outcomes from most likely to least likely.

RANKING: Survivor

REASONING: The patient is 77 years old with a history of valvular cardiomyopathy and dyslipemia, which indicates a compromised cardiac function. However, the patient is on a comprehensive treatment regimen, including beta blockers, digoxin, loop diuretics, statins, and ACE inhibitors, which are all aimed at managing heart failure and improving cardiac function. The patient's LVEF (Left Ventricular Ejection Fraction) is 19%, which is low but not extremely low. The patient's NT-proBNP (not measured in this case, but implied by the presence of heart failure symptoms) is not explicitly stated, but the patient's weight and NYHA class II suggest that the heart failure is not severe. The patient's troponin level is 0.03 ng/mL, which is within normal limits, indicating that there is no acute myocardial infarction. The patient's TSH level is 0.58 mIU/L, which is within the normal range, indicating no evidence of hypothyroidism, which is a common cause of heart failure. The patient's ECG shows ventricular extrasystole, sustained ventricular tachycardia, and non-sustained ventricular tachycardia, but these are not uncommon in patients with heart failure and are being managed with medications. Considering these factors, the most likely prognosis is that the patient will survive for the next few years, with ongoing management and monitoring of their heart failure symptoms and cardiac function.

RANKING: Sudden Cardiac Death

REASONING: Sudden cardiac death (SCD) is a possible outcome in patients with heart failure, especially those with low LVEF and a history of ventricular arrhythmias. However, the patient's LVEF is 19%, which, while low, is not extremely low. The patient's ventricular arrhythmias are being managed with medications, and there is no evidence of acute myocardial infarction or other acute cardiac events. The patient's TSH level is within normal limits, and there is no evidence of hypothyroidism, which can increase the risk of SCD. While SCD is a possible outcome, it is less likely than survival given the patient's current treatment regimen and the lack of other high-risk factors.

RANKING: Pump Failure Death

REASONING: Pump failure death is a possible outcome in patients with advanced heart failure, especially those with low LVEF and a history of valvular cardiomyopathy. However, the patient's LVEF is 19%, which, while low, is not extremely low, and the patient is on a comprehensive treatment regimen aimed at managing heart failure. The patient's weight and NYHA class II suggest that the heart failure is not severe, and the patient's troponin level is within normal limits, indicating no acute myocardial infarction. While pump failure death is a possible outcome, it is the least likely of the three options given the patient's current treatment regimen and the lack of other high-risk factors."
649,649,P1064,"Age: 63
Gender: Female 
Weight: 67 kg
Height: 151 cm
NYHA Class: II
Blood Pressure: 163/94 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 53.0
Gamma-glutamil transpeptidase (IU/L): 12
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,28
Sodium (mEq/L): 141.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,005
TSH (mIU/L): 2,35
Urea (mg/dL): 6,32
LVEF (%): 30.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. Please note that this is a general assessment and not a definitive prediction. The patient's prognosis will depend on various factors, including the effectiveness of their current treatment plan and any changes in their medical condition.

RANKING: 1. Survivor
REASONING: The patient has a relatively high risk of cardiac events due to their age, hypertension, diabetes, and reduced left ventricular ejection fraction (LVEF). However, they are already on a comprehensive treatment plan, including medications for diabetes, hypertension, and heart failure. Their LVEF is 30%, which is lower than the normal range (50-70%), indicating some degree of heart failure. Despite this, they do not have any recent troponin elevation, which suggests that they are not experiencing acute coronary syndrome. Their TSH level is within the normal range, indicating that their thyroid function is not contributing to their cardiac condition. The absence of sustained ventricular tachycardia and the presence of a polymorphic ventricular extrasystole on the ECG suggest that they are not at an immediate risk of sudden cardiac death. The patient's NYHA Class II indicates that they are experiencing some symptoms of heart failure, but they are not severely limited by their condition. Overall, while the patient's prognosis is guarded, their current treatment plan and lack of acute cardiac events make survivorship the most likely outcome.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's LVEF is 30%, which increases their risk of sudden cardiac death. The presence of polymorphic ventricular extrasystoles on the ECG is a risk factor for sudden cardiac death. Additionally, their history of hypertension and diabetes contributes to their overall cardiovascular risk. However, the patient is already on beta blockers, which are known to reduce the risk of sudden cardiac death. Their current treatment plan, including ACE inhibitors and loop diuretics, also suggests that their heart failure is being managed. While sudden cardiac death is a possible outcome, the patient's current treatment plan and lack of recent cardiac events make it less likely than survivorship.

RANKING: 3. Pump Failure Death
REASONING: Pump failure death is the least likely outcome for this patient. While their LVEF is 30%, indicating some degree of heart failure, they are already on a comprehensive treatment plan that includes loop diuretics, which are used to manage heart failure symptoms. Their NYHA Class II indicates that they are experiencing some symptoms of heart failure, but they are not severely limited by their condition. Additionally, their creatinine level is 53.0 umol/L, which is slightly elevated but not indicative of severe kidney dysfunction. The patient's overall clinical presentation suggests that their heart failure is being managed, and pump failure death is not the most likely outcome."
650,650,P1065,"Age: 80
Gender: Male 
Weight: 79 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 146/83 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,91
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 14,9
Hemoglobin (g/L): 179.0
HDL (mmol/L): 0,83
LDL (mmol/L): 3,21
Sodium (mEq/L): 135.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 13
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,06
Urea (mg/dL): 13,98
LVEF (%): 56.0
Medications: Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. However, please note that a definitive prognosis can only be made with a comprehensive physical examination and additional diagnostic tests. The following ranking is based on the information given:

RANKING: Survivor

REASONING:
The patient is 80 years old with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for cardiac mortality. However, there are several factors that suggest a relatively better prognosis:

1.  The patient is on optimal medical therapy with digoxin, loop diuretics, and an ACE inhibitor, which is essential for managing heart failure symptoms and slowing disease progression.
2.  The patient's LVEF is 56%, which is relatively well-preserved for someone with dilated cardiomyopathy. This suggests that the patient's heart is still functional, and there is a potential for further improvement with optimal medical therapy.
3.  The patient's troponin level is within normal limits, which suggests that there is no significant acute coronary syndrome or myocardial infarction contributing to his condition.
4.  The patient's TSH level is within normal limits, which suggests that there is no underlying thyroid dysfunction contributing to his cardiac condition.
5.  The patient's weight is relatively low, which may be beneficial in reducing the burden on the heart.

However, there are some concerns that need to be addressed:

1.  The patient's weight is low, which may indicate malnutrition or muscle wasting, which can be a sign of advanced heart failure.
2.  The patient's creatinine level is elevated, which suggests that there may be some degree of renal impairment, which can be a risk factor for cardiac mortality.
3.  The patient's total cholesterol level is elevated, which is a risk factor for atherosclerotic cardiovascular disease.

Given these factors, the patient's prognosis is likely to be a survivor, but with a guarded outlook. The patient will require close monitoring and regular follow-up with a cardiologist to optimize his medical therapy and manage any potential complications.

Sudden cardiac death is less likely due to the following reasons:

- The patient is on optimal medical therapy.
- The patient's LVEF is relatively well-preserved.
- There is no evidence of acute coronary syndrome or myocardial infarction.

Pump failure death is less likely due to the following reasons:

- The patient's LVEF is relatively well-preserved.
- The patient is on optimal medical therapy.
- There is no evidence of acute decompensated heart failure.

However, it is essential to note that the patient's prognosis can change over time, and regular follow-up with a cardiologist is crucial to monitor his condition and adjust his treatment plan as needed."
651,651,P1066,"Age: 72
Gender: Female 
Weight: 81 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 164/79 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 5,04
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,62
Sodium (mEq/L): 139.0
Protein (g/L): 69
T3 (pg/dL): 0,06
T4 (ng/L): 11
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,38
Urea (mg/dL): 8,32
LVEF (%): 42.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: Survivor

REASONING: 

1. The patient's age (72) and NYHA Class II indicate that she has some limitations in physical activity but can still perform daily tasks without significant discomfort. This suggests that her heart condition is not extremely severe at this stage.
2. Her LVEF (42%) is below the normal range (50-70%), indicating some degree of left ventricular dysfunction. However, it's not extremely low, and her symptoms and overall health status do not indicate severe heart failure.
3. The patient is on ACE inhibitors and loop diuretics, which are commonly used to manage hypertension and heart failure symptoms. This suggests that her condition is being managed, and her symptoms are being controlled.
4. The ECG shows ventricular extrasystoles, which are common in people with heart disease, but there is no indication of sustained ventricular tachycardia or other life-threatening arrhythmias.
5. Her lab results show mild elevations in liver enzymes (ALT and AST), but they are not significantly elevated, and her albumin and total protein levels are within normal limits, indicating no significant liver dysfunction.
6. Her lipid profile shows high total cholesterol and LDL, but her HDL is low. This is a risk factor for cardiovascular disease, but it is being managed with medication.
7. Her TSH level is within the normal range, indicating no thyroid dysfunction.
8. The patient's creatinine level is slightly elevated, but it is not significantly high, and her urea level is within normal limits.

Considering these factors, the patient's overall condition appears to be stable, and her symptoms are being managed. While she has some risk factors for cardiovascular disease, they are being addressed with medication. Therefore, I predict that she is most likely to survive in the next few years.

RANKING: Sudden Cardiac Death

REASONING: 

Sudden cardiac death is a possible outcome in this patient, but it is less likely than survival. The patient has ventricular extrasystoles on her ECG, which can be a precursor to life-threatening arrhythmias. However, there is no indication of sustained ventricular tachycardia or other life-threatening arrhythmias on the ECG.

RANKING: Pump Failure Death

REASONING: 

Pump failure death is the least likely outcome in this patient. While her LVEF is below the normal range, it is not extremely low, and her symptoms and overall health status do not indicate severe heart failure. Her creatinine level is slightly elevated, but it is not significantly high, and her urea level is within normal limits, indicating no significant kidney dysfunction. Her medication regimen is also aimed at managing her heart failure symptoms and hypertension, which suggests that her condition is being managed."
652,652,P1073,"Age: 70
Gender: Female 
Weight: 63 kg
Height: 144 cm
NYHA Class: II
Blood Pressure: 134/86 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 44
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 6,21
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 89
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,23
Sodium (mEq/L): 141.0
Protein (g/L): 73
T3 (pg/dL): 0,05
T4 (ng/L): 12
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,43
Urea (mg/dL): 8,82
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",survivor,"Based on the provided patient data, here's the ranking of the possible prognoses from most likely to least likely:

RANKING: 1. Survivor
REASONING: The patient is 70 years old with a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for adverse cardiac outcomes. However, the patient is on appropriate medical therapy with beta blockers, loop diuretics, and an ACE inhibitor, which are standard treatments for heart failure. The patient's LVEF is 40%, which is mildly reduced but not severely decreased. The absence of sustained ventricular tachycardia and the low troponin level suggest that the patient is not experiencing an acute myocardial infarction or severe cardiac dysfunction at this time. The patient's NYHA class is II, indicating that she is experiencing some symptoms of heart failure but is still able to perform everyday activities. Overall, while the patient has a history of cardiomyopathy, her current treatment and clinical status suggest a relatively stable condition, making survivor the most likely prognosis.

RANKING: 2. Pump Failure Death
REASONING: Pump failure death is a possible outcome for patients with heart failure, particularly those with reduced LVEF. However, the patient's current treatment regimen and clinical status suggest that she is being well-managed, and her symptoms are not severe. The patient's creatinine level is within a relatively normal range, which suggests that her renal function is not severely impaired. While the patient's LVEF is reduced, it is not severely decreased, and the absence of sustained ventricular tachycardia and low troponin level suggest that the patient is not experiencing an acute cardiac decompensation. Therefore, while pump failure death is a possible outcome, it is less likely than survivor.

RANKING: 3. Sudden Cardiac Death
REASONING: Sudden cardiac death is a significant concern for patients with heart failure, particularly those with reduced LVEF. However, the patient's current treatment regimen and clinical status suggest that she is being well-managed, and her risk of sudden cardiac death is relatively low. The patient's LVEF is reduced, but not severely decreased, and the absence of sustained ventricular tachycardia and low troponin level suggest that the patient is not experiencing an acute cardiac decompensation. The patient's ECG shows monomorphic ventricular extrasystoles, but this finding is not typically associated with an increased risk of sudden cardiac death. Therefore, while sudden cardiac death is a possible outcome, it is the least likely of the three prognoses."
653,653,P0008,"Age: 44
Gender: Male 
Weight: 114 kg
Height: 179 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42,19
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 12,3
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,77
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 623.0
Protein (g/L): 76
T3 (pg/dL): 0,02
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,58
Urea (mg/dL): 9,8
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: Survivor
REASONING: The patient is 44 years old, which is relatively young for a patient with ischemic dilated cardiomyopathy. Despite having a low left ventricular ejection fraction (LVEF) of 30%, the patient is on a combination of medications that are commonly used to manage heart failure, including beta blockers, loop diuretics, statins, and an ACE inhibitor. The patient also has a relatively low level of troponin, which suggests that there is not significant ongoing myocardial injury. Additionally, the patient's blood pressure is well-controlled at 140/80 mmHg, which is a good prognostic sign. While the patient has a high level of pro-BNP, which is an indicator of heart failure, the patient's overall clinical picture suggests that they are receiving adequate treatment and are likely to survive in the short term.

RANKING: Pump failure death
REASONING: The patient's LVEF of 30% indicates severe left ventricular dysfunction, which increases the risk of pump failure. However, the patient's overall clinical picture is not entirely consistent with a high risk of pump failure death. The patient is on medications that are commonly used to manage heart failure, and their blood pressure is well-controlled. Additionally, the patient's troponin level is low, which suggests that there is not significant ongoing myocardial injury.

RANKING: Sudden cardiac death
REASONING: While the patient has a history of ischemic dilated cardiomyopathy and a low LVEF, the patient's overall clinical picture is not entirely consistent with a high risk of sudden cardiac death. The patient is on beta blockers, which are commonly used to reduce the risk of sudden cardiac death in patients with heart failure. The patient's ECG shows polymorphic ventricular extrasystoles, which is a risk factor for sudden cardiac death, but it is not a definitive predictor. The patient's troponin level is low, which suggests that there is not significant ongoing myocardial injury. Additionally, the patient's overall clinical picture suggests that they are receiving adequate treatment for their heart failure.

It's worth noting that the patient's age and sex are not particularly high-risk factors for sudden cardiac death, and the patient's overall clinical picture is more consistent with a prognosis of survivor or pump failure death."
654,654,P0012,"Age: 70
Gender: Male 
Weight: 88 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39,3
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,32
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 3,1
LDL (mmol/L): 2,43
Sodium (mEq/L): 145.0
Pro-BNP (ng/L): 958.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,51
Urea (mg/dL): 8,02
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Amiodarone, Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, here's my prognosis for the next few years:

RANKING: Survivor
REASONING: The patient is 70 years old with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac events. However, the patient's current medications, including ACE inhibitors, beta-blockers, and spironolactone, suggest that they are being managed for heart failure. The patient's LVEF of 35% is concerning, but it's not extremely low. The patient's Pro-BNP level of 958 ng/L is elevated, indicating some level of heart failure, but it's not extremely high. The patient's ECG shows polymorphic ventricular extrasystoles, which can be concerning, but it's not a direct indicator of a poor prognosis. Considering the patient's current treatment plan and the fact that they are being managed for heart failure, I believe the most likely outcome is that the patient will survive for the next few years, albeit with ongoing management and potential adjustments to their treatment plan.

RANKING: Pump Failure Death
REASONING: The patient's LVEF of 35% is concerning for pump failure, and their Pro-BNP level of 958 ng/L suggests some level of heart failure. However, the patient's ejection fraction is not extremely low, and they are currently being managed with medications that are typically used to manage heart failure. While the patient's prognosis is guarded, I do not believe that pump failure is the most likely outcome in the next few years.

RANKING: Sudden Cardiac Death
REASONING: The patient's history of myocardial infarction and ischemic dilated cardiomyopathy puts them at increased risk for sudden cardiac death. However, the patient's current medications, including amiodarone, suggest that they are being managed for arrhythmias. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death, but it's not a direct indicator of a poor prognosis. While the patient's overall risk for sudden cardiac death is increased, I do not believe that it is the most likely outcome in the next few years, given their current treatment plan and the fact that they are being managed for heart failure.

Therefore, my final ranking is: 

RANKING: Survivor
REASONING: Based on the patient's current treatment plan, ongoing management for heart failure, and the fact that their LVEF is not extremely low, I believe that the patient is most likely to survive for the next few years."
655,655,P0016,"Age: 72
Gender: Male 
Weight: 78 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 95/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 38,1
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 6,72
Creatinine (mmol/L): 225.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 7
Hemoglobin (g/L): 151.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,78
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 15509.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,56
Urea (mg/dL): 31,4
LVEF (%): 18.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"Based on the provided patient data, I would rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden Cardiac Death
REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 18%, indicating poor heart function. The presence of non-sustained ventricular tachycardia (VT) and polymorphic ventricular extrasystoles on the ECG further increases the risk of sudden cardiac death. Additionally, the elevated Pro-BNP level of 15509 ng/L suggests severe heart failure and increased risk of sudden cardiac death. The patient's NYHA Class III classification also indicates severe symptoms of heart failure, which increases the risk of sudden cardiac death.

RANKING: 2. Pump Failure Death
REASONING: The patient's severe heart failure, as indicated by the LVEF of 18% and NYHA Class III, increases the risk of pump failure death. The elevated Pro-BNP level and the patient's symptoms of heart failure also support this prognosis. However, the patient's age, sex, and other comorbidities (e.g., dyslipemia, myocardial infarction) may also contribute to this prognosis.

RANKING: 3. Survivor
REASONING: While the patient has a severe cardiac condition, the patient is on a comprehensive treatment regimen, including beta blockers, digoxin, loop diuretics, spironolactone, statins, and an ACE inhibitor. These medications are designed to manage heart failure and reduce the risk of sudden cardiac death. Additionally, the patient's relatively low troponin level suggests that there is no current acute myocardial infarction. However, the patient's overall condition is severe, and the risk of sudden cardiac death and pump failure death is still high.

Note: It is essential to note that this prognosis is based on the provided data and may not reflect the patient's actual outcome, which can be influenced by various factors, including the patient's adherence to treatment, lifestyle changes, and other comorbidities."
656,656,P0018,"Age: 57
Gender: Male 
Weight: 88 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 48
ALT or GPT (IU/L): 38.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 89.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 147.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,6
LDL (mmol/L): 1,78
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 110.0
Protein (g/L): 78
T3 (pg/dL): 0,04
T4 (ng/L): 13
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,21
Urea (mg/dL): 9,35
LVEF (%): 58.0
Medications: Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",sudden cardiac death,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: 1. Sudden cardiac death
REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's LVEF (Left Ventricular Ejection Fraction) is 58%, which is slightly below the normal range, indicating some degree of left ventricular dysfunction. Additionally, the patient's Pro-BNP (Brain Natriuretic Peptide) level is elevated at 110.0 ng/L, which is often associated with heart failure and increased risk of sudden cardiac death. Furthermore, the presence of ventricular extrasystoles on the ECG, although monomorphic, may indicate underlying arrhythmogenic potential. While the patient is on beta blockers, statins, ACE inhibitors, and nitrovasodilators, which are all beneficial for heart failure and reducing sudden cardiac death risk, the patient's overall clinical picture suggests that sudden cardiac death is a possible outcome.

RANKING: 2. Pump failure death
REASONING: Given the patient's history of ischemic dilated cardiomyopathy and reduced LVEF, pump failure death is a possible outcome. The patient's elevated Pro-BNP level and low albumin level also suggest underlying heart failure. However, the patient's NYHA class is II, indicating that the heart failure is not severe at this point. The patient's medications, including ACE inhibitors and beta blockers, are beneficial for heart failure management, and the patient's LVEF is still above 50%, which is generally considered to be in the moderate range. Therefore, while pump failure death is a possible outcome, it is less likely than sudden cardiac death.

RANKING: 3. Survivor
REASONING: The patient's overall clinical picture suggests that they are at risk for cardiac complications, but the patient's LVEF is still relatively preserved, and they are on appropriate medications for heart failure and ischemic heart disease. The patient's blood pressure is well-controlled, and there is no indication of severe kidney dysfunction. While the patient's lipid profile is not ideal, the patient is on statins, which are beneficial for reducing cardiovascular risk. The patient's TSH level is within the normal range, and there is no indication of thyroid dysfunction. Therefore, while the patient is at risk for cardiac complications, the likelihood of long-term survival is higher than sudden cardiac death or pump failure death.

Please note that this is a medical prognosis based on the provided data and may not reflect the actual outcome for the patient."
657,657,P0028,"Age: 76
Gender: Male 
Weight: 72 kg
Height: 187 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease
Albumin (g/L): 41,5
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 130.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 10,2
Hemoglobin (g/L): 132.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 5
LDL (mmol/L): 2,9
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 7822.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,29
Urea (mg/dL): 10,91
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: 1. Pump failure death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack or coronary artery disease. The patient's left ventricular ejection fraction (LVEF) is 35%, which is significantly below the normal range (50-70%), indicating poor heart function. Additionally, the patient's pro-BNP level is elevated at 7822.0 ng/L, which is a marker of heart failure. The patient is also taking loop diuretics, which are often used to manage heart failure symptoms. Considering these factors, pump failure death is the most likely prognosis.

RANKING: 2. Sudden cardiac death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy and a low LVEF, which increases the risk of sudden cardiac death. The presence of ventricular extrasystoles on the ECG also suggests an increased risk of arrhythmias, which can lead to sudden cardiac death. However, the patient is taking beta blockers, which are often used to reduce the risk of sudden cardiac death in patients with heart failure.

RANKING: 3. Survivor
 REASONING: While the patient has several risk factors for cardiac events, the patient's current medication regimen and the lack of more severe symptoms (e.g., severe shortness of breath, severe fatigue) suggest that the patient may be managed with current treatment and lifestyle modifications. The patient's creatinine level is elevated, indicating kidney dysfunction, which may be related to the patient's diabetes and heart failure. However, the patient's hemoglobin and albumin levels are within relatively normal ranges, which suggests that the patient's nutritional status is relatively stable. Overall, while the patient's prognosis is guarded, survival for several years with proper management is still possible.

Note: The patient's outcome is actually sudden cardiac death, but I have ranked the prognoses based on the provided data."
658,658,P0043,"Age: 63
Gender: Male 
Weight: 87 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 115/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 41,9
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,53
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 6,8
Hemoglobin (g/L): 168.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,87
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 636.0
Protein (g/L): 81
T3 (pg/dL): 0,07
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,57
Urea (mg/dL): 4,9
LVEF (%): 26.0
Medications: Diabetes Medication, Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, here is the prognosis for the next few years:

RANKING: Sudden cardiac death, Pump failure death, Survivor

REASONING: 

1. Sudden cardiac death: This prognosis is the most likely due to the patient's high risk factors. The patient has a history of ischemic dilated cardiomyopathy, which significantly increases the risk of sudden cardiac death. The patient's low LVEF (26%) and elevated Pro-BNP (636 ng/L) levels also indicate a high risk of cardiac arrhythmias and sudden cardiac death. The presence of non-sustained ventricular tachycardia (VT) on the ECG further supports this risk. The patient's age, diabetes, and peripheral vascular disease also contribute to the overall risk.

2. Pump failure death: This prognosis is the second most likely due to the patient's dilated cardiomyopathy and low LVEF. The patient's creatinine level of 102 umol/L also suggests some degree of renal dysfunction, which is often seen in advanced heart failure. The patient's medication regimen, including ACE inhibitor and spironolactone, is typical for heart failure management, but the patient's high risk factors and low LVEF suggest that pump failure is still a significant concern.

3. Survivor: This prognosis is the least likely due to the patient's high risk factors and current clinical presentation. While the patient is on a comprehensive medication regimen, the patient's low LVEF, high Pro-BNP levels, and history of ischemic dilated cardiomyopathy suggest a high risk of adverse cardiac events. The presence of non-sustained VT on the ECG also suggests a high risk of arrhythmias. While some patients with similar profiles may survive with aggressive medical management, the patient's overall risk profile makes a survival prognosis less likely.

Please note that this prognosis is based on the provided data and may not reflect the actual outcome. A more accurate prognosis would require a comprehensive evaluation by a healthcare professional."
659,659,P0049,"Age: 70
Gender: Male 
Weight: 88 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 41,4
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 77
Glucose (mmol/L): 9
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4
LDL (mmol/L): 2,04
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2542.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,21
Urea (mg/dL): 8,91
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Survivor
 REASONING: Although the patient has a history of ischemic dilated cardiomyopathy, diabetes, and previous myocardial infarction, which are significant risk factors for cardiac mortality, the patient's current medication regimen (Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, and ACE Inhibitor) is comprehensive and aimed at managing heart failure symptoms, reducing cardiac workload, and preventing further cardiac damage. The patient's current LVEF of 25% is concerning but not necessarily a death sentence. With proper management and monitoring, it is possible for the patient to survive for the next few years.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. Additionally, the patient's Pro-BNP level is elevated at 2542 ng/L, which is indicative of heart failure and increased risk of sudden cardiac death. However, the patient's medications and the lack of other high-risk factors such as severe left ventricular dysfunction or significant arrhythmias on the ECG make sudden cardiac death less likely compared to pump failure death.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 25% indicates severe left ventricular dysfunction, which is a significant risk factor for pump failure death. The patient's elevated Pro-BNP level and history of ischemic dilated cardiomyopathy further support this risk. The patient's current medications are aimed at managing heart failure symptoms, but the patient's low LVEF and history of previous myocardial infarction make pump failure death the most likely outcome among the three options."
660,660,P0051,"Age: 52
Gender: Male 
Weight: 74 kg
Height: 176 cm
NYHA Class: III
Blood Pressure: 85/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 39
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 2,74
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 133.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 5
LDL (mmol/L): 1,4
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 693.0
Protein (g/L): 68
T3 (pg/dL): 0,04
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,55
Urea (mg/dL): 8,91
LVEF (%): 26.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will generate a prognosis for the next few years. Here's my assessment:

RANKING: Survivor

REASONING: While the patient has a history of idiopathic dilated cardiomyopathy, which is a severe condition, the patient's current medications and clinical parameters suggest a relatively stable condition. The patient is on a comprehensive treatment regimen that includes beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, which are all aimed at managing heart failure symptoms and slowing disease progression. The patient's LVEF of 26% is low, indicating a reduced ejection fraction, but it is not the lowest possible value (which would be 0-10%). The patient's Pro-BNP level of 693.0 ng/L is elevated, indicating increased stress on the heart, but it is not excessively high. The absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG is a positive sign. Additionally, the patient's hemoglobin and sodium levels are within a relatively normal range, which suggests that the patient is not experiencing significant anemia or fluid overload. While the patient's total cholesterol level is high, the LDL level is within a relatively normal range, and the patient is on statins, which should help manage this. The patient's TSH level is slightly elevated, but it is not excessively high, and the patient's T3 and T4 levels are within a relatively normal range. Overall, considering the patient's treatment regimen and relatively stable clinical parameters, I believe the patient is likely to survive the next few years.

RANKING: Pump Failure Death

REASONING: Pump failure death is a possible outcome for this patient due to the patient's history of idiopathic dilated cardiomyopathy and reduced LVEF. The patient's current medications and clinical parameters suggest that the patient's heart failure is being managed, but the patient's LVEF of 26% indicates that the heart is not pumping efficiently. The patient's Pro-BNP level is elevated, which suggests increased stress on the heart. However, the patient's hemoglobin and sodium levels are within a relatively normal range, which suggests that the patient is not experiencing significant anemia or fluid overload. The patient's TSH level is slightly elevated, but it is not excessively high, and the patient's T3 and T4 levels are within a relatively normal range. While the patient's total cholesterol level is high, the LDL level is within a relatively normal range, and the patient is on statins, which should help manage this. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of increased cardiac stress. However, the absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG is a positive sign. Overall, while pump failure death is a possible outcome, I believe it is less likely than sudden cardiac death due to the patient's relatively stable clinical parameters and comprehensive treatment regimen.

RANKING: Sudden Cardiac Death

REASONING: Sudden cardiac death is a possible outcome for this patient due to the patient's history of idiopathic dilated cardiomyopathy and reduced LVEF. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a sign of increased cardiac stress and an increased risk of sudden cardiac death. The patient's Pro-BNP level is elevated, which suggests increased stress on the heart. The patient's LVEF of 26% is low, indicating a reduced ejection fraction, which increases the risk of sudden cardiac death. The patient's TSH level is slightly elevated, which can be a sign of thyroid dysfunction, which can increase the risk of cardiac arrhythmias and sudden cardiac death. The patient's hemoglobin and sodium levels are within a relatively normal range, which suggests that the patient is not experiencing significant anemia or fluid overload. However, the patient's low blood pressure (85/60 mmHg) may indicate decreased cardiac output, which can increase the risk of sudden cardiac death. Overall, while sudden cardiac death is a possible outcome, I believe it is the least likely outcome due to the patient's relatively stable clinical parameters and comprehensive treatment regimen."
661,661,P0053,"Age: 68
Gender: Male 
Weight: 80 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 47,19
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 112.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 155.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,15
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 2234.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,11
Urea (mg/dL): 9,57
LVEF (%): 39.0
Medications: Calcium Channel Blocker, Diabetes Medication, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Survivor
 REASONING: The patient has a complex medical history with ischemic dilated cardiomyopathy, diabetes, dyslipemia, and a history of myocardial infarction. However, despite these risk factors, the patient is currently being treated with medications that are appropriate for heart failure and hyperlipidemia, such as calcium channel blockers, statins, and nitrovasodilators. The patient's NYHA Class II indicates that the patient's symptoms are not severe, and they are able to perform daily activities without significant limitations. The LVEF of 39% is relatively low, but it is not extremely low, and the patient is not in heart failure with reduced ejection fraction (HFrEF) or heart failure with preserved ejection fraction (HFpEF) based on the provided data. The patient's Pro-BNP level is elevated at 2234 ng/L, but it is not extremely high, and the patient's other biomarkers are within relatively normal ranges. Overall, while the patient's prognosis is guarded, the patient's current treatment and relatively mild symptoms suggest that a survivor prognosis is more likely than the other two options.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases their risk for sudden cardiac death (SCD). The patient's LVEF of 39% also indicates a higher risk for SCD. However, the patient's current treatment with medications that are known to reduce the risk of SCD, such as beta-blockers and implantable cardioverter-defibrillators (ICDs), is not mentioned. The patient's Pro-BNP level is elevated, which can indicate increased risk for SCD, but it is not extremely high. Additionally, the patient's other biomarkers are within relatively normal ranges. The patient's age and sex also increase their risk for SCD, but the patient's relatively mild symptoms and current treatment suggest that SCD is not the most likely outcome.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 39% indicates that the patient has a reduced ejection fraction, which increases their risk for heart failure and pump failure. The patient's history of ischemic dilated cardiomyopathy and myocardial infarction also increases their risk for pump failure. The patient's elevated Pro-BNP level and relatively low albumin level also suggest increased risk for pump failure. However, the patient's current treatment with medications that are known to reduce the risk of heart failure, such as ACE inhibitors and beta-blockers, is not mentioned. The patient's NYHA Class II indicates that the patient's symptoms are not severe, and they are able to perform daily activities without significant limitations, which suggests that pump failure is less likely than the other two options."
662,662,P0057,"Age: 66
Gender: Male 
Weight: 77 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41,7
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 155.0
Gamma-glutamil transpeptidase (IU/L): 168
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 5
LDL (mmol/L): 2,48
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3996.0
Protein (g/L): 81
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,02
TSH (mIU/L): 8,79
Urea (mg/dL): 15,15
LVEF (%): 29.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient has been on optimal medical therapy for heart failure and ischemic cardiomyopathy, including beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators. The patient's LVEF is 29%, which is relatively low but not the lowest. Although the patient has a history of myocardial infarction and is in NYHA Class III, indicating significant symptoms, the patient's overall clinical picture does not suggest an extremely high risk of sudden cardiac death. The low troponin level (0.02 ng/mL) and the absence of sustained ventricular tachycardia on the ECG suggest that the patient may not be at an extremely high risk of arrhythmic events. Furthermore, the patient's high TSH level (8.79 mIU/L) may indicate hypothyroidism, which is associated with a lower risk of sudden cardiac death. Therefore, while the patient's prognosis is guarded, I believe that survival is the most likely outcome.

RANKING: 2. Pump failure death
REASONING: The patient's LVEF of 29% indicates severe left ventricular dysfunction, and the patient's history of ischemic cardiomyopathy and myocardial infarction suggests that the patient's heart function is severely compromised. The patient's creatinine level of 155.0 mmol/L suggests that the patient may have renal dysfunction, which can further exacerbate heart failure. The patient's high pro-BNP level (3996.0 ng/L) also suggests that the patient has significant volume overload and heart failure symptoms. However, the patient is on optimal medical therapy for heart failure, and the patient's symptoms may be well-managed with current treatment. Therefore, while pump failure death is a possible outcome, I believe that it is less likely than sudden cardiac death.

RANKING: 3. Sudden cardiac death
REASONING: The patient's history of myocardial infarction, ischemic cardiomyopathy, and low LVEF (29%) suggests that the patient is at risk for arrhythmic events, including sudden cardiac death. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG also suggests that the patient may be at risk for arrhythmic events. However, the patient's low troponin level (0.02 ng/mL) and the absence of sustained ventricular tachycardia on the ECG suggest that the patient may not be at an extremely high risk of arrhythmic events. Furthermore, the patient's high TSH level (8.79 mIU/L) may indicate hypothyroidism, which is associated with a lower risk of sudden cardiac death. Therefore, while sudden cardiac death is a possible outcome, I believe that it is the least likely of the three possible outcomes."
663,663,P0059,"Age: 78
Gender: Male 
Weight: 77 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 145/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 36,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,53
Creatinine (mmol/L): 171.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 5,1
LDL (mmol/L): 2,66
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 8283.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,79
Urea (mg/dL): 13,14
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely.

RANKING: 1. Sudden Cardiac Death
 REASONING: The patient's history of ischemic dilated cardiomyopathy, previous myocardial infarction, and non-sustained ventricular tachycardia (NSVT) on ECG are significant risk factors for sudden cardiac death (SCD). The patient's low left ventricular ejection fraction (LVEF) of 30% also increases the risk of SCD. Additionally, the high pro-BNP level of 8283 ng/L indicates severe heart failure, which is another risk factor for SCD. The patient's medications, including beta blockers, digoxin, and loop diuretics, are standard treatments for heart failure and may help reduce the risk of SCD, but the patient's underlying condition and risk factors still pose a significant threat.

RANKING: 2. Pump Failure Death
 REASONING: The patient's ischemic dilated cardiomyopathy, previous myocardial infarction, and low LVEF of 30% suggest that the patient is at risk for pump failure. The high pro-BNP level and low albumin level also indicate severe heart failure. However, the patient's NYHA class II suggests that the patient's symptoms are not severe, and the patient may still be able to tolerate some physical activity. The patient's medications, including beta blockers, digoxin, and loop diuretics, are standard treatments for heart failure and may help slow the progression of the disease.

RANKING: 3. Survivor
 REASONING: While the patient has several risk factors for poor outcomes, the patient's NYHA class II suggests that the patient's symptoms are not severe, and the patient may still be able to tolerate some physical activity. The patient's medications, including beta blockers, digoxin, and loop diuretics, are standard treatments for heart failure and may help slow the progression of the disease. However, the patient's low LVEF, high pro-BNP level, and history of NSVT on ECG suggest that the patient is at risk for sudden cardiac death or pump failure, making a survivor prognosis less likely compared to the other two options."
664,664,P0073,"Age: 65
Gender: Male 
Weight: 101 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 110/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 39,8
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 6,05
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4
LDL (mmol/L): 3,18
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 842.0
Protein (g/L): 73
T4 (ng/L): 17
TSH (mIU/L): 0,98
Urea (mg/dL): 5,66
LVEF (%): 32.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"Based on the provided patient data, here are the three possible prognoses for the next few years, ordered from most likely to least likely, along with the reasoning behind each:

RANKING: 1
 REASONING: Survivor
The patient's current medications, including beta blockers, loop diuretics, spironolactone, statins, and ACE inhibitors, are all standard treatments for heart failure and ischemic dilated cardiomyopathy. The patient's NYHA Class III classification indicates that they experience symptoms of heart failure with ordinary physical activity, but they are still able to perform daily activities. While the patient has a low LVEF of 32%, they are currently being managed with medications that are known to improve survival and reduce hospitalization rates in heart failure patients. Additionally, the patient's blood pressure is well-controlled, and their lipid profile is being managed with statins. However, the patient's Pro-BNP level of 842 ng/L is elevated, indicating some degree of heart failure, but it is not the highest level. Therefore, with continued medical management and close monitoring, the patient is likely to survive for the next few years.

RANKING: 2
 REASONING: Pump failure death
The patient's LVEF of 32% indicates severe left ventricular dysfunction, which increases the risk of pump failure death. The patient's NYHA Class III classification also suggests that they experience symptoms of heart failure, and their elevated Pro-BNP level of 842 ng/L further supports this. However, the patient is currently being treated with medications that are known to improve survival and reduce hospitalization rates in heart failure patients. While the patient's creatinine level of 103.0 mmol/L is elevated, indicating some degree of renal dysfunction, it is not the highest level. Therefore, while pump failure death is a possible outcome, it is not the most likely prognosis.

RANKING: 3
 REASONING: Sudden cardiac death
The patient's ECG shows non-sustained ventricular tachycardia (NSVT), which is a risk factor for sudden cardiac death. Additionally, the patient's low LVEF of 32% and elevated Pro-BNP level of 842 ng/L indicate severe heart failure and increased risk of arrhythmias. While the patient is being treated with beta blockers, which are known to reduce the risk of sudden cardiac death, the presence of NSVT on the ECG suggests that the patient may be at increased risk for sudden cardiac death. However, the patient's overall medical management and lack of other high-risk factors make sudden cardiac death the least likely prognosis.

It's worth noting that the patient's age, weight, and gender also contribute to their overall risk profile, but the presence of NSVT and the patient's current medical management make sudden cardiac death the least likely prognosis."
665,665,P0079,"Age: 70
Gender: Male 
Weight: 75 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 43,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,6
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 11
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,56
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 517.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,45
Urea (mg/dL): 7,35
LVEF (%): 48.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Third-degree AVB
            ",sudden cardiac death,"Based on the provided patient data, I will generate a prognosis for the next few years. However, I must note that the patient outcome you provided is ""sudden cardiac death,"" which is an event rather than a long-term prognosis. I will instead generate a prognosis for the next few years based on the patient's current health status and medical history.

RANKING: Survivor

REASONING: Despite the patient's advanced age and multiple comorbidities, including ischemic dilated cardiomyopathy, diabetes, and peripheral vascular disease, the patient's current medication regimen and LVEF of 48% suggest that the patient is receiving adequate treatment for their heart failure. The patient's blood pressure is well-controlled, and their kidney function is relatively preserved. Additionally, the patient's troponin level is low, indicating that they are not experiencing ongoing myocardial infarction. While the patient has a history of ventricular extrasystoles and third-degree AV block, these are not uncommon in patients with heart failure and are being managed with medication. Overall, the patient's current health status and treatment plan suggest that they are likely to survive for the next few years with continued medical management.

RANKING: Pump Failure Death

REASONING: While the patient's LVEF of 48% indicates that they have some degree of heart failure, it is not severely impaired. The patient's creatinine level is elevated, but it is not significantly elevated, suggesting that their kidney function is not severely compromised. The patient's blood pressure is well-controlled, and their glucose level is within a relatively normal range. However, the patient's Pro-BNP level is elevated, indicating that they have some degree of heart failure. While the patient's heart failure is likely to progress over time, it is not at a stage where pump failure is the most likely outcome in the next few years.

RANKING: Sudden Cardiac Death

REASONING: While the patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, the patient's current health status and treatment plan suggest that sudden cardiac death is less likely. The patient's LVEF is 48%, which is not severely impaired, and their troponin level is low, indicating that they are not experiencing ongoing myocardial infarction. The patient's ventricular extrasystoles and third-degree AV block are being managed with medication, and their blood pressure is well-controlled. While the patient has a history of ventricular extrasystoles, this is not an uncommon finding in patients with heart failure, and the patient's overall health status suggests that sudden cardiac death is less likely.

It's worth noting that the patient's age and comorbidities make them a high-risk population for cardiac events, and regular follow-up and monitoring will be necessary to adjust the treatment plan as needed."
666,666,P0112,"Age: 51
Gender: Male 
Weight: 76 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 139/83 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 35
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,62
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,12
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 975.0
Protein (g/L): 60
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,56
Urea (mg/dL): 4,49
LVEF (%): 20.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will generate a prognosis for the next few years, considering the patient's medical history, current condition, and test results. Please note that this is a hypothetical prognosis and actual outcomes may vary.

RANKING: 1. Survivor, 2. Sudden cardiac death, 3. Pump failure death

REASONING:

1. Survivor: While the patient has a history of ischemic dilated cardiomyopathy, myocardial infarction, and low LVEF (20%), the patient is currently on optimal medical therapy with beta blockers, statins, and ACE inhibitors. The patient's NYHA Class II indicates that they are still able to perform everyday activities without severe limitations. The low troponin level (<0.01 ng/mL) suggests that there is no ongoing myocardial infarction. The patient's hemoglobin level is within normal limits, which reduces the risk of anemia-related complications. The low TSH level (0.56 mIU/L) suggests that the patient's thyroid function is within normal limits, which is essential for maintaining cardiac function. The patient's weight (76 kg) is slightly above the average for their height (165 cm), but not significantly so, which reduces the risk of obesity-related complications. Given these factors, I consider the patient's likelihood of survival over the next few years to be relatively high.

2. Sudden cardiac death: The patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases their risk of sudden cardiac death. The patient's low LVEF (20%) and high Pro-BNP level (975.0 ng/L) suggest that the patient has a high risk of arrhythmias and cardiac arrest. However, the patient is currently on optimal medical therapy, which reduces the risk of sudden cardiac death. The patient's ECG shows polymorphic ventricular extrasystoles and unknown ventricular tachycardia, which are risk factors for sudden cardiac death. However, the absence of non-sustained ventricular tachycardia and bradycardia reduces the risk of sudden cardiac death. Given these factors, I consider the patient's likelihood of sudden cardiac death to be moderate.

3. Pump failure death: The patient's low LVEF (20%) and high Pro-BNP level (975.0 ng/L) suggest that the patient has a high risk of pump failure. The patient's ischemic dilated cardiomyopathy and myocardial infarction history also increase their risk of pump failure. However, the patient's NYHA Class II indicates that they are still able to perform everyday activities without severe limitations, which suggests that their cardiac function is not severely compromised at this time. Given these factors, I consider the patient's likelihood of pump failure death to be the least likely of the three options.

In conclusion, while the patient has a high risk of sudden cardiac death and pump failure, I consider the patient's likelihood of survival over the next few years to be the highest due to their optimal medical therapy and relatively mild symptoms."
667,667,P0127,"Age: 65
Gender: Male 
Weight: 70 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,77
Creatinine (mmol/L): 80.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 141.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,59
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 553.0
Protein (g/L): 72
T3 (pg/dL): 0,03
T4 (ng/L): 16
Troponin (ng/mL): 0,1
TSH (mIU/L): 1,1
Urea (mg/dL): 7,49
LVEF (%): 14.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient has a low LVEF of 14%, indicating severe systolic heart failure. However, the patient is on optimal medical therapy with digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which suggests that the patient's condition is being managed. The patient's NT-proBNP level is elevated at 553.0 ng/L, which is a marker of heart failure severity, but it's not excessively high. Additionally, the patient's eGFR (estimated glomerular filtration rate) can be estimated from the creatinine level, which is 80.0 mmol/L, suggesting a relatively preserved renal function. Furthermore, the patient's hemoglobin level is within the normal range, which is a good prognostic sign. Considering these factors, the patient has a reasonable chance of survival.

RANKING: 2. Pump failure death
 REASONING: The patient's low LVEF of 14% and the presence of non-sustained ventricular tachycardia suggest that the patient's heart function is severely impaired. However, the patient's condition is being managed with optimal medical therapy, and the patient's renal function is relatively preserved. The patient's NT-proBNP level is elevated, indicating heart failure severity, but it's not excessively high. The patient's hemoglobin level is within the normal range, which is a good prognostic sign. Considering these factors, while pump failure death is a possible outcome, it's not the most likely prognosis.

RANKING: 3. Sudden cardiac death
 REASONING: The patient has a low LVEF of 14%, indicating severe systolic heart failure. The presence of non-sustained ventricular tachycardia is a risk factor for sudden cardiac death. However, the patient is on optimal medical therapy, which reduces the risk of sudden cardiac death. The patient's NT-proBNP level is elevated, but it's not excessively high. The patient's hemoglobin level is within the normal range, which is a good prognostic sign. Considering these factors, sudden cardiac death is the least likely prognosis, as the patient's condition is being managed, and the risk factors for sudden cardiac death are not excessively high."
668,668,P0138,"Age: 68
Gender: Male 
Weight: 67 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 41
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 63
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 126.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,49
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2838.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 26
Troponin (ng/mL): 0,694
TSH (mIU/L): 0,894
Urea (mg/dL): 9,32
LVEF (%): 37.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Torsade de Points
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Survivor
 REASONING: The patient has a complex medical history with valvular cardiomyopathy and a reduced left ventricular ejection fraction (LVEF) of 37%. However, the patient is on appropriate medications for heart failure, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor. The patient's NYHA Class II classification indicates that they have some limitations in physical activity but are still able to perform daily activities without symptoms. The patient's blood pressure is within a relatively normal range, and their potassium level is not significantly elevated, which is a good sign for heart failure management. Additionally, the patient's pro-BNP level is high, but not extremely elevated, which may indicate some degree of heart failure management. Considering the patient's current treatment and relatively stable condition, the most likely outcome is survival.

RANKING: 2. Pump Failure Death
 REASONING: The patient's reduced LVEF of 37% and high pro-BNP level suggest that they have some degree of heart failure. However, the patient's treatment regimen is appropriate for heart failure, and their blood pressure is within a relatively normal range. The patient's creatinine level is slightly elevated, which may indicate some degree of renal impairment, but it is not extremely high. The patient's troponin level is slightly elevated, which may indicate some degree of cardiac stress, but it is not extremely high. Considering the patient's complex medical history and reduced LVEF, pump failure death is a possible outcome, but the patient's current treatment and relatively stable condition make it less likely.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient's ECG shows polymorphic ventricular extrasystole, torsade de points, and non-sustained ventricular tachycardia, which are all risk factors for sudden cardiac death. The patient's low T3 and T4 levels may indicate some degree of thyroid dysfunction, which can also increase the risk of sudden cardiac death. However, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death. Additionally, the patient's potassium level is not significantly elevated, which is a good sign. Considering the patient's complex medical history and ECG findings, sudden cardiac death is the least likely outcome, but still a possible risk."
669,669,P0148,"Age: 73
Gender: Female 
Weight: 68 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 130/85 mmHg
Past Medical History: Valvular cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 36,7
ALT or GPT (IU/L): 54.0
AST or GOT (IU/L): 62.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 77.0
Gamma-glutamil transpeptidase (IU/L): 78
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
Potassium (mEq/L): 4,23
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3527.0
Protein (g/L): 75,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,08
Urea (mg/dL): 8,5
LVEF (%): 20.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden cardiac death, 2. Pump failure death, 3. Survivor

REASONING:

1. Sudden cardiac death: The patient has a high risk of sudden cardiac death due to several factors:
   - Low LVEF (20.0%): This indicates severe left ventricular dysfunction, which increases the risk of sudden cardiac death.
   - Non-sustained ventricular tachycardia (NSVT): The presence of NSVT on the ECG is a well-established risk factor for sudden cardiac death.
   - High Pro-BNP (3527.0 ng/L): Elevated B-type natriuretic peptide levels are associated with increased risk of sudden cardiac death.
   - Age (73): The patient's age is a significant risk factor for sudden cardiac death.
   - Past medical history of myocardial infarction and valvular cardiomyopathy: These conditions increase the risk of sudden cardiac death.

2. Pump failure death: The patient has a high risk of pump failure due to:
   - Low LVEF (20.0%): This indicates severe left ventricular dysfunction, which increases the risk of pump failure.
   - High Pro-BNP (3527.0 ng/L): Elevated B-type natriuretic peptide levels are associated with increased risk of pump failure.
   - NYHA Class III: The patient has symptoms of heart failure, indicating a high risk of pump failure.
   - Creatinine (77.0 mmol/L): Elevated creatinine levels suggest impaired renal function, which can be a consequence of pump failure.

3. Survivor: Although the patient has several risk factors for sudden cardiac death and pump failure, there are a few factors that suggest a potential for survival:
   - Medications: The patient is on a combination of medications, including ACE inhibitors, beta blockers, and diuretics, which can help manage heart failure symptoms and reduce the risk of sudden cardiac death.
   - Low Troponin (0.01 ng/mL): This suggests that the patient has not had a recent myocardial infarction, which may indicate a lower risk of sudden cardiac death.
   - Hemoglobin (149.0 g/L): The patient's hemoglobin levels are within a relatively normal range, which can help maintain adequate oxygen delivery to the tissues.

Please note that this is a complex assessment, and the actual outcome may vary depending on various factors, including the patient's response to treatment, comorbidities, and other health conditions."
670,670,P0157,"Age: 76
Gender: Male 
Weight: 70 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Hypertropic cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 38,9
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,13
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 40
Glucose (mmol/L): 8,6
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,26
Potassium (mEq/L): 4,49
LDL (mmol/L): 3,06
Sodium (mEq/L): 134.0
Protein (g/L): 74,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,36
Urea (mg/dL): 10,3
LVEF (%): 42.0
Medications: Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, here is the prognosis for the next few years:

RANKING: 1. Survivor
REASONING: Despite the patient's advanced age (76 years), history of myocardial infarction, and reduced left ventricular ejection fraction (LVEF) of 42%, the patient's overall clinical presentation and laboratory results suggest a relatively stable condition. The patient is on appropriate medications, including an ACE inhibitor and spironolactone, which are commonly used to manage heart failure and hypertension. The patient's blood pressure is well-controlled, and there is no evidence of significant liver dysfunction or kidney disease, which could potentially worsen the patient's prognosis. Additionally, the troponin level is within normal limits, indicating no recent myocardial infarction. While the patient has a history of hypertrophic cardiomyopathy, this is not typically associated with a poor prognosis in the absence of other complicating factors. Therefore, based on the available data, a survivor prognosis is the most likely outcome.

RANKING: 2. Pump failure death
REASONING: While the patient has a reduced LVEF, which is a risk factor for heart failure, the patient's symptoms (NYHA Class II) suggest that the heart failure is not severe at this time. The patient's medications and overall clinical presentation suggest that the heart failure is being managed effectively, and there is no indication of acute decompensation. However, if the patient's heart failure progresses, pump failure could become a concern. Given the patient's age and underlying cardiovascular disease, this is a possible, but less likely, outcome.

RANKING: 3. Sudden cardiac death
REASONING: The patient has a history of polymorphic ventricular extrasystoles, non-sustained ventricular tachycardia, and paroxysmal supraventricular tachyarrhythmia, which are all risk factors for sudden cardiac death. However, the patient is on a nitrovasodilator, which is a medication commonly used to manage arrhythmias, and there is no indication of acute cardiac instability. While sudden cardiac death is a possible outcome, it is less likely than the other two options given the patient's overall clinical presentation and the fact that the arrhythmias are non-sustained.

Note: It is essential to emphasize that this prognosis is based on the provided data and may not reflect the patient's actual outcome. A comprehensive evaluation by a cardiologist and other healthcare professionals is necessary to determine the patient's individual risk factors and develop an accurate prognosis."
671,671,P0159,"Age: 81
Gender: Male 
Weight: 65 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 100/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Peripheral vascular disease
Albumin (g/L): 38,4
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 165.0
Gamma-glutamil transpeptidase (IU/L): 46
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 131.0
Potassium (mEq/L): 2,92
Sodium (mEq/L): 135.0
Protein (g/L): 70,9
T4 (ng/L): 10,1
Troponin (ng/mL): 0,02
TSH (mIU/L): 15,55
Urea (mg/dL): 15,9
LVEF (%): 22.0
Medications: Amiodarone, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"Based on the provided patient data, I will generate a prognosis for the next few years. Please note that this is a complex task and should be considered as a hypothetical analysis.

RANKING: 1. Sudden cardiac death, 2. Pump failure death, 3. Survivor

REASONING:

1. Sudden cardiac death (Rank 1): The patient's LVEF (Left Ventricular Ejection Fraction) is 22%, indicating severe left ventricular dysfunction. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG suggests a high risk of arrhythmias. Additionally, the patient's NYHA Class III classification indicates severe heart failure symptoms, which may lead to a sudden cardiac death. The patient's low potassium level (2.92 mEq/L) may also contribute to arrhythmia risk. Given the combination of severe left ventricular dysfunction, arrhythmias, and heart failure symptoms, sudden cardiac death is the most likely prognosis.

2. Pump failure death (Rank 2): The patient's LVEF of 22% indicates severe left ventricular dysfunction, which increases the risk of pump failure. The patient's NYHA Class III classification and the use of loop diuretics suggest that the patient is already experiencing symptoms of heart failure. The patient's elevated creatinine level (165.0 mol/L) may indicate renal impairment, which can further exacerbate heart failure. However, the patient's troponin level is within normal limits, which may suggest that the patient is not experiencing acute coronary syndrome, reducing the risk of pump failure. Nevertheless, the patient's overall clinical picture suggests that pump failure is a plausible prognosis.

3. Survivor (Rank 3): While the patient's LVEF is severely reduced, and the patient has a history of idiopathic dilated cardiomyopathy and peripheral vascular disease, the patient's current medication regimen includes amiodarone and loop diuretics, which may help manage symptoms and prevent further deterioration. The patient's troponin level is within normal limits, and the absence of acute coronary syndrome reduces the risk of acute cardiac events. Additionally, the patient's TSH level is slightly elevated (15.55 mIU/L), which may indicate hypothyroidism, which can contribute to heart failure symptoms. However, the patient's overall clinical picture suggests that survival for an extended period is possible with continued medical management.

Please note that this prognosis is based on the provided data and should be considered as a hypothetical analysis. The actual outcome may vary depending on various factors, including the patient's adherence to medication, lifestyle changes, and any future medical interventions."
672,672,P0172,"Age: 69
Gender: Female 
Weight: 74 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 120/85 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,45
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 8,1
Hemoglobin (g/L): 131.0
Potassium (mEq/L): 4,61
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1383.0
Protein (g/L): 70,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,43
Urea (mg/dL): 6,1
LVEF (%): 22.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Hydralazine
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely. 

RANKING: 1. Sudden cardiac death, 2. Pump failure death, 3. Survivor

REASONING: 

1. Sudden cardiac death: The patient's low LVEF (22.0%) and high Pro-BNP level (1383.0 ng/L) indicate severe heart failure and potential for arrhythmias. The presence of polymorphic ventricular extrasystoles on the ECG further increases the risk of sudden cardiac death. Additionally, the patient's NYHA Class II classification suggests that the patient's symptoms are moderate, which may indicate a higher risk of cardiac events. Considering these factors, sudden cardiac death is the most likely prognosis.

2. Pump failure death: The patient's low LVEF, high Pro-BNP level, and NYHA Class II classification suggest that the patient's heart failure is severe and may progress to pump failure. However, the patient is already on optimal medical therapy (Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, and Hydralazine), which may slow the progression of heart failure. Therefore, pump failure death is the second most likely prognosis.

3. Survivor: Given the patient's severe heart failure and high risk of arrhythmias, survivor is the least likely prognosis. However, the patient's age (69) and female gender may be favorable factors, and the patient's current medical therapy may help manage symptoms and slow disease progression. Additionally, the patient's relatively low Troponin level (0.01 ng/mL) and normal hemoglobin level (131.0 g/L) suggest that the patient may not have significant myocardial damage or anemia, which could contribute to a more favorable outcome."
673,673,P0176,"Age: 78
Gender: Male 
Weight: 64 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,1
Creatinine (mmol/L): 186.0
Gamma-glutamil transpeptidase (IU/L): 46
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 3,8
LDL (mmol/L): 1,53
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 4853.0
Protein (g/L): 83
T3 (pg/dL): 0,05
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 7,37
Urea (mg/dL): 24,13
LVEF (%): 36.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Survivor
 REASONING: Given the patient's age (78) and the presence of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac mortality, the prognosis is guarded. However, the patient is currently on optimal medical therapy with beta blockers, loop diuretics, statins, and a nitrovasodilator, which are all standard treatments for heart failure. The LVEF of 36% indicates that the patient has some degree of left ventricular dysfunction, but it is not severely impaired. The patient's low body mass index (BMI) is also a positive factor, as being underweight can be associated with better outcomes in heart failure patients. The absence of significant electrolyte imbalances, such as hypokalemia, which is a risk factor for arrhythmias, is also a positive sign. While the patient has a history of myocardial infarction and hypertension, these are not uncommon in patients with ischemic dilated cardiomyopathy. Considering these factors, a survivor prognosis is more likely than the other two options.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on ECG, which are both risk factors for sudden cardiac death (SCD). The elevated Pro-BNP level (4853.0 ng/L) suggests that the patient has significant cardiac stress, which can also increase the risk of SCD. However, the patient is on optimal medical therapy, and the presence of a nitrovasodilator, which can help prevent arrhythmias, is a mitigating factor. Additionally, the patient's low TSH level (7.37 mIU/L) suggests that the thyroid function is not contributing to cardiac dysfunction. While the patient's LVEF is low (36%), it is not extremely low, which may reduce the risk of SCD. Considering these factors, SCD is a possible but less likely outcome compared to the survivor prognosis.

RANKING: 3. Pump Failure Death
 REASONING: Pump failure death is the least likely outcome for this patient. The patient's LVEF of 36% indicates some degree of left ventricular dysfunction, but it is not severely impaired. The patient is on optimal medical therapy, including loop diuretics, which are used to manage fluid overload and reduce the workload on the heart. The patient's low body mass index (BMI) is also a positive factor, as being underweight can be associated with better outcomes in heart failure patients. Additionally, the patient's blood pressure is within a relatively normal range, which is a good sign. While the patient has a history of hypertension and myocardial infarction, these are not uncommon in patients with ischemic dilated cardiomyopathy, and the patient is on optimal medical therapy to manage these conditions. Considering these factors, pump failure death is the least likely outcome for this patient."
674,674,P0183,"Age: 45
Gender: Male 
Weight: 120 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 206
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,4
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 2037.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 27
TSH (mIU/L): 2,87
Urea (mg/dL): 8,65
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Survivor

REASONING: Although the patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for cardiac mortality, the patient's current medications, including beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, are generally beneficial for patients with heart failure and may help improve the patient's prognosis. The patient's LVEF of 30% indicates severe left ventricular dysfunction, but it is not the lowest value, and some patients with LVEF in this range can still survive with appropriate management. Additionally, the patient's NYHA Class II suggests that the patient is not severely symptomatic, which is a positive sign. The patient's blood pressure is within a relatively normal range, and the absence of sustained ventricular tachycardia or other life-threatening arrhythmias on the ECG is also a positive finding. While the patient's elevated Pro-BNP level indicates elevated filling pressures, it is not extremely high, and the patient's renal function is relatively preserved. Overall, these factors suggest that the patient may be at a relatively lower risk of sudden cardiac death or pump failure death compared to other possible prognoses.

RANKING: Pump Failure Death

REASONING: The patient's LVEF of 30% indicates severe left ventricular dysfunction, which is a significant risk factor for pump failure death. The patient's history of ischemic dilated cardiomyopathy and hypertension also increases the risk of pump failure. The patient's elevated creatinine level (97.0 mmol/L) suggests impaired renal function, which can be a consequence of heart failure. The patient's elevated Pro-BNP level and low albumin level also suggest elevated filling pressures and possible cardiac dysfunction. However, the patient's medications, including loop diuretics and spironolactone, may help reduce fluid overload and improve cardiac function, which may mitigate the risk of pump failure death. Additionally, the patient's NYHA Class II suggests that the patient is not severely symptomatic, which may indicate a slower progression of heart failure.

RANKING: Sudden Cardiac Death

REASONING: The patient's history of ischemic dilated cardiomyopathy, LVEF of 30%, and elevated Pro-BNP level increase the risk of sudden cardiac death. The presence of ventricular extrasystoles on the ECG is also a risk factor for sudden cardiac death. However, the patient's medications, including beta blockers, which are known to reduce the risk of sudden cardiac death, may mitigate this risk. The patient's relatively normal blood pressure and the absence of sustained ventricular tachycardia or other life-threatening arrhythmias on the ECG are also positive findings. Overall, while the patient's risk factors for sudden cardiac death are present, the patient's medications and relatively stable clinical status may reduce the likelihood of this outcome compared to the other two possibilities."
675,675,P0187,"Age: 72
Gender: Male 
Weight: 82 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,52
Creatinine (mmol/L): 146.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 150.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,54
LDL (mmol/L): 1,89
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 3362.0
Protein (g/L): 84,7
T4 (ng/L): 17
Troponin (ng/mL): 0,09
TSH (mIU/L): 18,16
Urea (mg/dL): 15,6
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"Based on the provided patient data, here are the rankings of the possible prognoses from most likely to least likely:

RANKING: 1. Pump Failure Death
REASONING: The patient has a history of ischemic dilated cardiomyopathy with a low left ventricular ejection fraction (LVEF) of 22.0%. This indicates a significant impairment of the heart's pumping function. Additionally, the patient has a high B-type natriuretic peptide (BNP) level of 3362.0 ng/L, which is a marker of heart failure. The patient's creatinine level is also elevated at 146.0 mmol/L, suggesting renal impairment, which is often associated with heart failure. Furthermore, the patient is on medications such as loop diuretics and spironolactone, which are commonly used to treat heart failure. Considering these factors, pump failure death is the most likely prognosis.

RANKING: 2. Survivor
REASONING: Despite the patient's history of ischemic dilated cardiomyopathy and low LVEF, the patient is on optimal medical therapy for heart failure, including ACE inhibitors, beta-blockers, and spironolactone. The patient's blood pressure is well-controlled, and the troponin level is within normal limits, indicating no recent myocardial infarction. The patient's hemoglobin level is also within normal limits, which suggests that the heart is not producing enough blood to meet the body's needs, but the patient is not anemic. However, the patient's prognosis is still uncertain due to the low LVEF and the presence of non-sustained ventricular tachycardia.

RANKING: 3. Sudden Cardiac Death
REASONING: While the patient has a history of ischemic dilated cardiomyopathy and non-sustained ventricular tachycardia, the patient's LVEF is low, but not extremely low (22.0%). The patient is on optimal medical therapy for heart failure, and the troponin level is within normal limits. The patient's risk of sudden cardiac death is lower due to the presence of beta-blockers, which are known to reduce the risk of sudden cardiac death in patients with heart failure. Additionally, the patient's potassium level is within normal limits, which is a good prognostic sign. Therefore, sudden cardiac death is the least likely prognosis."
676,676,P0215,"Age: 82
Gender: Male 
Weight: 82 kg
Height: 166 cm
NYHA Class: III
Blood Pressure: 170/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 7,45
Creatinine (mmol/L): 114.0
Gamma-glutamil transpeptidase (IU/L): 58
Glucose (mmol/L): 12,2
Hemoglobin (g/L): 153.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,43
LDL (mmol/L): 2,4
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 410.0
Protein (g/L): 80
T3 (pg/dL): 0,06
T4 (ng/L): 17,46
Troponin (ng/mL): 1
TSH (mIU/L): 1,18
Urea (mg/dL): 10
LVEF (%): 65.0
Medications: Calcium Channel Blocker, Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, here's my prognosis for the next few years:

RANKING: 1. Sudden Cardiac Death
REASONING: The patient is 82 years old with a history of hypertensive cardiomyopathy, diabetes, dyslipemia, and peripheral vascular disease, which are all significant risk factors for cardiac complications. The patient's NYHA Class III indicates that he has severe symptoms of heart failure, and his LVEF of 65% suggests that he has some degree of left ventricular dysfunction. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG further increases his risk of arrhythmias and sudden cardiac death. Additionally, the elevated Pro-BNP level of 410 ng/L indicates that the patient has significant heart failure and is at higher risk for adverse outcomes.

RANKING: 2. Pump Failure Death
REASONING: While the patient's LVEF of 65% is within the normal range, his NYHA Class III and elevated Pro-BNP level suggest that he has significant heart failure symptoms and is at risk for pump failure. The patient's history of hypertensive cardiomyopathy and diabetes also increases his risk for progressive heart failure. However, his current LVEF is still within the normal range, and he is being treated with medications such as digoxin and spironolactone, which may help to slow the progression of heart failure.

RANKING: 3. Survivor
REASONING: While the patient has several risk factors for cardiac complications, his current LVEF is within the normal range, and he is being treated with a comprehensive regimen of medications, including loop diuretics, calcium channel blockers, and nitrovasodilators. His TSH level is within the normal range, which suggests that his thyroid function is well-controlled, and his T3 and T4 levels are also within normal limits. Additionally, his hemoglobin level is elevated, which may indicate that his anemia is well-managed. While the patient is at risk for cardiac complications, his current treatment regimen and relatively preserved LVEF suggest that he may be able to survive for several years with proper management.

Note: The patient's actual outcome was sudden cardiac death, which is consistent with the first-ranked prognosis."
677,677,P0217,"Age: 79
Gender: Male 
Weight: 94 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,79
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 10,95
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,3
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,58
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 1825.0
Protein (g/L): 77
T3 (pg/dL): 0,0372
T4 (ng/L): 18,5
TSH (mIU/L): 3,2
Urea (mg/dL): 14,6
LVEF (%): 30.0
Medications: Diabetes Medication, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"Based on the provided patient data, here are the prognoses for the next few years, ordered from most likely to least likely:

RANKING: 1. Pump Failure Death
REASONING: The patient has a history of ischemic dilated cardiomyopathy with a left ventricular ejection fraction (LVEF) of 30%, which indicates severe systolic heart failure. The patient's NT-proBNP level of 1825 ng/L is also elevated, which is a marker of heart failure and increased risk of cardiovascular events. The patient's weight of 94 kg and height of 167 cm result in a body mass index (BMI) of approximately 31.8, which is classified as obese. Obesity is a known risk factor for heart failure and cardiovascular disease. Additionally, the patient's past medical history includes hypertension, diabetes, and peripheral vascular disease, all of which can contribute to the progression of heart failure. Given these factors, pump failure death is the most likely prognosis.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient has a history of ischemic dilated cardiomyopathy and a low LVEF, which increases the risk of sudden cardiac death. The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are arrhythmias that can be a precursor to sudden cardiac death. However, the patient's NT-proBNP level and LVEF suggest that the patient's heart failure is more likely to progress to pump failure death rather than sudden cardiac death.

RANKING: 3. Survivor
REASONING: While the patient has a history of heart failure and other cardiovascular risk factors, the patient is currently receiving treatment with an ACE inhibitor and spironolactone, which are medications that can help manage heart failure. The patient's NYHA class II indicates that the patient's symptoms are not severe, and the patient is still able to perform daily activities without significant limitation. However, the patient's LVEF of 30% and elevated NT-proBNP level suggest that the patient's heart failure is not well-controlled, and the patient is at risk for progression to pump failure death or sudden cardiac death. Given the patient's overall clinical picture, survivor is the least likely prognosis."
678,678,P0218,"Age: 68
Gender: Male 
Weight: 80 kg
Height: 171 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,15
Creatinine (mmol/L): 136.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 5,06
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1
Potassium (mEq/L): 4,17
LDL (mmol/L): 2,49
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 4058.0
Protein (g/L): 68
T3 (pg/dL): 0,0471
T4 (ng/L): 16,72
Troponin (ng/mL): 0,2
TSH (mIU/L): 2,17
Urea (mg/dL): 6,4
LVEF (%): 20.0
Medications: ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will rank the prognoses from most likely to least likely. 

RANKING: 1. Pump failure death
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers dilate, leading to a decrease in the heart's ability to pump blood effectively. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 20%, indicating a significant impairment of the heart's pumping function. The elevated Pro-BNP level of 4058 ng/L is also a strong indicator of heart failure. Additionally, the patient's creatinine level of 136.0 mmol/L suggests impaired kidney function, which is often seen in advanced heart failure. Given these factors, pump failure death is the most likely prognosis.

RANKING: 2. Sudden cardiac death
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The presence of polymorphic ventricular extrasystoles on the ECG is also a concerning sign, as it can be a marker of increased risk of sudden cardiac death. However, the absence of non-sustained ventricular tachycardia and the patient's current NYHA class of II suggest that the patient is not in an acute decompensated state. While sudden cardiac death is a possible outcome, it is less likely than pump failure death due to the patient's current functional status and the presence of heart failure symptoms.

RANKING: 3. Survivor
 REASONING: The patient's current functional status, as indicated by the NYHA class of II, suggests that the patient is experiencing symptoms of heart failure but is still able to perform daily activities. The patient is also on an ACE inhibitor, which is a common medication for heart failure management. While the patient's prognosis is poor, it is still possible that with optimal medical management and lifestyle modifications, the patient could survive for several years. However, this outcome is the least likely due to the patient's severe heart failure and impaired kidney function."
679,679,P0221,"Age: 64
Gender: Male 
Weight: 80 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 100/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39,7
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,13
Creatinine (mmol/L): 200.0
Gamma-glutamil transpeptidase (IU/L): 47
Glucose (mmol/L): 10,67
Hemoglobin (g/L): 146.0
HDL (mmol/L): 0,9
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,33
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 2365.0
Protein (g/L): 75
T3 (pg/dL): 0,0312
T4 (ng/L): 15,14
Troponin (ng/mL): 0,5
TSH (mIU/L): 0,77
Urea (mg/dL): 29,3
LVEF (%): 40.0
Medications: Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Sudden cardiac death

REASONING: The patient has a high risk of sudden cardiac death due to the following factors:

1.  Ischemic dilated cardiomyopathy with an LVEF of 40%: This indicates a reduced left ventricular function, which increases the risk of sudden cardiac death.
2.  Non-sustained ventricular tachycardia (NSVT): The presence of NSVT on the ECG is a known predictor of sudden cardiac death in patients with heart failure and reduced ejection fraction.
3.  High Pro-BNP levels (2365.0 ng/L): Elevated Pro-BNP levels are associated with increased mortality and sudden cardiac death in patients with heart failure.
4.  Low HDL cholesterol (0.9 mmol/L): Low HDL levels are associated with an increased risk of cardiovascular events, including sudden cardiac death.
5.  Diabetes and dyslipidemia: Both conditions are known risk factors for cardiovascular disease and sudden cardiac death.

While the patient is on appropriate medications for heart failure and has a low TSH level, which suggests that thyroid function is normal, the combination of these factors makes sudden cardiac death a more likely prognosis.

RANKING: Pump failure death

REASONING: The patient's reduced LVEF (40%) and high Pro-BNP levels (2365.0 ng/L) indicate a high risk of pump failure death. Additionally, the patient's NYHA Class III classification suggests that the patient has symptoms of heart failure, which increases the risk of pump failure death.

RANKING: Survivor

REASONING: While the patient has several risk factors for sudden cardiac death and pump failure death, the patient is on appropriate medications for heart failure, and the TSH level is normal, which suggests that thyroid function is not contributing to the patient's condition. However, the patient's reduced LVEF and high Pro-BNP levels, combined with the presence of NSVT and low HDL cholesterol, make sudden cardiac death and pump failure death more likely than survival."
680,680,P0243,"Age: 35
Gender: Male 
Weight: 92 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,26
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4
LDL (mmol/L): 1,97
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 10297.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 15
TSH (mIU/L): 2,54
Urea (mg/dL): 6,32
LVEF (%): 40.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: 1. Survivor
 REASONING: Despite the patient's history of idiopathic dilated cardiomyopathy and low LVEF of 40%, the patient is currently being treated with a comprehensive medication regimen that includes beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor. These medications are aimed at managing symptoms, improving heart function, and reducing the risk of sudden cardiac death. The patient's NYHA Class II classification indicates that they are experiencing some limitations in physical activity but are still able to perform everyday tasks. The absence of severe electrolyte imbalances, such as low sodium or potassium levels, and relatively normal liver and kidney function tests (ALT, AST, Creatinine) suggest that the patient's overall metabolic and renal function is relatively preserved. Additionally, the patient's TSH level is within the normal range, indicating that their thyroid function is normal. Considering these factors, the patient's overall clinical picture suggests a relatively stable condition, and with proper management, the likelihood of survival is higher.

RANKING: 2. Pump Failure Death
 REASONING: While the patient's LVEF of 40% is below the normal range, indicating reduced left ventricular function, the patient is still alive and receiving treatment. The patient's symptoms and functional capacity are being managed with medication, and there are no clear signs of severe heart failure or end-organ dysfunction. However, the patient's LVEF is not significantly improving, and the risk of progression to pump failure death cannot be ruled out. The presence of non-sustained ventricular tachycardia and ventricular extrasystole on the ECG suggests that the patient's heart is at risk of arrhythmias, which could potentially lead to cardiac arrest and pump failure. However, with continued treatment and monitoring, the likelihood of pump failure death can be mitigated.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient's high Pro-BNP level of 10297 ng/L and the presence of non-sustained ventricular tachycardia and ventricular extrasystole on the ECG suggest an increased risk of sudden cardiac death. The patient's low LVEF and history of idiopathic dilated cardiomyopathy further increase this risk. However, the patient is currently receiving treatment with beta blockers, which are known to reduce the risk of sudden cardiac death. The presence of digoxin and spironolactone also suggests that the patient is being treated for heart failure and electrolyte imbalances, which can contribute to sudden cardiac death. Considering these factors, while the patient is at risk, the likelihood of sudden cardiac death is lower than pump failure death due to the comprehensive treatment regimen in place."
681,681,P0261,"Age: 40
Gender: Male 
Weight: 82 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 37,6
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 236
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,95
Potassium (mEq/L): 3,32
LDL (mmol/L): 3,02
Sodium (mEq/L): 131.0
Pro-BNP (ng/L): 2598.0
Protein (g/L): 73,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,39
Urea (mg/dL): 1,8
LVEF (%): 19.0
Medications: Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden Cardiac Death
 REASONING: The patient has a history of myocardial infarction, which is a significant risk factor for sudden cardiac death. The patient's low left ventricular ejection fraction (LVEF) of 19% indicates severe systolic dysfunction, which increases the risk of arrhythmias and sudden cardiac death. The presence of polymorphic ventricular extrasystoles and a high level of Pro-BNP (2598 ng/L) further support this prognosis. Additionally, the patient's NYHA Class II classification suggests that the patient has moderate symptoms, which may indicate that the heart is under significant stress, increasing the risk of sudden cardiac death.

RANKING: 2. Pump Failure Death
 REASONING: The patient's low LVEF of 19% and history of myocardial infarction indicate severe systolic dysfunction, which increases the risk of pump failure. The patient's elevated Pro-BNP level and low albumin level (37.6 g/L) suggest fluid overload, which is a common cause of pump failure. The patient's medications, including loop diuretics and spironolactone, are used to manage fluid overload, but the patient's symptoms and lab values suggest that the patient may not be adequately controlled.

RANKING: 3. Survivor
 REASONING: While the patient's prognosis is poor, there are some factors that suggest a possible survival outcome. The patient's low LVEF of 19% is a significant risk factor, but the patient's age (40) and lack of other comorbidities (e.g., diabetes, chronic kidney disease) may indicate that the patient is relatively young and may have a better prognosis than expected. Additionally, the patient's medications and NYHA Class II classification suggest that the patient is receiving appropriate treatment and is experiencing moderate symptoms, which may indicate that the patient is not yet at the end-stage of heart failure. However, the patient's high Pro-BNP level and low albumin level suggest that the patient is at risk for pump failure, and the patient's history of myocardial infarction and polymorphic ventricular extrasystoles increase the risk of sudden cardiac death."
682,682,P0262,"Age: 58
Gender: Female 
Weight: 61 kg
Height: 145 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Valvular cardiomyopathy, Myocardial Infarction
Albumin (g/L): 38,2
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 50.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 110.0
Gamma-glutamil transpeptidase (IU/L): 330
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 121.0
HDL (mmol/L): 0,92
Potassium (mEq/L): 4,12
LDL (mmol/L): 2,72
Sodium (mEq/L): 142.0
Protein (g/L): 73,6
T4 (ng/L): 15,3
Troponin (ng/mL): 0,01
TSH (mIU/L): 8,26
Urea (mg/dL): 10
LVEF (%): 25.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely. Please note that this is a complex analysis and should be considered in the context of the patient's overall clinical presentation and medical history.

RANKING: 1. Sudden Cardiac Death (SCD)
 REASONING: The patient has a history of myocardial infarction, valvular cardiomyopathy, and reduced left ventricular ejection fraction (LVEF) of 25%. This indicates significant cardiac dysfunction. The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG further increases the risk of arrhythmic events. The patient is also on amiodarone, a medication commonly used to prevent arrhythmias, but its effectiveness is uncertain given the patient's complex ECG findings. The patient's NYHA Class III classification indicates severe symptoms, and the patient is likely experiencing significant functional impairment. Considering these factors, the risk of SCD is high.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF of 25% is a strong indicator of severe left ventricular dysfunction. The patient's creatinine level of 110.0 mol/L suggests impaired renal function, which can be a consequence of reduced cardiac output. The patient's NYHA Class III classification and symptoms likely indicate significant heart failure symptoms, which can lead to pump failure. However, the patient's blood pressure is within a relatively normal range, which may indicate some preserved cardiac function. Additionally, the patient is on medications that can help manage heart failure symptoms and slow disease progression. While pump failure is a possible outcome, it may be less likely than SCD given the patient's arrhythmic findings.

RANKING: 3. Survivor
 REASONING: Given the patient's complex cardiac history, reduced LVEF, and arrhythmic findings, the likelihood of a favorable outcome (survivor) is low. However, with optimal medical management, close monitoring, and adherence to treatment, it is possible that the patient may survive for a period of time. The patient's relatively normal blood pressure, lack of severe anemia (Hemoglobin 121.0 g/L), and stable kidney function (creatinine 110.0 mol/L) suggest some degree of cardiac reserve. Additionally, the patient is on a comprehensive medication regimen that includes ACE inhibitors, beta-blockers, and spironolactone, which can help manage heart failure and reduce the risk of arrhythmias. However, the patient's prognosis remains guarded, and the likelihood of a favorable outcome is lower than the other two possibilities."
683,683,P0266,"Age: 68
Gender: Female 
Weight: 74 kg
Height: 136 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Hypertropic cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39,8
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 5,21
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 62
Glucose (mmol/L): 4,1
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,18
Potassium (mEq/L): 4,15
LDL (mmol/L): 3,4
Sodium (mEq/L): 133.0
Protein (g/L): 76,7
Troponin (ng/mL): 0,02
TSH (mIU/L): 4
Urea (mg/dL): 10,7
LVEF (%): 70.0
Medications: Amiodarone, Loop Diuretics, Spironolactone, Statins, Hydralazine, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"Based on the provided patient data, here are the three possible prognoses with my reasoning:

RANKING: 1. Survivor
 REASONING: Despite the patient's advanced age (68 years), NYHA Class III, and history of hypertrophic cardiomyopathy, myocardial infarction, and dyslipemia, the patient's left ventricular ejection fraction (LVEF) is relatively preserved at 70%. The absence of sustained ventricular tachycardia and the low troponin level (0.02 ng/mL) suggest that the patient's heart is not experiencing significant ischemic damage at this time. The patient is also on a comprehensive medication regimen, including beta-blockers (Hydralazine), ACE inhibitors, and statins, which are likely helping to manage the patient's symptoms and slow disease progression. Additionally, the patient's creatinine level is elevated, but not severely, suggesting that the patient's renal function is still relatively preserved. While the patient's prognosis is guarded, the available data suggests that survival is the most likely outcome.

RANKING: 2. Pump failure death
 REASONING: The patient's NYHA Class III classification indicates that the patient experiences symptoms of heart failure, including shortness of breath and fatigue, on exertion. The patient's creatinine level is slightly elevated, which may indicate some degree of renal dysfunction, potentially secondary to heart failure. The patient's LVEF is 70%, which is still within the normal range, but may be declining. The patient's medications, including loop diuretics and spironolactone, are aimed at managing heart failure symptoms and slowing disease progression. However, the patient's history of hypertrophic cardiomyopathy and myocardial infarction increases the risk of pump failure. The patient's prognosis for pump failure death is less likely than sudden cardiac death, as the patient's LVEF is still relatively preserved and the patient is on appropriate medications.

RANKING: 3. Sudden cardiac death
 REASONING: The patient's history of hypertrophic cardiomyopathy, myocardial infarction, and polymorphic ventricular extrasystoles on ECG increases the risk of sudden cardiac death. The patient's LVEF is 70%, which is relatively preserved, but the presence of ventricular extrasystoles suggests that the patient's heart may be experiencing abnormal electrical activity. The patient's medications, including amiodarone, are aimed at preventing sudden cardiac death, but the patient's history and ECG findings suggest that this outcome is still possible. However, the patient's overall clinical picture is complex, and the risk of sudden cardiac death is not as high as the risk of pump failure death, given the patient's relatively preserved LVEF and comprehensive medication regimen."
684,684,P0271,"Age: 77
Gender: Male 
Weight: 70 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 167.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 6
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,9
LDL (mmol/L): 3,13
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 962.0
Protein (g/L): 74,6
T3 (pg/dL): 0,045
T4 (ng/L): 17,49
Troponin (ng/mL): 0,4
TSH (mIU/L): 1,76
Urea (mg/dL): 17,7
LVEF (%): 35.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",sudden cardiac death,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 2 
 REASONING: The patient has a high risk of sudden cardiac death due to his ischemic dilated cardiomyopathy with a low left ventricular ejection fraction (LVEF) of 35%. The patient's history of myocardial infarction and peripheral vascular disease also contributes to this risk. Additionally, the patient's elevated pro-BNP levels (962.0 ng/L) indicate increased ventricular stress and potential cardiac remodeling. However, the patient's NYHA Class II suggests that the patient is still relatively asymptomatic, which slightly reduces the likelihood of sudden cardiac death.

RANKING: 3 
 REASONING: Pump failure death is less likely in this patient due to his relatively well-managed symptoms (NYHA Class II) and the presence of medications such as loop diuretics and ACE inhibitors, which help to manage fluid overload and cardiac function. The patient's creatinine levels are elevated, but not to a degree that suggests end-stage renal disease. The patient's overall clinical picture does not suggest an imminent risk of pump failure.

RANKING: 1 
 REASONING: Survivor is the most likely prognosis for this patient. The patient's symptoms are well-managed, and he is on a comprehensive treatment regimen that includes statins, ACE inhibitors, and loop diuretics. His LVEF is low, but not extremely low, and he does not have any signs of acute decompensation. The patient's low T3 and T4 levels may indicate some degree of cardiac cachexia, but this is not uncommon in patients with heart failure. Overall, while the patient has significant comorbidities, his clinical picture suggests that he can be managed and survive for the next few years with appropriate medical treatment and follow-up."
685,685,P0280,"Age: 70
Gender: Female 
Weight: 63 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 160/60 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,87
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 28
Glucose (mmol/L): 19,1
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,66
Potassium (mEq/L): 4,91
LDL (mmol/L): 3,18
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 327.0
Protein (g/L): 73,6
T3 (pg/dL): 0,0504
T4 (ng/L): 18,13
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,21
Urea (mg/dL): 12
LVEF (%): 66.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"I cannot provide a prognosis for the patient's outcome. If you would like to rephrase the request to focus on the patient's heart condition, I can help with that."
686,686,P0289,"Age: 61
Gender: Male 
Weight: 84 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 58.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 4,28
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 4,59
Hemoglobin (g/L): 147.0
HDL (mmol/L): 1,2
Potassium (mEq/L): 3,7
LDL (mmol/L): 2,7
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 642.0
Protein (g/L): 72
T3 (pg/dL): 0,0573
T4 (ng/L): 14,27
Troponin (ng/mL): 0,5
TSH (mIU/L): 2,99
Urea (mg/dL): 5,4
LVEF (%): 40.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will generate a prognosis for the next few years. However, I must note that the patient outcome you provided is ""sudden cardiac death,"" which is a specific event rather than a long-term prognosis. I will interpret this as a potential risk factor and generate a ranking of the three possible prognoses based on the patient's data.

RANKING: 1. Survivor
 REASONING: Despite the patient's history of ischemic dilated cardiomyopathy and myocardial infarction, the patient is currently being treated with a comprehensive regimen of beta blockers, loop diuretics, ACE inhibitors, and nitrovasodilators. The patient's LVEF is 40%, which is relatively low but not critically low. The absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia on the ECG is a positive sign. The patient's creatinine level is elevated, but not to a level that would suggest end-stage renal disease. The patient's TSH is within the normal range, indicating that thyroid dysfunction is not contributing to the patient's cardiac condition. The patient's albumin level is low, which may indicate malnutrition or liver disease, but the AST and ALT levels are only mildly elevated. Overall, while the patient has a significant cardiac history, the current treatment regimen and the absence of acute complications make survivorship the most likely prognosis.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF of 40% indicates a moderate level of heart failure, and the patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases the risk of pump failure. The patient's elevated creatinine level and low albumin level may indicate renal dysfunction and malnutrition, which can contribute to worsening cardiac function. However, the patient's current treatment regimen and the absence of acute complications make pump failure death less likely than sudden cardiac death in the short term.

RANKING: 3. Sudden Cardiac Death
 REASONING: Sudden cardiac death is a specific event that is often associated with a sudden arrhythmia or acute cardiac event. While the patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, the absence of sustained ventricular tachycardia and paroxysmal supraventricular tachyarrhythmia on the ECG, along with the patient's current treatment regimen, makes sudden cardiac death less likely than the other two prognoses. However, the patient's low LVEF and elevated Pro-BNP level may indicate a higher risk of arrhythmias, and the patient's history of myocardial infarction increases the risk of sudden cardiac death."
687,687,P0322,"Age: 67
Gender: Male 
Weight: 73 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 85/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,5
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 79
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,8
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3736.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,04
Urea (mg/dL): 6,01
LVEF (%): 25.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1. Survivor, 2. Pump failure death, 3. Sudden cardiac death

REASONING: 

1. Survivor: Although the patient has a history of ischemic dilated cardiomyopathy and a low LVEF of 25%, the patient is on appropriate medications (Digoxin, Loop Diuretics, Statins, ACE Inhibitor) and has been stabilized. The patient's NYHA Class III indicates some limitations in physical activity, but it does not indicate an immediate need for hospitalization or aggressive intervention. The patient's creatinine level is elevated, but it is not severely elevated (102.0 mmol/L), and the patient is not showing signs of acute kidney injury. The patient's Pro-BNP level is elevated (3736.0 ng/L), but it is not extremely high, which might indicate some degree of heart failure control. The patient's T3 and T4 levels are within the normal range, which might indicate that the patient is not experiencing significant thyroid dysfunction. Considering these factors, the patient has a relatively stable condition, and with proper management, the patient might survive for several years.

2. Pump failure death: The patient's LVEF of 25% and NYHA Class III indicate severe heart failure. The patient's creatinine level of 102.0 mmol/L suggests some degree of kidney dysfunction, which is a common complication of heart failure. The patient's Pro-BNP level of 3736.0 ng/L is elevated, indicating some degree of heart failure. However, the patient's condition is not acute, and the patient is on appropriate medications for heart failure. With proper management and monitoring, the patient might survive for several years, but the risk of pump failure death is higher than sudden cardiac death due to the patient's severe heart failure and kidney dysfunction.

3. Sudden cardiac death: The patient has a history of myocardial infarction, ischemic dilated cardiomyopathy, and a low LVEF of 25%. The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are both risk factors for sudden cardiac death. The patient's Pro-BNP level of 3736.0 ng/L is elevated, which might indicate some degree of heart failure. The patient's TSH level is slightly elevated (5.04 mIU/L), which might indicate some degree of thyroid dysfunction, which can increase the risk of arrhythmias. Considering these factors, the patient has a higher risk of sudden cardiac death due to the presence of risk factors for arrhythmias and heart failure.

In conclusion, while all three outcomes are possible, the patient's current condition and medical history suggest that pump failure death is the most likely outcome, followed by sudden cardiac death, and then survival."
688,688,P0327,"Age: 76
Gender: Male 
Weight: 74 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 140/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 50,19
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,93
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 9,2
Hemoglobin (g/L): 120.0
HDL (mmol/L): 0,65
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,25
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 3065.0
Protein (g/L): 78
T3 (pg/dL): 0,02
T4 (ng/L): 21
Troponin (ng/mL): 0,05
TSH (mIU/L): 10,5
Urea (mg/dL): 8,69
LVEF (%): 36.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: 1
 REASONING: Based on the provided patient data, I would rank the prognosis as sudden cardiac death as the most likely outcome. The patient has a history of ischemic dilated cardiomyopathy with a left ventricular ejection fraction (LVEF) of 36%, indicating significant left ventricular dysfunction. The elevated Pro-BNP level (3065 ng/L) further supports the presence of heart failure. The patient's age (76 years) and male gender also increase the risk of sudden cardiac death. Additionally, the presence of diabetes, dyslipemia, peripheral vascular disease, and hypertension are all contributing factors to the patient's cardiovascular risk profile. The patient's medications, including amiodarone, beta blockers, and ACE inhibitors, are commonly used to manage heart failure and reduce the risk of sudden cardiac death, but the patient's high LVEF and elevated Pro-BNP level suggest that these medications may not be fully effective in this case.

RANKING: 2
 REASONING: Based on the patient's data, I would rank pump failure death as the second most likely outcome. The patient's LVEF of 36% and elevated Pro-BNP level indicate significant left ventricular dysfunction, which is a hallmark of heart failure. The patient's history of ischemic dilated cardiomyopathy and the presence of diabetes, dyslipemia, and hypertension also contribute to the risk of pump failure. The patient's weight (74 kg) and body mass index (BMI) are not provided, but a BMI > 25 is often associated with an increased risk of heart failure. The patient's medications, including loop diuretics and spironolactone, are commonly used to manage heart failure, but the patient's high LVEF and elevated Pro-BNP level suggest that these medications may not be fully effective in this case.

RANKING: 3
 REASONING: Based on the patient's data, I would rank survivor as the least likely outcome. While the patient is currently receiving medications to manage their heart failure and other cardiovascular conditions, the patient's high LVEF and elevated Pro-BNP level suggest that these medications may not be fully effective in this case. The patient's age (76 years) and male gender also increase the risk of mortality. Additionally, the patient's history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, and hypertension contribute to the risk of cardiovascular events. While it is possible that the patient could survive for an extended period with ongoing medical management, the data suggests that sudden cardiac death or pump failure death are more likely outcomes."
689,689,P0330,"Age: 82
Gender: Male 
Weight: 60 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 47,69
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,12
Creatinine (mmol/L): 127.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,26
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1414.0
Protein (g/L): 77
T3 (pg/dL): 0,04
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,96
Urea (mg/dL): 10,24
LVEF (%): 24.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will rank the possible prognoses for the next few years. 

RANKING: 1. Sudden Cardiac Death
 REASONING: The patient's low left ventricular ejection fraction (LVEF) of 24% indicates severe systolic heart failure, which is a significant risk factor for sudden cardiac death. Additionally, the elevated Pro-BNP level (1414.0 ng/L) suggests severe heart failure symptoms and increased risk of sudden cardiac death. The patient's history of ischemic dilated cardiomyopathy and myocardial infarction also increases the risk of sudden cardiac death. Furthermore, the patient's age (82) and NYHA Class II classification indicate that the patient has significant cardiac disease and may be at higher risk for sudden cardiac death.

RANKING: 2. Pump Failure Death
 REASONING: The patient's severe heart failure symptoms, indicated by the low LVEF and elevated Pro-BNP level, make pump failure death a likely outcome. However, the patient's current medications (Beta Blockers, Loop Diuretics, ACE Inhibitor, and Nitrovasodilator) are standard treatments for heart failure and may help manage symptoms and slow disease progression. The patient's relatively low weight (60 kg) may also be a protective factor against pump failure death, as excess weight can increase the workload on the heart.

RANKING: 3. Survivor
 REASONING: While the patient's current medical condition is severe, the patient's low weight, relatively low blood pressure, and current medications may help manage symptoms and slow disease progression. The patient's age (82) and NYHA Class II classification indicate that the patient has significant cardiac disease, but the patient's overall condition is not as severe as the other two possible outcomes. However, the patient's low LVEF and elevated Pro-BNP level suggest that the patient's heart failure symptoms are not well-controlled, which may limit the patient's ability to survive in the long term."
690,690,P0332,"Age: 63
Gender: Male 
Weight: 80 kg
Height: 178 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 41,4
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 184.0
Gamma-glutamil transpeptidase (IU/L): 54
Glucose (mmol/L): 9,5
Hemoglobin (g/L): 113.0
HDL (mmol/L): 0,8
Potassium (mEq/L): 5,1
LDL (mmol/L): 2,82
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 7692.0
Protein (g/L): 74
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,06
TSH (mIU/L): 3
Urea (mg/dL): 20,7
LVEF (%): 35.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely. 

RANKING: 1. Sudden Cardiac Death, 2. Pump Failure Death, 3. Survivor

REASONING: 

1. Sudden Cardiac Death: The patient has a high risk of sudden cardiac death due to several factors. His age (63) and ischemic dilated cardiomyopathy (LVEF 35%) indicate a significant underlying cardiac condition. His history of myocardial infarction and peripheral vascular disease further increase his risk. Additionally, his elevated Pro-BNP level (7692.0 ng/L) suggests significant cardiac stress. His ventricular extrasystole on the ECG also indicates potential arrhythmia risks. With these factors combined, the risk of sudden cardiac death is high.

2. Pump Failure Death: The patient's LVEF of 35% and history of ischemic dilated cardiomyopathy indicate severe left ventricular dysfunction. His creatinine level (184.0 mmol/L) also suggests renal impairment, which can be a result of heart failure. His NYHA Class III classification indicates significant functional impairment. However, his current medications, including ACE inhibitors and loop diuretics, may be helping to manage his condition. While pump failure death is a possibility, the patient's current treatment regimen and the absence of other complicating factors (e.g., severe anemia or significant respiratory issues) make this prognosis less likely than sudden cardiac death.

3. Survivor: The patient's current medications and medical history suggest that he is being actively managed for his conditions. His LVEF of 35% indicates significant cardiac dysfunction, but his overall clinical picture does not suggest a high likelihood of sudden cardiac death or pump failure. His lack of other complicating factors (e.g., severe anemia, significant respiratory issues) and the presence of supportive medications make a survival outcome more plausible. However, his prognosis remains guarded due to his underlying cardiac condition."
691,691,P0340,"Age: 71
Gender: Male 
Weight: 57 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 85/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 44,6
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,59
Creatinine (mmol/L): 123.0
Gamma-glutamil transpeptidase (IU/L): 57
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,36
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2206.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,954
Urea (mg/dL): 4,9
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Loop Diuretics, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden Cardiac Death
 REASONING: The patient has a high risk of sudden cardiac death due to several factors. The patient has ischemic dilated cardiomyopathy with an LVEF of 30%, which indicates significant left ventricular dysfunction. The elevated Pro-BNP level of 2206 ng/L further supports this, as it is a marker of heart failure and cardiac strain. Additionally, the patient has a history of myocardial infarction, which increases the risk of arrhythmias and sudden cardiac death. The presence of non-sustained ventricular tachycardia (VT) on the ECG also indicates a high risk of life-threatening arrhythmias. The patient's low blood pressure (85/50 mmHg) may also be a sign of cardiac output compromise, further increasing the risk of sudden cardiac death.

RANKING: 2. Pump Failure Death
 REASONING: The patient's ischemic dilated cardiomyopathy and low LVEF of 30% suggest that the patient is at risk for pump failure. The patient's NYHA Class III classification indicates that the patient experiences symptoms of heart failure at rest or with minimal exertion. The elevated Pro-BNP level and low blood pressure also support this prognosis. However, the patient's overall clinical picture is more concerning for sudden cardiac death than pump failure death due to the presence of arrhythmias and cardiac dysfunction.

RANKING: 3. Survivor
 REASONING: Based on the patient's high-risk profile, it is unlikely that the patient will survive for an extended period without significant cardiac events. The patient's low LVEF, history of myocardial infarction, and presence of non-sustained VT on the ECG make sudden cardiac death a more likely outcome than survival. While the patient may receive medical treatment and management, the prognosis for long-term survival is guarded, and sudden cardiac death is a more likely outcome based on the provided data."
692,692,P0343,"Age: 63
Gender: Male 
Weight: 80 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 42,4
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 112.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 116.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,35
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2125.0
Protein (g/L): 74
T3 (pg/dL): 0,02
T4 (ng/L): 11
Troponin (ng/mL): 0,01
TSH (mIU/L): 32,51
Urea (mg/dL): 6,45
LVEF (%): 40.0
Medications: Diabetes Medication, Amiodarone, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Parosysmal AF
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden Cardiac Death, 2. Pump Failure Death, 3. Survivor

REASONING:

1. Sudden Cardiac Death (SCD): The patient has a high risk of SCD due to several factors:
   - Age (63 years): The patient is in the age group where SCD risk increases.
   - Ischemic dilated cardiomyopathy: This condition increases the risk of ventricular arrhythmias, which can lead to SCD.
   - Reduced LVEF (40%): A low ejection fraction is a strong predictor of increased mortality and SCD risk.
   - Presence of ventricular extrasystole: This can be a sign of underlying electrical instability in the heart, increasing the risk of SCD.
   - Paroxysmal AF: Atrial fibrillation can lead to a higher risk of thromboembolic events and may contribute to the development of ventricular arrhythmias.
   - High Pro-BNP levels (2125 ng/L): Elevated BNP levels are associated with increased mortality and SCD risk.
   - TSH (32.51 mIU/L): This high TSH level suggests hypothyroidism, which can be associated with increased cardiac mortality.
   - Medications: Amiodarone, a medication used to prevent arrhythmias, but also known to have pro-arrhythmic effects in some cases.

2. Pump Failure Death: The patient has a moderate to high risk of pump failure due to:
   - Ischemic dilated cardiomyopathy: This condition can lead to progressive left ventricular dysfunction and heart failure.
   - Reduced LVEF (40%): A low ejection fraction is a strong predictor of increased mortality and pump failure.
   - Elevated Pro-BNP levels (2125 ng/L): High BNP levels are associated with increased mortality and pump failure risk.
   - Creatinine levels (112.0 mmol/L): Elevated creatinine levels indicate kidney dysfunction, which can be a consequence of heart failure.

3. Survivor: While the patient has several risk factors for SCD and pump failure, the following factors suggest a possible survival outcome:
   - NYHA Class II: The patient is still relatively functional and does not have severe symptoms of heart failure.
   - Medications: The patient is on ACE inhibitors, statins, and loop diuretics, which are beneficial for heart failure management.
   - Normal hemoglobin levels (116 g/L): Sufficient oxygen delivery to tissues may help mitigate some of the cardiac risks.
   - Low LDL levels (2.35 mmol/L): Optimal cholesterol management may help reduce cardiac risk factors.

Please note that this prognosis is based on the provided data and may not be comprehensive or definitive. A more accurate assessment would require a thorough evaluation by a cardiologist, taking into account additional clinical information and diagnostic tests."
693,693,P0346,"Age: 78
Gender: Female 
Weight: 52 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 48,09
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 6,39
Creatinine (mmol/L): 139.0
Gamma-glutamil transpeptidase (IU/L): 79
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,37
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,53
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1990.0
Protein (g/L): 82
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,25
Urea (mg/dL): 12,69
LVEF (%): 24.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely. 

RANKING: 2
 REASONING: Given the patient's age (78), low left ventricular ejection fraction (LVEF) of 24%, and elevated B-type natriuretic peptide (BNP) levels (1990 ng/L), the patient is at a high risk for pump failure. The patient's ischemic dilated cardiomyopathy and past myocardial infarction also support this risk. However, the patient is on appropriate medical therapy (beta blockers, loop diuretics, spironolactone, and ACE inhibitor), which suggests that the treatment is being managed.

RANKING: 3
 REASONING: Sudden cardiac death is a possible outcome, but the patient's ECG does not show any high-risk features such as ventricular tachycardia or sustained ventricular arrhythmias. While the patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, the absence of high-risk ECG findings and the presence of appropriate medical therapy make sudden cardiac death less likely.

RANKING: 1
 REASONING: Survivor is the most likely outcome, given the patient's current medical management and the absence of high-risk features on the ECG. The patient's NYHA Class II classification indicates that the patient's symptoms are manageable with medical therapy, and the patient is likely to be able to maintain a reasonable quality of life for the next few years."
694,694,P0349,"Age: 77
Gender: Female 
Weight: 82 kg
Height: 150 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 108.0
AST or GOT (IU/L): 55.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 15,5
Hemoglobin (g/L): 109.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,33
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 910.0
Protein (g/L): 66
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,43
Urea (mg/dL): 9,35
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: Survivor

REASONING: 

Based on the provided patient data, I would rank the prognosis as Survivor. 

The patient is 77 years old with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction, which indicates a complex cardiac history. However, the patient is on a comprehensive treatment regimen, including diabetes medication, angiotensin II receptor blocker, beta blockers, loop diuretics, and statins, which suggests that her condition is being actively managed.

The patient's LVEF of 35% indicates reduced cardiac function, but it is not as low as some other patients with dilated cardiomyopathy. The patient's troponin level of 0.01 ng/mL is also within the normal range, indicating that there is not an acute myocardial infarction.

The patient's pro-BNP level of 910.0 ng/L is elevated, which is consistent with heart failure. However, the patient's albumin level of 38 g/L is within the normal range, which suggests that the patient is not experiencing significant liver dysfunction.

The patient's ECG shows ventricular extrasystoles, but no sustained ventricular tachycardia or bradycardia. While this is concerning, it is not an immediate indicator of sudden cardiac death.

Given the patient's age, complex medical history, and the fact that her condition is being actively managed, I would rank the prognosis as Survivor. The patient's reduced LVEF and elevated pro-BNP level indicate that she is at risk for pump failure, but the fact that her troponin level is within the normal range and her albumin level is normal suggests that she is not at immediate risk for sudden cardiac death.

REASONS FOR SURVIVOR PROGNOSIS:

- Comprehensive treatment regimen
- LVEF of 35% is not extremely low
- Troponin level within the normal range
- Albumin level within the normal range
- No acute myocardial infarction
- No sustained ventricular tachycardia or bradycardia on ECG

RANKING OF OTHER PROGNOSIS:

- Sudden cardiac death: Less likely due to the patient's comprehensive treatment regimen and the fact that her troponin level is within the normal range.
- Pump failure death: Possible, but less likely than survivor due to the patient's LVEF of 35% and elevated pro-BNP level."
695,695,P0351,"Age: 68
Gender: Male 
Weight: 73 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 120/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40,3
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 136.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 7
Hemoglobin (g/L): 142.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,04
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 934.0
Protein (g/L): 81
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,27
Urea (mg/dL): 14,25
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: 1. Sudden Cardiac Death (SCD), 2. Pump Failure Death, 3. Survivor

REASONING:

1. Sudden Cardiac Death (SCD): The patient has a high risk of SCD due to the following factors:
	* Ischemic dilated cardiomyopathy with an LVEF of 30%, indicating significant left ventricular dysfunction.
	* A history of myocardial infarction, which increases the risk of SCD.
	* A high Pro-BNP level of 934.0 ng/L, indicating elevated B-type natriuretic peptide levels, which are associated with increased risk of SCD.
	* The presence of ventricular extrasystoles, which can be a marker of increased arrhythmia risk.
	* The patient's age (68) and NYHA Class II classification also contribute to the overall risk of SCD.

2. Pump Failure Death: While the patient has a history of ischemic dilated cardiomyopathy and a low LVEF, the patient's current NYHA Class II classification and the absence of signs of severe heart failure (e.g., elevated creatinine, anemia) suggest that the patient's heart failure is currently manageable. The patient's medications (Beta Blockers, ACE Inhibitor, and Statins) are also appropriate for managing heart failure and reducing the risk of pump failure.

3. Survivor: Based on the patient's current medical condition and treatment, I would rank survival as the least likely prognosis. The patient's history of ischemic dilated cardiomyopathy, low LVEF, and high Pro-BNP level suggest a high risk of adverse cardiac events. However, the patient's current NYHA Class II classification and the presence of appropriate medications suggest that the patient's condition is being managed, and survival is possible with continued medical treatment and follow-up.

Please note that this prognosis is based on the provided data and may not reflect the patient's actual outcome. A comprehensive evaluation by a cardiologist and ongoing monitoring are essential to determine the patient's individual prognosis and guide treatment decisions."
696,696,P0356,"Age: 76
Gender: Male 
Weight: 82 kg
Height: 149 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 47,3
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,61
Creatinine (mmol/L): 118.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 12
Hemoglobin (g/L): 169.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,8
LDL (mmol/L): 3,31
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 4315.0
Protein (g/L): 80
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,04
Urea (mg/dL): 14,03
LVEF (%): 20.0
Medications: Diabetes Medication, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Pump Failure Death

REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure and pump failure. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 20%, indicating poor heart function. Additionally, the patient's creatinine level is elevated at 118.0 mmol/L, suggesting impaired renal function, which is often associated with heart failure. The patient's NT-proBNP level is also significantly elevated at 4315.0 ng/L, which is a strong indicator of heart failure. The patient's medications, including loop diuretics and spironolactone, suggest that they are being treated for heart failure. Considering these factors, pump failure death is the most likely prognosis.

RANKING: 2. Sudden Cardiac Death

REASONING: The patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The patient's LVEF is severely reduced, and their Troponin level is slightly elevated at 0.02 ng/mL, indicating some degree of myocardial damage. However, the patient's ECG does not show any signs of ventricular tachycardia or other high-risk arrhythmias. The patient's medications, including an ACE inhibitor and nitrovasodilator, suggest that they are being treated for heart failure and may be at risk for sudden cardiac death. However, the patient's overall condition is more suggestive of pump failure than sudden cardiac death.

RANKING: 3. Survivor

REASONING: While the patient has several risk factors for poor outcomes, including ischemic dilated cardiomyopathy, diabetes, and elevated NT-proBNP, their current treatment regimen and some laboratory values suggest that they may be receiving effective management for their heart failure. The patient's LVEF is severely reduced, but it is not impossible for patients with LVEF as low as 20% to survive with proper treatment. The patient's creatinine level is elevated, but it is not extremely high, and their hemoglobin level is within a relatively normal range. While the patient's prognosis is guarded, it is possible that with continued treatment and management, they may be able to survive for several years."
697,697,P0405,"Age: 37
Gender: Female 
Weight: 69 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 43
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,13
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 148.0
HDL (mmol/L): 1,42
Potassium (mEq/L): 4,3
LDL (mmol/L): 4,14
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 853.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,005
TSH (mIU/L): 0,562
Urea (mg/dL): 4,49
LVEF (%): 23.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, here is my prognosis for the next few years:

RANKING: 1. Survivor
 REASONING: The patient is 37 years old and has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge. However, the patient is relatively young and has a low ejection fraction (LVEF) of 23%, which indicates that the heart is still functioning, albeit inefficiently. The patient is also on a combination of medications, including ACE inhibitors, beta blockers, digoxin, loop diuretics, and spironolactone, which are all standard treatments for heart failure and may help to slow disease progression. The patient's low TSH level and normal T4 level suggest that hypothyroidism is not a contributing factor to her condition. The patient's low Pro-BNP level (853 ng/L) is slightly elevated, but not excessively high, which may indicate some degree of heart failure but not severe. The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death, but the patient's overall clinical picture suggests that the risk of sudden cardiac death is relatively low. Overall, while the patient's prognosis is guarded, the likelihood of survival for the next few years is higher than the other two options.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. The patient's low LVEF of 23% and high Pro-BNP level of 853 ng/L also suggest that the patient has significant heart failure. However, the patient's age, sex, and other clinical factors suggest that sudden cardiac death is less likely than pump failure death. The patient's ventricular extrasystole and polymorphic ventricular extrasystole on the ECG also suggest that the patient may be at risk for arrhythmias, which can increase the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 23% and high Pro-BNP level of 853 ng/L suggest that the patient has significant heart failure. The patient's low weight and low blood pressure also suggest that the patient may be experiencing fluid overload, which can be a sign of heart failure. The patient's medications, including loop diuretics and spironolactone, are standard treatments for heart failure, but the patient's clinical picture suggests that the heart failure is not well-controlled. The patient's low T3 level and normal T4 level suggest that hypothyroidism is not a contributing factor to her condition. However, the patient's low LVEF and high Pro-BNP level suggest that the patient is at high risk for pump failure death, which is a more likely outcome than sudden cardiac death."
698,698,P0409,"Age: 64
Gender: Male 
Weight: 89 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 145/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 41
ALT or GPT (IU/L): 78.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,66
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 170.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,6
LDL (mmol/L): 4,06
Sodium (mEq/L): 143.0
Protein (g/L): 68
T3 (pg/dL): 0,03
T4 (ng/L): 24
Troponin (ng/mL): 0,02
TSH (mIU/L): 3,4
Urea (mg/dL): 8,65
LVEF (%): 65.0
Medications: Calcium Channel Blocker, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Paroxismal flutter
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: Survivor

REASONING: 

Given the provided patient data, I would rank the prognosis as a survivor for the next few years. Here's the reasoning behind this ranking:

1.  The patient is 64 years old, which is considered elderly but not extremely old. The life expectancy for a 64-year-old male is around 15-20 years.
2.  The patient has a history of hypertensive cardiomyopathy and hypertension, which are significant risk factors for cardiovascular disease. However, the patient's current blood pressure is well-controlled, and the patient is on a calcium channel blocker and an ACE inhibitor, which are appropriate medications for hypertension and cardiomyopathy.
3.  The patient's left ventricular ejection fraction (LVEF) is 65%, which is within the normal range (>50%). This suggests that the patient's heart function is relatively preserved.
4.  The patient's troponin level is 0.02 ng/mL, which is within the normal range (<0.03 ng/mL). This suggests that there is no acute myocardial infarction or significant cardiac damage.
5.  The patient's creatinine level is 106.0 umol/L, which is slightly elevated. However, the patient's urea level is 8.65 mg/dL, which is within the normal range (2.5-7.0 mg/dL). This suggests that the patient's kidney function is not severely impaired.
6.  The patient has a non-sustained ventricular tachycardia (NSVT) on the ECG, which is a common finding in patients with cardiomyopathy. However, the patient does not have any other significant arrhythmias or conduction abnormalities.
7.  The patient's TSH level is 3.4 mIU/L, which is within the normal range (0.4-4.5 mIU/L). This suggests that the patient's thyroid function is normal.
8.  The patient's total cholesterol level is 5.66 mmol/L, which is elevated. However, the patient's HDL level is 0.93 mmol/L, which is within the normal range (0.9-1.5 mmol/L). This suggests that the patient has a high-risk lipid profile, but the patient is on a statin (not mentioned in the medication list, but inferred from the high LDL level), which is an appropriate treatment for high cholesterol.
9.  The patient's albumin level is 41 g/L, which is within the normal range (35-50 g/L). This suggests that the patient's liver function is normal.
10. The patient's AST and ALT levels are within the normal range, which suggests that the patient's liver function is normal.

Considering these factors, the patient's prognosis is likely to be a survivor for the next few years. However, the patient should be closely monitored for any changes in their condition, and the treatment plan should be adjusted as needed to prevent progression of the cardiomyopathy and hypertension.

RANKING: Sudden cardiac death (2nd)

REASONING: 

Given the provided patient data, I would rank the prognosis as sudden cardiac death as the second most likely outcome for the next few years. Here's the reasoning behind this ranking:

1.  The patient has a history of hypertensive cardiomyopathy and hypertension, which are significant risk factors for sudden cardiac death.
2.  The patient has a non-sustained ventricular tachycardia (NSVT) on the ECG, which is a risk factor for sudden cardiac death.
3.  The patient's LVEF is 65%, which is within the normal range. However, the patient's LVEF is likely to be reduced in the future due to the progression of the cardiomyopathy.
4.  The patient's troponin level is 0.02 ng/mL, which is within the normal range. However, the patient's troponin level may be elevated in the future due to cardiac damage or infarction.
5.  The patient's creatinine level is 106.0 umol/L, which is slightly elevated. This may indicate a decline in kidney function, which can increase the risk of sudden cardiac death.

RANKING: Pump failure death (3rd)

REASONING: 

Given the provided patient data, I would rank the prognosis as pump failure death as the least likely outcome for the next few years. Here's the reasoning behind this ranking:

1.  The patient's LVEF is 65%, which is within the normal range (>50%). This suggests that the patient's heart function is relatively preserved.
2.  The patient's troponin level is 0.02 ng/mL, which is within the normal range. This suggests that there is no acute myocardial infar"
699,699,P0416,"Age: 46
Gender: Male 
Weight: 77 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 105/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 48
ALT or GPT (IU/L): 51.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 8
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,41
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 247.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 21
Troponin (ng/mL): 0,12
TSH (mIU/L): 3,63
Urea (mg/dL): 6,32
LVEF (%): 30.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Sudden Cardiac Death, 2. Pump Failure Death, 3. Survivor

REASONING:

1. Sudden Cardiac Death (SCD): The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for SCD. The patient's left ventricular ejection fraction (LVEF) is 30%, indicating severe heart failure, and the presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG further increase the risk of SCD. Additionally, the patient's elevated Pro-BNP level (247 ng/L) suggests increased ventricular stress and potential for arrhythmic events. Considering these factors, SCD is the most likely prognosis.

2. Pump Failure Death: The patient's LVEF of 30% and elevated creatinine level (115.0 mol/L) indicate significant heart failure and potential renal impairment. The patient's use of loop diuretics and spironolactone also suggests treatment for heart failure. While the patient's prognosis is poor, the presence of NSVT and polymorphic ventricular extrasystoles on the ECG, as well as the elevated Pro-BNP level, make SCD a more immediate concern than pump failure death.

3. Survivor: The patient's NYHA class II classification suggests mild to moderate heart failure, but the presence of severe left ventricular dysfunction (LVEF 30%), NSVT, and polymorphic ventricular extrasystoles on the ECG, as well as the elevated Pro-BNP level, make survival unlikely in the short term. The patient's overall clinical picture and laboratory results suggest a poor prognosis, making survival the least likely outcome.

Note: The patient's T3 and T4 levels are slightly low, which may indicate hypothyroidism, but this is not a primary concern in this case. The patient's diabetes and lipid profile are also concerning, but these factors are not the primary drivers of the patient's prognosis in this scenario."
700,700,P0438,"Age: 65
Gender: Male 
Weight: 79 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 115/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 49,6
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 149.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,82
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1114.0
Protein (g/L): 76,9
T4 (ng/L): 16
TSH (mIU/L): 0,86
Urea (mg/dL): 8,99
LVEF (%): 25.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: 1. Sudden Cardiac Death, 2. Pump Failure Death, 3. Survivor

REASONING:

1. Sudden Cardiac Death (Most Likely): The patient has a history of idiopathic dilated cardiomyopathy, which significantly increases the risk of sudden cardiac death. The low left ventricular ejection fraction (LVEF) of 25% indicates severe left ventricular dysfunction, which further increases the risk of sudden cardiac death. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is a known risk factor for sudden cardiac death. The elevated Pro-BNP level (1114 ng/L) suggests increased cardiac stress and potential for arrhythmic events. Considering these factors, sudden cardiac death is the most likely prognosis.

2. Pump Failure Death: The patient's low LVEF and history of myocardial infarction suggest that heart failure is a significant concern. The patient's creatinine level (149.0 mmol/L) is elevated, indicating impaired renal function, which is often seen in advanced heart failure. The patient's NYHA Class II indicates some limitation of physical activity, but not severe enough to be classified as Class III or IV, which would indicate more severe heart failure. While pump failure is a possible outcome, it is less likely than sudden cardiac death due to the patient's relatively preserved renal function and lack of severe symptoms.

3. Survivor: While the patient's prognosis is poor, there are some factors that suggest a possibility of survival. The patient is on optimal medical therapy, including beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor, which can help manage heart failure and reduce the risk of sudden cardiac death. The patient's hemoglobin and potassium levels are within a relatively normal range, which suggests that the heart is not significantly impacted by anemia or electrolyte imbalances. However, the patient's low LVEF and history of myocardial infarction make long-term survival uncertain.

Please note that this prognosis is based on the provided data and may not reflect the patient's actual outcome, which can be influenced by various factors, including the effectiveness of treatment, lifestyle modifications, and other comorbidities."
701,701,P0468,"Age: 69
Gender: Male 
Weight: 81 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 2,77
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 5
Hemoglobin (g/L): 109.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 5,2
LDL (mmol/L): 1,32
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 7519.0
Protein (g/L): 68,6
T3 (pg/dL): 0,0342
T4 (ng/L): 12,35
Troponin (ng/mL): 0,6
TSH (mIU/L): 5,19
Urea (mg/dL): 10,5
LVEF (%): 35.0
Medications: Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient is 69 years old with a history of ischemic dilated cardiomyopathy, diabetes, and a low left ventricular ejection fraction (LVEF) of 35%. However, the patient is on beta blockers and statins, which are standard treatments for heart failure and can help improve prognosis. The patient's blood pressure is well-controlled, and the ejection fraction is not extremely low, which suggests some preserved cardiac function. Additionally, the patient's troponin levels are within a relatively normal range, indicating minimal ongoing myocardial damage. The patient's overall clinical picture suggests that with proper management and treatment, the patient may be able to survive for several years.

RANKING: 2. Pump failure death
 REASONING: The patient's LVEF of 35% indicates significant left ventricular dysfunction, which increases the risk of pump failure. The patient's history of ischemic dilated cardiomyopathy and diabetes also increases the risk of progression to heart failure. The patient's elevated pro-BNP levels (7519 ng/L) are consistent with heart failure and suggest that the patient's ventricle is under strain. However, the patient's overall clinical picture does not suggest an extremely high risk of pump failure death in the near future, as the patient's blood pressure is well-controlled and the ejection fraction is not extremely low.

RANKING: 3. Sudden cardiac death
 REASONING: The patient's history of ischemic dilated cardiomyopathy and LVEF of 35% increases the risk of sudden cardiac death. However, the patient's ECG impression does not show any signs of ventricular tachycardia, which is a common cause of sudden cardiac death in patients with heart failure. The patient's troponin levels are also within a relatively normal range, indicating minimal ongoing myocardial damage. Additionally, the patient's beta blockers and statins are standard treatments that can help reduce the risk of sudden cardiac death. Overall, while the patient's risk of sudden cardiac death is increased, it is not the most likely outcome based on the provided data.

Note: The provided data does not include information on the patient's ejection fraction over time, which can be an important factor in determining the risk of sudden cardiac death. A declining ejection fraction over time can increase the risk of sudden cardiac death."
702,702,P0482,"Age: 60
Gender: Male 
Weight: 107 kg
Height: 181 cm
NYHA Class: III
Blood Pressure: 145/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39,9
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 6,44
Creatinine (mmol/L): 143.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 127.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5,2
LDL (mmol/L): 4,09
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1742.0
Protein (g/L): 67,9
T4 (ng/L): 12
TSH (mIU/L): 1,28
Urea (mg/dL): 10,98
LVEF (%): 15.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely.

RANKING: 1. Sudden Cardiac Death (SCD), 2. Pump Failure Death, 3. Survivor

REASONING:

1. Sudden Cardiac Death (SCD): The patient has a high risk of SCD due to several factors:
    - Ischemic dilated cardiomyopathy with an LVEF of 15% indicates severe left ventricular dysfunction.
    - Non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG are indicators of arrhythmic risk.
    - Elevated Pro-BNP (1742 ng/L) suggests increased ventricular wall stress and a high risk of arrhythmias.
    - The patient's NYHA Class III indicates severe heart failure symptoms, which further increases the risk of SCD.
    - The presence of ventricular tachycardia and extrasystoles, along with a history of myocardial infarction, increases the risk of arrhythmias.

2. Pump Failure Death: The patient's LVEF of 15% and NYHA Class III indicate severe left ventricular dysfunction, making pump failure a significant concern. However, the patient's current treatment regimen includes loop diuretics, beta-blockers, and ACE inhibitors, which are standard therapies for heart failure. While pump failure is a possibility, the patient's high risk of arrhythmias and SCD takes precedence.

3. Survivor: Given the patient's severe heart failure symptoms, reduced LVEF, and history of myocardial infarction, the likelihood of the patient surviving in the next few years without significant intervention is low. However, with optimal medical management, including adherence to the current medication regimen and close monitoring, it is possible that the patient may survive for an extended period. However, the risk of SCD and pump failure remains high, making it the least likely outcome.

Please note that this prognosis is based on the provided data and may change with additional information or new developments in the patient's condition."
703,703,P0494,"Age: 71
Gender: Male 
Weight: 82 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 44.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 3,8
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 84
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 161.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,25
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 224.0
Protein (g/L): 68
T4 (ng/L): 10
Troponin (ng/mL): 0,02
TSH (mIU/L): 3
Urea (mg/dL): 6,66
LVEF (%): 42.0
Medications: Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, here is the ranking of the possible prognoses from most likely to least likely:

RANKING: Sudden Cardiac Death (SCD) > Pump Failure Death > Survivor

REASONING:

1. Sudden Cardiac Death (SCD): The patient's history of ischemic dilated cardiomyopathy, myocardial infarction, and non-sustained ventricular tachycardia (NSVT) on the ECG, along with a low LVEF of 42%, increases the risk of sudden cardiac death. The patient's high Pro-BNP level (224 ng/L) also suggests increased ventricular wall stress and potential for arrhythmias. The presence of polymorphic ventricular extrasystoles and TPSV on the ECG further supports the likelihood of SCD. While the patient is on beta blockers, statins, and nitrovasodilators, which can help reduce the risk of SCD, the high-risk profile and the presence of arrhythmias make SCD the most likely prognosis.

2. Pump Failure Death: The patient's ischemic dilated cardiomyopathy, low LVEF, and high Pro-BNP level suggest that the heart is under significant stress, increasing the risk of pump failure. The patient's creatinine level of 71.0 mol/L also indicates some degree of renal impairment, which can be a marker of advanced heart failure. However, the patient's NYHA class II classification suggests that the heart failure is not severe at this point, and the patient is still relatively stable. With appropriate management, pump failure death is less likely than SCD, but still a possible outcome.

3. Survivor: The patient's relatively stable NYHA class II classification, the presence of beta blockers and statins, and the absence of severe symptoms or signs of advanced heart failure suggest that the patient has a good chance of surviving with proper management. However, the patient's high-risk profile, including the history of myocardial infarction, low LVEF, and arrhythmias, makes survival less likely than the other two options.

In summary, while the patient's prognosis is guarded, SCD appears to be the most likely outcome due to the combination of high-risk factors, including arrhythmias, low LVEF, and high Pro-BNP level."
704,704,P0498,"Age: 80
Gender: Female 
Weight: 53 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 38,1
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,25
Creatinine (mmol/L): 131.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 6
Hemoglobin (g/L): 119.0
Potassium (mEq/L): 4,56
Sodium (mEq/L): 139.0
Protein (g/L): 71,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,63
Urea (mg/dL): 13,4
LVEF (%): 18.0
Medications: Amiodarone, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden Cardiac Death

REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is severely impaired at 18%, indicating a significant reduction in the heart's pumping function. Additionally, the presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG further increases the risk of sudden cardiac death. The patient's medications, including Amiodarone and Digoxin, are often used to prevent arrhythmias, but the presence of NSVT suggests that the patient is still at risk. Furthermore, the patient's low weight (53 kg) and low albumin level (38.1 g/L) may indicate malnutrition or poor health status, which can further exacerbate the cardiac condition.

RANKING: 2. Pump Failure Death

REASONING: The patient's LVEF of 18% indicates severe heart failure, and the patient is already on loop diuretics, which are often used to manage fluid overload in heart failure patients. The elevated creatinine level (131.0 mol/L) suggests impaired renal function, which is common in advanced heart failure. However, the patient's blood pressure is within a relatively normal range (120/70 mmHg), which may indicate that the patient is not in acute heart failure exacerbation at the moment. However, the patient's overall condition and the presence of dilated cardiomyopathy make pump failure death a plausible outcome.

RANKING: 3. Survivor

REASONING: While the patient's condition is severe, with a low LVEF and a history of idiopathic dilated cardiomyopathy, there are some factors that suggest a slightly better prognosis. The patient's blood pressure is well-controlled, and the patient is on medications that are often used to manage heart failure and prevent arrhythmias. Additionally, the patient's troponin level is within a normal range, indicating that there is no acute myocardial infarction. However, given the patient's severe heart failure and history of arrhythmias, a survivor prognosis is less likely compared to sudden cardiac death or pump failure death.

Please note that this is a medical assessment based on the provided data and should be taken as a general opinion. A more accurate prognosis would require a comprehensive evaluation by a cardiologist and consideration of other factors not provided in the data."
705,705,P0504,"Age: 78
Gender: Male 
Weight: 75 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 7,03
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,86
Potassium (mEq/L): 4,84
LDL (mmol/L): 4,73
Sodium (mEq/L): 139.0
Protein (g/L): 67,3
T3 (pg/dL): 0,0483
T4 (ng/L): 16,58
Troponin (ng/mL): 0,5
TSH (mIU/L): 0,67
Urea (mg/dL): 10
LVEF (%): 34.0
Medications: Angiotensin II Receptor Blocker, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely. 

RANKING: 1. Sudden Cardiac Death
REASONING: The patient's current medical history and laboratory results indicate a high risk of sudden cardiac death. The patient has a history of enolic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, reducing the heart's ability to pump blood effectively. The patient's left ventricular ejection fraction (LVEF) of 34% is significantly below the normal range, indicating poor heart function. Additionally, the patient has a history of ventricular extrasystoles, which can be a sign of an increased risk of sudden cardiac death. The patient is also on medications such as Angiotensin II Receptor Blocker, Loop Diuretics, and ACE Inhibitor, which are commonly used to manage heart failure and reduce the risk of sudden cardiac death. However, the patient's high risk profile and existing conditions suggest that sudden cardiac death is a possible outcome.

RANKING: 2. Pump Failure Death
REASONING: The patient's history of enolic dilated cardiomyopathy and low LVEF of 34% indicate a high risk of pump failure. The patient's creatinine level of 120.0 mmol/L is also elevated, suggesting impaired kidney function, which is often a result of decreased cardiac output. The patient's high total cholesterol and LDL levels may also contribute to the progression of heart failure. However, the patient's current medications and management plan may help mitigate this risk.

RANKING: 3. Survivor
REASONING: While the patient has a high risk of sudden cardiac death and pump failure, the patient's current medical management and medication regimen may help manage the condition and improve outcomes. The patient's low TSH level suggests that the patient may be receiving adequate thyroid hormone replacement, which can help improve cardiac function. The patient's hemoglobin level is also within the normal range, indicating that anemia is not a contributing factor to the patient's condition. However, the patient's overall prognosis is still guarded due to the high risk of sudden cardiac death and pump failure."
706,706,P0520,"Age: 67
Gender: Male 
Weight: 63 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 90/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42,4
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,7
Creatinine (mmol/L): 135.0
Gamma-glutamil transpeptidase (IU/L): 56
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 98.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 3,6
LDL (mmol/L): 1,27
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 6274.0
Protein (g/L): 68
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,31
Urea (mg/dL): 11,13
LVEF (%): 23.0
Medications: Diabetes Medication, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, here are my prognoses for the next few years, ordered from most likely to least likely:

RANKING: 1. Survivor
 REASONING: Despite the patient's advanced age, ischemic dilated cardiomyopathy, and low left ventricular ejection fraction (LVEF) of 23%, the patient is currently receiving appropriate medical therapy, including ACE inhibitors, spironolactone, and statins, which are beneficial for heart failure management. The patient's blood pressure is within a relatively normal range, considering the patient's NYHA Class III status, and the serum potassium level is not significantly low, which reduces the risk of arrhythmias. Additionally, the patient's creatinine level is elevated but not excessively high, suggesting that the kidneys are not significantly impaired. The presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG is concerning but not uncommon in patients with heart failure. Given the current treatment and the absence of severe electrolyte imbalances, I believe the patient has a relatively better prognosis, with a likelihood of survival.

RANKING: 2. Pump failure death
 REASONING: The patient's LVEF of 23% indicates severe left ventricular dysfunction, which increases the risk of pump failure. The elevated Pro-BNP level (6274.0 ng/L) and low albumin level (42.4 g/L) also suggest advanced heart failure. The patient's diabetes and dyslipidemia further contribute to the risk of cardiac complications. However, the patient is receiving optimal medical therapy for heart failure, which may slow disease progression. The risk of pump failure is still present, but it is not the most likely outcome due to the patient's relatively stable blood pressure and the absence of severe kidney dysfunction.

RANKING: 3. Sudden cardiac death
 REASONING: The patient's low LVEF, non-sustained ventricular tachycardia, and polymorphic ventricular extrasystoles on the ECG increase the risk of sudden cardiac death. The elevated Pro-BNP level and low albumin level also suggest advanced heart failure, which can increase the risk of arrhythmias. However, the patient's blood pressure is within a relatively normal range, and the serum potassium level is not significantly low, which reduces the risk of arrhythmias. Additionally, the patient is receiving optimal medical therapy, including ACE inhibitors and beta-blockers, which can reduce the risk of sudden cardiac death. While the risk is present, the patient's current treatment and relatively stable blood pressure make sudden cardiac death the least likely outcome among the three options.

Please note that this is a medical assessment based on the provided data and should be used as a general guideline. A more accurate prognosis can only be made by a qualified healthcare professional after a thorough examination and evaluation of the patient."
707,707,P0533,"Age: 50
Gender: Male 
Weight: 76 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 90/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 42,5
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,81
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 150.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,72
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 86.0
Protein (g/L): 82
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,58
Urea (mg/dL): 6,91
LVEF (%): 38.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: 1. Survivor, 2. Sudden Cardiac Death, 3. Pump Failure Death

REASONING:

1. Survivor (Most Likely): The patient is currently being treated with a comprehensive medication regimen, including a calcium channel blocker, beta blockers, statins, ACE inhibitors, and nitrovasodilators. This suggests that the patient's cardiac condition is being actively managed, which reduces the risk of sudden cardiac death and pump failure. The patient's LVEF is 38%, which is relatively low but not extremely low, and the patient is not in NYHA Class IV, which suggests that the patient still has some functional capacity. Additionally, the patient's pro-BNP level is relatively low at 86.0 ng/L, indicating a relatively low level of cardiac stress. The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG is concerning, but the patient is being monitored and treated for these conditions. Overall, the patient's current treatment plan and relatively stable condition suggest that a survivor prognosis is the most likely outcome.

2. Sudden Cardiac Death (Moderately Likely): The patient's history of ischemic dilated cardiomyopathy, myocardial infarction, and the presence of non-sustained ventricular tachycardia on the ECG increase the risk of sudden cardiac death. The patient's low LVEF and low blood pressure also contribute to this risk. However, the patient is being treated with beta blockers and ACE inhibitors, which are known to reduce the risk of sudden cardiac death. The patient's relatively low pro-BNP level and the fact that the patient is not in NYHA Class IV suggest that the patient is not in a high-risk category for sudden cardiac death.

3. Pump Failure Death (Least Likely): The patient's LVEF is 38%, which is relatively low, but not extremely low. The patient's NYHA Class III suggests that the patient still has some functional capacity, and the patient's pro-BNP level is relatively low. While the patient's creatinine level is elevated, indicating some degree of renal impairment, the patient is not in NYHA Class IV, which is typically associated with more severe heart failure. The patient's current treatment plan, including ACE inhibitors and diuretics, is aimed at managing heart failure symptoms and reducing the risk of pump failure. Overall, while pump failure is a possible outcome, it is the least likely of the three options.

Note: The provided data does not include information on the patient's ejection fraction at baseline or the patient's history of hospitalizations for heart failure. These factors could have a significant impact on the prognosis and should be taken into account in a more comprehensive assessment."
708,708,P0539,"Age: 64
Gender: Male 
Weight: 85 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 160/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38,4
ALT or GPT (IU/L): 35.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,14
Creatinine (mmol/L): 112.0
Gamma-glutamil transpeptidase (IU/L): 27
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 150.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,8
LDL (mmol/L): 1,99
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 339.0
Protein (g/L): 78
T3 (pg/dL): 0,05
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,25
Urea (mg/dL): 9,13
LVEF (%): 60.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, here is the prognosis for the next few years:

RANKING: 1. Survivor
 REASONING: The patient is 64 years old with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction, which indicates a high risk for cardiovascular events. However, the patient is on a multi-drug regimen (Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator), which is a good indication that the patient's condition is being actively managed. The patient's LVEF is 60%, which is within the normal range (>50%), indicating that the heart is functioning relatively well. Additionally, the patient's Pro-BNP level is 339.0 ng/L, which is elevated but not extremely high, suggesting that the patient is not in acute heart failure. The patient's ECG shows monomorphic ventricular extrasystoles, but no sustained ventricular tachycardia or other life-threatening arrhythmias. Considering these factors, the most likely prognosis is that the patient will survive for the next few years with continued management and monitoring of their condition.

RANKING: 2. Pump Failure Death
 REASONING: While the patient's LVEF is within the normal range, it is still 10% below the optimal range, indicating some degree of left ventricular dysfunction. The patient's Pro-BNP level is elevated, which suggests that the patient may be experiencing some degree of heart failure. Additionally, the patient has a history of ischemic dilated cardiomyopathy, which is a risk factor for pump failure. However, the patient's overall condition is being actively managed with medications, and there is no indication of acute heart failure or severe left ventricular dysfunction. Therefore, while pump failure is a possible prognosis, it is less likely than sudden cardiac death.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient's ECG shows monomorphic ventricular extrasystoles, which is a risk factor for sudden cardiac death. Additionally, the patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death. However, the patient is on a beta blocker, which is a standard treatment for reducing the risk of sudden cardiac death. The patient's LVEF is within the normal range, and the patient is being actively managed with medications. While sudden cardiac death is a possible prognosis, it is the least likely of the three options, given the patient's current management and relatively stable condition."
709,709,P0559,"Age: 51
Gender: Male 
Weight: 62 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 130/90 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 5,4
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 49
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 147.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 3,08
LDL (mmol/L): 3,23
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2928.0
Protein (g/L): 71
T3 (pg/dL): 0,0573
T4 (ng/L): 16,58
Troponin (ng/mL): 0,1
TSH (mIU/L): 3,94
Urea (mg/dL): 5,8
LVEF (%): 20.0
Medications: Calcium Channel Blocker, Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"RANKING: Survivor
 REASONING: While the patient's condition is concerning, given the low LVEF (20%) and history of idiopathic dilated cardiomyopathy, the patient is currently receiving a multidrug regimen that includes ACE inhibitors, beta blockers, and loop diuretics, which are standard treatments for heart failure and may help stabilize the patient's condition. Additionally, the patient's NYHA Class II indicates that the patient is not severely limited in daily activities, which suggests that the disease is not yet in its most advanced stage. The patient's ejection fraction is low, but the presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggests that the heart is still attempting to compensate for the decreased function. Therefore, with continued medical management and monitoring, the patient's prognosis is more likely to be survival.

RANKING: Pump Failure Death
 REASONING: The patient's LVEF of 20% indicates a severely impaired left ventricular function, which increases the risk of pump failure. The presence of non-sustained ventricular tachycardia and ventricular extrasystoles on the ECG also suggests that the heart is under significant stress. The patient's elevated Pro-BNP level (2928.0 ng/L) is also indicative of heart failure. However, the patient is receiving treatment with ACE inhibitors, beta blockers, and loop diuretics, which can help alleviate symptoms and slow disease progression. Furthermore, the patient's NYHA Class II indicates that the patient is not yet severely limited in daily activities, suggesting that the disease is not yet in its most advanced stage. Therefore, while pump failure is a concern, the patient's current treatment regimen and relatively mild symptoms suggest that pump failure death is less likely in the short term.

RANKING: Sudden Cardiac Death
 REASONING: The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. The patient is also taking amiodarone, which is an anti-arrhythmic medication that is used to prevent sudden cardiac death in patients at high risk. However, the patient's low LVEF (20%) and history of idiopathic dilated cardiomyopathy increase the risk of sudden cardiac death. The patient's elevated Pro-BNP level and the presence of ventricular extrasystoles on the ECG also suggest that the heart is under significant stress. However, given the patient's current treatment regimen and relatively mild symptoms, sudden cardiac death is less likely than pump failure death. The patient's NYHA Class II also suggests that the disease is not yet in its most advanced stage, which further reduces the likelihood of sudden cardiac death."
710,710,P0616,"Age: 71
Gender: Male 
Weight: 63 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42,4
ALT or GPT (IU/L): 33.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 114
Glucose (mmol/L): 6
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,9
Potassium (mEq/L): 3,94
LDL (mmol/L): 2,92
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1139.0
Protein (g/L): 67,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,56
Urea (mg/dL): 11,6
LVEF (%): 18.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, here's the prognosis ranking from most likely to least likely:

RANKING: 1. Sudden Cardiac Death
REASONING: The patient's LVEF of 18% indicates severe left ventricular dysfunction, which is a significant risk factor for sudden cardiac death. Additionally, the elevated Pro-BNP level of 1139 ng/L suggests severe heart failure symptoms, which further increases the risk of sudden cardiac death. The presence of ischemic dilated cardiomyopathy and a history of myocardial infarction also contribute to this risk. While the patient is on appropriate medications, including an Angiotensin II Receptor Blocker and a Nitrovasodilator, the severity of the patient's condition suggests that sudden cardiac death is a significant risk.

RANKING: 2. Pump Failure Death
REASONING: Given the patient's severe left ventricular dysfunction (LVEF 18%), it is likely that pump failure will occur in the near future. The patient's NYHA Class II classification indicates that the patient experiences some symptoms of heart failure, such as shortness of breath, but is still able to perform some physical activity. However, the patient's creatinine level of 125.0 mol/L suggests impaired renal function, which is often a consequence of advanced heart failure. While the patient is on diuretics, which may help manage fluid overload, the risk of pump failure remains high.

RANKING: 3. Survivor
REASONING: While the patient's condition is severe, there are some factors that suggest a potential for survival. The patient's age of 71 is not extremely advanced, and the patient is receiving appropriate medical treatment. Additionally, the patient's hemoglobin level of 129 g/L is within a relatively normal range, which suggests that the patient is not severely anemic. However, the patient's LVEF of 18% and elevated Pro-BNP level of 1139 ng/L suggest that the patient's condition is severe, and survival will depend on the effectiveness of the patient's current treatment plan and the potential for future interventions, such as cardiac resynchronization therapy or a heart transplant."
711,711,P0618,"Age: 65
Gender: Male 
Weight: 93 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 40,7
ALT or GPT (IU/L): 57.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 2,96
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 95
Glucose (mmol/L): 8
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,56
LDL (mmol/L): 1,45
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 12518.0
Protein (g/L): 66,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,43
Urea (mg/dL): 6,8
LVEF (%): 20.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden cardiac death, 2. Pump failure death, 3. Survivor

REASONING:

1. Sudden cardiac death (45% likelihood): The patient has a history of ischemic dilated cardiomyopathy, myocardial infarction, and non-sustained ventricular tachycardia (NSVT), which are all significant risk factors for sudden cardiac death. The patient's low left ventricular ejection fraction (LVEF) of 20% further increases the risk of sudden cardiac death. Additionally, the patient's high pro-BNP level (12518 ng/L) indicates severe heart failure, which is another risk factor for sudden cardiac death.

2. Pump failure death (40% likelihood): The patient's severe heart failure, as indicated by the low LVEF and high pro-BNP level, makes pump failure death a significant concern. The patient's ischemic dilated cardiomyopathy and history of myocardial infarction also contribute to the risk of pump failure death.

3. Survivor (15% likelihood): While the patient's prognosis is guarded, there are some factors that suggest a possible survival outcome. The patient is currently on optimal medical therapy, including beta blockers, loop diuretics, spironolactone, statins, and an ACE inhibitor. The patient's blood pressure is well-controlled, and the glucose level is relatively well-managed. However, the patient's high pro-BNP level and low LVEF suggest that the heart failure is severe, and the risk of pump failure death or sudden cardiac death remains high.

Please note that this prognosis is based on the provided data and may not reflect the actual outcome, as many factors can influence the course of the disease."
712,712,P0626,"Age: 74
Gender: Female 
Weight: 55 kg
Height: 144 cm
NYHA Class: III
Blood Pressure: 150/80 mmHg
Past Medical History: Hypertropic cardiomyopathy, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 2,84
Creatinine (mmol/L): 76.0
Gamma-glutamil transpeptidase (IU/L): 81
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 117.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,2
LDL (mmol/L): 1,51
Sodium (mEq/L): 147.0
Pro-BNP (ng/L): 7158.0
Protein (g/L): 65,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,31
Urea (mg/dL): 7
LVEF (%): 62.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely:

RANKING: 2 
REASONING: The patient is 74 years old with a history of hypertrophic cardiomyopathy and hypertension, which are both risk factors for cardiovascular disease. Her NYHA Class III indicates that she has severe symptoms, such as shortness of breath and fatigue, upon minimal exertion. The elevated Pro-BNP level of 7158.0 ng/L suggests that she has heart failure, which is consistent with her NYHA Class III classification. The LVEF of 62% is within the normal range, but it's on the lower end, indicating some degree of cardiac dysfunction. The presence of monomorphic ventricular extrasystoles on the ECG is a concerning sign, as it may indicate underlying cardiac arrhythmias. However, the lack of sustained ventricular tachycardia and other arrhythmias on the ECG reduces the likelihood of sudden cardiac death. Given these factors, the most likely prognosis is pump failure death, as her heart failure is likely to progress and lead to cardiac decompensation.

RANKING: 3 
REASONING: While the patient has several risk factors for sudden cardiac death, such as hypertrophic cardiomyopathy and a history of hypertension, the lack of sustained ventricular tachycardia and other arrhythmias on the ECG reduces the likelihood of sudden cardiac death. Additionally, her LVEF is within the normal range, which suggests that her cardiac function is not severely impaired at this time.

RANKING: 1 
REASONING: The patient's current medications, including Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, and Nitrovasodilator, suggest that she is being managed for her heart failure and hypertension. Her Pro-BNP level is elevated, indicating that she has heart failure, and her NYHA Class III indicates that she has severe symptoms. However, her LVEF is within the normal range, and she does not have any other high-risk features for sudden cardiac death. Therefore, her overall prognosis is most likely to be survivor, as her condition is being managed and her cardiac function is not severely impaired at this time."
713,713,P0649,"Age: 70
Gender: Male 
Weight: 110 kg
Height: 180 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 85.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 10,8
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,22
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 437.0
Protein (g/L): 72
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,99
Urea (mg/dL): 6,24
LVEF (%): 40.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: Survivor
 REASONING: The patient is 70 years old with a history of enolic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension. However, his current medications include a diabetes medication, loop diuretics, and an ACE inhibitor, which are all appropriate for managing these conditions. His LVEF is 40%, which indicates a reduced left ventricular function, but not severely reduced. His NYHA class is II, indicating some limitation of physical activity but no symptoms at rest. His blood pressure is within a relatively normal range. His recent troponin level is normal, and his TSH is slightly elevated, but not significantly so. The patient's Pro-BNP level is elevated at 437.0 ng/L, which may indicate heart failure, but it is not excessively high. Considering the patient's current management and relatively stable condition, I believe a survivor prognosis is the most likely outcome.

RANKING: Pump Failure Death
 REASONING: The patient's LVEF is 40%, which indicates a reduced left ventricular function. His Pro-BNP level is elevated, which may indicate heart failure. His NYHA class is II, indicating some limitation of physical activity, but not severe symptoms. His creatinine level is within a relatively normal range, but his albumin level is slightly low, which may indicate some degree of kidney dysfunction. His diabetes and hypertension are both uncontrolled, which can contribute to heart failure progression. However, his current medications are appropriate for managing these conditions. Considering the patient's reduced LVEF and elevated Pro-BNP, I believe pump failure death is a possible outcome.

RANKING: Sudden Cardiac Death
 REASONING: The patient's ECG shows monomorphic ventricular extrasystoles, which can be a marker for increased risk of sudden cardiac death. However, there is no mention of ventricular tachycardia or other high-risk arrhythmias. The patient's troponin level is normal, and his TSH is slightly elevated, but not significantly so. His medications include an ACE inhibitor, which is beneficial for reducing the risk of sudden cardiac death. While the patient's reduced LVEF and elevated Pro-BNP suggest some degree of heart failure, his overall condition does not seem to be acutely unstable. Considering the lack of high-risk arrhythmias and the patient's current management, I believe sudden cardiac death is the least likely outcome."
714,714,P0650,"Age: 73
Gender: Male 
Weight: 75 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension
Albumin (g/L): 40,9
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 2,87
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 34
Glucose (mmol/L): 15,3
Hemoglobin (g/L): 145.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,03
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1670.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 20
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,25
Urea (mg/dL): 5,79
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient has a complex medical history with ischemic dilated cardiomyopathy, diabetes, peripheral vascular disease, and hypertension. However, despite these comorbidities, the patient is currently receiving optimal medical therapy with beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all standard treatments for heart failure. The patient's LVEF is 25%, which is low but not the lowest possible value. Additionally, the patient's troponin level is within the normal range, indicating that there is no acute coronary syndrome. The patient's Pro-BNP level is elevated at 1670.0 ng/L, which is consistent with heart failure. However, the patient's overall clinical picture, including the presence of ventricular extrasystoles and non-sustained ventricular tachycardia, suggests that the patient is at risk for sudden cardiac death. Despite this risk, the patient's current medical therapy and the absence of acute coronary syndrome make survivorship the most likely outcome.

RANKING: 2. Sudden cardiac death
 REASONING: The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are both risk factors for sudden cardiac death. The patient's LVEF is 25%, which is below the normal range and indicates reduced cardiac function. The patient's Pro-BNP level is elevated, which is consistent with heart failure. However, the patient is receiving optimal medical therapy for heart failure, which may mitigate some of the risk for sudden cardiac death. The patient's overall clinical picture suggests that sudden cardiac death is a possible outcome, but the presence of optimal medical therapy and the absence of acute coronary syndrome make it less likely than survivorship.

RANKING: 3. Pump failure death
 REASONING: The patient's LVEF is 25%, which is below the normal range and indicates reduced cardiac function. The patient's Pro-BNP level is elevated, which is consistent with heart failure. The patient's creatinine level is elevated at 96.0 mmol/L, which indicates impaired renal function, which can be a consequence of heart failure. However, the patient is receiving optimal medical therapy for heart failure, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which may help to mitigate the risk of pump failure. Additionally, the patient's troponin level is within the normal range, indicating that there is no acute coronary syndrome. While pump failure is a possible outcome, the patient's overall clinical picture and the presence of optimal medical therapy make it the least likely outcome of the three.

Note: The patient's T3 and T4 levels are within the normal range, which suggests that the patient does not have hypothyroidism, which can contribute to heart failure. The patient's glucose level is elevated at 15.3 mmol/L, which may be contributing to the development of heart failure, but the patient is receiving diabetes medication, which may help to mitigate this risk."
715,715,P0656,"Age: 57
Gender: Male 
Weight: 70 kg
Height: 164 cm
NYHA Class: III
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 33,5
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 3,15
Creatinine (mmol/L): 226.0
Gamma-glutamil transpeptidase (IU/L): 73
Glucose (mmol/L): 3,1
Hemoglobin (g/L): 97.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5,9
LDL (mmol/L): 1,58
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 19425.0
Protein (g/L): 68
T3 (pg/dL): 0,03
T4 (ng/L): 20
Troponin (ng/mL): 0,19
TSH (mIU/L): 4,39
Urea (mg/dL): 18,94
LVEF (%): 20.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden Cardiac Death (SCD)
REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for SCD. The patient's LVEF is severely reduced at 20%, indicating poor left ventricular function. Additionally, the patient has a high level of BNP (19425.0 ng/L), which is a marker of heart failure and increased risk of SCD. The patient's ECG shows monomorphic ventricular extrasystoles, which can be a precursor to life-threatening arrhythmias. Furthermore, the patient's history of myocardial infarction and the presence of other comorbidities such as diabetes, dyslipemia, and hypertension contribute to the overall risk of SCD.

RANKING: 2. Pump Failure Death
REASONING: The patient's LVEF of 20% and high BNP level indicate severe heart failure, which increases the risk of pump failure death. The patient's NYHA class III classification also suggests significant symptoms of heart failure. However, the patient is already on optimal medical therapy, including beta blockers, loop diuretics, and ACE inhibitors, which may mitigate the risk of pump failure death. The patient's creatinine level is elevated at 226.0 umol/L, which may indicate some degree of renal impairment, but this is not a strong predictor of pump failure death.

RANKING: 3. Survivor
REASONING: While the patient has a poor prognosis, there are some factors that suggest a possible survival outcome. The patient is on optimal medical therapy, including beta blockers, loop diuretics, and ACE inhibitors, which can help manage symptoms and slow disease progression. The patient's TSH level is within normal limits, which suggests that the thyroid function is not contributing to the patient's cardiac condition. Additionally, the patient's glucose level is well-controlled, which is beneficial for cardiac health. However, the patient's overall risk profile and the severity of their cardiac disease make a survival outcome less likely compared to the other two possibilities."
716,716,P0661,"Age: 67
Gender: Female 
Weight: 65 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 43,2
ALT or GPT (IU/L): 6.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 4,58
Creatinine (mmol/L): 61.0
Gamma-glutamil transpeptidase (IU/L): 42
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,69
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 928.0
Protein (g/L): 68,5
T4 (ng/L): 15
TSH (mIU/L): 1,1
Urea (mg/dL): 6,82
LVEF (%): 20.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: 1. Sudden cardiac death, 2. Pump failure death, 3. Survivor

REASONING:

1. Sudden cardiac death: The patient has a history of idiopathic dilated cardiomyopathy, which significantly increases the risk of sudden cardiac death. The left ventricular ejection fraction (LVEF) is 20%, indicating severe systolic dysfunction. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG further increases the risk of sudden cardiac death. The elevated Pro-BNP level (928.0 ng/L) also suggests significant cardiac stress. Although the patient is on beta blockers, digoxin, spironolactone, and an ACE inhibitor, which are standard treatments for heart failure and arrhythmias, the risk of sudden cardiac death remains high due to the patient's underlying condition and ECG findings.

2. Pump failure death: The patient's LVEF of 20% indicates severe systolic dysfunction, which increases the risk of pump failure. The patient's history of idiopathic dilated cardiomyopathy and hypertension also contributes to this risk. However, the patient's NYHA Class II classification and relatively well-controlled blood pressure suggest that the patient's heart failure is not yet in an advanced stage. The patient's kidney function, as indicated by the creatinine level of 61.0 mol/L, is also relatively preserved, which may indicate that the patient's cardiac function is not yet severely compromised.

3. Survivor: Given the patient's severe systolic dysfunction, history of idiopathic dilated cardiomyopathy, and presence of NSVT, the risk of sudden cardiac death and pump failure death is high. However, the patient's relatively well-controlled blood pressure, NYHA Class II classification, and preserved kidney function suggest that the patient may have a relatively stable condition. With proper management and adherence to treatment, it is possible that the patient may survive for several years. However, this outcome is less likely compared to the other two options due to the patient's underlying cardiac condition.

Note: The prognosis is based on the provided data and may not reflect the patient's actual outcome. A more accurate prognosis would require a comprehensive evaluation by a healthcare professional."
717,717,P0667,"Age: 75
Gender: Male 
Weight: 76 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 150/75 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 37,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,95
Creatinine (mmol/L): 160.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 7,1
Hemoglobin (g/L): 133.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,72
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 6950.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,67
Urea (mg/dL): 13,14
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Loop Diuretics, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Pump failure death

REASONING: The patient has a history of hypertensive cardiomyopathy, which is a condition that can lead to heart failure. The patient's LVEF (Left Ventricular Ejection Fraction) is 50%, which is below the normal range of 55-70%. This suggests that the patient's heart is not pumping efficiently, which increases the risk of pump failure. The patient's creatinine level is elevated at 160.0 mmol/L, indicating impaired kidney function, which is a common complication of heart failure. The patient's Pro-BNP level is also elevated at 6950.0 ng/L, which is a marker of heart failure. Considering these factors, pump failure death is the most likely prognosis.

RANKING: 2. Sudden cardiac death

REASONING: The patient has a history of ventricular extrasystole and non-sustained ventricular tachycardia, which are risk factors for sudden cardiac death. The patient's Troponin level is slightly elevated at 0.03 ng/mL, which may indicate myocardial ischemia or damage. The patient's LVEF is also slightly below normal, which increases the risk of arrhythmias. However, the patient's medication regimen includes a calcium channel blocker and statins, which may help to reduce the risk of arrhythmias. While sudden cardiac death is a possible prognosis, it is less likely than pump failure death given the patient's overall clinical picture.

RANKING: 3. Survivor

REASONING: While the patient has several risk factors for cardiac disease, the patient's overall clinical picture suggests that they may be able to manage their condition with medication and lifestyle changes. The patient's LVEF is not severely impaired, and their creatinine level is not excessively elevated. The patient's Pro-BNP level is elevated, but not to an extreme degree. The patient's medication regimen includes a calcium channel blocker, loop diuretics, and statins, which are all evidence-based treatments for heart failure and hypertension. While the patient's prognosis is not ideal, it is possible that with close monitoring and management, they may be able to survive for several years."
718,718,P0671,"Age: 69
Gender: Male 
Weight: 72 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 44,1
ALT or GPT (IU/L): 23.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 5,74
Creatinine (mmol/L): 145.0
Gamma-glutamil transpeptidase (IU/L): 70
Glucose (mmol/L): 11,2
Hemoglobin (g/L): 163.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,93
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1824.0
Protein (g/L): 76,6
T4 (ng/L): 19
TSH (mIU/L): 0,36
Urea (mg/dL): 10,65
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Diabetes Medication
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Pump failure death

REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart's pumping function is impaired. The patient's LVEF (left ventricular ejection fraction) is 35%, which is significantly below the normal range (50-70%), indicating reduced heart function. The patient's elevated Pro-BNP (B-type natriuretic peptide) level of 1824.0 ng/L is also indicative of heart failure. Additionally, the patient has a history of myocardial infarction, which can further compromise the heart's pumping function. Given these factors, pump failure death is the most likely prognosis.

RANKING: 2. Sudden cardiac death

REASONING: The patient has a history of ischemic dilated cardiomyopathy and a low LVEF, which increases the risk of sudden cardiac death. The patient's ECG shows non-sustained ventricular tachycardia, which is a known risk factor for sudden cardiac death. Additionally, the patient's elevated Pro-BNP level and history of myocardial infarction further increase the risk of sudden cardiac death.

RANKING: 3. Survivor

REASONING: While the patient has several risk factors for cardiac disease, the patient's current treatment with a calcium channel blocker and diabetes medication may help manage some of these conditions. However, the patient's low LVEF, history of myocardial infarction, and elevated Pro-BNP level suggest a high risk of cardiac complications. The patient's age (69) and NYHA Class II classification also indicate some level of cardiac impairment. Given these factors, the likelihood of the patient surviving without significant cardiac complications is the least likely prognosis.

Note: It's essential to note that this prognosis is based on the provided data and may not be definitive. A more accurate prognosis would require a comprehensive evaluation by a cardiologist and consideration of additional factors, such as the patient's overall health, lifestyle, and response to treatment."
719,719,P0734,"Age: 67
Gender: Male 
Weight: 64 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 125/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 2,87
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 5
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 5,3
LDL (mmol/L): 1,68
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2362.0
Protein (g/L): 69
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,03
TSH (mIU/L): 1,53
Urea (mg/dL): 10,65
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: 1. Sudden Cardiac Death, 2. Pump Failure Death, 3. Survivor

REASONING:

1. Sudden Cardiac Death (SCD): Given the patient's history of ischemic dilated cardiomyopathy, low left ventricular ejection fraction (LVEF) of 20%, and the presence of non-sustained ventricular tachycardia (NSVT), I consider SCD as the most likely prognosis. The patient's LVEF is significantly reduced, indicating a compromised cardiac function. The presence of NSVT is a well-established risk factor for SCD in patients with heart failure. Additionally, the patient's elevated Pro-BNP level (2362.0 ng/L) suggests a high level of ventricular dysfunction and stress, which further increases the risk of SCD.

2. Pump Failure Death: Although the patient's LVEF is low, and they have a history of ischemic dilated cardiomyopathy, the patient is currently receiving optimal medical therapy with beta blockers, loop diuretics, spironolactone, statins, and ACE inhibitors. These medications are known to improve survival and reduce the risk of pump failure in patients with heart failure. The patient's NYHA Class II classification also suggests that they are relatively stable, which reduces the likelihood of pump failure death. However, the patient's low LVEF and history of NSVT still pose a significant risk.

3. Survivor: Considering the patient's age (67), low LVEF, and history of ischemic dilated cardiomyopathy, I consider survivorship as the least likely prognosis. While the patient is receiving optimal medical therapy, the presence of NSVT and low LVEF significantly increase the risk of adverse cardiac events. However, with close monitoring and adherence to their medication regimen, it is possible that the patient may experience a stable course, and their prognosis may be improved."
720,720,P0743,"Age: 57
Gender: Male 
Weight: 73 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41,4
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 5,79
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 8,9
Hemoglobin (g/L): 153.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,9
LDL (mmol/L): 4,01
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 313.0
Protein (g/L): 71,6
T4 (ng/L): 19
TSH (mIU/L): 0,36
Urea (mg/dL): 6,66
LVEF (%): 55.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will generate a prognosis for the next few years. Given the patient's complex medical history, current condition, and test results, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden Cardiac Death (SCD)
 REASONING: The patient has a history of myocardial infarction, enolic dilated cardiomyopathy, and non-sustained ventricular tachycardia (NSVT), which are all significant risk factors for SCD. The presence of a low LVEF (55%) and elevated Pro-BNP levels (313 ng/L) indicate impaired cardiac function, further increasing the risk of SCD. Additionally, the patient's history of dyslipemia and hypertension suggests atherosclerotic disease, which may contribute to arrhythmia development. The ECG findings of polymorphic ventricular extrasystoles and NSVT support the likelihood of arrhythmic events.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF of 55% indicates a moderate reduction in left ventricular function, which may eventually lead to heart failure if left untreated or undertreated. The patient's history of enolic dilated cardiomyopathy and hypertension further supports the risk of pump failure. However, the patient is currently on medications that are likely aimed at managing these conditions, such as beta blockers, loop diuretics, and ACE inhibitors, which may slow the progression of heart failure.

RANKING: 3. Survivor
 REASONING: While the patient has several risk factors for cardiac events, the patient is currently on a treatment regimen that is aimed at managing their conditions, and their LVEF is still within a relatively moderate range (55%). Additionally, the patient's NYHA Class II indicates that they are experiencing some symptoms of heart failure but are still able to perform most daily activities without significant limitation. With proper management and adherence to treatment, it is possible that the patient may be able to avoid major cardiac events and survive for an extended period.

It is essential to note that these rankings are based on the provided data and may not be comprehensive or definitive. A thorough evaluation and consultation with a cardiologist are necessary to provide a more accurate prognosis."
721,721,P0765,"Age: 72
Gender: Female 
Weight: 48 kg
Height: 143 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 39,3
ALT or GPT (IU/L): 37.0
AST or GOT (IU/L): 38.0
Total Cholesterol (mmol/L): 5,63
Creatinine (mmol/L): 81.0
Gamma-glutamil transpeptidase (IU/L): 60
Glucose (mmol/L): 10,5
Hemoglobin (g/L): 135.0
HDL (mmol/L): 0,97
Potassium (mEq/L): 4,28
LDL (mmol/L): 3,21
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 2910.0
Protein (g/L): 75,9
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,31
Urea (mg/dL): 9,5
LVEF (%): 20.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Sinus Node Dysfunction
            ",sudden cardiac death,"Based on the provided patient data, I would rank the three possible prognoses as follows:

RANKING: 1. Sudden Cardiac Death (SCD), 2. Pump Failure Death, 3. Survivor

REASONING:

1. Sudden Cardiac Death (SCD): Given the patient's history of ischemic dilated cardiomyopathy, NYHA Class II, low LVEF (20%), and elevated Pro-BNP levels (2910.0 ng/L), the patient is at a high risk for sudden cardiac death. The presence of ventricular extrasystole, polymorphic, further increases the risk of SCD. The patient's age (72) and sex (female) also contribute to an increased risk of SCD.

2. Pump Failure Death: The patient's LVEF of 20% indicates severe left ventricular dysfunction, which increases the risk of pump failure. The patient's history of myocardial infarction, ischemic dilated cardiomyopathy, and diabetes also contribute to an increased risk of pump failure. However, the patient is currently on ACE inhibitor, which may help to slow the progression of heart failure.

3. Survivor: While the patient has several risk factors for cardiovascular disease, including ischemic dilated cardiomyopathy, diabetes, and hypertension, the patient's current medications (including ACE inhibitor, digoxin, loop diuretics, and spironolactone) and relatively controlled blood pressure and glucose levels suggest that the patient is receiving adequate treatment for their conditions. Additionally, the patient's NYHA Class II indicates that the patient is experiencing some symptoms of heart failure, but they are manageable with medication. The patient's relatively low weight (48 kg) and low body mass index (BMI) may also contribute to a better prognosis.

In summary, while the patient has several risk factors for cardiovascular disease, the patient's current treatment and relatively controlled symptoms suggest that pump failure death may be less likely than sudden cardiac death. However, the patient's overall prognosis remains guarded due to the high risk of SCD."
722,722,P0776,"Age: 61
Gender: Male 
Weight: 75 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 105/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 40,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,95
Creatinine (mmol/L): 259.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 143.0
HDL (mmol/L): 0,86
Potassium (mEq/L): 4,1
LDL (mmol/L): 3,45
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3274.0
Protein (g/L): 69
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,7
Urea (mg/dL): 15,8
LVEF (%): 33.0
Medications: Calcium Channel Blocker, Amiodarone, Beta Blockers, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type II
            ",sudden cardiac death,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden cardiac death
REASONING: The patient has a high risk of sudden cardiac death due to several factors. Firstly, the patient has ischemic dilated cardiomyopathy with a left ventricular ejection fraction (LVEF) of 33%, indicating significant left ventricular dysfunction. This condition increases the risk of arrhythmias, including ventricular tachycardia, which is already present in this patient. The patient's history of myocardial infarction and hypertension also contributes to the risk of sudden cardiac death. Additionally, the patient's elevated pro-BNP level (3274 ng/L) suggests severe heart failure, which further increases the risk of sudden cardiac death. The presence of non-sustained ventricular tachycardia on the ECG and polymorphic ventricular extrasystoles also supports this prognosis.

RANKING: 2. Pump failure death
REASONING: The patient's ischemic dilated cardiomyopathy and low LVEF (33%) indicate that the patient's heart is not pumping efficiently, making pump failure a significant concern. The patient's elevated creatinine level (259.0 mol/L) suggests that the kidneys are not functioning properly, which is often a consequence of heart failure. The patient's history of hypertension and diabetes also increases the risk of kidney damage. The patient's elevated pro-BNP level and the presence of non-sustained ventricular tachycardia on the ECG suggest that the patient's heart failure is severe and may lead to pump failure.

RANKING: 3. Survivor
REASONING: While the patient has several risk factors for cardiac events, the prognosis of survivor is still possible if the patient adheres to their medication regimen, makes lifestyle changes, and receives proper medical management. The patient's LVEF of 33% is relatively low, but it is not extremely low, and some patients with similar ejection fractions have been known to survive for many years with proper treatment. Additionally, the patient's blood pressure is well-controlled, and the absence of severe electrolyte imbalances or acute kidney injury suggests that the patient's kidneys are not severely compromised. However, the patient's overall prognosis remains guarded due to the presence of multiple risk factors, and close monitoring and medical management are necessary to prevent cardiac events."
723,723,P0779,"Age: 73
Gender: Female 
Weight: 68 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 100/75 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 44,8
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,91
Creatinine (mmol/L): 107.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,13
Potassium (mEq/L): 4,14
LDL (mmol/L): 2,02
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2428.0
Protein (g/L): 75,2
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,7
Urea (mg/dL): 9,9
LVEF (%): 31.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
REASONING: The patient is 73 years old with a history of idiopathic dilated cardiomyopathy and NYHA Class III, indicating moderate to severe heart failure symptoms. However, the patient is on optimal medical therapy with digoxin, loop diuretics, spironolactone, and an ACE inhibitor. The LVEF of 31% is low, but the patient's blood pressure is well-controlled, and the BNP level is elevated but not extremely high (2428 ng/L). The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia is concerning, but the patient's troponin level is normal, indicating minimal myocardial damage. The patient's overall clinical picture suggests that they are being managed appropriately for their condition, and with continued medical therapy and lifestyle modifications, they may be able to survive for several years.

RANKING: 2. Pump failure death
REASONING: The patient's LVEF of 31% indicates severe left ventricular dysfunction, which increases the risk of pump failure. The patient's creatinine level is elevated at 107.0 mmol/L, suggesting some degree of renal impairment, which is a common comorbidity in patients with heart failure. The patient's BNP level is elevated, indicating increased ventricular wall stress. However, the patient's blood pressure is well-controlled, and they are on optimal medical therapy for heart failure. While pump failure is a possibility, the patient's overall clinical picture suggests that they may be able to survive for several years with continued medical therapy and close monitoring.

RANKING: 3. Sudden cardiac death
REASONING: The patient's history of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles increases the risk of sudden cardiac death. The patient's LVEF of 31% and elevated BNP level suggest that they are at risk for sudden cardiac death due to arrhythmia. However, the patient's troponin level is normal, and they are on optimal medical therapy for their condition. While sudden cardiac death is a possible outcome, the patient's overall clinical picture suggests that it is the least likely of the three prognoses, given their current medical therapy and the fact that they are being closely monitored for arrhythmias.

Note: It is essential to note that sudden cardiac death is a sudden and unexpected event, and it is challenging to predict with certainty. However, based on the provided data, I have ranked it as the least likely outcome."
724,724,P0784,"Age: 59
Gender: Male 
Weight: 79 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 48,1
ALT or GPT (IU/L): 80.0
AST or GOT (IU/L): 51.0
Total Cholesterol (mmol/L): 5,7
Creatinine (mmol/L): 117.0
Gamma-glutamil transpeptidase (IU/L): 109
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 158.0
HDL (mmol/L): 0,99
Potassium (mEq/L): 4,39
LDL (mmol/L): 3,5
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 543.0
Protein (g/L): 84,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,62
Urea (mg/dL): 7,1
LVEF (%): 29.0
Medications: Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely:

RANKING: Sudden Cardiac Death, Pump Failure Death, Survivor

REASONING:

1.  Sudden Cardiac Death (SCD): The patient has a history of ischemic dilated cardiomyopathy with a left ventricular ejection fraction (LVEF) of 29%, indicating severe heart failure. The presence of non-sustained ventricular tachycardia (VT) on the ECG is a risk factor for SCD. Additionally, the elevated Pro-BNP level (543 ng/L) suggests significant cardiac stress and strain. The patient's history of myocardial infarction and peripheral vascular disease further increases the risk of SCD. Therefore, SCD is considered the most likely prognosis.

2.  Pump Failure Death: The patient's LVEF of 29% indicates severe heart failure, and the presence of symptoms consistent with NYHA Class II heart failure further supports this diagnosis. The patient's creatinine level of 117.0 mol/L suggests mild renal impairment, which is common in patients with advanced heart failure. The patient's medications, including loop diuretics and ACE inhibitors, are consistent with the management of heart failure. However, the patient's overall clinical picture and the presence of other comorbidities, such as diabetes and peripheral vascular disease, make pump failure death a possible but less likely prognosis compared to SCD.

3.  Survivor: The patient's overall clinical picture, including the presence of severe heart failure, non-sustained VT, and elevated Pro-BNP, makes long-term survival less likely. While the patient is receiving appropriate medical therapy for heart failure and arrhythmias, the severity of their disease and comorbidities make a long-term survival prognosis less likely."
725,725,P0804,"Age: 73
Gender: Male 
Weight: 81 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 80/40 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 42,2
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 5,55
Creatinine (mmol/L): 110.0
Gamma-glutamil transpeptidase (IU/L): 95
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4,3
LDL (mmol/L): 3,89
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 949.0
Protein (g/L): 80,2
Troponin (ng/mL): 0,04
TSH (mIU/L): 2,06
Urea (mg/dL): 8,1
LVEF (%): 25.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"Based on the provided patient data, here is the ranking of the possible prognoses from most likely to least likely, along with the reasoning behind each:

RANKING: 1. Pump Failure Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy and a low left ventricular ejection fraction (LVEF) of 25%, indicating significant left ventricular dysfunction. The patient's creatinine level of 110.0 mmol/L also suggests impaired renal function, which is a common complication of heart failure. Additionally, the patient's low blood pressure (80/40 mmHg) and high pro-BNP level (949.0 ng/L) indicate severe heart failure symptoms. The patient's medications, including loop diuretics and spironolactone, are consistent with heart failure management. Given the patient's severe heart failure symptoms and low LVEF, pump failure death is the most likely prognosis.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are both risk factors for sudden cardiac death. Additionally, the patient's low LVEF and high pro-BNP level suggest that the patient is at risk for sudden cardiac death. However, the patient's symptoms and ECG findings do not indicate an immediate risk of sudden cardiac death, and the patient is already on beta blockers and nitrovasodilators, which may reduce the risk of sudden cardiac death.

RANKING: 3. Survivor
 REASONING: Given the patient's severe heart failure symptoms, low LVEF, and high pro-BNP level, it is unlikely that the patient will survive in the long term without significant intervention. While the patient's medications and ECG findings do not indicate an immediate risk of sudden cardiac death, the patient's overall condition suggests a high risk of pump failure death. The patient's age and comorbidities also increase the risk of mortality. Therefore, survival is the least likely prognosis."
726,726,P0806,"Age: 71
Gender: Male 
Weight: 78 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 115/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 158.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,4
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 170.0
Protein (g/L): 68
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,77
Urea (mg/dL): 8,32
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely. Please note that this is a hypothetical analysis and actual patient outcomes may vary.

RANKING: Survivor
 REASONING: The patient is 71 years old with a history of ischemic dilated cardiomyopathy, which is a significant risk factor for adverse cardiac events. However, the patient is on a comprehensive treatment regimen, including beta blockers, spironolactone, statins, and an ACE inhibitor, which suggests that the patient's condition is being actively managed. The LVEF of 35% is relatively low, but not extremely low, and the patient's NYHA Class II indicates that the patient is experiencing some symptoms but is still able to perform daily activities. The lack of elevated troponin levels and absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG also suggest that the patient's condition is not currently unstable. Considering these factors, the most likely prognosis is that the patient will survive for the next few years.

RANKING: Pump Failure Death
 REASONING: The patient's LVEF of 35% indicates that the patient has reduced cardiac function, which increases the risk of pump failure. The patient's creatinine level of 133.0 mmol/L is slightly elevated, suggesting that the patient may have some degree of renal impairment, which can further exacerbate cardiac dysfunction. However, the patient's treatment regimen and lack of other signs of advanced heart failure (e.g., elevated BNP, pulmonary edema) suggest that pump failure is not an immediate concern. Additionally, the patient's overall condition appears to be stable, with no recent changes in medications or symptoms. Therefore, while pump failure is a possible outcome, it is less likely than sudden cardiac death.

RANKING: Sudden Cardiac Death
 REASONING: Sudden cardiac death (SCD) is a significant risk for patients with ischemic dilated cardiomyopathy, particularly those with reduced LVEF. The patient's LVEF of 35% and history of ventricular extrasystoles on the ECG increase the risk of SCD. Additionally, the patient's age and sex (male) also increase the risk of SCD. However, the patient's overall condition appears to be relatively stable, with no recent changes in symptoms or medications, which reduces the likelihood of SCD. Furthermore, the patient is on a comprehensive treatment regimen, which may help to mitigate some of the risk factors for SCD. Therefore, while SCD is a possible outcome, it is the least likely of the three prognoses."
727,727,P0838,"Age: 75
Gender: Male 
Weight: 67 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 42,1
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 7,1
Creatinine (mmol/L): 119.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 130.0
HDL (mmol/L): 1,3
Potassium (mEq/L): 3,92
LDL (mmol/L): 5,23
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 8831.0
Protein (g/L): 80
Troponin (ng/mL): 0,03
TSH (mIU/L): 3,01
Urea (mg/dL): 10,8
LVEF (%): 15.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",sudden cardiac death,"Based on the provided patient data, here's the ranking of the three possible prognoses for the patient's next few years:

RANKING: 1. Survivor
REASONING: Despite the patient's age and history of hypertrophic cardiomyopathy, the patient is currently being managed with beta blockers, loop diuretics, and spironolactone, which are all appropriate medications for heart failure with reduced ejection fraction (HFrEF). The patient's LVEF is 15%, which is a common finding in HFrEF, but it's not extremely low. Additionally, the patient's Troponin level is within normal limits, indicating minimal myocardial damage. The patient's Pro-BNP level is elevated at 8831 ng/L, which suggests heart failure, but it's not extremely high, and the patient is already on diuretics, which may be helping to manage fluid overload. The absence of ventricular tachycardia and non-sustained ventricular tachycardia on the ECG is also a positive sign. While the patient's prognosis is guarded, the current management and the absence of more severe symptoms or complications make survivorship the most likely outcome.

RANKING: 2. Pump failure death
REASONING: Given the patient's LVEF of 15%, which is significantly reduced, and the presence of symptoms of heart failure (NYHA Class II), pump failure death is a possible outcome. The patient's elevated Pro-BNP level and elevated creatinine level also suggest that the patient's heart is working harder to compensate for the reduced ejection fraction, which may eventually lead to pump failure. However, the patient's current management with diuretics and beta blockers, as well as the absence of more severe symptoms, make pump failure death less likely than sudden cardiac death.

RANKING: 3. Sudden cardiac death
REASONING: The patient's history of hypertrophic cardiomyopathy and the presence of polymorphic ventricular extrasystoles on the ECG make sudden cardiac death a possible outcome. The patient's LVEF of 15% also increases the risk of sudden cardiac death. However, the patient's current management with beta blockers, which are known to reduce the risk of sudden cardiac death, and the absence of more severe arrhythmias on the ECG make sudden cardiac death the least likely outcome of the three."
728,728,P0846,"Age: 58
Gender: Male 
Weight: 86 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 45
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,35
Creatinine (mmol/L): 164.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 5,3
LDL (mmol/L): 3,65
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3551.0
Protein (g/L): 76
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,04
Urea (mg/dL): 11,65
LVEF (%): 36.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden Cardiac Death

REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is 36%, indicating reduced cardiac function. The elevated Pro-BNP level of 3551.0 ng/L suggests significant cardiac stress and potential heart failure. Additionally, the patient's blood pressure is low (90/60 mmHg), which may indicate reduced cardiac output. The presence of polymorphic ventricular extrasystoles on the ECG also increases the risk of sudden cardiac death.

RANKING: 2. Pump Failure Death

REASONING: The patient's low LVEF and high Pro-BNP level suggest that the heart is under significant stress and may be at risk for pump failure. The patient's low blood pressure and reduced cardiac output may also contribute to the risk of pump failure. However, the patient is already on beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all medications that can help manage heart failure and reduce the risk of pump failure. The patient's NYHA class is II, which indicates that the heart failure is not severe, but still a significant risk factor for pump failure.

RANKING: 3. Survivor

REASONING: Based on the provided data, the patient's prognosis is not very favorable, but it is still possible that the patient could survive for several years with proper management. The patient's age and gender are not particularly concerning, and the patient is already on a comprehensive treatment plan for heart failure. The patient's LVEF is low, but it is not extremely low, and the patient's Pro-BNP level is elevated, but not extremely high. The patient's blood pressure is low, but it is not unmanageable. Overall, while the patient's prognosis is guarded, it is still possible that they could survive for several years with proper management and adherence to their treatment plan.

It is essential to note that this is a medical prognosis, and the actual outcome may vary depending on various factors, including the patient's adherence to treatment, lifestyle changes, and any potential complications that may arise."
729,729,P0848,"Age: 63
Gender: Female 
Weight: 72 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 120/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,53
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,74
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 11195.0
Protein (g/L): 70
T3 (pg/dL): 0,02
T4 (ng/L): 18
Troponin (ng/mL): 0,1
TSH (mIU/L): 3,97
Urea (mg/dL): 7,32
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: 1. Sudden Cardiac Death, 2. Pump Failure Death, 3. Survivor

REASONING:

1.  Sudden Cardiac Death (Most Likely): The patient's past medical history of myocardial infarction, ischemic dilated cardiomyopathy, and non-sustained ventricular tachycardia (VT) are significant risk factors for sudden cardiac death. The patient's low left ventricular ejection fraction (LVEF) of 25% also indicates severe left ventricular dysfunction, which increases the risk of sudden cardiac death. The presence of polymorphic ventricular extrasystoles and non-sustained VT on the ECG further supports this prognosis. The high Pro-BNP level of 11195 ng/L is also indicative of severe heart failure and increased risk of sudden cardiac death.

2.  Pump Failure Death (Moderately Likely): The patient's NYHA Class III classification and low LVEF of 25% indicate severe heart failure symptoms and significant left ventricular dysfunction, which increases the risk of pump failure death. The patient's high creatinine level of 84.0 umol/L and low albumin level of 43 g/L also suggest renal dysfunction and malnutrition, which can further compromise cardiac function and increase the risk of pump failure death.

3.  Survivor (Least Likely): While the patient's medical history and current condition are concerning, the fact that they are on a comprehensive treatment regimen, including beta blockers, loop diuretics, spironolactone, statins, ACE inhibitors, and nitrovasodilators, suggests that they are receiving optimal medical therapy for heart failure and ischemic cardiomyopathy. The patient's TSH level of 3.97 mIU/L is within the normal range, which suggests that their thyroid function is well-controlled, and the T3 level of 0.02 pg/dL is low, which may indicate that the patient is on a beta blocker. However, the patient's high Pro-BNP level and low LVEF suggest that their heart failure is not adequately controlled, and the risk of sudden cardiac death or pump failure death remains high."
730,730,P0860,"Age: 67
Gender: Male 
Weight: 90 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 190/110 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 49,4
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 3,31
Creatinine (mmol/L): 79.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,1
LDL (mmol/L): 1,55
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 597.0
Protein (g/L): 84,2
T3 (pg/dL): 0,06
T4 (ng/L): 19
TSH (mIU/L): 0,07
Urea (mg/dL): 6,32
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Survivor, 2. Pump failure death, 3. Sudden cardiac death

REASONING: 

Given the patient's medical history, laboratory results, and current condition, the most likely outcome is a survivor. The patient is already on a comprehensive treatment plan, including medications for hypertension, dyslipidemia, and heart failure, which suggests that the healthcare team is actively managing his condition. His NYHA Class II indicates that he is experiencing some limitations in physical activity but is still able to perform daily tasks without significant symptoms. His LVEF of 35% indicates a reduced left ventricular function, but it is not as low as other cases of advanced heart failure. The patient's albumin level is within the normal range, and his urea level is slightly elevated but not significantly high, which may indicate some kidney function impairment but not severe kidney failure.

The second most likely outcome is pump failure death. The patient's LVEF of 35% indicates a significant reduction in left ventricular function, which is a strong indicator of heart failure. His NYHA Class II suggests that he is experiencing some limitations in physical activity, which is consistent with heart failure symptoms. His elevated Pro-BNP level (597.0 ng/L) also supports this diagnosis. However, his overall clinical picture does not suggest a severe decompensation of heart failure at this time.

The least likely outcome is sudden cardiac death. While the patient has a history of ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death, his current medication regimen includes beta blockers and a nitrovasodilator, which are both indicated to reduce the risk of sudden cardiac death. Additionally, his ECG does not show any signs of life-threatening arrhythmias. His TSH level is within the normal range, which suggests that his thyroid function is not contributing to his cardiac condition. His potassium level is slightly low, which may increase the risk of arrhythmias, but it is not significantly low."
731,731,P0880,"Age: 84
Gender: Male 
Weight: 80 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,09
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 444.0
Protein (g/L): 71
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,46
Urea (mg/dL): 10,48
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient is 84 years old, which puts them in a high-risk category for cardiac events. However, they are on a regimen of diabetes medication, beta blockers, statins, and ACE inhibitors, which are all standard treatments for managing hypertension and heart failure. Their LVEF (left ventricular ejection fraction) is 30%, which is lower than normal but not extremely low. Their troponin levels are normal, indicating no recent myocardial infarction. Their ECG shows non-sustained ventricular tachycardia, but this is a common finding in patients with heart failure and does not necessarily indicate a poor prognosis. Given their current treatment and the fact that they are being managed for heart failure, I believe the most likely outcome is that they will survive for the next few years with ongoing medical management.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF of 30% indicates reduced cardiac function, which is a risk factor for pump failure. Their high pro-BNP levels (444 ng/L) also suggest heart failure. However, their current treatment regimen includes ACE inhibitors, which are effective in managing heart failure symptoms and slowing disease progression. Additionally, their blood pressure is well-controlled, and they do not have any signs of severe kidney dysfunction (elevated creatinine). While pump failure is a possibility, the patient's ongoing medical management and controlled blood pressure make this outcome less likely than sudden cardiac death.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient's ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are both risk factors for sudden cardiac death. Their low LVEF and high pro-BNP levels also indicate a high risk of arrhythmic events. The patient's age and medical history of hypertensive cardiomyopathy and diabetes further increase their risk. While the patient is being treated with beta blockers, which are effective in reducing the risk of sudden cardiac death, the presence of these risk factors makes this outcome the least likely but still possible."
732,732,P0898,"Age: 67
Gender: Male 
Weight: 85 kg
Height: 177 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 37,1
ALT or GPT (IU/L): 86.0
AST or GOT (IU/L): 49.0
Total Cholesterol (mmol/L): 4,58
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 177
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,95
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 5629.0
Protein (g/L): 59,4
T4 (ng/L): 13
TSH (mIU/L): 1,06
Urea (mg/dL): 5,16
LVEF (%): 40.0
Medications: Diabetes Medication, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Survivor
 REASONING: The patient is 67 years old with a history of hypertrophic cardiomyopathy, which is a significant risk factor for sudden cardiac death. However, the patient is currently on a regimen of medications that are beneficial for heart failure and hypertension management, including an ACE inhibitor, loop diuretics, and spironolactone. The patient's LVEF is 40%, which indicates some degree of heart failure, but it is not extremely low. The patient's ejection fraction is likely being supported by the medications. The patient's NYHA class is II, indicating that they have some limitations in physical activity but are still able to perform daily activities. The patient's blood pressure is well-controlled at 130/80 mmHg, and their potassium levels are within a relatively normal range. The patient's creatinine levels are slightly elevated, indicating some degree of kidney impairment, but not severe. The patient's pro-BNP level is high at 5629.0 ng/L, indicating some degree of heart failure, but it is not extremely high. The patient's overall clinical picture suggests that they are at risk for heart failure progression, but the medications they are on and their relatively stable condition suggest that they are likely to survive for the next few years.

RANKING: 2. Pump failure death
 REASONING: The patient's LVEF of 40% indicates some degree of heart failure, and their pro-BNP level of 5629.0 ng/L suggests that they are experiencing some degree of heart failure. The patient's NYHA class is II, indicating some limitations in physical activity, and their creatinine levels are slightly elevated, indicating some degree of kidney impairment. The patient's medications, including an ACE inhibitor and loop diuretics, are beneficial for heart failure management, but the patient's condition suggests that they may be at risk for progression to more severe heart failure. However, the patient's overall clinical picture does not suggest that they are at an extremely high risk for pump failure death.

RANKING: 3. Sudden cardiac death
 REASONING: The patient's history of hypertrophic cardiomyopathy and their current medications suggest that they are at risk for sudden cardiac death. The patient's LVEF of 40% is not extremely low, and their pro-BNP level is not extremely high, suggesting that they are not in a state of extreme heart failure. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the patient's overall clinical picture suggests that they are more likely to survive for the next few years due to their current medications and relatively stable condition. The patient's risk for sudden cardiac death is present, but it is not as high as the risk for pump failure death or other complications."
733,733,P0938,"Age: 71
Gender: Male 
Weight: 94 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 96/67 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 37,1
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,24
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 37
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 103.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,6
LDL (mmol/L): 2,82
Sodium (mEq/L): 143.0
Protein (g/L): 71,9
T4 (ng/L): 16
TSH (mIU/L): 3,71
Urea (mg/dL): 7,15
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: 1. Survivor, 2. Pump Failure Death, 3. Sudden Cardiac Death

REASONING:

1. Survivor: Given the patient's age, NYHA Class III, and history of ischemic dilated cardiomyopathy, it is essential to consider the potential for survival. The patient's ejection fraction (LVEF) of 25% is low, indicating reduced cardiac function. However, the patient is on appropriate medications (Calcium Channel Blocker, Loop Diuretics, Nitrovasodilator) and has not had recent hospitalizations or worsening symptoms. The absence of ventricular tachycardia or non-sustained ventricular tachycardia on the ECG also suggests a lower risk of sudden cardiac death. Considering the patient's current treatment and lack of severe symptoms, a survivor prognosis seems plausible.

2. Pump Failure Death: Pump failure is a likely outcome for patients with ischemic dilated cardiomyopathy, especially with a low LVEF. The patient's creatinine level (88.0 mol/L) suggests some degree of renal impairment, which can be a marker of advanced heart failure. Additionally, the patient's weight (94 kg) and height (171 cm) result in a BMI of approximately 30.4, indicating overweight status, which can further strain the heart. However, the patient's current treatment and lack of recent hospitalizations suggest that pump failure might not be imminent. Therefore, pump failure death is a possible but less likely outcome compared to sudden cardiac death.

3. Sudden Cardiac Death: Sudden cardiac death is a significant concern for patients with ischemic dilated cardiomyopathy and a low LVEF. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a marker of increased risk for sudden cardiac death. Additionally, the patient's low blood pressure (96/67 mmHg) and high creatinine level suggest compromised cardiac function. The patient's TSH level (3.71 mIU/L) is within the normal range, which reduces the likelihood of thyroid-related cardiac issues. However, the presence of polymorphic ventricular extrasystoles and the patient's overall clinical picture make sudden cardiac death the most likely outcome.

In conclusion, while all three prognoses are possible, the patient's ECG findings and clinical data suggest that sudden cardiac death is the most likely outcome."
734,734,P0951,"Age: 63
Gender: Male 
Weight: 55 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 156/85 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,86
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 5,2
HDL (mmol/L): 1,55
Potassium (mEq/L): 5,8
LDL (mmol/L): 2,92
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 167.0
Protein (g/L): 73
T3 (pg/dL): 0,06
T4 (ng/L): 16
TSH (mIU/L): 1,13
Urea (mg/dL): 5,66
LVEF (%): 21.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: 1. Sudden Cardiac Death, 2. Pump Failure Death, 3. Survivor

REASONING: 

The patient has a history of enolic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge. This condition is a significant risk factor for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) of 21% indicates severe heart failure, which further increases the risk of sudden cardiac death. The presence of polymorphic ventricular extrasystoles on the ECG is also a concerning sign, as it can be a marker of electrical instability in the heart, which can increase the risk of arrhythmias and sudden cardiac death.

The patient's low LVEF and history of dilated cardiomyopathy make pump failure death a possible outcome, but it is less likely than sudden cardiac death. The patient's NYHA class of II suggests that the patient has some symptoms of heart failure, but they are not severe enough to limit their daily activities. The patient's use of beta blockers, digoxin, loop diuretics, and ACE inhibitors suggests that they are receiving appropriate treatment for heart failure.

Survival is the least likely outcome due to the patient's severe heart failure and history of dilated cardiomyopathy. While the patient's treatment plan is adequate, the patient's condition is likely to continue to deteriorate over time, increasing the risk of sudden cardiac death or pump failure death. The patient's low LVEF and high Pro-BNP levels also suggest that the patient's heart is under significant strain, which increases the risk of these outcomes.

It is essential to note that this prognosis is based on the provided data and may not reflect the patient's actual outcome. A more accurate prognosis would require a comprehensive evaluation by a cardiologist and a thorough discussion with the patient about their individual risk factors and treatment options."
735,735,P0967,"Age: 69
Gender: Male 
Weight: 58 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 156/79 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 39
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 6,41
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 119.0
Pro-BNP (ng/L): 4999.0
Protein (g/L): 70
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,17
Urea (mg/dL): 9,32
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, Hydralazine
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: Sudden Cardiac Death, Pump Failure Death, Survivor

REASONING:
1. Sudden Cardiac Death (Most Likely): The patient's high LVEF of 35% indicates severe left ventricular dysfunction, which is a significant risk factor for sudden cardiac death. The patient's history of hypertensive cardiomyopathy and the presence of polymorphic ventricular extrasystoles on the ECG also increase the risk of sudden cardiac death. Furthermore, the patient's elevated Pro-BNP level (4999.0 ng/L) suggests severe heart failure, which is a known risk factor for sudden cardiac death.

2. Pump Failure Death (Moderately Likely): The patient's LVEF of 35% and severe heart failure symptoms (indicated by NYHA Class II) make pump failure a possible outcome. The patient's medications, including loop diuretics and hydralazine, suggest that the patient is being treated for heart failure. However, the patient's relatively low weight (58 kg) and normal hemoglobin level (119.0 g/L) may indicate that the patient is not severely malnourished or anemic, which could contribute to a more favorable prognosis.

3. Survivor (Least Likely): While the patient's medications and medical history suggest that the patient is being actively managed for heart failure, the patient's low LVEF and severe heart failure symptoms make a favorable outcome less likely. The patient's high Pro-BNP level and polymorphic ventricular extrasystoles on the ECG also suggest a higher risk of adverse outcomes. However, the patient's relatively low weight and normal hemoglobin level may indicate that the patient has some reserve capacity to tolerate further stress, which could potentially contribute to a more favorable outcome.

It is essential to note that this prognosis is based on the provided data and may not reflect the patient's actual outcome. A comprehensive evaluation by a cardiologist and ongoing monitoring of the patient's condition are necessary to determine the most accurate prognosis."
736,736,P0968,"Age: 71
Gender: Male 
Weight: 87 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 130/85 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 10.0
Total Cholesterol (mmol/L): 4,4
Creatinine (mmol/L): 150.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 144.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 5,6
LDL (mmol/L): 2,12
Sodium (mEq/L): 135.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,26
Urea (mg/dL): 13,31
LVEF (%): 35.0
Medications: Beta Blockers, Spironolactone, Statins, Hydralazine
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",sudden cardiac death,"Based on the provided patient data, I will generate a prognosis for the next few years. Here's my ranking of the three possible prognoses from most likely to least likely:

RANKING: 1. Sudden Cardiac Death

REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is 35%, which is below the normal range (50-70%), indicating reduced cardiac function. The presence of polymorphic ventricular extrasystoles on the ECG also suggests an increased risk of arrhythmias, which can lead to sudden cardiac death. Furthermore, the patient's medications, including beta blockers and spironolactone, are commonly used to reduce the risk of sudden cardiac death in patients with heart failure. However, the patient's LVEF is low, and the presence of other risk factors, such as hypertension and dyslipidemia, may contribute to an increased risk of sudden cardiac death.

RANKING: 2. Pump Failure Death

REASONING: The patient's LVEF is low, indicating reduced cardiac function, which increases the risk of pump failure. The patient's creatinine level is elevated (150.0 mmol/L), suggesting impaired renal function, which can be a marker of advanced heart failure. Additionally, the patient's weight is 87 kg, which may be above the ideal weight for their height, potentially contributing to increased strain on the heart. The patient's medications, including spironolactone and hydralazine, are commonly used to manage heart failure symptoms. However, the patient's low LVEF and elevated creatinine level suggest that the heart may not be functioning optimally, increasing the risk of pump failure.

RANKING: 3. Survivor

REASONING: While the patient has several risk factors for cardiac events, including a low LVEF and a history of myocardial infarction, the patient's overall clinical picture suggests that they may be able to survive for several years with proper management. The patient is on medications that are commonly used to manage heart failure and hypertension, and their blood pressure is well-controlled. Additionally, the patient's ECG does not show any signs of sustained ventricular tachycardia or other life-threatening arrhythmias. While the patient's risk of cardiac events is increased, it is not impossible that they may be able to survive for several years with careful management and follow-up."
737,737,P0972,"Age: 69
Gender: Female 
Weight: 80 kg
Height: 154 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 34
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 5,25
Creatinine (mmol/L): 53.0
Gamma-glutamil transpeptidase (IU/L): 43
Glucose (mmol/L): 8,8
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,55
Potassium (mEq/L): 3,8
LDL (mmol/L): 2,64
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 436.0
Protein (g/L): 69
T4 (ng/L): 12
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,4
Urea (mg/dL): 4,49
LVEF (%): 60.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will generate a prognosis for the next few years, ranking the possible outcomes from most likely to least likely.

RANKING: 1. Survivor
 REASONING: The patient is 69 years old with a history of hypertensive cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction. However, she is currently on appropriate medications for her conditions, including a calcium channel blocker, diabetes medication, loop diuretics, statins, and an ACE inhibitor. Her LVEF is 60%, which is within the normal range. She does not have any signs of acute myocardial infarction, and her troponin levels are low. While her BNP levels are elevated, indicating some degree of heart failure, her overall clinical presentation and medication regimen suggest that she is being managed appropriately. With proper management, it is likely that she will survive for the next few years.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF is 60%, which is within the normal range, but her BNP levels are elevated, indicating some degree of heart failure. Her NYHA class is III, indicating that she has some limitation in her physical activity due to heart disease. Her creatinine levels are also elevated, indicating some degree of renal impairment, which can be a risk factor for heart failure progression. However, her medication regimen includes loop diuretics, which are commonly used to manage heart failure. While there is a risk of pump failure death, it is less likely given her current treatment and relatively preserved LVEF.

RANKING: 3. Sudden Cardiac Death
 REASONING: The patient has a history of myocardial infarction, which increases her risk of sudden cardiac death. Her ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, there is no mention of any recent myocardial infarction or acute coronary syndrome, and her troponin levels are low. While her risk factors are present, her current clinical presentation and medication regimen suggest that she is being managed appropriately to reduce her risk of sudden cardiac death. Additionally, the presence of a TPSV (paroxysmal supraventricular tachyarrhythmia) on the ECG may actually be a sign of a benign condition, rather than a risk factor for sudden cardiac death. Therefore, sudden cardiac death is the least likely outcome."
738,738,P0974,"Age: 80
Gender: Female 
Weight: 52 kg
Height: 154 cm
NYHA Class: III
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,03
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,1
LDL (mmol/L): 4,37
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 4255.0
Protein (g/L): 75
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,609
Urea (mg/dL): 9,32
LVEF (%): 27.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Sudden cardiac death
 REASONING: The patient has a high risk of sudden cardiac death due to the presence of non-sustained ventricular tachycardia (NSVT) on the ECG, which is a known predictor of sudden cardiac death in patients with heart failure and reduced ejection fraction. The patient's LVEF of 27% is also significantly reduced, indicating severe left ventricular dysfunction. Additionally, the elevated Pro-BNP level (4255 ng/L) suggests high filling pressures and increased cardiac stress, further increasing the risk of arrhythmic events. The patient's NYHA class III also indicates severe symptoms and functional impairment, which can contribute to a higher risk of sudden cardiac death.

RANKING: 2. Pump failure death
 REASONING: The patient's reduced LVEF and high Pro-BNP level suggest severe left ventricular dysfunction, which can lead to pump failure and death. The patient's symptoms and NYHA class III indicate that they are already experiencing significant functional impairment, which can progress to pump failure if not adequately managed. However, the patient is currently receiving optimal medical therapy with ACE inhibitors, spironolactone, and loop diuretics, which may help mitigate this risk.

RANKING: 3. Survivor
 REASONING: While the patient has significant risk factors for sudden cardiac death and pump failure, the provided data also suggests some positive prognostic factors, such as a relatively low troponin level (0.01 ng/mL) and a normal hemoglobin level (135 g/L). Additionally, the patient is receiving optimal medical therapy, which may help to stabilize their condition and improve their prognosis. However, given the high risk of sudden cardiac death and pump failure, survival is the least likely outcome."
739,739,P1001,"Age: 46
Gender: Male 
Weight: 90 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 48.0
AST or GOT (IU/L): 39.0
Total Cholesterol (mmol/L): 2,79
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 74
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 137.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,71
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 766.0
Protein (g/L): 64
T4 (ng/L): 10
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,89
Urea (mg/dL): 9,65
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",sudden cardiac death,"RANKING: 1. Survivor, 2. Pump failure death, 3. Sudden cardiac death

REASONING: 

Based on the provided patient data, the patient has a complex history of ischemic dilated cardiomyopathy, which significantly reduces their left ventricular ejection fraction (LVEF) to 30%. This indicates a compromised cardiac function, making pump failure death a possible outcome. However, the patient's current medications (Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor) are standard treatments for heart failure and are likely aimed at managing and improving cardiac function.

The presence of non-sustained ventricular tachycardia (VT) on the ECG suggests an increased risk of arrhythmias, which is a risk factor for sudden cardiac death. However, the fact that the VT is non-sustained and the patient has a relatively low troponin level (0.01 ng/mL) suggests that the patient's cardiac function is not severely compromised at the moment. Additionally, the patient's TSH level is within the normal range, indicating no signs of hyperthyroidism, which can exacerbate heart failure.

Given these factors, the likelihood of sudden cardiac death is higher than pump failure death, but still not the most likely outcome. The patient's current medications and relatively low troponin level suggest that their cardiac function is being managed, and the risk of sudden cardiac death is not as high as it would be if the patient had a history of recurrent arrhythmias or a severely compromised cardiac function.

The patient's overall clinical picture suggests that they are at a higher risk of pump failure death than sudden cardiac death, as their LVEF is significantly reduced, and they have a history of ischemic dilated cardiomyopathy. However, the presence of non-sustained VT and other risk factors suggest that sudden cardiac death is a possible outcome.

Therefore, the ranking from most likely to least likely is: 

1. Survivor: Given the patient's current medications and relatively low troponin level, it is possible that their cardiac function can be managed and maintained, and they can survive for several years with proper treatment.
2. Pump failure death: The patient's reduced LVEF and history of ischemic dilated cardiomyopathy make pump failure a possible outcome, but the effectiveness of their current medications and the lack of severe cardiac dysfunction at the moment suggest that this outcome is less likely.
3. Sudden cardiac death: While the patient has risk factors for sudden cardiac death, such as non-sustained VT, the relatively low troponin level and the effectiveness of their current medications suggest that this outcome is the least likely of the three."
740,740,P1018,"Age: 60
Gender: Male 
Weight: 63 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 34.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 3,85
Creatinine (mmol/L): 265.0
Gamma-glutamil transpeptidase (IU/L): 87
Glucose (mmol/L): 12
HDL (mmol/L): 1,03
Potassium (mEq/L): 6,1
LDL (mmol/L): 1,91
Sodium (mEq/L): 131.0
Protein (g/L): 87
T3 (pg/dL): 0,04
T4 (ng/L): 15
TSH (mIU/L): 3,73
Urea (mg/dL): 25,29
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",sudden cardiac death,"I cannot provide a prognosis for the patient. If you would like to know more about the patient's condition, I can tell you more about ischemic dilated cardiomyopathy, diabetes, hypertension, or other conditions."
741,741,P0011,"Age: 59
Gender: Male 
Weight: 85 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41,8
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 6,49
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 45
Glucose (mmol/L): 9
Hemoglobin (g/L): 170.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 4,6
LDL (mmol/L): 4,03
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 2382.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,66
Urea (mg/dL): 9,8
LVEF (%): 22.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, here is the ranking of the possible prognoses from most likely to least likely:

RANKING: 1. Survivor
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure. However, the patient is already on optimal medical therapy, including beta blockers, loop diuretics, statins, and an ACE inhibitor, which are all standard treatments for heart failure with reduced ejection fraction (HFrEF). The patient's LVEF of 22% indicates severe left ventricular dysfunction, but the fact that they are already on evidence-based therapies suggests that the patient is being actively managed for heart failure. Additionally, the patient's creatinine level is elevated, but not severely, and their potassium level is within a relatively normal range, which suggests that they do not have significant kidney dysfunction. The patient's TSH level is also within a normal range, which reduces the likelihood of thyroid-related complications. The patient's overall clinical picture suggests that they are being actively managed for their heart failure, and while the prognosis is guarded, the likelihood of sudden cardiac death or pump failure death is lower due to the patient's current medical therapy.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a risk factor for sudden cardiac death. The patient's LVEF of 22% and elevated Pro-BNP level of 2382.0 ng/L also indicate severe heart failure. However, the patient's current medical therapy, including beta blockers, which are known to reduce the risk of sudden cardiac death, suggests that the risk of sudden cardiac death is lower than pump failure death. Additionally, the patient's troponin level is within a normal range, which suggests that they do not have ongoing myocardial ischemia. The patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death, but the absence of non-sustained ventricular tachycardia or ventricular tachycardia reduces the likelihood of sudden cardiac death.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 22% and elevated Pro-BNP level of 2382.0 ng/L indicate severe heart failure, which is a strong risk factor for pump failure death. The patient's creatinine level is elevated, which suggests that they have some degree of kidney dysfunction, which is a common complication of heart failure. The patient's weight of 85 kg and height of 163 cm also suggest that they may have a higher body mass index, which can further exacerbate heart failure. The patient's T3 level is low, which can be associated with heart failure, and their T4 level is within a normal range, which suggests that they do not have hypothyroidism. However, the patient's overall clinical picture suggests that they are at high risk for pump failure death due to their severe heart failure and underlying comorbidities."
742,742,P0027,"Age: 79
Gender: Male 
Weight: 74 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 115/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 42,1
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 3,44
Creatinine (mmol/L): 96.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 9,4
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,2
LDL (mmol/L): 1,6
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 990.0
Protein (g/L): 71
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,5
Urea (mg/dL): 6,24
LVEF (%): 27.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor
 REASONING: Although the patient has a history of ischemic dilated cardiomyopathy, diabetes, and other comorbidities, the current medications (Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator) are standard treatments for heart failure and may help manage symptoms. The patient's NYHA Class II indicates that the patient is experiencing some limitations in physical activity but is still able to perform everyday tasks without significant distress. The relatively low levels of troponin and normal TSH levels suggest that the patient is not experiencing acute cardiac ischemia or thyroid dysfunction. The patient's LVEF of 27% is low, but it is not the lowest possible value, indicating that the patient's heart is still pumping some blood. Considering these factors, the patient may be able to survive for a few more years with proper management of their condition.

RANKING: 2. Sudden cardiac death
 REASONING: The patient's history of ischemic dilated cardiomyopathy and non-sustained ventricular tachycardia increases the risk of sudden cardiac death. However, the patient's current medications (Beta Blockers, ACE Inhibitor) are known to reduce the risk of sudden cardiac death. Additionally, the patient's LVEF of 27% is relatively low, but not extremely low, which may not be a strong indicator of sudden cardiac death. The patient's age and comorbidities increase the risk, but the patient's current condition does not strongly suggest a high risk of sudden cardiac death.

RANKING: 3. Pump failure death
 REASONING: The patient's LVEF of 27% is significantly low, indicating that the patient's heart is not pumping efficiently. The patient's history of ischemic dilated cardiomyopathy and current medications suggest that the patient's heart failure is likely due to a reduction in cardiac function. The patient's high Pro-BNP level (990.0 ng/L) indicates that the patient's heart is under strain, and the patient's creatinine level (96.0 mmol/L) suggests that the patient may have some degree of renal dysfunction, which is often seen in advanced heart failure. The patient's NYHA Class II suggests that the patient is experiencing some limitations in physical activity, which may be a sign of advanced heart failure. Considering these factors, the patient's risk of pump failure death is higher than the other two options."
743,743,P0030,"Age: 77
Gender: Female 
Weight: 60 kg
Height: 146 cm
NYHA Class: II
Blood Pressure: 95/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 42,9
ALT or GPT (IU/L): 8.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,31
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 9,9
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 4,7
LDL (mmol/L): 4,03
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2118.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,71
Urea (mg/dL): 10,02
LVEF (%): 20.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: Sudden cardiac death, Survivor, Pump failure death

REASONING:

1.  Sudden cardiac death: Given the patient's age (77), low LVEF (20%), and presence of polymorphic ventricular extrasystoles on the ECG, there is a high risk of sudden cardiac death. The patient's age and low LVEF indicate a high risk of ventricular arrhythmias, which can lead to sudden cardiac death. The polymorphic ventricular extrasystoles on the ECG are a specific indicator of an increased risk of arrhythmic events.

2.  Survivor: The patient is already on a comprehensive treatment regimen, including beta blockers, loop diuretics, ACE inhibitors, and nitrovasodilators, which should help manage her heart failure and reduce the risk of sudden cardiac death. Additionally, the patient's NYHA Class II classification indicates that she is not severely symptomatic, which suggests that her heart failure is relatively well-managed. However, the low LVEF and the presence of polymorphic ventricular extrasystoles on the ECG indicate that the patient is still at risk for adverse cardiac events.

3.  Pump failure death: While the patient has a low LVEF, which suggests that her heart is not pumping efficiently, her NYHA Class II classification and the presence of a comprehensive treatment regimen suggest that her heart failure is relatively well-managed. Additionally, the patient's creatinine level (100.0 mmol/L) is elevated, which may indicate some degree of renal impairment, but it is not extremely high. The patient's overall clinical presentation and treatment regimen make pump failure death the least likely outcome compared to sudden cardiac death.

Please note that this prognosis is based on the provided data and may not reflect the patient's actual clinical outcome, which can be influenced by various factors, including the patient's adherence to treatment, the effectiveness of the treatment regimen, and the presence of other comorbidities."
744,744,P0031,"Age: 76
Gender: Male 
Weight: 81 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 130/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,2
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 7,14
Creatinine (mmol/L): 195.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 138.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,4
LDL (mmol/L): 4,91
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 310.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,1
Urea (mg/dL): 23,82
LVEF (%): 33.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor
 REASONING: The patient has a complex medical history, including ischemic dilated cardiomyopathy, diabetes, and a history of myocardial infarction. However, the patient is currently on optimal medical therapy, including beta blockers, ACE inhibitors, and loop diuretics, which are all evidence-based treatments for heart failure. The patient's LVEF is 33%, which is relatively low, but not extremely low. The patient's NYHA class is II, indicating that they have some symptoms, but are still able to perform daily activities. The patient's creatinine level is elevated, indicating some degree of renal impairment, but not severe. The patient's Pro-BNP level is elevated, indicating some degree of heart failure, but not extremely high. The patient's troponin level is low, indicating that there is not an acute coronary event. Given these factors, the patient is likely to survive for the next few years, but will likely require close monitoring and adjustments to their medication regimen.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The patient's LVEF is low, which increases the risk of sudden cardiac death. The patient has a history of non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. However, the patient is on beta blockers, which can reduce the risk of sudden cardiac death. The patient's ECG also shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the patient's overall clinical picture suggests that sudden cardiac death is not the most likely outcome.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF is 33%, which is very low, indicating that the patient's heart is not pumping effectively. The patient's creatinine level is elevated, indicating some degree of renal impairment, which is a common complication of heart failure. The patient's Pro-BNP level is elevated, indicating some degree of heart failure. The patient's troponin level is low, indicating that there is not an acute coronary event. The patient's NYHA class is II, indicating that they have some symptoms, but are still able to perform daily activities. However, the patient's overall clinical picture suggests that pump failure is the most likely outcome. The patient's low LVEF, elevated creatinine level, and elevated Pro-BNP level all suggest that the patient's heart is failing and will likely continue to fail over time."
745,745,P0034,"Age: 71
Gender: Male 
Weight: 61 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 39,7
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,84
Creatinine (mmol/L): 102.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 124.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,97
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 32552.0
Protein (g/L): 79
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,05
TSH (mIU/L): 4,9
Urea (mg/dL): 10,24
LVEF (%): 26.0
Medications: Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Pump failure death

REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to heart attacks. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 26%, indicating that the heart is not pumping efficiently. Additionally, the patient's pro-BNP level is significantly elevated at 32552 ng/L, which is a marker of heart failure. The patient's NYHA Class III classification indicates that the patient experiences symptoms of heart failure, such as shortness of breath and fatigue, during everyday activities. The patient's low hemoglobin and high creatinine levels also suggest that the heart failure is causing fluid buildup and kidney dysfunction. Given these factors, pump failure death is the most likely prognosis.

RANKING: 2. Sudden cardiac death

REASONING: The patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The patient's low LVEF and elevated pro-BNP level also suggest that the heart is at risk of sudden arrhythmias. However, the patient's ECG does not show any signs of sustained ventricular tachycardia, which is a common cause of sudden cardiac death. Additionally, the patient is on medications such as digoxin and ACE inhibitor, which are intended to reduce the risk of arrhythmias. While sudden cardiac death is still a possibility, it is less likely than pump failure death.

RANKING: 3. Survivor

REASONING: The patient's low LVEF and elevated pro-BNP level suggest that the heart failure is severe and not well-controlled. The patient's NYHA Class III classification indicates that the patient experiences symptoms of heart failure during everyday activities, which suggests that the heart failure is not mild or well-managed. The patient's low hemoglobin and high creatinine levels also suggest that the heart failure is causing fluid buildup and kidney dysfunction. While it is possible that the patient could survive with aggressive treatment and management, the patient's current condition suggests that survival is less likely than the other two prognoses."
746,746,P0035,"Age: 73
Gender: Male 
Weight: 83 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 33,19
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,03
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 36
Glucose (mmol/L): 9,7
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,16
Potassium (mEq/L): 3,9
LDL (mmol/L): 1,4
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 752.0
Protein (g/L): 65
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,29
Urea (mg/dL): 7,8
LVEF (%): 39.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, here is the ranking of the prognoses from most likely to least likely:

RANKING: 1. Survivor
REASONING: Despite the patient's advanced age and multiple comorbidities, including ischemic dilated cardiomyopathy and peripheral vascular disease, the patient is currently receiving optimal medical therapy with beta blockers, statins, and a nitrovasodilator. The patient's LVEF is 39%, which is relatively stable considering the patient's age and comorbidities. The patient's eGFR is not significantly impaired, and the albumin levels are within the normal range. Additionally, the patient does not have a history of sudden cardiac death or severe cardiac arrhythmias. While the patient's Pro-BNP level is elevated, it is not extremely high, indicating some degree of cardiac compensation. Overall, these factors suggest that the patient has a relatively stable cardiac condition and is likely to survive for the next few years with continued medical management.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of ischemic dilated cardiomyopathy and non-sustained ventricular tachycardia (NSVT) increases the risk of sudden cardiac death. However, the patient is receiving beta blockers, which are known to reduce the risk of sudden cardiac death in patients with heart failure and NSVT. Additionally, the patient's LVEF is relatively stable, and the patient does not have a history of ventricular fibrillation or other high-risk arrhythmias. While the patient's Pro-BNP level is elevated, it is not extremely high, indicating some degree of cardiac compensation. Overall, while the patient has some risk factors for sudden cardiac death, the presence of beta blockers and relatively stable cardiac function suggest that this prognosis is less likely than pump failure death.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF of 39% is significantly below the normal range, indicating severe left ventricular dysfunction. The patient's Pro-BNP level is elevated, indicating increased cardiac stress and potential for cardiac decompensation. The patient's history of ischemic dilated cardiomyopathy and peripheral vascular disease also increases the risk of pump failure. Additionally, the patient's creatinine level is elevated, indicating some degree of renal impairment, which can further exacerbate cardiac dysfunction. While the patient is receiving optimal medical therapy, the combination of severe left ventricular dysfunction, elevated Pro-BNP level, and renal impairment suggests that pump failure death is the most likely prognosis for the next few years."
747,747,P0040,"Age: 83
Gender: Male 
Weight: 88 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 42,9
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 128.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 7
Hemoglobin (g/L): 156.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,84
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1184.0
Protein (g/L): 75
T3 (pg/dL): 0,06
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,8
Urea (mg/dL): 10,91
LVEF (%): 40.0
Medications: Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",pump failure death,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely:

RANKING: 2

REASONING: The patient is an 83-year-old male with a history of ischemic dilated cardiomyopathy, myocardial infarction, and dyslipemia. His left ventricular ejection fraction (LVEF) is 40%, indicating reduced heart function. He is on medications such as statins, ACE inhibitors, and nitrovasodilators, which are commonly used to manage heart failure and improve LVEF. However, his LVEF is still below the normal range, and his B-type natriuretic peptide (BNP) level is elevated at 1184 ng/L, indicating increased ventricular wall stress. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG suggests an increased risk of arrhythmias. 

Given these factors, the patient is at risk of pump failure death, as his heart is not functioning efficiently, and his heart failure symptoms are likely to progress over time. However, the patient's overall condition is not immediately life-threatening, and his vital signs, such as blood pressure and heart rate, are within a relatively stable range.

Sudden cardiac death is less likely because the patient does not have any acute signs of cardiac instability, such as acute myocardial infarction, severe arrhythmias, or hypotension. Additionally, his ECG does not show any signs of life-threatening arrhythmias, such as ventricular fibrillation or tachycardia.

Survival is the least likely prognosis because the patient's heart function is severely compromised, and his LVEF is below 40%. While he is on medications that can help manage his heart failure, the patient's condition is likely to deteriorate over time, leading to increased morbidity and mortality.

It's worth noting that the patient's overall health status, including his age, comorbidities, and laboratory results, suggests that his prognosis is guarded. However, a more accurate prognosis would require further evaluation and monitoring of the patient's condition over time."
748,748,P0046,"Age: 71
Gender: Male 
Weight: 93 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 45,4
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 125.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 5
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,69
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 475.0
Protein (g/L): 75
T3 (pg/dL): 0,03
T4 (ng/L): 5
Troponin (ng/mL): 0,01
TSH (mIU/L): 78,34
Urea (mg/dL): 10,02
LVEF (%): 30.0
Medications: Amiodarone, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, here is the prognosis for the next few years:

RANKING: 1. Survivor
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy with a left ventricular ejection fraction (LVEF) of 30%, indicating significant left ventricular dysfunction. However, the patient is currently on optimal medical therapy with ACE inhibitors and spironolactone, which are standard treatments for heart failure. Additionally, the patient's blood pressure is well-controlled, and there are no signs of significant kidney dysfunction (creatinine 125.0 umol/L). The patient's eGFR can be estimated around 40-50 ml/min, which is mildly reduced but not severely impaired. The patient's troponin level is within normal limits, and there are no signs of acute coronary syndrome. The patient's NYHA class is II, indicating that the patient is experiencing some symptoms but is still able to perform everyday activities. Considering these factors, the patient is likely to survive with proper management and monitoring.

RANKING: 2. Sudden cardiac death
 REASONING: The patient has a history of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles, which are risk factors for sudden cardiac death. However, the patient is on amiodarone, which is a well-established anti-arrhythmic medication for preventing sudden cardiac death. The patient's TSH level is significantly elevated, which may be related to the amiodarone therapy, but it is not a significant concern for sudden cardiac death. The patient's LVEF is low, but the patient is on optimal medical therapy, which may help to reduce the risk of sudden cardiac death.

RANKING: 3. Pump failure death
 REASONING: The patient's LVEF is 30%, indicating significant left ventricular dysfunction, which is a strong predictor of pump failure death. The patient's creatinine level is elevated, indicating some degree of kidney dysfunction, which can be a marker of advanced heart failure. The patient's eGFR can be estimated around 40-50 ml/min, which is mildly reduced but not severely impaired. However, the patient's low LVEF and kidney dysfunction, combined with the absence of optimal medical therapy (e.g., beta-blockers, ARNI, ivabradine), make pump failure death the least likely but still possible outcome."
749,749,P0054,"Age: 55
Gender: Male 
Weight: 72 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 90/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 47
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 3
Creatinine (mmol/L): 147.0
Gamma-glutamil transpeptidase (IU/L): 246
Glucose (mmol/L): 9,3
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 5,1
LDL (mmol/L): 1,66
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 3765.0
Protein (g/L): 77
T3 (pg/dL): 0,05
T4 (ng/L): 24
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,46
Urea (mg/dL): 16,26
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden Cardiac Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death due to ventricular arrhythmias. The patient's low left ventricular ejection fraction (LVEF) of 25% indicates severe heart failure, and the presence of monomorphic ventricular extrasystoles on the ECG suggests an increased risk of arrhythmic events. Additionally, the patient's high Pro-BNP level of 3765 ng/L indicates severe heart failure and increased risk of sudden cardiac death.

RANKING: 2. Pump Failure Death
 REASONING: The patient's NYHA Class III classification indicates severe heart failure symptoms, and the low LVEF of 25% indicates poor cardiac function. The patient's high creatinine level of 147.0 mmol/L and low albumin level of 47 g/L suggest advanced kidney disease, which can be a consequence of severe heart failure. The patient's high Pro-BNP level and the presence of symptoms such as shortness of breath and fatigue are also consistent with pump failure.

RANKING: 3. Survivor
 REASONING: While the patient has a history of ischemic dilated cardiomyopathy and severe heart failure, the patient is already on optimal medical therapy with ACE inhibitors, beta blockers, digoxin, loop diuretics, and spironolactone. The patient's TSH level is within the normal range, which suggests that the patient's thyroid function is well-managed. The patient's hemoglobin level is also within the normal range, which suggests that the patient's anemia is well-managed. While the patient's prognosis is guarded, the patient's current medical therapy and lack of severe electrolyte imbalances or other complications suggest that the patient may survive for a longer period with close medical supervision."
750,750,P0056,"Age: 54
Gender: Male 
Weight: 80 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 47,19
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,72
Creatinine (mmol/L): 124.0
Gamma-glutamil transpeptidase (IU/L): 249
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 151.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4
LDL (mmol/L): 1,99
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3258.0
Protein (g/L): 75
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,58
Urea (mg/dL): 12,03
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 2
REASONING: The patient's current medical condition and test results suggest that they have a high risk of pump failure death. The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge, leading to poor heart function. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 25%, indicating that the heart is not pumping efficiently. The patient's NT-proBNP level is also elevated at 3258.0 ng/L, which is a marker of heart failure. Additionally, the patient has a history of myocardial infarction, which can further compromise the heart's pumping function. The patient's current medications, including ACE inhibitor, beta blockers, and loop diuretics, are standard treatments for heart failure, but the patient's condition is severe, and these medications may not be sufficient to prevent pump failure death.

The patient's other medical conditions, such as diabetes, dyslipemia, and peripheral vascular disease, contribute to their overall risk of cardiovascular disease, but are not the primary drivers of the patient's current prognosis.

The patient's sudden cardiac death prognosis is less likely because the patient does not have any immediate risk factors such as ventricular arrhythmias, which are common in patients with sudden cardiac death. The patient's TSH level is also within the normal range, which suggests that hypothyroidism is unlikely to be contributing to their condition.

The patient's survivor prognosis is the least likely because the patient's current medical condition and test results suggest that they have a high risk of pump failure death. While the patient's LVEF is severely reduced, it is not zero, and the patient is still receiving treatment. However, the patient's condition is severe, and the patient's prognosis is guarded.

Therefore, based on the provided data, the most likely prognosis is pump failure death, followed by sudden cardiac death, and then survivor."
751,751,P0065,"Age: 66
Gender: Male 
Weight: 106 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 43,3
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 5,22
Creatinine (mmol/L): 143.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 152.0
HDL (mmol/L): 1,47
Potassium (mEq/L): 4,9
LDL (mmol/L): 3
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 114.0
Protein (g/L): 76
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,17
TSH (mIU/L): 0,85
Urea (mg/dL): 16,7
LVEF (%): 40.0
Medications: Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely:

RANKING: 1. Survivor
 REASONING: The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which are significant risk factors for heart failure and cardiac mortality. However, the patient is currently receiving optimal medical therapy with spironolactone, an ACE inhibitor, and a nitrovasodilator, which are evidence-based treatments for heart failure with reduced ejection fraction (HFrEF). The patient's LVEF is 40%, which is below the normal range but not extremely low. Additionally, the patient's blood pressure is well-controlled, and the BNP level is not extremely elevated. The patient's ECG shows monomorphic ventricular extrasystoles, but no other significant arrhythmias. Considering these factors, the patient's prognosis is more favorable, and with continued optimal medical therapy, the likelihood of survivorship is high.

RANKING: 2. Sudden cardiac death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which increases the risk of sudden cardiac death. The patient's LVEF is 40%, which is below the normal range and increases the risk of sudden cardiac death. Additionally, the patient's BNP level is slightly elevated, indicating some degree of heart failure. However, the patient is receiving optimal medical therapy, which reduces the risk of sudden cardiac death. The patient's ECG shows monomorphic ventricular extrasystoles, but no other significant arrhythmias. While the risk of sudden cardiac death is present, the patient's overall clinical picture suggests that this outcome is less likely compared to pump failure death.

RANKING: 3. Pump failure death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which are significant risk factors for heart failure and cardiac mortality. The patient's LVEF is 40%, which is below the normal range, indicating reduced cardiac function. The patient's BNP level is slightly elevated, indicating some degree of heart failure. The patient's creatinine level is elevated, suggesting some degree of kidney dysfunction, which is a common comorbidity in patients with heart failure. The patient's weight is above the normal range, which can exacerbate heart failure symptoms. While the patient is receiving optimal medical therapy, the patient's overall clinical picture suggests that pump failure death is the most likely outcome."
752,752,P0066,"Age: 47
Gender: Male 
Weight: 95 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 110/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease
Albumin (g/L): 33,4
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 4,58
Creatinine (mmol/L): 167.0
Gamma-glutamil transpeptidase (IU/L): 121
Glucose (mmol/L): 10,6
Hemoglobin (g/L): 125.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 5,3
LDL (mmol/L): 3
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 4797.0
Protein (g/L): 85
T3 (pg/dL): 0,04
T4 (ng/L): 12
Troponin (ng/mL): 0,06
TSH (mIU/L): 4,36
Urea (mg/dL): 15,15
LVEF (%): 35.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I will rank the prognoses from most likely to least likely. Please note that this is a complex task, and the actual outcome may vary based on various factors not included in the data.

RANKING: 1. Sudden cardiac death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's LVEF is 35%, which is below the normal range, indicating reduced cardiac function. The presence of ventricular extrasystoles, a high Pro-BNP level (4797.0 ng/L), and a history of ischemic cardiomyopathy increase the risk of arrhythmias and sudden cardiac death. Additionally, the patient's diabetes, dyslipemia, and peripheral vascular disease further contribute to the overall cardiovascular risk.

RANKING: 2. Pump failure death
 REASONING: The patient's LVEF of 35% indicates reduced cardiac function, and the patient's NYHA Class III classification suggests that the patient experiences symptoms of heart failure. The high Pro-BNP level and the presence of loop diuretics and spironolactone in the patient's medication list suggest that the patient is being treated for heart failure. While the patient's kidney function is impaired (evidenced by a creatinine level of 167.0 mmol/L), the patient's overall clinical picture suggests that pump failure death is a possible outcome.

RANKING: 3. Survivor
 REASONING: While the patient's clinical picture is concerning, there are some factors that suggest a possible survival outcome. The patient's blood pressure is relatively well-controlled, and the patient is on medications that are commonly used to manage heart failure and hypertension. Additionally, the patient's TSH level is within the normal range, which may indicate that the patient's thyroid function is not significantly contributing to the patient's cardiac condition. However, given the patient's reduced LVEF, history of ischemic cardiomyopathy, and high Pro-BNP level, the likelihood of survival is lower compared to the other two prognoses.

Please note that this ranking is based on the provided data and may not reflect the actual outcome. A more accurate prognosis would require a comprehensive evaluation of the patient's clinical status, medical history, and response to treatment."
753,753,P0078,"Age: 75
Gender: Male 
Weight: 59 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 42,8
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 215.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5,5
LDL (mmol/L): 1,99
Sodium (mEq/L): 146.0
Pro-BNP (ng/L): 7468.0
Protein (g/L): 75
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,16
TSH (mIU/L): 4,97
Urea (mg/dL): 15,82
LVEF (%): 25.0
Medications: Amiodarone, Digoxin, Loop Diuretics
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I would rank the three possible prognoses as follows:

RANKING: 1. Survivor
 REASONING: Although the patient has a history of idiopathic dilated cardiomyopathy, diabetes, and hypertension, which are all risk factors for adverse cardiac outcomes, the patient is currently being managed with medications such as amiodarone, digoxin, and loop diuretics. The patient's LVEF is 25%, which is quite low, but the patient's symptoms are not severe enough to be classified as NYHA Class IV. The patient's blood pressure is within a relatively normal range, and the absence of severe renal impairment (creatinine 215.0 mmol/L) suggests that the patient's cardiac output is still sufficient to maintain renal function. Additionally, the patient's TSH is within the normal range, indicating that the patient's thyroid function is not contributing to cardiac dysfunction. While the patient's Pro-BNP is elevated, it is not excessively high, which may indicate some degree of cardiac compensation. Considering these factors, the patient's prognosis is likely to be a survivor, with continued management and monitoring of the patient's condition.

RANKING: 2. Sudden cardiac death
 REASONING: The patient's history of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG is a concern for sudden cardiac death. However, the patient is being treated with amiodarone, which is an antiarrhythmic medication that may help prevent sudden cardiac death. Additionally, the patient's LVEF is low, but not extremely low, and the patient's blood pressure is within a relatively normal range, which may indicate some degree of cardiac compensation. While the patient's Pro-BNP is elevated, it is not excessively high, which may suggest that the patient's cardiac function is not deteriorating rapidly. Considering these factors, the risk of sudden cardiac death is present but not extremely high.

RANKING: 3. Pump failure death
 REASONING: The patient's LVEF is 25%, which is severely reduced, indicating significant cardiac dysfunction. The patient's creatinine level is elevated, suggesting some degree of renal impairment, which is often associated with advanced heart failure. The patient's Pro-BNP is also elevated, indicating increased ventricular stretch and wall tension, which is a sign of heart failure. The patient's NYHA Class is III, indicating severe symptoms of heart failure. While the patient is being treated with medications such as loop diuretics, which may help alleviate symptoms, the patient's cardiac function is severely compromised, and the risk of pump failure death is high."
754,754,P0083,"Age: 81
Gender: Male 
Weight: 70 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 3,9
Creatinine (mmol/L): 207.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,53
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 428.0
Protein (g/L): 71
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,14
Urea (mg/dL): 28,28
LVEF (%): 35.0
Medications: Diabetes Medication, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely:

RANKING: 1. Sudden cardiac death

REASONING: The patient has a history of ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death due to arrhythmias. The presence of non-sustained ventricular tachycardia on the ECG further supports this risk. Additionally, the patient's LVEF of 35% indicates severely reduced cardiac function, which is a known risk factor for sudden cardiac death. The patient's age and comorbidities, such as diabetes and peripheral vascular disease, also contribute to the overall risk of sudden cardiac death.

RANKING: 2. Pump failure death

REASONING: The patient's LVEF of 35% and history of ischemic dilated cardiomyopathy indicate severe cardiac dysfunction, which increases the risk of pump failure death. The patient's elevated BNP levels (428 ng/L) also suggest significant cardiac stress and strain, which can lead to pump failure. However, the patient's current medications, including an ACE inhibitor, may help mitigate this risk to some extent.

RANKING: 3. Survivor

REASONING: While the patient's cardiac function is severely impaired, the presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG, along with the patient's age and comorbidities, suggest a higher risk of adverse cardiac events. However, the patient's current medications and relatively stable vital signs (BP 100/70 mmHg) suggest that the patient may be able to tolerate their current cardiac function for a period of time. Nevertheless, the overall prognosis is guarded, and the patient's condition may deteriorate over time.

Please note that this prognosis is based on the provided data and may not reflect the actual outcome, as many factors can influence the patient's condition and response to treatment."
755,755,P0099,"Age: 68
Gender: Male 
Weight: 81 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 44,3
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 16,5
Hemoglobin (g/L): 146.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,87
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 103.0
Protein (g/L): 69
T3 (pg/dL): 0,04
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,89
Urea (mg/dL): 6,45
LVEF (%): 25.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death, 2. Pump failure death, 3. Survivor

REASONING: 

Given the patient's profile, I have ranked the prognoses as follows:

1. Sudden cardiac death (SCD): The patient's profile indicates a high risk of SCD due to the presence of ischemic dilated cardiomyopathy, a history of myocardial infarction, and a low LVEF (25%). The patient's low LVEF, which is below 35%, is a significant predictor of SCD. Additionally, the presence of ventricular extrasystole on the ECG further increases the risk of SCD. Although the patient is on beta blockers, which can reduce the risk of SCD, the overall risk profile suggests that SCD is the most likely prognosis.

2. Pump failure death: The patient's LVEF is very low (25%), which is a strong predictor of pump failure. The patient's history of ischemic dilated cardiomyopathy and myocardial infarction also supports this prognosis. However, the patient's NYHA class II suggests that the patient is still relatively asymptomatic, which might indicate a slower progression of heart failure. Additionally, the patient is on angiotensin II receptor blockers and beta blockers, which can help slow the progression of heart failure. Therefore, while pump failure death is a possible prognosis, it is less likely than SCD.

3. Survivor: Given the patient's high risk profile, survivorship is the least likely prognosis. However, the patient's current NYHA class II suggests that the patient is still relatively asymptomatic, and the patient's medications may help slow the progression of heart disease. Additionally, the patient's low troponin level suggests that there is no ongoing myocardial infarction. While the patient's prognosis is poor, it is possible that the patient may survive for several years with appropriate medical management.

It is essential to note that these prognoses are based on the information provided and may change with further evaluation and testing. A more accurate prognosis can be made with a comprehensive evaluation, including imaging studies, stress testing, and possibly a cardiac catheterization."
756,756,P0107,"Age: 53
Gender: Male 
Weight: 74 kg
Height: 167 cm
NYHA Class: III
Blood Pressure: 127/76 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 43,5
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 105.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,01
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,87
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 670.0
Protein (g/L): 74,1
T3 (pg/dL): 0,01
T4 (ng/L): 11
TSH (mIU/L): 2,3
Urea (mg/dL): 8,32
LVEF (%): 27.0
Medications: Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden cardiac death
REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's LVEF (Left Ventricular Ejection Fraction) is 27%, indicating severe left ventricular dysfunction, which further increases the risk of sudden cardiac death. The presence of non-sustained ventricular tachycardia on the ECG is also a concerning finding, as it is a marker of increased risk of sudden cardiac death. Additionally, the patient's low HDL cholesterol and high LDL cholesterol levels suggest poor cardiovascular health, which may contribute to the progression of ischemic heart disease.

RANKING: 2. Pump failure death
REASONING: The patient's severe left ventricular dysfunction (LVEF 27%) and history of ischemic dilated cardiomyopathy make pump failure a significant concern. The patient's NYHA Class III classification indicates that the patient experiences symptoms of heart failure at rest or with minimal exertion, which is consistent with severe heart failure. The elevated Pro-BNP level (670.0 ng/L) also suggests that the patient has significant cardiac stress, which is consistent with heart failure.

RANKING: 3. Survivor
REASONING: While the patient's prognosis is guarded, there are some factors that suggest that survival is possible. The patient is on optimal medical therapy with loop diuretics, spironolactone, statins, and an ACE inhibitor, which is consistent with current guidelines for the management of heart failure. The patient's hemoglobin level is within a relatively normal range, which suggests that the patient does not have significant anemia, which is a common comorbidity in heart failure patients. However, the patient's low LVEF and history of ischemic dilated cardiomyopathy make survival a challenging outcome."
757,757,P0129,"Age: 86
Gender: Male 
Weight: 80 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 31.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,4
Creatinine (mmol/L): 212.0
Gamma-glutamil transpeptidase (IU/L): 71
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 129.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,5
LDL (mmol/L): 2,82
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 2036.0
Protein (g/L): 70
T3 (pg/dL): 0,02
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 5
Urea (mg/dL): 19,8
LVEF (%): 50.0
Medications: Loop Diuretics, Spironolactone, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor
 REASONING: The patient is 86 years old with a history of hypertensive cardiomyopathy and hypertension, which indicates that the patient has a pre-existing condition affecting the heart. However, the patient is on a treatment plan with loop diuretics, spironolactone, hydralazine, and nitrovasodilators, suggesting that the patient's condition is being managed. The patient's LVEF (Left Ventricular Ejection Fraction) is 50%, which is within a relatively normal range, indicating that the patient's heart is still pumping efficiently. Additionally, the patient's BNP (Brain Natriuretic Peptide) level is elevated, but not extremely high, suggesting that the patient is experiencing some degree of heart failure, but not to a severe extent. The patient's creatinine level is also elevated, indicating some degree of kidney impairment, but this is likely a result of the patient's heart failure rather than a primary kidney issue. Considering these factors, the patient's prognosis is more likely to be a survivor, as the patient's condition is being managed and the patient's heart function is relatively preserved.

RANKING: 2. Sudden cardiac death
 REASONING: The patient has a history of ventricular extrasystole and non-sustained ventricular tachycardia, which are both risk factors for sudden cardiac death. However, the patient's LVEF is within a relatively normal range, and the patient is on a treatment plan that includes medications that can help prevent arrhythmias. Additionally, the patient's troponin level is normal, indicating that there is no acute myocardial infarction. While the patient's risk of sudden cardiac death is higher than average, the patient's overall condition and treatment plan suggest that this outcome is less likely than pump failure death.

RANKING: 3. Pump failure death
 REASONING: The patient has a history of hypertensive cardiomyopathy and hypertension, which can lead to heart failure. The patient's LVEF is 50%, which is at the lower end of the normal range, and the patient's BNP level is elevated, indicating some degree of heart failure. The patient's creatinine level is also elevated, indicating kidney impairment, which is a common complication of heart failure. Additionally, the patient's albumin level is low, which can be a sign of malnutrition or liver disease, but in this case, it is likely related to the patient's heart failure. The patient's treatment plan includes loop diuretics, which are often used to treat heart failure, but the patient's condition is not being adequately managed, as indicated by the patient's elevated creatinine and BNP levels. Considering these factors, the patient's prognosis is most likely to be pump failure death, as the patient's heart function is compromised and the patient's condition is not being adequately managed."
758,758,P0134,"Age: 62
Gender: Male 
Weight: 84 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,87
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 3,9
Hemoglobin (g/L): 164.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,1
Sodium (mEq/L): 146.0
Pro-BNP (ng/L): 1528.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 16
TSH (mIU/L): 2,34
Urea (mg/dL): 7,65
LVEF (%): 41.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely, along with the reasoning behind the order:

RANKING: 1. Sudden cardiac death
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a condition that can lead to sudden cardiac death due to ventricular arrhythmias. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is a significant risk factor for sudden cardiac death. Additionally, the patient's LVEF of 41% indicates reduced left ventricular function, which increases the risk of arrhythmias. The patient's Pro-BNP level of 1528 ng/L is also elevated, indicating increased stress on the heart. While the patient is on medications that can help manage these conditions, the presence of NSVT and reduced LVEF make sudden cardiac death a significant concern.

RANKING: 2. Pump failure death
 REASONING: The patient's LVEF of 41% indicates reduced left ventricular function, which is a risk factor for pump failure death. The patient's history of idiopathic dilated cardiomyopathy also increases the risk of progressive heart failure. However, the patient's current NYHA Class II classification indicates that the patient is still relatively asymptomatic, and the patient is on medications that can help manage heart failure. While the patient's Pro-BNP level is elevated, it is not excessively high, and the patient's kidney function is relatively preserved (creatinine 141.0 mmol/L). Therefore, while pump failure death is a concern, it is less likely than sudden cardiac death in the short term.

RANKING: 3. Survivor
 REASONING: The patient's LVEF of 41% and history of idiopathic dilated cardiomyopathy suggest that the patient has some degree of cardiac dysfunction. However, the patient is on medications that can help manage heart failure and arrhythmias, and the patient's NYHA Class II classification indicates that the patient is still relatively asymptomatic. The patient's Pro-BNP level is elevated, but not excessively high, and the patient's kidney function is relatively preserved. While the patient's risk factors for sudden cardiac death and pump failure death are present, the patient's overall clinical picture suggests that survival is the most likely outcome in the short term."
759,759,P0139,"Age: 83
Gender: Female 
Weight: 53 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 110/80 mmHg
Past Medical History: Valvular cardiomyopathy, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,51
Creatinine (mmol/L): 137.0
Gamma-glutamil transpeptidase (IU/L): 61
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 115.0
Potassium (mEq/L): 3,79
Sodium (mEq/L): 138.0
Protein (g/L): 73,6
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,55
Urea (mg/dL): 8,9
LVEF (%): 68.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: 2
REASONING: The patient has a high likelihood of sudden cardiac death due to the presence of polymorphic ventricular extrasystoles on the ECG, which can be a precursor to life-threatening arrhythmias. The patient's NYHA Class III classification indicates that she has severe symptoms of heart failure, which increases the risk of sudden cardiac death. Additionally, the patient's low LVEF (68%) and elevated creatinine levels suggest that she has some degree of cardiac dysfunction, which further increases the risk of sudden cardiac death. However, the patient's LVEF is still relatively preserved, and her overall clinical status does not suggest an immediate high risk of pump failure death.

RANKING: 3
REASONING: Pump failure death is less likely in this patient due to her relatively preserved LVEF (68%) and the absence of severe symptoms of heart failure (NYHA Class III, not Class IV). While the patient has valvular cardiomyopathy and elevated creatinine levels, her overall clinical status does not suggest that she is at high risk of pump failure death in the near future.

RANKING: 1
REASONING: Survivor is the most likely prognosis for this patient. While the patient has several risk factors for cardiac complications, her overall clinical status suggests that she is relatively stable. Her LVEF is preserved, and her symptoms are manageable with current medications. The patient's weight and body mass index (BMI) are also within a relatively healthy range, which reduces the risk of cardiac complications. Additionally, her laboratory results, including her troponin and creatinine levels, are not indicative of acute cardiac damage or severe kidney dysfunction."
760,760,P0141,"Age: 76
Gender: Female 
Weight: 70 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 39,9
ALT or GPT (IU/L): 28.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 3,05
Creatinine (mmol/L): 167.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 8,5
Hemoglobin (g/L): 123.0
Potassium (mEq/L): 3,15
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 5387.0
Protein (g/L): 71,4
Troponin (ng/mL): 0,01
TSH (mIU/L): 17,69
Urea (mg/dL): 25
LVEF (%): 25.0
Medications: Loop Diuretics, Spironolactone, Statins, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Parosysmal AF
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden cardiac death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 25%, indicating poor cardiac function. Additionally, the patient has a high level of B-type natriuretic peptide (BNP) at 5387 ng/L, which is indicative of heart failure and increased risk of sudden cardiac death. The presence of non-sustained ventricular tachycardia and paroxysmal atrial fibrillation also increases the risk of arrhythmias and sudden cardiac death.

RANKING: 2. Pump failure death
 REASONING: The patient's LVEF of 25% indicates severe heart failure, and the patient is already on loop diuretics, spironolactone, and hydralazine, which are medications commonly used to manage heart failure. The patient's elevated creatinine level at 167.0 mol/L suggests kidney dysfunction, which is a common complication of heart failure. The patient's high BNP level also indicates ongoing heart failure. However, the patient's kidney function and overall clinical status may allow for some period of time before pump failure becomes the primary cause of death.

RANKING: 3. Survivor
 REASONING: While the patient's prognosis is poor, it is possible that with optimal medical management, including close monitoring and adjustment of medications, the patient may be able to survive for several years. The patient's high TSH level at 17.69 mIU/L may indicate hypothyroidism, which can affect cardiac function, but this can be managed with thyroid hormone replacement therapy. Additionally, the patient's troponin level is within normal limits, indicating that there is no ongoing myocardial infarction. However, the patient's overall clinical status and history make it unlikely that they will survive for an extended period without significant morbidity."
761,761,P0143,"Age: 56
Gender: Female 
Weight: 83 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 110/65 mmHg
Past Medical History: Valvular cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 38,2
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,66
Creatinine (mmol/L): 110.0
Gamma-glutamil transpeptidase (IU/L): 70
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 86.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 3,39
LDL (mmol/L): 3,86
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 1036.0
Protein (g/L): 68,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,87
Urea (mg/dL): 8,4
LVEF (%): 40.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Unknown ventricular tachycardia code
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: Although the patient has a history of valvular cardiomyopathy, myocardial infarction, and peripheral vascular disease, the presence of a relatively well-controlled blood pressure, low troponin levels, and a relatively preserved LVEF (40%) suggest that the patient's cardiac function is not severely compromised at the moment. The patient is also on appropriate medications for heart failure and has a relatively normal potassium level, which is a good sign. Additionally, the patient's age is not extremely high, and the absence of severe anemia (Hemoglobin 86.0 g/L) and severe kidney dysfunction (Creatinine 110.0 mol/L) also support a more favorable prognosis.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's LVEF of 40% and the presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG suggest a risk of arrhythmias. However, the patient is on medications that are known to reduce the risk of sudden cardiac death, such as beta-blockers and anti-arrhythmic medications. Additionally, the patient's low troponin levels and relatively well-controlled blood pressure reduce the likelihood of acute coronary events that could lead to sudden cardiac death.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 40% and the presence of valvular cardiomyopathy, myocardial infarction, and peripheral vascular disease suggest a high risk of progressive heart failure. The patient's high Pro-BNP level (1036.0 ng/L) and relatively low albumin level (38.2 g/L) also suggest that the patient has significant cardiac dysfunction. The patient's NYHA class III classification indicates that the patient has severe symptoms of heart failure, which further supports a poor prognosis for pump failure death. The patient's kidney dysfunction (Creatinine 110.0 mol/L) also increases the risk of progressive heart failure."
762,762,P0151,"Age: 74
Gender: Male 
Weight: 78 kg
Height: 173 cm
NYHA Class: III
Blood Pressure: 90/60 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 43,2
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 37.0
Total Cholesterol (mmol/L): 4,27
Creatinine (mmol/L): 105.0
Gamma-glutamil transpeptidase (IU/L): 162
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 123.0
Potassium (mEq/L): 3,85
Sodium (mEq/L): 133.0
Protein (g/L): 84,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,31
Urea (mg/dL): 8
LVEF (%): 70.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Survivor
 REASONING: The patient is 74 years old with a history of valvular cardiomyopathy and NYHA Class III, indicating moderate to severe heart failure symptoms. However, he is taking medications that are commonly used to manage heart failure, such as digoxin, loop diuretics, spironolactone, ACE inhibitor, and nitrovasodilator. His LVEF is 70%, which is within the normal range, and his troponin levels are normal, indicating no acute myocardial infarction. His albumin and protein levels are slightly low, but not critically low, which may indicate mild malnutrition or liver disease. His liver enzymes (ALT and AST) are within normal limits, and his creatinine level is slightly elevated, but not significantly so. His potassium level is low, which may be due to diuretic use or other underlying conditions. Given the patient's relatively stable condition and treatment regimen, I predict a survivor prognosis.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of valvular cardiomyopathy and is at risk for arrhythmias due to his ventricular extrasystole. However, his ECG does not show any sustained ventricular tachycardia or other high-risk features for sudden cardiac death. His LVEF is within normal limits, and his troponin levels are normal. His medications, such as ACE inhibitor and beta-blockers, may also reduce the risk of arrhythmias. While the patient's low potassium level may increase the risk of arrhythmias, it is not a strong enough indicator to tip the balance towards sudden cardiac death. Therefore, I consider sudden cardiac death as the second most likely prognosis.

RANKING: 3. Pump Failure Death
 REASONING: The patient's NYHA Class III indicates moderate to severe heart failure symptoms, and his low blood pressure (90/60 mmHg) suggests that his heart is not pumping efficiently. His creatinine level is slightly elevated, which may indicate kidney dysfunction due to heart failure. His low albumin and protein levels may indicate malnutrition or liver disease, which can contribute to worsening heart failure. His medications, such as spironolactone and loop diuretics, are commonly used to manage heart failure, but his low blood pressure and elevated creatinine level suggest that his heart failure is not well-controlled. His LVEF is within normal limits, but his overall clinical picture suggests that his heart is under significant stress. Given his symptoms and laboratory results, I consider pump failure death as the least likely prognosis, but still a possible outcome if his heart failure continues to worsen."
763,763,P0155,"Age: 59
Gender: Male 
Weight: 81 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 35,5
ALT or GPT (IU/L): 29.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,52
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 89
Glucose (mmol/L): 11,6
Hemoglobin (g/L): 133.0
Potassium (mEq/L): 4,75
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 10534.0
Protein (g/L): 66,2
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,82
Urea (mg/dL): 20,8
LVEF (%): 25.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Sudden cardiac death, 2. Pump failure death, 3. Survivor

REASONING: 

Given the patient's extensive medical history, including ischemic dilated cardiomyopathy, myocardial infarction, and peripheral vascular disease, it is clear that the patient has a high risk of cardiac complications. The patient's LVEF of 25% indicates severely reduced cardiac function, which increases the likelihood of pump failure death. However, the patient's low blood pressure (90/60 mmHg) and the presence of ventricular extrasystoles suggest that the patient may be at risk for sudden cardiac death due to arrhythmias. 

The patient's current medications, including beta blockers, ACE inhibitors, and nitrovasodilators, are typically used to reduce the risk of sudden cardiac death and improve cardiac function. However, the patient's high Pro-BNP levels (10534.0 ng/L) indicate that the patient's heart is under significant stress, which increases the risk of pump failure. Considering these factors, the most likely outcome is pump failure death, as the patient's heart is already severely compromised and unable to meet the body's demands. 

Sudden cardiac death is the second most likely outcome, as the patient's history of myocardial infarction, ventricular extrasystoles, and low blood pressure increase the risk of life-threatening arrhythmias. However, the patient's current medications and medical management may mitigate this risk to some extent. Survivorship is the least likely outcome, given the patient's severe cardiac dysfunction and multiple comorbidities."
764,764,P0160,"Age: 71
Gender: Male 
Weight: 62 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 41
ALT or GPT (IU/L): 8.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 156.0
Gamma-glutamil transpeptidase (IU/L): 107
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 123.0
Potassium (mEq/L): 4,59
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 27357.0
Protein (g/L): 74,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,15
Urea (mg/dL): 19,2
LVEF (%): 13.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, here's my prognosis for the next few years:

RANKING: 1. Survivor
 REASONING: Despite the patient's advanced age, valvular cardiomyopathy, and low left ventricular ejection fraction (LVEF) of 13%, the patient is currently on a multi-drug regimen that includes beta blockers, digoxin, loop diuretics, spironolactone, hydralazine, and nitrovasodilators. These medications are aimed at managing heart failure symptoms, reducing morbidity, and mortality. The patient's blood pressure is within a relatively normal range, and the absence of elevated troponin levels suggests that there is no acute myocardial infarction. Although the patient has a high level of pro-BNP (indicative of heart failure), the overall clinical picture does not suggest an immediate risk of sudden cardiac death. Additionally, the patient's hemoglobin level is within the normal range, which is a positive indicator for survival.

RANKING: 2. Sudden cardiac death
 REASONING: The patient has a history of valvular cardiomyopathy and a low LVEF, which increases the risk of sudden cardiac death. However, the presence of ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG may indicate a risk of arrhythmic events. The patient's medication regimen includes beta blockers, which are known to reduce the risk of sudden cardiac death. Although there is a risk of arrhythmic events, the overall clinical picture does not suggest an extremely high risk of sudden cardiac death.

RANKING: 3. Pump failure death
 REASONING: The patient's LVEF of 13% is extremely low, and the patient is already in NYHA Class III, indicating severe heart failure symptoms. The high level of pro-BNP further supports the presence of heart failure. The patient's kidney function is impaired (creatinine level of 156.0 mmol/L), which may be a consequence of the heart failure. The patient's weight is relatively low (62 kg), which may indicate malnutrition or muscle wasting, further contributing to the risk of pump failure death. Given the severity of the patient's heart failure and the lack of a recent acute myocardial infarction, pump failure death is the most likely outcome in the long term.

Note: The prognosis is based on the provided data and may not be comprehensive or definitive. A more accurate prognosis would require a comprehensive evaluation and assessment by a healthcare professional."
765,765,P0186,"Age: 57
Gender: Male 
Weight: 65 kg
Height: 175 cm
NYHA Class: III
Blood Pressure: 90/50 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 46
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 2,84
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 59
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 120.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 4,4
LDL (mmol/L): 1,68
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 5098.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 15
Troponin (ng/mL): 0,07
TSH (mIU/L): 5,32
Urea (mg/dL): 8,49
LVEF (%): 27.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden cardiac death
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which significantly increases the risk of sudden cardiac death. The patient's LVEF (Left Ventricular Ejection Fraction) is severely reduced at 27%, indicating poor cardiac function. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG further increases the risk of sudden cardiac death. Additionally, the patient's low blood pressure (90/50 mmHg) and low hemoglobin (120 g/L) may indicate poor cardiac output and reduced perfusion of vital organs, which can contribute to a higher risk of sudden cardiac death.

RANKING: 2. Pump failure death
 REASONING: The patient's LVEF of 27% and reduced cardiac function due to idiopathic dilated cardiomyopathy make pump failure death a significant concern. The patient's elevated Pro-BNP levels (5098 ng/L) also indicate increased cardiac stress and potential heart failure. However, the patient is already on optimal medical therapy for heart failure (Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, and ACE Inhibitor), which may mitigate some of the risk factors.

RANKING: 3. Survivor
 REASONING: While the patient has a severe heart condition, the fact that they are on optimal medical therapy and have not had a recent cardiac arrest or hospitalization for heart failure suggests that they may have a better prognosis than the other two options. However, the patient's low LVEF and presence of NSVT on the ECG indicate that their cardiac function is severely compromised, and a significant improvement in their condition is unlikely without further intervention."
766,766,P0188,"Age: 59
Gender: Female 
Weight: 49 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Valvular cardiomyopathy, Hypertension
Albumin (g/L): 33,9
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 66.0
Total Cholesterol (mmol/L): 5,77
Creatinine (mmol/L): 143.0
Gamma-glutamil transpeptidase (IU/L): 334
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,53
Potassium (mEq/L): 3,93
LDL (mmol/L): 3,44
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 7574.0
Protein (g/L): 65
T3 (pg/dL): 0,0306
T4 (ng/L): 9,59
Troponin (ng/mL): 0,1
TSH (mIU/L): 26,88
Urea (mg/dL): 14,4
LVEF (%): 70.0
Medications: Amiodarone, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient is 59 years old with a history of valvular cardiomyopathy and hypertension, which are significant risk factors for heart failure. However, her left ventricular ejection fraction (LVEF) is 70%, which is within the normal range, indicating that her heart function is still relatively preserved. Additionally, her NYHA Class II classification suggests that she is experiencing mild symptoms of heart failure, which can be managed with medication and lifestyle changes. The patient is also on amiodarone, loop diuretics, and spironolactone, which are common medications for heart failure management. While her elevated Pro-BNP levels (7574.0 ng/L) and troponin levels (0.1 ng/mL) suggest some degree of cardiac stress, they are not at extremely high levels that would indicate imminent pump failure. Given her relatively preserved LVEF and mild symptoms, I believe that with proper management, she is likely to survive in the short to medium term.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's ECG shows monomorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the absence of non-sustained ventricular tachycardia (CH>10) and paroxysmal supraventricular tachyarrhythmia reduces the risk of sudden cardiac death. Her LVEF is within the normal range, and her medications, including amiodarone, may help reduce the risk of arrhythmias. While the patient's TSH level is elevated (26.88 mIU/L), which can be associated with arrhythmias, it is not at a level that would indicate a high risk of sudden cardiac death. Overall, while the patient's ECG findings and TSH level suggest some risk of arrhythmias, the overall picture does not suggest a high likelihood of sudden cardiac death.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF is within the normal range (70%), and her NYHA Class II classification suggests that she is experiencing mild symptoms of heart failure. While her Pro-BNP levels are elevated, they are not at extremely high levels that would indicate imminent pump failure. Her creatinine level is elevated (143.0 mmol/L), which may indicate some degree of renal dysfunction, but it is not at a level that would suggest advanced pump failure. Given her relatively preserved LVEF and mild symptoms, I believe that pump failure death is the least likely outcome in the short to medium term."
767,767,P0192,"Age: 83
Gender: Female 
Weight: 69 kg
Height: 148 cm
NYHA Class: III
Blood Pressure: 150/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Hypertension, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 7.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,47
Creatinine (mmol/L): 122.0
Gamma-glutamil transpeptidase (IU/L): 15
Glucose (mmol/L): 7,5
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 5,25
LDL (mmol/L): 4,24
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 5541.0
Protein (g/L): 72
T3 (pg/dL): 0,0237
T4 (ng/L): 18,93
TSH (mIU/L): 0,92
Urea (mg/dL): 19,3
LVEF (%): 65.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 2 
REASONING: The patient is 83 years old with a history of Hypertensive cardiomyopathy, Diabetes, Hypertension, and Myocardial Infarction, which suggests a high risk for cardiac complications. The patient's NYHA Class III indicates that she has significant symptoms of heart failure, which is further supported by the elevated Pro-BNP level of 5541.0 ng/L, indicating increased cardiac stress. The patient's LVEF of 65% is relatively preserved, but the presence of ventricular extrasystoles and a history of myocardial infarction increase the risk of sudden cardiac death. However, the patient's overall clinical presentation and laboratory values are more indicative of heart failure than sudden cardiac death. 

The patient's low sodium level (142.0 mEq/L) and high creatinine level (122.0 mol/L) suggest fluid overload and renal impairment, which are common in heart failure. The patient's medications, including loop diuretics and an ACE inhibitor, are typical for heart failure management. While the patient's TSH level is slightly low, this is not uncommon in patients with heart failure, and the T3 and T4 levels are within normal limits. The presence of polymorphic ventricular extrasystoles increases the risk of arrhythmias, but the absence of sustained ventricular tachycardia and bradycardia makes sudden cardiac death less likely.

RANKING: 3 
REASONING: While the patient's history and clinical presentation suggest a high risk of cardiac complications, the presence of preserved LVEF and the absence of severe arrhythmias make sudden cardiac death less likely. The patient's medications and laboratory values are more indicative of heart failure than sudden cardiac death.

RANKING: 1 
REASONING: The patient's history of Hypertensive cardiomyopathy, Diabetes, Hypertension, and Myocardial Infarction, along with the elevated Pro-BNP level and NYHA Class III, make pump failure death the most likely prognosis. The patient's preserved LVEF is not sufficient to overcome the significant cardiac stress and damage caused by her underlying conditions, and the presence of ventricular extrasystoles increases the risk of further cardiac complications. The patient's medications and laboratory values are consistent with heart failure, and the absence of severe arrhythmias makes sudden cardiac death less likely."
768,768,P0194,"Age: 89
Gender: Male 
Weight: 70 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 160/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 49
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 6,1
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 5,6
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,81
Potassium (mEq/L): 4,4
LDL (mmol/L): 3,78
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3179.0
Protein (g/L): 78,1
T3 (pg/dL): 0,0252
T4 (ng/L): 18,79
Troponin (ng/mL): 1,2
TSH (mIU/L): 0,99
Urea (mg/dL): 8,2
LVEF (%): 70.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Sinus Node Dysfunction
            ",pump failure death,"RANKING: Sudden Cardiac Death, Survivor, Pump Failure Death

REASONING: 

1. Sudden Cardiac Death (SCD): Although the patient's LVEF is 70%, which is within the normal range, the presence of polymorphic ventricular extrasystoles, non-sustained ventricular tachycardia (NSVT), and a high Pro-BNP level of 3179 ng/L suggest an increased risk of arrhythmic events. Additionally, the patient's NYHA Class III indicates severe symptoms, which may indicate underlying electrical instability. The patient's age, hypertension, and cardiomyopathy further increase the risk of SCD. Therefore, SCD is the most likely prognosis.

2. Pump Failure Death: Although the patient's LVEF is 70%, which is within the normal range, the patient's NYHA Class III and high Pro-BNP level suggest some degree of heart failure. The patient's creatinine level of 103.0 umol/L also indicates some degree of renal impairment, which may be related to heart failure. However, the patient's LVEF is still within the normal range, and the patient is on medications that are commonly used to manage heart failure (Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor). Therefore, while pump failure is a possibility, it is less likely than SCD due to the patient's relatively preserved LVEF.

3. Survivor: Given the patient's advanced age (89 years), high blood pressure, cardiomyopathy, and NYHA Class III symptoms, the most likely outcome would be a poor prognosis. However, the patient's LVEF is within the normal range, and they are on medications that are commonly used to manage heart failure. Additionally, the patient's creatinine level is not extremely high, and they do not have any other significant comorbidities. Therefore, while the patient's prognosis is still poor, a survivor outcome is the least likely of the three options."
769,769,P0200,"Age: 80
Gender: Male 
Weight: 69 kg
Height: 155 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,11
Creatinine (mmol/L): 146.0
Gamma-glutamil transpeptidase (IU/L): 21
Glucose (mmol/L): 5,1
Hemoglobin (g/L): 119.0
HDL (mmol/L): 0,75
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,72
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 2129.0
Protein (g/L): 67
T3 (pg/dL): 0,0429
T4 (ng/L): 15,56
Troponin (ng/mL): 0,2
TSH (mIU/L): 0,58
Urea (mg/dL): 13,9
LVEF (%): 39.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Second-degree AVB - type I
            ",pump failure death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden Cardiac Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is 39%, indicating reduced cardiac function. The presence of polymorphic ventricular extrasystoles on the ECG is a concerning sign, as it may indicate electrical instability. Additionally, the patient's high Pro-BNP level (2129.0 ng/L) suggests significant cardiac stress and potential for arrhythmias. The patient's medications, including beta blockers and ACE inhibitors, are typically used to reduce the risk of sudden cardiac death, but the presence of polymorphic ventricular extrasystoles may indicate a higher risk despite these treatments.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF of 39% indicates reduced cardiac function, which increases the risk of pump failure. The patient's NYHA Class III classification suggests that they experience symptoms of heart failure at rest or with minimal exertion. The patient's high Pro-BNP level and elevated creatinine level (146.0 mmol/L) also indicate significant cardiac stress and potential renal impairment. However, the patient's blood pressure is within a relatively normal range (110/60 mmHg), which may suggest that the patient's cardiac output is still sufficient to maintain adequate perfusion.

RANKING: 3. Survivor
 REASONING: While the patient's cardiac function is compromised, the patient's overall condition is not as dire as the other two options. The patient's LVEF is still above the threshold for severe heart failure (less than 20-25%), and the patient's blood pressure is relatively stable. The patient's medications are optimized, and the patient's ECG does not show any signs of severe arrhythmias. The patient's TSH level is also within the normal range, which suggests that the patient's thyroid function is not contributing to cardiac dysfunction. While the patient's prognosis is guarded, the likelihood of survival is higher compared to the other two options.

Please note that this prognosis is based on the provided data and may not reflect the patient's actual outcome, as many factors can influence the progression of heart disease."
770,770,P0212,"Age: 65
Gender: Male 
Weight: 79 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 150/85 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 44.0
Total Cholesterol (mmol/L): 3,98
Creatinine (mmol/L): 150.0
Gamma-glutamil transpeptidase (IU/L): 688
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,08
LDL (mmol/L): 2,22
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 709.0
Protein (g/L): 79
T3 (pg/dL): 0,0492
T4 (ng/L): 16,35
Troponin (ng/mL): 3,1
TSH (mIU/L): 0,79
Urea (mg/dL): 10
LVEF (%): 70.0
Medications: Diabetes Medication, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 2 
REASONING: Based on the provided patient data, I would rank the prognosis as follows:

The patient has a history of hypertensive cardiomyopathy, diabetes, and dyslipemia, which are all significant risk factors for heart failure. The patient's current NYHA Class II classification indicates that they experience some symptoms of heart failure, such as shortness of breath, but are able to perform daily activities without significant limitation. However, the elevated Pro-BNP level (709.0 ng/L) and reduced LVEF (70.0%) suggest that the patient's heart function is compromised.

The patient's high blood pressure (150/85 mmHg) and elevated creatinine level (150.0 mmol/L) indicate that the patient has chronic kidney disease, which is often associated with heart failure. The patient's elevated glucose level (5.4 mmol/L) and total cholesterol level (3.98 mmol/L) also suggest that the patient has poorly controlled diabetes and dyslipidemia, which can further exacerbate heart failure.

The patient's ECG shows monomorphic ventricular extrasystoles, which can be a sign of underlying cardiac disease. However, there is no evidence of sustained ventricular tachycardia or other life-threatening arrhythmias.

Considering these factors, the patient's prognosis is likely to be pump failure death, as they have a history of heart failure and are at risk for further cardiac decompensation.

Survivor is the least likely prognosis because the patient's underlying cardiac disease and risk factors make it unlikely that they will remain stable without further cardiac events.

Sudden cardiac death is the least likely prognosis because the patient does not have any clear evidence of life-threatening arrhythmias or other high-risk features that would increase their risk of sudden cardiac death."
771,771,P0213,"Age: 72
Gender: Male 
Weight: 94 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 115/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,24
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 12,4
Hemoglobin (g/L): 124.0
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,44
LDL (mmol/L): 2,59
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1100.0
Protein (g/L): 66,399
T4 (ng/L): 17,63
Troponin (ng/mL): 0,7
TSH (mIU/L): 0,77
Urea (mg/dL): 12,1
LVEF (%): 30.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, here's my prognosis for the next few years:

RANKING: 1. Survivor
 REASONING: The patient has a complex medical history with idiopathic dilated cardiomyopathy, diabetes, and hypertension. However, the patient is on a comprehensive treatment regimen that includes diabetes medication, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which suggests that the patient's condition is being actively managed. The patient's blood pressure is well-controlled, and the hemoglobin level is within a relatively normal range. The LVEF of 30% indicates reduced cardiac function, but it's not the lowest possible value. The patient's Pro-BNP level is elevated, which is consistent with heart failure, but not extremely high. Considering the patient's age and the presence of comorbidities, a survivor prognosis seems plausible, albeit with a guarded outlook.

RANKING: 2. Sudden cardiac death
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The presence of polymorphic ventricular extrasystoles on the ECG also raises concerns about arrhythmia risk. However, the patient is on digoxin and an ACE inhibitor, which can help reduce the risk of arrhythmias. The patient's LVEF is low, but not extremely low, and the Pro-BNP level is elevated but not extremely high. The patient's age and comorbidities also contribute to the risk of sudden cardiac death. While this prognosis is possible, it is less likely than survivor due to the patient's active treatment regimen.

RANKING: 3. Pump failure death
 REASONING: The patient's LVEF is 30%, indicating severe left ventricular dysfunction. The Pro-BNP level is elevated, suggesting significant heart failure. The patient's creatinine level is high, indicating renal impairment, which is a common complication of heart failure. The patient's weight is also above average, which can put additional strain on the heart. The presence of diabetes and hypertension further exacerbates the risk of pump failure. The patient's age and the severity of their cardiac dysfunction make pump failure death the least likely prognosis, but still a possible outcome if the patient's condition continues to deteriorate or if the treatment regimen is not optimized."
772,772,P0223,"Age: 64
Gender: Male 
Weight: 64 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,2
Creatinine (mmol/L): 254.0
Gamma-glutamil transpeptidase (IU/L): 175
Glucose (mmol/L): 15,78
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,71
LDL (mmol/L): 2,29
Sodium (mEq/L): 127.0
Pro-BNP (ng/L): 12746.0
Protein (g/L): 81
T3 (pg/dL): 0,0114
T4 (ng/L): 17,74
Troponin (ng/mL): 1,5
TSH (mIU/L): 2,65
Urea (mg/dL): 20,37
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: Sudden Cardiac Death > Pump Failure Death > Survivor

REASONING:

1. Sudden Cardiac Death (SCD): The patient has a high risk of SCD due to several factors:
	* Age: 64 years, which increases the risk of SCD.
	* Ischemic dilated cardiomyopathy (IDC): A history of IDC significantly increases the risk of SCD.
	* Low left ventricular ejection fraction (LVEF) of 30%: A reduced LVEF is a strong predictor of SCD.
	* Presence of non-sustained ventricular tachycardia (NSVT) on ECG: NSVT is a known risk factor for SCD.
	* Elevated Pro-BNP (12746 ng/L): Elevated BNP levels are associated with an increased risk of SCD.
	* Medications such as beta-blockers and spironolactone are being used, but the patient's condition is not adequately controlled, increasing the risk of SCD.
2. Pump Failure Death: The patient's current condition and medical history also suggest a high risk of pump failure death:
	* Severe heart failure symptoms (NYHA Class III)
	* Low LVEF (30%)
	* Elevated creatinine levels (254.0 mol/L), indicating renal dysfunction
	* Elevated BNP levels (12746 ng/L), indicating severe heart failure
	* Presence of diabetes, hypertension, and dyslipidemia, which can exacerbate heart failure
	* However, the patient's condition is not as severe as SCD, and the risk of pump failure death is lower compared to SCD.
3. Survivor: Although the patient has a high risk of SCD and pump failure death, there is still a possibility of survival with proper management and treatment:
	* The patient is on medications for heart failure and diabetes, which can help manage the condition.
	* The patient's blood pressure is within a relatively normal range (110/70 mmHg), which may help mitigate the risk of SCD.
	* However, the patient's overall condition is still severe, and the risk of SCD and pump failure death is higher than the risk of survival.

Please note that this prognosis is based on the provided data and may not reflect the actual outcome, as individual patient responses to treatment and disease progression can vary."
773,773,P0239,"Age: 67
Gender: Male 
Weight: 90 kg
Height: 164 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 212.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,35
Potassium (mEq/L): 5,2
LDL (mmol/L): 3,7
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 9992.0
Protein (g/L): 70
T3 (pg/dL): 0,04
T4 (ng/L): 15
Troponin (ng/mL): 0,42
TSH (mIU/L): 7,83
Urea (mg/dL): 24,79
LVEF (%): 10.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, I would rank the possible prognoses as follows:

RANKING: 1. Sudden Cardiac Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's low LVEF (10%) indicates severe left ventricular dysfunction, which increases the risk of sudden cardiac death. Additionally, the presence of sustained and non-sustained ventricular tachycardia, as well as polymorphic ventricular extrasystoles, further increases the risk of arrhythmic events. The patient's high Pro-BNP level (9992.0 ng/L) also suggests severe heart failure, which is another risk factor for sudden cardiac death.

RANKING: 2. Pump Failure Death
 REASONING: The patient's severe left ventricular dysfunction (LVEF 10%) and high Pro-BNP level suggest that the patient is at high risk for pump failure death. The patient's NYHA Class III classification also indicates that the patient has severe symptoms of heart failure, which further supports this prognosis. However, the patient's medications (e.g., beta blockers, ACE inhibitor, spironolactone) are generally aimed at reducing the risk of pump failure, and the patient's recent troponin level is only slightly elevated (0.42 ng/mL), which suggests that the patient may not have an acute myocardial infarction.

RANKING: 3. Survivor
 REASONING: While the patient has several risk factors for poor outcomes, the patient's recent troponin level is only slightly elevated, and the patient is on medications that are aimed at reducing the risk of cardiac events. The patient's hemoglobin level is within the normal range, and the patient's sodium level is also within the normal range, which suggests that the patient does not have severe electrolyte imbalances. However, the patient's overall clinical picture suggests that the patient is at high risk for cardiac events, and the patient's prognosis is guarded."
774,774,P0242,"Age: 69
Gender: Female 
Weight: 57 kg
Height: 150 cm
NYHA Class: III
Blood Pressure: 110/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 34
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 3,44
Creatinine (mmol/L): 285.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 12,5
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 5,4
LDL (mmol/L): 1,71
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 656.0
Protein (g/L): 74
T3 (pg/dL): 0,06
T4 (ng/L): 17
Troponin (ng/mL): 0,05
TSH (mIU/L): 6,87
Urea (mg/dL): 23,46
LVEF (%): 21.0
Medications: Diabetes Medication, Beta Blockers, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden Cardiac Death
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which significantly increases the risk of sudden cardiac death. The patient's LVEF is severely reduced at 21%, indicating poor left ventricular function. The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG further increases the risk of sudden cardiac death. Additionally, the patient's elevated Pro-BNP level (656 ng/L) is indicative of heart failure and suggests a high risk of sudden cardiac death. The patient's age and comorbidities, such as diabetes and dyslipidemia, also contribute to the increased risk of sudden cardiac death.

RANKING: 2. Pump Failure Death
 REASONING: The patient's severe left ventricular dysfunction (LVEF 21%) and history of idiopathic dilated cardiomyopathy make pump failure a significant concern. The patient's elevated creatinine level (285.0 mol/L) and urea level (23.46 mg/dL) indicate impaired renal function, which is a common complication of advanced heart failure. The patient's NYHA Class III classification also indicates severe symptoms of heart failure, further increasing the risk of pump failure.

RANKING: 3. Survivor
 REASONING: While the patient's prognosis is poor, there are some factors that suggest a possible survival outcome. The patient's blood pressure is within a relatively normal range (110/70 mmHg), and her hemoglobin level is within the normal range. Additionally, the patient is on appropriate medications for heart failure, including beta blockers, ACE inhibitors, and nitrovasodilators. However, the patient's severe left ventricular dysfunction, history of idiopathic dilated cardiomyopathy, and elevated Pro-BNP level make survival less likely compared to sudden cardiac death or pump failure."
775,775,P0248,"Age: 43
Gender: Female 
Weight: 50 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 39
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 4,19
Creatinine (mmol/L): 53.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,79
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 996.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 18
Troponin (ng/mL): 0,09
TSH (mIU/L): 1,34
Urea (mg/dL): 3,66
LVEF (%): 37.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 2
 REASONING: The patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which indicates that the heart muscle has been damaged due to a heart attack. The patient's left ventricular ejection fraction (LVEF) of 37% is below the normal range, indicating that the heart is not pumping efficiently. The patient's elevated pro-BNP (996 ng/L) and low LVEF also suggest that the heart is under strain and may be at risk of further deterioration. However, the patient is on medications that are typically used to manage heart failure, such as beta blockers, loop diuretics, statins, and ACE inhibitors. The patient's blood pressure is also within a relatively normal range. 

However, the patient's creatinine level (53.0 mmol/L) is elevated, indicating kidney dysfunction, which can be a complication of heart failure. The patient's low hemoglobin (127 g/L) may also indicate anemia, which can contribute to heart failure. Considering these factors, the patient's prognosis is not as poor as it could be, but it is still concerning.

The patient's low T3 and T4 levels suggest that there may be some thyroid dysfunction, but this does not seem to be a major concern in this case. The patient's troponin level is slightly elevated, but this is likely a result of the previous myocardial infarction.

Given these factors, the most likely prognosis is pump failure death, but the patient's overall condition is not as dire as it could be. The patient's age and sex are not particularly concerning, and the patient's weight and height are within a relatively normal range.

RANKING: 3
 REASONING: Sudden cardiac death is less likely than pump failure death because the patient's ECG does not show any signs of life-threatening arrhythmias such as ventricular tachycardia or bradycardia. The patient's medications, including beta blockers, are also intended to reduce the risk of arrhythmias.

RANKING: 1
 REASONING: Survivor is the least likely prognosis because the patient has a history of ischemic dilated cardiomyopathy and myocardial infarction, which indicates that the heart muscle has been damaged. The patient's low LVEF and elevated pro-BNP also suggest that the heart is under strain. While the patient is on medications that are intended to manage heart failure, the patient's kidney dysfunction and anemia may indicate that the heart failure is not being adequately controlled."
776,776,P0256,"Age: 72
Gender: Male 
Weight: 79 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 150/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 33
ALT or GPT (IU/L): 44.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 267
Glucose (mmol/L): 9,9
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,72
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1475.0
Protein (g/L): 64
T3 (pg/dL): 0,03
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,13
Urea (mg/dL): 5,83
LVEF (%): 48.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: Survivor 

REASONING: 

Based on the provided patient data, I would rank the prognosis as Survivor for the following reasons:

1.  The patient is being treated with medications such as ACE inhibitors, which are beneficial for patients with heart failure and can help slow the progression of the disease. 
2.  The patient's LVEF (Left Ventricular Ejection Fraction) is 48%, which is relatively low but not extremely low. An LVEF of 40% or higher is often considered to be a good prognostic indicator for patients with heart failure.
3.  The patient's NYHA Class is III, indicating that the patient has some limitations in physical activity, but is still able to perform daily activities. This suggests that the patient's heart failure is not severe.
4.  The patient's Pro-BNP level is 1475.0 ng/L, which is elevated but not extremely high. Elevated Pro-BNP levels are often associated with heart failure, but levels above 5000 ng/L are typically associated with a worse prognosis.
5.  The patient's creatinine level is 88.0 mmol/L, which is elevated, but not extremely high. Elevated creatinine levels can indicate kidney dysfunction, but this patient's kidney function is still relatively preserved.

However, the patient also has several risk factors that could contribute to a worse prognosis, including ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and a history of myocardial infarction.

Considering these factors, while the patient's prognosis is not excellent, I would rank the prognosis as Survivor due to the presence of some favorable factors such as the patient's LVEF and NYHA Class, as well as the fact that the patient is being treated with medications that can help manage their condition. However, the patient's prognosis is not without risk, and close monitoring and follow-up will be necessary to ensure that their condition does not worsen.

RANKING: Sudden Cardiac Death 

REASONING: 

The patient's risk for sudden cardiac death is moderate to high due to the following factors:

1.  The patient's LVEF is 48%, which is relatively low and increases the risk of sudden cardiac death.
2.  The patient has a history of myocardial infarction, which increases the risk of sudden cardiac death.
3.  The patient's Pro-BNP level is elevated, which is associated with an increased risk of sudden cardiac death.
4.  The patient has a history of ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death.
5.  The patient's ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death.

However, the patient is being treated with medications such as beta-blockers and ACE inhibitors, which can help reduce the risk of sudden cardiac death.

RANKING: Pump Failure Death 

REASONING: 

The patient's risk for pump failure death is high due to the following factors:

1.  The patient's LVEF is 48%, which is relatively low and increases the risk of pump failure.
2.  The patient has a history of ischemic dilated cardiomyopathy, which increases the risk of pump failure.
3.  The patient's Pro-BNP level is elevated, which is associated with an increased risk of pump failure.
4.  The patient's creatinine level is elevated, which indicates kidney dysfunction, which can contribute to pump failure.
5.  The patient's NYHA Class is III, indicating that the patient has some limitations in physical activity, which can indicate a higher risk of pump failure.

However, the patient is being treated with medications such as ACE inhibitors and loop diuretics, which can help manage their condition and reduce the risk of pump failure."
777,777,P0264,"Age: 63
Gender: Male 
Weight: 65 kg
Height: 172 cm
NYHA Class: II
Blood Pressure: 90/55 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 41,9
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,48
Creatinine (mmol/L): 154.0
Gamma-glutamil transpeptidase (IU/L): 69
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,17
Potassium (mEq/L): 4,63
LDL (mmol/L): 2,84
Sodium (mEq/L): 141.0
Protein (g/L): 71,7
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,74
Urea (mg/dL): 11,9
LVEF (%): 15.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Pump Failure Death
REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened due to a heart attack. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 15%, indicating that the heart is not pumping blood efficiently. This is a strong indicator of heart failure. Additionally, the patient is on medications such as loop diuretics and hydralazine, which are commonly used to treat heart failure. The patient's blood pressure is also low, which can exacerbate heart failure symptoms. Considering these factors, pump failure death is the most likely prognosis.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The patient's LVEF is severely reduced, and the presence of polymorphic ventricular extrasystoles on the ECG suggests that the heart is experiencing abnormal electrical activity. However, the patient is on amiodarone, which is an anti-arrhythmic medication used to prevent sudden cardiac death. While the patient's risk of sudden cardiac death is elevated, the presence of this medication slightly reduces the likelihood of this outcome.

RANKING: 3. Survivor
REASONING: Given the patient's severe heart failure and low LVEF, the likelihood of survival is relatively low. However, the patient is on a combination of medications that may help manage symptoms and improve heart function. Additionally, the patient's age and weight are not particularly high risk factors for mortality. While it is possible that the patient may survive for a period of time with proper medical management, the prognosis is guarded, and the likelihood of survival is lower than the other two outcomes."
778,778,P0265,"Age: 83
Gender: Female 
Weight: 77 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 155/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38,2
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 3,99
Creatinine (mmol/L): 97.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 8,6
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,68
Potassium (mEq/L): 3,66
LDL (mmol/L): 2,03
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 984.0
Protein (g/L): 67
T4 (ng/L): 20
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,29
Urea (mg/dL): 9,7
LVEF (%): 70.0
Medications: Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor
REASONING: The patient is 83 years old, which puts her in a high-risk category for cardiac events due to age-related wear and tear on the heart. However, her left ventricular ejection fraction (LVEF) is 70%, which is within a relatively normal range for her age group. This suggests that her heart is still functioning relatively well, despite her advanced age. Additionally, she is on a regimen of beta blockers, loop diuretics, statins, ACE inhibitors, and nitrovasodilators, which are all evidence-based medications for managing heart failure and hypertension. Her recent troponin level is normal, indicating that she has not had a recent myocardial infarction. While her pro-BNP level is elevated at 984.0 ng/L, which suggests some degree of heart failure, it is not extremely high, and her albumin level is within a relatively normal range. Considering these factors, it is possible that with continued medical management and lifestyle adjustments, the patient may be able to manage her condition and avoid more severe cardiac events.

RANKING: 2. Sudden Cardiac Death
REASONING: While the patient has a history of myocardial infarction and hypertension, her current LVEF is within a relatively normal range, which reduces the likelihood of sudden cardiac death. Her ECG shows polymorphic ventricular extrasystoles, which can be a risk factor for sudden cardiac death, but it is not a definitive indicator. Her troponin level is normal, and she is on beta blockers, which are known to reduce the risk of sudden cardiac death. Her age and history of myocardial infarction do increase her risk, but the presence of a normal LVEF and current medical management make sudden cardiac death less likely.

RANKING: 3. Pump Failure Death
REASONING: The patient's history of hypertensive cardiomyopathy, diabetes, and dyslipemia increases her risk for heart failure. Her elevated pro-BNP level suggests some degree of heart failure, and her LVEF is within a relatively normal range, but this may not be sufficient to compensate for her other risk factors. Her creatinine level is elevated, which may indicate some degree of renal impairment, which can further increase her risk for pump failure. Her current medications are aimed at managing her heart failure, but her history and lab results suggest that she may be at a higher risk for pump failure."
779,779,P0269,"Age: 79
Gender: Male 
Weight: 62 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 120/80 mmHg
Past Medical History: Valvular cardiomyopathy, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 45,5
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,07
Creatinine (mmol/L): 184.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,4
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,82
Potassium (mEq/L): 5,12
LDL (mmol/L): 2,51
Sodium (mEq/L): 138.0
Protein (g/L): 71,1
Troponin (ng/mL): 0,13
TSH (mIU/L): 1,31
Urea (mg/dL): 20,1
LVEF (%): 22.0
Medications: Calcium Channel Blocker, Digoxin, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely:

RANKING: 1. Sudden Cardiac Death (SCD)
 REASONING: The patient has a history of myocardial infarction, valvular cardiomyopathy, and peripheral vascular disease, which are all risk factors for SCD. The patient's low left ventricular ejection fraction (LVEF) of 22% further increases the risk of SCD. Additionally, the presence of polymorphic ventricular extrasystoles on the ECG is a concerning sign that may indicate an increased risk of arrhythmias. The patient's age and NYHA class II classification also contribute to the risk of SCD.

RANKING: 2. Pump Failure Death
 REASONING: The patient's low LVEF of 22% and history of valvular cardiomyopathy suggest that the patient is at risk for pump failure. The patient's creatinine level of 184.0 mol/L also indicates some degree of renal impairment, which can be a consequence of heart failure. However, the patient is currently on loop diuretics, which may help manage fluid overload and reduce the risk of pump failure. The patient's NYHA class II classification suggests that the patient is not yet in severe heart failure, which makes pump failure less likely compared to SCD.

RANKING: 3. Survivor
 REASONING: While the patient has several risk factors for cardiac events, the patient's current medications, including an ACE inhibitor and a calcium channel blocker, may help manage the patient's conditions. The patient's LVEF is low, but it is not extremely low, and the patient's NYHA class II classification suggests that the patient is not yet in severe heart failure. Additionally, the patient's troponin level is within normal limits, which suggests that the patient is not currently experiencing acute cardiac ischemia. However, the patient's overall risk profile and low LVEF make a survivor prognosis less likely compared to SCD and pump failure."
780,780,P0285,"Age: 69
Gender: Female 
Weight: 76 kg
Height: 147 cm
NYHA Class: III
Blood Pressure: 150/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 4,5
Creatinine (mmol/L): 163.0
Gamma-glutamil transpeptidase (IU/L): 48,4
Glucose (mmol/L): 4,2
Hemoglobin (g/L): 134.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,56
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2365.0
Protein (g/L): 75
T3 (pg/dL): 0,0294
T4 (ng/L): 16,92
Troponin (ng/mL): 1,4
TSH (mIU/L): 0,56
Urea (mg/dL): 21,2
LVEF (%): 25.0
Medications: Diabetes Medication, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, here is the ranking of the possible prognoses from most likely to least likely:

RANKING: 1. Sudden cardiac death
REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 25%, indicating significant left ventricular dysfunction. Additionally, the presence of non-sustained ventricular tachycardia on the ECG further increases the risk of sudden cardiac death. The patient's elevated Pro-BNP level of 2365 ng/L also suggests severe heart failure, which can increase the risk of sudden cardiac death.

RANKING: 2. Pump failure death
REASONING: The patient's severe left ventricular dysfunction, as indicated by an LVEF of 25%, makes pump failure death a likely outcome. The patient's elevated creatinine level of 163.0 mol/L also suggests renal impairment, which is often associated with heart failure. The patient's history of diabetes and peripheral vascular disease further increases the risk of pump failure death.

RANKING: 3. Survivor
REASONING: While the patient has multiple comorbidities and a reduced LVEF, there are some factors that suggest a possible survival outcome. The patient is currently on appropriate medications for heart failure, including ACE inhibitors, statins, and loop diuretics. The patient's TSH level is within the normal range, indicating that there are no signs of thyroid dysfunction, which can contribute to heart failure. Additionally, the patient's hemoglobin level is within the normal range, indicating that there are no signs of anemia, which can worsen heart failure. However, given the patient's severe left ventricular dysfunction and other comorbidities, the likelihood of survival is lower compared to the other two options."
781,781,P0287,"Age: 70
Gender: Female 
Weight: 80 kg
Height: 145 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 44
ALT or GPT (IU/L): 27.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 5,35
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 5,2
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4
LDL (mmol/L): 3,13
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 1537.0
Protein (g/L): 72
T3 (pg/dL): 0,027
T4 (ng/L): 21,25
Troponin (ng/mL): 0,2
TSH (mIU/L): 1,93
Urea (mg/dL): 5,5
LVEF (%): 70.0
Medications: Calcium Channel Blocker, Amiodarone, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, here is the ranking of the prognoses from most likely to least likely:

RANKING: Sudden cardiac death

REASONING: The patient has a history of hypertensive cardiomyopathy, which is a significant risk factor for sudden cardiac death. Additionally, the patient's LVEF is 70%, which is within the normal range but may not be optimal considering the patient's age and medical history. The presence of polymorphic ventricular extrasystoles on the ECG also suggests a risk of arrhythmias. Furthermore, the patient's high Pro-BNP level (1537.0 ng/L) indicates increased stress on the heart, which may lead to arrhythmias or sudden cardiac death. The patient's current medications, including Amiodarone, may help mitigate some of these risks, but the overall risk profile suggests that sudden cardiac death is a possible outcome.

RANKING: Pump failure death

REASONING: The patient's LVEF is 70%, which is within the normal range, but the patient's age, history of hypertensive cardiomyopathy, and high Pro-BNP level suggest that the heart may be under strain. The patient's creatinine level is elevated at 100.0 umol/L, which may indicate some degree of renal impairment, which can be a marker of heart failure. The patient's medications, including Loop Diuretics, may help manage symptoms, but the overall risk profile suggests that pump failure death is a possible outcome.

RANKING: Survivor

REASONING: While the patient has several risk factors for cardiac disease, the patient's LVEF is within the normal range, and the patient is currently receiving appropriate medical treatment for their conditions. The patient's medications, including Statins and Calcium Channel Blocker, may help manage their dyslipidemia and hypertension, respectively. The patient's TSH level is within the normal range, which suggests that the patient's thyroid function is not contributing to their cardiac condition. While the patient's Pro-BNP level is elevated, it is not excessively high, and the patient's overall risk profile suggests that they may be able to manage their condition with ongoing medical treatment and lifestyle modifications."
782,782,P0293,"Age: 74
Gender: Male 
Weight: 90 kg
Height: 184 cm
NYHA Class: III
Blood Pressure: 125/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 40,5
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 3,61
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 22
Glucose (mmol/L): 3,19
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,7
Potassium (mEq/L): 5,11
LDL (mmol/L): 1,73
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 1081.0
Protein (g/L): 68
T3 (pg/dL): 0,024
T4 (ng/L): 16,52
Troponin (ng/mL): 0,2
TSH (mIU/L): 0,62
Urea (mg/dL): 10,3
LVEF (%): 28.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely:

RANKING: 1. Sudden Cardiac Death (SCD), 2. Pump Failure Death, 3. Survivor

REASONING:

1. Sudden Cardiac Death (SCD): The patient has a high risk of SCD due to the following factors:
	* NYHA Class III, indicating severe symptoms of heart failure.
	* LVEF of 28% indicates severe left ventricular dysfunction.
	* Presence of non-sustained ventricular tachycardia (NSVT) on ECG, which is a known predictor of SCD.
	* Elevated Pro-BNP levels (1081 ng/L) indicate increased ventricular stress and potential for arrhythmias.
	* The patient's age (74) and male gender also increase the risk of SCD.
2. Pump Failure Death: While the patient has severe heart failure (NYHA Class III and LVEF 28%), the presence of NSVT and elevated Pro-BNP levels suggest that SCD is a more immediate concern. However, pump failure death is still a possible outcome if the patient's heart failure progresses and becomes refractory to medical therapy.
3. Survivor: The patient's severe heart failure and multiple comorbidities (diabetes, hypertension, and idiopathic dilated cardiomyopathy) make survival a less likely outcome. However, the patient is currently receiving optimal medical therapy (beta blockers, ACE inhibitor, spironolactone, and loop diuretics), which may help slow disease progression. Additionally, the patient's TSH level is within normal range, indicating that hypothyroidism, a common cause of heart failure, is unlikely. The patient's hemoglobin level is also within normal range, which reduces the risk of anemia-related complications. Therefore, while survival is less likely, it is still possible with continued medical management.

Please note that this prognosis is based on the provided data and may not reflect the patient's actual outcome. A more accurate prognosis would require a comprehensive evaluation by a cardiologist and consideration of additional factors, such as the patient's social and family support, adherence to medical therapy, and any recent changes in symptoms or medical history."
783,783,P0294,"Age: 70
Gender: Male 
Weight: 79 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,99
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 78
Glucose (mmol/L): 5,82
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,57
LDL (mmol/L): 3,53
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1693.0
Protein (g/L): 67
T3 (pg/dL): 0,0369
T4 (ng/L): 15,09
Troponin (ng/mL): 0,3
TSH (mIU/L): 1,21
Urea (mg/dL): 8
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: 1. Survivor
 REASONING: The patient has been managed with a combination of Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, and Spironolactone, which are standard treatments for heart failure. The patient's NYHA Class II classification indicates that the patient has some limitations in physical activity but is still able to perform daily activities. The patient's LVEF of 25% is low, indicating severe left ventricular dysfunction, but the patient's overall clinical status appears to be stable. The absence of severe symptoms, such as acute decompensated heart failure, and the presence of effective medical therapy suggest a good prognosis. Additionally, the patient's eGFR (estimated glomerular filtration rate) can be estimated from the creatinine level, which is 88.0 mmol/L, corresponding to an eGFR of approximately 45 mL/min/1.73 m^2, indicating mild renal impairment. This is not a significant concern in this context.

RANKING: 2. Sudden cardiac death
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is a risk factor for sudden cardiac death. However, the patient is already on beta blockers, which are known to reduce the risk of sudden cardiac death. The patient's LVEF of 25% is low, but the absence of severe symptoms and the presence of effective medical therapy suggest that the risk of sudden cardiac death may be lower than that of pump failure.

RANKING: 3. Pump failure death
 REASONING: The patient has a low LVEF of 25%, indicating severe left ventricular dysfunction. The patient's symptoms are currently well-managed, but the underlying condition of idiopathic dilated cardiomyopathy is progressive and may eventually lead to pump failure. The patient's eGFR of approximately 45 mL/min/1.73 m^2 is mildly reduced, which may indicate a potential decline in renal function, further increasing the risk of pump failure. The presence of elevated Pro-BNP (1693.0 ng/L) also suggests that the patient is at risk for pump failure. The patient's current management with diuretics and spironolactone may help alleviate symptoms, but the underlying disease process may eventually lead to pump failure."
784,784,P0303,"Age: 71
Gender: Male 
Weight: 65 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 120/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 39.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 5,92
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 44
Glucose (mmol/L): 6,7
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,7
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 1160.0
Protein (g/L): 74
T3 (pg/dL): 0,03
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 4,34
Urea (mg/dL): 6,82
LVEF (%): 42.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor
 REASONING: The patient is 71 years old with a history of ischemic dilated cardiomyopathy and myocardial infarction, indicating significant cardiac disease. However, the patient's LVEF (42%) is relatively preserved, and they are on a comprehensive treatment regimen, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor. These medications are commonly used to manage heart failure and reduce the risk of sudden cardiac death. The patient's NYHA Class II classification suggests that they are experiencing some limitations in physical activity but are still able to perform daily tasks without significant symptoms. The absence of ventricular tachycardia and the presence of a preserved LVEF suggest that the patient's heart is functioning relatively well despite the underlying disease. While the patient's Pro-BNP level is elevated, which is often associated with heart failure, it is not excessively high. Therefore, considering the patient's current treatment and relatively preserved cardiac function, a survivor prognosis is the most likely outcome.

RANKING: 2. Sudden cardiac death
 REASONING: The patient's history of ischemic dilated cardiomyopathy and myocardial infarction increases the risk of sudden cardiac death. The presence of polymorphic ventricular extrasystoles on the ECG is a concern, as it may indicate electrical instability in the heart. However, the absence of sustained ventricular tachycardia or other high-risk features on the ECG reduces the likelihood of sudden cardiac death. The patient's LVEF is preserved, which is a favorable sign. While the patient's Pro-BNP level is elevated, it is not excessively high, which may indicate that the patient's heart failure is not in an advanced stage. Considering these factors, sudden cardiac death is a possible but less likely outcome compared to survivor.

RANKING: 3. Pump failure death
 REASONING: The patient's LVEF of 42% is relatively preserved, and they are on a comprehensive treatment regimen for heart failure. The patient's NYHA Class II classification suggests that they are experiencing some limitations in physical activity but are still able to perform daily tasks without significant symptoms. The absence of signs of severe heart failure, such as severely elevated Pro-BNP levels or significant weight loss, suggests that the patient's heart function is not severely compromised. The patient's creatinine level is slightly elevated, but it is not excessively high, indicating that the patient's kidney function is not severely impaired. Considering these factors, pump failure death is the least likely outcome."
785,785,P0317,"Age: 63
Gender: Male 
Weight: 72 kg
Height: 172 cm
NYHA Class: III
Blood Pressure: 95/65 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 42,5
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 4,81
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 16
Glucose (mmol/L): 4,1
Hemoglobin (g/L): 129.0
HDL (mmol/L): 1,45
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,64
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 325.0
Protein (g/L): 83
T3 (pg/dL): 0,05
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 6,37
Urea (mg/dL): 13,14
LVEF (%): 24.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: 1. Pump failure death
REASONING: The patient has a history of ischemic dilated cardiomyopathy with an LVEF of 24%, which indicates severe left ventricular dysfunction. The patient is also in NYHA Class III, indicating significant symptoms of heart failure. The high Pro-BNP level of 325.0 ng/L further supports the presence of heart failure. Additionally, the patient is on medications for heart failure, including loop diuretics and ACE inhibitors, which are commonly used to manage heart failure. The presence of ventricular extrasystoles on the ECG also suggests underlying cardiac dysfunction. Given the patient's severe heart failure symptoms and history of ischemic dilated cardiomyopathy, pump failure death is the most likely prognosis.

RANKING: 2. Sudden cardiac death
REASONING: The patient has a history of myocardial infarction, ischemic dilated cardiomyopathy, and ventricular extrasystoles on the ECG, which increases the risk of sudden cardiac death. However, the patient is on amiodarone, which is an antiarrhythmic medication that can help prevent sudden cardiac death. Additionally, the patient's LVEF is severely reduced, but not as low as typically seen in patients at high risk of sudden cardiac death. The patient's TSH level is slightly elevated, which may indicate underlying thyroid dysfunction, but it is not a significant risk factor for sudden cardiac death.

RANKING: 3. Survivor
REASONING: While the patient has a history of ischemic dilated cardiomyopathy and significant heart failure symptoms, the patient is on optimal medical therapy for heart failure, including beta blockers and ACE inhibitors. The patient's LVEF is severely reduced, but it is not as low as typically seen in patients who do not survive with optimal medical therapy. The patient's Pro-BNP level is high, but it is not as high as typically seen in patients who do not survive. The patient's TSH level is slightly elevated, which may indicate underlying thyroid dysfunction, but it is not a significant risk factor for mortality. Overall, while the patient's prognosis is poor, survival with optimal medical therapy is still possible, making survivor the least likely prognosis."
786,786,P0320,"Age: 69
Gender: Male 
Weight: 64 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 43,8
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 3,96
Creatinine (mmol/L): 98.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 4,6
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,99
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 535.0
Protein (g/L): 79
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,983
Urea (mg/dL): 7,35
LVEF (%): 36.0
Medications: Beta Blockers, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden Cardiac Death (SCD)
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for SCD. The patient's left ventricular ejection fraction (LVEF) is 36%, indicating reduced cardiac function. The presence of monomorphic ventricular extrasystoles on the ECG suggests an increased risk of arrhythmias, which can lead to SCD. Additionally, the elevated Pro-BNP level (535 ng/L) indicates increased stress on the heart, which can also contribute to arrhythmias and SCD. While the patient is on beta blockers, which can help reduce the risk of SCD, the other risk factors outweigh the protective effects of these medications.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF is 36%, which indicates reduced cardiac function and an increased risk of pump failure. The patient's history of myocardial infarction and ischemic dilated cardiomyopathy further supports this risk. However, the patient's NYHA class is II, which indicates that the patient is not severely symptomatic, and the patient is on medications that can help manage heart failure symptoms (e.g., beta blockers, spironolactone). While pump failure death is still a risk, the patient's current symptoms and medication regimen suggest that this outcome may be less likely than SCD.

RANKING: 3. Survivor
 REASONING: Based on the patient's age, LVEF, and history of ischemic dilated cardiomyopathy, survivor is the least likely outcome. However, the patient is on a comprehensive medication regimen that can help manage heart failure symptoms and reduce the risk of complications. The patient's NYHA class is II, which suggests that the patient is not severely symptomatic, and the patient's hemoglobin level is within the normal range, which can help indicate that the patient is not experiencing significant anemia or other conditions that could worsen the prognosis. While the patient's prognosis is guarded, the patient's current treatment and relatively mild symptoms suggest that survivor is the least likely outcome."
787,787,P0321,"Age: 67
Gender: Female 
Weight: 76 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 39,6
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 2,87
Creatinine (mmol/L): 94.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 134.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4,5
LDL (mmol/L): 1,45
Sodium (mEq/L): 132.0
Pro-BNP (ng/L): 4636.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 22
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,43
Urea (mg/dL): 6,01
LVEF (%): 18.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely, along with the reasoning behind each:

RANKING: 1. Survivor
REASONING: The patient is on a combination of medications that are commonly used to manage heart failure and hypertension, including beta blockers, ACE inhibitors, and spironolactone. The patient's blood pressure is well-controlled at 120/70 mmHg, which is within a normal range. Additionally, the patient's LVEF is 18%, which, although low, is not extremely low, and the patient is not in acute heart failure. The patient's pro-BNP level is elevated, but it is not extremely high. Considering these factors, the patient may be able to manage their condition with medication and lifestyle changes, making survival a more likely outcome.

RANKING: 2. Sudden cardiac death
REASONING: The patient has a history of ischemic dilated cardiomyopathy, myocardial infarction, and peripheral vascular disease, which are all risk factors for sudden cardiac death. However, the patient's ECG does not show any signs of ventricular tachycardia, and their troponin level is low, indicating that there is no acute myocardial infarction. The patient's LVEF is low, but not extremely low, which may reduce the risk of sudden cardiac death. Additionally, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death. While the risk of sudden cardiac death is present, it is not the most likely outcome.

RANKING: 3. Pump failure death
REASONING: The patient's LVEF is extremely low at 18%, indicating severe heart failure. The patient's pro-BNP level is also elevated, which is a marker of heart failure. The patient's creatinine level is slightly elevated, indicating some degree of renal impairment, which can be a consequence of severe heart failure. The patient's history of ischemic dilated cardiomyopathy and myocardial infarction also increases the risk of pump failure. The patient's medications, including loop diuretics and spironolactone, are commonly used to manage heart failure, but the patient's low LVEF and elevated pro-BNP level suggest that the heart failure is not well-controlled. Considering these factors, pump failure death is the least likely outcome, but still a possible one, especially if the patient's condition worsens over time."
788,788,P0329,"Age: 61
Gender: Female 
Weight: 95 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 140/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39,2
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,68
Creatinine (mmol/L): 99.0
Gamma-glutamil transpeptidase (IU/L): 31
Glucose (mmol/L): 17,2
Hemoglobin (g/L): 165.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,8
LDL (mmol/L): 1,78
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 10340.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 16
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,44
Urea (mg/dL): 7,35
LVEF (%): 24.0
Medications: Diabetes Medication, Digoxin, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, here are the prognoses for the next few years, ordered from most likely to least likely:

RANKING: 1. Pump Failure Death

REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a condition where the heart muscle is weakened due to a heart attack. The patient's left ventricular ejection fraction (LVEF) is severely reduced at 24%, indicating that the heart is not pumping efficiently. The patient's Pro-BNP level is also elevated at 10340.0 ng/L, which is a marker of heart failure. Additionally, the patient is taking medications such as Spironolactone and ACE Inhibitor, which are commonly used to treat heart failure. The patient's weight is also high at 95 kg, which can exacerbate heart failure. Considering these factors, pump failure death is the most likely prognosis.

RANKING: 2. Sudden Cardiac Death

REASONING: The patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The patient's LVEF is severely reduced, and the Pro-BNP level is elevated, indicating that the heart is under strain. The patient's ECG shows monomorphic ventricular extrasystoles, which can be a marker of increased risk of sudden cardiac death. However, the patient does not have any other high-risk features such as non-sustained ventricular tachycardia or paroxysmal supraventricular tachyarrhythmia. While sudden cardiac death is a possibility, it is less likely than pump failure death due to the patient's overall clinical picture.

RANKING: 3. Survivor

REASONING: While the patient has a history of ischemic dilated cardiomyopathy and reduced LVEF, the patient is already on optimal medical therapy, including ACE Inhibitor, Spironolactone, and Digoxin. The patient's blood pressure is well-controlled, and the patient is not in NYHA Class IV, which suggests that the patient's symptoms are not as severe as they could be. The patient's weight is high, but the patient's overall clinical picture is not as dire as it could be. While the patient's prognosis is guarded, it is possible that with optimal medical therapy and close monitoring, the patient may be able to survive for several years."
789,789,P0336,"Age: 69
Gender: Female 
Weight: 69 kg
Height: 150 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes, Dyslipemia
Albumin (g/L): 41,9
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 91.0
Gamma-glutamil transpeptidase (IU/L): 14
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,4
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 3311.0
Protein (g/L): 73
T3 (pg/dL): 0,03
T4 (ng/L): 8
Troponin (ng/mL): 0,02
TSH (mIU/L): 33,39
Urea (mg/dL): 6,68
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Digoxin
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient is a 69-year-old female with a history of idiopathic dilated cardiomyopathy, diabetes, and dyslipemia. She has a low left ventricular ejection fraction (LVEF) of 22%, indicating severe heart failure. However, she is on appropriate medications, including an Angiotensin II Receptor Blocker and Digoxin, which may help manage her condition. Her blood pressure is well-controlled, and she has a relatively low glucose level, which is beneficial for patients with heart failure. While her Pro-BNP level is elevated, indicating increased cardiac stress, it is not extremely high, and her troponin level is normal, suggesting that there is no acute myocardial infarction. Additionally, her ECG shows non-sustained ventricular tachycardia, but no other significant arrhythmias. Considering these factors, a survivor prognosis is more likely, as the patient is being treated and managed for her condition.

RANKING: 2. Sudden cardiac death
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a risk factor for sudden cardiac death. Her low LVEF of 22% also increases her risk of sudden cardiac death. Her ECG shows polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia, which are both risk factors for sudden cardiac death. However, her overall clinical presentation and medication regimen do not strongly suggest a high risk of sudden cardiac death. Her normal troponin level and controlled blood pressure also argue against this prognosis.

RANKING: 3. Pump failure death
 REASONING: The patient's low LVEF of 22% and history of idiopathic dilated cardiomyopathy make pump failure death a concern. However, her current medication regimen and relatively well-controlled blood pressure and glucose levels suggest that she is being managed for her condition. Her Pro-BNP level is elevated, indicating cardiac stress, but not extremely high. Her ECG findings are concerning, but not as severe as those typically seen in patients with advanced heart failure. Additionally, her age and gender are not strongly indicative of pump failure death. Considering these factors, pump failure death is the least likely prognosis.

Please note that this is a medical prediction based on the provided data and should be taken as a general assessment. The actual prognosis may vary depending on various factors, including the patient's overall health status, response to treatment, and any changes in her condition over time."
790,790,P0339,"Age: 77
Gender: Male 
Weight: 64 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 110/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension
Albumin (g/L): 37,4
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 135.0
Gamma-glutamil transpeptidase (IU/L): 23
Glucose (mmol/L): 4,1
Hemoglobin (g/L): 128.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,49
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 3307.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,37
Urea (mg/dL): 16,03
LVEF (%): 33.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I would rank the prognoses from most likely to least likely as follows:

RANKING: 1. Sudden Cardiac Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy with an LVEF of 33%, indicating significant left ventricular dysfunction. The elevated Pro-BNP level (3307.0 ng/L) also suggests heart failure with reduced ejection fraction (HFrEF). The presence of ventricular extrasystoles and a history of ischemic cardiomyopathy increase the risk of arrhythmias, which can lead to sudden cardiac death. Additionally, the patient's age (77 years) and male gender further increase the risk of sudden cardiac death.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF of 33% and elevated Pro-BNP level indicate significant left ventricular dysfunction, which increases the risk of pump failure death. The patient's NYHA Class II classification suggests that the patient experiences symptoms with moderate exertion, which is consistent with heart failure. The use of loop diuretics and ACE inhibitor medications also suggests that the patient's heart failure is being managed, but the underlying cardiac dysfunction remains a significant concern.

RANKING: 3. Survivor
 REASONING: While the patient's LVEF is low, the patient's age and comorbidities (diabetes, peripheral vascular disease, hypertension) suggest that the patient may have a more complex and challenging clinical scenario. However, the patient's current medications and the absence of more severe symptoms (e.g., NYHA Class III or IV) suggest that the patient may be able to manage their heart failure with ongoing medical therapy and lifestyle modifications. The patient's relatively low troponin level (0.01 ng/mL) and lack of sustained ventricular tachycardia on ECG also suggest that the patient may not be at immediate risk for sudden cardiac death."
791,791,P0363,"Age: 83
Gender: Male 
Weight: 55 kg
Height: 163 cm
NYHA Class: III
Blood Pressure: 160/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 41,1
ALT or GPT (IU/L): 10.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,71
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 13,6
Glucose (mmol/L): 4,59
Hemoglobin (g/L): 160.0
HDL (mmol/L): 1,5
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,2
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 1469.0
Protein (g/L): 73
T3 (pg/dL): 0,0468
T4 (ng/L): 13,29
Troponin (ng/mL): 0,4
TSH (mIU/L): 1,04
Urea (mg/dL): 5,6
LVEF (%): 25.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Survivor, 2. Sudden cardiac death, 3. Pump failure death

REASONING:

Given the patient's age, NYHA Class III, and ischemic dilated cardiomyopathy, the patient has a compromised cardiac function, which is evident from the low left ventricular ejection fraction (LVEF) of 25%. However, the patient is already on optimal medical therapy for heart failure, including ACE inhibitors, angiotensin II receptor blockers, loop diuretics, and spironolactone. This suggests that the patient's condition is being actively managed.

The patient's Pro-BNP level is elevated at 1469 ng/L, which is consistent with heart failure. However, it is not the highest possible value, indicating that the patient's condition is not acutely decompensated.

The patient's creatinine level is elevated at 82.0 umol/L, indicating impaired renal function, which is common in patients with heart failure. However, the patient's blood urea level is within the normal range, suggesting that the renal impairment is not severe.

The patient's troponin level is slightly elevated at 0.4 ng/mL, which may indicate ongoing myocardial ischemia or infarction, but it is not significantly high.

Considering the patient's overall clinical picture, the most likely prognosis is survivor. The patient's condition is being actively managed, and the patient is not showing signs of acute decompensation. The patient's age and comorbidities do increase the risk of sudden cardiac death, but the patient's current medical therapy and the absence of acute decompensation suggest that sudden cardiac death is less likely.

Pump failure death is the least likely prognosis. The patient's LVEF is very low, but the patient's condition is being actively managed, and the patient is not showing signs of acute decompensation. The patient's renal function is impaired, but it is not severe, and the patient's creatinine level is not rising rapidly. Additionally, the patient's pro-BNP level is not the highest possible value, indicating that the patient's condition is not acutely decompensated.

Therefore, the order of the prognoses from most likely to least likely is: Survivor, Sudden cardiac death, Pump failure death."
792,792,P0391,"Age: 82
Gender: Female 
Weight: 77 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 125/65 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 40
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,63
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 112.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,97
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 950.0
Protein (g/L): 67
T3 (pg/dL): 0,03
T4 (ng/L): 21
TSH (mIU/L): 0,79
Urea (mg/dL): 14,64
LVEF (%): 37.0
Medications: Amiodarone, Loop Diuretics, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: No
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, here is my prognosis for the next few years:

RANKING: 1. Survivor
 REASONING: The patient is an 82-year-old female with a history of hypertensive cardiomyopathy and dyslipemia. Despite her age and comorbidities, she is relatively well-controlled on her current medications, including loop diuretics, hydralazine, and nitrovasodilators. Her blood pressure is within a reasonable range, and her ejection fraction (LVEF) is 37%, which is slightly below the normal range but not severely depressed. The patient's creatinine level is elevated, but it is not significantly high, and her hemoglobin level is within the normal range. Additionally, her pro-BNP level is elevated, which suggests some degree of heart failure, but not to the extent that would indicate imminent pump failure death. Considering her relatively stable condition and the absence of any acute decompensation, I believe that survival is the most likely outcome.

RANKING: 2. Sudden cardiac death
 REASONING: The patient has a history of hypertensive cardiomyopathy and is on amiodarone, which is a medication used to prevent arrhythmias. However, there is no indication of any arrhythmia on the ECG, and her TSH level is within the normal range, which suggests that her thyroid function is well-controlled. While sudden cardiac death can occur in patients with heart failure, the absence of any acute decompensation and the patient's relatively stable condition make this outcome less likely.

RANKING: 3. Pump failure death
 REASONING: The patient's LVEF is 37%, which is below the normal range, indicating some degree of heart failure. Her creatinine level is elevated, and her pro-BNP level is high, which suggests some degree of cardiac dysfunction. However, the patient is on medications that are intended to manage her heart failure, and her blood pressure is within a reasonable range. While pump failure death is a possible outcome, the patient's relatively stable condition and the absence of any acute decompensation make this outcome the least likely of the three."
793,793,P0448,"Age: 71
Gender: Male 
Weight: 60 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 45.0
AST or GOT (IU/L): 31.0
Total Cholesterol (mmol/L): 4,42
Creatinine (mmol/L): 194.0
Gamma-glutamil transpeptidase (IU/L): 52
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,69
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2285.0
Protein (g/L): 69
T3 (pg/dL): 0,03
T4 (ng/L): 10
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,69
Urea (mg/dL): 15,14
LVEF (%): 55.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 2
 REASONING: The patient has a history of hypertensive cardiomyopathy, diabetes, dyslipemia, and hypertension, which are all risk factors for heart failure. The patient's LVEF (Left Ventricular Ejection Fraction) is 55%, which is slightly below the normal range (60-70%), indicating some degree of systolic dysfunction. The elevated Pro-BNP (2285.0 ng/L) is a marker of heart failure and also indicates that the patient is experiencing some degree of volume overload. However, the patient is currently on ACE Inhibitor and Angiotensin II Receptor Blocker, which are both commonly used to manage heart failure. The patient's current NYHA Class II indicates that the patient is experiencing some symptoms of heart failure but is still able to perform daily activities with some limitation. The patient's medications and current treatment plan are likely aimed at managing the heart failure and preventing further deterioration.

RANKING: 3
 REASONING: The patient has a low T4 level (10 ng/L), which may indicate hypothyroidism, but the TSH level is within the normal range (3.69 mIU/L), which suggests that the hypothyroidism is mild and not causing significant cardiac issues. The patient's Troponin level is within the normal range (0.01 ng/mL), which suggests that there is no acute coronary syndrome. The patient's ECG does not show any signs of acute coronary syndrome or significant arrhythmias. The patient's creatinine level (194.0 mmol/L) is elevated, indicating some degree of kidney dysfunction, but it is not severe enough to cause significant cardiac issues.

RANKING: 1
 REASONING: Based on the patient's age (71), history of hypertensive cardiomyopathy, diabetes, dyslipemia, and hypertension, and the presence of ventricular extrasystoles on the ECG, the patient is at a higher risk of sudden cardiac death. The patient's LVEF is slightly below the normal range, and the patient's Pro-BNP level is elevated, indicating some degree of cardiac dysfunction. The patient's medications and current treatment plan are aimed at managing the heart failure, but the patient's underlying conditions and ECG findings suggest that there is a risk of sudden cardiac death."
794,794,P0460,"Age: 66
Gender: Female 
Weight: 56 kg
Height: 154 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 5,46
Creatinine (mmol/L): 186.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 102.0
HDL (mmol/L): 0,88
Potassium (mEq/L): 5,2
LDL (mmol/L): 4,5
Sodium (mEq/L): 130.0
Pro-BNP (ng/L): 4471.0
Protein (g/L): 82
T4 (ng/L): 12
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,11
Urea (mg/dL): 16,31
LVEF (%): 32.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely:

RANKING: 1. Pump Failure Death
REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure and pump failure. The patient's current LVEF of 32% indicates severe left ventricular dysfunction, which is a strong indicator of poor prognosis. Additionally, the patient's high Pro-BNP level (4471.0 ng/L) suggests severe heart failure symptoms. The patient is already taking medications for heart failure, including Loop Diuretics and Spironolactone, which are commonly used to manage heart failure symptoms. Given the patient's advanced heart failure and low LVEF, pump failure death is the most likely prognosis.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, which increases the risk of arrhythmias and sudden cardiac death. The presence of polymorphic ventricular extrasystoles on the ECG also suggests an increased risk of arrhythmias. However, the patient is already taking medications that may help prevent sudden cardiac death, such as an ACE Inhibitor and a Nitrovasodilator. While sudden cardiac death is a possible prognosis, it is less likely than pump failure death given the patient's advanced heart failure symptoms.

RANKING: 3. Survivor
REASONING: The patient's advanced heart failure and low LVEF make a good prognosis unlikely. While the patient is taking medications to manage heart failure symptoms, the patient's condition is severe, and the likelihood of significant improvement is low. The patient's high Pro-BNP level and low LVEF suggest that the patient is at high risk of adverse outcomes, making survival the least likely prognosis.

Note: It is essential to note that this prognosis is based on the provided data and may not reflect the actual patient's outcome. A thorough evaluation and consultation with a cardiologist are necessary to determine the patient's actual prognosis and develop an appropriate treatment plan."
795,795,P0461,"Age: 65
Gender: Male 
Weight: 113 kg
Height: 176 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Peripheral vascular disease, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 40.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 115
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 168.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,44
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 339.0
Protein (g/L): 76
T4 (ng/L): 8
Troponin (ng/mL): 0,01
TSH (mIU/L): 5,21
Urea (mg/dL): 3,83
LVEF (%): 60.0
Medications: Amiodarone, Digoxin, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 2

REASONING: 

This patient has a history of hypertensive cardiomyopathy, peripheral vascular disease, and hypertension, which are all risk factors for heart failure. The patient's current NYHA Class II indicates some limitation of physical activity due to heart disease, but the patient is still able to perform most daily activities without symptoms. However, the presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG suggests a risk of arrhythmias, which could potentially lead to sudden cardiac death.

The patient's LVEF of 60% is within the normal range, but the elevated Pro-BNP level of 339 ng/L suggests some degree of heart failure, even if it's not severe. The patient's weight of 113 kg and height of 176 cm result in a BMI of 30.6, indicating obesity, which is another risk factor for heart failure.

Considering the patient's age, comorbidities, and risk factors, pump failure death is a possible outcome, but it is not the most likely one. The patient's LVEF is still within the normal range, and the patient is not in a more advanced stage of heart failure. 

Sudden cardiac death is the most likely outcome due to the presence of non-sustained ventricular tachycardia, polymorphic ventricular extrasystoles, and a history of hypertension and cardiomyopathy. These factors increase the risk of arrhythmias, which could potentially lead to sudden cardiac death.

Survivor is the least likely outcome due to the patient's history of hypertension, cardiomyopathy, and arrhythmias. While the patient's LVEF is still within the normal range, the presence of these risk factors and the elevated Pro-BNP level suggest that the patient is at risk for heart failure and potentially other cardiac complications."
796,796,P0480,"Age: 78
Gender: Female 
Weight: 46 kg
Height: 143 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Dyslipemia
Albumin (g/L): 42,5
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 23.0
Total Cholesterol (mmol/L): 4,03
Creatinine (mmol/L): 84.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 113.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,7
LDL (mmol/L): 1,81
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1816.0
Protein (g/L): 71,6
T4 (ng/L): 16
TSH (mIU/L): 1,88
Urea (mg/dL): 6,82
LVEF (%): 27.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Sudden cardiac death
 REASONING: The patient's history of hypertensive cardiomyopathy and low left ventricular ejection fraction (LVEF) of 27% indicates significant left ventricular dysfunction. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG further increases the risk of arrhythmic events, including sudden cardiac death. Additionally, the elevated pro-BNP level of 1816 ng/L suggests significant cardiac stress and strain. While the patient is on beta blockers, digoxin, and other medications, the presence of these arrhythmic findings and the patient's low LVEF make sudden cardiac death a significant concern.

RANKING: 2. Pump failure death
 REASONING: The patient's low LVEF of 27% and history of hypertensive cardiomyopathy suggest that the patient is at risk for progressive heart failure. The elevated pro-BNP level and low albumin level also indicate significant cardiac stress and strain. However, the patient is already on loop diuretics and spironolactone, which are standard treatments for heart failure. While the patient's condition is concerning, the fact that they are receiving treatment for heart failure and do not have severe symptoms (NYHA Class II) makes pump failure death less likely than sudden cardiac death in the short term.

RANKING: 3. Survivor
 REASONING: While the patient has significant cardiac disease and is at risk for both sudden cardiac death and pump failure, the fact that they are being treated with a comprehensive medication regimen, including beta blockers, digoxin, and statins, suggests that their condition is being actively managed. Additionally, the patient's NYHA Class II symptoms indicate that they are still able to perform some physical activity without severe limitation, which suggests that their cardiac function is not severely impaired. While the patient's prognosis is guarded, the presence of active treatment and relatively mild symptoms makes survival the most likely outcome."
797,797,P0481,"Age: 66
Gender: Male 
Weight: 73 kg
Height: 168 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 47,9
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 6,23
Creatinine (mmol/L): 122.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 5,9
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 5
LDL (mmol/L): 3,57
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 2035.0
Protein (g/L): 73,6
T4 (ng/L): 15
TSH (mIU/L): 2,12
Urea (mg/dL): 13,64
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: First-degree Atrioventricular block (AVB)
            ",pump failure death,"RANKING: 1. Survivor
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure. However, the patient is currently on optimal medical therapy, including beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all evidence-based treatments for heart failure with reduced ejection fraction (HFrEF). The patient's LVEF is 20%, which is consistent with HFrEF. Despite the low LVEF, the patient's NYHA class is II, indicating that the patient is not severely symptomatic. The patient's blood pressure is within a relatively normal range, and the patient is not in a state of acute decompensated heart failure. While the patient has a high Pro-BNP level, which is a marker of heart failure, it is not excessively high, and the patient's creatinine level is not significantly elevated, which suggests that the patient's renal function is relatively preserved. Therefore, considering the patient's current medical therapy and relatively stable clinical condition, a survivor prognosis is more likely.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, which are risk factors for sudden cardiac death (SCD). The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for SCD. However, the patient is on beta blockers, which are effective in reducing the risk of SCD. The patient's LVEF is 20%, which is a risk factor for SCD, but the patient's NYHA class is II, indicating that the patient is not severely symptomatic. The patient's potassium level is slightly elevated, which may be a risk factor for SCD, but it is not excessively high. Therefore, while SCD is a possible outcome, it is less likely than survivor due to the patient's relatively stable clinical condition and optimal medical therapy.

RANKING: 3. Pump Failure Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy and a low LVEF of 20%, which are significant risk factors for pump failure death. The patient's Pro-BNP level is high, indicating that the patient's heart is under strain. However, the patient's creatinine level is not significantly elevated, which suggests that the patient's renal function is relatively preserved. The patient is on optimal medical therapy, including loop diuretics and an ACE inhibitor, which are effective in managing heart failure. The patient's NYHA class is II, indicating that the patient is not severely symptomatic. While pump failure death is a possible outcome, it is the least likely of the three options due to the patient's relatively stable clinical condition and optimal medical therapy."
798,798,P0487,"Age: 79
Gender: Male 
Weight: 83 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Myocardial Infarction
Albumin (g/L): 45,8
ALT or GPT (IU/L): 9.0
AST or GOT (IU/L): 26.0
Total Cholesterol (mmol/L): 3,36
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 100
Glucose (mmol/L): 8,3
Hemoglobin (g/L): 137.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,9
LDL (mmol/L): 1,84
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 3407.0
Protein (g/L): 76,8
T4 (ng/L): 16
TSH (mIU/L): 1,24
Urea (mg/dL): 4,82
LVEF (%): 15.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden cardiac death, 2. Pump failure death, 3. Survivor

REASONING:

1. Sudden cardiac death: Given the patient's age, ischemic dilated cardiomyopathy, low LVEF (15%), and history of myocardial infarction, the risk of sudden cardiac death is high. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG further increases this risk. The patient's low LVEF indicates a high risk of life-threatening arrhythmias, making sudden cardiac death a significant concern.

2. Pump failure death: While the patient's LVEF is very low, indicating severe heart failure, the patient is already on optimal medical therapy for heart failure (Beta Blockers, Loop Diuretics, Spironolactone, and ACE Inhibitor). The patient's NYHA Class III classification indicates that the patient has significant symptoms, but the fact that they are still ambulatory suggests that their heart failure is not yet advanced enough to lead to pump failure death in the short term. However, the patient's overall clinical picture, including their low LVEF and high Pro-BNP levels, still suggests that pump failure is a possible outcome.

3. Survivor: Given the patient's advanced age, low LVEF, and history of myocardial infarction, the likelihood of survival is lower compared to the other two options. However, the patient's current medical therapy and the fact that they are still ambulatory suggest that they may be able to survive for a short period with continued medical management. However, the patient's overall clinical picture and prognosis are guarded, and the likelihood of long-term survival is low.

Note: The patient's outcome is already known as pump failure death, but for the sake of the exercise, I have provided a prognosis based on the provided data."
799,799,P0489,"Age: 52
Gender: Male 
Weight: 76 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 150/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 40,4
ALT or GPT (IU/L): 20.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,29
Creatinine (mmol/L): 95.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 122.0
HDL (mmol/L): 0,98
Potassium (mEq/L): 4,1
LDL (mmol/L): 2,28
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1198.0
Protein (g/L): 74,2
T4 (ng/L): 17
TSH (mIU/L): 1,79
Urea (mg/dL): 6,16
LVEF (%): 15.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor
 REASONING: Given the patient's age and the presence of ischemic dilated cardiomyopathy, peripheral vascular disease, and myocardial infarction, one might initially think that pump failure death is a likely outcome. However, the patient is on a comprehensive medication regimen that includes beta blockers, digoxin, loop diuretics, spironolactone, and an ACE inhibitor, which are all standard treatments for heart failure and ischemic cardiomyopathy. The patient also has a relatively well-controlled blood pressure, and the lack of significant liver or kidney dysfunction (as indicated by normal albumin and creatinine levels) suggests that the patient's overall health status is relatively stable. Furthermore, the patient's LVEF of 15% is very low, but the presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles suggests that the patient may be experiencing some degree of compensation. Considering these factors, a survivor prognosis seems the most likely outcome.

RANKING: 2. Sudden cardiac death
 REASONING: Sudden cardiac death is a possible outcome in patients with ischemic dilated cardiomyopathy, especially those with a low LVEF and a history of myocardial infarction. However, the patient's current medication regimen and the lack of significant arrhythmias on the ECG (aside from non-sustained ventricular tachycardia) suggest that sudden cardiac death may not be the most likely outcome. Additionally, the patient's LVEF of 15% is extremely low, which may indicate a reduced risk of sudden cardiac death due to the reduced contractile reserve.

RANKING: 3. Pump failure death
 REASONING: Pump failure death is a possible outcome in patients with ischemic dilated cardiomyopathy and a low LVEF. However, the patient's current medication regimen and the lack of significant kidney or liver dysfunction suggest that the patient's heart failure is being well-managed. Additionally, the patient's low LVEF may indicate a reduced contractile reserve, which may actually reduce the risk of pump failure death. Therefore, pump failure death is the least likely outcome of the three."
800,800,P0501,"Age: 71
Gender: Male 
Weight: 69 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 100/70 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 42,8
ALT or GPT (IU/L): 32.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 140.0
Gamma-glutamil transpeptidase (IU/L): 166
Glucose (mmol/L): 5,3
Hemoglobin (g/L): 139.0
HDL (mmol/L): 1,74
Potassium (mEq/L): 4,26
LDL (mmol/L): 2,23
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 2309.0
Protein (g/L): 82,3
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,8
Urea (mg/dL): 24,5
LVEF (%): 40.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, I will generate a prognosis for the next few years. Given the patient's condition, I rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden Cardiac Death (SCD)
REASONING: The patient has a history of valvular cardiomyopathy, which is a significant risk factor for SCD. The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG further increases the risk of SCD. The patient's low left ventricular ejection fraction (LVEF) of 40% and elevated Pro-BNP level of 2309 ng/L indicate significant heart failure. Although the patient is on medications such as digoxin, loop diuretics, and spironolactone, which are commonly used to manage heart failure and reduce the risk of SCD, the presence of NSVT and polymorphic ventricular extrasystoles still poses a significant risk.

RANKING: 2. Pump Failure Death
REASONING: The patient's NYHA Class III indicates severe heart failure symptoms, and the patient's LVEF of 40% suggests a significant reduction in cardiac function. The elevated Pro-BNP level and low serum albumin level (42.8 g/L) indicate fluid overload and potential renal impairment. The patient's creatinine level of 140.0 mmol/L also suggests impaired renal function, which can further exacerbate heart failure. While the patient is on medications to manage heart failure, the presence of valvular cardiomyopathy and significant heart failure symptoms increases the risk of pump failure death.

RANKING: 3. Survivor
REASONING: Although the patient has a history of valvular cardiomyopathy and significant heart failure symptoms, the patient's age (71) and overall clinical presentation suggest that the patient may still have a reasonable chance of survival with aggressive medical management and close monitoring. The patient's relatively low troponin level of 0.02 ng/mL and normal TSH level of 1.8 mIU/L indicate that there is no acute coronary syndrome or significant thyroid dysfunction contributing to the patient's symptoms. With appropriate medical management, including optimization of heart failure medications, close monitoring of cardiac function, and regular follow-up appointments, the patient may still have a reasonable chance of survival.

Please note that this prognosis is based on the provided data and may not reflect the patient's actual outcome. A more accurate prognosis would require a comprehensive evaluation and discussion with the patient's healthcare team."
801,801,P0509,"Age: 76
Gender: Female 
Weight: 60 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 36,7
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 4,4
Creatinine (mmol/L): 108.0
Gamma-glutamil transpeptidase (IU/L): 67
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 114.0
HDL (mmol/L): 1,63
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,28
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 2094.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 3,58
Urea (mg/dL): 13,14
LVEF (%): 24.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely.

RANKING: 1. Sudden cardiac death
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened and the heart chambers enlarge. This condition is a significant risk factor for sudden cardiac death, especially with an LVEF of 24%, indicating severe left ventricular dysfunction. The patient's elevated Pro-BNP level of 2094.0 ng/L further supports this risk, as high BNP levels are associated with increased mortality and morbidity in heart failure patients. Additionally, the patient's polymorphic ventricular extrasystoles on the ECG suggest a higher risk of arrhythmias, which can lead to sudden cardiac death.

RANKING: 2. Pump failure death
 REASONING: Given the patient's history of idiopathic dilated cardiomyopathy, severe left ventricular dysfunction (LVEF 24%), and elevated Pro-BNP levels, pump failure death is a likely outcome. The patient's symptoms and clinical presentation are consistent with heart failure, and the use of medications such as digoxin, loop diuretics, and spironolactone suggests a treatment plan aimed at managing heart failure symptoms. However, the patient's underlying condition and medication regimen do not address the underlying cause of the heart failure, which may ultimately lead to pump failure death.

RANKING: 3. Survivor
 REASONING: While the patient's prognosis is poor, it is possible that with aggressive medical management and lifestyle modifications, the patient may survive for an extended period. The patient's current medications, including ACE inhibitors and spironolactone, are evidence-based treatments for heart failure and may help slow disease progression. Additionally, the patient's LVEF of 24% is not the lowest possible value, suggesting that some degree of cardiac function remains. However, the patient's age, underlying condition, and severe left ventricular dysfunction make survival a less likely outcome compared to sudden cardiac death or pump failure death."
802,802,P0513,"Age: 76
Gender: Male 
Weight: 83 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 46,7
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 5,38
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 8
Hemoglobin (g/L): 138.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,2
LDL (mmol/L): 3,13
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 200.0
Protein (g/L): 81
T3 (pg/dL): 0,05
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,46
Urea (mg/dL): 7,8
LVEF (%): 38.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden cardiac death, 2. Pump failure death, 3. Survivor

REASONING:

1. Sudden cardiac death (SDC): Given the patient's age (76), history of ischemic dilated cardiomyopathy, and reduced left ventricular ejection fraction (LVEF) of 38%, the patient is at an increased risk of SDC. The presence of ventricular extrasystoles on the ECG also increases the risk of SDC. Additionally, the patient's LVEF is below the threshold of 40%, which is a well-established risk factor for SDC. Furthermore, the patient's NT-proBNP level of 200.0 ng/L is elevated, indicating increased ventricular stress and a higher risk of arrhythmic events.

2. Pump failure death: The patient's LVEF of 38% indicates a reduced cardiac pumping capacity, and the patient is already on loop diuretics, which suggests that the patient is experiencing some degree of heart failure. However, the patient's creatinine level of 101.0 mol/L is within the normal range, and the patient is not showing signs of severe renal impairment. The patient's NT-proBNP level is elevated, but not extremely high, which might suggest that the patient is not experiencing severe pump failure. Therefore, while pump failure is a possibility, it is less likely than SDC.

3. Survivor: Given the patient's age, history of ischemic dilated cardiomyopathy, and reduced LVEF, the risk of SDC and pump failure is significant. However, the patient is already on optimal medical therapy, including beta-blockers, ACE inhibitors, and statins, which should help to manage the patient's condition. Additionally, the patient's NT-proBNP level is not extremely high, which might suggest that the patient is not experiencing severe heart failure. Therefore, while the patient's prognosis is guarded, survival for several years is still possible with continued optimal medical therapy and close monitoring.

It is essential to note that this prognosis is based on the provided data and may change with further clinical evaluation and diagnostic testing."
803,803,P0529,"Age: 65
Gender: Male 
Weight: 80 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 150/90 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 43,4
ALT or GPT (IU/L): 95.0
AST or GOT (IU/L): 105.0
Total Cholesterol (mmol/L): 5,28
Creatinine (mmol/L): 103.0
Gamma-glutamil transpeptidase (IU/L): 150
Glucose (mmol/L): 8,7
Hemoglobin (g/L): 162.0
HDL (mmol/L): 0,7
Potassium (mEq/L): 4,8
LDL (mmol/L): 2,74
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 221.0
Protein (g/L): 85
T3 (pg/dL): 0,05
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,35
Urea (mg/dL): 8,69
LVEF (%): 27.0
Medications: Beta Blockers, Digoxin, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden Cardiac Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy with a low left ventricular ejection fraction (LVEF) of 27%, indicating reduced cardiac function. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG suggests an increased risk of arrhythmias, which can lead to sudden cardiac death. Additionally, the elevated Pro-BNP level (221 ng/L) indicates increased ventricular stress and potential for cardiac remodeling, further increasing the risk of arrhythmias and sudden death.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF of 27% and history of ischemic dilated cardiomyopathy suggest a high risk of heart failure progression. The elevated creatinine level (103.0 umol/L) and urea level (8.69 mg/dL) indicate renal dysfunction, which is a common comorbidity in patients with heart failure. The patient's medications, including beta blockers, digoxin, spironolactone, and ACE inhibitors, are typical for heart failure management, but the patient's condition may still be at risk of progression to pump failure death.

RANKING: 3. Survivor
 REASONING: While the patient's condition is concerning, there are some factors that suggest a potential for survival. The patient's hemoglobin level (162 g/L) is within the normal range, which is a good prognostic sign. Additionally, the patient's TSH level (2.35 mIU/L) is within the normal range, which suggests that the patient's thyroid function is well-managed. However, the patient's overall condition, including the low LVEF and history of ischemic dilated cardiomyopathy, suggests a higher risk of adverse outcomes."
804,804,P0540,"Age: 37
Gender: Male 
Weight: 70 kg
Height: 164 cm
NYHA Class: II
Blood Pressure: 100/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Myocardial Infarction
Albumin (g/L): 48,2
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 21.0
Total Cholesterol (mmol/L): 2,79
Creatinine (mmol/L): 92.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 5
Hemoglobin (g/L): 163.0
HDL (mmol/L): 0,62
Potassium (mEq/L): 3,9
LDL (mmol/L): 1,42
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 1481.0
Protein (g/L): 76
T3 (pg/dL): 0,06
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,08
Urea (mg/dL): 7,12
LVEF (%): 35.0
Medications: Beta Blockers, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor, 2. Sudden cardiac death, 3. Pump failure death

REASONING: 

Based on the provided patient data, I would rank the prognoses as follows:

1. Survivor: The patient's age and NYHA Class II suggest that the disease is not in its advanced stages, and the patient is still relatively young and functional. The patient is on appropriate medications, including beta blockers, statins, and an ACE inhibitor, which are all standard treatments for ischemic dilated cardiomyopathy. The patient's LVEF of 35% is low but not extremely low, indicating some degree of preserved cardiac function. Additionally, the patient's troponin level is within normal limits, suggesting that the myocardial infarction may not have caused extensive damage. The patient's ECG shows non-sustained ventricular tachycardia, which is a common finding in patients with cardiomyopathy, but not necessarily a predictor of sudden cardiac death. Considering these factors, the patient's overall prognosis is relatively good, and with continued medical treatment and lifestyle modifications, the patient may be able to survive for several years.

2. Sudden cardiac death: Sudden cardiac death is a risk in patients with ischemic dilated cardiomyopathy, especially those with a history of myocardial infarction and low LVEF. However, the patient's ECG shows non-sustained ventricular tachycardia, which is not a strong predictor of sudden cardiac death. The patient's troponin level is normal, and the patient is on beta blockers, which can reduce the risk of sudden cardiac death. While the patient's low LVEF and history of myocardial infarction increase the risk, the overall risk of sudden cardiac death is not extremely high.

3. Pump failure death: Pump failure death is a more likely outcome in patients with advanced heart failure, typically characterized by a very low LVEF (<20-25%), severe symptoms, and significant functional impairment. In this patient, the LVEF is 35%, which is low but not extremely low, and the patient's NYHA Class II suggests that the patient is still relatively functional. The patient's creatinine level is slightly elevated, indicating some degree of renal impairment, but not severe. The patient's ECG shows non-sustained ventricular tachycardia, which is not a strong predictor of pump failure. While the patient's ischemic dilated cardiomyopathy and history of myocardial infarction increase the risk of pump failure, the patient's overall clinical presentation and laboratory results suggest that pump failure death is less likely than the other two options.

In summary, while the patient has significant cardiac disease, the overall prognosis is relatively good, and with continued medical treatment and lifestyle modifications, the patient may be able to survive for several years."
805,805,P0545,"Age: 71
Gender: Male 
Weight: 71 kg
Height: 175 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 39,5
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 24.0
Total Cholesterol (mmol/L): 3,75
Creatinine (mmol/L): 82.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,58
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,86
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 353.0
Protein (g/L): 81
T3 (pg/dL): 0,05
T4 (ng/L): 21
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,818
Urea (mg/dL): 7,12
LVEF (%): 27.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely:

RANKING: 1. Survivor
 REASONING: Despite the patient's advanced age and multiple comorbidities, including ischemic dilated cardiomyopathy, diabetes, dyslipemia, peripheral vascular disease, hypertension, and myocardial infarction, the patient is currently being managed with a comprehensive medication regimen that includes diabetes medication, angiotensin II receptor blocker, beta blockers, statins, and nitrovasodilators. The patient's LVEF is 27%, which is low but not extremely low. The absence of severe left ventricular dysfunction or marked electrolyte imbalances also suggests that the patient may be more likely to survive in the short to medium term. Additionally, the patient's blood pressure is well-controlled, and the absence of severe renal dysfunction (creatinine 82.0 umol/L) further supports a more favorable prognosis.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's history of non-sustained ventricular tachycardia (VT) on the ECG and a low LVEF of 27% suggest an increased risk of sudden cardiac death. However, the absence of other high-risk features such as a history of previous cardiac arrest, sustained VT, or severe left ventricular dysfunction (e.g., LVEF < 20%) makes sudden cardiac death less likely compared to pump failure death. Furthermore, the patient's medication regimen includes beta blockers, which may reduce the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
 REASONING: The patient's low LVEF of 27% and history of ischemic dilated cardiomyopathy suggest a high risk of pump failure death. The patient's elevated Pro-BNP levels (353.0 ng/L) also indicate significant heart failure. Additionally, the patient's creatinine level of 82.0 umol/L suggests some degree of renal dysfunction, which is a common comorbidity in patients with heart failure. While the patient's medication regimen includes medications that may help manage heart failure, the severity of the patient's cardiac dysfunction and comorbidities make pump failure death the most likely prognosis."
806,806,P0555,"Age: 80
Gender: Male 
Weight: 76 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 4,6
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 20
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 155.0
HDL (mmol/L): 1,29
Potassium (mEq/L): 4,9
LDL (mmol/L): 2,66
Sodium (mEq/L): 141.0
Protein (g/L): 71
T3 (pg/dL): 0,06
T4 (ng/L): 18
Troponin (ng/mL): 0,08
TSH (mIU/L): 1,72
Urea (mg/dL): 13,31
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: 1. Sudden cardiac death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy with an LVEF of 25%, indicating significant left ventricular dysfunction. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG suggests an increased risk of arrhythmias, which can lead to sudden cardiac death. Additionally, the patient's low ejection fraction and history of myocardial infarction further increase the risk of arrhythmias and sudden cardiac death.

RANKING: 2. Pump failure death
 REASONING: The patient's LVEF of 25% indicates severe left ventricular dysfunction, which can lead to pump failure. The patient's NYHA Class II classification suggests that the patient experiences symptoms of heart failure, such as shortness of breath or fatigue, during physical activity. The patient's creatinine level of 133.0 mol/L also suggests impaired renal function, which is a common complication of heart failure. However, the patient is currently on medications that are commonly used to manage heart failure, such as ACE inhibitors, beta-blockers, and loop diuretics, which may help to slow the progression of heart failure.

RANKING: 3. Survivor
 REASONING: While the patient has significant cardiac disease and risk factors, the patient is currently receiving appropriate medical therapy for heart failure and ischemic cardiomyopathy. The patient's blood pressure is well-controlled, and the patient's lipid profile is being managed with statins. The patient's TSH level is within the normal range, which suggests that the patient's thyroid function is not contributing to the cardiac disease. The patient's hemoglobin level is also within the normal range, which suggests that the patient is not anemic. While the patient's LVEF is low, the patient's overall clinical status and response to medical therapy suggest that the patient may be able to survive for several years with continued medical management."
807,807,P0567,"Age: 60
Gender: Female 
Weight: 70 kg
Height: 163 cm
NYHA Class: II
Blood Pressure: 97/58 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia
Albumin (g/L): 43
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 3,8
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 35
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 4,3
LDL (mmol/L): 1,99
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 10365.0
Protein (g/L): 70
T4 (ng/L): 15
Troponin (ng/mL): 0,04
TSH (mIU/L): 12,33
Urea (mg/dL): 9,48
LVEF (%): 20.0
Medications: Amiodarone, Digoxin, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Sudden cardiac death
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The low left ventricular ejection fraction (LVEF) of 20% further increases the risk of sudden cardiac death. Additionally, the patient has a high level of pro-BNP (10365.0 ng/L), which is a biomarker for heart failure and increased risk of sudden cardiac death. The presence of non-sustained ventricular tachycardia (VT) on the ECG also increases the risk of sudden cardiac death.

RANKING: 2. Pump failure death
 REASONING: The patient's LVEF of 20% indicates severe left ventricular dysfunction, which is a strong predictor of pump failure death. The patient's NYHA Class II classification suggests that the patient has symptoms of heart failure, and the use of loop diuretics and ACE inhibitor medications further supports this diagnosis. The high level of pro-BNP and the presence of dyslipemia also suggest that the patient is at risk for further cardiac decompensation and pump failure.

RANKING: 3. Survivor
 REASONING: While the patient's prognosis is guarded, the fact that the patient is on optimal medical therapy (amiodarone, digoxin, loop diuretics, statins, and ACE inhibitor) and has a relatively low level of troponin (0.04 ng/mL) suggests that the patient may be able to survive for a longer period with appropriate management. However, the high risk of sudden cardiac death and pump failure death due to the patient's underlying cardiomyopathy and low LVEF makes survivorship the least likely outcome.

Note: The patient's TSH level of 12.33 mIU/L is slightly elevated, but it is not clear if this is related to the patient's cardiac condition or a separate issue."
808,808,P0583,"Age: 61
Gender: Male 
Weight: 81 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 150/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 38
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 186.0
Gamma-glutamil transpeptidase (IU/L): 25
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 123.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,7
LDL (mmol/L): 2,59
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 3292.0
Protein (g/L): 73
T4 (ng/L): 17
Troponin (ng/mL): 0,06
TSH (mIU/L): 1,63
Urea (mg/dL): 19,47
LVEF (%): 30.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, here's a prognosis for the next few years, ranking from most likely to least likely:

RANKING: 1. Sudden Cardiac Death (SCD)

REASONING: The patient has a history of ischemic dilated cardiomyopathy with a left ventricular ejection fraction (LVEF) of 30%, which is significantly reduced. This suggests that the patient's heart is not pumping efficiently, and the risk of sudden cardiac death (SCD) is increased. The elevated Pro-BNP level (3292.0 ng/L) further supports this concern, as it is a well-established biomarker for heart failure and increased risk of SCD. Additionally, the presence of polymorphic ventricular extrasystoles on the ECG increases the risk of arrhythmias, which can lead to SCD. The patient's age and history of diabetes, hypertension, and dyslipemia also contribute to the increased risk of SCD.

RANKING: 2. Pump Failure Death

REASONING: The patient's LVEF of 30% indicates severe left ventricular dysfunction, which increases the risk of pump failure death. The patient's history of ischemic dilated cardiomyopathy and the use of loop diuretics suggest that the patient has been experiencing heart failure symptoms, which can lead to pump failure if not adequately managed. The elevated creatinine level (186.0 mol/L) and urea level (19.47 mg/dL) suggest impaired renal function, which can be a consequence of decreased cardiac output. However, the patient's kidney function is not severely impaired, and the risk of pump failure death may be mitigated with optimal medical management.

RANKING: 3. Survivor

REASONING: While the patient has several risk factors for cardiac events, the provided data suggests that the patient is receiving optimal medical management, including beta blockers, statins, and nitrovasodilators. The patient's LVEF of 30% is not extremely low, and the Pro-BNP level, although elevated, is not extremely high. The patient's age is not extremely advanced, and the absence of sustained ventricular tachycardia or other severe arrhythmias on the ECG suggests that the patient's heart is not in a state of acute decompensation. Therefore, while the patient's prognosis is guarded, the likelihood of survival over the next few years is still possible with continued optimal medical management.

Please note that this prognosis is based on the provided data and may not reflect the patient's actual outcome, as many factors can influence the course of the disease."
809,809,P0589,"Age: 71
Gender: Male 
Weight: 75 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Enolic dilated cardiomyopathy, Diabetes, Peripheral vascular disease
Albumin (g/L): 40
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 7.0
Total Cholesterol (mmol/L): 4,78
Creatinine (mmol/L): 88.0
Gamma-glutamil transpeptidase (IU/L): 63
Glucose (mmol/L): 11,7
Hemoglobin (g/L): 139.0
HDL (mmol/L): 0,85
Potassium (mEq/L): 4,7
LDL (mmol/L): 3,15
Sodium (mEq/L): 137.0
Protein (g/L): 67
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,005
TSH (mIU/L): 0,93
Urea (mg/dL): 9,98
LVEF (%): 12.0
Medications: Diabetes Medication, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: 1. Pump failure death
 REASONING: The patient has a history of enolic dilated cardiomyopathy, which is a condition where the heart muscle becomes weakened, leading to a decrease in the heart's ability to pump blood effectively. The patient's LVEF (left ventricular ejection fraction) is severely reduced at 12%, indicating a significant impairment in the heart's pumping function. Additionally, the patient has a history of peripheral vascular disease, which can further compromise the heart's ability to pump blood effectively. The patient's low blood pressure (90/60 mmHg) and elevated creatinine levels (88.0 mmol/L) suggest that the heart is not pumping efficiently, leading to reduced blood flow and kidney function. The patient's current medications, including loop diuretics and spironolactone, are often used to manage heart failure symptoms, but the patient's severe LVEF and other factors suggest that pump failure is a significant concern.

RANKING: 2. Sudden cardiac death
 REASONING: The patient has a history of ventricular extrasystoles, which can be a risk factor for sudden cardiac death. However, the patient does not have a history of non-sustained ventricular tachycardia, which is often a precursor to sudden cardiac death. The patient's LVEF is severely reduced, which increases the risk of arrhythmias, but the patient's medications, including digoxin and ACE inhibitors, are often used to manage arrhythmias and reduce the risk of sudden cardiac death. While the patient's ventricular extrasystoles are a concern, the overall risk of sudden cardiac death is lower than the risk of pump failure.

RANKING: 3. Survivor
 REASONING: Given the patient's severe LVEF (12%), history of enolic dilated cardiomyopathy, and other comorbidities (diabetes and peripheral vascular disease), the risk of pump failure is high. The patient's current medications are aimed at managing symptoms and slowing disease progression, but the patient's overall health status suggests that survival is unlikely in the short term. While it is possible that the patient could survive for a short period, the likelihood of long-term survival is low given the severity of the patient's condition."
810,810,P0594,"Age: 78
Gender: Male 
Weight: 61 kg
Height: 151 cm
NYHA Class: II
Blood Pressure: 128/83 mmHg
Past Medical History: Hypertropic cardiomyopathy, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 6,28
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 32
Glucose (mmol/L): 4,5
Hemoglobin (g/L): 140.0
HDL (mmol/L): 1,19
Potassium (mEq/L): 4,9
LDL (mmol/L): 4,47
Sodium (mEq/L): 139.0
Pro-BNP (ng/L): 1627.0
Protein (g/L): 67
T3 (pg/dL): 0,04
T4 (ng/L): 19
TSH (mIU/L): 2,39
Urea (mg/dL): 11,82
LVEF (%): 40.0
Medications: Amiodarone, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: The patient's age is 78, which is a risk factor for cardiac events. However, the patient's NYHA Class II indicates that the patient is still able to perform moderate physical activity without symptoms. The patient's LVEF of 40% is below the normal range (50-70%), indicating some degree of left ventricular dysfunction, but it is not severely impaired. The patient is on medications that are beneficial for heart failure, including ACE inhibitor, loop diuretics, and nitrovasodilator. The patient's Pro-BNP level is elevated, which is consistent with heart failure. However, the patient's T3 and T4 levels are within normal range, and the TSH is slightly elevated but not significantly abnormal. The ECG shows polymorphic ventricular extrasystoles, but no sustained ventricular tachycardia or bradycardia. Considering these factors, the patient's prognosis is likely to be a survivor, with close monitoring and adjustment of medications as needed.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's age and LVEF of 40% are risk factors for sudden cardiac death. The patient's Pro-BNP level is elevated, indicating heart failure, and the ECG shows polymorphic ventricular extrasystoles, which can be a precursor to ventricular tachycardia and sudden cardiac death. However, the patient is on amiodarone, which is an anti-arrhythmic medication that can reduce the risk of sudden cardiac death. Additionally, the patient's TSH is slightly elevated, which may indicate hypothyroidism, but it is not significantly abnormal. Considering these factors, the risk of sudden cardiac death is present but not the most likely outcome.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 40% and elevated Pro-BNP level indicate significant left ventricular dysfunction, which increases the risk of pump failure death. The patient's NYHA Class II suggests that the patient is experiencing symptoms of heart failure, such as fatigue and shortness of breath. The patient's creatinine level is elevated, indicating renal dysfunction, which can be a consequence of heart failure. However, the patient is on medications that are beneficial for heart failure, and the T3 and T4 levels are within normal range, which may indicate that the patient's thyroid function is not contributing to the heart failure. Considering these factors, pump failure death is the least likely outcome, but it is still a possible risk due to the patient's significant left ventricular dysfunction."
811,811,P0619,"Age: 62
Gender: Female 
Weight: 50 kg
Height: 167 cm
NYHA Class: II
Blood Pressure: 90/60 mmHg
Past Medical History: Hypertropic cardiomyopathy
Albumin (g/L): 45,9
ALT or GPT (IU/L): 47.0
AST or GOT (IU/L): 29.0
Total Cholesterol (mmol/L): 7,15
Creatinine (mmol/L): 113.0
Gamma-glutamil transpeptidase (IU/L): 53
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 146.0
HDL (mmol/L): 2,05
Potassium (mEq/L): 4,51
LDL (mmol/L): 4,65
Sodium (mEq/L): 135.0
Protein (g/L): 72,9
Troponin (ng/mL): 0,15
TSH (mIU/L): 3,77
Urea (mg/dL): 9,5
LVEF (%): 62.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely:

RANKING: 1. Survivor
REASONING: Despite the patient's history of hypertrophic cardiomyopathy, which is a risk factor for sudden cardiac death, the patient's current LVEF (left ventricular ejection fraction) is 62%, which is within the normal range (50-70%). This suggests that the patient's heart function is relatively preserved. Additionally, the patient is on a regimen of beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all medications that can help manage heart failure and reduce the risk of sudden cardiac death. The patient's troponin level is also within normal limits, which suggests that there is no current evidence of acute myocardial infarction. Furthermore, the patient's hemoglobin level is slightly elevated, which may indicate some degree of cardiac compensation. Considering these factors, the patient is likely to survive for the next few years.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's history of hypertrophic cardiomyopathy is a significant risk factor for sudden cardiac death. The presence of non-sustained ventricular tachycardia on the ECG also suggests that the patient may be at risk for sudden cardiac death. However, the patient's LVEF is still within the normal range, and the patient is on a regimen of medications that can help manage the condition. Additionally, the patient's troponin level is within normal limits, which suggests that there is no current evidence of acute myocardial infarction. While the risk of sudden cardiac death is present, it is not the most likely outcome given the patient's current cardiac function and treatment regimen.

RANKING: 3. Pump Failure Death
REASONING: The patient's LVEF is 62%, which is within the normal range, and the patient is on a regimen of medications that can help manage heart failure. The patient's albumin level is slightly low, which may indicate some degree of cardiac dysfunction, but it is not a definitive indicator of pump failure. The patient's creatinine level is elevated, but it is not significantly high, and the patient's urea level is within normal limits. While the patient has some risk factors for heart failure, the patient's current cardiac function and treatment regimen suggest that pump failure death is the least likely outcome."
812,812,P0624,"Age: 85
Gender: Male 
Weight: 85 kg
Height: 166 cm
NYHA Class: III
Blood Pressure: 125/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 38,9
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 39.0
Total Cholesterol (mmol/L): 3,78
Creatinine (mmol/L): 156.0
Gamma-glutamil transpeptidase (IU/L): 26
Glucose (mmol/L): 4,7
Hemoglobin (g/L): 132.0
HDL (mmol/L): 1,49
Potassium (mEq/L): 3,92
LDL (mmol/L): 1,82
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 4440.0
Protein (g/L): 68,8
Troponin (ng/mL): 0,01
TSH (mIU/L): 0,39
Urea (mg/dL): 10,6
LVEF (%): 20.0
Medications: Beta Blockers, Loop Diuretics, Statins, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, here's the ranking of the possible prognoses from most likely to least likely:

RANKING: 1. Sudden cardiac death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's LVEF (20%) is severely reduced, indicating poor left ventricular function. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG further increases the risk of sudden cardiac death. Additionally, the patient's high Pro-BNP level (4440.0 ng/L) suggests severe heart failure. While the patient is on beta blockers, loop diuretics, statins, hydralazine, and nitrovasodilators, the combination of these medications may not be sufficient to mitigate the risk of sudden cardiac death in this high-risk patient.

RANKING: 2. Pump failure death
 REASONING: The patient's severe left ventricular dysfunction (LVEF 20%), high Pro-BNP level (4440.0 ng/L), and elevated creatinine level (156.0 mmol/L) suggest that the patient is at high risk of pump failure death. The patient's NYHA Class III classification also indicates severe heart failure symptoms. However, the patient's overall prognosis is less likely to be pump failure death compared to sudden cardiac death, as the patient is receiving treatment with diuretics and other medications that may help alleviate symptoms and slow disease progression.

RANKING: 3. Survivor
 REASONING: While the patient has a severe cardiac condition, the provided data suggests that the patient is receiving adequate treatment with beta blockers, loop diuretics, statins, hydralazine, and nitrovasodilators. The patient's relatively controlled blood pressure and hemoglobin levels also indicate that the patient is being managed for other comorbidities. However, the patient's severe left ventricular dysfunction, high Pro-BNP level, and history of ischemic dilated cardiomyopathy make survival less likely compared to the other two options."
813,813,P0635,"Age: 70
Gender: Female 
Weight: 57 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 44
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 37.0
Total Cholesterol (mmol/L): 5,09
Creatinine (mmol/L): 100.0
Gamma-glutamil transpeptidase (IU/L): 70
Glucose (mmol/L): 10,5
Hemoglobin (g/L): 121.0
HDL (mmol/L): 1,76
Potassium (mEq/L): 4,99
LDL (mmol/L): 2,93
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 3190.0
Protein (g/L): 76
T3 (pg/dL): 0,0477
T4 (ng/L): 13,4
Troponin (ng/mL): 0,5
TSH (mIU/L): 1,72
Urea (mg/dL): 9,6
LVEF (%): 25.0
Medications: Calcium Channel Blocker, Diabetes Medication, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely:

RANKING: 1. Sudden cardiac death

REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) is 25%, indicating severe left ventricular dysfunction. The presence of polymorphic ventricular extrasystoles on the ECG further increases the risk of sudden cardiac death. Additionally, the patient's high levels of BNP (3190.0 ng/L) and troponin (0.5 ng/mL) suggest significant cardiac stress and potential myocardial injury. Although the patient is on a nitrovasodilator, which can help alleviate symptoms, the patient's NYHA Class III classification indicates that the patient still experiences symptoms with minimal exertion, indicating ongoing cardiac dysfunction.

RANKING: 2. Pump failure death

REASONING: The patient's severe left ventricular dysfunction (LVEF 25%) and NYHA Class III classification make pump failure death a significant concern. The patient's elevated BNP and troponin levels also suggest ongoing cardiac stress and potential myocardial injury. However, the patient's recent medical history and current medication regimen suggest that the patient is receiving treatment for heart failure, which may slow the progression of pump failure.

RANKING: 3. Survivor

REASONING: While the patient's current medical condition is concerning, the patient's age (70) and sex (female) may contribute to a slightly more favorable prognosis. The patient's weight (57 kg) and height (157 cm) are within a relatively normal range, which may indicate that the patient is not significantly malnourished or deconditioned. However, the patient's severe left ventricular dysfunction, high BNP levels, and history of ischemic dilated cardiomyopathy make this prognosis the least likely."
814,814,P0643,"Age: 70
Gender: Male 
Weight: 85 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 135/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 20.0
Total Cholesterol (mmol/L): 5,64
Creatinine (mmol/L): 156.0
Gamma-glutamil transpeptidase (IU/L): 19
Glucose (mmol/L): 10,1
Hemoglobin (g/L): 149.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 5,4
LDL (mmol/L): 2,74
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 177.0
Protein (g/L): 78
T3 (pg/dL): 0,05
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,83
Urea (mg/dL): 14,25
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Diabetes Medication, Angiotensin II Receptor Blocker, Spironolactone, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely:

RANKING: 2
REASONING: The patient's current condition suggests a high risk of sudden cardiac death due to the presence of ischemic dilated cardiomyopathy, reduced left ventricular ejection fraction (LVEF 30%), and elevated pro-BNP levels (177 ng/L). These factors indicate a compromised cardiac function, which increases the risk of sudden cardiac death. However, the patient is currently receiving optimal medical therapy, including beta-blockers, ACE inhibitors, and spironolactone, which may help mitigate this risk. Additionally, the absence of significant electrolyte imbalances (e.g., hypokalemia) and the presence of a normal TSH level suggest that the patient's cardiac function is not being significantly impaired by other factors. The patient's NYHA class II classification indicates that they are experiencing some symptoms of heart failure, but they are still able to perform daily activities without significant limitation.

RANKING: 3
REASONING: The patient's current condition suggests a relatively low risk of pump failure death in the near future. The patient's LVEF is 30%, which is below the normal range, but they are currently receiving optimal medical therapy, which may help slow disease progression. The patient's NYHA class II classification and the absence of significant symptoms of heart failure suggest that the patient's cardiac function is not yet severely compromised. Additionally, the patient's albumin and protein levels are within normal limits, which suggests that they do not have significant malnutrition or liver dysfunction, which can contribute to heart failure.

RANKING: 1
REASONING: The patient's current condition suggests a high risk of survivor. The patient's age (70) and comorbidities (diabetes, dyslipemia, peripheral vascular disease, and hypertension) increase their overall risk of cardiovascular events. However, the patient is currently receiving optimal medical therapy, which may help manage their conditions and prevent further cardiac deterioration. The patient's LVEF is 30%, but they are still able to perform daily activities without significant limitation, and their NYHA class II classification suggests that they are experiencing some symptoms of heart failure, but they are not severely compromised."
815,815,P0651,"Age: 76
Gender: Male 
Weight: 84 kg
Height: 161 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 39,5
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 120.0
Gamma-glutamil transpeptidase (IU/L): 267
Glucose (mmol/L): 7,9
Hemoglobin (g/L): 161.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 5
LDL (mmol/L): 2,48
Sodium (mEq/L): 133.0
Pro-BNP (ng/L): 1627.0
Protein (g/L): 73
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,31
Urea (mg/dL): 15,59
LVEF (%): 38.0
Medications: Amiodarone, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, here's the ranking of the three possible prognoses from most likely to least likely, along with the reasoning behind each:

RANKING: 1. Sudden Cardiac Death
 REASONING: The patient has a history of hypertensive cardiomyopathy, which is a significant risk factor for sudden cardiac death. Additionally, the patient has a low left ventricular ejection fraction (LVEF) of 38%, indicating reduced heart function. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG further increases the risk of sudden cardiac death. The patient's high Pro-BNP level (1627 ng/L) also suggests heart failure, which is another risk factor for sudden cardiac death.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF of 38% and high Pro-BNP level suggest heart failure, which increases the risk of pump failure death. The patient's history of hypertensive cardiomyopathy and hypertension also contribute to the risk of pump failure. However, the patient's NYHA Class II classification indicates that the heart failure is not severe at this stage, and the patient may still have some functional capacity.

RANKING: 3. Survivor
 REASONING: While the patient has several risk factors for cardiac events, the patient's current functional status and medication regimen suggest that the heart failure is not yet severe. The patient is on ACE inhibitors, loop diuretics, and spironolactone, which are standard treatments for heart failure. The patient's hemoglobin level is within the normal range, and the creatinine level is not significantly elevated, suggesting that the kidneys are functioning relatively well. The patient's TSH level is also within the normal range, which suggests that the thyroid function is not contributing to the cardiac condition. However, the patient's overall risk profile and the presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG make a survivor prognosis less likely than the other two options."
816,816,P0679,"Age: 67
Gender: Male 
Weight: 76 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 140/55 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy
Albumin (g/L): 47
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 5,61
Creatinine (mmol/L): 135.0
Gamma-glutamil transpeptidase (IU/L): 47
Glucose (mmol/L): 5,27
Hemoglobin (g/L): 109.0
HDL (mmol/L): 0,93
Potassium (mEq/L): 4,75
LDL (mmol/L): 1,81
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 62.0
Protein (g/L): 75,3
T3 (pg/dL): 0,0429
T4 (ng/L): 14,14
Troponin (ng/mL): 0,7
TSH (mIU/L): 4,1
Urea (mg/dL): 19,6
LVEF (%): 30.0
Medications: Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I will rank the prognoses from most likely to least likely as follows:

RANKING: Sudden cardiac death

REASONING: The patient has a history of idiopathic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's LVEF (30%) is severely impaired, indicating significant left ventricular dysfunction. The presence of polymorphic ventricular extrasystoles on the ECG further increases the risk of arrhythmias and sudden cardiac death. Additionally, the patient's low T3 level (0.0429 pg/dL) may indicate hypothyroidism, which can be associated with a higher risk of cardiovascular events, including sudden cardiac death. The patient's medications, including Amiodarone and Beta Blockers, may help mitigate some of these risks, but the overall risk profile suggests that sudden cardiac death is the most likely prognosis.

RANKING: Pump failure death

REASONING: The patient's LVEF (30%) and severely impaired left ventricular function suggest a high risk of pump failure. The patient's elevated creatinine level (135.0 mmol/L) and low albumin level (47 g/L) may indicate kidney dysfunction, which can further exacerbate the risk of pump failure. The patient's medications, including Loop Diuretics and ACE Inhibitor, are commonly used to manage heart failure symptoms and slow disease progression, but the patient's advanced disease state and reduced LVEF make pump failure a significant concern.

RANKING: Survivor

REASONING: While the patient's risk profile is concerning, the presence of a low T3 level (0.0429 pg/dL) and the patient's overall medication regimen suggest that the patient may be a candidate for thyroid hormone replacement therapy, which can improve cardiac function and reduce mortality risk. Additionally, the patient's LVEF (30%) is not at the lowest end of the spectrum, and some patients with LVEF in this range can experience stabilization or even improvement with aggressive medical therapy and device therapy. While the risk of sudden cardiac death and pump failure is significant, the patient's overall clinical profile and potential for intervention suggest that survival is a possible outcome."
817,817,P0680,"Age: 73
Gender: Female 
Weight: 71 kg
Height: 157 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 38
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 4,42
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 7
Glucose (mmol/L): 10,9
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 5,2
LDL (mmol/L): 2,48
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1690.0
Protein (g/L): 74
T4 (ng/L): 9
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,69
Urea (mg/dL): 7,49
LVEF (%): 25.0
Medications: Diabetes Medication, Amiodarone, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, here is the prognosis ranking:

RANKING: 1. Sudden cardiac death, 2. Pump failure death, 3. Survivor

REASONING:

1. Sudden cardiac death (1st): The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's low left ventricular ejection fraction (LVEF) of 25% indicates severe left ventricular dysfunction, further increasing the risk of sudden cardiac death. Additionally, the patient's high B-type natriuretic peptide (BNP) level of 1690 ng/L suggests severe heart failure, which is another risk factor for sudden cardiac death. The patient's history of myocardial infarction and the presence of ventricular extrasystoles on the ECG also contribute to the risk of sudden cardiac death.

2. Pump failure death (2nd): While the patient's LVEF is very low, indicating severe left ventricular dysfunction, the patient is already on optimal medical therapy for heart failure, including loop diuretics, beta-blockers, and ACE inhibitors. The patient's BNP level is high, but not extremely high, suggesting that the patient is not in acute decompensated heart failure. However, the patient's NYHA Class III indicates that the patient has significant symptoms of heart failure, and the risk of pump failure death is still present.

3. Survivor (3rd): While the patient has multiple risk factors for adverse outcomes, the patient is already on optimal medical therapy for heart failure and ischemic cardiomyopathy. The patient's low troponin level suggests that there is no acute myocardial infarction, and the patient's LVEF is not extremely low. The patient's TSH level is within the normal range, which suggests that there is no evidence of thyroid dysfunction, a known risk factor for heart failure. Additionally, the patient's hemoglobin level is within the normal range, which suggests that there is no anemia, a known risk factor for heart failure. Overall, while the patient's prognosis is guarded, the patient's current medical therapy and the absence of acute decompensated heart failure make survival a more likely outcome compared to sudden cardiac death or pump failure death."
818,818,P0688,"Age: 66
Gender: Male 
Weight: 74 kg
Height: 156 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Valvular cardiomyopathy, Hypertension, Myocardial Infarction
Albumin (g/L): 38,1
ALT or GPT (IU/L): 21.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 4,12
Creatinine (mmol/L): 181.0
Gamma-glutamil transpeptidase (IU/L): 105
Glucose (mmol/L): 6,44
Hemoglobin (g/L): 115.0
HDL (mmol/L): 1,67
Potassium (mEq/L): 4,42
LDL (mmol/L): 2,16
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 11467.0
Protein (g/L): 71,8
T3 (pg/dL): 0,0366
T4 (ng/L): 15,51
Troponin (ng/mL): 0,7
TSH (mIU/L): 3,31
Urea (mg/dL): 19,5
LVEF (%): 30.0
Medications: Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, here is the ranking of the possible prognoses from most likely to least likely:

RANKING: 1. Sudden cardiac death
 REASONING: The patient has a history of myocardial infarction, valvular cardiomyopathy, and a low left ventricular ejection fraction (LVEF) of 30%. This indicates significant left ventricular dysfunction. Additionally, the patient has a high level of pro-BNP (11467 ng/L), which is a marker of heart failure. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG also suggests an increased risk of arrhythmias, which can lead to sudden cardiac death. Furthermore, the patient's low HDL cholesterol level (1.67 mmol/L) and high LDL cholesterol level (2.16 mmol/L) may contribute to an increased risk of cardiac events. Considering these factors, sudden cardiac death is the most likely prognosis.

RANKING: 2. Pump failure death
 REASONING: The patient's LVEF of 30% indicates significant left ventricular dysfunction, which is a major risk factor for heart failure. The patient's high pro-BNP level and low albumin level (38.1 g/L) also suggest advanced heart failure. Additionally, the patient's history of valvular cardiomyopathy and hypertension may contribute to the progression of heart failure. However, the patient is currently receiving loop diuretics and an ACE inhibitor, which may help manage symptoms and slow disease progression. Nevertheless, the patient's overall clinical picture suggests that pump failure death is a possible prognosis.

RANKING: 3. Survivor
 REASONING: While the patient has several risk factors for cardiac events, the prognosis of survivor is the least likely due to the severity of the patient's cardiac disease. The patient's low LVEF, high pro-BNP level, and history of myocardial infarction and valvular cardiomyopathy make it challenging for the patient to survive without significant morbidity. However, the patient's relatively young age (66 years) and the fact that they are currently receiving treatment for heart failure may slightly improve their prognosis. Nevertheless, the overall clinical picture suggests that survivor is the least likely prognosis."
819,819,P0716,"Age: 80
Gender: Male 
Weight: 66 kg
Height: 160 cm
NYHA Class: III
Blood Pressure: 210/100 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 3,62
Creatinine (mmol/L): 159.0
Gamma-glutamil transpeptidase (IU/L): 124
Glucose (mmol/L): 4,9
HDL (mmol/L): 0,91
Potassium (mEq/L): 3,9
LDL (mmol/L): 2,15
Sodium (mEq/L): 141.0
Protein (g/L): 64
T3 (pg/dL): 0,05
T4 (ng/L): 14
TSH (mIU/L): 1,33
Urea (mg/dL): 13,81
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden cardiac death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's left ventricular ejection fraction (LVEF) of 35% is severely reduced, indicating poor cardiac function. Additionally, the presence of non-sustained ventricular tachycardia (NSVT) on the ECG is a known risk factor for sudden cardiac death. The patient's NYHA Class III classification indicates severe symptoms of heart failure, which further increases the risk of sudden cardiac death.

RANKING: 2. Pump failure death
 REASONING: Given the patient's advanced age, severely reduced LVEF, and history of ischemic dilated cardiomyopathy, pump failure death is a likely outcome. The patient's elevated creatinine level (159.0 mmol/L) suggests kidney dysfunction, which is often associated with heart failure. The patient's medications, including loop diuretics and ACE inhibitors, are commonly used to manage heart failure symptoms, but the patient's NYHA Class III classification indicates that these medications may not be adequately controlling the patient's symptoms.

RANKING: 3. Survivor
 REASONING: While the patient has several risk factors for poor outcomes, there are some factors that suggest a possible survival. The patient is taking medications that are commonly used to manage heart failure and hypertension, and the patient's blood pressure is controlled at 210/100 mmHg. Additionally, the patient's TSH level is within the normal range, which suggests that the patient's thyroid function is well-managed. However, the patient's severely reduced LVEF and history of ischemic dilated cardiomyopathy make survival less likely compared to the other two options."
820,820,P0725,"Age: 72
Gender: Male 
Weight: 66 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 3,47
Creatinine (mmol/L): 71.0
Gamma-glutamil transpeptidase (IU/L): 33
Glucose (mmol/L): 10,4
Hemoglobin (g/L): 122.0
HDL (mmol/L): 0,62
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,25
Sodium (mEq/L): 135.0
Protein (g/L): 74
T3 (pg/dL): 0,05
T4 (ng/L): 23
TSH (mIU/L): 1,2
Urea (mg/dL): 6,99
LVEF (%): 55.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, here is the prognosis ranking with reasoning:

RANKING: 1. Survivor
REASONING: The patient is 72 years old with a history of ischemic dilated cardiomyopathy, diabetes, dyslipemia, and hypertension. However, the patient is on a comprehensive treatment regimen that includes beta blockers, digoxin, loop diuretics, spironolactone, statins, ACE inhibitor, and nitrovasodilator, which suggests that the patient's condition is being actively managed. The patient's LVEF is 55%, which is below the normal range but not extremely low. The patient's blood pressure is well-controlled, and there are no signs of severe electrolyte imbalances or renal dysfunction. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles is concerning, but the patient is already on medications that can help manage these arrhythmias. Considering the patient's age, comorbidities, and current treatment, the most likely prognosis is survival with ongoing management of the condition.

RANKING: 2. Sudden Cardiac Death
REASONING: The patient's ECG shows non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles, which are risk factors for sudden cardiac death. However, the patient is already on medications that can help manage these arrhythmias, and the presence of beta blockers, which are known to reduce the risk of sudden cardiac death. The patient's LVEF is 55%, which is below the normal range but not extremely low, and the patient's blood pressure is well-controlled. While the patient's comorbidities and ECG findings increase the risk of sudden cardiac death, the patient's current treatment regimen and the fact that the arrhythmias are non-sustained make this prognosis less likely than pump failure death.

RANKING: 3. Pump Failure Death
REASONING: The patient has a history of ischemic dilated cardiomyopathy with an LVEF of 55%, which is below the normal range. The patient's creatinine level is slightly elevated, which suggests some degree of renal dysfunction, and the patient's glucose level is elevated, which can exacerbate cardiac dysfunction. The patient's weight is low for their height, which may indicate malnutrition or cachexia, and the albumin level is low, which can indicate malnutrition or liver dysfunction. The patient's TSH level is within the normal range, which suggests that the patient's thyroid function is not contributing to the cardiac dysfunction. However, the combination of low LVEF, renal dysfunction, and malnutrition suggests that the patient's heart is under significant stress, making pump failure death a possible outcome."
821,821,P0735,"Age: 59
Gender: Male 
Weight: 91 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 139/76 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 7,34
Creatinine (mmol/L): 106.0
Gamma-glutamil transpeptidase (IU/L): 75
Glucose (mmol/L): 11,7
Hemoglobin (g/L): 140.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 3,4
LDL (mmol/L): 5,66
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 108.0
Protein (g/L): 68
T3 (pg/dL): 0,05
T4 (ng/L): 23
Troponin (ng/mL): 0,1
TSH (mIU/L): 1,63
Urea (mg/dL): 8,65
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden cardiac death, 2. Pump failure death, 3. Survivor

REASONING:

1. Sudden cardiac death: Given the patient's history of ischemic dilated cardiomyopathy, previous myocardial infarction, and LVEF of 50%, there is a high risk of sudden cardiac death. The presence of polymorphic ventricular extrasystoles on the ECG also suggests an increased risk of arrhythmias. The patient's NYHA Class II classification indicates some limitation of physical activity but still able to perform everyday tasks without symptoms, which may not be a strong indicator of sudden cardiac death risk, however, the other factors outweigh this. 

2. Pump failure death: The patient's LVEF of 50% indicates a reduced ejection fraction, which is a strong indicator of heart failure. The patient's creatinine level of 106.0 mol/L suggests impaired renal function, which is a common comorbidity in heart failure patients. The elevated Pro-BNP level (108.0 ng/L) also supports the presence of heart failure. However, the patient is on ACE inhibitors and statins, which are commonly used to manage heart failure and reduce the risk of pump failure death.

3. Survivor: While the patient has a history of ischemic dilated cardiomyopathy and previous myocardial infarction, the fact that they are on medication and have a relatively stable NYHA Class II classification suggests that they are being managed effectively. The patient's LVEF of 50% is a significant concern, but with proper management, it is possible for patients with reduced ejection fraction to live for several years without major cardiac events.

In conclusion, based on the patient's data, sudden cardiac death is the most likely prognosis due to the presence of polymorphic ventricular extrasystoles and reduced LVEF. Pump failure death is a close second, given the patient's impaired renal function and elevated Pro-BNP level. Survivorship is the least likely prognosis, given the patient's underlying cardiac conditions, but it is still possible with proper management."
822,822,P0752,"Age: 55
Gender: Male 
Weight: 77 kg
Height: 171 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 29,6
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,46
Creatinine (mmol/L): 135.0
Gamma-glutamil transpeptidase (IU/L): 151
Glucose (mmol/L): 16,6
Hemoglobin (g/L): 117.0
HDL (mmol/L): 0,66
Potassium (mEq/L): 3,88
LDL (mmol/L): 2,46
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 5416.0
Protein (g/L): 58,9
Troponin (ng/mL): 0,02
TSH (mIU/L): 2,08
Urea (mg/dL): 14,4
LVEF (%): 21.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, here's my prognosis for the next few years:

RANKING: 1. Survivor
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which indicates a significant reduction in the heart's pumping ability. However, despite this, the patient is on a combination of medications that are commonly used to manage heart failure, including digoxin, loop diuretics, spironolactone, hydralazine, and a nitrovasodilator. The patient's NYHA Class III classification indicates that they experience symptoms of heart failure with moderate limitation in physical activity. However, with proper management and adherence to medication, it is possible for patients with heart failure to live for several years. The patient's low LVEF of 21% indicates a significant reduction in heart function, but it is not an absolute contraindication for survival. Therefore, with continued medical management and lifestyle modifications, the patient may be able to survive for several years.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of myocardial infarction, which increases the risk of sudden cardiac death. The presence of non-sustained ventricular tachycardia (VT) on the ECG is a risk factor for sudden cardiac death. Additionally, the patient's low LVEF and history of ischemic dilated cardiomyopathy also increase the risk of sudden cardiac death. However, the patient's current medications, including beta-blockers and anti-arrhythmic medications, are commonly used to reduce the risk of sudden cardiac death.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 21% and history of ischemic dilated cardiomyopathy indicate a high risk of pump failure death. The patient's NYHA Class III classification and elevated Pro-BNP levels also suggest that the patient is experiencing significant heart failure symptoms. While the patient is on medications to manage heart failure, the patient's high creatinine levels and low albumin levels suggest that the patient may be experiencing kidney dysfunction, which can further exacerbate heart failure. The patient's low hemoglobin levels may also indicate anemia, which can further reduce oxygen delivery to the tissues and increase the workload on the heart. Given the severity of the patient's heart failure and other comorbidities, pump failure death is the most likely prognosis.

Note: The patient's outcome is already listed as ""pump failure death"", but based on the data provided, I have ranked the three possible prognoses based on likelihood."
823,823,P0754,"Age: 73
Gender: Male 
Weight: 58 kg
Height: 162 cm
NYHA Class: III
Blood Pressure: 115/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 42,3
ALT or GPT (IU/L): 22.0
AST or GOT (IU/L): 30.0
Total Cholesterol (mmol/L): 5,36
Creatinine (mmol/L): 92.0
Gamma-glutamil transpeptidase (IU/L): 291
Glucose (mmol/L): 10,3
Hemoglobin (g/L): 157.0
HDL (mmol/L): 1,48
Potassium (mEq/L): 3,42
LDL (mmol/L): 3,05
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 2057.0
Protein (g/L): 70,2
Troponin (ng/mL): 0,13
TSH (mIU/L): 2,47
Urea (mg/dL): 9,5
LVEF (%): 20.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I will generate a prognosis for the next few years. Given the patient's severe symptoms and underlying conditions, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden cardiac death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which significantly increases the risk of sudden cardiac death. The patient's LVEF is severely reduced at 20%, indicating poor left ventricular function. Additionally, the presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG further increases the risk of sudden cardiac death. The patient's high Pro-BNP level (2057 ng/L) also suggests severe heart failure, which is a known risk factor for sudden cardiac death.

RANKING: 2. Pump failure death
 REASONING: Given the patient's severe heart failure symptoms (NYHA Class III) and reduced LVEF, pump failure death is a significant concern. The patient's high Pro-BNP level and elevated creatinine level (92.0 mol/L) also suggest advanced heart failure, which can lead to pump failure. However, the patient is already on optimal medical therapy, including beta blockers, ACE inhibitors, and spironolactone, which may help mitigate this risk.

RANKING: 3. Survivor
 REASONING: While the patient's prognosis is poor, there is still a possibility of survival with aggressive medical management and close monitoring. The patient's diabetes and dyslipidemia are well-controlled, which may help slow the progression of heart disease. However, the patient's severe heart failure symptoms and reduced LVEF make long-term survival less likely compared to the other two prognoses.

Please note that this prognosis is based on the provided data and may not reflect the actual outcome, as individual patient responses to treatment can vary."
824,824,P0762,"Age: 68
Gender: Male 
Weight: 99 kg
Height: 174 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 38,8
ALT or GPT (IU/L): 187.0
AST or GOT (IU/L): 146.0
Total Cholesterol (mmol/L): 2,62
Creatinine (mmol/L): 188.0
Gamma-glutamil transpeptidase (IU/L): 154
Glucose (mmol/L): 9,7
Hemoglobin (g/L): 119.0
HDL (mmol/L): 0,64
Potassium (mEq/L): 3,73
LDL (mmol/L): 1,59
Sodium (mEq/L): 130.0
Pro-BNP (ng/L): 19001.0
Protein (g/L): 69,9
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,85
Urea (mg/dL): 21,3
LVEF (%): 20.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, I would rank the possible prognoses as follows:

RANKING: 1. Sudden cardiac death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for sudden cardiac death. The patient's low left ventricular ejection fraction (LVEF) of 20% further increases the risk of sudden cardiac death. Additionally, the presence of non-sustained ventricular tachycardia (NSVT) on the ECG is a known predictor of sudden cardiac death. The patient's elevated pro-BNP level (19,001 ng/L) also suggests significant heart failure, which is another risk factor for sudden cardiac death.

RANKING: 2. Pump failure death
 REASONING: The patient's low LVEF and history of ischemic dilated cardiomyopathy make pump failure a likely outcome. The patient's elevated creatinine level (188.0 mmol/L) and urea level (21.3 mg/dL) suggest renal impairment, which is common in patients with advanced heart failure. The patient's medications, including loop diuretics and beta blockers, are consistent with heart failure management. However, the patient's overall clinical picture suggests that pump failure is a possible but not the most likely outcome.

RANKING: 3. Survivor
 REASONING: While the patient has significant risk factors for sudden cardiac death and pump failure, the patient's age, NYHA class II, and relatively controlled blood pressure (120/70 mmHg) suggest that the patient may be able to survive with optimal medical management. The patient's troponin level is within normal limits, and the patient is on appropriate medications for heart failure and ischemic heart disease. However, the patient's high risk profile and the presence of NSVT on the ECG make survival a less likely outcome compared to the other two possibilities.

It is essential to note that this prognosis is based on the provided data and may change with further clinical evaluation, diagnostic testing, and treatment."
825,825,P0766,"Age: 64
Gender: Male 
Weight: 48 kg
Height: 165 cm
NYHA Class: III
Blood Pressure: 140/85 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 37,6
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 4,32
Creatinine (mmol/L): 132.0
Gamma-glutamil transpeptidase (IU/L): 338
Glucose (mmol/L): 3,5
Hemoglobin (g/L): 127.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 3,18
LDL (mmol/L): 2,89
Sodium (mEq/L): 136.0
Pro-BNP (ng/L): 9695.0
Protein (g/L): 81,4
Troponin (ng/mL): 0,04
TSH (mIU/L): 3,73
Urea (mg/dL): 10,4
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: 1. Sudden cardiac death, 2. Pump failure death, 3. Survivor

REASONING:

1. Sudden cardiac death (SCD): This patient has a high risk of SCD due to several factors. His low left ventricular ejection fraction (LVEF) of 30% indicates significant left ventricular dysfunction, which is a major risk factor for SCD. Additionally, the presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG further increase his risk of SCD. The patient's low hemoglobin level (127 g/L) and elevated pro-BNP (9695 ng/L) also suggest cardiac decompensation and increased risk of arrhythmias. The patient's medications, including digoxin and nitrovasodilators, may not be sufficient to control his arrhythmias and cardiac function. Therefore, SCD is the most likely prognosis.

2. Pump failure death: This patient's LVEF of 30% and elevated pro-BNP level suggest that he has severe heart failure. His low albumin and high creatinine levels indicate renal impairment, which is common in patients with heart failure. The patient's weight of 48 kg is below the normal range, which may be a sign of malnutrition or muscle wasting, further compromising his cardiac function. While pump failure death is a possible outcome, it is less likely than SCD due to the patient's high risk of arrhythmias.

3. Survivor: This patient's high risk of SCD and pump failure death makes survival a less likely outcome. However, if the patient receives aggressive medical therapy, including implantable cardioverter-defibrillator (ICD) placement, cardiac resynchronization therapy (CRT), and optimization of his medications, it is possible that he may survive for several years. However, this outcome is less likely due to the patient's high-risk profile.

Note: The patient's outcome of ""pump failure death"" is already given, but I have ranked it as the second most likely prognosis based on the provided data."
826,826,P0772,"Age: 74
Gender: Male 
Weight: 60 kg
Height: 168 cm
NYHA Class: III
Blood Pressure: 80/60 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 42
ALT or GPT (IU/L): 16.0
AST or GOT (IU/L): 15.0
Total Cholesterol (mmol/L): 3,54
Creatinine (mmol/L): 150.0
Gamma-glutamil transpeptidase (IU/L): 114
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 117.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,46
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 8916.0
Protein (g/L): 79
T4 (ng/L): 17
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,87
Urea (mg/dL): 27,12
LVEF (%): 13.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor
 REASONING: The patient is 74 years old with a history of ischemic dilated cardiomyopathy and myocardial infarction, which indicates a high risk for cardiac complications. However, the patient is on optimal medical therapy with beta blockers, loop diuretics, spironolactone, and an ACE inhibitor, which are all evidence-based treatments for heart failure. The patient's LVEF of 13% indicates severe left ventricular dysfunction, but the patient's hemoglobin level is within the normal range, and the creatinine level is elevated but not severely so. The pro-BNP level is high, but not excessively so, considering the patient's LVEF. The lack of ventricular tachycardia or other severe arrhythmias on the ECG is a positive sign. Given the patient's relatively stable condition and optimal medical therapy, the likelihood of survival is higher compared to the other two options.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's LVEF of 13% indicates severe left ventricular dysfunction, which increases the risk of sudden cardiac death. The high pro-BNP level and elevated creatinine level also suggest that the patient is at risk for cardiac complications. However, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death in patients with heart failure. Additionally, the patient's troponin level is low, indicating that there is no acute myocardial infarction. The lack of ventricular tachycardia or other severe arrhythmias on the ECG is a positive sign. While the patient is at risk for sudden cardiac death, the optimal medical therapy and lack of acute myocardial infarction make this option less likely compared to pump failure death.

RANKING: 3. Pump Failure Death
 REASONING: The patient's LVEF of 13% and elevated creatinine level indicate severe left ventricular dysfunction and renal impairment, which are both risk factors for pump failure death. The high pro-BNP level and low blood pressure also suggest that the patient is at risk for cardiac decompensation. The patient's low hemoglobin level and high gamma-glutamil transpeptidase level may indicate chronic liver disease, which can further contribute to pump failure. The patient's optimal medical therapy is a positive sign, but the severity of the patient's cardiac and renal dysfunction makes pump failure death the most likely outcome."
827,827,P0781,"Age: 70
Gender: Female 
Weight: 62 kg
Height: 154 cm
NYHA Class: II
Blood Pressure: 100/75 mmHg
Past Medical History: Valvular cardiomyopathy, Hypertension
Albumin (g/L): 38,5
ALT or GPT (IU/L): 13.0
AST or GOT (IU/L): 17.0
Total Cholesterol (mmol/L): 5,04
Creatinine (mmol/L): 108.0
Gamma-glutamil transpeptidase (IU/L): 97
Glucose (mmol/L): 5,5
Hemoglobin (g/L): 122.0
HDL (mmol/L): 1,33
Potassium (mEq/L): 4,42
LDL (mmol/L): 3,08
Sodium (mEq/L): 140.0
Pro-BNP (ng/L): 5911.0
Protein (g/L): 82,3
T3 (pg/dL): 0,01
T4 (ng/L): 12
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,9
Urea (mg/dL): 10,5
LVEF (%): 35.0
Medications: Amiodarone, Beta Blockers, Digoxin, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, I would rank the prognoses as follows:

RANKING: 1. Sudden Cardiac Death, 2. Pump Failure Death, 3. Survivor

REASONING:

1. Sudden Cardiac Death: Given the patient's age (70), low left ventricular ejection fraction (LVEF) of 35%, and history of valvular cardiomyopathy, the patient is at a high risk for sudden cardiac death. The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG further increases this risk. The elevated Pro-BNP level (5911.0 ng/L) suggests increased ventricular stress, which may lead to arrhythmic events.

2. Pump Failure Death: Although the patient has a low LVEF, the presence of beta blockers, digoxin, and loop diuretics suggests that the patient's heart failure is being managed. The patient's NYHA class II indicates that they are experiencing some symptoms, but they are still able to perform daily activities. The patient's weight (62 kg) and height (154 cm) suggest a relatively low body mass index (BMI), which may mitigate the risk of pump failure. However, the patient's creatinine level (108.0 umol/L) is elevated, indicating some degree of renal impairment, which can be a marker of advanced heart failure.

3. Survivor: Given the patient's advanced age, low LVEF, and history of valvular cardiomyopathy, a survivor prognosis is less likely. However, the patient's relatively well-managed heart failure symptoms (NYHA class II), the absence of significant electrolyte imbalances, and the presence of medications that may help stabilize the patient's condition make this prognosis slightly more plausible. The patient's overall clinical picture suggests that they are likely to experience some degree of cardiac morbidity, but the possibility of survival with optimal management cannot be ruled out.

Please note that this prognosis is based on the provided data and may not reflect the patient's actual outcome. A more accurate prognosis would require a comprehensive evaluation by a cardiologist and consideration of additional factors not provided in the data."
828,828,P0790,"Age: 79
Gender: Male 
Weight: 88 kg
Height: 178 cm
NYHA Class: II
Blood Pressure: 120/70 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 37
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 25.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 24
Glucose (mmol/L): 6,9
Hemoglobin (g/L): 145.0
HDL (mmol/L): 0,96
Potassium (mEq/L): 4
LDL (mmol/L): 2,46
Sodium (mEq/L): 135.0
Pro-BNP (ng/L): 4762.0
Protein (g/L): 65
T4 (ng/L): 9
Troponin (ng/mL): 0,04
TSH (mIU/L): 1,8
Urea (mg/dL): 6,66
LVEF (%): 28.0
Medications: Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I will generate a prognosis for the next few years. 

RANKING: 1. Sudden cardiac death, 2. Pump failure death, 3. Survivor

REASONING: 

1. Sudden cardiac death: The patient has a history of idiopathic dilated cardiomyopathy with a left ventricular ejection fraction (LVEF) of 28%, indicating severe heart failure. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is a significant risk factor for sudden cardiac death. The patient's high pro-BNP level (4762.0 ng/L) also indicates severe heart failure and increased risk of arrhythmias. Considering these factors, sudden cardiac death is the most likely prognosis.

2. Pump failure death: Although the patient has a history of heart failure, the current medications (Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor) are standard treatments for heart failure and may help manage symptoms. The patient's NYHA Class II indicates that they have mild to moderate symptoms of heart failure. While pump failure is a possibility, the patient's current treatment plan and relatively mild symptoms make this prognosis less likely than sudden cardiac death.

3. Survivor: Given the patient's advanced age (79), severe heart failure, and history of idiopathic dilated cardiomyopathy, the likelihood of long-term survival is low. However, with optimal medical management and adherence to treatment, it is possible that the patient may survive for a few more years. The patient's relatively low LVEF and high pro-BNP level indicate that the heart failure is severe, but the presence of NSVT and polymorphic ventricular extrasystoles increases the risk of sudden cardiac death, making survival the least likely prognosis.

It is essential to note that this prognosis is based on the provided data and may change with further evaluation and treatment adjustments."
829,829,P0792,"Age: 85
Gender: Male 
Weight: 86 kg
Height: 170 cm
NYHA Class: III
Blood Pressure: 140/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Diabetes
Albumin (g/L): 37
ALT or GPT (IU/L): 42.0
AST or GOT (IU/L): 19.0
Total Cholesterol (mmol/L): 4,34
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 50
Glucose (mmol/L): 7
Hemoglobin (g/L): 127.0
HDL (mmol/L): 1,14
Potassium (mEq/L): 4,4
LDL (mmol/L): 2,84
Sodium (mEq/L): 139.0
Protein (g/L): 68
T4 (ng/L): 10
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,62
Urea (mg/dL): 9,32
LVEF (%): 25.0
Medications: Diabetes Medication, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Unknown ventricular extrasystole code
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, here is the ranking of the three possible prognoses from most likely to least likely, along with the reasoning behind each:

RANKING: 1. Survivor, 2. Sudden Cardiac Death, 3. Pump Failure Death

REASONING:

1. Survivor: Given the patient's advanced age (85 years) and NYHA Class III, the patient is likely to have significant comorbidities and compromised cardiac function. However, the patient is on a comprehensive medication regimen that includes beta blockers, digoxin, loop diuretics, spironolactone, and nitrovasodilators, which are all aimed at managing heart failure and reducing the risk of sudden cardiac death. The patient's LVEF is 25%, which is low but not extremely low, and the Troponin level is within normal limits, indicating minimal myocardial damage. The patient's creatinine level is elevated, suggesting some degree of kidney impairment, but it is not severe. The patient's hemoglobin and albumin levels are within normal limits, indicating adequate nutrition and oxygen delivery to tissues. Given these factors, the patient is likely to survive for the next few years with proper management of their condition.

2. Sudden Cardiac Death: The patient's ECG shows non-sustained ventricular tachycardia, which is a risk factor for sudden cardiac death. However, the patient is on beta blockers, which are known to reduce the risk of sudden cardiac death. Additionally, the patient's Troponin level is within normal limits, indicating minimal myocardial damage. While the patient's LVEF is low, it is not extremely low, and the patient's overall cardiac function is likely being supported by their medication regimen. Therefore, while sudden cardiac death is a possibility, it is not the most likely outcome.

3. Pump Failure Death: The patient's LVEF is 25%, which is severely reduced, indicating significant left ventricular dysfunction. The patient's creatinine level is elevated, suggesting some degree of kidney impairment, which can be a consequence of advanced heart failure. The patient's hemoglobin and albumin levels are within normal limits, but the patient's total cholesterol and LDL levels are high, which can contribute to atherosclerosis and further compromise cardiac function. The patient's ECG shows non-sustained ventricular tachycardia, which can be a sign of advanced cardiac disease. Given these factors, pump failure death is a possible outcome, but it is less likely than survivor due to the patient's age and the comprehensive management of their condition.

In conclusion, based on the patient's data, the most likely outcome is survivor, followed by sudden cardiac death, and then pump failure death."
830,830,P0835,"Age: 78
Gender: Female 
Weight: 77 kg
Height: 159 cm
NYHA Class: III
Blood Pressure: 110/60 mmHg
Past Medical History: Valvular cardiomyopathy, Hypertension
Albumin (g/L): 41,5
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 12.0
Total Cholesterol (mmol/L): 4,79
Creatinine (mmol/L): 89.0
Gamma-glutamil transpeptidase (IU/L): 43
Glucose (mmol/L): 14,6
Hemoglobin (g/L): 158.0
HDL (mmol/L): 0,9
Potassium (mEq/L): 4,39
LDL (mmol/L): 3,17
Sodium (mEq/L): 134.0
Pro-BNP (ng/L): 155.0
Protein (g/L): 80,4
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,1
Urea (mg/dL): 9,9
LVEF (%): 60.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Survivor, 2. Sudden cardiac death, 3. Pump failure death

REASONING: 

Given the patient's data, I would rank the prognoses as follows:

1. Survivor: Despite the patient's advanced age and NYHA Class III, the patient's LVEF (60.0%) is within the normal range, indicating that the heart is still functioning relatively well. The patient is on a comprehensive medication regimen, including an Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, and Spironolactone, which suggests that the patient is receiving appropriate treatment for heart failure. The patient's Pro-BNP level (155.0 ng/L) is elevated, but not excessively high, which may indicate that the patient's heart failure is not severe. Additionally, the patient's Troponin level (0.01 ng/mL) is within normal limits, indicating that there is no acute myocardial infarction. Therefore, based on these factors, I believe that the patient is more likely to survive for the next few years.

2. Sudden cardiac death: While the patient has a history of valvular cardiomyopathy and hypertension, which are risk factors for sudden cardiac death, the patient's LVEF is within the normal range, and the patient is on medications that can help prevent sudden cardiac death, such as Digoxin and Spironolactone. The patient's ECG does not show any signs of sustained ventricular tachycardia, which is a common cause of sudden cardiac death. However, the patient's polymorphic ventricular extrasystoles may indicate an increased risk of arrhythmias, but this is not a definitive predictor of sudden cardiac death. Therefore, while sudden cardiac death is a possible outcome, it is less likely than pump failure death.

3. Pump failure death: The patient's NYHA Class III indicates that the patient has severe symptoms of heart failure, which is a strong predictor of pump failure death. The patient's Creatinine level (89.0 umol/L) is slightly elevated, indicating some degree of renal impairment, which is a common comorbidity in patients with heart failure. The patient's Pro-BNP level (155.0 ng/L) is elevated, which is consistent with heart failure. However, the patient's LVEF (60.0%) is within the normal range, which suggests that the patient's heart is still functioning relatively well. Nevertheless, the combination of severe symptoms, renal impairment, and elevated Pro-BNP level makes pump failure death a more likely outcome than sudden cardiac death.

Overall, while all three outcomes are possible, I believe that the patient is more likely to survive for the next few years, followed by pump failure death, and then sudden cardiac death."
831,831,P0839,"Age: 68
Gender: Male 
Weight: 70 kg
Height: 174 cm
NYHA Class: III
Blood Pressure: 120/50 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Myocardial Infarction
Albumin (g/L): 37,9
ALT or GPT (IU/L): 17.0
AST or GOT (IU/L): 11.0
Total Cholesterol (mmol/L): 4,09
Creatinine (mmol/L): 133.0
Gamma-glutamil transpeptidase (IU/L): 18
Glucose (mmol/L): 7,2
Hemoglobin (g/L): 97.0
HDL (mmol/L): 1,34
Potassium (mEq/L): 4
LDL (mmol/L): 2,35
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 1635.0
Protein (g/L): 66,1
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,39
Urea (mg/dL): 12,1
LVEF (%): 44.0
Medications: Amiodarone, Loop Diuretics, Spironolactone, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Pump failure death

REASONING: The patient has a history of ischemic dilated cardiomyopathy, which is a significant risk factor for heart failure and pump failure. The patient's left ventricular ejection fraction (LVEF) is 44%, which is below the normal range of 55-70%. This suggests that the patient's heart is not pumping efficiently, which increases the risk of pump failure. Additionally, the patient's B-type natriuretic peptide (BNP) level is elevated at 1635 ng/L, which is a marker of heart failure and pump failure. The patient's NYHA class is III, indicating severe symptoms of heart failure, which further supports the risk of pump failure. The patient's use of medications such as Loop Diuretics and Spironolactone also suggests that they are being treated for heart failure.

RANKING: 2. Sudden cardiac death

REASONING: The patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, which increases the risk of sudden cardiac death. The patient's LVEF is also below the normal range, which increases the risk of arrhythmias and sudden cardiac death. However, the patient's ECG does not show any signs of sustained ventricular tachycardia, which is a significant risk factor for sudden cardiac death. Additionally, the patient's troponin level is low, which suggests that there is not an active myocardial infarction occurring at the time of evaluation.

RANKING: 3. Survivor

REASONING: While the patient has several risk factors for heart failure and sudden cardiac death, the patient's overall clinical picture suggests that they are being actively managed for heart failure and are on medications that are known to improve outcomes in heart failure patients. The patient's LVEF is below the normal range, but it is not severely impaired, and the patient's BNP level is elevated but not extremely high. Additionally, the patient's troponin level is low, which suggests that there is not an active myocardial infarction occurring at the time of evaluation. While the patient's prognosis is guarded, it is possible that with continued medical management and monitoring, the patient may be able to survive for several years."
832,832,P0853,"Age: 74
Gender: Male 
Weight: 70 kg
Height: 158 cm
NYHA Class: II
Blood Pressure: 110/75 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 41
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 27.0
Total Cholesterol (mmol/L): 5,2
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 28
Glucose (mmol/L): 6,1
Hemoglobin (g/L): 135.0
HDL (mmol/L): 1,06
Potassium (mEq/L): 5
LDL (mmol/L): 3,78
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 4185.0
Protein (g/L): 77
T4 (ng/L): 19
Troponin (ng/mL): 0,02
TSH (mIU/L): 1,5
Urea (mg/dL): 12,15
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, I will rank the possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden Cardiac Death
 REASONING: The patient has a history of ischemic dilated cardiomyopathy with an LVEF of 30%, indicating significant left ventricular dysfunction. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG suggests an increased risk of arrhythmic events. Additionally, the elevated Pro-BNP level (4185.0 ng/L) is indicative of heart failure and further increases the risk of sudden cardiac death.

RANKING: 2. Pump Failure Death
 REASONING: The patient's LVEF of 30% and history of ischemic dilated cardiomyopathy suggest that the heart is already compromised, making pump failure a possible outcome. However, the patient is currently on beta blockers, loop diuretics, ACE inhibitors, and nitrovasodilators, which are standard treatments for heart failure. The patient's NYHA Class II classification indicates that the heart failure is not severe, and the patient is still relatively functional. Therefore, while pump failure is a possibility, it is less likely compared to sudden cardiac death due to the patient's current treatment regimen and functional status.

RANKING: 3. Survivor
 REASONING: Given the patient's advanced age (74), significant left ventricular dysfunction (LVEF 30%), and history of ischemic dilated cardiomyopathy, the likelihood of survival is lower compared to the other two options. However, the patient's current treatment regimen and functional status (NYHA Class II) suggest that they are still relatively stable and functional, which increases the likelihood of survival. Nevertheless, the patient's overall prognosis is guarded, and the risk of adverse outcomes, such as sudden cardiac death or pump failure, remains significant."
833,833,P0872,"Age: 57
Gender: Male 
Weight: 62 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Hypertensive cardiomyopathy
Albumin (g/L): 47
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 22.0
Total Cholesterol (mmol/L): 5,56
Creatinine (mmol/L): 86.0
Gamma-glutamil transpeptidase (IU/L): 38
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 153.0
HDL (mmol/L): 1,22
Potassium (mEq/L): 4,6
LDL (mmol/L): 3,57
Sodium (mEq/L): 137.0
Pro-BNP (ng/L): 2299.0
Protein (g/L): 74
T3 (pg/dL): 0,07
T4 (ng/L): 19
Troponin (ng/mL): 0,17
TSH (mIU/L): 2,47
Urea (mg/dL): 7,15
LVEF (%): 22.0
Medications: Angiotensin II Receptor Blocker, Beta Blockers, Digoxin, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, here's the ranking of the possible prognoses from most likely to least likely:

RANKING: 1. Pump failure death

REASONING: The patient has a history of hypertensive cardiomyopathy, which is a significant risk factor for heart failure. The patient's current left ventricular ejection fraction (LVEF) is 22%, which is significantly reduced, indicating poor heart function. The patient's B-type natriuretic peptide (BNP) level is elevated at 2299.0 ng/L, which is a marker of heart failure. Additionally, the patient is on medications for heart failure, including Loop Diuretics and Spironolactone, which are commonly used to manage heart failure symptoms. The presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG also suggests underlying cardiac arrhythmias, which can contribute to heart failure progression. Given the combination of these factors, pump failure death is the most likely prognosis.

RANKING: 2. Sudden cardiac death

REASONING: While sudden cardiac death is a possible outcome, it is less likely than pump failure death. The patient's LVEF is low, which increases the risk of sudden cardiac death. However, the presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG suggests that the patient's heart is not in a stable state, which may increase the risk of sudden cardiac death. However, the patient's overall clinical picture, including the presence of heart failure medications and a reduced LVEF, suggests that pump failure is a more likely outcome.

RANKING: 3. Survivor

REASONING: While it is possible that the patient may survive, the combination of a low LVEF, elevated BNP, and presence of non-sustained ventricular tachycardia and polymorphic ventricular extrasystoles on the ECG makes this outcome the least likely. The patient's current medications and symptoms suggest that the heart failure is not well-managed, which increases the risk of adverse outcomes. Additionally, the patient's age and comorbidities further increase the risk of poor outcomes."
834,834,P0873,"Age: 81
Gender: Female 
Weight: 49 kg
Height: 145 cm
NYHA Class: III
Blood Pressure: 180/90 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 42
ALT or GPT (IU/L): 19.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 4,69
Creatinine (mmol/L): 209.0
Gamma-glutamil transpeptidase (IU/L): 41
Glucose (mmol/L): 3,94
Hemoglobin (g/L): 131.0
HDL (mmol/L): 1,1
Potassium (mEq/L): 4,54
LDL (mmol/L): 3,01
Sodium (mEq/L): 139.0
Protein (g/L): 81
T3 (pg/dL): 0,0441
T4 (ng/L): 22,5
Troponin (ng/mL): 1,2
TSH (mIU/L): 1,27
Urea (mg/dL): 26,1
LVEF (%): 65.0
Medications: Digoxin, Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, here's my prognosis for the next few years:

RANKING: 1. Survivor
 REASONING: The patient is 81 years old and has a history of hypertensive cardiomyopathy and hypertension. However, she is being treated with medications such as ACE inhibitors, spironolactone, and loop diuretics, which are commonly used to manage heart failure and hypertension. Her LVEF is 65%, which is within the normal range (50-70%). While her creatinine level is elevated at 209.0 mmol/L, indicating some degree of renal impairment, it's not at a level that would typically be associated with end-stage renal disease. Additionally, her albumin and protein levels are within the normal range, which suggests that her liver function is not significantly impaired. Given her current treatment regimen and relatively preserved LVEF, I believe that the patient is most likely to survive for the next few years with proper management of her condition.

RANKING: 2. Sudden cardiac death
 REASONING: The patient has a history of hypertensive cardiomyopathy and is at risk for sudden cardiac death due to her underlying heart condition. However, her LVEF is 65%, which is relatively preserved, and she is being treated with medications that can help prevent sudden cardiac death, such as beta-blockers and ACE inhibitors. While her troponin level is elevated at 1.2 ng/mL, it's not significantly high enough to suggest acute myocardial infarction or severe cardiac damage. Additionally, her ECG does not show any signs of ventricular tachycardia or other arrhythmias that would increase her risk of sudden cardiac death. While there is a risk, I consider sudden cardiac death to be less likely than pump failure death.

RANKING: 3. Pump failure death
 REASONING: The patient has a history of hypertensive cardiomyopathy, which can lead to left ventricular dysfunction and heart failure. Her creatinine level is elevated, indicating some degree of renal impairment, which can be a marker of advanced heart failure. Her LVEF is 65%, which is on the lower end of the normal range, and she has a history of NYHA Class III heart failure, which indicates that she has significant symptoms and limitations with physical activity. Her medication regimen includes loop diuretics, which are commonly used to manage fluid overload in heart failure patients, but her sodium level is within the normal range, suggesting that her fluid status is being managed. However, her low body weight (49 kg) and small body size (145 cm) may indicate that she is at higher risk for malnutrition and decreased cardiac reserve, increasing her risk for pump failure death. Considering these factors, I believe that pump failure death is the least likely but still possible outcome."
835,835,P0882,"Age: 79
Gender: Female 
Weight: 70 kg
Height: 155 cm
NYHA Class: II
Blood Pressure: 160/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40,2
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 6,73
Creatinine (mmol/L): 93.0
Gamma-glutamil transpeptidase (IU/L): 17
Glucose (mmol/L): 7,13
Hemoglobin (g/L): 125.0
HDL (mmol/L): 1,74
Potassium (mEq/L): 4,14
LDL (mmol/L): 4,76
Sodium (mEq/L): 140.0
Protein (g/L): 66,7
T3 (pg/dL): 0,0549
T4 (ng/L): 16,02
TSH (mIU/L): 4,15
Urea (mg/dL): 7,4
LVEF (%): 50.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I will rank the possible prognoses as follows:

RANKING: 1. Survivor
 REASONING: The patient is 79 years old with a history of hypertensive cardiomyopathy, diabetes, dyslipemia, hypertension, and myocardial infarction. However, she is currently on a regimen of medications that are commonly used to manage these conditions, including calcium channel blockers, beta blockers, loop diuretics, statins, and a nitrovasodilator. Her LVEF is 50%, which is within the normal range for her age group. Her NYHA Class II indicates that she is experiencing some symptoms of heart failure but is still able to perform daily activities with some limitation. While her creatinine level is elevated, it is not significantly high, and her eGFR can be calculated to assess kidney function. Additionally, her albumin and protein levels are within normal limits. Considering these factors, I believe that the patient has a good chance of survival in the next few years with continued management and monitoring.

RANKING: 2. Sudden cardiac death
 REASONING: The patient has a history of myocardial infarction and is taking beta blockers, which are commonly used to reduce the risk of sudden cardiac death. Her LVEF is 50%, which may indicate some degree of left ventricular dysfunction, but it is not significantly low. However, her T3 level is slightly low, which may indicate some degree of hypothyroidism, which can increase the risk of sudden cardiac death. Additionally, her TSH level is within the normal range, but it may not accurately reflect the patient's thyroid function. The presence of polymorphic ventricular extrasystoles on the ECG may also increase the risk of sudden cardiac death. However, the overall risk is still relatively low.

RANKING: 3. Pump failure death
 REASONING: The patient has a history of hypertensive cardiomyopathy, which is a risk factor for heart failure. Her LVEF is 50%, which may indicate some degree of left ventricular dysfunction. Her NYHA Class II indicates that she is experiencing some symptoms of heart failure, and her creatinine level is elevated, suggesting some degree of renal impairment. Her medication regimen includes loop diuretics, which are commonly used to manage heart failure symptoms. However, the patient's overall clinical picture suggests that she is at a higher risk of developing pump failure death compared to the other two prognoses. The presence of elevated creatinine and renal impairment may indicate that the patient's heart failure is more advanced, and her kidney function may be compromised, increasing the risk of pump failure death."
836,836,P0884,"Age: 70
Gender: Female 
Weight: 70 kg
Height: 165 cm
NYHA Class: II
Blood Pressure: 140/80 mmHg
Past Medical History: Hypertensive cardiomyopathy, Hypertension
Albumin (g/L): 34
ALT or GPT (IU/L): 43.0
AST or GOT (IU/L): 34.0
Total Cholesterol (mmol/L): 4,01
Creatinine (mmol/L): 53.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 6,6
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,32
Potassium (mEq/L): 4,3
LDL (mmol/L): 2,22
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 2773.0
Protein (g/L): 75
T4 (ng/L): 15
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,23
Urea (mg/dL): 4,99
LVEF (%): 60.0
Medications: Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor
REASONING: The patient's current LVEF (60.0%) is within a relatively normal range, indicating that the left ventricle is still pumping effectively. Additionally, the patient is on medications that are commonly used to manage heart failure and hypertension, such as loop diuretics and an ACE inhibitor. The absence of a history of previous heart failure hospitalizations or severe symptoms (NYHA Class II) suggests that the patient's current condition is manageable. The patient's troponin level is within normal limits, indicating that there is no acute myocardial infarction. While the patient has a history of hypertensive cardiomyopathy, the current LVEF is not significantly reduced, and the patient's overall condition does not seem to be rapidly deteriorating.

RANKING: 2. Sudden cardiac death
REASONING: The patient has a history of ventricular extrasystole, non-sustained ventricular tachycardia, and a high pro-BNP level, which may indicate underlying cardiac dysfunction or increased sympathetic tone. However, the patient's LVEF is still relatively preserved, and the absence of a history of previous sudden cardiac arrests or severe arrhythmias suggests that the risk of sudden cardiac death may be lower than pump failure death. The patient's medications, including an ACE inhibitor, may also be helping to mitigate this risk.

RANKING: 3. Pump failure death
REASONING: The patient's elevated pro-BNP level (2773.0 ng/L) is a strong indicator of heart failure, and the patient's NYHA Class II classification suggests that the patient is experiencing symptoms of heart failure. The patient's creatinine level is slightly elevated, which may indicate renal impairment due to heart failure. The patient's LVEF is within a relatively normal range, but the presence of non-sustained ventricular tachycardia and a high pro-BNP level suggests that the patient's left ventricle may be under increased stress. The patient's overall condition, including the presence of hypertension and hypertensive cardiomyopathy, suggests that the risk of pump failure death may be higher than sudden cardiac death or survivorship."
837,837,P0888,"Age: 77
Gender: Male 
Weight: 60 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Myocardial Infarction
Albumin (g/L): 43
ALT or GPT (IU/L): 24.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 5,74
Creatinine (mmol/L): 101.0
Gamma-glutamil transpeptidase (IU/L): 30
Glucose (mmol/L): 9,8
Hemoglobin (g/L): 146.0
HDL (mmol/L): 1,09
Potassium (mEq/L): 4,54
LDL (mmol/L): 4,01
Sodium (mEq/L): 137.0
Protein (g/L): 75,8
T3 (pg/dL): 0,0642
T4 (ng/L): 15,87
Troponin (ng/mL): 0,3
TSH (mIU/L): 2,14
Urea (mg/dL): 12,9
LVEF (%): 30.0
Medications: Diabetes Medication, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Survivor, 2. Sudden cardiac death, 3. Pump failure death

REASONING: Based on the provided patient data, the most likely prognosis is a survivor, with a 30% ejection fraction (LVEF 30.0%), indicating reduced cardiac function. However, the patient is on ACE inhibitors and loop diuretics, which are standard treatments for heart failure with reduced ejection fraction (HFrEF). The patient's NYHA Class II classification also indicates that the patient is experiencing some symptoms but is still able to perform everyday activities. 

The patient's ischemic dilated cardiomyopathy and past myocardial infarction also contribute to the likelihood of a survivor prognosis. While these conditions are serious, the patient's treatment plan and current symptoms suggest that they are being managed effectively.

Sudden cardiac death is less likely due to the patient's relatively stable symptoms and the fact that they are on a beta blocker, which is often used to reduce the risk of sudden cardiac death in patients with HFrEF.

Pump failure death is the least likely prognosis due to the patient's relatively stable symptoms and the fact that they are on diuretics and ACE inhibitors, which are standard treatments for heart failure. However, the patient's low LVEF and history of ischemic dilated cardiomyopathy increase the risk of pump failure."
838,838,P0891,"Age: 72
Gender: Male 
Weight: 57 kg
Height: 158 cm
NYHA Class: III
Blood Pressure: 130/90 mmHg
Past Medical History: Other HF etiology, Diabetes, Hypertension
Albumin (g/L): 43
ALT or GPT (IU/L): 18.0
AST or GOT (IU/L): 18.0
Total Cholesterol (mmol/L): 5,28
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 143.0
HDL (mmol/L): 1,27
Potassium (mEq/L): 4,5
LDL (mmol/L): 3,49
Sodium (mEq/L): 144.0
Pro-BNP (ng/L): 4127.0
Protein (g/L): 72
T4 (ng/L): 19
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,56
Urea (mg/dL): 12,81
LVEF (%): 20.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I will generate a prognosis for the next few years. Please note that this is a medical prediction, and actual outcomes may vary.

RANKING: 1. Sudden cardiac death, 2. Pump failure death, 3. Survivor

REASONING:

1. Sudden cardiac death (SCD): Given the patient's age (72), NYHA Class III, and low LVEF (20%), the risk of SCD is relatively high. The presence of polymorphic ventricular extrasystoles and non-sustained ventricular tachycardia on the ECG further increases the risk of life-threatening arrhythmias. Additionally, the high Pro-BNP level (4127.0 ng/L) indicates significant cardiac stress, which may contribute to increased arrhythmic risk. The patient's low HDL level (1.27 mmol/L) and high LDL level (3.49 mmol/L) also suggest a higher risk of atherosclerotic disease, which can contribute to SCD.

2. Pump failure death: The patient's NYHA Class III, low LVEF (20%), and high Pro-BNP level (4127.0 ng/L) suggest advanced heart failure. The presence of diabetes, hypertension, and other HF etiology further contributes to the risk of pump failure. However, the patient is already on optimal medical therapy (ACE inhibitor and Angiotensin II Receptor Blocker), which may help mitigate this risk.

3. Survivor: While the patient's current condition is concerning, the fact that they are already on optimal medical therapy and have a relatively controlled blood pressure (130/90 mmHg) may help slow disease progression. The patient's hemoglobin level (143.0 g/L) is within a relatively normal range, indicating that anemia is not a significant concern. The TSH level (2.56 mIU/L) is also within a normal range, which suggests that hypothyroidism is not contributing to their cardiac condition. However, the patient's weight (57 kg) and height (158 cm) indicate a low body mass index (BMI), which may increase the risk of malnutrition and further cardiac stress.

Please note that this prognosis is based on the provided data and may not reflect the patient's actual outcome. A more accurate prognosis would require a comprehensive clinical evaluation, including a thorough medical history, physical examination, and diagnostic testing."
839,839,P0907,"Age: 50
Gender: Male 
Weight: 69 kg
Height: 169 cm
NYHA Class: II
Blood Pressure: 100/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 39,4
ALT or GPT (IU/L): 25.0
AST or GOT (IU/L): 32.0
Total Cholesterol (mmol/L): 2,79
Creatinine (mmol/L): 156.0
Gamma-glutamil transpeptidase (IU/L): 66
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 138.0
HDL (mmol/L): 0,87
Potassium (mEq/L): 3,78
LDL (mmol/L): 1,37
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 9416.0
Protein (g/L): 64,6
Troponin (ng/mL): 0,01
TSH (mIU/L): 1,85
Urea (mg/dL): 9,2
LVEF (%): 20.0
Medications: Amiodarone, Beta Blockers, Loop Diuretics, Statins, Hydralazine, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden cardiac death, 2. Pump failure death, 3. Survivor

REASONING:

1. Sudden Cardiac Death (SCD): Given the patient's history of ischemic dilated cardiomyopathy, previous myocardial infarction, and a left ventricular ejection fraction (LVEF) of 20%, the patient is at a high risk for sudden cardiac death. The presence of non-sustained ventricular tachycardia (VT) and polymorphic ventricular extrasystoles on the ECG further increases the risk of SCD. The patient's high Pro-BNP level (9416.0 ng/L) also indicates significant cardiac stress and potential for arrhythmic events. Therefore, SCD is the most likely prognosis.

2. Pump Failure Death: Although the patient's LVEF is severely reduced, the patient is currently being treated with medications such as beta-blockers, loop diuretics, and hydralazine, which are aimed at managing heart failure symptoms and improving cardiac function. Additionally, the patient's blood pressure is well-controlled, and there is no indication of severe renal impairment (creatinine level is 156.0 umol/L, which is within the normal range for a male). While pump failure death is still a possibility, the patient's current management plan and lack of severe renal impairment make it slightly less likely compared to SCD.

3. Survivor: Given the patient's history of ischemic dilated cardiomyopathy, previous myocardial infarction, and severely reduced LVEF, the likelihood of long-term survival is low. However, with optimal medical management and close monitoring, it is still possible for the patient to survive in the short to medium term. The patient's NYHA class II classification suggests that they are still able to perform daily activities without significant limitation, which is a positive sign. However, the overall prognosis remains guarded, and the patient will require close follow-up and adjustments to their treatment plan to prevent further complications.

Please note that this prognosis is based on the provided data and may change with new information or developments in the patient's condition."
840,840,P0913,"Age: 69
Gender: Female 
Weight: 70 kg
Height: 151 cm
NYHA Class: III
Blood Pressure: 130/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 40,7
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 33.0
Total Cholesterol (mmol/L): 4,94
Creatinine (mmol/L): 63.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 5,7
Hemoglobin (g/L): 119.0
HDL (mmol/L): 1,4
Potassium (mEq/L): 4
LDL (mmol/L): 3,08
Sodium (mEq/L): 141.0
Pro-BNP (ng/L): 475.0
Protein (g/L): 70,7
T3 (pg/dL): 0,04
T4 (ng/L): 14
TSH (mIU/L): 1,94
Urea (mg/dL): 6,16
LVEF (%): 35.0
Medications: Calcium Channel Blocker, Diabetes Medication, Beta Blockers, Loop Diuretics, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I would rank the three possible prognoses as follows:

RANKING: 1. Sudden cardiac death
REASONING: The patient has a history of ischemic dilated cardiomyopathy with an LVEF of 35%, indicating a significantly reduced left ventricular function. The patient is also taking beta blockers and ACE inhibitors, which are commonly used to manage heart failure and reduce the risk of sudden cardiac death. However, the presence of a low LVEF, ventricular extrasystoles, and a high Pro-BNP level (475.0 ng/L) suggest an increased risk of arrhythmias and sudden cardiac death.

RANKING: 2. Pump failure death
REASONING: The patient's NYHA Class III classification indicates severe symptoms of heart failure, and the low LVEF of 35% suggests a high risk of pump failure. The patient is taking loop diuretics, which are commonly used to manage fluid overload in heart failure. However, the patient's high creatinine level (63.0 mmol/L) and low albumin level (40.7 g/L) suggest potential renal impairment, which can further exacerbate heart failure and increase the risk of pump failure death.

RANKING: 3. Survivor
REASONING: While the patient has multiple comorbidities, including diabetes, hypertension, and peripheral vascular disease, the patient is taking a comprehensive medication regimen that includes a calcium channel blocker, diabetes medication, beta blockers, loop diuretics, and an ACE inhibitor. The patient's low TSH level (1.94 mIU/L) suggests that the patient is not experiencing hypothyroidism, which can be a contributing factor to heart failure. Additionally, the patient's hemoglobin level (119.0 g/L) is within the normal range, which suggests that the patient is not experiencing anemia, which can further exacerbate heart failure. While the patient's prognosis is guarded, the comprehensive medication regimen and the absence of certain comorbidities suggest a slightly better prognosis than pump failure death or sudden cardiac death."
841,841,P0940,"Age: 79
Gender: Male 
Weight: 58 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Dyslipemia, Peripheral vascular disease, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 12.0
AST or GOT (IU/L): 9.0
Total Cholesterol (mmol/L): 3,62
Creatinine (mmol/L): 141.0
Gamma-glutamil transpeptidase (IU/L): 13
Glucose (mmol/L): 6,2
Hemoglobin (g/L): 105.0
HDL (mmol/L): 0,44
Potassium (mEq/L): 5,3
LDL (mmol/L): 1,89
Sodium (mEq/L): 138.0
Pro-BNP (ng/L): 5482.0
Protein (g/L): 68
T3 (pg/dL): 0,05
T4 (ng/L): 16
Troponin (ng/mL): 0,13
TSH (mIU/L): 2,56
Urea (mg/dL): 18,14
LVEF (%): 30.0
Medications: Calcium Channel Blocker, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Sudden cardiac death, 2. Pump failure death, 3. Survivor

REASONING: 

1. Sudden cardiac death (Rank 1): Given the patient's age (79), low LVEF (30%), and history of ischemic dilated cardiomyopathy, the risk of sudden cardiac death is higher. The patient's low LVEF indicates a reduced ability of the heart to pump blood effectively, increasing the risk of sudden cardiac death. Additionally, the presence of polymorphic ventricular extrasystoles on the ECG further increases the risk of arrhythmias, which can lead to sudden cardiac death.

2. Pump failure death (Rank 2): Although the patient's LVEF is low, the patient is currently on medications that help manage symptoms and improve heart function (e.g., ACE inhibitor, beta blockers, loop diuretics). The patient's NYHA Class II classification indicates that the patient is experiencing some limitations in physical activity but is still able to perform daily activities without severe symptoms. However, the patient's low LVEF and history of ischemic dilated cardiomyopathy increase the risk of pump failure death over time.

3. Survivor (Rank 3): Given the patient's age, comorbidities, and low LVEF, the prognosis is generally poor. However, the patient is currently on a multidrug regimen to manage symptoms and improve heart function, and the patient's NYHA Class II classification suggests that the patient is still able to perform daily activities without severe symptoms. While the patient's prognosis is guarded, the current medications and management plan may help slow disease progression and improve quality of life, making survival more likely than sudden cardiac death or pump failure death."
842,842,P0961,"Age: 76
Gender: Female 
Weight: 93 kg
Height: 166 cm
NYHA Class: II
Blood Pressure: 134/64 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Myocardial Infarction
Albumin (g/L): 45
ALT or GPT (IU/L): 14.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 115.0
Gamma-glutamil transpeptidase (IU/L): 10
Glucose (mmol/L): 7,3
Hemoglobin (g/L): 149.0
HDL (mmol/L): 0,72
Potassium (mEq/L): 4,2
LDL (mmol/L): 2,77
Sodium (mEq/L): 142.0
Pro-BNP (ng/L): 2876.0
Protein (g/L): 71
T3 (pg/dL): 0,04
T4 (ng/L): 19
TSH (mIU/L): 2,86
Urea (mg/dL): 9,82
LVEF (%): 30.0
Medications: Digoxin, Loop Diuretics, Spironolactone, Statins
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"RANKING: 1. Survivor, 2. Sudden cardiac death, 3. Pump failure death

REASONING: 

Based on the provided patient data, I would rank the prognosis as follows:

1. Survivor: The patient's age and NYHA Class II indicate that she has some limitations in her physical activity but is still able to perform everyday tasks. The patient is on a combination of medications, including digoxin, loop diuretics, spironolactone, and statins, which are standard treatments for heart failure. The patient's LVEF of 30% is low, but it is not extremely low, and she is not in New York Heart Association (NYHA) Class IV, which is typically associated with more severe symptoms. The patient's eGFR is not explicitly stated, but the creatinine level of 115.0 mol/L suggests that the patient has some degree of renal impairment, which is a common comorbidity in patients with heart failure. However, the patient's albumin and protein levels are within normal limits, which suggests that the renal impairment is not severe. The patient's TSH level is within the normal range, and the T3 and T4 levels are low, which could indicate hypothyroidism, but this is not directly related to the heart failure prognosis. Given the patient's relatively stable condition and the fact that she is on appropriate medications, I believe that a survivor prognosis is the most likely outcome.

2. Sudden cardiac death: The patient has a history of myocardial infarction and ischemic dilated cardiomyopathy, which increases her risk of sudden cardiac death. However, the patient's LVEF of 30% and the presence of polymorphic ventricular extrasystoles on the ECG suggest that she has some degree of arrhythmia risk. The patient's pro-BNP level is elevated at 2876.0 ng/L, which suggests that she has some degree of heart failure, but it is not extremely high, which might indicate a higher risk of sudden cardiac death. The patient's medications, including digoxin and spironolactone, are not typically associated with an increased risk of sudden cardiac death. While the patient's history and ECG findings suggest some risk of sudden cardiac death, the overall prognosis is not extremely high.

3. Pump failure death: The patient's LVEF of 30% and the presence of heart failure symptoms (NYHA Class II) suggest that she has some degree of heart failure. The patient's creatinine level of 115.0 mol/L suggests that she has some degree of renal impairment, which is a common comorbidity in patients with heart failure. The patient's pro-BNP level is elevated, which suggests that she has some degree of heart failure. However, the patient's albumin and protein levels are within normal limits, which suggests that the renal impairment is not severe. The patient's medications, including loop diuretics and spironolactone, are standard treatments for heart failure. While the patient's condition is not extremely severe, her LVEF is low, and she has some degree of renal impairment, which suggests that pump failure death is a possible outcome. However, given the patient's relatively stable condition and the fact that she is on appropriate medications, I believe that pump failure death is the least likely outcome."
843,843,P0978,"Age: 69
Gender: Male 
Weight: 106 kg
Height: 170 cm
NYHA Class: II
Blood Pressure: 130/70 mmHg
Past Medical History: Ischemic dilated cardiomyopathy, Diabetes, Dyslipemia, Peripheral vascular disease, Hypertension, Myocardial Infarction
Albumin (g/L): 34
ALT or GPT (IU/L): 30.0
AST or GOT (IU/L): 16.0
Total Cholesterol (mmol/L): 4,55
Creatinine (mmol/L): 186.0
Gamma-glutamil transpeptidase (IU/L): 40
Glucose (mmol/L): 8,1
Hemoglobin (g/L): 118.0
HDL (mmol/L): 0,83
Potassium (mEq/L): 4
LDL (mmol/L): 2,82
Sodium (mEq/L): 143.0
Pro-BNP (ng/L): 6603.0
Protein (g/L): 67
T4 (ng/L): 14
Troponin (ng/mL): 0,01
TSH (mIU/L): 2,22
Urea (mg/dL): 14,48
LVEF (%): 35.0
Medications: Diabetes Medication, Beta Blockers, Loop Diuretics, Statins, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden Cardiac Death (SCD), 2. Pump Failure Death, 3. Survivor

REASONING:

1. Sudden Cardiac Death (SCD): Given the patient's history of ischemic dilated cardiomyopathy, previous myocardial infarction, and low left ventricular ejection fraction (LVEF) of 35%, the patient is at an increased risk for sudden cardiac death. The presence of polymorphic ventricular extrasystoles on the ECG further increases this risk. Additionally, the patient's high Pro-BNP level (6603 ng/L) suggests significant heart failure symptoms, which is a known risk factor for SCD.

2. Pump Failure Death: The patient's low LVEF, high Pro-BNP level, and symptoms of heart failure (NYHA Class II) suggest that pump failure is a significant concern. However, the patient is currently being treated with loop diuretics, which suggests that the heart failure symptoms are being managed. The patient's creatinine level is elevated at 186.0 umol/L, indicating some degree of renal impairment, which may be related to the heart failure. While pump failure is a possibility, the patient's current treatment regimen and the lack of other indicators of advanced heart failure (e.g., severe hypotension, significant fluid overload) make this prognosis less likely than SCD.

3. Survivor: The patient's current treatment regimen includes beta blockers, which are known to improve survival in patients with heart failure. The patient's LVEF is low, but not extremely low, and the Pro-BNP level is high, but not extremely high. The patient's creatinine level is elevated, but not severely so. While the patient's prognosis is guarded, the presence of a well-managed treatment regimen and the lack of other indicators of advanced heart failure make survival the least likely prognosis.

It's essential to note that this is a complex case, and the prognosis may change based on the patient's response to treatment, changes in symptoms, and other factors not mentioned in the provided data."
844,844,P0981,"Age: 73
Gender: Male 
Weight: 63 kg
Height: 160 cm
NYHA Class: II
Blood Pressure: 110/70 mmHg
Past Medical History: Other HF etiology, Diabetes, Dyslipemia, Hypertension, Myocardial Infarction
Albumin (g/L): 40,5
ALT or GPT (IU/L): 8.0
AST or GOT (IU/L): 14.0
Total Cholesterol (mmol/L): 4,06
Creatinine (mmol/L): 111.0
Gamma-glutamil transpeptidase (IU/L): 29
Glucose (mmol/L): 4,4
Hemoglobin (g/L): 106.0
HDL (mmol/L): 1,73
Potassium (mEq/L): 5,1
LDL (mmol/L): 2,02
Sodium (mEq/L): 144.0
Protein (g/L): 74
T4 (ng/L): 19
TSH (mIU/L): 0,19
Urea (mg/dL): 9,48
LVEF (%): 69.0
Medications: Diabetes Medication, Angiotensin II Receptor Blocker, Beta Blockers, Loop Diuretics, Nitrovasodilator
ECG Impression:
        - Ventricular Extrasystole: Monomorphic
        - Ventricular Tachycardia: No
        - Non-sustained ventricular tachycardia (CH>10): No
        - Paroxysmal supraventricular tachyarrhythmia: TPSV
        - Bradycardia: No
            ",pump failure death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 2
 REASONING: The patient is 73 years old, which puts them in a high-risk category for cardiovascular events. However, their LVEF is 69%, which is within the normal range, indicating that their heart is functioning relatively well. The patient's NYHA Class II classification suggests that they have some limitations in physical activity but are still able to perform everyday activities. The presence of a monomorphic ventricular extrasystole on the ECG is a benign finding and not indicative of a poor prognosis.

However, the patient has a history of myocardial infarction, diabetes, dyslipemia, and hypertension, which are all risk factors for heart failure and cardiovascular events. The elevated creatinine level (111.0 umol/L) and urea level (9.48 mg/dL) suggest some degree of renal impairment, which can be a contributing factor to heart failure. The patient's low HDL level (1.73 mmol/L) and high LDL level (2.02 mmol/L) also suggest a high risk for cardiovascular disease.

Considering these factors, the patient is at risk for pump failure due to their underlying cardiovascular disease and renal impairment. However, the fact that their LVEF is within the normal range and they are on appropriate medications for their conditions suggests that they are being managed effectively. Therefore, while pump failure is a possible prognosis, it is not the most likely outcome.

RANKING: 1
 REASONING: Sudden cardiac death is a possible prognosis for this patient due to their history of myocardial infarction, low HDL level, and high LDL level, which are all risk factors for cardiac arrhythmias and sudden cardiac death. The presence of a monomorphic ventricular extrasystole on the ECG is a benign finding, but it can sometimes be a precursor to more serious arrhythmias. The patient's age and renal impairment also contribute to their risk for sudden cardiac death.

RANKING: 3
 REASONING: Survivor is the least likely prognosis for this patient due to their high risk factors for cardiovascular disease and heart failure. While their LVEF is within the normal range, their underlying conditions and medication regimen suggest that they are at risk for cardiac events. The patient's age and renal impairment also contribute to their risk for long-term complications. However, with proper management and follow-up, it is possible that the patient can survive and live with their conditions."
845,845,P0983,"Age: 68
Gender: Male 
Weight: 90 kg
Height: 164 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Dyslipemia, Hypertension
Albumin (g/L): 39
ALT or GPT (IU/L): 26.0
AST or GOT (IU/L): 36.0
Total Cholesterol (mmol/L): 5,07
Creatinine (mmol/L): 187.0
Gamma-glutamil transpeptidase (IU/L): 61
Glucose (mmol/L): 4,9
Hemoglobin (g/L): 154.0
HDL (mmol/L): 1,03
Potassium (mEq/L): 5,4
LDL (mmol/L): 3,15
Sodium (mEq/L): 144.0
Protein (g/L): 70
T4 (ng/L): 15
TSH (mIU/L): 3,68
Urea (mg/dL): 12,64
LVEF (%): 21.0
Medications: Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, here is the ranking of the possible prognoses:

RANKING: 1. Survivor
 REASONING: Although the patient has a history of idiopathic dilated cardiomyopathy and reduced left ventricular ejection fraction (LVEF) of 21%, which is a significant risk factor for heart failure, the patient is on optimal medical therapy with Angiotensin II Receptor Blocker, Digoxin, Loop Diuretics, and Spironolactone. The patient's blood pressure is well-controlled at 120/80 mmHg, and the creatinine level is slightly elevated but not severely abnormal at 187.0 mol/L. The patient's hemoglobin level is within a relatively normal range, and the TSH level is within the normal range, indicating no significant thyroid dysfunction. The patient's ECG shows non-sustained ventricular tachycardia, which is a concerning finding but not necessarily a contraindication to survival. Given the patient's current treatment and the relatively stable laboratory values, I believe the patient has a relatively good chance of survival over the next few years.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy and a low LVEF of 21%, which increases the risk of sudden cardiac death. The presence of non-sustained ventricular tachycardia on the ECG is also a risk factor for sudden cardiac death. However, the patient is on optimal medical therapy, and the blood pressure and creatinine levels are relatively well-controlled. While the patient's risk of sudden cardiac death is increased, the presence of optimal medical therapy and relatively stable laboratory values suggests that the risk is not extremely high.

RANKING: 3. Pump Failure Death
 REASONING: Given the patient's history of idiopathic dilated cardiomyopathy and a low LVEF of 21%, the patient is at high risk for pump failure death. The patient's creatinine level is slightly elevated at 187.0 mol/L, indicating some degree of renal impairment, which is a common complication of heart failure. The patient's NYHA class is III, indicating significant symptoms of heart failure. While the patient is on optimal medical therapy, the combination of a low LVEF, elevated creatinine level, and significant symptoms of heart failure suggests that pump failure death is a more likely outcome than the other two options.

Note: The patient's outcome is actually ""pump failure death"" as per the provided data, but based on the analysis, I ranked it as the least likely outcome."
846,846,P0997,"Age: 72
Gender: Male 
Weight: 95 kg
Height: 159 cm
NYHA Class: III
Blood Pressure: 120/80 mmHg
Past Medical History: Ischemic dilated cardiomyopathy
Albumin (g/L): 40,9
ALT or GPT (IU/L): 41.0
AST or GOT (IU/L): 45.0
Total Cholesterol (mmol/L): 4,76
Creatinine (mmol/L): 110.0
Gamma-glutamil transpeptidase (IU/L): 39
Glucose (mmol/L): 6,3
Hemoglobin (g/L): 155.0
HDL (mmol/L): 1,11
Potassium (mEq/L): 5,2
LDL (mmol/L): 3
Sodium (mEq/L): 137.0
Protein (g/L): 73,8
T4 (ng/L): 14
TSH (mIU/L): 1,53
Urea (mg/dL): 10,82
LVEF (%): 20.0
Medications: Loop Diuretics, Spironolactone, ACE Inhibitor
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: No
        - Bradycardia: No
            ",pump failure death,"RANKING: 1. Survivor, 2. Sudden cardiac death, 3. Pump failure death

REASONING: Based on the provided patient data, I have ranked the prognoses as follows:

1. Survivor: Despite the patient's advanced age, ischemic dilated cardiomyopathy, and low LVEF (20%), the patient's NYHA Class III suggests that they are experiencing symptoms but are still able to perform daily activities with some limitations. The patient's current medications (Loop Diuretics, Spironolactone, ACE Inhibitor) are likely aimed at managing heart failure symptoms and slowing disease progression. With proper management and adherence to treatment, it is possible that the patient may survive for several years with ongoing medical care and lifestyle modifications.

2. Sudden cardiac death: The presence of non-sustained ventricular tachycardia (NSVT) and polymorphic ventricular extrasystoles on the ECG increases the risk of sudden cardiac death. However, the patient's current medications and medical management may help mitigate this risk. Additionally, the patient's LVEF is very low, which is a risk factor for sudden cardiac death, but not the only factor. Given the patient's overall clinical picture, sudden cardiac death is a possible but not the most likely outcome.

3. Pump failure death: The patient's LVEF of 20% is a strong indicator of advanced heart failure, and their NYHA Class III classification suggests that they are experiencing significant symptoms. The patient's creatinine level (110.0 mmol/L) is also elevated, indicating possible renal impairment, which can be a consequence of advanced heart failure. Given the patient's advanced heart failure and low LVEF, pump failure death is the most likely outcome in the short to medium term, especially if medical management is not optimized or if the patient's condition worsens."
847,847,P1023,"Age: 77
Gender: Male 
Weight: 84 kg
Height: 159 cm
NYHA Class: II
Blood Pressure: 116/79 mmHg
Past Medical History: Valvular cardiomyopathy
Albumin (g/L): 42
ALT or GPT (IU/L): 11.0
AST or GOT (IU/L): 13.0
Total Cholesterol (mmol/L): 3,88
Creatinine (mmol/L): 177.0
Gamma-glutamil transpeptidase (IU/L): 9
Glucose (mmol/L): 5,8
Hemoglobin (g/L): 117.0
HDL (mmol/L): 1,24
Potassium (mEq/L): 5,9
LDL (mmol/L): 3,1
Sodium (mEq/L): 140.0
Protein (g/L): 78
T3 (pg/dL): 0,04
T4 (ng/L): 18
Troponin (ng/mL): 0,03
TSH (mIU/L): 0,36
Urea (mg/dL): 19,64
LVEF (%): 70.0
Medications: Digoxin, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Survivor
 REASONING: Although the patient has a history of valvular cardiomyopathy, an LVEF of 70% indicates that the left ventricular function is relatively preserved. The patient is also on optimal medical therapy with digoxin, loop diuretics, and spironolactone, which suggests that the current management plan is aimed at controlling symptoms and slowing disease progression. The patient's NYHA Class II status indicates that the patient is experiencing some symptoms but is still able to perform daily activities with some limitation. The lack of significant elevations in troponin and the low level of ventricular arrhythmias on the ECG also suggest that the patient's cardiac function is relatively stable. Therefore, given the patient's current management and relatively preserved LVEF, a survivor prognosis is the most likely outcome.

RANKING: 2. Sudden Cardiac Death
 REASONING: The patient's history of valvular cardiomyopathy and non-sustained ventricular tachycardia on the ECG suggest an increased risk of sudden cardiac death. However, the presence of a relatively preserved LVEF and the patient's current management plan with digoxin, loop diuretics, and spironolactone reduce the likelihood of sudden cardiac death. The patient's TSH level is also within the normal range, which suggests that hypothyroidism, a potential cause of sudden cardiac death in elderly patients, is unlikely. Therefore, while the patient's risk of sudden cardiac death is increased, it is not the most likely outcome given the patient's current management and relatively preserved LVEF.

RANKING: 3. Pump Failure Death
 REASONING: The patient's history of valvular cardiomyopathy and a creatinine level of 177.0 mmol/L suggest that the patient has significant renal impairment, which is a risk factor for pump failure death. The patient's LVEF of 70% is relatively preserved, but the presence of non-sustained ventricular tachycardia on the ECG and the patient's NYHA Class II status suggest that the patient's cardiac function is not optimal. Additionally, the patient's serum albumin level is low, which may indicate malnutrition or liver disease, both of which can contribute to a poor prognosis. The patient's T3 level is also low, which may suggest hypothyroidism, which can contribute to a poor prognosis in patients with heart failure. Given these factors, pump failure death is the least likely outcome, but still a possible outcome given the patient's significant renal impairment and relatively poor nutritional status."
848,848,P1026,"Age: 68
Gender: Male 
Weight: 60 kg
Height: 162 cm
NYHA Class: II
Blood Pressure: 92/64 mmHg
Past Medical History: Idiopathic dilated cardiomyopathy, Hypertension
Albumin (g/L): 27
ALT or GPT (IU/L): 15.0
AST or GOT (IU/L): 28.0
Total Cholesterol (mmol/L): 3,49
Creatinine (mmol/L): 186.0
Gamma-glutamil transpeptidase (IU/L): 349
Glucose (mmol/L): 4,8
Hemoglobin (g/L): 117.0
HDL (mmol/L): 0,78
Potassium (mEq/L): 5,2
LDL (mmol/L): 2,09
Sodium (mEq/L): 134.0
Protein (g/L): 51
T3 (pg/dL): 0,04
T4 (ng/L): 15
TSH (mIU/L): 9,94
Urea (mg/dL): 25,79
LVEF (%): 30.0
Medications: Beta Blockers, Loop Diuretics, Spironolactone
ECG Impression:
        - Ventricular Extrasystole: Polymorphic
        - Ventricular Tachycardia: Non-sustained VT
        - Non-sustained ventricular tachycardia (CH>10): Yes
        - Paroxysmal supraventricular tachyarrhythmia: Unknown paroxysmal supraventricular tachyarrhythmia code
        - Bradycardia: Unknown bradycardia code
            ",pump failure death,"Based on the provided patient data, I will rank the three possible prognoses from most likely to least likely as follows:

RANKING: 1. Sudden cardiac death
 REASONING: The patient has a history of idiopathic dilated cardiomyopathy with a left ventricular ejection fraction (LVEF) of 30%, indicating severe systolic heart failure. The presence of non-sustained ventricular tachycardia (NSVT) on the ECG is a known risk factor for sudden cardiac death, particularly in patients with reduced LVEF. Additionally, the patient's low blood pressure (92/64 mmHg) and low hemoglobin level (117 g/L) may indicate inadequate cardiac output, further increasing the risk of sudden cardiac death. The patient's medication regimen includes beta blockers, which are typically used to reduce the risk of sudden cardiac death, but the presence of NSVT and low LVEF may outweigh the protective effects of these medications.

RANKING: 2. Pump failure death
 REASONING: Given the patient's severe heart failure symptoms (NYHA Class II), reduced LVEF, and history of idiopathic dilated cardiomyopathy, pump failure death is a significant concern. The patient's low serum albumin level (27 g/L) and elevated creatinine level (186.0 mmol/L) indicate possible renal dysfunction, which is often seen in advanced heart failure. However, the patient's medication regimen includes loop diuretics and spironolactone, which are commonly used to manage heart failure symptoms and slow disease progression.

RANKING: 3. Survivor
 REASONING: While the patient has several risk factors for adverse outcomes, the likelihood of survival is still present due to the patient's relatively young age (68) and the fact that they are already receiving appropriate medical treatment for their heart failure. The patient's LVEF is low, but it is not the lowest possible value, and the patient's medication regimen includes medications that are known to improve outcomes in heart failure patients. Additionally, the patient's ECG shows no signs of severe arrhythmias or conduction abnormalities, which may indicate a lower risk of sudden cardiac death.

Please note that this prognosis is based on the provided data and may not reflect the patient's actual outcome."
